thalidomide has been researched along with Multiple Myeloma in 2729 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bortezomib is active in heavily pretreated multiple myeloma patients; the dose-limiting toxicity is peripheral neuropathy (PN)." | 10.22 | Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. ( Akpek, G; Badros, A; Can, I; Dalal, JS; Fenton, RG; Goloubeva, O; Heyman, M; Rapoport, AP; Thompson, J, 2007) |
| "Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (D-RVd) in the GRIFFIN study improved the stringent complete response rate by the end of consolidation in transplantation-eligible patients with newly diagnosed multiple myeloma." | 9.69 | Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. ( Anderson, LD; Bumma, N; Chari, A; Cortoos, A; Costa, LJ; Costello, C; Cowan, AJ; Dinner, S; Efebera, YA; Holstein, SA; Jakubowiak, A; Kaufman, JL; Laubach, J; Lin, TS; Nathwani, N; Orlowski, RZ; Patel, S; Pei, H; Reeves, B; Richardson, PG; Rodriguez, C; Sborov, DW; Shah, N; Shain, KH; Silbermann, R; Usmani, SZ; Voorhees, PM; Wildes, TM, 2023) |
| "Elotuzumab plus pomalidomide/dexamethasone (E-Pd) demonstrated efficacy and safety in relapsed and refractory multiple myeloma (RRMM)." | 9.51 | Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma. ( Ide, T; Osawa, M; Sanghavi, K; Vezina, HE, 2022) |
| " We aimed to determine whether melflufen plus dexamethasone would provide a progression-free survival benefit compared with pomalidomide plus dexamethasone in patients with previously treated multiple myeloma." | 9.51 | Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. ( Alekseeva, Y; Bakker, NA; Byrne, C; Coriu, D; Delimpasi, S; Dimopoulos, MA; Doronin, V; Hájek, R; Harmenberg, J; Lazzaro, A; Legiec, W; Liberati, AM; Maisnar, V; Masszi, T; Mateos, MV; Mikala, G; Minarik, J; Moody, V; Pour, L; Richardson, PG; Robak, P; Rosiñol, L; Salogub, G; Schjesvold, FH; Sonneveld, P; Špička, I; Symeonidis, A; Thuresson, M, 2022) |
| "Multiple myeloma (MM) patients typically receive several lines of combination therapy and first-line treatment commonly includes lenalidomide." | 9.51 | Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial. ( Darif, M; Demarquette, H; Dimopoulos, MA; Doronin, V; Du, J; Fenk, R; Kumar, S; Labotka, R; Lee, C; Leleu, X; Levin, MD; Mellqvist, UH; Montes, YG; Pompa, A; Quach, H; Ramasamy, K; Sati, H; Schjesvold, F; Vinogradova, O; Vorog, A, 2022) |
| "Patients with relapsed/refractory multiple myeloma (RRMM) need proven subsequent therapies after early-line lenalidomide treatment failure." | 9.51 | Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial. ( Acosta-Rivera, M; Agarwal, A; Anz, B; Bahlis, NJ; Bar, M; Berdeja, J; Chung, W; Fonseca, G; Ganguly, S; Lee, K; Matous, J; Mouro, J; Quick, D; Reece, D; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, K, 2022) |
| "The primary analysis of the ICARIA-MM study showed significant improvement in progression-free survival with addition of isatuximab to pomalidomide-dexamethasone in relapsed and refractory multiple myeloma." | 9.51 | Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. ( Anderson, KC; Beksac, M; Cavo, M; Dimopoulos, MA; Dubin, F; Huang, JS; Leleu, X; Malinge, L; Minarik, J; Moreau, P; Perrot, A; Prince, HM; Richardson, PG; San-Miguel, J; Schjesvold, F; Spicka, I; van de Velde, H, 2022) |
| " An exposure-response (E-R) analysis using data from patients with relapsed/refractory multiple myeloma (RRMM) enrolled in a phase Ib clinical study who received isatuximab at doses from 5 to 20 mg/kg weekly for 1 cycle (4 weeks) followed by every 2 weeks thereafter (qw/q2w) in combination with pomalidomide/dexamethasone (n = 44) was first used to determine the optimal dose/schedule for the phase III ICARIA-MM study." | 9.51 | Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma. ( Brillac, C; Fau, JB; Gaudel-Dedieu, N; Koiwai, K; Nguyen, L; Rachedi, F; Sebastien, B; Semiond, D; Thai, HT; van de Velde, H; Veyrat-Follet, C, 2022) |
| "Pomalidomide in combination with dexamethasone has demonstrated positive results in patients with relapsed or refractory multiple myeloma (RRMM), but no data are available in China." | 9.51 | Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial. ( Bai, H; Fang, BJ; Fu, WJ; Liao, AJ; Lu, J; Niu, T; Wang, YF; Zhao, HG, 2022) |
| "CASSIOPEIA part 1 showed superior depth of response and significantly improved progression-free survival with daratumumab, bortezomib, thalidomide, and dexamethasone (D-VTd) versus bortezomib, thalidomide, and dexamethasone (VTd) as induction and consolidation in patients with autologous stem-cell transplant (ASCT)-eligible newly diagnosed multiple myeloma." | 9.41 | Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, ( Ahmadi, T; Arnulf, B; Avet-Loiseau, H; Belhadj, K; Benboubker, L; Béné, MC; Broijl, A; Caillon, H; Caillot, D; Corre, J; de Boer, C; Dejoie, T; Delforge, M; Doyen, C; Escoffre-Barbe, M; Eveillard, JR; Facon, T; Fontan, J; Garidi, R; Hulin, C; Jie, KS; Kampfenkel, T; Karlin, L; Klein, SK; Krevvata, M; Kuhnowski, F; Lambert, J; Leleu, X; Levin, MD; Macro, M; Marolleau, JP; Meuleman, N; Mohty, M; Moreau, P; Offner, F; Orsini-Piocelle, F; Perrot, A; Roussel, M; Sonneveld, P; Sonntag, C; Stoppa, AM; Tiab, M; Touzeau, C; van de Donk, NWCJ; Vanquickelberghe, V; Vara, S; Vekemans, MC; Vermeulen, J; Westerman, M; Wuillème, S; Zhang, K; Zweegman, S, 2021) |
| "Preclinical studies have demonstrated activity of the oral proteasome inhibitor (PI) ixazomib (IXA) in bortezomib-resistant multiple myeloma (MM) and synergy with immunomodulatory drugs." | 9.41 | A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). ( Bova-Solem, M; Carlisle, D; Efebera, YA; Hassoun, H; Laubach, JP; McCarthy, PL; Mulkey, F; Richardson, PG; Santo, K; Suman, VJ; Tuchman, SA; Voorhees, PM, 2021) |
| "The objective was to assess the benefit of pomalidomide-based combination regimens in patients with relapsed/refractory multiple myeloma (RRMM) previously treated with lenalidomide." | 9.41 | A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure. ( Davies, FE; Dhanasiri, S; Le Nouveau, P; Leleu, X; Vogel, P; Weisel, K, 2023) |
| "The randomized, phase 3 ICARIA-MM study investigated isatuximab (Isa) with pomalidomide and dexamethasone (Pd) versus Pd in patients with relapsed/refractory multiple myeloma and ≥2 prior lines." | 9.41 | Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. ( Assadourian, S; Campana, F; Dimopoulos, MA; Harrison, SJ; Leleu, X; Liberati, AM; Malinge, L; Miles Prince, H; Moreau, P; Ocio, EM; Richardson, PG; Sémiond, D; van de Velde, H; Yong, K, 2021) |
| "In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior efficacy vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma previously treated with lenalidomide, including those refractory to lenalidomide." | 9.41 | Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. ( Anderson, LD; Biyukov, T; Casal, E; Corso, A; Dimopoulos, M; Dürig, J; Engelhardt, M; Jenner, M; Moreau, P; Nguyen, TV; Pavic, M; Peluso, T; Richardson, P; Salomo, M; San-Miguel, J; Sonneveld, P; Srinivasan, S; Weisel, K; White, D; Yu, X, 2021) |
| "The global, randomized, open-label KEYNOTE-183 phase 3 study was closed early after an interim analysis showed unfavorable risk-benefit when pembrolizumab was added to pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (MM)." | 9.41 | Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients. ( Ando, K; Farooqui, M; Iida, S; Kher, U; Koh, Y; Kosugi, H; Kuroda, J; Liao, J; Marinello, P; Maruyama, D; Matsuda, K; Matsumoto, M; Shimamoto, T; Sunami, K; Suzuki, K; Taniwaki, M; Tobinai, K, 2021) |
| "In a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response or better rate of 42% and was well tolerated in patients with heavily pretreated multiple myeloma." | 9.41 | Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. ( Ahmadi, T; Amin, H; Baldini, L; Beksac, M; Bila, J; Boccadoro, M; Carson, R; Delimpasi, S; Dimopoulos, MA; Einsele, H; Kampfenkel, T; Katodritou, E; Mateos, MV; Moreau, P; Orfanidis, I; Oriol, A; Qiu, Y; Schecter, JM; Sonneveld, P; Symeonidis, A; Terpos, E; Ukropec, J; Vermeulen, J, 2021) |
| "Isatuximab is an anti-CD38 monoclonal antibody approved in combination with pomalidomide-dexamethasone and carfilzomib-dexamethasone for relapsed or refractory multiple myeloma." | 9.41 | Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. ( Asset, G; Baker, R; Capra, M; Dimopoulos, MA; Facon, T; Hajek, R; Kim, K; Koh, Y; Leleu, X; Macé, S; Martin, T; Martinez, G; Mikhael, J; Min, CK; Moreau, P; Oriol, A; Pour, L; Risse, ML; Špička, I; Suzuki, K; Yong, K, 2021) |
| " On May 30, 2020, a marketing authorization valid through the European Union (EU) was issued for isatuximab in combination with pomalidomide and dexamethasone (IsaPd) for the treatment of adult patients with relapsed and refractory (RR) multiple myeloma (MM)." | 9.41 | EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma. ( Delgado, J; Enzmann, H; Gisselbrecht, C; Moreau, A; Pignatti, F; van Hennik, PB; Zienowicz, M, 2021) |
| "This study sought to understand how the programmed death ligand 1 (PD-L1) inhibitor durvalumab and the immunomodulatory agent pomalidomide regulate immune cell activation and function in patients with relapsed/refractory (RR) multiple myeloma (MM)." | 9.41 | Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma. ( Copeland, W; Fox, BA; Newhall, KJ; Pietz, G; Thompson, E; Whalen, E; Young, MH, 2021) |
| " The HOVON-87/NMSG18 study was a randomized, phase 3 study in newly diagnosed transplant ineligible patients with multiple myeloma, comparing melphalan-prednisolone in combination with thalidomide or lenalidomide, followed by maintenance therapy until progression (MPT-T or MPR-R)." | 9.34 | Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. ( Abildgaard, N; Bos, G; Brouwer, R; Coenen, J; Deenik, W; Durian, M; Gimsing, P; Hansson, M; Haukås, E; Hinge, M; Klein, S; Levin, MD; Leys, R; Lissenberg-Witte, B; Mellqvist, UH; Nielsen, LK; Salomo, M; Sinnige, H; Sonneveld, P; Stege, C; Szatkowski, D; Tanis, B; van de Donk, N; van der Hem, K; van der Holt, B; van der Velden, A; Visser-Wisselaar, H; Waage, A; Westerman, M; Zweegman, S, 2020) |
| "Patients with relapsed/refractory multiple myeloma (RRMM) for whom the benefits of lenalidomide have been exhausted in early treatment lines need effective therapies." | 9.34 | Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure. ( Agajanian, R; Agarwal, A; Bahlis, NJ; Chung, W; Kaya, H; Malek, E; Mouro, J; Pierceall, WE; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, KW; Srinivasan, S; Stockerl-Goldstein, K; Talamo, G; Zafar, F, 2020) |
| "In POLLUX, daratumumab (D) plus lenalidomide/dexamethasone (Rd) reduced the risk of disease progression or death by 63% and increased the overall response rate (ORR) versus Rd in relapsed/refractory multiple myeloma (RRMM)." | 9.34 | Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. ( Bahlis, NJ; Benboubker, L; Chiu, C; Cook, G; Dimopoulos, MA; Ho, PJ; Kaufman, JL; Kim, K; Krevvata, M; Leiba, M; Moreau, P; Okonkwo, L; Qi, M; Qin, X; San-Miguel, J; Takezako, N; Trivedi, S; Ukropec, J; White, DJ, 2020) |
| "In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib and dexamethasone (PVd) significantly improved the progression-free survival (PFS) and the overall response rate (ORR) vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma." | 9.34 | Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM. ( Biyukov, T; Matsue, K; Peluso, T; Richardson, P; Sakurai, S; Shinagawa, A; Sunami, K; Suzuki, K; Takezako, N; Tamakoshi, H, 2020) |
| "Patients with multiple myeloma who have relapsed after or become refractory to lenalidomide in early treatment lines represent a clinically important population in need of effective therapies." | 9.34 | Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment. ( Acosta-Rivera, M; Agarwal, A; Anz, B; Bahlis, NJ; Bar, M; Berdeja, J; Chung, W; Fonseca, G; Ganguly, S; Matous, J; Pierceall, WE; Quick, D; Reece, D; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, K; Talamo, G; Zafar, F, 2020) |
| "Relapsed/refractory multiple myeloma patients treated with pomalidomide and dexamethasone have an overall response rate (ORR) of ∼30% and median progression-free survival (PFS) of 4-5 months." | 9.34 | A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma. ( Chan, E; Chari, A; Cho, HJ; Couto, S; Florendo, E; Ip, C; Jagannath, S; Kim-Schulze, S; La, L; Laganà, A; Lau, K; Leshchenko, VV; Madduri, D; Mancia, IS; Melnekoff, DT; Parekh, S; Pierceall, WE; Richter, J; Strumolo, G; Thakurta, A; Thomas, J; Van Oekelen, O; Verina, D; Vishnuvardhan, N; Wang, M; Zarychta, K, 2020) |
| "In part 1 of the two-part CASSIOPEIA study, treatment before and after autologous haematopoietic stem-cell transplantation (HSCT) with daratumumab plus bortezomib, thalidomide, and dexamethasone (D-VTd) significantly improved rates of stringent complete response and progression-free survival versus bortezomib, thalidomide, and dexamethasone (VTd) in patients with newly diagnosed multiple myeloma." | 9.34 | Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial. ( Broijl, A; de Boer, C; Dib, M; Dorvaux, V; Fastenau, J; Frenzel, L; Gries, KS; Hebraud, B; Jaccard, A; Jie, KS; Kampfenkel, T; Klein, SK; Laribi, K; Moreau, P; Roussel, M; Royer, B; Slama, B; Sonneveld, P; Vanquickelberghe, V; Wang, J; Zweegman, S, 2020) |
| "The phase 3 GIMEMA-MMY-3006 trial, which compared bortezomib, thalidomide, and dexamethasone (VTD) combination therapy with thalidomide and dexamethasone (TD) as induction therapy before and consolidation therapy after double autologous haematopoietic stem-cell transplantation (HSCT) for newly diagnosed multiple myeloma, showed the superiority of the triplet regimen over the doublet in terms of increased complete response rate and improved progression-free survival." | 9.34 | Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. ( Barbato, S; Boccadoro, M; Cangialosi, C; Catalano, L; Cavo, M; Cellini, C; Ciambelli, F; Crippa, C; De Sabbata, G; Di Raimondo, F; Dozza, L; Elice, F; Galieni, P; Galli, M; Gobbi, M; Lazzaro, A; Marzocchi, G; Montefusco, V; Musto, P; Narni, F; Pantani, L; Patriarca, F; Pescosta, N; Petrucci, MT; Ronconi, S; Spadano, A; Tacchetti, P; Terragna, C; Testoni, N; Tosi, P; Zamagni, E, 2020) |
| "Ixazomib-revlimid-dexamethason showed significant activity in relapsed/refractory multiple myeloma (RRMM)." | 9.30 | Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. ( Egle, A; Einsele, H; Greil, R; Gunsilius, E; Hajek, R; Knop, S; Krenosz, KJ; Lechner, D; Ludwig, H; Melchardt, T; Niederwieser, D; Petzer, A; Poenisch, W; Schreder, M; Weisel, K; Willenbacher, W; Zojer, N, 2019) |
| "Pomalidomide is a third generation immunomodulatory drug which in combination with dexamethasone, has been shown to be active in relapsed/refractory multiple myeloma." | 9.30 | Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network. ( Asaoku, H; Chim, CS; Chng, WJ; Durie, B; Gopalakrishnan, SK; Huang, SY; Kim, JS; Kim, K; Kimura, H; Kosugi, H; Lee, JH; Lee, JJ; Lee, SL; Min, CK; Moorakonda, R; Nagarajan, C; Sakamoto, J; Soekojo, CY; Takezako, N; Wei, Y; Yoon, SS, 2019) |
| " In a previous phase 1b study, around 65% of patients with relapsed and refractory multiple myeloma achieved an overall response with a combination of isatuximab with pomalidomide and low-dose dexamethasone." | 9.30 | Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. ( Anderson, KC; Attal, M; Beksac, M; Campana, F; Cavo, M; Corzo, KP; Dimopoulos, MA; Dubin, F; Huang, JS; Le-Guennec, S; Leleu, X; Macé, S; Minarik, J; Moreau, P; Prince, HM; Rajkumar, SV; Richardson, PG; San-Miguel, J; Schjesvold, F; Spicka, I, 2019) |
| "The addition of clarithromycin enhances the efficacy of lenalidomide plus dexamethasone in treatment-naive multiple myeloma (MM)." | 9.30 | Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma. ( Boyer, A; Coleman, M; Forsberg, PA; Jayabalan, D; Mark, TM; Niesvizky, R; Pearse, RN; Pekle, KA; Perry, A; Rossi, AC; Tegnestam, L, 2019) |
| "This phase 1b dose-escalation study evaluated isatuximab plus pomalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM)." | 9.30 | A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. ( Anderson, K; Bensinger, W; Campana, F; Dubin, F; Kanagavel, D; Karanes, C; Liu, Q; Mikhael, J; Raje, N; Richardson, P; Semiond, D; Usmani, SZ, 2019) |
| "Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell transplantation is standard treatment in Europe for transplant-eligible patients with newly diagnosed multiple myeloma." | 9.30 | Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. ( Ahmadi, T; Arnulf, B; Attal, M; Avet-Loiseau, H; Belhadj, K; Benboubker, L; Béné, MC; Broijl, A; Caillon, H; Caillot, D; Chiu, C; Corre, J; de Boer, C; Dejoie, T; Delforge, M; Deraedt, W; Doyen, C; Escoffre-Barbe, M; Eveillard, JR; Facon, T; Fermand, JP; Fontan, J; Garderet, L; Garidi, R; Hulin, C; Jie, KS; Kampfenkel, T; Karlin, L; Klein, SK; Kolb, B; Kuhnowski, F; Lambert, J; Leleu, X; Lenain, P; Levin, MD; Macro, M; Marolleau, JP; Mathiot, C; Meuleman, N; Moreau, P; Orsini-Piocelle, F; Pei, L; Perrot, A; Roussel, M; Schecter, J; Smith, E; Sonneveld, P; Sonntag, C; Stoppa, AM; Tiab, M; Touzeau, C; van de Donk, NW; Vekemans, MC; Vermeulen, J; Westerman, M; Wuilleme, S; Zhuang, S; Zweegman, S, 2019) |
| "We conducted a phase I study to determine the recommended dose of thalidomide combined with melphalan plus prednisolone (MPT) and a phase II study evaluating the efficacy and safety of this MPT regimen in transplant-ineligible Japanese patients with untreated multiple myeloma." | 9.30 | Report of phase I and II trials of melphalan, prednisolone, and thalidomide triplet combination therapy versus melphalan and prednisolone doublet combination therapy in Japanese patients with newly diagnosed multiple myeloma ineligible for autologous stem ( Doki, N; Kosugi, H; Meguro, K; Murakami, H; Sasaki, O; Shimizu, K; Sunami, K; Suzuki, K; Takagi, T, 2019) |
| "Pomalidomide and dexamethasone is a standard of care for patients with multiple myeloma in whom bortezomib and lenalidomide treatment has failed." | 9.30 | Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. ( Avivi, I; Benyamini, N; Blacklock, H; Chanan-Khan, A; Farooqui, M; George, A; Goldschmidt, H; Iida, S; Jagannath, S; Kher, U; Larocca, A; Liao, J; Lonial, S; Marinello, P; Mateos, MV; Matsumoto, M; Ocio, EM; Oriol, A; Ribrag, V; Rodriguez-Otero, P; San Miguel, J; Schjesvold, F; Sherbenou, D; Simpson, D; Suzuki, K; Usmani, SZ, 2019) |
| "This phase 1 study investigated the safety of the anthracycline amrubicin combined with lenalidomide and dexamethasone in adults with relapsed or refractory multiple myeloma." | 9.27 | A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. ( Berube, C; Coutré, SE; Dinner, S; Dunn, TJ; Gotlib, J; Kaufman, GP; Liedtke, M; Medeiros, BC; Price, E, 2018) |
| "Patients with multiple myeloma that was refractory or relapsed and refractory to lenalidomide and a proteasome inhibitor were randomly assigned to receive elotuzumab plus pomalidomide and dexamethasone (elotuzumab group) or pomalidomide and dexamethasone alone (control group)." | 9.27 | Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. ( Dimopoulos, MA; Dytfeld, D; Grosicki, S; Hori, M; Jou, YM; LeBlanc, R; Leleu, X; Moreau, P; Popa McKiver, M; Raab, MS; Rafferty, B; Richardson, PG; Robbins, M; San-Miguel, J; Shelat, SG; Suzuki, K; Takezako, N, 2018) |
| "Carfilzomib, a proteasome inhibitor, is approved as monotherapy and in combination with dexamethasone or lenalidomide-dexamethasone (Rd) for relapsed or refractory multiple myeloma." | 9.24 | Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. ( Aggarwal, S; Dimopoulos, MA; Goranova-Marinova, V; Hájek, R; Jakubowiak, A; Ludwig, H; Masszi, T; Mihaylov, GG; Moreau, P; Niesvizky, R; Oriol, A; Palumbo, A; Rajnics, P; Ro, S; Rosiñol, L; San-Miguel, J; Siegel, D; Špička, I; Stewart, AK; Suvorov, A, 2017) |
| "This phase 1b, open-label, dose-escalation study assessed the safety, efficacy, and pharmacokinetics of anti-CD38 monoclonal antibody isatuximab given in 2 schedules (3, 5, or 10 mg/kg every other week [Q2W] or 10 or 20 mg/kg weekly [QW] for 4 weeks and then Q2W thereafter [QW/Q2W]), in combination with lenalidomide 25 mg (days 1-21) and dexamethasone 40 mg (QW), in patients with relapsed/refractory multiple myeloma (RRMM)." | 9.24 | A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. ( Baz, R; Benson, DM; Campana, F; Charpentier, E; Lendvai, N; Lesokhin, AM; Martin, T; Munster, P; Vij, R; Wack, C; Wolf, J, 2017) |
| "The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy." | 9.24 | Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. ( Avivi, I; Berg, D; Einsele, H; Esseltine, DL; Gupta, N; Hájek, R; Hari, P; Kumar, S; Liberati, AM; Lin, J; Lonial, S; Ludwig, H; Masszi, T; Mateos, MV; Minnema, MC; Moreau, P; Richardson, PG; Romeril, K; Shustik, C; Spencer, A, 2017) |
| "Circularly permuted TRAIL (CPT) has exhibited promising efficacy as a mono-therapy or in combination with thalidomide for patients with multiple myeloma (MM)." | 9.24 | Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study. ( Chang, N; Chen, W; Hou, J; Jiang, B; Jiang, H; Jin, J; Ke, X; Leng, Y; Li, J; Li, W; Liu, J; Liu, L; Liu, Y; Meng, H; Pan, L; Pang, H; Qiu, L; Shen, Z; Wang, J; Wang, Z; Wei, P; Yang, L; Yang, S; Zhang, M; Zheng, X; Zhou, F, 2017) |
| "Daratumumab plus pomalidomide and dexamethasone (pom-dex) was evaluated in patients with relapsed/refractory multiple myeloma with ≥2 prior lines of therapy who were refractory to their last treatment." | 9.24 | Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. ( Ahmadi, T; Arnulf, B; Chari, A; Chiu, C; Comenzo, R; Fay, JW; Ifthikharuddin, JJ; Kaufman, JL; Khokhar, NZ; Krishnan, A; Lentzsch, S; Lonial, S; Nottage, K; Suvannasankha, A; Wang, J; Weiss, BM, 2017) |
| "The randomized phase III ELOQUENT-2 study (NCT01239797) evaluated the efficacy and safety of elotuzumab + lenalidomide/dexamethasone (ELd) versus lenalidomide/dexamethasone (Ld) in relapsed/refractory multiple myeloma." | 9.24 | Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. ( Anderson, K; Beksac, M; Belch, A; Bleickardt, E; Dimopoulos, MA; Grosicki, S; Katz, J; Lonial, S; Magen, H; Mateos, MV; Moreau, P; Palumbo, A; Poulart, V; Reece, D; Richardson, P; San-Miguel, J; Sheng, J; Shpilberg, O; Singhal, A; Spicka, I; Sy, O; Walter-Croneck, A; White, D, 2017) |
| "The China Continuation study was a separate regional expansion of the global, double-blind, placebo-controlled, randomized phase III TOURMALINE-MM1 study of ixazomib plus lenalidomide-dexamethasone (Rd) in patients with relapsed/refractory multiple myeloma (RRMM) following one to three prior therapies." | 9.24 | Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. ( Chen, X; Du, X; Gupta, N; Hanley, MJ; Hou, J; Hua, Z; Jin, J; Ke, X; Li, H; Li, J; Liu, J; Lu, J; Moreau, P; Richardson, PG; van de Velde, H; Wang, B; Wang, H; Wu, D; Xu, Y; Zhang, X; Zhou, D, 2017) |
| "On November 19, 2015, a marketing authorization valid through the European Union was issued for carfilzomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy." | 9.24 | The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy. ( Bergh, J; Camarero Jiménez, J; Demolis, P; Garcia, I; Gisselbrecht, C; Laane, E; Ludwig, H; Martin, M; Moreau, A; Pignatti, F; Salmonson, T; Sancho-López, A; Tzogani, K, 2017) |
| "This study investigated the efficacy and safety of low-dose lenalidomide combined with dexamethasone in elderly patients with relapsed and refractory multiple myeloma (MM)." | 9.24 | Low-dose lenalidomide and dexamethasone combination treatment in elderly patients with relapsed and refractory multiple myeloma. ( Chen, Y; Chen, Z; He, Z; Shi, Y; Wang, C; Yu, L; Zhang, L, 2017) |
| " We report a phase 1 study (NCT01241292) in which we evaluated the safety, efficacy and pharmacokinetics of elotuzumab combined with lenalidomide and dexamethasone in Japanese patients with relapsed/refractory multiple myeloma (RRMM)." | 9.24 | Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study. ( Bleickardt, E; Chou, T; Iida, S; Kinoshita, G; Miyoshi, M; Nagai, H; Pandya, D; Robbins, M, 2017) |
| "Clinical trials of vorinostat, a Class I/II histone deacetylase inhibitor, in combination with proteasome inhibitors and immunomodulatory agents have shown activity in relapsed/refractory multiple myeloma." | 9.24 | A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens. ( Anand, P; Bilotti, E; Biran, N; Ivanovski, K; McBride, L; Richter, JR; Sanchez, L; Siegel, DS; Vesole, DH, 2017) |
| "We report the first clinical investigation conducted in Japan to confirm the safety, tolerability, and pharmacokinetics of ixazomib alone and combined with lenalidomide-dexamethasone (Rd) in Japanese patients with relapsed/refractory multiple myeloma." | 9.24 | Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma. ( Chou, T; Handa, H; Ishizawa, K; Kase, Y; Suzuki, K; Takubo, T, 2017) |
| "Lenalidomide is an immunomodulatory compound with high clinical activity in multiple myeloma." | 9.24 | IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM). ( Bargou, R; Bassermann, F; Bullinger, L; Bunjes, D; Döhner, H; Einsele, H; Engelhardt, M; Greiner, A; Knop, S; Kolmus, S; Köpff, S; Krönke, J; Kuchenbauer, F; Kull, M; Langer, C; Mügge, LO; Schreder, M; Straka, C; Teleanu, V, 2017) |
| "The phase 3 FIRST (Frontline Investigation of REVLIMID + Dexamethasone Versus Standard Thalidomide) trial demonstrated that lenalidomide plus low-dose dexamethasone (Rd) until disease progression (Rd continuous) is an effective treatment option for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)." | 9.24 | Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. ( Chen, G; Chen, WM; Eom, HS; Ervin-Haynes, A; Facon, T; Huang, SY; Hulin, C; Kim, HJ; Kim, K; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Liu, T; Lu, J; Min, CK; Qiu, L; Shen, ZX; Yiu, W; Yoon, SS, 2017) |
| "The phase III trial GEM05MENOS65 randomized 390 patients 65 years old or younger with newly diagnosed symptomatic multiple myeloma (MM) to receive induction with thalidomide/dexamethasone, bortezomib/thalidomide/dexamethasone and Vincristine, BCNU, melphalan, cyclophosphamide, prednisone/vincristine, BCNU, doxorubicin, dexamethasone bortezomib (VBMCP/VBAD/B) followed by autologous stem cell transplantation (ASCT) with MEL-200." | 9.24 | Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial. ( Alegre, A; Bladé, J; Blanchard, M; Cibeira, M; de Arriba, F; de la Guía, AL; de la Rubia, J; Etxebeste, M; González, Y; Granell, M; Hernández, MT; Lahuerta, JJ; Martínez-López, J; Martínez-Martínez, R; Mateos, M; Oriol, A; Palomera, L; Rosiñol, L; Sampol, M; San Miguel, J; Teruel, AI, 2017) |
| "The combination of lenalidomide and dexamethasone is an established treatment for patients with multiple myeloma (MM)." | 9.24 | Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. ( Baker, B; Blacklock, H; Browett, P; Cannell, P; Corbett, G; Cowan, L; Dimopoulos, MA; Fernyhough, L; Forsyth, C; Harrison, S; Henderson, R; Link, E; Miles Prince, H; Neylon, A; Quach, H; Swern, A; Trotman, J; Underhill, C, 2017) |
| "A primary analysis of the ASPIRE study found that the addition of carfilzomib to lenalidomide and dexamethasone (carfilzomib group) significantly improved progression-free survival (PFS) compared with lenalidomide and dexamethasone alone (control group) in patients with relapsed multiple myeloma (RMM)." | 9.24 | Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. ( Aggarwal, S; Dimopoulos, MA; Goranova-Marinova, V; Hájek, R; Jakubowiak, A; Ludwig, H; Masszi, T; Mihaylov, GG; Moreau, P; Niesvizky, R; Obreja, M; Oriol, A; Palumbo, A; Rajnics, P; Rosiñol, L; San-Miguel, J; Siegel, D; Špička, I; Stewart, AK; Suvorov, A, 2017) |
| " In a previous phase 3 study in patients with relapsed/refractory multiple myeloma (RRMM), elotuzumab (10 mg/kg, ∼3-h infusion), combined with lenalidomide and dexamethasone, demonstrated durable efficacy and acceptable safety; 10% (33/321) of patients had infusion reactions (IRs; Grade 1/2: 29; Grade 3: 4)." | 9.24 | A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma. ( Badarinath, S; Berenson, J; Cartmell, A; Harb, W; Lyons, R; Manges, R; McIntyre, K; Mohamed, H; Nourbakhsh, A; Rifkin, R, 2017) |
| "Triplet regimens based on pomalidomide and dexamethasone have been applied to treat relapsed/refractory multiple myeloma, but the safety and efficacy are not yet very clear." | 9.22 | The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis. ( Chen, XM; Huang, CL; Liao, KY; Liu, Y; Xiong, H; Zhang, XW, 2022) |
| " There are few prospective, randomized studies investigating mobilization regimens in multiple myeloma (MM), especially after lenalidomide-based induction." | 9.22 | A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma. ( Anttila, P; Bazia, P; Heiskanen, J; Jantunen, E; Kakko, S; Kananen, K; Kuittinen, T; Kutila, A; Launonen, K; Lundan, T; Ollikainen, H; Putkonen, M; Räsänen, A; Remes, K; Säily, M; Selander, T; Siitonen, TM; Sikiö, A; Silvennoinen, R; Suominen, M; Terävä, V, 2016) |
| "The introduction of agents such as thalidomide, lenalidomide, and bortezomib has changed the management of patients with multiple myeloma who are not eligible for autologous transplantation, many of whom are elderly." | 9.22 | Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible. ( Almeida, MS; Bittencourt, R; Chiattone, CS; Crusoé, EQ; Cury, P; Fantl, D; Hisgashi, F; Hungria, VT; Maciel, JF; Maiolino, A; Peres, AL; Pessoa de Magalhaes, RJ, 2016) |
| "Lenalidomide-dexamethasone improved outcome in newly diagnosed elderly multiple myeloma patients." | 9.22 | Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. ( Benevolo, G; Bernardini, A; Boccadoro, M; Bringhen, S; Ciccone, G; Conticello, C; De Paoli, L; Falcone, AP; Gentili, S; Giuliani, N; Guglielmelli, T; Hajek, R; Ledda, A; Liberati, AM; Magarotto, V; Maisnar, V; Mina, R; Montefusco, V; Musolino, C; Offidani, M; Palumbo, A; Patriarca, F; Pietrantuono, G; Pulini, S; Ruggeri, M; Zambello, R, 2016) |
| "The present study evaluated the pharmacokinetics and safety of elotuzumab, a humanized IgG1 monoclonal antibody against signaling lymphocyte activation molecule-F7, combined with lenalidomide and dexamethasone, in patients with multiple myeloma (MM) and renal impairment." | 9.22 | Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study. ( Badros, A; Berdeja, J; Bleickardt, E; Gupta, M; Jagannath, S; Kaufman, JL; Lynch, M; Manges, R; Paliwal, P; Tendolkar, A; Vij, R; Zonder, J, 2016) |
| "The combination of melphalan, prednisone, and thalidomide (MPT) is considered standard therapy for newly diagnosed patients with multiple myeloma who are ineligible for stem cell transplantation." | 9.22 | Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. ( Bos, GM; Brouwer, RE; Coenen, JL; Deenik, W; Durian, MF; Gruber, A; Hansson, M; Haukås, E; Klein, SK; Levin, MD; Leys, MR; Mattijssen, EV; Mellqvist, UH; Plesner, T; Salomo, M; Sinnige, HA; Sonneveld, P; Stevens-Kroef, MJ; Szatkowski, DL; Tanis, BC; van de Donk, NW; van der Hem, KG; van der Holt, B; van der Velden, AW; Visser-Wisselaar, H; Waage, A; Westerman, M; Zweegman, S, 2016) |
| "The efficacy and safety of lenalidomide plus low-dose dexamethasone (Rd) in Chinese patients with relapsed/refractory multiple myeloma (RRMM) was demonstrated in a phase 2, multicenter trial (MM-021)." | 9.22 | Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program. ( Cai, Z; Chen, F; DeMarco, D; Du, X; Hou, J; Jin, J; Ke, X; Li, X; Mei, J; Meng, F; Wu, D; Yu, L; Zhang, J; Zhou, DB, 2016) |
| "The safety and efficacy of siltuximab (CNTO 328) was tested in combination with lenalidomide, bortezomib and dexamethasone (RVD) in patients with newly-diagnosed, previously untreated symptomatic multiple myeloma." | 9.22 | Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. ( Berkova, Z; Champlin, RE; Cleeland, C; Feng, L; Mendoza, TR; Orlowski, RZ; Qazilbash, MH; Shah, JJ; Thomas, SK; Wang, M; Weber, DM, 2016) |
| "Marizomib (MRZ) is a novel, irreversible proteasome inhibitor in clinical development for the treatment of relapsed or relapsed and refractory multiple myeloma (RRMM)." | 9.22 | Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. ( Anderson, KC; Chanan-Khan, AA; Chauhan, D; Hofmeister, CC; Jakubowiak, AJ; Kaufman, JL; Laubach, JP; Reich, S; Richardson, PG; Talpaz, M; Trikha, M; Zimmerman, TM, 2016) |
| "Pomalidomide + low-dose dexamethasone is effective and well tolerated for refractory or relapsed and refractory multiple myeloma after bortezomib and lenalidomide failure." | 9.22 | Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. ( Alegre, A; Banos, A; Cavo, M; Chen, C; Delforge, M; Dimopoulos, MA; Garderet, L; Goldschmidt, H; Hong, K; Ivanova, V; Jacques, C; Karlin, L; Knop, S; Lacy, MQ; Martinez-Lopez, J; Moreau, P; Oriol, A; San Miguel, J; Song, KW; Sternas, L; Weisel, KC; Yu, X; Zaki, MH, 2016) |
| "In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 722 patients who had relapsed, refractory, or relapsed and refractory multiple myeloma to receive ixazomib plus lenalidomide-dexamethasone (ixazomib group) or placebo plus lenalidomide-dexamethasone (placebo group)." | 9.22 | Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. ( Bahlis, NJ; Baker, BW; Berg, DT; Buadi, FK; Cavo, M; Di Bacco, A; Ganly, P; Garderet, L; Gimsing, P; Grzasko, N; Hansson, M; Hui, AM; Jackson, SR; Kumar, S; Laubach, JP; Lin, J; Masszi, T; Moreau, P; Palumbo, A; Pour, L; Richardson, PG; Sandhu, I; Simpson, DR; Stoppa, AM; Touzeau, C; van de Velde, H, 2016) |
| "New drugs for the treatment of multiple myeloma (MM) comprise immunomodulatory substances such as lenalidomide and related compounds." | 9.22 | Lenalidomide consolidation treatment in patients with multiple myeloma suppresses myelopoieses but spares erythropoiesis. ( Boquoi, A; Bruns, I; Cadeddu, RP; Deenen, R; Dienst, A; Fenk, R; Haas, R; Heinzler, N; Kobbe, G; Köhrer, K; Majidi, F; Schroeder, T; Strapatsas, T; Wilk, CM, 2016) |
| " Patients aged 18 years or older with high-risk smouldering multiple myeloma were randomly assigned (1:1), via a computerised random number generator, to receive either early treatment with lenalidomide plus dexamethasone or observation, with dynamic balancing to maintain treatment balance within the two groups." | 9.22 | Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. ( Arguiñano, JM; Bargay, J; Bladé, J; Corral, LL; de Arriba, F; de la Rubia, J; García, JL; Giraldo, P; Hernández, MT; Lahuerta, JJ; López, J; Mateos, MV; Miguel, JS; Oriol, A; Paiva, B; Palomera, L; Prosper, F; Quintana, N; Rosiñol, L, 2016) |
| " We evaluated the safety and tolerability of elotuzumab 10 mg/kg combined with thalidomide 50-200 mg and dexamethasone 40 mg (with/without cyclophosphamide 50 mg) in patients with relapsed/refractory multiple myeloma (RRMM)." | 9.22 | Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma. ( Blade, J; Bleickardt, E; Gironella, M; Granell, M; Hernandez, MT; Lynch, M; Martín, J; Martinez-Lopez, J; Mateos, MV; Oriol, A; Paliwal, P; San-Miguel, J; Singhal, A, 2016) |
| "Purpose To determine the effects of carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) on health-related quality of life (HR-QoL) in the Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone for the Treatment of Patients With Relapsed Multiple Myeloma (ASPIRE) trial." | 9.22 | Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. ( Buchanan, J; Cocks, K; Dimopoulos, MA; Hájek, R; Jakubowiak, AJ; Ludwig, H; Masszi, T; Moreau, P; Niesvizky, R; Oriol, A; Palumbo, A; Rosiñol, L; San-Miguel, JF; Siegel, DS; Špička, I; Stewart, AK; Tonda, M; Xing, B; Yang, X; Zojwalla, N, 2016) |
| "The findings from this study provide preliminary evidence that ricolinostat is a safe and well tolerated selective HDAC6 inhibitor, which might partner well with lenalidomide and dexamethasone to enhance their efficacy in relapsed or refractory multiple myeloma." | 9.22 | Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. ( Bensinger, WI; Berdeja, JG; Birrer, NE; Burke, JN; Jones, SS; Libby, EN; Markelewicz, RJ; Raje, NS; Richardson, PG; Supko, JG; Tamang, DL; Voorhees, PM; Wallace, EE; Wheeler, CA; Yang, M; Yee, AJ, 2016) |
| "The prognosis of multiple myeloma (MM) patients who become refractory to lenalidomide and bortezomib is very poor, indicating the need for new therapeutic strategies for these patients." | 9.22 | Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. ( Beeker, A; Bloem, AC; Bos, GMJ; Broijl, A; Faber, LM; Franssen, LE; Klein, SK; Koene, HR; Levin, MD; Lokhorst, HM; Mutis, T; Nijhof, IS; Oostvogels, R; Raymakers, R; Sonneveld, P; van de Donk, NWCJ; van der Spek, E; van Kessel, B; van Spronsen, DJ; van Velzen, J; Westerweel, PE; Ypma, PF; Zweegman, S, 2016) |
| "Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed or refractory multiple myeloma." | 9.22 | Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. ( Ahmadi, T; Bahlis, NJ; Ben Yehuda, D; Chiu, C; Dimopoulos, MA; Goldschmidt, H; Guckert, M; Khokhar, NZ; Komarnicki, M; Lisby, S; Moreau, P; Nahi, H; O'Rourke, L; Oriol, A; Orlowski, RZ; Plesner, T; Qin, X; Rabin, N; Reece, D; Richardson, PG; San-Miguel, J; Suzuki, K; Usmani, SZ; Yoon, SS, 2016) |
| "Panobinostat 20 mg in combination with bortezomib, thalidomide, and dexamethasone is an efficacious and well tolerated regimen for patients with relapsed multiple myeloma." | 9.22 | Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. ( Brown, SR; Cavenagh, J; Cook, G; Flanagan, L; Gregory, W; Hall, A; Kishore, B; Low, E; Oakervee, H; Popat, R; Streetly, M; Yong, K, 2016) |
| "This single institution, open label Phase I-II dose escalation trial evaluated the safety and efficacy of the combination of lenalidomide (Revlimid®), cyclophosphamide and prednisone (CPR) in patients with relapsed/refractory multiple myeloma." | 9.20 | Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma. ( Anglin, P; Atenafu, EG; Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Masih-Khan, E; Mikhael, JR; Reece, DE; Trudel, S, 2015) |
| "This multicenter phase 2 study of the European Myeloma Network investigated the combination of carfilzomib, thalidomide, and dexamethasone (KTd) as induction/consolidation therapy for transplant-eligible patients with previously untreated multiple myeloma (N = 91)." | 9.20 | Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. ( Asselbergs, E; Broyl, A; de Weerdt, O; Kersten, MJ; Lokhorst, H; Lonergan, S; Palumbo, A; Sonneveld, P; van der Holt, B; van Marwijk-Kooy, M; Vellenga, E; Zweegman, S, 2015) |
| "In the phase III MM-003 trial, pomalidomide plus low-dose dexamethasone (POM+LoDEX) improved overall survival (OS) versus high-dose dexamethasone (HiDEX) in 455 patients with relapsed and refractory multiple myeloma (RRMM) after treatment with bortezomib and lenalidomide." | 9.20 | Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone. ( Akehurst, R; Delforge, M; Dhanasiri, S; Dimopoulos, MA; Facon, T; Jacques, C; Lee, D; Morgan, G; Offner, F; Oriol, A; Palumbo, A; Sternas, L; Weisel, K; Yu, X; Zaki, M, 2015) |
| "Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma." | 9.20 | Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. ( Ben-Yehuda, D; Bensinger, WI; Dimopoulos, MA; Goranova-Marinova, V; Hájek, R; Jakubowiak, AJ; Kukreti, V; Ludwig, H; Maisnar, V; Masszi, T; Mateos, MV; Mihaylov, GG; Minarik, J; Moreau, P; Niesvizky, R; Oriol, A; Palumbo, A; Rajkumar, SV; Rajnics, P; Rosiñol, L; San-Miguel, JF; Siegel, DS; Špička, I; Stewart, AK; Suvorov, A; Tonda, ME; Wang, M; Xing, B; Yang, X; Zojwalla, N, 2015) |
| "The Japanese POEMS syndrome with Thalidomide (J-POST) Trial is a phase II/III multicentre, double-blinded, randomised, controlled trial that aims to evaluate the efficacy and safety of a 24-week treatment with thalidomide in POEMS syndrome, with an additional 48-week open-label safety study." | 9.20 | Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trial. ( Hanaoka, H; Ikeda, S; Kanda, T; Katayama, K; Kikuchi, S; Kira, J; Kohara, N; Kusunoki, S; Kuwabara, S; Misawa, S; Nakashima, I; Nishizawa, M; Sato, Y; Sobue, G; Watanabe, O; Yabe, I, 2015) |
| "The combination of pomalidomide and low-dose dexamethasone (Pom-Dex) can be safely administered to patients with end-stage relapsed/refractory multiple myeloma (RRMM)." | 9.20 | Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. ( Arnulf, B; Attal, M; Avet-Loiseau, H; Banos, A; Benboubker, L; Brechiniac, S; Caillot, D; Decaux, O; Dib, M; Escoffre-Barbe, M; Facon, T; Fermand, JP; Fuzibet, JG; Garderet, L; Hulin, C; Karlin, L; Kolb, B; Lacotte, L; Legros, L; Leleu, X; Macro, M; Marit, G; Mathiot, C; Moreau, P; Onraed, B; Pegourie, B; Petillon, MO; Rodon, P; Roussel, M; Royer, B; Stoppa, AM; Thielemans, B; Tiab, M; Wetterwald, M, 2015) |
| "Toward our goal of personalized medicine, we comprehensively profiled pre-treatment malignant plasma cells from multiple myeloma patients and prospectively identified pathways predictive of favourable response to bortezomib-based treatment regimens." | 9.20 | Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens. ( Alonge, MM; Dytfeld, D; Jakubowiak, AJ; Jasielec, J; Kandarpa, M; Mayampurath, A; Mellacheruvu, D; Nesvizhskii, AI; Ngoka, L; Richardson, PG; Rosebeck, S; Sreekumar, A; Volchenboum, S, 2015) |
| "These findings suggest that lenalidomide in combination with antiinhibitory KIR therapy warrants further investigation in multiple myeloma as a steroid-sparing, dual immune therapy." | 9.20 | A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. ( Andre, P; Benson, DM; Caligiuri, MA; Cohen, AD; Efebera, YA; Hofmeister, CC; Jagannath, S; Munshi, NC; Spitzer, G; Zerbib, R, 2015) |
| "Single-agent post-autologous transplant maintenance therapy with lenalidomide is standard of care for patients with multiple myeloma." | 9.20 | Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma. ( Benson, DM; Bowers, MA; Devine, S; Efebera, Y; Hofmeister, CC; Huang, Y; Humphries, K; Sborov, DW; Williams, N, 2015) |
| "This follow-up extension of a randomised phase II study assessed differences in long-term outcomes between bortezomib-thalidomide-dexamethasone (VTD) and VTD-cyclophosphamide (VTDC) induction therapy in multiple myeloma." | 9.20 | Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up. ( Ataman, O; Chaturvedi, S; Dmoszynska, A; Enny, C; Esteves, G; Feng, H; Greil, R; Hajek, R; Ludwig, H; Masszi, T; Paiva, B; Robinson, D; Shpilberg, O; Spicka, I; Stoppa, AM; van de Velde, H; Vidriales, MB; Viterbo, L, 2015) |
| "This phase 3 trial (Eastern Cooperative Oncology Group [ECOG] E1A06) compared melphalan, prednisone, and thalidomide (MPT-T) with melphalan, prednisone, and lenalidomide (mPR-R) in patients with untreated multiple myeloma (MM)." | 9.20 | Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. ( Callander, NS; Chanan-Khan, AA; Fonseca, R; Jacobus, S; Rajkumar, SV; Stewart, AK; Weiss, M, 2015) |
| "Lenalidomide treatment in combination with dexamethasone and/or chemotherapy is associated with a significant risk of venous thromboembolism (VTE) in patients with multiple myeloma (MM)." | 9.20 | Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide. ( Isoda, A; Koumoto, M; Matsumoto, M; Matsumoto, Y; Miyazawa, Y; Ookawa, M; Sato, N; Sawamura, M, 2015) |
| "Carfilzomib-lenalidomide-dexamethasone therapy yields deep responses in patients with newly diagnosed multiple myeloma (NDMM)." | 9.20 | Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. ( Arthur, DC; Bhutani, M; Braylan, R; Burton, D; Calvo, KR; Carpenter, A; Carter, G; Choyke, P; Costello, R; Cunningham, SC; Faham, M; Figg, W; Gounden, V; Kazandjian, D; Kong, KA; Korde, N; Kurdziel, K; Kwok, M; Lamping, L; Landgren, O; Lindenberg, L; Mailankody, S; Manasanch, EE; Maric, I; Morrison, C; Mulquin, M; Peer, C; Roschewski, M; Sissung, TM; Steinberg, SM; Stetler-Stevenson, M; Tageja, N; Wall, Y; Weng, L; Wu, P; Yuan, C; Zhang, Y; Zingone, A; Zuchlinski, D, 2015) |
| "This phase 1, open-label, dose-escalation study investigated the tolerated dose (recommended dose), safety, efficacy, and pharmacokinetics of pomalidomide alone or pomalidomide plus low-dose dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma." | 9.20 | Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma. ( Chou, T; Doerr, T; Iida, S; Iwasaki, H; Kurihara, M; Matsue, K; Midorikawa, S; Ogawa, Y; Sunami, K; Tobinai, K; Zaki, M, 2015) |
| "Consolidation with high-dose melphalan and ASCT remains the preferred option in transplant-eligible patients with multiple myeloma, despite a better toxicity profile with chemotherapy plus lenalidomide." | 9.20 | Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. ( Boccadoro, M; Campbell, P; Carella, A; Catalano, L; Conticello, C; Corradini, P; Evangelista, A; Gay, F; Hajek, R; Liberati, AM; Magarotto, V; Malfitano, A; Offidani, M; Oliva, S; Omedè, P; Palumbo, A; Patriarca, F; Pescosta, N; Petrò, D; Petrucci, MT; Pour, L; Pulini, S; Ria, R; Siniscalchi, A; Spada, S; Spencer, A, 2015) |
| "In the MM-015 trial, melphalan-prednisone-lenalidomide followed by lenalidomide maintenance (MPR-R) significantly prolonged progression-free survival versus melphalan-prednisone (MP) in newly diagnosed patients with multiple myeloma aged ≥ 65 years." | 9.19 | Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial. ( Delforge, M; Dimopoulos, MA; Hajek, R; Kropff, M; Lewis, P; Mei, J; Millar, S; Palumbo, A; Petrucci, MT; Zhang, J, 2014) |
| "Initial therapy of multiple myeloma with lenalidomide-based regimens can compromise stem cell collection, which can be overcome with the addition of plerixafor." | 9.19 | Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy. ( Bergsagel, LP; Buadi, FK; Dingli, D; Dispenzieri, A; Gastineau, DA; Gertz, MA; Hayman, SR; Kumar, SK; Lacy, MQ; Laplant, B; Laumann, K; Mahlman, M; Miceli, T; Mikhael, J; Reeder, C; Stewart, AK; Winters, JL, 2014) |
| "A previous interim report of MM-011, the first study that combined lenalidomide with anthracycline-based chemotherapy followed by lenalidomide maintenance for relapsed and/or refractory multiple myeloma (RRMM), showed promising safety and activity." | 9.19 | Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma. ( Andresen, S; Ann Karam, M; Baz, R; Bruening, K; Dean, R; Faiman, B; Habecker, B; Hamilton, K; Hussein, MA; Kalaycio, M; Knight, R; Lazaryan, A; Reed, J; Reu, FJ; Sobecks, R; Srkalovic, G; Sweetenham, JW; Waksman, J; Zeldis, JB, 2014) |
| "This multicenter, open-label, randomized phase 2 study assessed the efficacy and safety of pomalidomide (POM) with/without low-dose dexamethasone (LoDEX) in patients with relapsed/refractory multiple myeloma (RRMM)." | 9.19 | Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. ( Anderson, KC; Bahlis, N; Baz, R; Belch, A; Chen, C; Chen, M; Hofmeister, CC; Jacques, C; Jagannath, S; Jakubowiak, A; Lacy, M; Lentzsch, S; Lonial, S; Matous, J; Mikhael, J; Raje, N; Richardson, PG; Shustik, C; Siegel, DS; Song, K; Vesole, D; Vij, R; Yu, Z; Zaki, MH, 2014) |
| "Bortezomib and thalidomide significantly improved OS in multiple myeloma patients not eligible for transplantation." | 9.19 | Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. ( Benevolo, G; Boccadoro, M; Bringhen, S; Cavo, M; Di Raimondo, F; Falcone, AP; Franceschini, L; Gaidano, G; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Magarotto, V; Marasca, R; Mina, R; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, ID; Zambello, R, 2014) |
| "We studied T-BiRD (thalidomide [Thalomid(®)], clarithromycin [Biaxin(®)], lenalidomide [Revlimid(®)] and dexamethasone) in symptomatic, newly diagnosed multiple myeloma." | 9.19 | Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. ( Bowman, IA; Chen-Kiang, S; Coleman, M; Ely, S; Jayabalan, D; Mark, TM; Niesvizky, R; Pearse, RN; Pekle, K; Quinn, R; Rodriguez, M; Rossi, AC; Shah, M; Zafar, F, 2014) |
| "Everolimus, an oral mammalian target of rapamycin (mTOR) inhibitor, has been studied in multiple myeloma (MM) but lacks significant single agent activity." | 9.19 | Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. ( Anderson, KC; Burke, JN; Cirstea, DD; Ghobrial, IM; Hari, P; Hideshima, T; Laubach, JP; Mahindra, AK; Marcheselli, R; Munshi, NC; Raje, NS; Richardson, PG; Rodig, SJ; Schlossman, RL; Scullen, TA; Weller, EA; Yee, AJ, 2014) |
| "This single-arm study evaluated feasibility, safety, and initial efficacy of electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy (PN) in cancer patients with multiple myeloma." | 9.19 | Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. ( Alexanian, R; Badillo, M; Chen, Y; Chiang, J; Cohen, L; Delasalle, K; Garcia, MK; Green, V; Guo, Y; Lee, R; Orlowski, RZ; Romaguera, J; Shah, J; Thomas, S; Wang, M; Weber, D; Wei, Q; You, B; Zhang, L; Zhou, Y, 2014) |
| "Standard carfilzomib (20 mg/m(2) cycle 1, 27 mg/m(2) thereafter; 2- to 10-minute infusion) is safe and effective in relapsed or refractory multiple myeloma (R/RMM)." | 9.19 | A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. ( Chung, DJ; Devlin, S; Giralt, SA; Hassoun, H; Hilden, P; Koehne, G; Landau, H; Lendvai, N; Lesokhin, AM; Redling, K; Schaffer, WL; Tsakos, I, 2014) |
| "The three-drug combination of lenalidomide, bortezomib, and dexamethasone (RVD) has shown significant efficacy in multiple myeloma (MM)." | 9.19 | Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélo ( Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Chretien, ML; Corre, J; Facon, T; Fruchart, C; Gentil, C; Hebraud, B; Hulin, C; Huynh, A; Lauwers-Cances, V; Leleu, X; Marit, G; Moreau, P; Pegourie, B; Robillard, N; Roussel, M; Stoppa, AM; Wuilleme, S, 2014) |
| "We compared the three arms of the MM-015 randomized phase III clinical trial [melphalan and prednisone (MP), MP plus lenalidomide (MPR), and MPR plus lenalidomide maintenance (MPR-R)] to determine whether the addition of lenalidomide maintenance therapy for primary treatment of multiple myeloma is cost-effective." | 9.19 | Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma. ( Ailawadhi, S; Alamgir, A; Asano, H; Chanan-Khan, A; Kim, MY; Sposto, R; Swaika, A, 2014) |
| "A subanalysis of the GIMEMA-MMY-3006 trial was performed to characterize treatment-emergent peripheral neuropathy (PN) in patients randomized to thalidomide-dexamethasone (TD) or bortezomib-TD (VTD) before and after double autologous transplantation (ASCT) for multiple myeloma (MM)." | 9.19 | Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. ( Baldini, L; Cavaletti, G; Cavo, M; Elice, F; Galli, M; Gozzetti, A; Lazzaro, A; Martello, M; Montefusco, V; Palumbo, A; Pantani, L; Peccatori, J; Petrucci, MT; Pezzi, A; Rocchi, S; Ruggieri, M; Tacchetti, P; Terragna, C; Tosi, P; Zamagni, E, 2014) |
| "Data from two randomized pivotal, phase 3 trials evaluating the combination of lenalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM) were pooled to characterize the subset of patients who achieved long-term benefit of therapy (progression-free survival ⩾ 3 years)." | 9.19 | Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. ( Baz, R; Dimopoulos, MA; Hussein, M; Li, JS; Nagarwala, Y; Swern, AS; Weiss, L, 2014) |
| "The combination of bortezomib, lenalidomide, and dexamethasone is a highly effective therapy for newly diagnosed multiple myeloma." | 9.19 | Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. ( Berdeja, JG; Berg, D; Di Bacco, A; Estevam, J; Gupta, N; Hamadani, M; Hari, P; Hui, AM; Kaufman, JL; Kumar, SK; Laubach, JP; Liao, E; Lonial, S; Niesvizky, R; Rajkumar, V; Richardson, PG; Roy, V; Stewart, AK; Vescio, R, 2014) |
| "Carfilzomib, a selective proteasome inhibitor, has shown safety and efficacy in relapsed and/or refractory multiple myeloma." | 9.17 | Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. ( Alsina, M; Bensinger, WI; Kunkel, LA; Lee, S; Martin, TG; Niesvizky, R; Orlowski, RZ; Siegel, DS; Wang, M; Wong, AF, 2013) |
| "We performed a molecular study aimed at identifying a gene expression profile (GEP) signature predictive of attainment of at least near complete response (CR) to thalidomide-dexamethasone (TD) as induction regimen in preparation for double autologous stem cell transplantation in 112 younger patients with newly diagnosed multiple myeloma." | 9.17 | Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation. ( Angelucci, E; Brioli, A; Cavo, M; Di Raimondo, F; Dico, F; Galieni, P; Gozzetti, A; Ledda, A; Mancuso, K; Martello, M; Martinelli, G; Marzocchi, G; Masini, L; Patriarca, F; Remondini, D; Renzulli, M; Roncaglia, E; Tacchetti, P; Tagliafico, E; Terragna, C; Testoni, N; Tosi, P; Zamagni, E, 2013) |
| "This phase II study is the first prospective evaluation of bortezomib-dexamethasone as second-line therapy for relapsed/refractory multiple myeloma." | 9.17 | Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. ( Allietta, N; Angermund, R; Beksac, M; Benboubker, L; Broer, E; Couturier, C; Dimopoulos, MA; Facon, T; Mazier, MA; Roddie, H, 2013) |
| "We designed a trial using two sequential cycles of modified high-dose melphalan at 100 mg/m(2) and autologous SCT (mHDM/SCT) in AL amyloidosis (light-chain amyloidosis, AL), AL with myeloma (ALM) and host-based high-risk myeloma (hM) patients through SWOG-0115." | 9.17 | Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115. ( Barlogie, B; Dean, RM; Fennessey, SA; Finn, KT; Hoering, A; Holmberg, LA; Mattar, B; Orlowski, RZ; Safah, HF; Sanchorawala, V; Seldin, DC; Sexton, R, 2013) |
| "Pomalidomide plus low-dose dexamethasone, an oral regimen, could be considered a new treatment option in patients with refractory or relapsed and refractory multiple myeloma." | 9.17 | Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. ( Alegre, A; Banos, A; Belch, A; Cavo, M; Chen, C; Delforge, M; Dimopoulos, M; Garderet, L; Goldschmidt, H; Ivanova, V; Jacques, C; Karlin, L; Lacy, M; Martinez-Lopez, J; Miguel, JS; Moreau, P; Oriol, A; Palumbo, A; Schey, S; Song, K; Sonneveld, P; Sternas, L; Weisel, K; Yu, X; Zaki, M, 2013) |
| "We previously reported a phase 1b dose-escalation study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in relapsed or progressive multiple myeloma where the maximum planned dose (MPD) was carfilzomib 20 mg/m2 days 1 and 2 of cycle 1 and 27 mg/m2 days 8, 9, 15, 16, and thereafter; lenalidomide 25 mg days 1 to 21; and dexamethasone 40 mg once weekly on 28-day cycles." | 9.17 | Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. ( Alsina, M; Bensinger, W; Huang, M; Kavalerchik, E; Martin, T; Niesvizky, R; Orlowski, RZ; Siegel, DS; Wang, M, 2013) |
| "Bortezomib-thalidomide-dexamethasone (VTD) is an effective induction therapy in multiple myeloma (MM)." | 9.17 | Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. ( Cakana, A; Dmoszynska, A; Enny, C; Esteves, G; Feng, H; Greil, R; Hajek, R; Harousseau, JL; Ludwig, H; Masszi, T; Paiva, B; Ricci, D; Robinson, D; Shpilberg, O; Spicka, I; Stoppa, AM; van de Velde, H; Vidriales, MB; Viterbo, L, 2013) |
| "We conducted a phase II trial that evaluated the tolerability and efficacy of combining lenalidomide with melphalan in previously untreated patients with multiple myeloma who were not candidates for autologous stem cell transplantation." | 9.17 | Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial. ( Bahlis, NJ; Belch, A; Chapman, JA; Chen, C; Couban, S; Harnett, E; Kovacs, MJ; Macdonald, DA; Marcellus, DC; Meyer, RM; Reece, DE; Reiman, T; Stewart, AK; White, DJ, 2013) |
| "Interferon (INF)-α was the maintenance treatment of choice after autologous stem cell transplantation in multiple myeloma in the past, but currently Thalidomide is commonly used." | 9.17 | Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma. ( Beckhove, P; Engelhardt, M; Goldschmidt, H; Haas, J; Herth, I; Ho, AD; Hose, D; Hundemer, M; Klein, B; Meissner, T; Neben, K; Neuber, B; Witzens-Harig, M, 2013) |
| " Patients (n=459) with newly diagnosed multiple myeloma aged 65 years or over were randomized 1:1:1 to nine 4-week cycles of lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance; or lenalidomide, melphalan, and prednisone, or melphalan and prednisone, with no maintenance therapy." | 9.17 | Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. ( Delforge, M; Dimopoulos, MA; Hájek, R; Kropff, M; Lewis, P; Mei, J; Nixon, A; Palumbo, A; Petrucci, MT; Zhang, J, 2013) |
| "This phase 1 dose-escalation study determined the maximum tolerated dose (MTD) of oral pomalidomide (4 dose levels) administered on days 1 to 21 of each 28-day cycle in patients with relapsed and refractory multiple myeloma (RRMM)." | 9.17 | Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. ( Alsina, M; Anand, P; Anderson, KC; Baz, R; Bilotti, E; Chen, M; Doss, D; Ghobrial, IM; Jacques, C; Kelley, SL; Larkins, G; Laubach, J; Loughney, N; McBride, L; Munshi, NC; Nardelli, L; Richardson, PG; Schlossman, R; Siegel, D; Sullivan, D; Wear, S; Zaki, MH, 2013) |
| "The combination of pomalidomide and dexamethasone can be safely administered to patients with multiple myeloma (MM) and has significant efficacy, although the optimal regimen remains to be determined." | 9.17 | Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. ( Arnulf, B; Attal, M; Avet-Loiseau, H; Benboubker, L; Bréchignac, S; Caillot, D; Decaux, O; Escoffre-Barbe, M; Facon, T; Fermand, JP; Garderet, L; Hennache, B; Hulin, C; Kolb, B; Leleu, X; Macro, M; Marit, G; Mathiot, C; Meuleman, N; Michallet, M; Moreau, P; Pegourie, B; Petillon, MO; Roussel, M; Royer, B; Stoppa, AM; Thielemans, B; Traulle, C, 2013) |
| "We evaluated sequential bortezomib, liposomal doxorubicin and dexamethasone (BDD) followed by thalidomide and dexamethasone (TD) if ≥ partial response (PR) or bortezomib and TD (BTD) if < PR in untreated patients with multiple myeloma with International Staging System stage II/III or extramedullary disease." | 9.16 | Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease. ( Bello, C; Cohen, A; Comenzo, RL; Drullinsky, P; Hassoun, H; Hoover, E; Jhanwar, S; Landau, H; Lendvai, N; Lesokhin, A; Nimer, SD; Pandit-Taskar, N; Riedel, E; Schulman, P, 2012) |
| "Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE)." | 9.16 | Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. ( Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB, 2012) |
| "Thalidomide maintenance has the potential to modulate residual multiple myeloma (MM) after an initial response." | 9.16 | The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. ( Bell, SE; Brown, JM; Child, JA; Cook, G; Coy, NN; Davies, FE; Drayson, MT; Gregory, WM; Jackson, GH; Morgan, GJ; Owen, RG; Roddie, H; Ross, FM; Rudin, C; Russell, NH; Szubert, AJ, 2012) |
| "Thalidomide is active in multiple myeloma and is associated with minimal myelosuppression, making it a good candidate for induction therapy prior to high-dose therapy with autologous stem-cell transplantation." | 9.16 | Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. ( Bell, SE; Child, JA; Cook, G; Davies, FE; Drayson, MT; Feyler, S; Gregory, WM; Jackson, GH; Johnson, PR; Morgan, GJ; Navarro Coy, N; Owen, RG; Ross, FM; Rudin, C; Russell, NH; Szubert, AJ, 2012) |
| "Thalidomide has potent antimyeloma activity, but no prospective, randomized controlled trial has evaluated thalidomide monotherapy in patients with relapsed/refractory multiple myeloma." | 9.16 | Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. ( Avet-Loiseau, H; Baylon, HG; Bladé, J; Caravita, T; Facon, T; Glasmacher, A; Goranov, S; Hajek, R; Hillengass, J; Hulin, C; Kropff, M; Kueenburg, E; Liebisch, P; Lucy, L; Moehler, TM; Pattou, C; Robak, T; Zerbib, R, 2012) |
| "We report feasibility and response results of a phase II study investigating prolonged weekly bortezomib and dexamethasone followed by thalidomide and dexamethasone as maintenance therapy after single autologous stem cell transplantation (ASCT) in patients with multiple myeloma." | 9.16 | Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma. ( Cai, JL; Duarte, L; Farol, L; Forman, SJ; Frankel, PH; Htut, M; Karanes, C; Kogut, NM; Krishnan, AY; Murata-Collins, JL; Parker, PM; Popplewell, LL; Reburiano, E; Ruel, C; Sahebi, F; Somlo, G; Spielberger, RT; Thomas, SH, 2012) |
| "Physicians in Asia have anecdotally reported that Asian patients with multiple myeloma (MM) are frequently intolerant of conventional doses of dexamethasone (Dex) and/or thalidomide (Thal)." | 9.16 | Lower dose dexamethasone/thalidomide and zoledronic acid every 3 weeks in previously untreated multiple myeloma. ( Chen, Y; Kim, K; Kim, YK; Pai, VR; Srivastava, A; Suh, C; Teoh, G; Yoon, SS, 2012) |
| "To show that the immunomodulatory drug lenalidomide can be used in patients with relapsed multiple myeloma to augment vaccine responses." | 9.16 | Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. ( Borrello, I; Emerling, A; Ferguson, A; Huff, CA; Noonan, K; Pasetti, MF; Rudraraju, L, 2012) |
| "Here we report the efficacy, safety and health-related quality-of-life (HRQoL) associated with long-term lenalidomide and dexamethasone (Len + Dex) treatment in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in the Spanish cohort of the MM-018 study." | 9.16 | Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience. ( Aguado, B; Alegre, A; Cibeira, MT; Garcia-Larana, J; Knight, R; Martinez-Chamorro, C; Mateos, MV; Oriol-Rocafiguera, A; Rosettani, B; Sureda, A, 2012) |
| "The combination of melphalan, prednisone and thalidomide (MPT) has demonstrated efficacy and acceptable toxicity in newly diagnosed and relapsed/refractory patients with multiple myeloma (MM)." | 9.16 | Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. ( Alesiani, F; Ballanti, S; Boccadoro, M; Caraffa, P; Catarini, M; Cavallo, F; Corvatta, L; Gentili, S; Leoni, P; Liberati, AM; Offidani, M; Palumbo, A; Polloni, C; Pulini, S, 2012) |
| "Our previous studies have shown that lowering the dose of pegylated liposomal doxorubicin (PLD) and bortezomib in combination with intravenous dexamethasone on a longer 4-week cycle maintained efficacy and improved tolerability in both previously untreated and relapsed/refractory (R/R) multiple myeloma (MM) patients." | 9.16 | A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma. ( Berenson, JR; Bravin, E; Cartmell, A; Chen, CS; Flam, M; Hilger, JD; Kazamel, T; Nassir, Y; Swift, RA; Vescio, R; Woliver, T; Yellin, O, 2012) |
| "Treatment with 3-6 cycles of PS-341/bortezomib, adriamycin, and dexamethasone (PAD) has been explored in terms of induction therapy prior to autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM)." | 9.16 | Two cycles of the PS-341/bortezomib, adriamycin, and dexamethasone combination followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients. ( Choi, Y; Kang, YA; Kim, DY; Kim, SD; Lee, JH; Lee, KH; Seol, M, 2012) |
| "Over the past decade, the novel agents thalidomide, lenalidomide, and bortezomib have emerged as effective treatment in patients with multiple myeloma (MM)." | 9.16 | Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma. ( Anand, P; Bello, E; Bendarz, U; Bilotti, E; McBride, L; McNeill, A; Olivo, K; Siegel, DS; Tufail, M; Vesole, DH, 2012) |
| "This multicenter phase 1/2 trial investigated the combination of bendamustine, lenalidomide, and dexamethasone in repeating 4-week cycles as treatment for relapsed refractory multiple myeloma (MM)." | 9.16 | Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. ( Abbas, M; Agha, M; Boyiadzis, M; Burt, S; Dai, L; Kennedy, RC; Lentzsch, S; Mapara, MY; Normolle, D; O'Sullivan, A; Pregja, SL; Roodman, GD; Shuai, Y; Waas, J; Zonder, JA, 2012) |
| "This phase I study evaluated elotuzumab, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (MM)." | 9.16 | Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. ( Facon, T; Harousseau, JL; Jagannath, S; Kaufman, JL; Leleu, X; Lonial, S; Mazumder, A; Moreau, P; Singhal, AK; Tsao, LC; Vij, R; Westland, C, 2012) |
| "Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma." | 9.16 | Continuous lenalidomide treatment for newly diagnosed multiple myeloma. ( Beksac, M; Ben Yehuda, D; Bladé, J; Cascavilla, N; Catalano, J; Cavo, M; Corso, A; Delforge, M; Dimopoulos, MA; Gisslinger, H; Hajek, R; Herbein, L; Iosava, G; Jacques, C; Kloczko, J; Kropff, M; Langer, C; Mei, J; Palumbo, A; Petrucci, MT; Plesner, T; Radke, J; Spicka, I; Weisel, K; Wiktor-Jędrzejczak, W; Yu, Z; Zodelava, M, 2012) |
| "Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma." | 9.16 | Lenalidomide after stem-cell transplantation for multiple myeloma. ( Anderson, KC; Barry, S; Bashey, A; Bennett, E; Bressler, L; Callander, NS; Devine, SM; Gabriel, DA; Gentile, T; Giralt, S; Hari, P; Hars, V; Hassoun, H; Hofmeister, CC; Horowitz, MM; Hurd, DD; Isola, L; Jiang, C; Kelly, M; Landau, H; Levitan, D; Linker, C; Martin, T; Maziarz, RT; McCarthy, PL; McClune, B; Moreb, JS; Owzar, K; Pasquini, MC; Postiglione, J; Qazilbash, MH; Richardson, PG; Rosenbaum, C; Schlossman, R; Seiler, M; Shea, TC; Stadtmauer, EA; Van Besien, K; Vij, R; Weisdorf, DJ, 2012) |
| "Lenalidomide maintenance after transplantation significantly prolonged progression-free and event-free survival among patients with multiple myeloma." | 9.16 | Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. ( Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Decaux, O; Dumontet, C; Facon, T; Garderet, L; Harousseau, JL; Hulin, C; Lauwers-Cances, V; Leleu, X; Leyvraz, S; Marit, G; Mathiot, C; Michallet, M; Moreau, P; Payen, C; Pegourie, B; Roussel, M; Stoppa, AM; Vekemans, MC; Voillat, L, 2012) |
| "This prospective multicenter phase III study compared the efficacy and safety of a triple combination (bortezomib-thalidomide-dexamethasone [VTD]) versus a dual combination (thalidomide-dexamethasone [TD]) in patients with multiple myeloma (MM) progressing or relapsing after autologous stem-cell transplantation (ASCT)." | 9.16 | Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomi ( Cakana, A; Casassus, P; Chaleteix, C; de Witte, T; Dib, M; Doyen, C; Fontan, J; Gahrton, G; Garderet, L; Gorin, NC; Gratwohl, A; Hajek, R; Harousseau, JL; Hertenstein, B; Iacobelli, S; Ketterer, N; Koenecke, C; Kolb, B; Lafon, I; Ludwig, H; Masszi, T; Michallet, M; Milone, G; Mohty, M; Moreau, P; Morris, C; Niederwieser, D; Onida, F; Pegourie, B; van Os, M, 2012) |
| "The combination of lenalidomide-dexamethasone is active in multiple myeloma (MM)." | 9.16 | Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. ( Alsina, M; Anderson, KC; Gardner, L; Giusti, K; Harvey, C; Hideshima, T; Jakubowiak, AJ; Kandarpa, M; Kaufman, JL; Kraftson, S; Poradosu, E; Richardson, PG; Ross, CW; Sportelli, P; Zimmerman, T, 2012) |
| "This phase 1/2 study in patients with newly diagnosed multiple myeloma (N = 53) assessed CRd--carfilzomib (20, 27, or 36 mg/m2, days 1, 2, 8, 9, 15, 16 and 1, 2, 15, 16 after cycle 8), lenalidomide (25 mg/d, days 1-21), and weekly dexamethasone (40/20 mg cycles 1-4/5+)--in 28-day cycles." | 9.16 | A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. ( Ahmed, A; Al-Zoubi, A; Anderson, T; Couriel, D; Detweiler-Short, K; Durecki, DE; Dytfeld, D; Griffith, KA; Jagannath, S; Jakubowiak, AJ; Jobkar, T; Kaminski, M; Lebovic, D; McDonnell, K; Mietzel, M; Nordgren, B; Stockerl-Goldstein, K; Vesole, DH; Vij, R, 2012) |
| " We carried out a single-arm study to assess the toxicity and efficacy of a short block of consolidation therapy with cyclophosphamide, low dose thalidomide and dexamethasone (CTD) in patients within 6 months following ASCT, as part of frontline therapy for symptomatic multiple myeloma." | 9.16 | Improved response with post-ASCT consolidation by low dose thalidomide, cyclophosphamide and dexamethasone as first line treatment for multiple myeloma. ( D'Sa, S; Khan, I; Percy, L; Quinn, J; Rabin, N; Yong, KL, 2012) |
| "The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine, BCNU, melphalan, cyclophosphamide, prednisone/vincristine, BCNU, doxorubicin, dexamethasone/bortezomib (VBMCP/VBAD/B) in patients aged 65 years or younger with multiple myeloma." | 9.16 | Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. ( Alegre, A; Besalduch, J; Bladé, J; Cibeira, MT; de Arriba, F; de la Rubia, J; Díaz-Mediavilla, J; Etxebeste, MA; González, Y; Granell, M; Gutiérrez, NC; Hernández, D; Hernández, MT; Lahuerta, JJ; López-Jiménez, J; Martín-Ramos, ML; Martínez, J; Mateos, MV; Oriol, A; Palomera, L; Rosiñol, L; San Miguel, J; Teruel, AI, 2012) |
| "We investigated whether bortezomib during induction and maintenance improves survival in newly diagnosed multiple myeloma (MM)." | 9.16 | Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. ( Bertsch, U; Blau, IW; Bos, GM; Broyl, A; Duehrsen, U; El Jarari, L; Goldschmidt, HM; Hose, D; Jauch, A; Kersten, MJ; Lindemann, W; Lokhorst, HM; Pfreundschuh, M; Raymakers, R; Salwender, H; Schaafsma, MR; Scheid, C; Schmidt-Wolf, IG; Sonneveld, P; Stevens-Kroef, M; van der Holt, B; van der Velde, H; van Marwijk-Kooy, M; Vellenga, E; Weisel, KC; Wijermans, PW; Wittebol, S; Zweegman, S, 2012) |
| "In order to test for improved survival following autologous transplantation (ASCT), we conducted a prospective clinical trial of post-ASCT thalidomide therapy in Japanese patients with multiple myeloma (MM)." | 9.16 | Post-transplant consolidation therapy using thalidomide alone for the patients with multiple myeloma: a feasibility study in Japanese population. ( Asakura, K; Hattori, Y; Iino, R; Ikeda, Y; Ishizawa, J; Matsuki, E; Okamoto, S; Tsukada, Y; Ueda, T; Yokoyama, K, 2012) |
| "Thalidomide monotherapy has demonstrated consistent results in the treatment of advanced multiple myeloma." | 9.16 | Predictive factors of survival after thalidomide therapy in advanced multiple myeloma: long-term follow-up of a prospective multicenter nonrandomized phase II study in 120 patients. ( Attal, M; Bellissant, E; Decaux, O; Facon, T; Grosbois, B; Moreau, P; Pegourie, B; Renault, A; Sébille, V; Tiab, M; Voillat, L; Zerbib, R, 2012) |
| "In two randomized phase III trials (MM-009 and MM-010), lenalidomide plus dexamethasone significantly prolonged time to progression and overall survival (OS) in patients with relapsed/refractory multiple myeloma compared with dexamethasone alone." | 9.15 | Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. ( Bravo, ML; Dimopoulos, MA; Harousseau, JL; Knight, RD; Olesnyckyj, M; Rajkumar, SV; San-Miguel, JF; Siegel, D; Stadtmauer, EA; Weber, DM; Zeldis, JB, 2011) |
| " In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens." | 9.15 | Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Caravita, T; Carella, AM; Cavo, M; Cellini, C; Crippa, C; Elice, F; Evangelista, A; Galli, M; Gentilini, F; Magarotto, V; Marasca, R; Montefusco, V; Morabito, F; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Polloni, C; Pulini, S; Ria, R; Romano, A; Rossi, D; Tacchetti, P; Tosi, P; Zamagni, E; Zambello, R, 2011) |
| "We studied 174 consecutive patients with relapsed refractory multiple myeloma (MM) enrolled on a phase II clinical trial of pomalidomide plus low-dose dexamethasone at Mayo Clinic." | 9.15 | Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. ( Buadi, F; Dispenzieri, A; Gertz, M; Hayman, S; Kumar, S; Kyle, RA; Lacy, MQ; Larson, D; Mikhael, J; Rajkumar, SV; Roy, V; Short, KD, 2011) |
| "We evaluated the clinical results of lenalidomide (Len) as a compassionate salvage therapy in refractory/relapsed multiple myeloma (MM) patients." | 9.15 | Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients. ( Aguado, B; Alegre, A; Calvo, JM; Cánovas, A; Castillo, I; de la Serna, J; García, FL; Giraldo, P; Hernández, MT; Ibáñez, Á; Lahuerta, JJ; Martínez-Chamorro, C; Oriol, A; Palomera, L; Ríos, E; Rodríguez, JN, 2011) |
| "Single nucleotide polymorphisms (SNPs) in 12 genes involving multidrug resistance, drug metabolic pathways, DNA repair systems and cytokines were examined in 28 patients with relapsed/refractory multiple myeloma (MM) treated with single agent thalidomide and the results were correlated with response, toxicity and overall survival (OS)." | 9.15 | Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide. ( Bladé, J; Cibeira, MT; de Larrea, CF; Díaz, T; Fuster, D; Monzó, M; Navarro, A; Rosiñol, L; Tovar, N, 2011) |
| "Thalidomide with melphalan/prednisone (MPT) was defined as standard treatment in elderly patients with multiple myeloma (MM) based on five randomized trials." | 9.15 | Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. ( Ammerlaan, AH; Lokhorst, HM; Schaafsma, MR; Sinnige, HA; Sonneveld, P; Termorshuizen, F; Uyl-de Groot, CA; van der Griend, R; van Marwijk Kooy, M; Verelst, SG; Wijermans, PW; Wittebol, S; Zweegman, S, 2011) |
| "This phase 1/2 trial evaluated combination lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone (RVDD) in newly diagnosed multiple myeloma (MM) patients." | 9.15 | Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. ( Anderson, KC; Anderson, T; Barrickman, JC; Campagnaro, EL; Esseltine, DL; Griffith, KA; Harvey, CK; Hofmeister, CC; Jakubowiak, AJ; Kaminski, MS; Kelley, SL; Laubach, JP; Lonial, S; Mietzel, MA; Raje, NS; Reece, DE; Richardson, PG; Schlossman, RL; Tendler, CL; Wear, SM; Zimmerman, TM, 2011) |
| "The aim of this phase II study was to determine the efficacy and safety of combined bortezomib and thalidomide (VT) regime as initial treatment for newly diagnosed multiple myeloma (MM) in China." | 9.15 | [The efficacy and safety of bortezomib plus thalidomide in treatment of newly diagnosed multiple myeloma]. ( Chen, SL; Gao, W; Jiang, B; Qiu, LG; Yu, L; Zhong, YP, 2011) |
| "The combination of lenalidomide and low-dose dexamethasone is an effective treatment for multiple myeloma (MM)." | 9.15 | Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. ( Allred, J; Bergsagel, PL; Buadi, FK; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, SK; Lacy, MQ; Laumann, K; Lust, JA; Mikhael, JR; Rajkumar, SV; Reeder, CB; Russell, SJ; Stewart, K; Witzig, TE; Zeldenrust, SR, 2011) |
| "As part of the randomized MRC Myeloma IX trial, we compared an attenuated regimen of cyclophosphamide, thalidomide, and dexamethasone (CTDa; n = 426) with melphalan and prednisolone (MP; n = 423) in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation." | 9.15 | Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. ( Bell, SE; Byrne, JL; Child, JA; Cook, G; Davies, FE; Drayson, MT; Feyler, S; Gregory, WM; Jackson, GH; Morgan, GJ; Navarro Coy, N; Owen, RG; Roddie, H; Ross, FM; Rudin, C; Russell, NH; Szubert, AJ, 2011) |
| "Several trials comparing the efficacy of standard melphalan and prednisone (MP) therapy with MP plus thalidomide (MPT) in elderly patients with multiple myeloma (MM) have been reported, with inconsistent results." | 9.15 | A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant. ( Balleari, E; Buda, G; Consoli, U; Di Renzo, N; Ferrara, R; Fragasso, A; Lazzaro, A; Marcheselli, R; Masini, L; Morabito, F; Musto, P; Neri, S; Pastorini, A; Polimeno, G; Quarta, G; Sacchi, S; Vigliotti, ML; Zoboli, A, 2011) |
| "To improve the outcome of allogeneic stem cell transplantation (allo-SCT) in multiple myeloma as part of first-line treatment, we prospectively investigated the feasibility and efficacy of lenalidomide maintenance." | 9.15 | Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. ( Bruijnen, CP; Cornelisse, PB; Cornelissen, JJ; Emmelot, M; Huisman, C; Huls, G; Janssen, JJ; Kersten, MJ; Kneppers, E; Lokhorst, HM; Meijer, E; Minnema, MC; Mutis, T; Sonneveld, P; van der Holt, B; Zweegman, S, 2011) |
| "The treatment of patients with multiple myeloma usually includes many drugs including thalidomide, lenalidomide and bortezomib." | 9.15 | Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. ( Adamczyk-Cioch, M; Dmoszynska, A; Grzasko, N; Helbig, G; Hus, M; Jawniak, D; Kozinska, J; Legiec, W; Morawska, M; Pluta, A; Szostek, M; Waciński, P; Woszczyk, D, 2011) |
| "The Intergroupe Francophone du Myelome conducted a randomized trial to compare bortezomib-dexamethasone (VD) as induction before high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) to a combination consisting of reduced doses of bortezomib and thalidomide plus dexamethasone (vtD) in patients with multiple myeloma." | 9.15 | Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. ( Araujo, C; Attal, M; Avet-Loiseau, H; Benboubker, L; Berthou, C; Caillot, D; Chaleteix, C; Decaux, O; Dib, M; Doyen, C; Escoffre, M; Facon, T; Fontan, J; Fuzibet, JG; Garderet, L; Harousseau, JL; Hulin, C; Kolb, B; Lenain, P; Lepeu, G; Lioure, B; Marit, G; Mathiot, C; Moreau, P; Pégourié, B; Randriamalala, E; Sebban, C; Stoppa, AM; Tiab, M; Traullé, C; Wetterwald, M, 2011) |
| "We assessed efficacy, safety, and reversal of renal impairment (RI) in untreated patients with multiple myeloma given bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide (VMPT-VT) maintenance or bortezomib-melphalan-prednisone (VMP)." | 9.15 | Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Cascavilla, N; Cavo, M; Di Raimondo, F; Gentile, M; Grasso, M; Guglielmelli, T; Majolino, I; Marasca, R; Mazzone, C; Montefusco, V; Morabito, F; Musolino, C; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, I, 2011) |
| "Introduction of lenalidomide has expanded the therapeutic options for refractory and recurrent multiple myeloma (MM) patients." | 9.15 | Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma. ( Glasmacher, A; Gorschlüter, M; Schmidt-Wolf, IG; Schwamborn, K, 2011) |
| "This randomized, retrospective study evaluated the effect of thalidomide combined with bortezomib-dexamethasone (TBD) or vincristine-doxorubicin-dexamethasone (T-VAD) on 46 patients with multiple myeloma." | 9.15 | Bortezomib-dexamethasone or vincristine-doxorubicin-dexamethasone as induction therapy followed by thalidomide as maintenance therapy in untreated multiple myeloma patients. ( Cao, Y; Chen, RA; Liang, Y; Liu, L; Tu, Y, 2011) |
| "We compared thalidomide-dexamethasone (TD) with melphalan-prednisolone (MP) in 289 elderly patients with multiple myeloma (MM)." | 9.14 | Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. ( Adam, Z; Drach, J; Egyed, M; Gisslinger, H; Greil, R; Hajek, R; Hinke, A; Kuhn, I; Labar, B; Ludwig, H; Spicka, I; Tóthová, E; Zojer, N, 2009) |
| "Maintenance therapy was explored in multiple myeloma (MM) patients after conventional thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD)." | 9.14 | Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study. ( Alesiani, F; Brunori, M; Burattini, M; Candela, M; Catarini, M; Centurioni, R; Corvatta, L; Ferranti, M; Galieni, P; Gentili, S; Giuliodori, L; Leoni, P; Marconi, M; Mele, A; Offidani, M; Piersantelli, MN; Polloni, C; Samori, A; Visani, G, 2009) |
| "The aim of the present study was to evaluate the effectiveness of bortezomib combined with epirubicin, dexamethasone, and thalidomide (BADT) for the treatment of multiple myeloma (MM)." | 9.14 | Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience. ( Hu, X; Huang, C; Lü, S; Ni, X; Qiu, H; Wang, J; Xu, X; Yang, J, 2009) |
| "The aim of this study was to investigate the efficacy and safety of bortezomib-combined with dexamethasone, methylprednisolone and other drugs in the treatment of patients with multiple myeloma (MM)." | 9.14 | [Bortezomib combined with other drugs for treating 60 cases of multiple myeloma]. ( Chen, SL; Hu, Y; Li, X; Zhang, JJ; Zhong, YP, 2009) |
| "Thalidomide is effective in the treatment of newly diagnosed and relapsed/refractory multiple myeloma (MM)." | 9.14 | Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. ( Bradstock, KF; Coyle, L; Gill, DS; Horvath, N; Kennedy, N; Prince, HM; Prosser, IW; Reynolds, J; Roberts, AW; Spencer, A, 2009) |
| "This subset analysis of data from two phase III studies in patients with relapsed or refractory multiple myeloma (MM) evaluated the benefit of initiating lenalidomide plus dexamethasone at first relapse." | 9.14 | Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. ( Belch, A; Dimopoulos, MA; Facon, T; Knight, RD; Niesvizky, R; Olesnyckyj, M; Prince, MH; San Miguel, JF; Stadtmauer, EA; Weber, DM; Yu, Z; Zeldis, JB, 2009) |
| "Although the combination of lenalidomide and dexamethasone is effective therapy for patients with relapsed/refractory multiple myeloma, the influence of high-risk cytogenetic abnormalities on outcomes is unknown." | 9.14 | Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. ( Bahlis, NJ; Bruyere, H; Chang, H; Chen, C; Fu, T; Horsman, DE; Mansoor, A; Masih-Khan, E; Reece, D; Roland, B; Song, KW; Stewart, DA; Trieu, Y, 2009) |
| "To obtain approval from the Ministry of Health, Labor and Welfare of Japan, a phase II study was conducted to assess the pharmacokinetics and pharmacodynamics of thalidomide along with its efficacy and safety in Japanese patients with multiple myeloma." | 9.14 | Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed/refractory multiple myeloma. ( Abe, M; Kosugi, H; Murakami, H; Sawamura, M; Shimazaki, C; Shimizu, K; Sugiura, I; Suzuki, K; Takagi, T; Taniwaki, M, 2009) |
| "Initial analysis of the combination melphalan, prednisone, plus lenalidomide (MPR) showed significant antimyeloma activity in patients with untreated multiple myeloma, with neutropenia and thrombocytopenia as the most frequent side effects." | 9.14 | Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results. ( Benevolo, G; Boccadoro, M; Canepa, L; Falco, P; Falcone, A; Gay, F; Gozzetti, A; Knight, RD; Larocca, A; Luraschi, A; Magarotto, V; Morabito, F; Nozza, A; Palumbo, A; Petrucci, MT; Zeldis, JB, 2009) |
| "Until recently, melphalan and prednisone were the standards of care in elderly patients with multiple myeloma." | 9.14 | Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. ( Azaïs, I; Benboubker, L; Casassus, P; Decaux, O; Dib, M; Doyen, C; Eschard, JP; Facon, T; Fontan, J; Garderet, L; Guillerm, G; Hulin, C; Lafon, I; Lenain, P; Mathiot, C; Moreau, P; Pegourie, B; Rodon, P; Salles, B; Virion, JM, 2009) |
| "Lenalidomide plus dexamethasone is effective for the treatment of relapsed and refractory multiple myeloma (MM); however, toxicities from dexamethasone can be dose limiting." | 9.14 | Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. ( Anderson, KC; Badros, AZ; Bensinger, W; Berenson, J; Hussein, M; Irwin, D; Jagannath, S; Kenvin, L; Knight, R; Olesnyckyj, M; Richardson, P; Singhal, S; Vescio, R; Williams, SF; Yu, Z; Zeldis, J, 2009) |
| "PURPOSE Thalidomide-dexamethasone (THAL-DEX) is standard induction therapy for multiple myeloma (MM)." | 9.14 | Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204). ( Barlogie, B; Bolejack, V; Crowley, JJ; Durie, BG; Hussein, MA; Jakubowiak, AJ; Zonder, JA, 2009) |
| "The plasma concentrations of leptin and adiponectin, but not resistin, were abnormal in newly diagnosed multiple myeloma." | 9.14 | Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma. ( Brenne, AT; Hjorth-Hansen, H; Iversen, PO; Olstad, OK; Reppe, S; Reseland, JE; Syversen, U; Waage, A, 2009) |
| "Thalidomide and lenalidomide are immunomodulatory drugs (IMiDs) that produce high remission rates in the treatment of multiple myeloma." | 9.14 | Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. ( Allred, JB; Bergsagel, PL; Buadi, F; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Kyle, RA; Lacy, MQ; Laumann, K; Lust, JA; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Roy, V; Russell, SJ; Stewart, AK, 2009) |
| "Lenalidomide and bortezomib are active in relapsed and relapsed/refractory multiple myeloma (MM)." | 9.14 | Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. ( Alsina, M; Anderson, KC; Avigan, DE; Dalton, W; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Knight, R; Lunde, LE; Mazumder, A; McKenney, M; Mitsiades, CS; Munshi, NC; Richardson, PG; Schlossman, RL; Warren, DL; Weller, E, 2009) |
| "The phase 3 trial HOVON-50 was designed to evaluate the effect of thalidomide during induction treatment and as maintenance in patients with multiple myeloma who were transplant candidates." | 9.14 | A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. ( Berenschot, H; Bos, GM; Croockewit, S; de Weerdt, O; Delforge, M; Jie, KS; Joosten, P; Lokhorst, HM; Minnema, MC; Schaafsma, R; Sinnige, H; Sonneveld, P; van Ammerlaan, R; van der Holt, B; van Marwijk-Kooy, M; van Oers, MH; Vellenga, E; von dem Borne, P; Wijermans, P; Wittebol, S; Zweegman, S, 2010) |
| "The clinical efficacy and safety of a four-drug combination of bortezomib, cyclophosphamide, thalidomide, and dexamethasone was assessed for patients with relapsed or refractory multiple myeloma." | 9.14 | Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study. ( Ahn, JS; Kim, HJ; Kim, YK; Lee, JH; Lee, JJ; Moon, JH; Sohn, SK; Yang, DH, 2010) |
| "Bortezomib (VELCADE), thalidomide and dexamethasone (VTD), as well as melphalan, prednisolone, and thalidomide (MPT) therapy, are highly effective in patients with multiple myeloma." | 9.14 | Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multip ( Chung, JS; Do, YR; Eom, HS; Jin, JY; Kim, CS; Kim, HJ; Kim, HY; Kim, K; Kim, YK; Lee, DS; Lee, JH; Oh, SJ; Seong, CM; Suh, C, 2010) |
| " This phase I/II study was conducted to identify the most appropriate dose of defibrotide in combination with melphalan, prednisone and thalidomide in patients with relapsed and relapsed/refractory multiple myeloma, and to determine its safety and tolerability as part of this regimen." | 9.14 | Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. ( Anderson, K; Benevolo, G; Boccadoro, M; Bringhen, S; Cavallo, F; Gaidano, G; Gay, F; Genuardi, M; Iacobelli, M; Kotwica, K; Larocca, A; Magarotto, V; Masini, L; Mitsiades, C; Palumbo, A; Richardson, P; Rossi, D; Rus, C, 2010) |
| "Venous thromboembolism (VTE) is a major complication of myeloma therapy recently observed with the increasing use of up-front thalidomide and dexamethasone (thal-dex)." | 9.14 | Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. ( Catalano, L; Cavo, M; Cini, M; Gozzetti, A; Legnani, C; Masini, L; Palareti, G; Patriarca, F; Tacchetti, P; Tosi, P; Valdré, L; Zamagni, E, 2010) |
| "The aim of this study was to evaluate the efficacy and the toxicity of thalidomide-dexamethasone (Thal-Dex) as induction therapy before autologous peripheral blood stem cell (PBSC) transplantation in patients with newly diagnosed multiple myeloma (MM) with renal insufficiency." | 9.14 | Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. ( Baccarani, M; Brioli, A; Cavo, M; Ceccolini, M; Pallotti, MC; Pantani, L; Perrone, G; Petrucci, A; Tacchetti, P; Tosi, P; Zamagni, E, 2010) |
| "Thalidomide has alternative mechanisms of action; it can be combined with dexamethasone or alkylating agents for the treatment of multiple myeloma (MM); however, the optimal doses and appropriate intervals of thalidomide continue to be debated." | 9.14 | Induction treatment with cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma: a phase II study. ( Ahn, JS; Choi, YJ; Chung, JS; Joo, YD; Kim, HJ; Kim, YK; Lee, JH; Lee, JJ; Lee, JL; Lee, WS; Moon, JH; Shin, HJ; Sohn, SK; Yang, DH, 2010) |
| "We conducted a phase 2 study with bortezomib, doxorubicin, and dexamethasone (PAD) followed by thalidomide and dexamethasone (TD) in patients with relapsed multiple myeloma (MM)." | 9.14 | Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety. ( Bang, SM; Chung, J; Do, YR; Jin, JY; Joo, YD; Kang, HJ; Kim, BS; Kim, HY; Kim, K; Lee, DS; Lee, GW; Lee, JH; Lee, JJ; Lee, MH; Lee, SS; Park, J; Ryoo, HM; Shim, H; Suh, C; Yoon, SS, 2010) |
| "This multicenter, open-label, non-comparative phase II trial evaluated the safety and efficacy of salvage therapy with lenalidomide, melphalan, prednisone and thalidomide (RMPT) in patients with relapsed/refractory multiple myeloma (MM)." | 9.14 | Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. ( Boccadoro, M; Canepa, L; Crugnola, M; Falco, P; Falcone, AP; Federico, V; Genuardi, M; Larocca, A; Magarotto, V; Palumbo, A; Petrucci, MT; Sanpaolo, G, 2010) |
| "Bortezomib-based regimens have significant activities in multiple myeloma (MM)." | 9.14 | A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma. ( Chan, EY; Chan, SY; Cheung, SC; Chim, CS; Kwong, YL; Leung, YY; Liang, R; Lie, AK, 2010) |
| "In this double-blind, placebo-controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan-prednisone and thalidomide (MPT) or melphalan-prednisone and placebo (MP)." | 9.14 | Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. ( Abildgaard, N; Ahlberg, L; Björkstrand, B; Carlson, K; Dahl, IM; Fayers, P; Forsberg, K; Gimsing, P; Gulbrandsen, N; Haukås, E; Hjertner, O; Hjorth, M; Juliusson, G; Karlsson, T; Knudsen, LM; Linder, O; Mellqvist, UH; Nesthus, I; Nielsen, JL; Rolke, J; Strandberg, M; Sørbø, JH; Turesson, I; Waage, A; Wisløff, F, 2010) |
| "gov: NCT00507442) was conducted to determine the maximum tolerated dose (MTD) of cyclophosphamide in combination with bortezomib, dexamethasone and lenalidomide (VDCR) and to assess the safety and efficacy of this combination in untreated multiple myeloma patients." | 9.14 | Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. ( Bhandari, M; Callander, N; Flinn, I; Gasparetto, C; Glass, J; Grosman, D; Hari, P; Krishnan, A; Kumar, SK; Noga, SJ; Rajkumar, SV; Richardson, PG; Rifkin, R; Sahovic, EA; Shi, H; Webb, IJ; Wolf, JL, 2010) |
| "A randomized phase III trial compared standard MP with MP-T (thalidomide 200 mg/d) in newly diagnosed patients with multiple myeloma older than age 65 years." | 9.14 | Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. ( Ammerlaan, R; Lokhorst, H; Schaafsma, M; Sinnige, H; Sonneveld, P; Termorshuizen, F; van der Griend, R; van Marwijk Kooy, M; Wijermans, P; Wittebol, S; Zweegman, S, 2010) |
| "We conducted a multicenter, open-label study to investigate the safety, efficacy, and pharmacokinetics of lenalidomide in Japanese patients with relapsed or refractory multiple myeloma The study was composed of the "monotherapy phase", a dose-escalation phase, to determine the tolerability to single agent lenalidomide and the "combination phase" to determine the safety and obtain preliminary data on the efficacy of lenalidomide plus dexamethasone." | 9.14 | Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma. ( Chou, T; Hatake, K; Hotta, T; Iida, S; Lau, H; Murakami, H; Nagai, H; Okamoto, S; Shimizu, K; Takagi, T; Takatoku, M; Takeshita, K, 2010) |
| "The results from this study indicated that, with careful monitoring of the CLCr level and adverse events as well as appropriate dose adjustments, lenalidomide plus dexamethasone is an effective and well tolerated treatment option for patients with multiple myeloma who have RI." | 9.14 | The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. ( Alegre, A; de Castro, CM; Dimopoulos, M; Goldschmidt, H; Masliak, Z; Olesnyckyj, M; Reece, D; Stadtmauer, EA; Weber, DM; Yu, Z; Zonder, JA, 2010) |
| "Bortezomib has proven to be active in patients with multiple myeloma (MM), including elderly patients." | 9.14 | Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: a Chinese experience. ( Chen, F; Chen, H; Guo, H; Jiang, Y; Lu, M; Mao, J; Qian, X; Shen, Y; Sun, C; Sun, H; Xia, J; Yang, G; Zhou, X; Zhuang, Y, 2010) |
| "The aim of this Phase II study was to determine the efficacy and safety of combined bortezomib and thalidomide (VT) regime as initial treatment for newly diagnosed patients with multiple myeloma (MM) in China." | 9.14 | Bortezomib plus thalidomide for newly diagnosed multiple myeloma in China. ( Chen, SL; Gao, W; Jiang, B; Qiu, LG; Yu, L; Zhong, YP, 2010) |
| "The combination of bortezomib-melphalan-prednisone (VMP) is a new standard of care for newly diagnosed multiple myeloma." | 9.14 | Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cavalli, M; Ciccone, G; Falcone, AP; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Leonardi, G; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rizzo, M; Rossi, D, 2010) |
| " We aimed to assess the efficacy and safety of addition of bortezomib to TD (VTD) versus TD alone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma." | 9.14 | Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 ( Baccarani, M; Caravita, T; Cavo, M; Cellini, C; Corradini, P; Crippa, C; Deliliers, GL; Di Raimondo, F; Galli, M; Ledda, A; Narni, F; Offidani, M; Palumbo, A; Pantani, L; Patriarca, F; Pescosta, N; Petrucci, MT; Spadano, A; Tacchetti, P; Tosi, P; Zamagni, E, 2010) |
| "A total of 28 treatment-naïve patients with stage II or III multiple myeloma (MM) were treated with the combination of clarithromycin, lenalidomide, and dexamethasone (BiRD)." | 9.13 | Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. ( Christos, PJ; Coleman, M; Furst, JR; Harpel, J; Jayabalan, D; LaRow, A; Leonard, JP; Mark, T; Niesvizky, R; Pearse, RN; Schuster, MW; Shore, T; Stern, J; Zafar, F, 2008) |
| "To investigate the efficacy and toxicity of bortezomib based combination therapy for Chinese patients with relapsed or refractory multiple myeloma (MM), and to determine the combination regimen, dosage and cycles in application of bortezomib for MM therapy." | 9.13 | [Bortezomib-based combination therapy for relapsed or refractory multiple myeloma]. ( Chen, YB; Fu, WJ; Hou, J; Wang, DX; Xi, H; Yuan, ZG, 2008) |
| "Thalidomide is an effective agent for advanced refractory or relapsed multiple myeloma (MM), although dose-limiting toxicity (DLT) may limit its use." | 9.13 | Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. ( Boldt, T; Goldschmidt, H; Haas, A; Hoffmann, FA; Kreibich, U; Niederwieser, D; Pönisch, W; Ritter, U; Rohrberg, R; Rozanski, M; Schirmer, V; Schwalbe, E; Schwarzer, A; Uhlig, J; Zehrfeld, T, 2008) |
| "The study was aimed to investigate the clinical efficacy and adverse reactions of different thalidomide regimens in the treatment of multiple myeloma (MM), and to explore the relationship between efficacy of thalidomide and serum level of TNF-alpha in MM patients." | 9.13 | [Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level]. ( Cao, XM; Chen, YX; He, AL; Liu, J; Ma, XR; Yang, Y; Zhang, WG, 2008) |
| "This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (BiRD) as first-line therapy for multiple myeloma." | 9.13 | BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. ( Chen-Kiang, S; Cho, HJ; Christos, PJ; Coleman, M; Ely, S; Furst, JR; Harpel, J; Jalbrzikowski, J; Jayabalan, DS; Larow, A; Lent, R; Leonard, JP; Mark, T; Mathew, S; Mazumdar, M; Naib, T; Niesvizky, R; Pearse, RN; Pekle, K; Schuster, MW; Shore, T; Tepler, J; Zafar, F, 2008) |
| "Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM)." | 9.13 | Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. ( Bladé, J; Hajek, R; Harousseau, JL; Nagler, A; Orlowski, RZ; Robak, T; Sonneveld, P; Spencer, A; Zhuang, SH, 2008) |
| "The long-term impact of thalidomide plus dexamethasone (thal/dex) as primary therapy for newly diagnosed multiple myeloma (MM) is unknown." | 9.13 | Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. ( Bladé, J; Catalano, J; Hussein, M; Jedrzejczak, W; Knight, R; Lucy, L; Olesnyckyj, M; Rajkumar, SV; Rosiñol, L; Yu, Z; Zeldis, JB, 2008) |
| "We previously reported a pilot study of thalidomide monotherapy for Japanese patients with refractory or relapsed multiple myeloma." | 9.13 | Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma: prognostic factors and unique toxicity profile. ( Hattori, Y; Ikeda, Y; Kakimoto, T; Morita, K; Okamoto, S; Shimada, N; Tanigawara, Y, 2008) |
| "Thalidomide has been estimated as a useful drug in therapy of refractory or relapsed multiple myeloma." | 9.13 | Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma. ( Adam, Z; Bacovsky, J; Gregora, E; Minarik, J; Pavlicek, P; Pika, T; Pour, L; Scudla, V; Zemanova, M, 2008) |
| "To determine if thalidomide plus dexamethasone yields superior response rates compared with dexamethasone alone as induction therapy for newly diagnosed multiple myeloma." | 9.12 | Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. ( Blood, E; Fonseca, R; Greipp, PR; Rajkumar, SV; Vesole, D, 2006) |
| " on days 1-4 and 9-12 and thalidomide 100 mg daily in 50 patients with advanced multiple myeloma." | 9.12 | Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. ( Alesiani, F; Brunori, M; Burattini, M; Candela, M; Capelli, D; Catarini, M; Centurioni, R; Corvatta, L; Galieni, P; Giuliodori, L; Leoni, P; Marconi, M; Montanari, M; Offidani, M; Olivieri, A; Piersantelli, MN; Rupoli, S; Scortechini, AR; Visani, G, 2006) |
| "Fifty patients with multiple myeloma >or=75 years of age received primary treatment with melphalan (M) 8 mg/m(2) on days 1-4, dexamethasone (D) 12 mg/m2 on days 1-4 and 17-20 and thalidomide (T) 300 mg at bedtime on days 1-4 and 17-20." | 9.12 | Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. ( Anagnostopoulos, A; Anagnostopoulos, N; Delibasi, S; Dimopoulos, MA; Katodritou, E; Kyrtsonis, MC; Maniatis, A; Pouli, A; Repoussis, P; Terpos, E; Vassou, A; Zervas, K; Zomas, A, 2006) |
| "High-dose therapy with melphalan can prolong survival among patients with multiple myeloma." | 9.12 | Thalidomide and hematopoietic-cell transplantation for multiple myeloma. ( Anaissie, E; Barlogie, B; Crowley, J; Fassas, A; Fox, M; Hollmig, K; Kiwan, E; Krishna, S; Lee, C; Pineda-Roman, M; Rasmussen, E; Shaughnessy, J; Talamo, G; Thertulien, R; Tricot, G; van Rhee, F; Zangari, M, 2006) |
| "Patients with newly diagnosed multiple myeloma were randomly assigned to receive oral MP for six 4-week cycles plus thalidomide (n=129; 100 mg per day continuously until any sign of relapse or progressive disease) or MP alone (n=126)." | 9.12 | Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. ( Ambrosini, MT; Avonto, I; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Capparella, V; Caravita, T; Catalano, L; Ceccarelli, M; Ciccone, G; De Stefano, V; Falco, P; Galli, M; Grasso, M; Liberati, AM; Merla, E; Musto, P; Palumbo, A; Petrucci, MT; Rossini, F; Zamagni, E, 2006) |
| "A major limitation to the treatment of multiple myeloma by the thalidomide analogue CC-4047 (Actimid) is the development of a severe neutropenia." | 9.12 | The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64. ( Brown, KA; Macey, MG; McCarthy, DA; Schey, SA; Streetly, M, 2006) |
| "We present the results of a phase 2 study using thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) in the treatment of 50 patients older than 65 years with newly diagnosed multiple myeloma." | 9.12 | Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. ( Alesiani, F; Brunori, M; Burattini, M; Candela, M; Capelli, D; Catarini, M; Centurioni, R; Corvatta, L; Ferranti, M; Galieni, P; Giuliodori, L; Leoni, P; Marconi, M; Montanari, M; Offidani, M; Olivieri, A; Piersantelli, MN; Polloni, C; Poloni, A; Rupoli, S; Scortechini, AR; Visani, G, 2006) |
| "To evaluate the efficacy and safety of adding thalidomide to the pegylated liposomal doxorubicin, vincristine, and decreased-frequency dexamethasone (DVd) regimen for multiple myeloma." | 9.12 | Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. ( Agrawal, N; Andresen, S; Baz, R; Faiman, B; Hsi, E; Hussein, MA; Karam, MA; Kelly, M; Reed, J; Srkalovic, G; Suppiah, R; Walker, E, 2006) |
| "Lenalidomide is active and well tolerated in relapsed and refractory multiple myeloma." | 9.12 | Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. ( Andresen, S; Baz, R; Brand, C; Bruening, K; Choueiri, TK; Ellis, Y; Faiman, B; Hussein, MA; Jawde, RA; Karam, MA; Knight, R; Reed, J; Srkalovic, G; Walker, E; Zeldis, J, 2006) |
| "Thalidomide has been used for the treatment of refractory multiple myeloma, the dosage in Japan is lower than in other countries; however, there is little information on the pharmacokinetics and their relationship with the drug response." | 9.12 | The pharmacokinetics of low-dose thalidomide in Japanese patients with refractory multiple myeloma. ( Asaoku, H; Ikawa, K; Iwato, K; Kamikawa, R; Morikawa, N; Sasaki, A, 2006) |
| "In multiple myeloma (MM), the addition of thalidomide or bortezomib to the standard oral melphalan/prednisone combination significantly increased response rate and event-free survival." | 9.12 | Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. ( Ambrosini, MT; Avonto, I; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Caravita, T; Cavallo, F; Falco, P; Morabito, F; Musto, P; Palumbo, A; Pescosta, N; Pregno, P, 2007) |
| "3 mg/m2 intravenously on days 1, 4, and 8 to DT-PACE (cisplatin 10 mg/m2, doxorubicin 10 mg/m2, cyclophosphamide 400 mg/m2, and etoposide 40 mg/m2 per day by intravenous continuous infusion on days 1-4) plus oral dexamethasone 40 mg on days 1-4 and thalidomide 200 mg on days 1-8 in newly diagnosed patients with multiple myeloma." | 9.12 | Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma. ( Akpek, G; Badros, A; Fenton, R; Goloubeva, O; Harris, C; Meisenberg, B; Rapoport, AP; Ruehle, K; Westphal, S, 2006) |
| "In a phase III randomized, multicenter study, the German-speaking Myeloma-Multicenter Group (GMMG) and the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) group investigated the influence of thalidomide (Thal) on the outcome of peripheral blood stem cell (PBSC) collection in multiple myeloma (MM) before peripheral autologous blood stem cell transplantation (ABSCT)." | 9.12 | Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. ( Blau, IW; Breitkreutz, I; Cremer, FW; Glasmacher, A; Goldschmidt, H; Haenel, A; Herrmann, D; Holt, Bv; Lokhorst, HM; Martin, H; Raab, MS; Salwender, H; Schmidt-Wolf, IG; Sonneveld, P, 2007) |
| "In a previous trial among 137 previously untreated patients with multiple myeloma, the combination of thalidomide-dexamethasone induced remission in 66% of patients, including complete remission in 13%." | 9.12 | Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. ( Alexanian, R; Delasalle, K; Giralt, S; Handy, B; Wang, M, 2007) |
| "We report the results of a non-randomized phase II study of low-dose thalidomide plus low-dose dexamethasone therapy in 66 patients with refractory multiple myeloma." | 9.12 | Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. ( Abe, M; Fujii, H; Fukuhara, T; Handa, H; Hata, H; Iida, S; Ishida, T; Ishii, A; Ishikawa, T; Kosaka, M; Miyata, A; Murakami, H; Oota, M; Ozaki, S; Sakai, A; Sawamura, M; Shimazaki, C; Shimizu, K; Takagi, T; Takatsuki, K; Wakayama, T, 2007) |
| "Thalidomide is effective as a first-line therapy for the treatment of multiple myeloma (MM), but its use is limited by peripheral neurotoxicity." | 9.12 | Neuropathy in multiple myeloma treated with thalidomide: a prospective study. ( Bartolomei, I; Cangini, D; Cavo, M; Michelucci, R; Pastorelli, F; Petracci, E; Plasmati, R; Salvi, F; Tacchetti, P; Tassinari, CA; Tosi, P; Zamagni, E, 2007) |
| " Oral melphalan, prednisone, and thalidomide have been regarded as the standard of care in elderly multiple myeloma patients." | 9.12 | Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. ( Ambrosini, MT; Boccadoro, M; Bringhen, S; Ciccone, G; Corradini, P; Crippa, C; Di Raimondo, F; Falco, P; Falcone, A; Foà, R; Gay, F; Giuliani, N; Knight, R; Musto, P; Omedè, P; Palumbo, A; Petrucci, MT; Zeldis, JB, 2007) |
| "Between May 22, 2000, and Aug 8, 2005, 447 previously untreated patients with multiple myeloma, who were aged between 65 and 75 years, were randomly assigned to receive either melphalan and prednisone (MP; n=196), melphalan and prednisone plus thalidomide (MPT; n=125), or reduced-intensity stem cell transplantation using melphalan 100 mg/m2 (MEL100; n=126)." | 9.12 | Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. ( Anglaret, B; Attal, M; Avet-Loiseau, H; Benboubker, L; Casassus, P; Chaleteix, C; Dib, M; Dorvaux, V; Doyen, C; Facon, T; Grosbois, B; Guillerm, G; Harousseau, JL; Hulin, C; Jardel, H; Jaubert, J; Kolb, B; Maisonneuve, H; Martin, C; Mary, JY; Mathiot, C; Monconduit, M; Pegourie, B; Renaud, M; Troncy, J; Voillat, L; Yakoub-Agha, I, 2007) |
| "Lenalidomide plus dexamethasone is more effective than high-dose dexamethasone alone in relapsed or refractory multiple myeloma." | 9.12 | Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. ( Attal, M; Corso, A; Dimopoulos, M; Dmoszynska, A; Facon, T; Foà, R; Harousseau, JL; Hellmann, A; Knight, RD; Masliak, Z; Olesnyckyj, M; Patin, J; Prince, HM; San Miguel, J; Spencer, A; Yu, Z; Zeldis, JB, 2007) |
| "Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma." | 9.12 | Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. ( Belch, A; Borrello, I; Chanan-Khan, AA; Chen, C; Knight, RD; Lonial, S; Niesvizky, R; Olesnyckyj, M; Patin, J; Rajkumar, SV; Siegel, D; Stadtmauer, EA; Wang, M; Weber, DM; Yu, Z; Zeldis, JB, 2007) |
| "Thalidomide is effective in treating refractory and relapsed multiple myeloma (MM)." | 9.12 | [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma]. ( Chen, YB; Fu, WJ; Hou, J; Wang, DX; Xi, H; Yuan, ZG, 2007) |
| "We evaluate the efficacy of the oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) in 71 refractory/relapsed multiple myeloma patients, including a prognostic analysis to predict both response and survival." | 9.11 | The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. ( Alegre, A; Barrenetxea, C; García-Sanz, R; González-Porras, JR; Grande-García, C; Gutiérrez, ON; Hernández, JM; López, R; Palomera, L; Polo-Zarzuela, M; Rodríguez, JA; San Miguel, JF; Sureda, A; Vargas-Pabón, M, 2004) |
| "Thalidomide has demonstrated a remarkable efficacy in the treatment of multiple myeloma but its use may cause several toxicities." | 9.11 | Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. ( Brunori, M; Candela, M; Capelli, D; Catarini, M; Corvatta, L; Leoni, P; Malerba, L; Marconi, M; Mele, A; Montanari, M; Offidani, M; Olivieri, A; Rupoli, S, 2004) |
| "Recent reports have shown that thalidomide has antiangiogenic activity and is effective for the treatment of refractory multiple myeloma." | 9.11 | Thalidomide-induced severe neutropenia during treatment of multiple myeloma. ( Hattori, Y; Ikeda, Y; Kakimoto, T; Okamoto, S; Sato, N, 2004) |
| "To determine the progression-free survival at 12 weeks, to evaluate the toxic effects, and to analyze the biological activity of thalidomide in patients with relapsed multiple myeloma (MM) after high-dose chemotherapy and stem cell transplantation." | 9.11 | Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. ( Alsina, M; Anderson, K; Blood, E; Bosch, J; Dalton, W; Davies, F; Desikan, R; Doss, D; Freeman, A; Hideshima, T; Jagannath, S; Knight, R; Mitsiades, C; Patin, J; Richardson, P; Schlossman, R; Weller, E; Zeldis, J, 2004) |
| "The marked synergy of thalidomide and dexamethasone in advanced and refractory multiple myeloma (MM) provided the basis for a phase 2 clinical study aimed at investigating the efficacy and toxicity of this combination as first-line therapy for patients less than 65 years old with newly diagnosed disease." | 9.11 | First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. ( Baccarani, M; Cangini, D; Cavo, M; Cellini, C; de Vivo, A; Palareti, G; Tacchetti, P; Testoni, N; Tonelli, M; Tosi, P; Tura, S; Zamagni, E, 2004) |
| "Thalidomide, the prototype of a new class of agents active against multiple myeloma (MM), exerts synergistic/additive effects when combined with other drugs." | 9.11 | Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. ( Brunori, M; Candela, M; Capelli, D; Catarini, M; Corvatta, L; Leoni, P; Malerba, L; Marconi, M; Mele, A; Montanari, M; Offidani, M; Olivieri, A, 2004) |
| "To quantify changes of bone marrow microcirculation in multiple myeloma (MM) using contrast enhanced dynamic MRI (dMRI) during thalidomide as antiangiogenic monotherapy or in combination with chemotherapy (cyclophosphamide, etoposide, dexamethasone)." | 9.11 | [Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy]. ( Delorme, S; Düber, C; Goldschmidt, H; Heiss, J; Hillengass, J; Kauczor, HU; Moehler, T; Neben, K; Nosas, S; Wasser, K, 2004) |
| "Thalidomide is an effective agent for patients with refractory multiple myeloma (MM) with a response rate of 30-40% at doses of 200-800 mg but with considerable side effects." | 9.11 | Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study. ( Daenen, SM; de Wolf, JT; Hovenga, S; Kluin-Nelemans, HC; Sluiter, WJ; van Imhoff, GW; Vellenga, E, 2005) |
| "We report a multicenter, randomized phase II trial conducted to assess the tolerability of combined thalidomide and prednisone maintenance in multiple myeloma." | 9.11 | Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. ( Belch, AR; Chen, CI; Ding, K; Howson-Jan, K; Kovacs, MJ; Meyer, RM; Roy, J; Sadura, A; Shepherd, L; Shustik, C; Stewart, AK; White, D, 2004) |
| "Thalidomide is remarkably active in advanced relapsed and refractory multiple myeloma (MM), so that its use has been recently proposed either in newly diagnosed patients or as maintenance treatment after conventional or high-dose therapy." | 9.11 | Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. ( Baccarani, M; Cangini, D; Cavo, M; Cellini, C; Pastorelli, F; Perrone, G; Plasmati, R; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E, 2005) |
| "The aim of this study was to assess the side effects and the efficacy of thalidomide alone or in combination with dexamethasone in relapsed multiple myeloma (MM) and to evaluate possible predictive factors for response rate and survival." | 9.11 | Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival. ( Brandhorst, D; Buttkereit, U; Ebeling, P; Flasshove, M; Moritz, T; Müller, S; Nowrousian, MR; Opalka, B; Poser, M; Schütt, P; Seeber, S, 2005) |
| "Thalidomide (THAL) is currently used as a novel drug in patients with chemotherapy resistant or relapsed multiple myeloma." | 9.11 | The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma. ( Bojarska-Junak, A; Dmoszynska, A; Manko, J; Podhorecka, M; Rolinski, J; Skomra, D, 2005) |
| "G3139, dexamethasone, and thalidomide are well tolerated and result in encouraging clinical responses in relapsed multiple myeloma patients." | 9.11 | Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. ( Badros, AZ; Fenton, RG; Flaws, JA; Gahres, N; Gocke, CD; Goloubeva, O; Heyman, M; Meisenberg, B; Rapoport, AP; Ratterree, B; Streicher, H; Takebe, N; Tomic, D; Zhang, B; Zwiebel, J, 2005) |
| "The feasibility and efficacy of a triple regimen of oral weekly cyclophosphamide, monthly pulsed dexamethasone and low-dose Thalidomide (CDT) was studied in 52 patients with relapsed or refractory multiple myeloma (MM)." | 9.11 | Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. ( D'Sa, S; Flory, A; Goldstone, AH; Hanslip, J; Kyriakou, C; Thomson, K; Yong, KL, 2005) |
| "Thalidomide-dexamethasone therapy was given in patients (<61 years) with previously untreated symptomatic multiple myeloma." | 9.11 | First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma. ( Abdelkefi, A; Aissaouï, L; Bellaj, H; Ben Abdeladhim, A; Ben Othman, T; Ben Romdhane, N; Boukef, K; Dellagi, K; El Omri, H; Elloumi, M; Hsaïri, M; Jeddi, R; Ladeb, S; Lakhal, A; Saad, A; Torjman, L, 2005) |
| "The value of thalidomide-dexamethasone was assessed in 26 consecutive, previously untreated patients with multiple myeloma of high tumor mass." | 9.11 | Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. ( Alexanian, R; Delasalle, K; Wang, M; Weber, DM, 2005) |
| "The feasibility and efficacy of a combination of thalidomide, incadronate, and dexamethasone (TID) were studied in 12 patients with relapsed or refractory multiple myeloma." | 9.11 | Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma. ( Ashihara, E; Fuchida, S; Hatsuse, M; Ochiai, N; Okamoto, M; Okano, A; Shimazaki, C; Uchida, R; Yamada, N, 2005) |
| "To study the efficacy of daily low-dose aspirin (81 mg orally) in decreasing the incidence of venous thromboembolic events (VTEs) in patients with multiple myeloma receiving pegylated doxorubicin, vincristine, and decreased-frequency dexamethasone, plus thalidomide (DVd-T)." | 9.11 | The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. ( Andresen, S; Baz, R; Faiman, B; Hussein, MA; Jawde, RA; Karam, MA; Kottke-Marchant, K; Li, L; McGowan, B; Srkalovic, G; Yiannaki, E; Zeldis, J, 2005) |
| "Although thalidomide (Thal) was introduced successfully in the treatment of multiple myeloma (MM), the optimal Thal dosage and schedule are still controversial." | 9.10 | Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. ( Benner, A; Egerer, G; Goldschmidt, H; Ho, AD; Kraemer, A; Moehler, T; Neben, K, 2002) |
| "To evaluate the activity of thalidomide in patients with asymptomatic multiple myeloma and of thalidomide-dexamethasone in patients with previously untreated symptomatic myeloma." | 9.10 | Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. ( Alexanian, R; Delasalle, K; Gavino, M; Rankin, K; Weber, D, 2003) |
| "Thalidomide is active both as single agent and in combination-therapy against refractory or relapsing multiple myeloma." | 9.10 | Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): results, prognostic factors and side effects in eight patients previously treated with multiple myeloma. ( Bemardeschi, P; Dentico, P; Fiorentini, G; Giustarini, G; Rossi, S; Turano, E, 2003) |
| "13 patients with treatment-resistant multiple myeloma with advanced osteolytic lesions received combined pamidronate and thalidomide therapy." | 9.10 | Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. ( Baran, W; Ciepłuch, H; Hellmann, A, 2002) |
| "Thalidomide is an effective treatment for relapsed multiple myeloma (MM), but is associated with a significant side effect profile at higher doses." | 9.10 | Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. ( Abdalla, SH; Johnston, RE, 2002) |
| "Although thalidomide (Thal) was initially used to treat multiple myeloma (MM) because of its known antiangiogenic effects, the mechanism of its anti-MM activity is unclear." | 9.09 | Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. ( Anderson, KC; Chauhan, D; Davies, FE; Hideshima, T; Lin, B; Muller, G; Raje, N; Richardson, P; Schlossman, RL; Shima, Y; Stirling, DI; Tai, YT; Treon, SP, 2000) |
| "Thalidomide is currently used as a very promising drug in patients with recurrent multiple myeloma or those refractory to chemotherapy." | 9.09 | Thalidomide treatment of resistant or relapsed multiple myeloma patients. ( Ciepnuch, H; Dmoszynska, A; Hellmann, A; Hus, M; Jawniak, D; Legiec, W; Manko, J; Skotnicki, A; Soroka-Wojtaszko, M; Wolska-Smolen, T, 2001) |
| "We conducted a clinical trial of thalidomide as initial therapy for asymptomatic smoldering (SMM) or indolent multiple myeloma (IMM)." | 9.09 | Thalidomide for previously untreated indolent or smoldering multiple myeloma. ( Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, S; Greipp, PR; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE, 2001) |
| "The occurrence of deep-vein thrombosis (DVT) in patients with newly diagnosed multiple myeloma, who were randomly assigned to receive identical induction chemotherapy with or without thalidomide, are reported in this study." | 9.09 | Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. ( Anaissie, E; Badros, A; Barlogie, B; Desikan, R; Fink, L; Gopal, AV; Morris, C; Siegel, E; Toor, A; Tricot, G; Zangari, M, 2001) |
| "Thalidomide is effective in approximately 30% of patients with refractory multiple myeloma." | 9.09 | Thalidomide and dexamethasone combination for refractory multiple myeloma. ( Anagnostopoulos, N; Christakis, I; Dimopoulos, MA; Economou, O; Galani, E; Gika, D; Grigoraki, V; Kiamouris, C; Kouvatseas, G; Panayiotidis, P; Papadimitriou, C; Samantas, E; Vervessou, E; Zervas, K, 2001) |
| "The aim of this study was to define prognostic factors that might be predictive for response to thalidomide (Thal) in progressive multiple myeloma (n = 54)." | 9.09 | High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. ( Benner, A; Egerer, G; Goldschmidt, H; Hillengass, J; Ho, AD; Kraemer, A; Moehler, T; Neben, K, 2001) |
| "Recently, a report has suggested the efficacy and safety of thalidomide in refractory multiple myeloma." | 9.09 | Thalidomide in patients with advanced multiple myeloma. ( Attal, M; Beris, P; Berthou, C; Duguet, C; Dumontet, C; Facon, T; Grosbois, B; Harousseau, JL; Leyvraz, S; Moreau, P; Payen, C; Yakoub-Agha, I, 2000) |
| "We sought to evaluate the activity and safety of carfilzomib-/ixazomib-containing combinations for patients with relapsed/refractory multiple myeloma (RRMM)." | 8.98 | Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma. ( Guo, H; Sun, X; Wang, B; Xu, W, 2018) |
| "The immunomodulatory drug lenalidomide is highly effective against newly diagnosed and relapsed/refractory multiple myeloma (MM), but serious and even fatal infections have been associated with its use." | 8.95 | Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis. ( Sun, H; Ying, L; YinHui, T; Yunliang, Z, 2017) |
| "This overview summarizes evidence for the efficacy and safety of bortezomib, thalidomide, and lenalidomide in patients with multiple myeloma." | 8.95 | Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses. ( Aguiar, PM; Colleoni, GWB; de Mendonça Lima, T; Storpirtis, S, 2017) |
| " Within the past decade, combination lenalidomide and dexamethasone has become a standard of therapy for multiple myeloma and is now widely used." | 8.95 | Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma. ( Chang, S; Maharaj, S; Seegobin, K; Serrano-Santiago, I; Zuberi, L, 2017) |
| "Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or observation in several randomized controlled trials (RCTs) of patients with newly diagnosed multiple myeloma (NDMM)." | 8.95 | Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. ( Anderson, KC; Attal, M; Bringhen, S; Caillot, D; Gay, F; Holstein, SA; Hulin, C; Jung, SH; Knight, RD; Marit, G; McCarthy, PL; Moreau, P; Musto, P; Palumbo, A; Petrucci, MT; Richardson, PG; Tosi, P; Winograd, B; Yu, Z, 2017) |
| "BiRd combination therapy, which comprises clarithromycin(CAM: Biaxin®), lenalidomide(LEN: Revlimid®), and dexamethasone( DEX), is a highly effective treatment for newly diagnosed symptomatic multiple myeloma(MM)." | 8.95 | [Effective BiRd Therapy after the Addition of Clarithromycin for Lenalidomide and Dexamethasone Resistant Multiple Myeloma Ineligible for Stem Cell Transplantation]. ( Abe, T; Ameda, S; Fujii, S; Kato, J; Kobune, M; Kuroda, H; Maeda, M; Miura, S; Sakano, H; Sato, K; Shibata, T; Uemura, N; Yamada, M, 2017) |
| "The use of carfilzomib/pomalidomide single-agent or in combination with other agents in patients with refractory/relapsed multiple myeloma (RRMM) was not clearly clarified in clinical practice." | 8.95 | Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials. ( Fan, L; Hu, C; Ma, X; Ran, X; Yu, H; Zou, Y, 2017) |
| "To investigate the activity and safety of carfilzomib-containing combinations as frontline therapy for multiple myeloma." | 8.95 | Carfilzomib-containing combinations as frontline therapy for multiple myeloma: A meta-analysis of 13 trials. ( Li, B; Li, G; Liu, Y; Sheng, Z; Wang, L, 2017) |
| "The use of pomalidomide after lenalidomide and (or) bortezomib failure in patients with multiple myeloma is not clearly clarified in clinical practice." | 8.93 | Pooled analysis of the reports of pomalidomide after failure of lenalidomide and (or) bortezomib for multiple myeloma. ( Liu, G; Sheng, Z, 2016) |
| " Trials comparing efficacy of standard melphalan and prednisone (MP) therapy with MP plus thalidomide (MPT) in transplant-ineligible or elderly patients with multiple myeloma (MM) have provided conflicting evidence." | 8.93 | Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis. ( Ding, ZX; Li, BY; Lyu, WW; Song, DH; Wei, CM; Zhang, JJ; Zhao, QC, 2016) |
| "Pomalidomide, a derivative of thalidomide and member of the immunomodulatory drugs is licenced for use in relapsed and refractory multiple myeloma (RRMM) in Europe, USA, Canada and Japan." | 8.93 | The safety of pomalidomide for the treatment of multiple myeloma. ( Davies, FE; Jones, JR; Morgan, GJ; Pawlyn, C, 2016) |
| "Studies have consistently demonstrated the need for venous thromboembolism (VTE) prophylaxis in patients with newly diagnosed multiple myeloma (NDMM) or relapsed refractory multiple myeloma (RRMM), receiving lenalidomide-based therapy." | 8.93 | Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review. ( Al-Ani, F; Bermejo, JM; Louzada, M; Mateos, MV, 2016) |
| "A 64-year-old man with recurrent multiple myeloma (BJP-κ type) was treated with 15 mg of lenalidomide (LEN) and dexamethasone." | 8.93 | Quincke's edema and hypersensitivity pneumonitis induced by lenalidomide for multiple myeloma. ( Fuchida, SI; Hatsuse, M; Murakami, S; Odaira, E; Okano, A; Shimazaki, C, 2016) |
| "On August 5, 2013, a marketing authorization valid throughout the European Union (EU) was issued for pomalidomide in combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy." | 8.91 | The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use. ( Camarero, J; Flores, B; Gisselbrecht, C; Hanaizi, Z; Hemmings, R; Laane, E; Pignatti, F; Salmonson, T; Sancho-Lopez, A, 2015) |
| "In the last couple of years major progress has been made in the treatment of multiple myeloma (MM) through the introduction of novel agents like thalidomide, lenalidomide, bortezomib and pomalidomide, mostly in combination with autologous stem cell transplantation." | 8.91 | Lenalidomide in multiple myeloma. ( Kim, Y; Schmidt-Wolf, IG, 2015) |
| "The availability of novel drugs with different and innovative mechanisms of action such as proteasome inhibitors such as bortezomib and immunomdulatory agents as thalidomide and lenalidomide have changed the landscape of the treatment of patients with newly diagnosed multiple myeloma, allowing the development of several new therapeutic regimens both for transplant-eligible and -ineligible patients." | 8.91 | Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma. ( Cejalvo, MJ; de la Rubia, J, 2015) |
| "Lenalidomide (Revlimid(®)) is a second-generation immunomodulatory drug structurally related to thalidomide, with improved efficacy and tolerability, for which the label in the EU was recently expanded to include continuous therapy in patients with previously untreated multiple myeloma not eligible for stem-cell transplantation." | 8.91 | Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation. ( McCormack, PL, 2015) |
| "The long-term outcome of multiple myeloma (MM) has been greatly improved through new agents, one being lenalidomide (LEN)." | 8.91 | Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy. ( Kobayashi, T; Kuroda, J; Taniwaki, M, 2015) |
| "Lenalidomide has emerged as an important treatment for patients with multiple myeloma (MM)." | 8.91 | Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials. ( Guo, XN; Qiao, SK; Ren, HY; Ren, JH, 2015) |
| "Lenalidomide , an immunomodulatory agent with unique mechanism of action, represents the cornerstone in the treatment of patients with multiple myeloma (MM) providing rapid and sustained control of the disease with a manageable safety profile." | 8.91 | An update on the use of lenalidomide for the treatment of multiple myeloma. ( Dimopoulos, MA; Kastritis, E; Terpos, E; Zagouri, F, 2015) |
| "Once characterized by a very poor outcome, multiple myeloma (MM) now has a significantly prolonged survival, with major improvements allowed by the use of "novel agents": proteasome inhibitors (first-in-class bortezomib) and immunomodulatory compounds (IMiDs; first-in-class thalidomide and lenalidomide)." | 8.91 | [Pomalidomide for multiple myeloma]. ( Arnulf, B; Benboubker, L; Bories, C; Decaux, O; Demarquette, H; Fohrer, C; Fouquet, G; Guidez, S; Herbaux, C; Hulin, C; Karlin, L; Le Grand, C; Leleu, X; Macro, M; Prodhomme, C; Renaud, L; Roussel, M, 2015) |
| "The aim of the study was to evaluate the clinical efficacy and safety of bortezomib-based regimens for the treatment of multiple myeloma through meta-analysis." | 8.90 | Bortezomib in combination with thalidomide or lenalidomide or doxorubicin regimens for the treatment of multiple myeloma: a meta-analysis of 14 randomized controlled trials. ( Wang, L; Xu, YL; Zhang, XQ, 2014) |
| "The objective of the study was to investigate the effects and safety of novel agents such as bortezomib and lenalidomide in the treatment of newly diagnosed patients with multiple myeloma." | 8.90 | Bortezomib and lenalidomide as front-line therapy for multiple myeloma. ( Lin, M; Niu, S; Sheng, Z; Zou, Y, 2014) |
| "In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM)." | 8.90 | Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. ( Cavo, M; Davies, FE; Delforge, M; Dimopoulos, MA; Facon, T; Hansson, M; Leleu, X; Ludwig, H; Mateos, MV; Miguel, JF; Moreau, P; Morgan, GJ; Palumbo, A; Schey, SA; Sonneveld, P; Weisel, K; Zweegman, S, 2014) |
| "Oral pomalidomide (Imnovid® [EU]; Pomalyst® [USA]) in combination with dexamethasone (in the EU), is approved in several countries for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy (or progression within the last 60 days in the USA)." | 8.90 | Pomalidomide: a review of its use in patients with recurrent multiple myeloma. ( Scott, LJ, 2014) |
| "The pharmacology, pharmacokinetics, clinical efficacy, safety, dosage and administration, and place in therapy of pomalidomide for the management of refractory multiple myeloma are reviewed." | 8.90 | Pomalidomide for the management of refractory multiple myeloma. ( Cole, SW; Olin, JL; Summers, BB, 2014) |
| "Once characterized by a very poor outcome, multiple myeloma (MM) now has a significantly prolonged survival, with major improvements allowed by the use of 'novel agents': proteasome inhibitors (first-in-class bortezomib) and immunomodulatory compounds (IMiDs; first-in-class thalidomide and lenalidomide)." | 8.90 | Pomalidomide for multiple myeloma. ( Bories, C; Facon, T; Fouquet, G; Guidez, S; Herbaux, C; Javed, S; Leleu, X; Renaud, L, 2014) |
| "In recent years, a number of randomized controlled trials (RCTs) have reported on lenalidomide as a treatment for multiple myeloma (MM)." | 8.89 | Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. ( Chi, XH; Lu, XC; Yang, B; Yu, RL, 2013) |
| "Thalidomide, the first clinically available immunomodulatory drug, reaches monotherapy treatment response in about 1/ 3 of significantly pretreated patients with multiple myeloma, and in combination with glucocorticoids approximately 50% response rate." | 8.89 | [Thalidomide in the treatment of multiple myeloma: focus on combination with bortezomib]. ( Gumulec, J; Hájek, R; Plonková, H, 2013) |
| "Although several mechanisms have been proposed to explain the activity of thalidomide, lenalidomide and pomalidomide in multiple myeloma (MM), including demonstrable anti-angiogenic, anti-proliferative and immunomodulatory effects, the precise cellular targets and molecular mechanisms have only recently become clear." | 8.89 | Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. ( Kortuem, KM; Stewart, AK; Zhu, YX, 2013) |
| " Here, we describe a patient with SJS while receiving lenalidomide in combination with prednisolone for treatment-naïve multiple myeloma." | 8.88 | Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options. ( Allegra, A; Alonci, A; Catena, S; D'Angelo, A; Gerace, D; Greve, B; Musolino, C; Penna, G; Russo, S, 2012) |
| "Lenalidomide is an IMiDs® oral immunomodulatory compound developed for the treatment of patients with multiple myeloma (MM) and myelodysplastic syndromes (MDS)." | 8.88 | The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes. ( Fenaux, P; Freeman, J; Palumbo, A; Weiss, L, 2012) |
| "To define whether or not thalidomide exposure upfront to newly diagnosed patients with multiple myeloma would adversely impact postrelapse survival (PRS), we performed a meta-analysis of randomized controlled trials." | 8.88 | Postrelapse survival rate correlates with first-line treatment strategy with thalidomide in patients with newly diagnosed multiple myeloma: a meta-analysis. ( Cui, J; Liu, L; Sheng, Z; Wang, L, 2012) |
| "Lenalidomide in combination with dexamethasone is approved by the US Food and Drug Administration and the European Medicines Agency for the second-line treatment of patients with multiple myeloma." | 8.88 | Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide. ( Esteves, GV; Mariz, JM, 2012) |
| "In a retrospective pooled analysis of 11 clinical trials of lenalidomide-based therapy for relapsed/refractory multiple myeloma (MM; N = 3846), the overall incidence rate (IR, events per 100 patient-years) of second primary malignancies (SPMs) was 3." | 8.88 | A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. ( Brandenburg, N; Dimopoulos, MA; Morgan, GJ; Niesvizky, R; Richardson, PG; Weber, DM; Yu, Z, 2012) |
| "We performed a meta-analysis of randomized controlled trials comparing thalidomide maintenance with other regimens after induction chemotherapy for multiple myeloma." | 8.88 | Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis. ( Kagoya, Y; Kurokawa, M; Nannya, Y, 2012) |
| "The clinical development of lenalidomide (Revlimid™), then pomalidomide (Actimid™) as members of immunomodulatory drugs (IMiDs) for the treatment of multiple myeloma (MM), exemplifies how insight into disease biology can lead to design of effective therapeutic agents." | 8.88 | Lenalidomide in multiple myeloma: Current status and future potential. ( Kalff, A; Quach, H; Spencer, A, 2012) |
| "Lenalidomide is an oral immunomodulatory drug, which was recently introduced for the treatment of multiple myeloma (MM)." | 8.88 | Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma. ( Boccadoro, M; Bringhen, S; Cerrato, C; Gay, F; Palumbo, A; Pautasso, C, 2012) |
| "Currently multiple antithrombotic agents are used for thalidomide thromboprophylaxis in multiple myeloma patients." | 8.88 | Thalidomide thromboprophylaxis in multiple myeloma: a review of current evidence. ( Alexander, M; Kirsa, S; Mellor, JD, 2012) |
| "Trials comparing efficacy of melphalan prednisone (MP) with MP plus thalidomide in transplant ineligible, elderly patients with multiple myeloma have provided conflicting evidence." | 8.87 | Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. ( Dingli, D; Dispenzieri, A; Gertz, MA; Greipp, PR; Kapoor, P; Kumar, S; Kyle, RA; Lacy, MQ; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Roy, V, 2011) |
| "The incidence of venous thromboembolism (VTE) in patients with multiple myeloma (MM) treated with thalidomide- and lenalidomide-based regimens is high." | 8.87 | Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. ( Carrier, M; Le Gal, G; Lee, AY; Tay, J; Wu, C, 2011) |
| "Bortezomib, thalidomide and lenalidomide can be aimed at treating patients with newly diagnosed multiple myeloma (both eligible and ineligible for transplantation) as well as those with relapsed or refractory disease." | 8.87 | The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information. ( Bosi, A; Maratea, D; Messori, A; Nozzoli, C, 2011) |
| "The introduction of new agents in the treatment of multiple myeloma, such as thalidomide, bortezomib, or lenalidomide, has represented an important step forward in the management of this disease, with improvement in both treatment response and patient survival." | 8.87 | Management of the adverse effects of lenalidomide in multiple myeloma. ( González Rodríguez, AP, 2011) |
| "In several countries, including the US and in Europe, oral lenalidomide in combination with oral dexamethasone is approved for the treatment of multiple myeloma patients (aged ≥ 18 years) who have received at least one prior antimyeloma therapy." | 8.87 | Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. ( Lyseng-Williamson, KA; Scott, LJ, 2011) |
| "The role of thalidomide for previously untreated elderly patients with multiple myeloma remains unclear." | 8.87 | Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. ( Beksaç, M; Benboubker, L; Bringhen, S; Caravita, T; Facon, T; Fayers, PM; Gimsing, P; Haznedar, R; Hulin, C; Mary, JY; Moreau, P; Musto, P; Palumbo, A; Schaafsma, M; Sonneveld, P; Termorshuizen, F; Turesson, I; Waage, A; Wijermans, P, 2011) |
| "In several countries, including the US and in Europe, oral lenalidomide in combination with oral dexamethasone is approved for the treatment of multiple myeloma patients (aged ≥18 years) who have received at least one prior antimyeloma therapy." | 8.87 | Spotlight on lenalidomide in relapsed or refractory multiple myeloma. ( Lyseng-Williamson, KA; Scott, LJ, 2011) |
| "lenalidomide is a thalidomide analogue approved for treatment of myelodysplastic syndromes (MDS) associated with a cytogenetic 5q deletion." | 8.86 | The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes. ( Bonkowski, J; Kolesar, JM; Vermeulen, LC, 2010) |
| "Lenalidomide and other new agents are improving survival of multiple myeloma patients." | 8.86 | Lenalidomide in multiple myeloma: current role and future directions. ( Bizzari, JP; Jacques, C; Knight, RD; Tozer, A; Zeldis, JB, 2010) |
| "Lenalidomide is a promising new drug in the treatment of patients with multiple myeloma." | 8.86 | [The use of lenalidomide in the treatment of multiple myeloma]. ( Hájek, R; Holánek, M, 2010) |
| "To estimate the cost-effectiveness of bortezomib (BTZ) compared with dexamethasone (DEX) and lenalidomide plus dexamethasone (LEN/DEX) for the treatment of relapsed/refractory multiple myeloma in Sweden." | 8.86 | The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. ( Aschan, J; Dhawan, R; Hornberger, J; Liwing, J; Löthgren, M; Rickert, J, 2010) |
| "Recent studies have shown a clinical benefit of lenalidomide, an oral immunomodulatory drug, plus dexamethasone in patients with relapsed/refractory multiple myeloma (MM)." | 8.85 | Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. ( Attal, M; Dimopoulos, M; Harousseau, JL; Hussein, M; Knop, S; Ludwig, H; Palumbo, A; San Miguel, J; Sonneveld, P; von Lilienfeld-Toal, M, 2009) |
| "Lenalidomide, a derivate of thalidomide, has recently been approved in Europe for the treatment of patients with multiple myeloma." | 8.84 | Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates. ( Gieseler, F, 2008) |
| "After the tragic events in the early 1960s, thalidomide has re-emerged as therapeutic for multiple myeloma (MM)." | 8.84 | Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity. ( Anderson, KC; Breitkreutz, I, 2008) |
| "Thalidomide monotherapy in relapsed/refractory multiple myeloma (MM) has a response rate of 30%." | 8.84 | A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. ( Bargou, R; Cook, G; Furkert, K; Glasmacher, A; Hahn-Ast, C; Hoffmann, F; Naumann, R; von Lilienfeld-Toal, M, 2008) |
| "Thalidomide represents one of the most relevant therapeutic advances for patients with multiple myeloma over the last 10 years." | 8.84 | Role of thalidomide in previously untreated patients with multiple myeloma. ( Boccadoro, M; Bringhen, S; D'Auria, F; Di Raimondo, F; Morabito, F; Musto, P; Palumbo, A; Pietrantuono, G; Pozzi, S; Sacchi, S, 2008) |
| "Given that the efficacy/safety of thalidomide for relapsed or refractory multiple myeloma have not been well characterized in a randomized, controlled setting, an analysis of larger, single-agent trials was conducted." | 8.84 | An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. ( Mileshkin, L; Prince, HM; Schenkel, B, 2007) |
| "Lenalidomide is a potent, novel thalidomide analog that has demonstrated promising clinical activity in patients with relapsed or refractory multiple myeloma (MM)." | 8.84 | Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma. ( Tariman, JD, 2007) |
| "The pharmacology, clinical use, adverse effects, dosage and administration, and cost of lenalidomide in the treatment of multiple myeloma (MM) are reviewed." | 8.84 | Lenalidomide in the treatment of multiple myeloma. ( Rao, KV, 2007) |
| "We presented a patient suffered from stroke related to thalidomide therapy." | 8.84 | [Brief report: stroke in multiple myeloma patient treated with thalidomide]. ( Hashimoto, Y; Hirano, T; Ito, Y; Mori, A; Uchino, M; Yonemura, K, 2007) |
| "Thalidomide is now regarded as one of the most promising salvage therapies for refractory or relapsed multiple myeloma." | 8.84 | [Application and safety of thalidomide in the treatment of multiple myeloma]. ( Hattori, Y, 2007) |
| "The proteasome inhibitor bortezomib is approved for the treatment of patients with relapsed/refractory multiple myeloma." | 8.84 | [Role of bortezomib in the treatment of multiple myeloma]. ( Gotoh, A; Ohyashiki, K, 2007) |
| " The risk of VTE is higher in multiple myeloma (MM) patients who receive thalidomide or lenalidomide, especially in combination with dexamethasone or chemotherapy." | 8.84 | Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. ( Anderson, KC; Attal, M; Barlogie, B; Belch, A; Bladé, J; Boccadoro, M; Bringhen, S; Cavo, M; Dimopoulos, MA; Durie, BG; Harousseau, J; Hussein, MA; Joshua, D; Knop, S; Kyle, R; Lonial, S; Ludwig, H; Morgan, GJ; Niesvizky, R; Orlowski, RZ; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Shimizu, K; Sonneveld, P; Vesole, D; von Lilienfeld-Toal, M; Waage, A; Weber, D; Westin, J; Zangari, M; Zonder, JA, 2008) |
| "To evaluate lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome (MDS)." | 8.83 | Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome. ( Hammond, JM; Maier, SK, 2006) |
| "The activity of thalidomide in relapsed or refractory multiple myeloma is widely accepted but not yet demonstrated in a randomised-controlled trial." | 8.83 | A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. ( Glasmacher, A; Goldschmidt, H; Gorschlüter, M; Hahn, C; Hoffmann, F; Naumann, R; Orlopp, K; Schmidt-Wolf, I; von Lilienfeld-Toal, M, 2006) |
| "Although multiple myeloma (MM) is incurable with currently available treatments, the introduction of thalidomide and the development of safer and more active thalidomide analogues represent a major advance in the therapy of this disease." | 8.83 | Thalidomide and lenalidomide in the treatment of multiple myeloma. ( Kumar, S; Rajkumar, SV, 2006) |
| "Thalidomide has been demonstrated to be active as a first-line and salvage therapy in patients with multiple myeloma." | 8.83 | The role of thalidomide in multiple myeloma. ( Jagannath, S; Schwab, C, 2006) |
| "Thalidomide was introduced in the treatment of multiple myeloma in the late 1990s." | 8.83 | Thalidomide in multiple myeloma: past, present and future. ( Harousseau, JL, 2006) |
| "To evaluate the literature regarding the dosing of thalidomide in multiple myeloma." | 8.82 | Thalidomide dosing in patients with relapsed or refractory multiple myeloma. ( Hansen, LA; Thompson, JL, 2003) |
| "Both thalidomide and intermittent high-dose dexamethasone are agents with established activity against multiple myeloma." | 8.82 | Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. ( Alexanian, R; Anagnostopoulos, A; Delasalle, K; Rankin, K; Wang, M; Weber, D, 2003) |
| "Recently completed phase II trials and retrospective analyses conducted outside the United States, primarily in Europe and Australia, have confirmed results of landmark US trials that established the efficacy of thalidomide in multiple myeloma." | 8.82 | Thalidomide in relapsed/refractory multiple myeloma: pivotal trials conducted outside the United States. ( Anagnostopoulos, A; Dimopoulos, MA, 2003) |
| "Based on the activity of single-agent thalidomide demonstrated in relapsed or refractory multiple myeloma, investigators have evaluated the role of this agent in the treatment of earlier stage disease." | 8.82 | Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease. ( Rajkumar, SV, 2003) |
| "Based on the activity of single-agent thalidomide in relapsed/refractory multiple myeloma in a landmark phase II study of 169 patients conducted at the University of Arkansas for Medical Sciences (UAMS), UAMS initiated several trials of thalidomide and the more potent thalidomide analog CC-5013." | 8.82 | Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience. ( Barlogie, B, 2003) |
| "We report the case of a 54-year-old African-American male with IgG multiple myeloma (MM) with disease resistant to multiple chemotherapy regimens and immunomodulatory treatment with thalidomide." | 8.82 | Unusual cutaneous involvement during plasma cell leukaemia phase in a multiple myeloma patient after treatment with thalidomide: a case report and review of the literature. ( Alexandrescu, DT; Koulova, L; Wiernik, PH, 2005) |
| "Thalidomide--banned from clinical use in the 1960s because of severe teratogenicity--is now back in clinical practice as an effective agent in the treatment of relapsed and refractory multiple myeloma." | 8.81 | Thalidomide in the treatment of multiple myeloma. ( Rajkumar, SV, 2001) |
| "Thalidomide is the first drug in over 20 years to demonstrate clinically significant activity in patients with multiple myeloma." | 8.81 | Thalidomide for the treatment of relapsed and refractory multiple myeloma. ( Cool, RM; Herrington, JD, 2002) |
| "Thalidomide was first evaluated in patients with refractory multiple myeloma in the mid-90s." | 8.81 | Thalidomide treatment in multiple myeloma. ( Ludwig, H; Strasser, K, 2002) |
| "The discovery that multiple myeloma is associated with new vessel formation and is correlated with survival and proliferation led initially to the use of thalidomide for patients with relapsed or refractory disease." | 8.81 | Thalidomide in the management of multiple myeloma. ( Schey, SA, 2002) |
| "Thalidomide has recently been shown to have significant activity in refractory multiple myeloma (MM)." | 8.81 | Thalidomide in the management of multiple myeloma. ( Anaissie, E; Badros, A; Barlogie, B; Cromer, J; Fassas, A; Spencer, T; Tricot, G; Zangari, M, 2001) |
| "A phase II trial of thalidomide in refractory multiple myeloma was initiated using a dose schedule that escalated from 200 mg/d to 800 mg/d." | 8.81 | Thalidomide in the management of multiple myeloma. ( Anaissie, E; Barlogie, B; Tricot, G, 2001) |
| "Treatment with thalidomide and dexamethasone was given to 26 patients with active, previously untreated multiple myeloma (MM)." | 8.81 | Therapeutic application of thalidomide in multiple myeloma. ( Kyle, RA; Rajkumar, SV, 2001) |
| "Objective To evaluate the safety profile of ixazomib combined with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) in clinical practice in Japan through an all-case post-marketing surveillance." | 8.12 | Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance. ( Chou, T; Hashimoto, M; Hiraizumi, M; Hoshino, M; Kakimoto, Y; Shimizu, K, 2022) |
| "Biomarkers that predict response to lenalidomide maintenance therapy in patients with multiple myeloma (MM) have remained elusive." | 8.12 | MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma. ( Bassermann, F; Bertsch, U; Eichner, R; Emde-Rajaratnam, M; Goldschmidt, H; Heider, M; Hose, D; Keller, U; Rudelius, M; Salwender, H; Scheid, C; Schick, M; Seckinger, A; Slawska, J; Stroh, J; Weisel, K, 2022) |
| "In the phase 3 APOLLO trial, daratumumab in combination with pomalidomide and dexamethasone (D-Pd) significantly reduced the rate of disease progression or death by 37% relative to Pd alone in patients with relapsed/refractory multiple myeloma (RRMM) who had received ≥1 prior line of therapy including lenalidomide and a proteasome inhibitor." | 8.12 | Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial. ( Amin, H; Beksac, M; Bila, J; Boccadoro, M; Carson, R; Delimpasi, S; Dimopoulos, MA; Einsele, H; Fastenau, J; Gries, KS; He, J; Kampfenkel, T; Katodritou, E; Liu, K; Mateos, MV; Moreau, P; Orfanidis, I; Oriol, A; Pompa, A; Qiu, Y; Sonneveld, P; Symeonidis, A; Terpos, E, 2022) |
| "In cohort C of the phase 2 MM-014 trial, the efficacy and safety of pomalidomide, dexamethasone, and daratumumab therapy were investigated in 18 Japanese patients with relapsed/refractory multiple myeloma (RRMM) after their most recent regimen of lenalidomide-based therapy (NCT01946477)." | 8.12 | Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment. ( Chung, W; Iida, S; Iwasaki, H; Kuroda, J; Kuwayama, S; Lee, K; Matsue, K; Matsumoto, M; Nishio, M; Sugiura, I; Sunami, K, 2022) |
| "The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple myeloma (RRMM)." | 8.12 | Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials. ( Antonioli, E; Ballanti, S; Belotti, A; Boccadoro, M; Bonalumi, A; Botta, C; Bringhen, S; Brunori, M; Bruzzese, A; Califano, C; Cascavilla, N; Cavo, M; Cerchione, C; Consoli, U; Conticello, C; Criscuolo, C; Cupelli, L; Curci, P; De Stefano, V; Derudas, D; Di Raimondo, F; Di Renzo, N; Farina, G; Frigeri, F; Gagliardi, A; Galli, M; Gamberi, B; Gangemi, D; Gentile, M; Giuliani, N; Iaccino, E; Lombardo, A; Mangiacavalli, S; Marcacci, G; Martino, EA; Martino, M; Mele, G; Mendicino, F; Mimmi, S; Morabito, F; Musto, P; Neri, A; Offidani, M; Palmieri, S; Palumbo, G; Patriarca, F; Petrucci, MT; Pietrantuono, G; Pompa, A; Ria, R; Rocco, S; Rossi, E; Sgherza, N; Stocchi, R; Tripepi, G; Uccello, G; Vigna, E; Vincelli, D; Zamagni, E; Zambello, R, 2022) |
| "In the pivotal phase III, randomized, multicenter ICARIA-MM study (NCT02990338), isatuximab plus pomalidomide and dexamethasone (Isa-Pd) improved progression-free survival and overall response rate versus pomalidomide and dexamethasone (Pd) in the overall population of patients with relapsed/refractory multiple myeloma." | 8.12 | Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis. ( Campana, F; Huang, SY; Iida, S; Ikeda, T; Iyama, S; Kaneko, H; Kim, JS; Kim, K; Koh, Y; Lee, JH; Lin, TL; Matsumoto, M; Min, CK; Shimazaki, C; Sunami, K; Suzuki, K; Tada, K; Uchiyama, M; Wang, MC; Yeh, SP, 2022) |
| "Lenalidomide is a synthetic analog of thalidomide formed by the removal of one keto group (plus the addition of an amino group); it has anti-tumor activities beneficial for the treatment of hematologic malignancies." | 8.12 | Low cerebrospinal fluid-to-plasma ratios of orally administered lenalidomide mediated by its low cell membrane permeability in patients with hematologic malignancies. ( Ando, K; Kamiya, Y; Machida, S; Murayama, N; Ogiya, D; Saito, R; Shiraiwa, S; Suzuki, R; Tazume, K; Yamazaki, H, 2022) |
| "The phase 3 APOLLO study demonstrated significantly better progression-free survival (PFS) and clinical responses with daratumumab, pomalidomide, and dexamethasone (D-Pd) versus pomalidomide and dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM)." | 8.12 | Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma. ( Bathija, S; Berringer, H; Dwarakanathan, HR; He, J; Heeg, B; Johnston, S; Kampfenkel, T; Lam, A; Mackay, E; Mendes, J; Ruan, H, 2022) |
| "Lenalidomide (LEN) is increasingly being used for the treatment of multiple myeloma (MM)." | 8.02 | Delayed-onset cutaneous eruption associated with lenalidomide in setting of multiple myeloma. ( Buonomo, M; El Jurdi, N; Giubellino, A; Kabbur, G; Schultz, B, 2021) |
| " Here we demonstrated that DC vaccination in combination with pomalidomide and programmed death-ligand 1 (PD-L1) blockade inhibited tumor growth of a multiple myeloma (MM) mouse model." | 8.02 | Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma. ( Chu, TH; Jung, SH; Kim, HJ; Lakshmi, TJ; Lee, JJ; Park, HS; Vo, MC, 2021) |
| "The immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide are approved drugs for the treatment of multiple myeloma." | 8.02 | Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn ( Beilhack, A; Brandl, A; Köpff, S; Krönke, J; Lindner, S; Ng, YLD; Röhner, L; Scheffold, A, 2021) |
| "Lenalidomide is an important component of initial therapy in newly diagnosed multiple myeloma, either as maintenance therapy post-autologous stem cell transplantation (ASCT) or as first-line therapy with dexamethasone for patients' ineligible for ASCT (non-ASCT)." | 8.02 | Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada. ( Aslam, M; Atenafu, EG; Cherniawsky, H; Gul, E; Jimenez-Zepeda, VH; Kotb, R; LeBlanc, R; Louzada, ML; Masih-Khan, E; McCurdy, A; Reece, DE; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D, 2021) |
| "This study compared the use of bortezomib in different combination regimens in newly diagnosed multiple myeloma (NDMM) patients who were transplant ineligible." | 8.02 | Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. ( Brožová, L; Hájek, R; Heindorfer, A; Jelínek, T; Jungová, A; Kessler, P; Maisnar, V; Minařík, J; Pavlíček, P; Pika, T; Pour, L; Radocha, J; Sandecká, V; Ševčíková, S; Špička, I; Starostka, D; Stejskal, L; Štork, M; Straub, J; Sýkora, M; Ullrychová, J; Wróbel, M, 2021) |
| "This trial evaluated quality of life (QoL) using the EORTC QLQ-C30 and the EORTC QLQ-MY20 instruments in 90 patients with relapsed/refractory multiple myeloma during induction and maintenance therapy with eight cycles of ixazomib-thalidomide-dexamethasone, followed by 12 months of ixazomib maintenance therapy." | 7.96 | Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. ( Egle, A; Einsele, H; Greil, R; Gunsilius, E; Hajek, R; Hinke, A; Jelinek, T; Knop, S; Krenosz, KJ; Lechner, D; Ludwig, H; Meckl, A; Melchardt, T; Niederwieser, D; Nolte, S; Petzer, A; Pönisch, W; Pour, L; Rumpold, H; Schreder, M; Weisel, K; Willenbacher, W; Zojer, N, 2020) |
| "For patients with multiple myeloma (MM) that relapsed after treatment with bortezomib- and lenalidomide-based regimens, there were no other treatment options in Korea until 2016." | 7.96 | Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study. ( Eom, HS; Jung, KS; Kim, HJ; Kim, JS; Kim, K; Kim, SH; Lee, JJ; Lee, JO; Min, CK; Shin, HJ, 2020) |
| " Argentinean Society of Hematology recommends bortezomib-based triplets for induction treatment of transplant eligible newly diagnosed multiple myeloma patients." | 7.96 | Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentin ( Corzo, A; Duarte, P; Fantl, D; Fernández, V; García, CA; Lopresti, S; Ochoa, P; Orlando, S; Quiroga, L; Remaggi, G; Schütz, NP; Shanley, C; Verri, V; Yantorno, S; Zabaljauregui, S, 2020) |
| "In the randomized phase-3 OPTIMISMM study, the addition of pomalidomide to bortezomib and low-dose dexamethasone (PVd) resulted in significant improvement in progression-free survival (PFS) in lenalidomide-pretreated patients with relapsed or refractory multiple myeloma (RRMM), including lenalidomide refractory patients." | 7.96 | Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. ( Anttila, P; Basu, S; Ben-Yehuda, D; Biyukov, T; Byeff, P; Cascavilla, N; Dhanasiri, S; Dimopoulos, M; Grote, L; Guo, S; Hayden, PJ; Hus, M; Johnson, P; Kanate, AS; Krauth, MT; Larocca, A; Lucio, P; Mendeleeva, L; Moreau, P; Muelduer, E; Richardson, P; Rodríguez-Otero, P; Vural, F; Weisel, K; Yagci, M; Yu, X, 2020) |
| "Although there are several case reports of progressive multifocal leukoencephalopathy (PML) in multiple myeloma (MM), there are few reports of cases associated with pomalidomide." | 7.96 | Pomalidomide-associated progressive multifocal leukoencephalopathy in multiple myeloma: cortical susceptibility-weighted imaging hypointense findings prior to clinical deterioration. ( Ichinohe, T; Ishibashi, H; Kikumto, M; Maruyama, H; Nakamichi, K; Saijo, M; Takahashi, T; Takebayashi, Y; Ueno, H; Umemoto, K; Yasutomi, H, 2020) |
| " The aim of the study was to assess the value of NLR and PLR in predicting the effects of therapy and prognosis in multiple myeloma patients treated with thalidomide-based regimen." | 7.96 | Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen. ( Filip, A; Homa-Mlak, I; Hus, M; Kuśmierczuk, K; Małecka-Massalska, T; Mielnik, M; Mlak, R; Nowaczyńska, A; Sompor, J; Szczyrek, M; Szudy-Szczyrek, A; Zmorzyński, S, 2020) |
| "Lenalidomide is a backbone agent in the treatment of multiple myeloma, but dose adjustment is required for those with renal impairment (RI)." | 7.96 | An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines. ( Cao, Y; Chen, CI; Chen, E; Chen, H; Kakar, S; Kukreti, V; Lau, A; Le, LW; Levina, O; Paul, H; Prica, A; Reece, DE; Tiedemann, R; Trudel, S, 2020) |
| "To compare the efficacy and side effect profile of different bortezomib-based triplet regimens for remission induction in patients with multiple myeloma (MM)." | 7.96 | Bortezomib-based Triplet Regimens for Remission Induction in Multiple Myeloma. ( Iftikhar, R; Mahmood, SK; Rehman, JU; Satti, TM; Shamshad, GU; Toor, SH, 2020) |
| "We investigated here the novel immunomodulation and anti-multiple myeloma (MM) function of T cells engaged by the bispecific T-cell engager molecule AMG 701, and further examined the impact of AMG 701 in combination with immunomodulatory drugs (IMiDs; lenalidomide and pomalidomide)." | 7.96 | The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. ( Anderson, KC; Arvedson, T; Cho, SF; Friedrich, M; Hsieh, PA; Li, Y; Lin, L; Matthes, K; Munshi, N; Tai, YT; Wahl, J; Wen, K; Xing, L; Yu, T, 2020) |
| "Addition of daratumumab to pomalidomide and low-dose dexamethasone (LoDEX) is a safe and effective combination for relapsed/refractory multiple myeloma treatment." | 7.96 | Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma. ( Agarwal, A; Amatangelo, MD; Bahlis, NJ; Chung, W; Neri, P; Parekh, S; Pierceall, WE; Rahman, A; Serbina, N; Siegel, DS; Thakurta, A; Van Oekelen, O; Young, M, 2020) |
| "Thalidomide-and bortezomib-containing regimens are widely used for transplant-ineligible newly diagnosed multiple myeloma patients." | 7.91 | Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up. ( Adam, Z; Boichuk, I; Brozova, L; Krejci, M; Pour, L; Sandecká, V; Sevcikova, S; Stork, M, 2019) |
| "Lenalidomide and pomalidomide are two immunomodulatory medications with the potential to improve outcomes for patients with multiple myeloma; however, a black box warning for venous thromboembolism exists." | 7.91 | Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma. ( Anderson, SM; Beck, B; Lockhorst, R; Ngorsuraches, S; Sterud, S, 2019) |
| "We analyzed gene expression levels of CRBN, cMYC, IRF4, BLIMP1, and XBP1 in 224 patients with multiple myeloma treated with pomalidomide and low-dose dexamethasone in the STRATUS study (ClinicalTrials." | 7.91 | Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS. ( Amatangelo, M; Bjorklund, C; Dimopoulos, MA; Flynt, E; Moreau, P; Ocio, EM; Peluso, T; Qian, X; Sternas, L; Thakurta, A; Towfic, F; Weisel, KC; Yu, X; Zaki, M, 2019) |
| " Carfilzomib (Kyprolis™) is a new proteasome inhibitor that shows promise for the treatment of relapsing multiple myeloma." | 7.91 | Apremilast ameliorates carfilzomib-induced pulmonary inflammation and vascular injuries. ( Al-Harbi, MM; Al-Harbi, NO; Alanazi, AZ; Alhazzani, K; Aljerian, K; Alsanea, S; Belali, OM; Imam, F; Qamar, W, 2019) |
| "In conclusion, pomalidomide and dexamethasone has limited efficacy in patients with advanced MM and soft-tissue plasmacytomas." | 7.91 | Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma. ( Abella, E; Bladé, J; Cabezudo, E; Cibeira, MT; Clapés, V; Escoda, L; Fernández de Larrea, C; García-Guiñón, A; Gironella, M; Granell, M; Isola, I; Jiménez-Segura, R; López-Pardo, J; Oriol, A; Rosiñol, L; Soler, JA; Tovar, N, 2019) |
| "Pomalidomide dexamethasone is a standard of care for relapsed multiple myeloma (MM) patients who received at least two prior lines of therapy, including both lenalidomide and proteasome inhibitors (PI)." | 7.91 | Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study. ( Blin, N; Bonnet, A; Chevallier, P; Dubruille, V; Garnier, A; Gastinne, T; Guillaume, T; Jullien, M; Le Bourgeois, A; Le Gouill, S; Lok, A; Mahé, B; Moreau, P; Peterlin, P; Tessoulin, B; Touzeau, C; Trudel, S, 2019) |
| "Thalidomide is commonly used in treatment of multiple myeloma (MM)." | 7.91 | Polymorphisms in the promotor region of the CRBN gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients. ( Chocholska, S; Homa-Mlak, I; Hus, M; Jankowska-Łęcka, O; Mazurek, M; Małecka-Massalska, T; Mielnik, M; Mlak, R; Szczyrek, M; Szudy-Szczyrek, A, 2019) |
| "Bortezomib in combination with cyclophosphamide and dexamethasone (CyBorD, is a well-established frontline chemotherapy regimen for patients with multiple myeloma, but prospective data on elderly non-transplant eligible patients is limited." | 7.91 | Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data. ( Chai, K; Chan, H; Chen, K; Jackson, S; Lewsey, R; McDiarmid, B; Shih, S; Simpson, D, 2019) |
| "This phase Ib study evaluated oprozomib, an oral proteasome inhibitor, plus pomalidomide-dexamethasone in relapsed/refractory multiple myeloma (RRMM)." | 7.91 | Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma. ( Berdeja, JG; Berenson, JR; Chang, YL; Klippel, Z; Lyons, RM; Niesvizky, R; Rifkin, RM; Shah, J; Stadtmauer, EA; Usmani, S, 2019) |
| "The FIRST trial demonstrated that continuous therapy with lenalidomide and dexamethasone (Rd) prolongs overall survival (OS) and improves health-related quality of life (HRQoL) during the first 18 months of therapy in newly diagnosed multiple myeloma (NDMM) patients." | 7.88 | Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone. ( Delforge, M; Ervin-Haynes, A; Facon, T; Gibson, CJ; Guo, S; Song, K; Vogl, DT, 2018) |
| "Daratumumab (a human CD38-directed monoclonal antibody) and pomalidomide (an immunomodulatory drug) plus dexamethasone are both relatively new treatment options for patients with heavily pretreated multiple myeloma." | 7.88 | Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison. ( Belch, A; Diels, J; Ito, T; Oriol, A; Van Sanden, S; Vogel, M, 2018) |
| "Determinants of the efficacy and safety of pomalidomide (POM) monotherapy or POM plus dexamethasone (DEX) (POM/DEX) for relapsed and refractory multiple myeloma (RRMM) were examined retrospectively in a real-world clinical practice setting in Japan." | 7.88 | Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum. ( Fuchida, SI; Hino, M; Iida, M; Imada, K; Ishikawa, J; Kamitsuji, Y; Kanakura, Y; Kaneko, H; Kobayashi, M; Kosugi, S; Kuroda, J; Matsuda, M; Matsui, T; Matsumura, I; Matsumura-Kimoto, Y; Nakaya, A; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Takaori-Kondo, A; Tanaka, H; Uchiyama, H; Uoshima, N; Wada, K; Yagi, H; Yokota, I, 2018) |
| "To investigate the efficacy, safety, and cost of a pomalidomide-dexamethasone regimen in patients with relapsed and refractory multiple myeloma (RRMM)." | 7.88 | Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma. ( Aho, LS; Boulin, M; Caillot, D; Chretien, ML; Cransac-Miet, A; Favennec, C; Gueneau, P; Guy, J; Lafon, I, 2018) |
| "We presented a very rare case report describing the successful treatment of LCDD (λ chain)-induced nephrotic syndrome with lenalidomide." | 7.88 | Successful treatment of nephrotic syndrome induced by lambda light chain deposition disease using lenalidomide: A case report and review of the literature . ( Mima, A; Nagahara, D; Tansho, K, 2018) |
| "To explore the effects of thalidomide on the ratio of Th17 to Treg cells in peripheral blood and expression of IL-17 and IL-35 in patients with multiple myeloma(MM), so as to provide reference for the clinical treatment of patients with MM." | 7.88 | [Effects of Thalidomide on the Ratio of Th17 to Treg Cells in Peripheral Blood and Expression of IL-17 and IL-35 in Patients with Multiple Myeloma]. ( Gao, S; Li, X; Zhao, LJ, 2018) |
| "We performed analyses of the randomized phase 3 ASPIRE and ENDEAVOR trials to investigate the efficacy of carfilzomib among subgroups of relapsed or refractory multiple myeloma patients who had early or late disease relapse following initiation of the immediately prior therapy." | 7.88 | Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. ( Blaedel, J; DeCosta, L; Goldschmidt, H; Leleu, X; Mateos, MV; Mikhael, J; Obreja, M; San-Miguel, J; Szabo, Z; Zhou, L, 2018) |
| "The successful dexamethasone-free regimen clearly shows that dexamethasone is not a requisite component in treating multiple myeloma, and it can be substituted with clarithromycin." | 7.88 | A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report. ( Hoshino, K; Imai, G; Kojima, M; Ooi, A; Takemori, N, 2018) |
| "Lenalidomide, a thalidomide analogue, is an immunomodulatory drug currently used as a chemotherapeutic agent in treating certain hematologic malignancies, including multiple myeloma." | 7.88 | Severe Renal Allograft Rejection Resulting from Lenalidomide Therapy for Multiple Myeloma: Case Report. ( Adey, DB; Jen, KY; Laszik, ZG; Walavalkar, V, 2018) |
| "To study the clinical efficacy and safety of dexamethasone of different doses combined with bortezomib and thalidomide for treatment of primary multiple myeloma." | 7.88 | [Clinical Efficacy and Safety of Different Doses of Dexamethasone Combined with Bortezomib and Thalidomide for Treating Patients with Multiple Myeloma]. ( Fu, LP; Ji, Y; Li, CS; Zhang, WP, 2018) |
| " Current National Comprehensive Cancer Network guidelines give bortezomib-based combinations a central role in the management of multiple myeloma (MM)." | 7.88 | Bortezomib Prescription Pattern for the Treatment of Multiple Myeloma by Hematologists in Nigeria. ( Korubo, KI; Madu, AJ; Nwogoh, B; Okoye, HC, 2018) |
| "To evaluate the therapeutic effect and adverse reactions of the maintenance therapies with Thalidomine or Bortezomib in the patients with newly diagnosed multiple myeloma (MM), so as to provide a reference for clinical treatment." | 7.88 | [Clinical Analysis of Maintenance Therapy with Thalidomine and Bortezomib for Multiple Myeloma]. ( Wang, CY; Wang, L; Wang, XF; Wang, YF; Xia, B; Xu, YJ; Yang, HL; Yu, Y; Zhang, YZ; Zhao, HF, 2018) |
| "Lenalidomide has a central role in the treatment of multiple myeloma and results in improved survival." | 7.85 | Hepatitis E during lenalidomide treatment for multiple myeloma in complete remission. ( Faber, LM; Kootte, RS, 2017) |
| "Lenalidomide (LEN) acts directly on multiple myeloma (MM) cells by inducing cereblon-mediated degradation of interferon regulatory factor 4, Ikaros (IKZF)1 and IKZF3, transcription factors that are essential for MM cell survival." | 7.85 | MUC1-C is a target in lenalidomide resistant multiple myeloma. ( Anderson, K; Avigan, D; Gali, R; Hideshima, T; Kufe, D; Tagde, A; Tai, YT; Yin, L, 2017) |
| "Lenalidomide is an immunomodulatory drug administered orally in the treatment of multiple myeloma." | 7.85 | Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World Experience. ( Azuma, Y; Fujita, S; Hotta, M; Ishii, K; Ito, T; Nakanishi, T; Nakaya, A; Nomura, S; Satake, A; Tsubokura, Y; Yoshimura, H, 2017) |
| "Pomalidomide plus low-dose dexamethasone (POM-d), daratumumab monotherapy (DARA), and carfilzomib monotherapy (CAR) have been approved for use in the treatment of patients with heavily pretreated relapsed-refractory multiple myeloma (RRMM) in the US, based on findings from the MM-002, SIRIUS, and PX-171-003-A1 studies, respectively." | 7.85 | Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States. ( Abouzaid, S; Ailawadhi, S; Chandler, C; Guo, S; Mouro, J; Parikh, K; Pelligra, CG, 2017) |
| "The role of thalidomide in induction and long-term maintenance therapy in patients with multiple myeloma not eligible for stem cell transplantation remains unclear." | 7.85 | Evaluation of low-dose thalidomide as induction and maintenance therapy in patients with multiple myeloma not eligible for stem cell transplantation. ( Aznab, M; Moieni, A; Navabi, J; Rezaei, M, 2017) |
| "Risk of subsequent primary malignancies (SPMs) associated with lenalidomide therapy in multiple myeloma (MM) patients, outside the context of melphalan-based therapy is not established." | 7.85 | Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide. ( Alsina, M; Baz, R; Dalton, W; Fisher, K; Fulp, W; Hampras, S; Kenvin, L; Knight, R; Komrokji, R; Lee, JH; Nishihori, T; Olesnyckyj, M; Rollison, DE; Shain, KH; Sullivan, D; Xu, Q, 2017) |
| "In the UK, the standard of care for patients with multiple myeloma who received ≥2 prior treatments is lenalidomide plus dexamethasone (LEN + DEX) and pomalidomide plus DEX (POM + DEX) (in Wales only)." | 7.85 | Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data. ( Gray, E; Krishna, A; Majer, I; Polanyi, Z; Roy, A; van de Wetering, G, 2017) |
| "Bortezomib- and thalidomide-based therapies have significantly contributed to improved survival of multiple myeloma (MM) patients." | 7.85 | Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array. ( Alcoceba, M; Barrio, S; Blanchard, MJ; Chillon, MC; Corchete, LA; de la Rubia, J; García-Álvarez, M; García-Sanz, R; González Díaz, M; Jiménez, C; Lahuerta, JJ; Martínez, R; Martínez-López, J; Mateos, MV; Oriol, A; Prieto, I; Puig, N; Rapado, I; San Miguel, JF; Sarasquete, ME, 2017) |
| "The proteasome inhibitor carfilzomib is highly effective in the treatment of multiple myeloma." | 7.85 | Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. ( Bhutani, M; Burton, D; Calvo, KR; Carter, G; Costello, R; de Larrea, CF; Figg, WD; Gil, LA; Kazandjian, D; Korde, N; Kwok, M; Lamping, L; Landgren, O; Manasanch, EE; Maric, I; Mulquin, M; Roschewski, M; Steinberg, SM; Stetler-Stevenson, M; Tageja, N; Wu, P; Yuan, C; Zingone, A; Zuchlinski, D, 2017) |
| "To investigate the safety and efficacy of the combination regimen vincristine, cyclophosphamide, melphalan or mitoxantrone and prednisone (VCMP) plus thalidomide as first-line induction therapy for newly diagnosed multiple myeloma (MM)." | 7.85 | Therapeutic experience of vincristine/cyclophosphamide/melphalan or mitoxantrone/prednisone combination therapy plus thalidomide as first-line induction therapy for newly diagnosed multiple myeloma in a single institution of China. ( Guo, C; He, P; Sun, C; Wang, X; Zhang, M, 2017) |
| "Lenalidomide in combination with dexamethasone (Len-dex) represents a highly effective treatment in relapsed/refractory multiple myeloma (RRMM) patients." | 7.85 | Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients. ( Atenafu, EG; Chen, C; Chu, CM; Kotchetkov, R; Kukreti, V; Masih-Khan, E; Reece, DE; Tiedemann, R; Trudel, S, 2017) |
| "The comparative effectiveness of thalidomide and lenalidomide in the treatment of multiple myeloma has not been established." | 7.85 | Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study. ( Avorn, J; Gagne, JJ; Kesselheim, AS; Landon, J; Luo, J, 2017) |
| "We analyzed the treatment responses, toxicities, and survival outcomes of patients with relapsed or refractory multiple myeloma who received daily thalidomide, cyclophosphamide, and dexamethasone (CTD) or daily thalidomide, melphalan, and prednisolone (MTP) at 17 medical centers in Korea." | 7.85 | Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. ( Choi, YS; Eom, HS; Han, JJ; Kang, HJ; Kim, HJ; Kim, K; Kim, MK; Kim, SH; Kwon, J; Lee, JH; Lee, JJ; Lee, JO; Lee, WS; Min, CK; Moon, JH; Yoon, DH; Yoon, SS, 2017) |
| "New classes of drugs including the proteasome inhibitors (PI) bortezomib and, more recently, carfilzomib and the immunomodulatory agent lenalidomide have shown improved outcomes for multiple myeloma (MM) patients during the past decade." | 7.85 | Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib. ( Berenson, A; Berenson, JR; David, M; Eades, B; Eshaghian, S; Gottlieb, J; Halleluyan, R; Harutyunyan, NM; Nassir, Y; Spektor, TM; Swift, R; Udd, KA; Vardanyan, S; Wang, J, 2017) |
| "We present the case of a 70-year-old man diagnosed with multiple myeloma in 2008, who after four therapy lines initiated a fifth-line treatment with pomalidomide (4 mg orally, days 1-21 of a 28-day cycle) and low-dose dexamethasone (40 mg weekly orally)." | 7.85 | Pomalidomide in heavily pretreated refractory multiple myeloma: a case report. ( Asproni, R; Latte, G; Monne, M; Murineddu, M; Palmas, A; Piras, G; Stradoni, R; Uras, A, 2017) |
| "Here we discuss the case of a heavily pretreated male patient with relapsed-refractory multiple myeloma and previous monoclonal gammopathy of undetermined significance who initiated a fifth-line treatment with pomalidomide (4 mg orally, days 1-21 of a 28-day cycle) and low-dose dexamethasone (40 mg weekly orally)." | 7.85 | Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma. ( Ancora, F; Calafiore, V; Consoli, ML; Conticello, C; Di Raimondo, F; La Fauci, A; Parisi, M; Romano, A, 2017) |
| "On November 30, 2015, the FDA approved elotuzumab (Empliciti; Bristol-Myers Squibb) in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who received one to three prior therapies." | 7.85 | FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma. ( Deisseroth, A; Farrell, AT; Goldberg, KB; Gormley, NJ; Kaminskas, E; Ko, CW; Kormanik, N; Nie, L; Pazdur, R, 2017) |
| "Pomalidomide is an analog of thalidomide with immunomodulatory, anti-angiogenic, and anti-neoplastic activity indicated for the treatment of multiple myeloma refractory to at least two prior therapies." | 7.83 | A case of acute kidney injury from crystal nephropathy secondary to pomalidomide and levofloxacin use. ( Babalola, O; Baird, P; Devoe, CE; Hoang, H; Jhaveri, KD; Leung, S; Wanchoo, R, 2016) |
| "We describe the case of a 54-year-old woman with relapse of multiple myeloma 3 years after myeloablative allogeneic stem cell transplant who developed abdominal pain and bloody diarrhea following 7 months of lenalidomide therapy." | 7.83 | Ischemic colitis diagnosed by magnetic resonance imaging during lenalidomide treatment in a patient with relapsed multiple myeloma. ( Bucalossi, A; Cioffi Squitieri, N; Guerrini, S; Mazzei, FG; Mazzei, MA; Volterrani, L, 2016) |
| "To conduct a cost-effectiveness assessment of lenalidomide plus dexamethasone (Rd) vs bortezomib plus melphalan and prednisone (VMP) as initial treatment for transplant-ineligible patients with newly-diagnosed multiple myeloma (MM), from a U." | 7.83 | Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma. ( Basu, S; Belch, AR; Berger, A; Binder, G; Cavenagh, JD; Ervin-Haynes, A; Facon, T; Gibson, CJ; Guo, S; Hulin, C; Nagarwala, Y; Nooka, A; Pelligra, CG; Usmani, SZ; White, D; Yiu, W, 2016) |
| "The aim of the multi-centre retrospective study was to evaluate the efficacy and safety of lenalidomide (LEN) therapy in patients with resistant or relapsed multiple myeloma (MM) as well as in patients with stable disease (LEN used due to neurological complications)." | 7.83 | Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients--Report of the Polish Myeloma Group. ( Becht, R; Bołkun, Ł; Butrym, A; Błońska, D; Charliński, G; Dębski, J; Dmoszyńska, A; Druzd-Sitek, A; Dytfeld, D; Hałka, J; Hołojda, J; Hus, M; Januszczyk, J; Jurczyszyn, A; Knopińska-Posłuszny, W; Kuliczkowski, K; Kłoczko, J; Lech-Marańda, E; Legieć, W; Malenda, A; Nowicki, A; Pogrzeba, J; Rymko, M; Rzepecki, P; Stella-Hołowiecka, B; Subocz, E; Torosian, T; Urbanowicz, A; Urbańska-Ryś, H; Usnarska-Zubkiewicz, L; Zaucha, JM; Zdziarska, B; Zubkiewicz-Kucharska, A, 2016) |
| " We studied the relationship between 25-hydroxyvitamin D (25D) levels and motor and sensory peripheral neuropathy (PN) among multiple myeloma (MM) patients who have been treated with bortezomib and/or thalidomide." | 7.83 | Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy. ( Berenson, JR; Bravin, E; Ibrahim, E; Masri, M; Spektor, TM; Swift, RA; Treisman, J; Udd, KA; Vidisheva, A; Wang, J, 2016) |
| "Pomalidomide is an IMiD(®) immunomodulatory agent, which has shown clinically significant benefits in relapsed and/or refractory multiple myeloma (rrMM) patients when combined with dexamethasone, regardless of refractory status to lenalidomide or bortezomib." | 7.83 | Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. ( Bjorklund, CC; Cathers, BE; Chopra, R; Daniel, TO; Gandhi, AK; Leisten, J; Lopez-Girona, A; Lu, L; Mendy, D; Miller, K; Narla, RK; Ning, Y; Orlowski, RZ; Raymon, HK; Rychak, E; Shi, T; Thakurta, A, 2016) |
| "In real clinical settings (not clinical trials), thalidomide has been accepted as maintenance therapy to patients with multiple myeloma (MM) because of the cost of drugs, the limitations of medical insurance, etc." | 7.83 | The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea. ( Do, YR; Eom, HS; Jo, JC; Kim, K; Kim, SJ; Lee, H; Lee, HS; Lee, JH; Lee, JJ; Lee, MH; Lee, WS; Min, CK; Mun, YC; Park, Y; Shin, HJ; Yoon, DH, 2016) |
| " Recent studies led to the development of a novel molecule RRx-001 with hypoxia-selective epigenetic and nitric oxide-donating properties." | 7.83 | A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. ( Anderson, KC; Chauhan, D; Das, A; Das, DS; Oronsky, B; Ray, A; Richardson, P; Scicinski, J; Song, Y; Tian, Z, 2016) |
| "Multiple myeloma (MM) patients who have progressed following treatment with both bortezomib and lenalidomide have a poor prognosis." | 7.83 | Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden. ( Borg, S; Elvidge, J; Hansson, M; Lee, D; Nahi, H; Persson, U, 2016) |
| "To explore the clinical efficacy and safety of lenalidomide plus low dose dexamethasone for treating patients with multiple myeloma (MM)." | 7.83 | [Curative Efficacy of Lenalidomide plus Low Dose Dexamethasone for Multiple Myeloma]. ( Chen, LM; Liu, HB, 2016) |
| "Neutropenia is a well-known dose-limiting toxicity associated with lenalidomide plus dexamethasone treatment in patients with multiple myeloma; however, little is known about its management and associated outcomes in the real world setting." | 7.83 | An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM). ( Cooney, J; Gray, D; Greil, R; Leleu, X; Minarik, J; O'Gorman, P; Sanz, RG; Szabo, Z; Terpos, E; Williams, C, 2016) |
| "To assess the economic value of carfilzomib (Kyprolis), this study developed the Kyprolis Global Economic Model (K-GEM), which examined from a United States (US) payer perspective the cost-effectiveness of carfilzomib-lenalidomide-dexamethasone (KRd) versus lenalidomide-dexamethasone (Rd) in relapsed multiple myeloma (RMM; 1-3 prior therapies) based on results from the phase III ASPIRE trial that directly compared these regimens." | 7.83 | Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. ( Aggarwal, SK; Barber, BL; Benedict, Á; Campioni, M; Giannopoulou, A; Houisse, I; Jakubowiak, AJ; Panjabi, S; Tichy, E, 2016) |
| "Circulating vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and selectins were prospectively measured in 145 newly-diagnosed patients with symptomatic myeloma (NDMM), 61 patients with asymptomatic/smoldering myeloma (SMM), 47 with monoclonal gammopathy of undetermined significance (MGUS) and 87 multiple myeloma (MM) patients at first relapse who received lenalidomide- or bortezomib-based treatment (RD, n=47; or VD, n=40)." | 7.83 | Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment. ( Christoulas, D; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Fotiou, D; Gavriatopoulou, M; Iakovaki, M; Kanellias, N; Kastritis, E; Migkou, M; Panagiotidis, I; Terpos, E; Ziogas, DC, 2016) |
| "In order to evaluate the main adverse effects of drug protocols using bortezomib and/or thalidomide for the treatment of multiple myeloma, we conducted a prospective study." | 7.83 | Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide. ( Atalla, A; Castro, TB; Hallack Neto, AE; Ribeiro, LC, 2016) |
| "Although the antimyeloma effect of lenalidomide is associated with activation of the immune system, the exact in vivo immunomodulatory mechanisms of lenalidomide combined with low-dose dexamethasone (Len-dex) in refractory/relapsed multiple myeloma (RRMM) patients remain unclear." | 7.83 | Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma. ( Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, M; Kim, TW; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Lim, JY; Min, CK; Min, WS; Ryu, DB; Yoon, JH, 2016) |
| " In this study, we evaluated CRBN expression in bone marrow (BM) tissue at diagnosis and investigated the relationship between CRBN expression and treatment outcomes after thalidomide- or bortezomib-based front-line therapies in 89 elderly patients with multiple myeloma (MM)." | 7.83 | Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression. ( Ahn, JS; Cho, MS; Choi, HJ; Hwang, EC; Jung, SH; Jung, TY; Kim, HJ; Kim, YK; Lee, JJ; Lee, SS; Shin, MG; Yang, DH, 2016) |
| "A 75-year-old woman diagnosed with multiple myeloma in 2007 began treatment with monthly melphalan and prednisone for a total of 9 cycles in combination with thalidomide in 2009." | 7.83 | Hair repigmentation associated with thalidomide use for the treatment of multiple myeloma. ( Amato, D; Bailie, T; Lovering, S; Miao, W, 2016) |
| "Neutropenia may develop as an adverse event in patients with multiple myeloma receiving lenalidomide (LEN) plus dexamethasone (DEX) therapy." | 7.83 | Risk factors for neutropenia with lenalidomide plus dexamethasone therapy for multiple myeloma. ( Kimura, M; Kokuryou, T; Matsuoka, T; Mitani, Y; Nakao, T; Okada, K; Usami, E; Yamakawa, M; Yoshimura, T, 2016) |
| "In Eastern Cooperative Oncology Group-ACRIN E4A03, on completion of four cycles of therapy, newly diagnosed multiple myeloma patients had the option of proceeding to autologous peripheral blood stem cell transplant (ASCT) or continuing on their assigned therapy lenalidomide plus low-dose dexamethasone (Ld) or lenalidomide plus high-dose dexamethasone (LD)." | 7.83 | Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up. ( Abonour, R; Biran, N; Callander, NS; Fonseca, R; Greipp, PR; Jacobus, S; Katz, MS; Rajkumar, SV; Siegel, DS; Vesole, DH; Williams, ME, 2016) |
| "Although lenalidomide maintenance therapy has demonstrated improved outcomes after autologous hematopoietic stem cell transplantation (auto-HCT) for patients with multiple myeloma (MM), the impact of the duration of this therapy is not clearly known." | 7.83 | Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. ( Bashir, Q; Champlin, RE; Kebriaei, P; Manasanch, EE; Mian, I; Milton, DR; Nieto, Y; Oran, B; Orlowski, RZ; Parmar, S; Popat, UR; Qazilbash, MH; Shah, JJ; Shah, N; Shpall, EJ, 2016) |
| " The aim of this retrospective study was to evaluate the efficacy and safety of Compound Danshen Tablet (CDT) in preventing thromboembolism in multiple myeloma (MM) patients treated with thalidomide-based regimens." | 7.83 | Efficacy and Safety of Danshen Compound Tablets in Preventing Thalidomide-Associated Thromboembolism in Patients with Multiple Myeloma: A Multicenter Retrospective Study. ( Ai, H; Chen, L; Liu, XJ; Mi, RH; Wei, XD; Yin, JJ; Yin, QS, 2016) |
| "This is a retrospective chart review to evaluate the efficacy of the addition of vorinostat to lenalidomide and dexamethasone in patients with multiple myeloma relapsed/refractory to lenalidomide and dexamethasone." | 7.83 | Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma. ( Bednarz, U; Bilotti, E; Gao, Z; Gilani, M; Graef, T; Mato, A; McBride, L; McNeill, A; Richter, J; Schmidt, L; Siegel, DS; Vesole, DH, 2016) |
| "The aim of this study is to assess nucleoprotein expression of IKZF1/3 in patients with relapsed/refractory multiple myeloma (MM) who received lenalidomide-based therapy and correlated them with their clinical outcomes." | 7.83 | High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide. ( Atenafu, EG; Bahmanyar, M; Chang, H; Hou, J; Pourabdollah, M; Reece, D, 2016) |
| "In this invited paper, I was asked to critically review available literature and seek scientific and clinical evidence to argue in support of carfilzomib, lenalidomide, and dexamethasone (KRd) as the new default therapy for fit patients with a new diagnosis of multiple myeloma (MM)." | 7.83 | Combination therapy for fit (younger and older) newly diagnosed multiple myeloma patients: Data support carfilzomib, lenalidomide, and dexamethasone independent of cytogenetic risk status. ( Landgren, O, 2016) |
| "Thalidomide was the first immunomodulatory drug used as maintenance after autologous stem cell transplant (ASCT) in multiple myeloma (MM)." | 7.83 | Recommend maintenance therapy with lenalidomide in multiple myeloma. ( Manasanch, EE, 2016) |
| "Neutropenia is a major dose-limiting toxicity associated with lenalidomide in relapsed/refractory multiple myeloma (MM)." | 7.81 | Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. ( Atenafu, EG; Chen, C; Kukreti, V; Masih-Khan, E; Reece, DE; Sun, HL; Trudel, S; Winter, A; Yeboah, E, 2015) |
| "Lenalidomide was approved for the treatment of relapsed and refractory multiple myeloma (rrMM) based on MM009 and MM010 clinical trials." | 7.81 | Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma--real life experience of a tertiary cancer center. ( Coelho, I; Costa, C; Esteves, S; João, C; Lucio, P, 2015) |
| "We retrospectively investigated the prognostic factor of lenalidomide plus low-dose dexamethasone (Rd) in Japanese patients with refractory or relapsed multiple myeloma (RRMM) registered in the Kansai Myeloma Forum from January 2006 to December 2013." | 7.81 | Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma. ( Adachi, Y; Fuchida, S; Ishii, K; Kanakura, Y; Kaneko, H; Kobayashi, M; Kobayashi, T; Kosugi, S; Kuroda, J; Matsuda, M; Matsumura, I; Nakatani, E; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Takaori-Kondo, A; Tanaka, H; Taniwaki, M; Tsudo, M; Uchiyama, H; Uoshima, N; Yagi, H, 2015) |
| "To identify molecular targets that modify sensitivity to lenalidomide, we measured proliferation in multiple myeloma (MM) cells transfected with 27 968 small interfering RNAs in the presence of increasing concentrations of drug and identified 63 genes that enhance activity of lenalidomide upon silencing." | 7.81 | RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2. ( Aziz, M; Braggio, E; Bruins, LA; Champion, M; Jedlowski, P; Keith Stewart, A; Kortuem, KM; Schmidt, JE; Sereduk, C; Shi, CX; Yin, H; Zhu, YX, 2015) |
| "In ex vivo assays, mainly evaluating antibody-dependent cell-mediated cytotoxicity, and in an in vivo xenograft mouse model, we evaluated daratumumab alone or in combination with lenalidomide or bortezomib as a potential therapy for lenalidomide- and bortezomib-refractory multiple myeloma patients." | 7.81 | Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib. ( Bakker, J; de Jong-Korlaar, R; Groen, RW; Lokhorst, HM; Martens, AC; Mutis, T; Nijhof, IS; Noort, WA; Parren, PW; van Bueren, JJ; van de Donk, NW; van Kessel, B, 2015) |
| "The introduction of immunomodulatory drugs such as lenalidomide combined with dexamethasone (Len/Dex) has improved the outcome of patients with relapsed/refractory multiple myeloma (RRMM)." | 7.81 | Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide. ( Bacchiarri, F; Bosi, A; Donnini, I; Guarrera, A; Longo, G; Nozzoli, C; Staderini, M; Veltroni, A, 2015) |
| "In the past decade, the introduction of bortezomib, thalidomide, and lenalidomide has changed the treatment of multiple myeloma (MM) dramatically." | 7.81 | [Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy]. ( Nakaseko, C; Sakaida, E; Takeda, Y, 2015) |
| "Thalidomide is highly effective against multiple myeloma, but some patients must discontinue this medication due to adverse effects." | 7.81 | [Thalidomide-associated hypothyroidism in a patient with multiple myeloma]. ( Ikeda, T; Kimura, F; Okamura, I; Sato, K, 2015) |
| "Thalidomide (Thal) treatment of patients with multiple myeloma (MM) is associated with vascular thrombosis, but the underlying mechanism is unknown." | 7.81 | Thalidomide and multiple myeloma serum synergistically induce a hemostatic imbalance in endothelial cells in vitro. ( Gao, Y; Liu, S; Ma, G; Su, Y; Teng, Y; Wang, Y, 2015) |
| "Clinical studies evaluating the efffectiveness of pomalidomide based regimens on response and safety for patients with refractory and relapsed multiple myeloma were identified using a predefined search strategy." | 7.81 | Pooled analysis of pomalidomide for treating patients with multiple myeloma. ( Sun, JJ; Yang, HL; Zhang, C; Zhou, J, 2015) |
| " Here, we assessed the impact of single and dual blockade of PD-1/PD-L1, alone or in combination with lenalidomide, on accessory and immune cell function as well as multiple myeloma cell growth in the bone marrow (BM) milieu." | 7.81 | Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. ( Anderson, JE; Anderson, KC; Avet-Loiseau, H; Bianchi, G; Cowens, KB; Dorfman, DM; Görgün, G; Harada, T; Hideshima, T; Kikuchi, S; Laubach, JP; Magrangeas, F; Minvielle, S; Munshi, NC; Ohguchi, H; Paula, S; Raje, N; Richardson, PG; Samur, MK; Singh, A; Suzuki, R; Tai, YT; White, RE, 2015) |
| "To explore the clinical efficacies and toxicities of lenalidomide combination chemotherapy in the treatment of relapsing or refractory multiple myeloma (MM) patients." | 7.81 | [Clinical observations of lenalidomide combination chemotherapy for relapsing or refractory multiple myeloma]. ( An, N; Chen, S; Hu, Y; Huang, Z; Li, X; Shen, M; Sun, W; Zhan, X; Zhang, J; Zhong, Y, 2015) |
| "To observe the cytotoxity of CD138-CAR-T cells on human multiple myeloma cell RPMI8226 and U266 cells and explore the impact of pomalidomide on the cytotoxity of CD138-CAR-T on RPMI8226 and U266 cells." | 7.81 | [Cytotoxity of pomalidomide combined CAR-T cell for multiple myeloma cell RPMI8226 and U266]. ( Bai, H; Ou, J; Wang, L; Zhang, S, 2015) |
| "In this retrospective real-life study in relapsed/refractory multiple myeloma patients, we analyzed clinical and biologic features distinguishing patients with rapidly progressing disease while receiving lenalidomide therapy from those without progression." | 7.81 | Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation. ( Battistutta, C; Berno, T; Bonaldi, L; Branca, A; Briani, C; Cavraro, M; De March, E; Gurrieri, C; Lico, A; Martines, A; Minotto, C; Piazza, F; Sechettin, E; Semenzato, G; Temporin, F; Trentin, L; Zambello, R, 2015) |
| "The aim of this study was to assess the safety and efficacy of lenalidomide (Len), with the dose adjusted according to the renal function, plus low-dose dexamethasone (Dex) in older patients with bortezomib (Bor)-resistant multiple myeloma (MM)." | 7.81 | Dose-adjusted Lenalidomide Combined with Low-dose Dexamethasone Rescues Older Patients with Bortezomib-resistant Multiple Myeloma. ( Kadowaki, M; Kohno, K; Okamura, S; Takase, K; Yamasaki, S, 2015) |
| "Multiple laboratory tests and a rigorous review of the samples, time of collection, and laboratory results revealed that only samples collected shortly after lenalidomide administration showed hemolysis." | 7.81 | Transiently Pink-Tinged Serum in a Patient With Multiple Myeloma and Anemia Undergoing Lenalidomide Treatment. ( Sofronescu, AG; Wedel, W, 2015) |
| "Two multiple myeloma (MM) patients developed venous thromboembolism (VTE) while being treated with lenalidomide and low-dose dexamethasone." | 7.81 | [Successful treatment of venous thromboembolism with a Factor Xa inhibitor, edoxaban, in patients with lenalidomide-treated multiple myeloma]. ( Kawaguchi, M; Konuma, S; Nehashi, Y; Okuda, Y; Uchimura, N, 2015) |
| "The purpose of this study was to determine the correlations between inflammatory factors-including absolute lymphocyte count, lactate dehydrogenase, β2-microglobulin, albumin, C-reactive protein, and ferritin-and the prognosis for survival in patients with multiple myeloma (MM) treated with induction chemotherapy containing thalidomide and who underwent autologous stem cell transplantation (ASCT)." | 7.81 | The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea. ( Do, YR; Eom, HS; Jo, JC; Kim, C; Kim, K; Lee, H; Lee, HS; Lee, JH; Lee, JJ; Lee, WS; Min, CK; Mun, YC; Park, Y; Shin, HJ; Yoon, DH, 2015) |
| "To investigate the efficacy and safety of the treatment of the newly diagnosed multiple myeloma (MM) patients with the therapy of subcutaneous (subQ) administration of bortezomib and dexamethasone plus thalidomide (VTD) regimen." | 7.81 | Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients. ( Cai, X; Chen, S; Chen, Y; Lin, B; Shi, Y; Wu, S; Zheng, C, 2015) |
| "Recent discoveries suggest that the critical events leading to the anti-proliferative activity of the IMiD immunomodulatory agents lenalidomide and pomalidomide in multiple myeloma (MM) cells are initiated by Cereblon-dependent ubiquitination and proteasomal degradation of substrate proteins Ikaros (IKZF1) and Aiolos (IKZF3)." | 7.81 | Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. ( Amatangelo, M; Bjorklund, CC; Breider, M; Chopra, R; Couto, S; Daniel, TO; Gandhi, AK; Hagner, PR; Havens, CG; Kang, J; Klippel, A; Lu, L; Ning, Y; Ren, Y; Thakurta, AG; Wang, M, 2015) |
| "We studied all patients at our institution with a diagnosis of multiple myeloma (MM), from 1 January 2004 to 1 July 2009, who received lenalidomide-dexamethasone (Rd) as initial therapy and had a time to progression of 72 months or longer." | 7.81 | Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma. ( Buadi, F; Dispenzieri, A; Gertz, MA; Gonsalves, W; Kumar, S; Lacy, MQ; Rajkumar, SV; Vu, T, 2015) |
| "To explore the change of T help cell 17 (Th17) in the peripheral blood of patients with multiple myeloma (MM) before and after treatment with thalidomide." | 7.81 | [Effects of Thalidomide on Peripheral Blood Th17 Cells of Patients with Multiple Myeloma]. ( Bai, J; He, AL; Liu, J; Wang, JL; Yang, Y; Zhao, WH, 2015) |
| "We investigated the mechanisms of action of immuno-modulatory drug (lenalidomide) on the protein expression of cereblon (CRBN) and their therapeutic targets in the multiple myeloma cell line RPMI8226." | 7.81 | Lenalidomide affect expression level of cereblon protein in multiple myeloma cell line RPMI8226. ( Cai, XY; Guo, XF; Guo, XL; Guo, XN; Ren, JH; Yang, DY; Zhang, JN, 2015) |
| "The incidence of herpes zoster is substantial during bortezomib treatment in patients with multiple myeloma (MM)." | 7.81 | Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy. ( Choe, PG; Kim, BS; Kim, I; Kim, JW; Koh, Y; Kwon, JH; Min, CK; Mun, YC; Nam, SH; Park, WB; Park, Y, 2015) |
| "The onset of thrombocytopenia and related factors was analyzed in patients with multiple myeloma (MM) who were receiving lenalidomide (Len) therapy at the Department of Hematology, Gifu Municipal Hospital between July 2010 and March 2014." | 7.81 | The Establishment of Indicators of Thrombocytopenia in Patients Receiving Lenalidomide Therapy. ( Goto, C; Goto, H; Ichihashi, A; Kasahara, S; Nagaya, K; Osawa, T; Tachi, T; Takahashi, T; Teramachi, H; Umeda, M; Yasuda, M, 2015) |
| "This study investigated the relationship between quality of life (QOL) and efficacy or occurrence of adverse events in patients who were administered lenalidomide and dexamethasone (Len+Dex) therapy for relapsed or refractory multiple myeloma (MM) in the hematology department at Obihiro Kosei Hospital from September 2010 to September 2012." | 7.81 | [Quality of Life Is Associated with Combined Lenalidomide and Dexamethasone Treatment in Japanese Patients with Relapsed or Refractory Multiple Myeloma]. ( Kobayashi, H; Komori, H; Nakamura, Y; Namba, K; Oi, N; Sato, H; Taniguchi, Y; Yahata, H, 2015) |
| "Thalidomide, a sedative popular in the 1950s and withdrawn from the market in the 1960s because of its teratogenic effects, has emerged again on the market in the last decade as an effective agent in the treatment of multiple myeloma." | 7.81 | [Thalidomide induced peripheral neuropathy in multiple myeloma patients]. ( Banach, M; Jurczyszyn, A; Skotnicki, A, 2015) |
| "The multikinase inhibitor dasatinib blocks the constitutive activation of oncogenic Src kinases in multiple myeloma (MM) cells and potentially enhances natural killer (NK) cell activity." | 7.80 | Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells. ( Einsele, H; Jungkunz-Stier, I; Seggewiss-Bernhardt, R; Stühmer, T; Zekl, M, 2014) |
| "Type, frequency, severity, time of onset and management of cADR were collected and the medical records of all multiple myeloma patients receiving bortezomib or lenalidomide in the Hematology and Medical Oncology Institute of the University of Bologna, were analyzed." | 7.80 | Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects. ( Brandi, G; Dika, E; Maibach, H; Patrizi, A; Tacchetti, P; Venturi, M, 2014) |
| "Patients with multiple myeloma who are refractory or intolerant to both bortezomib and lenalidomide have a poor prognosis." | 7.80 | The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide. ( Ahluwalia, R; Carson, KR; Cox, DP; Fiala, MA; Jaenicke, M; Moliske, CC; Stockerl-Goldstein, KE; Tomasson, MH; Trinkaus, KM; Vij, R; Wang, TF; Wildes, TM, 2014) |
| "Lenalidomide and dexamethasone (RD) is a standard of care for relapsed/refractory multiple myeloma (RRMM), but there is limited published data on its efficacy and safety in the "real world" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition." | 7.80 | "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. ( Anagnostopoulos, N; Anargyrou, K; Briasoulis, E; Giannakoulas, N; Hatzimichael, E; Karras, G; Katodritou, E; Kotsopoulou, M; Kyriakou, D; Kyrtsonis, MC; Lalagianni, C; Maniatis, A; Matsouka, P; Michali, E; Papageorgiou, G; Spanoudakis, E; Symeonidis, A; Terpos, E; Tsakiridou, A; Tsionos, K; Vadikolia, C; Zikos, P, 2014) |
| "The combination of melphalan and prednisone (MP) has been the standard treatment of multiple myeloma (MM)." | 7.80 | Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients. ( Alici, E; Aschan, J; Gahrton, G; Holmberg, E; Liwing, J; Lund, J; Nahi, H; Uttervall, K, 2014) |
| "Whether the efficacy of lenalidomide in the treatment of multiple myeloma (MM) is due to direct tumor toxicity only or to additional immunomodulatory effects is unclear." | 7.80 | Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis. ( Bompoint, C; Busson, M; Carmagnat, M; Clave, E; Coman, T; Douay, C; Garderet, L; Glauzy, S; Gorin, NC; Moins-Teisserenc, H; Toubert, A, 2014) |
| "Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM)." | 7.80 | Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. ( Beksac, M; Boccadoro, M; Bringhen, S; Catalano, L; Cavalli, M; Cavo, M; Cerrato, C; Gentile, M; Gimsing, P; Gottardi, D; Isabel Turel, A; José Lahuerta, J; Juliusson, G; Larocca, A; Magarotto, V; Marina Liberati, A; Mazzone, C; Morabito, F; Musto, P; Offidani, M; Omedè, P; Oriol, A; Palumbo, A; Passera, R; Rossi, D; Rosso, S; San Miguel, J; Schaafsma, M; Sonneveld, P; Victoria Mateos, M; Waage, A; Wijermans, P; Zambello, R; Zweegman, S, 2014) |
| "Lenalidomide is a drug with clinical efficacy in multiple myeloma and other B cell neoplasms, but its mechanism of action is unknown." | 7.80 | Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. ( Carr, SA; Ciarlo, C; Comer, E; Ebert, BL; Grauman, P; Hartman, E; Heckl, D; Hurst, SN; Krönke, J; Li, X; McConkey, M; Munshi, N; Narla, A; Schenone, M; Schreiber, SL; Svinkina, T; Udeshi, ND, 2014) |
| "The aim of this study was to develop a model able to predict the area under the lenalidomide plasma concentration-time curve (AUC) in multiple myeloma (MM) patients using a limited sampling strategy." | 7.80 | A limited sampling model to estimate exposure to lenalidomide in multiple myeloma patients. ( Abumiya, M; Fujishima, N; Hagihara, M; Hirokawa, M; Kameoka, Y; Kobayashi, T; Matsumoto, M; Miura, M; Niioka, T; Sawada, K; Shida, S; Tagawa, H; Takahashi, N, 2014) |
| "Lenalidomide (Revlimid®) combined with intermittent dexamethasone (the RD regimen) is one of the current standards for treatment of patients with relapsed/refractory multiple myeloma (MM)." | 7.80 | Treatment with lenalidomide (Revlimid®), cyclophosphamide (Endoxan®) and prednisone (REP) in relapsed/refractory multiple myeloma patients: results of a single centre retrospective study. ( Delforge, M; Devos, T; Dierickx, D; Janssens, A; Raddoux, J; Verhoef, G; Zelis, N, 2014) |
| " We present a 75-year-old Caucasian man with a violaceous ring-like firm, papular eruption, localized on the dorsal aspect of both hands, with histological features of GA, which subsequently resolved with the discontinuation of thalidomide he had started 1 month earlier for the treatment of a multiple myeloma." | 7.80 | Thalidomide-induced granuloma annulare. ( Atzori, L; Caddori, A; Ferreli, C; Manunza, F; Pau, M, 2014) |
| " Patients receiving thalidomide, especially in combination with steroids, are at increased risk of venous thromboembolism (VTE), while the incidence of VTE on bortezomib is low." | 7.80 | Inhibitory effects of bortezomib on platelet aggregation in patients with multiple myeloma. ( Dytfeld, D; Gil, L; Kaźmierczak, M; Komarnicki, M; Nowicki, A; Rupa-Matysek, J; Wojtasińska, E, 2014) |
| "A 54-year-old woman developed psoriasis on the plantar surface of her feet after 2 weeks of thalidomide 100 mg daily for the treatment of multiple IgG myeloma." | 7.80 | Psoriasis induced by thalidomide in a patient with multiple myeloma. ( Alaibac, M; Ferrazzi, A; Russo, I; Zambello, R, 2014) |
| "Lenalidomide in combination with dexamethasone is an effective and well-established treatment of relapsed or refractory multiple myeloma (rrMM) disease." | 7.80 | Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment. ( Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M, 2014) |
| "A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants." | 7.80 | Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. ( Hobeika, L; Self, SE; Velez, JC, 2014) |
| "The mechanisms involved in anti-myeloma activity of statins combined with thalidomide were studied in multiple myeloma (MM) cells." | 7.79 | Induction of apoptosis in multiple myeloma cells by a statin-thalidomide combination can be enhanced by p38 MAPK inhibition. ( Kandefer-Szerszen, M; Mizerska-Dudka, M; Slawinska-Brych, A; Zdzisinska, B, 2013) |
| "Lenalidomide is now widely used for the treatment of multiple myeloma in virtue of its potent anti-tumor activity and low toxicity." | 7.79 | Lenalidomide-induced acute lung injury in case of multiple myeloma. ( Aoki, T; Danbara, M; Higashihara, M; Katayama, T; Miyazaki, K; Tadera, N; Togano, T, 2013) |
| "Lenalidomide (LEN) is a relatively new and very effective therapy for multiple myeloma (MM)." | 7.79 | Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma. ( Abidi, MH; Abrams, J; Al-Kadhimi, Z; Ayash, L; Bhutani, D; Deol, A; Lum, L; Ratanatharathorn, V; Tageja, N; Uberti, J; Valent, J; Zonder, J, 2013) |
| "Transient inflammatory reactions have been reported in a subpopulation of patients with multiple myeloma (MM) during lenalidomide (Len) plus dexamethasone (DEX) therapy." | 7.79 | Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma. ( Abe, M; Fujii, S; Harada, T; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Oda, A; Ozaki, S; Takeuchi, K, 2013) |
| "Lenalidomide is an active immunomodulatory and antiproliferative agent in multiple myeloma." | 7.79 | Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma. ( Amiot, M; Bonnaud, S; Gomez-Bougie, P; Gratas, C; Le Gouill, S; Maïga, S; Moreau, P; Pellat-Deceunynck, C, 2013) |
| "The combination of lenalidomide and dexamethasone (Len-Dex) is a commonly used initial therapy for newly diagnosed multiple myeloma (MM)." | 7.79 | Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. ( Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Hayman, SR; Kapoor, P; Kumar, S; Kyle, R; Lacy, MQ; McCurdy, A; Rajkumar, SV; Rana, V; Russell, S; Srivastava, G; Zeldenrust, S, 2013) |
| "A 61-year-old man, who was diagnosed with Bence-Jones protein (BJP)-λ type multiple myeloma, was treated with bortezomib." | 7.79 | [The appearance of t(9;22)(q34;q11.2) in BJP-λ type multiple myeloma during maintenance therapy including lenalidomide]. ( Arakaki, H; Uchihara, JN, 2013) |
| "Lenalidomide treatment for refractory or relapsed multiple myeloma in elderly patients may be feasible in an outpatient setting." | 7.79 | Very low-dose lenalidomide therapy for elderly multiple myeloma patients. ( Hirata, T; Inagaki, T; Iwai, M; Katayama, Y; Kawano, H; Kimura, S; Kishi, M; Koide, T; Matsui, T; Minagawa, K; Suzuki, T; Takechi, M, 2013) |
| "Studies comparing the efficacy and cost of peripheral blood stem and progenitor cells mobilization with low-dose cyclophosphamide (LD-CY) and granulocyte-colony stimulating factor (G-CSF) against plerixafor and G-CSF, in multiple myeloma (MM) patients treated in the novel therapy-era are not available." | 7.79 | Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. ( Awan, F; Chaudhary, L; Craig, M; Cumpston, A; Hamadani, M; Leadmon, S; Tse, W; Watkins, K, 2013) |
| "In our efforts to develop effective treatment agents for human multiple myeloma (MM), a series of hybrid molecules based on the structures of thalidomide (1) and curcumin (2) were designed, synthesized, and biologically characterized in human multiple myeloma MM1S, RPMI8226, U266 cells, and human lung cancer A549 cells." | 7.79 | Design and biological characterization of hybrid compounds of curcumin and thalidomide for multiple myeloma. ( Chojnacki, J; Du, Y; Fu, H; Grant, S; Liu, K; Zhang, D; Zhang, S, 2013) |
| "The novel agents bortezomib and lenalidomide improve outcomes in multiple myeloma, yet most patients will relapse after exhausting treatment." | 7.79 | Pomalidomide in the treatment of relapsed multiple myeloma. ( Forsberg, PA; Mark, TM, 2013) |
| "We analyzed 1156 multiple myeloma (MM) patients treated with thalidomide." | 7.79 | 10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group. ( Adam, Z; Adamova, D; Bacovsky, J; Gregora, E; Gumulec, J; Hajek, R; Jarkovsky, J; Maisnar, V; Melicharova, H; Minarik, J; Pavlicek, P; Pika, T; Plonkova, H; Pour, L; Radocha, J; Sandecka, V; Scudla, V; Spicka, I; Starostka, D; Straub, J; Walterova, L; Wrobel, M, 2013) |
| "Lenalidomide in combination with dexamethasone (Len/Dex) is indicated for patients with recurrent/refractory multiple myeloma (RRMM) who were treated with 1 prior therapy until evidence of disease progression." | 7.79 | Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma. ( Avet Loiseau, H; Bonnet, S; Debarri, H; Demarquette, H; Facon, T; Fouquet, G; Gay, J; Guidez, S; Herbaux, C; Hulin, C; Leleu, X; Michel, J; Miljkovic, D; Perrot, A; Serrier, C; Tardy, S, 2013) |
| "Treatment with thalidomide is associated with vascular thrombosis." | 7.79 | Increased PAC-1 expression among patients with multiple myeloma on concurrent thalidomide and warfarin. ( Abdullah, D; Abdullah, WZ; Hussin, A; Roshan, TM; Zain, WS, 2013) |
| "Bortezomib (Btz) has emerged as a standard of care in the treatment of patients with multiple myeloma (MM), but Btz-induced peripheral neuropathy (PNP) has a particularly negative impact on patients' quality of life." | 7.79 | Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma. ( Drach, J; Drach-Schauer, B; Eder, S; Lamm, W, 2013) |
| "To determine the cost effectiveness of lenalidomide plus dexamethasone (LEN/DEX) versus DEX alone in managing multiple myeloma (MM) patients who have failed one prior therapy." | 7.79 | Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales. ( Brown, RE; Dhanasiri, S; Schey, S; Stern, S, 2013) |
| "The combination of lenalidomide, bortezomib and dexamethasone (RVD) has shown excellent efficacy in patients with relapsed or refractory multiple myeloma (RRMM)." | 7.79 | Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma. ( Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S, 2013) |
| "To assess thromboprophylaxis prescribing patterns against current guidelines and report thromboembolism (TE) incidence in multiple myeloma (MM) patients treated with thalidomide (thal) or lenalidomide (len) at a specialist cancer hospital over a one-year period." | 7.79 | Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital. ( Alexander, M; Kirsa, S; Lingaratnam, S; Mellor, JD; Teoh, KC, 2013) |
| "Multiple myeloma (MM)-induced osteoclast (OC) formation is mainly due to an imbalance of the receptor activator NF-κB ligand (RANKL)-osteoprotegerin (OPG) ratio in favor of RANKL in the bone microenvironment and to the CCL3 production by MM cells." | 7.79 | Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. ( Agnelli, L; Bolzoni, M; Bonomini, S; Giuliani, N; Guasco, D; Neri, A; Rizzoli, V; Storti, P; Todoerti, K; Toscani, D, 2013) |
| "The CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen is known to be an effective primary therapy in patients with newly diagnosed multiple myeloma (MM)." | 7.79 | Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen. ( Ahn, JS; Jung, SH; Kim, HJ; Kim, MY; Kim, YK; Lee, JJ; Park, H; Yang, DH, 2013) |
| "In this prospective study of patients with relapsed or relapsed and refractory multiple myeloma (MM) treated with lenalidomide and dexamethasone, relationships between markers of endothelial stress and drug administration and incidence of venous thromboembolism (VTE) were assessed." | 7.79 | Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. ( Anderson, KC; Bradwin, G; Connell, B; Doyle, M; Ghobrial, I; Hong, F; Lockridge, L; Mitsiades, C; Munshi, N; Richardson, P; Rosovsky, R; Schlossman, R; Soiffer, RJ; Tocco, D; Warren, D; Weller, E, 2013) |
| "The combination of clarithromycin, lenalidomide, and dexamethasone (BiRd) was evaluated as therapy for treatment-naive symptomatic multiple myeloma (MM), with overall response at 2 years of 90%." | 7.79 | BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. ( Chen-Kiang, S; Christos, P; Coleman, M; Jayabalan, D; Mark, T; Niesvizky, R; Pearse, R; Pekle, K; Rossi, A; Zafar, F, 2013) |
| "The chemotherapeutic regimen melphalan, prednisolone, and thalidomide (MPT) is the standard of care for symptomatic multiple myeloma patients who are not eligible for high dose chemotherapy followed by autologous stem cell therapy." | 7.78 | Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma. ( Jena, RK; Kansurkar, SS; Swain, M; Swain, TR, 2012) |
| "Few data are available on the efficacy of the combination of lenalidomide plus dexamethasone (Len/Dex) in very elderly patients above 75 years of age with relapsed multiple myeloma (MM)." | 7.78 | Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma. ( Blin, N; Clavert, A; Dubruille, V; Le Gouill, S; Loirat, M; Mahe, B; Malard, F; Mohty, M; Moreau, P; Pennetier, M; Peterlin, P; Planche, L; Roland, V; Tessoulin, B; Touzeau, C, 2012) |
| "del(17p13)(TP53) seems to be an independent poor prognostic factor in patients with relapsed/refractory multiple myeloma (MM) receiving lenalidomide." | 7.78 | p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide. ( Chang, H; Chen, MH; Qi, CX; Saha, MN, 2012) |
| "We present the case of a woman with relapsed multiple myeloma (MM) who received combination lenalidomide and bortezomib therapy for 90 cycles followed by continuous lenalidomide monotherapy and has completed over 100 cycles of treatment to date." | 7.78 | The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. ( Anderson, KC; Colson, K; Doss, D; Ghobrial, IM; Hideshima, T; Laubach, JP; Lunde, L; McKenney, M; Mitsiades, C; Munshi, NC; Noonan, K; Redman, KC; Richardson, PG; Schlossman, RL; Warren, D, 2012) |
| "Retrospective multicenter analysis of 26 patients with multiple myeloma to assess the efficacy and toxicity of relapse treatment with lenalidomide/dexamethasone in renal-function impairment." | 7.78 | Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers. ( Hahn-Ast, C; Kuhn, S; Langer, C; Oehrlein, K; Pönisch, W; Sturm, I; Weisel, KC, 2012) |
| " We hypothesized that growth factor plus preemptive plerixafor is an effective strategy for AHSC mobilization in multiple myeloma (MM) despite prior exposure to lenalidomide." | 7.78 | Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. ( Abbas, J; Butcher, CD; Costa, LJ; Hogan, KR; Kang, Y; Kramer, C; Littleton, A; McDonald, K; Shoptaw, K; Stuart, RK, 2012) |
| "Two pivotal, phase III, randomised, placebo-controlled, registration trials (MM-009 and MM-010) showed that lenalidomide plus dexamethasone was more effective than placebo plus dexamethasone in the treatment of patients with relapsed or refractory multiple myeloma." | 7.78 | Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma. ( Borrello, I; Chanan-Khan, AA; Dimopoulos, M; Foà, R; Hellmann, A; Knight, R; Lonial, S; Swern, AS; Weber, D, 2012) |
| "Thromboembolic events (TEE) are a serious clinical problem in multiple myeloma (MM) patients receiving thalidomide (T)." | 7.78 | Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma. ( Chojnowski, K; Robak, M; Treliński, J, 2012) |
| "Bortezomib therapy has proven successful for the treatment of relapsed/refractory, relapsed, and newly diagnosed multiple myeloma (MM); however, dose-limiting toxicities and the development of resistance limit its long-term utility." | 7.78 | A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. ( Altun, M; Anderson, KC; Carrasco, R; Chauhan, D; Fulcinniti, M; Hideshima, T; Kessler, BM; Kingsbury, WD; Kodrasov, MP; Kumar, KG; Leach, CA; McDermott, JL; Minvielle, S; Munshi, N; Nicholson, B; Orlowski, R; Richardson, P; Shah, PK; Tian, Z; Weinstock, J; Zhou, B, 2012) |
| "The introduction of bortezomib, a first-generation proteasome inhibitor, changed the standard-of-care for newly diagnosed and relapsed multiple myeloma patients." | 7.78 | Role of carfilzomib in the treatment of multiple myeloma. ( Badros, A; Khan, RZ, 2012) |
| "Treatment of patients with multiple myeloma (MM) has drastically changed with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, but treatment outcome of elderly patients has remained dismal mainly due to toxicities." | 7.78 | Attainment of a stringent complete response in multiple myeloma with thalidomide monotherapy. ( Aritaka, N; Hirano, T; Ichikawa, K; Komatsu, N; Matsumoto, T; Nakamura, H; Ogura, K; Yasuda, H, 2012) |
| "To investigate the relationship between the efficacy and safety of different doses of thalidomide (Thal) plus dexamethasone (Dex) as the initial therapy in elderly patients with newly diagnosed multiple myeloma (MM)." | 7.78 | Clinical study of thalidomide combined with dexamethasone for the treatment of elderly patients with newly diagnosed multiple myeloma. ( Chen, HF; Cui, QY; Ding, J; Jin, LJ; Li, ZY; Qin, LM; Ren, YY; Shen, HS; Tang, JQ; Wang, J; Wang, KY; Wang, ZY; Wu, TQ; Yu, ZQ; Zhu, JJ, 2012) |
| "Lenalidomide and other new agents have considerable activity in multiple myeloma (MM) and have changed the landscape of treatment." | 7.77 | Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide. ( Calandra, G; Gandhi, PJ; Ho, AD; Klein, LM; Marulkar, S; McSweeney, PA; Micallef, IN, 2011) |
| "An expert panel convened to reach a consensus regarding the optimal use of lenalidomide in combination with dexamethasone (Len/Dex) in patients with relapsed or refractory multiple myeloma (RRMM)." | 7.77 | Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. ( Attal, M; Beksaç, M; da Costa, FL; Davies, FE; Delforge, M; Dimopoulos, MA; Einsele, H; Hajek, R; Harousseau, JL; Ludwig, H; Mellqvist, UH; Morgan, GJ; Palumbo, A; San-Miguel, JF; Sonneveld, P; Zweegman, S, 2011) |
| "To determine the in vivo and in vitro antiangiogenic power of lenalidomide, a "lead compound" of IMiD immunomodulatory drugs in bone marrow (BM) endothelial cells (EC) of patients with multiple myeloma (MM) in active phase (MMEC)." | 7.77 | Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. ( Basile, A; Berardi, S; Caivano, A; Capalbo, S; Cascavilla, N; Coluccia, AM; Dammacco, F; de Luca, E; De Luisi, A; Di Pietro, G; Ditonno, P; Ferrucci, A; Guarini, A; Maffia, M; Moschetta, M; Pieroni, L; Quarta, G; Ranieri, G; Ria, R; Ribatti, D; Urbani, A; Vacca, A, 2011) |
| "A total of 106 relapsed or refractory multiple myeloma patients received lenalidomide 25mg plus dexamethasone as salvage therapy; 80 patients progressed on thalidomide treatment (thalidomide-resistant) and 26 patients discontinued thalidomide in at least partial remission (thalidomide-sensitive)." | 7.77 | Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. ( Benevolo, G; Berruti, A; Boccadoro, M; Bringhen, S; Caravita, T; Cavallo, F; Corradini, P; Gay, F; Guglielmelli, T; Montefusco, V; Offidani, M; Palumbo, A; Petrucci, MT; Piro, E; Rrodhe, S; Saglio, G, 2011) |
| "We studied the efficacy and safety of bortezomib (BOR) for treatment of multiple myeloma in comparison with thalidomide (THAL) by reference to adverse events, and searched for laboratory markers that could be used for prognostication of patients." | 7.77 | Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide. ( Akiba, T; Aotsuka, N; Matsuura, Y; Oguro, R; Satoh, M; Takada, K; Tani, Y; Wakita, H; Yamanaka, C, 2011) |
| "In the era of novel agents such as lenalidomide and bortezomib, risk stratification by chromosomal abnormalities may enable a more rational selection of therapeutic approaches in patients with multiple myeloma (MM)." | 7.77 | Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. ( Goldschmidt, H; Hielscher, T; Hillengass, J; Ho, AD; Hose, D; Jauch, A; Klein, U; Neben, K; Raab, MS; Seckinger, A, 2011) |
| "Evidence of long-term response to lenalidomide in heavily pretreated patients with multiple myeloma is lacking." | 7.77 | Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant. ( Citro, A; Corradini, P; Crippa, C; De Muro, M; Falcone, AP; Galli, M; Gentili, S; Grasso, M; Guglielmelli, T; Montefusco, V; Olivero, B; Patriarca, F; Rossi, D; Sammassimo, S; Spina, F, 2011) |
| "Venous thromboembolism (VTE), with the subsequent risk of pulmonary embolism, is a common adverse effect of thalidomide treatment in patients with multiple myeloma (MM)." | 7.77 | Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide. ( Almasi, M; Hajek, R; Kaisarova, P; Maisnar, V; Penka, M; Pika, T; Pour, L; Radocha, J; Scudla, V; Sevcikova, S; Slaby, O; Svachova, H, 2011) |
| "To estimate the cost-effectiveness (cost per additional life-year [LY] and quality-adjusted life-year [QALY] gained) of lenalidomide plus dexamethasone (LEN/DEX) compared with bortezomib for the treatment of relapsed-refractory multiple myeloma (rrMM) in Norway." | 7.77 | Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib. ( Möller, J; Murthy, A; Nicklasson, L, 2011) |
| " Lenalidomide is a derivative of thalidomide used in the treatment of multiple myeloma." | 7.77 | Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma. ( Bolesta, S; Boruah, PK; Shetty, SM, 2011) |
| "Thalidomide was approved in Japan for multiple myeloma treatment in October 2008." | 7.77 | [Reported use of thalidomide in multiple myeloma: presentation of problems in the Thaled® outpatient department]. ( Aimono, Y; Aoyama, Y; Chikatsu, N; Ebata, S; Hakozaki, M; Isa, S; Kudo, D; Monma, Y; Onozaki, M; Otani, E; Saito, Y; Sato, W; Sawahata, T; Shinagawa, A; Suzuki, M, 2011) |
| "The clinical efficacy and safety of a three-drug combination of melphalan, prednisone, and thalidomide were assessed in patients with multiple myeloma who were not candidates for high-dose therapy as a first-line treatment." | 7.77 | A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma. ( Bae, SH; Bang, SM; Chang, HJ; Do, YR; Lee, JH; Lee, JL; Nam, SH; Yoon, SS, 2011) |
| "Thalidomide has emerged as an effective agent for treating multiple myeloma, however the precise mechanism of action remains unknown." | 7.76 | Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. ( Hohl, RJ; Holstein, SA; Tong, H, 2010) |
| "The frequency of thromboembolic events (TE) in Caucasian patients with multiple myeloma (MM) receiving thalidomide as the initial treatment has been reported to be 10~58% without prophylactic anticoagulation." | 7.76 | Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. ( Bang, SM; Do, YR; Eom, H; Kim, HJ; Kim, K; Kim, MK; Kim, SJ; Koh, Y; Lee, JH; Lee, MH; Lee, N; Mun, YC; Rhee, KH; Ryoo, HM; Shin, HC; Won, JH; Yoon, HJ; Yoon, SS, 2010) |
| "We analyzed proliferative index of myeloma plasmocytes (PC-PI) in acohort of 217 patients with multiple myeloma (MM) treated with conventional chemotherapy and biological agents, thalidomide and bortezomib." | 7.76 | Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma. ( Bacovsky, J; Langova, K; Minarik, J; Ordeltova, M; Pika, T; Scudla, V; Zemanova, M, 2010) |
| " Whether betulinic acid, a pentacyclic triterpene, can modulate the STAT3 pathway, was investigated in human multiple myeloma (MM) cells." | 7.76 | Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. ( Aggarwal, BB; Pandey, MK; Sung, B, 2010) |
| "Combinations of drug treatments based on bortezomib or lenalidomide plus steroids have resulted in very high response rates in multiple myeloma." | 7.76 | In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. ( Atadja, P; Crusoe, E; de Alava, E; Fernández-Lázaro, D; Garayoa, M; Hernández-Iglesias, T; Maiso, P; Ocio, EM; Pandiella, A; San-Miguel, JF; San-Segundo, L; Shao, W; Vilanova, D; Yao, YM, 2010) |
| "Thalidomide based regimen is an effective and well tolerated therapy in multiple myeloma (MM) patients, however, there were a small number of studies written about the results of thalidomide therapy in non-transplant MM patients." | 7.76 | Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand. ( Atichartakarn, V; Aungchaisuksiri, P; Chuncharunee, S; Jootar, S; Niparuck, P; Puavilai, T; Sorakhunpipitkul, L; Ungkanont, A, 2010) |
| "This retrospective analysis investigated the prognostic value of del(13) and t(4;14) abnormalities and the impact of prior treatment on outcomes in 207 heavily pretreated patients with relapsed or refractory multiple myeloma (MM) treated with lenalidomide plus dexamethasone." | 7.76 | Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone. ( Attal, M; Avet-Loiseau, H; Belhadj, K; Dorvaux, V; Fermand, JP; Garderet, L; Hulin, C; Minvielle, S; Moreau, P; Soulier, J; Yakoub-Agha, I, 2010) |
| "To determine the effect of dexamethasone on the antimyeloma effects of lenalidomide, we tested in vitro proliferation, tumor suppressor gene expression, caspase activity, cell cycling, and apoptosis levels in a series of multiple myeloma (MM) and plasma cell leukemia cell lines treated with lenalidomide and dexamethasone, alone or in combination." | 7.76 | Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. ( Bartlett, JB; Capone, L; Fang, W; Gandhi, AK; Hampton, G; Kang, J; Lopez-Girona, A; Mendy, D; Parton, A; Sapinoso, L; Schafer, P; Tran, T; Wu, L; Xu, S; Zhang, LH, 2010) |
| "The role of TNF-α promoter polymorphisms in the development of multiple myeloma (MM) were tested in 210 patients and 218 healthy individuals and their impact on the clinical outcome were evaluated in 98 patients treated with thalidomide and dexamethasone (Thal+Dex) regimen." | 7.76 | Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone. ( Chen, B; Du, J; Fu, W; Hou, J; Jiang, H; Yuan, Z; Zhang, C, 2010) |
| "Lenalidomide and dexamethasone (LenDex) is an active regimen for relapsed/refractory multiple myeloma (MM)." | 7.76 | Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. ( Christoulas, D; Dimopoulos, MA; Efstathiou, E; Gavriatopoulou, M; Grapsa, I; Kastritis, E; Matsouka, C; Migkou, M; Mparmparoussi, D; Psimenou, E; Roussou, M; Terpos, E, 2010) |
| "Thalidomide has received approval from the European Agency for the Evaluation of Medicinal Products for the treatment of newly diagnosed multiple myeloma (MM) patients older than 65 years or ineligible for transplant." | 7.76 | Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. ( Bladé, J; Davies, F; Delforge, M; Facon, T; Garcia Sanz, R; Kropff, M; Leal da Costa, F; Moreau, P; Morgan, G; Palumbo, A; Schey, S, 2010) |
| "Bortezomib, an inhibitor of 26S proteosome, is recently approved treatment option for multiple myeloma." | 7.76 | Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient. ( Chang, J; Cho, SH; Kang, W; Kim, JS; Kim, SK; Park, MS, 2010) |
| "Thalidomide is now recognized as an important agent for multiple myeloma." | 7.76 | [Retrospective analysis of thalidomide therapy in patients with relapsed/refractory multiple myeloma]. ( Akagi, T; Goto, K; Ikebe, T; Ikewaki, J; Imamura, T; Kadota, J; Kohno, K; Miyazaki, M; Miyazaki, Y; Ogata, M; Ohtsuka, E; Saburi, Y; Uno, N, 2010) |
| "Factors that affect the response of multiple myeloma patients to thalidomide were evaluated in 40 patients who were not eligible for chemotherapy (untreated: 14, relapse/refractory: 26)." | 7.76 | [Factors affecting the response of thalidomide therapy for patients with multiple myeloma]. ( Agata, M; Ishiyama, M; Kazama, H; Kondo, T; Mori, N; Motoji, T; Oda, T; Okamura, T; Sagawa, K; Sameshima, Y; Shiseki, M; Teramura, M; Yamada, O; Yasunami, T; Yoshinaga, K, 2010) |
| "Between April 2006 and June 2009, 34 newly diagnosed patients with multiple myeloma received one to three courses of bortezomib 1." | 7.76 | Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD). ( Alexanian, R; Delasalle, K; Giralt, S; Wang, M, 2010) |
| "This single-center retrospective study determined the efficacy of bortezomib, thalidomide, and dexamethasone (BTD) as induction for patients with multiple myeloma (MM) who were eligible for autologous stem cell transplantation (ASCT)." | 7.76 | Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. ( Gleason, C; Heffner, LT; Kaufman, JL; Lonial, S; Nooka, A; Vrana, M, 2010) |
| "There was no association between functional CYP2C19 and CYP2D6 alleles and treatment outcome in multiple myeloma patients treated with cyclophosphamide, thalidomide or bortezomib." | 7.76 | No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma. ( Abildgaard, N; Andersen, NF; Gimsing, P; Gregersen, H; Klausen, TW; Rasmussen, HB; Søeby, K; Vangsted, AJ; Vogel, U; Werge, T, 2010) |
| "Previous literature suggests that cytogenetics may be used for risk-adapted therapy in patients with relapsed/refractory multiple myeloma (MM) treated with lenalidomide and dexamethasone." | 7.76 | Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. ( Chang, H; Chen, C; Jiang, A; Qi, C; Reece, D; Trieu, Y, 2010) |
| "The introduction of thalidomide, lenalidomide, and bortezomib has changed the way that multiple myeloma (MM) is treated and has greatly improved survival outcomes." | 7.76 | Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies. ( Morgan, G, 2010) |
| "The immunomodulatory drugs thalidomide and lenalidomide have enhanced activity in patients with multiple myeloma (MM)." | 7.75 | Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. ( Goldschmidt, H; Hegenbart, U; Hillengass, J; Ho, AD; Hundemer, M; Klein, U; Kosely, F; Moehler, T; Neben, K; Schmitt, S, 2009) |
| "Lenalidomide is an important contemporary treatment option for patients with multiple myeloma (MM)." | 7.75 | A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma. ( Alexandrescu, DT; Dasanu, CA, 2009) |
| " Here we report a case of severe ischemic cholangitis in a patient with multiple myeloma receiving chemotherapy with melphalan, prednisone, and lenalidomide." | 7.75 | Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide. ( Bianchi, L; Böckeler, M; Kanz, L; Mayer, F; Terracciano, LM; Weisel, KC, 2009) |
| " Osteonecrosis of the jaw (ONJ) is an emerging serious side effect of the new generation bisphosphonates with a growing number of reports related to this pathological entity." | 7.75 | Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. ( Aki, SZ; Cetiner, M; Cetiner, S; Gultekin, SE; Haznedar, R; Kahraman, SA; Kocakahyaoglu, B; Sucak, GT, 2009) |
| "The therapeutic use of thalidomide in patients with multiple myeloma is often complicated by the development of venous thromboembolism." | 7.75 | Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. ( Claxton, D; Fink, LM; Ibrahim, S; Talamo, GP; Tricot, GJ; Zangari, M, 2009) |
| "Curcumin (diferuloylmethane), a yellow pigment in turmeric, has been shown to inhibit the activation of nuclear factor-kappaB (NF-kappaB), a transcription factor closely linked to chemoresistance in multiple myeloma cells." | 7.75 | Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. ( Aggarwal, BB; Anand, P; Guha, S; Kunnumakkara, AB; Sethi, G; Sung, B, 2009) |
| "A prospective subgroup analysis of two prospective, randomized, double-blind, placebo-controlled phase III clinical trials showed that the combination of lenalidomide plus dexamethasone is superior to dexamethasone alone in patients with relapsed or refractory multiple myeloma who had been previously treated with thalidomide; the implications for clinical practice are discussed." | 7.75 | Hematology: Lenalidomide plus dexamethasone is effective in multiple myeloma. ( Meijer, E; Sonneveld, P, 2009) |
| "The serum concentration of thalidomide in multiple myeloma (MM) patients with renal insufficiency has not been investigated in Japan." | 7.75 | [Analysis of plasma concentration of thalidomide in Japanese patients of multiple myeloma with renal dysfunction]. ( Arai, A; Fukuda, T; Hirota, A; Miura, O; Mori, Y; Sasaki, S; Terada, Y; Tohda, S, 2009) |
| "Lenalidomide is an agent that has shown great activity in patients with multiple myeloma (MM)." | 7.75 | Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. ( Alousi, A; Anderlini, P; Andersson, B; Champlin, R; de Lima, M; Giralt, S; Hosing, C; Jones, R; Kebriaei, P; Khouri, I; Körbling, M; McMannis, J; Nieto, Y; Popat, U; Qazilbash, M; Saliba, R; Shpall, E; Thandi, R; Thomas, S; Wang, M; Weber, D, 2009) |
| "Lenalidomide gained Food and Drug Administration (FDA) approval for treatment of patients with relapsed or refractory multiple myeloma (MM) in combination with dexamethasone in June 2006." | 7.75 | Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. ( Abonour, R; Alsina, M; Bahlis, NJ; Boccia, RV; Chen, C; Coutre, SE; Knight, RD; Kumar, S; Matous, J; Niesvizky, R; Pietronigro, D; Rajkumar, V; Reece, DE; Richardson, P; Siegel, D; Stadtmauer, EA; Vescio, R; Zeldis, JB, 2009) |
| "We present a pooled update of two large, multicenter MM-009 and MM-010 placebo-controlled randomized phase III trials that included 704 patients and assessed lenalidomide plus dexamethasone versus dexamethasone plus placebo in patients with relapsed/refractory multiple myeloma (MM)." | 7.75 | Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. ( Attal, M; Chen, C; Dimopoulos, MA; Knight, RD; Niesvizky, R; Olesnyckyj, M; Petrucci, MT; Spencer, A; Stadtmauer, EA; Weber, DM; Yu, Z; Zeldis, JB, 2009) |
| "The purpose of this study was to investigate the effect of thalidomide (THD) combined with dexamethasone (Dx) on multiple myeloma KM3 cells and its mechanism." | 7.75 | [Effect of thalidomide combined with dexamethasone on multiple myeloma KM3 cells]. ( Gao, B; Gao, N; Gu, J; He, B; Li, JY; Zhang, Y; Zhou, W, 2009) |
| "We present the case of a 58-year old patient with relapsed multiple myeloma, in which lenalidomide was used in combination with dexamethasone after the failure of previous treatment modalities." | 7.75 | [Lenalidomide in the treatment of multiple myeloma]. ( Machálková, K; Maisnar, V, 2009) |
| "To assess potential benefits with thalidomide incorporated into double autologous stem-cell transplantation (ASCT) for younger patients with newly diagnosed multiple myeloma (MM)." | 7.75 | Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. ( Baccarani, M; Ballerini, F; Bigazzi, C; Brioli, A; Califano, C; Casulli, AF; Cavo, M; Ceccolini, M; de Vivo, A; Di Raimondo, F; Fiacchini, M; Ledda, A; Offidani, M; Patriarca, F; Perrone, G; Stefani, P; Tacchetti, P; Tosi, P; Volpe, S; Zamagni, E, 2009) |
| "Bortezomib-dexamethasone-thalidomide has been reported to be effective in newly-diagnosed multiple myeloma (MM) with an overall response rate of 92% and a CR rate of 18% (Alexanian et al, Hematology 2007;12(3):235-9), but this regimen has not been tested in the Chinese patients." | 7.75 | Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience. ( Cai, Z; He, J; Huang, H; Huang, W; Li, L; Lin, M; Luo, Y; Shi, J; Wei, G; Wu, W; Xie, W; Xue, X; Ye, X; Zhang, J; Zheng, W, 2009) |
| "To evaluate the effect of polymorphism at the -238 and -308 position of the TNF-alpha promotor region on the clinical outcome of thalidomide (Thal)-based regimens for the treatment of multiple myeloma (MM)." | 7.75 | [Effect of TNF-alpha gene polymorphism on outcome of thalidomide-based regimens for multiple myeloma]. ( Chen, BA; DU, J; Fu, WJ; Hou, J; Jiang, H; Yuan, ZG; Zhang, CY, 2009) |
| "To investigate the expression of B7 co-stimulatory molecules in human multiple myeloma (MM) and the immunoregulatory effects of thalidomide on B7." | 7.75 | [Regulatory effect of thalidomide on the expression of costimulatory molecules in patients with multiple myeloma]. ( He, AL; Tian, W; Wang, Y; Yang, HY; Yang, Y; Zhang, WG, 2009) |
| "The study was purposed to explore the changes of CD4(+)CD25(+) T regulatory cells in patients with multiple myeloma before and (MM) after treatment with thalidomide so as to provide evidences for effective immunotherapy." | 7.74 | [Effects of thalidomide on CD4(+)CD25(+) T regulatory cells in patients with multiple myeloma]. ( He, AL; Tian, W; Wang, JL; Yang, HY; Yang, Y; Zhang, WG, 2008) |
| "Bortezomib is a first-in-class proteasome inhibitor with remarkable antitumor activity that is approved for the treatment of patients with multiple myeloma." | 7.74 | Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma. ( Auran-Schleinitz, T; Blaise, D; Bouabdallah, R; Coso, D; de Collela, JM; de Lavallade, H; El-Cheikh, J; Gastaut, JA; Mohty, M; Stoppa, AM, 2008) |
| "This analysis assessed the efficacy and safety of lenalidomide + dexamethasone in patients with relapsed or refractory multiple myeloma (MM) previously treated with thalidomide." | 7.74 | Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. ( Attal, M; Chen, C; Cibeira, MT; Dimopoulos, MA; Knight, RD; Olesnyckyj, M; Rajkumar, SV; Spencer, A; Wang, M; Weber, DM; Yu, Z; Zeldis, JB, 2008) |
| "To analyse the efficacy and safety of thalidomide (Thal) for patients with multiple myeloma (MM)." | 7.74 | [The efficacy of thalidomide for multiple myeloma: a clinical analysis of 102 Chinese patients]. ( Li, YN; Qi, PJ; Qiu, LG; Wang, YF; Xiao, ZJ; Xu, Y; Zhao, YZ; Zou, DH, 2008) |
| "Few studies have focused on factors affecting outcome in patients with multiple myeloma (MM) treated with thalidomide-based therapy." | 7.74 | Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapy. ( Alesiani, F; Brunori, M; Burattini, M; Candela, M; Catarini, M; Centurioni, R; Corvatta, L; Ferranti, M; Galieni, P; Giuliodori, L; Leoni, P; Marconi, M; Mele, A; Offidani, M; Piersantelli, MN; Polloni, C; Visani, G, 2008) |
| "We activated and expanded iNKT cells from multiple myeloma patients with alpha-galactosylceramide (alpha-GalCer)-pulsed dendritic cells, characterized their antitumor effects by the cytokine production profile and cytotoxicity against multiple myeloma cells, and explored the effects of immunomodulatory drug lenalidomide on these iNKT cells." | 7.74 | Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. ( Anderson, KC; Balk, SP; Catley, L; Exley, MA; Munshi, NC; Podar, K; Prabhala, R; Shammas, MA; Song, W; Tai, YT; van der Vliet, HJ; Wang, R, 2008) |
| "To investigate the efficacy and adverse reaction of bortezomib plus chemotherapy with or without stem cell transplantation (SCT) for treatment of multiple myeloma (MM)." | 7.74 | [Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma]. ( Deng, SH; Qiu, LG; Wang, Y; Wang, YF; Wu, T; Xu, Y; Zhao, YZ; Zou, DH, 2008) |
| "Whether resveratrol, a component of red grapes, berries, and peanuts, could suppress the proliferation of multiple myeloma (MM) cells by interfering with NF-kappaB and STAT3 pathways, was investigated." | 7.74 | Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. ( Aggarwal, BB; Bhardwaj, A; Bueso-Ramos, C; Gaur, U; Nair, AS; Sethi, G; Shishodia, S; Takada, Y; Vadhan-Raj, S, 2007) |
| "Thalidomide is one of the drugs which are newly used in the therapy of multiple myeloma." | 7.74 | [Low-dose thalidomide in refractory and relapsing multiple myeloma]. ( Maisnar, V; Radocha, J, 2007) |
| "Lenalidomide is an immunomodulatory agent approved for use in patients with myelodysplastic syndrome, and in combination with dexamethasone for refractory or relapsed multiple myeloma." | 7.74 | Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide. ( Abonour, R; Knox, K; Smith, P; Thornburg, A; Twigg, HL, 2007) |
| "We present a patient with refractory multiple myeloma who showed a good response to a combination therapy with oral melphalan, dexamethasone, and thalidomide (MDT)." | 7.74 | Oral melphalan, dexamethasone, and thalidomide for the treatment of refractory multiple myeloma. ( Asou, N; Hata, H; Ide, K; Izuno, Y; Kawakita, M; Mitsuya, H; Okubo, T; Ueno, H, 2007) |
| "Thalidomide is successfully used in the treatment of multiple myeloma, leprosy and various autoimmune diseases due to its anti-angiogenic, immunomodulatory and anti-inflammatory effects." | 7.74 | Leukocytoclastic vasculitis due to thalidomide in multiple myeloma. ( Alpay, N; Ayer, M; Küçükkaya, RD; Mete, O; Nalçaci, M; Yavuz, AS; Yenerel, MN; Yildirim, ND, 2007) |
| "Thalidomide is an immunomodulatory drug used in the treatment of relapsed or refractory multiple myeloma (MM)." | 7.74 | Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment. ( Bláha, V; Büchler, T; Hájek, R; Maisnar, V; Malý, J; Radocha, J, 2007) |
| "Lenalidomide combined with dexamethasone has significant clinical activity in the treatment of multiple myeloma (MM)." | 7.74 | Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy? ( Colado, E; García-Sanz, R; Mateos, MV; Olazábal, J; San-Miguel, J, 2008) |
| "In this single-center analysis, we assessed whether lower thalidomide doses are feasible and result in favourable treatment response in multiple myeloma (MM) patients." | 7.74 | Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses. ( Denz, U; Engelhardt, M; Haas, PS; Ihorst, G, 2008) |
| "A pooled analysis was performed of patients with previously untreated multiple myeloma enrolled in clinical trials of lenalidomide-based therapy at the Mayo Clinic, Rochester, Minnesota, and the Italian Myeloma Network, Italy." | 7.74 | Thromboembolic events with lenalidomide-based therapy for multiple myeloma. ( Falco, P; Lacy, M; Menon, SP; Palumbo, A; Rajkumar, SV, 2008) |
| "To study the distribution of different genotypes of CYP2C19 in multiple myeloma (MM), and investigate the effect of its polymorphism on efficacy of thalidomide-based regimens for the treatment of MM and discuss the role of antiangiogenesis in MM." | 7.74 | [Effect of CYP2C19 gene polymorphism on efficacy of thalidomide-based regimens for the treatment of multiple myeloma]. ( Hou, J; Li, YH, 2007) |
| "Massive pulmonary embolism is an uncommon complication of multiple myeloma treated with thalidomide-dexamethasone regimen." | 7.74 | Pulmonary embolism in a patient with multiple myeloma receiving thalidomide-dexamethasone therapy. ( Chu, PH; Jeng, WJ; Kuo, MC; Shih, LY, 2008) |
| "We examined the effect of thalidomide and dexamethasone on the migration of multiple myeloma (MM) cell lines, U266, RPMI8226, and NCI-H929, using chemotaxis chamber plates." | 7.74 | The effects of thalidomide on chemotactic migration of multiple myeloma cell lines. ( Akamatsu, S; Fuchida, SI; Hirai, H; Inaba, T; Okamoto, M; Okano, A; Shimazaki, C; Taniwaki, M; Uchida, R; Yamada, N, 2008) |
| " Thalidomide has been associated with an increased risk of thromboembolic pulmonary hypertension (PH)." | 7.74 | Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study. ( Barbetakis, N; Bischiniotis, T; Lafaras, C; Mandala, E; Platogiannis, D; Verrou, E; Zervas, K, 2008) |
| "Thalidomide is effective in multiple myeloma (MM), even in patients who have relapsed after high-dose therapy." | 7.73 | Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC). ( Attal, M; Blaise, D; Bulabois, CE; Cahn, JY; Facon, T; Garban, F; Gratecos, N; Jouet, JP; Marit, G; Mohty, M; Rio, B; Sotto, JJ; Vernant, JP; Yakoub-Agha, I, 2005) |
| " Thalidomide is an immunomodulatory drug with numerous properties that has proven effective in relapsed multiple myeloma and, to a lesser extent, in other hematologic diseases." | 7.73 | Single-agent thalidomide induces response in T-cell lymphoma. ( Bilger, K; Bouabdallah, R; Damaj, G; Gastaut, JA; Mohty, M; Vey, N, 2005) |
| "Thalidomide and its analogs have been extensively studied in patients with multiple myeloma." | 7.73 | Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide. ( Carbonell, AL; del Giglio, A; Manhani, AR; Mitteldorf, CA; Weinschenker, P, 2005) |
| "The aim of the present study was to compare thalidomide-dexamethasone (Thal-Dex) and vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous peripheral blood stem-cell (PBSC) transplantation for multiple myeloma (MM)." | 7.73 | Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. ( Baccarani, M; Cangini, D; Cavo, M; Ceccolini, M; Cellini, C; de Vivo, A; Grafone, T; Nicci, C; Perrone, G; Tacchetti, P; Terragna, C; Testoni, N; Tosi, P; Tura, S; Zamagni, E, 2005) |
| "The expression of key angiogenic genes was studied in bone marrow endothelial cells (ECs) of patients with active and nonactive multiple myeloma (MM), monoclonal gammopathies unattributed/unassociated (MG[u]), diffuse large B-cell non-Hodgkin's lymphoma, in a Kaposi's sarcoma (KS) cell line, and in healthy human umbilical vein ECs (HUVECs) following exposure to therapeutic doses of thalidomide." | 7.73 | Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. ( Bicciato, S; Corradini, P; Dammacco, F; Di Pietro, G; Mattioli, M; Montefusco, V; Neri, A; Nico, B; Ribatti, D; Scavelli, C; Vacca, A, 2005) |
| "The use of the proteasome inhibitor bortezomib has been recently introduced into the treatment of relapsed, refractory multiple myeloma (MM)." | 7.73 | Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma. ( Graeven, U; König, M; Schmiegel, W; Schmielau, J; Teschendorf, C, 2005) |
| "The prompt response to bortezomib observed in a 63-year-old woman with multiple myeloma was associated with a significant increase in alkaline phosphatase (ALP)." | 7.73 | Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. ( Barlogie, B; Burns, MJ; Elice, F; Esseltine, D; Kang, SH; Lee, CK; Najarian, K; Richardson, P; Sonneveld, P; Tricot, G; Yaccoby, S; Zangari, M, 2005) |
| "To report thrombocytopenia in a patient prescribed thalidomide for multiple myeloma (MM)." | 7.73 | Thalidomide-associated thrombocytopenia. ( Brouwers, JR; Duyvendak, M; Kingma, BJ; Naunton, M, 2005) |
| "Thalidomide represents a recent and innovative therapeutic approach in multiple myeloma." | 7.73 | Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis. ( Bocchia, M; Bucalossi, A; Gozzetti, A; Lauria, F; Mazzotta, S; Pirrotta, MT; Sammassimo, S, 2005) |
| "Thalidomide plus dexamethasone (Thal/Dex) has emerged as an effective alternative to vincristine, doxorubicin and dexamethasone as a pre-transplant induction therapy for newly diagnosed multiple myeloma." | 7.73 | Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. ( Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, S; Kyle, RA; Lacy, MQ; Lust, JA; Nowakowski, GS; Rajkumar, SV; Witzig, TE, 2005) |
| "Based on our research we conclude that the mixture of lovastatin and thalidomide may increase the rate of multiple myeloma cells apoptosis in comparison to the single drug and the precise mechanism of this effect should be approved by further research." | 7.73 | Lovastatin and thalidomide have a combined effect on the rate of multiple myeloma cell apoptosis in short term cell cultures. ( Dmoszynska, A; Grzasko, N; Klimek, P; Podhorecka, M, 2006) |
| "The expression of proteins of the tumor necrosis factor (TNF) family on erythroblasts was measured during thalidomide treatment in 29 patients with multiple myeloma (MM)." | 7.73 | Stimulation of erythropoiesis by thalidomide in multiple myeloma patients: its influence on FasL, TRAIL and their receptors on erythroblasts. ( Dmoszynska, A; Grzasko, N; Hus, M; Soroka-Wojtaszko, M, 2006) |
| "To investigate the effect of the combination of thalidomide, cyclophosphamide and dexamethasone for the treatment of relapsed/refractory multiple myeloma." | 7.73 | [The effect of cyclophosphamide, thalidomide and dexamethasone combination therapy in relapsed/refractory multiple myeloma]. ( An, N; Chen, SL; Gao, W, 2006) |
| "The proteasome inhibitor bortezomib has demonstrated clinical activity in patients with multiple myeloma (MM)." | 7.73 | A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma. ( Bang, SM; Cho, KS; Jo, DY; Kim, CC; Kim, CS; Kim, K; Lee, JH; Lee, JJ; Lee, KH; Lee, NR; Min, CK; Min, YH; Park, S; Seong, CM; Sohn, SK; Suh, C; Yoon, HJ; Yoon, SS, 2006) |
| "Thalidomide administered as a single agent produces a response rate of about 40% in patients with refractory or relapsed multiple myeloma (MM)." | 7.73 | Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. ( Bladé, J; Cibeira, MT; Esteve, J; Ramiro, L; Rosiñol, L; Torrebadell, M, 2006) |
| "To examine dermatologic adverse effects of lenalidomide in patients with amyloidosis and multiple myeloma and to determine whether the adverse effects are different when lenalidomide is used alone compared with when it is used in combination with dexamethasone." | 7.73 | Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. ( Davis, MD; Dispenzieri, A; Rajkumar, SV; Sviggum, HP, 2006) |
| "A retrospective case-matched study was conducted to compare the oral regimen CTD (cyclophosphamide - thalidomide - dexamethasone) and infusional CVAMP (cyclophosphamide - vincristine - doxorubicin - methylprednisolone) as induction therapy followed by autologous peripheral blood stem-cell transplantation (PBSCT) for newly diagnosed multiple myeloma patients." | 7.73 | The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case- ( Alvares, CL; Davies, FE; Dines, S; Ethell, ME; Horton, C; Jenner, MW; Krishnan, B; McCormack, R; Morgan, GJ; Potter, MN; Saso, R; Treleaven, JG; Wu, P, 2006) |
| "Thalidomide (Thal) has been used for a few years as salvage treatment for patients with multiple myeloma (MM)." | 7.73 | Prognostic factors for the efficacy of thalidomide in the treatment of multiple myeloma: a clinical study of 110 patients in China. ( Chen, Y; Fu, W; Hou, J; Li, Y; Tao, Z; Wang, D; Yuan, Z, 2006) |
| "To assess response rate, duration of response, progression-free survival, and toxicity of thalidomide in patients with relapsed multiple myeloma." | 7.72 | Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. ( Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, SM; Greipp, PR; Hayman, SR; Iturria, NL; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE, 2003) |
| "We report the dermatologic side effects in 87 patients with multiple myeloma enrolled in a comparative, open-label, clinical trial treated with thalidomide alone (50 patients) or thalidomide and dexamethasone (37 patients)." | 7.72 | Dermatologic side effects of thalidomide in patients with multiple myeloma. ( Bouwhuis, S; El-Azhary, RA; Hall, VC; Rajkumar, SV, 2003) |
| "Thalidomide can not only inhibit angiogenesis, but also abrogate the adhesion of multiple myeloma cells to bone marrow stromal cells." | 7.72 | [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma]. ( Hong, WD; Li, J; Luo, SK; Zhou, ZH; Zou, WY, 2003) |
| "This research examines the profile of metabolites of thalidomide that are formed in refractory multiple myeloma patients undergoing thalidomide therapy in comparison with those that are detected in healthy mice." | 7.72 | Thalidomide metabolites in mice and patients with multiple myeloma. ( Baguley, BC; Browett, P; Ching, LM; Kestell, P; Lu, J; Muller, G; Palmer, BD, 2003) |
| "Between November 1998 and April 2000, the combination of thalidomide and dexamethasone was evaluated in 47 consecutive patients with multiple myeloma that was resistant to prior high-dose dexamethasone-based therapies." | 7.72 | Thalidomide and dexamethasone for resistant multiple myeloma. ( Alexanian, R; Anagnostopoulos, A; Delasalle, K; Rankin, K; Weber, D, 2003) |
| "Thalidomide has antiangiogenic properties and was found to be effective in patients with multiple myeloma (MM) when used in the setting of posttransplantation relapse." | 7.72 | Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. ( Barlogie, B; Eddleman, P; Fassas, A; Fink, L; Jacobson, J; Lee, CK; Talamo, G; Thertulien, R; Tricot, G; Van Rhee, F; Zangari, M, 2003) |
| "The optimum dose and duration of treatment with thalidomide for relapsed or refractory multiple myeloma are not known." | 7.72 | Thalidomide in relapsed or refractory multiple myeloma: how much and for how long? ( Abdalla, SH; Mahmoud, S, 2003) |
| "Thalidomide (Thd), a potent teratogen, was shown to have therapeutic potential in cancer, primarily in multiple myeloma (MM), yet its mechanism of action has not been elucidated." | 7.72 | Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma. ( Drucker, L; Lahav, M; Lishner, M; Radnay, J; Shapiro, H; Tohami, T; Uziel, O; Yarkoni, S, 2003) |
| "Venous thromboembolism (VTE) is a major complication in patients with multiple myeloma (MM) during treatment with thalidomide combined with chemotherapy and/or dexamethasone." | 7.72 | Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. ( De Groot, PG; Fijnheer, R; Lokhorst, HM; Minnema, MC, 2003) |
| "To investigate the effect of thalidomide on bone marrow cells gene expression in multiple myeloma (MM) patients with suppression subtractive hybridization (SSH) and explore the molecular mechanism of thalidomide therapy for MM." | 7.72 | [The changes of gene expression in multiple myeloma treated with thalidomide]. ( Chen, SL; Chen, ZB; Liu, JZ; Wang, HJ; Xiao, B; Zhang, HB, 2003) |
| "Fifty Taiwanese patients with relapsed and/or refractory multiple myeloma (MM) were treated with thalidomide on a dose-escalation schedule, commencing with 100 mg/d nightly and incremented either to the maximally tolerated dose or 800 mg/d." | 7.72 | Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma. ( Chen, YC; Hong, RL; Huang, SY; Ko, BS; Shen, MC; Tang, JL; Tien, HF; Tsai, W; Wang, CH; Yao, M, 2003) |
| "The purpose of this study was to determine the effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma." | 7.72 | Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. ( Bundy, KL; Christensen, BR; Dispenzieri, A; Gastineau, DA; Gertz, MA; Ghobrial, IM; Hayman, S; Lacy, MQ; Litzow, MR; Pribula, CG; Rajkumar, SV; Therneau, TM; Witzig, TE, 2003) |
| "Thalidomide, an agent with antiangiogenic and immunomodulatory properties, is therapeutically effective in multiple myeloma, leprosy, and autoimmune diseases." | 7.72 | Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide. ( Fruehauf, S; Goldschmidt, H; Hartschuh, W; Ho, AD; Moehler, T; Neben, K; Witzens, M, 2004) |
| "Remarkable results of the treatment of refractory multiple myeloma with thalidomide have been reported." | 7.72 | Low dose thalidomide in patients with relapsed or refractory multiple myeloma. ( Ackermann, J; Dimou, G; Drach, J; Gisslinger, H; Kees, M; Lechner, K; Sillaber, C, 2003) |
| "A proteasome inhibitor with a new molecular target (PS-341: bortezomib) was recently developed, and its efficacy in the treatment of refractory multiple myeloma has been reported in the United States." | 7.72 | [Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma]. ( Kikuchi, S; Komatsu, N; Mori, M; Muroi, K; Noborio-Hatano, K; Ozawa, K; Takahashi, S; Takatoku, M, 2004) |
| "Thalidomide has been shown to be effective in approximately 30% of patients with refractory or advanced multiple myeloma (MM)." | 7.72 | Possible multiple myeloma dedifferentiation following thalidomide therapy: a report of four cases. ( Balleari, E; Falcone, A; Ghio, R; Musto, P, 2004) |
| "s-Thalidomide has proven efficacy in multiple myeloma." | 7.72 | s-thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line. ( Chaplin, T; Joel, SP; Liu, WM; Malpas, JS; Propper, DJ; Shahin, S; Strauss, SJ; Young, BD, 2004) |
| "Thalidomide is an antiangiogenic drug that produces a response rate ranging from 32 to 64% in patients with refractory/relapsed multiple myeloma (MM)." | 7.72 | Extramedullary multiple myeloma escapes the effect of thalidomide. ( Aymerich, M; Bladé, J; Cibeira, MT; Cid, MC; Esteve, J; Filella, X; Montserrat, E; Rosiñol, L; Rozman, M; Segarra, M, 2004) |
| "To improve the antimyeloma effect of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation in multiple myeloma, we investigated in a phase 1/2 study the effect of low-dose thalidomide (100 mg) followed by DLI in 18 patients with progressive disease or residual disease and prior ineffective DLI after allografting." | 7.72 | Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. ( Ayuk, F; Fehse, B; Kröger, N; Lioznov, M; Nagler, A; Renges, H; Schieder, H; Shimoni, A; Zabelina, T; Zagrivnaja, M; Zander, AR, 2004) |
| "Thalidomide has been proved to play an important role in rescue treatment of patients with refractory/relapsed multiple myeloma (MM)." | 7.72 | Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide. ( Bladé, J; Bosch, F; Montagut, C; Rosiñol, L; Villela, L, 2004) |
| "Among 199 patients treated with thalidomide for multiple myeloma, four thromboses occurred in 49 cases during erythropoietin therapy (prevalence 8." | 7.72 | Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. ( Barbui, T; Comotti, B; Crippa, C; Elice, F; Galli, M; Rodeghiero, F, 2004) |
| "In this study, we analyzed the relationship between the plasma concentration of thalidomide and the therapeutic effect obtained by using thalidomide alone in patients with refractory multiple myeloma." | 7.72 | Unstable plasma thalidomide concentration in patients with refractory multiple myeloma. ( Horiuchi, R; Kodama, T; Murakami, H; Nojima, Y; Tsukamoto, N, 2004) |
| "We report a case of acute fatal exacerbation of chronic hepatitis B in a 50-year-old man with multiple myeloma being treated with thalidomide." | 7.72 | Acute exacerbation of chronic hepatitis B during thalidomide therapy for multiple myeloma: a case report. ( Ahn, JY; Bang, SM; Cho, EK; Kim, SS; Lee, JH; Park, SH; Shin, DB, 2004) |
| "A 66-year-old man was referred to our hospital for the treatment of refractory multiple myeloma with thalidomide." | 7.72 | [Interstitial pneumonia during treatment with thalidomide in a patient with multiple myeloma]. ( Chen, CK; Hattori, Y; Iguchi, T; Ikeda, Y; Okamoto, S; Sakoda, M; Yokoyama, K, 2004) |
| "The aim of this study was to assess the prognostic value of pretreatment clinical and laboratory parameters in refractory or relapsed multiple myeloma (MM) patients who have a long-term response to thalidomide (THAL), lasting at least 18 months." | 7.72 | An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma. ( Ciepluch, H; Dmoszynska, A; Hellmann, A; Hus, I; Hus, M; Jawniak, D; Kloczko, J; Konopka, L; Manko, J; Robak, T; Skotnicki, A; Soroka-Wojtaszko, M; Sulek, K; Wolska-Smolen, T, 2004) |
| "The aim of the study was to assess the influence of thalidomide on megakaryocytes (MK) in patients with multiple myeloma (MM)." | 7.72 | Influence of thalidomide on megakaryocytes in multiple myeloma. ( Dziecioł, J; Kłoczko, J; Lebelt, A; Lemancewicz, D; Piszcz, J; Szkudlarek, M, 2004) |
| "Seven cases of thromboembolism were found amongst 23 patients treated with thalidomide for myeloma over a total of 141." | 7.71 | Thromboembolism in patients on thalidomide for myeloma. ( Bowcock, SJ; Laffan, M; Rassam, SM; Turner, JT; Ward, SM, 2002) |
| "To evaluate treatment by thalidomide and identify predictive factors of survival, event free survival and response among patients with advanced multiple myeloma treated with thalidomide as single agent therapy." | 7.71 | Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM). ( Attal, M; Bay, JO; Berthou, C; Dauriac, C; Delannoy, V; Dorvaux, V; Duguet, C; Duhamel, A; Dumontet, C; Facon, T; Grosbois, B; Harousseau, JL; Lamy, T; Monconduit, M; Moreau, P; Yakoub-Agha, I, 2002) |
| "To determine the efficacy and side effects of thalidomide in the treatment of refractory multiple myeloma." | 7.71 | [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%]. ( Lokhorst, HM; Schaafsma, MR; Sonneveld, P; van der Holt, B; Wijermans, PW; Wu, KL, 2002) |
| "Recent reports showed that thalidomide has anti-angiogenic activity and is effective for the treatment of refractory multiple myeloma (MM)." | 7.71 | Thalidomide for the treatment of refractory multiple myeloma: association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome. ( Hattori, Y; Ikeda, Y; Kakimoto, T; Kamata, T; Morita, K; Okamoto, S; Sato, N; Shimada, N; Takayama, N; Tanigawara, Y; Uchida, H; Yamada, T; Yamaguchi, M, 2002) |
| "Thalidomide has shown efficacy in relapsed or refractory patients of multiple myeloma (MM)." | 7.71 | The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma. ( Grover, JK; Raina, V; Uppal, G, 2002) |
| "To observe the effective mechanism and side effects of thalidomide to multiple myeloma (MM)." | 7.71 | [Therapeutic effectiveness of thalidomide to multiple myeloma and its mechanism]. ( Li, Y; Liu, Y; Wang, M; Wu, H, 2002) |
| "To investigate the pro-angiogenic effects of several multiple myeloma (MM) cell line culture supernatants on human bone marrow endothelial cell (HBMEC) proliferation, migration, and capillary formation, and the anti-angiogenic effects of thalidomide." | 7.71 | [Thalidomide inhibits the angiogenic activity of culture supernatants of multiple myeloma cell line]. ( Chen, W; Mirshahi, F; Mirshahi, M; Soria, C; Soria, J; Zhu, J, 2002) |
| "Twenty-one patients with relapsed and refractory Durie-Salmon stage III multiple myeloma who had either failed at least three previous regimens or presented with poor performance status, neutropenia, or thrombocytopenia were treated with up to four cycles of combination melphalan (50 mg intravenously), thalidomide (titrated to target of 400 mg orally daily), and dexamethasone (40 mg/day orally on d 1 to 4) every 4-6 wk." | 7.71 | Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma. ( Elson, P; Hussein, MA; Karam, MA; Srkalovic, G; Trebisky, B, 2002) |
| "To investigate the influence of the thalidomide on the growth of multiple myeloma cells from untreated, relapsed or refractory patients and summarize its mechanisms, thalidomide influence on colony growth of untreated, relapsed or refractory multiple myeloma cells cultured by semisolid methylcellulose was observed." | 7.71 | [In vitro inhibition and mechanism of multiple myeloma cells growth by thalidomide]. ( Hong, WD; Huang, JQ; Li, J; Luo, SK, 2002) |
| "To evaluate the mechanism and influence of thalidomide on interleukin-6 (IL-6), IL-6 receptor (IL-6R) and its transmitting chain in multiple myeloma patients." | 7.71 | [Influence of thalidomide on interleukin-6 and its transmission in multiple myeloma patients]. ( Hong, W; Li, J; Luo, S; Zhou, Z; Zou, W, 2002) |
| "The antiangiogenic activity of thalidomide (Thal), coupled with an increase in bone marrow angiogenesis in multiple myeloma (MM), provided the rationale for the use of Thal in MM." | 7.71 | Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. ( Anderson, KC; Chauhan, D; Davies, FE; Gupta, D; Hideshima, T; Lentzsch, S; Lin, B; Morgan, GJ; Muller, GW; Podar, K; Raje, N; Richardson, PG; Schlossman, RL; Stirling, DI; Tai, YT; Treon, SP; Young, G, 2001) |
| "We evaluated thalidomide as a single agent in myeloma, myelodysplastic syndromes (MDS) and histiocytosis, i." | 7.71 | Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. ( Alietti, A; Bertolini, F; Burlini, A; Cineri, S; Cinieri, S; Cocorocchio, E; Corsini, C; Ferrucci, PF; Mancuso, P; Martinelli, G; Mingrone, W; Peccatori, F; Zucca, E, 2001) |
| "We report two patients who were treated with thalidomide for resistant multiple myeloma (MM) and developed extramedullary plasmacytomas despite a good response in the bone marrow." | 7.71 | Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. ( Avigdor, A; Ben-Bassat, I; Hardan, I; Levi, I; Raanani, P, 2001) |
| "The feasibility and efficacy of a combination of thalidomide, cyclophosphamide, etoposide, and dexamethasone were studied in 56 patients with poor-prognosis multiple myeloma." | 7.71 | Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. ( Benner, A; Egerer, G; Goldschmidt, H; Ho, AD; Krasniqi, F; Moehler, TM; Neben, K, 2001) |
| "Three cases of multiple myeloma treated with thalidomide are presented which highlight therapeutic dilemmas presented by therapy with this new agent." | 7.71 | Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions. ( Desikan, RK; Jagannath, S, 2001) |
| "Thalidomide has recently proven to be a useful drug for treatment of refractory and relapsed multiple myeloma patients, up to 35% of whom achieve remission." | 7.71 | The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma. ( García-Sanz, R; González, M; González-Fraile, MI; López, C; San Miguel, JF; Sierra, M, 2002) |
| "Several trials have shown the activity of thalidomide (THAL) in relapsed multiple myeloma (MM) patients failing PBSCT or conventional chemotherapy." | 7.71 | Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. ( Ahmad, I; Alam, AR; Becker, JL; Chanan-Khan, A; Hahn, T; Islam, T; McCarthy, PL; Wentling, D, 2002) |
| "Recently a growing number of studies have suggested the efficacy of thalidomide (THAL) in the treatment of relapsed or resistant multiple myeloma." | 7.71 | Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. ( Bojarska-Junak, A; Dmoszyńska, A; Domański, D; Hus, M; Roliński, J; Soroka-Wojtaszko, M, 2002) |
| "Thalidomide (Thal) achieves responses even in the setting of refractory multiple myeloma (MM)." | 7.71 | Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. ( Anderson, KC; Chauhan, D; Hideshima, T; Mitsiades, CS; Mitsiades, N; Munshi, NC; Poulaki, V; Richardson, PG; Treon, SP, 2002) |
| " We present a case of coinfection with disseminated HSV and VZV infection in a patient taking thalidomide for relapsed multiple myeloma." | 7.71 | Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma. ( Curley, MJ; Hassoun, PM; Hussein, SA, 2002) |
| "We have treated 17 refractory or relapsed multiple myeloma patients resistant to chemotherapy with thalidomide at a dose of 200-800 mg/day." | 7.70 | Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug. ( Avigdor, A; Ben-Bassat, I; Berkowicz, M; Hardan, I; Kneller, A; Levi, I; Raanani, P, 2000) |
| "To describe the efficacy of therapy with thalidomide, a drug that has antiangiogenic properties, in patients with relapsed multiple myeloma." | 7.70 | Thalidomide in the treatment of relapsed multiple myeloma. ( Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE, 2000) |
| " The novel quadruplet combination was overall well-tolerated, with clinically manageable adverse events." | 7.11 | A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma. ( Berenson, JR; Eades, B; Eshaghian, S; Ghermezi, M; Lim, S; Martinez, D; Schwartz, G; Spektor, TM; Swift, RA; Vescio, R; Yashar, D, 2022) |
| " Preliminary safety data, particularly the occurrence of cytopenias, can be used to guide dosing strategies for future combinations of venetoclax with immunomodulatory agents." | 7.01 | A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma. ( Abdallah, AO; Arriola, E; Bowles, KM; Bueno, OF; Coppola, S; Gasparetto, C; Mander, G; Mateos, MV; Morris, L; Ross, JA; Wang, J, 2021) |
| "Patients with relapsed/refractory multiple myeloma (RRMM) experience several relapses, and become refractory to successive therapies." | 7.01 | Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. ( Benboubker, L; Bringhen, S; Campana, F; Karlin, L; Koh, Y; Le Guennec, S; Maisnar, V; Menas, F; Pavic, M; Pour, L; Richardson, PG; van de Velde, H; Vorobyev, V; Vural, F; Warzocha, K, 2021) |
| "Melflufen is a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells." | 6.94 | OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma. ( Aschan, J; Pour, L; Robak, P; Schjesvold, F; Sonneveld, P, 2020) |
| " In routine practice, few patients received ixazomib-based induction therapy due to reasons including (1) patients' preference on oral regimens, (2) concerns on adverse events (AEs) of other intravenous/subcutaneous regimens, (3) requirements for less center visits, and (4) fears of COVID-19 and other infectious disease exposures." | 6.94 | Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study. ( Bao, L; Chen, B; Ding, K; Fu, C; Hua, L; Huang, Y; Li, B; Li, J; Liu, P; Luo, J; Wang, L; Wang, S; Wang, W; Wu, G; Xia, Z; Xu, T; Yang, W; Yang, Y; Zhang, W; Zhou, X, 2020) |
| "Ixazomib is a next generation inhibitor of the 20S proteasome and is thought to be an effective treatment for those who have relapsed from bortezomib." | 6.94 | The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a prote ( Auner, HW; Bailey, L; Brown, S; Brudenell Straw, F; Cook, G; Cook, M; Dawkins, B; Flanagan, L; Hinsley, S; Kaiser, MF; McKee, S; Meads, D; Reed, S; Sherratt, D; Walker, K, 2020) |
| "Despite therapeutic advances, multiple myeloma remains incurable, with limited options for patients with refractory disease." | 6.87 | Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. ( Ailawadhi, S; Bergsagel, PL; Buadi, FK; Chanan-Khan, AA; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Go, RS; Gonsalves, WI; Hayman, SR; Kapoor, P; Kourelis, T; Kumar, S; Kyle, RA; Lacy, MQ; LaPlant, BR; Laumann, KM; Leung, N; Lin, Y; Lust, JA; Mikhael, JR; Rajkumar, SV; Reeder, CB; Roy, V; Russell, SJ; Sher, T; Stewart, AK, 2018) |
| "Treatment for relapsed/refractory multiple myeloma (RRMM) remains an unmet need." | 6.87 | Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design. ( Anderson, KC; Attal, M; Campana, F; Corzo, K; Hui, AM; Le-Guennec, S; Richardson, PG; Risse, ML, 2018) |
| "Autoimmune events included pneumonitis (6 [13%]) and hypothyroidism (5 [10%]), mostly ≤ grade 2." | 6.84 | Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. ( Badros, A; Dell, C; Dogan, A; Goloubeva, O; Hyjek, E; Kocoglu, M; Lederer, E; Lesokhin, A; Ma, N; Milliron, T; Philip, S; Rapoport, AP; Singh, Z, 2017) |
| " This analysis of the pivotal phase 3 FIRST trial examined the impact of renally adapted dosing of lenalidomide and dexamethasone on outcomes of patients with different degrees of renal impairment." | 6.82 | Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. ( Belhadj, K; Bensinger, W; Chen, G; Cheung, MC; Derigs, HG; Dib, M; Dimopoulos, MA; Eom, H; Ervin-Haynes, A; Facon, T; Gamberi, B; Hall, R; Jaccard, A; Jardel, H; Karlin, L; Kolb, B; Lenain, P; Leupin, N; Liu, T; Marek, J; Rigaudeau, S; Roussel, M; Schots, R; Tosikyan, A; Van der Jagt, R, 2016) |
| "Proteasome inhibitors (PIs) in combination with immunomodulatory drugs (IMiDs) have been shown to be effective against relapsed/refractory multiple myeloma (RRMM)." | 6.82 | Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma. ( Hagiwara, S; Iida, S; Ishida, T; Ito, A; Kanamori, T; Kato, C; Kinoshita, S; Komatsu, H; Kusumoto, S; Masuda, A; Murakami, S; Nakashima, T; Narita, T; Ri, M; Suzuki, N; Totani, H; Yoshida, T, 2016) |
| "Relapsed/refractory multiple myeloma (RRMM) patients have poor overall survival (OS)." | 6.82 | Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS). ( Dimopoulos, MA; Gibson, CJ; Hong, K; Moreau, P; Saunders, O; Song, KW; Sternas, LA; Weisel, KC; Zaki, MH, 2016) |
| "Pomalidomide 4 mg was given on days 1-21 of 28-day cycles with low-dose dexamethasone 40 mg (20 mg for patients aged >75 years) on days 1, 8, 15, and 22 until progressive disease or unacceptable toxicity." | 6.82 | Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. ( Anttila, P; Blanchard, MJ; Cafro, AM; Cavo, M; Corradini, P; de Arriba, F; Delforge, M; Di Raimondo, F; Dimopoulos, MA; Doyen, C; Goldschmidt, H; Hansson, M; Herring, J; Kaiser, M; Knop, S; Miller, N; Moreau, P; Morgan, G; Ocio, EM; Oriol, A; Palumbo, A; Peluso, T; Petrini, M; Raymakers, R; Röllig, C; San-Miguel, J; Simcock, M; Sternas, L; Vacca, A; Weisel, KC; Zaki, MH, 2016) |
| " Dosing was based on the lenalidomide label." | 6.82 | Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment. ( Abraham, J; Arnulf, B; Bridoux, F; Chen, N; Desport, E; Fermand, JP; Jaccard, A; Moreau, S; Moumas, E, 2016) |
| "Pomalidomide is a distinct oral IMiD(®) immunomodulatory agent with direct antimyeloma, stromal-support inhibitory, and immunomodulatory effects." | 6.80 | Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. ( Alegre, A; Bahlis, NJ; Banos, A; Cavo, M; Chen, C; Delforge, M; Dimopoulos, MA; Garderet, L; Goldschmidt, H; Ivanova, V; Jacques, C; Karlin, L; Martinez-Lopez, J; Moreau, P; Oriol, A; Renner, C; San Miguel, JF; Song, KW; Sternas, L; Teasdale, T; Weisel, KC; Yu, X; Zaki, MH, 2015) |
| "Lenalidomide is an immunomodulatory drug with co-stimulatory effects on NKT cells in vitro and is an approved treatment for MM, although its mode of action in that context is not well defined." | 6.79 | Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy. ( Berzins, SP; Chan, AC; Godfrey, DI; Harrison, SJ; Leeansyah, E; Neeson, P; Prince, HM; Quach, H; Ritchie, D; Tainton, K, 2014) |
| " A total of 43 patients were recruited into three CPT plus thalidomide cohorts based on CPT dosage in sequence: 5 mg/kg (n = 11), 8 mg/kg (n = 17), and 10 mg/kg (n = 15)." | 6.79 | A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma. ( Chen, WM; Geng, C; Hou, J; Huang, Z; Ke, X; Liu, Y; Qiu, L; Wang, F; Wang, Z; Wei, N; Wei, P; Xi, H; Yang, S; Zhao, Y; Zheng, X; Zhu, B, 2014) |
| "Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24." | 6.78 | Sorafenib in patients with refractory or recurrent multiple myeloma. ( Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A, 2013) |
| "The lenalidomide dose was 25 mg/day, and was adjusted according to baseline renal function." | 6.78 | A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. ( Ai, H; Cai, Z; Chen, F; Chen, N; Du, X; Hou, J; Jin, J; Ke, X; Li, X; Mei, J; Meng, F; Wang, J; Wortman-Vayn, H; Wu, D; Yu, L; Zhang, J; Zhou, DB, 2013) |
| "For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop." | 6.78 | Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. ( Bargay, J; Bladé, J; de Arriba, F; de la Rubia, J; García, JL; Giraldo, P; Hernández, MT; Lahuerta, JJ; López Corral, L; López, J; Mateos, MV; Olavarría, E; Oriol, A; Paiva, B; Palomera, L; Prosper, F; Quintana, N; Rosiñol, L; San Miguel, JF, 2013) |
| "Pomalidomide was given at 1 to 2." | 6.78 | Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. ( Baldi, I; Boccadoro, M; Bringhen, S; Carella, AM; Corradini, P; Crippa, C; Galli, M; Giuliani, N; Guglielmelli, T; La Verde, G; Larocca, A; Magarotto, V; Marcatti, M; Mina, R; Montefusco, V; Omedé, P; Palumbo, A; Rossi, D; Rota-Scalabrini, D; Santagostino, A, 2013) |
| "Patients with asymptomatic (smoldering) multiple myeloma (AMM) have a high risk of transformation to active multiple myeloma (MM)." | 6.78 | A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. ( Dispenzieri, A; Gertz, MA; Greipp, PR; Hassoun, H; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, KM; Lust, JA; Mandrekar, SJ; Rajkumar, SV; Reeder, CB; Roy, V; Witzig, TE, 2013) |
| "Patients with newly diagnosed multiple myeloma were included in the HOVON-65/GMMG-HD4 trial, in which postintensification treatment in 1 arm consisted of daily thalidomide (50 mg) for 2 years." | 6.78 | High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. ( Bertsch, U; Broyl, A; Buijs, A; el Jarari, L; Goldschmidt, H; Hose, D; Kuiper, R; Lokhorst, HM; Sonneveld, P; van der Holt, B; van Duin, M; Zweegman, S, 2013) |
| "Thrombocytopenia was the most common grade ≥ 3 AE (35%)." | 6.78 | A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. ( Allietta, N; Angermund, R; Bladé, J; Blau, IW; Broer, E; Corradini, P; Dimopoulos, MA; Drach, J; Giraldo, P; Mitchell, V; Petrucci, MT; Teixeira, A, 2013) |
| "Thalidomide 100 mg/day was better tolerated than 400 mg/day with less high-grade somnolence, constipation, nausea/vomiting and peripheral neuropathy (P < 0." | 6.77 | Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome. ( Benboubker, L; Berthou, C; Casassus, P; Damaj, G; Dib, M; Doyen, C; Facon, T; Harousseau, JL; Hulin, C; Maloisel, F; Marit, G; Mary, JY; Mohty, M; Moreau, P; Pegourie, B; Rodon, P; Slama, B; Stoppa, AM; Voillat, L; Yakoub-Agha, I; Zerbib, R, 2012) |
| "Patients with multiple myeloma (MM) undergoing high dose therapy and autologous stem cell transplantation (SCT) remain at risk for disease progression." | 6.77 | Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity. ( Chung, HM; Clark, WB; Hazlett, AF; Kmieciak, M; Manjili, MH; McCarty, JM; Payne, KK; Roberts, CH; Sabo, RT; Sanford, K; Toor, AA; Williams, DC, 2012) |
| "Newly diagnosed patients with multiple myeloma (MM) (n=122) aged greater than 55 yr, not eligible for transplantation were randomized to receive 8 cycles of M (9 mg/m(2) /d) and P (60 mg/m(2) /d) for 4d every 6 wk (n=62) or MP and thalidomide (100 mg/d) continuously (n=60)." | 6.76 | Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. ( Ali, R; Aydogdu, I; Beksac, M; Firatli-Tuglular, T; Goker, H; Gulbas, Z; Haznedar, R; Karakus, S; Kaya, E; Kaygusuz, I; Konuk, N; Ozdogu, H; Ozet, G; Sucak, G; Undar, L, 2011) |
| "In newly diagnosed multiple myeloma (MM), three/four-drug combinations as induction therapy seem to be more effective compared with two-drug associations in terms of response rate and duration of remission." | 6.76 | Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma. ( Blasi, N; Brunori, M; Caraffa, P; Catarini, M; Corvatta, L; Ferranti, M; Gentili, S; Leoni, P; Malerba, L; Mele, A; Offidani, M; Polloni, C; Rizzi, R; Samori, A, 2011) |
| "Forty-three newly diagnosed multiple myeloma patients requiring treatment were enrolled on this study." | 6.76 | A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. ( Ailawadhi, S; Chanan-Khan, A; Czuczman, MS; Hernandez-Ilizaliturri, FJ; Hong, F; Iancu, D; Jamshed, S; Lawrence, W; Lee, K; Manfredi, D; Masood, A; Miller, KC; Sher, T; Soniwala, S; Sood, R; Tan, W; Wilding, G; Wood, M, 2011) |
| "Thalidomide maintenance was associated with impaired OS, although our analysis suggests that this effect may have been due to confounding variables." | 6.76 | The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. ( Boyd, KD; Chiecchio, L; Child, JA; Dagrada, G; Davies, FE; Gonzalez, D; Gregory, WM; Hockley, SL; Jackson, GH; Konn, ZJ; Morgan, GJ; Ross, FM; Tapper, WJ; Walker, BA; Wardell, CP, 2011) |
| "Lenalidomide was generally well tolerated and no grade 4 hematologic toxicities were noted." | 6.75 | Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis. ( Baz, R; Chanan-Khan, AA; Finley-Oliver, E; Hussein, MA; Lebovic, D; Lee, K; Miller, KC; Patel, M; Sher, T; Wood, M, 2010) |
| " Phase 2 dosing was determined to be bortezomib 1." | 6.75 | Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. ( Anderson, KC; Avigan, DE; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, AJ; Joyce, R; Kaster, S; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Mazumder, A; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, DL; Weller, E; Xie, W, 2010) |
| " Nonhematologic grade 3/4 adverse events were reported in 35% of once-weekly patients and 51% of twice-weekly patients (P = ." | 6.75 | Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. ( Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Cavalli, M; Cavo, M; De Rosa, L; Evangelista, A; Falcone, AP; Gaidano, G; Gentili, S; Genuardi, M; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Liberati, AM; Musto, P; Nozzoli, C; Palumbo, A; Patriarca, F; Ria, R; Rizzo, V; Rossi, D, 2010) |
| "Novel agents have demonstrated enhanced efficacy when combined with other antimyeloma agents especially dexamethasone." | 6.74 | Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. ( Ailawadhi, S; Barcos, M; Bernstein, ZP; Chanan-Khan, A; Czuczman, MS; Iancu, D; Lee, K; Miller, KC; Mohr, A; Musial, L; Padmanabhan, S; Patel, M; Sher, T; Yu, J, 2009) |
| "Thalidomide therapy was associated with a significant increase in the incidence of patients with multiple expansions (49% vs." | 6.74 | Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. ( Aklilu, E; Brown, RD; Gibson, J; Ho, PJ; Joshua, DE; Kabani, K; Kennedy, N; Spencer, A; Sze, DM; Yang, S, 2009) |
| "Osteolytic bone disease in multiple myeloma (MM) is caused by enhanced osteoclast (OCL) activation and inhibition of osteoblast function." | 6.73 | Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. ( Anderson, KC; Breitkreutz, I; Chauhan, D; Hideshima, T; Mitsiades, C; Munshi, NC; Okawa, Y; Raab, MS; Raje, N; Richardson, PG; Vallet, S, 2008) |
| " Food and Drug Administration (FDA) on June 29, 2006, for use in combination with dexamethasone in patients with multiple myeloma (MM) who have received at least one prior therapy." | 6.73 | Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy. ( Booth, B; Dagher, R; Farrell, A; Hazarika, M; Justice, R; Pazdur, R; Rock, E; Sridhara, R; Williams, G, 2008) |
| "Thalidomide has direct antimyeloma and immunomodulatory effects." | 6.73 | Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21. ( Abonour, R; Ansari, RH; Cripe, LD; Fausel, C; Fisher, WB; Juliar, BE; Smith, GG; Suvannasankha, A; Wood, LL; Yiannoutsos, CT, 2007) |
| "Thalidomide maintenance has unresolved issues regarding dosage and toxicity." | 6.73 | Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study. ( Cocks, K; Feyler, S; Jackson, G; Johnson, RJ; Rawstron, A; Snowden, JA, 2007) |
| "Bortezomib (V) was combined with thalidomide (T) and dexamethasone (D) in a phase I/II trial to determine dose-limiting toxicities (DLT's) and clinical activity of the VTD regimen in 85 patients with advanced and refractory myeloma." | 6.73 | VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. ( Anaissie, E; Barlogie, B; Crowley, J; Epstein, J; Hoering, A; Petty, N; Pineda-Roman, M; Shaughnessy, J; Szymonifka, J; van Rhee, F; Zangari, M, 2008) |
| "In the present study, markers of bone resorption [urinary free pyridinoline (PYD), deoxypyridinoline (DPYD), N-terminal telopeptide of collagen I (NTX) and C-terminal telopeptide (serum crosslaps)] and of bone formation [bone alkaline phosphatase (BAP) and osteocalcin] were evaluated at diagnosis and after induction therapy in 40 patients (23M, 17F, median age = 53." | 6.72 | First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. ( Baccarani, M; Boni, P; Cangini, D; Cavo, M; Ceccolini, M; Cellini, C; Parente, R; Perrone, G; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E, 2006) |
| "Significant peripheral neuropathy and deep vein thrombosis each occurred in only 3%." | 6.72 | A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ( Alsina, M; Anderson, KC; Blood, E; Dalton, WS; Desikan, KR; Doss, D; Freeman, A; Gorelik, S; Hideshima, T; Jagannath, S; Kelly-Colson, K; Knight, R; McKenney, ML; Mitsiades, CS; Munshi, NC; Olesnyckyj, M; Rajkumar, SV; Rich, R; Richardson, PG; Schlossman, RL; Warren, D; Weller, E; Wride, K; Wu, A; Zeldenrust, SR; Zeldis, J, 2006) |
| "Thalidomide is an effective maintenance therapy in patients with multiple myeloma." | 6.72 | Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. ( Attal, M; Avet-Loiseau, H; Benboubker, L; Berthou, C; Bourhis, JH; Caillot, D; Doyen, C; Dumontet, C; Facon, T; Garderet, L; Grobois, B; Harousseau, JL; Hulin, C; Leyvraz, S; Marit, G; Monconduit, M; Moreau, P; Pegourie, B; Renaud, M; Voillat, L; Yakoub Agha, I, 2006) |
| "Relapsed or refractory multiple myeloma has a poor outlook." | 6.71 | Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. ( Bell, R; Biagi, JJ; Briggs, P; Grigg, A; Lillie, K; McKendrick, J; Mileshkin, L; Mitchell, P; Prince, HM; Seymour, JF; Smith, JG; Underhill, C; Zeldis, JB, 2003) |
| "Neutropenia was a dose limiting factor with half of the cases (7/14) presenting with severe neutropenia (grade 3-4), but a response was observed in all of them on administration of G-CSF." | 6.71 | [Single-agent thalidomide for advanced and refractory multiple myeloma]. ( Fujimura, K; Imagawa, J; Katayama, Y; Kimura, A; Noda, M; Okikawa, Y; Okita, H; Sakai, A; Takimoto, Y, 2003) |
| "Sixty patients with advanced multiple myeloma received 2-6 monthly treatment courses combining hyperfractionated cyclophosphamide (300 mg/m2 i." | 6.71 | Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. ( Berdel, WE; Bisping, G; Dominé, N; Fenk, R; Heinecke, A; Hentrich, M; Innig, G; Kienast, J; Koch, OM; Kropff, MH; Lang, N; Mitterer, M; Ostermann, H; Straka, C; Südhoff, T, 2003) |
| "We treated with thalidomide 17 patients (12 males, 5 females), average age 51 (range 42-73 years), mean time since diagnosis to the start of thalidomide treatment was 24 months (range 5-48)." | 6.71 | [Preliminary results of monotherapy with thalidomide in recurrent and treatment resistant cases of multiple myeloma]. ( Helbig, G; Hołowiecki, J; Kyrcz-Krzemień, S; Stella-Hołowiecka, B, 2003) |
| "Thalidomide was given daily at a dose of 200 mg at bedtime." | 6.71 | Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. ( Anagnostopoulos, A; Dimopoulos, MA; Hatzicharissi, E; Korantzis, J; Maniatis, A; Mitsouli, Ch; Panagiotidis, P; Papaioannou, M; Tzilianos, M; Zervas, K, 2004) |
| "Thalidomide is an oral agent with significant activity in one-third of patients with refractory myeloma." | 6.71 | Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. ( Anagnostopoulos, A; Anagnostopoulos, N; Dimopoulos, MA; Efstathiou, E; Gika, D; Grigoraki, V; Hamilos, G; Poziopoulos, C; Xilouri, I; Zomas, A; Zorzou, MP, 2004) |
| "Thalidomide has recently been recognized as an effective new agent for previously untreated, refractory or relapsed myeloma." | 6.71 | Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program. ( Gastl, G; Mitterer, M; Spizzo, G; Steurer, M, 2004) |
| " Thalidomide, both alone and in combination with dexamethasone, has been demonstrated to be useful in patients with advanced MM, as responses could be achieved in 30-60% of the cases." | 6.71 | Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. ( Baccarani, M; Cangini, D; Cavo, M; Cellini, C; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E, 2004) |
| "The incidence of deep vein thrombosis (DVT) was significantly higher in the thalidomide arm hazard ratio: 4." | 6.71 | Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. ( Anaissie, E; Barlogie, B; Eddlemon, P; Fassas, A; Fink, L; Jacobson, J; Lee, CK; Saghafifar, F; Talamo, G; Thertulien, R; Thomas, T; Tricot, G; Van Rhee, F; Zangari, M, 2004) |
| "Bortezomib was found to be cost effective relative to BSC and thalidomide." | 6.71 | Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma. ( Duff, SB; Gupta, S; Mehta, J, 2004) |
| "Thalidomide (400 mg/d) was combined with bolus injections of vincristine and epirubicin and oral dexamethasone (VED)." | 6.71 | Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. ( Bojko, P; Brandhorst, D; Buttkereit, U; Ebeling, P; Flasshove, M; Hense, J; Hoiczyk, M; Metz, K; Moritz, T; Nowrousian, MR; Opalka, B; Schütt, P; Seeber, S, 2005) |
| "Thalidomide (Thal) is a drug with antiangiogenic, anti-inflammatory, and immunomodulatory properties that was found to inhibit the production of tumor necrosis factor-alpha (TNF-alpha) in vitro." | 6.70 | Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. ( Goldschmidt, H; Ho, AD; Kraemer, A; Moehler, TM; Mytilineos, J; Neben, K; Opelz, G; Preiss, A, 2002) |
| " Response rates were higher and survival was longer especially in high-risk patients given more than 42 g THAL in 3 months (median cumulative dose) (landmark analysis); this supports a THAL dose-response effect in advanced MM." | 6.70 | Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. ( Anaissie, E; Ayers, D; Badros, A; Barlogie, B; Desikan, R; Eddlemon, P; Epstein, J; Munshi, N; Shaughnessy, J; Spencer, T; Spoon, D; Tricot, G; Zangari, M; Zeldis, J, 2001) |
| "Thalidomide (Thal) is a drug with anti-angiogenic properties." | 6.70 | Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. ( Benner, A; Egerer, G; Goldschmidt, H; Ho, AD; Kraemer, A; Moehler, T; Neben, K, 2001) |
| "Thalidomide was initially administered at a dose of 100 mg/day; if well tolerated, the dose was to be increased serially by 200mg every other week to a maximum of 800 mg/day." | 6.70 | Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. ( Baccarani, M; Ballerini, F; Cangini, D; Cavo, M; Cellini, C; Di Raimondo, F; Gobbi, M; Lauria, F; Ledda, A; Masini, L; Musto, P; Patriarca, F; Ria, R; Ronconi, S; Tosi, P; Tura, S; Vacca, A; Zamagni, E, 2002) |
| "Multiple myeloma is a bone marrow-based hematological malignancy accounting for approximately two per cent of cancers." | 6.61 | Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. ( Adams, A; Estcourt, LJ; Jakob, T; Kuhr, K; Langer, P; Monsef, I; Ocheni, S; Piechotta, V; Scheckel, B; Scheid, C; Skoetz, N; Theurich, S, 2019) |
| "Pomalidomide (Pom) has demonstrated synergistic antiproliferative activity in combination regimens as a result of its distinct anticancer, antiangiogenic, and immunomodulatory effects." | 6.61 | Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials. ( Ali, Z; Anwer, F; Hassan, H; Hassan, SF; Iftikhar, A; Kamal, A; Lakhani, M; Mushtaq, A; Raychaudhuri, S; Razzaq, F; Safdar, A; Sagar, F; Zahid, U; Zar, MA, 2019) |
| " Carfilzomib (CFZ) has high selectivity and minimal off-target adverse effects including lower rates of PNP." | 6.58 | Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review. ( Abraham, I; Anwer, F; Iftikhar, A; Kapoor, V; Latif, A; McBride, A; Mushtaq, A; Riaz, IB; Zahid, U, 2018) |
| " The treatment outcomes of MAbs versus HDACi in combination with bortezomib or lenalidomide plus dexamethasone remain unknown." | 6.58 | Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trial ( Chen, X; Feng, J; Gao, G; Shen, H; Tang, H; Xu, L; Zhang, N; Zheng, Y, 2018) |
| "Thalidomide is a drug with interesting therapeutic properties but also with severe side effects which require a careful and monitored use." | 6.55 | A Mini-Review on Thalidomide: Chemistry, Mechanisms of Action, Therapeutic Potential and Anti-Angiogenic Properties in Multiple Myeloma. ( Adriani, G; Carocci, A; Catalano, A; Cavalluzzi, MM; Corbo, F; Franchini, C; Lentini, G; Mercurio, A; Rao, L; Vacca, A, 2017) |
| "Multiple myeloma is a very heterogeneous disease with variable survival." | 6.55 | Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy. ( Alarcón-Payer, C; Cabeza Barrera, J; de la Guardia, AMDVD; García Collado, CG; Jiménez Morales, A; Jurado Chacón, M; Martín-García, A; Ríos-Tamayo, R; Sánchez-Rodríguez, D, 2017) |
| "Lenalidomide has multifaceted antimyeloma properties, including direct tumoricidal and immunomodulatory effects." | 6.55 | Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. ( Anderson, KC; Attal, M; Holstein, SA; McCarthy, PL; Richardson, PG; Schlossman, RL, 2017) |
| " These studies provide further support for clinical trials evaluating OPZ in combination with Pom and Dex." | 6.55 | Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex). ( Berenson, JR; Chen, H; Gillespie, A; Li, M; Sanchez, E; Tang, G; Wang, CS, 2017) |
| "Sorafenib is an orally available compound that acts predominantly by targeting the Ras/Raf/MEK/ERK pathway and by inhibiting the vascular endothelial growth factor (VEGF)." | 6.53 | Sorafenib for the treatment of multiple myeloma. ( Gentile, M; Martino, M; Morabito, F; Morabito, L; Recchia, AG; Vigna, E, 2016) |
| "Clarithromycin is a 14-membered ring macrolide antibiotics that is widely used in the treatment of infectious disease." | 6.52 | [Progress of research on clarithromycin for treatment of multiple myeloma]. ( Qiu, XH; Zhai, YP, 2015) |
| "Pomalidomide is a distinct IMiD agent recently approved in the US and Europe." | 6.50 | Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma. ( Coleman, M; Mark, TM; Niesvizky, R, 2014) |
| "Pomalidomide is a new IMiD with a similar structure to the commonly used IMiD thalidomide and lenalidomide." | 6.50 | Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data. ( Caraffa, P; Corvatta, L; Larocca, A; Leoni, P; Offidani, M; Palumbo, A; Pautasso, C, 2014) |
| "Pomalidomide (Pomalyst(®)) is a synthetic compound derived by modifying the chemical structure of thalidomide to improve its potency and reduce its side effects and third drug in the class of immunomodulatory drugs." | 6.50 | Impact of pomalidomide therapy in multiple myeloma: a recent survey. ( Kumar, A; Mishra, AK; Porwal, M; Verma, A, 2014) |
| "Multiple myeloma is a hematologic malignancy characterized by plasma cell clonal expansion as well as end-organ damage due to increased levels of monoclonal proteins in both the plasma and urine." | 6.50 | Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma. ( Chen, SE; Highsmith, KN; Horowitz, S, 2014) |
| "Pomalidomide is a potent second-generation immunomodulatory agent with direct antiproliferative, pro-apoptotic, and antiangiogenic effects, as well as modulatory effects on bone resorption and on the immune system." | 6.50 | [Pomalidomide in the treatment of relapsed and refractory multiple myeloma]. ( Bátorová, A; Mistrík, M; Roziaková, L, 2014) |
| "Lenalidomide (15 mg) was administered for 2 courses." | 6.49 | Safety and effectiveness of low-dose lenalidomide therapy for multiple myeloma complicated with bortezomib-associated interstitial pneumonia. ( Ihara, K; Inomata, H; Kato, J; Kikuchi, S; Koyama, R; Muramatsu, H; Nagamachi, Y; Nishisato, T; Nozawa, E; Okamoto, T; Ono, K; Tanaka, S; Yamada, H; Yamauchi, N; Yano, T, 2013) |
| "Lenalidomide was associated with a significantly increased progression free survival and in one study with a significant survival benefit." | 6.49 | [Lenalidomide maintenance therapy in patients with multiple myeloma]. ( Mistrík, M; Roziaková, L, 2013) |
| "Treatment with thalidomide is associated with an increased risk of developing peripheral neuropathy, which can be managed with dose reductions and discontinuation, and venous thromboembolism, which warrants thromboprophylaxis." | 6.49 | Role of thalidomide in the treatment of patients with multiple myeloma. ( Davies, FE; Morgan, GJ, 2013) |
| "Pomalidomide is an orally active thalidomide analogue that has a pleiotropic mechanism of action involving oncolytic, antiangiogenic, immunomodulatory and anti-inflammatory activities." | 6.49 | Pomalidomide for patients with multiple myeloma. ( Gras, J, 2013) |
| "Lenalidomide (LEN) is an immunomodulatory drug (IMiD) which exerts tumoricidal effects and has immunomodulatory, anti-inflammatory and anti-angiogenic properties that synergistically keep the tumor in remission." | 6.49 | Novel lenalidomide-based combinations for treatment of multiple myeloma. ( Brunetti, O; Cives, M; Longo, V; Silvestris, F; Simone, V, 2013) |
| "Lenalidomide (LEN) is a structural analogue of Thalidomide and is currently considered a promising compound among immunomodulatory drugs." | 6.48 | Lenalidomide in multiple myeloma: current experimental and clinical data. ( Cives, M; Dammacco, F; Milano, A; Silvestris, F, 2012) |
| "Although multiple myeloma remains an essentially incurable disease, treatment options and patients' quality of life have improved over the last years with the introduction of more effective and less toxic agents." | 6.48 | Advantageous use of lenalidomide in multiple myeloma: discussion of three case studies. ( Figueiredo, A; João, C; Martins, HF, 2012) |
| "Lenalidomide has a predominantly renal route of excretion and in patients with RI the plasma concentration and half-life of the drug are significantly increased." | 6.48 | Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment. ( Alegre, A; Dimopoulos, MA; Goldschmidt, H; Mark, T; Niesvizky, R; Terpos, E, 2012) |
| "The field of multiple myeloma therapeutics has been an active one for many years, but perhaps no more so than in the past decade." | 6.47 | Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. ( Anderson, KC; Laubach, JP; Mitsiades, CS; Richardson, PG; Schlossman, RL, 2011) |
| "Bortezomib has shown antihemostatic effects in patients with relapsed or refractory MM, which supports that it exerts antithrombotic actions and thus potentially provides a protective effect in combination with regimens with an elevated VTE risk." | 6.47 | Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. ( Fink, L; Tricot, G; Zangari, M; Zhan, F, 2011) |
| "Lenalidomide is an immunomodulatory drug, which has anti-myeloma activity in vitro." | 6.45 | United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma. ( Behrens, J; Bird, J; Cavenagh, J; Cook, G; Davies, F; Morgan, G; Morris, C; Schey, S; Tighe, J; Williams, C, 2009) |
| "Lenalidomide is an oral analogue of thalidomide that lacks the neurotoxic side effects associated with the parent drug, and has shown significant antimyeloma activity." | 6.44 | Lenalidomide and its role in the management of multiple myeloma. ( Boccadoro, M; Cavallo, F; Falco, P; Larocca, A; Liberati, AM; Musto, P; Palumbo, A, 2008) |
| "Bortezomib was associated with a significantly higher response rate and complete remission rate using both M-protein and EBMT criteria." | 6.44 | Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison. ( Adena, M; Hertel, J; Prince, HM; Smith, DK, 2007) |
| "Lenalidomide does not produce significant sedation, constipation or neuropathy, but does lead to significant myelosuppression, unlike thalidomide." | 6.44 | Lenalidomide in myelodysplastic syndrome and multiple myeloma. ( Shah, SR; Tran, TM, 2007) |
| "For many years the treatment of multiple myeloma was limited to such regimens as melphalan-prednisone, high-dose dexamethasone, and vincristine-doxorubicin-dexamethasone (VAD)." | 6.44 | Lenalidomide in multiple myeloma. ( Richards, TA; Thomas, SK; Weber, DM, 2007) |
| "When thalidomide was added to standard, non-transplantation myeloma therapy, overall survival (OS) improved (HR 0." | 6.44 | A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. ( Haynes, AE; Herst, JA; Hicks, LK; Imrie, K; Meyer, RM; Reece, DE; Walker, IR, 2008) |
| "Lenalidomide is an immunomodulatory drug derived from thalidomide." | 6.44 | Lenalidomide in the treatment of multiple myeloma: a review. ( Armoiry, X; Aulagner, G; Facon, T, 2008) |
| "Thalidomide treatment compares favourably with other typical treatments for multiple myeloma." | 6.43 | The current status of thalidomide in the management of multiple myeloma. ( Glasmacher, A; von Lilienfeld-Toal, M, 2005) |
| "Thalidomide is an interesting maintenance therapy." | 6.43 | The future role of thalidomide in multiple myeloma. ( Attal, M; Blade, J; Boccadoro, M; Palumbo, A, 2005) |
| "Multiple myeloma is a plasma cell malignancy that remains incurable with current treatment approaches including high-dose therapy and autologous stem cell transplantation." | 6.43 | Thalidomide and dexamethasone: therapy for multiple myeloma. ( Kumar, S; Rajkumar, SV, 2005) |
| "Multiple myeloma is an incurable bone marrow cancer, the treatment of which is notoriously difficult." | 6.43 | Thalidomide in multiple myeloma. ( García-Sanz, R, 2006) |
| "Thalidomide has demonstrated a broad spectrum of pharmacological and immunological effects, with potential therapeutic applications that span a wide spectrum of diseases: cancer and related conditions; infectious diseases; autoimmune diseases; dermatological diseases; and other disorders such as sarcoidosis, macular degeneration and diabetic retinopathy." | 6.43 | Current therapeutic uses of lenalidomide in multiple myeloma. ( Anderson, KC; Hideshima, T; Richardson, PG, 2006) |
| "Thalidomide has changed the treatment paradigm for patients with myeloma." | 6.43 | Immunomodulatory analogues of thalidomide in the treatment of multiple myeloma. ( Hussein, MA; Srkalovic, JG; Suppiah, R, 2006) |
| "Multiple myeloma is a clonal disorder of plasma cells which is considered incurable with currently available therapies." | 6.43 | The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma. ( Hussein, MA; Kalmadi, SR, 2006) |
| "Lenalidomide (Revlimid) is an immunomodulatory drug that has undergone rapid clinical development in multiple myeloma and was recently approved by the US FDA for use in patients with relapsed disease." | 6.43 | Lenalidomide in multiple myeloma. ( Anderson, KC; Hideshima, T; Mitsiades, C; Richardson, PG, 2006) |
| "Multiple myeloma is a treatable but not necessarily a curable plasma-cell cancer." | 6.43 | Thalidomide and lenalidomide in multiple myeloma. ( Jagannath, S; Mazumder, A, 2006) |
| "Thalidomide (Thal) has antiangiogenic and immunomodulatory activity." | 6.43 | Thalidomide in multiple myeloma. ( Glasmacher, A; Goldschmidt, H; Hillengass, J; Moehler, TM, 2006) |
| "Cure for multiple myeloma is rare; the success of treatment is measured by response, and length of remissions and survival." | 6.43 | Management of multiple myeloma with bortezomib: experts review the data and debate the issues. ( Boccadoro, M; Cavenagh, J; Dicato, M; Harousseau, JL; Ludwig, H; San Miguel, J; Sonneveld, P, 2006) |
| "Thalidomide (Thal) has been successfully used in such situations and it's use has also been expanded to the up-front therapy and as adjuvant to stem cell transplantation." | 6.42 | Advances in the treatment of multiple myeloma: the role of thalidomide. ( Colleoni, GW; Ribas, C, 2003) |
| "The case of an HIV-infected man in whom multiple myeloma was diagnosed following progressive anemia and fatigue is described." | 6.42 | Thalidomide-based treatment for HIV-associated multiple myeloma: a case report. ( Aboulafia, DM, 2003) |
| "The occurrence of a left atrial thrombus without a haemodynamic predisposing factor (arrhythmia, mitral valvulopathy, severe left ventricular dysfunction) is a rare event." | 6.42 | [Left atrial thrombus in multiple myeloma treated with thalidomide]. ( Barbou, F; Bonal, J; Bouchiat, C; Cellarier, G; de Jaureguiberry, JP; Dussarat, GV; Gisserot, O; Jégo, C; Landais, C; Laurent, P, 2003) |
| "Thalidomide has anti-inflammatory, immuno-modulating and antiangiogeneic properties but the mechanism of its action is not yet completely understood." | 6.42 | [Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide]. ( Jurczyszyn, A; Skotnicki, AB; Wolska-Smoleń, T, 2003) |
| "Thalidomide was developed in the 1950s as a sedative having only a low toxicity." | 6.42 | [New pharmacological availability of thalidomide based on experience in patients with multiple myeloma]. ( Murakami, H, 2004) |
| "Thalidomide is an infamous molecule for its teratogenicity, yet it possesses potent immunomodulatory, anti-angiogeneic and, in higher concentrations, direct anti-myeloma-cell properties." | 6.41 | [Role of thalidomide in the treatment of multiple myeloma]. ( Jákó, J; Mikala, G; Vályi-Nagy, I, 2001) |
| "Bortezomib is active in heavily pretreated multiple myeloma patients; the dose-limiting toxicity is peripheral neuropathy (PN)." | 6.22 | Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. ( Akpek, G; Badros, A; Can, I; Dalal, JS; Fenton, RG; Goloubeva, O; Heyman, M; Rapoport, AP; Thompson, J, 2007) |
| "In conclusion, replacing Revlimid® with its generic version Rivelime® in singlet, doublet or triplet lenalidomide containing RRMM regimens seems not to compromise the efficacy of treatment, and to yield a similarly improved response rates and survival outcome and no additional toxic effects, enabling a long-term therapy." | 5.91 | Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome. ( Beksac, M; Gurman, G; Ilhan, O; Koyun, D; Seval, GC; Topcuoglu, P; Yuksel, MK, 2023) |
| " The primary outcomes were Overall Survival (OS) and Progression Free Survival (PFS, measured as time to next treatment), and the secondary outcomes were Adverse Events (AE)." | 5.91 | Real-world effectiveness and safety of multiple myeloma treatments based on thalidomide and bortezomib: A retrospective cohort study from 2009 to 2020 in a Brazilian metropolis. ( Costa, IHFD; Drummond, PLM; Malta, JS; Menezes de Pádua, CA; Reis, AMM; Santos, RMMD; Silveira, LP, 2023) |
| "The incidence of multiple myeloma (MM) is two to three times higher in Black patients compared with other races, making it the most common hematologic malignancy in this patient population." | 5.91 | Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction. ( Cao, Y; Dhodapkar, M; Hall, KH; Harvey, RD; Hofmeister, CC; Joseph, NS; Kaufman, JL; Liu, Y; Lonial, S; Maples, KT; Nooka, AK; Sun, LF, 2023) |
| "Lenalidomide is an important medication used in induction therapy for MM and is also used for maintenance therapy for standard risk patients." | 5.72 | Three Cases of Lenalidomide Therapy for Multiple Myeloma and Subsequent Development of Secondary B-ALL. ( Asawa, P; Chahine, Z; Lister, J; Sadashiv, S; Samhouri, Y; Vusqa, UT, 2022) |
| "The treatment of multiple myeloma has dramatically improved due to the availability of novel therapies that are highly effective and are quickly moving into first-line therapy." | 5.72 | Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database. ( Aslam, M; Gul, E; Jimenez-Zepeda, VH; Kardjadj, M; Kotb, R; LeBlanc, R; Louzada, M; Masih-Khan, E; McCurdy, A; Mian, H; Reece, D; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D, 2022) |
| "The treatment of multiple myeloma (MM) has advanced with the introduction of immunomodulators (IMiDS)." | 5.72 | Adherence to thalidomide in patients with multiple myeloma: A cross-sectional study in a Brazilian metropolis. ( Costa, NL; Drummond, PLM; Hauck, LM; Machado, TRL; Malta, JS; Pádua, CAM; Reis, AMM; Santos, RMMD; Silveira, LP, 2022) |
| "Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (D-RVd) in the GRIFFIN study improved the stringent complete response rate by the end of consolidation in transplantation-eligible patients with newly diagnosed multiple myeloma." | 5.69 | Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. ( Anderson, LD; Bumma, N; Chari, A; Cortoos, A; Costa, LJ; Costello, C; Cowan, AJ; Dinner, S; Efebera, YA; Holstein, SA; Jakubowiak, A; Kaufman, JL; Laubach, J; Lin, TS; Nathwani, N; Orlowski, RZ; Patel, S; Pei, H; Reeves, B; Richardson, PG; Rodriguez, C; Sborov, DW; Shah, N; Shain, KH; Silbermann, R; Usmani, SZ; Voorhees, PM; Wildes, TM, 2023) |
| "Pomalidomide was given at 4 mg orally on days 1 to 21 of a 28-day cycle, and dexamethasone at 20 or 40 mg weekly." | 5.62 | Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma. ( Abdallah, AO; Atrash, S; Ganguly, S; Kawsar, H; Mahmoudjafari, Z; McGuirk, J; Mohyuddin, GR; Shune, L; Sigle, M, 2021) |
| "The prognosis of relapsed and refractory multiple myeloma (RRMM) that is refractory to bortezomib and lenalidomide is very poor wherein the median survival is between 3 and 9 months." | 5.62 | Real-World Outcomes With Generic Pomalidomide in Relapsed Refractory Multiple Myeloma-Experience From a Tertiary Care Cancer Center. ( Bagal, B; Bonda, A; Bondili, SK; Gokarn, A; Jain, H; Khattry, N; Nayak, L; Punatar, S; Sengar, M; Thorat, J; Ventrapati, P; Zawar, A, 2021) |
| "Pomalidomide is a second-generation immunomodulatory drug that has shown activity in lenalidomide-refractory disease in the setting of different combinations." | 5.62 | Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience. ( Anguita, M; Arguiñano, JM; Arnao, M; Bladé, J; Blanchard, MJ; Cabañas, V; Casado, F; de Cabo, E; de Coca, AG; Encinas, C; García, R; González-Rodríguez, AP; Hernández-Rivas, JÁ; Iñigo, B; Lafuente, AP; Lahuerta, JJ; Lavilla, E; López, A; Maldonado, R; Martí, JM; Mateos, MV; Motlló, C; Murillo, I; Pérez-Persona, E; Ribas, P; Rodriguez-Otero, P; Sampol, A; San Miguel, JF; Sirvent, M, 2021) |
| "Major progress has occurred in multiple myeloma (MM) treatment in recent years, but this is not seen in low- and middle-income countries." | 5.62 | Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up. ( Aliaga, K; Casanova, L; Quintana, S; Ruiz, R; Valencia, F; Vasquez, J; Vidaurre, T; Villena, M, 2021) |
| "Multiple myeloma is an incurable progressive neoplastic disease that accounts for 10% of all hematologic malignancies." | 5.56 | Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone. ( Kassir, N; Li, Y; Palmisano, M; Wang, X; Zhou, S, 2020) |
| "We evaluated the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and high-risk cytogenetic abnormalities in lenalidomide-pretreated patients with multiple myeloma at first relapse." | 5.51 | Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. ( Anderson, LD; Beksac, M; Corso, A; Dimopoulos, M; Dürig, J; Engelhardt, M; Galli, M; Grote, L; Jenner, M; Jiang, R; Kanate, AS; Larocca, A; Liberati, AM; Lindsay, J; Moreau, P; Oriol, A; Pavic, M; Peluso, T; Richardson, PG; Robak, P; Rodriguez-Otero, P; Salomo, M; Schjesvold, F; Sonneveld, P; Vural, F; Weisel, K; White, D; Yagci, M, 2022) |
| "Elotuzumab plus pomalidomide/dexamethasone (E-Pd) demonstrated efficacy and safety in relapsed and refractory multiple myeloma (RRMM)." | 5.51 | Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma. ( Ide, T; Osawa, M; Sanghavi, K; Vezina, HE, 2022) |
| " We aimed to determine whether melflufen plus dexamethasone would provide a progression-free survival benefit compared with pomalidomide plus dexamethasone in patients with previously treated multiple myeloma." | 5.51 | Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. ( Alekseeva, Y; Bakker, NA; Byrne, C; Coriu, D; Delimpasi, S; Dimopoulos, MA; Doronin, V; Hájek, R; Harmenberg, J; Lazzaro, A; Legiec, W; Liberati, AM; Maisnar, V; Masszi, T; Mateos, MV; Mikala, G; Minarik, J; Moody, V; Pour, L; Richardson, PG; Robak, P; Rosiñol, L; Salogub, G; Schjesvold, FH; Sonneveld, P; Špička, I; Symeonidis, A; Thuresson, M, 2022) |
| "Multiple myeloma (MM) patients typically receive several lines of combination therapy and first-line treatment commonly includes lenalidomide." | 5.51 | Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial. ( Darif, M; Demarquette, H; Dimopoulos, MA; Doronin, V; Du, J; Fenk, R; Kumar, S; Labotka, R; Lee, C; Leleu, X; Levin, MD; Mellqvist, UH; Montes, YG; Pompa, A; Quach, H; Ramasamy, K; Sati, H; Schjesvold, F; Vinogradova, O; Vorog, A, 2022) |
| "Patients with relapsed/refractory multiple myeloma (RRMM) need proven subsequent therapies after early-line lenalidomide treatment failure." | 5.51 | Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial. ( Acosta-Rivera, M; Agarwal, A; Anz, B; Bahlis, NJ; Bar, M; Berdeja, J; Chung, W; Fonseca, G; Ganguly, S; Lee, K; Matous, J; Mouro, J; Quick, D; Reece, D; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, K, 2022) |
| "The primary analysis of the ICARIA-MM study showed significant improvement in progression-free survival with addition of isatuximab to pomalidomide-dexamethasone in relapsed and refractory multiple myeloma." | 5.51 | Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. ( Anderson, KC; Beksac, M; Cavo, M; Dimopoulos, MA; Dubin, F; Huang, JS; Leleu, X; Malinge, L; Minarik, J; Moreau, P; Perrot, A; Prince, HM; Richardson, PG; San-Miguel, J; Schjesvold, F; Spicka, I; van de Velde, H, 2022) |
| " An exposure-response (E-R) analysis using data from patients with relapsed/refractory multiple myeloma (RRMM) enrolled in a phase Ib clinical study who received isatuximab at doses from 5 to 20 mg/kg weekly for 1 cycle (4 weeks) followed by every 2 weeks thereafter (qw/q2w) in combination with pomalidomide/dexamethasone (n = 44) was first used to determine the optimal dose/schedule for the phase III ICARIA-MM study." | 5.51 | Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma. ( Brillac, C; Fau, JB; Gaudel-Dedieu, N; Koiwai, K; Nguyen, L; Rachedi, F; Sebastien, B; Semiond, D; Thai, HT; van de Velde, H; Veyrat-Follet, C, 2022) |
| "Pomalidomide in combination with dexamethasone has demonstrated positive results in patients with relapsed or refractory multiple myeloma (RRMM), but no data are available in China." | 5.51 | Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial. ( Bai, H; Fang, BJ; Fu, WJ; Liao, AJ; Lu, J; Niu, T; Wang, YF; Zhao, HG, 2022) |
| "Pomalidomide is an immunomodulatory compound that has demonstrated activity in MM patients with disease refractory to lenalidomide and bortezomib." | 5.48 | The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience. ( Bernatowicz, P; Charlinski, G; Dmoszynska, A; Grzasko, N; Guzicka-Kazimierczak, R; Janczarski, M; Jurczyszyn, A; Lech-Maranda, E; Swiderska, A; Szczepaniak, A; Szeremet, A; Waszczuk-Gajda, A; Wichary, R, 2018) |
| " Adverse events (AEs) occurred in 69 (57." | 5.48 | Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/\ refractory multiple myeloma: a real-life experience ( Duran, M; Durusoy, R; Patır, P; Şahin, F; Saydam, G; Soyer, N; Töbü, M; Tombuloğlu, M; Ünal, HD; Uysal, A; Vural, F, 2018) |
| "An 85-year-old female was diagnosed with multiple myeloma(MM)(IgG-l)with t(4 ;14)(p16;q32)in 200X." | 5.48 | [Successful Treatment with Pomalidomide, Bortezomib, and Dexamethasone in a Patient with Frail Refractory and Relapsed Multiple Myeloma with Extramedullary Disease]. ( Nougawa, M; Oka, S; Shimazu, Y; Shiragami, H; Takeuchi, S, 2018) |
| "Heavily pretreated patients with relapsed and refractory multiple myeloma are susceptible to treatment-related adverse events (AEs)." | 5.46 | Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. ( Anttila, P; Bahlis, N; Biyukov, T; Cavo, M; Chen, C; Cook, G; Corradini, P; Delforge, M; Dimopoulos, MA; Hansson, M; Herring, J; Hong, K; Joao, C; Kaiser, M; Moreau, P; O'Gorman, P; Oriol, A; Raymakers, R; Richardson, PG; San-Miguel, J; Siegel, DS; Slaughter, A; Song, K; Sternas, L; Weisel, K; Yu, X; Zaki, M, 2017) |
| "Pomalidomide is a second-generation immunomodulatory drug (IMID)." | 5.46 | [Pomalidomide for multiple myeloma]. ( Chaleteix, C; Dougé, A; Lemal, R, 2017) |
| "Lenalidomide (LEN) has been used as an immunomodulatory drug with direct and indirect anti-tumor effects." | 5.46 | Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma. ( Anh-NguyenThi, T; Jaya Lakshmi, T; Jung, SH; Kim, HJ; Lee, HJ; Lee, JJ; Nguyen-Pham, TN; Vo, MC, 2017) |
| " A set of blood samples was taken in order to develop a pharmacokinetic model accounting for lenalidomide concentrations in this setting." | 5.46 | Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure. ( Buclin, T; Burnier, M; Dao, K; Figg, WD; Kissling, S; Lu, Y; Peer, CJ; Stadelmann, R, 2017) |
| "The incidence of multiple myeloma in Asia has risen in the past 30 years." | 5.46 | A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in Taiwan. ( Chen, CC; Chen, TY; DeMarco, D; Dunn, P; Hua, Y; Huang, SY; Jacques, C; Kao, WY; Lin, HY; Lin, SF; Lin, TH; Puccio-Pick, M; Wang, MC; Yeh, SP; Yu, YB, 2017) |
| " The aim of this study was to conduct a population pharmacokinetic analysis of lenalidomide in multiple myeloma patients to identify and evaluate non-studied covariates that could be used for dose individualization." | 5.46 | Population pharmacokinetics of lenalidomide in multiple myeloma patients. ( Climente-Martí, M; Guchelaar, HJ; Guglieri-López, B; Merino-Sanjuán, M; Moes, DJ; Pérez-Pitarch, A; Porta-Oltra, B, 2017) |
| "Bortezomib was used as first-line induction therapy against both tumors and lenalidomide was used for maintenance." | 5.46 | Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case report. ( Deng, M; Lin, Q; Mei, Z; Song, Y; Yang, J; Yin, Q; Zhu, X; Zuo, W, 2017) |
| "The apixaban treatment resulted in favorable and effective control of the patient's VTE on day33." | 5.46 | Successful management of venous thromboembolism with apixaban in a multiple myeloma patient on lenalidomide therapy. ( Hamahata, K; Nohgawa, M; Oka, S; Shiragami, H; Takeuchi, S, 2017) |
| "Pomalidomide has shown improved survival and good tolerability in this patient cohort in clinical trials, but real world data are scarce." | 5.46 | Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience. ( Benjamin, R; Cerner, A; Cheesman, S; D'sa, S; Jenner, M; Maciocia, N; Maciocia, P; Melville, A; Popat, R; Rabin, N; Ramasamy, K; Rismani, A; Schey, S; Sharpley, F; Streetly, M; Yong, K, 2017) |
| "Treatment advances for multiple myeloma (MM) that have prolonged survival emphasise the importance of measuring patients' health-related quality of life (HRQoL) in clinical studies." | 5.46 | Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment. ( Arnould, B; Bacon, P; Gilet, H; Kyriakou, C; Leleu, X; Lewis, P; Murphy, P; Petrucci, MT; Vande Broek, I, 2017) |
| "Rash is a frequent side effect of IMiDs, particularly lenalidomide, often leading to treatment discontinuation." | 5.43 | Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma. ( Agarwal, S; Barley, K; Chari, A; He, W; Jagannath, S, 2016) |
| "Treatment of multiple myeloma (MM) has significantly improved, although the disease remains incurable." | 5.43 | Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma? ( Berno, T; Cortelazzo, S; DE March, E; Marabese, A; Meneghini, V; Mian, M; Mondello, P; Patriarca, F; Pescosta, N; Pizzolo, G; Semenzato, G; Tinelli, M; Turri, G; Zambello, R, 2016) |
| " LenDex was interrupted in three cases because of adverse events (infections and cutaneous events); 78 % of the patients were on thromboprophylaxis with aspirin." | 5.43 | Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment. ( Coelho, I; Esteves, GV; Esteves, S; Freitas, J; Geraldes, C; Gomes, F; João, C; Lúcio, P; Neves, M, 2016) |
| "A 63-year-old man with Bence Jones-κ multiple myeloma (MM) presented with renal impairment." | 5.43 | Achievement of hemodialysis discontinuation with lenalidomide and dexamethasone therapy in a refractory BJP-type multiple myeloma patient. ( Hagihara, M; Hua, J; Inoue, M; Uchida, T, 2016) |
| " The dosing and safety profile of POM + LoDEX was similar across RI subgroups." | 5.43 | Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. ( Baz, R; Cavo, M; Delforge, M; Dimopoulos, MA; Goldschmidt, H; Hong, K; Jagannath, S; Moreau, P; Palumbo, A; Richardson, P; San Miguel, JF; Siegel, DS; Song, KW; Sternas, L; Weisel, KC; Yu, X; Zaki, M, 2016) |
| "Thalidomide was added to the BD therapy but was discontinued because of drug-induced eczema." | 5.43 | Efficacy of pomalidomide in a multiple myeloma patient requiring hemodialysis. ( Hangaishi, A; Hirao, M; Iizuka, H; Kida, M; Usuki, K, 2016) |
| "Pyoderma gangrenosum has been described in association with multiple myeloma and usually affects patients with active/untreated disease." | 5.42 | Pyoderma gangrenosum due to lenalidomide use for multiple myeloma. ( Alexandrescu, DT; Bockorny, B; Dasanu, CA, 2015) |
| "Patients with multiple myeloma and advanced disease managed with multiple lines of therapy are at risk for vRTI, and targeted interventions for prevention/treatment are required." | 5.42 | Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital. ( Harrison, SJ; Slavin, MA; Teh, BW; Thursky, KA; Worth, LJ, 2015) |
| "Despite recent treatment improvements, multiple myeloma remains an incurable disease." | 5.42 | Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. ( Andre, P; Lammerts van Bueren, JJ; Lokhorst, HM; Morel, Y; Mutis, T; Nijhof, IS; Parren, PW; van de Donk, NW; van Kessel, B, 2015) |
| "KMA was detected on kappa human multiple myeloma cell lines (κHMCLs), on plasma cells (PCs) from kappa multiple myeloma (κMM) patients and on κPC dyscrasia tissue cryosections." | 5.42 | MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide. ( Asvadi, P; Cuddihy, A; Dunn, RD; Jiang, V; Jones, DR; Khong, T; Spencer, A; Wong, MX, 2015) |
| "Lenalidomide was discontinued after 10 days due to exacerbation of renal dysfunction." | 5.42 | Development of acquired hemophilia A during treatment of multiple myeloma with lenalidomide. ( Ikebe, T; Itani, K; Miyazaki, Y; Nagamatsu, K; Ogata, M; Ohtsuka, E; Saburi, M; Saburi, Y, 2015) |
| "Lenalidomide is an oral immunomodulatory drug (IMiD) approved in the United States for patients with MM." | 5.42 | A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide. ( Qian, W; Wang, B; Xu, G; Yang, M, 2015) |
| "In the Phase III ICARIA-MM study (NCT02990338), the addition of the anti-CD38 monoclonal antibody isatuximab to pomalidomide and dexamethasone led to increased progression-free survival and improved response rates in patients with relapsed/refractory multiple myeloma." | 5.41 | Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. ( Bringhen, S; Campana, F; Dimopoulos, MA; Harrison, SJ; Le-Guennec, S; Macé, S; Richardson, PG; Schjesvold, F; Yong, K, 2021) |
| "CASSIOPEIA part 1 showed superior depth of response and significantly improved progression-free survival with daratumumab, bortezomib, thalidomide, and dexamethasone (D-VTd) versus bortezomib, thalidomide, and dexamethasone (VTd) as induction and consolidation in patients with autologous stem-cell transplant (ASCT)-eligible newly diagnosed multiple myeloma." | 5.41 | Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, ( Ahmadi, T; Arnulf, B; Avet-Loiseau, H; Belhadj, K; Benboubker, L; Béné, MC; Broijl, A; Caillon, H; Caillot, D; Corre, J; de Boer, C; Dejoie, T; Delforge, M; Doyen, C; Escoffre-Barbe, M; Eveillard, JR; Facon, T; Fontan, J; Garidi, R; Hulin, C; Jie, KS; Kampfenkel, T; Karlin, L; Klein, SK; Krevvata, M; Kuhnowski, F; Lambert, J; Leleu, X; Levin, MD; Macro, M; Marolleau, JP; Meuleman, N; Mohty, M; Moreau, P; Offner, F; Orsini-Piocelle, F; Perrot, A; Roussel, M; Sonneveld, P; Sonntag, C; Stoppa, AM; Tiab, M; Touzeau, C; van de Donk, NWCJ; Vanquickelberghe, V; Vara, S; Vekemans, MC; Vermeulen, J; Westerman, M; Wuillème, S; Zhang, K; Zweegman, S, 2021) |
| "Preclinical studies have demonstrated activity of the oral proteasome inhibitor (PI) ixazomib (IXA) in bortezomib-resistant multiple myeloma (MM) and synergy with immunomodulatory drugs." | 5.41 | A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). ( Bova-Solem, M; Carlisle, D; Efebera, YA; Hassoun, H; Laubach, JP; McCarthy, PL; Mulkey, F; Richardson, PG; Santo, K; Suman, VJ; Tuchman, SA; Voorhees, PM, 2021) |
| "The immunomodulatory imide drug (IMiD) class, which includes the founding drug member thalidomide and later generation drugs, lenalidomide and pomalidomide, has dramatically improved the clinical treatment of specific cancers, such as multiple myeloma, and it combines potent anticancer and anti-inflammatory actions." | 5.41 | A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders. ( Glotfelty, EJ; Greer, ME; Greig, NH; Hsueh, SC; Kim, DS; Kopp, KO; Reale, M; Tweedie, D; Vargesson, N, 2023) |
| "The objective was to assess the benefit of pomalidomide-based combination regimens in patients with relapsed/refractory multiple myeloma (RRMM) previously treated with lenalidomide." | 5.41 | A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure. ( Davies, FE; Dhanasiri, S; Le Nouveau, P; Leleu, X; Vogel, P; Weisel, K, 2023) |
| "The randomized, phase 3 ICARIA-MM study investigated isatuximab (Isa) with pomalidomide and dexamethasone (Pd) versus Pd in patients with relapsed/refractory multiple myeloma and ≥2 prior lines." | 5.41 | Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. ( Assadourian, S; Campana, F; Dimopoulos, MA; Harrison, SJ; Leleu, X; Liberati, AM; Malinge, L; Miles Prince, H; Moreau, P; Ocio, EM; Richardson, PG; Sémiond, D; van de Velde, H; Yong, K, 2021) |
| "In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior efficacy vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma previously treated with lenalidomide, including those refractory to lenalidomide." | 5.41 | Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. ( Anderson, LD; Biyukov, T; Casal, E; Corso, A; Dimopoulos, M; Dürig, J; Engelhardt, M; Jenner, M; Moreau, P; Nguyen, TV; Pavic, M; Peluso, T; Richardson, P; Salomo, M; San-Miguel, J; Sonneveld, P; Srinivasan, S; Weisel, K; White, D; Yu, X, 2021) |
| "The global, randomized, open-label KEYNOTE-183 phase 3 study was closed early after an interim analysis showed unfavorable risk-benefit when pembrolizumab was added to pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (MM)." | 5.41 | Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients. ( Ando, K; Farooqui, M; Iida, S; Kher, U; Koh, Y; Kosugi, H; Kuroda, J; Liao, J; Marinello, P; Maruyama, D; Matsuda, K; Matsumoto, M; Shimamoto, T; Sunami, K; Suzuki, K; Taniwaki, M; Tobinai, K, 2021) |
| "gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma patients." | 5.41 | Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. ( Bensinger, WI; Bianchi, G; Campana, F; D'Souza, A; Dubin, F; Kanagavel, D; Karanes, C; Laubach, JP; Raje, N; Richardson, PG; Saleem, R; Sborov, D; Tuchman, SA; Usmani, SZ, 2021) |
| "In a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response or better rate of 42% and was well tolerated in patients with heavily pretreated multiple myeloma." | 5.41 | Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. ( Ahmadi, T; Amin, H; Baldini, L; Beksac, M; Bila, J; Boccadoro, M; Carson, R; Delimpasi, S; Dimopoulos, MA; Einsele, H; Kampfenkel, T; Katodritou, E; Mateos, MV; Moreau, P; Orfanidis, I; Oriol, A; Qiu, Y; Schecter, JM; Sonneveld, P; Symeonidis, A; Terpos, E; Ukropec, J; Vermeulen, J, 2021) |
| "Isatuximab is an anti-CD38 monoclonal antibody approved in combination with pomalidomide-dexamethasone and carfilzomib-dexamethasone for relapsed or refractory multiple myeloma." | 5.41 | Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. ( Asset, G; Baker, R; Capra, M; Dimopoulos, MA; Facon, T; Hajek, R; Kim, K; Koh, Y; Leleu, X; Macé, S; Martin, T; Martinez, G; Mikhael, J; Min, CK; Moreau, P; Oriol, A; Pour, L; Risse, ML; Špička, I; Suzuki, K; Yong, K, 2021) |
| " On May 30, 2020, a marketing authorization valid through the European Union (EU) was issued for isatuximab in combination with pomalidomide and dexamethasone (IsaPd) for the treatment of adult patients with relapsed and refractory (RR) multiple myeloma (MM)." | 5.41 | EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma. ( Delgado, J; Enzmann, H; Gisselbrecht, C; Moreau, A; Pignatti, F; van Hennik, PB; Zienowicz, M, 2021) |
| "This study sought to understand how the programmed death ligand 1 (PD-L1) inhibitor durvalumab and the immunomodulatory agent pomalidomide regulate immune cell activation and function in patients with relapsed/refractory (RR) multiple myeloma (MM)." | 5.41 | Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma. ( Copeland, W; Fox, BA; Newhall, KJ; Pietz, G; Thompson, E; Whalen, E; Young, MH, 2021) |
| "We conclude that RD reduces bone resorption only in responding patients with relapsed/refractory myeloma but has no effect on bone formation." | 5.40 | The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group. ( Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Gkotzamanidou, M; Kastritis, E; Katodritou, E; Koulieris, E; Kyrtsonis, MC; Michalis, E; Papanikolaou, X; Papatheodorou, A; Pouli, A; Terpos, E; Zervas, K, 2014) |
| "Consolidation therapy for patients with multiple myeloma (MM) has been widely adopted to improve treatment response following autologous stem cell transplantation." | 5.40 | Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients. ( Akashi, K; Aoki, T; Ito, Y; Iwasaki, H; Kadowaki, M; Kamimura, T; Kato, K; Miyamoto, T; Muta, T; Shima, T; Shiratsuchi, M; Takase, K; Takashima, S; Takenaka, K; Teshima, T; Yoshimoto, G, 2014) |
| "Cryoglobulinemia (Cg) in multiple myeloma (MM) is rare and no standard treatment has yet been established." | 5.40 | [Successful treatment with a combination of lenalidomide and dexamethasone for cryoglobulinemia associated with multiple myeloma]. ( Ando, K; Hata, T; Imaizumi, Y; Imanishi, D; Makiyama, J; Miyazaki, Y; Sawayama, Y; Taguchi, J; Taniguchi, H; Tsushima, H, 2014) |
| "Lenalidomide treatment resulted in significant increases in CT/FEM-derived estimates of bone strength." | 5.40 | A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography. ( Awai, K; Date, S; Kaichi, Y; Kiguchi, M; Kuroda, Y; Sakai, A; Sakoda, Y; Takasu, M; Tani, C, 2014) |
| "Treatment options for multiple myeloma dwindle with each relapse." | 5.40 | Pomalidomide. A last-line treatment option for multiple myeloma. ( , 2014) |
| "Lenalidomide is a thalidomide analog used for the treatment of myelodysplastic syndromes, with pleiotropic activities including induction of apoptosis, inhibition of angiogenesis and broad immunomodulatory effects." | 5.39 | Lenalidomide-induced regenerative macronodules infarction in a cirrhosis patient. ( Arrivé, L; Carbonell, N; Cervera, P; Dangouloff-Ros, V, 2013) |
| "Treatment with lenalidomide, as the final therapeutic option, resolved the intractable melena and improved both the intestinal lesions and myeloma." | 5.39 | Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis. ( Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S, 2013) |
| "Optimal salvage treatment for multiple myeloma relapsing after allogeneic stem cell transplantation remains to be determined." | 5.39 | Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy. ( Bachy, E; Bourhis, JH; Brebion, A; Coman, T; François, S; Hermine, O; Huynh, A; Lapusan, S; Lioure, B; Maury, S; Michallet, M; Milpied, N; Mohty, M; Rubio, MT; Socié, G; Uzunov, M; Vigouroux, S; Yakoub-Agha, I, 2013) |
| "Prognostic impact of specific chromosomal aberrations in patients with relapsed multiple myeloma (MM) treated with the novel agents is briefly described." | 5.39 | Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib. ( Adam, Z; Almasi, M; Berankova, K; Frohlich, J; Greslikova, H; Hajek, R; Jarkovsky, J; Jurczyszyn, A; Kaisarova, P; Krejci, M; Kuglik, P; Kupska, R; Melicharova, H; Mikulasova, A; Nemec, P; Penka, M; Sandecka, V; Sevcikova, S; Smetana, J; Zahradova, L; Zaoralova, R, 2013) |
| "The outlook for transplant-ineligible multiple myeloma patients has improved enormously over recent years with the incorporation of new agents into standard regimens." | 5.39 | The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenan ( Ba-Mancini, A; Cakana, A; Chen, K; Corzo, D; Dhawan, R; Duh, MS; Garrison, LP; Huang, H; Korves, C; Shi, H; van de Velde, H; Wang, ST, 2013) |
| "Lenalidomide was well tolerated in intensively pretreated and elderly MM patients, including those with RI." | 5.38 | Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal. ( Engelhardt, M; Ihorst, G; Kleber, M; Koch, B; Udi, J; Wäsch, R, 2012) |
| "Lenalidomide (len) is an analog of thalidomide (thal), and both are used in the treatment of a diverse group of medical conditions." | 5.38 | Lenalidomide alone or lenalidomide plus dexamethasone significantly inhibit IgG and IgM in vitro... A possible explanation for their mechanism of action in treating multiple myeloma. ( Greig, N; Sandoval, F; Shannon, E; Stagg, P, 2012) |
| "Bone disease is a major symptom of multiple myeloma, which results from excessive osteoclast activation and impaired osteoblast function." | 5.38 | Therapy with lenalidomide plus dexamethasone-induced bone formation in a patient with refractory multiple myeloma. ( Tsuda, H; Tsuji, T; Yamasaki, H; Yokoo, E, 2012) |
| "POEMS syndrome is a rare paraneoplastic condition associated to an underlying plasmacellular dyscrasia." | 5.38 | Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation. ( Balducci, M; Chiusolo, P; De Stefano, V; Giannotta, C; Laurenti, L; Leone, G; Luigetti, M; Sabatelli, M; Sica, S; Sorà, F; Vannata, B, 2012) |
| "Preclinical and clinical studies have shown that proteasome inhibitors (PIs) have anti-MM activity in combination with dexamethasone or lenalidomide." | 5.38 | CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma. ( Berenson, JR; Chen, H; Hunter, K; Jones-Bolin, S; Li, J; Li, M; Ruggeri, B; Sanchez, E; Wang, C, 2012) |
| "Lenalidomide is an immunomodulatory drug derived from thalidomide, developed to maximize its anti-inflammatory and antineoplastic properties while reducing toxicity." | 5.38 | Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. ( Boccadoro, M; Cavallo, F; Larocca, A; Mina, R; Palumbo, A, 2012) |
| "Multiple myeloma is a plasma cell malignancy that leads to bone pain, pathological fracture, anaemia, renal failure and recurrent bacterial infections." | 5.37 | Clinical profile of multiple myeloma and effect of thalidomide based treatment on its outcome. ( Basu, D; Dutta, TK; Sridhar, S, 2011) |
| "Thalidomide has recently been shown to have significant antimyeloma activity." | 5.37 | Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma. ( Jang, G; Jo, JC; Kang, BW; Kim, S; Kim, SW; Lee, DH; Lee, JS; Lee, SS; Suh, C; Sym, SJ, 2011) |
| "Patients with multiple myeloma (MM) are at relatively high risk of developing thromboembolic event (TEE), especially during treatment with immunomodulatory agents." | 5.37 | Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma. ( Guo, H; Jiang, Y; Shen, Y; Sun, C; Tong, Y; Wang, J; Wang, Z; Yang, G; Zhou, X, 2011) |
| "Griseofulvin (GF) has similar chemical features as compared to ciclopirox olamine." | 5.37 | In vivo efficacy of griseofulvin against multiple myeloma. ( Alpmann, P; Blaum-Feder, S; Carson, D; Endo, T; Kim, Y; Krämer, S; Lu, D; Schmidt-Wolf, IG, 2011) |
| "We analyzed DNA from 1,495 patients with multiple myeloma." | 5.37 | Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. ( Child, JA; Corthals, SL; Davies, FE; Dickens, NJ; Durie, BG; Goldschmidt, H; Gregory, WM; Johnson, DC; Lokhorst, HM; Morgan, GJ; Ross, FM; Sonneveld, P; Van Ness, B; Walker, BA, 2011) |
| "Recurrence of multiple myeloma (MM) after therapy suggests the presence of tumor-initiating subpopulations." | 5.37 | Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. ( Adamia, S; Anderson, KC; Blotta, S; Cervi, D; Cholujova, D; Daley, JF; Delmore, J; Jakubikova, J; Klippel, S; Kong, SY; Kost-Alimova, M; Laubach, J; Leiba, M; Mitsiades, CS; Ooi, M; Richardson, PG; Sedlak, J, 2011) |
| " The major adverse events (AEs) associated with lenalidomide include: hematological toxicities (myelosuppression), mainly neutropenia, venous thromboembolism, gastrointestinal disturbance, skin toxicity, atrial fibrillation, asthenia, and decreased peripheral blood stem cell yield during stem cell collection when lenalidomide is used after a long period of time." | 5.37 | Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events. ( García Sánchez, PJ; González Rodríguez, AP; Mesa, MG; Pérez Persona, E, 2011) |
| "Patients with relapsed or refractory multiple myeloma (RRMM) who received lenalidomide plus dexamethasone in the MM-009 and MM-010 trials were pooled and those who had not progressed and were still receiving lenalidomide at 12 months were included." | 5.37 | Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. ( Dimopoulos, MA; Hussein, M; Swern, AS; Weber, D, 2011) |
| "There is predominance of paresthesiae in some of them while in others pain or deep sensation failure can dominate." | 5.37 | [Thalidomide-induced sensory neuropaty in patients with multiple myeloma]. ( Bilińska, M; Kuliczkowski, K; Noga, L; Podemski, R; Potoczek, S; Szymczyk, M; Usnarska-Zubkiewicz, L, 2011) |
| "Lenalidomide was given at a dose of 15 mg (n=4), or 25 mg (n=20), orally once daily on day 1 to day 1 every 28 days, with (n=20) or without (n=4) DHAP." | 5.36 | Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. ( Atanackovic, D; Ayuk, F; Bacher, U; Badbaran, A; Blaise, D; El-Cheikh, J; Fehse, B; Hildebrandt, Y; Hoffmann, F; Kröger, N; Lioznov, M; Mohty, M; Schilling, G; Wolschke, C; Zander, AR, 2010) |
| "Bortezomib has been shown to be highly active in MM patients with RI." | 5.36 | Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. ( Baldini, L; Boccadoro, M; Bringhen, S; Callea, V; Casulli, AF; Catalano, L; Cavo, M; Ciolli, S; Di Raimondo, F; Galimberti, S; Gentile, M; Mannina, D; Mele, G; Morabito, F; Musto, P; Offidani, M; Palmieri, S; Palumbo, A; Petrucci, MT; Pinotti, G; Piro, E; Tosi, P, 2010) |
| "The lenalidomide dose was gradually increased up to 15 mg daily and the dexamethasone dose reduced to 40 mg once a week." | 5.36 | Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma. ( Ludwig, H; Zojer, N, 2010) |
| "LBH589 may be very effective in multiple myeloma after a multitude of preceding treatments that could not induce a long-term anti-myeloma effect." | 5.36 | The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide. ( Goldschmidt, H; Ho, AD; Schmitt, S, 2010) |
| "The outcome of patients with multiple myeloma (MM) aged over 75 years remains poor, and the best therapeutic approach has still to be defined." | 5.36 | Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study. ( Alesiani, F; Blasi, N; Boccadoro, M; Bringhen, S; Brunori, M; Catarini, M; Corvatta, L; Ferranti, M; Galieni, P; Gentili, S; Larocca, A; Leoni, P; Mele, A; Offidani, M; Oliva, S; Palumbo, A; Polloni, C; Visani, G, 2010) |
| "The impact of cumulative dosing and premature drug discontinuation (PMDD) of bortezomib (V), thalidomide (T), and dexamethasone (D) on overall survival (OS), event-free survival (EFS), time to next therapy, and post-relapse survival in Total Therapy 3 were examined, using time-dependent methodology, relevant to induction, peritransplantation, consolidation, and maintenance phases." | 5.36 | Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. ( Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Hoering, A; Nair, B; Petty, N; Shaughnessy, JD; Szymonifka, J; van Rhee, F; Waheed, S, 2010) |
| "Pomalidomide was given orally (2 mg) daily, continuously in 28-day cycles along with dexamethasone (40 mg) given weekly." | 5.36 | Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). ( Allred, JB; Bergsagel, PL; Buadi, F; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, K; Lust, JA; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Roy, V; Russell, SJ; Short, KD; Stewart, AK; Zeldenrust, S, 2010) |
| "Thalidomide is a drug with pleiotropic effects." | 5.35 | Two cases of bacterial meningitis accompanied by thalidomide therapy in patients with multiple myeloma: is thalidomide associated with bacterial meningitis? ( Altintas, A; Ayyildiz, O; Bayan, K; Cil, T; Danis, R; Pasa, S; Tuzun, Y; Urakci, Z; Ustun, C, 2009) |
| "The occurrence of multiple myeloma and chronic lymphocytic leukemia in the same patient is very uncommon." | 5.35 | Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide. ( Schiffer, CA; Srinivasan, S, 2009) |
| "The outcome of patients with multiple myeloma is dictated primarily by cytogenetic abnormalities and proliferative capacity of plasma cells." | 5.35 | Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. ( Bergsagel, PL; Buadi, F; Dalton, RJ; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kapoor, P; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Mikhael, JR; Rajkumar, SV; Reeder, CB; Roy, V; Russell, SJ; Stewart, AK; Witzig, TE; Zeldenrust, SR, 2009) |
| "Thalidomide was reduced for toxicity in 68 patients (24%) and permanently discontinued in 36 (12%)." | 5.35 | Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects. ( Barbarano, L; Cafro, AM; Caravita, T; Corso, A; Gay, F; Lazzarino, M; Mangiacavalli, S; Morra, E; Palumbo, A; Petrucci, MT; Varettoni, M; Zappasodi, P, 2009) |
| "Thalidomide was administered orally at 100 mg/day for the first week." | 5.35 | A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma. ( Abe, M; Iida, S; Kodama, T; Miyata, A; Murakami, H; Ozaki, S; Sakai, A; Sawamura, M; Shimazaki, C; Wakayama, T, 2009) |
| "A 74-year-old man with multiple myeloma was refractory to melphalan/prednisolone (MP), high-dose dexamethasone and VAD chemotherapy." | 5.35 | Refractory plasmablastic type myeloma with multiple extramedullary plasmacytomas and massive myelomatous effusion: remarkable response with a combination of thalidomide and dexamethasone. ( Kakimoto, T; Mihara, A; Nakazato, T; Sanada, Y; Suzuki, K, 2009) |
| "Thalidomide is an antiangiogenic drug used in cancer therapy." | 5.35 | Arterial thrombosis and thalidomide. ( Cakir, O; Eren, MN; Goz, M, 2008) |
| "Seventy-four multiple myeloma patients (MM pts) uniformly treated, were retrospectively studied." | 5.35 | Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy. ( Barbarano, L; Corso, A; Fava, S; Lazzarino, M; Mangiacavalli, S; Mazzone, A; Montalbetti, L; Morra, E; Varettoni, M; Zappasodi, P, 2008) |
| " The HOVON-87/NMSG18 study was a randomized, phase 3 study in newly diagnosed transplant ineligible patients with multiple myeloma, comparing melphalan-prednisolone in combination with thalidomide or lenalidomide, followed by maintenance therapy until progression (MPT-T or MPR-R)." | 5.34 | Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. ( Abildgaard, N; Bos, G; Brouwer, R; Coenen, J; Deenik, W; Durian, M; Gimsing, P; Hansson, M; Haukås, E; Hinge, M; Klein, S; Levin, MD; Leys, R; Lissenberg-Witte, B; Mellqvist, UH; Nielsen, LK; Salomo, M; Sinnige, H; Sonneveld, P; Stege, C; Szatkowski, D; Tanis, B; van de Donk, N; van der Hem, K; van der Holt, B; van der Velden, A; Visser-Wisselaar, H; Waage, A; Westerman, M; Zweegman, S, 2020) |
| "Patients with relapsed/refractory multiple myeloma (RRMM) for whom the benefits of lenalidomide have been exhausted in early treatment lines need effective therapies." | 5.34 | Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure. ( Agajanian, R; Agarwal, A; Bahlis, NJ; Chung, W; Kaya, H; Malek, E; Mouro, J; Pierceall, WE; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, KW; Srinivasan, S; Stockerl-Goldstein, K; Talamo, G; Zafar, F, 2020) |
| "In POLLUX, daratumumab (D) plus lenalidomide/dexamethasone (Rd) reduced the risk of disease progression or death by 63% and increased the overall response rate (ORR) versus Rd in relapsed/refractory multiple myeloma (RRMM)." | 5.34 | Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. ( Bahlis, NJ; Benboubker, L; Chiu, C; Cook, G; Dimopoulos, MA; Ho, PJ; Kaufman, JL; Kim, K; Krevvata, M; Leiba, M; Moreau, P; Okonkwo, L; Qi, M; Qin, X; San-Miguel, J; Takezako, N; Trivedi, S; Ukropec, J; White, DJ, 2020) |
| " response-adapted (in case of complete response, CR) lenalidomide (LEN) maintenance therapy (MT) in newly diagnosed, transplant-eligible multiple myeloma (MM)." | 5.34 | Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. ( Bernhard, H; Bertsch, U; Blau, IW; Brossart, P; Dürig, J; Elmaagacli, A; Fuhrmann, S; Giesen, N; Goerner, M; Goldschmidt, H; Hänel, M; Hielscher, T; Hillengass, J; Hoffmann, M; Hose, D; Hügle-Dörr, B; Huhn, S; Jauch, A; Kunz, C; Lindemann, HW; Luntz, S; Mai, EK; Merz, M; Munder, M; Raab, MS; Rabold, B; Salwender, HJ; Scheid, C; Seckinger, A; Tichy, D; Weisel, KC, 2020) |
| "In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib and dexamethasone (PVd) significantly improved the progression-free survival (PFS) and the overall response rate (ORR) vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma." | 5.34 | Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM. ( Biyukov, T; Matsue, K; Peluso, T; Richardson, P; Sakurai, S; Shinagawa, A; Sunami, K; Suzuki, K; Takezako, N; Tamakoshi, H, 2020) |
| "Patients with multiple myeloma who have relapsed after or become refractory to lenalidomide in early treatment lines represent a clinically important population in need of effective therapies." | 5.34 | Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment. ( Acosta-Rivera, M; Agarwal, A; Anz, B; Bahlis, NJ; Bar, M; Berdeja, J; Chung, W; Fonseca, G; Ganguly, S; Matous, J; Pierceall, WE; Quick, D; Reece, D; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, K; Talamo, G; Zafar, F, 2020) |
| "Relapsed/refractory multiple myeloma patients treated with pomalidomide and dexamethasone have an overall response rate (ORR) of ∼30% and median progression-free survival (PFS) of 4-5 months." | 5.34 | A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma. ( Chan, E; Chari, A; Cho, HJ; Couto, S; Florendo, E; Ip, C; Jagannath, S; Kim-Schulze, S; La, L; Laganà, A; Lau, K; Leshchenko, VV; Madduri, D; Mancia, IS; Melnekoff, DT; Parekh, S; Pierceall, WE; Richter, J; Strumolo, G; Thakurta, A; Thomas, J; Van Oekelen, O; Verina, D; Vishnuvardhan, N; Wang, M; Zarychta, K, 2020) |
| "The phase 3 FIRST trial demonstrated significant improvement in progression-free survival (PFS) and overall survival (OS) with an immune-stimulatory agent, lenalidomide, in combination with low-dose dexamethasone until disease progression (Rd continuous) vs melphalan +prednisone + thalidomide (MPT) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)." | 5.34 | Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients. ( Anderson, K; Bahlis, N; Belch, A; Brown, D; Chen, C; Cheung, M; Dispenzieri, A; Facon, T; Robinson, S; Shustik, C; Song, K; Srinivasan, S; Tosikyan, A; White, D, 2020) |
| "In part 1 of the two-part CASSIOPEIA study, treatment before and after autologous haematopoietic stem-cell transplantation (HSCT) with daratumumab plus bortezomib, thalidomide, and dexamethasone (D-VTd) significantly improved rates of stringent complete response and progression-free survival versus bortezomib, thalidomide, and dexamethasone (VTd) in patients with newly diagnosed multiple myeloma." | 5.34 | Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial. ( Broijl, A; de Boer, C; Dib, M; Dorvaux, V; Fastenau, J; Frenzel, L; Gries, KS; Hebraud, B; Jaccard, A; Jie, KS; Kampfenkel, T; Klein, SK; Laribi, K; Moreau, P; Roussel, M; Royer, B; Slama, B; Sonneveld, P; Vanquickelberghe, V; Wang, J; Zweegman, S, 2020) |
| "The phase 3 GIMEMA-MMY-3006 trial, which compared bortezomib, thalidomide, and dexamethasone (VTD) combination therapy with thalidomide and dexamethasone (TD) as induction therapy before and consolidation therapy after double autologous haematopoietic stem-cell transplantation (HSCT) for newly diagnosed multiple myeloma, showed the superiority of the triplet regimen over the doublet in terms of increased complete response rate and improved progression-free survival." | 5.34 | Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. ( Barbato, S; Boccadoro, M; Cangialosi, C; Catalano, L; Cavo, M; Cellini, C; Ciambelli, F; Crippa, C; De Sabbata, G; Di Raimondo, F; Dozza, L; Elice, F; Galieni, P; Galli, M; Gobbi, M; Lazzaro, A; Marzocchi, G; Montefusco, V; Musto, P; Narni, F; Pantani, L; Patriarca, F; Pescosta, N; Petrucci, MT; Ronconi, S; Spadano, A; Tacchetti, P; Terragna, C; Testoni, N; Tosi, P; Zamagni, E, 2020) |
| "Nearly all patients with multiple myeloma (MM) relapse or become refractory to front-line therapy." | 5.34 | Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma. ( Avonto, I; Boccadoro, M; Bringhen, S; Corvatta, L; Falco, P; Leoni, P; Marconi, M; Offidani, M; Palumbo, A; Piersantelli, MN; Polloni, C, 2007) |
| "Thalidomide has become an important agent in the treatment of myeloma." | 5.34 | Thalidomide induced impotence in male hematology patients: a common but ignored complication? ( Murphy, PT; O'Donnell, JR, 2007) |
| "Thalidomide has been associated with venous thrombotic events, as reported in the post-marketing surveillance reports by Celgene Corporation; as well as case reports in the literature." | 5.33 | Arterial thrombosis in four patients treated with thalidomide. ( Brown, K; Chanan-Khan, A; Hahn, T; McCarthy, PL; Paplham, P; Roy, H; Scarpace, SL; van Besien, K, 2005) |
| "Thalidomide is a rediscovered old drug with anti-angiogenic, immunomodulatory and anti-inflammatory properties." | 5.33 | Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma. ( Cem Ar, M; Hatemi, G; Salihoglu, A; Soysal, T; Ulku, B; Yazici, H, 2005) |
| "Survival of patients with multiple myeloma (MM) showed no improvement between the 1960s and 1990s." | 5.33 | Do new therapeutic approaches (autotransplants, thalidomide, dexamethasone) improve the survival of patients with multiple myeloma followed in a rheumatology department? ( Arnaud, C; Attal, M; Cantagrel, A; Constantin, A; El Mahou, S; Jamard, B; Laroche, M; Mazières, B, 2006) |
| "Pretreatment with lenalidomide sensitized MM cells to SGN-40-induced cell death." | 5.33 | Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. ( Anderson, KC; Bae, J; Breitkreutz, I; Catley, L; Chauhan, D; Coffey, R; Grewal, IS; Hideshima, T; Li, XF; Munshi, NC; Podar, K; Richardson, P; Schlossman, R; Song, W; Tai, YT; Treon, SP, 2005) |
| "As thalidomide has become an accepted component in therapeutic strategies for multiple myeloma, careful attention must be paid to the prevention of thrombosis." | 5.33 | [Deep vein thrombosis and pulmonary embolism in a patient with multiple myeloma treated with thalidomide and dexamethasone]. ( Handa, H; Irisawa, H; Karasawa, M; Matsushima, T; Miyazawa, Y; Murakami, H; Nojima, Y; Saitoh, T; Tsukamoto, N; Uchiumi, H, 2006) |
| "Thalidomide, an antiemetic administered in 60th of the 20th century to pregnant women, has become notorious for a range of adverse effects which led to its taking off market." | 5.32 | [Desirable and undesirable effects of thalidomide in patients with multiple myeloma]. ( Foldyna, D; Hájek, R; Kamelander, J; Krejcí, M, 2003) |
| "Thalidomide appears to be a safe drug in the post-transplant setting, perhaps adding to the response achieved post-transplant without major toxicity." | 5.32 | Thalidomide effects in the post-transplantation setting in patients with multiple myeloma. ( Byrnes, JJ; Fernandez, HF; Goodman, M; Santos, ES, 2004) |
| "Thalidomide has antiangiogenic and immunomodulatory effects, mediated by several cytokines such as vascular endothelial growth factor (VEGF), fibroblastic growth factor (FGF-2), hepatocyte growth factor (HGF), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha)." | 5.32 | Response to thalidomide in multiple myeloma: impact of angiogenic factors. ( Arenillas, L; Aymerich, M; Bladé, J; Cibeira, MT; Cid, MC; Esteve, J; Filella, X; Montserrat, E; Rosiñol, L; Rozman, M; Segarra, M, 2004) |
| "Thalidomide has a variety of biological effects that vary considerably according to the species tested." | 5.32 | Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients. ( Baguley, BC; Browett, P; Ching, LM; Chung, F; Kestell, P; Lu, J; Palmer, BD; Tingle, M, 2004) |
| "Thalidomide-dexamethasone was given within 15 months after intensive therapy provided myeloma protein production had been reduced by >75% to a constant level for at least 4 months." | 5.31 | Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. ( Alexanian, R; Delasalle, K; Giralt, S; Weber, D, 2002) |
| "Thalidomide was administered at relatively high doses (escalated up to 700 mg daily and continued for 4 months)." | 5.31 | Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent. ( Anagnostopoulos, N; Dimopoulos, MA; Zomas, A, 2000) |
| "Thalidomide has recently shown antitumor activity in patients with refractory myeloma." | 5.31 | Thalidomide in refractory and relapsing multiple myeloma. ( Bladé, J; Esteve, J; Montoto, S; Montserrat, E; Perales, M; Rosiñol, L; Tuset, M, 2001) |
| "Ixazomib-revlimid-dexamethason showed significant activity in relapsed/refractory multiple myeloma (RRMM)." | 5.30 | Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. ( Egle, A; Einsele, H; Greil, R; Gunsilius, E; Hajek, R; Knop, S; Krenosz, KJ; Lechner, D; Ludwig, H; Melchardt, T; Niederwieser, D; Petzer, A; Poenisch, W; Schreder, M; Weisel, K; Willenbacher, W; Zojer, N, 2019) |
| "Pomalidomide is a third generation immunomodulatory drug which in combination with dexamethasone, has been shown to be active in relapsed/refractory multiple myeloma." | 5.30 | Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network. ( Asaoku, H; Chim, CS; Chng, WJ; Durie, B; Gopalakrishnan, SK; Huang, SY; Kim, JS; Kim, K; Kimura, H; Kosugi, H; Lee, JH; Lee, JJ; Lee, SL; Min, CK; Moorakonda, R; Nagarajan, C; Sakamoto, J; Soekojo, CY; Takezako, N; Wei, Y; Yoon, SS, 2019) |
| " In a previous phase 1b study, around 65% of patients with relapsed and refractory multiple myeloma achieved an overall response with a combination of isatuximab with pomalidomide and low-dose dexamethasone." | 5.30 | Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. ( Anderson, KC; Attal, M; Beksac, M; Campana, F; Cavo, M; Corzo, KP; Dimopoulos, MA; Dubin, F; Huang, JS; Le-Guennec, S; Leleu, X; Macé, S; Minarik, J; Moreau, P; Prince, HM; Rajkumar, SV; Richardson, PG; San-Miguel, J; Schjesvold, F; Spicka, I, 2019) |
| "A prospective, multicenter, phase II study was performed to assess the efficacy and safety of thalidomide maintenance therapy at different doses in Japanese multiple myeloma (MM) patients." | 5.30 | Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study). ( Handa, H; Kanematsu, T; Kasamatsu, T; Kiguchi, T; Kosugi, H; Miki, H; Morishita, T; Murakami, H; Murakami, J; Ogawa, D; Ozaki, S; Shimizu, K; Takahashi, T; Takamatsu, H; Takeo, T; Yamauchi, T, 2019) |
| "The addition of clarithromycin enhances the efficacy of lenalidomide plus dexamethasone in treatment-naive multiple myeloma (MM)." | 5.30 | Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma. ( Boyer, A; Coleman, M; Forsberg, PA; Jayabalan, D; Mark, TM; Niesvizky, R; Pearse, RN; Pekle, KA; Perry, A; Rossi, AC; Tegnestam, L, 2019) |
| "This phase 1b dose-escalation study evaluated isatuximab plus pomalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM)." | 5.30 | A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. ( Anderson, K; Bensinger, W; Campana, F; Dubin, F; Kanagavel, D; Karanes, C; Liu, Q; Mikhael, J; Raje, N; Richardson, P; Semiond, D; Usmani, SZ, 2019) |
| "Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell transplantation is standard treatment in Europe for transplant-eligible patients with newly diagnosed multiple myeloma." | 5.30 | Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. ( Ahmadi, T; Arnulf, B; Attal, M; Avet-Loiseau, H; Belhadj, K; Benboubker, L; Béné, MC; Broijl, A; Caillon, H; Caillot, D; Chiu, C; Corre, J; de Boer, C; Dejoie, T; Delforge, M; Deraedt, W; Doyen, C; Escoffre-Barbe, M; Eveillard, JR; Facon, T; Fermand, JP; Fontan, J; Garderet, L; Garidi, R; Hulin, C; Jie, KS; Kampfenkel, T; Karlin, L; Klein, SK; Kolb, B; Kuhnowski, F; Lambert, J; Leleu, X; Lenain, P; Levin, MD; Macro, M; Marolleau, JP; Mathiot, C; Meuleman, N; Moreau, P; Orsini-Piocelle, F; Pei, L; Perrot, A; Roussel, M; Schecter, J; Smith, E; Sonneveld, P; Sonntag, C; Stoppa, AM; Tiab, M; Touzeau, C; van de Donk, NW; Vekemans, MC; Vermeulen, J; Westerman, M; Wuilleme, S; Zhuang, S; Zweegman, S, 2019) |
| "We conducted a phase I study to determine the recommended dose of thalidomide combined with melphalan plus prednisolone (MPT) and a phase II study evaluating the efficacy and safety of this MPT regimen in transplant-ineligible Japanese patients with untreated multiple myeloma." | 5.30 | Report of phase I and II trials of melphalan, prednisolone, and thalidomide triplet combination therapy versus melphalan and prednisolone doublet combination therapy in Japanese patients with newly diagnosed multiple myeloma ineligible for autologous stem ( Doki, N; Kosugi, H; Meguro, K; Murakami, H; Sasaki, O; Shimizu, K; Sunami, K; Suzuki, K; Takagi, T, 2019) |
| "Pomalidomide and dexamethasone is a standard of care for patients with multiple myeloma in whom bortezomib and lenalidomide treatment has failed." | 5.30 | Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. ( Avivi, I; Benyamini, N; Blacklock, H; Chanan-Khan, A; Farooqui, M; George, A; Goldschmidt, H; Iida, S; Jagannath, S; Kher, U; Larocca, A; Liao, J; Lonial, S; Marinello, P; Mateos, MV; Matsumoto, M; Ocio, EM; Oriol, A; Ribrag, V; Rodriguez-Otero, P; San Miguel, J; Schjesvold, F; Sherbenou, D; Simpson, D; Suzuki, K; Usmani, SZ, 2019) |
| "This phase 1 study investigated the safety of the anthracycline amrubicin combined with lenalidomide and dexamethasone in adults with relapsed or refractory multiple myeloma." | 5.27 | A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. ( Berube, C; Coutré, SE; Dinner, S; Dunn, TJ; Gotlib, J; Kaufman, GP; Liedtke, M; Medeiros, BC; Price, E, 2018) |
| "Patients with multiple myeloma that was refractory or relapsed and refractory to lenalidomide and a proteasome inhibitor were randomly assigned to receive elotuzumab plus pomalidomide and dexamethasone (elotuzumab group) or pomalidomide and dexamethasone alone (control group)." | 5.27 | Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. ( Dimopoulos, MA; Dytfeld, D; Grosicki, S; Hori, M; Jou, YM; LeBlanc, R; Leleu, X; Moreau, P; Popa McKiver, M; Raab, MS; Rafferty, B; Richardson, PG; Robbins, M; San-Miguel, J; Shelat, SG; Suzuki, K; Takezako, N, 2018) |
| "The phase 3, randomized Frontline Investigation of Revlimid and Dexamethasone Versus Standard Thalidomide (FIRST) trial investigating lenalidomide plus low-dose dexamethasone until disease progression (Rd continuous) vs melphalan, prednisone and thalidomide for 12 cycles (MPT) and Rd for 18 cycles (Rd18) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) showed that Rd continuous prolonged progression-free survival and overall survival compared with MPT." | 5.24 | Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial. ( Bahlis, NJ; Basu, S; Chen, G; Corso, A; de Revel, T; Decaux, O; Demuynck, H; Desjardins, P; Ervin-Haynes, A; Facon, T; Granell, M; Guthrie, TH; Huang, SY; Marek, J; Marit, G; Mugge, LO; Nahi, H; Shen, ZX; Stoppa, AM, 2017) |
| "Carfilzomib, a proteasome inhibitor, is approved as monotherapy and in combination with dexamethasone or lenalidomide-dexamethasone (Rd) for relapsed or refractory multiple myeloma." | 5.24 | Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. ( Aggarwal, S; Dimopoulos, MA; Goranova-Marinova, V; Hájek, R; Jakubowiak, A; Ludwig, H; Masszi, T; Mihaylov, GG; Moreau, P; Niesvizky, R; Oriol, A; Palumbo, A; Rajnics, P; Ro, S; Rosiñol, L; San-Miguel, J; Siegel, D; Špička, I; Stewart, AK; Suvorov, A, 2017) |
| "This phase 1b, open-label, dose-escalation study assessed the safety, efficacy, and pharmacokinetics of anti-CD38 monoclonal antibody isatuximab given in 2 schedules (3, 5, or 10 mg/kg every other week [Q2W] or 10 or 20 mg/kg weekly [QW] for 4 weeks and then Q2W thereafter [QW/Q2W]), in combination with lenalidomide 25 mg (days 1-21) and dexamethasone 40 mg (QW), in patients with relapsed/refractory multiple myeloma (RRMM)." | 5.24 | A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. ( Baz, R; Benson, DM; Campana, F; Charpentier, E; Lendvai, N; Lesokhin, AM; Martin, T; Munster, P; Vij, R; Wack, C; Wolf, J, 2017) |
| "The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy." | 5.24 | Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. ( Avivi, I; Berg, D; Einsele, H; Esseltine, DL; Gupta, N; Hájek, R; Hari, P; Kumar, S; Liberati, AM; Lin, J; Lonial, S; Ludwig, H; Masszi, T; Mateos, MV; Minnema, MC; Moreau, P; Richardson, PG; Romeril, K; Shustik, C; Spencer, A, 2017) |
| "Circularly permuted TRAIL (CPT) has exhibited promising efficacy as a mono-therapy or in combination with thalidomide for patients with multiple myeloma (MM)." | 5.24 | Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study. ( Chang, N; Chen, W; Hou, J; Jiang, B; Jiang, H; Jin, J; Ke, X; Leng, Y; Li, J; Li, W; Liu, J; Liu, L; Liu, Y; Meng, H; Pan, L; Pang, H; Qiu, L; Shen, Z; Wang, J; Wang, Z; Wei, P; Yang, L; Yang, S; Zhang, M; Zheng, X; Zhou, F, 2017) |
| "Daratumumab plus pomalidomide and dexamethasone (pom-dex) was evaluated in patients with relapsed/refractory multiple myeloma with ≥2 prior lines of therapy who were refractory to their last treatment." | 5.24 | Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. ( Ahmadi, T; Arnulf, B; Chari, A; Chiu, C; Comenzo, R; Fay, JW; Ifthikharuddin, JJ; Kaufman, JL; Khokhar, NZ; Krishnan, A; Lentzsch, S; Lonial, S; Nottage, K; Suvannasankha, A; Wang, J; Weiss, BM, 2017) |
| "The randomized phase III ELOQUENT-2 study (NCT01239797) evaluated the efficacy and safety of elotuzumab + lenalidomide/dexamethasone (ELd) versus lenalidomide/dexamethasone (Ld) in relapsed/refractory multiple myeloma." | 5.24 | Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. ( Anderson, K; Beksac, M; Belch, A; Bleickardt, E; Dimopoulos, MA; Grosicki, S; Katz, J; Lonial, S; Magen, H; Mateos, MV; Moreau, P; Palumbo, A; Poulart, V; Reece, D; Richardson, P; San-Miguel, J; Sheng, J; Shpilberg, O; Singhal, A; Spicka, I; Sy, O; Walter-Croneck, A; White, D, 2017) |
| "The China Continuation study was a separate regional expansion of the global, double-blind, placebo-controlled, randomized phase III TOURMALINE-MM1 study of ixazomib plus lenalidomide-dexamethasone (Rd) in patients with relapsed/refractory multiple myeloma (RRMM) following one to three prior therapies." | 5.24 | Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. ( Chen, X; Du, X; Gupta, N; Hanley, MJ; Hou, J; Hua, Z; Jin, J; Ke, X; Li, H; Li, J; Liu, J; Lu, J; Moreau, P; Richardson, PG; van de Velde, H; Wang, B; Wang, H; Wu, D; Xu, Y; Zhang, X; Zhou, D, 2017) |
| " Food and Drug Administration granted regular approval to daratumumab in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy." | 5.24 | FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy. ( Bhatnagar, V; Farrell, AT; Goldberg, KB; Gormley, NJ; Luo, L; Ma, L; McKee, AE; Pazdur, R; Shen, G; Shen, YL; Shord, S; Sridhara, R; Subramaniam, S, 2017) |
| "On November 19, 2015, a marketing authorization valid through the European Union was issued for carfilzomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy." | 5.24 | The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy. ( Bergh, J; Camarero Jiménez, J; Demolis, P; Garcia, I; Gisselbrecht, C; Laane, E; Ludwig, H; Martin, M; Moreau, A; Pignatti, F; Salmonson, T; Sancho-López, A; Tzogani, K, 2017) |
| "This study investigated the efficacy and safety of low-dose lenalidomide combined with dexamethasone in elderly patients with relapsed and refractory multiple myeloma (MM)." | 5.24 | Low-dose lenalidomide and dexamethasone combination treatment in elderly patients with relapsed and refractory multiple myeloma. ( Chen, Y; Chen, Z; He, Z; Shi, Y; Wang, C; Yu, L; Zhang, L, 2017) |
| " We report a phase 1 study (NCT01241292) in which we evaluated the safety, efficacy and pharmacokinetics of elotuzumab combined with lenalidomide and dexamethasone in Japanese patients with relapsed/refractory multiple myeloma (RRMM)." | 5.24 | Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study. ( Bleickardt, E; Chou, T; Iida, S; Kinoshita, G; Miyoshi, M; Nagai, H; Pandya, D; Robbins, M, 2017) |
| "Clinical trials of vorinostat, a Class I/II histone deacetylase inhibitor, in combination with proteasome inhibitors and immunomodulatory agents have shown activity in relapsed/refractory multiple myeloma." | 5.24 | A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens. ( Anand, P; Bilotti, E; Biran, N; Ivanovski, K; McBride, L; Richter, JR; Sanchez, L; Siegel, DS; Vesole, DH, 2017) |
| "We report the first clinical investigation conducted in Japan to confirm the safety, tolerability, and pharmacokinetics of ixazomib alone and combined with lenalidomide-dexamethasone (Rd) in Japanese patients with relapsed/refractory multiple myeloma." | 5.24 | Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma. ( Chou, T; Handa, H; Ishizawa, K; Kase, Y; Suzuki, K; Takubo, T, 2017) |
| "Lenalidomide is an immunomodulatory compound with high clinical activity in multiple myeloma." | 5.24 | IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM). ( Bargou, R; Bassermann, F; Bullinger, L; Bunjes, D; Döhner, H; Einsele, H; Engelhardt, M; Greiner, A; Knop, S; Kolmus, S; Köpff, S; Krönke, J; Kuchenbauer, F; Kull, M; Langer, C; Mügge, LO; Schreder, M; Straka, C; Teleanu, V, 2017) |
| "The phase 3 FIRST (Frontline Investigation of REVLIMID + Dexamethasone Versus Standard Thalidomide) trial demonstrated that lenalidomide plus low-dose dexamethasone (Rd) until disease progression (Rd continuous) is an effective treatment option for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)." | 5.24 | Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. ( Chen, G; Chen, WM; Eom, HS; Ervin-Haynes, A; Facon, T; Huang, SY; Hulin, C; Kim, HJ; Kim, K; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Liu, T; Lu, J; Min, CK; Qiu, L; Shen, ZX; Yiu, W; Yoon, SS, 2017) |
| "The phase III trial GEM05MENOS65 randomized 390 patients 65 years old or younger with newly diagnosed symptomatic multiple myeloma (MM) to receive induction with thalidomide/dexamethasone, bortezomib/thalidomide/dexamethasone and Vincristine, BCNU, melphalan, cyclophosphamide, prednisone/vincristine, BCNU, doxorubicin, dexamethasone bortezomib (VBMCP/VBAD/B) followed by autologous stem cell transplantation (ASCT) with MEL-200." | 5.24 | Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial. ( Alegre, A; Bladé, J; Blanchard, M; Cibeira, M; de Arriba, F; de la Guía, AL; de la Rubia, J; Etxebeste, M; González, Y; Granell, M; Hernández, MT; Lahuerta, JJ; Martínez-López, J; Martínez-Martínez, R; Mateos, M; Oriol, A; Palomera, L; Rosiñol, L; Sampol, M; San Miguel, J; Teruel, AI, 2017) |
| "The combination of lenalidomide and dexamethasone is an established treatment for patients with multiple myeloma (MM)." | 5.24 | Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. ( Baker, B; Blacklock, H; Browett, P; Cannell, P; Corbett, G; Cowan, L; Dimopoulos, MA; Fernyhough, L; Forsyth, C; Harrison, S; Henderson, R; Link, E; Miles Prince, H; Neylon, A; Quach, H; Swern, A; Trotman, J; Underhill, C, 2017) |
| "A primary analysis of the ASPIRE study found that the addition of carfilzomib to lenalidomide and dexamethasone (carfilzomib group) significantly improved progression-free survival (PFS) compared with lenalidomide and dexamethasone alone (control group) in patients with relapsed multiple myeloma (RMM)." | 5.24 | Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. ( Aggarwal, S; Dimopoulos, MA; Goranova-Marinova, V; Hájek, R; Jakubowiak, A; Ludwig, H; Masszi, T; Mihaylov, GG; Moreau, P; Niesvizky, R; Obreja, M; Oriol, A; Palumbo, A; Rajnics, P; Rosiñol, L; San-Miguel, J; Siegel, D; Špička, I; Stewart, AK; Suvorov, A, 2017) |
| " In a previous phase 3 study in patients with relapsed/refractory multiple myeloma (RRMM), elotuzumab (10 mg/kg, ∼3-h infusion), combined with lenalidomide and dexamethasone, demonstrated durable efficacy and acceptable safety; 10% (33/321) of patients had infusion reactions (IRs; Grade 1/2: 29; Grade 3: 4)." | 5.24 | A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma. ( Badarinath, S; Berenson, J; Cartmell, A; Harb, W; Lyons, R; Manges, R; McIntyre, K; Mohamed, H; Nourbakhsh, A; Rifkin, R, 2017) |
| " On the other hand, the efficiency of Thalidomide derivates in myelodysplastic syndromes (MDS), such as Lenalidomide, acted as the starting point for the development of targeted leukemia-associated protein degradation molecules." | 5.22 | Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML. ( Buzoianu, AD; Ciechanover, A; Dima, D; Drula, R; Ghiaur, G; Gulei, D; Iluta, S; Iuga, C; Tomuleasa, C, 2022) |
| "Triplet regimens based on pomalidomide and dexamethasone have been applied to treat relapsed/refractory multiple myeloma, but the safety and efficacy are not yet very clear." | 5.22 | The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis. ( Chen, XM; Huang, CL; Liao, KY; Liu, Y; Xiong, H; Zhang, XW, 2022) |
| " There are few prospective, randomized studies investigating mobilization regimens in multiple myeloma (MM), especially after lenalidomide-based induction." | 5.22 | A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma. ( Anttila, P; Bazia, P; Heiskanen, J; Jantunen, E; Kakko, S; Kananen, K; Kuittinen, T; Kutila, A; Launonen, K; Lundan, T; Ollikainen, H; Putkonen, M; Räsänen, A; Remes, K; Säily, M; Selander, T; Siitonen, TM; Sikiö, A; Silvennoinen, R; Suominen, M; Terävä, V, 2016) |
| "Bortezomib plus melphalan and prednisone (VMP) and lenalidomide plus low-dose dexamethasone (Rd) are 2 standards of care for elderly untreated multiple myeloma (MM) patients." | 5.22 | Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. ( Bargay, J; Bengoechea, E; Bladé, J; Cabrera, C; Cedena, MT; Encinas, C; Gironella, M; González, Y; Gutiérrez, NC; Hernández, MT; Lahuerta, JJ; Martín Ramos, ML; Martín, J; Martínez, R; Martínez-López, J; Mateos, MV; Ocio, EM; Oriol, A; Paiva, B; Pérez de Oteyza, J; Puig, N; Rosiñol, L; San-Miguel, J; Teruel, AI, 2016) |
| "The introduction of agents such as thalidomide, lenalidomide, and bortezomib has changed the management of patients with multiple myeloma who are not eligible for autologous transplantation, many of whom are elderly." | 5.22 | Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible. ( Almeida, MS; Bittencourt, R; Chiattone, CS; Crusoé, EQ; Cury, P; Fantl, D; Hisgashi, F; Hungria, VT; Maciel, JF; Maiolino, A; Peres, AL; Pessoa de Magalhaes, RJ, 2016) |
| "Lenalidomide-dexamethasone improved outcome in newly diagnosed elderly multiple myeloma patients." | 5.22 | Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. ( Benevolo, G; Bernardini, A; Boccadoro, M; Bringhen, S; Ciccone, G; Conticello, C; De Paoli, L; Falcone, AP; Gentili, S; Giuliani, N; Guglielmelli, T; Hajek, R; Ledda, A; Liberati, AM; Magarotto, V; Maisnar, V; Mina, R; Montefusco, V; Musolino, C; Offidani, M; Palumbo, A; Patriarca, F; Pietrantuono, G; Pulini, S; Ruggeri, M; Zambello, R, 2016) |
| "The present study evaluated the pharmacokinetics and safety of elotuzumab, a humanized IgG1 monoclonal antibody against signaling lymphocyte activation molecule-F7, combined with lenalidomide and dexamethasone, in patients with multiple myeloma (MM) and renal impairment." | 5.22 | Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study. ( Badros, A; Berdeja, J; Bleickardt, E; Gupta, M; Jagannath, S; Kaufman, JL; Lynch, M; Manges, R; Paliwal, P; Tendolkar, A; Vij, R; Zonder, J, 2016) |
| "The combination of melphalan, prednisone, and thalidomide (MPT) is considered standard therapy for newly diagnosed patients with multiple myeloma who are ineligible for stem cell transplantation." | 5.22 | Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. ( Bos, GM; Brouwer, RE; Coenen, JL; Deenik, W; Durian, MF; Gruber, A; Hansson, M; Haukås, E; Klein, SK; Levin, MD; Leys, MR; Mattijssen, EV; Mellqvist, UH; Plesner, T; Salomo, M; Sinnige, HA; Sonneveld, P; Stevens-Kroef, MJ; Szatkowski, DL; Tanis, BC; van de Donk, NW; van der Hem, KG; van der Holt, B; van der Velden, AW; Visser-Wisselaar, H; Waage, A; Westerman, M; Zweegman, S, 2016) |
| "The efficacy and safety of lenalidomide plus low-dose dexamethasone (Rd) in Chinese patients with relapsed/refractory multiple myeloma (RRMM) was demonstrated in a phase 2, multicenter trial (MM-021)." | 5.22 | Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program. ( Cai, Z; Chen, F; DeMarco, D; Du, X; Hou, J; Jin, J; Ke, X; Li, X; Mei, J; Meng, F; Wu, D; Yu, L; Zhang, J; Zhou, DB, 2016) |
| "The safety and efficacy of siltuximab (CNTO 328) was tested in combination with lenalidomide, bortezomib and dexamethasone (RVD) in patients with newly-diagnosed, previously untreated symptomatic multiple myeloma." | 5.22 | Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. ( Berkova, Z; Champlin, RE; Cleeland, C; Feng, L; Mendoza, TR; Orlowski, RZ; Qazilbash, MH; Shah, JJ; Thomas, SK; Wang, M; Weber, DM, 2016) |
| "The Intergroupe Francophone du Myélome conducted a randomized trial to compare bortezomib-thalidomide-dexamethasone (VTD) with bortezomib-cyclophosphamide-dexamethasone (VCD) as induction before high-dose therapy and autologous stem cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma." | 5.22 | VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. ( Allangba, O; Araujo, C; Attal, M; Avet-Loiseau, H; Belhadj, K; Biron, L; Brechignac, S; Caillon, H; Caillot, D; Chaleteix, C; Chaoui, D; Dejoie, T; Dib, M; Dorvaux, V; Eisenmann, JC; Escoffre, M; Facon, T; Fermand, JP; Fontan, J; Garderet, L; Glaisner, S; Godmer, P; Hulin, C; Jaccard, A; Kolb, B; Laribi, K; Lenain, P; Luycx, O; Macro, M; Malfuson, JV; Marit, G; Moreau, P; Pegourie, B; Planche, L; Puyade, M; Rodon, P; Roussel, M; Royer, B; Slama, B; Stoppa, AM; Tiab, M; Wetterwald, M, 2016) |
| "Marizomib (MRZ) is a novel, irreversible proteasome inhibitor in clinical development for the treatment of relapsed or relapsed and refractory multiple myeloma (RRMM)." | 5.22 | Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. ( Anderson, KC; Chanan-Khan, AA; Chauhan, D; Hofmeister, CC; Jakubowiak, AJ; Kaufman, JL; Laubach, JP; Reich, S; Richardson, PG; Talpaz, M; Trikha, M; Zimmerman, TM, 2016) |
| "Pomalidomide + low-dose dexamethasone is effective and well tolerated for refractory or relapsed and refractory multiple myeloma after bortezomib and lenalidomide failure." | 5.22 | Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. ( Alegre, A; Banos, A; Cavo, M; Chen, C; Delforge, M; Dimopoulos, MA; Garderet, L; Goldschmidt, H; Hong, K; Ivanova, V; Jacques, C; Karlin, L; Knop, S; Lacy, MQ; Martinez-Lopez, J; Moreau, P; Oriol, A; San Miguel, J; Song, KW; Sternas, L; Weisel, KC; Yu, X; Zaki, MH, 2016) |
| "In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 722 patients who had relapsed, refractory, or relapsed and refractory multiple myeloma to receive ixazomib plus lenalidomide-dexamethasone (ixazomib group) or placebo plus lenalidomide-dexamethasone (placebo group)." | 5.22 | Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. ( Bahlis, NJ; Baker, BW; Berg, DT; Buadi, FK; Cavo, M; Di Bacco, A; Ganly, P; Garderet, L; Gimsing, P; Grzasko, N; Hansson, M; Hui, AM; Jackson, SR; Kumar, S; Laubach, JP; Lin, J; Masszi, T; Moreau, P; Palumbo, A; Pour, L; Richardson, PG; Sandhu, I; Simpson, DR; Stoppa, AM; Touzeau, C; van de Velde, H, 2016) |
| "New drugs for the treatment of multiple myeloma (MM) comprise immunomodulatory substances such as lenalidomide and related compounds." | 5.22 | Lenalidomide consolidation treatment in patients with multiple myeloma suppresses myelopoieses but spares erythropoiesis. ( Boquoi, A; Bruns, I; Cadeddu, RP; Deenen, R; Dienst, A; Fenk, R; Haas, R; Heinzler, N; Kobbe, G; Köhrer, K; Majidi, F; Schroeder, T; Strapatsas, T; Wilk, CM, 2016) |
| " Patients aged 18 years or older with high-risk smouldering multiple myeloma were randomly assigned (1:1), via a computerised random number generator, to receive either early treatment with lenalidomide plus dexamethasone or observation, with dynamic balancing to maintain treatment balance within the two groups." | 5.22 | Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. ( Arguiñano, JM; Bargay, J; Bladé, J; Corral, LL; de Arriba, F; de la Rubia, J; García, JL; Giraldo, P; Hernández, MT; Lahuerta, JJ; López, J; Mateos, MV; Miguel, JS; Oriol, A; Paiva, B; Palomera, L; Prosper, F; Quintana, N; Rosiñol, L, 2016) |
| " We evaluated the safety and tolerability of elotuzumab 10 mg/kg combined with thalidomide 50-200 mg and dexamethasone 40 mg (with/without cyclophosphamide 50 mg) in patients with relapsed/refractory multiple myeloma (RRMM)." | 5.22 | Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma. ( Blade, J; Bleickardt, E; Gironella, M; Granell, M; Hernandez, MT; Lynch, M; Martín, J; Martinez-Lopez, J; Mateos, MV; Oriol, A; Paliwal, P; San-Miguel, J; Singhal, A, 2016) |
| "Purpose To determine the effects of carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) on health-related quality of life (HR-QoL) in the Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone for the Treatment of Patients With Relapsed Multiple Myeloma (ASPIRE) trial." | 5.22 | Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. ( Buchanan, J; Cocks, K; Dimopoulos, MA; Hájek, R; Jakubowiak, AJ; Ludwig, H; Masszi, T; Moreau, P; Niesvizky, R; Oriol, A; Palumbo, A; Rosiñol, L; San-Miguel, JF; Siegel, DS; Špička, I; Stewart, AK; Tonda, M; Xing, B; Yang, X; Zojwalla, N, 2016) |
| "The findings from this study provide preliminary evidence that ricolinostat is a safe and well tolerated selective HDAC6 inhibitor, which might partner well with lenalidomide and dexamethasone to enhance their efficacy in relapsed or refractory multiple myeloma." | 5.22 | Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. ( Bensinger, WI; Berdeja, JG; Birrer, NE; Burke, JN; Jones, SS; Libby, EN; Markelewicz, RJ; Raje, NS; Richardson, PG; Supko, JG; Tamang, DL; Voorhees, PM; Wallace, EE; Wheeler, CA; Yang, M; Yee, AJ, 2016) |
| "The prognosis of multiple myeloma (MM) patients who become refractory to lenalidomide and bortezomib is very poor, indicating the need for new therapeutic strategies for these patients." | 5.22 | Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. ( Beeker, A; Bloem, AC; Bos, GMJ; Broijl, A; Faber, LM; Franssen, LE; Klein, SK; Koene, HR; Levin, MD; Lokhorst, HM; Mutis, T; Nijhof, IS; Oostvogels, R; Raymakers, R; Sonneveld, P; van de Donk, NWCJ; van der Spek, E; van Kessel, B; van Spronsen, DJ; van Velzen, J; Westerweel, PE; Ypma, PF; Zweegman, S, 2016) |
| "Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed or refractory multiple myeloma." | 5.22 | Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. ( Ahmadi, T; Bahlis, NJ; Ben Yehuda, D; Chiu, C; Dimopoulos, MA; Goldschmidt, H; Guckert, M; Khokhar, NZ; Komarnicki, M; Lisby, S; Moreau, P; Nahi, H; O'Rourke, L; Oriol, A; Orlowski, RZ; Plesner, T; Qin, X; Rabin, N; Reece, D; Richardson, PG; San-Miguel, J; Suzuki, K; Usmani, SZ; Yoon, SS, 2016) |
| "Panobinostat 20 mg in combination with bortezomib, thalidomide, and dexamethasone is an efficacious and well tolerated regimen for patients with relapsed multiple myeloma." | 5.22 | Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. ( Brown, SR; Cavenagh, J; Cook, G; Flanagan, L; Gregory, W; Hall, A; Kishore, B; Low, E; Oakervee, H; Popat, R; Streetly, M; Yong, K, 2016) |
| "This single institution, open label Phase I-II dose escalation trial evaluated the safety and efficacy of the combination of lenalidomide (Revlimid®), cyclophosphamide and prednisone (CPR) in patients with relapsed/refractory multiple myeloma." | 5.20 | Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma. ( Anglin, P; Atenafu, EG; Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Masih-Khan, E; Mikhael, JR; Reece, DE; Trudel, S, 2015) |
| "This multicenter phase 2 study of the European Myeloma Network investigated the combination of carfilzomib, thalidomide, and dexamethasone (KTd) as induction/consolidation therapy for transplant-eligible patients with previously untreated multiple myeloma (N = 91)." | 5.20 | Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. ( Asselbergs, E; Broyl, A; de Weerdt, O; Kersten, MJ; Lokhorst, H; Lonergan, S; Palumbo, A; Sonneveld, P; van der Holt, B; van Marwijk-Kooy, M; Vellenga, E; Zweegman, S, 2015) |
| "In the phase III MM-003 trial, pomalidomide plus low-dose dexamethasone (POM+LoDEX) improved overall survival (OS) versus high-dose dexamethasone (HiDEX) in 455 patients with relapsed and refractory multiple myeloma (RRMM) after treatment with bortezomib and lenalidomide." | 5.20 | Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone. ( Akehurst, R; Delforge, M; Dhanasiri, S; Dimopoulos, MA; Facon, T; Jacques, C; Lee, D; Morgan, G; Offner, F; Oriol, A; Palumbo, A; Sternas, L; Weisel, K; Yu, X; Zaki, M, 2015) |
| "Multiple myeloma (MM) is a heterogeneous disease, and the benefit from bortezomib treatment is not uniform among all patients subgroups." | 5.20 | Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment. ( Acharya, C; An, G; Cheng, T; Deng, S; Feng, X; Hao, M; Li, Z; Qi, J; Qin, X; Qiu, L; Ru, K; Shi, L; Sui, W; Tai, YT; Wang, J; Xu, Y; Yi, S; Zang, M; Zhao, Y; Zou, D, 2015) |
| "Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma." | 5.20 | Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. ( Ben-Yehuda, D; Bensinger, WI; Dimopoulos, MA; Goranova-Marinova, V; Hájek, R; Jakubowiak, AJ; Kukreti, V; Ludwig, H; Maisnar, V; Masszi, T; Mateos, MV; Mihaylov, GG; Minarik, J; Moreau, P; Niesvizky, R; Oriol, A; Palumbo, A; Rajkumar, SV; Rajnics, P; Rosiñol, L; San-Miguel, JF; Siegel, DS; Špička, I; Stewart, AK; Suvorov, A; Tonda, ME; Wang, M; Xing, B; Yang, X; Zojwalla, N, 2015) |
| "The Japanese POEMS syndrome with Thalidomide (J-POST) Trial is a phase II/III multicentre, double-blinded, randomised, controlled trial that aims to evaluate the efficacy and safety of a 24-week treatment with thalidomide in POEMS syndrome, with an additional 48-week open-label safety study." | 5.20 | Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trial. ( Hanaoka, H; Ikeda, S; Kanda, T; Katayama, K; Kikuchi, S; Kira, J; Kohara, N; Kusunoki, S; Kuwabara, S; Misawa, S; Nakashima, I; Nishizawa, M; Sato, Y; Sobue, G; Watanabe, O; Yabe, I, 2015) |
| "The combination of pomalidomide and low-dose dexamethasone (Pom-Dex) can be safely administered to patients with end-stage relapsed/refractory multiple myeloma (RRMM)." | 5.20 | Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. ( Arnulf, B; Attal, M; Avet-Loiseau, H; Banos, A; Benboubker, L; Brechiniac, S; Caillot, D; Decaux, O; Dib, M; Escoffre-Barbe, M; Facon, T; Fermand, JP; Fuzibet, JG; Garderet, L; Hulin, C; Karlin, L; Kolb, B; Lacotte, L; Legros, L; Leleu, X; Macro, M; Marit, G; Mathiot, C; Moreau, P; Onraed, B; Pegourie, B; Petillon, MO; Rodon, P; Roussel, M; Royer, B; Stoppa, AM; Thielemans, B; Tiab, M; Wetterwald, M, 2015) |
| "Sixty-four transplant-eligible patients with newly diagnosed multiple myeloma (NDMM) received carfilzomib (days 1, 2, 8, 9, 15, 16), 300 mg/m(2) cyclophosphamide (days 1, 8, 15), 100 mg thalidomide (days 1-28) and 40 mg dexamethasone (days 1, 8, 15, 22) in 28-day cycles (CYKLONE regimen)." | 5.20 | Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma. ( Bergsagel, PL; Buadi, F; Costa, LJ; Dueck, AC; Gano, K; Libby, EN; Mayo, A; Mikhael, JR; Nagi Reddy, SK; Reeder, CB; Stewart, AK, 2015) |
| "Toward our goal of personalized medicine, we comprehensively profiled pre-treatment malignant plasma cells from multiple myeloma patients and prospectively identified pathways predictive of favourable response to bortezomib-based treatment regimens." | 5.20 | Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens. ( Alonge, MM; Dytfeld, D; Jakubowiak, AJ; Jasielec, J; Kandarpa, M; Mayampurath, A; Mellacheruvu, D; Nesvizhskii, AI; Ngoka, L; Richardson, PG; Rosebeck, S; Sreekumar, A; Volchenboum, S, 2015) |
| "These findings suggest that lenalidomide in combination with antiinhibitory KIR therapy warrants further investigation in multiple myeloma as a steroid-sparing, dual immune therapy." | 5.20 | A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. ( Andre, P; Benson, DM; Caligiuri, MA; Cohen, AD; Efebera, YA; Hofmeister, CC; Jagannath, S; Munshi, NC; Spitzer, G; Zerbib, R, 2015) |
| "Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma." | 5.20 | Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. ( Anderson, KC; Beksac, M; Belch, A; Bleickardt, E; Dimopoulos, M; Einsele, H; Grosicki, S; Katz, J; Lonial, S; Magen, H; Mateos, MV; Matsumoto, M; Moreau, P; Oakervee, H; Orlowski, RZ; Palumbo, A; Poulart, V; Reece, D; Richardson, P; Röllig, C; San-Miguel, J; Singhal, A; Spencer, A; Spicka, I; Taniwaki, M; Walter-Croneck, A; White, D; Wu, KL, 2015) |
| "Single-agent post-autologous transplant maintenance therapy with lenalidomide is standard of care for patients with multiple myeloma." | 5.20 | Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma. ( Benson, DM; Bowers, MA; Devine, S; Efebera, Y; Hofmeister, CC; Huang, Y; Humphries, K; Sborov, DW; Williams, N, 2015) |
| "This follow-up extension of a randomised phase II study assessed differences in long-term outcomes between bortezomib-thalidomide-dexamethasone (VTD) and VTD-cyclophosphamide (VTDC) induction therapy in multiple myeloma." | 5.20 | Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up. ( Ataman, O; Chaturvedi, S; Dmoszynska, A; Enny, C; Esteves, G; Feng, H; Greil, R; Hajek, R; Ludwig, H; Masszi, T; Paiva, B; Robinson, D; Shpilberg, O; Spicka, I; Stoppa, AM; van de Velde, H; Vidriales, MB; Viterbo, L, 2015) |
| "This phase 3 trial (Eastern Cooperative Oncology Group [ECOG] E1A06) compared melphalan, prednisone, and thalidomide (MPT-T) with melphalan, prednisone, and lenalidomide (mPR-R) in patients with untreated multiple myeloma (MM)." | 5.20 | Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. ( Callander, NS; Chanan-Khan, AA; Fonseca, R; Jacobus, S; Rajkumar, SV; Stewart, AK; Weiss, M, 2015) |
| "Lenalidomide treatment in combination with dexamethasone and/or chemotherapy is associated with a significant risk of venous thromboembolism (VTE) in patients with multiple myeloma (MM)." | 5.20 | Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide. ( Isoda, A; Koumoto, M; Matsumoto, M; Matsumoto, Y; Miyazawa, Y; Ookawa, M; Sato, N; Sawamura, M, 2015) |
| "Carfilzomib-lenalidomide-dexamethasone therapy yields deep responses in patients with newly diagnosed multiple myeloma (NDMM)." | 5.20 | Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. ( Arthur, DC; Bhutani, M; Braylan, R; Burton, D; Calvo, KR; Carpenter, A; Carter, G; Choyke, P; Costello, R; Cunningham, SC; Faham, M; Figg, W; Gounden, V; Kazandjian, D; Kong, KA; Korde, N; Kurdziel, K; Kwok, M; Lamping, L; Landgren, O; Lindenberg, L; Mailankody, S; Manasanch, EE; Maric, I; Morrison, C; Mulquin, M; Peer, C; Roschewski, M; Sissung, TM; Steinberg, SM; Stetler-Stevenson, M; Tageja, N; Wall, Y; Weng, L; Wu, P; Yuan, C; Zhang, Y; Zingone, A; Zuchlinski, D, 2015) |
| "This phase 1, open-label, dose-escalation study investigated the tolerated dose (recommended dose), safety, efficacy, and pharmacokinetics of pomalidomide alone or pomalidomide plus low-dose dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma." | 5.20 | Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma. ( Chou, T; Doerr, T; Iida, S; Iwasaki, H; Kurihara, M; Matsue, K; Midorikawa, S; Ogawa, Y; Sunami, K; Tobinai, K; Zaki, M, 2015) |
| "The oral proteasome inhibitor ixazomib is under phase 3 clinical investigation in multiple myeloma (MM) in combination with lenalidomide-dexamethasone." | 5.20 | Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. ( Chim, CS; Chng, WJ; Esseltine, DL; Goh, YT; Gupta, N; Hanley, MJ; Hui, AM; Kim, K; Lee, JH; Min, CK; Venkatakrishnan, K; Wong, RS; Yang, H, 2015) |
| "Consolidation with high-dose melphalan and ASCT remains the preferred option in transplant-eligible patients with multiple myeloma, despite a better toxicity profile with chemotherapy plus lenalidomide." | 5.20 | Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. ( Boccadoro, M; Campbell, P; Carella, A; Catalano, L; Conticello, C; Corradini, P; Evangelista, A; Gay, F; Hajek, R; Liberati, AM; Magarotto, V; Malfitano, A; Offidani, M; Oliva, S; Omedè, P; Palumbo, A; Patriarca, F; Pescosta, N; Petrò, D; Petrucci, MT; Pour, L; Pulini, S; Ria, R; Siniscalchi, A; Spada, S; Spencer, A, 2015) |
| "In the MM-015 trial, melphalan-prednisone-lenalidomide followed by lenalidomide maintenance (MPR-R) significantly prolonged progression-free survival versus melphalan-prednisone (MP) in newly diagnosed patients with multiple myeloma aged ≥ 65 years." | 5.19 | Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial. ( Delforge, M; Dimopoulos, MA; Hajek, R; Kropff, M; Lewis, P; Mei, J; Millar, S; Palumbo, A; Petrucci, MT; Zhang, J, 2014) |
| "Initial therapy of multiple myeloma with lenalidomide-based regimens can compromise stem cell collection, which can be overcome with the addition of plerixafor." | 5.19 | Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy. ( Bergsagel, LP; Buadi, FK; Dingli, D; Dispenzieri, A; Gastineau, DA; Gertz, MA; Hayman, SR; Kumar, SK; Lacy, MQ; Laplant, B; Laumann, K; Mahlman, M; Miceli, T; Mikhael, J; Reeder, C; Stewart, AK; Winters, JL, 2014) |
| "A previous interim report of MM-011, the first study that combined lenalidomide with anthracycline-based chemotherapy followed by lenalidomide maintenance for relapsed and/or refractory multiple myeloma (RRMM), showed promising safety and activity." | 5.19 | Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma. ( Andresen, S; Ann Karam, M; Baz, R; Bruening, K; Dean, R; Faiman, B; Habecker, B; Hamilton, K; Hussein, MA; Kalaycio, M; Knight, R; Lazaryan, A; Reed, J; Reu, FJ; Sobecks, R; Srkalovic, G; Sweetenham, JW; Waksman, J; Zeldis, JB, 2014) |
| "We conducted a retrospective evaluation of response and survival for 293 patients with multiple myeloma treated since June 2000 with primary thalidomide- or bortezomib-based combinations, of whom 207 patients received intensive therapy supported by autologous blood stem cells within the first year." | 5.19 | Value of novel agents and intensive therapy for patients with multiple myeloma. ( Alexanian, R; Delasalle, K; Handy, B; Qazilbash, M; Wang, M; Wang, S; Weber, D, 2014) |
| "This multicenter, open-label, randomized phase 2 study assessed the efficacy and safety of pomalidomide (POM) with/without low-dose dexamethasone (LoDEX) in patients with relapsed/refractory multiple myeloma (RRMM)." | 5.19 | Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. ( Anderson, KC; Bahlis, N; Baz, R; Belch, A; Chen, C; Chen, M; Hofmeister, CC; Jacques, C; Jagannath, S; Jakubowiak, A; Lacy, M; Lentzsch, S; Lonial, S; Matous, J; Mikhael, J; Raje, N; Richardson, PG; Shustik, C; Siegel, DS; Song, K; Vesole, D; Vij, R; Yu, Z; Zaki, MH, 2014) |
| "In this prospective, multicenter, phase 2 study, 64 patients with relapsed or relapsed and refractory multiple myeloma (MM) received up to 8 21-day cycles of bortezomib 1." | 5.19 | A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. ( Alsina, M; Anderson, KC; Colson, K; Esseltine, DL; Feather, J; Francis, D; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, A; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Maglio, ME; Mazumder, A; McKenney, M; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, D; Weller, E; Xie, W, 2014) |
| "Bortezomib and thalidomide significantly improved OS in multiple myeloma patients not eligible for transplantation." | 5.19 | Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. ( Benevolo, G; Boccadoro, M; Bringhen, S; Cavo, M; Di Raimondo, F; Falcone, AP; Franceschini, L; Gaidano, G; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Magarotto, V; Marasca, R; Mina, R; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, ID; Zambello, R, 2014) |
| "We studied T-BiRD (thalidomide [Thalomid(®)], clarithromycin [Biaxin(®)], lenalidomide [Revlimid(®)] and dexamethasone) in symptomatic, newly diagnosed multiple myeloma." | 5.19 | Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. ( Bowman, IA; Chen-Kiang, S; Coleman, M; Ely, S; Jayabalan, D; Mark, TM; Niesvizky, R; Pearse, RN; Pekle, K; Quinn, R; Rodriguez, M; Rossi, AC; Shah, M; Zafar, F, 2014) |
| "This phase II study prospectively evaluated the efficacy and tolerability of an early change in induction therapy before autologous stem cell transplantation (ASCT) in multiple myeloma (MM) patients who failed to achieve more than a partial response (PR) after two cycles of a cyclophosphamide, thalidomide, and dexamethasone (CTD) regimen." | 5.19 | Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study. ( Ahn, SY; Choi, CW; Joo, YD; Jung, SH; Kim, K; Kim, SJ; Lee, JJ; Lee, SM; Lee, WS, 2014) |
| "Everolimus, an oral mammalian target of rapamycin (mTOR) inhibitor, has been studied in multiple myeloma (MM) but lacks significant single agent activity." | 5.19 | Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. ( Anderson, KC; Burke, JN; Cirstea, DD; Ghobrial, IM; Hari, P; Hideshima, T; Laubach, JP; Mahindra, AK; Marcheselli, R; Munshi, NC; Raje, NS; Richardson, PG; Rodig, SJ; Schlossman, RL; Scullen, TA; Weller, EA; Yee, AJ, 2014) |
| "This single-arm study evaluated feasibility, safety, and initial efficacy of electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy (PN) in cancer patients with multiple myeloma." | 5.19 | Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. ( Alexanian, R; Badillo, M; Chen, Y; Chiang, J; Cohen, L; Delasalle, K; Garcia, MK; Green, V; Guo, Y; Lee, R; Orlowski, RZ; Romaguera, J; Shah, J; Thomas, S; Wang, M; Weber, D; Wei, Q; You, B; Zhang, L; Zhou, Y, 2014) |
| "Standard carfilzomib (20 mg/m(2) cycle 1, 27 mg/m(2) thereafter; 2- to 10-minute infusion) is safe and effective in relapsed or refractory multiple myeloma (R/RMM)." | 5.19 | A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. ( Chung, DJ; Devlin, S; Giralt, SA; Hassoun, H; Hilden, P; Koehne, G; Landau, H; Lendvai, N; Lesokhin, AM; Redling, K; Schaffer, WL; Tsakos, I, 2014) |
| "The three-drug combination of lenalidomide, bortezomib, and dexamethasone (RVD) has shown significant efficacy in multiple myeloma (MM)." | 5.19 | Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélo ( Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Chretien, ML; Corre, J; Facon, T; Fruchart, C; Gentil, C; Hebraud, B; Hulin, C; Huynh, A; Lauwers-Cances, V; Leleu, X; Marit, G; Moreau, P; Pegourie, B; Robillard, N; Roussel, M; Stoppa, AM; Wuilleme, S, 2014) |
| "We compared the three arms of the MM-015 randomized phase III clinical trial [melphalan and prednisone (MP), MP plus lenalidomide (MPR), and MPR plus lenalidomide maintenance (MPR-R)] to determine whether the addition of lenalidomide maintenance therapy for primary treatment of multiple myeloma is cost-effective." | 5.19 | Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma. ( Ailawadhi, S; Alamgir, A; Asano, H; Chanan-Khan, A; Kim, MY; Sposto, R; Swaika, A, 2014) |
| "A subanalysis of the GIMEMA-MMY-3006 trial was performed to characterize treatment-emergent peripheral neuropathy (PN) in patients randomized to thalidomide-dexamethasone (TD) or bortezomib-TD (VTD) before and after double autologous transplantation (ASCT) for multiple myeloma (MM)." | 5.19 | Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. ( Baldini, L; Cavaletti, G; Cavo, M; Elice, F; Galli, M; Gozzetti, A; Lazzaro, A; Martello, M; Montefusco, V; Palumbo, A; Pantani, L; Peccatori, J; Petrucci, MT; Pezzi, A; Rocchi, S; Ruggieri, M; Tacchetti, P; Terragna, C; Tosi, P; Zamagni, E, 2014) |
| "This open-label, randomized, phase 3 study compared melphalan at a dose of 200 mg per square meter of body-surface area plus autologous stem-cell transplantation with melphalan-prednisone-lenalidomide (MPR) and compared lenalidomide maintenance therapy with no maintenance therapy in patients with newly diagnosed multiple myeloma." | 5.19 | Autologous transplantation and maintenance therapy in multiple myeloma. ( Ben Yehuda, D; Boccadoro, M; Cafro, A; Caravita, T; Carella, AM; Catalano, L; Cavallo, F; Cavo, M; Cerrato, C; Ciccone, G; Corradini, P; Crippa, C; Di Raimondo, F; Evangelista, A; Gay, F; Genuardi, M; Marcatti, M; Musto, P; Nagler, A; Offidani, M; Omedé, P; Palumbo, A; Patriarca, F; Petrucci, MT; Pezzatti, S; Ribakovsky, E; Zamagni, E, 2014) |
| "As compared with MPT, continuous lenalidomide-dexamethasone given until disease progression was associated with a significant improvement in progression-free survival, with an overall survival benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation." | 5.19 | Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. ( Anderson, K; Attal, M; Avet-Loiseau, H; Bahlis, N; Banos, A; Belch, AR; Benboubker, L; Binder, D; Catalano, J; Cavenagh, J; Cavo, M; Chen, C; Chen, G; de la Rubia, J; Delforge, M; Dimopoulos, MA; Dispenzieri, A; Ervin-Haynes, A; Facon, T; Fermand, JP; Geraldes, C; Hulin, C; Jacques, C; Knight, R; Lee, JJ; Ludwig, H; Moreau, P; Oriol, A; Pinto, A; Qiu, L; Tiab, M; Van Oostendorp, J; Weisel, K; White, DJ, 2014) |
| "Data from two randomized pivotal, phase 3 trials evaluating the combination of lenalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM) were pooled to characterize the subset of patients who achieved long-term benefit of therapy (progression-free survival ⩾ 3 years)." | 5.19 | Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. ( Baz, R; Dimopoulos, MA; Hussein, M; Li, JS; Nagarwala, Y; Swern, AS; Weiss, L, 2014) |
| "The combination of bortezomib, lenalidomide, and dexamethasone is a highly effective therapy for newly diagnosed multiple myeloma." | 5.19 | Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. ( Berdeja, JG; Berg, D; Di Bacco, A; Estevam, J; Gupta, N; Hamadani, M; Hari, P; Hui, AM; Kaufman, JL; Kumar, SK; Laubach, JP; Liao, E; Lonial, S; Niesvizky, R; Rajkumar, V; Richardson, PG; Roy, V; Stewart, AK; Vescio, R, 2014) |
| "Carfilzomib, a selective proteasome inhibitor, has shown safety and efficacy in relapsed and/or refractory multiple myeloma." | 5.17 | Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. ( Alsina, M; Bensinger, WI; Kunkel, LA; Lee, S; Martin, TG; Niesvizky, R; Orlowski, RZ; Siegel, DS; Wang, M; Wong, AF, 2013) |
| "We performed a molecular study aimed at identifying a gene expression profile (GEP) signature predictive of attainment of at least near complete response (CR) to thalidomide-dexamethasone (TD) as induction regimen in preparation for double autologous stem cell transplantation in 112 younger patients with newly diagnosed multiple myeloma." | 5.17 | Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation. ( Angelucci, E; Brioli, A; Cavo, M; Di Raimondo, F; Dico, F; Galieni, P; Gozzetti, A; Ledda, A; Mancuso, K; Martello, M; Martinelli, G; Marzocchi, G; Masini, L; Patriarca, F; Remondini, D; Renzulli, M; Roncaglia, E; Tacchetti, P; Tagliafico, E; Terragna, C; Testoni, N; Tosi, P; Zamagni, E, 2013) |
| "This phase II study is the first prospective evaluation of bortezomib-dexamethasone as second-line therapy for relapsed/refractory multiple myeloma." | 5.17 | Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. ( Allietta, N; Angermund, R; Beksac, M; Benboubker, L; Broer, E; Couturier, C; Dimopoulos, MA; Facon, T; Mazier, MA; Roddie, H, 2013) |
| "We designed a trial using two sequential cycles of modified high-dose melphalan at 100 mg/m(2) and autologous SCT (mHDM/SCT) in AL amyloidosis (light-chain amyloidosis, AL), AL with myeloma (ALM) and host-based high-risk myeloma (hM) patients through SWOG-0115." | 5.17 | Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115. ( Barlogie, B; Dean, RM; Fennessey, SA; Finn, KT; Hoering, A; Holmberg, LA; Mattar, B; Orlowski, RZ; Safah, HF; Sanchorawala, V; Seldin, DC; Sexton, R, 2013) |
| "Medical Research Council (MRC) Myeloma IX was a phase III trial evaluating bisphosphonate and thalidomide-based therapy for newly diagnosed multiple myeloma." | 5.17 | Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. ( Bell, SE; Child, JA; Cook, G; Davies, FE; Drayson, MT; Gregory, WM; Jackson, GH; Morgan, GJ; Owen, RG; Ross, FM; Szubert, AJ, 2013) |
| "Pomalidomide plus low-dose dexamethasone, an oral regimen, could be considered a new treatment option in patients with refractory or relapsed and refractory multiple myeloma." | 5.17 | Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. ( Alegre, A; Banos, A; Belch, A; Cavo, M; Chen, C; Delforge, M; Dimopoulos, M; Garderet, L; Goldschmidt, H; Ivanova, V; Jacques, C; Karlin, L; Lacy, M; Martinez-Lopez, J; Miguel, JS; Moreau, P; Oriol, A; Palumbo, A; Schey, S; Song, K; Sonneveld, P; Sternas, L; Weisel, K; Yu, X; Zaki, M, 2013) |
| "We previously reported a phase 1b dose-escalation study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in relapsed or progressive multiple myeloma where the maximum planned dose (MPD) was carfilzomib 20 mg/m2 days 1 and 2 of cycle 1 and 27 mg/m2 days 8, 9, 15, 16, and thereafter; lenalidomide 25 mg days 1 to 21; and dexamethasone 40 mg once weekly on 28-day cycles." | 5.17 | Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. ( Alsina, M; Bensinger, W; Huang, M; Kavalerchik, E; Martin, T; Niesvizky, R; Orlowski, RZ; Siegel, DS; Wang, M, 2013) |
| "Two randomized trials have demonstrated improved progression-free survival (PFS) with lenalidomide maintenance after autologous transplantation for multiple myeloma (MM)." | 5.17 | Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies. ( Burnette, BL; Dispenzieri, A; Harris, AM; Kumar, S; Kyle, RA; Rajkumar, SV; Sloan, JA; Tilburt, JC, 2013) |
| " BU and CY followed by lenalidomide maintenance therapy in 33 patients with multiple myeloma (MM) who relapsed following an autograft after a median of 12 months." | 5.17 | Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. ( Atanackovic, D; Ayuk, F; Bacher, U; Badbaran, A; Burchert, A; Hansen, T; Hildebrandt, Y; Klyuchnikov, E; Kröger, N; Kropff, M; Pflüger, KH; Schilling, G; Stübig, T; Wolschke, C; Zabelina, T; Zander, AR, 2013) |
| "Bortezomib-thalidomide-dexamethasone (VTD) is an effective induction therapy in multiple myeloma (MM)." | 5.17 | Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. ( Cakana, A; Dmoszynska, A; Enny, C; Esteves, G; Feng, H; Greil, R; Hajek, R; Harousseau, JL; Ludwig, H; Masszi, T; Paiva, B; Ricci, D; Robinson, D; Shpilberg, O; Spicka, I; Stoppa, AM; van de Velde, H; Vidriales, MB; Viterbo, L, 2013) |
| "We conducted a phase II trial that evaluated the tolerability and efficacy of combining lenalidomide with melphalan in previously untreated patients with multiple myeloma who were not candidates for autologous stem cell transplantation." | 5.17 | Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial. ( Bahlis, NJ; Belch, A; Chapman, JA; Chen, C; Couban, S; Harnett, E; Kovacs, MJ; Macdonald, DA; Marcellus, DC; Meyer, RM; Reece, DE; Reiman, T; Stewart, AK; White, DJ, 2013) |
| "Interferon (INF)-α was the maintenance treatment of choice after autologous stem cell transplantation in multiple myeloma in the past, but currently Thalidomide is commonly used." | 5.17 | Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma. ( Beckhove, P; Engelhardt, M; Goldschmidt, H; Haas, J; Herth, I; Ho, AD; Hose, D; Hundemer, M; Klein, B; Meissner, T; Neben, K; Neuber, B; Witzens-Harig, M, 2013) |
| " Patients (n=459) with newly diagnosed multiple myeloma aged 65 years or over were randomized 1:1:1 to nine 4-week cycles of lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance; or lenalidomide, melphalan, and prednisone, or melphalan and prednisone, with no maintenance therapy." | 5.17 | Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. ( Delforge, M; Dimopoulos, MA; Hájek, R; Kropff, M; Lewis, P; Mei, J; Nixon, A; Palumbo, A; Petrucci, MT; Zhang, J, 2013) |
| "This phase 1 dose-escalation study determined the maximum tolerated dose (MTD) of oral pomalidomide (4 dose levels) administered on days 1 to 21 of each 28-day cycle in patients with relapsed and refractory multiple myeloma (RRMM)." | 5.17 | Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. ( Alsina, M; Anand, P; Anderson, KC; Baz, R; Bilotti, E; Chen, M; Doss, D; Ghobrial, IM; Jacques, C; Kelley, SL; Larkins, G; Laubach, J; Loughney, N; McBride, L; Munshi, NC; Nardelli, L; Richardson, PG; Schlossman, R; Siegel, D; Sullivan, D; Wear, S; Zaki, MH, 2013) |
| "The combination of pomalidomide and dexamethasone can be safely administered to patients with multiple myeloma (MM) and has significant efficacy, although the optimal regimen remains to be determined." | 5.17 | Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. ( Arnulf, B; Attal, M; Avet-Loiseau, H; Benboubker, L; Bréchignac, S; Caillot, D; Decaux, O; Escoffre-Barbe, M; Facon, T; Fermand, JP; Garderet, L; Hennache, B; Hulin, C; Kolb, B; Leleu, X; Macro, M; Marit, G; Mathiot, C; Meuleman, N; Michallet, M; Moreau, P; Pegourie, B; Petillon, MO; Roussel, M; Royer, B; Stoppa, AM; Thielemans, B; Traulle, C, 2013) |
| "We evaluated sequential bortezomib, liposomal doxorubicin and dexamethasone (BDD) followed by thalidomide and dexamethasone (TD) if ≥ partial response (PR) or bortezomib and TD (BTD) if < PR in untreated patients with multiple myeloma with International Staging System stage II/III or extramedullary disease." | 5.16 | Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease. ( Bello, C; Cohen, A; Comenzo, RL; Drullinsky, P; Hassoun, H; Hoover, E; Jhanwar, S; Landau, H; Lendvai, N; Lesokhin, A; Nimer, SD; Pandit-Taskar, N; Riedel, E; Schulman, P, 2012) |
| "Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE)." | 5.16 | Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. ( Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB, 2012) |
| "Fludarabine and lenalidomide are essential drugs in the front-line treatment of non-Hodgkin lymphoma (NHL) and multiple myeloma (MM), respectively." | 5.16 | Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. ( Apperley, JF; Basak, GW; Douglas, KW; Duarte, RF; Gabriel, IH; Geraldes, C; Hübel, K; Jaksic, O; Koristek, Z; Kröger, N; Lanza, F; Lemoli, R; Malard, F; Mikala, G; Mohty, M; Selleslag, D; Worel, N, 2012) |
| "Thalidomide maintenance has the potential to modulate residual multiple myeloma (MM) after an initial response." | 5.16 | The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. ( Bell, SE; Brown, JM; Child, JA; Cook, G; Coy, NN; Davies, FE; Drayson, MT; Gregory, WM; Jackson, GH; Morgan, GJ; Owen, RG; Roddie, H; Ross, FM; Rudin, C; Russell, NH; Szubert, AJ, 2012) |
| "Thalidomide is active in multiple myeloma and is associated with minimal myelosuppression, making it a good candidate for induction therapy prior to high-dose therapy with autologous stem-cell transplantation." | 5.16 | Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. ( Bell, SE; Child, JA; Cook, G; Davies, FE; Drayson, MT; Feyler, S; Gregory, WM; Jackson, GH; Johnson, PR; Morgan, GJ; Navarro Coy, N; Owen, RG; Ross, FM; Rudin, C; Russell, NH; Szubert, AJ, 2012) |
| "Thalidomide has potent antimyeloma activity, but no prospective, randomized controlled trial has evaluated thalidomide monotherapy in patients with relapsed/refractory multiple myeloma." | 5.16 | Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. ( Avet-Loiseau, H; Baylon, HG; Bladé, J; Caravita, T; Facon, T; Glasmacher, A; Goranov, S; Hajek, R; Hillengass, J; Hulin, C; Kropff, M; Kueenburg, E; Liebisch, P; Lucy, L; Moehler, TM; Pattou, C; Robak, T; Zerbib, R, 2012) |
| "We report feasibility and response results of a phase II study investigating prolonged weekly bortezomib and dexamethasone followed by thalidomide and dexamethasone as maintenance therapy after single autologous stem cell transplantation (ASCT) in patients with multiple myeloma." | 5.16 | Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma. ( Cai, JL; Duarte, L; Farol, L; Forman, SJ; Frankel, PH; Htut, M; Karanes, C; Kogut, NM; Krishnan, AY; Murata-Collins, JL; Parker, PM; Popplewell, LL; Reburiano, E; Ruel, C; Sahebi, F; Somlo, G; Spielberger, RT; Thomas, SH, 2012) |
| "Physicians in Asia have anecdotally reported that Asian patients with multiple myeloma (MM) are frequently intolerant of conventional doses of dexamethasone (Dex) and/or thalidomide (Thal)." | 5.16 | Lower dose dexamethasone/thalidomide and zoledronic acid every 3 weeks in previously untreated multiple myeloma. ( Chen, Y; Kim, K; Kim, YK; Pai, VR; Srivastava, A; Suh, C; Teoh, G; Yoon, SS, 2012) |
| "To show that the immunomodulatory drug lenalidomide can be used in patients with relapsed multiple myeloma to augment vaccine responses." | 5.16 | Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. ( Borrello, I; Emerling, A; Ferguson, A; Huff, CA; Noonan, K; Pasetti, MF; Rudraraju, L, 2012) |
| "Here we report the efficacy, safety and health-related quality-of-life (HRQoL) associated with long-term lenalidomide and dexamethasone (Len + Dex) treatment in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in the Spanish cohort of the MM-018 study." | 5.16 | Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience. ( Aguado, B; Alegre, A; Cibeira, MT; Garcia-Larana, J; Knight, R; Martinez-Chamorro, C; Mateos, MV; Oriol-Rocafiguera, A; Rosettani, B; Sureda, A, 2012) |
| "The combination of melphalan, prednisone and thalidomide (MPT) has demonstrated efficacy and acceptable toxicity in newly diagnosed and relapsed/refractory patients with multiple myeloma (MM)." | 5.16 | Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. ( Alesiani, F; Ballanti, S; Boccadoro, M; Caraffa, P; Catarini, M; Cavallo, F; Corvatta, L; Gentili, S; Leoni, P; Liberati, AM; Offidani, M; Palumbo, A; Polloni, C; Pulini, S, 2012) |
| "Our previous studies have shown that lowering the dose of pegylated liposomal doxorubicin (PLD) and bortezomib in combination with intravenous dexamethasone on a longer 4-week cycle maintained efficacy and improved tolerability in both previously untreated and relapsed/refractory (R/R) multiple myeloma (MM) patients." | 5.16 | A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma. ( Berenson, JR; Bravin, E; Cartmell, A; Chen, CS; Flam, M; Hilger, JD; Kazamel, T; Nassir, Y; Swift, RA; Vescio, R; Woliver, T; Yellin, O, 2012) |
| "Treatment with 3-6 cycles of PS-341/bortezomib, adriamycin, and dexamethasone (PAD) has been explored in terms of induction therapy prior to autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM)." | 5.16 | Two cycles of the PS-341/bortezomib, adriamycin, and dexamethasone combination followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients. ( Choi, Y; Kang, YA; Kim, DY; Kim, SD; Lee, JH; Lee, KH; Seol, M, 2012) |
| "Over the past decade, the novel agents thalidomide, lenalidomide, and bortezomib have emerged as effective treatment in patients with multiple myeloma (MM)." | 5.16 | Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma. ( Anand, P; Bello, E; Bendarz, U; Bilotti, E; McBride, L; McNeill, A; Olivo, K; Siegel, DS; Tufail, M; Vesole, DH, 2012) |
| "This multicenter phase 1/2 trial investigated the combination of bendamustine, lenalidomide, and dexamethasone in repeating 4-week cycles as treatment for relapsed refractory multiple myeloma (MM)." | 5.16 | Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. ( Abbas, M; Agha, M; Boyiadzis, M; Burt, S; Dai, L; Kennedy, RC; Lentzsch, S; Mapara, MY; Normolle, D; O'Sullivan, A; Pregja, SL; Roodman, GD; Shuai, Y; Waas, J; Zonder, JA, 2012) |
| "The Medical Research Council Myeloma IX Trial (ISRCTNG8454111) examined traditional and thalidomide-based induction and maintenance regimens and IV zoledronic acid (ZOL) and oral clodronate (CLO) in 1960 patients with newly diagnosed multiple myeloma." | 5.16 | Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. ( Ashcroft, AJ; Bell, SE; Child, JA; Davies, FE; Drayson, MT; Gregory, WM; Jackson, GH; Morgan, GJ; Owen, RG; Szubert, AJ, 2012) |
| "This phase I study evaluated elotuzumab, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (MM)." | 5.16 | Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. ( Facon, T; Harousseau, JL; Jagannath, S; Kaufman, JL; Leleu, X; Lonial, S; Mazumder, A; Moreau, P; Singhal, AK; Tsao, LC; Vij, R; Westland, C, 2012) |
| "Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma." | 5.16 | Continuous lenalidomide treatment for newly diagnosed multiple myeloma. ( Beksac, M; Ben Yehuda, D; Bladé, J; Cascavilla, N; Catalano, J; Cavo, M; Corso, A; Delforge, M; Dimopoulos, MA; Gisslinger, H; Hajek, R; Herbein, L; Iosava, G; Jacques, C; Kloczko, J; Kropff, M; Langer, C; Mei, J; Palumbo, A; Petrucci, MT; Plesner, T; Radke, J; Spicka, I; Weisel, K; Wiktor-Jędrzejczak, W; Yu, Z; Zodelava, M, 2012) |
| "Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma." | 5.16 | Lenalidomide after stem-cell transplantation for multiple myeloma. ( Anderson, KC; Barry, S; Bashey, A; Bennett, E; Bressler, L; Callander, NS; Devine, SM; Gabriel, DA; Gentile, T; Giralt, S; Hari, P; Hars, V; Hassoun, H; Hofmeister, CC; Horowitz, MM; Hurd, DD; Isola, L; Jiang, C; Kelly, M; Landau, H; Levitan, D; Linker, C; Martin, T; Maziarz, RT; McCarthy, PL; McClune, B; Moreb, JS; Owzar, K; Pasquini, MC; Postiglione, J; Qazilbash, MH; Richardson, PG; Rosenbaum, C; Schlossman, R; Seiler, M; Shea, TC; Stadtmauer, EA; Van Besien, K; Vij, R; Weisdorf, DJ, 2012) |
| "Lenalidomide maintenance after transplantation significantly prolonged progression-free and event-free survival among patients with multiple myeloma." | 5.16 | Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. ( Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Decaux, O; Dumontet, C; Facon, T; Garderet, L; Harousseau, JL; Hulin, C; Lauwers-Cances, V; Leleu, X; Leyvraz, S; Marit, G; Mathiot, C; Michallet, M; Moreau, P; Payen, C; Pegourie, B; Roussel, M; Stoppa, AM; Vekemans, MC; Voillat, L, 2012) |
| "This prospective multicenter phase III study compared the efficacy and safety of a triple combination (bortezomib-thalidomide-dexamethasone [VTD]) versus a dual combination (thalidomide-dexamethasone [TD]) in patients with multiple myeloma (MM) progressing or relapsing after autologous stem-cell transplantation (ASCT)." | 5.16 | Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomi ( Cakana, A; Casassus, P; Chaleteix, C; de Witte, T; Dib, M; Doyen, C; Fontan, J; Gahrton, G; Garderet, L; Gorin, NC; Gratwohl, A; Hajek, R; Harousseau, JL; Hertenstein, B; Iacobelli, S; Ketterer, N; Koenecke, C; Kolb, B; Lafon, I; Ludwig, H; Masszi, T; Michallet, M; Milone, G; Mohty, M; Moreau, P; Morris, C; Niederwieser, D; Onida, F; Pegourie, B; van Os, M, 2012) |
| "The combination of lenalidomide-dexamethasone is active in multiple myeloma (MM)." | 5.16 | Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. ( Alsina, M; Anderson, KC; Gardner, L; Giusti, K; Harvey, C; Hideshima, T; Jakubowiak, AJ; Kandarpa, M; Kaufman, JL; Kraftson, S; Poradosu, E; Richardson, PG; Ross, CW; Sportelli, P; Zimmerman, T, 2012) |
| "This phase 1/2 study in patients with newly diagnosed multiple myeloma (N = 53) assessed CRd--carfilzomib (20, 27, or 36 mg/m2, days 1, 2, 8, 9, 15, 16 and 1, 2, 15, 16 after cycle 8), lenalidomide (25 mg/d, days 1-21), and weekly dexamethasone (40/20 mg cycles 1-4/5+)--in 28-day cycles." | 5.16 | A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. ( Ahmed, A; Al-Zoubi, A; Anderson, T; Couriel, D; Detweiler-Short, K; Durecki, DE; Dytfeld, D; Griffith, KA; Jagannath, S; Jakubowiak, AJ; Jobkar, T; Kaminski, M; Lebovic, D; McDonnell, K; Mietzel, M; Nordgren, B; Stockerl-Goldstein, K; Vesole, DH; Vij, R, 2012) |
| " We carried out a single-arm study to assess the toxicity and efficacy of a short block of consolidation therapy with cyclophosphamide, low dose thalidomide and dexamethasone (CTD) in patients within 6 months following ASCT, as part of frontline therapy for symptomatic multiple myeloma." | 5.16 | Improved response with post-ASCT consolidation by low dose thalidomide, cyclophosphamide and dexamethasone as first line treatment for multiple myeloma. ( D'Sa, S; Khan, I; Percy, L; Quinn, J; Rabin, N; Yong, KL, 2012) |
| "The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine, BCNU, melphalan, cyclophosphamide, prednisone/vincristine, BCNU, doxorubicin, dexamethasone/bortezomib (VBMCP/VBAD/B) in patients aged 65 years or younger with multiple myeloma." | 5.16 | Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. ( Alegre, A; Besalduch, J; Bladé, J; Cibeira, MT; de Arriba, F; de la Rubia, J; Díaz-Mediavilla, J; Etxebeste, MA; González, Y; Granell, M; Gutiérrez, NC; Hernández, D; Hernández, MT; Lahuerta, JJ; López-Jiménez, J; Martín-Ramos, ML; Martínez, J; Mateos, MV; Oriol, A; Palomera, L; Rosiñol, L; San Miguel, J; Teruel, AI, 2012) |
| "We investigated whether bortezomib during induction and maintenance improves survival in newly diagnosed multiple myeloma (MM)." | 5.16 | Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. ( Bertsch, U; Blau, IW; Bos, GM; Broyl, A; Duehrsen, U; El Jarari, L; Goldschmidt, HM; Hose, D; Jauch, A; Kersten, MJ; Lindemann, W; Lokhorst, HM; Pfreundschuh, M; Raymakers, R; Salwender, H; Schaafsma, MR; Scheid, C; Schmidt-Wolf, IG; Sonneveld, P; Stevens-Kroef, M; van der Holt, B; van der Velde, H; van Marwijk-Kooy, M; Vellenga, E; Weisel, KC; Wijermans, PW; Wittebol, S; Zweegman, S, 2012) |
| "Exercise is safe and has physiologic benefits for patients undergoing MM treatment; exercise combined with epoetin alfa helped alleviate anemia." | 5.16 | Effects of exercise on fatigue, sleep, and performance: a randomized trial. ( Anaissie, EJ; Coleman, EA; Coon, SK; Enderlin, C; Goodwin, JA; Kennedy, R; Lockhart, K; McNatt, P; Richards, K; Stewart, CB, 2012) |
| "In order to test for improved survival following autologous transplantation (ASCT), we conducted a prospective clinical trial of post-ASCT thalidomide therapy in Japanese patients with multiple myeloma (MM)." | 5.16 | Post-transplant consolidation therapy using thalidomide alone for the patients with multiple myeloma: a feasibility study in Japanese population. ( Asakura, K; Hattori, Y; Iino, R; Ikeda, Y; Ishizawa, J; Matsuki, E; Okamoto, S; Tsukada, Y; Ueda, T; Yokoyama, K, 2012) |
| "Thalidomide monotherapy has demonstrated consistent results in the treatment of advanced multiple myeloma." | 5.16 | Predictive factors of survival after thalidomide therapy in advanced multiple myeloma: long-term follow-up of a prospective multicenter nonrandomized phase II study in 120 patients. ( Attal, M; Bellissant, E; Decaux, O; Facon, T; Grosbois, B; Moreau, P; Pegourie, B; Renault, A; Sébille, V; Tiab, M; Voillat, L; Zerbib, R, 2012) |
| "In two randomized phase III trials (MM-009 and MM-010), lenalidomide plus dexamethasone significantly prolonged time to progression and overall survival (OS) in patients with relapsed/refractory multiple myeloma compared with dexamethasone alone." | 5.15 | Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. ( Bravo, ML; Dimopoulos, MA; Harousseau, JL; Knight, RD; Olesnyckyj, M; Rajkumar, SV; San-Miguel, JF; Siegel, D; Stadtmauer, EA; Weber, DM; Zeldis, JB, 2011) |
| " In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens." | 5.15 | Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Caravita, T; Carella, AM; Cavo, M; Cellini, C; Crippa, C; Elice, F; Evangelista, A; Galli, M; Gentilini, F; Magarotto, V; Marasca, R; Montefusco, V; Morabito, F; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Polloni, C; Pulini, S; Ria, R; Romano, A; Rossi, D; Tacchetti, P; Tosi, P; Zamagni, E; Zambello, R, 2011) |
| "We studied 174 consecutive patients with relapsed refractory multiple myeloma (MM) enrolled on a phase II clinical trial of pomalidomide plus low-dose dexamethasone at Mayo Clinic." | 5.15 | Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. ( Buadi, F; Dispenzieri, A; Gertz, M; Hayman, S; Kumar, S; Kyle, RA; Lacy, MQ; Larson, D; Mikhael, J; Rajkumar, SV; Roy, V; Short, KD, 2011) |
| "We evaluated the clinical results of lenalidomide (Len) as a compassionate salvage therapy in refractory/relapsed multiple myeloma (MM) patients." | 5.15 | Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients. ( Aguado, B; Alegre, A; Calvo, JM; Cánovas, A; Castillo, I; de la Serna, J; García, FL; Giraldo, P; Hernández, MT; Ibáñez, Á; Lahuerta, JJ; Martínez-Chamorro, C; Oriol, A; Palomera, L; Ríos, E; Rodríguez, JN, 2011) |
| "Single nucleotide polymorphisms (SNPs) in 12 genes involving multidrug resistance, drug metabolic pathways, DNA repair systems and cytokines were examined in 28 patients with relapsed/refractory multiple myeloma (MM) treated with single agent thalidomide and the results were correlated with response, toxicity and overall survival (OS)." | 5.15 | Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide. ( Bladé, J; Cibeira, MT; de Larrea, CF; Díaz, T; Fuster, D; Monzó, M; Navarro, A; Rosiñol, L; Tovar, N, 2011) |
| "Thalidomide with melphalan/prednisone (MPT) was defined as standard treatment in elderly patients with multiple myeloma (MM) based on five randomized trials." | 5.15 | Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. ( Ammerlaan, AH; Lokhorst, HM; Schaafsma, MR; Sinnige, HA; Sonneveld, P; Termorshuizen, F; Uyl-de Groot, CA; van der Griend, R; van Marwijk Kooy, M; Verelst, SG; Wijermans, PW; Wittebol, S; Zweegman, S, 2011) |
| "This phase 1/2 trial evaluated combination lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone (RVDD) in newly diagnosed multiple myeloma (MM) patients." | 5.15 | Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. ( Anderson, KC; Anderson, T; Barrickman, JC; Campagnaro, EL; Esseltine, DL; Griffith, KA; Harvey, CK; Hofmeister, CC; Jakubowiak, AJ; Kaminski, MS; Kelley, SL; Laubach, JP; Lonial, S; Mietzel, MA; Raje, NS; Reece, DE; Richardson, PG; Schlossman, RL; Tendler, CL; Wear, SM; Zimmerman, TM, 2011) |
| "The aim of this phase II study was to determine the efficacy and safety of combined bortezomib and thalidomide (VT) regime as initial treatment for newly diagnosed multiple myeloma (MM) in China." | 5.15 | [The efficacy and safety of bortezomib plus thalidomide in treatment of newly diagnosed multiple myeloma]. ( Chen, SL; Gao, W; Jiang, B; Qiu, LG; Yu, L; Zhong, YP, 2011) |
| "The combination of lenalidomide and low-dose dexamethasone is an effective treatment for multiple myeloma (MM)." | 5.15 | Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. ( Allred, J; Bergsagel, PL; Buadi, FK; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, SK; Lacy, MQ; Laumann, K; Lust, JA; Mikhael, JR; Rajkumar, SV; Reeder, CB; Russell, SJ; Stewart, K; Witzig, TE; Zeldenrust, SR, 2011) |
| "As part of the randomized MRC Myeloma IX trial, we compared an attenuated regimen of cyclophosphamide, thalidomide, and dexamethasone (CTDa; n = 426) with melphalan and prednisolone (MP; n = 423) in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation." | 5.15 | Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. ( Bell, SE; Byrne, JL; Child, JA; Cook, G; Davies, FE; Drayson, MT; Feyler, S; Gregory, WM; Jackson, GH; Morgan, GJ; Navarro Coy, N; Owen, RG; Roddie, H; Ross, FM; Rudin, C; Russell, NH; Szubert, AJ, 2011) |
| "Several trials comparing the efficacy of standard melphalan and prednisone (MP) therapy with MP plus thalidomide (MPT) in elderly patients with multiple myeloma (MM) have been reported, with inconsistent results." | 5.15 | A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant. ( Balleari, E; Buda, G; Consoli, U; Di Renzo, N; Ferrara, R; Fragasso, A; Lazzaro, A; Marcheselli, R; Masini, L; Morabito, F; Musto, P; Neri, S; Pastorini, A; Polimeno, G; Quarta, G; Sacchi, S; Vigliotti, ML; Zoboli, A, 2011) |
| "To improve the outcome of allogeneic stem cell transplantation (allo-SCT) in multiple myeloma as part of first-line treatment, we prospectively investigated the feasibility and efficacy of lenalidomide maintenance." | 5.15 | Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. ( Bruijnen, CP; Cornelisse, PB; Cornelissen, JJ; Emmelot, M; Huisman, C; Huls, G; Janssen, JJ; Kersten, MJ; Kneppers, E; Lokhorst, HM; Meijer, E; Minnema, MC; Mutis, T; Sonneveld, P; van der Holt, B; Zweegman, S, 2011) |
| "Pomalidomide at doses of 2 or 4 mg/d has demonstrated excellent activity in patients with multiple myeloma (MM)." | 5.15 | Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. ( Allred, JB; Bergsagel, PL; Buadi, F; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, K; Lust, JA; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Reeder, C; Roy, V; Russell, SJ; Short, KD; Stewart, AK; Zeldenrust, S, 2011) |
| "The treatment of patients with multiple myeloma usually includes many drugs including thalidomide, lenalidomide and bortezomib." | 5.15 | Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. ( Adamczyk-Cioch, M; Dmoszynska, A; Grzasko, N; Helbig, G; Hus, M; Jawniak, D; Kozinska, J; Legiec, W; Morawska, M; Pluta, A; Szostek, M; Waciński, P; Woszczyk, D, 2011) |
| "The Intergroupe Francophone du Myelome conducted a randomized trial to compare bortezomib-dexamethasone (VD) as induction before high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) to a combination consisting of reduced doses of bortezomib and thalidomide plus dexamethasone (vtD) in patients with multiple myeloma." | 5.15 | Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. ( Araujo, C; Attal, M; Avet-Loiseau, H; Benboubker, L; Berthou, C; Caillot, D; Chaleteix, C; Decaux, O; Dib, M; Doyen, C; Escoffre, M; Facon, T; Fontan, J; Fuzibet, JG; Garderet, L; Harousseau, JL; Hulin, C; Kolb, B; Lenain, P; Lepeu, G; Lioure, B; Marit, G; Mathiot, C; Moreau, P; Pégourié, B; Randriamalala, E; Sebban, C; Stoppa, AM; Tiab, M; Traullé, C; Wetterwald, M, 2011) |
| "We prospectively analyzed the prognostic relevance of positron emission tomography-computed tomography (PET/CT) at diagnosis, after thalidomide-dexamethasone (TD) induction therapy and double autotransplantation (ASCT) in 192 newly diagnosed multiple myeloma (MM) patients." | 5.15 | Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. ( Baccarani, M; Brioli, A; Buttignol, S; Carobolante, F; Cavo, M; Englaro, E; Fanin, R; Fanti, S; Nanni, C; Pantani, L; Patriarca, F; Perrone, G; Pezzi, A; Tacchetti, P; Terragna, C; Zamagni, E; Zannetti, B, 2011) |
| "We assessed efficacy, safety, and reversal of renal impairment (RI) in untreated patients with multiple myeloma given bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide (VMPT-VT) maintenance or bortezomib-melphalan-prednisone (VMP)." | 5.15 | Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Cascavilla, N; Cavo, M; Di Raimondo, F; Gentile, M; Grasso, M; Guglielmelli, T; Majolino, I; Marasca, R; Mazzone, C; Montefusco, V; Morabito, F; Musolino, C; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, I, 2011) |
| "Introduction of lenalidomide has expanded the therapeutic options for refractory and recurrent multiple myeloma (MM) patients." | 5.15 | Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma. ( Glasmacher, A; Gorschlüter, M; Schmidt-Wolf, IG; Schwamborn, K, 2011) |
| "This randomized, retrospective study evaluated the effect of thalidomide combined with bortezomib-dexamethasone (TBD) or vincristine-doxorubicin-dexamethasone (T-VAD) on 46 patients with multiple myeloma." | 5.15 | Bortezomib-dexamethasone or vincristine-doxorubicin-dexamethasone as induction therapy followed by thalidomide as maintenance therapy in untreated multiple myeloma patients. ( Cao, Y; Chen, RA; Liang, Y; Liu, L; Tu, Y, 2011) |
| "We compared thalidomide-dexamethasone (TD) with melphalan-prednisolone (MP) in 289 elderly patients with multiple myeloma (MM)." | 5.14 | Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. ( Adam, Z; Drach, J; Egyed, M; Gisslinger, H; Greil, R; Hajek, R; Hinke, A; Kuhn, I; Labar, B; Ludwig, H; Spicka, I; Tóthová, E; Zojer, N, 2009) |
| "Maintenance therapy was explored in multiple myeloma (MM) patients after conventional thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD)." | 5.14 | Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study. ( Alesiani, F; Brunori, M; Burattini, M; Candela, M; Catarini, M; Centurioni, R; Corvatta, L; Ferranti, M; Galieni, P; Gentili, S; Giuliodori, L; Leoni, P; Marconi, M; Mele, A; Offidani, M; Piersantelli, MN; Polloni, C; Samori, A; Visani, G, 2009) |
| "The aim of the present study was to evaluate the effectiveness of bortezomib combined with epirubicin, dexamethasone, and thalidomide (BADT) for the treatment of multiple myeloma (MM)." | 5.14 | Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience. ( Hu, X; Huang, C; Lü, S; Ni, X; Qiu, H; Wang, J; Xu, X; Yang, J, 2009) |
| "The aim of this study was to investigate the efficacy and safety of bortezomib-combined with dexamethasone, methylprednisolone and other drugs in the treatment of patients with multiple myeloma (MM)." | 5.14 | [Bortezomib combined with other drugs for treating 60 cases of multiple myeloma]. ( Chen, SL; Hu, Y; Li, X; Zhang, JJ; Zhong, YP, 2009) |
| "Thalidomide is effective in the treatment of newly diagnosed and relapsed/refractory multiple myeloma (MM)." | 5.14 | Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. ( Bradstock, KF; Coyle, L; Gill, DS; Horvath, N; Kennedy, N; Prince, HM; Prosser, IW; Reynolds, J; Roberts, AW; Spencer, A, 2009) |
| "This subset analysis of data from two phase III studies in patients with relapsed or refractory multiple myeloma (MM) evaluated the benefit of initiating lenalidomide plus dexamethasone at first relapse." | 5.14 | Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. ( Belch, A; Dimopoulos, MA; Facon, T; Knight, RD; Niesvizky, R; Olesnyckyj, M; Prince, MH; San Miguel, JF; Stadtmauer, EA; Weber, DM; Yu, Z; Zeldis, JB, 2009) |
| "Although the combination of lenalidomide and dexamethasone is effective therapy for patients with relapsed/refractory multiple myeloma, the influence of high-risk cytogenetic abnormalities on outcomes is unknown." | 5.14 | Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. ( Bahlis, NJ; Bruyere, H; Chang, H; Chen, C; Fu, T; Horsman, DE; Mansoor, A; Masih-Khan, E; Reece, D; Roland, B; Song, KW; Stewart, DA; Trieu, Y, 2009) |
| "To obtain approval from the Ministry of Health, Labor and Welfare of Japan, a phase II study was conducted to assess the pharmacokinetics and pharmacodynamics of thalidomide along with its efficacy and safety in Japanese patients with multiple myeloma." | 5.14 | Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed/refractory multiple myeloma. ( Abe, M; Kosugi, H; Murakami, H; Sawamura, M; Shimazaki, C; Shimizu, K; Sugiura, I; Suzuki, K; Takagi, T; Taniwaki, M, 2009) |
| "Initial analysis of the combination melphalan, prednisone, plus lenalidomide (MPR) showed significant antimyeloma activity in patients with untreated multiple myeloma, with neutropenia and thrombocytopenia as the most frequent side effects." | 5.14 | Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results. ( Benevolo, G; Boccadoro, M; Canepa, L; Falco, P; Falcone, A; Gay, F; Gozzetti, A; Knight, RD; Larocca, A; Luraschi, A; Magarotto, V; Morabito, F; Nozza, A; Palumbo, A; Petrucci, MT; Zeldis, JB, 2009) |
| "Until recently, melphalan and prednisone were the standards of care in elderly patients with multiple myeloma." | 5.14 | Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. ( Azaïs, I; Benboubker, L; Casassus, P; Decaux, O; Dib, M; Doyen, C; Eschard, JP; Facon, T; Fontan, J; Garderet, L; Guillerm, G; Hulin, C; Lafon, I; Lenain, P; Mathiot, C; Moreau, P; Pegourie, B; Rodon, P; Salles, B; Virion, JM, 2009) |
| "Lenalidomide plus dexamethasone is effective for the treatment of relapsed and refractory multiple myeloma (MM); however, toxicities from dexamethasone can be dose limiting." | 5.14 | Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. ( Anderson, KC; Badros, AZ; Bensinger, W; Berenson, J; Hussein, M; Irwin, D; Jagannath, S; Kenvin, L; Knight, R; Olesnyckyj, M; Richardson, P; Singhal, S; Vescio, R; Williams, SF; Yu, Z; Zeldis, J, 2009) |
| "PURPOSE Thalidomide-dexamethasone (THAL-DEX) is standard induction therapy for multiple myeloma (MM)." | 5.14 | Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204). ( Barlogie, B; Bolejack, V; Crowley, JJ; Durie, BG; Hussein, MA; Jakubowiak, AJ; Zonder, JA, 2009) |
| "The plasma concentrations of leptin and adiponectin, but not resistin, were abnormal in newly diagnosed multiple myeloma." | 5.14 | Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma. ( Brenne, AT; Hjorth-Hansen, H; Iversen, PO; Olstad, OK; Reppe, S; Reseland, JE; Syversen, U; Waage, A, 2009) |
| "Thalidomide and lenalidomide are immunomodulatory drugs (IMiDs) that produce high remission rates in the treatment of multiple myeloma." | 5.14 | Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. ( Allred, JB; Bergsagel, PL; Buadi, F; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Kyle, RA; Lacy, MQ; Laumann, K; Lust, JA; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Roy, V; Russell, SJ; Stewart, AK, 2009) |
| "Lenalidomide and bortezomib are active in relapsed and relapsed/refractory multiple myeloma (MM)." | 5.14 | Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. ( Alsina, M; Anderson, KC; Avigan, DE; Dalton, W; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Knight, R; Lunde, LE; Mazumder, A; McKenney, M; Mitsiades, CS; Munshi, NC; Richardson, PG; Schlossman, RL; Warren, DL; Weller, E, 2009) |
| "The phase 3 trial HOVON-50 was designed to evaluate the effect of thalidomide during induction treatment and as maintenance in patients with multiple myeloma who were transplant candidates." | 5.14 | A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. ( Berenschot, H; Bos, GM; Croockewit, S; de Weerdt, O; Delforge, M; Jie, KS; Joosten, P; Lokhorst, HM; Minnema, MC; Schaafsma, R; Sinnige, H; Sonneveld, P; van Ammerlaan, R; van der Holt, B; van Marwijk-Kooy, M; van Oers, MH; Vellenga, E; von dem Borne, P; Wijermans, P; Wittebol, S; Zweegman, S, 2010) |
| "The clinical efficacy and safety of a four-drug combination of bortezomib, cyclophosphamide, thalidomide, and dexamethasone was assessed for patients with relapsed or refractory multiple myeloma." | 5.14 | Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study. ( Ahn, JS; Kim, HJ; Kim, YK; Lee, JH; Lee, JJ; Moon, JH; Sohn, SK; Yang, DH, 2010) |
| "Bortezomib (VELCADE), thalidomide and dexamethasone (VTD), as well as melphalan, prednisolone, and thalidomide (MPT) therapy, are highly effective in patients with multiple myeloma." | 5.14 | Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multip ( Chung, JS; Do, YR; Eom, HS; Jin, JY; Kim, CS; Kim, HJ; Kim, HY; Kim, K; Kim, YK; Lee, DS; Lee, JH; Oh, SJ; Seong, CM; Suh, C, 2010) |
| " This phase I/II study was conducted to identify the most appropriate dose of defibrotide in combination with melphalan, prednisone and thalidomide in patients with relapsed and relapsed/refractory multiple myeloma, and to determine its safety and tolerability as part of this regimen." | 5.14 | Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. ( Anderson, K; Benevolo, G; Boccadoro, M; Bringhen, S; Cavallo, F; Gaidano, G; Gay, F; Genuardi, M; Iacobelli, M; Kotwica, K; Larocca, A; Magarotto, V; Masini, L; Mitsiades, C; Palumbo, A; Richardson, P; Rossi, D; Rus, C, 2010) |
| "Venous thromboembolism (VTE) is a major complication of myeloma therapy recently observed with the increasing use of up-front thalidomide and dexamethasone (thal-dex)." | 5.14 | Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. ( Catalano, L; Cavo, M; Cini, M; Gozzetti, A; Legnani, C; Masini, L; Palareti, G; Patriarca, F; Tacchetti, P; Tosi, P; Valdré, L; Zamagni, E, 2010) |
| "The aim of this study was to evaluate the efficacy and the toxicity of thalidomide-dexamethasone (Thal-Dex) as induction therapy before autologous peripheral blood stem cell (PBSC) transplantation in patients with newly diagnosed multiple myeloma (MM) with renal insufficiency." | 5.14 | Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. ( Baccarani, M; Brioli, A; Cavo, M; Ceccolini, M; Pallotti, MC; Pantani, L; Perrone, G; Petrucci, A; Tacchetti, P; Tosi, P; Zamagni, E, 2010) |
| "Thalidomide has alternative mechanisms of action; it can be combined with dexamethasone or alkylating agents for the treatment of multiple myeloma (MM); however, the optimal doses and appropriate intervals of thalidomide continue to be debated." | 5.14 | Induction treatment with cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma: a phase II study. ( Ahn, JS; Choi, YJ; Chung, JS; Joo, YD; Kim, HJ; Kim, YK; Lee, JH; Lee, JJ; Lee, JL; Lee, WS; Moon, JH; Shin, HJ; Sohn, SK; Yang, DH, 2010) |
| "PURPOSE We investigated the effect on minimal residual disease, by qualitative and real-time quantitative polymerase chain reaction (RQ-PCR), of a consolidation regimen that included bortezomib, thalidomide, and dexamethasone (VTD) in patients with multiple myeloma (MM) responding to autologous stem-cell transplantation (auto-SCT)." | 5.14 | Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. ( Boccadoro, M; Callea, V; Cangialosi, C; Caravita, T; Cavallo, F; Crippa, C; De Rosa, L; Drandi, D; Ferrero, S; Grasso, M; Guglielmelli, T; Ladetto, M; Liberati, AM; Musto, P; Pagliano, G; Palumbo, A; Passera, R; Pisani, F; Pregno, P; Santo, L, 2010) |
| "We conducted a phase 2 study with bortezomib, doxorubicin, and dexamethasone (PAD) followed by thalidomide and dexamethasone (TD) in patients with relapsed multiple myeloma (MM)." | 5.14 | Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety. ( Bang, SM; Chung, J; Do, YR; Jin, JY; Joo, YD; Kang, HJ; Kim, BS; Kim, HY; Kim, K; Lee, DS; Lee, GW; Lee, JH; Lee, JJ; Lee, MH; Lee, SS; Park, J; Ryoo, HM; Shim, H; Suh, C; Yoon, SS, 2010) |
| "This multicenter, open-label, non-comparative phase II trial evaluated the safety and efficacy of salvage therapy with lenalidomide, melphalan, prednisone and thalidomide (RMPT) in patients with relapsed/refractory multiple myeloma (MM)." | 5.14 | Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. ( Boccadoro, M; Canepa, L; Crugnola, M; Falco, P; Falcone, AP; Federico, V; Genuardi, M; Larocca, A; Magarotto, V; Palumbo, A; Petrucci, MT; Sanpaolo, G, 2010) |
| "Thalidomide maintenance therapy after stem cell transplantation resulted in increased progression-free survival and overall survival in a few trials, but its role in non-transplant eligible patients with multiple myeloma remains unclear." | 5.14 | Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. ( Adam, Z; Drach, J; Egyed, M; Gisslinger, H; Hajek, R; Hinke, A; Kuhn, I; Labar, B; Ludwig, H; Spicka, I; Tóthová, E; Zojer, N, 2010) |
| "Bortezomib-based regimens have significant activities in multiple myeloma (MM)." | 5.14 | A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma. ( Chan, EY; Chan, SY; Cheung, SC; Chim, CS; Kwong, YL; Leung, YY; Liang, R; Lie, AK, 2010) |
| "In this double-blind, placebo-controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan-prednisone and thalidomide (MPT) or melphalan-prednisone and placebo (MP)." | 5.14 | Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. ( Abildgaard, N; Ahlberg, L; Björkstrand, B; Carlson, K; Dahl, IM; Fayers, P; Forsberg, K; Gimsing, P; Gulbrandsen, N; Haukås, E; Hjertner, O; Hjorth, M; Juliusson, G; Karlsson, T; Knudsen, LM; Linder, O; Mellqvist, UH; Nesthus, I; Nielsen, JL; Rolke, J; Strandberg, M; Sørbø, JH; Turesson, I; Waage, A; Wisløff, F, 2010) |
| "gov: NCT00507442) was conducted to determine the maximum tolerated dose (MTD) of cyclophosphamide in combination with bortezomib, dexamethasone and lenalidomide (VDCR) and to assess the safety and efficacy of this combination in untreated multiple myeloma patients." | 5.14 | Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. ( Bhandari, M; Callander, N; Flinn, I; Gasparetto, C; Glass, J; Grosman, D; Hari, P; Krishnan, A; Kumar, SK; Noga, SJ; Rajkumar, SV; Richardson, PG; Rifkin, R; Sahovic, EA; Shi, H; Webb, IJ; Wolf, JL, 2010) |
| "A randomized phase III trial compared standard MP with MP-T (thalidomide 200 mg/d) in newly diagnosed patients with multiple myeloma older than age 65 years." | 5.14 | Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. ( Ammerlaan, R; Lokhorst, H; Schaafsma, M; Sinnige, H; Sonneveld, P; Termorshuizen, F; van der Griend, R; van Marwijk Kooy, M; Wijermans, P; Wittebol, S; Zweegman, S, 2010) |
| "We conducted a multicenter, open-label study to investigate the safety, efficacy, and pharmacokinetics of lenalidomide in Japanese patients with relapsed or refractory multiple myeloma The study was composed of the "monotherapy phase", a dose-escalation phase, to determine the tolerability to single agent lenalidomide and the "combination phase" to determine the safety and obtain preliminary data on the efficacy of lenalidomide plus dexamethasone." | 5.14 | Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma. ( Chou, T; Hatake, K; Hotta, T; Iida, S; Lau, H; Murakami, H; Nagai, H; Okamoto, S; Shimizu, K; Takagi, T; Takatoku, M; Takeshita, K, 2010) |
| "The results from this study indicated that, with careful monitoring of the CLCr level and adverse events as well as appropriate dose adjustments, lenalidomide plus dexamethasone is an effective and well tolerated treatment option for patients with multiple myeloma who have RI." | 5.14 | The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. ( Alegre, A; de Castro, CM; Dimopoulos, M; Goldschmidt, H; Masliak, Z; Olesnyckyj, M; Reece, D; Stadtmauer, EA; Weber, DM; Yu, Z; Zonder, JA, 2010) |
| "Bortezomib has proven to be active in patients with multiple myeloma (MM), including elderly patients." | 5.14 | Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: a Chinese experience. ( Chen, F; Chen, H; Guo, H; Jiang, Y; Lu, M; Mao, J; Qian, X; Shen, Y; Sun, C; Sun, H; Xia, J; Yang, G; Zhou, X; Zhuang, Y, 2010) |
| "We report the long-term follow-up results of a phase II trial of thalidomide for early-stage multiple myeloma (MM)." | 5.14 | Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. ( Detweiler-Short, K; Dispenzieri, A; Gertz, MA; Greipp, PR; Hayman, S; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Russell, SJ; Vincent Rajkumar, S; Witzig, TE; Zeldenrust, SR, 2010) |
| "The aim of this Phase II study was to determine the efficacy and safety of combined bortezomib and thalidomide (VT) regime as initial treatment for newly diagnosed patients with multiple myeloma (MM) in China." | 5.14 | Bortezomib plus thalidomide for newly diagnosed multiple myeloma in China. ( Chen, SL; Gao, W; Jiang, B; Qiu, LG; Yu, L; Zhong, YP, 2010) |
| "Between March, 2006, and October, 2008, 260 patients with untreated multiple myeloma, 65 years and older, from 63 Spanish centres, were randomly assigned to receive six cycles of VMP (n=130) or bortezomib plus thalidomide and prednisone (VTP; n=130) as induction therapy, consisting of one cycle of bortezomib twice per week for 6 weeks (1·3 mg/m² on days 1, 4, 8, 11, 22, 25, 29, and 32), plus either melphalan (9 mg/m² on days 1-4) or daily thalidomide (100 mg), and prednisone (60 mg/m² on days 1-4)." | 5.14 | Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom ( Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; Cibeira, MT; de Arriba, F; de Paz, R; García-Laraña, J; García-Sanz, R; González, Y; Gutiérrez, N; Hernández, JM; Lahuerta, JJ; Martín, A; Martín-Mateos, ML; Martínez-López, J; Mateos, MV; Mediavilla, JD; Miguel, JF; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Ramos, ML; Ribera, JM; Sureda, A; Teruel, AI; Vidriales, MB, 2010) |
| "The combination of bortezomib-melphalan-prednisone (VMP) is a new standard of care for newly diagnosed multiple myeloma." | 5.14 | Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cavalli, M; Ciccone, G; Falcone, AP; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Leonardi, G; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rizzo, M; Rossi, D, 2010) |
| " We aimed to assess the efficacy and safety of addition of bortezomib to TD (VTD) versus TD alone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma." | 5.14 | Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 ( Baccarani, M; Caravita, T; Cavo, M; Cellini, C; Corradini, P; Crippa, C; Deliliers, GL; Di Raimondo, F; Galli, M; Ledda, A; Narni, F; Offidani, M; Palumbo, A; Pantani, L; Patriarca, F; Pescosta, N; Petrucci, MT; Spadano, A; Tacchetti, P; Tosi, P; Zamagni, E, 2010) |
| "A total of 28 treatment-naïve patients with stage II or III multiple myeloma (MM) were treated with the combination of clarithromycin, lenalidomide, and dexamethasone (BiRD)." | 5.13 | Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. ( Christos, PJ; Coleman, M; Furst, JR; Harpel, J; Jayabalan, D; LaRow, A; Leonard, JP; Mark, T; Niesvizky, R; Pearse, RN; Schuster, MW; Shore, T; Stern, J; Zafar, F, 2008) |
| "To investigate the efficacy and toxicity of bortezomib based combination therapy for Chinese patients with relapsed or refractory multiple myeloma (MM), and to determine the combination regimen, dosage and cycles in application of bortezomib for MM therapy." | 5.13 | [Bortezomib-based combination therapy for relapsed or refractory multiple myeloma]. ( Chen, YB; Fu, WJ; Hou, J; Wang, DX; Xi, H; Yuan, ZG, 2008) |
| "Thalidomide is an effective agent for advanced refractory or relapsed multiple myeloma (MM), although dose-limiting toxicity (DLT) may limit its use." | 5.13 | Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. ( Boldt, T; Goldschmidt, H; Haas, A; Hoffmann, FA; Kreibich, U; Niederwieser, D; Pönisch, W; Ritter, U; Rohrberg, R; Rozanski, M; Schirmer, V; Schwalbe, E; Schwarzer, A; Uhlig, J; Zehrfeld, T, 2008) |
| "Recent studies have demonstrated that novel therapeutic combinations are challenging melphalan and prednisone (MP) as the standard of care in elderly patients with multiple myeloma." | 5.13 | Update on recent developments for patients with newly diagnosed multiple myeloma. ( Boccadoro, M; Bringhen, S; Falco, P; Gay, F; Magarotto, V; Palumbo, A, 2008) |
| "The study was aimed to investigate the clinical efficacy and adverse reactions of different thalidomide regimens in the treatment of multiple myeloma (MM), and to explore the relationship between efficacy of thalidomide and serum level of TNF-alpha in MM patients." | 5.13 | [Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level]. ( Cao, XM; Chen, YX; He, AL; Liu, J; Ma, XR; Yang, Y; Zhang, WG, 2008) |
| "This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (BiRD) as first-line therapy for multiple myeloma." | 5.13 | BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. ( Chen-Kiang, S; Cho, HJ; Christos, PJ; Coleman, M; Ely, S; Furst, JR; Harpel, J; Jalbrzikowski, J; Jayabalan, DS; Larow, A; Lent, R; Leonard, JP; Mark, T; Mathew, S; Mazumdar, M; Naib, T; Niesvizky, R; Pearse, RN; Pekle, K; Schuster, MW; Shore, T; Tepler, J; Zafar, F, 2008) |
| "Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM)." | 5.13 | Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. ( Bladé, J; Hajek, R; Harousseau, JL; Nagler, A; Orlowski, RZ; Robak, T; Sonneveld, P; Spencer, A; Zhuang, SH, 2008) |
| "The long-term impact of thalidomide plus dexamethasone (thal/dex) as primary therapy for newly diagnosed multiple myeloma (MM) is unknown." | 5.13 | Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. ( Bladé, J; Catalano, J; Hussein, M; Jedrzejczak, W; Knight, R; Lucy, L; Olesnyckyj, M; Rajkumar, SV; Rosiñol, L; Yu, Z; Zeldis, JB, 2008) |
| "We previously reported a pilot study of thalidomide monotherapy for Japanese patients with refractory or relapsed multiple myeloma." | 5.13 | Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma: prognostic factors and unique toxicity profile. ( Hattori, Y; Ikeda, Y; Kakimoto, T; Morita, K; Okamoto, S; Shimada, N; Tanigawara, Y, 2008) |
| "Total Therapy 2 examined the clinical benefit of adding thalidomide up-front to a tandem transplant regimen for newly diagnosed patients with multiple myeloma." | 5.13 | Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. ( Alsayed, Y; Anaissie, E; Barer, S; Barlogie, B; Crowley, J; Epstein, J; Haessler, J; Hollmig, K; Petty, N; Pineda-Roman, M; Shaughnessy, JD; Tricot, G; van Rhee, F; Waheed, S; Zangari, M; Zeldis, J, 2008) |
| "Thalidomide has been estimated as a useful drug in therapy of refractory or relapsed multiple myeloma." | 5.13 | Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma. ( Adam, Z; Bacovsky, J; Gregora, E; Minarik, J; Pavlicek, P; Pika, T; Pour, L; Scudla, V; Zemanova, M, 2008) |
| "Twenty-one patients with multiple myeloma, all relapsed after frontline autologous stem cell transplantation and all relapsed again after or resistant to thalidomide (employed as second line treatment) received bortezomib (1." | 5.12 | Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. ( Balleari, E; Boccadoro, M; Bodenizza, C; Carella, AM; Cascavilla, N; Catalano, L; Cavallo, F; Dell'Olio, M; Falcone, A; Greco, MM; Guglielmelli, T; La Sala, A; Mantuano, S; Melillo, L; Merla, E; Musto, P; Nobile, M; Palumbo, A; Sanpaolo, G; Scalzulli, PR; Spriano, M; Zambello, R, 2006) |
| "To determine if thalidomide plus dexamethasone yields superior response rates compared with dexamethasone alone as induction therapy for newly diagnosed multiple myeloma." | 5.12 | Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. ( Blood, E; Fonseca, R; Greipp, PR; Rajkumar, SV; Vesole, D, 2006) |
| " on days 1-4 and 9-12 and thalidomide 100 mg daily in 50 patients with advanced multiple myeloma." | 5.12 | Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. ( Alesiani, F; Brunori, M; Burattini, M; Candela, M; Capelli, D; Catarini, M; Centurioni, R; Corvatta, L; Galieni, P; Giuliodori, L; Leoni, P; Marconi, M; Montanari, M; Offidani, M; Olivieri, A; Piersantelli, MN; Rupoli, S; Scortechini, AR; Visani, G, 2006) |
| "Fifty patients with multiple myeloma >or=75 years of age received primary treatment with melphalan (M) 8 mg/m(2) on days 1-4, dexamethasone (D) 12 mg/m2 on days 1-4 and 17-20 and thalidomide (T) 300 mg at bedtime on days 1-4 and 17-20." | 5.12 | Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. ( Anagnostopoulos, A; Anagnostopoulos, N; Delibasi, S; Dimopoulos, MA; Katodritou, E; Kyrtsonis, MC; Maniatis, A; Pouli, A; Repoussis, P; Terpos, E; Vassou, A; Zervas, K; Zomas, A, 2006) |
| "High-dose therapy with melphalan can prolong survival among patients with multiple myeloma." | 5.12 | Thalidomide and hematopoietic-cell transplantation for multiple myeloma. ( Anaissie, E; Barlogie, B; Crowley, J; Fassas, A; Fox, M; Hollmig, K; Kiwan, E; Krishna, S; Lee, C; Pineda-Roman, M; Rasmussen, E; Shaughnessy, J; Talamo, G; Thertulien, R; Tricot, G; van Rhee, F; Zangari, M, 2006) |
| "Patients with newly diagnosed multiple myeloma were randomly assigned to receive oral MP for six 4-week cycles plus thalidomide (n=129; 100 mg per day continuously until any sign of relapse or progressive disease) or MP alone (n=126)." | 5.12 | Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. ( Ambrosini, MT; Avonto, I; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Capparella, V; Caravita, T; Catalano, L; Ceccarelli, M; Ciccone, G; De Stefano, V; Falco, P; Galli, M; Grasso, M; Liberati, AM; Merla, E; Musto, P; Palumbo, A; Petrucci, MT; Rossini, F; Zamagni, E, 2006) |
| "A major limitation to the treatment of multiple myeloma by the thalidomide analogue CC-4047 (Actimid) is the development of a severe neutropenia." | 5.12 | The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64. ( Brown, KA; Macey, MG; McCarthy, DA; Schey, SA; Streetly, M, 2006) |
| "We present the results of a phase 2 study using thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) in the treatment of 50 patients older than 65 years with newly diagnosed multiple myeloma." | 5.12 | Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. ( Alesiani, F; Brunori, M; Burattini, M; Candela, M; Capelli, D; Catarini, M; Centurioni, R; Corvatta, L; Ferranti, M; Galieni, P; Giuliodori, L; Leoni, P; Marconi, M; Montanari, M; Offidani, M; Olivieri, A; Piersantelli, MN; Polloni, C; Poloni, A; Rupoli, S; Scortechini, AR; Visani, G, 2006) |
| "To evaluate the efficacy and safety of adding thalidomide to the pegylated liposomal doxorubicin, vincristine, and decreased-frequency dexamethasone (DVd) regimen for multiple myeloma." | 5.12 | Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. ( Agrawal, N; Andresen, S; Baz, R; Faiman, B; Hsi, E; Hussein, MA; Karam, MA; Kelly, M; Reed, J; Srkalovic, G; Suppiah, R; Walker, E, 2006) |
| "Peripheral neuropathy frequently limits the duration of treatment with thalidomide for patients with multiple myeloma." | 5.12 | Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. ( Day, B; Mileshkin, L; Prince, HM; Seymour, JF; Stark, R; Zeldis, JB, 2006) |
| "Lenalidomide is active and well tolerated in relapsed and refractory multiple myeloma." | 5.12 | Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. ( Andresen, S; Baz, R; Brand, C; Bruening, K; Choueiri, TK; Ellis, Y; Faiman, B; Hussein, MA; Jawde, RA; Karam, MA; Knight, R; Reed, J; Srkalovic, G; Walker, E; Zeldis, J, 2006) |
| "Thalidomide has been used for the treatment of refractory multiple myeloma, the dosage in Japan is lower than in other countries; however, there is little information on the pharmacokinetics and their relationship with the drug response." | 5.12 | The pharmacokinetics of low-dose thalidomide in Japanese patients with refractory multiple myeloma. ( Asaoku, H; Ikawa, K; Iwato, K; Kamikawa, R; Morikawa, N; Sasaki, A, 2006) |
| "In multiple myeloma (MM), the addition of thalidomide or bortezomib to the standard oral melphalan/prednisone combination significantly increased response rate and event-free survival." | 5.12 | Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. ( Ambrosini, MT; Avonto, I; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Caravita, T; Cavallo, F; Falco, P; Morabito, F; Musto, P; Palumbo, A; Pescosta, N; Pregno, P, 2007) |
| " The tandem transplant trial, Total Therapy 2, enrolled 668 patients, who were randomised up-front to thalidomide (THAL) or no THAL; 56 patients were identified as having had, for at least 6 months prior to initiation of therapy, monoclonal gammopathy of undetermined significance (MGUS, n = 21), smouldering MM (SMM, n = 22) or solitary plasmacytoma of bone (SPC, n = 13)." | 5.12 | Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. ( Anaissie, E; Arzoumanian, V; Barlogie, B; Bolejack, V; Crowley, J; Epstein, J; Hollmig, K; Krishna, S; Pineda-Roman, M; Shaughnessy, JD; van Rhee, F; Walker, R; Zangari, M, 2007) |
| "3 mg/m2 intravenously on days 1, 4, and 8 to DT-PACE (cisplatin 10 mg/m2, doxorubicin 10 mg/m2, cyclophosphamide 400 mg/m2, and etoposide 40 mg/m2 per day by intravenous continuous infusion on days 1-4) plus oral dexamethasone 40 mg on days 1-4 and thalidomide 200 mg on days 1-8 in newly diagnosed patients with multiple myeloma." | 5.12 | Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma. ( Akpek, G; Badros, A; Fenton, R; Goloubeva, O; Harris, C; Meisenberg, B; Rapoport, AP; Ruehle, K; Westphal, S, 2006) |
| "In a phase III randomized, multicenter study, the German-speaking Myeloma-Multicenter Group (GMMG) and the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) group investigated the influence of thalidomide (Thal) on the outcome of peripheral blood stem cell (PBSC) collection in multiple myeloma (MM) before peripheral autologous blood stem cell transplantation (ABSCT)." | 5.12 | Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. ( Blau, IW; Breitkreutz, I; Cremer, FW; Glasmacher, A; Goldschmidt, H; Haenel, A; Herrmann, D; Holt, Bv; Lokhorst, HM; Martin, H; Raab, MS; Salwender, H; Schmidt-Wolf, IG; Sonneveld, P, 2007) |
| "The impact of high dose dexamethasone containing regimens with or without the novel agents thalidomide and bortezomib on the reversal of renal failure (RF) was evaluated in 41 consecutive newly diagnosed patients with multiple myeloma (MM) treated in a single institution." | 5.12 | Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. ( Anagnostopoulos, A; Bamias, A; Barmparousi, D; Dimopoulos, MA; Gika, D; Grapsa, I; Kastritis, E; Matsouka, C; Psimenou, E; Roussou, M, 2007) |
| "In a previous trial among 137 previously untreated patients with multiple myeloma, the combination of thalidomide-dexamethasone induced remission in 66% of patients, including complete remission in 13%." | 5.12 | Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. ( Alexanian, R; Delasalle, K; Giralt, S; Handy, B; Wang, M, 2007) |
| "We report the results of a non-randomized phase II study of low-dose thalidomide plus low-dose dexamethasone therapy in 66 patients with refractory multiple myeloma." | 5.12 | Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. ( Abe, M; Fujii, H; Fukuhara, T; Handa, H; Hata, H; Iida, S; Ishida, T; Ishii, A; Ishikawa, T; Kosaka, M; Miyata, A; Murakami, H; Oota, M; Ozaki, S; Sakai, A; Sawamura, M; Shimazaki, C; Shimizu, K; Takagi, T; Takatsuki, K; Wakayama, T, 2007) |
| "Thalidomide is effective as a first-line therapy for the treatment of multiple myeloma (MM), but its use is limited by peripheral neurotoxicity." | 5.12 | Neuropathy in multiple myeloma treated with thalidomide: a prospective study. ( Bartolomei, I; Cangini, D; Cavo, M; Michelucci, R; Pastorelli, F; Petracci, E; Plasmati, R; Salvi, F; Tacchetti, P; Tassinari, CA; Tosi, P; Zamagni, E, 2007) |
| "Data on 72 patients receiving lenalidomide/dexamethasone for multiple myeloma (MM) was used to determine the factors that are associated with lenalidomide-induced myelosuppression." | 5.12 | Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. ( Chen-Kiang, S; Christos, PJ; Coleman, M; Ely, S; Furst, JR; Jalbrzikowski, J; Jayabalan, D; Lent, R; Leonard, JP; Mark, T; Mazumdar, M; Naib, T; Niesvizky, R; Pearse, RN; Zafar, F, 2007) |
| " Oral melphalan, prednisone, and thalidomide have been regarded as the standard of care in elderly multiple myeloma patients." | 5.12 | Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. ( Ambrosini, MT; Boccadoro, M; Bringhen, S; Ciccone, G; Corradini, P; Crippa, C; Di Raimondo, F; Falco, P; Falcone, A; Foà, R; Gay, F; Giuliani, N; Knight, R; Musto, P; Omedè, P; Palumbo, A; Petrucci, MT; Zeldis, JB, 2007) |
| " We have analyzed the prognostic impact of the development of a thrombotic episode in newly diagnosed multiple myeloma patients who received chemotherapy either with or without thalidomide on our Total Therapy 2 protocol." | 5.12 | Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients. ( Barlogie, B; Bolejack, V; Cavallo, F; Fink, L; Tricot, G; Zangari, M, 2007) |
| "Between May 22, 2000, and Aug 8, 2005, 447 previously untreated patients with multiple myeloma, who were aged between 65 and 75 years, were randomly assigned to receive either melphalan and prednisone (MP; n=196), melphalan and prednisone plus thalidomide (MPT; n=125), or reduced-intensity stem cell transplantation using melphalan 100 mg/m2 (MEL100; n=126)." | 5.12 | Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. ( Anglaret, B; Attal, M; Avet-Loiseau, H; Benboubker, L; Casassus, P; Chaleteix, C; Dib, M; Dorvaux, V; Doyen, C; Facon, T; Grosbois, B; Guillerm, G; Harousseau, JL; Hulin, C; Jardel, H; Jaubert, J; Kolb, B; Maisonneuve, H; Martin, C; Mary, JY; Mathiot, C; Monconduit, M; Pegourie, B; Renaud, M; Troncy, J; Voillat, L; Yakoub-Agha, I, 2007) |
| "Lenalidomide plus dexamethasone is more effective than high-dose dexamethasone alone in relapsed or refractory multiple myeloma." | 5.12 | Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. ( Attal, M; Corso, A; Dimopoulos, M; Dmoszynska, A; Facon, T; Foà, R; Harousseau, JL; Hellmann, A; Knight, RD; Masliak, Z; Olesnyckyj, M; Patin, J; Prince, HM; San Miguel, J; Spencer, A; Yu, Z; Zeldis, JB, 2007) |
| "Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma." | 5.12 | Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. ( Belch, A; Borrello, I; Chanan-Khan, AA; Chen, C; Knight, RD; Lonial, S; Niesvizky, R; Olesnyckyj, M; Patin, J; Rajkumar, SV; Siegel, D; Stadtmauer, EA; Wang, M; Weber, DM; Yu, Z; Zeldis, JB, 2007) |
| "Thalidomide is effective in treating refractory and relapsed multiple myeloma (MM)." | 5.12 | [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma]. ( Chen, YB; Fu, WJ; Hou, J; Wang, DX; Xi, H; Yuan, ZG, 2007) |
| "We evaluate the efficacy of the oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) in 71 refractory/relapsed multiple myeloma patients, including a prognostic analysis to predict both response and survival." | 5.11 | The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. ( Alegre, A; Barrenetxea, C; García-Sanz, R; González-Porras, JR; Grande-García, C; Gutiérrez, ON; Hernández, JM; López, R; Palomera, L; Polo-Zarzuela, M; Rodríguez, JA; San Miguel, JF; Sureda, A; Vargas-Pabón, M, 2004) |
| "Thalidomide has demonstrated a remarkable efficacy in the treatment of multiple myeloma but its use may cause several toxicities." | 5.11 | Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. ( Brunori, M; Candela, M; Capelli, D; Catarini, M; Corvatta, L; Leoni, P; Malerba, L; Marconi, M; Mele, A; Montanari, M; Offidani, M; Olivieri, A; Rupoli, S, 2004) |
| "Recent reports have shown that thalidomide has antiangiogenic activity and is effective for the treatment of refractory multiple myeloma." | 5.11 | Thalidomide-induced severe neutropenia during treatment of multiple myeloma. ( Hattori, Y; Ikeda, Y; Kakimoto, T; Okamoto, S; Sato, N, 2004) |
| "To determine the progression-free survival at 12 weeks, to evaluate the toxic effects, and to analyze the biological activity of thalidomide in patients with relapsed multiple myeloma (MM) after high-dose chemotherapy and stem cell transplantation." | 5.11 | Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. ( Alsina, M; Anderson, K; Blood, E; Bosch, J; Dalton, W; Davies, F; Desikan, R; Doss, D; Freeman, A; Hideshima, T; Jagannath, S; Knight, R; Mitsiades, C; Patin, J; Richardson, P; Schlossman, R; Weller, E; Zeldis, J, 2004) |
| "The marked synergy of thalidomide and dexamethasone in advanced and refractory multiple myeloma (MM) provided the basis for a phase 2 clinical study aimed at investigating the efficacy and toxicity of this combination as first-line therapy for patients less than 65 years old with newly diagnosed disease." | 5.11 | First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. ( Baccarani, M; Cangini, D; Cavo, M; Cellini, C; de Vivo, A; Palareti, G; Tacchetti, P; Testoni, N; Tonelli, M; Tosi, P; Tura, S; Zamagni, E, 2004) |
| "Thalidomide, the prototype of a new class of agents active against multiple myeloma (MM), exerts synergistic/additive effects when combined with other drugs." | 5.11 | Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. ( Brunori, M; Candela, M; Capelli, D; Catarini, M; Corvatta, L; Leoni, P; Malerba, L; Marconi, M; Mele, A; Montanari, M; Offidani, M; Olivieri, A, 2004) |
| "To quantify changes of bone marrow microcirculation in multiple myeloma (MM) using contrast enhanced dynamic MRI (dMRI) during thalidomide as antiangiogenic monotherapy or in combination with chemotherapy (cyclophosphamide, etoposide, dexamethasone)." | 5.11 | [Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy]. ( Delorme, S; Düber, C; Goldschmidt, H; Heiss, J; Hillengass, J; Kauczor, HU; Moehler, T; Neben, K; Nosas, S; Wasser, K, 2004) |
| "Thalidomide is an effective agent for patients with refractory multiple myeloma (MM) with a response rate of 30-40% at doses of 200-800 mg but with considerable side effects." | 5.11 | Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study. ( Daenen, SM; de Wolf, JT; Hovenga, S; Kluin-Nelemans, HC; Sluiter, WJ; van Imhoff, GW; Vellenga, E, 2005) |
| "We report a multicenter, randomized phase II trial conducted to assess the tolerability of combined thalidomide and prednisone maintenance in multiple myeloma." | 5.11 | Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. ( Belch, AR; Chen, CI; Ding, K; Howson-Jan, K; Kovacs, MJ; Meyer, RM; Roy, J; Sadura, A; Shepherd, L; Shustik, C; Stewart, AK; White, D, 2004) |
| "Thalidomide is remarkably active in advanced relapsed and refractory multiple myeloma (MM), so that its use has been recently proposed either in newly diagnosed patients or as maintenance treatment after conventional or high-dose therapy." | 5.11 | Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. ( Baccarani, M; Cangini, D; Cavo, M; Cellini, C; Pastorelli, F; Perrone, G; Plasmati, R; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E, 2005) |
| "The aim of this study was to assess the side effects and the efficacy of thalidomide alone or in combination with dexamethasone in relapsed multiple myeloma (MM) and to evaluate possible predictive factors for response rate and survival." | 5.11 | Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival. ( Brandhorst, D; Buttkereit, U; Ebeling, P; Flasshove, M; Moritz, T; Müller, S; Nowrousian, MR; Opalka, B; Poser, M; Schütt, P; Seeber, S, 2005) |
| "Thalidomide (THAL) is currently used as a novel drug in patients with chemotherapy resistant or relapsed multiple myeloma." | 5.11 | The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma. ( Bojarska-Junak, A; Dmoszynska, A; Manko, J; Podhorecka, M; Rolinski, J; Skomra, D, 2005) |
| "G3139, dexamethasone, and thalidomide are well tolerated and result in encouraging clinical responses in relapsed multiple myeloma patients." | 5.11 | Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. ( Badros, AZ; Fenton, RG; Flaws, JA; Gahres, N; Gocke, CD; Goloubeva, O; Heyman, M; Meisenberg, B; Rapoport, AP; Ratterree, B; Streicher, H; Takebe, N; Tomic, D; Zhang, B; Zwiebel, J, 2005) |
| "The feasibility and efficacy of a triple regimen of oral weekly cyclophosphamide, monthly pulsed dexamethasone and low-dose Thalidomide (CDT) was studied in 52 patients with relapsed or refractory multiple myeloma (MM)." | 5.11 | Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. ( D'Sa, S; Flory, A; Goldstone, AH; Hanslip, J; Kyriakou, C; Thomson, K; Yong, KL, 2005) |
| "Thalidomide-dexamethasone therapy was given in patients (<61 years) with previously untreated symptomatic multiple myeloma." | 5.11 | First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma. ( Abdelkefi, A; Aissaouï, L; Bellaj, H; Ben Abdeladhim, A; Ben Othman, T; Ben Romdhane, N; Boukef, K; Dellagi, K; El Omri, H; Elloumi, M; Hsaïri, M; Jeddi, R; Ladeb, S; Lakhal, A; Saad, A; Torjman, L, 2005) |
| "The value of thalidomide-dexamethasone was assessed in 26 consecutive, previously untreated patients with multiple myeloma of high tumor mass." | 5.11 | Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. ( Alexanian, R; Delasalle, K; Wang, M; Weber, DM, 2005) |
| "The feasibility and efficacy of a combination of thalidomide, incadronate, and dexamethasone (TID) were studied in 12 patients with relapsed or refractory multiple myeloma." | 5.11 | Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma. ( Ashihara, E; Fuchida, S; Hatsuse, M; Ochiai, N; Okamoto, M; Okano, A; Shimazaki, C; Uchida, R; Yamada, N, 2005) |
| "To study the efficacy of daily low-dose aspirin (81 mg orally) in decreasing the incidence of venous thromboembolic events (VTEs) in patients with multiple myeloma receiving pegylated doxorubicin, vincristine, and decreased-frequency dexamethasone, plus thalidomide (DVd-T)." | 5.11 | The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. ( Andresen, S; Baz, R; Faiman, B; Hussein, MA; Jawde, RA; Karam, MA; Kottke-Marchant, K; Li, L; McGowan, B; Srkalovic, G; Yiannaki, E; Zeldis, J, 2005) |
| " Thalidomide has proven activity in refractory multiple myeloma (MM), and although single-agent thalidomide has minimal prothrombogenic activity, its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT." | 5.10 | Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. ( Anaissie, E; Barlogie, B; Fassas, A; Fink, L; Morris, C; Saghafifar, F; Siegel, E; Tricot, G; Zangari, M, 2002) |
| "Thalidomide (Thal) can overcome drug resistance in multiple myeloma (MM) but is associated with somnolence, constipation, and neuropathy." | 5.10 | Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. ( Anderson, KC; Balinski, K; Catley, LP; Chauhan, D; Davies, F; Deocampo, R; Doss, D; Freeman, A; Hideshima, T; Kelly, K; LeBlanc, R; McKenney, M; Mechlowicz, J; Mitsiades, C; Rich, R; Richardson, PG; Ryoo, JJ; Schlossman, RL; Weller, E; Zeldis, J, 2002) |
| "We conclude that the combination of thalidomide plus dexamethasone is a feasible and active regimen in the treatment of multiple myeloma." | 5.10 | Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. ( Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, S; Greipp, PR; Hayman, S; Iturria, N; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE, 2002) |
| "Although thalidomide (Thal) was introduced successfully in the treatment of multiple myeloma (MM), the optimal Thal dosage and schedule are still controversial." | 5.10 | Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. ( Benner, A; Egerer, G; Goldschmidt, H; Ho, AD; Kraemer, A; Moehler, T; Neben, K, 2002) |
| "To evaluate the activity of thalidomide in patients with asymptomatic multiple myeloma and of thalidomide-dexamethasone in patients with previously untreated symptomatic myeloma." | 5.10 | Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. ( Alexanian, R; Delasalle, K; Gavino, M; Rankin, K; Weber, D, 2003) |
| " We report the final results of a phase II trial of thalidomide as initial therapy for early-stage multiple myeloma in an attempt to delay progression to symptomatic disease." | 5.10 | Thalidomide as initial therapy for early-stage myeloma. ( Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, SM; Greipp, PR; Iturria, N; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE, 2003) |
| "Thalidomide is active both as single agent and in combination-therapy against refractory or relapsing multiple myeloma." | 5.10 | Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): results, prognostic factors and side effects in eight patients previously treated with multiple myeloma. ( Bemardeschi, P; Dentico, P; Fiorentini, G; Giustarini, G; Rossi, S; Turano, E, 2003) |
| " We report the results of a prospective randomized trial of 62 newly diagnosed MM patients tested at baseline for hypercoagulability and treated with intensive chemotherapy with or without thalidomide in a randomized fashion." | 5.10 | Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. ( Anaissie, E; Badros, A; Barlogie, B; Desikan, R; Fassas, A; Fink, L; Mehta, P; Morris, C; Saghafifar, F; Siegel, E; Toor, A; Tricot, G; Whitfield, D; Zangari, M, 2002) |
| "13 patients with treatment-resistant multiple myeloma with advanced osteolytic lesions received combined pamidronate and thalidomide therapy." | 5.10 | Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. ( Baran, W; Ciepłuch, H; Hellmann, A, 2002) |
| "Thalidomide is an effective treatment for relapsed multiple myeloma (MM), but is associated with a significant side effect profile at higher doses." | 5.10 | Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. ( Abdalla, SH; Johnston, RE, 2002) |
| "Although thalidomide (Thal) was initially used to treat multiple myeloma (MM) because of its known antiangiogenic effects, the mechanism of its anti-MM activity is unclear." | 5.09 | Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. ( Anderson, KC; Chauhan, D; Davies, FE; Hideshima, T; Lin, B; Muller, G; Raje, N; Richardson, P; Schlossman, RL; Shima, Y; Stirling, DI; Tai, YT; Treon, SP, 2000) |
| "Thalidomide is currently used as a very promising drug in patients with recurrent multiple myeloma or those refractory to chemotherapy." | 5.09 | Thalidomide treatment of resistant or relapsed multiple myeloma patients. ( Ciepnuch, H; Dmoszynska, A; Hellmann, A; Hus, M; Jawniak, D; Legiec, W; Manko, J; Skotnicki, A; Soroka-Wojtaszko, M; Wolska-Smolen, T, 2001) |
| "We conducted a clinical trial of thalidomide as initial therapy for asymptomatic smoldering (SMM) or indolent multiple myeloma (IMM)." | 5.09 | Thalidomide for previously untreated indolent or smoldering multiple myeloma. ( Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, S; Greipp, PR; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE, 2001) |
| "The occurrence of deep-vein thrombosis (DVT) in patients with newly diagnosed multiple myeloma, who were randomly assigned to receive identical induction chemotherapy with or without thalidomide, are reported in this study." | 5.09 | Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. ( Anaissie, E; Badros, A; Barlogie, B; Desikan, R; Fink, L; Gopal, AV; Morris, C; Siegel, E; Toor, A; Tricot, G; Zangari, M, 2001) |
| "Thalidomide is effective in approximately 30% of patients with refractory multiple myeloma." | 5.09 | Thalidomide and dexamethasone combination for refractory multiple myeloma. ( Anagnostopoulos, N; Christakis, I; Dimopoulos, MA; Economou, O; Galani, E; Gika, D; Grigoraki, V; Kiamouris, C; Kouvatseas, G; Panayiotidis, P; Papadimitriou, C; Samantas, E; Vervessou, E; Zervas, K, 2001) |
| "The aim of this study was to define prognostic factors that might be predictive for response to thalidomide (Thal) in progressive multiple myeloma (n = 54)." | 5.09 | High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. ( Benner, A; Egerer, G; Goldschmidt, H; Hillengass, J; Ho, AD; Kraemer, A; Moehler, T; Neben, K, 2001) |
| "Recently, a report has suggested the efficacy and safety of thalidomide in refractory multiple myeloma." | 5.09 | Thalidomide in patients with advanced multiple myeloma. ( Attal, M; Beris, P; Berthou, C; Duguet, C; Dumontet, C; Facon, T; Grosbois, B; Harousseau, JL; Leyvraz, S; Moreau, P; Payen, C; Yakoub-Agha, I, 2000) |
| "Established treatments for transplant-ineligible (TNE) patients with newly diagnosed multiple myeloma (NDMM) include melphalan and prednisone (MP) combined with either bortezomib (VMP) or thalidomide (MPT), or lenalidomide plus low-dose dexamethasone (Rd)." | 5.05 | Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis. ( Buchanan, V; D'Souza, VK; Dhanasiri, S; Ramasamy, K; Robinson, S; Thom, H; Weisel, K, 2020) |
| "With ten years of follow-up since the advent of the modern paradigm of combination induction therapy, consolidative autologous stem-cell transplant, and lenalidomide maintenance, median survival for multiple myeloma has increased to almost 50% at 10 years." | 5.05 | Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future. ( Chung, DJ; Diamond, B; Lesokhin, AM; Maclachlan, K; Ola Landgren, C, 2020) |
| "We sought to evaluate the activity and safety of carfilzomib-/ixazomib-containing combinations for patients with relapsed/refractory multiple myeloma (RRMM)." | 4.98 | Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma. ( Guo, H; Sun, X; Wang, B; Xu, W, 2018) |
| "Thalidomide changed the treatment of patients with multiple myeloma, however, its effectiveness has been compromised due to its side effects." | 4.98 | [Immunomodulator drugs for the treatment of multiple myeloma]. ( Caballero García, A; Córdova Martínez, A; Fernández-Lázaro, CI; Fernández-Lázaro, D, 2018) |
| "The immunomodulatory drug lenalidomide is highly effective against newly diagnosed and relapsed/refractory multiple myeloma (MM), but serious and even fatal infections have been associated with its use." | 4.95 | Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis. ( Sun, H; Ying, L; YinHui, T; Yunliang, Z, 2017) |
| "This overview summarizes evidence for the efficacy and safety of bortezomib, thalidomide, and lenalidomide in patients with multiple myeloma." | 4.95 | Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses. ( Aguiar, PM; Colleoni, GWB; de Mendonça Lima, T; Storpirtis, S, 2017) |
| " Within the past decade, combination lenalidomide and dexamethasone has become a standard of therapy for multiple myeloma and is now widely used." | 4.95 | Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma. ( Chang, S; Maharaj, S; Seegobin, K; Serrano-Santiago, I; Zuberi, L, 2017) |
| "Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or observation in several randomized controlled trials (RCTs) of patients with newly diagnosed multiple myeloma (NDMM)." | 4.95 | Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. ( Anderson, KC; Attal, M; Bringhen, S; Caillot, D; Gay, F; Holstein, SA; Hulin, C; Jung, SH; Knight, RD; Marit, G; McCarthy, PL; Moreau, P; Musto, P; Palumbo, A; Petrucci, MT; Richardson, PG; Tosi, P; Winograd, B; Yu, Z, 2017) |
| "BiRd combination therapy, which comprises clarithromycin(CAM: Biaxin®), lenalidomide(LEN: Revlimid®), and dexamethasone( DEX), is a highly effective treatment for newly diagnosed symptomatic multiple myeloma(MM)." | 4.95 | [Effective BiRd Therapy after the Addition of Clarithromycin for Lenalidomide and Dexamethasone Resistant Multiple Myeloma Ineligible for Stem Cell Transplantation]. ( Abe, T; Ameda, S; Fujii, S; Kato, J; Kobune, M; Kuroda, H; Maeda, M; Miura, S; Sakano, H; Sato, K; Shibata, T; Uemura, N; Yamada, M, 2017) |
| "The use of carfilzomib/pomalidomide single-agent or in combination with other agents in patients with refractory/relapsed multiple myeloma (RRMM) was not clearly clarified in clinical practice." | 4.95 | Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials. ( Fan, L; Hu, C; Ma, X; Ran, X; Yu, H; Zou, Y, 2017) |
| " Lenalidomide, a more potent second generation IMiD with fewer side effects than thalidomide, is commonly used in newly-diagnosed multiple myeloma, relapsed refractory myeloma and as maintenance therapy after autologous stem cell transplantation (ASCT)." | 4.95 | Immunomodulatory Drugs (IMiDs) in Multiple Myeloma. ( Lentzsch, S; Raza, S; Safyan, RA, 2017) |
| "To investigate the activity and safety of carfilzomib-containing combinations as frontline therapy for multiple myeloma." | 4.95 | Carfilzomib-containing combinations as frontline therapy for multiple myeloma: A meta-analysis of 13 trials. ( Li, B; Li, G; Liu, Y; Sheng, Z; Wang, L, 2017) |
| "The use of pomalidomide after lenalidomide and (or) bortezomib failure in patients with multiple myeloma is not clearly clarified in clinical practice." | 4.93 | Pooled analysis of the reports of pomalidomide after failure of lenalidomide and (or) bortezomib for multiple myeloma. ( Liu, G; Sheng, Z, 2016) |
| "Thalidomide- or lenalidomide-based maintenance therapy improves PFS but not OS in MM and increases risks of grade 3-4 adverse events, including thromboembolism, peripheral neuropathy, neutropenia, and infection." | 4.93 | Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. ( Andersson, BS; Berenson, JR; Champlin, RE; Chang, VT; Guan, X; Qazilbash, MH; Shen, Y; Wang, J; Wang, ML; Wang, Y; Yang, F; Zhang, W, 2016) |
| "Despite significant improvement in outcomes have been observed for multiple myeloma (MM) patients over the past 10-15 years, mainly due to the introduction of novel agents targeting the tumor clone and the bone marrow microenvironment, treatment of refractory and/or relapsed (RR) disease remains a challenge, particularly for patients who have failed prior bortezomib- and lenalidomide-based therapies." | 4.93 | Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma. ( Brioli, A; Cavo, M; Mancuso, K; Martello, M; Pantani, L; Rizzello, I; Rocchi, S; Tacchetti, P; Terragna, C; Zamagni, E; Zannetti, BA, 2016) |
| " The increasing use of post-transplant maintenance therapy with lenalidomide in patients with multiple myeloma adds to this risk after autologous HSCT." | 4.93 | Venous thromboembolism in hematopoietic stem cell transplant recipients. ( Chaturvedi, S; Mohty, M; Nagler, A; Neff, A; Savani, BN; Savani, U, 2016) |
| " Trials comparing efficacy of standard melphalan and prednisone (MP) therapy with MP plus thalidomide (MPT) in transplant-ineligible or elderly patients with multiple myeloma (MM) have provided conflicting evidence." | 4.93 | Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis. ( Ding, ZX; Li, BY; Lyu, WW; Song, DH; Wei, CM; Zhang, JJ; Zhao, QC, 2016) |
| "Pomalidomide, a derivative of thalidomide and member of the immunomodulatory drugs is licenced for use in relapsed and refractory multiple myeloma (RRMM) in Europe, USA, Canada and Japan." | 4.93 | The safety of pomalidomide for the treatment of multiple myeloma. ( Davies, FE; Jones, JR; Morgan, GJ; Pawlyn, C, 2016) |
| "This study aimed at comparing bortezomib, thalidomide, and lenalidomide in patients with multiple myeloma (MM) for safety and efficacy using meta-analysis." | 4.93 | Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis. ( Li, Y; Wang, X; Yan, X, 2016) |
| "Studies have consistently demonstrated the need for venous thromboembolism (VTE) prophylaxis in patients with newly diagnosed multiple myeloma (NDMM) or relapsed refractory multiple myeloma (RRMM), receiving lenalidomide-based therapy." | 4.93 | Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review. ( Al-Ani, F; Bermejo, JM; Louzada, M; Mateos, MV, 2016) |
| "With the introduction of thalidomide and multi-agent chemotherapy in the treatment of multiple myeloma around 15years ago a strongly increased risk of venous thrombosis was observed." | 4.93 | Update of thrombosis in multiple myeloma. ( Leebeek, FW, 2016) |
| " Thalidomide and its more potent analogs, lenalidomide and pomalidomide, are nowadays approved treatments for multiple myeloma and myelodysplastic syndrome with deletion of chromosome 5q." | 4.93 | The molecular mechanism of thalidomide analogs in hematologic malignancies. ( Krönke, J; Lindner, S, 2016) |
| "Elotuzumab, a first-in-class immunostimulatory monoclonal antibody, is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received 1-3 prior therapies." | 4.93 | Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. ( Kaufman, J; Laubach, J; Lonial, S; Mateos, MV; Reece, D; Richardson, P, 2016) |
| "A 64-year-old man with recurrent multiple myeloma (BJP-κ type) was treated with 15 mg of lenalidomide (LEN) and dexamethasone." | 4.93 | Quincke's edema and hypersensitivity pneumonitis induced by lenalidomide for multiple myeloma. ( Fuchida, SI; Hatsuse, M; Murakami, S; Odaira, E; Okano, A; Shimazaki, C, 2016) |
| "The treatment of multiple myeloma has evolved significantly over the past 2 decades due to the use of high-dose chemotherapy and autologous stem cell transplantation, and the subsequent introduction of the immunomodulatory agents (thalidomide and lenalidomide) and the proteasome inhibitor (bortezomib)." | 4.91 | Emerging therapies in multiple myeloma. ( El-Amm, J; Tabbara, IA, 2015) |
| "On August 5, 2013, a marketing authorization valid throughout the European Union (EU) was issued for pomalidomide in combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy." | 4.91 | The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use. ( Camarero, J; Flores, B; Gisselbrecht, C; Hanaizi, Z; Hemmings, R; Laane, E; Pignatti, F; Salmonson, T; Sancho-Lopez, A, 2015) |
| "In the last couple of years major progress has been made in the treatment of multiple myeloma (MM) through the introduction of novel agents like thalidomide, lenalidomide, bortezomib and pomalidomide, mostly in combination with autologous stem cell transplantation." | 4.91 | Lenalidomide in multiple myeloma. ( Kim, Y; Schmidt-Wolf, IG, 2015) |
| "The availability of novel drugs with different and innovative mechanisms of action such as proteasome inhibitors such as bortezomib and immunomdulatory agents as thalidomide and lenalidomide have changed the landscape of the treatment of patients with newly diagnosed multiple myeloma, allowing the development of several new therapeutic regimens both for transplant-eligible and -ineligible patients." | 4.91 | Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma. ( Cejalvo, MJ; de la Rubia, J, 2015) |
| "Lenalidomide (Revlimid(®)) is a second-generation immunomodulatory drug structurally related to thalidomide, with improved efficacy and tolerability, for which the label in the EU was recently expanded to include continuous therapy in patients with previously untreated multiple myeloma not eligible for stem-cell transplantation." | 4.91 | Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation. ( McCormack, PL, 2015) |
| "The long-term outcome of multiple myeloma (MM) has been greatly improved through new agents, one being lenalidomide (LEN)." | 4.91 | Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy. ( Kobayashi, T; Kuroda, J; Taniwaki, M, 2015) |
| "Lenalidomide has emerged as an important treatment for patients with multiple myeloma (MM)." | 4.91 | Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials. ( Guo, XN; Qiao, SK; Ren, HY; Ren, JH, 2015) |
| "Lenalidomide , an immunomodulatory agent with unique mechanism of action, represents the cornerstone in the treatment of patients with multiple myeloma (MM) providing rapid and sustained control of the disease with a manageable safety profile." | 4.91 | An update on the use of lenalidomide for the treatment of multiple myeloma. ( Dimopoulos, MA; Kastritis, E; Terpos, E; Zagouri, F, 2015) |
| "Once characterized by a very poor outcome, multiple myeloma (MM) now has a significantly prolonged survival, with major improvements allowed by the use of "novel agents": proteasome inhibitors (first-in-class bortezomib) and immunomodulatory compounds (IMiDs; first-in-class thalidomide and lenalidomide)." | 4.91 | [Pomalidomide for multiple myeloma]. ( Arnulf, B; Benboubker, L; Bories, C; Decaux, O; Demarquette, H; Fohrer, C; Fouquet, G; Guidez, S; Herbaux, C; Hulin, C; Karlin, L; Le Grand, C; Leleu, X; Macro, M; Prodhomme, C; Renaud, L; Roussel, M, 2015) |
| "Lenalidomide (LEN) is an immunomodulatory drug with US Food and Drug Administration approval for use in myelodysplastic syndromes (MDS), multiple myeloma (MM), and mantle cell lymphoma (MCL)." | 4.91 | Practical Management of Lenalidomide-Related Rash. ( Kurtin, SE; Ridgeway, JA; Tinsley, SM, 2015) |
| "The aim of the study was to evaluate the clinical efficacy and safety of bortezomib-based regimens for the treatment of multiple myeloma through meta-analysis." | 4.90 | Bortezomib in combination with thalidomide or lenalidomide or doxorubicin regimens for the treatment of multiple myeloma: a meta-analysis of 14 randomized controlled trials. ( Wang, L; Xu, YL; Zhang, XQ, 2014) |
| "The objective of the study was to investigate the effects and safety of novel agents such as bortezomib and lenalidomide in the treatment of newly diagnosed patients with multiple myeloma." | 4.90 | Bortezomib and lenalidomide as front-line therapy for multiple myeloma. ( Lin, M; Niu, S; Sheng, Z; Zou, Y, 2014) |
| "In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM)." | 4.90 | Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. ( Cavo, M; Davies, FE; Delforge, M; Dimopoulos, MA; Facon, T; Hansson, M; Leleu, X; Ludwig, H; Mateos, MV; Miguel, JF; Moreau, P; Morgan, GJ; Palumbo, A; Schey, SA; Sonneveld, P; Weisel, K; Zweegman, S, 2014) |
| " Randomised, controlled, phase 3 trials that recruited patients with newly diagnosed multiple myeloma between Jan 1, 2000, and Dec 15, 2012, and in which at least one group received lenalidomide were eligible for inclusion." | 4.90 | Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. ( Anderson, K; Barlogie, B; Boccadoro, M; Bringhen, S; Cavo, M; Ciccone, G; Dimopoulos, MA; Evangelista, A; Hajek, R; Kumar, SK; Larocca, A; Lonial, S; Lupparelli, G; McCarthy, PL; Musto, P; Nooka, AK; Offidani, M; Palumbo, A; Petrucci, MT; Richardson, P; Sonneveld, P; Spencer, A; Usmani, S; van der Holt, B; Waage, A; Zweegman, S, 2014) |
| "Oral pomalidomide (Imnovid® [EU]; Pomalyst® [USA]) in combination with dexamethasone (in the EU), is approved in several countries for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy (or progression within the last 60 days in the USA)." | 4.90 | Pomalidomide: a review of its use in patients with recurrent multiple myeloma. ( Scott, LJ, 2014) |
| "Despite the introduction of novel agents, such as thalidomide, lenalidomide and bortezomib, multiple myeloma (MM) remains an incurable disease and new therapies are needed." | 4.90 | Monoclonal antibodies currently in Phase II and III trials for multiple myeloma. ( Bringhen, S; Donato, F; Gay, F; Palumbo, A; Troia, R, 2014) |
| "Lenalidomide is an immunomodulatory drug (IMiD), which is well established and approved in the treatment of multiple myeloma (MM) and 5q-myelodysplastic syndrome (MDS)." | 4.90 | Lenalidomide. ( Kanz, L; Weisel, K, 2014) |
| "The pharmacology, pharmacokinetics, clinical efficacy, safety, dosage and administration, and place in therapy of pomalidomide for the management of refractory multiple myeloma are reviewed." | 4.90 | Pomalidomide for the management of refractory multiple myeloma. ( Cole, SW; Olin, JL; Summers, BB, 2014) |
| "Once characterized by a very poor outcome, multiple myeloma (MM) now has a significantly prolonged survival, with major improvements allowed by the use of 'novel agents': proteasome inhibitors (first-in-class bortezomib) and immunomodulatory compounds (IMiDs; first-in-class thalidomide and lenalidomide)." | 4.90 | Pomalidomide for multiple myeloma. ( Bories, C; Facon, T; Fouquet, G; Guidez, S; Herbaux, C; Javed, S; Leleu, X; Renaud, L, 2014) |
| "The outcomes and management of multiple myeloma (MM) in the United States have changed dramatically over the past 15 years with the approval by the US Food and Drug Administration (FDA) of 6 new drugs (thalidomide, lenalidomide, bortezomib, pegylated liposomal doxorubicin [Doxil], carfilzomib, and pomalidomide)." | 4.90 | Novel drug combinations for the management of relapsed/refractory multiple myeloma. ( Lonial, S; Usmani, SZ, 2014) |
| "The development of novel therapeutic agents over the past decade, including the proteasome inhibitor, bortezomib, and the immunomodulatory drugs, lenalidomide and thalidomide, has resulted in improved outcomes for patients with multiple myeloma." | 4.89 | Current approaches for the treatment of multiple myeloma. ( Kizaki, M; Tokuhira, M; Watanabe, R, 2013) |
| "To examine the role of novel agents such as bortezomib, lenalidomide, and thalidomide as continuous therapy (induction and consolidation/maintenance) in the treatment of newly diagnosed patients with multiple myeloma, we carried out a meta-analysis of randomized-controlled trials." | 4.89 | Continuous treatment with new agents for newly diagnosed multiple myeloma. ( Lu, H; Sheng, Z; Yu, J; Zou, Y, 2013) |
| "Many advances in the treatment of multiple myeloma have been made due to the use of transplantation and the introduction of novel agents including thalidomide, lenalidomide, and bortezomib." | 4.89 | Diagnosis and therapy of multiple myeloma. ( Cerrato, C; Palumbo, A, 2013) |
| "In recent years, a number of randomized controlled trials (RCTs) have reported on lenalidomide as a treatment for multiple myeloma (MM)." | 4.89 | Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. ( Chi, XH; Lu, XC; Yang, B; Yu, RL, 2013) |
| "Thalidomide, the first clinically available immunomodulatory drug, reaches monotherapy treatment response in about 1/ 3 of significantly pretreated patients with multiple myeloma, and in combination with glucocorticoids approximately 50% response rate." | 4.89 | [Thalidomide in the treatment of multiple myeloma: focus on combination with bortezomib]. ( Gumulec, J; Hájek, R; Plonková, H, 2013) |
| "Lenalidomide is indicated for treatment of multiple myeloma in combination with dexamethasone and as a single agent in myelodysplastic syndromes." | 4.89 | Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis. ( Garden, BC; Lacouture, ME; Nardone, B; Reich, LM; West, DP; Wu, S, 2013) |
| "New treatment options are urgently needed for patients with relapsed multiple myeloma (MM) who are refractory to thalidomide, lenalidomide, and bortezomib therapy." | 4.89 | Pomalidomide: new immunomodulatory agent with potent antiproliferative effects. ( Lacy, MQ; Mark, TM; Richardson, PG, 2013) |
| "Widespread use of the novel agents bortezomib and lenalidomide has improved outcomes in multiple myeloma (MM)." | 4.89 | Management of double-refractory multiple myeloma. ( Mark, TM; Meadows, JP, 2013) |
| "Treatment with melphalan-prednisone-thalidomide improves the outcome of patients with multiple myeloma and is now considered a standard of care for patients not eligible for transplantation." | 4.89 | Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. ( Baldi, I; Beksac, M; Boccadoro, M; Ciccone, G; Galli, M; Gay, F; Gimsing, P; Hulin, C; Juliusson, G; Kolb, B; Leleu, X; Lokhorst, H; Palumbo, A; Pégourié, B; Pezzatti, S; Rodon, P; Rolke, J; Schaafsma, M; Sonneveld, P; Sucak, G; Turesson, I; van der Holt, B; Waage, A; Wetterwald, M; Wijermans, P; Zweegman, S, 2013) |
| "Although several mechanisms have been proposed to explain the activity of thalidomide, lenalidomide and pomalidomide in multiple myeloma (MM), including demonstrable anti-angiogenic, anti-proliferative and immunomodulatory effects, the precise cellular targets and molecular mechanisms have only recently become clear." | 4.89 | Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. ( Kortuem, KM; Stewart, AK; Zhu, YX, 2013) |
| "Many advances were made in the treatment of multiple myeloma since the introduction of the immunomodulatory drugs thalidomide and lenalidomide and the proteasome inhibitor bortezomib." | 4.89 | Part II: role of maintenance therapy in transplant-ineligible patients. ( Mina, R; Palumbo, A, 2013) |
| " Here, we describe a patient with SJS while receiving lenalidomide in combination with prednisolone for treatment-naïve multiple myeloma." | 4.88 | Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options. ( Allegra, A; Alonci, A; Catena, S; D'Angelo, A; Gerace, D; Greve, B; Musolino, C; Penna, G; Russo, S, 2012) |
| "To investigate the effect of novel agents like bortezomib, lenalidomide and thalidomide as part of induction treatment prior to autologous stem-cell transplantation (ASCT) for previously untreated patients with multiple myeloma, we performed a meta-analysis of randomized controlled trials (RCTs)." | 4.88 | Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. ( Liu, L; Ran, X; Sheng, Z; Wang, B; Wang, L, 2012) |
| "Lenalidomide is an IMiDs® oral immunomodulatory compound developed for the treatment of patients with multiple myeloma (MM) and myelodysplastic syndromes (MDS)." | 4.88 | The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes. ( Fenaux, P; Freeman, J; Palumbo, A; Weiss, L, 2012) |
| "To define whether or not thalidomide exposure upfront to newly diagnosed patients with multiple myeloma would adversely impact postrelapse survival (PRS), we performed a meta-analysis of randomized controlled trials." | 4.88 | Postrelapse survival rate correlates with first-line treatment strategy with thalidomide in patients with newly diagnosed multiple myeloma: a meta-analysis. ( Cui, J; Liu, L; Sheng, Z; Wang, L, 2012) |
| "Lenalidomide in combination with dexamethasone is approved by the US Food and Drug Administration and the European Medicines Agency for the second-line treatment of patients with multiple myeloma." | 4.88 | Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide. ( Esteves, GV; Mariz, JM, 2012) |
| "In a retrospective pooled analysis of 11 clinical trials of lenalidomide-based therapy for relapsed/refractory multiple myeloma (MM; N = 3846), the overall incidence rate (IR, events per 100 patient-years) of second primary malignancies (SPMs) was 3." | 4.88 | A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. ( Brandenburg, N; Dimopoulos, MA; Morgan, GJ; Niesvizky, R; Richardson, PG; Weber, DM; Yu, Z, 2012) |
| "Thrombosis is a frequent feature in individuals with myeloma, particularly those treated with oral immunomodulatory drugs (IMID) such as thalidomide or lenalidomide concomitantly with anthracyclines or dexamethasone." | 4.88 | Thrombosis in multiple myeloma (MM). ( Braggio, E; Cesarman-Maus, G; Fonseca, R, 2012) |
| "We performed a meta-analysis of randomized controlled trials comparing thalidomide maintenance with other regimens after induction chemotherapy for multiple myeloma." | 4.88 | Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis. ( Kagoya, Y; Kurokawa, M; Nannya, Y, 2012) |
| "The clinical development of lenalidomide (Revlimid™), then pomalidomide (Actimid™) as members of immunomodulatory drugs (IMiDs) for the treatment of multiple myeloma (MM), exemplifies how insight into disease biology can lead to design of effective therapeutic agents." | 4.88 | Lenalidomide in multiple myeloma: Current status and future potential. ( Kalff, A; Quach, H; Spencer, A, 2012) |
| "Thalidomide and its one analogue, lenalidomide (CC5103 or revlimid) are recently approved for the treatment of multiple myeloma." | 4.88 | Thalidomide: chemistry, therapeutic potential and oxidative stress induced teratogenicity. ( Kumar, N; Sharma, U; Singh, B; Singh, C, 2012) |
| " Thalidomide is nowadays used for the treatment of several conditions including multiple myeloma (MM)." | 4.88 | Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature. ( Gonçalves, R; Lopes, J; Macedo, G; Sobrinho Simões, M; Vilas-Boas, F, 2012) |
| "Lenalidomide is an oral immunomodulatory drug, which was recently introduced for the treatment of multiple myeloma (MM)." | 4.88 | Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma. ( Boccadoro, M; Bringhen, S; Cerrato, C; Gay, F; Palumbo, A; Pautasso, C, 2012) |
| "Most patients with multiple myeloma in both the frontline and relapsed/refractory settings are now treated with a combination of dexamethasone with the proteasome inhibitor bortezomib and/or an immunomodulatory agent thalidomide or lenalidomide." | 4.88 | Multiple myeloma: improved outcomes with new therapeutic approaches. ( Berenson, JR; Eshaghian, S, 2012) |
| "Currently multiple antithrombotic agents are used for thalidomide thromboprophylaxis in multiple myeloma patients." | 4.88 | Thalidomide thromboprophylaxis in multiple myeloma: a review of current evidence. ( Alexander, M; Kirsa, S; Mellor, JD, 2012) |
| "Novel agents such as thalidomide, bortezomib, and lenalidomide have improved outcomes and extended survival in patients with relapsed and/or refractory multiple myeloma (RRMM)." | 4.88 | Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy? ( Ludwig, H; Sonneveld, P, 2012) |
| "Thalidomide, lenalidomide, and bortezomib have considerably improved the survival of patients with multiple myeloma." | 4.88 | How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events. ( Mateos, MV, 2012) |
| "In the past decade we have seen four new agents approved by the US Food and Drug Administration for treatment of multiple myeloma: the proteasome inhibitor (PI) bortezomib (Velcade), the immunomodulatory agents lenalidomide (Revlimid) and thalidomide (Thalomid), and liposomal doxorubicin." | 4.87 | Treatment-related adverse events in patients with relapsed/refractory multiple myeloma. ( Vij, R, 2011) |
| "Immunomodulatory agents which include thalidomide and its analogue lenalidomide have recently emerged as an effective chemotherapy option for patients with Multiple Myeloma." | 4.87 | Thromboembolism with immunomodulatory agents in the treatment of multiple myeloma. ( Gajra, A; Singh, A, 2011) |
| "Trials comparing efficacy of melphalan prednisone (MP) with MP plus thalidomide in transplant ineligible, elderly patients with multiple myeloma have provided conflicting evidence." | 4.87 | Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. ( Dingli, D; Dispenzieri, A; Gertz, MA; Greipp, PR; Kapoor, P; Kumar, S; Kyle, RA; Lacy, MQ; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Roy, V, 2011) |
| "The incidence of venous thromboembolism (VTE) in patients with multiple myeloma (MM) treated with thalidomide- and lenalidomide-based regimens is high." | 4.87 | Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. ( Carrier, M; Le Gal, G; Lee, AY; Tay, J; Wu, C, 2011) |
| "Bortezomib, thalidomide and lenalidomide can be aimed at treating patients with newly diagnosed multiple myeloma (both eligible and ineligible for transplantation) as well as those with relapsed or refractory disease." | 4.87 | The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information. ( Bosi, A; Maratea, D; Messori, A; Nozzoli, C, 2011) |
| "The introduction of new agents in the treatment of multiple myeloma, such as thalidomide, bortezomib, or lenalidomide, has represented an important step forward in the management of this disease, with improvement in both treatment response and patient survival." | 4.87 | Management of the adverse effects of lenalidomide in multiple myeloma. ( González Rodríguez, AP, 2011) |
| "The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved." | 4.87 | Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. ( Beksac, M; Bladé, J; Cavenagh, J; Cavo, M; Delforge, M; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Harousseau, JL; Hess, U; Kropff, M; Leal da Costa, F; Louw, V; Ludwig, H; Magen-Nativ, H; Mendeleeva, L; Nahi, H; Palumbo, A; Plesner, T; San-Miguel, J; Sondergeld, P; Sonneveld, P; Udvardy, M, 2011) |
| "In several countries, including the US and in Europe, oral lenalidomide in combination with oral dexamethasone is approved for the treatment of multiple myeloma patients (aged ≥ 18 years) who have received at least one prior antimyeloma therapy." | 4.87 | Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. ( Lyseng-Williamson, KA; Scott, LJ, 2011) |
| "The current standard of care for elderly patients with newly diagnosed multiple myeloma is melphalan and prednisone (MP) in combination with either bortezomib (VMP) or thalidomide (MPT), with lenalidomide plus dexamethasone increasingly being employed." | 4.87 | Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients? ( Bringhen, S; Mateos, MV; Palumbo, A; San Miguel, JF, 2011) |
| "The role of thalidomide for previously untreated elderly patients with multiple myeloma remains unclear." | 4.87 | Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. ( Beksaç, M; Benboubker, L; Bringhen, S; Caravita, T; Facon, T; Fayers, PM; Gimsing, P; Haznedar, R; Hulin, C; Mary, JY; Moreau, P; Musto, P; Palumbo, A; Schaafsma, M; Sonneveld, P; Termorshuizen, F; Turesson, I; Waage, A; Wijermans, P, 2011) |
| " With the introduction of the immunomodulatory drugs thalidomide and lenalidomide, a novel class of compounds was integrated into therapy of multiple myeloma." | 4.87 | Continuous treatment in multiple myeloma - ready for prime time? ( Knop, S, 2011) |
| "In several countries, including the US and in Europe, oral lenalidomide in combination with oral dexamethasone is approved for the treatment of multiple myeloma patients (aged ≥18 years) who have received at least one prior antimyeloma therapy." | 4.87 | Spotlight on lenalidomide in relapsed or refractory multiple myeloma. ( Lyseng-Williamson, KA; Scott, LJ, 2011) |
| "After decades of disuse because of its teratogenic effects, thalidomide has had a resurgence of use as a promising therapeutic agent for multiple myeloma." | 4.86 | Palliative oncology: thalidomide. ( Prommer, EE, 2010) |
| "lenalidomide is a thalidomide analogue approved for treatment of myelodysplastic syndromes (MDS) associated with a cytogenetic 5q deletion." | 4.86 | The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes. ( Bonkowski, J; Kolesar, JM; Vermeulen, LC, 2010) |
| "The management of multiple myeloma has benefited substantially from the introduction of three new drugs, namely, the proteasome inhibitor bortezomib and the immunomodulators thalidomide and lenalidomide." | 4.86 | New treatments for myeloma. ( Azaïs, I; Brault, R; Debiais, F, 2010) |
| "Lenalidomide and other new agents are improving survival of multiple myeloma patients." | 4.86 | Lenalidomide in multiple myeloma: current role and future directions. ( Bizzari, JP; Jacques, C; Knight, RD; Tozer, A; Zeldis, JB, 2010) |
| "Lenalidomide is a promising new drug in the treatment of patients with multiple myeloma." | 4.86 | [The use of lenalidomide in the treatment of multiple myeloma]. ( Hájek, R; Holánek, M, 2010) |
| "The introduction of novel antimyeloma therapies, including thalidomide, lenalidomide and bortezomib, has expanded treatment options for patients with multiple myeloma." | 4.86 | Management of treatment-related adverse events in patients with multiple myeloma. ( Mateos, MV, 2010) |
| "In the last decade, the novel agents lenalidomide, bortezomib, and thalidomide have dramatically improved outcomes for patients with multiple myeloma (MM)." | 4.86 | Development of target-specific treatments in multiple myeloma. ( Borrello, I; Chanan-Khan, AA; Lee, KP; Reece, DE, 2010) |
| "To estimate the cost-effectiveness of bortezomib (BTZ) compared with dexamethasone (DEX) and lenalidomide plus dexamethasone (LEN/DEX) for the treatment of relapsed/refractory multiple myeloma in Sweden." | 4.86 | The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. ( Aschan, J; Dhawan, R; Hornberger, J; Liwing, J; Löthgren, M; Rickert, J, 2010) |
| "Introduction of the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and lenalidomide has substantially improved outcomes for patients with multiple myeloma." | 4.86 | Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. ( Bladé, J; Delforge, M; Dimopoulos, MA; Facon, T; Kropff, M; Ludwig, H; Palumbo, A; San-Miguel, JF; Sonneveld, P; Van Damme, P, 2010) |
| "The introduction of new drugs such as thalidomide, lenalidomide, and bortezomib has led to novel treatment strategies and significantly improved the outcome of patients with multiple myeloma (MM)." | 4.86 | Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials. ( Ballanti, S; Corvatta, L; Gentili, S; Gozzetti, A; Leoni, P; Liberati, AM; Nozzoli, C; Offidani, M; Palumbo, A; Polloni, C; Pulini, S, 2010) |
| "Until recently, standard treatment of multiple myeloma (MM) in elderly patients who were not candidates for autologous stem cell transplantation was with the combination of melphalan plus prednisone (MP)." | 4.86 | Multiple myeloma in the elderly: when to treat, when to go to transplant. ( Harousseau, JL, 2010) |
| "Recent studies have shown a clinical benefit of lenalidomide, an oral immunomodulatory drug, plus dexamethasone in patients with relapsed/refractory multiple myeloma (MM)." | 4.85 | Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. ( Attal, M; Dimopoulos, M; Harousseau, JL; Hussein, M; Knop, S; Ludwig, H; Palumbo, A; San Miguel, J; Sonneveld, P; von Lilienfeld-Toal, M, 2009) |
| "The introduction of thalidomide, bortezomib and lenalidomide has dramatically changed the treatment paradigm of multiple myeloma (MM)." | 4.85 | Treatment of newly diagnosed myeloma. ( Palumbo, A; Rajkumar, SV, 2009) |
| "Thalidomide and its derivatives represent a new class of antineoplastic drugs (IMiDs), which has been especially effective in certain hematologic malignancies." | 4.85 | Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs). ( Wiernik, PH, 2009) |
| "A PubMed search (1980-June 2008) restricted to English-language publications was conducted using the key words multiple myeloma, clinical trials, targeted therapy, thalidomide, lenalidomide, bortezomib, dexamethasone, melphalan, autologous stem-cell transplantation, and tumor biology." | 4.85 | Treatment of multiple myeloma in the targeted therapy era. ( Higa, GM; Saad, AA; Sharma, M, 2009) |
| "The development of three novel chemotherapeutic agents - thalidomide, lenalidomide, and bortezomib - has resulted in a fundamental shift in the management of multiple myeloma." | 4.85 | Initial therapy in multiple myeloma: investigating the new treatment paradigm. ( Baker, RD; Finkbiner, KL; Henry, DW; Kettle, JK; Klenke, SE; Williams, CB, 2009) |
| "Treatment strategies for multiple myeloma have changed substantially over the past 10 years following the introduction of bortezomib and the immunomodulatory drugs thalidomide and lenalidomide." | 4.85 | Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. ( Cavenagh, J; Lonial, S, 2009) |
| "Although the increased risk of venous thrombotic events with thalidomide in multiple myeloma (MM) has been well described, an association with an increased risk of arterial events is less well appreciated." | 4.85 | Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature. ( Martin, MG; Vij, R, 2009) |
| "Thalidomide and bortezomib are remarkably efficacious in the treatment of multiple myeloma." | 4.85 | Multiple myeloma, painful neuropathy, acupuncture? ( Chang, DZ; Chiang, J; Delasalle, K; Fang, W; Forman, A; Garcia, MK; Guo, Y; Lu, J; Romaguera, J; Wang, M; Yi, Q; Zhou, Y, 2009) |
| "Lenalidomide, a derivate of thalidomide, has recently been approved in Europe for the treatment of patients with multiple myeloma." | 4.84 | Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates. ( Gieseler, F, 2008) |
| "Until 2007, frontline chemotherapy with melphalan and prednisone (MP) was considered as the standard of care in the treatment of elderly patients with multiple myeloma (MM)." | 4.84 | Frontline treatment of multiple myeloma in elderly patients. ( Facon, T; Hulin, C; Moreau, P, 2008) |
| " Thalidomide, lenalidomide and bortezomib have all been shown to be highly effective in multiple myeloma, and JAK2-inhibitors have entered phase II studies of patients with JAK2-positive primary myelofibrosis and related diseases." | 4.84 | [Novel medical treatment modalities in hematology]. ( Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A, 2008) |
| "After the tragic events in the early 1960s, thalidomide has re-emerged as therapeutic for multiple myeloma (MM)." | 4.84 | Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity. ( Anderson, KC; Breitkreutz, I, 2008) |
| "Thalidomide monotherapy in relapsed/refractory multiple myeloma (MM) has a response rate of 30%." | 4.84 | A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. ( Bargou, R; Cook, G; Furkert, K; Glasmacher, A; Hahn-Ast, C; Hoffmann, F; Naumann, R; von Lilienfeld-Toal, M, 2008) |
| "During the past decade new multiple myeloma therapies featuring bortezomib and lenalidomide have come to light, whereas known agents such as thalidomide and arsenic trioxide have been reintroduced as key factors in multiple myeloma management." | 4.84 | New drugs in multiple myeloma. ( Berenson, JR; Yellin, O, 2008) |
| "Thalidomide represents one of the most relevant therapeutic advances for patients with multiple myeloma over the last 10 years." | 4.84 | Role of thalidomide in previously untreated patients with multiple myeloma. ( Boccadoro, M; Bringhen, S; D'Auria, F; Di Raimondo, F; Morabito, F; Musto, P; Palumbo, A; Pietrantuono, G; Pozzi, S; Sacchi, S, 2008) |
| "Lenalidomide, an analog of thalidomide, is an effective new treatment for multiple myeloma." | 4.84 | Risk of thrombosis with lenalidomide and its prevention with aspirin. ( Hirsh, J, 2007) |
| "Given that the efficacy/safety of thalidomide for relapsed or refractory multiple myeloma have not been well characterized in a randomized, controlled setting, an analysis of larger, single-agent trials was conducted." | 4.84 | An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. ( Mileshkin, L; Prince, HM; Schenkel, B, 2007) |
| "With the increase in the number of reports and trials on the use of thalidomide as a part of the treatment of different medical conditions, particularly multiple myeloma (MM), it was observed that this drug might be associated with an increase in the risk of venous thromboembolic (VTE) events." | 4.84 | Thalidomide and thrombosis. A meta-analysis. ( El Accaoui, RN; Shamseddeen, WA; Taher, AT, 2007) |
| "After decades of minimal progress, two new classes of drugs with novels mechanisms of action: immunomodulatory drugs (thalidomide and lenalidomide) and proteasome inhibitors (bortezomib) have shown great activity for the treatment of multiple myeloma." | 4.84 | [New treatment of multiple myeloma]. ( Hulin, C, 2007) |
| "Although multiple myeloma remains incurable with conventional treatments, management of the disease has recently been transformed with the introduction of three novel agents, bortezomib, thalidomide, and lenalidomide." | 4.84 | New drugs for myeloma. ( Anderson, K; Mitsiades, C; Munshi, N; Richardson, PG; Schlossman, R, 2007) |
| "Lenalidomide is a potent, novel thalidomide analog that has demonstrated promising clinical activity in patients with relapsed or refractory multiple myeloma (MM)." | 4.84 | Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma. ( Tariman, JD, 2007) |
| "The pharmacology, clinical use, adverse effects, dosage and administration, and cost of lenalidomide in the treatment of multiple myeloma (MM) are reviewed." | 4.84 | Lenalidomide in the treatment of multiple myeloma. ( Rao, KV, 2007) |
| "Thalidomide, lenalidomide and bortezomib have been approved for the treatment of relapsed or refractory multiple myeloma in the recent years." | 4.84 | Targeted treatments to improve stem cell outcome: old and new drugs. ( Anderson, KC; Breitkreutz, I; Raab, MS, 2007) |
| "Studies of bortezomib, thalidomide, and lenalidomide have shown promising clinical activity in relapsed/refractory multiple myeloma (MM)." | 4.84 | Management of relapsed and relapsed refractory myeloma. ( Dimopoulos, MA; Kastritis, E; Mitsiades, CS; Richardson, PG, 2007) |
| "We presented a patient suffered from stroke related to thalidomide therapy." | 4.84 | [Brief report: stroke in multiple myeloma patient treated with thalidomide]. ( Hashimoto, Y; Hirano, T; Ito, Y; Mori, A; Uchino, M; Yonemura, K, 2007) |
| "Immunomodulating agents such as thalidomide and its newly emerged derivative, lenalidomide, are becoming increasingly popular in the treatment of multiple myeloma because of their ability to combat drug resistance." | 4.84 | Multiple myeloma and treatment-related thromboembolism: oncology nurses' role in prevention, assessment, and diagnosis. ( Wiley, KE, 2007) |
| "The prognosis of patients with multiple myeloma has been improved in the last decade due to the induction of autologous stem cell transplantation and novel drugs including thalidomide, lenalidomide, and bortezomib into the treatment." | 4.84 | [Diagnosis and management guideline for multiple myeloma]. ( Handa, H; Murakami, H; Saitoh, T, 2007) |
| "The combination of the melphalan and prednisolone (MP) can induce objective responses in about 50% of patients with multiple myeloma (MM) since its introduction in 1960." | 4.84 | [Chemotherapy for multiple myeloma]. ( Ishida, T, 2007) |
| "Thalidomide is now regarded as one of the most promising salvage therapies for refractory or relapsed multiple myeloma." | 4.84 | [Application and safety of thalidomide in the treatment of multiple myeloma]. ( Hattori, Y, 2007) |
| "The proteasome inhibitor bortezomib is approved for the treatment of patients with relapsed/refractory multiple myeloma." | 4.84 | [Role of bortezomib in the treatment of multiple myeloma]. ( Gotoh, A; Ohyashiki, K, 2007) |
| " The risk of VTE is higher in multiple myeloma (MM) patients who receive thalidomide or lenalidomide, especially in combination with dexamethasone or chemotherapy." | 4.84 | Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. ( Anderson, KC; Attal, M; Barlogie, B; Belch, A; Bladé, J; Boccadoro, M; Bringhen, S; Cavo, M; Dimopoulos, MA; Durie, BG; Harousseau, J; Hussein, MA; Joshua, D; Knop, S; Kyle, R; Lonial, S; Ludwig, H; Morgan, GJ; Niesvizky, R; Orlowski, RZ; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Shimizu, K; Sonneveld, P; Vesole, D; von Lilienfeld-Toal, M; Waage, A; Weber, D; Westin, J; Zangari, M; Zonder, JA, 2008) |
| "Thalidomide and its analogue lenalidomide are potent anti-inflammatory, anti-angiogenic and immunomodulatory drugs, successfully used for the treatment of hematological cancers, in particular multiple myeloma (MM)." | 4.84 | Thalidomide and lenalidomide: Mechanism-based potential drug combinations. ( Anderson, KC; Boccadoro, M; Palumbo, A; Raje, N; Vallet, S, 2008) |
| "To evaluate lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome (MDS)." | 4.83 | Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome. ( Hammond, JM; Maier, SK, 2006) |
| "The activity of thalidomide in relapsed or refractory multiple myeloma is widely accepted but not yet demonstrated in a randomised-controlled trial." | 4.83 | A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. ( Glasmacher, A; Goldschmidt, H; Gorschlüter, M; Hahn, C; Hoffmann, F; Naumann, R; Orlopp, K; Schmidt-Wolf, I; von Lilienfeld-Toal, M, 2006) |
| "Although multiple myeloma (MM) is incurable with currently available treatments, the introduction of thalidomide and the development of safer and more active thalidomide analogues represent a major advance in the therapy of this disease." | 4.83 | Thalidomide and lenalidomide in the treatment of multiple myeloma. ( Kumar, S; Rajkumar, SV, 2006) |
| "Thalidomide has been demonstrated to be active as a first-line and salvage therapy in patients with multiple myeloma." | 4.83 | The role of thalidomide in multiple myeloma. ( Jagannath, S; Schwab, C, 2006) |
| "Although multiple myeloma (MM) remains an incurable disease, there has been a concerted effort toward understanding its molecular pathogenesis, which has paved the way for the development of highly effective, novel therapeutic agents such as the immunomodulatory agents thalidomide and lenalidomide, and the proteasome inhibitor bortezomib." | 4.83 | Emerging role of novel combinations for induction therapy in multiple myeloma. ( Orlowski, RZ; Voorhees, PM, 2006) |
| "Immunomodulatory drugs, such as thalidomide, lenalidomide (Revlimid, CC-5013) and actimid (CC-4047), have a broad spectrum of activity and have shown remarkable responses in patients with multiple myeloma and related hematological diseases, such as myelodysplastic syndrome." | 4.83 | Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma. ( Anderson, KC; Hideshima, T; Raje, N, 2006) |
| "Thalidomide was introduced in the treatment of multiple myeloma in the late 1990s." | 4.83 | Thalidomide in multiple myeloma: past, present and future. ( Harousseau, JL, 2006) |
| "To evaluate the literature regarding the dosing of thalidomide in multiple myeloma." | 4.82 | Thalidomide dosing in patients with relapsed or refractory multiple myeloma. ( Hansen, LA; Thompson, JL, 2003) |
| "In 1999, investigators reported promising results of a phase II study of thalidomide in patients with resistant multiple myeloma (MM)." | 4.82 | Treatment of plasma cell dyscrasias with thalidomide and its derivatives. ( Anagnostopoulos, A; Dimopoulos, MA; Weber, D, 2003) |
| "Both thalidomide and intermittent high-dose dexamethasone are agents with established activity against multiple myeloma." | 4.82 | Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. ( Alexanian, R; Anagnostopoulos, A; Delasalle, K; Rankin, K; Wang, M; Weber, D, 2003) |
| "Recently completed phase II trials and retrospective analyses conducted outside the United States, primarily in Europe and Australia, have confirmed results of landmark US trials that established the efficacy of thalidomide in multiple myeloma." | 4.82 | Thalidomide in relapsed/refractory multiple myeloma: pivotal trials conducted outside the United States. ( Anagnostopoulos, A; Dimopoulos, MA, 2003) |
| "Based on the activity of single-agent thalidomide demonstrated in relapsed or refractory multiple myeloma, investigators have evaluated the role of this agent in the treatment of earlier stage disease." | 4.82 | Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease. ( Rajkumar, SV, 2003) |
| "Thalidomide has shown promise in the treatment of newly diagnosed multiple myeloma and relapsed/refractory disease, but side effects such as somnolence, constipation, and neuropathy limit its use." | 4.82 | The role of immunomodulatory drugs in multiple myeloma. ( Anderson, KC, 2003) |
| "Based on the activity of single-agent thalidomide in relapsed/refractory multiple myeloma in a landmark phase II study of 169 patients conducted at the University of Arkansas for Medical Sciences (UAMS), UAMS initiated several trials of thalidomide and the more potent thalidomide analog CC-5013." | 4.82 | Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience. ( Barlogie, B, 2003) |
| " Thalidomide which has antiangiogenic effects and direct cytotoxic effects was found to be effective in multiple myeloma and is considered as an established treatment modality for patients with refractory or relapsed multiple myeloma." | 4.82 | Antiangiogenic therapy in hematologic malignancies. ( Goldschmidt, H; Hillengass, J; Ho, AD; Moehler, TM, 2004) |
| "We report the case of a 54-year-old African-American male with IgG multiple myeloma (MM) with disease resistant to multiple chemotherapy regimens and immunomodulatory treatment with thalidomide." | 4.82 | Unusual cutaneous involvement during plasma cell leukaemia phase in a multiple myeloma patient after treatment with thalidomide: a case report and review of the literature. ( Alexandrescu, DT; Koulova, L; Wiernik, PH, 2005) |
| "Thalidomide is effective in the treatment of multiple myeloma." | 4.82 | Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. ( Bartlett, JB; Stirling, D; Tozer, A; Zeldis, JB, 2005) |
| "Bortezomib is approved in the US and Europe as single-agent therapy for the treatment of relapsed or refractory multiple myeloma." | 4.82 | Overview of drug therapy for multiple myeloma. ( Saunders, G, 2005) |
| "Thalidomide--banned from clinical use in the 1960s because of severe teratogenicity--is now back in clinical practice as an effective agent in the treatment of relapsed and refractory multiple myeloma." | 4.81 | Thalidomide in the treatment of multiple myeloma. ( Rajkumar, SV, 2001) |
| "Thalidomide is the first drug in over 20 years to demonstrate clinically significant activity in patients with multiple myeloma." | 4.81 | Thalidomide for the treatment of relapsed and refractory multiple myeloma. ( Cool, RM; Herrington, JD, 2002) |
| "Thalidomide was first evaluated in patients with refractory multiple myeloma in the mid-90s." | 4.81 | Thalidomide treatment in multiple myeloma. ( Ludwig, H; Strasser, K, 2002) |
| "The efficacy of thalidomide at doses as low as 50 mg every other day was first reported at the VII International Multiple Myeloma Workshop in Stockholm, Sweden, in September 1999." | 4.81 | Low-dose thalidomide in myeloma: efficacy and biologic significance. ( Durie, BG, 2002) |
| "The discovery that multiple myeloma is associated with new vessel formation and is correlated with survival and proliferation led initially to the use of thalidomide for patients with relapsed or refractory disease." | 4.81 | Thalidomide in the management of multiple myeloma. ( Schey, SA, 2002) |
| "Thalidomide has recently been shown to have significant activity in refractory multiple myeloma (MM)." | 4.81 | Thalidomide in the management of multiple myeloma. ( Anaissie, E; Badros, A; Barlogie, B; Cromer, J; Fassas, A; Spencer, T; Tricot, G; Zangari, M, 2001) |
| " When all conventional therapy has failed, an angiogenesis inhibitor may be successfully used alone, as has been demonstrated in the treatment of multiple myeloma by thalidomide." | 4.81 | Angiogenesis-dependent diseases. ( Folkman, J, 2001) |
| "A phase II trial of thalidomide in refractory multiple myeloma was initiated using a dose schedule that escalated from 200 mg/d to 800 mg/d." | 4.81 | Thalidomide in the management of multiple myeloma. ( Anaissie, E; Barlogie, B; Tricot, G, 2001) |
| "Treatment with thalidomide and dexamethasone was given to 26 patients with active, previously untreated multiple myeloma (MM)." | 4.81 | Therapeutic application of thalidomide in multiple myeloma. ( Kyle, RA; Rajkumar, SV, 2001) |
| "Melphalan was the first described treatment for patients with multiple myeloma in the 1960s and is still being used in clinical practice." | 4.81 | Treatment of myeloma: recent developments. ( Huijgens, PC; Zweegman, S, 2002) |
| "A man in his late 60s who had received the first cycle of a chemotherapeutic regimen of ixazomib, lenalidomide, and dexamethasone for multiple myeloma presented to the dermatologic clinic with a 10-day history of fever and tender lesions on the neck and trunk." | 4.31 | Fever, Pancytopenia, and Tender Erythematous Plaques in a Patient With Multiple Myeloma. ( Katayama, S; Ota, M; Yamaga, M, 2023) |
| "We evaluated re-induction incorporating carfilzomib-thalidomide-dexamethasone (KTd) and autologous stem cell transplantation (ASCT) for newly diagnosed multiple myeloma (NDMM) refractory, or demonstrating a suboptimal response, to non-IMID bortezomib-based induction." | 4.31 | Response adaptive salvage with KTd and ASCT for functional high-risk multiple myeloma-The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial. ( Horvath, N; Kalff, A; Kerridge, I; Khong, T; Lee, E; Morris, E; Quach, H; Reynolds, J; Spencer, A; Turner, R, 2023) |
| "Objective To evaluate the safety profile of ixazomib combined with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) in clinical practice in Japan through an all-case post-marketing surveillance." | 4.12 | Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance. ( Chou, T; Hashimoto, M; Hiraizumi, M; Hoshino, M; Kakimoto, Y; Shimizu, K, 2022) |
| "Addition of isatuximab (Isa) to pomalidomide/dexamethasone (Pd) significantly improved progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma (RRMM)." | 4.12 | Joint modelling and simulation of M-protein dynamics and progression-free survival for alternative isatuximab dosing with pomalidomide/dexamethasone. ( Ayral, G; Cerou, M; Fau, JB; Gaudel, N; Sebastien, B; Semiond, D; Thai, HT; van de Velde, H; Veyrat-Follet, C, 2022) |
| "Biomarkers that predict response to lenalidomide maintenance therapy in patients with multiple myeloma (MM) have remained elusive." | 4.12 | MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma. ( Bassermann, F; Bertsch, U; Eichner, R; Emde-Rajaratnam, M; Goldschmidt, H; Heider, M; Hose, D; Keller, U; Rudelius, M; Salwender, H; Scheid, C; Schick, M; Seckinger, A; Slawska, J; Stroh, J; Weisel, K, 2022) |
| "In the phase 3 APOLLO trial, daratumumab in combination with pomalidomide and dexamethasone (D-Pd) significantly reduced the rate of disease progression or death by 37% relative to Pd alone in patients with relapsed/refractory multiple myeloma (RRMM) who had received ≥1 prior line of therapy including lenalidomide and a proteasome inhibitor." | 4.12 | Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial. ( Amin, H; Beksac, M; Bila, J; Boccadoro, M; Carson, R; Delimpasi, S; Dimopoulos, MA; Einsele, H; Fastenau, J; Gries, KS; He, J; Kampfenkel, T; Katodritou, E; Liu, K; Mateos, MV; Moreau, P; Orfanidis, I; Oriol, A; Pompa, A; Qiu, Y; Sonneveld, P; Symeonidis, A; Terpos, E, 2022) |
| "In cohort C of the phase 2 MM-014 trial, the efficacy and safety of pomalidomide, dexamethasone, and daratumumab therapy were investigated in 18 Japanese patients with relapsed/refractory multiple myeloma (RRMM) after their most recent regimen of lenalidomide-based therapy (NCT01946477)." | 4.12 | Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment. ( Chung, W; Iida, S; Iwasaki, H; Kuroda, J; Kuwayama, S; Lee, K; Matsue, K; Matsumoto, M; Nishio, M; Sugiura, I; Sunami, K, 2022) |
| "Triplet regimens, such as lenalidomide, bortezomib, and dexamethasone (RVd) or thalidomide, bortezomib, and dexamethasone (VTd), are standard induction therapies for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM)." | 4.12 | Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma. ( Ashizawa, M; Fujiwara, SI; Fukui, Y; Hatano, K; Ikeda, T; Ito, S; Kanda, Y; Kawaguchi, SI; Koyama, S; Matsuoka, S; Minakata, D; Morita, K; Murahashi, R; Nagayama, T; Nakano, H; Nakashima, H; Ohmine, K; Sato, K; Sekiguchi, K; Toda, Y; Ueda, M; Umino, K; Yamamoto, C; Yamasaki, R, 2022) |
| " Pomalidomide, a kind of immunomodulatory drug, is widely used for the treatment of relapsed or refractory multiple myeloma and could be administered without dose modification in patients with renal dysfunction." | 4.12 | Successful Treatment of the TEMPI Syndrome with Pomalidomide Plus Dexamethasone Followed by Autologous Stem Cell Transplantation. ( Akahoshi, Y; Gomyo, A; Kako, S; Kameda, K; Kanda, Y; Kawamura, M; Kawamura, S; Kimura, SI; Kusuda, M; Matsumi, S; Misaki, Y; Nakamura, Y; Nakasone, H; Okada, Y; Takeshita, J; Tamaki, M; Tanihara, A; Yoshimura, K; Yoshino, N, 2022) |
| "The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple myeloma (RRMM)." | 4.12 | Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials. ( Antonioli, E; Ballanti, S; Belotti, A; Boccadoro, M; Bonalumi, A; Botta, C; Bringhen, S; Brunori, M; Bruzzese, A; Califano, C; Cascavilla, N; Cavo, M; Cerchione, C; Consoli, U; Conticello, C; Criscuolo, C; Cupelli, L; Curci, P; De Stefano, V; Derudas, D; Di Raimondo, F; Di Renzo, N; Farina, G; Frigeri, F; Gagliardi, A; Galli, M; Gamberi, B; Gangemi, D; Gentile, M; Giuliani, N; Iaccino, E; Lombardo, A; Mangiacavalli, S; Marcacci, G; Martino, EA; Martino, M; Mele, G; Mendicino, F; Mimmi, S; Morabito, F; Musto, P; Neri, A; Offidani, M; Palmieri, S; Palumbo, G; Patriarca, F; Petrucci, MT; Pietrantuono, G; Pompa, A; Ria, R; Rocco, S; Rossi, E; Sgherza, N; Stocchi, R; Tripepi, G; Uccello, G; Vigna, E; Vincelli, D; Zamagni, E; Zambello, R, 2022) |
| "In the pivotal phase III, randomized, multicenter ICARIA-MM study (NCT02990338), isatuximab plus pomalidomide and dexamethasone (Isa-Pd) improved progression-free survival and overall response rate versus pomalidomide and dexamethasone (Pd) in the overall population of patients with relapsed/refractory multiple myeloma." | 4.12 | Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis. ( Campana, F; Huang, SY; Iida, S; Ikeda, T; Iyama, S; Kaneko, H; Kim, JS; Kim, K; Koh, Y; Lee, JH; Lin, TL; Matsumoto, M; Min, CK; Shimazaki, C; Sunami, K; Suzuki, K; Tada, K; Uchiyama, M; Wang, MC; Yeh, SP, 2022) |
| "Lenalidomide is a synthetic analog of thalidomide formed by the removal of one keto group (plus the addition of an amino group); it has anti-tumor activities beneficial for the treatment of hematologic malignancies." | 4.12 | Low cerebrospinal fluid-to-plasma ratios of orally administered lenalidomide mediated by its low cell membrane permeability in patients with hematologic malignancies. ( Ando, K; Kamiya, Y; Machida, S; Murayama, N; Ogiya, D; Saito, R; Shiraiwa, S; Suzuki, R; Tazume, K; Yamazaki, H, 2022) |
| "The phase 3 APOLLO study demonstrated significantly better progression-free survival (PFS) and clinical responses with daratumumab, pomalidomide, and dexamethasone (D-Pd) versus pomalidomide and dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM)." | 4.12 | Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma. ( Bathija, S; Berringer, H; Dwarakanathan, HR; He, J; Heeg, B; Johnston, S; Kampfenkel, T; Lam, A; Mackay, E; Mendes, J; Ruan, H, 2022) |
| "Lenalidomide (LEN) is increasingly being used for the treatment of multiple myeloma (MM)." | 4.02 | Delayed-onset cutaneous eruption associated with lenalidomide in setting of multiple myeloma. ( Buonomo, M; El Jurdi, N; Giubellino, A; Kabbur, G; Schultz, B, 2021) |
| " Here we demonstrated that DC vaccination in combination with pomalidomide and programmed death-ligand 1 (PD-L1) blockade inhibited tumor growth of a multiple myeloma (MM) mouse model." | 4.02 | Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma. ( Chu, TH; Jung, SH; Kim, HJ; Lakshmi, TJ; Lee, JJ; Park, HS; Vo, MC, 2021) |
| "The immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide are approved drugs for the treatment of multiple myeloma." | 4.02 | Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn ( Beilhack, A; Brandl, A; Köpff, S; Krönke, J; Lindner, S; Ng, YLD; Röhner, L; Scheffold, A, 2021) |
| "Lenalidomide is an important component of initial therapy in newly diagnosed multiple myeloma, either as maintenance therapy post-autologous stem cell transplantation (ASCT) or as first-line therapy with dexamethasone for patients' ineligible for ASCT (non-ASCT)." | 4.02 | Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada. ( Aslam, M; Atenafu, EG; Cherniawsky, H; Gul, E; Jimenez-Zepeda, VH; Kotb, R; LeBlanc, R; Louzada, ML; Masih-Khan, E; McCurdy, A; Reece, DE; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D, 2021) |
| "This study compared the use of bortezomib in different combination regimens in newly diagnosed multiple myeloma (NDMM) patients who were transplant ineligible." | 4.02 | Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. ( Brožová, L; Hájek, R; Heindorfer, A; Jelínek, T; Jungová, A; Kessler, P; Maisnar, V; Minařík, J; Pavlíček, P; Pika, T; Pour, L; Radocha, J; Sandecká, V; Ševčíková, S; Špička, I; Starostka, D; Stejskal, L; Štork, M; Straub, J; Sýkora, M; Ullrychová, J; Wróbel, M, 2021) |
| "A population pharmacokinetic (PPK) model to describe the pharmacokinetics of thalidomide in different patient populations was developed using data pooled from healthy subjects and patients with Hansen's disease, human immunodeficiency virus (HIV), and multiple myeloma (MM)." | 3.96 | Population Pharmacokinetic Model to Assess the Impact of Disease State on Thalidomide Pharmacokinetics. ( Chen, N; Gaudy, A; Hwang, R; Palmisano, M, 2020) |
| "This trial evaluated quality of life (QoL) using the EORTC QLQ-C30 and the EORTC QLQ-MY20 instruments in 90 patients with relapsed/refractory multiple myeloma during induction and maintenance therapy with eight cycles of ixazomib-thalidomide-dexamethasone, followed by 12 months of ixazomib maintenance therapy." | 3.96 | Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. ( Egle, A; Einsele, H; Greil, R; Gunsilius, E; Hajek, R; Hinke, A; Jelinek, T; Knop, S; Krenosz, KJ; Lechner, D; Ludwig, H; Meckl, A; Melchardt, T; Niederwieser, D; Nolte, S; Petzer, A; Pönisch, W; Pour, L; Rumpold, H; Schreder, M; Weisel, K; Willenbacher, W; Zojer, N, 2020) |
| "Pomalidomide is an immunomodulating agent that is used to treat relapsed and/or refractory multiple myeloma." | 3.96 | Pomalidomide desensitization for hypersensitivity: A case report. ( Cooper, DL; Huang, E; Kane, MP; Monteleone, CA; Park, JJ, 2020) |
| "For patients with multiple myeloma (MM) that relapsed after treatment with bortezomib- and lenalidomide-based regimens, there were no other treatment options in Korea until 2016." | 3.96 | Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study. ( Eom, HS; Jung, KS; Kim, HJ; Kim, JS; Kim, K; Kim, SH; Lee, JJ; Lee, JO; Min, CK; Shin, HJ, 2020) |
| "Pomalidomide, a derivative of thalidomide, is an effective treatment for multiple myeloma." | 3.96 | Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide. ( Fujii, S; Handa, H; Iida, M; Ito, T; Katayama, M; Sakamoto, S; Suwa, T; Tateno, S; Tokuyama, H; Yamaguchi, Y; Yamamoto, J, 2020) |
| " Argentinean Society of Hematology recommends bortezomib-based triplets for induction treatment of transplant eligible newly diagnosed multiple myeloma patients." | 3.96 | Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentin ( Corzo, A; Duarte, P; Fantl, D; Fernández, V; García, CA; Lopresti, S; Ochoa, P; Orlando, S; Quiroga, L; Remaggi, G; Schütz, NP; Shanley, C; Verri, V; Yantorno, S; Zabaljauregui, S, 2020) |
| "In the randomized phase-3 OPTIMISMM study, the addition of pomalidomide to bortezomib and low-dose dexamethasone (PVd) resulted in significant improvement in progression-free survival (PFS) in lenalidomide-pretreated patients with relapsed or refractory multiple myeloma (RRMM), including lenalidomide refractory patients." | 3.96 | Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. ( Anttila, P; Basu, S; Ben-Yehuda, D; Biyukov, T; Byeff, P; Cascavilla, N; Dhanasiri, S; Dimopoulos, M; Grote, L; Guo, S; Hayden, PJ; Hus, M; Johnson, P; Kanate, AS; Krauth, MT; Larocca, A; Lucio, P; Mendeleeva, L; Moreau, P; Muelduer, E; Richardson, P; Rodríguez-Otero, P; Vural, F; Weisel, K; Yagci, M; Yu, X, 2020) |
| "Although there are several case reports of progressive multifocal leukoencephalopathy (PML) in multiple myeloma (MM), there are few reports of cases associated with pomalidomide." | 3.96 | Pomalidomide-associated progressive multifocal leukoencephalopathy in multiple myeloma: cortical susceptibility-weighted imaging hypointense findings prior to clinical deterioration. ( Ichinohe, T; Ishibashi, H; Kikumto, M; Maruyama, H; Nakamichi, K; Saijo, M; Takahashi, T; Takebayashi, Y; Ueno, H; Umemoto, K; Yasutomi, H, 2020) |
| " The aim of the study was to assess the value of NLR and PLR in predicting the effects of therapy and prognosis in multiple myeloma patients treated with thalidomide-based regimen." | 3.96 | Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen. ( Filip, A; Homa-Mlak, I; Hus, M; Kuśmierczuk, K; Małecka-Massalska, T; Mielnik, M; Mlak, R; Nowaczyńska, A; Sompor, J; Szczyrek, M; Szudy-Szczyrek, A; Zmorzyński, S, 2020) |
| "Lenalidomide is a backbone agent in the treatment of multiple myeloma, but dose adjustment is required for those with renal impairment (RI)." | 3.96 | An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines. ( Cao, Y; Chen, CI; Chen, E; Chen, H; Kakar, S; Kukreti, V; Lau, A; Le, LW; Levina, O; Paul, H; Prica, A; Reece, DE; Tiedemann, R; Trudel, S, 2020) |
| "To compare the efficacy and side effect profile of different bortezomib-based triplet regimens for remission induction in patients with multiple myeloma (MM)." | 3.96 | Bortezomib-based Triplet Regimens for Remission Induction in Multiple Myeloma. ( Iftikhar, R; Mahmood, SK; Rehman, JU; Satti, TM; Shamshad, GU; Toor, SH, 2020) |
| " Here, we report eight patients with multiple myeloma that underwent immunomodulatory therapies with daratumumab or lenalidomide-based combination treatments and one patient with smoldering multiple myeloma, all of which presented with symptomatic COVID-19." | 3.96 | Outcome of COVID-19 in multiple myeloma patients in relation to treatment. ( Alici, E; Gran, C; Ljunggren, HG; Nahi, H; Susek, KH, 2020) |
| "Longer survival in patients with multiple myeloma (MM) after treatment with novel agents (NA) such as thalidomide, bortezomib, and lenalidomide may be associated with increased risks of developing second primary malignancies (SPM)." | 3.96 | Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan. ( Hou, HA; Liu, Y; Qiu, H; Tang, CH, 2020) |
| "We investigated here the novel immunomodulation and anti-multiple myeloma (MM) function of T cells engaged by the bispecific T-cell engager molecule AMG 701, and further examined the impact of AMG 701 in combination with immunomodulatory drugs (IMiDs; lenalidomide and pomalidomide)." | 3.96 | The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. ( Anderson, KC; Arvedson, T; Cho, SF; Friedrich, M; Hsieh, PA; Li, Y; Lin, L; Matthes, K; Munshi, N; Tai, YT; Wahl, J; Wen, K; Xing, L; Yu, T, 2020) |
| "Addition of daratumumab to pomalidomide and low-dose dexamethasone (LoDEX) is a safe and effective combination for relapsed/refractory multiple myeloma treatment." | 3.96 | Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma. ( Agarwal, A; Amatangelo, MD; Bahlis, NJ; Chung, W; Neri, P; Parekh, S; Pierceall, WE; Rahman, A; Serbina, N; Siegel, DS; Thakurta, A; Van Oekelen, O; Young, M, 2020) |
| " The patient re-achieved molecular remission after resumption of imatinib, but his MGUS progressed to smoldering myeloma and he was eventually diagnosed with multiple myeloma (MM) and initiated on treatment for MM with thalidomide, bortezomib and dexamethasone." | 3.96 | Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient. ( Dourado, C; Gupta, S; Swaminathan, N, 2020) |
| " The results of single factor analysis showed that age, hypoproteinemia, severe anemia, paraplegia, renal injury, amyloidosis, complex karyotype, complete remission and thalidomide maintenance therapy were the factors affecting the prognosis of the patients (all P＜0." | 3.91 | [Effects of Clinical Characteristics, Laboratory Parameters and Treatment Regimens on Prognosis of Patients with Multiple Myeloma]. ( Chen, Y; Chen, ZL; Hu, M; Su, GH; Tao, S; Xu, L, 2019) |
| "In April 2017, the National Sanitary Surveillance Agency (ANVISA-Brazil) approved lenalidomide (LEN) for multiple myeloma (MM) and myelodysplastic syndrome." | 3.91 | The tale of lenalidomide clinical superiority over thalidomide and regulatory and cost-effectiveness issues. ( Paumgartten, FJR, 2019) |
| "To gain insights into the characteristics of clinical resistance to lenalidomide, we evaluated the outcomes of 147 consecutive patients with multiple myeloma (MM) homogeneously treated with immunomodulatory imide drugs (IMiDs) pomalidomide and dexamethasone (Pd) for relapsed and/or refractory MM (median, 3 prior lines of treatment)." | 3.91 | Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. ( Delimpasi, S; Dialoupi, I; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Fotiou, D; Gavriatopoulou, M; Giannouli, S; Kanellias, N; Kastritis, E; Migkou, M; Mparmparousi, D; Ntanasis-Stathopoulos, I; Roussou, M; Spyropoulou-Vlachou, M; Terpos, E; Tsirigotis, P; Xirokosta, A; Ziogas, DC, 2019) |
| "To explore the effects of different concentration of pomalidomide on human multiple myeloma cell line MM1." | 3.91 | [Effect of Pomalidomide on Activity of Myeloma Cell Line MM1.S and Expression of CRBN]. ( Bai, H; Fan, WJ; Fan, ZQ; Pan, YZ; Yang, K; Yao, H; Yin, JJ; Zhao, XC, 2019) |
| "Thalidomide-and bortezomib-containing regimens are widely used for transplant-ineligible newly diagnosed multiple myeloma patients." | 3.91 | Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up. ( Adam, Z; Boichuk, I; Brozova, L; Krejci, M; Pour, L; Sandecká, V; Sevcikova, S; Stork, M, 2019) |
| "Lenalidomide and pomalidomide are two immunomodulatory medications with the potential to improve outcomes for patients with multiple myeloma; however, a black box warning for venous thromboembolism exists." | 3.91 | Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma. ( Anderson, SM; Beck, B; Lockhorst, R; Ngorsuraches, S; Sterud, S, 2019) |
| "We analyzed gene expression levels of CRBN, cMYC, IRF4, BLIMP1, and XBP1 in 224 patients with multiple myeloma treated with pomalidomide and low-dose dexamethasone in the STRATUS study (ClinicalTrials." | 3.91 | Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS. ( Amatangelo, M; Bjorklund, C; Dimopoulos, MA; Flynt, E; Moreau, P; Ocio, EM; Peluso, T; Qian, X; Sternas, L; Thakurta, A; Towfic, F; Weisel, KC; Yu, X; Zaki, M, 2019) |
| " Carfilzomib (Kyprolis™) is a new proteasome inhibitor that shows promise for the treatment of relapsing multiple myeloma." | 3.91 | Apremilast ameliorates carfilzomib-induced pulmonary inflammation and vascular injuries. ( Al-Harbi, MM; Al-Harbi, NO; Alanazi, AZ; Alhazzani, K; Aljerian, K; Alsanea, S; Belali, OM; Imam, F; Qamar, W, 2019) |
| "In conclusion, pomalidomide and dexamethasone has limited efficacy in patients with advanced MM and soft-tissue plasmacytomas." | 3.91 | Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma. ( Abella, E; Bladé, J; Cabezudo, E; Cibeira, MT; Clapés, V; Escoda, L; Fernández de Larrea, C; García-Guiñón, A; Gironella, M; Granell, M; Isola, I; Jiménez-Segura, R; López-Pardo, J; Oriol, A; Rosiñol, L; Soler, JA; Tovar, N, 2019) |
| "The treatment of multiple myeloma (MM) with proteasome inhibitor (PI) bortezomib has significantly improved the survival of patients with MM." | 3.91 | Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study. ( An, G; Deng, SH; Feng, XY; Li, ZJ; Liu, LT; Lv, R; Ma, YP; Qin, XQ; Qin, Y; Qiu, LG; Sui, WW; Wang, TY; Xu, Y; Yang, LH; Yang, WJ; Yi, SH; Zang, MR; Zhang, YR; Zhao, YZ; Zou, DH, 2019) |
| "Pomalidomide dexamethasone is a standard of care for relapsed multiple myeloma (MM) patients who received at least two prior lines of therapy, including both lenalidomide and proteasome inhibitors (PI)." | 3.91 | Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study. ( Blin, N; Bonnet, A; Chevallier, P; Dubruille, V; Garnier, A; Gastinne, T; Guillaume, T; Jullien, M; Le Bourgeois, A; Le Gouill, S; Lok, A; Mahé, B; Moreau, P; Peterlin, P; Tessoulin, B; Touzeau, C; Trudel, S, 2019) |
| "Thalidomide is commonly used in treatment of multiple myeloma (MM)." | 3.91 | Polymorphisms in the promotor region of the CRBN gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients. ( Chocholska, S; Homa-Mlak, I; Hus, M; Jankowska-Łęcka, O; Mazurek, M; Małecka-Massalska, T; Mielnik, M; Mlak, R; Szczyrek, M; Szudy-Szczyrek, A, 2019) |
| "The immunomodulatory drugs (IMiDs) thalidomide and its analogs, lenalidomide and pomalidomide, all FDA approved drugs for the treatment of multiple myeloma, induce ubiquitination and degradation of the lymphoid transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) via the cereblon (CRBN) E3 ubiquitin ligase for proteasomal degradation." | 3.91 | Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs. ( Gütschow, M; Kehm, H; Krönke, J; Lindner, S; Mangold, M; Steinebach, C, 2019) |
| "Bortezomib in combination with cyclophosphamide and dexamethasone (CyBorD, is a well-established frontline chemotherapy regimen for patients with multiple myeloma, but prospective data on elderly non-transplant eligible patients is limited." | 3.91 | Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data. ( Chai, K; Chan, H; Chen, K; Jackson, S; Lewsey, R; McDiarmid, B; Shih, S; Simpson, D, 2019) |
| "This phase Ib study evaluated oprozomib, an oral proteasome inhibitor, plus pomalidomide-dexamethasone in relapsed/refractory multiple myeloma (RRMM)." | 3.91 | Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma. ( Berdeja, JG; Berenson, JR; Chang, YL; Klippel, Z; Lyons, RM; Niesvizky, R; Rifkin, RM; Shah, J; Stadtmauer, EA; Usmani, S, 2019) |
| "The FIRST trial demonstrated that continuous therapy with lenalidomide and dexamethasone (Rd) prolongs overall survival (OS) and improves health-related quality of life (HRQoL) during the first 18 months of therapy in newly diagnosed multiple myeloma (NDMM) patients." | 3.88 | Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone. ( Delforge, M; Ervin-Haynes, A; Facon, T; Gibson, CJ; Guo, S; Song, K; Vogl, DT, 2018) |
| "Thalidomide and its derivatives, lenalidomide and pomalidomide (also known as IMiDs), have significantly changed the treatment landscape of multiple myeloma, and the recent discovery of cereblon (CRBN) as their direct biological target has led to a deeper understanding of their complex mechanism of action." | 3.88 | Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner. ( Asmar, F; Christensen, J; Dimopoulos, K; Fibiger Munch-Petersen, H; Gimsing, P; Grønbaek, K; Hermansen, NEU; Liang, G; O'Connel, C; Sjö, L; Sommer Kristensen, L; Søgaard Helbo, A, 2018) |
| "Daratumumab (a human CD38-directed monoclonal antibody) and pomalidomide (an immunomodulatory drug) plus dexamethasone are both relatively new treatment options for patients with heavily pretreated multiple myeloma." | 3.88 | Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison. ( Belch, A; Diels, J; Ito, T; Oriol, A; Van Sanden, S; Vogel, M, 2018) |
| "The combination of pomalidomide and low-dose dexamethasone (Pom-Dex) has proved effective and safe in patients with end-stage relapsed/refractory multiple myeloma (RRMM), otherwise characterized by a very poor outcome." | 3.88 | Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma. ( Araujo, C; Arnulf, B; Attal, M; Avet-Loiseau, H; Benboubker, L; Brechiniac, S; Caillot, D; Decaux, O; Dib, M; Escoffre-Barbe, M; Facon, T; Fermand, JP; Fouquet, G; Garderet, L; Hulin, C; Karlin, L; Kolb, B; Leleu, X; Macro, M; Mathiot, C; Moreau, P; Pegourie, B; Perrot, A; Petillon, MO; Richez, V; Rodon, P; Roussel, M; Royer, B; Stoppa, AM; Tiab, M; Wetterwald, M, 2018) |
| "Determinants of the efficacy and safety of pomalidomide (POM) monotherapy or POM plus dexamethasone (DEX) (POM/DEX) for relapsed and refractory multiple myeloma (RRMM) were examined retrospectively in a real-world clinical practice setting in Japan." | 3.88 | Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum. ( Fuchida, SI; Hino, M; Iida, M; Imada, K; Ishikawa, J; Kamitsuji, Y; Kanakura, Y; Kaneko, H; Kobayashi, M; Kosugi, S; Kuroda, J; Matsuda, M; Matsui, T; Matsumura, I; Matsumura-Kimoto, Y; Nakaya, A; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Takaori-Kondo, A; Tanaka, H; Uchiyama, H; Uoshima, N; Wada, K; Yagi, H; Yokota, I, 2018) |
| "To investigate the efficacy, safety, and cost of a pomalidomide-dexamethasone regimen in patients with relapsed and refractory multiple myeloma (RRMM)." | 3.88 | Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma. ( Aho, LS; Boulin, M; Caillot, D; Chretien, ML; Cransac-Miet, A; Favennec, C; Gueneau, P; Guy, J; Lafon, I, 2018) |
| "We presented a very rare case report describing the successful treatment of LCDD (λ chain)-induced nephrotic syndrome with lenalidomide." | 3.88 | Successful treatment of nephrotic syndrome induced by lambda light chain deposition disease using lenalidomide: A case report and review of the literature . ( Mima, A; Nagahara, D; Tansho, K, 2018) |
| "To explore the effects of thalidomide on the ratio of Th17 to Treg cells in peripheral blood and expression of IL-17 and IL-35 in patients with multiple myeloma(MM), so as to provide reference for the clinical treatment of patients with MM." | 3.88 | [Effects of Thalidomide on the Ratio of Th17 to Treg Cells in Peripheral Blood and Expression of IL-17 and IL-35 in Patients with Multiple Myeloma]. ( Gao, S; Li, X; Zhao, LJ, 2018) |
| "We performed analyses of the randomized phase 3 ASPIRE and ENDEAVOR trials to investigate the efficacy of carfilzomib among subgroups of relapsed or refractory multiple myeloma patients who had early or late disease relapse following initiation of the immediately prior therapy." | 3.88 | Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. ( Blaedel, J; DeCosta, L; Goldschmidt, H; Leleu, X; Mateos, MV; Mikhael, J; Obreja, M; San-Miguel, J; Szabo, Z; Zhou, L, 2018) |
| "The successful dexamethasone-free regimen clearly shows that dexamethasone is not a requisite component in treating multiple myeloma, and it can be substituted with clarithromycin." | 3.88 | A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report. ( Hoshino, K; Imai, G; Kojima, M; Ooi, A; Takemori, N, 2018) |
| "Lenalidomide, a thalidomide analogue, is an immunomodulatory drug currently used as a chemotherapeutic agent in treating certain hematologic malignancies, including multiple myeloma." | 3.88 | Severe Renal Allograft Rejection Resulting from Lenalidomide Therapy for Multiple Myeloma: Case Report. ( Adey, DB; Jen, KY; Laszik, ZG; Walavalkar, V, 2018) |
| "The immunomodulatory drugs (IMiDs) thalidomide, pomalidomide, and lenalidomide have been approved for the treatment of multiple myeloma for many years." | 3.88 | Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships. ( Burslem, GM; Crews, CM; Cromm, PM; Jaime-Figueroa, S; Morgan, A; Ottis, P; Toure, M, 2018) |
| "To study the clinical efficacy and safety of dexamethasone of different doses combined with bortezomib and thalidomide for treatment of primary multiple myeloma." | 3.88 | [Clinical Efficacy and Safety of Different Doses of Dexamethasone Combined with Bortezomib and Thalidomide for Treating Patients with Multiple Myeloma]. ( Fu, LP; Ji, Y; Li, CS; Zhang, WP, 2018) |
| " Current National Comprehensive Cancer Network guidelines give bortezomib-based combinations a central role in the management of multiple myeloma (MM)." | 3.88 | Bortezomib Prescription Pattern for the Treatment of Multiple Myeloma by Hematologists in Nigeria. ( Korubo, KI; Madu, AJ; Nwogoh, B; Okoye, HC, 2018) |
| "Pomalidomide, previously used to treat multiple myeloma, has been reported to cause acute pulmonary toxicity that improves with drug discontinuation." | 3.88 | Pulmonary toxicity associated with pomalidomide. ( Blanc, PD; Brown, JK; Callahan, EC; Elicker, B; Gajic, S; Ley, B, 2018) |
| "To evaluate the therapeutic effect and adverse reactions of the maintenance therapies with Thalidomine or Bortezomib in the patients with newly diagnosed multiple myeloma (MM), so as to provide a reference for clinical treatment." | 3.88 | [Clinical Analysis of Maintenance Therapy with Thalidomine and Bortezomib for Multiple Myeloma]. ( Wang, CY; Wang, L; Wang, XF; Wang, YF; Xia, B; Xu, YJ; Yang, HL; Yu, Y; Zhang, YZ; Zhao, HF, 2018) |
| "To explore the clinical effects of T-VD regimen (bortezomib+dexamethasone+thalidomid) and T-VAD regimen (vincristine+adriamycin+dexamethasone+thalidomide) on the patients with multiple myeloma(MM)." | 3.85 | [Clinical Effects of Different Chemotherapeutic Regimens on the Patients with Multiple Myeloma]. ( Guan, HM; Wang, S, 2017) |
| "Lenalidomide has a central role in the treatment of multiple myeloma and results in improved survival." | 3.85 | Hepatitis E during lenalidomide treatment for multiple myeloma in complete remission. ( Faber, LM; Kootte, RS, 2017) |
| "The combination of carfilzomib, lenalidomide, and dexamethasone (CRd) has induced deep responses in patients with newly diagnosed multiple myeloma." | 3.85 | Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms. ( Figg, WD; Kazandjian, D; Korde, N; Landgren, O; Mailankody, S; Peer, CJ; Sissung, TM; Venzon, DJ, 2017) |
| "Lenalidomide (LEN) acts directly on multiple myeloma (MM) cells by inducing cereblon-mediated degradation of interferon regulatory factor 4, Ikaros (IKZF)1 and IKZF3, transcription factors that are essential for MM cell survival." | 3.85 | MUC1-C is a target in lenalidomide resistant multiple myeloma. ( Anderson, K; Avigan, D; Gali, R; Hideshima, T; Kufe, D; Tagde, A; Tai, YT; Yin, L, 2017) |
| "Lenalidomide is an immunomodulatory drug that is also currently used in transplant-eligible patients with multiple myeloma." | 3.85 | Impact of lenalidomide-based induction therapy on the mobilization of CD34 ( Jantunen, E; Mäntymaa, P; Partanen, A; Pelkonen, J; Putkonen, M; Ropponen, A; Sankelo, M; Siitonen, T; Silvennoinen, R; Valtola, J; Varmavuo, V, 2017) |
| "Lenalidomide is an immunomodulatory drug administered orally in the treatment of multiple myeloma." | 3.85 | Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World Experience. ( Azuma, Y; Fujita, S; Hotta, M; Ishii, K; Ito, T; Nakanishi, T; Nakaya, A; Nomura, S; Satake, A; Tsubokura, Y; Yoshimura, H, 2017) |
| "Over the last few years, thalidomide has become one of the most important anti-tumour drugs for the treatment of relapsed-refractory multiple myeloma." | 3.85 | Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others. ( Akiyama, H; Hara, H; Inoue, Y; Shibata, N; Soloshonok, VA; Tokunaga, E, 2017) |
| "The aim of this study was to examine whether novel agents proteasome inhibitor bortezomib and immunomodulatory drugs lenalidomide and thalidomide are effective in prolonging overall survival (OS) for patients with newly diagnosed multiple myeloma (MM) in the real-world practice setting." | 3.85 | Improved survival in Medicare patients with multiple myeloma: findings from a large nationwide and population-based cohort. ( Chan, W; Chen, Y; Du, XL; Lairson, DR, 2017) |
| "Pomalidomide plus low-dose dexamethasone (POM-d), daratumumab monotherapy (DARA), and carfilzomib monotherapy (CAR) have been approved for use in the treatment of patients with heavily pretreated relapsed-refractory multiple myeloma (RRMM) in the US, based on findings from the MM-002, SIRIUS, and PX-171-003-A1 studies, respectively." | 3.85 | Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States. ( Abouzaid, S; Ailawadhi, S; Chandler, C; Guo, S; Mouro, J; Parikh, K; Pelligra, CG, 2017) |
| "Lenalidomide is often used in the maintenance setting for multiple myeloma and has been linked to the development of secondary primary malignancies." | 3.85 | Lenalidomide and secondary acute lymphoblastic leukemia: a case series. ( Fong, R; Lo, M; Tan, M; Young, R, 2017) |
| "The role of thalidomide in induction and long-term maintenance therapy in patients with multiple myeloma not eligible for stem cell transplantation remains unclear." | 3.85 | Evaluation of low-dose thalidomide as induction and maintenance therapy in patients with multiple myeloma not eligible for stem cell transplantation. ( Aznab, M; Moieni, A; Navabi, J; Rezaei, M, 2017) |
| "Risk of subsequent primary malignancies (SPMs) associated with lenalidomide therapy in multiple myeloma (MM) patients, outside the context of melphalan-based therapy is not established." | 3.85 | Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide. ( Alsina, M; Baz, R; Dalton, W; Fisher, K; Fulp, W; Hampras, S; Kenvin, L; Knight, R; Komrokji, R; Lee, JH; Nishihori, T; Olesnyckyj, M; Rollison, DE; Shain, KH; Sullivan, D; Xu, Q, 2017) |
| "In the UK, the standard of care for patients with multiple myeloma who received ≥2 prior treatments is lenalidomide plus dexamethasone (LEN + DEX) and pomalidomide plus DEX (POM + DEX) (in Wales only)." | 3.85 | Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data. ( Gray, E; Krishna, A; Majer, I; Polanyi, Z; Roy, A; van de Wetering, G, 2017) |
| "Bortezomib- and thalidomide-based therapies have significantly contributed to improved survival of multiple myeloma (MM) patients." | 3.85 | Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array. ( Alcoceba, M; Barrio, S; Blanchard, MJ; Chillon, MC; Corchete, LA; de la Rubia, J; García-Álvarez, M; García-Sanz, R; González Díaz, M; Jiménez, C; Lahuerta, JJ; Martínez, R; Martínez-López, J; Mateos, MV; Oriol, A; Prieto, I; Puig, N; Rapado, I; San Miguel, JF; Sarasquete, ME, 2017) |
| "The proteasome inhibitor carfilzomib is highly effective in the treatment of multiple myeloma." | 3.85 | Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. ( Bhutani, M; Burton, D; Calvo, KR; Carter, G; Costello, R; de Larrea, CF; Figg, WD; Gil, LA; Kazandjian, D; Korde, N; Kwok, M; Lamping, L; Landgren, O; Manasanch, EE; Maric, I; Mulquin, M; Roschewski, M; Steinberg, SM; Stetler-Stevenson, M; Tageja, N; Wu, P; Yuan, C; Zingone, A; Zuchlinski, D, 2017) |
| "To investigate the safety and efficacy of the combination regimen vincristine, cyclophosphamide, melphalan or mitoxantrone and prednisone (VCMP) plus thalidomide as first-line induction therapy for newly diagnosed multiple myeloma (MM)." | 3.85 | Therapeutic experience of vincristine/cyclophosphamide/melphalan or mitoxantrone/prednisone combination therapy plus thalidomide as first-line induction therapy for newly diagnosed multiple myeloma in a single institution of China. ( Guo, C; He, P; Sun, C; Wang, X; Zhang, M, 2017) |
| "Lenalidomide in combination with dexamethasone (Len-dex) represents a highly effective treatment in relapsed/refractory multiple myeloma (RRMM) patients." | 3.85 | Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients. ( Atenafu, EG; Chen, C; Chu, CM; Kotchetkov, R; Kukreti, V; Masih-Khan, E; Reece, DE; Tiedemann, R; Trudel, S, 2017) |
| "The comparative effectiveness of thalidomide and lenalidomide in the treatment of multiple myeloma has not been established." | 3.85 | Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study. ( Avorn, J; Gagne, JJ; Kesselheim, AS; Landon, J; Luo, J, 2017) |
| "We analyzed the treatment responses, toxicities, and survival outcomes of patients with relapsed or refractory multiple myeloma who received daily thalidomide, cyclophosphamide, and dexamethasone (CTD) or daily thalidomide, melphalan, and prednisolone (MTP) at 17 medical centers in Korea." | 3.85 | Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. ( Choi, YS; Eom, HS; Han, JJ; Kang, HJ; Kim, HJ; Kim, K; Kim, MK; Kim, SH; Kwon, J; Lee, JH; Lee, JJ; Lee, JO; Lee, WS; Min, CK; Moon, JH; Yoon, DH; Yoon, SS, 2017) |
| "New classes of drugs including the proteasome inhibitors (PI) bortezomib and, more recently, carfilzomib and the immunomodulatory agent lenalidomide have shown improved outcomes for multiple myeloma (MM) patients during the past decade." | 3.85 | Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib. ( Berenson, A; Berenson, JR; David, M; Eades, B; Eshaghian, S; Gottlieb, J; Halleluyan, R; Harutyunyan, NM; Nassir, Y; Spektor, TM; Swift, R; Udd, KA; Vardanyan, S; Wang, J, 2017) |
| "Lenalidomide is an immunomodulatory drug (IMiDs) with clinical efficacy in multiple myeloma (MM) and other late B-cell neoplasms." | 3.85 | Multiple myeloma cells' capacity to decompose H ( Ahmann, GJ; Bergsagel, PL; Braggio, E; Chesi, M; Fonseca, R; Panchabhai, SC; Sebastian, S; Shi, CX; Stewart, AK; Van Wier, SA; Zhu, YX, 2017) |
| " Pharmacological inhibition or genetic ablation of the Abl-DDB1-DDA1 axis decreases the ubiquitination of CRL4 substrates, including IKZF1 and IKZF3, in lenalidomide-treated multiple myeloma cells." | 3.85 | Activation of c-Abl Kinase Potentiates the Anti-myeloma Drug Lenalidomide by Promoting DDA1 Protein Recruitment to the CRL4 Ubiquitin Ligase. ( Cai, Z; Cang, Y; Gao, S; Geng, C; Lin, X; Liu, J; Song, T, 2017) |
| "We present the case of a 70-year-old man diagnosed with multiple myeloma in 2008, who after four therapy lines initiated a fifth-line treatment with pomalidomide (4 mg orally, days 1-21 of a 28-day cycle) and low-dose dexamethasone (40 mg weekly orally)." | 3.85 | Pomalidomide in heavily pretreated refractory multiple myeloma: a case report. ( Asproni, R; Latte, G; Monne, M; Murineddu, M; Palmas, A; Piras, G; Stradoni, R; Uras, A, 2017) |
| "Here we discuss the case of a heavily pretreated male patient with relapsed-refractory multiple myeloma and previous monoclonal gammopathy of undetermined significance who initiated a fifth-line treatment with pomalidomide (4 mg orally, days 1-21 of a 28-day cycle) and low-dose dexamethasone (40 mg weekly orally)." | 3.85 | Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma. ( Ancora, F; Calafiore, V; Consoli, ML; Conticello, C; Di Raimondo, F; La Fauci, A; Parisi, M; Romano, A, 2017) |
| "On November 30, 2015, the FDA approved elotuzumab (Empliciti; Bristol-Myers Squibb) in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who received one to three prior therapies." | 3.85 | FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma. ( Deisseroth, A; Farrell, AT; Goldberg, KB; Gormley, NJ; Kaminskas, E; Ko, CW; Kormanik, N; Nie, L; Pazdur, R, 2017) |
| "Pomalidomide is an analog of thalidomide with immunomodulatory, anti-angiogenic, and anti-neoplastic activity indicated for the treatment of multiple myeloma refractory to at least two prior therapies." | 3.83 | A case of acute kidney injury from crystal nephropathy secondary to pomalidomide and levofloxacin use. ( Babalola, O; Baird, P; Devoe, CE; Hoang, H; Jhaveri, KD; Leung, S; Wanchoo, R, 2016) |
| "The use of thalidomide derivatives (IMIDs) has improved multiple myeloma prognosis, through an unknown mechanism of action." | 3.83 | Modulation of cereblon levels by anti-myeloma agents. ( Díaz-Rodríguez, E; Pandiella, A, 2016) |
| "We describe the case of a 54-year-old woman with relapse of multiple myeloma 3 years after myeloablative allogeneic stem cell transplant who developed abdominal pain and bloody diarrhea following 7 months of lenalidomide therapy." | 3.83 | Ischemic colitis diagnosed by magnetic resonance imaging during lenalidomide treatment in a patient with relapsed multiple myeloma. ( Bucalossi, A; Cioffi Squitieri, N; Guerrini, S; Mazzei, FG; Mazzei, MA; Volterrani, L, 2016) |
| "To conduct a cost-effectiveness assessment of lenalidomide plus dexamethasone (Rd) vs bortezomib plus melphalan and prednisone (VMP) as initial treatment for transplant-ineligible patients with newly-diagnosed multiple myeloma (MM), from a U." | 3.83 | Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma. ( Basu, S; Belch, AR; Berger, A; Binder, G; Cavenagh, JD; Ervin-Haynes, A; Facon, T; Gibson, CJ; Guo, S; Hulin, C; Nagarwala, Y; Nooka, A; Pelligra, CG; Usmani, SZ; White, D; Yiu, W, 2016) |
| "The aim of the multi-centre retrospective study was to evaluate the efficacy and safety of lenalidomide (LEN) therapy in patients with resistant or relapsed multiple myeloma (MM) as well as in patients with stable disease (LEN used due to neurological complications)." | 3.83 | Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients--Report of the Polish Myeloma Group. ( Becht, R; Bołkun, Ł; Butrym, A; Błońska, D; Charliński, G; Dębski, J; Dmoszyńska, A; Druzd-Sitek, A; Dytfeld, D; Hałka, J; Hołojda, J; Hus, M; Januszczyk, J; Jurczyszyn, A; Knopińska-Posłuszny, W; Kuliczkowski, K; Kłoczko, J; Lech-Marańda, E; Legieć, W; Malenda, A; Nowicki, A; Pogrzeba, J; Rymko, M; Rzepecki, P; Stella-Hołowiecka, B; Subocz, E; Torosian, T; Urbanowicz, A; Urbańska-Ryś, H; Usnarska-Zubkiewicz, L; Zaucha, JM; Zdziarska, B; Zubkiewicz-Kucharska, A, 2016) |
| "The IFM2009-02 trial studied pomalidomide (4 mg daily, 21/28 versus 28/28) and dexamethasone in very advanced relapsed or refractory multiple myeloma (RRMM)." | 3.83 | Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma. ( Arnulf, B; Attal, M; Avet-Loiseau, H; Banos, A; Benbouker, L; Brechiniac, S; Caillot, D; Decaux, O; Escoffre-Barbe, M; Facon, T; Fermand, JP; Fouquet, G; Garderet, L; Hulin, C; Karlin, L; Kolb, B; Leleu, X; Macro, M; Marit, G; Mathiot, C; Moreau, P; Pegourie, B; Petillon, MO; Richez, V; Rodon, P; Roussel, M; Royer, B; Stoppa, AM; Wetterwald, M, 2016) |
| " We studied the relationship between 25-hydroxyvitamin D (25D) levels and motor and sensory peripheral neuropathy (PN) among multiple myeloma (MM) patients who have been treated with bortezomib and/or thalidomide." | 3.83 | Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy. ( Berenson, JR; Bravin, E; Ibrahim, E; Masri, M; Spektor, TM; Swift, RA; Treisman, J; Udd, KA; Vidisheva, A; Wang, J, 2016) |
| "Pomalidomide is an IMiD(®) immunomodulatory agent, which has shown clinically significant benefits in relapsed and/or refractory multiple myeloma (rrMM) patients when combined with dexamethasone, regardless of refractory status to lenalidomide or bortezomib." | 3.83 | Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. ( Bjorklund, CC; Cathers, BE; Chopra, R; Daniel, TO; Gandhi, AK; Leisten, J; Lopez-Girona, A; Lu, L; Mendy, D; Miller, K; Narla, RK; Ning, Y; Orlowski, RZ; Raymon, HK; Rychak, E; Shi, T; Thakurta, A, 2016) |
| "To compare the outcomes of patients with relapsed or refractory multiple myeloma (RRMM) who were treated with lenalidomide combined with high versus low dose of dexamethasone." | 3.83 | Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma. ( Christoulas, D; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kalapanida, D; Kanellias, N; Kastritis, E; Migkou, M; Roussou, M; Terpos, E; Zagouri, F, 2016) |
| "In real clinical settings (not clinical trials), thalidomide has been accepted as maintenance therapy to patients with multiple myeloma (MM) because of the cost of drugs, the limitations of medical insurance, etc." | 3.83 | The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea. ( Do, YR; Eom, HS; Jo, JC; Kim, K; Kim, SJ; Lee, H; Lee, HS; Lee, JH; Lee, JJ; Lee, MH; Lee, WS; Min, CK; Mun, YC; Park, Y; Shin, HJ; Yoon, DH, 2016) |
| "Thalidomide, lenalidomide and pomalidomide have greatly improved the outcome of patients with multiple myeloma." | 3.83 | Differential effects of lenalidomide during plasma cell differentiation. ( Cartron, G; Ceballos, P; Chopra, R; Cren, M; Duperray, C; Jourdan, M; Klein, B; Moreaux, J; Robert, N; Rossi, JF; Schafer, P; Vincent, L, 2016) |
| " Recent studies led to the development of a novel molecule RRx-001 with hypoxia-selective epigenetic and nitric oxide-donating properties." | 3.83 | A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. ( Anderson, KC; Chauhan, D; Das, A; Das, DS; Oronsky, B; Ray, A; Richardson, P; Scicinski, J; Song, Y; Tian, Z, 2016) |
| "Multiple myeloma (MM) patients who have progressed following treatment with both bortezomib and lenalidomide have a poor prognosis." | 3.83 | Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden. ( Borg, S; Elvidge, J; Hansson, M; Lee, D; Nahi, H; Persson, U, 2016) |
| "Immunomodulatory drugs (IMiDs), such as lenalidomide, are therapeutically active compounds that bind and modulate the E3 ubiquitin ligase substrate recruiter cereblon, thereby affect steady-state levels of cereblon and cereblon binding partners, such as ikaros and aiolos, and induce many cellular responses, including cytotoxicity to multiple myeloma (MM) cells." | 3.83 | Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival. ( Chang, XB; Erickson, P; Hou, YX; Langlais, P; Luo, M; Mandarino, LJ; Shi, CX; Stewart, K; Xu, Q; Xu, Y; Zhu, J; Zhu, Y, 2016) |
| "To explore the clinical efficacy and safety of lenalidomide plus low dose dexamethasone for treating patients with multiple myeloma (MM)." | 3.83 | [Curative Efficacy of Lenalidomide plus Low Dose Dexamethasone for Multiple Myeloma]. ( Chen, LM; Liu, HB, 2016) |
| "Neutropenia is a well-known dose-limiting toxicity associated with lenalidomide plus dexamethasone treatment in patients with multiple myeloma; however, little is known about its management and associated outcomes in the real world setting." | 3.83 | An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM). ( Cooney, J; Gray, D; Greil, R; Leleu, X; Minarik, J; O'Gorman, P; Sanz, RG; Szabo, Z; Terpos, E; Williams, C, 2016) |
| "To assess the economic value of carfilzomib (Kyprolis), this study developed the Kyprolis Global Economic Model (K-GEM), which examined from a United States (US) payer perspective the cost-effectiveness of carfilzomib-lenalidomide-dexamethasone (KRd) versus lenalidomide-dexamethasone (Rd) in relapsed multiple myeloma (RMM; 1-3 prior therapies) based on results from the phase III ASPIRE trial that directly compared these regimens." | 3.83 | Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. ( Aggarwal, SK; Barber, BL; Benedict, Á; Campioni, M; Giannopoulou, A; Houisse, I; Jakubowiak, AJ; Panjabi, S; Tichy, E, 2016) |
| "Circulating vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and selectins were prospectively measured in 145 newly-diagnosed patients with symptomatic myeloma (NDMM), 61 patients with asymptomatic/smoldering myeloma (SMM), 47 with monoclonal gammopathy of undetermined significance (MGUS) and 87 multiple myeloma (MM) patients at first relapse who received lenalidomide- or bortezomib-based treatment (RD, n=47; or VD, n=40)." | 3.83 | Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment. ( Christoulas, D; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Fotiou, D; Gavriatopoulou, M; Iakovaki, M; Kanellias, N; Kastritis, E; Migkou, M; Panagiotidis, I; Terpos, E; Ziogas, DC, 2016) |
| "In order to evaluate the main adverse effects of drug protocols using bortezomib and/or thalidomide for the treatment of multiple myeloma, we conducted a prospective study." | 3.83 | Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide. ( Atalla, A; Castro, TB; Hallack Neto, AE; Ribeiro, LC, 2016) |
| "Immunomodulatory drugs (IMiDs), such as thalidomide and its derivatives lenalidomide and pomalidomide, are key treatment modalities for hematologic malignancies, particularly multiple myeloma (MM) and del(5q) myelodysplastic syndrome (MDS)." | 3.83 | Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. ( Bassermann, F; Eichner, R; Einsele, H; Fernández-Sáiz, V; Garz, AK; Germing, U; Götze, KS; Haass, C; Heider, M; Jacobs, L; Keller, U; Knop, S; Knorn, AM; Kuster, B; Langer, C; Lemeer, S; Peschel, C; Platzbecker, U; Rudelius, M; Schmid, B; Slawska, J; Targosz, BS; van Bebber, F, 2016) |
| "Lenalidomide, thalidomide, and pomalidomide (LTP) are immunomodulatory agents approved for use in multiple myeloma, but in some settings, especially with alkylating agents, an increase in Hodgkin lymphoma and other secondary primary malignancies (SPM) has been noted." | 3.83 | Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression. ( Baladandayuthapani, V; Dawson, CW; Iempridee, T; Jones, RJ; Kenney, SC; Lee, HC; Lin, HC; Mertz, JE; Orlowski, RZ; Shah, JJ; Wang, X; Weber, DM, 2016) |
| "Although the antimyeloma effect of lenalidomide is associated with activation of the immune system, the exact in vivo immunomodulatory mechanisms of lenalidomide combined with low-dose dexamethasone (Len-dex) in refractory/relapsed multiple myeloma (RRMM) patients remain unclear." | 3.83 | Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma. ( Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, M; Kim, TW; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Lim, JY; Min, CK; Min, WS; Ryu, DB; Yoon, JH, 2016) |
| " In this study, we evaluated CRBN expression in bone marrow (BM) tissue at diagnosis and investigated the relationship between CRBN expression and treatment outcomes after thalidomide- or bortezomib-based front-line therapies in 89 elderly patients with multiple myeloma (MM)." | 3.83 | Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression. ( Ahn, JS; Cho, MS; Choi, HJ; Hwang, EC; Jung, SH; Jung, TY; Kim, HJ; Kim, YK; Lee, JJ; Lee, SS; Shin, MG; Yang, DH, 2016) |
| "A 75-year-old woman diagnosed with multiple myeloma in 2007 began treatment with monthly melphalan and prednisone for a total of 9 cycles in combination with thalidomide in 2009." | 3.83 | Hair repigmentation associated with thalidomide use for the treatment of multiple myeloma. ( Amato, D; Bailie, T; Lovering, S; Miao, W, 2016) |
| "Neutropenia may develop as an adverse event in patients with multiple myeloma receiving lenalidomide (LEN) plus dexamethasone (DEX) therapy." | 3.83 | Risk factors for neutropenia with lenalidomide plus dexamethasone therapy for multiple myeloma. ( Kimura, M; Kokuryou, T; Matsuoka, T; Mitani, Y; Nakao, T; Okada, K; Usami, E; Yamakawa, M; Yoshimura, T, 2016) |
| " We herein report the findings of a 53-year-old woman who was receiving lenalidomide for multiple myeloma and subsequently developed multiple amoebic abscesses." | 3.83 | Multiple Medium Amoebic Liver Abscesses Successfully Treated with Medication and Comprehensive Percutaneous Catheter Drainage. ( Goto, T; Iida, K; Kasamatsu, Y; Shimizu, S; Shirano, M, 2016) |
| "To investigate the expression of PIGF and its receptor Flt-1 in patients with multiple myeloma, and to analyze their correlation with the efficacy of thalidomide-based chemotherapy so as to provide further theoretical basis for individualized treatment." | 3.83 | [Expression of PIGF and Its receptor Flt-1 in Patients with Multiple Myeloma and their Correlation with Chemotherapeutic Efficacy]. ( Miao, LL; Xiao, Y, 2016) |
| "2 years) underwent clinical and neurophysiologic assessment at baseline and at 2 (8 patients, group A) or 5 years (11 patients, group B) after starting lenalidomide therapy for relapsed/refractory multiple myeloma." | 3.83 | Lenalidomide long-term neurotoxicity: Clinical and neurophysiologic prospective study. ( Barilà, G; Berno, T; Briani, C; Cacciavillani, M; Campagnolo, M; Dalla Torre, C; De March, E; Ermani, M; Lico, A; Lucchetta, M; Salvalaggio, A; Zambello, R, 2016) |
| "In Eastern Cooperative Oncology Group-ACRIN E4A03, on completion of four cycles of therapy, newly diagnosed multiple myeloma patients had the option of proceeding to autologous peripheral blood stem cell transplant (ASCT) or continuing on their assigned therapy lenalidomide plus low-dose dexamethasone (Ld) or lenalidomide plus high-dose dexamethasone (LD)." | 3.83 | Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up. ( Abonour, R; Biran, N; Callander, NS; Fonseca, R; Greipp, PR; Jacobus, S; Katz, MS; Rajkumar, SV; Siegel, DS; Vesole, DH; Williams, ME, 2016) |
| "Although lenalidomide maintenance therapy has demonstrated improved outcomes after autologous hematopoietic stem cell transplantation (auto-HCT) for patients with multiple myeloma (MM), the impact of the duration of this therapy is not clearly known." | 3.83 | Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. ( Bashir, Q; Champlin, RE; Kebriaei, P; Manasanch, EE; Mian, I; Milton, DR; Nieto, Y; Oran, B; Orlowski, RZ; Parmar, S; Popat, UR; Qazilbash, MH; Shah, JJ; Shah, N; Shpall, EJ, 2016) |
| " The aim of this retrospective study was to evaluate the efficacy and safety of Compound Danshen Tablet (CDT) in preventing thromboembolism in multiple myeloma (MM) patients treated with thalidomide-based regimens." | 3.83 | Efficacy and Safety of Danshen Compound Tablets in Preventing Thalidomide-Associated Thromboembolism in Patients with Multiple Myeloma: A Multicenter Retrospective Study. ( Ai, H; Chen, L; Liu, XJ; Mi, RH; Wei, XD; Yin, JJ; Yin, QS, 2016) |
| "This is a retrospective chart review to evaluate the efficacy of the addition of vorinostat to lenalidomide and dexamethasone in patients with multiple myeloma relapsed/refractory to lenalidomide and dexamethasone." | 3.83 | Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma. ( Bednarz, U; Bilotti, E; Gao, Z; Gilani, M; Graef, T; Mato, A; McBride, L; McNeill, A; Richter, J; Schmidt, L; Siegel, DS; Vesole, DH, 2016) |
| "The aim of this study is to assess nucleoprotein expression of IKZF1/3 in patients with relapsed/refractory multiple myeloma (MM) who received lenalidomide-based therapy and correlated them with their clinical outcomes." | 3.83 | High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide. ( Atenafu, EG; Bahmanyar, M; Chang, H; Hou, J; Pourabdollah, M; Reece, D, 2016) |
| "In this invited paper, I was asked to critically review available literature and seek scientific and clinical evidence to argue in support of carfilzomib, lenalidomide, and dexamethasone (KRd) as the new default therapy for fit patients with a new diagnosis of multiple myeloma (MM)." | 3.83 | Combination therapy for fit (younger and older) newly diagnosed multiple myeloma patients: Data support carfilzomib, lenalidomide, and dexamethasone independent of cytogenetic risk status. ( Landgren, O, 2016) |
| "Thalidomide was the first immunomodulatory drug used as maintenance after autologous stem cell transplant (ASCT) in multiple myeloma (MM)." | 3.83 | Recommend maintenance therapy with lenalidomide in multiple myeloma. ( Manasanch, EE, 2016) |
| " The diagnosis of multiple myeloma and Evan's syndrome was made, we underwent chemotherapy by BTD (bortezomib-thalidomide-dexamethasone) and continuous corticosteroid therapy but unfortunately the patient died secondary of a Lactic acidosis." | 3.83 | Multiple myeloma associated with an Evan's syndrome. ( Abderrahim, K; Amina, BB; Asma, A; Bechir, A; Emna, B; Haifa, R; Mondher, K; Mrabet, S; Nesrine, BS; Senda, M; Yosra, BY, 2016) |
| "Neutropenia is a major dose-limiting toxicity associated with lenalidomide in relapsed/refractory multiple myeloma (MM)." | 3.81 | Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. ( Atenafu, EG; Chen, C; Kukreti, V; Masih-Khan, E; Reece, DE; Sun, HL; Trudel, S; Winter, A; Yeboah, E, 2015) |
| "Lenalidomide was approved for the treatment of relapsed and refractory multiple myeloma (rrMM) based on MM009 and MM010 clinical trials." | 3.81 | Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma--real life experience of a tertiary cancer center. ( Coelho, I; Costa, C; Esteves, S; João, C; Lucio, P, 2015) |
| "Treatment options are limited in myeloma relapsed or refractory to both bortezomib and lenalidomide (double-relapsed/refractory multiple myeloma; DRMM)." | 3.81 | Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide. ( Aitchison, R; Blesing, N; Lau, IJ; Peniket, A; Rabin, N; Ramasamy, K; Roberts, P; Smith, D; Yong, K, 2015) |
| "We retrospectively investigated the prognostic factor of lenalidomide plus low-dose dexamethasone (Rd) in Japanese patients with refractory or relapsed multiple myeloma (RRMM) registered in the Kansai Myeloma Forum from January 2006 to December 2013." | 3.81 | Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma. ( Adachi, Y; Fuchida, S; Ishii, K; Kanakura, Y; Kaneko, H; Kobayashi, M; Kobayashi, T; Kosugi, S; Kuroda, J; Matsuda, M; Matsumura, I; Nakatani, E; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Takaori-Kondo, A; Tanaka, H; Taniwaki, M; Tsudo, M; Uchiyama, H; Uoshima, N; Yagi, H, 2015) |
| "To identify molecular targets that modify sensitivity to lenalidomide, we measured proliferation in multiple myeloma (MM) cells transfected with 27 968 small interfering RNAs in the presence of increasing concentrations of drug and identified 63 genes that enhance activity of lenalidomide upon silencing." | 3.81 | RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2. ( Aziz, M; Braggio, E; Bruins, LA; Champion, M; Jedlowski, P; Keith Stewart, A; Kortuem, KM; Schmidt, JE; Sereduk, C; Shi, CX; Yin, H; Zhu, YX, 2015) |
| "In ex vivo assays, mainly evaluating antibody-dependent cell-mediated cytotoxicity, and in an in vivo xenograft mouse model, we evaluated daratumumab alone or in combination with lenalidomide or bortezomib as a potential therapy for lenalidomide- and bortezomib-refractory multiple myeloma patients." | 3.81 | Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib. ( Bakker, J; de Jong-Korlaar, R; Groen, RW; Lokhorst, HM; Martens, AC; Mutis, T; Nijhof, IS; Noort, WA; Parren, PW; van Bueren, JJ; van de Donk, NW; van Kessel, B, 2015) |
| "7% avoided lenalidomide to prevent mobilization impairment in patients with multiple myeloma (MM)." | 3.81 | Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma. ( Costa, LJ; Dermer, SJ; Kumar, S; Stowell, SA, 2015) |
| "The introduction of immunomodulatory drugs such as lenalidomide combined with dexamethasone (Len/Dex) has improved the outcome of patients with relapsed/refractory multiple myeloma (RRMM)." | 3.81 | Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide. ( Bacchiarri, F; Bosi, A; Donnini, I; Guarrera, A; Longo, G; Nozzoli, C; Staderini, M; Veltroni, A, 2015) |
| "In the past decade, the introduction of bortezomib, thalidomide, and lenalidomide has changed the treatment of multiple myeloma (MM) dramatically." | 3.81 | [Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy]. ( Nakaseko, C; Sakaida, E; Takeda, Y, 2015) |
| " The level of plasma TM and D-Dimer can be elevated when thalidomide used, which indirectly suggested the tendency for thrombosis in MM patients." | 3.81 | [Hypercoagulable state in patients with multiple myeloma]. ( Gao, N; Liu, ZY; Lu, H; Sun, JR; Wang, XX; Yu, WZ; Zhang, GQ, 2015) |
| "Thalidomide is highly effective against multiple myeloma, but some patients must discontinue this medication due to adverse effects." | 3.81 | [Thalidomide-associated hypothyroidism in a patient with multiple myeloma]. ( Ikeda, T; Kimura, F; Okamura, I; Sato, K, 2015) |
| "Thalidomide (Thal) treatment of patients with multiple myeloma (MM) is associated with vascular thrombosis, but the underlying mechanism is unknown." | 3.81 | Thalidomide and multiple myeloma serum synergistically induce a hemostatic imbalance in endothelial cells in vitro. ( Gao, Y; Liu, S; Ma, G; Su, Y; Teng, Y; Wang, Y, 2015) |
| "Clinical studies evaluating the efffectiveness of pomalidomide based regimens on response and safety for patients with refractory and relapsed multiple myeloma were identified using a predefined search strategy." | 3.81 | Pooled analysis of pomalidomide for treating patients with multiple myeloma. ( Sun, JJ; Yang, HL; Zhang, C; Zhou, J, 2015) |
| "Immunomodulatory drugs (IMiDs) thalidomide, lenalidomide (Len) and pomalidomide trigger anti-tumor activities in multiple myeloma (MM) by targetting cereblon and thereby impacting IZF1/3, c-Myc and IRF4." | 3.81 | Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma. ( Anderson, KC; Cottini, F; Gorgun, G; Hideshima, T; Jakubikova, J; Mimura, N; Munshi, NC; Ohguchi, H; Richardson, PG; Tai, YT, 2015) |
| " Here, we assessed the impact of single and dual blockade of PD-1/PD-L1, alone or in combination with lenalidomide, on accessory and immune cell function as well as multiple myeloma cell growth in the bone marrow (BM) milieu." | 3.81 | Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. ( Anderson, JE; Anderson, KC; Avet-Loiseau, H; Bianchi, G; Cowens, KB; Dorfman, DM; Görgün, G; Harada, T; Hideshima, T; Kikuchi, S; Laubach, JP; Magrangeas, F; Minvielle, S; Munshi, NC; Ohguchi, H; Paula, S; Raje, N; Richardson, PG; Samur, MK; Singh, A; Suzuki, R; Tai, YT; White, RE, 2015) |
| "With the availability of a new proteasome inhibitor, carfilzomib, and a new immunomodulatory drug, pomalidomide, the treatment of multiple myeloma has become more effective." | 3.81 | Multiple myeloma: new uses for available agents, excitement for the future. ( Anderson, KC, 2015) |
| "To explore the clinical efficacies and toxicities of lenalidomide combination chemotherapy in the treatment of relapsing or refractory multiple myeloma (MM) patients." | 3.81 | [Clinical observations of lenalidomide combination chemotherapy for relapsing or refractory multiple myeloma]. ( An, N; Chen, S; Hu, Y; Huang, Z; Li, X; Shen, M; Sun, W; Zhan, X; Zhang, J; Zhong, Y, 2015) |
| "To observe the cytotoxity of CD138-CAR-T cells on human multiple myeloma cell RPMI8226 and U266 cells and explore the impact of pomalidomide on the cytotoxity of CD138-CAR-T on RPMI8226 and U266 cells." | 3.81 | [Cytotoxity of pomalidomide combined CAR-T cell for multiple myeloma cell RPMI8226 and U266]. ( Bai, H; Ou, J; Wang, L; Zhang, S, 2015) |
| "In this retrospective real-life study in relapsed/refractory multiple myeloma patients, we analyzed clinical and biologic features distinguishing patients with rapidly progressing disease while receiving lenalidomide therapy from those without progression." | 3.81 | Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation. ( Battistutta, C; Berno, T; Bonaldi, L; Branca, A; Briani, C; Cavraro, M; De March, E; Gurrieri, C; Lico, A; Martines, A; Minotto, C; Piazza, F; Sechettin, E; Semenzato, G; Temporin, F; Trentin, L; Zambello, R, 2015) |
| "The authors performed a single-institution study comparing 3 salvage chemotherapy regimens in 107 patients with recurrent/refractory multiple myeloma: dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP) in 52 patients; bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide (VTD-PACE) in 22 patients; and cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD) in 33 patients." | 3.81 | A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma. ( Alsina, M; Baz, RC; Fulp, W; Griffin, PT; Ho, VQ; Nishihori, T; Shain, KH, 2015) |
| "The aim of this study was to assess the safety and efficacy of lenalidomide (Len), with the dose adjusted according to the renal function, plus low-dose dexamethasone (Dex) in older patients with bortezomib (Bor)-resistant multiple myeloma (MM)." | 3.81 | Dose-adjusted Lenalidomide Combined with Low-dose Dexamethasone Rescues Older Patients with Bortezomib-resistant Multiple Myeloma. ( Kadowaki, M; Kohno, K; Okamura, S; Takase, K; Yamasaki, S, 2015) |
| "Multiple laboratory tests and a rigorous review of the samples, time of collection, and laboratory results revealed that only samples collected shortly after lenalidomide administration showed hemolysis." | 3.81 | Transiently Pink-Tinged Serum in a Patient With Multiple Myeloma and Anemia Undergoing Lenalidomide Treatment. ( Sofronescu, AG; Wedel, W, 2015) |
| "Two multiple myeloma (MM) patients developed venous thromboembolism (VTE) while being treated with lenalidomide and low-dose dexamethasone." | 3.81 | [Successful treatment of venous thromboembolism with a Factor Xa inhibitor, edoxaban, in patients with lenalidomide-treated multiple myeloma]. ( Kawaguchi, M; Konuma, S; Nehashi, Y; Okuda, Y; Uchimura, N, 2015) |
| "The purpose of this study was to determine the correlations between inflammatory factors-including absolute lymphocyte count, lactate dehydrogenase, β2-microglobulin, albumin, C-reactive protein, and ferritin-and the prognosis for survival in patients with multiple myeloma (MM) treated with induction chemotherapy containing thalidomide and who underwent autologous stem cell transplantation (ASCT)." | 3.81 | The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea. ( Do, YR; Eom, HS; Jo, JC; Kim, C; Kim, K; Lee, H; Lee, HS; Lee, JH; Lee, JJ; Lee, WS; Min, CK; Mun, YC; Park, Y; Shin, HJ; Yoon, DH, 2015) |
| "Double relapsed and/or refractory multiple myeloma (DRMM), MM that is relapsed and/or refractory to bortezomib and lenalidomide, carries a poor prognosis." | 3.81 | Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs. ( Bullement, A; Dickens, E; Elvidge, J; Gooding, S; Lau, IJ; Lee, D; Ramasamy, K; Roberts, P; Sheikh, M; Wong, J, 2015) |
| "To investigate the efficacy and safety of the treatment of the newly diagnosed multiple myeloma (MM) patients with the therapy of subcutaneous (subQ) administration of bortezomib and dexamethasone plus thalidomide (VTD) regimen." | 3.81 | Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients. ( Cai, X; Chen, S; Chen, Y; Lin, B; Shi, Y; Wu, S; Zheng, C, 2015) |
| "Recent discoveries suggest that the critical events leading to the anti-proliferative activity of the IMiD immunomodulatory agents lenalidomide and pomalidomide in multiple myeloma (MM) cells are initiated by Cereblon-dependent ubiquitination and proteasomal degradation of substrate proteins Ikaros (IKZF1) and Aiolos (IKZF3)." | 3.81 | Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. ( Amatangelo, M; Bjorklund, CC; Breider, M; Chopra, R; Couto, S; Daniel, TO; Gandhi, AK; Hagner, PR; Havens, CG; Kang, J; Klippel, A; Lu, L; Ning, Y; Ren, Y; Thakurta, AG; Wang, M, 2015) |
| "We studied all patients at our institution with a diagnosis of multiple myeloma (MM), from 1 January 2004 to 1 July 2009, who received lenalidomide-dexamethasone (Rd) as initial therapy and had a time to progression of 72 months or longer." | 3.81 | Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma. ( Buadi, F; Dispenzieri, A; Gertz, MA; Gonsalves, W; Kumar, S; Lacy, MQ; Rajkumar, SV; Vu, T, 2015) |
| "To explore the change of T help cell 17 (Th17) in the peripheral blood of patients with multiple myeloma (MM) before and after treatment with thalidomide." | 3.81 | [Effects of Thalidomide on Peripheral Blood Th17 Cells of Patients with Multiple Myeloma]. ( Bai, J; He, AL; Liu, J; Wang, JL; Yang, Y; Zhao, WH, 2015) |
| "We investigated the mechanisms of action of immuno-modulatory drug (lenalidomide) on the protein expression of cereblon (CRBN) and their therapeutic targets in the multiple myeloma cell line RPMI8226." | 3.81 | Lenalidomide affect expression level of cereblon protein in multiple myeloma cell line RPMI8226. ( Cai, XY; Guo, XF; Guo, XL; Guo, XN; Ren, JH; Yang, DY; Zhang, JN, 2015) |
| "The incidence of herpes zoster is substantial during bortezomib treatment in patients with multiple myeloma (MM)." | 3.81 | Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy. ( Choe, PG; Kim, BS; Kim, I; Kim, JW; Koh, Y; Kwon, JH; Min, CK; Mun, YC; Nam, SH; Park, WB; Park, Y, 2015) |
| " Treatment of multiple myeloma has changed markedly in the past decade due to the development of new drugs such as bortezomib, lenalidomide and thalidomide, which have greatly improved the outcome of PCM." | 3.81 | CD200 Expression on Plasma Cell Myeloma Cells is Associated with the Efficacies of Bortezomib, Lenalidomide and Thalidomide. ( Arai, N; Fujiwara, S; Homma, M; Kabasawa, N; Kawaguchi, Y; Kobayashi, K; Nakamaki, T; Okino, K; Shiozawa, E; Takimoto, M; Tate, G; Tazawa, S; Yamochi, T, 2015) |
| "The onset of thrombocytopenia and related factors was analyzed in patients with multiple myeloma (MM) who were receiving lenalidomide (Len) therapy at the Department of Hematology, Gifu Municipal Hospital between July 2010 and March 2014." | 3.81 | The Establishment of Indicators of Thrombocytopenia in Patients Receiving Lenalidomide Therapy. ( Goto, C; Goto, H; Ichihashi, A; Kasahara, S; Nagaya, K; Osawa, T; Tachi, T; Takahashi, T; Teramachi, H; Umeda, M; Yasuda, M, 2015) |
| "This study investigated the relationship between quality of life (QOL) and efficacy or occurrence of adverse events in patients who were administered lenalidomide and dexamethasone (Len+Dex) therapy for relapsed or refractory multiple myeloma (MM) in the hematology department at Obihiro Kosei Hospital from September 2010 to September 2012." | 3.81 | [Quality of Life Is Associated with Combined Lenalidomide and Dexamethasone Treatment in Japanese Patients with Relapsed or Refractory Multiple Myeloma]. ( Kobayashi, H; Komori, H; Nakamura, Y; Namba, K; Oi, N; Sato, H; Taniguchi, Y; Yahata, H, 2015) |
| "Thalidomide, a sedative popular in the 1950s and withdrawn from the market in the 1960s because of its teratogenic effects, has emerged again on the market in the last decade as an effective agent in the treatment of multiple myeloma." | 3.81 | [Thalidomide induced peripheral neuropathy in multiple myeloma patients]. ( Banach, M; Jurczyszyn, A; Skotnicki, A, 2015) |
| "The multikinase inhibitor dasatinib blocks the constitutive activation of oncogenic Src kinases in multiple myeloma (MM) cells and potentially enhances natural killer (NK) cell activity." | 3.80 | Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells. ( Einsele, H; Jungkunz-Stier, I; Seggewiss-Bernhardt, R; Stühmer, T; Zekl, M, 2014) |
| "Type, frequency, severity, time of onset and management of cADR were collected and the medical records of all multiple myeloma patients receiving bortezomib or lenalidomide in the Hematology and Medical Oncology Institute of the University of Bologna, were analyzed." | 3.80 | Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects. ( Brandi, G; Dika, E; Maibach, H; Patrizi, A; Tacchetti, P; Venturi, M, 2014) |
| "Patients with multiple myeloma who are refractory or intolerant to both bortezomib and lenalidomide have a poor prognosis." | 3.80 | The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide. ( Ahluwalia, R; Carson, KR; Cox, DP; Fiala, MA; Jaenicke, M; Moliske, CC; Stockerl-Goldstein, KE; Tomasson, MH; Trinkaus, KM; Vij, R; Wang, TF; Wildes, TM, 2014) |
| "Lenalidomide and dexamethasone (RD) is a standard of care for relapsed/refractory multiple myeloma (RRMM), but there is limited published data on its efficacy and safety in the "real world" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition." | 3.80 | "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. ( Anagnostopoulos, N; Anargyrou, K; Briasoulis, E; Giannakoulas, N; Hatzimichael, E; Karras, G; Katodritou, E; Kotsopoulou, M; Kyriakou, D; Kyrtsonis, MC; Lalagianni, C; Maniatis, A; Matsouka, P; Michali, E; Papageorgiou, G; Spanoudakis, E; Symeonidis, A; Terpos, E; Tsakiridou, A; Tsionos, K; Vadikolia, C; Zikos, P, 2014) |
| "Introduction of high-dose chemotherapy and the novel agents including bortezomib, Lenalidomide, and Thalidomide has provided a significant progress in the treatment of multiple myeloma (MM) with an increase in median overall survival up to 6-8 years." | 3.80 | Brain abscess caused by Nocardia cyriacigeorgica in two patients with multiple myeloma: novel agents, new spectrum of infections. ( Cırak, MY; Emmez, H; Oner, AY; Pamukçuoğlu, M; Senol, E; Sucak, GT; Tunçcan, OG, 2014) |
| "We conducted a retrospective analysis of lenalidomide with dexamethasone for patients with relapsed/refractory multiple myeloma (RRMM) who were treated within the Korean patient access program." | 3.80 | Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients. ( Eom, HS; Jo, DY; Jun, HJ; Kim, JS; Kim, K; Kim, KH; Kim, SH; Kim, SJ; Kim, YS; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Min, CK; Moon, JH; Mun, YC; Park, SK; Ryoo, HM; Suh, C; Voelter, V; Yoon, SS, 2014) |
| "The combination of melphalan and prednisone (MP) has been the standard treatment of multiple myeloma (MM)." | 3.80 | Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients. ( Alici, E; Aschan, J; Gahrton, G; Holmberg, E; Liwing, J; Lund, J; Nahi, H; Uttervall, K, 2014) |
| "Cereblon, a member of the cullin 4 ring ligase complex (CRL4), is the molecular target of the immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide and is required for the antiproliferative activity of these agents in multiple myeloma (MM) and immunomodulatory activity in T cells." | 3.80 | Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. ( Abbasian, M; Breider, M; Carmel, G; Cathers, BE; Chen, G; Chopra, R; Daniel, TO; Gaidarova, S; Gandhi, AK; Jackson, P; Lopez-Girona, A; Mahmoudi, A; Mendy, D; Miller, K; Ren, Y; Rychak, E; Schafer, PH; Thakurta, A; Waldman, M; Wang, M, 2014) |
| "Whether the efficacy of lenalidomide in the treatment of multiple myeloma (MM) is due to direct tumor toxicity only or to additional immunomodulatory effects is unclear." | 3.80 | Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis. ( Bompoint, C; Busson, M; Carmagnat, M; Clave, E; Coman, T; Douay, C; Garderet, L; Glauzy, S; Gorin, NC; Moins-Teisserenc, H; Toubert, A, 2014) |
| "Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM)." | 3.80 | Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. ( Beksac, M; Boccadoro, M; Bringhen, S; Catalano, L; Cavalli, M; Cavo, M; Cerrato, C; Gentile, M; Gimsing, P; Gottardi, D; Isabel Turel, A; José Lahuerta, J; Juliusson, G; Larocca, A; Magarotto, V; Marina Liberati, A; Mazzone, C; Morabito, F; Musto, P; Offidani, M; Omedè, P; Oriol, A; Palumbo, A; Passera, R; Rossi, D; Rosso, S; San Miguel, J; Schaafsma, M; Sonneveld, P; Victoria Mateos, M; Waage, A; Wijermans, P; Zambello, R; Zweegman, S, 2014) |
| "Bortezomib has been known as the most promising anti-cancer drug for multiple myeloma (MM)." | 3.80 | Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis. ( Ahn, KS; Bae, EK; Choi, JH; Jung, WJ; Lee, C; Park, J; Yoon, SS, 2014) |
| "Thalidomide-like drugs such as lenalidomide are clinically important treatments for multiple myeloma and show promise for other B cell malignancies." | 3.80 | The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. ( Bradner, JE; Kaelin, WG; Lu, G; Middleton, RE; Mitsiades, CS; Naniong, M; Ott, CJ; Sun, H; Wong, KK, 2014) |
| "Lenalidomide is a drug with clinical efficacy in multiple myeloma and other B cell neoplasms, but its mechanism of action is unknown." | 3.80 | Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. ( Carr, SA; Ciarlo, C; Comer, E; Ebert, BL; Grauman, P; Hartman, E; Heckl, D; Hurst, SN; Krönke, J; Li, X; McConkey, M; Munshi, N; Narla, A; Schenone, M; Schreiber, SL; Svinkina, T; Udeshi, ND, 2014) |
| "This article describes, for the first time, a highly sensitive and specific enzyme-linked immunosorbent assay (ELISA) for therapeutic monitoring and pharmacokinetic studies of lenalidomide (LND), the potent drug for treatment of multiple myeloma (MM)." | 3.80 | A highly sensitive polyclonal antibody-based ELISA for therapeutic monitoring and pharmacokinetic studies of lenalidomide. ( Abuhejail, RM; Alzoman, NZ; Darwish, IA, 2014) |
| "HIF-1α mRNA and protein were evaluated in patients with multiple myeloma endothelial cells (MMEC) at diagnosis, at relapse after bortezomib- or lenalidomide-based therapies or on refractory phase to these drugs, at remission; in endothelial cells of patients with monoclonal gammapathies of undetermined significance (MGUS; MGECs), and of those with benign anemia (controls)." | 3.80 | HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target. ( Angelucci, E; Annese, T; Berardi, S; Caivano, A; Catacchio, I; Dammacco, F; De Luisi, A; Derudas, D; Ditonno, P; Frassanito, MA; Guarini, A; Minoia, C; Moschetta, M; Nico, B; Piccoli, C; Ria, R; Ribatti, D; Ruggieri, S; Ruggieri, V; Vacca, A, 2014) |
| "The outcome for multiple myeloma patients has improved since the introduction of bortezomib, thalidomide and lenalidomide." | 3.80 | Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population. ( Aldrin, A; Alici, E; Aschan, J; Blimark, C; Carlson, K; Enestig, J; Flogegård, M; Forsberg, K; Gahrton, G; Gruber, A; Haglöf Kviele, H; Johansson, P; Lauri, B; Liwing, J; Lund, J; Mellqvist, UH; Nahi, H; Näsman, P; Svensson, M; Swedin, A; Uttervall, K, 2014) |
| "Current chemotherapy for multiple myeloma is based on bortezomib (BOR), dexamethasone (DEX), and thalidomide (THA)." | 3.80 | Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ( Devine, E; Krause, B; Krieter, DH; Lemke, HD; Storr, M; Wanner, C, 2014) |
| "Three cost effectiveness models for the treatment of multiple myeloma, were compared that had been developed to inform resource allocation in the UK for the chemotherapy regimens bortezomib, melphalan and prednisolone (BMP); and melphalan, prednisolone and thalidomide (MPT) versus melphalan and prednisolone (MP)." | 3.80 | Comparative cost-effectiveness models for the treatment of multiple myeloma. ( Bryant, J; Clegg, A; Cooper, K; Picot, J, 2014) |
| "The aim of this study was to develop a model able to predict the area under the lenalidomide plasma concentration-time curve (AUC) in multiple myeloma (MM) patients using a limited sampling strategy." | 3.80 | A limited sampling model to estimate exposure to lenalidomide in multiple myeloma patients. ( Abumiya, M; Fujishima, N; Hagihara, M; Hirokawa, M; Kameoka, Y; Kobayashi, T; Matsumoto, M; Miura, M; Niioka, T; Sawada, K; Shida, S; Tagawa, H; Takahashi, N, 2014) |
| "We retrospectively investigated clinical outcomes and prognostic factors of 131 patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) who received melphalan and prednisolone (MP) as first-line therapy from 2006 to 2013." | 3.80 | Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents. ( Fuchida, S; Hino, M; Ishii, K; Kanakura, Y; Kaneko, H; Kobayashi, M; Kosugi, S; Kuroda, J; Matsumura, I; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Shimura, Y; Takaori-Kondo, A; Tanaka, H; Taniwaki, M; Tsudo, M; Uoshima, N, 2014) |
| "Novel agents such as thalidomide, lenalidomide and bortezomib have dramatically changed the treatment paradigm of multiple myeloma (MM)." | 3.80 | Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network. ( Asaoku, H; Chou, T; Harada, T; Hayashi, K; Itagaki, M; Kuroda, Y; Mina, R; Murakami, H; Ozaki, S; Palumbo, A; Saitoh, T; Shimazaki, C; Shimizu, K; Suzuki, K; Yoshiki, Y, 2014) |
| "Lenalidomide (Revlimid®) combined with intermittent dexamethasone (the RD regimen) is one of the current standards for treatment of patients with relapsed/refractory multiple myeloma (MM)." | 3.80 | Treatment with lenalidomide (Revlimid®), cyclophosphamide (Endoxan®) and prednisone (REP) in relapsed/refractory multiple myeloma patients: results of a single centre retrospective study. ( Delforge, M; Devos, T; Dierickx, D; Janssens, A; Raddoux, J; Verhoef, G; Zelis, N, 2014) |
| " We present a 75-year-old Caucasian man with a violaceous ring-like firm, papular eruption, localized on the dorsal aspect of both hands, with histological features of GA, which subsequently resolved with the discontinuation of thalidomide he had started 1 month earlier for the treatment of a multiple myeloma." | 3.80 | Thalidomide-induced granuloma annulare. ( Atzori, L; Caddori, A; Ferreli, C; Manunza, F; Pau, M, 2014) |
| "The use of new agents (NAs) such as bortezomib, thalidomide, and lenalidomide has extended the survival of patients with multiple myeloma (MM)." | 3.80 | Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia. ( Abe, Y; Hamano, A; Hattori, Y; Miyazaki, K; Nakagawa, Y; Sekine, R; Shingaki, S; Suzuki, K; Tsukada, N, 2014) |
| " Here, we show how the addition of the PDE5 inhibitor, tadalafil, in a patient with end-stage relapsed/refractory multiple myeloma reduced MDSC function and generated a dramatic and durable antimyeloma immune and clinical response." | 3.80 | Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. ( Borrello, I; Bui, M; Ghosh, N; Noonan, KA; Rudraraju, L, 2014) |
| " Patients receiving thalidomide, especially in combination with steroids, are at increased risk of venous thromboembolism (VTE), while the incidence of VTE on bortezomib is low." | 3.80 | Inhibitory effects of bortezomib on platelet aggregation in patients with multiple myeloma. ( Dytfeld, D; Gil, L; Kaźmierczak, M; Komarnicki, M; Nowicki, A; Rupa-Matysek, J; Wojtasińska, E, 2014) |
| "A 54-year-old woman developed psoriasis on the plantar surface of her feet after 2 weeks of thalidomide 100 mg daily for the treatment of multiple IgG myeloma." | 3.80 | Psoriasis induced by thalidomide in a patient with multiple myeloma. ( Alaibac, M; Ferrazzi, A; Russo, I; Zambello, R, 2014) |
| "Lenalidomide in combination with dexamethasone is an effective and well-established treatment of relapsed or refractory multiple myeloma (rrMM) disease." | 3.80 | Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment. ( Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M, 2014) |
| " Although thalidomide and its derivatives, lenalidomide and pomalidomide, are widely used as an essential component in the treatment of selected hematologic neoplasms including multiple myeloma, the precise mechanisms by which these agents exert anti-tumor effects have yet to be clarified." | 3.80 | [Immunomodulatory drugs (IMiDs)]. ( Ichinohe, T; Oshima, K, 2014) |
| "A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants." | 3.80 | Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. ( Hobeika, L; Self, SE; Velez, JC, 2014) |
| "The mechanisms involved in anti-myeloma activity of statins combined with thalidomide were studied in multiple myeloma (MM) cells." | 3.79 | Induction of apoptosis in multiple myeloma cells by a statin-thalidomide combination can be enhanced by p38 MAPK inhibition. ( Kandefer-Szerszen, M; Mizerska-Dudka, M; Slawinska-Brych, A; Zdzisinska, B, 2013) |
| "In this issue of Blood, Leleu and colleagues(1) and Richardson and colleagues(2) publish two different trials using pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma (MM)." | 3.79 | "IM iD"eally treating multiple myeloma. ( Lacy, MQ, 2013) |
| "Lenalidomide is now widely used for the treatment of multiple myeloma in virtue of its potent anti-tumor activity and low toxicity." | 3.79 | Lenalidomide-induced acute lung injury in case of multiple myeloma. ( Aoki, T; Danbara, M; Higashihara, M; Katayama, T; Miyazaki, K; Tadera, N; Togano, T, 2013) |
| "Lenalidomide (LEN) is a relatively new and very effective therapy for multiple myeloma (MM)." | 3.79 | Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma. ( Abidi, MH; Abrams, J; Al-Kadhimi, Z; Ayash, L; Bhutani, D; Deol, A; Lum, L; Ratanatharathorn, V; Tageja, N; Uberti, J; Valent, J; Zonder, J, 2013) |
| "Dexamethasone ± thalidomide with infusion of cisplatin, doxorubicin, cyclophosphamide, and etoposide [D(T)PACE] is generally reserved as salvage therapy for aggressive multiple myeloma (MM) or plasma cell leukaemia (PCL) resistant to conventional therapies." | 3.79 | D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma. ( Chen, CI; Cheng, L; Gerrie, AS; Jiang, H; Kukreti, V; Mikhael, JR; Panzarella, T; Reece, D; Stewart, KA; Trieu, Y; Trudel, S, 2013) |
| " Total therapy trials (TT; TT2(-/+) thalidomide) and TT3 (TT3a with bortezomib, thalidomide; TT3b with additional lenalidomide) offered the opportunity to examine the contribution of these immune-modulatory agents to MDS-associated cytogenetic abnormalities (MDS-CA) and clinical MDS or acute leukemia ("clinical MDS/AL")." | 3.79 | Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. ( Abdallah, AO; Bailey, C; Barlogie, B; Chauhan, N; Cottler-Fox, M; Crowley, J; Epstein, J; Heuck, CJ; Hoering, A; Johann, D; Muzaffar, J; Petty, N; Rosenthal, A; Sawyer, J; Sexton, R; Singh, Z; Usmani, SZ; van Rhee, F; Waheed, S; Yaccoby, S, 2013) |
| "Transient inflammatory reactions have been reported in a subpopulation of patients with multiple myeloma (MM) during lenalidomide (Len) plus dexamethasone (DEX) therapy." | 3.79 | Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma. ( Abe, M; Fujii, S; Harada, T; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Oda, A; Ozaki, S; Takeuchi, K, 2013) |
| "Lenalidomide is an active immunomodulatory and antiproliferative agent in multiple myeloma." | 3.79 | Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma. ( Amiot, M; Bonnaud, S; Gomez-Bougie, P; Gratas, C; Le Gouill, S; Maïga, S; Moreau, P; Pellat-Deceunynck, C, 2013) |
| "The combination of lenalidomide and dexamethasone (Len-Dex) is a commonly used initial therapy for newly diagnosed multiple myeloma (MM)." | 3.79 | Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. ( Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Hayman, SR; Kapoor, P; Kumar, S; Kyle, R; Lacy, MQ; McCurdy, A; Rajkumar, SV; Rana, V; Russell, S; Srivastava, G; Zeldenrust, S, 2013) |
| "A 61-year-old man, who was diagnosed with Bence-Jones protein (BJP)-λ type multiple myeloma, was treated with bortezomib." | 3.79 | [The appearance of t(9;22)(q34;q11.2) in BJP-λ type multiple myeloma during maintenance therapy including lenalidomide]. ( Arakaki, H; Uchihara, JN, 2013) |
| "The introduction of autologous stem cell transplantation as well as novel agents such as proteasome inhibitors (bortezomib) and immunomodulatory drugs (IMiDs; thalidomide and lenalidomide) have significantly improved long-term outcome of multiple myeloma patients." | 3.79 | New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients. ( Lokhorst, HM; van de Donk, NW, 2013) |
| "Lenalidomide treatment for refractory or relapsed multiple myeloma in elderly patients may be feasible in an outpatient setting." | 3.79 | Very low-dose lenalidomide therapy for elderly multiple myeloma patients. ( Hirata, T; Inagaki, T; Iwai, M; Katayama, Y; Kawano, H; Kimura, S; Kishi, M; Koide, T; Matsui, T; Minagawa, K; Suzuki, T; Takechi, M, 2013) |
| "Studies comparing the efficacy and cost of peripheral blood stem and progenitor cells mobilization with low-dose cyclophosphamide (LD-CY) and granulocyte-colony stimulating factor (G-CSF) against plerixafor and G-CSF, in multiple myeloma (MM) patients treated in the novel therapy-era are not available." | 3.79 | Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. ( Awan, F; Chaudhary, L; Craig, M; Cumpston, A; Hamadani, M; Leadmon, S; Tse, W; Watkins, K, 2013) |
| "In our efforts to develop effective treatment agents for human multiple myeloma (MM), a series of hybrid molecules based on the structures of thalidomide (1) and curcumin (2) were designed, synthesized, and biologically characterized in human multiple myeloma MM1S, RPMI8226, U266 cells, and human lung cancer A549 cells." | 3.79 | Design and biological characterization of hybrid compounds of curcumin and thalidomide for multiple myeloma. ( Chojnacki, J; Du, Y; Fu, H; Grant, S; Liu, K; Zhang, D; Zhang, S, 2013) |
| "Lenalidomide and bortezomib have not been compared prospectively and are currently used in sequence for patients with multiple myeloma; however, it is unknown whether a sequence of administration could result in improved outcomes." | 3.79 | Sequence of novel agents in multiple myeloma: an instrumental variable analysis. ( Alsina, M; Baz, R; Dalton, WS; Djulbegovic, B; Ho, VQ; Miladinovic, B; Nishihori, T; Ochoa-Bayona, JL; Patel, A; Shain, KH; Sullivan, DM, 2013) |
| "The novel agents bortezomib and lenalidomide improve outcomes in multiple myeloma, yet most patients will relapse after exhausting treatment." | 3.79 | Pomalidomide in the treatment of relapsed multiple myeloma. ( Forsberg, PA; Mark, TM, 2013) |
| "We analyzed 1156 multiple myeloma (MM) patients treated with thalidomide." | 3.79 | 10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group. ( Adam, Z; Adamova, D; Bacovsky, J; Gregora, E; Gumulec, J; Hajek, R; Jarkovsky, J; Maisnar, V; Melicharova, H; Minarik, J; Pavlicek, P; Pika, T; Plonkova, H; Pour, L; Radocha, J; Sandecka, V; Scudla, V; Spicka, I; Starostka, D; Straub, J; Walterova, L; Wrobel, M, 2013) |
| "Lenalidomide in combination with dexamethasone (Len/Dex) is indicated for patients with recurrent/refractory multiple myeloma (RRMM) who were treated with 1 prior therapy until evidence of disease progression." | 3.79 | Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma. ( Avet Loiseau, H; Bonnet, S; Debarri, H; Demarquette, H; Facon, T; Fouquet, G; Gay, J; Guidez, S; Herbaux, C; Hulin, C; Leleu, X; Michel, J; Miljkovic, D; Perrot, A; Serrier, C; Tardy, S, 2013) |
| "Two male patients (aged 41 and 70) with multiple myeloma developed severe, rapidly progressing cognitive impairment (mostly involving episodic memory) and loss of independence in activities of daily living during lenalidomide-based treatment." | 3.79 | Memory loss during lenalidomide treatment: a report on two cases. ( Delbeuck, X; Facon, T; Le Rhun, E; Leleu, X; Lenfant, P; Mackowiak, MA; Noel, MP; Pasquier, F; Pollet, M; Rollin-Sillaire, A, 2013) |
| "Treatment with thalidomide is associated with vascular thrombosis." | 3.79 | Increased PAC-1 expression among patients with multiple myeloma on concurrent thalidomide and warfarin. ( Abdullah, D; Abdullah, WZ; Hussin, A; Roshan, TM; Zain, WS, 2013) |
| "Bortezomib (Btz) has emerged as a standard of care in the treatment of patients with multiple myeloma (MM), but Btz-induced peripheral neuropathy (PNP) has a particularly negative impact on patients' quality of life." | 3.79 | Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma. ( Drach, J; Drach-Schauer, B; Eder, S; Lamm, W, 2013) |
| "During the last two decades, many steps forward have been made in the treatment of multiple myeloma (MM) thanks to the introduction of the novel agents thalidomide, lenalidomide, and bortezomib." | 3.79 | Initial treatment of nontransplant patients with multiple myeloma. ( Cerrato, C; Palumbo, A, 2013) |
| "We report the first case of progressive hair repigmentation associated with the use of lenalidomide in an elderly patient with multiple myeloma." | 3.79 | Hair repigmentation associated with the use of lenalidomide: graying may not be an irreversible process! ( Alexandrescu, DT; Dasanu, CA; Mitsis, D, 2013) |
| "This retrospective study compares the overall survival (OS) of multiple myeloma (MM) patients following treatment at a New Zealand hospital over a period in which novel therapies were available but restricted, almost exclusively, to thalidomide as a second-line therapy." | 3.79 | Survival of myeloma patients following the introduction of thalidomide as a second-line therapy: a retrospective study at a single New Zealand centre. ( Fernyhough, LJ; Ganly, P; Hock, BD; Pearson, J; Taylor, J, 2013) |
| "To determine the cost effectiveness of lenalidomide plus dexamethasone (LEN/DEX) versus DEX alone in managing multiple myeloma (MM) patients who have failed one prior therapy." | 3.79 | Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales. ( Brown, RE; Dhanasiri, S; Schey, S; Stern, S, 2013) |
| "Lenalidomide is an effective therapeutic agent for multiple myeloma that exhibits immunomodulatory properties including the activation of T and NK cells." | 3.79 | Lenalidomide enhances anti-myeloma cellular immunity. ( Anderson, KC; Arnason, J; Avigan, D; Glotzbecker, B; Joyce, RM; Kufe, D; Kufe, T; Levine, JD; Luptakova, K; Mills, H; Rosenblatt, J; Stroopinsky, D; Tzachanis, D; Vasir, B; Zwicker, JI, 2013) |
| "The role of thalidomide, bortezomib and lenalidomide in multiple myeloma patients presenting with renal impairment was evaluated in 133 consecutive newly diagnosed patients who were treated with a novel agent-based regimen." | 3.79 | The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. ( Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Matsouka, C; Mparmparoussi, D; Nikitas, N; Psimenou, E; Roussou, M; Spyropoulou-Vlachou, M; Terpos, E, 2013) |
| "The combination of lenalidomide, bortezomib and dexamethasone (RVD) has shown excellent efficacy in patients with relapsed or refractory multiple myeloma (RRMM)." | 3.79 | Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma. ( Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S, 2013) |
| " In this study we report for the first time that ibrutinib is cytotoxic to malignant plasma cells from patients with multiple myeloma (MM) and furthermore that treatment with ibrutinib significantly augments the cytotoxic activity of bortezomib and lenalidomide chemotherapies." | 3.79 | BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB. ( Barrera, LN; Bowles, KM; MacEwan, DJ; Murray, MY; Rushworth, SA; Zaitseva, L, 2013) |
| "To assess thromboprophylaxis prescribing patterns against current guidelines and report thromboembolism (TE) incidence in multiple myeloma (MM) patients treated with thalidomide (thal) or lenalidomide (len) at a specialist cancer hospital over a one-year period." | 3.79 | Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital. ( Alexander, M; Kirsa, S; Lingaratnam, S; Mellor, JD; Teoh, KC, 2013) |
| "Multiple myeloma (MM)-induced osteoclast (OC) formation is mainly due to an imbalance of the receptor activator NF-κB ligand (RANKL)-osteoprotegerin (OPG) ratio in favor of RANKL in the bone microenvironment and to the CCL3 production by MM cells." | 3.79 | Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. ( Agnelli, L; Bolzoni, M; Bonomini, S; Giuliani, N; Guasco, D; Neri, A; Rizzoli, V; Storti, P; Todoerti, K; Toscani, D, 2013) |
| "Lenalidomide (LEN) treatment in multiple myeloma (MM) results in a superior outcome." | 3.79 | Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide. ( Dai, L; Gollin, SM; Lentzsch, S; Mapara, MY; Monaghan, SA; Normolle, DP, 2013) |
| "The CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen is known to be an effective primary therapy in patients with newly diagnosed multiple myeloma (MM)." | 3.79 | Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen. ( Ahn, JS; Jung, SH; Kim, HJ; Kim, MY; Kim, YK; Lee, JJ; Park, H; Yang, DH, 2013) |
| "In this prospective study of patients with relapsed or relapsed and refractory multiple myeloma (MM) treated with lenalidomide and dexamethasone, relationships between markers of endothelial stress and drug administration and incidence of venous thromboembolism (VTE) were assessed." | 3.79 | Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. ( Anderson, KC; Bradwin, G; Connell, B; Doyle, M; Ghobrial, I; Hong, F; Lockridge, L; Mitsiades, C; Munshi, N; Richardson, P; Rosovsky, R; Schlossman, R; Soiffer, RJ; Tocco, D; Warren, D; Weller, E, 2013) |
| "In an effort to maintain high primary response rates against multiple myeloma and without serious toxicity, we assessed 3 different bortezomib combinations in small numbers of patients, with combinations that included cyclophosphamide and lenalidomide in modest doses and for short courses." | 3.79 | High frequencies of response after limited primary therapy for multiple myeloma. ( Alexanian, R; Delasalle, K; Wang, M, 2013) |
| "The combination of clarithromycin, lenalidomide, and dexamethasone (BiRd) was evaluated as therapy for treatment-naive symptomatic multiple myeloma (MM), with overall response at 2 years of 90%." | 3.79 | BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. ( Chen-Kiang, S; Christos, P; Coleman, M; Jayabalan, D; Mark, T; Niesvizky, R; Pearse, R; Pekle, K; Rossi, A; Zafar, F, 2013) |
| " Treatment of multiple myeloma has dramatically improved with the introduction of bortezomib (BOR), thalidomide (THAL), and lenalidomide (LEN)." | 3.79 | Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. ( Ba-Mancini, A; Henk, HJ; Huang, H; Teitelbaum, A, 2013) |
| "Thalidomide, lenalidomide and bortezomib have increasingly been incorporated in first-line induction therapies for multiple myeloma." | 3.79 | Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center. ( Adel, N; Chen, X; Chimento, D; Chung, DJ; Comenzo, R; Giralt, S; Hassoun, H; Landau, H; Lendvai, N; Lesokhin, A; Pozotrigo, M; Reich, L; Riedel, E, 2013) |
| "Lenalidomide is a derivative of thalidomide and is FDA-approved for the treatment of myelodysplastic syndrome and, in combination with dexamethasone, for the treatment of relapsed multiple myeloma." | 3.78 | Reversible pulmonary toxicity due to lenalidomide. ( Barker, A; Coates, S; Spurgeon, S, 2012) |
| "The chemotherapeutic regimen melphalan, prednisolone, and thalidomide (MPT) is the standard of care for symptomatic multiple myeloma patients who are not eligible for high dose chemotherapy followed by autologous stem cell therapy." | 3.78 | Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma. ( Jena, RK; Kansurkar, SS; Swain, M; Swain, TR, 2012) |
| "Few data are available on the efficacy of the combination of lenalidomide plus dexamethasone (Len/Dex) in very elderly patients above 75 years of age with relapsed multiple myeloma (MM)." | 3.78 | Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma. ( Blin, N; Clavert, A; Dubruille, V; Le Gouill, S; Loirat, M; Mahe, B; Malard, F; Mohty, M; Moreau, P; Pennetier, M; Peterlin, P; Planche, L; Roland, V; Tessoulin, B; Touzeau, C, 2012) |
| "del(17p13)(TP53) seems to be an independent poor prognostic factor in patients with relapsed/refractory multiple myeloma (MM) receiving lenalidomide." | 3.78 | p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide. ( Chang, H; Chen, MH; Qi, CX; Saha, MN, 2012) |
| "We present the case of a woman with relapsed multiple myeloma (MM) who received combination lenalidomide and bortezomib therapy for 90 cycles followed by continuous lenalidomide monotherapy and has completed over 100 cycles of treatment to date." | 3.78 | The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. ( Anderson, KC; Colson, K; Doss, D; Ghobrial, IM; Hideshima, T; Laubach, JP; Lunde, L; McKenney, M; Mitsiades, C; Munshi, NC; Noonan, K; Redman, KC; Richardson, PG; Schlossman, RL; Warren, D, 2012) |
| "Retrospective multicenter analysis of 26 patients with multiple myeloma to assess the efficacy and toxicity of relapse treatment with lenalidomide/dexamethasone in renal-function impairment." | 3.78 | Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers. ( Hahn-Ast, C; Kuhn, S; Langer, C; Oehrlein, K; Pönisch, W; Sturm, I; Weisel, KC, 2012) |
| " We hypothesized that growth factor plus preemptive plerixafor is an effective strategy for AHSC mobilization in multiple myeloma (MM) despite prior exposure to lenalidomide." | 3.78 | Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. ( Abbas, J; Butcher, CD; Costa, LJ; Hogan, KR; Kang, Y; Kramer, C; Littleton, A; McDonald, K; Shoptaw, K; Stuart, RK, 2012) |
| "Two pivotal, phase III, randomised, placebo-controlled, registration trials (MM-009 and MM-010) showed that lenalidomide plus dexamethasone was more effective than placebo plus dexamethasone in the treatment of patients with relapsed or refractory multiple myeloma." | 3.78 | Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma. ( Borrello, I; Chanan-Khan, AA; Dimopoulos, M; Foà, R; Hellmann, A; Knight, R; Lonial, S; Swern, AS; Weber, D, 2012) |
| "Thromboembolic events (TEE) are a serious clinical problem in multiple myeloma (MM) patients receiving thalidomide (T)." | 3.78 | Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma. ( Chojnowski, K; Robak, M; Treliński, J, 2012) |
| "Bortezomib therapy has proven successful for the treatment of relapsed/refractory, relapsed, and newly diagnosed multiple myeloma (MM); however, dose-limiting toxicities and the development of resistance limit its long-term utility." | 3.78 | A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. ( Altun, M; Anderson, KC; Carrasco, R; Chauhan, D; Fulcinniti, M; Hideshima, T; Kessler, BM; Kingsbury, WD; Kodrasov, MP; Kumar, KG; Leach, CA; McDermott, JL; Minvielle, S; Munshi, N; Nicholson, B; Orlowski, R; Richardson, P; Shah, PK; Tian, Z; Weinstock, J; Zhou, B, 2012) |
| "The introduction of novel agents (thalidomide, bortezomib and lenalidomide) in the frontline therapy of multiple myeloma has markedly improved the outcome both in younger patients who are candidates for high-dose therapy plus autologous stem-cell transplantation (HDT/ASCT) and in elderly patients." | 3.78 | How to select among available options for the treatment of multiple myeloma. ( Harousseau, JL, 2012) |
| "The introduction of bortezomib, a first-generation proteasome inhibitor, changed the standard-of-care for newly diagnosed and relapsed multiple myeloma patients." | 3.78 | Role of carfilzomib in the treatment of multiple myeloma. ( Badros, A; Khan, RZ, 2012) |
| "Treatment of patients with multiple myeloma (MM) has drastically changed with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, but treatment outcome of elderly patients has remained dismal mainly due to toxicities." | 3.78 | Attainment of a stringent complete response in multiple myeloma with thalidomide monotherapy. ( Aritaka, N; Hirano, T; Ichikawa, K; Komatsu, N; Matsumoto, T; Nakamura, H; Ogura, K; Yasuda, H, 2012) |
| "To investigate the relationship between the efficacy and safety of different doses of thalidomide (Thal) plus dexamethasone (Dex) as the initial therapy in elderly patients with newly diagnosed multiple myeloma (MM)." | 3.78 | Clinical study of thalidomide combined with dexamethasone for the treatment of elderly patients with newly diagnosed multiple myeloma. ( Chen, HF; Cui, QY; Ding, J; Jin, LJ; Li, ZY; Qin, LM; Ren, YY; Shen, HS; Tang, JQ; Wang, J; Wang, KY; Wang, ZY; Wu, TQ; Yu, ZQ; Zhu, JJ, 2012) |
| "Lenalidomide is an active treatment for multiple myeloma (MM) and is increasingly used as part of the initial treatment of this disease." | 3.77 | Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen. ( Cook, R; Cunningham, K; Gardler, M; Hummel, K; Luger, SM; Mangan, PA; Nazha, A; O'Doherty, U; Porter, DL; Schuster, S; Siegel, D; Stadtmauer, EA; Vogl, DT, 2011) |
| "Lenalidomide and other new agents have considerable activity in multiple myeloma (MM) and have changed the landscape of treatment." | 3.77 | Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide. ( Calandra, G; Gandhi, PJ; Ho, AD; Klein, LM; Marulkar, S; McSweeney, PA; Micallef, IN, 2011) |
| "Lenalidomide combined with dexamethasone is an effective treatment for refractory/relapsed multiple myeloma (MM)." | 3.77 | The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. ( Harrison, SJ; Hsu, AK; Neeson, P; Prince, HM; Quach, H; Ritchie, DS; Smyth, MJ; Tai, T; Trapani, JA, 2011) |
| "In our efforts to develop novel effective treatment regimens for multiple myeloma we evaluated the potential benefits of combining the immunomodulatory drug lenalidomide with daratumumab." | 3.77 | Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. ( Bakker, JM; de Weers, M; Lokhorst, HM; Mutis, T; Parren, PW; van der Veer, MS; van Kessel, B; Wittebol, S, 2011) |
| "The treatment of multiple myeloma (MM) has changed with the advent of thalidomide, bortezomib, and lenalidomide, the so-called novel agents (NAs)." | 3.77 | Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months). ( Barnett, MJ; Broady, R; Connors, JM; Forrest, DL; Hamata, L; Hogge, DE; Mourad, YA; Nantel, SH; Narayanan, S; Nevill, TJ; Nitta, J; Power, MM; Shepherd, JD; Smith, CA; Song, KW; Sutherland, HJ; Toze, CL; Venner, CP, 2011) |
| "Lenalidomide plays an important role in our chemotherapeutic armamentarium against multiple myeloma, in part by exerting direct anti-proliferative and pro-apoptotic effects." | 3.77 | Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. ( Bjorklund, CC; Davis, RE; Kornblau, SM; Kuhn, DJ; Ma, W; Orlowski, RZ; Shah, JJ; Wang, M; Wang, ZQ, 2011) |
| " For relapsed or refractory multiple myeloma (RRMM), a series of novel agents (thalidomide, bortezomib and lenalidomide) has emerged during the latest decade, but their use in routine clinical practice is not well documented as well as the cost of RRMM." | 3.77 | Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study. ( Armoiry, X; Aulagner, G; Benboubker, L; Facon, T; Fagnani, F; Fermand, JP; Hulin, C; Moreau, P, 2011) |
| "An expert panel convened to reach a consensus regarding the optimal use of lenalidomide in combination with dexamethasone (Len/Dex) in patients with relapsed or refractory multiple myeloma (RRMM)." | 3.77 | Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. ( Attal, M; Beksaç, M; da Costa, FL; Davies, FE; Delforge, M; Dimopoulos, MA; Einsele, H; Hajek, R; Harousseau, JL; Ludwig, H; Mellqvist, UH; Morgan, GJ; Palumbo, A; San-Miguel, JF; Sonneveld, P; Zweegman, S, 2011) |
| "To determine the in vivo and in vitro antiangiogenic power of lenalidomide, a "lead compound" of IMiD immunomodulatory drugs in bone marrow (BM) endothelial cells (EC) of patients with multiple myeloma (MM) in active phase (MMEC)." | 3.77 | Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. ( Basile, A; Berardi, S; Caivano, A; Capalbo, S; Cascavilla, N; Coluccia, AM; Dammacco, F; de Luca, E; De Luisi, A; Di Pietro, G; Ditonno, P; Ferrucci, A; Guarini, A; Maffia, M; Moschetta, M; Pieroni, L; Quarta, G; Ranieri, G; Ria, R; Ribatti, D; Urbani, A; Vacca, A, 2011) |
| "A total of 106 relapsed or refractory multiple myeloma patients received lenalidomide 25mg plus dexamethasone as salvage therapy; 80 patients progressed on thalidomide treatment (thalidomide-resistant) and 26 patients discontinued thalidomide in at least partial remission (thalidomide-sensitive)." | 3.77 | Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. ( Benevolo, G; Berruti, A; Boccadoro, M; Bringhen, S; Caravita, T; Cavallo, F; Corradini, P; Gay, F; Guglielmelli, T; Montefusco, V; Offidani, M; Palumbo, A; Petrucci, MT; Piro, E; Rrodhe, S; Saglio, G, 2011) |
| "Immunomodulatory derivatives of thalidomide (IMiD compounds), such as pomalidomide and lenalidomide, are highly active in multiple myeloma (MM) treatment." | 3.77 | IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. ( Galson, DL; Lentzsch, S; Li, S; Mapara, M; Monaghan, SA; Ouyang, H; Pal, R; Schafer, P, 2011) |
| "Nine plasma cell myeloma patients spontaneously developed histologically proven autologous graft-versus-host disease (GVHD) limited predominantly to the gastrointestinal tract within 1 month of initial autologous hematopoietic cell transplantation (AHCT) using high-dose melphalan conditioning." | 3.77 | Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts. ( Arfons, LM; Ataergin, SA; Barr, PM; Cooper, BW; Creger, RJ; Fu, P; Gerson, SL; Kaplan, D; Kaye, NM; Kindwall-Keller, TL; Laughlin, MJ; Lazarus, HM; Liu, F; Sommers, SR, 2011) |
| "We studied the efficacy and safety of bortezomib (BOR) for treatment of multiple myeloma in comparison with thalidomide (THAL) by reference to adverse events, and searched for laboratory markers that could be used for prognostication of patients." | 3.77 | Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide. ( Akiba, T; Aotsuka, N; Matsuura, Y; Oguro, R; Satoh, M; Takada, K; Tani, Y; Wakita, H; Yamanaka, C, 2011) |
| "Thalidomide was a widely used drug in the late 1950s and early 1960s for the treatment of nausea in pregnant women." | 3.77 | Thalidomide: the tragedy of birth defects and the effective treatment of disease. ( Kim, JH; Scialli, AR, 2011) |
| "In the era of novel agents such as lenalidomide and bortezomib, risk stratification by chromosomal abnormalities may enable a more rational selection of therapeutic approaches in patients with multiple myeloma (MM)." | 3.77 | Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. ( Goldschmidt, H; Hielscher, T; Hillengass, J; Ho, AD; Hose, D; Jauch, A; Klein, U; Neben, K; Raab, MS; Seckinger, A, 2011) |
| "Evidence of long-term response to lenalidomide in heavily pretreated patients with multiple myeloma is lacking." | 3.77 | Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant. ( Citro, A; Corradini, P; Crippa, C; De Muro, M; Falcone, AP; Galli, M; Gentili, S; Grasso, M; Guglielmelli, T; Montefusco, V; Olivero, B; Patriarca, F; Rossi, D; Sammassimo, S; Spina, F, 2011) |
| "To explore the difference of effects of two regimens (bortezomib and dexamethasone, BD; and thalidomide and dexamethasone, TD) on bone disease in multiple myeloma (MM)." | 3.77 | [Effect of different regimens on bone disease of multiple myeloma]. ( Bao, L; Huang, XJ; Lai, YY; Lu, J; Lu, XJ; Zhang, XH; Zhu, HH, 2011) |
| "Combining thalidomide (Thal) with chemotherapeutic agents or steroid preparations led to improved response rates in the treatment of multiple myeloma." | 3.77 | Activation of coagulation by a thalidomide-based regimen. ( Chung, J; Hoshi, A; Isozumi, Y; Koyama, T; Matsumoto, A, 2011) |
| "The success of bortezomib therapy for treatment of multiple myeloma (MM) led to the development of structurally and pharmacologically distinct novel proteasome inhibitors." | 3.77 | In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. ( Anderson, KC; Chauhan, D; Kuhn, D; Orlowski, R; Raje, N; Richardson, P; Tian, Z; Zhou, B, 2011) |
| "Pomalidomide is an immunomodulatory derivative (IMiD) active in multiple myeloma." | 3.77 | Acute lung toxicity related to pomalidomide. ( Geyer, HL; Lacy, MQ; Leslie, KO; Mikhael, JR; Stewart, K; Viggiano, RW; Witzig, TE, 2011) |
| "Venous thromboembolism (VTE), with the subsequent risk of pulmonary embolism, is a common adverse effect of thalidomide treatment in patients with multiple myeloma (MM)." | 3.77 | Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide. ( Almasi, M; Hajek, R; Kaisarova, P; Maisnar, V; Penka, M; Pika, T; Pour, L; Radocha, J; Scudla, V; Sevcikova, S; Slaby, O; Svachova, H, 2011) |
| "To estimate the cost-effectiveness (cost per additional life-year [LY] and quality-adjusted life-year [QALY] gained) of lenalidomide plus dexamethasone (LEN/DEX) compared with bortezomib for the treatment of relapsed-refractory multiple myeloma (rrMM) in Norway." | 3.77 | Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib. ( Möller, J; Murthy, A; Nicklasson, L, 2011) |
| " Lenalidomide is a derivative of thalidomide used in the treatment of multiple myeloma." | 3.77 | Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma. ( Bolesta, S; Boruah, PK; Shetty, SM, 2011) |
| "Thalidomide was approved in Japan for multiple myeloma treatment in October 2008." | 3.77 | [Reported use of thalidomide in multiple myeloma: presentation of problems in the Thaled® outpatient department]. ( Aimono, Y; Aoyama, Y; Chikatsu, N; Ebata, S; Hakozaki, M; Isa, S; Kudo, D; Monma, Y; Onozaki, M; Otani, E; Saito, Y; Sato, W; Sawahata, T; Shinagawa, A; Suzuki, M, 2011) |
| "The clinical efficacy and safety of a three-drug combination of melphalan, prednisone, and thalidomide were assessed in patients with multiple myeloma who were not candidates for high-dose therapy as a first-line treatment." | 3.77 | A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma. ( Bae, SH; Bang, SM; Chang, HJ; Do, YR; Lee, JH; Lee, JL; Nam, SH; Yoon, SS, 2011) |
| "To explore the efficacies and toxicities in multiple myeloma (MM) patients on the maintenance therapies of thalidomide and interferon-α so as to seek the optimal chemotherapeutic regimen." | 3.77 | [Maintenance therapies of thalidomine and interferon-α in multiple myeloma]. ( Cai, JH; Huang, BH; Li, J; Liu, JR; Zheng, D, 2011) |
| "The treatment approach in patients with multiple myeloma (MM) has been essentially changed with introduction of novel agents such as thalidomide, bortezomib and lenalidomide." | 3.77 | Timing of the high-dose therapy in the area of new drugs. ( Bertsch, U; Goldschmidt, H; Hose, D; Schmitt, S, 2011) |
| "Thalidomide has emerged as an effective agent for treating multiple myeloma, however the precise mechanism of action remains unknown." | 3.76 | Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. ( Hohl, RJ; Holstein, SA; Tong, H, 2010) |
| "Bortezomib and Lenalidomide have been shown to be effective in the control of multiple myeloma (MM) progression." | 3.76 | Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide. ( Brunetti, AE; Cafforio, P; Dammacco, F; De Matteo, M; Maiorano, E; Silvestris, F, 2010) |
| "The frequency of thromboembolic events (TE) in Caucasian patients with multiple myeloma (MM) receiving thalidomide as the initial treatment has been reported to be 10~58% without prophylactic anticoagulation." | 3.76 | Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. ( Bang, SM; Do, YR; Eom, H; Kim, HJ; Kim, K; Kim, MK; Kim, SJ; Koh, Y; Lee, JH; Lee, MH; Lee, N; Mun, YC; Rhee, KH; Ryoo, HM; Shin, HC; Won, JH; Yoon, HJ; Yoon, SS, 2010) |
| "Thalidomide and its analogs are effective agents in the treatment of multiple myeloma." | 3.76 | Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways. ( Bladé, J; Cibeira, MT; Cid, MC; Corbera-Bellalta, M; Esparza, J; Izco, N; Lozano, E; Segarra, M; Vilardell, C, 2010) |
| "We analyzed proliferative index of myeloma plasmocytes (PC-PI) in acohort of 217 patients with multiple myeloma (MM) treated with conventional chemotherapy and biological agents, thalidomide and bortezomib." | 3.76 | Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma. ( Bacovsky, J; Langova, K; Minarik, J; Ordeltova, M; Pika, T; Scudla, V; Zemanova, M, 2010) |
| " Whether betulinic acid, a pentacyclic triterpene, can modulate the STAT3 pathway, was investigated in human multiple myeloma (MM) cells." | 3.76 | Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. ( Aggarwal, BB; Pandey, MK; Sung, B, 2010) |
| "Combinations of drug treatments based on bortezomib or lenalidomide plus steroids have resulted in very high response rates in multiple myeloma." | 3.76 | In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. ( Atadja, P; Crusoe, E; de Alava, E; Fernández-Lázaro, D; Garayoa, M; Hernández-Iglesias, T; Maiso, P; Ocio, EM; Pandiella, A; San-Miguel, JF; San-Segundo, L; Shao, W; Vilanova, D; Yao, YM, 2010) |
| "The immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide yield high response rates in patients with multiple myeloma, but the use of IMiDs in multiple myeloma is associated with neutropenia and increased risk for venous thromboembolism (VTE) by mechanisms that are unknown." | 3.76 | Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. ( Hassett, AC; Lentzsch, S; List, A; Mapara, MY; Monaghan, SA; Moscinski, L; Pal, R; Ragni, MV; Roodman, GD; Schafer, P, 2010) |
| "Thalidomide based regimen is an effective and well tolerated therapy in multiple myeloma (MM) patients, however, there were a small number of studies written about the results of thalidomide therapy in non-transplant MM patients." | 3.76 | Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand. ( Atichartakarn, V; Aungchaisuksiri, P; Chuncharunee, S; Jootar, S; Niparuck, P; Puavilai, T; Sorakhunpipitkul, L; Ungkanont, A, 2010) |
| "This retrospective analysis investigated the prognostic value of del(13) and t(4;14) abnormalities and the impact of prior treatment on outcomes in 207 heavily pretreated patients with relapsed or refractory multiple myeloma (MM) treated with lenalidomide plus dexamethasone." | 3.76 | Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone. ( Attal, M; Avet-Loiseau, H; Belhadj, K; Dorvaux, V; Fermand, JP; Garderet, L; Hulin, C; Minvielle, S; Moreau, P; Soulier, J; Yakoub-Agha, I, 2010) |
| "To determine the effect of dexamethasone on the antimyeloma effects of lenalidomide, we tested in vitro proliferation, tumor suppressor gene expression, caspase activity, cell cycling, and apoptosis levels in a series of multiple myeloma (MM) and plasma cell leukemia cell lines treated with lenalidomide and dexamethasone, alone or in combination." | 3.76 | Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. ( Bartlett, JB; Capone, L; Fang, W; Gandhi, AK; Hampton, G; Kang, J; Lopez-Girona, A; Mendy, D; Parton, A; Sapinoso, L; Schafer, P; Tran, T; Wu, L; Xu, S; Zhang, LH, 2010) |
| "The role of TNF-α promoter polymorphisms in the development of multiple myeloma (MM) were tested in 210 patients and 218 healthy individuals and their impact on the clinical outcome were evaluated in 98 patients treated with thalidomide and dexamethasone (Thal+Dex) regimen." | 3.76 | Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone. ( Chen, B; Du, J; Fu, W; Hou, J; Jiang, H; Yuan, Z; Zhang, C, 2010) |
| "Lenalidomide and dexamethasone (LenDex) is an active regimen for relapsed/refractory multiple myeloma (MM)." | 3.76 | Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. ( Christoulas, D; Dimopoulos, MA; Efstathiou, E; Gavriatopoulou, M; Grapsa, I; Kastritis, E; Matsouka, C; Migkou, M; Mparmparoussi, D; Psimenou, E; Roussou, M; Terpos, E, 2010) |
| "Thalidomide has received approval from the European Agency for the Evaluation of Medicinal Products for the treatment of newly diagnosed multiple myeloma (MM) patients older than 65 years or ineligible for transplant." | 3.76 | Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. ( Bladé, J; Davies, F; Delforge, M; Facon, T; Garcia Sanz, R; Kropff, M; Leal da Costa, F; Moreau, P; Morgan, G; Palumbo, A; Schey, S, 2010) |
| "To obtain efficacy and safety data on lenalidomide treatment outside of clinical trials, we analyzed the clinical data of 114 patients with refractory or relapsed multiple myeloma treated with lenalidomide on a compassionate use basis." | 3.76 | Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program. ( Eeltink, CM; Huls, G; Kersten, MJ; Kneppers, E; Koedam, J; Lokhorst, HM; Minnema, MC; Raymakers, RA; Schaafsma, MR; Sonneveld, P; van Oers, MH; Vellenga, E; Wijermans, PW; Wittebol, S; Zweegman, S, 2010) |
| "Bortezomib, an inhibitor of 26S proteosome, is recently approved treatment option for multiple myeloma." | 3.76 | Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient. ( Chang, J; Cho, SH; Kang, W; Kim, JS; Kim, SK; Park, MS, 2010) |
| "Thalidomide is now recognized as an important agent for multiple myeloma." | 3.76 | [Retrospective analysis of thalidomide therapy in patients with relapsed/refractory multiple myeloma]. ( Akagi, T; Goto, K; Ikebe, T; Ikewaki, J; Imamura, T; Kadota, J; Kohno, K; Miyazaki, M; Miyazaki, Y; Ogata, M; Ohtsuka, E; Saburi, Y; Uno, N, 2010) |
| "Factors that affect the response of multiple myeloma patients to thalidomide were evaluated in 40 patients who were not eligible for chemotherapy (untreated: 14, relapse/refractory: 26)." | 3.76 | [Factors affecting the response of thalidomide therapy for patients with multiple myeloma]. ( Agata, M; Ishiyama, M; Kazama, H; Kondo, T; Mori, N; Motoji, T; Oda, T; Okamura, T; Sagawa, K; Sameshima, Y; Shiseki, M; Teramura, M; Yamada, O; Yasunami, T; Yoshinaga, K, 2010) |
| "Between April 2006 and June 2009, 34 newly diagnosed patients with multiple myeloma received one to three courses of bortezomib 1." | 3.76 | Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD). ( Alexanian, R; Delasalle, K; Giralt, S; Wang, M, 2010) |
| "Lenalidomide is a new immunomodulatory drug, FDA-approved for the treatment of the 5q-myelodysplastic syndrome and refractory or relapsed multiple myeloma (MM)." | 3.76 | A case of lenalidomide-induced hypersensitivity pneumonitis. ( Feilchenfeldt, J; Györik, S; Lerch, E; Mazzucchelli, L; Quadri, F, 2010) |
| "This single-center retrospective study determined the efficacy of bortezomib, thalidomide, and dexamethasone (BTD) as induction for patients with multiple myeloma (MM) who were eligible for autologous stem cell transplantation (ASCT)." | 3.76 | Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. ( Gleason, C; Heffner, LT; Kaufman, JL; Lonial, S; Nooka, A; Vrana, M, 2010) |
| " Inclusion criteria were diagnosis of stage III multiple myeloma and clinical indication for therapeutical administration of bortezomib or lenalidomide." | 3.76 | Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results. ( Brodoefel, H; Claussen, CD; Fenchel, M; Horger, M; Konaktchieva, M; Kraus, S; Weisel, K, 2010) |
| "There was no association between functional CYP2C19 and CYP2D6 alleles and treatment outcome in multiple myeloma patients treated with cyclophosphamide, thalidomide or bortezomib." | 3.76 | No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma. ( Abildgaard, N; Andersen, NF; Gimsing, P; Gregersen, H; Klausen, TW; Rasmussen, HB; Søeby, K; Vangsted, AJ; Vogel, U; Werge, T, 2010) |
| "Previous literature suggests that cytogenetics may be used for risk-adapted therapy in patients with relapsed/refractory multiple myeloma (MM) treated with lenalidomide and dexamethasone." | 3.76 | Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. ( Chang, H; Chen, C; Jiang, A; Qi, C; Reece, D; Trieu, Y, 2010) |
| "The introduction of thalidomide, lenalidomide, and bortezomib has changed the way that multiple myeloma (MM) is treated and has greatly improved survival outcomes." | 3.76 | Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies. ( Morgan, G, 2010) |
| "The immunomodulatory drugs thalidomide and lenalidomide have enhanced activity in patients with multiple myeloma (MM)." | 3.75 | Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. ( Goldschmidt, H; Hegenbart, U; Hillengass, J; Ho, AD; Hundemer, M; Klein, U; Kosely, F; Moehler, T; Neben, K; Schmitt, S, 2009) |
| "Lenalidomide is an important contemporary treatment option for patients with multiple myeloma (MM)." | 3.75 | A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma. ( Alexandrescu, DT; Dasanu, CA, 2009) |
| " Here we report a case of severe ischemic cholangitis in a patient with multiple myeloma receiving chemotherapy with melphalan, prednisone, and lenalidomide." | 3.75 | Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide. ( Bianchi, L; Böckeler, M; Kanz, L; Mayer, F; Terracciano, LM; Weisel, KC, 2009) |
| "This study was aimed to investigate the effect of metabolic system in human hepatic cell microsome on antiangiogenic in vitro activity of thalidomide used in treating multiple myeloma and to explore the role of cytochrome CYP2C19." | 3.75 | [Antiangiogenic activity of thalidomide in vitro mediated by cytochrome CYP2C19]. ( Hou, J; Huang, HM; Jiang, H; Li, YH, 2009) |
| " Osteonecrosis of the jaw (ONJ) is an emerging serious side effect of the new generation bisphosphonates with a growing number of reports related to this pathological entity." | 3.75 | Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. ( Aki, SZ; Cetiner, M; Cetiner, S; Gultekin, SE; Haznedar, R; Kahraman, SA; Kocakahyaoglu, B; Sucak, GT, 2009) |
| "The therapeutic use of thalidomide in patients with multiple myeloma is often complicated by the development of venous thromboembolism." | 3.75 | Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. ( Claxton, D; Fink, LM; Ibrahim, S; Talamo, GP; Tricot, GJ; Zangari, M, 2009) |
| "Curcumin (diferuloylmethane), a yellow pigment in turmeric, has been shown to inhibit the activation of nuclear factor-kappaB (NF-kappaB), a transcription factor closely linked to chemoresistance in multiple myeloma cells." | 3.75 | Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. ( Aggarwal, BB; Anand, P; Guha, S; Kunnumakkara, AB; Sethi, G; Sung, B, 2009) |
| "A prospective subgroup analysis of two prospective, randomized, double-blind, placebo-controlled phase III clinical trials showed that the combination of lenalidomide plus dexamethasone is superior to dexamethasone alone in patients with relapsed or refractory multiple myeloma who had been previously treated with thalidomide; the implications for clinical practice are discussed." | 3.75 | Hematology: Lenalidomide plus dexamethasone is effective in multiple myeloma. ( Meijer, E; Sonneveld, P, 2009) |
| "The serum concentration of thalidomide in multiple myeloma (MM) patients with renal insufficiency has not been investigated in Japan." | 3.75 | [Analysis of plasma concentration of thalidomide in Japanese patients of multiple myeloma with renal dysfunction]. ( Arai, A; Fukuda, T; Hirota, A; Miura, O; Mori, Y; Sasaki, S; Terada, Y; Tohda, S, 2009) |
| "Lenalidomide is an agent that has shown great activity in patients with multiple myeloma (MM)." | 3.75 | Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. ( Alousi, A; Anderlini, P; Andersson, B; Champlin, R; de Lima, M; Giralt, S; Hosing, C; Jones, R; Kebriaei, P; Khouri, I; Körbling, M; McMannis, J; Nieto, Y; Popat, U; Qazilbash, M; Saliba, R; Shpall, E; Thandi, R; Thomas, S; Wang, M; Weber, D, 2009) |
| "A 68-year-old man with multiple myeloma was admitted to our hospital complaining of slight fever and dyspnea on effort 4 months after treatment with thalidomide." | 3.75 | [Case of thalidomide-induced interstitial pneumonia]. ( Hasejima, N; Matsushima, H; Oda, T; Sato, A; Takezawa, S; Yamamoto, M, 2009) |
| "Lenalidomide gained Food and Drug Administration (FDA) approval for treatment of patients with relapsed or refractory multiple myeloma (MM) in combination with dexamethasone in June 2006." | 3.75 | Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. ( Abonour, R; Alsina, M; Bahlis, NJ; Boccia, RV; Chen, C; Coutre, SE; Knight, RD; Kumar, S; Matous, J; Niesvizky, R; Pietronigro, D; Rajkumar, V; Reece, DE; Richardson, P; Siegel, D; Stadtmauer, EA; Vescio, R; Zeldis, JB, 2009) |
| "The past decade has witnessed a paradigm shift in the initial treatment of multiple myeloma with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, leading to improved outcomes." | 3.75 | Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. ( Anderson, KC; Bensinger, W; Bergsagel, L; Blade, J; Cavo, M; Comenzo, RL; Durie, BG; Einsele, H; Giralt, S; Harousseau, JL; Kumar, S; Lentzsch, S; Lonial, S; Ludwig, H; Munshi, N; Niesvizky, R; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Sonneveld, P; Stadtmauer, EA; Tosi, P; Vesole, D, 2009) |
| "Lenalidomide, a derivative of thalidomide, is an immunomodulatory agent introduced in 2004 for the treatment of multiple myeloma in combination with dexamethasone." | 3.75 | Neutrophilic dermatosis complicating lenalidomide therapy. ( Kist, JM; Rosenbach, M; Thieu, KP; Xu, X, 2009) |
| "Patients with complicated extramedullary plasmacytomas at the time of diagnosis received traditional treatment, including vincristine adriamycin, dexamethasone, medphalan, prednisone, thalidomide and bortezomib." | 3.75 | [A clinical analysis of 25 cases of multiple myeloma complicated by extramedullary plasmacytomas]. ( Chen, SL; Zhong, YP, 2009) |
| "We present a pooled update of two large, multicenter MM-009 and MM-010 placebo-controlled randomized phase III trials that included 704 patients and assessed lenalidomide plus dexamethasone versus dexamethasone plus placebo in patients with relapsed/refractory multiple myeloma (MM)." | 3.75 | Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. ( Attal, M; Chen, C; Dimopoulos, MA; Knight, RD; Niesvizky, R; Olesnyckyj, M; Petrucci, MT; Spencer, A; Stadtmauer, EA; Weber, DM; Yu, Z; Zeldis, JB, 2009) |
| "Fifteen patients who had previously received 100 mg/day of thalidomide for the treatment of multiple myeloma were evaluated retrospectively." | 3.75 | Clinical and electrophysiological evaluation of patients with thalidomide-induced neuropathy. ( Aki, Z; Erdogmus, NI; Haznedar, R; Kocer, B; Kuruoglu, R; Sucak, G, 2009) |
| "The purpose of this study was to investigate the effect of thalidomide (THD) combined with dexamethasone (Dx) on multiple myeloma KM3 cells and its mechanism." | 3.75 | [Effect of thalidomide combined with dexamethasone on multiple myeloma KM3 cells]. ( Gao, B; Gao, N; Gu, J; He, B; Li, JY; Zhang, Y; Zhou, W, 2009) |
| "We present the case of a 58-year old patient with relapsed multiple myeloma, in which lenalidomide was used in combination with dexamethasone after the failure of previous treatment modalities." | 3.75 | [Lenalidomide in the treatment of multiple myeloma]. ( Machálková, K; Maisnar, V, 2009) |
| "To assess potential benefits with thalidomide incorporated into double autologous stem-cell transplantation (ASCT) for younger patients with newly diagnosed multiple myeloma (MM)." | 3.75 | Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. ( Baccarani, M; Ballerini, F; Bigazzi, C; Brioli, A; Califano, C; Casulli, AF; Cavo, M; Ceccolini, M; de Vivo, A; Di Raimondo, F; Fiacchini, M; Ledda, A; Offidani, M; Patriarca, F; Perrone, G; Stefani, P; Tacchetti, P; Tosi, P; Volpe, S; Zamagni, E, 2009) |
| "Bortezomib-dexamethasone-thalidomide has been reported to be effective in newly-diagnosed multiple myeloma (MM) with an overall response rate of 92% and a CR rate of 18% (Alexanian et al, Hematology 2007;12(3):235-9), but this regimen has not been tested in the Chinese patients." | 3.75 | Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience. ( Cai, Z; He, J; Huang, H; Huang, W; Li, L; Lin, M; Luo, Y; Shi, J; Wei, G; Wu, W; Xie, W; Xue, X; Ye, X; Zhang, J; Zheng, W, 2009) |
| " For 2 months he had received second-line treatment with dexamethasone and thalidomide for a multiple myeloma." | 3.75 | [Interstitial pneumonitis as an adverse effect of thalidomide]. ( Custers, FL; Lie, KS; Potjewijd, J; Scholte, JB; Voogt, PJ, 2009) |
| "To investigate the effect of thalidomide on Annexin II (AnxA2) gene regulation in multiple myeloma cell line RPMI8226 and human microvascular endothelial cell line HMEC-1 cells in vitro, and explore the potential mechanism of thrombosis induced by thalidomide." | 3.75 | [Effects of thalidomide on Annexin II gene regulation]. ( Bao, HY; Jiang, M; Ruan, CG; Shen, F; Zhu, MQ, 2009) |
| "To evaluate the effect of polymorphism at the -238 and -308 position of the TNF-alpha promotor region on the clinical outcome of thalidomide (Thal)-based regimens for the treatment of multiple myeloma (MM)." | 3.75 | [Effect of TNF-alpha gene polymorphism on outcome of thalidomide-based regimens for multiple myeloma]. ( Chen, BA; DU, J; Fu, WJ; Hou, J; Jiang, H; Yuan, ZG; Zhang, CY, 2009) |
| " Screening for cancer revealed coexistence of two neoplasms: colon sigmoid cancer (operated on 6 weeks after pulmonary embolism onset), and multiple myeloma (treated successfully with thalidomide and dexamethasone)." | 3.75 | [Pulmonary embolism as a first manifestation of synchronous occurrence of two neoplasms]. ( Elikowski, W; Krokowicz, P; Lewandowska, M; Małek, M; Piotrowska-Stelmaszyk, G; Zawilska, K, 2009) |
| "To investigate the expression of B7 co-stimulatory molecules in human multiple myeloma (MM) and the immunoregulatory effects of thalidomide on B7." | 3.75 | [Regulatory effect of thalidomide on the expression of costimulatory molecules in patients with multiple myeloma]. ( He, AL; Tian, W; Wang, Y; Yang, HY; Yang, Y; Zhang, WG, 2009) |
| " For 2 months he had received second-line treatment with dexamethasone and thalidomide for a multiple myeloma." | 3.75 | [Interstitial pneumonitis as an adverse effect of thalidomide]. ( Custers, FL; Jie, KS; Potjewijd, J; Scholte, JB; Voogt, PJ, 2009) |
| "The study was purposed to explore the changes of CD4(+)CD25(+) T regulatory cells in patients with multiple myeloma before and (MM) after treatment with thalidomide so as to provide evidences for effective immunotherapy." | 3.74 | [Effects of thalidomide on CD4(+)CD25(+) T regulatory cells in patients with multiple myeloma]. ( He, AL; Tian, W; Wang, JL; Yang, HY; Yang, Y; Zhang, WG, 2008) |
| "Bortezomib is a first-in-class proteasome inhibitor with remarkable antitumor activity that is approved for the treatment of patients with multiple myeloma." | 3.74 | Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma. ( Auran-Schleinitz, T; Blaise, D; Bouabdallah, R; Coso, D; de Collela, JM; de Lavallade, H; El-Cheikh, J; Gastaut, JA; Mohty, M; Stoppa, AM, 2008) |
| " In newly diagnosed patients with multiple myeloma (MM), microarray data were obtained on tumor cells prior to and 48 hours after in vivo treatment using dexamethasone (n = 45) or thalidomide (n = 42); in the case of relapsed MM, microarray data were obtained prior to (n = 36) and after (n = 19) lenalidomide administration." | 3.74 | Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma. ( Barlogie, B; Burington, B; Crowley, J; Shaughnessy, JD; Zhan, F, 2008) |
| "This analysis assessed the efficacy and safety of lenalidomide + dexamethasone in patients with relapsed or refractory multiple myeloma (MM) previously treated with thalidomide." | 3.74 | Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. ( Attal, M; Chen, C; Cibeira, MT; Dimopoulos, MA; Knight, RD; Olesnyckyj, M; Rajkumar, SV; Spencer, A; Wang, M; Weber, DM; Yu, Z; Zeldis, JB, 2008) |
| "A venous thromboembolism (VTE) with the subsequent risk of pulmonary embolism is a major concern in the treatment of patients with multiple myeloma with thalidomide." | 3.74 | Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. ( Baris, D; Bell, SE; Child, JA; Cocks, K; Corthals, S; Crowley, J; Davies, FE; Dickens, NJ; Durie, BG; Goldschmidt, H; Haessler, J; Hoering, A; Jackson, G; Johnson, DC; Morgan, GJ; Rajkumar, SV; Ramos, C; Sonneveld, P; Van Ness, B, 2008) |
| "To analyse the efficacy and safety of thalidomide (Thal) for patients with multiple myeloma (MM)." | 3.74 | [The efficacy of thalidomide for multiple myeloma: a clinical analysis of 102 Chinese patients]. ( Li, YN; Qi, PJ; Qiu, LG; Wang, YF; Xiao, ZJ; Xu, Y; Zhao, YZ; Zou, DH, 2008) |
| "Few studies have focused on factors affecting outcome in patients with multiple myeloma (MM) treated with thalidomide-based therapy." | 3.74 | Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapy. ( Alesiani, F; Brunori, M; Burattini, M; Candela, M; Catarini, M; Centurioni, R; Corvatta, L; Ferranti, M; Galieni, P; Giuliodori, L; Leoni, P; Marconi, M; Mele, A; Offidani, M; Piersantelli, MN; Polloni, C; Visani, G, 2008) |
| "We activated and expanded iNKT cells from multiple myeloma patients with alpha-galactosylceramide (alpha-GalCer)-pulsed dendritic cells, characterized their antitumor effects by the cytokine production profile and cytotoxicity against multiple myeloma cells, and explored the effects of immunomodulatory drug lenalidomide on these iNKT cells." | 3.74 | Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. ( Anderson, KC; Balk, SP; Catley, L; Exley, MA; Munshi, NC; Podar, K; Prabhala, R; Shammas, MA; Song, W; Tai, YT; van der Vliet, HJ; Wang, R, 2008) |
| "To investigate the efficacy and adverse reaction of bortezomib plus chemotherapy with or without stem cell transplantation (SCT) for treatment of multiple myeloma (MM)." | 3.74 | [Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma]. ( Deng, SH; Qiu, LG; Wang, Y; Wang, YF; Wu, T; Xu, Y; Zhao, YZ; Zou, DH, 2008) |
| "The prognosis of multiple myeloma (MM) has substantially improved during last decades due to new, so-called targeted drugs--proteasome inhibitor bortezomib and immunomodulatory drugs (ImiDs), thalidomide and lenalidomide." | 3.74 | [Lenalidomid (Revlimid) in the treatment of multiple myeloma--first experience in the Czech Republic]. ( Jonásová, A; Neuwirtová, R; Novotová, E; Spicka, I; Straub, J, 2008) |
| "Whether resveratrol, a component of red grapes, berries, and peanuts, could suppress the proliferation of multiple myeloma (MM) cells by interfering with NF-kappaB and STAT3 pathways, was investigated." | 3.74 | Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. ( Aggarwal, BB; Bhardwaj, A; Bueso-Ramos, C; Gaur, U; Nair, AS; Sethi, G; Shishodia, S; Takada, Y; Vadhan-Raj, S, 2007) |
| "Thalidomide is one of the drugs which are newly used in the therapy of multiple myeloma." | 3.74 | [Low-dose thalidomide in refractory and relapsing multiple myeloma]. ( Maisnar, V; Radocha, J, 2007) |
| "Lenalidomide is an immunomodulatory agent approved for use in patients with myelodysplastic syndrome, and in combination with dexamethasone for refractory or relapsed multiple myeloma." | 3.74 | Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide. ( Abonour, R; Knox, K; Smith, P; Thornburg, A; Twigg, HL, 2007) |
| "The effect of capsaicin on both constitutive and interleukin-6-induced STAT3 activation, associated protein kinases, and STAT3-regulated gene products involved in proliferation, survival and angiogenesis, cellular proliferation, and apoptosis in multiple myeloma cells was investigated." | 3.74 | Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation. ( Aggarwal, BB; Bhutani, M; Guha, S; Kunnumakkara, AB; Nair, AS; Pathak, AK; Sethi, G, 2007) |
| "We present a patient with refractory multiple myeloma who showed a good response to a combination therapy with oral melphalan, dexamethasone, and thalidomide (MDT)." | 3.74 | Oral melphalan, dexamethasone, and thalidomide for the treatment of refractory multiple myeloma. ( Asou, N; Hata, H; Ide, K; Izuno, Y; Kawakita, M; Mitsuya, H; Okubo, T; Ueno, H, 2007) |
| "Thalidomide is successfully used in the treatment of multiple myeloma, leprosy and various autoimmune diseases due to its anti-angiogenic, immunomodulatory and anti-inflammatory effects." | 3.74 | Leukocytoclastic vasculitis due to thalidomide in multiple myeloma. ( Alpay, N; Ayer, M; Küçükkaya, RD; Mete, O; Nalçaci, M; Yavuz, AS; Yenerel, MN; Yildirim, ND, 2007) |
| "Thalidomide is an immunomodulatory drug used in the treatment of relapsed or refractory multiple myeloma (MM)." | 3.74 | Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment. ( Bláha, V; Büchler, T; Hájek, R; Maisnar, V; Malý, J; Radocha, J, 2007) |
| "To determine the long-term effects of a combined regimen of lenalidomide and dexamethasone (Rev-Dex) on time to progression, progression-free survival, and overall survival (OS) in patients with multiple myeloma." | 3.74 | Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. ( Bergsagel, PL; Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, S; Greipp, PR; Hayman, SR; Kabat, B; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Russell, SJ; Stewart, AK; Witzig, TE; Zeldenrust, SR, 2007) |
| "Multiple myeloma (MM) patients have a propensity for thromboembolic events (TE), and treatment with thalidomide/dexamethasone or lenalidomide/dexamethasone increases this risk." | 3.74 | Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. ( Christos, P; Coleman, M; De Sancho, M; Furst, J; Jalbrzikowski, J; Jayabalan, D; Leonard, J; Mark, T; Martínez-Baños, D; Mazumdar, M; Niesvizky, R; Pearse, R; Pekle, K; Zafar, F, 2007) |
| "Lenalidomide combined with dexamethasone has significant clinical activity in the treatment of multiple myeloma (MM)." | 3.74 | Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy? ( Colado, E; García-Sanz, R; Mateos, MV; Olazábal, J; San-Miguel, J, 2008) |
| "In this single-center analysis, we assessed whether lower thalidomide doses are feasible and result in favourable treatment response in multiple myeloma (MM) patients." | 3.74 | Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses. ( Denz, U; Engelhardt, M; Haas, PS; Ihorst, G, 2008) |
| "A pooled analysis was performed of patients with previously untreated multiple myeloma enrolled in clinical trials of lenalidomide-based therapy at the Mayo Clinic, Rochester, Minnesota, and the Italian Myeloma Network, Italy." | 3.74 | Thromboembolic events with lenalidomide-based therapy for multiple myeloma. ( Falco, P; Lacy, M; Menon, SP; Palumbo, A; Rajkumar, SV, 2008) |
| "To study the distribution of different genotypes of CYP2C19 in multiple myeloma (MM), and investigate the effect of its polymorphism on efficacy of thalidomide-based regimens for the treatment of MM and discuss the role of antiangiogenesis in MM." | 3.74 | [Effect of CYP2C19 gene polymorphism on efficacy of thalidomide-based regimens for the treatment of multiple myeloma]. ( Hou, J; Li, YH, 2007) |
| "Massive pulmonary embolism is an uncommon complication of multiple myeloma treated with thalidomide-dexamethasone regimen." | 3.74 | Pulmonary embolism in a patient with multiple myeloma receiving thalidomide-dexamethasone therapy. ( Chu, PH; Jeng, WJ; Kuo, MC; Shih, LY, 2008) |
| "Azotemia associated with the use of lenalidomide, a new and effective therapy for multiple myeloma, has not been reported in patients with multiple myeloma." | 3.74 | Azotemia associated with use of lenalidomide in plasma cell dyscrasias. ( Batts, ED; Hegerfeldt, Y; Lazarus, HM; Sanchorawala, V, 2008) |
| "We examined the effect of thalidomide and dexamethasone on the migration of multiple myeloma (MM) cell lines, U266, RPMI8226, and NCI-H929, using chemotaxis chamber plates." | 3.74 | The effects of thalidomide on chemotactic migration of multiple myeloma cell lines. ( Akamatsu, S; Fuchida, SI; Hirai, H; Inaba, T; Okamoto, M; Okano, A; Shimazaki, C; Taniwaki, M; Uchida, R; Yamada, N, 2008) |
| " Thalidomide has been associated with an increased risk of thromboembolic pulmonary hypertension (PH)." | 3.74 | Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study. ( Barbetakis, N; Bischiniotis, T; Lafaras, C; Mandala, E; Platogiannis, D; Verrou, E; Zervas, K, 2008) |
| "Thalidomide is effective in multiple myeloma (MM), even in patients who have relapsed after high-dose therapy." | 3.73 | Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC). ( Attal, M; Blaise, D; Bulabois, CE; Cahn, JY; Facon, T; Garban, F; Gratecos, N; Jouet, JP; Marit, G; Mohty, M; Rio, B; Sotto, JJ; Vernant, JP; Yakoub-Agha, I, 2005) |
| " Thalidomide is an immunomodulatory drug with numerous properties that has proven effective in relapsed multiple myeloma and, to a lesser extent, in other hematologic diseases." | 3.73 | Single-agent thalidomide induces response in T-cell lymphoma. ( Bilger, K; Bouabdallah, R; Damaj, G; Gastaut, JA; Mohty, M; Vey, N, 2005) |
| "Thalidomide and its analogs have been extensively studied in patients with multiple myeloma." | 3.73 | Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide. ( Carbonell, AL; del Giglio, A; Manhani, AR; Mitteldorf, CA; Weinschenker, P, 2005) |
| "The aim of the present study was to compare thalidomide-dexamethasone (Thal-Dex) and vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous peripheral blood stem-cell (PBSC) transplantation for multiple myeloma (MM)." | 3.73 | Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. ( Baccarani, M; Cangini, D; Cavo, M; Ceccolini, M; Cellini, C; de Vivo, A; Grafone, T; Nicci, C; Perrone, G; Tacchetti, P; Terragna, C; Testoni, N; Tosi, P; Tura, S; Zamagni, E, 2005) |
| "Thalidomide alone or in combination with steroids has significant activity in multiple myeloma (MM)." | 3.73 | Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs. ( Anderson, KC; Figg, WD; Hamasaki, M; Hideshima, T; Ishitsuka, K; Kumar, S; Munshi, NC; Raje, N; Richardson, P; Roccaro, A; Shiraishi, N; Yasui, H, 2005) |
| "The expression of key angiogenic genes was studied in bone marrow endothelial cells (ECs) of patients with active and nonactive multiple myeloma (MM), monoclonal gammopathies unattributed/unassociated (MG[u]), diffuse large B-cell non-Hodgkin's lymphoma, in a Kaposi's sarcoma (KS) cell line, and in healthy human umbilical vein ECs (HUVECs) following exposure to therapeutic doses of thalidomide." | 3.73 | Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. ( Bicciato, S; Corradini, P; Dammacco, F; Di Pietro, G; Mattioli, M; Montefusco, V; Neri, A; Nico, B; Ribatti, D; Scavelli, C; Vacca, A, 2005) |
| "The use of the proteasome inhibitor bortezomib has been recently introduced into the treatment of relapsed, refractory multiple myeloma (MM)." | 3.73 | Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma. ( Graeven, U; König, M; Schmiegel, W; Schmielau, J; Teschendorf, C, 2005) |
| "The feasibility and efficacy of the combination of melphalan, prednisone, and thalidomide (MPT) have been valuated in 49 newly diagnosed patients with multiple myeloma." | 3.73 | Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. ( Bertola, A; Boccadoro, M; Callea, V; Cangialosi, C; Caravita, T; Falco, P; Grasso, M; Musto, P; Nunzi, M; Palumbo, A, 2005) |
| "Thalidomide acts on the microenvironment of myelodysplastic syndromes (MDS) by influencing cytokine networks, and growing evidence supports thalidomide's usefulness in the management of haematological malignancies, such as MDS." | 3.73 | Future directions in haematology: beyond multiple myeloma. ( Prentice, HG; Russell, N; Sacchi, S, 2005) |
| "The prompt response to bortezomib observed in a 63-year-old woman with multiple myeloma was associated with a significant increase in alkaline phosphatase (ALP)." | 3.73 | Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. ( Barlogie, B; Burns, MJ; Elice, F; Esseltine, D; Kang, SH; Lee, CK; Najarian, K; Richardson, P; Sonneveld, P; Tricot, G; Yaccoby, S; Zangari, M, 2005) |
| "To report thrombocytopenia in a patient prescribed thalidomide for multiple myeloma (MM)." | 3.73 | Thalidomide-associated thrombocytopenia. ( Brouwers, JR; Duyvendak, M; Kingma, BJ; Naunton, M, 2005) |
| "Thalidomide represents a recent and innovative therapeutic approach in multiple myeloma." | 3.73 | Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis. ( Bocchia, M; Bucalossi, A; Gozzetti, A; Lauria, F; Mazzotta, S; Pirrotta, MT; Sammassimo, S, 2005) |
| "Thalidomide plus dexamethasone (Thal/Dex) has emerged as an effective alternative to vincristine, doxorubicin and dexamethasone as a pre-transplant induction therapy for newly diagnosed multiple myeloma." | 3.73 | Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. ( Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, S; Kyle, RA; Lacy, MQ; Lust, JA; Nowakowski, GS; Rajkumar, SV; Witzig, TE, 2005) |
| "CC-4047, an immunomodulatory analog of thalidomide, inhibits multiple myeloma with unknown effects on the human osteoclast lineage." | 3.73 | Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. ( Anderson, G; Anderson, J; Donnenberg, A; Donnenberg, V; Ghobrial, I; Gries, M; Honjo, T; Kurihara, N; Lentzsch, S; Mapara, MY; Roodman, D; Stirling, D, 2006) |
| " This patient developed acute, multiple cerebral infarctions 5 months into the treatment with thalidomide." | 3.73 | Should we screen patients for inherited thrombophilia before starting thalidomide? ( El-Hajj, II; Harb, MI; Mahfouz, RA; Otrock, ZK; Sawaya, RA, 2006) |
| " Accordingly, TNF-alpha inhibitors, such as thalidomide, infliximab (Remicade), adalimumab (Humira), and etanercept (Enbrel), have been used with success in the treatment of autoimmune disorders, including psoriasis, rheumatoid arthritis, inflammatory bowel diseases, and lymphoproliferative disorders." | 3.73 | Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. ( Badros, A; Deng, A; Gaspari, A; Harvey, V; Junkins-Hopkins, JM; Oghilikhan, M; Samuels, A; Sina, B; Strobel, D, 2006) |
| "Based on our research we conclude that the mixture of lovastatin and thalidomide may increase the rate of multiple myeloma cells apoptosis in comparison to the single drug and the precise mechanism of this effect should be approved by further research." | 3.73 | Lovastatin and thalidomide have a combined effect on the rate of multiple myeloma cell apoptosis in short term cell cultures. ( Dmoszynska, A; Grzasko, N; Klimek, P; Podhorecka, M, 2006) |
| "The expression of proteins of the tumor necrosis factor (TNF) family on erythroblasts was measured during thalidomide treatment in 29 patients with multiple myeloma (MM)." | 3.73 | Stimulation of erythropoiesis by thalidomide in multiple myeloma patients: its influence on FasL, TRAIL and their receptors on erythroblasts. ( Dmoszynska, A; Grzasko, N; Hus, M; Soroka-Wojtaszko, M, 2006) |
| "To investigate the effect of the combination of thalidomide, cyclophosphamide and dexamethasone for the treatment of relapsed/refractory multiple myeloma." | 3.73 | [The effect of cyclophosphamide, thalidomide and dexamethasone combination therapy in relapsed/refractory multiple myeloma]. ( An, N; Chen, SL; Gao, W, 2006) |
| "The proteasome inhibitor bortezomib has demonstrated clinical activity in patients with multiple myeloma (MM)." | 3.73 | A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma. ( Bang, SM; Cho, KS; Jo, DY; Kim, CC; Kim, CS; Kim, K; Lee, JH; Lee, JJ; Lee, KH; Lee, NR; Min, CK; Min, YH; Park, S; Seong, CM; Sohn, SK; Suh, C; Yoon, HJ; Yoon, SS, 2006) |
| "We evaluated the combination of thalidomide, pulsed dexamethasone and weekly cyclophosphamide (CTD) for the treatment of patients with newly diagnosed, relapsed or VAD-refractory multiple myeloma." | 3.73 | Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. ( Byrne, JL; Myers, B; Russell, NH; Sidra, G; Williams, CD; Zaman, S, 2006) |
| "Thalidomide is a relatively safe and efficacious form of therapy in the treatment of advanced, refractory multiple myeloma." | 3.73 | Thalidomide-induced severe hepatotoxicity. ( Hanje, AJ; Meis, GM; Shamp, JL; Thomas, FB, 2006) |
| "Thalidomide administered as a single agent produces a response rate of about 40% in patients with refractory or relapsed multiple myeloma (MM)." | 3.73 | Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. ( Bladé, J; Cibeira, MT; Esteve, J; Ramiro, L; Rosiñol, L; Torrebadell, M, 2006) |
| "To examine dermatologic adverse effects of lenalidomide in patients with amyloidosis and multiple myeloma and to determine whether the adverse effects are different when lenalidomide is used alone compared with when it is used in combination with dexamethasone." | 3.73 | Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. ( Davis, MD; Dispenzieri, A; Rajkumar, SV; Sviggum, HP, 2006) |
| "A retrospective case-matched study was conducted to compare the oral regimen CTD (cyclophosphamide - thalidomide - dexamethasone) and infusional CVAMP (cyclophosphamide - vincristine - doxorubicin - methylprednisolone) as induction therapy followed by autologous peripheral blood stem-cell transplantation (PBSCT) for newly diagnosed multiple myeloma patients." | 3.73 | The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case- ( Alvares, CL; Davies, FE; Dines, S; Ethell, ME; Horton, C; Jenner, MW; Krishnan, B; McCormack, R; Morgan, GJ; Potter, MN; Saso, R; Treleaven, JG; Wu, P, 2006) |
| "Thalidomide (Thal) has been used for a few years as salvage treatment for patients with multiple myeloma (MM)." | 3.73 | Prognostic factors for the efficacy of thalidomide in the treatment of multiple myeloma: a clinical study of 110 patients in China. ( Chen, Y; Fu, W; Hou, J; Li, Y; Tao, Z; Wang, D; Yuan, Z, 2006) |
| "This study was purposed to investigate the effects of thalidomide on proliferation of peripheral blood mononuclear cells (PBMNCs), levels of lymphocyte subsets, secretion of cytokines and its killing activity, and to elucidate the immunoregulation mechanisms in treatment of multiple myeloma with thalidomide." | 3.73 | [Positive immunoregulation of thalidomide on human peripheral blood mononuclear cell cultures]. ( Cao, XM; Chen, YX; He, AL; Tian, W; Yang, HY; Yang, Y; Zhang, WG, 2006) |
| "To assess response rate, duration of response, progression-free survival, and toxicity of thalidomide in patients with relapsed multiple myeloma." | 3.72 | Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. ( Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, SM; Greipp, PR; Hayman, SR; Iturria, NL; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE, 2003) |
| "We have previously shown that thalidomide and its potent immunomodulatory derivatives (IMiDs) inhibit the in vitro growth of multiple myeloma (MM) cell lines and patient MM cells that are resistant to conventional therapy." | 3.72 | Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. ( Anderson, KC; Catley, L; Davies, F; Hideshima, T; LeBlanc, R; Lentzsch, S; Lin, B; Podar, K; Stirling, DI, 2003) |
| "We report the dermatologic side effects in 87 patients with multiple myeloma enrolled in a comparative, open-label, clinical trial treated with thalidomide alone (50 patients) or thalidomide and dexamethasone (37 patients)." | 3.72 | Dermatologic side effects of thalidomide in patients with multiple myeloma. ( Bouwhuis, S; El-Azhary, RA; Hall, VC; Rajkumar, SV, 2003) |
| "Thalidomide can not only inhibit angiogenesis, but also abrogate the adhesion of multiple myeloma cells to bone marrow stromal cells." | 3.72 | [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma]. ( Hong, WD; Li, J; Luo, SK; Zhou, ZH; Zou, WY, 2003) |
| "This research examines the profile of metabolites of thalidomide that are formed in refractory multiple myeloma patients undergoing thalidomide therapy in comparison with those that are detected in healthy mice." | 3.72 | Thalidomide metabolites in mice and patients with multiple myeloma. ( Baguley, BC; Browett, P; Ching, LM; Kestell, P; Lu, J; Muller, G; Palmer, BD, 2003) |
| "Between November 1998 and April 2000, the combination of thalidomide and dexamethasone was evaluated in 47 consecutive patients with multiple myeloma that was resistant to prior high-dose dexamethasone-based therapies." | 3.72 | Thalidomide and dexamethasone for resistant multiple myeloma. ( Alexanian, R; Anagnostopoulos, A; Delasalle, K; Rankin, K; Weber, D, 2003) |
| "Thalidomide has antiangiogenic properties and was found to be effective in patients with multiple myeloma (MM) when used in the setting of posttransplantation relapse." | 3.72 | Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. ( Barlogie, B; Eddleman, P; Fassas, A; Fink, L; Jacobson, J; Lee, CK; Talamo, G; Thertulien, R; Tricot, G; Van Rhee, F; Zangari, M, 2003) |
| "The optimum dose and duration of treatment with thalidomide for relapsed or refractory multiple myeloma are not known." | 3.72 | Thalidomide in relapsed or refractory multiple myeloma: how much and for how long? ( Abdalla, SH; Mahmoud, S, 2003) |
| "To improve outcome in previously treated patients (at least two cycles of standard therapy) with multiple myeloma, thalidomide was combined with cytotoxic chemotherapy as induction therapy." | 3.72 | DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. ( Barlogie, B; Cottler-Fox, M; Fassas, A; Jacobson, J; Lee, CK; Munshi, N; Muwalla, F; Tricot, G; van Rhee, F; Zangari, M, 2003) |
| "Thalidomide (Thd), a potent teratogen, was shown to have therapeutic potential in cancer, primarily in multiple myeloma (MM), yet its mechanism of action has not been elucidated." | 3.72 | Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma. ( Drucker, L; Lahav, M; Lishner, M; Radnay, J; Shapiro, H; Tohami, T; Uziel, O; Yarkoni, S, 2003) |
| "Venous thromboembolism (VTE) is a major complication in patients with multiple myeloma (MM) during treatment with thalidomide combined with chemotherapy and/or dexamethasone." | 3.72 | Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. ( De Groot, PG; Fijnheer, R; Lokhorst, HM; Minnema, MC, 2003) |
| "To investigate the effect of thalidomide on bone marrow cells gene expression in multiple myeloma (MM) patients with suppression subtractive hybridization (SSH) and explore the molecular mechanism of thalidomide therapy for MM." | 3.72 | [The changes of gene expression in multiple myeloma treated with thalidomide]. ( Chen, SL; Chen, ZB; Liu, JZ; Wang, HJ; Xiao, B; Zhang, HB, 2003) |
| "Fifty Taiwanese patients with relapsed and/or refractory multiple myeloma (MM) were treated with thalidomide on a dose-escalation schedule, commencing with 100 mg/d nightly and incremented either to the maximally tolerated dose or 800 mg/d." | 3.72 | Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma. ( Chen, YC; Hong, RL; Huang, SY; Ko, BS; Shen, MC; Tang, JL; Tien, HF; Tsai, W; Wang, CH; Yao, M, 2003) |
| "The purpose of this study was to determine the effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma." | 3.72 | Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. ( Bundy, KL; Christensen, BR; Dispenzieri, A; Gastineau, DA; Gertz, MA; Ghobrial, IM; Hayman, S; Lacy, MQ; Litzow, MR; Pribula, CG; Rajkumar, SV; Therneau, TM; Witzig, TE, 2003) |
| "Thalidomide, an agent with antiangiogenic and immunomodulatory properties, is therapeutically effective in multiple myeloma, leprosy, and autoimmune diseases." | 3.72 | Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide. ( Fruehauf, S; Goldschmidt, H; Hartschuh, W; Ho, AD; Moehler, T; Neben, K; Witzens, M, 2004) |
| " We report the first case of stiff-limb syndrome in a patient with multiple myeloma undergoing treatment with thalidomide, and explore the potential link to the cancer and its treatment." | 3.72 | Anti-GAD antibody positive stiff-limb syndrome in multiple myeloma. ( Dalmau, J; Myers, DJ; Schiff, D, 2003) |
| "Remarkable results of the treatment of refractory multiple myeloma with thalidomide have been reported." | 3.72 | Low dose thalidomide in patients with relapsed or refractory multiple myeloma. ( Ackermann, J; Dimou, G; Drach, J; Gisslinger, H; Kees, M; Lechner, K; Sillaber, C, 2003) |
| "Thalidomide is a promising therapy for multiple myeloma." | 3.72 | Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features. ( Barbero, P; Bergamasco, B; Bergui, M; Bertola, A; Boccadoro, M; Ciaramitaro, P; Cocito, D; Durelli, L; Isoardo, G; Palumbo, A, 2004) |
| "A proteasome inhibitor with a new molecular target (PS-341: bortezomib) was recently developed, and its efficacy in the treatment of refractory multiple myeloma has been reported in the United States." | 3.72 | [Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma]. ( Kikuchi, S; Komatsu, N; Mori, M; Muroi, K; Noborio-Hatano, K; Ozawa, K; Takahashi, S; Takatoku, M, 2004) |
| "Thalidomide-based regimens (TBR) are now widely used for the treatment of refractory multiple myeloma and have shown significant activity in newly diagnosed patients." | 3.72 | Discordant response or progression in patients with myeloma treated with thalidomide-based regimens. ( Anagnostopoulos, A; Anagnostou, D; Dimopoulos, MA; Grigoraki, V; Hamilos, G; Zorzou, MP, 2004) |
| "Thalidomide has been shown to be effective in approximately 30% of patients with refractory or advanced multiple myeloma (MM)." | 3.72 | Possible multiple myeloma dedifferentiation following thalidomide therapy: a report of four cases. ( Balleari, E; Falcone, A; Ghio, R; Musto, P, 2004) |
| "s-Thalidomide has proven efficacy in multiple myeloma." | 3.72 | s-thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line. ( Chaplin, T; Joel, SP; Liu, WM; Malpas, JS; Propper, DJ; Shahin, S; Strauss, SJ; Young, BD, 2004) |
| "In our experience with thalidomide treatment for refractory multiple myeloma (MM), most patients with progressive disease (PD) did not show an increase in M-protein despite the tumor burden of myeloma cells." | 3.72 | Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cells. ( Fujimura, K; Imagawa, J; Katayama, Y; Kimura, A; Kuroda, Y; Noda, M; Okikawa, Y; Okita, H; Sakai, A; Takimoto, Y, 2004) |
| "Deep venous thrombosis (DVT) has been variably reported in multiple myeloma patients during treatment with thalidomide alone or in combination with chemotherapy or dexamethasone." | 3.72 | Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. ( Airò, F; Corso, A; Lazzarino, M; Lorenzi, A; Mangiacavalli, S; Rusconi, C; Terulla, V; Varettoni, M; Zappasodi, P, 2004) |
| "Thalidomide is an antiangiogenic drug that produces a response rate ranging from 32 to 64% in patients with refractory/relapsed multiple myeloma (MM)." | 3.72 | Extramedullary multiple myeloma escapes the effect of thalidomide. ( Aymerich, M; Bladé, J; Cibeira, MT; Cid, MC; Esteve, J; Filella, X; Montserrat, E; Rosiñol, L; Rozman, M; Segarra, M, 2004) |
| "Venous thromboembolic disease (VTD) is a recently recognized complication of thalidomide in combination therapy for patients with multiple myeloma (MM)." | 3.72 | Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. ( Cameron, MG; Deitcher, SR; Hussein, MA; Kattke-Marchant, K; Rybicki, L; Srkalovic, G, 2004) |
| "To improve the antimyeloma effect of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation in multiple myeloma, we investigated in a phase 1/2 study the effect of low-dose thalidomide (100 mg) followed by DLI in 18 patients with progressive disease or residual disease and prior ineffective DLI after allografting." | 3.72 | Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. ( Ayuk, F; Fehse, B; Kröger, N; Lioznov, M; Nagler, A; Renges, H; Schieder, H; Shimoni, A; Zabelina, T; Zagrivnaja, M; Zander, AR, 2004) |
| "Previous studies have demonstrated the in vitro and in vivo activity of CC-5013 (Revlimid), an immunomodulatory analog (IMiD) of thalidomide, in multiple myeloma (MM)." | 3.72 | Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. ( Anderson, KC; Antin, JH; Chauhan, D; Hideshima, T; Ishitsuka, K; Kumar, S; Le Gouill, S; Mitsiades, C; Munshi, NC; Podar, K; Raje, N; Richardson, P; Stirling, DI, 2004) |
| "Thalidomide has been proved to play an important role in rescue treatment of patients with refractory/relapsed multiple myeloma (MM)." | 3.72 | Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide. ( Bladé, J; Bosch, F; Montagut, C; Rosiñol, L; Villela, L, 2004) |
| "Among 199 patients treated with thalidomide for multiple myeloma, four thromboses occurred in 49 cases during erythropoietin therapy (prevalence 8." | 3.72 | Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. ( Barbui, T; Comotti, B; Crippa, C; Elice, F; Galli, M; Rodeghiero, F, 2004) |
| "In this study, we analyzed the relationship between the plasma concentration of thalidomide and the therapeutic effect obtained by using thalidomide alone in patients with refractory multiple myeloma." | 3.72 | Unstable plasma thalidomide concentration in patients with refractory multiple myeloma. ( Horiuchi, R; Kodama, T; Murakami, H; Nojima, Y; Tsukamoto, N, 2004) |
| "We report a case of acute fatal exacerbation of chronic hepatitis B in a 50-year-old man with multiple myeloma being treated with thalidomide." | 3.72 | Acute exacerbation of chronic hepatitis B during thalidomide therapy for multiple myeloma: a case report. ( Ahn, JY; Bang, SM; Cho, EK; Kim, SS; Lee, JH; Park, SH; Shin, DB, 2004) |
| "A 66-year-old man was referred to our hospital for the treatment of refractory multiple myeloma with thalidomide." | 3.72 | [Interstitial pneumonia during treatment with thalidomide in a patient with multiple myeloma]. ( Chen, CK; Hattori, Y; Iguchi, T; Ikeda, Y; Okamoto, S; Sakoda, M; Yokoyama, K, 2004) |
| "The aim of this study was to assess the prognostic value of pretreatment clinical and laboratory parameters in refractory or relapsed multiple myeloma (MM) patients who have a long-term response to thalidomide (THAL), lasting at least 18 months." | 3.72 | An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma. ( Ciepluch, H; Dmoszynska, A; Hellmann, A; Hus, I; Hus, M; Jawniak, D; Kloczko, J; Konopka, L; Manko, J; Robak, T; Skotnicki, A; Soroka-Wojtaszko, M; Sulek, K; Wolska-Smolen, T, 2004) |
| "The aim of the study was to assess the influence of thalidomide on megakaryocytes (MK) in patients with multiple myeloma (MM)." | 3.72 | Influence of thalidomide on megakaryocytes in multiple myeloma. ( Dziecioł, J; Kłoczko, J; Lebelt, A; Lemancewicz, D; Piszcz, J; Szkudlarek, M, 2004) |
| "Seven cases of thromboembolism were found amongst 23 patients treated with thalidomide for myeloma over a total of 141." | 3.71 | Thromboembolism in patients on thalidomide for myeloma. ( Bowcock, SJ; Laffan, M; Rassam, SM; Turner, JT; Ward, SM, 2002) |
| "To evaluate treatment by thalidomide and identify predictive factors of survival, event free survival and response among patients with advanced multiple myeloma treated with thalidomide as single agent therapy." | 3.71 | Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM). ( Attal, M; Bay, JO; Berthou, C; Dauriac, C; Delannoy, V; Dorvaux, V; Duguet, C; Duhamel, A; Dumontet, C; Facon, T; Grosbois, B; Harousseau, JL; Lamy, T; Monconduit, M; Moreau, P; Yakoub-Agha, I, 2002) |
| "To determine the efficacy and side effects of thalidomide in the treatment of refractory multiple myeloma." | 3.71 | [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%]. ( Lokhorst, HM; Schaafsma, MR; Sonneveld, P; van der Holt, B; Wijermans, PW; Wu, KL, 2002) |
| "Recent reports showed that thalidomide has anti-angiogenic activity and is effective for the treatment of refractory multiple myeloma (MM)." | 3.71 | Thalidomide for the treatment of refractory multiple myeloma: association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome. ( Hattori, Y; Ikeda, Y; Kakimoto, T; Kamata, T; Morita, K; Okamoto, S; Sato, N; Shimada, N; Takayama, N; Tanigawara, Y; Uchida, H; Yamada, T; Yamaguchi, M, 2002) |
| "In this report, we describe two new venous thrombosis cases occurring during a treatment with thalidomide." | 3.71 | [Thrombotic accidents induced by thalidomide: two cases]. ( Gachon, J; Grob, JJ; Richard, MA, 2002) |
| "Thalidomide has shown efficacy in relapsed or refractory patients of multiple myeloma (MM)." | 3.71 | The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma. ( Grover, JK; Raina, V; Uppal, G, 2002) |
| "To observe the effective mechanism and side effects of thalidomide to multiple myeloma (MM)." | 3.71 | [Therapeutic effectiveness of thalidomide to multiple myeloma and its mechanism]. ( Li, Y; Liu, Y; Wang, M; Wu, H, 2002) |
| "To investigate the pro-angiogenic effects of several multiple myeloma (MM) cell line culture supernatants on human bone marrow endothelial cell (HBMEC) proliferation, migration, and capillary formation, and the anti-angiogenic effects of thalidomide." | 3.71 | [Thalidomide inhibits the angiogenic activity of culture supernatants of multiple myeloma cell line]. ( Chen, W; Mirshahi, F; Mirshahi, M; Soria, C; Soria, J; Zhu, J, 2002) |
| "Twenty-one patients with relapsed and refractory Durie-Salmon stage III multiple myeloma who had either failed at least three previous regimens or presented with poor performance status, neutropenia, or thrombocytopenia were treated with up to four cycles of combination melphalan (50 mg intravenously), thalidomide (titrated to target of 400 mg orally daily), and dexamethasone (40 mg/day orally on d 1 to 4) every 4-6 wk." | 3.71 | Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma. ( Elson, P; Hussein, MA; Karam, MA; Srkalovic, G; Trebisky, B, 2002) |
| "To investigate the influence of the thalidomide on the growth of multiple myeloma cells from untreated, relapsed or refractory patients and summarize its mechanisms, thalidomide influence on colony growth of untreated, relapsed or refractory multiple myeloma cells cultured by semisolid methylcellulose was observed." | 3.71 | [In vitro inhibition and mechanism of multiple myeloma cells growth by thalidomide]. ( Hong, WD; Huang, JQ; Li, J; Luo, SK, 2002) |
| "To evaluate the mechanism and influence of thalidomide on interleukin-6 (IL-6), IL-6 receptor (IL-6R) and its transmitting chain in multiple myeloma patients." | 3.71 | [Influence of thalidomide on interleukin-6 and its transmission in multiple myeloma patients]. ( Hong, W; Li, J; Luo, S; Zhou, Z; Zou, W, 2002) |
| "The antiangiogenic activity of thalidomide (Thal), coupled with an increase in bone marrow angiogenesis in multiple myeloma (MM), provided the rationale for the use of Thal in MM." | 3.71 | Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. ( Anderson, KC; Chauhan, D; Davies, FE; Gupta, D; Hideshima, T; Lentzsch, S; Lin, B; Morgan, GJ; Muller, GW; Podar, K; Raje, N; Richardson, PG; Schlossman, RL; Stirling, DI; Tai, YT; Treon, SP; Young, G, 2001) |
| "We evaluated thalidomide as a single agent in myeloma, myelodysplastic syndromes (MDS) and histiocytosis, i." | 3.71 | Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. ( Alietti, A; Bertolini, F; Burlini, A; Cineri, S; Cinieri, S; Cocorocchio, E; Corsini, C; Ferrucci, PF; Mancuso, P; Martinelli, G; Mingrone, W; Peccatori, F; Zucca, E, 2001) |
| "We report two patients who were treated with thalidomide for resistant multiple myeloma (MM) and developed extramedullary plasmacytomas despite a good response in the bone marrow." | 3.71 | Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. ( Avigdor, A; Ben-Bassat, I; Hardan, I; Levi, I; Raanani, P, 2001) |
| "The feasibility and efficacy of a combination of thalidomide, cyclophosphamide, etoposide, and dexamethasone were studied in 56 patients with poor-prognosis multiple myeloma." | 3.71 | Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. ( Benner, A; Egerer, G; Goldschmidt, H; Ho, AD; Krasniqi, F; Moehler, TM; Neben, K, 2001) |
| "Three cases of multiple myeloma treated with thalidomide are presented which highlight therapeutic dilemmas presented by therapy with this new agent." | 3.71 | Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions. ( Desikan, RK; Jagannath, S, 2001) |
| " Thalidomide, an antineoplastic agent, has been shown to be effective in multiple myeloma through proposed mechanisms that may include angiogenesis inhibition." | 3.71 | Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. ( Biagi, JJ; Grigg, AP; Mileshkin, L; Prince, HM; Westerman, DW, 2001) |
| "Thalidomide has recently been shown to be useful in the treatment of multiple myeloma and may also be useful in the treatment of other hematological malignancies." | 3.71 | S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. ( Anderson, KC; Birsner, AE; D'Amato, RJ; LeBlanc, R; Lentzsch, S; Rogers, MS; Shah, JH; Treston, AM, 2002) |
| "Thalidomide has recently proven to be a useful drug for treatment of refractory and relapsed multiple myeloma patients, up to 35% of whom achieve remission." | 3.71 | The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma. ( García-Sanz, R; González, M; González-Fraile, MI; López, C; San Miguel, JF; Sierra, M, 2002) |
| "Several trials have shown the activity of thalidomide (THAL) in relapsed multiple myeloma (MM) patients failing PBSCT or conventional chemotherapy." | 3.71 | Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. ( Ahmad, I; Alam, AR; Becker, JL; Chanan-Khan, A; Hahn, T; Islam, T; McCarthy, PL; Wentling, D, 2002) |
| "Recently a growing number of studies have suggested the efficacy of thalidomide (THAL) in the treatment of relapsed or resistant multiple myeloma." | 3.71 | Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. ( Bojarska-Junak, A; Dmoszyńska, A; Domański, D; Hus, M; Roliński, J; Soroka-Wojtaszko, M, 2002) |
| "Thalidomide (Thal) achieves responses even in the setting of refractory multiple myeloma (MM)." | 3.71 | Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. ( Anderson, KC; Chauhan, D; Hideshima, T; Mitsiades, CS; Mitsiades, N; Munshi, NC; Poulaki, V; Richardson, PG; Treon, SP, 2002) |
| " We present a case of coinfection with disseminated HSV and VZV infection in a patient taking thalidomide for relapsed multiple myeloma." | 3.71 | Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma. ( Curley, MJ; Hassoun, PM; Hussein, SA, 2002) |
| "We have treated 17 refractory or relapsed multiple myeloma patients resistant to chemotherapy with thalidomide at a dose of 200-800 mg/day." | 3.70 | Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug. ( Avigdor, A; Ben-Bassat, I; Berkowicz, M; Hardan, I; Kneller, A; Levi, I; Raanani, P, 2000) |
| "To describe the efficacy of therapy with thalidomide, a drug that has antiangiogenic properties, in patients with relapsed multiple myeloma." | 3.70 | Thalidomide in the treatment of relapsed multiple myeloma. ( Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE, 2000) |
| "Anti-angiogenesis therapy with thalidomide has been reported to have marked activity in multiple myeloma (MM)." | 3.70 | Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization. ( Ackermann, J; Aletaha, K; Chott, A; Drach, J; Gisslinger, H; Huber, H; Kaufmann, H; Obermair, A; Schreiber, S; Urbauer, E, 2000) |
| " The novel quadruplet combination was overall well-tolerated, with clinically manageable adverse events." | 3.11 | A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma. ( Berenson, JR; Eades, B; Eshaghian, S; Ghermezi, M; Lim, S; Martinez, D; Schwartz, G; Spektor, TM; Swift, RA; Vescio, R; Yashar, D, 2022) |
| " Preliminary safety data, particularly the occurrence of cytopenias, can be used to guide dosing strategies for future combinations of venetoclax with immunomodulatory agents." | 3.01 | A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma. ( Abdallah, AO; Arriola, E; Bowles, KM; Bueno, OF; Coppola, S; Gasparetto, C; Mander, G; Mateos, MV; Morris, L; Ross, JA; Wang, J, 2021) |
| " The most appropriate delivery and dosing regimens of these therapies for patients at advanced age and frailty status is also unclear." | 3.01 | Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. ( Cairns, DA; Collett, C; Cook, G; Davies, FE; Drayson, MT; Garg, M; Gregory, WM; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Karunanithi, K; Kishore, B; Lindsay, J; Morgan, GJ; Owen, RG; Pawlyn, C; Russell, NH; Striha, A; Taylor, C; Waterhouse, A; Williams, CD; Wilson, J, 2021) |
| "This phase 2 study evaluated isatuximab as monotherapy or combined with dexamethasone in relapsed/refractory multiple myeloma (RRMM)." | 3.01 | Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. ( Anttila, P; Bringhen, S; Capra, M; Cavo, M; Cole, C; Dimopoulos, M; Gasparetto, C; Hellet, M; Hungria, V; Jenner, M; Macé, S; Paiva, B; Ruiz, EY; Saleem, R; Vij, R; Vorobyev, V; Yin, JY, 2021) |
| "Patients with relapsed/refractory multiple myeloma (RRMM) experience several relapses, and become refractory to successive therapies." | 3.01 | Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. ( Benboubker, L; Bringhen, S; Campana, F; Karlin, L; Koh, Y; Le Guennec, S; Maisnar, V; Menas, F; Pavic, M; Pour, L; Richardson, PG; van de Velde, H; Vorobyev, V; Vural, F; Warzocha, K, 2021) |
| "Patients with multiple myeloma are generally older and vary in fitness levels, which may influence the clinical benefit of treatment." | 2.94 | A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. ( Attal, M; Belch, A; Boyle, E; Chen, WM; Costa, B; Dimopoulos, MA; Facon, T; Guo, S; Houck, V; Hulin, C; Kim, K; Leleu, X; Lorraine Chretien, M; Ludwig, H; Macro, M; Manier, S; Meuleman, N; Mohty, M; Moreau, P; Renwick, W; Rodriguez-Otero, P; Rose, C; Silvia Monzini, M; Sturniolo, M; Tempescul, A; Tinel, A; Yves Mary, J; Zamagni, E, 2020) |
| "Melflufen is a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells." | 2.94 | OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma. ( Aschan, J; Pour, L; Robak, P; Schjesvold, F; Sonneveld, P, 2020) |
| "Treatment of multiple myeloma is not curative, but targeting CD38 improves patient survival." | 2.94 | MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial. ( Agis, H; Blank, A; Blau, IW; Chatterjee, M; Einsele, H; Engelhardt, M; Ferstl, B; Goldschmidt, H; Griese, J; Härtle, S; Jarutat, T; Peschel, C; Raab, MS; Röllig, C; Schub, N; Weirather, J; Weisel, K; Winderlich, M, 2020) |
| "Thrombosis was not associated with inferior progression-free survival (PFS) or overall survival (OS), apart from inferior OS for patients with arterial events (aHR, 1." | 2.94 | Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. ( Bradbury, CA; Cairns, DA; Child, JA; Cook, G; Craig, Z; Davies, FE; Drayson, MT; Gregory, WM; Hockaday, A; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Morgan, GJ; Owen, RG; Paterson, A; Pawlyn, C, 2020) |
| " In routine practice, few patients received ixazomib-based induction therapy due to reasons including (1) patients' preference on oral regimens, (2) concerns on adverse events (AEs) of other intravenous/subcutaneous regimens, (3) requirements for less center visits, and (4) fears of COVID-19 and other infectious disease exposures." | 2.94 | Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study. ( Bao, L; Chen, B; Ding, K; Fu, C; Hua, L; Huang, Y; Li, B; Li, J; Liu, P; Luo, J; Wang, L; Wang, S; Wang, W; Wu, G; Xia, Z; Xu, T; Yang, W; Yang, Y; Zhang, W; Zhou, X, 2020) |
| "Ixazomib is a next generation inhibitor of the 20S proteasome and is thought to be an effective treatment for those who have relapsed from bortezomib." | 2.94 | The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a prote ( Auner, HW; Bailey, L; Brown, S; Brudenell Straw, F; Cook, G; Cook, M; Dawkins, B; Flanagan, L; Hinsley, S; Kaiser, MF; McKee, S; Meads, D; Reed, S; Sherratt, D; Walker, K, 2020) |
| "The standard prognostic marker for multiple myeloma (MM) patients is the revised International Staging System (R-ISS)." | 2.94 | Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial. ( Beverloo, HB; Broijl, A; Dumee, B; Hansson, M; Koenders, J; Kuiper, R; Levin, MD; Sonneveld, P; Stevens-Kroef, M; van Beers, EH; van der Holt, B; van der Velden, AWG; van Duin, M; van Vliet, MH; Vermeulen, M; Visser-Wisselaar, H; Waage, A; Zweegman, S, 2020) |
| "Apixaban is an oral direct anti-Xa." | 2.90 | Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study. ( Auger-Quittet, S; Bareau, B; Belhadj-Merzoug, K; Benboubker, L; Bosson, JL; Boyle, E; Cliquennois, M; Decaux, O; Fuzibet, JG; Karlin, L; Leleu, X; Leyronnas, C; Orsini-Piocelle, F; Pegourie, B; Pernod, G; Rey, P; Rodon, P; Royer, B; Slama, B; Tiab, M; Voog, E; Zarnitsky, C, 2019) |
| "Despite therapeutic advances, multiple myeloma remains incurable, with limited options for patients with refractory disease." | 2.87 | Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. ( Ailawadhi, S; Bergsagel, PL; Buadi, FK; Chanan-Khan, AA; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Go, RS; Gonsalves, WI; Hayman, SR; Kapoor, P; Kourelis, T; Kumar, S; Kyle, RA; Lacy, MQ; LaPlant, BR; Laumann, KM; Leung, N; Lin, Y; Lust, JA; Mikhael, JR; Rajkumar, SV; Reeder, CB; Roy, V; Russell, SJ; Sher, T; Stewart, AK, 2018) |
| "Treatment for relapsed/refractory multiple myeloma (RRMM) remains an unmet need." | 2.87 | Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design. ( Anderson, KC; Attal, M; Campana, F; Corzo, K; Hui, AM; Le-Guennec, S; Richardson, PG; Risse, ML, 2018) |
| "Treatment of relapsed/refractory multiple myeloma (RRMM) aims to prolong survival while maintaining health-related quality of life (HRQoL) by managing disease-related symptoms and complications-one of the most frequent and debilitating being bone pain." | 2.87 | Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study. ( Cella, D; Davis, C; Kudlac, A; McKendrick, J; Oukessou, A; Palumbo, A; Vij, R; Zyczynski, T, 2018) |
| "We randomly assigned 700 patients with multiple myeloma to receive induction therapy with three cycles of RVD and then consolidation therapy with either five additional cycles of RVD (350 patients) or high-dose melphalan plus stem-cell transplantation followed by two additional cycles of RVD (350 patients)." | 2.84 | Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. ( Anderson, KC; Arnulf, B; Attal, M; Avet-Loiseau, H; Belhadj, K; Caillot, D; Escoffre, M; Facon, T; Fermand, JP; Garderet, L; Harousseau, JL; Hulin, C; Lauwers-Cances, V; Leleu, X; Macro, M; Maglio, ME; Mathiot, C; Meuleman, N; Moreau, P; Munshi, N; Payen, C; Richardson, PG; Rollet, S; Roussel, M; Weller, EA; Zeytoonjian, AA, 2017) |
| "Autoimmune events included pneumonitis (6 [13%]) and hypothyroidism (5 [10%]), mostly ≤ grade 2." | 2.84 | Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. ( Badros, A; Dell, C; Dogan, A; Goloubeva, O; Hyjek, E; Kocoglu, M; Lederer, E; Lesokhin, A; Ma, N; Milliron, T; Philip, S; Rapoport, AP; Singh, Z, 2017) |
| "Multiple myeloma is currently incurable, and the incidence rate is increasing year by year worldwide." | 2.82 | A review on the treatment of multiple myeloma with small molecular agents in the past five years. ( Chen, W; Li, J; Liu, X; Shi, J; Zhang, Z; Zhao, L; Zhou, Y, 2022) |
| "Thalidomide is an old well-known drug firstly used as morning sickness relief in pregnant women and then withdrawn from the market due to its severe side effects on fetal normal development." | 2.82 | Recent Advances in the Development of Thalidomide-Related Compounds as Anticancer Drugs. ( Barbarossa, A; Carocci, A; Franchini, C; Iacopetta, D; Sinicropi, MS, 2022) |
| "Response criteria for multiple myeloma are based upon changes in monoclonal protein levels quantified using serum and/or urine protein electrophoresis." | 2.82 | Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma. ( Attal, M; Avet-Loiseau, H; Dejoie, T; Harousseau, JL; Moreau, P, 2016) |
| " This analysis of the pivotal phase 3 FIRST trial examined the impact of renally adapted dosing of lenalidomide and dexamethasone on outcomes of patients with different degrees of renal impairment." | 2.82 | Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. ( Belhadj, K; Bensinger, W; Chen, G; Cheung, MC; Derigs, HG; Dib, M; Dimopoulos, MA; Eom, H; Ervin-Haynes, A; Facon, T; Gamberi, B; Hall, R; Jaccard, A; Jardel, H; Karlin, L; Kolb, B; Lenain, P; Leupin, N; Liu, T; Marek, J; Rigaudeau, S; Roussel, M; Schots, R; Tosikyan, A; Van der Jagt, R, 2016) |
| "Proteasome inhibitors (PIs) in combination with immunomodulatory drugs (IMiDs) have been shown to be effective against relapsed/refractory multiple myeloma (RRMM)." | 2.82 | Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma. ( Hagiwara, S; Iida, S; Ishida, T; Ito, A; Kanamori, T; Kato, C; Kinoshita, S; Komatsu, H; Kusumoto, S; Masuda, A; Murakami, S; Nakashima, T; Narita, T; Ri, M; Suzuki, N; Totani, H; Yoshida, T, 2016) |
| "Persistence of chemoresistant minimal residual disease (MRD) plasma cells (PCs) is associated with inferior survival in multiple myeloma (MM)." | 2.82 | Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. ( Alignani, D; Barcena, P; Barlogie, B; Blade, J; Burgos, L; Corchete, LA; De Arriba, F; Echeveste, MA; Epstein, J; García-Sanz, R; Gironella, M; Gonzalez, Y; Hernandez, MT; Johnson, SK; Lahuerta, JJ; Maiso, P; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Palomera, L; Puig, N; Rodriguez, I; San Miguel, JF; Sanchez, ML; Vidriales, MB, 2016) |
| "Despite novel therapeutic agents, most multiple myeloma (MM) patients eventually relapse." | 2.82 | Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantatio ( Baertsch, MA; Fenk, R; Goerner, M; Goldschmidt, H; Graeven, U; Haenel, M; Hielscher, T; Hillengaß, J; Ho, AD; Hose, D; Jauch, A; Klein, S; Kunz, C; Lindemann, HW; Luntz, S; Mai, EK; Martin, H; Merz, M; Nogai, A; Noppeney, R; Raab, MS; Reimer, P; Salwender, H; Scheid, C; Schlenzka, J; Schmidt-Hieber, M; Schmidt-Wolf, IG; Weisel, K; Wuchter, P, 2016) |
| "The value of minimal residual disease (MRD) in multiple myeloma (MM) has been more frequently investigated in transplant-eligible patients than in elderly patients." | 2.82 | Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. ( Arana, P; Bargay, J; Bladé, J; Cabrera, C; Cedena, MT; Cordon, L; Echeveste, MA; Encinas, C; Flores-Montero, J; Gironella, M; Gonzalez, Y; Gutierrez, NC; Hernandez, MT; Lahuerta, JJ; Martin, J; Martín-Ramos, ML; Martinez, R; Martinez-Lopez, J; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Puig, N; Rosiñol, L; San Miguel, JF; Teruel, AI; Van Dongen, JJ; Vidriales, MB, 2016) |
| "Relapsed/refractory multiple myeloma (RRMM) patients have poor overall survival (OS)." | 2.82 | Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS). ( Dimopoulos, MA; Gibson, CJ; Hong, K; Moreau, P; Saunders, O; Song, KW; Sternas, LA; Weisel, KC; Zaki, MH, 2016) |
| "Pomalidomide 4 mg was given on days 1-21 of 28-day cycles with low-dose dexamethasone 40 mg (20 mg for patients aged >75 years) on days 1, 8, 15, and 22 until progressive disease or unacceptable toxicity." | 2.82 | Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. ( Anttila, P; Blanchard, MJ; Cafro, AM; Cavo, M; Corradini, P; de Arriba, F; Delforge, M; Di Raimondo, F; Dimopoulos, MA; Doyen, C; Goldschmidt, H; Hansson, M; Herring, J; Kaiser, M; Knop, S; Miller, N; Moreau, P; Morgan, G; Ocio, EM; Oriol, A; Palumbo, A; Peluso, T; Petrini, M; Raymakers, R; Röllig, C; San-Miguel, J; Simcock, M; Sternas, L; Vacca, A; Weisel, KC; Zaki, MH, 2016) |
| " Dosing was based on the lenalidomide label." | 2.82 | Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment. ( Abraham, J; Arnulf, B; Bridoux, F; Chen, N; Desport, E; Fermand, JP; Jaccard, A; Moreau, S; Moumas, E, 2016) |
| " This prompted us to explore the concept of less intense drug dosing with shorter intervals between courses with the aim of preventing inter-course relapse." | 2.82 | Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma. ( Alapat, D; Avery, D; Bailey, C; Barlogie, B; Crowley, J; Epstein, J; Heuck, CJ; Hoering, A; Jethava, Y; Khan, R; Mitchell, A; Morgan, G; Petty, N; Sawyer, J; Schinke, C; Smith, R; Stein, C; Steward, D; Thanendrarajan, S; Tian, E; van Rhee, F; Waheed, S; Yaccoby, S; Zangari, M, 2016) |
| "Polymerase chain reaction (PCR)-based minimal residual disease (MRD) analysis is a useful prognostic tool in multiple myeloma (MM), although its long-term impact still needs to be addressed." | 2.80 | Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. ( Boccadoro, M; Callea, V; Caltagirone, S; Cangialosi, C; Carovita, T; Cavallo, F; Crippa, C; De Rosa, L; Drandi, D; Falcone, AP; Ferrero, S; Genuardi, E; Grasso, M; Guglielmelli, T; Ladetto, M; Liberati, AM; Musto, P; Oliva, S; Palumbo, A; Passera, R; Pisani, F; Pregno, P; Rossini, F; Terragna, C; Urbano, M, 2015) |
| "The lenalidomide dose was adapted to the estimated glomerular filtration rate and dexamethasone was given at high dose in cycle one and at low dose thereafter." | 2.80 | Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study. ( Adam, Z; Autzinger, EM; Greil, R; Heintel, D; Kasparu, H; Kuehr, T; Ludwig, H; Müldür, E; Poenisch, W; Rauch, E; Weißmann, A; Zojer, N, 2015) |
| "We analyzed the prognostic impact of cytogenetic aberrations by fluorescence in situ hybridization at different cutoff values in a cohort of 333 patients with newly diagnosed myeloma and 92 patients with relapsed myeloma." | 2.80 | The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma. ( Acharya, C; An, G; Anderson, KC; Cheng, T; Deng, S; Feng, X; Hao, M; Li, C; Li, Q; Li, Z; Qi, J; Qin, X; Qiu, L; Ru, K; Shi, L; Sui, W; Tai, YT; Wang, J; Xu, Y; Yi, S; Zang, M; Zhao, J; Zhao, Y; Zou, D, 2015) |
| " Here we evaluated the clinical and pharmacodynamic effects of continuous or intermittent dosing strategies of pomalidomide/dexamethasone in lenalidomide-refractory myeloma in a randomized trial." | 2.80 | Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. ( Breider, M; Cooper, D; Couto, S; Das, R; Deng, Y; Dhodapkar, KM; Dhodapkar, MV; Hansel, D; Kocoglu, M; Koduru, S; Ren, Y; Sehgal, K; Seropian, S; Thakurta, A; Vasquez, J; Verma, R; Wang, M; Yao, X; Zhang, L, 2015) |
| "Bortezomib maintenance was feasible without producing cumulative toxicity." | 2.80 | Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens. ( Charu, V; Clowney, B; Elliott, J; Essell, J; Esseltine, DL; Flinn, IW; Gabrail, N; Gaffar, Y; Neuwirth, R; Niculescu, L; Niesvizky, R; Reeves, J; Rifkin, R; Warr, T; Zhu, Y, 2015) |
| "Pomalidomide is a distinct oral IMiD(®) immunomodulatory agent with direct antimyeloma, stromal-support inhibitory, and immunomodulatory effects." | 2.80 | Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. ( Alegre, A; Bahlis, NJ; Banos, A; Cavo, M; Chen, C; Delforge, M; Dimopoulos, MA; Garderet, L; Goldschmidt, H; Ivanova, V; Jacques, C; Karlin, L; Martinez-Lopez, J; Moreau, P; Oriol, A; Renner, C; San Miguel, JF; Song, KW; Sternas, L; Teasdale, T; Weisel, KC; Yu, X; Zaki, MH, 2015) |
| "Elotuzumab combined with lenalidomide and dexamethasone in patients with relapsed multiple myeloma showed acceptable safety and efficacy that seems better than that previously noted with lenalidomide and dexamethasone only." | 2.80 | Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. ( Anderson, KC; Benboubker, L; Bleickardt, E; Facon, T; Jagannath, S; Jakubowiak, AJ; Lonial, S; Moreau, P; Raab, MS; Reece, DE; Richardson, PG; Singhal, AK; Tsao, LC; Vij, R; White, D; Zonder, J, 2015) |
| "Lenalidomide is an immunomodulatory drug with co-stimulatory effects on NKT cells in vitro and is an approved treatment for MM, although its mode of action in that context is not well defined." | 2.79 | Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy. ( Berzins, SP; Chan, AC; Godfrey, DI; Harrison, SJ; Leeansyah, E; Neeson, P; Prince, HM; Quach, H; Ritchie, D; Tainton, K, 2014) |
| "In 36 multiple myeloma (MM) patients, we measured serial changes in iFLC and M-protein after start of treatment." | 2.79 | Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR. ( Abildgaard, N; Hansen, CT; Nielsen, LC; Pedersen, PT, 2014) |
| " A total of 43 patients were recruited into three CPT plus thalidomide cohorts based on CPT dosage in sequence: 5 mg/kg (n = 11), 8 mg/kg (n = 17), and 10 mg/kg (n = 15)." | 2.79 | A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma. ( Chen, WM; Geng, C; Hou, J; Huang, Z; Ke, X; Liu, Y; Qiu, L; Wang, F; Wang, Z; Wei, N; Wei, P; Xi, H; Yang, S; Zhao, Y; Zheng, X; Zhu, B, 2014) |
| "Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24." | 2.78 | Sorafenib in patients with refractory or recurrent multiple myeloma. ( Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A, 2013) |
| "To investigate the prognostic value of minimal residual disease (MRD) assessment in patients with multiple myeloma treated in the MRC (Medical Research Council) Myeloma IX trial." | 2.78 | Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. ( Bell, SE; Child, JA; Cook, G; Davies, FE; de Tute, RM; Drayson, MT; Feyler, S; Gregory, WM; Jackson, GH; Morgan, GJ; Navarro-Coy, N; Owen, RG; Rawstron, AC; Ross, FM; Szubert, AJ, 2013) |
| "The lenalidomide dose was 25 mg/day, and was adjusted according to baseline renal function." | 2.78 | A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. ( Ai, H; Cai, Z; Chen, F; Chen, N; Du, X; Hou, J; Jin, J; Ke, X; Li, X; Mei, J; Meng, F; Wang, J; Wortman-Vayn, H; Wu, D; Yu, L; Zhang, J; Zhou, DB, 2013) |
| "For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop." | 2.78 | Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. ( Bargay, J; Bladé, J; de Arriba, F; de la Rubia, J; García, JL; Giraldo, P; Hernández, MT; Lahuerta, JJ; López Corral, L; López, J; Mateos, MV; Olavarría, E; Oriol, A; Paiva, B; Palomera, L; Prosper, F; Quintana, N; Rosiñol, L; San Miguel, JF, 2013) |
| "Pomalidomide was given at 1 to 2." | 2.78 | Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. ( Baldi, I; Boccadoro, M; Bringhen, S; Carella, AM; Corradini, P; Crippa, C; Galli, M; Giuliani, N; Guglielmelli, T; La Verde, G; Larocca, A; Magarotto, V; Marcatti, M; Mina, R; Montefusco, V; Omedé, P; Palumbo, A; Rossi, D; Rota-Scalabrini, D; Santagostino, A, 2013) |
| "Patients with asymptomatic (smoldering) multiple myeloma (AMM) have a high risk of transformation to active multiple myeloma (MM)." | 2.78 | A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. ( Dispenzieri, A; Gertz, MA; Greipp, PR; Hassoun, H; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, KM; Lust, JA; Mandrekar, SJ; Rajkumar, SV; Reeder, CB; Roy, V; Witzig, TE, 2013) |
| "Lenalidomide was shown to mediate antigen-specific costimulation of human iNKT cells." | 2.78 | Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. ( Dhodapkar, KM; Dhodapkar, MV; Miesowicz, F; Monesmith, T; Nair, S; Neparidze, N; Richter, J; Sundaram, R; Zhang, L, 2013) |
| "Patients with newly diagnosed multiple myeloma were included in the HOVON-65/GMMG-HD4 trial, in which postintensification treatment in 1 arm consisted of daily thalidomide (50 mg) for 2 years." | 2.78 | High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. ( Bertsch, U; Broyl, A; Buijs, A; el Jarari, L; Goldschmidt, H; Hose, D; Kuiper, R; Lokhorst, HM; Sonneveld, P; van der Holt, B; van Duin, M; Zweegman, S, 2013) |
| "Thrombocytopenia was the most common grade ≥ 3 AE (35%)." | 2.78 | A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. ( Allietta, N; Angermund, R; Bladé, J; Blau, IW; Broer, E; Corradini, P; Dimopoulos, MA; Drach, J; Giraldo, P; Mitchell, V; Petrucci, MT; Teixeira, A, 2013) |
| "Thalidomide 100 mg/day was better tolerated than 400 mg/day with less high-grade somnolence, constipation, nausea/vomiting and peripheral neuropathy (P < 0." | 2.77 | Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome. ( Benboubker, L; Berthou, C; Casassus, P; Damaj, G; Dib, M; Doyen, C; Facon, T; Harousseau, JL; Hulin, C; Maloisel, F; Marit, G; Mary, JY; Mohty, M; Moreau, P; Pegourie, B; Rodon, P; Slama, B; Stoppa, AM; Voillat, L; Yakoub-Agha, I; Zerbib, R, 2012) |
| "Although multiple myeloma (MM) remains an incurable disease, considerable improvements in survival have been made with the introduction of autologous stem cell transplantation and new drugs." | 2.77 | Emergence of central nervous system myeloma in the era of novel agents. ( Carney, DA; Gangatharan, SA; Harrison, SJ; Januszewicz, EH; Prince, HM; Ritchie, DS; Wolf, MM, 2012) |
| " The dosage of thalidomide, concentrations of (R)- and (S)-thalidomide in whole blood, and clinical laboratory test results were used as pharmacokinetic and pharmacodynamic indices." | 2.77 | Influence of cytochrome P450 2C19 gene variations on pharmacokinetic parameters of thalidomide in Japanese patients. ( Ishida, F; Matsuda, M; Matsuzawa, N; Nakamura, K; Ohmori, S, 2012) |
| "Patients with multiple myeloma (MM) undergoing high dose therapy and autologous stem cell transplantation (SCT) remain at risk for disease progression." | 2.77 | Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity. ( Chung, HM; Clark, WB; Hazlett, AF; Kmieciak, M; Manjili, MH; McCarty, JM; Payne, KK; Roberts, CH; Sabo, RT; Sanford, K; Toor, AA; Williams, DC, 2012) |
| "Newly diagnosed patients with multiple myeloma (MM) (n=122) aged greater than 55 yr, not eligible for transplantation were randomized to receive 8 cycles of M (9 mg/m(2) /d) and P (60 mg/m(2) /d) for 4d every 6 wk (n=62) or MP and thalidomide (100 mg/d) continuously (n=60)." | 2.76 | Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. ( Ali, R; Aydogdu, I; Beksac, M; Firatli-Tuglular, T; Goker, H; Gulbas, Z; Haznedar, R; Karakus, S; Kaya, E; Kaygusuz, I; Konuk, N; Ozdogu, H; Ozet, G; Sucak, G; Undar, L, 2011) |
| "In newly diagnosed multiple myeloma (MM), three/four-drug combinations as induction therapy seem to be more effective compared with two-drug associations in terms of response rate and duration of remission." | 2.76 | Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma. ( Blasi, N; Brunori, M; Caraffa, P; Catarini, M; Corvatta, L; Ferranti, M; Gentili, S; Leoni, P; Malerba, L; Mele, A; Offidani, M; Polloni, C; Rizzi, R; Samori, A, 2011) |
| "Forty-three newly diagnosed multiple myeloma patients requiring treatment were enrolled on this study." | 2.76 | A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. ( Ailawadhi, S; Chanan-Khan, A; Czuczman, MS; Hernandez-Ilizaliturri, FJ; Hong, F; Iancu, D; Jamshed, S; Lawrence, W; Lee, K; Manfredi, D; Masood, A; Miller, KC; Sher, T; Soniwala, S; Sood, R; Tan, W; Wilding, G; Wood, M, 2011) |
| "Detection of specific chromosomal abnormalities by FISH and metaphase cytogenetics allows risk stratification in multiple myeloma; however, gene expression profiling (GEP) based signatures may enable more specific risk categorization." | 2.76 | Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. ( Ahmann, GJ; Callander, NS; Fonseca, R; Greipp, PR; Haug, JL; Henderson, KJ; Jacobus, SJ; Kumar, SK; Rajkumar, SV; Siegel, DS; Uno, H; Van Wier, SA, 2011) |
| "Thalidomide maintenance was associated with impaired OS, although our analysis suggests that this effect may have been due to confounding variables." | 2.76 | The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. ( Boyd, KD; Chiecchio, L; Child, JA; Dagrada, G; Davies, FE; Gonzalez, D; Gregory, WM; Hockley, SL; Jackson, GH; Konn, ZJ; Morgan, GJ; Ross, FM; Tapper, WJ; Walker, BA; Wardell, CP, 2011) |
| "Lenalidomide was generally well tolerated and no grade 4 hematologic toxicities were noted." | 2.75 | Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis. ( Baz, R; Chanan-Khan, AA; Finley-Oliver, E; Hussein, MA; Lebovic, D; Lee, K; Miller, KC; Patel, M; Sher, T; Wood, M, 2010) |
| " Phase 2 dosing was determined to be bortezomib 1." | 2.75 | Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. ( Anderson, KC; Avigan, DE; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, AJ; Joyce, R; Kaster, S; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Mazumder, A; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, DL; Weller, E; Xie, W, 2010) |
| " Nonhematologic grade 3/4 adverse events were reported in 35% of once-weekly patients and 51% of twice-weekly patients (P = ." | 2.75 | Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. ( Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Cavalli, M; Cavo, M; De Rosa, L; Evangelista, A; Falcone, AP; Gaidano, G; Gentili, S; Genuardi, M; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Liberati, AM; Musto, P; Nozzoli, C; Palumbo, A; Patriarca, F; Ria, R; Rizzo, V; Rossi, D, 2010) |
| "Novel agents have demonstrated enhanced efficacy when combined with other antimyeloma agents especially dexamethasone." | 2.74 | Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. ( Ailawadhi, S; Barcos, M; Bernstein, ZP; Chanan-Khan, A; Czuczman, MS; Iancu, D; Lee, K; Miller, KC; Mohr, A; Musial, L; Padmanabhan, S; Patel, M; Sher, T; Yu, J, 2009) |
| "Thalidomide therapy was associated with a significant increase in the incidence of patients with multiple expansions (49% vs." | 2.74 | Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. ( Aklilu, E; Brown, RD; Gibson, J; Ho, PJ; Joshua, DE; Kabani, K; Kennedy, N; Spencer, A; Sze, DM; Yang, S, 2009) |
| "Osteolytic bone disease in multiple myeloma (MM) is caused by enhanced osteoclast (OCL) activation and inhibition of osteoblast function." | 2.73 | Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. ( Anderson, KC; Breitkreutz, I; Chauhan, D; Hideshima, T; Mitsiades, C; Munshi, NC; Okawa, Y; Raab, MS; Raje, N; Richardson, PG; Vallet, S, 2008) |
| "Thalidomide 50 mg per day was started on day > or = 60 after recovery of blood counts and was escalated to a maximum dose of 200 mg per day." | 2.73 | Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma. ( Callander, NS; Chang, JE; Gangnon, RE; Juckett, MB; Kahl, BS; Longo, WL; Mitchell, TL, 2008) |
| "Smoldering multiple myeloma (SMM) is usually followed expectantly without therapy." | 2.73 | Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. ( Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Epstein, J; Hoering, A; Hollmig, K; Jenkins, B; Kumar, NS; Petty, N; Pineda-Roman, M; Shaughnessy, JD; Srivastava, G; Szymonifka, J; van Rhee, F; Yaccoby, S; Zeldis, JB, 2008) |
| " Eight patients had permitted escalation of thalidomide dosage up to 200 mg daily." | 2.73 | Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma. ( Boyd, K; Clarke, P; Drake, M; Hull, DR; Jones, FC; Kettle, PJ; Morris, TC; Morrison, A; O'Reilly, P; Quinn, J, 2008) |
| "Bortezomib (1." | 2.73 | The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. ( Anagnostopoulos, N; Christoulas, D; Croucher, P; Dimopoulos, MA; Eleftherakis-Papaiakovou, E; Heath, D; Kastritis, E; Roussou, M; Terpos, E; Tsionos, K, 2008) |
| " Food and Drug Administration (FDA) on June 29, 2006, for use in combination with dexamethasone in patients with multiple myeloma (MM) who have received at least one prior therapy." | 2.73 | Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy. ( Booth, B; Dagher, R; Farrell, A; Hazarika, M; Justice, R; Pazdur, R; Rock, E; Sridhara, R; Williams, G, 2008) |
| "Thalidomide has direct antimyeloma and immunomodulatory effects." | 2.73 | Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21. ( Abonour, R; Ansari, RH; Cripe, LD; Fausel, C; Fisher, WB; Juliar, BE; Smith, GG; Suvannasankha, A; Wood, LL; Yiannoutsos, CT, 2007) |
| "Thalidomide maintenance has unresolved issues regarding dosage and toxicity." | 2.73 | Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study. ( Cocks, K; Feyler, S; Jackson, G; Johnson, RJ; Rawstron, A; Snowden, JA, 2007) |
| "Pomalidomide was continued following the 4-week MTD study in 17/20 patients for a median of 14 months." | 2.73 | Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. ( Daniel, Y; Gyertson, K; Kazmi, M; Schey, SA; Streetly, MJ; Zeldis, JB, 2008) |
| "Twenty-four patients who were enrolled in a large randomized trial of thalidomide vs no thalidomide maintenance therapy for myeloma, in which all patients also received zoledronic acid, were recruited to a pharmacokinetic and renal safety sub-study, and followed for up to 16 months." | 2.73 | Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study. ( Bilic, S; Copeman, M; Cremers, S; Kennedy, N; Lynch, K; Neeman, T; Ravera, C; Roberts, A; Schran, H; Spencer, A, 2008) |
| "Bortezomib (V) was combined with thalidomide (T) and dexamethasone (D) in a phase I/II trial to determine dose-limiting toxicities (DLT's) and clinical activity of the VTD regimen in 85 patients with advanced and refractory myeloma." | 2.73 | VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. ( Anaissie, E; Barlogie, B; Crowley, J; Epstein, J; Hoering, A; Petty, N; Pineda-Roman, M; Shaughnessy, J; Szymonifka, J; van Rhee, F; Zangari, M, 2008) |
| "The assessment of minimal residual disease (MRD) by next-generation flow cytometry or next-generation sequencing is established as a powerful predictor of long-term outcomes." | 2.72 | New regimens and directions in the management of newly diagnosed multiple myeloma. ( Bal, S; Costa, LJ; Giri, S; Godby, KN, 2021) |
| " The favorable effects of CR and rapidly sequenced second transplantation attest to the validity of a melphalan dose-response effect in myeloma." | 2.72 | Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. ( Anaissie, E; Barlogie, B; Crowley, J; Epstein, J; Fassas, A; Hollmig, K; Pineda-Roman, M; Rasmussen, E; Shaughnessy, J; Tricot, G; van Rhee, F; Zangari, M, 2006) |
| "In the present study, markers of bone resorption [urinary free pyridinoline (PYD), deoxypyridinoline (DPYD), N-terminal telopeptide of collagen I (NTX) and C-terminal telopeptide (serum crosslaps)] and of bone formation [bone alkaline phosphatase (BAP) and osteocalcin] were evaluated at diagnosis and after induction therapy in 40 patients (23M, 17F, median age = 53." | 2.72 | First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. ( Baccarani, M; Boni, P; Cangini, D; Cavo, M; Ceccolini, M; Cellini, C; Parente, R; Perrone, G; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E, 2006) |
| "We evaluated the risk factors for infection of 367 consecutive myeloma patients who underwent high-dose melphalan and autologous stem cell transplantation (ASCT)." | 2.72 | Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. ( Anaissie, EJ; Barlogie, B; Dong, L; Fassas, A; Grazziutti, ML; Miceli, MH; Thertulien, R; Van Rhee, F, 2006) |
| "Significant peripheral neuropathy and deep vein thrombosis each occurred in only 3%." | 2.72 | A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ( Alsina, M; Anderson, KC; Blood, E; Dalton, WS; Desikan, KR; Doss, D; Freeman, A; Gorelik, S; Hideshima, T; Jagannath, S; Kelly-Colson, K; Knight, R; McKenney, ML; Mitsiades, CS; Munshi, NC; Olesnyckyj, M; Rajkumar, SV; Rich, R; Richardson, PG; Schlossman, RL; Warren, D; Weller, E; Wride, K; Wu, A; Zeldenrust, SR; Zeldis, J, 2006) |
| "Thalidomide is an effective maintenance therapy in patients with multiple myeloma." | 2.72 | Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. ( Attal, M; Avet-Loiseau, H; Benboubker, L; Berthou, C; Bourhis, JH; Caillot, D; Doyen, C; Dumontet, C; Facon, T; Garderet, L; Grobois, B; Harousseau, JL; Hulin, C; Leyvraz, S; Marit, G; Monconduit, M; Moreau, P; Pegourie, B; Renaud, M; Voillat, L; Yakoub Agha, I, 2006) |
| "Patients with multiple myeloma or chronic lymphocytic leukemia who were treated on thalidomide based-combination therapies were treated on low-dose warfarin (1 or 2 mg) continuously through the duration of their therapy." | 2.72 | Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. ( Chanan-Khan, A; Depaolo, D; Dimicelli, L; Doran, V; Landrigan, B; Marshal, P; Miller, KC; Padmanabhan, S; Yu, J, 2006) |
| "Relapsed or refractory multiple myeloma has a poor outlook." | 2.71 | Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. ( Bell, R; Biagi, JJ; Briggs, P; Grigg, A; Lillie, K; McKendrick, J; Mileshkin, L; Mitchell, P; Prince, HM; Seymour, JF; Smith, JG; Underhill, C; Zeldis, JB, 2003) |
| "Neutropenia was a dose limiting factor with half of the cases (7/14) presenting with severe neutropenia (grade 3-4), but a response was observed in all of them on administration of G-CSF." | 2.71 | [Single-agent thalidomide for advanced and refractory multiple myeloma]. ( Fujimura, K; Imagawa, J; Katayama, Y; Kimura, A; Noda, M; Okikawa, Y; Okita, H; Sakai, A; Takimoto, Y, 2003) |
| "Sixty patients with advanced multiple myeloma received 2-6 monthly treatment courses combining hyperfractionated cyclophosphamide (300 mg/m2 i." | 2.71 | Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. ( Berdel, WE; Bisping, G; Dominé, N; Fenk, R; Heinecke, A; Hentrich, M; Innig, G; Kienast, J; Koch, OM; Kropff, MH; Lang, N; Mitterer, M; Ostermann, H; Straka, C; Südhoff, T, 2003) |
| "We treated with thalidomide 17 patients (12 males, 5 females), average age 51 (range 42-73 years), mean time since diagnosis to the start of thalidomide treatment was 24 months (range 5-48)." | 2.71 | [Preliminary results of monotherapy with thalidomide in recurrent and treatment resistant cases of multiple myeloma]. ( Helbig, G; Hołowiecki, J; Kyrcz-Krzemień, S; Stella-Hołowiecka, B, 2003) |
| "Thalidomide was given daily at a dose of 200 mg at bedtime." | 2.71 | Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. ( Anagnostopoulos, A; Dimopoulos, MA; Hatzicharissi, E; Korantzis, J; Maniatis, A; Mitsouli, Ch; Panagiotidis, P; Papaioannou, M; Tzilianos, M; Zervas, K, 2004) |
| "Thalidomide concentration was determined by HPLC." | 2.71 | Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. ( Don, BR; Eriksson, T; Höglund, P; Kaysen, GA; Scheffler, M; Turesson, I; Vu, J; Waage, A, 2003) |
| "Thalidomide is an oral agent with significant activity in one-third of patients with refractory myeloma." | 2.71 | Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. ( Anagnostopoulos, A; Anagnostopoulos, N; Dimopoulos, MA; Efstathiou, E; Gika, D; Grigoraki, V; Hamilos, G; Poziopoulos, C; Xilouri, I; Zomas, A; Zorzou, MP, 2004) |
| "Thalidomide has recently been recognized as an effective new agent for previously untreated, refractory or relapsed myeloma." | 2.71 | Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program. ( Gastl, G; Mitterer, M; Spizzo, G; Steurer, M, 2004) |
| " Thalidomide, both alone and in combination with dexamethasone, has been demonstrated to be useful in patients with advanced MM, as responses could be achieved in 30-60% of the cases." | 2.71 | Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. ( Baccarani, M; Cangini, D; Cavo, M; Cellini, C; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E, 2004) |
| "The incidence of deep vein thrombosis (DVT) was significantly higher in the thalidomide arm hazard ratio: 4." | 2.71 | Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. ( Anaissie, E; Barlogie, B; Eddlemon, P; Fassas, A; Fink, L; Jacobson, J; Lee, CK; Saghafifar, F; Talamo, G; Thertulien, R; Thomas, T; Tricot, G; Van Rhee, F; Zangari, M, 2004) |
| "Bortezomib was found to be cost effective relative to BSC and thalidomide." | 2.71 | Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma. ( Duff, SB; Gupta, S; Mehta, J, 2004) |
| "Thalidomide (400 mg/d) was combined with bolus injections of vincristine and epirubicin and oral dexamethasone (VED)." | 2.71 | Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. ( Bojko, P; Brandhorst, D; Buttkereit, U; Ebeling, P; Flasshove, M; Hense, J; Hoiczyk, M; Metz, K; Moritz, T; Nowrousian, MR; Opalka, B; Schütt, P; Seeber, S, 2005) |
| "Thalidomide-treated patients had a prevalence of AVN similar to that of the control group (8% v 10%, respectively; P = ." | 2.71 | Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy. ( Anaissie, E; Angtuaco, E; Barlogie, B; Dong, L; Miceli, MH; Talamo, G; Tricot, G; Walker, RC; Zangari, M, 2005) |
| "Lenalidomide was given orally 25 mg daily on days 1 to 21 of a 28-day cycle." | 2.71 | Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. ( Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, SM; Greipp, PR; Hayman, SR; Kabat, B; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Russell, SJ; Witzig, TE; Zeldenrust, SR, 2005) |
| "Treatment in patients with multiple myeloma remain to be defined." | 2.71 | Novel therapy in multiple myeloma. ( Avilés, A; Castañeda, C; Cleto, S; González, M; Huerta-Guzmán, J; Nambo, MJ; Neri, N; Talavera, A, 2005) |
| "Thalidomide (Thal) is a drug with antiangiogenic, anti-inflammatory, and immunomodulatory properties that was found to inhibit the production of tumor necrosis factor-alpha (TNF-alpha) in vitro." | 2.70 | Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. ( Goldschmidt, H; Ho, AD; Kraemer, A; Moehler, TM; Mytilineos, J; Neben, K; Opelz, G; Preiss, A, 2002) |
| "Thalidomide was well tolerated." | 2.70 | Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. ( Bertola, A; Boccadoro, M; Bringhen, S; Gallo, E; Giaccone, L; Palumbo, A; Pileri, A; Pregno, P; Rus, C; Triolo, S, 2001) |
| " Response rates were higher and survival was longer especially in high-risk patients given more than 42 g THAL in 3 months (median cumulative dose) (landmark analysis); this supports a THAL dose-response effect in advanced MM." | 2.70 | Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. ( Anaissie, E; Ayers, D; Badros, A; Barlogie, B; Desikan, R; Eddlemon, P; Epstein, J; Munshi, N; Shaughnessy, J; Spencer, T; Spoon, D; Tricot, G; Zangari, M; Zeldis, J, 2001) |
| "Thalidomide (Thal) is a drug with anti-angiogenic properties." | 2.70 | Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. ( Benner, A; Egerer, G; Goldschmidt, H; Ho, AD; Kraemer, A; Moehler, T; Neben, K, 2001) |
| "Thalidomide was initially administered at a dose of 100 mg/day; if well tolerated, the dose was to be increased serially by 200mg every other week to a maximum of 800 mg/day." | 2.70 | Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. ( Baccarani, M; Ballerini, F; Cangini, D; Cavo, M; Cellini, C; Di Raimondo, F; Gobbi, M; Lauria, F; Ledda, A; Masini, L; Musto, P; Patriarca, F; Ria, R; Ronconi, S; Tosi, P; Tura, S; Vacca, A; Zamagni, E, 2002) |
| "The risk of second malignancy after multiple myeloma is affected by a combination of patient-, disease- and therapy-related risk factors." | 2.66 | Second malignancies in multiple myeloma; emerging patterns and future directions. ( Diamond, B; Hillengass, J; Kazandjian, D; Landgren, CO; Maclachlan, K; Maura, F; Turesson, I, 2020) |
| "Finally, this article briefly reviews minimal residual disease directed therapy approaches, primarily in the context of whether eligible patients should be referred for high dose chemotherapy and autologous stem cell rescue." | 2.66 | Modern treatments and future directions for newly diagnosed multiple myeloma patients. ( Lu, SX, 2020) |
| " In this systematic review, associations of the efficacy of each approved regimen with adverse events (AEs) and the total cost per cycle were compared with a Bayesian network meta-analysis (NMA) of phase 3 randomized controlled trials (RCTs)." | 2.66 | Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. ( Aryal, M; Chhabra, S; D'Souza, A; Dhakal, B; Ghose, S; Giri, S; Hamadani, M; Hari, PN; Janz, S; Narra, RK; Pathak, LK; Smunt, TL; Szabo, A, 2020) |
| "Acquired hemophilia A is a rare autoimmune disease with clinically often significant bleeding diathesis resulting from circulating autoantibodies inhibiting coagulation factor VIII." | 2.66 | Acquired hemophilia A and plasma cell neoplasms: a case report and review of the literature. ( Andres, M; Angelillo-Scherrer, A; Dickenmann, M; Jalowiec, KA; Kremer Hovinga, JA; Musa, A; Rovó, A; Taleghani, BM, 2020) |
| "Multiple myeloma is the second most common blood cancer in New Zealand with higher incidence in Māori and Pacific Island populations." | 2.66 | Consensus statement on the treatment of transplant-eligible patients with newly diagnosed multiple myeloma in New Zealand. ( Baker, B; Chan, H; Chien, N; Goodman, H; Romeril, K, 2020) |
| " Based on this data, we would recommended incorporation of strategies combining novel agents (monoclonal antibodies, immunomodulatory imide drugs and proteasome inhibitors) in triplets or quadruplets and/or those comprising long term use of lenalidomide as standard frontline treatments." | 2.61 | Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: A systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials. ( Falcetta, FS; Manica, D; Morais, VD; Pithan, CDF; Ribeiro, MR; Ribeiro, RA; Salazar, AP; Sekine, L; Sosnoski, M; Ziegelmann, PK, 2019) |
| "Multiple myeloma is a bone marrow-based hematological malignancy accounting for approximately two per cent of cancers." | 2.61 | Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. ( Adams, A; Estcourt, LJ; Jakob, T; Kuhr, K; Langer, P; Monsef, I; Ocheni, S; Piechotta, V; Scheckel, B; Scheid, C; Skoetz, N; Theurich, S, 2019) |
| "Decision making for patients with multiple myeloma (MM) not transplant eligible (NTE) is complicated by a lack of head-to-head comparisons of standards of care, the increase in the choice of treatment modalities, and the promising results that are rapidly evolving from studies with novel regimens." | 2.61 | Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis. ( Blommestein, HM; Franken, MG; Sonneveld, P; Uyl-de Groot, CA; van Beurden-Tan, CHY; Zweegman, S, 2019) |
| "The survival of multiple myeloma patients is increasing due to new medications, the widespread implementation of autologous stem cell transplantation and better supportive treatments." | 2.61 | Risk adapted post-transplant maintenance in multiple myeloma. ( Gertz, M; Vaxman, I, 2019) |
| "Pomalidomide (Pom) has demonstrated synergistic antiproliferative activity in combination regimens as a result of its distinct anticancer, antiangiogenic, and immunomodulatory effects." | 2.61 | Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials. ( Ali, Z; Anwer, F; Hassan, H; Hassan, SF; Iftikhar, A; Kamal, A; Lakhani, M; Mushtaq, A; Raychaudhuri, S; Razzaq, F; Safdar, A; Sagar, F; Zahid, U; Zar, MA, 2019) |
| "Lenalidomide-based therapy was associated with a significant increase in risk of serious infection in patients treated compared with conventional therapy (RR = 2." | 2.58 | Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies. ( Chen, M; Mao, B; Wang, X; Xu, C; Zhang, X; Zhao, Y, 2018) |
| " Carfilzomib (CFZ) has high selectivity and minimal off-target adverse effects including lower rates of PNP." | 2.58 | Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review. ( Abraham, I; Anwer, F; Iftikhar, A; Kapoor, V; Latif, A; McBride, A; Mushtaq, A; Riaz, IB; Zahid, U, 2018) |
| " The treatment outcomes of MAbs versus HDACi in combination with bortezomib or lenalidomide plus dexamethasone remain unknown." | 2.58 | Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trial ( Chen, X; Feng, J; Gao, G; Shen, H; Tang, H; Xu, L; Zhang, N; Zheng, Y, 2018) |
| "Transplant-eligible patients with multiple myeloma (MM) now have extended survival after diagnosis owing to effective modern treatment strategies that include new agents in induction therapy, autologous stem cell transplant (ASCT), consolidation therapy and posttransplant maintenance therapy." | 2.55 | Posttransplant maintenance therapy in multiple myeloma: the changing landscape. ( Garderet, L; Malard, F; Mohty, M; Savani, BN; Sengsayadeth, S, 2017) |
| "Thalidomide is a drug with interesting therapeutic properties but also with severe side effects which require a careful and monitored use." | 2.55 | A Mini-Review on Thalidomide: Chemistry, Mechanisms of Action, Therapeutic Potential and Anti-Angiogenic Properties in Multiple Myeloma. ( Adriani, G; Carocci, A; Catalano, A; Cavalluzzi, MM; Corbo, F; Franchini, C; Lentini, G; Mercurio, A; Rao, L; Vacca, A, 2017) |
| "Multiple myeloma is a very heterogeneous disease with variable survival." | 2.55 | Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy. ( Alarcón-Payer, C; Cabeza Barrera, J; de la Guardia, AMDVD; García Collado, CG; Jiménez Morales, A; Jurado Chacón, M; Martín-García, A; Ríos-Tamayo, R; Sánchez-Rodríguez, D, 2017) |
| "Lenalidomide has multifaceted antimyeloma properties, including direct tumoricidal and immunomodulatory effects." | 2.55 | Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. ( Anderson, KC; Attal, M; Holstein, SA; McCarthy, PL; Richardson, PG; Schlossman, RL, 2017) |
| "Survival for patients with multiple myeloma has significantly improved in the last decade in large part due to the development of proteasome inhibitors and immunomodulatory drugs." | 2.55 | Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma. ( Abudayyeh, A; Doshi, M; Edeani, A; Glezerman, IG; Jhaveri, KD; Monga, D; Rosner, M; Wanchoo, R, 2017) |
| " We focused on adverse events associated with such agents and described how they should be managed." | 2.55 | Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma. ( Boccadoro, M; Bonello, F; Larocca, A; Salvini, M, 2017) |
| "Lenalidomide does not only promotes tumor apoptosis, but also stimulates T and NK cells, thereby facilitating NK-mediated tumor recognition and killing." | 2.55 | Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression. ( Berchem, G; Giuliani, M; Janji, B, 2017) |
| " These studies provide further support for clinical trials evaluating OPZ in combination with Pom and Dex." | 2.55 | Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex). ( Berenson, JR; Chen, H; Gillespie, A; Li, M; Sanchez, E; Tang, G; Wang, CS, 2017) |
| "The introduction of novel drugs in multiple myeloma therapy has changed disease survivals in last 15 years." | 2.53 | Maintenance Therapy in Multiple Myeloma: Novel Concepts in Clinical Practice from Recent Clinical Trials. ( Gozzetti, A, 2016) |
| "Multiple myeloma is a plasma cell skeletal malignancy." | 2.53 | Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities. ( Hazlehurst, L; Lynch, CC; Shay, G, 2016) |
| "Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder and bridges monoclonal gammopathy of undetermined significance to multiple myeloma (MM), based on higher levels of circulating monoclonal immunoglobulin and bone marrow plasmocytosis without end-organ damage." | 2.53 | The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. ( Beguin, Y; Caers, J; Decaux, O; Dimopoulos, M; Engelhardt, M; Fernández de Larrea, C; Heusschen, R; Jurczyszyn, A; Kastritis, E; Leleu, X; Ludwig, H; Mateos, MV; Minnema, M; Palumbo, A; Wäsch, R; Zojer, N, 2016) |
| "Sorafenib is an orally available compound that acts predominantly by targeting the Ras/Raf/MEK/ERK pathway and by inhibiting the vascular endothelial growth factor (VEGF)." | 2.53 | Sorafenib for the treatment of multiple myeloma. ( Gentile, M; Martino, M; Morabito, F; Morabito, L; Recchia, AG; Vigna, E, 2016) |
| "Multiple myeloma is a disease of the elderly, with about a third of patients at diagnosis older than 75 years of age." | 2.53 | Nuances in the Management of Older People With Multiple Myeloma. ( Ailawadhi, S; Gay, F; Larocca, A; Pawlyn, C; Roy, V, 2016) |
| "Advances in the treatment of multiple myeloma have resulted in dramatic improvements in outcomes for patients." | 2.53 | New Targets and New Agents in High-Risk Multiple Myeloma. ( Lonial, S; Nooka, AK, 2016) |
| "Multiple myeloma is the most common primary malignant disease of bone marrow." | 2.53 | [Multiple myeloma and other plasma cell dyscrasias]. ( Nagy, Z, 2016) |
| "In the last decades, treatment of multiple myeloma (MM) has greatly improved due to the introduction of novel agents, including proteasome inhibitors (PI) and immunomodulatory agents (IMiDs)." | 2.53 | Concise review - Treatment of multiple myeloma in the very elderly: How do novel agents fit in? ( Delforge, M; Kint, N, 2016) |
| "The rate of severe infection with the use of IMiD-based therapy was 13." | 2.53 | Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis. ( Harrison, SJ; Slavin, MA; Teh, BW; Thursky, KA; Worth, LJ, 2016) |
| "Multiple myeloma is an incurable malignant plasma cell-originating cancer." | 2.53 | Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice. ( Lee, HS; Min, CK, 2016) |
| "Multiple myeloma is the second most common type of blood cancer and remains incurable despite advances in therapy." | 2.53 | The role of maintenance therapy in multiple myeloma. ( Lipe, B; Mikhael, J; Vukas, R, 2016) |
| "Recent developments in the treatment of multiple myeloma have led to improvements in response rates and to increased survival; however, relapse is inevitable in almost all patients." | 2.52 | Current treatment landscape for relapsed and/or refractory multiple myeloma. ( Anderson, KC; Dimopoulos, MA; Moreau, P; Richardson, PG, 2015) |
| "Approximately 37% of patients with plasma cell myeloma are over the age of 75 and the median age of diagnosis is 70." | 2.52 | Managing multiple myeloma in the over 70s: a review. ( Gooding, S; King, AJ; Ramasamy, K, 2015) |
| " Treatment-specific tools and clinical assessments can be useful for optimizing dosing and schedule adjustments to increase therapy duration, and implementing supportive care strategies (e." | 2.52 | Treatment-related symptom management in patients with multiple myeloma: a review. ( Colson, K, 2015) |
| "Clarithromycin is a 14-membered ring macrolide antibiotics that is widely used in the treatment of infectious disease." | 2.52 | [Progress of research on clarithromycin for treatment of multiple myeloma]. ( Qiu, XH; Zhai, YP, 2015) |
| "Recent developments in the treatment of multiple myeloma (MM) have led to improvements in response rates and to increased survival." | 2.52 | Multiple myeloma: from front-line to relapsed therapies. ( Moreau, P; Touzeau, C, 2015) |
| "Multiple myeloma is the second most frequent haematological disease." | 2.52 | Treatment for patients with newly diagnosed multiple myeloma in 2015. ( Bladé, J; García-Sanz, R; Lahuerta, JJ; Martínez-López, J; Mateos, MV; Ocio, EM; Paiva, B; Rosiñol, L; San Miguel, JF, 2015) |
| "Despite many recent advances in the treatment of multiple myeloma, the course of the disease is characterized by a repeating pattern of periods of remission and relapse as patients cycle through the available treatment options." | 2.52 | Maintenance therapy for multiple myeloma in the era of novel agents. ( Facon, T, 2015) |
| "Smoldering multiple myeloma (SMM) is a precursor disease of multiple myeloma (MM) with an average annual risk of progression to MM of 10%." | 2.52 | [Significant changes in diagnostic and therapeutic procedures in smoldering multiple myeloma]. ( Jurczyszyn, A; Olszewska-Szopa, M; Skotnicki, AB, 2015) |
| "Over two-thirds of newly diagnosed multiple myeloma are over 65 years." | 2.50 | Initial treatment of transplant-ineligible patients in multiple myeloma. ( Leleu, X; Mateos, MV; Palumbo, A; San Miguel, JF, 2014) |
| "Progress in the treatment of multiple myeloma in the last decade has been able to delay, but ultimately not to prevent, the development of resistances and most patients still die of the disease or its related complications." | 2.50 | [New drugs in the treatment of multiple myeloma]. ( Motlló, C; Oriol, A, 2014) |
| "Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment." | 2.50 | New approaches to management of multiple myeloma. ( Cavallo, F; Genadieva-Stavric, S; Palumbo, A, 2014) |
| "Pomalidomide is a distinct IMiD agent recently approved in the US and Europe." | 2.50 | Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma. ( Coleman, M; Mark, TM; Niesvizky, R, 2014) |
| "Pomalidomide is a new IMiD with a similar structure to the commonly used IMiD thalidomide and lenalidomide." | 2.50 | Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data. ( Caraffa, P; Corvatta, L; Larocca, A; Leoni, P; Offidani, M; Palumbo, A; Pautasso, C, 2014) |
| "Pomalidomide has also been assessed in AL amyloidosis, MPNs (myelofibrosis [MF]), Waldenstrom's macroglobulinemia, solid tumors (sarcoma, lung cancer), or HIV and--for AL amyloidosis and MF--has already proven remarkable activity." | 2.50 | Pomalidomide. ( Engelhardt, M; Kleber, M; Reinhardt, H; Wäsch, R, 2014) |
| "Pomalidomide (Pomalyst(®)) is a synthetic compound derived by modifying the chemical structure of thalidomide to improve its potency and reduce its side effects and third drug in the class of immunomodulatory drugs." | 2.50 | Impact of pomalidomide therapy in multiple myeloma: a recent survey. ( Kumar, A; Mishra, AK; Porwal, M; Verma, A, 2014) |
| "Multiple myeloma is a hematologic malignancy characterized by plasma cell clonal expansion as well as end-organ damage due to increased levels of monoclonal proteins in both the plasma and urine." | 2.50 | Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma. ( Chen, SE; Highsmith, KN; Horowitz, S, 2014) |
| "Central nervous system localization of multiple myeloma (CNS-MM) accounts for about 1% of all MM." | 2.50 | Novel agents in CNS myeloma treatment. ( Cerase, A; Gozzetti, A, 2014) |
| "Pomalidomide is a potent second-generation immunomodulatory agent with direct antiproliferative, pro-apoptotic, and antiangiogenic effects, as well as modulatory effects on bone resorption and on the immune system." | 2.50 | [Pomalidomide in the treatment of relapsed and refractory multiple myeloma]. ( Bátorová, A; Mistrík, M; Roziaková, L, 2014) |
| "Treatment of multiple myeloma (MM), currently an incurable disease, aims to achieve complete remission." | 2.50 | [Cereblon - a new target of therapy in the treatment of multiple myeloma]. ( Bešše, L; Hájek, R; Sedlaříková, L; Sevčíková, S; Staňková, M; Vrábel, D, 2014) |
| "Pomalidomide (Pomalyst(®)) is a small molecule analogue of thalidomide under development with Celgene Corporation for the oral treatment of haematological and connective tissue diseases." | 2.49 | Pomalidomide: first global approval. ( Elkinson, S; McCormack, PL, 2013) |
| "Lenalidomide (15 mg) was administered for 2 courses." | 2.49 | Safety and effectiveness of low-dose lenalidomide therapy for multiple myeloma complicated with bortezomib-associated interstitial pneumonia. ( Ihara, K; Inomata, H; Kato, J; Kikuchi, S; Koyama, R; Muramatsu, H; Nagamachi, Y; Nishisato, T; Nozawa, E; Okamoto, T; Ono, K; Tanaka, S; Yamada, H; Yamauchi, N; Yano, T, 2013) |
| "Lenalidomide was associated with a significantly increased progression free survival and in one study with a significant survival benefit." | 2.49 | [Lenalidomide maintenance therapy in patients with multiple myeloma]. ( Mistrík, M; Roziaková, L, 2013) |
| "Treatment with thalidomide is associated with an increased risk of developing peripheral neuropathy, which can be managed with dose reductions and discontinuation, and venous thromboembolism, which warrants thromboprophylaxis." | 2.49 | Role of thalidomide in the treatment of patients with multiple myeloma. ( Davies, FE; Morgan, GJ, 2013) |
| "Multiple myeloma is one of the most common hematological malignancies with increasing prevalence." | 2.49 | [Multiple myeloma]. ( Klánová, M; Špička, I, 2013) |
| "Pomalidomide has shown to be a safe and active agent, both alone and in combination with dexamethasone, in heavily pretreated patients." | 2.49 | Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma. ( Bringhen, S; Gay, F; Mina, R; Troia, R, 2013) |
| "This drug was approved for patients with multiple myeloma who have received at least 2 prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of the last therapy." | 2.49 | Pomalidomide. ( Lacy, MQ; McCurdy, AR, 2013) |
| "Pomalidomide is an orally active thalidomide analogue that has a pleiotropic mechanism of action involving oncolytic, antiangiogenic, immunomodulatory and anti-inflammatory activities." | 2.49 | Pomalidomide for patients with multiple myeloma. ( Gras, J, 2013) |
| "Treatment of multiple myeloma (MM) has evolved significantly over the past two decades with high-dose chemotherapy and autologous stem cell transplant (ASCT), incorporating novel therapies such as proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) during induction and post-transplant maintenance therapies." | 2.49 | New developments in post-transplant maintenance treatment of multiple myeloma. ( Liu, H; McCarthy, P, 2013) |
| "Multiple myeloma is a highly treatable but still incurable malignancy." | 2.49 | Role of consolidation/maintenance therapy in multiple myeloma. ( Cavallo, F; Cerrato, C; Mina, R; Palumbo, A, 2013) |
| "Lenalidomide (LEN) is an immunomodulatory drug (IMiD) which exerts tumoricidal effects and has immunomodulatory, anti-inflammatory and anti-angiogenic properties that synergistically keep the tumor in remission." | 2.49 | Novel lenalidomide-based combinations for treatment of multiple myeloma. ( Brunetti, O; Cives, M; Longo, V; Silvestris, F; Simone, V, 2013) |
| "Thalidomide was the first in class drug." | 2.49 | Novel immunomodulatory compounds in multiple myeloma. ( Mahindra, A; Saini, N, 2013) |
| "Multiple myeloma is caused by the expansion of monoclonal plasma cells and secretion of M-protein (immunoglobulins, Bence Jones protein and free light chain)." | 2.49 | Current therapeutic strategy for multiple myeloma. ( Suzuki, K, 2013) |
| "Importantly, the IMiDs possess anti-cancer activity with selectivity for molecularly defined subgroups of hematological malignancies, specifically mature B-cell neoplasms and myelodysplasia with deletion of chromosome 5q." | 2.49 | Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. ( Hsu, AK; Johnstone, RW; Shortt, J, 2013) |
| "Lenalidomide (LEN) is a structural analogue of Thalidomide and is currently considered a promising compound among immunomodulatory drugs." | 2.48 | Lenalidomide in multiple myeloma: current experimental and clinical data. ( Cives, M; Dammacco, F; Milano, A; Silvestris, F, 2012) |
| "Although multiple myeloma remains an essentially incurable disease, treatment options and patients' quality of life have improved over the last years with the introduction of more effective and less toxic agents." | 2.48 | Advantageous use of lenalidomide in multiple myeloma: discussion of three case studies. ( Figueiredo, A; João, C; Martins, HF, 2012) |
| "Thalidomide is now an integral part of multiple myeloma (MM) therapy." | 2.48 | Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies. ( Jaeger, D; Podar, K; Vallet, S; Witzens-Harig, M, 2012) |
| "Thalidomide was originally developed in 1954 as a sedative that was commonly used to ameliorate morning sickness." | 2.48 | Deciphering the mystery of thalidomide teratogenicity. ( Handa, H; Ito, T, 2012) |
| "Effectively treating patients with multiple myeloma is challenging." | 2.48 | Latest advances and current challenges in the treatment of multiple myeloma. ( Anderson, K; Laubach, J; Mahindra, A; Munshi, N; Raje, N; Richardson, PG, 2012) |
| "Lenalidomide is an immunomodulatory, antiangiogenic drug that is a structural analog of thalidomide." | 2.48 | [Lenalidomide in hematological malignancies---review]. ( Jin, X; Zhang, YZ, 2012) |
| "The management of multiple myeloma has undergone profound changes over the recent past as a result of advances in our understanding of the disease biology as well as improvements in treatment and supportive care strategies." | 2.48 | European perspective on multiple myeloma treatment strategies: update following recent congresses. ( Avet-Loiseau, H; Bladé, J; Boccadoro, M; Cavenagh, J; Cavo, M; Davies, F; de la Rubia, J; Delimpasi, S; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Hess, U; Ludwig, H; Mellqvist, UH; Moreau, P; Palumbo, A; San-Miguel, J; Sondergeld, P; Sonneveld, P; Udvardy, M, 2012) |
| "Lenalidomide has a predominantly renal route of excretion and in patients with RI the plasma concentration and half-life of the drug are significantly increased." | 2.48 | Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment. ( Alegre, A; Dimopoulos, MA; Goldschmidt, H; Mark, T; Niesvizky, R; Terpos, E, 2012) |
| "In the Vienna Cancer and Thrombosis Study (CATS) the score was expanded by adding two biomarkers, and the prediction of VTE was considerably improved." | 2.48 | Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials. ( Ay, C; Pabinger, I; Thaler, J, 2012) |
| "Multiple myeloma (MM) and AL amyloidosis are caused by the expansion of monoclonal plasma cells and secretion of dysproteinemia (Bence Jones protein and free light chain) and some patients require the hemodialysis." | 2.48 | Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion. ( Suzuki, K, 2012) |
| "The treatment of multiple myeloma is evolving rapidly." | 2.48 | Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma? ( Rajkumar, SV, 2012) |
| "The most important chromosomal aberrations associated with poor outcome are del(17p), t(4;14), t(14;16) and t(14;20)." | 2.47 | Clinical impact of chromosomal aberrations in multiple myeloma. ( Alici, E; Gahrton, G; Jansson, M; Nahi, H; Sutlu, T, 2011) |
| "Over the last few decades therapy for multiple myeloma has improved remarkably." | 2.47 | Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma. ( Einsele, H; Knop, S; Kortüm, M, 2011) |
| "The field of multiple myeloma therapeutics has been an active one for many years, but perhaps no more so than in the past decade." | 2.47 | Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. ( Anderson, KC; Laubach, JP; Mitsiades, CS; Richardson, PG; Schlossman, RL, 2011) |
| " However, complications arising from their long-term use have prompted studies of schedule optimization and alternate strategies." | 2.47 | Advances in the biology and treatment of bone disease in multiple myeloma. ( Raje, N; Roodman, GD, 2011) |
| "Pomalidomide has a potent anti-myeloma activity in vitro and in vivo, acting both directly on myeloma cells and on the cells in the bone marrow microenvironment." | 2.47 | Pomalidomide therapy for myeloma. ( Ramasamy, K; Schey, S, 2011) |
| "Bortezomib has shown antihemostatic effects in patients with relapsed or refractory MM, which supports that it exerts antithrombotic actions and thus potentially provides a protective effect in combination with regimens with an elevated VTE risk." | 2.47 | Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. ( Fink, L; Tricot, G; Zangari, M; Zhan, F, 2011) |
| "Multiple myeloma is largely an incurable malignant plasma cell neoplasm; however, the landscape of its treatment is rapidly changing." | 2.47 | Advances in the autologous and allogeneic transplantation strategies for multiple myeloma. ( Alsina, M; Nishihori, T, 2011) |
| "Patients with multiple myeloma (MM) are at an increased risk of venous and arterial thrombosis." | 2.47 | [Thrombotic complications following the treatment of multiple myeloma with new agents]. ( Gil, L; Komarnicki, M; Rupa-Matysek, J, 2011) |
| "The treatment of multiple myeloma (MM) has undergone significant developments in recent years." | 2.46 | Current multiple myeloma treatment strategies with novel agents: a European perspective. ( Beksac, M; Bladé, J; Boccadoro, M; Cavenagh, J; Cavo, M; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Harousseau, JL; Hess, U; Ketterer, N; Kropff, M; Ludwig, H; Mendeleeva, L; Morgan, G; Palumbo, A; Plesner, T; San Miguel, J; Shpilberg, O; Sondergeld, P; Sonneveld, P; Zweegman, S, 2010) |
| "Recent advances in the treatment of multiple myeloma have resulted in improved response rates and overall survival in patients with multiple myeloma." | 2.46 | Advances in treatment for relapses and refractory multiple myeloma. ( Richards, T; Weber, D, 2010) |
| "The treatment of multiple myeloma has undergone significant changes in the recent past." | 2.46 | Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations. ( Bargetzi, M; Betticher, D; Gmür, J; Gregor, M; Heim, D; Hess, U; Ketterer, N; Lerch, E; Matthes, T; Mey, U; Pabst, T; Renner, C; Taverna, C, 2010) |
| "The outcome of patients with multiple myeloma has dramatically improved in the past decade, due to the introduction of new, more effective treatments, wider use of high-dose therapy, and better appreciation of potential complications and their management." | 2.46 | Multiple myeloma - current issues and controversies. ( Kumar, S, 2010) |
| "Multiple myeloma is an incurable clonal B-cell malignancy with terminally differentiated plasma cells that accounts for 1% of all malignancies in the United States." | 2.46 | Intracranial multifocal dural involvement in multiple myeloma: case report and review of the literature. ( Destian, S; Hwang, BJ; Jagannath, S; Mazumder, A; Méndez, CE; Vesole, DH, 2010) |
| "Thalidomide is a drug with bad reputation from the 1960's as it appeared to be teratogenic by causing foetal anomalies." | 2.46 | [Thalidomide in oncological and hematological diseases]. ( Anttila, P; Kivivuori, SM, 2010) |
| "Multiple myeloma is an immunologically relevant disease, which subverts and suppresses immunity, but that may also be amenable to immunological control." | 2.46 | Drug-mediated and cellular immunotherapy in multiple myeloma. ( Fielding, K; Neeson, P; Quach, H; Ritchie, DS, 2010) |
| "Lenalidomide is a functional and structural analogue of thalidomide with a relatively benign toxicity profile and pleiotropic anti-tumor activity, exhibiting anti-angiogenic and immunomodulatory effects." | 2.46 | Lenalidomide: a synthetic compound with an evolving role in cancer management. ( Grivas, PD; Saloura, V, 2010) |
| "The treatment of multiple myeloma has undergone significant changes in the last few years." | 2.46 | [Current treatment strategies for multiple myeloma]. ( Mey, UJ, 2010) |
| "The risk for venous thromboembolism is high when patients are treated with thalidomide or lenalidomide in combination with dexamethasone or multi-agent chemotherapy." | 2.46 | Thrombosis in multiple myeloma. ( Kristinsson, SY, 2010) |
| "The diagnosis of multiple myeloma (MM) has been associated to an increased risk of venous thromboembolic events (VTE)." | 2.45 | Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. ( Dahdaleh, FS; Musallam, KM; Shamseddine, AI; Taher, AT, 2009) |
| "Lenalidomide is an immunomodulatory drug, which has anti-myeloma activity in vitro." | 2.45 | United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma. ( Behrens, J; Bird, J; Cavenagh, J; Cook, G; Davies, F; Morgan, G; Morris, C; Schey, S; Tighe, J; Williams, C, 2009) |
| "Multiple myeloma is characterised by clonal proliferation of malignant plasma cells, and mounting evidence indicates that the bone marrow microenvironment of tumour cells has a pivotal role in myeloma pathogenesis." | 2.45 | Multiple myeloma. ( Anderson, KC; Breitkreutz, I; Podar, K; Raab, MS; Richardson, PG, 2009) |
| "Although systemic lupus erythematosus (SLE) is associated with lymphoid malignancies, concurrent multiple myeloma and SLE are rare." | 2.45 | Multiple myeloma and systemic lupus erythematosus in a young woman. ( Horvath, W; Irani, F; Okoli, K, 2009) |
| "Although outcomes for patients with multiple myeloma (MM) have improved over the past decade, the disease remains incurable and even patients who respond well to induction therapy ultimately relapse and require additional treatment." | 2.45 | The use of novel agents in the treatment of relapsed and refractory multiple myeloma. ( Anderson, KC; Carreau, N; Ghobrial, IM; Hideshima, T; Laubach, JP; Mahindra, A; Mitsiades, CS; Munshi, NC; Richardson, PG; Schlossman, RL, 2009) |
| "Thalidomide has changed the treatment paradigm of patients with MM." | 2.45 | Immunomodulatory compounds (IMiDs) in the treatment of multiple myeloma. ( Hussein, M; Srkalovic, G, 2009) |
| "Patients with multiple myeloma aged older than 65 years have traditionally received an oral regimen combining melphalan and prednisone (MP)." | 2.45 | How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. ( Gay, F; Palumbo, A, 2009) |
| "Lenalidomide is an immunomodulatory drug, structurally related to thalidomide, with pleiotropic activity including antiangiogenic and antineoplastic properties." | 2.44 | Treatment of plasma cell dyscrasias with lenalidomide. ( Dimopoulos, MA; Kastritis, E; Rajkumar, SV, 2008) |
| "Renal failure is a frequent complication in patients with multiple myeloma (MM) that causes significant morbidity." | 2.44 | Pathogenesis and treatment of renal failure in multiple myeloma. ( Bladé, J; Dimopoulos, MA; Kastritis, E; Ludwig, H; Rosinol, L, 2008) |
| "Lenalidomide is an oral analogue of thalidomide that lacks the neurotoxic side effects associated with the parent drug, and has shown significant antimyeloma activity." | 2.44 | Lenalidomide and its role in the management of multiple myeloma. ( Boccadoro, M; Cavallo, F; Falco, P; Larocca, A; Liberati, AM; Musto, P; Palumbo, A, 2008) |
| "Multiple myeloma is a malignancy of plasma cells that remains incurable and almost all patients will eventually require some form of salvage therapy." | 2.44 | Treatment of relapsed and refractory myeloma. ( Atkins, H; Belch, AR; Canning, LA; Kovacs, MJ; LeBlanc, R; Leitch, HA; Reece, DE; Voralia, M; White, D, 2008) |
| "To summarize the results of treatment of multiple myeloma in the era of novel agents." | 2.44 | Advances in therapy of multiple myeloma. ( Bladé, J; Rosiñol, L, 2008) |
| "Treatment options for patients with multiple myeloma (MM) have increased dramatically with the availability of novel agents." | 2.44 | Practical considerations for multiple myeloma: an overview of recent data and current options. ( Lonial, S, 2008) |
| "Multiple myeloma is still an incurable disease." | 2.44 | Diagnosis and the current trends in multiple myeloma therapy. ( Dmoszyńska, A, 2008) |
| "Thalidomide has been extensively studied alone and in combination in patients with relapsed myeloma, demonstrating substantial efficacy, and is therefore widely used in this setting." | 2.44 | The emerging role of novel therapies for the treatment of relapsed myeloma. ( Anderson, KC; Hideshima, T; Mitsiades, C; Richardson, PG, 2007) |
| "Lenalidomide is an immunomodulatory drug that was developed by modification of the first-generation immunomodulatory drug thalidomide in a drug discovery program." | 2.44 | Lenalidomide: the emerging role of a novel targeted agent in malignancies. ( Baz, R; Kalmadi, S; Mahindra, A, 2007) |
| "The treatment of multiple myeloma has seen significant changes from the time of the initial use of cytotoxic agents such as melphalan, to the introduction of high-dose chemotherapy and stem cell transplantation, and most recently the era of novel targeted agents." | 2.44 | Emerging drugs in multiple myeloma. ( Anderson, KC; Ghobrial, IM; Hatjiharissi, E; Hideshima, T; Leleu, X; Mitsiades, C; Richardson, P; Schlossman, R, 2007) |
| " This article provides the clinical rationale for the use of PLD in combination with immunomodulatory drugs to treat patients with MM and summarizes the clinical experience with these combinations to date." | 2.44 | Pegylated liposomal doxorubicin and immunomodulatory drug combinations in multiple myeloma: rationale and clinical experience. ( Chanan-Khan, AA; Lee, K, 2007) |
| "Bortezomib was associated with a significantly higher response rate and complete remission rate using both M-protein and EBMT criteria." | 2.44 | Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison. ( Adena, M; Hertel, J; Prince, HM; Smith, DK, 2007) |
| "Lenalidomide does not produce significant sedation, constipation or neuropathy, but does lead to significant myelosuppression, unlike thalidomide." | 2.44 | Lenalidomide in myelodysplastic syndrome and multiple myeloma. ( Shah, SR; Tran, TM, 2007) |
| "Bortezomib has been found to possess remarkable activity, especially in combination with other chemotherapeutic agents, in relapsed/refractory and newly diagnosed MM, as well as in patients presenting adverse prognostic factors." | 2.44 | New therapies in multiple myeloma. ( Dammacco, F; Merchionne, F; Perosa, F, 2007) |
| "Relapsed and refractory multiple myeloma (MM) constitutes a specific and unmet medical need." | 2.44 | The treatment of relapsed and refractory multiple myeloma. ( Anderson, K; Chauhan, D; Ghobrial, I; Hideshima, T; Mitsiades, C; Munshi, N; Richardson, P; Schlossman, R, 2007) |
| "Although no cure exists for multiple myeloma, current treatments, such as oral melphalan and prednisone, can slow disease progression and prolong overall survival." | 2.44 | Clinical updates and nursing considerations for patients with multiple myeloma. ( Faiman, B, 2007) |
| "Multiple myeloma is also one of the major therapeutic targets for using molecular based technology." | 2.44 | [Molecular targeting therapy for multiple myeloma]. ( Takatoku, M, 2007) |
| "For many years the treatment of multiple myeloma was limited to such regimens as melphalan-prednisone, high-dose dexamethasone, and vincristine-doxorubicin-dexamethasone (VAD)." | 2.44 | Lenalidomide in multiple myeloma. ( Richards, TA; Thomas, SK; Weber, DM, 2007) |
| "Multiple myeloma is the second most common haematological malignancy." | 2.44 | An update on drug combinations for treatment of myeloma. ( Davies, FE; Morgan, GJ; Srikanth, M, 2008) |
| "Therapeutic options for patients with multiple myeloma (MM) are rapidly changing." | 2.44 | Multiple myeloma: novel approaches for relapsed disease. ( Lonial, S, 2007) |
| "Lenalidomide is a novel anticancer agent that has made a major impact in the treatment of patients with B-cell malignancies." | 2.44 | Lenalidomide for the treatment of B-cell malignancies. ( Chanan-Khan, AA; Cheson, BD, 2008) |
| "When thalidomide was added to standard, non-transplantation myeloma therapy, overall survival (OS) improved (HR 0." | 2.44 | A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. ( Haynes, AE; Herst, JA; Hicks, LK; Imrie, K; Meyer, RM; Reece, DE; Walker, IR, 2008) |
| "Progress in the understanding of multiple myeloma (MM) cell biology has led to the identification of new relevant prognostic factors and subsequently different risk groups." | 2.44 | Individualizing treatment of patients with myeloma in the era of novel agents. ( Anderson, KC; Harousseau, JL; Joshua, D; San-Miguel, J, 2008) |
| "Lenalidomide is an immunomodulatory drug derived from thalidomide." | 2.44 | Lenalidomide in the treatment of multiple myeloma: a review. ( Armoiry, X; Aulagner, G; Facon, T, 2008) |
| "Several advances have been made in the treatment of multiple myeloma over the past decade, especially the arrival of new, active agents such as thalidomide (Thalomid), bortezomib (Velcade), and lenalidomide (Revlimid)." | 2.43 | Novel approaches to the management of myeloma. ( Rajkumar, SV, 2005) |
| "In most cases multiple myeloma is an incurable plasma cell malignancy." | 2.43 | Current treatment options for myeloma. ( Dimopoulos, MA; Rahemtulla, A; Terpos, E, 2005) |
| "The therapeutic management of multiple myeloma (MM) for the last several decades has mainly involved regimens based on use of glucocorticoids and cytotoxic chemotherapeutics." | 2.43 | Novel biological therapies for the treatment of multiple myeloma. ( Anderson, KC; Hideshima, T; Mitsiades, CS; Richardson, PG, 2005) |
| "Thalidomide and IMiDs inhibit the cytokines tumor necrosis factor-alpha (TNF-alpha), interleukins (IL) 1beta, 6, 12, and granulocyte macrophage-colony stimulating factor (GM-CSF)." | 2.43 | Properties of thalidomide and its analogues: implications for anticancer therapy. ( Teo, SK, 2005) |
| "Future therapy options for multiple myeloma may be directed at asymptomatic disease, as only symptomatic myeloma is treated currently." | 2.43 | Future directions in multiple myeloma treatment. ( Child, JA; Russell, N; Schey, S; Sonneveld, P, 2005) |
| "Thalidomide treatment compares favourably with other typical treatments for multiple myeloma." | 2.43 | The current status of thalidomide in the management of multiple myeloma. ( Glasmacher, A; von Lilienfeld-Toal, M, 2005) |
| "Thalidomide is an interesting maintenance therapy." | 2.43 | The future role of thalidomide in multiple myeloma. ( Attal, M; Blade, J; Boccadoro, M; Palumbo, A, 2005) |
| "Multiple myeloma is a plasma cell malignancy that remains incurable with current treatment approaches including high-dose therapy and autologous stem cell transplantation." | 2.43 | Thalidomide and dexamethasone: therapy for multiple myeloma. ( Kumar, S; Rajkumar, SV, 2005) |
| "The management of newly diagnosed multiple myeloma is currently being revolutionized by the emergence of novel therapeutic agents." | 2.43 | Treatment paradigms for the newly diagnosed patient with multiple myeloma. ( Greipp, P, 2005) |
| "Multiple myeloma is a B-cell malignancy characterized by an excess of monotypic plasma cells in the bone marrow." | 2.43 | Lenalidomide and thalidomide: mechanisms of action--similarities and differences. ( Anderson, KC, 2005) |
| "For patients with relapsed/refractory multiple myeloma, the MM-007 study has shown that lenalidomide alone or in combination with dexamethasone provides response rates between 37% and 41%." | 2.43 | Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. ( Richardson, P, 2005) |
| "Multiple myeloma is an incurable bone marrow cancer, the treatment of which is notoriously difficult." | 2.43 | Thalidomide in multiple myeloma. ( García-Sanz, R, 2006) |
| "Thalidomide has demonstrated a broad spectrum of pharmacological and immunological effects, with potential therapeutic applications that span a wide spectrum of diseases: cancer and related conditions; infectious diseases; autoimmune diseases; dermatological diseases; and other disorders such as sarcoidosis, macular degeneration and diabetic retinopathy." | 2.43 | Current therapeutic uses of lenalidomide in multiple myeloma. ( Anderson, KC; Hideshima, T; Richardson, PG, 2006) |
| "Treatment of patients with multiple myeloma has shown considerable progress these last two decades." | 2.43 | [Treatment of multiple myeloma]. ( Leleu, X; Terriou, L; Yakoub-Agha, I, 2006) |
| "Bortezomib recently was approved in the United States for the treatment of multiple myeloma in patients who have received at least one prior therapy." | 2.43 | New treatments for multiple myeloma. ( Anderson, KC; Hideshima, T; Richardson, PG; Schlossman, R, 2005) |
| "Treatment options for patients with multiple myeloma are a rapidly progressing area of clinical and scientific development." | 2.43 | Novel treatment approaches for patients with multiple myeloma. ( Kaufman, JL; Lonial, S; Sinha, R, 2006) |
| "Thalidomide has changed the treatment paradigm for patients with myeloma." | 2.43 | Immunomodulatory analogues of thalidomide in the treatment of multiple myeloma. ( Hussein, MA; Srkalovic, JG; Suppiah, R, 2006) |
| "Multiple myeloma is a blood disease that is often easy to diagnose, relying on a combination of an excessive medullary plasmacytosis, a serum and/or urinary monoclonal immunoglobulin and one or several signs of organ involvement (anemia, renal failure, bone lesions, hypercalcaemia, infections)." | 2.43 | [Prognostic factors and new treatments of multiple myeloma]. ( Coiteux, V; Facon, T; Leleu, X, 2006) |
| "There is no evidence that early treatment of multiple myeloma is advantageous." | 2.43 | Treatment of multiple myeloma: an emphasis on new developments. ( Kyle, RA; Vincent Rajkumar, S, 2006) |
| "Thalidomide, which has anti-angiogenetic activity, has a 30-40% response rate, and the combination of thalidomide and dexamethasone has a 40-50% response rate." | 2.43 | [New treatment strategy of multiple myeloma for cure]. ( Handa, H; Murakami, H, 2006) |
| "Multiple myeloma is a clonal disorder of plasma cells which is considered incurable with currently available therapies." | 2.43 | The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma. ( Hussein, MA; Kalmadi, SR, 2006) |
| "Thalidomide was first used because of its anti-angiogenic properties, however it is the immunomodulatory actions that involve increasing host tumour-specific immunosurveillance by both T cell and natural killer cells which may be the most important mode of action." | 2.43 | The use of thalidomide in myeloma therapy as an effective anticancer drug. ( Brown, R; Gibson, J; Ho, PJ; Joshua, D; Sze, DM; Yang, S, 2006) |
| "Lenalidomide (Revlimid) is an immunomodulatory drug that has undergone rapid clinical development in multiple myeloma and was recently approved by the US FDA for use in patients with relapsed disease." | 2.43 | Lenalidomide in multiple myeloma. ( Anderson, KC; Hideshima, T; Mitsiades, C; Richardson, PG, 2006) |
| "Lenalidomide has different toxicities than thalidomide, exhibiting greater myelosuppression but virtually no constipation, somnolence, or peripheral neuropathy." | 2.43 | Advances in oral therapy in the treatment of multiple myeloma. ( Doss, DS, 2006) |
| "Multiple myeloma is a treatable but not necessarily a curable plasma-cell cancer." | 2.43 | Thalidomide and lenalidomide in multiple myeloma. ( Jagannath, S; Mazumder, A, 2006) |
| "Although treatable, multiple myeloma remains incurable in virtually all cases, with a median survival of 3-4 years." | 2.43 | Current status of new drugs for the treatment of patients with multiple myeloma. ( Kenealy, M; Prince, HM, 2006) |
| "Thalidomide (Thal) has antiangiogenic and immunomodulatory activity." | 2.43 | Thalidomide in multiple myeloma. ( Glasmacher, A; Goldschmidt, H; Hillengass, J; Moehler, TM, 2006) |
| "Cure for multiple myeloma is rare; the success of treatment is measured by response, and length of remissions and survival." | 2.43 | Management of multiple myeloma with bortezomib: experts review the data and debate the issues. ( Boccadoro, M; Cavenagh, J; Dicato, M; Harousseau, JL; Ludwig, H; San Miguel, J; Sonneveld, P, 2006) |
| "Thalidomide has been found to be effective for relapsed or refractory myeloma and, more recently, also as induction therapy." | 2.42 | Pharmacotherapy of multiple myeloma: an economic perspective. ( Messori, A; Santarlasci, B; Trippoli, S, 2003) |
| "Thalidomide (Thal) has been successfully used in such situations and it's use has also been expanded to the up-front therapy and as adjuvant to stem cell transplantation." | 2.42 | Advances in the treatment of multiple myeloma: the role of thalidomide. ( Colleoni, GW; Ribas, C, 2003) |
| "Thalidomide is a new therapeutic option with promising results; however, it is associated with significant side effects including deep venous thrombosis and peripheral neuropathy." | 2.42 | Recent developments and future directions in the treatment of multiple myeloma. ( Mehta, J; Pichardo, D; Rosen, S; Singhal, S, 2003) |
| "The case of an HIV-infected man in whom multiple myeloma was diagnosed following progressive anemia and fatigue is described." | 2.42 | Thalidomide-based treatment for HIV-associated multiple myeloma: a case report. ( Aboulafia, DM, 2003) |
| "The occurrence of a left atrial thrombus without a haemodynamic predisposing factor (arrhythmia, mitral valvulopathy, severe left ventricular dysfunction) is a rare event." | 2.42 | [Left atrial thrombus in multiple myeloma treated with thalidomide]. ( Barbou, F; Bonal, J; Bouchiat, C; Cellarier, G; de Jaureguiberry, JP; Dussarat, GV; Gisserot, O; Jégo, C; Landais, C; Laurent, P, 2003) |
| "Thalidomide has anti-inflammatory, immuno-modulating and antiangiogeneic properties but the mechanism of its action is not yet completely understood." | 2.42 | [Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide]. ( Jurczyszyn, A; Skotnicki, AB; Wolska-Smoleń, T, 2003) |
| "Thalidomide was first produced in Germany in the 1950s." | 2.42 | [Thalidomide--new prospective therapy in oncology]. ( Pałgan, I; Pałgan, K, 2003) |
| "Thalidomide was first used in the late 1950s but it was withdrawn from the market in the 1960s for its notorious teratogenic effects." | 2.42 | The promise of thalidomide: evolving indications. ( Joglekar, S; Levin, M, 2004) |
| "The activity of thalidomide in solid tumors is less prominent." | 2.42 | Thalidomide in cancer medicine. ( Bamias, A; Dimopoulos, MA; Eleutherakis-Papaiakovou, V, 2004) |
| "Thalidomide was developed in the 1950s as a sedative having only a low toxicity." | 2.42 | [New pharmacological availability of thalidomide based on experience in patients with multiple myeloma]. ( Murakami, H, 2004) |
| "Although multiple myeloma (MM) is sensitive to chemotherapy and radiation therapy, long-term disease-free survival is rare, and MM remains incurable despite conventional and high-dose therapies." | 2.42 | Targeting multiple myeloma cells and their bone marrow microenvironment. ( Cardinale, G; Gervasi, F; Pagnucco, G, 2004) |
| "Novel treatment strategies for multiple myeloma include replacing conventional doxorubicin with pegylated liposomal doxorubicin and reducing the dexamethasone dose (DVd) in the widely accepted VAD (vincristine, conventional doxorubicin, dexamethasone) regimen to improve the safety profile." | 2.42 | New treatment strategies for multiple myeloma. ( Hussein, MA, 2004) |
| "Novel therapies that can target the multiple myeloma (MM) cell, the MM cell-patient bone marrow interaction, and the bone marrow milieu can overcome resistance to conventional therapy in preclinical models and clinical trials." | 2.42 | Clinical update: novel targets in multiple myeloma. ( Anderson, KC, 2004) |
| "Multiple myeloma is an incurable plasma cell malignancy that accounts for 10% of all hematologic cancers." | 2.41 | Current therapy for multiple myeloma. ( Gertz, MA; Greipp, PR; Kyle, RA; Rajkumar, SV, 2002) |
| "Thalidomide was withdrawn from the market in the early sixties because of its teratogenic effects." | 2.41 | [Thalidomide: new uses for an old drug]. ( Sonneveld, P; Wu, KL, 2002) |
| "Multiple myeloma is the second most common hematologic malignancy, with approximately 15,000 new cases each year in the United States." | 2.41 | Recent advances in multiple myeloma. ( Berenson, JR; Sjak-Shie, NN; Vescio, RA, 2000) |
| "Relapsing patients with multiple myeloma show a response rate higher than 50% with the resumption of the initial chemotherapy." | 2.41 | Treatment approaches for relapsing and refractory multiple myeloma. ( Bladé, J; Esteve, J, 2000) |
| "Thalidomide has been shown to block the activity of angiogenic substances like bFGF, VEGF and interleukin 6." | 2.41 | [Thalidomide. Clinical trials in cancer]. ( Politi, PM, 2000) |
| "Thalidomide is an infamous molecule for its teratogenicity, yet it possesses potent immunomodulatory, anti-angiogeneic and, in higher concentrations, direct anti-myeloma-cell properties." | 2.41 | [Role of thalidomide in the treatment of multiple myeloma]. ( Jákó, J; Mikala, G; Vályi-Nagy, I, 2001) |
| "Novel therapies in multiple myeloma (MM) target not only the tumor cell but also the bone marrow (BM) microenvironment." | 2.41 | Novel therapies targeting the myeloma cell and its bone marrow microenvironment. ( Anderson, KC; Chauhan, D; Hideshima, T; Podar, K; Richardson, P; Schlossman, RL, 2001) |
| "Multiple myeloma is a clonal B-cell tumor of slowly proliferating plasma cells within the bone marrow." | 2.41 | Multiple myeloma: present and future. ( Hussein, MA; Juturi, JV; Lieberman, I, 2002) |
| "Thalidomide, which was developed as a nonbarbiturate sedative agent, was taken off the market in 1961 after it was linked to a spate of major birth defects." | 2.41 | Thalidomide: new indications? ( Combe, B, 2001) |
| "Its use in other tumors is under evaluation, with promise in renal cell carcinoma, prostate cancer, glioma, and Kaposi's sarcoma." | 2.41 | Thalidomide: emerging role in cancer medicine. ( Anderson, K; Hideshima, T; Richardson, P, 2002) |
| "Additionally, multiple myeloma is primarily a disease of the elderly, many of whom cannot tolerate aggressive chemotherapy." | 2.41 | Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma. ( Hussein, MA, 2002) |
| "Thalidomide was first introduced to the market in Germany under the brand name of Contergan in 1956, as a non-barbiturate hypnotic, advocated to ensure a good nights sleep and to prevent morning sickness in pregnancy." | 2.41 | Mechanisms of action and potential therapeutic uses of thalidomide. ( Chabner, BA; Mujagić, H; Mujagić, Z, 2002) |
| "Future progress in treating multiple myeloma NRC depends on better identification of new therapeutic targets that control progression from the stable asymptomatic to the progressive symptomatic phase of multiple myeloma." | 2.41 | Smoldering, asymptomatic stage 1, and indolent myeloma. ( Greipp, PR, 2000) |
| "Although treatment options for multiple myeloma (MM) are rapidly evolving, there still remain difficult-to-treat situations, especially in relapsed and/or refractory (r/r) disease." | 1.91 | VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience. ( Alihodzic, D; Bokemeyer, C; Ghandili, S; Leypoldt, LB; Weisel, K; Wiessner, C, 2023) |
| "In conclusion, replacing Revlimid® with its generic version Rivelime® in singlet, doublet or triplet lenalidomide containing RRMM regimens seems not to compromise the efficacy of treatment, and to yield a similarly improved response rates and survival outcome and no additional toxic effects, enabling a long-term therapy." | 1.91 | Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome. ( Beksac, M; Gurman, G; Ilhan, O; Koyun, D; Seval, GC; Topcuoglu, P; Yuksel, MK, 2023) |
| "Pomalidomide combinations were well tolerated, no patient discontinued treatment due to adverse events." | 1.91 | Pomalidomide combinations are a safe and effective option after daratumumab failure. ( Binder, M; Brioli, A; Engelhardt, M; Ernst, T; Gengenbach, L; Heidel, FH; Hilgendorf, I; Hochhaus, A; Mancuso, K; Stauch, T; von Lilienfeld-Toal, M; Zamagni, E, 2023) |
| "Multiple myeloma is a hematologic malignancy of plasma cells that manifests with bone marrow tumors causing lytic bone lesions." | 1.91 | Revisiting checkpoint inhibitors for myeloma: maintenance after stem cell transplant. ( Bergsagel, PL; Meermeier, EW, 2023) |
| "No adequate data exist on the impact of multiple myeloma (MM) with extramedullary disease (EMD) after autograft and maintenance therapy." | 1.91 | Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study. ( Anagnostopoulos, A; Arcese, W; Beksac, M; Bolaman, AZ; Bulabois, CE; Bunjes, D; Deconinck, E; Delforge, M; Eikema, DJ; Fenk, R; Gagelmann, N; Hayden, PJ; Itälä-Remes, M; Koster, L; Labussière-Wallet, H; Lund, J; McDonald, A; Nabil, Y; Netelenbos, T; Reményi, P; Schönland, S; Stoppa, AM; Thurner, L; van Gorkom, G; Yakoub-Agha, I, 2023) |
| " The primary outcomes were Overall Survival (OS) and Progression Free Survival (PFS, measured as time to next treatment), and the secondary outcomes were Adverse Events (AE)." | 1.91 | Real-world effectiveness and safety of multiple myeloma treatments based on thalidomide and bortezomib: A retrospective cohort study from 2009 to 2020 in a Brazilian metropolis. ( Costa, IHFD; Drummond, PLM; Malta, JS; Menezes de Pádua, CA; Reis, AMM; Santos, RMMD; Silveira, LP, 2023) |
| "The incidence of multiple myeloma (MM) is two to three times higher in Black patients compared with other races, making it the most common hematologic malignancy in this patient population." | 1.91 | Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction. ( Cao, Y; Dhodapkar, M; Hall, KH; Harvey, RD; Hofmeister, CC; Joseph, NS; Kaufman, JL; Liu, Y; Lonial, S; Maples, KT; Nooka, AK; Sun, LF, 2023) |
| "Multiple myeloma is a highly heterogenous plasma cell malignancy, commonly seen in older patients." | 1.91 | The age-dependent changes in risk weights of the prognostic factors for multiple myeloma. ( An, G; Deng, S; Du, C; Fan, H; Hao, M; Li, C; Li, L; Liu, J; Mao, X; Qiu, L; Sui, W; Xu, Y; Yi, S; Zhao, J; Zhao, Y; Zou, D, 2023) |
| "Lenalidomide is an important medication used in induction therapy for MM and is also used for maintenance therapy for standard risk patients." | 1.72 | Three Cases of Lenalidomide Therapy for Multiple Myeloma and Subsequent Development of Secondary B-ALL. ( Asawa, P; Chahine, Z; Lister, J; Sadashiv, S; Samhouri, Y; Vusqa, UT, 2022) |
| "The treatment of multiple myeloma has dramatically improved due to the availability of novel therapies that are highly effective and are quickly moving into first-line therapy." | 1.72 | Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database. ( Aslam, M; Gul, E; Jimenez-Zepeda, VH; Kardjadj, M; Kotb, R; LeBlanc, R; Louzada, M; Masih-Khan, E; McCurdy, A; Mian, H; Reece, D; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D, 2022) |
| "A 69-year-old female patient with breast cancer experienced severe skin itching and rashes on the face, anterior chest wall, back, and trunk for two days before admission." | 1.72 | A case report of secondary synchronous diagnosis of multiple myeloma and systemic lupus erythematosus after breast cancer treatment: A CARE-compliant article. ( Chen, PH; Huang, KP; Lin, CH; Lin, CY; Ni, YL; Tung, HH, 2022) |
| "The treatment of multiple myeloma (MM) has advanced with the introduction of immunomodulators (IMiDS)." | 1.72 | Adherence to thalidomide in patients with multiple myeloma: A cross-sectional study in a Brazilian metropolis. ( Costa, NL; Drummond, PLM; Hauck, LM; Machado, TRL; Malta, JS; Pádua, CAM; Reis, AMM; Santos, RMMD; Silveira, LP, 2022) |
| "Pomalidomide was given at 4 mg orally on days 1 to 21 of a 28-day cycle, and dexamethasone at 20 or 40 mg weekly." | 1.62 | Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma. ( Abdallah, AO; Atrash, S; Ganguly, S; Kawsar, H; Mahmoudjafari, Z; McGuirk, J; Mohyuddin, GR; Shune, L; Sigle, M, 2021) |
| "The prognosis of relapsed and refractory multiple myeloma (RRMM) that is refractory to bortezomib and lenalidomide is very poor wherein the median survival is between 3 and 9 months." | 1.62 | Real-World Outcomes With Generic Pomalidomide in Relapsed Refractory Multiple Myeloma-Experience From a Tertiary Care Cancer Center. ( Bagal, B; Bonda, A; Bondili, SK; Gokarn, A; Jain, H; Khattry, N; Nayak, L; Punatar, S; Sengar, M; Thorat, J; Ventrapati, P; Zawar, A, 2021) |
| "Pomalidomide is a second-generation immunomodulatory drug that has shown activity in lenalidomide-refractory disease in the setting of different combinations." | 1.62 | Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience. ( Anguita, M; Arguiñano, JM; Arnao, M; Bladé, J; Blanchard, MJ; Cabañas, V; Casado, F; de Cabo, E; de Coca, AG; Encinas, C; García, R; González-Rodríguez, AP; Hernández-Rivas, JÁ; Iñigo, B; Lafuente, AP; Lahuerta, JJ; Lavilla, E; López, A; Maldonado, R; Martí, JM; Mateos, MV; Motlló, C; Murillo, I; Pérez-Persona, E; Ribas, P; Rodriguez-Otero, P; Sampol, A; San Miguel, JF; Sirvent, M, 2021) |
| "Treatment benefit in multiple myeloma (MM) patients with high-risk cytogenetics remains suboptimal." | 1.62 | Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. ( Alegre, A; Campana, F; Delimpasi, S; Facon, T; Harrison, SJ; Hulin, C; Inchauspé, M; Macé, S; Perrot, A; Richardson, P; Risse, ML; Simpson, D; Spencer, A; Sunami, K; van de Velde, H; Vlummens, P; Wang, MC; Yong, K, 2021) |
| "Major progress has occurred in multiple myeloma (MM) treatment in recent years, but this is not seen in low- and middle-income countries." | 1.62 | Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up. ( Aliaga, K; Casanova, L; Quintana, S; Ruiz, R; Valencia, F; Vasquez, J; Vidaurre, T; Villena, M, 2021) |
| "The treatment of patients with multiple myeloma (MM) has evolved in recent years, and the disease-associated prognosis has improved substantially." | 1.56 | Treatment of Persons with Multiple Myeloma in Underprivileged Circumstances: Real-World Data from a Single Institution. ( Cantero-Fortiz, Y; Cruz-Mora, A; García-Navarrete, YI; León-Peña, A; Murrieta-Álvarez, I; Olivares-Gazca, JC; Olivares-Gazca, M; Ruiz-Argüelles, A; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ; Steensma, DP, 2020) |
| "Multiple myeloma is an incurable progressive neoplastic disease that accounts for 10% of all hematologic malignancies." | 1.56 | Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone. ( Kassir, N; Li, Y; Palmisano, M; Wang, X; Zhou, S, 2020) |
| "Short-hairpin RNA silencing of CDK9 in Multiple Myeloma (MM) cell lines reduced cell viability compared to control cells showing the dependency of MM cells on CDK9." | 1.56 | Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor. ( Chng, WJ; Han, BC; Koeffler, HP; Lim, SL; Shyamsunder, P; Xu, L, 2020) |
| "Immunoglobulin M multiple myeloma and Waldenström macroglobulinemia are two different hematological diseases with the common finding of an immunoglobulin M monoclonal gammopathy of unknown significance." | 1.56 | Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports. ( Bonferroni, M; Castellino, A; Castellino, C; Celeghini, I; Drandi, D; Elba, S; Foglietta, M; Fraternali Orcioni, G; Giordano, F; Grasso, M; Massaia, M; Mattei, D; Mordini, N; Rapezzi, D; Soriasio, R; Strola, G, 2020) |
| "Isatuximab is used to treat multiple myeloma (MM), characterized by the excessive production of abnormal "myeloma proteins" (M-proteins) that may interact with therapeutic IgG mAb on the neonatal Fc receptor (FcRn)-mediated recycling pathway." | 1.56 | Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients. ( Brillac, C; Campana, F; El-Cheikh, R; Fau, JB; Koiwai, K; Mace, N; Nguyen, L; Semiond, D, 2020) |
| "SLAMF7 is expressed mainly on multiple myeloma (MM) cells and considered an ideal target for immunotherapeutic approaches." | 1.56 | Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7. ( Furukawa, Y; Hagiwara, S; Hori, M; Iha, H; Izumi, T; Kikuchi, J; Koyama, D; Kuroda, Y; Suzuki, A; Toyama-Sorimachi, N; Yasui, H, 2020) |
| "PFS and OS in the patients with multiple myeloma were different among three distrinct R-ISS stages." | 1.51 | [Clinical Application of R-ISS Staging System in 412 Newly Diagnosed Patients with Multiple Myeloma]. ( Chen, HM; Chen, XL; Peng, R; Shi, HT; Wei, W; Wu, LX; Zhou, F; Zhou, N, 2019) |
| "We provide a real-world overview of multiple myeloma (MM) treatment patterns, outcomes and healthcare resource use (HRU) in Portugal." | 1.51 | Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal. ( Antunes, L; Bento, MJ; Chacim, S; Lefèvre, C; Pereira, M; Pereira, S; Rocha-Gonçalves, F; Zagorska, A, 2019) |
| "Multiple myeloma is a malignancy of antibody-secreting plasma cells." | 1.51 | Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. ( Auclair, D; Bahlis, NJ; Barwick, BG; Boise, LH; Dhodapkar, MV; Gupta, VA; Hofmeister, CC; Jaye, DL; Kaufman, JL; Keats, JJ; Lonial, S; Neri, P; Nooka, AK; Vertino, PM, 2019) |
| "The clinical data of 116 patients with multiple myeloma from June 2011 to June 2015 were collected and analyzed retrospectively." | 1.51 | [Evaluation and Comparison of Thromboelastography and Conventional Coagulation Tests for Blood Coagulation Function in Children with Henoch-Schönlein Purpura]. ( Chen, XY; Dong, ZG; Xiao, HF; Xin, PL; Xu, WQ; Zhang, JY, 2019) |
| "We apply this method to a network of multiple myeloma treatments in newly diagnosed patients (ndMM), where the outcome is progression free survival." | 1.51 | Assessing the impact of a matching-adjusted indirect comparison in a Bayesian network meta-analysis. ( Leahy, J; Walsh, C, 2019) |
| "A thalidomide-based regimen was the most common induction treatment used at PubC, whereas a bortezomib-based regimen was used most often in PrivC." | 1.48 | Impact of the affordability of novel agents in patients with multiple myeloma: Real-world data of current clinical practice in Mexico. ( Arredondo-Campos, D; Cantú-Rodríguez, O; Gómez-Almaguer, D; Gómez-De León, A; Gutiérrez-Aguirre, CH; Jaime-Pérez, JC; Martínez-González, O; Martínez-Pacheco, V; Ramírez-López, A; Tarín-Arzaga, L, 2018) |
| "Thalidomide is a teratogenic drug which is known to inhibit angiogenesis and effectively inhibit cancer metastasis, yet the specific cellular targets for its effect are not well known." | 1.48 | CUL5 is required for thalidomide-dependent inhibition of cellular proliferation. ( Burnatowska-Hledin, MA; Dean, S; DeBruine, ZJ; Grossens, D; Hledin, MP; Kunkler, B; Madden, J; Marquez, GA; Ploch, C; Salamango, D; Schnell, A; Short, M, 2018) |
| "13." | 1.48 | Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. ( Adamopoulos, I; Aktypi, A; Anagnostopoulos, A; Briasoulis, E; Delimpasi, S; Douka, V; Fotiou, D; Giannakoulas, N; Giannopoulou, E; Gogos, D; Hatzimichael, E; Katodritou, E; Kioumi, A; Kokoviadou, K; Kotsopoulou, M; Kyriakou, D; Kyrtsonis, MC; Megalakaki, A; Nikolaou, E; Papadaki, E; Pappa, V; Repousis, P; Spanoudakis, E; Symeonidis, A; Terpos, E; Timotheatou, D; Vasilopoulos, G; Zikos, P, 2018) |
| "Pomalidomide is an immunomodulatory compound that has demonstrated activity in MM patients with disease refractory to lenalidomide and bortezomib." | 1.48 | The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience. ( Bernatowicz, P; Charlinski, G; Dmoszynska, A; Grzasko, N; Guzicka-Kazimierczak, R; Janczarski, M; Jurczyszyn, A; Lech-Maranda, E; Swiderska, A; Szczepaniak, A; Szeremet, A; Waszczuk-Gajda, A; Wichary, R, 2018) |
| "Multiple myeloma is an uncommon haematological cancer of plasma cells." | 1.48 | Multiple myeloma: Updated approach to management in 2018. ( Tomlinson, R, 2018) |
| " Adverse events (AEs) occurred in 69 (57." | 1.48 | Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/\ refractory multiple myeloma: a real-life experience ( Duran, M; Durusoy, R; Patır, P; Şahin, F; Saydam, G; Soyer, N; Töbü, M; Tombuloğlu, M; Ünal, HD; Uysal, A; Vural, F, 2018) |
| " Population pharmacokinetic analyses were conducted to determine the pharmacokinetics of intravenous daratumumab in combination therapy versus monotherapy, evaluate the effect of patient- and disease-related covariates on drug disposition, and examine the relationships between daratumumab exposure and efficacy/safety outcomes." | 1.48 | Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma. ( Belch, A; Capra, M; Clemens, PL; Dimopoulos, MA; Gomez, D; Ho, PJ; Iida, S; Jansson, R; Leiba, M; Medvedova, E; Min, CK; Schecter, J; Sonneveld, P; Sun, YN; Xu, XS; Zhang, L, 2018) |
| "An 85-year-old female was diagnosed with multiple myeloma(MM)(IgG-l)with t(4 ;14)(p16;q32)in 200X." | 1.48 | [Successful Treatment with Pomalidomide, Bortezomib, and Dexamethasone in a Patient with Frail Refractory and Relapsed Multiple Myeloma with Extramedullary Disease]. ( Nougawa, M; Oka, S; Shimazu, Y; Shiragami, H; Takeuchi, S, 2018) |
| "Multiple myeloma treatment." | 1.48 | [Multiple myeloma treatment]. ( Roussel, M; Royer, B; Talbot, A, 2018) |
| "Laboratory tests objectified severe renal failure with creatinine level 107mg, urea 1." | 1.48 | [Renal failure revealing multiple myeloma with preexisting lesions on radiological images]. ( Bouchemla, N; Chettati, M; Fadili, W; Laouad, I; Nadri, A, 2018) |
| "Pomalidomide entered treatment for the second relapse in 2015 (11% of patients)." | 1.46 | Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey. ( Goldschmidt, H; Kellermann, L; Knauf, W; Kohnke, J; Merz, M; Poenisch, W; Tischler, HJ, 2017) |
| "Novel therapies for multiple myeloma (MM) can target mechanism(s) in the host-MM bone marrow (BM) microenvironment mediating MM progression and chemoresistance." | 1.46 | A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells. ( Anderson, KC; Brooks, CL; Chauhan, D; Das, DS; Macri, V; Ray, A; Richardson, P; Song, Y, 2017) |
| "Heavily pretreated patients with relapsed and refractory multiple myeloma are susceptible to treatment-related adverse events (AEs)." | 1.46 | Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. ( Anttila, P; Bahlis, N; Biyukov, T; Cavo, M; Chen, C; Cook, G; Corradini, P; Delforge, M; Dimopoulos, MA; Hansson, M; Herring, J; Hong, K; Joao, C; Kaiser, M; Moreau, P; O'Gorman, P; Oriol, A; Raymakers, R; Richardson, PG; San-Miguel, J; Siegel, DS; Slaughter, A; Song, K; Sternas, L; Weisel, K; Yu, X; Zaki, M, 2017) |
| "Pomalidomide is a second-generation immunomodulatory drug (IMID)." | 1.46 | [Pomalidomide for multiple myeloma]. ( Chaleteix, C; Dougé, A; Lemal, R, 2017) |
| "Multiple myeloma is a haematological disease caused by proliferation of malignant plasma cells in bone marrow." | 1.46 | A case of multiple myeloma with navicular bone involvement. ( Canoz, O; Eser, B; Kaynar, L; Tiren, N; Yildizhan, E, 2017) |
| "Progression to multiple myeloma is the most common pattern of relapse." | 1.46 | Metachronous solitary plasmacytoma. ( Khosa, R; Nangia, S; Seth, S, 2017) |
| "Outcomes have improved considerably in multiple myeloma (MM), but disparities among racial-ethnic groups exist." | 1.46 | Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis. ( Advani, P; Ailawadhi, S; Chanan-Khan, AA; Colibaseanu, DT; Colon-Otero, G; Frank, RD; Hashmi, SK; Hodge, DO; Kakar, TS; Khera, N; Meghji, Z; Menghani, R; Paulus, A; Paulus, S; Roy, V; Sharma, M; Swaika, A; Temkit, M; Vizzini, MR, 2017) |
| " The basis of the RI treatment in MM is bortizomib-based regimen, which does not require dosage adjustment in patients with dialysis or renal insufficiency." | 1.46 | [Expert consensus for the diagnosis and treatment of patients with renal impairment of multiple myeloma]. ( , 2017) |
| "Multiple myeloma is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS), which is usually only treated by a form of anti-multiple myeloma therapy if it is causing substantial disease through deposition of secreted M proteins." | 1.46 | Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study. ( Afzal, Z; Bunce, CM; Cairns, DA; Campbell, JP; Child, JA; Drayson, MT; Gregory, W; Heaney, JLJ; Jackson, GH; Kaiser, M; Morgan, GJ; Owen, R; Pandya, S, 2017) |
| "We assessed minimal residual disease (MRD) by multi-parameter flow cytometry (MFC) and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction (ASO-RQ-PCR) after consolidation, after 3 and 6 courses of maintenance, and thereafter every 6 months until progression." | 1.46 | Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. ( Bernardini, A; Boccadoro, M; Caravita, T; Conticello, C; Drandi, D; Ferrero, S; Gambella, M; Gay, F; Genuardi, M; Gilestro, M; Liberati, AM; Muccio, VE; Musto, P; Oliva, S; Omedè, P; Palumbo, A; Passera, R; Patriarca, F; Pautasso, C; Pescosta, N; Petrucci, MT; Rocci, A; Saraci, E, 2017) |
| "Lenalidomide (LEN) has been used as an immunomodulatory drug with direct and indirect anti-tumor effects." | 1.46 | Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma. ( Anh-NguyenThi, T; Jaya Lakshmi, T; Jung, SH; Kim, HJ; Lee, HJ; Lee, JJ; Nguyen-Pham, TN; Vo, MC, 2017) |
| "Despite recent advances made in its treatment, multiple myeloma (MM) remains an incurable B cell malignancy." | 1.46 | Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic. ( Berenson, A; Berenson, JR; David, M; Eades, B; Eshaghian, S; Gottlieb, J; Halleluyan, R; Harutyunyan, NM; Nassir, Y; Spektor, TM; Swift, R; Udd, KA; Vardanyan, S; Wang, J, 2017) |
| " A set of blood samples was taken in order to develop a pharmacokinetic model accounting for lenalidomide concentrations in this setting." | 1.46 | Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure. ( Buclin, T; Burnier, M; Dao, K; Figg, WD; Kissling, S; Lu, Y; Peer, CJ; Stadelmann, R, 2017) |
| "The incidence of multiple myeloma in Asia has risen in the past 30 years." | 1.46 | A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in Taiwan. ( Chen, CC; Chen, TY; DeMarco, D; Dunn, P; Hua, Y; Huang, SY; Jacques, C; Kao, WY; Lin, HY; Lin, SF; Lin, TH; Puccio-Pick, M; Wang, MC; Yeh, SP; Yu, YB, 2017) |
| " The aim of this study was to conduct a population pharmacokinetic analysis of lenalidomide in multiple myeloma patients to identify and evaluate non-studied covariates that could be used for dose individualization." | 1.46 | Population pharmacokinetics of lenalidomide in multiple myeloma patients. ( Climente-Martí, M; Guchelaar, HJ; Guglieri-López, B; Merino-Sanjuán, M; Moes, DJ; Pérez-Pitarch, A; Porta-Oltra, B, 2017) |
| "Bortezomib was used as first-line induction therapy against both tumors and lenalidomide was used for maintenance." | 1.46 | Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case report. ( Deng, M; Lin, Q; Mei, Z; Song, Y; Yang, J; Yin, Q; Zhu, X; Zuo, W, 2017) |
| " We demonstrated that CK1α inactivation, while toxic for myeloma cells, is dispensable for the survival of healthy B lymphocytes and stromal cells." | 1.46 | Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways. ( Barilà, G; Bonaldi, L; Cabrelle, A; Carrino, M; Costacurta, M; Gianesin, K; Macaccaro, P; Manni, S; Manzoni, M; Martines, A; Neri, A; Nunes, SC; Piazza, F; Semenzato, G; Taiana, E; Trentin, L; Tubi, LQ; Zambello, R, 2017) |
| " CIPN is a common dose limiting side effect in patients with MM." | 1.46 | The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry. ( Beijers, AJ; Eurelings, M; Minnema, MC; Mols, F; Oerlemans, S; van de Poll-Franse, LV; Vreugdenhil, A, 2017) |
| "The apixaban treatment resulted in favorable and effective control of the patient's VTE on day33." | 1.46 | Successful management of venous thromboembolism with apixaban in a multiple myeloma patient on lenalidomide therapy. ( Hamahata, K; Nohgawa, M; Oka, S; Shiragami, H; Takeuchi, S, 2017) |
| "Pomalidomide has shown improved survival and good tolerability in this patient cohort in clinical trials, but real world data are scarce." | 1.46 | Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience. ( Benjamin, R; Cerner, A; Cheesman, S; D'sa, S; Jenner, M; Maciocia, N; Maciocia, P; Melville, A; Popat, R; Rabin, N; Ramasamy, K; Rismani, A; Schey, S; Sharpley, F; Streetly, M; Yong, K, 2017) |
| "Treatment advances for multiple myeloma (MM) that have prolonged survival emphasise the importance of measuring patients' health-related quality of life (HRQoL) in clinical studies." | 1.46 | Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment. ( Arnould, B; Bacon, P; Gilet, H; Kyriakou, C; Leleu, X; Lewis, P; Murphy, P; Petrucci, MT; Vande Broek, I, 2017) |
| "To describe multiple myeloma (MM) treatment patterns and comorbidities over time in the US." | 1.43 | Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. ( Cong, Z; Song, X; Wilson, K, 2016) |
| "Clarithromycin (CAM) is a macrolide antibiotic that is widely used in the treatment of respiratory tract infections, sexually transmitted diseases and infections caused by the Helicobacter pylori and Mycobacterium avium complex." | 1.43 | Clarithromycin Synergistically Enhances Thalidomide Cytotoxicity in Myeloma Cells. ( Cao, HQ; Li, HQ; Mei, JG; Qiu, XH; Shao, JJ, 2016) |
| "Current therapeutic strategies for sickle cell anemia are aimed at reactivating fetal hemoglobin." | 1.43 | Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors. ( Al-Abed, Y; Allen, SL; An, X; Appiah-Kubi, AO; Blanc, L; Chan, KW; Didier, S; Dulmovits, BM; Gallagher, PG; Gould, M; Hale, J; He, M; Husain-Krautter, S; Lipton, JM; Liu, JM; Marambaud, P; Mohandas, N; Papoin, J; Singh, SA; Taylor, N; Vlachos, A, 2016) |
| "To explore the efficacy and prognostic factors of induction therapy combined with autogenetic peripheral blood stem cells transplantation (APBSCT)in patients with multiple myeloma (MM)." | 1.43 | [Efficacy and prognostic factors of induction therapy combined with autologous stem cell transplantation in 201 patients with multiple myeloma]. ( Chang, H; Du, J; Fan, J; Fu, W; He, H; Hou, J; Jiang, H; Jin, L; Xi, H; Zeng, T; Zhang, C; Zhou, L, 2016) |
| "We analyzed the overall survival of 347 multiple myeloma patients in Austria by means of a national registry (AMR), focused on results from 3rd and later lines of therapy." | 1.43 | Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics. ( Rochau, U; Siebert, U; Weger, R; Willenbacher, E; Willenbacher, W, 2016) |
| "Rash is a frequent side effect of IMiDs, particularly lenalidomide, often leading to treatment discontinuation." | 1.43 | Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma. ( Agarwal, S; Barley, K; Chari, A; He, W; Jagannath, S, 2016) |
| "Treatment of multiple myeloma (MM) has significantly improved, although the disease remains incurable." | 1.43 | Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma? ( Berno, T; Cortelazzo, S; DE March, E; Marabese, A; Meneghini, V; Mian, M; Mondello, P; Patriarca, F; Pescosta, N; Pizzolo, G; Semenzato, G; Tinelli, M; Turri, G; Zambello, R, 2016) |
| "Lenalidomide is a potential treatment option for refractory bleeding in AVWS secondary to MG." | 1.43 | Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy. ( Brophy, TM; Browne, PV; Hayden, PJ; Lavin, M; O'Connell, N; O'Donnell, JS; O'Sullivan, JM; Rawley, O; Ryan, K, 2016) |
| " LenDex was interrupted in three cases because of adverse events (infections and cutaneous events); 78 % of the patients were on thromboprophylaxis with aspirin." | 1.43 | Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment. ( Coelho, I; Esteves, GV; Esteves, S; Freitas, J; Geraldes, C; Gomes, F; João, C; Lúcio, P; Neves, M, 2016) |
| "A 63-year-old man with Bence Jones-κ multiple myeloma (MM) presented with renal impairment." | 1.43 | Achievement of hemodialysis discontinuation with lenalidomide and dexamethasone therapy in a refractory BJP-type multiple myeloma patient. ( Hagihara, M; Hua, J; Inoue, M; Uchida, T, 2016) |
| " The dosing and safety profile of POM + LoDEX was similar across RI subgroups." | 1.43 | Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. ( Baz, R; Cavo, M; Delforge, M; Dimopoulos, MA; Goldschmidt, H; Hong, K; Jagannath, S; Moreau, P; Palumbo, A; Richardson, P; San Miguel, JF; Siegel, DS; Song, KW; Sternas, L; Weisel, KC; Yu, X; Zaki, M, 2016) |
| "The interactions of multiple myeloma (MM) cells with their microenvironment are crucial for pathogenesis." | 1.43 | Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells. ( Body, S; Bourgeais, J; Bustany, S; Gouilleux, F; Hérault, O; Sola, B; Tchakarska, G, 2016) |
| "To evaluate the efficacy and adverse effects of low dose thalidomide (TD) combined with modified VCMP (vincristine+cyclophosphamide+melphalan+prednisone) (TD+mVCMP) and VAD (vincristine+doxorubicin+dexamethsone) (TD+VAD) regimens for treating aged patients with MM." | 1.43 | [Efficacy Comparison of Low dose Thalidomide Combined with Modified VCMP and VAD regimens for Treatment of Aged MM Patients]. ( Liu, HB; Wang, W, 2016) |
| "Multiple myeloma is a clonal B-cell malignancy, characterised by proliferation of plasma cells and secretion of paraproteins." | 1.43 | Pleural effusion as a manifestation of multiple myeloma. ( Iqbal, N; Majid, H; Shaikh, MU; Tariq, MU, 2016) |
| "Multiple myeloma is a malignant hematological disorder of the mature B-cell lymphocytes originating in the bone marrow." | 1.43 | Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography. ( Bier, G; Fritz, J; Horger, M; Ioanoviciu, SD; Kum, S; Schabel, C; Weisel, K, 2016) |
| "Patients with multiple myeloma (MM) are at increased risk of arterial thrombosis." | 1.43 | Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study. ( Hinduja, A; Limaye, K; Papanikolaou, X; Ravilla, R; Sasapu, A; Torbey, M; Waheed, S; Wei, L, 2016) |
| "Thalidomide was added to the BD therapy but was discontinued because of drug-induced eczema." | 1.43 | Efficacy of pomalidomide in a multiple myeloma patient requiring hemodialysis. ( Hangaishi, A; Hirao, M; Iizuka, H; Kida, M; Usuki, K, 2016) |
| "Multiple myeloma is a plasma cell malignant clone proliferation diseases and has been remained incurable." | 1.43 | [Advances of CRBN in Immunomodulatory Drugs for Multiple Myeloma-Review]. ( An, R; Hou, J, 2016) |
| "Plasmacytomas are monoclonal plasma cell tumors." | 1.42 | Diplopia and variable ptosis as the sole initial findings in a case of orbital plasmacytoma and multiple myeloma. ( Galea, M; McMillan, N; Weir, C, 2015) |
| "Pyoderma gangrenosum has been described in association with multiple myeloma and usually affects patients with active/untreated disease." | 1.42 | Pyoderma gangrenosum due to lenalidomide use for multiple myeloma. ( Alexandrescu, DT; Bockorny, B; Dasanu, CA, 2015) |
| " Xenografts acquired resistance to two generations of immunomodulatory drugs (IMiDs; lenalidomide and pomalidomide) in combination with dexamethasone, that was reversible after a wash-out period." | 1.42 | In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. ( Bjorklund, CC; Corchete, LA; Couto, S; Delgado, M; Díaz-Rodríguez, E; Fernández-Lázaro, D; Garayoa, M; García-Gómez, A; Gutiérrez, NC; López-Corral, L; Mateos, MV; Montero, JC; Ocio, EM; Paíno, T; Pandiella, A; San-Miguel, JF; San-Segundo, L; Wang, M, 2015) |
| "Survival for patients with multiple myeloma has increased." | 1.42 | Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. ( Dimopoulos, MA; Dispenzieri, A; Gertz, MA; Kastritis, E; Kumar, S; Orlowski, R; Shah, J; Shah, RA; Terpos, E, 2015) |
| "Patients with multiple myeloma and advanced disease managed with multiple lines of therapy are at risk for vRTI, and targeted interventions for prevention/treatment are required." | 1.42 | Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital. ( Harrison, SJ; Slavin, MA; Teh, BW; Thursky, KA; Worth, LJ, 2015) |
| "Despite recent treatment improvements, multiple myeloma remains an incurable disease." | 1.42 | Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. ( Andre, P; Lammerts van Bueren, JJ; Lokhorst, HM; Morel, Y; Mutis, T; Nijhof, IS; Parren, PW; van de Donk, NW; van Kessel, B, 2015) |
| "A population pharmacokinetic (PPK) model of pomalidomide was developed and the influence of demographic and disease-related covariates on PPK parameters was assessed based on data from 6 clinical trials of pomalidomide (dose range, 0." | 1.42 | Population pharmacokinetics of pomalidomide. ( Li, Y; Liu, L; Palmisano, M; Wang, X; Xu, Y; Zhou, S, 2015) |
| "Despite the recent advances in the treatment of multiple myeloma (MM), MM patients with high-risk cytogenetic changes such as t(4;14) translocation or deletion of chromosome 17 still have extremely poor prognoses." | 1.42 | A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts. ( Du, W; Hasegawa, Y; Hattori, Y; Hozumi, M; Ichikawa, D; Matsuo, K; Matsushita, M; Oikawa, T; Ozaki, Y; Shiheido, H; Tabata, N; Terada, F; Yamada, T; Yanagawa, H, 2015) |
| "KMA was detected on kappa human multiple myeloma cell lines (κHMCLs), on plasma cells (PCs) from kappa multiple myeloma (κMM) patients and on κPC dyscrasia tissue cryosections." | 1.42 | MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide. ( Asvadi, P; Cuddihy, A; Dunn, RD; Jiang, V; Jones, DR; Khong, T; Spencer, A; Wong, MX, 2015) |
| "High-risk cytogenetic abnormalities were not associated with the diffuse/variegated MRI pattern (p = 0." | 1.42 | Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities. ( Chung, JS; Lee, GW; Lee, IS; Lee, JH; Lee, JJ; Lee, SM; Shin, DY; Song, IC; Song, MK, 2015) |
| "Prognosis of patients with multiple myeloma (MM) has substantially improved in recent years due to the incorporation of novel drugs into their treatment." | 1.42 | Long-term control in a patient with refractory multiple myeloma by oral cyclophosphamide and dexamethasone. ( Gunsilius, E; König, P; Nachbaur, D; Steiner, N; Willenbacher, W, 2015) |
| "Lenalidomide pre-treatment of MM cell lines reduced TReg generation and the concomitant TReg:TEff (CD4(+)CD25(+)FoxP3(-): effector T cells) ratio, as a consequence of reduced ICOSL transcription." | 1.42 | Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy. ( Carter, C; Cook, G; Parrish, C; Scott, GB; Wood, PM, 2015) |
| "Lenalidomide was discontinued after 10 days due to exacerbation of renal dysfunction." | 1.42 | Development of acquired hemophilia A during treatment of multiple myeloma with lenalidomide. ( Ikebe, T; Itani, K; Miyazaki, Y; Nagamatsu, K; Ogata, M; Ohtsuka, E; Saburi, M; Saburi, Y, 2015) |
| "In this issue of Blood, Sehgal et al report on the clinical and pharmacodynamics analysis of pomalidomide dosing strategies in multiple myeloma (MM) and their impact on immune activation and cereblon targets." | 1.42 | Toward optimizing pomalidomide therapy in MM patients. ( Podar, K, 2015) |
| "Lenalidomide is an oral immunomodulatory drug (IMiD) approved in the United States for patients with MM." | 1.42 | A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide. ( Qian, W; Wang, B; Xu, G; Yang, M, 2015) |
| "Multiple myeloma is a neoplasm of plasma cells that results in the overproduction of light and heavy chain monoclonal immunoglobulins." | 1.40 | Multiple myeloma: a descriptive study of 217 Egyptian patients. ( El Azeeim, HA; El Husseiny, NM; Kasem, N; Mattar, MW, 2014) |
| "We conclude that RD reduces bone resorption only in responding patients with relapsed/refractory myeloma but has no effect on bone formation." | 1.40 | The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group. ( Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Gkotzamanidou, M; Kastritis, E; Katodritou, E; Koulieris, E; Kyrtsonis, MC; Michalis, E; Papanikolaou, X; Papatheodorou, A; Pouli, A; Terpos, E; Zervas, K, 2014) |
| "Secondary monoclonal gammopathy of undetermined significance (MGUS) is a special phenomenon that occurs during the treatment of multiple myeloma (MM)." | 1.40 | Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias. ( An, G; Deng, S; Meng, H; Qiu, L; Shi, L; Sui, W; Wang, J; Xu, Y; Zhan, F; Zhu, G; Zou, D, 2014) |
| "The prognosis of multiple myeloma (MM) has improved in recent years." | 1.40 | Multiple myeloma and other malignancies: a pilot study from the Houston VA. ( Guo, S; Hayes, TG; Lin, D; Munker, R; Shi, R, 2014) |
| "Smoldering or asymptomatic multiple myeloma may be best described as a state of limbo where the patient has not developed any symptoms of disease and is being observed expectantly." | 1.40 | How long can we let the myeloma smolder? ( Usmani, SZ, 2014) |
| "We herein present a case of multiple myeloma with Fanconi syndrome and acute kidney injury due to light chain proximal tubulopathy with light chain cast nephropathy." | 1.40 | Acquired Fanconi syndrome with proximal tubular cytoplasmic fibrillary inclusions of λ light chain restriction. ( Liu, G; Liu, L; Wang, SX; Wang, Y; Yao, Y; Zhang, YK, 2014) |
| "Effective therapy for multiple myeloma has existed for a little more than the last half century." | 1.40 | An overview of the progress in the treatment of multiple myeloma. ( Kyle, RA; Rajkumar, SV, 2014) |
| "Our prior study in multiple myeloma (MM) patients showed increased numbers of plasmacytoid dendritic cells (pDCs) in the bone marrow (BM), which both contribute to immune dysfunction as well as promote tumor cell growth, survival and drug resistance." | 1.40 | A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib. ( Anderson, KC; Chauhan, D; Coffman, RL; Das, DS; Ray, A; Richardson, P; Tian, Z, 2014) |
| "Lenalidomide therapy was associated with increased amounts of a CD8(+) T cell subset, phenotypically staged between classical central memory T cells (TCM) and effector memory T cells (TEM), consequently termed TCM/TEM." | 1.40 | Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients. ( Brossart, P; Busch, A; Fingerhut, L; Hahn-Ast, C; Janzen, V; Maurer, O; Mügge, LO; von Lilienfeld-Toal, M; Wolf, D; Zeh, D, 2014) |
| "Four patients died due to disease progression and 17 were found to have progressed after ASCT (the median progression-free survival after ASCT was 19." | 1.40 | Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation. ( Chang, WJ; Kang, ES; Kim, DW; Kim, K; Kim, SH; Kim, SJ; Lee, ST, 2014) |
| "Consolidation therapy for patients with multiple myeloma (MM) has been widely adopted to improve treatment response following autologous stem cell transplantation." | 1.40 | Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients. ( Akashi, K; Aoki, T; Ito, Y; Iwasaki, H; Kadowaki, M; Kamimura, T; Kato, K; Miyamoto, T; Muta, T; Shima, T; Shiratsuchi, M; Takase, K; Takashima, S; Takenaka, K; Teshima, T; Yoshimoto, G, 2014) |
| "This is a retrospective study on six multiple myeloma patients with upfront coagulopathy and bleeding." | 1.40 | Clinical analysis of six cases of multiple myeloma first presenting with coagulopathy. ( Hu, H; Jia, Y; Peng, J; Wang, L; Xu, H, 2014) |
| "Cryoglobulinemia (Cg) in multiple myeloma (MM) is rare and no standard treatment has yet been established." | 1.40 | [Successful treatment with a combination of lenalidomide and dexamethasone for cryoglobulinemia associated with multiple myeloma]. ( Ando, K; Hata, T; Imaizumi, Y; Imanishi, D; Makiyama, J; Miyazaki, Y; Sawayama, Y; Taguchi, J; Taniguchi, H; Tsushima, H, 2014) |
| "Lenalidomide treatment resulted in significant increases in CT/FEM-derived estimates of bone strength." | 1.40 | A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography. ( Awai, K; Date, S; Kaichi, Y; Kiguchi, M; Kuroda, Y; Sakai, A; Sakoda, Y; Takasu, M; Tani, C, 2014) |
| "Treatment options for multiple myeloma dwindle with each relapse." | 1.40 | Pomalidomide. A last-line treatment option for multiple myeloma. ( , 2014) |
| "Lenalidomide is a known and approved treatment strategy for relapsed MM." | 1.39 | Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy. ( Cirstea, D; Eda, H; Fulciniti, M; Mahindra, A; Nemani, N; Patel, K; Raje, N; Santo, L; Scullen, T; Vallet, S; Yee, A, 2013) |
| "Lenalidomide is a thalidomide analog used for the treatment of myelodysplastic syndromes, with pleiotropic activities including induction of apoptosis, inhibition of angiogenesis and broad immunomodulatory effects." | 1.39 | Lenalidomide-induced regenerative macronodules infarction in a cirrhosis patient. ( Arrivé, L; Carbonell, N; Cervera, P; Dangouloff-Ros, V, 2013) |
| "The patient was diagnosed with multiple myeloma and received chemotherapy with thalidomide, cyclophosphamide and dexamethasone." | 1.39 | Multiple myeloma presenting as plasmacytoma of the jaws showing prominent bone formation during chemotherapy. ( An, CH; An, SY; Choi, KS; Heo, MS, 2013) |
| "Utilizing different multiple myeloma cell lines we determined the effect of TG02 over viability by MTT assays." | 1.39 | Potent antimyeloma activity of a novel ERK5/CDK inhibitor. ( Álvarez-Fernández, S; Burrows, FJ; Esparís-Ogando, A; Ocio, EM; Ortiz-Ruiz, MJ; Pandiella, A; Parrott, T; San Miguel, J; Zaknoen, S, 2013) |
| "A total of 200 patients with multiple myeloma who developed disease recurrence after treatment with upfront ASCT and received an autologous retransplantation as salvage therapy at the study center over a period of 15 years were retrospectively reviewed." | 1.39 | Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients. ( Benner, A; Egerer, G; Goldschmidt, H; Heiss, C; Hillengass, J; Ho, AD; Hose, D; Lehners, N; Neben, K; Raab, MS; Sellner, L, 2013) |
| "A 65-year-old male with multiple myeloma received chemotherapy which included cyclophosphamide, thalidomide and dexamethasone." | 1.39 | Negative chronotropic effects and coronary ischaemic abnormalities following thalidomide therapy. ( Ali, A; Hothi, SS; Malik, N; Thompson, A, 2013) |
| "Treatment with lenalidomide, as the final therapeutic option, resolved the intractable melena and improved both the intestinal lesions and myeloma." | 1.39 | Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis. ( Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S, 2013) |
| "Both T-cell and NK-cell LGL leukemia can manifest as indolent or aggressive neoplasia." | 1.39 | Very long-lasting remission of refractory T-large granular lymphocytes leukemia and myeloma by lenalidomide treatment. ( Alma, E; Cox, MC; Di Napoli, A; Naso, V; Pelliccia, S; Rebecchini, C, 2013) |
| "Acute lymphoblastic leukemia (ALL) is a hematological disorder involving at least 20% lymphoblasts in the bone marrow of the B-cell lineage." | 1.39 | Acute myelofibrosis and acute lymphoblastic leukemia in an elderly patient with previously treated multiple myeloma. ( Chen, L; Gonzalez, MM; Kidd, L; Nguyen, N; Quesada, J, 2013) |
| "Relapsed/refractory multiple myeloma represents a major challenge in multiple myeloma therapy." | 1.39 | Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma. ( Bailey, C; Barlogie, B; Crowley, J; Heuck, CJ; Hoering, A; Johann, D; Keller, J; Mitchell, A; Papanikolaou, X; Petty, N; Rosenthal, A; Szymonifka, J; Usmani, SZ; Van Rhee, F; Waheed, S, 2013) |
| "Lenalidomide has significant antimyeloma activity but it is associated with a significant risk of venous thromboembolism (VTE)." | 1.39 | Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. ( Bagratuni, T; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kanelias, N; Kastritis, E; Kostouros, E; Politou, M; Roussou, M; Terpos, E, 2013) |
| " Repeated dosing of lenalidomide significantly lowered the IC50 of the responsive HMCL ALMC-1 (IC50 = 2." | 1.39 | Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels. ( Greenberg, AJ; Jelinek, DF; Kumar, SK; Rajkumar, SV; Walters, DK, 2013) |
| "Acute kidney failure in multiple myeloma (MM) occurs in 12%-20% of patients and is a poor prognostic factor for patient survival." | 1.39 | Effectiveness of haemodiafiltration with ultrafiltrate regeneration in the reduction of light chains in multiple myeloma with renal failure. ( Aljama, P; Alonso, C; Alvarez-Lara, MA; Caballero-Villarraso, J; Carracedo, J; Martín-Malo, A; Ojeda-López, R; Pendón-Ruiz de Mier, MV, 2013) |
| "Real-world costs during treatment of relapsed/refractory multiple myeloma vary greatly." | 1.39 | Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents. ( Franken, MG; Gaultney, JG; Huijgens, PC; Redekop, WK; Sonneveld, P; Tan, SS; Uyl-de Groot, CA, 2013) |
| "Optimal salvage treatment for multiple myeloma relapsing after allogeneic stem cell transplantation remains to be determined." | 1.39 | Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy. ( Bachy, E; Bourhis, JH; Brebion, A; Coman, T; François, S; Hermine, O; Huynh, A; Lapusan, S; Lioure, B; Maury, S; Michallet, M; Milpied, N; Mohty, M; Rubio, MT; Socié, G; Uzunov, M; Vigouroux, S; Yakoub-Agha, I, 2013) |
| "Advances in survival in multiple myeloma have focused payer attention on the cost of care." | 1.39 | Total cost comparison in relapsed/refractory multiple myeloma. ( Binder, G; Borrello, I; Durie, B; Hussein, M; Khan, Z; Pashos, C, 2013) |
| "Prognostic impact of specific chromosomal aberrations in patients with relapsed multiple myeloma (MM) treated with the novel agents is briefly described." | 1.39 | Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib. ( Adam, Z; Almasi, M; Berankova, K; Frohlich, J; Greslikova, H; Hajek, R; Jarkovsky, J; Jurczyszyn, A; Kaisarova, P; Krejci, M; Kuglik, P; Kupska, R; Melicharova, H; Mikulasova, A; Nemec, P; Penka, M; Sandecka, V; Sevcikova, S; Smetana, J; Zahradova, L; Zaoralova, R, 2013) |
| "The outlook for transplant-ineligible multiple myeloma patients has improved enormously over recent years with the incorporation of new agents into standard regimens." | 1.39 | The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenan ( Ba-Mancini, A; Cakana, A; Chen, K; Corzo, D; Dhawan, R; Duh, MS; Garrison, LP; Huang, H; Korves, C; Shi, H; van de Velde, H; Wang, ST, 2013) |
| "Lenalidomide was well tolerated in intensively pretreated and elderly MM patients, including those with RI." | 1.38 | Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal. ( Engelhardt, M; Ihorst, G; Kleber, M; Koch, B; Udi, J; Wäsch, R, 2012) |
| "Lenalidomide (len) is an analog of thalidomide (thal), and both are used in the treatment of a diverse group of medical conditions." | 1.38 | Lenalidomide alone or lenalidomide plus dexamethasone significantly inhibit IgG and IgM in vitro... A possible explanation for their mechanism of action in treating multiple myeloma. ( Greig, N; Sandoval, F; Shannon, E; Stagg, P, 2012) |
| "HM1." | 1.38 | Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. ( Anderson, KC; Bernett, MJ; Cemerski, S; Chen, H; Chu, SY; Desjarlais, JR; Horton, HM; Karki, S; Kong, SY; Lazar, GA; Muchhal, US; Munshi, NC; Nguyen, DH; Pong, E; Tai, YT, 2012) |
| "Bone disease is a major symptom of multiple myeloma, which results from excessive osteoclast activation and impaired osteoblast function." | 1.38 | Therapy with lenalidomide plus dexamethasone-induced bone formation in a patient with refractory multiple myeloma. ( Tsuda, H; Tsuji, T; Yamasaki, H; Yokoo, E, 2012) |
| "POEMS syndrome is a rare paraneoplastic condition associated to an underlying plasmacellular dyscrasia." | 1.38 | Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation. ( Balducci, M; Chiusolo, P; De Stefano, V; Giannotta, C; Laurenti, L; Leone, G; Luigetti, M; Sabatelli, M; Sica, S; Sorà, F; Vannata, B, 2012) |
| "Carfilzomib is an irreversible proteasome inhibitor with favorable toxicity profile (minimal neuropathy) and response rates of 17-54% depending on the disease stage treated." | 1.38 | Novel therapeutics in multiple myeloma. ( Stewart, AK, 2012) |
| "The diagnosis of multiple myeloma requires the presence of monoclonal bone marrow plasma cells, a monoclonal (M) protein in serum and/or urine and evidence of end-organ damage from the plasma cell proliferative disorder." | 1.38 | Targeted therapy of multiple myeloma. ( Kyle, RA, 2012) |
| "Multiple myeloma is the second most common hematological disease caused by clonal proliferation of B cells." | 1.38 | [Prognostic significance of morphology in multiple myeloma]. ( Adam, Z; Al-Sahmani, M; Antošová, L; Antošová, M; Buliková, A; Hájek, R; Kaisarová, B; Kissová, J; Penka, M; Trnavská, I, 2012) |
| "Preclinical and clinical studies have shown that proteasome inhibitors (PIs) have anti-MM activity in combination with dexamethasone or lenalidomide." | 1.38 | CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma. ( Berenson, JR; Chen, H; Hunter, K; Jones-Bolin, S; Li, J; Li, M; Ruggeri, B; Sanchez, E; Wang, C, 2012) |
| "Multiple myeloma is a common malignancy accounting for approximately 1% of all malignancies worldwide." | 1.38 | Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma. ( Bruce, JT; Devine, SM; Elder, P; Hofmeister, CC; Mastronarde, JG; Phillips, G; Tran, JM; Wood, KL, 2012) |
| "Lenalidomide is an immunomodulatory drug derived from thalidomide, developed to maximize its anti-inflammatory and antineoplastic properties while reducing toxicity." | 1.38 | Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. ( Boccadoro, M; Cavallo, F; Larocca, A; Mina, R; Palumbo, A, 2012) |
| "Multiple myeloma is a plasma cell malignancy that leads to bone pain, pathological fracture, anaemia, renal failure and recurrent bacterial infections." | 1.37 | Clinical profile of multiple myeloma and effect of thalidomide based treatment on its outcome. ( Basu, D; Dutta, TK; Sridhar, S, 2011) |
| "Thalidomide has recently been shown to have significant antimyeloma activity." | 1.37 | Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma. ( Jang, G; Jo, JC; Kang, BW; Kim, S; Kim, SW; Lee, DH; Lee, JS; Lee, SS; Suh, C; Sym, SJ, 2011) |
| "Patients with multiple myeloma (MM) are at relatively high risk of developing thromboembolic event (TEE), especially during treatment with immunomodulatory agents." | 1.37 | Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma. ( Guo, H; Jiang, Y; Shen, Y; Sun, C; Tong, Y; Wang, J; Wang, Z; Yang, G; Zhou, X, 2011) |
| "Griseofulvin (GF) has similar chemical features as compared to ciclopirox olamine." | 1.37 | In vivo efficacy of griseofulvin against multiple myeloma. ( Alpmann, P; Blaum-Feder, S; Carson, D; Endo, T; Kim, Y; Krämer, S; Lu, D; Schmidt-Wolf, IG, 2011) |
| "We analyzed DNA from 1,495 patients with multiple myeloma." | 1.37 | Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. ( Child, JA; Corthals, SL; Davies, FE; Dickens, NJ; Durie, BG; Goldschmidt, H; Gregory, WM; Johnson, DC; Lokhorst, HM; Morgan, GJ; Ross, FM; Sonneveld, P; Van Ness, B; Walker, BA, 2011) |
| "Recurrence of multiple myeloma (MM) after therapy suggests the presence of tumor-initiating subpopulations." | 1.37 | Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. ( Adamia, S; Anderson, KC; Blotta, S; Cervi, D; Cholujova, D; Daley, JF; Delmore, J; Jakubikova, J; Klippel, S; Kong, SY; Kost-Alimova, M; Laubach, J; Leiba, M; Mitsiades, CS; Ooi, M; Richardson, PG; Sedlak, J, 2011) |
| "We evaluated the in vitro antimyeloma activity of AT9283 alone and in combination with lenalidomide and the in vivo efficacy by using a xenograft mouse model of human MM." | 1.37 | Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. ( Anderson, KC; Bandi, M; Chauhan, D; Cirstea, D; Gorgun, G; Hideshima, T; Hu, Y; Mahindra, A; Munshi, NC; Nelson, EA; Patel, K; Pozzi, S; Raje, N; Rodig, S; Santo, L; Squires, M; Unitt, C; Vallet, S, 2011) |
| " The major adverse events (AEs) associated with lenalidomide include: hematological toxicities (myelosuppression), mainly neutropenia, venous thromboembolism, gastrointestinal disturbance, skin toxicity, atrial fibrillation, asthenia, and decreased peripheral blood stem cell yield during stem cell collection when lenalidomide is used after a long period of time." | 1.37 | Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events. ( García Sánchez, PJ; González Rodríguez, AP; Mesa, MG; Pérez Persona, E, 2011) |
| "Among hematologic malignancies, multiple myeloma (MM) confers a high risk of developing such complications, with a VTE rate of nearly 10%." | 1.37 | Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. ( Brioli, A; Cavo, M; Pantani, L; Tacchetti, P; Zamagni, E; Zannetti, B, 2011) |
| "The authors have reviewed the treatment of multiple myeloma including the novel agents, thalidomide, bortezomib and lenalidomide." | 1.37 | History of multiple myeloma. ( Kyle, RA; Steensma, DP, 2011) |
| "Lenalidomide is an antiangiogenic drug associated with hypothyroidism." | 1.37 | Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: results of a retrospective case review. ( Brown, K; Clayton, W; Figaro, MK; Jagasia, S; Kassim, A; Lakhani, VT; Usoh, C, 2011) |
| "Lenalidomide is an IMiD immunomodulatory compound that has both tumouricidal and immunomodulatory activity in MM." | 1.37 | Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. ( Bartlett, JB; Bolomsky, A; Brady, H; Chopra, R; Daniel, T; Gaidarova, S; Gisslinger, H; Heintel, D; Hilgarth, B; Jäger, U; Lopez-Girona, A; Ludwig, H; Mendy, D; Schafer, PH; Schreder, M; Zhang, LH; Zojer, N, 2011) |
| "Patients with relapsed or refractory multiple myeloma (RRMM) who received lenalidomide plus dexamethasone in the MM-009 and MM-010 trials were pooled and those who had not progressed and were still receiving lenalidomide at 12 months were included." | 1.37 | Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. ( Dimopoulos, MA; Hussein, M; Swern, AS; Weber, D, 2011) |
| "There is predominance of paresthesiae in some of them while in others pain or deep sensation failure can dominate." | 1.37 | [Thalidomide-induced sensory neuropaty in patients with multiple myeloma]. ( Bilińska, M; Kuliczkowski, K; Noga, L; Podemski, R; Potoczek, S; Szymczyk, M; Usnarska-Zubkiewicz, L, 2011) |
| "Lenalidomide was given at a dose of 15 mg (n=4), or 25 mg (n=20), orally once daily on day 1 to day 1 every 28 days, with (n=20) or without (n=4) DHAP." | 1.36 | Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. ( Atanackovic, D; Ayuk, F; Bacher, U; Badbaran, A; Blaise, D; El-Cheikh, J; Fehse, B; Hildebrandt, Y; Hoffmann, F; Kröger, N; Lioznov, M; Mohty, M; Schilling, G; Wolschke, C; Zander, AR, 2010) |
| "Acute renal failure in patients with multiple myeloma (MM) requiring dialysis is a serious complication and is associated with extremely poor survival." | 1.36 | Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years. ( Fujiwara, H; Iwama, K; Kimura, S; Matsue, K; Takeuchi, M; Yamakura, M, 2010) |
| "Bortezomib has been shown to be highly active in MM patients with RI." | 1.36 | Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. ( Baldini, L; Boccadoro, M; Bringhen, S; Callea, V; Casulli, AF; Catalano, L; Cavo, M; Ciolli, S; Di Raimondo, F; Galimberti, S; Gentile, M; Mannina, D; Mele, G; Morabito, F; Musto, P; Offidani, M; Palmieri, S; Palumbo, A; Petrucci, MT; Pinotti, G; Piro, E; Tosi, P, 2010) |
| "Asthenia is the most common adverse effect of treatment, occurring in approximately 76% to 96% of patients receiving therapy." | 1.36 | Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. ( Anderson, K; Laubach, JP; Mitsiades, C; Richardson, PG; Schlossman, RL, 2010) |
| "Lenalidomide is a more potent and less toxic oral analog of thalidomide." | 1.36 | Lenalidomide-induced interstitial lung disease. ( Chen, Y; Kiatsimkul, P; Nugent, K; Raj, R, 2010) |
| "The lenalidomide dose was gradually increased up to 15 mg daily and the dexamethasone dose reduced to 40 mg once a week." | 1.36 | Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma. ( Ludwig, H; Zojer, N, 2010) |
| "LBH589 may be very effective in multiple myeloma after a multitude of preceding treatments that could not induce a long-term anti-myeloma effect." | 1.36 | The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide. ( Goldschmidt, H; Ho, AD; Schmitt, S, 2010) |
| "NK cells exert cytotoxicity against multiple myeloma (MM), an effect enhanced through novel therapies." | 1.36 | The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. ( Baiocchi, RA; Bakan, CE; Becknell, B; Benson, DM; Byrd, JC; Caligiuri, MA; Devine, SM; Efebera, Y; Greenfield, CN; Hofmeister, CC; Lozanski, G; Mishra, A; Porcu, P; Rotem-Yehudar, R; Smith, MK; Yu, J; Zhang, J, 2010) |
| "The outcome of patients with multiple myeloma (MM) aged over 75 years remains poor, and the best therapeutic approach has still to be defined." | 1.36 | Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study. ( Alesiani, F; Blasi, N; Boccadoro, M; Bringhen, S; Brunori, M; Catarini, M; Corvatta, L; Ferranti, M; Galieni, P; Gentili, S; Larocca, A; Leoni, P; Mele, A; Offidani, M; Oliva, S; Palumbo, A; Polloni, C; Visani, G, 2010) |
| "The impact of cumulative dosing and premature drug discontinuation (PMDD) of bortezomib (V), thalidomide (T), and dexamethasone (D) on overall survival (OS), event-free survival (EFS), time to next therapy, and post-relapse survival in Total Therapy 3 were examined, using time-dependent methodology, relevant to induction, peritransplantation, consolidation, and maintenance phases." | 1.36 | Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. ( Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Hoering, A; Nair, B; Petty, N; Shaughnessy, JD; Szymonifka, J; van Rhee, F; Waheed, S, 2010) |
| "Pomalidomide was given orally (2 mg) daily, continuously in 28-day cycles along with dexamethasone (40 mg) given weekly." | 1.36 | Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). ( Allred, JB; Bergsagel, PL; Buadi, F; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, K; Lust, JA; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Roy, V; Russell, SJ; Short, KD; Stewart, AK; Zeldenrust, S, 2010) |
| "Cranial nerve involvement in multiple myeloma and solitary plasmacytoma is rare." | 1.36 | Cranial nerve palsy in multiple myeloma and solitary plasmacytoma. ( Kashyap, R; Kumar, R; Kumar, S, 2010) |
| "Lenalidomide-based treatment is effective across the spectrum of MM disease phases, allowing for the long-term management of myeloma." | 1.36 | Lenalidomide: an update on evidence from clinical trials. ( Dimopoulos, MA; Terpos, E, 2010) |
| "The treatment of elderly patients with multiple myeloma was based for the last forty years on the combination of alkeran plus prednisone." | 1.35 | [Treatment of myeloma in the elderly]. ( Garderet, L; Gorin, NC; Isnard, F, 2008) |
| "Thalidomide is a drug with pleiotropic effects." | 1.35 | Two cases of bacterial meningitis accompanied by thalidomide therapy in patients with multiple myeloma: is thalidomide associated with bacterial meningitis? ( Altintas, A; Ayyildiz, O; Bayan, K; Cil, T; Danis, R; Pasa, S; Tuzun, Y; Urakci, Z; Ustun, C, 2009) |
| "The occurrence of multiple myeloma and chronic lymphocytic leukemia in the same patient is very uncommon." | 1.35 | Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide. ( Schiffer, CA; Srinivasan, S, 2009) |
| "Multiple myeloma is still an incurable disease, most commonly occurring in the elderly." | 1.35 | Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma. ( Abe, M; Amou, H; Harada, T; Hashimoto, T; Hiasa, M; Kitazoe, KI; Matsumoto, T; Nakano, A; Oda, A; Ozaki, S; Takeuchi, K, 2009) |
| "Human multiple myeloma (MM) cell lines U266, NCI-H929, RPMI 8226, LP-1 and CZ-1 were treated with TH or TH pre-incubated with human liver microsome." | 1.35 | [Effect of cytochrome CYP2C19 on the anti-myeloma activity of thalidomide in vitro]. ( Hou, J; Huang, HM; Jiang, H; Li, YH; Zhu, R, 2008) |
| "The outcome of patients with multiple myeloma is dictated primarily by cytogenetic abnormalities and proliferative capacity of plasma cells." | 1.35 | Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. ( Bergsagel, PL; Buadi, F; Dalton, RJ; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kapoor, P; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Mikhael, JR; Rajkumar, SV; Reeder, CB; Roy, V; Russell, SJ; Stewart, AK; Witzig, TE; Zeldenrust, SR, 2009) |
| "Thalidomide was reduced for toxicity in 68 patients (24%) and permanently discontinued in 36 (12%)." | 1.35 | Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects. ( Barbarano, L; Cafro, AM; Caravita, T; Corso, A; Gay, F; Lazzarino, M; Mangiacavalli, S; Morra, E; Palumbo, A; Petrucci, MT; Varettoni, M; Zappasodi, P, 2009) |
| "Thalidomide was administered orally at 100 mg/day for the first week." | 1.35 | A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma. ( Abe, M; Iida, S; Kodama, T; Miyata, A; Murakami, H; Ozaki, S; Sakai, A; Sawamura, M; Shimazaki, C; Wakayama, T, 2009) |
| "In the refractory multiple myelomas, other drug regimens have been successfully applied, including thalidomide treatments." | 1.35 | Thalidomide alters nuclear architecture without ABCB1 gene modulation in drug-resistant myeloma cells. ( Dufer, J; Gorisse, MC; Lavenus, S; Trussardi-Regnier, A, 2009) |
| "A 74-year-old man with multiple myeloma was refractory to melphalan/prednisolone (MP), high-dose dexamethasone and VAD chemotherapy." | 1.35 | Refractory plasmablastic type myeloma with multiple extramedullary plasmacytomas and massive myelomatous effusion: remarkable response with a combination of thalidomide and dexamethasone. ( Kakimoto, T; Mihara, A; Nakazato, T; Sanada, Y; Suzuki, K, 2009) |
| "IgA multiple myeloma is the second most frequent variant of multiple myeloma." | 1.35 | [IgA multiple myeloma with adverse prognostic factors--a case report]. ( Kumiega, B; Skotnicki, AB; Wolska-Smoleń, T, 2009) |
| "Thalidomide is an antiangiogenic drug used in cancer therapy." | 1.35 | Arterial thrombosis and thalidomide. ( Cakir, O; Eren, MN; Goz, M, 2008) |
| "Seventy-four multiple myeloma patients (MM pts) uniformly treated, were retrospectively studied." | 1.35 | Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy. ( Barbarano, L; Corso, A; Fava, S; Lazzarino, M; Mangiacavalli, S; Mazzone, A; Montalbetti, L; Morra, E; Varettoni, M; Zappasodi, P, 2008) |
| "Many agents are active in multiple myeloma, but the majority of patients relapse." | 1.35 | Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. ( Ambinder, RF; Barber, JP; Borrello, I; Brennan, S; Huff, CA; Jones, RJ; Lin, L; Matsui, W; McNiece, I; Peacock, C; Smith, BD; Wang, Q; Watkins, DN, 2008) |
| "Thalidomide was approved for the treatment of relapsed or refractory multiple myeloma (MM) as an orphan drug in Japan." | 1.35 | A new method for determination of both thalidomide enantiomers using HPLC systems. ( Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Sakurada, K; Sembongi, K; Tanaka, M, 2008) |
| "Nearly all patients with multiple myeloma (MM) relapse or become refractory to front-line therapy." | 1.34 | Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma. ( Avonto, I; Boccadoro, M; Bringhen, S; Corvatta, L; Falco, P; Leoni, P; Marconi, M; Offidani, M; Palumbo, A; Piersantelli, MN; Polloni, C, 2007) |
| "Thalidomide has been used as a salvage regimen at the study institution since 1999." | 1.34 | Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. ( Ambrosini, MT; Avonto, I; Boccadoro, M; Bringhen, S; Bruno, B; Caravita, T; Cavallo, F; Falco, P; Gay, F; Palumbo, A, 2007) |
| "Thalidomide has become an important agent in the treatment of myeloma." | 1.34 | Thalidomide induced impotence in male hematology patients: a common but ignored complication? ( Murphy, PT; O'Donnell, JR, 2007) |
| "Angiogenesis governs the progression of multiple myeloma (MM)." | 1.33 | Circulating endothelial progenitor cells in multiple myeloma: implications and significance. ( Akman, HO; Batuman, OA; Berenson, JR; Braunstein, M; Chen, L; Dai, K; Hussain, MM; Klueppelberg, U; Maroney, J; Norin, AJ; Ozçelik, T; Smith, EL; Vakil, V; Zhang, H, 2005) |
| "Thalidomide has been associated with venous thrombotic events, as reported in the post-marketing surveillance reports by Celgene Corporation; as well as case reports in the literature." | 1.33 | Arterial thrombosis in four patients treated with thalidomide. ( Brown, K; Chanan-Khan, A; Hahn, T; McCarthy, PL; Paplham, P; Roy, H; Scarpace, SL; van Besien, K, 2005) |
| "Thalidomide is a rediscovered old drug with anti-angiogenic, immunomodulatory and anti-inflammatory properties." | 1.33 | Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma. ( Cem Ar, M; Hatemi, G; Salihoglu, A; Soysal, T; Ulku, B; Yazici, H, 2005) |
| "Treatment regimens for multiple myeloma are evolving because of advances in both pharmacotherapy and transplantation strategies." | 1.33 | Treatment options for older myeloma patients. From the Multiple Myeloma Research Foundation. ( Anderson, KC; Palumbo, A, 2005) |
| "These cases of unconventional disease recurrence are likely to be seen due to sub-clinical seeding of tumour cells suggestive of the presence of an extramedullary (EM) clone of plasma cells with a high degree of chemoresistance." | 1.33 | Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. ( Apperley, JF; Basu, S; Milne, AE; Rahemtulla, A; Rezvani, K; Rose, PE; Samson, D; Scott, GL; Terpos, E, 2005) |
| "Survival of patients with multiple myeloma (MM) showed no improvement between the 1960s and 1990s." | 1.33 | Do new therapeutic approaches (autotransplants, thalidomide, dexamethasone) improve the survival of patients with multiple myeloma followed in a rheumatology department? ( Arnaud, C; Attal, M; Cantagrel, A; Constantin, A; El Mahou, S; Jamard, B; Laroche, M; Mazières, B, 2006) |
| "Pretreatment with lenalidomide sensitized MM cells to SGN-40-induced cell death." | 1.33 | Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. ( Anderson, KC; Bae, J; Breitkreutz, I; Catley, L; Chauhan, D; Coffey, R; Grewal, IS; Hideshima, T; Li, XF; Munshi, NC; Podar, K; Richardson, P; Schlossman, R; Song, W; Tai, YT; Treon, SP, 2005) |
| "As thalidomide has become an accepted component in therapeutic strategies for multiple myeloma, careful attention must be paid to the prevention of thrombosis." | 1.33 | [Deep vein thrombosis and pulmonary embolism in a patient with multiple myeloma treated with thalidomide and dexamethasone]. ( Handa, H; Irisawa, H; Karasawa, M; Matsushima, T; Miyazawa, Y; Murakami, H; Nojima, Y; Saitoh, T; Tsukamoto, N; Uchiumi, H, 2006) |
| "Serous effusions in multiple myeloma are uncommon but a myelomatous pleural effusion occurring in these patients is extremely rare." | 1.33 | Myelomatous pleural effusion. ( Advani, SH; Ghosh, S; Gopal, R, 2006) |
| "(2) Thalidomide has been granted temporary authorization in France for patients with multiple myeloma who have no other therapeutic option." | 1.32 | Thalidomide: new indication. A last resort in myeloma. ( , 2003) |
| "Thalidomide, an antiemetic administered in 60th of the 20th century to pregnant women, has become notorious for a range of adverse effects which led to its taking off market." | 1.32 | [Desirable and undesirable effects of thalidomide in patients with multiple myeloma]. ( Foldyna, D; Hájek, R; Kamelander, J; Krejcí, M, 2003) |
| "Thalidomide appears to be a safe drug in the post-transplant setting, perhaps adding to the response achieved post-transplant without major toxicity." | 1.32 | Thalidomide effects in the post-transplantation setting in patients with multiple myeloma. ( Byrnes, JJ; Fernandez, HF; Goodman, M; Santos, ES, 2004) |
| "Thalidomide has antiangiogenic and immunomodulatory effects, mediated by several cytokines such as vascular endothelial growth factor (VEGF), fibroblastic growth factor (FGF-2), hepatocyte growth factor (HGF), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha)." | 1.32 | Response to thalidomide in multiple myeloma: impact of angiogenic factors. ( Arenillas, L; Aymerich, M; Bladé, J; Cibeira, MT; Cid, MC; Esteve, J; Filella, X; Montserrat, E; Rosiñol, L; Rozman, M; Segarra, M, 2004) |
| "Thalidomide was used in 73 patients with refractory myeloma in 15 of 45 institutes participating in the Japan Myeloma Study Group." | 1.32 | [Thalidomide treatment of patients with refractory myeloma in the institutes participating in the Japan Myeloma Study Group]. ( Handa, H; Hata, H; Imai, K; Ishii, A; Kanakura, Y; Kosaka, M; Murakami, H; Sawamura, M; Shimazaki, C; Suzuki, K; Takagi, T; Takatsuki, K; Taniwaki, M; Togawa, A; Wakayama, T, 2004) |
| "Thalidomide has a variety of biological effects that vary considerably according to the species tested." | 1.32 | Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients. ( Baguley, BC; Browett, P; Ching, LM; Chung, F; Kestell, P; Lu, J; Palmer, BD; Tingle, M, 2004) |
| "She was diagnosed as having multiple myeloma and transferred to our department." | 1.32 | [Multiple myeloma of the IgD-lambda type invading CNS]. ( Aikawa, S; Hatta, Y; Horie, T; Ito, T; Kanbe, E; Kitamura, K; Kura, Y; Oka, H; Saiki, M; Sawada, U; Takeuchi, J; Yamazaki, T, 2004) |
| "Thalidomide-dexamethasone was given within 15 months after intensive therapy provided myeloma protein production had been reduced by >75% to a constant level for at least 4 months." | 1.31 | Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. ( Alexanian, R; Delasalle, K; Giralt, S; Weber, D, 2002) |
| " We conclude that severe lung toxicity should be included among the potential adverse effects of thalidomide." | 1.31 | [Lung toxicity due to thalidomide]. ( Bertomeu González, V; Carrión Valero, F, 2002) |
| "Thalidomide could enhance the inhibition of Mabthera on colony formation of MM patients' myeloma cells, which is related to that thalidomide enhances CD20 antigen expression of myeloma cells." | 1.31 | [Combination of thalidomide and rituximab in suppressing myeloma cells in vitro]. ( Li, J; Luo, SK; Xiong, WJ; Zhou, ZH, 2002) |
| "Thalidomide was administered at relatively high doses (escalated up to 700 mg daily and continued for 4 months)." | 1.31 | Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent. ( Anagnostopoulos, N; Dimopoulos, MA; Zomas, A, 2000) |
| "Multiple myeloma is a B-cell malignancy characterized by proliferation of neoplastic plasma cells." | 1.31 | A case of aggressive multiple myeloma with cleaved, multilobated, and monocytoid nuclei, and no serum monoclonal gammopathy. ( Butch, AW; Flick, JT; Pappas, AA; Yeh, YA, 2000) |
| "Thalidomide has recently shown antitumor activity in patients with refractory myeloma." | 1.31 | Thalidomide in refractory and relapsing multiple myeloma. ( Bladé, J; Esteve, J; Montoto, S; Montserrat, E; Perales, M; Rosiñol, L; Tuset, M, 2001) |
| "We describe a patient with multiple myeloma who presented with a morbilliform rash induced by thalidomide." | 1.31 | Thalidomide-induced morbilliform rash: diagnosis and continuation of therapy, premedicated with methylprednisolone. ( Lambert, J; Meuleman, L; Nijsten, T; Schroyens, W, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.04) | 18.7374 |
| 1990's | 5 (0.18) | 18.2507 |
| 2000's | 918 (33.64) | 29.6817 |
| 2010's | 1560 (57.16) | 24.3611 |
| 2020's | 245 (8.98) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Z | 1 |
| Liu, X | 3 |
| Zhao, L | 1 |
| Zhou, Y | 7 |
| Shi, J | 4 |
| Chen, W | 8 |
| Li, J | 16 |
| Chim, CS | 8 |
| Kumar, S | 55 |
| Wong, VKC | 1 |
| Ngai, C | 1 |
| Kwong, YL | 4 |
| Byun, JM | 1 |
| Kim, SA | 1 |
| Koh, Y | 7 |
| Shin, DY | 2 |
| Kwon, JH | 2 |
| Kim, JS | 10 |
| Kim, K | 25 |
| Min, CK | 26 |
| Eom, HS | 12 |
| Lee, JJ | 25 |
| Bang, SM | 6 |
| Yoon, SS | 15 |
| Richardson, PG | 93 |
| Schjesvold, F | 9 |
| Weisel, K | 25 |
| Moreau, P | 99 |
| Anderson, LD | 3 |
| White, D | 13 |
| Rodriguez-Otero, P | 6 |
| Sonneveld, P | 79 |
| Engelhardt, M | 16 |
| Jenner, M | 7 |
| Corso, A | 19 |
| Dürig, J | 3 |
| Pavic, M | 3 |
| Salomo, M | 5 |
| Beksac, M | 22 |
| Oriol, A | 38 |
| Lindsay, J | 6 |
| Liberati, AM | 21 |
| Galli, M | 14 |
| Robak, P | 3 |
| Larocca, A | 27 |
| Yagci, M | 2 |
| Vural, F | 4 |
| Kanate, AS | 2 |
| Jiang, R | 1 |
| Grote, L | 2 |
| Peluso, T | 5 |
| Dimopoulos, M | 18 |
| Gao, T | 1 |
| Shen, Q | 2 |
| Luo, Z | 1 |
| Feng, P | 1 |
| Miao, J | 1 |
| Zheng, L | 1 |
| Chen, D | 1 |
| Xiang, J | 1 |
| Harrison, SJ | 10 |
| Bringhen, S | 55 |
| Yong, K | 16 |
| Campana, F | 15 |
| Le-Guennec, S | 6 |
| Macé, S | 8 |
| Dimopoulos, MA | 111 |
| Hulin, C | 37 |
| Perrot, A | 9 |
| Arnulf, B | 13 |
| Belhadj, K | 9 |
| Benboubker, L | 23 |
| Béné, MC | 2 |
| Zweegman, S | 28 |
| Caillon, H | 3 |
| Caillot, D | 16 |
| Corre, J | 4 |
| Delforge, M | 29 |
| Dejoie, T | 4 |
| Doyen, C | 10 |
| Facon, T | 73 |
| Sonntag, C | 2 |
| Fontan, J | 6 |
| Mohty, M | 19 |
| Jie, KS | 6 |
| Karlin, L | 14 |
| Kuhnowski, F | 4 |
| Lambert, J | 4 |
| Leleu, X | 44 |
| Macro, M | 12 |
| Orsini-Piocelle, F | 4 |
| Roussel, M | 20 |
| Stoppa, AM | 21 |
| van de Donk, NWCJ | 8 |
| Wuillème, S | 3 |
| Broijl, A | 8 |
| Touzeau, C | 13 |
| Tiab, M | 12 |
| Marolleau, JP | 2 |
| Meuleman, N | 6 |
| Vekemans, MC | 3 |
| Westerman, M | 5 |
| Klein, SK | 6 |
| Levin, MD | 9 |
| Offner, F | 4 |
| Escoffre-Barbe, M | 8 |
| Eveillard, JR | 3 |
| Garidi, R | 2 |
| Ahmadi, T | 6 |
| Krevvata, M | 2 |
| Zhang, K | 1 |
| de Boer, C | 5 |
| Vara, S | 1 |
| Kampfenkel, T | 7 |
| Vanquickelberghe, V | 3 |
| Vermeulen, J | 4 |
| Avet-Loiseau, H | 24 |
| Gasparetto, C | 8 |
| Bowles, KM | 3 |
| Abdallah, AO | 4 |
| Morris, L | 1 |
| Mander, G | 1 |
| Coppola, S | 1 |
| Wang, J | 23 |
| Ross, JA | 1 |
| Bueno, OF | 1 |
| Arriola, E | 1 |
| Mateos, MV | 53 |
| Voorhees, PM | 6 |
| Suman, VJ | 2 |
| Tuchman, SA | 2 |
| Laubach, JP | 20 |
| Hassoun, H | 11 |
| Efebera, YA | 5 |
| Mulkey, F | 1 |
| Bova-Solem, M | 1 |
| Santo, K | 1 |
| Carlisle, D | 1 |
| McCarthy, PL | 18 |
| Del Giudice, ML | 1 |
| Gozzetti, A | 11 |
| Antonioli, E | 3 |
| Orciuolo, E | 3 |
| Ghio, F | 2 |
| Ciofini, S | 1 |
| Candi, V | 1 |
| Fontanelli, G | 1 |
| Attucci, I | 1 |
| Formica, G | 1 |
| Bocchia, M | 4 |
| Galimberti, S | 4 |
| Petrini, M | 4 |
| Buda, G | 4 |
| Kalff, A | 4 |
| Khong, T | 3 |
| Ramachandran, M | 1 |
| Ho, PJ | 8 |
| Mollee, P | 4 |
| D'Rozario, J | 1 |
| Taylor, K | 2 |
| Estell, J | 1 |
| Norton, S | 1 |
| Kemp, R | 1 |
| Mitchell, AJ | 1 |
| Reynolds, J | 4 |
| Kennedy, N | 4 |
| Quach, H | 12 |
| Spencer, A | 24 |
| Fang, YH | 1 |
| Wei, KC | 1 |
| Yu, MS | 1 |
| Kakimoto, Y | 1 |
| Hoshino, M | 1 |
| Hashimoto, M | 1 |
| Hiraizumi, M | 1 |
| Shimizu, K | 8 |
| Chou, T | 9 |
| Goodman, HJ | 1 |
| Spicka, I | 24 |
| Alegre, A | 16 |
| Prince, M | 1 |
| Finn, G | 1 |
| Muccio, S | 1 |
| Tavernier, A | 1 |
| Rouchon, MC | 1 |
| Thai, HT | 2 |
| Gaudel, N | 1 |
| Cerou, M | 1 |
| Ayral, G | 1 |
| Fau, JB | 3 |
| Sebastien, B | 2 |
| van de Velde, H | 18 |
| Semiond, D | 5 |
| Veyrat-Follet, C | 2 |
| Stroh, J | 1 |
| Seckinger, A | 4 |
| Heider, M | 2 |
| Rudelius, M | 2 |
| Eichner, R | 2 |
| Schick, M | 1 |
| Slawska, J | 2 |
| Emde-Rajaratnam, M | 1 |
| Salwender, H | 6 |
| Bertsch, U | 7 |
| Goldschmidt, H | 60 |
| Scheid, C | 8 |
| Keller, U | 2 |
| Hose, D | 14 |
| Bassermann, F | 4 |
| Yashar, D | 1 |
| Spektor, TM | 7 |
| Martinez, D | 1 |
| Ghermezi, M | 1 |
| Swift, RA | 5 |
| Eades, B | 4 |
| Schwartz, G | 1 |
| Eshaghian, S | 6 |
| Lim, S | 1 |
| Vescio, R | 9 |
| Berenson, JR | 16 |
| Ide, T | 1 |
| Osawa, M | 1 |
| Sanghavi, K | 1 |
| Vezina, HE | 1 |
| Mori, T | 1 |
| Verma, R | 4 |
| Nakamoto-Matsubara, R | 1 |
| Siu, KT | 1 |
| Panaroni, C | 1 |
| Fulzele, KS | 1 |
| Mukaihara, K | 1 |
| Onyewadume, C | 1 |
| Maebius, A | 1 |
| Kato, H | 2 |
| Wong, LP | 1 |
| Sadreyev, RI | 1 |
| Scadden, DT | 1 |
| Raje, NS | 6 |
| Wu, W | 5 |
| Nelson, GM | 1 |
| Koch, R | 1 |
| Donovan, KA | 1 |
| Nowak, RP | 1 |
| Heavican-Foral, TB | 1 |
| Nirmal, AJ | 1 |
| Liu, H | 4 |
| Yang, L | 5 |
| Duffy, J | 1 |
| Powers, F | 1 |
| Stevenson, KE | 1 |
| Jones, MK | 1 |
| Ng, SY | 1 |
| Wu, G | 2 |
| Jain, S | 1 |
| Xu, R | 1 |
| Amaka, S | 1 |
| Trevisani, C | 1 |
| Donaldson, NL | 1 |
| Hagner, PR | 2 |
| de Leval, L | 1 |
| Gaulard, P | 1 |
| Iqbal, J | 1 |
| Thakurta, A | 9 |
| Fischer, ES | 1 |
| Adelman, K | 1 |
| Weinstock, DM | 1 |
| Baljevic, M | 1 |
| Sborov, DW | 4 |
| Lim, MY | 1 |
| Hillengass, J | 16 |
| Martin, T | 7 |
| Castillo, JJ | 1 |
| Streiff, MB | 1 |
| Kumar, SK | 22 |
| Callander, NS | 10 |
| Vílchez-Sánchez, F | 1 |
| Busto Leis, JM | 1 |
| Sendagorta, E | 1 |
| Ramírez, E | 1 |
| Fiandor, A | 1 |
| Bellón, T | 1 |
| De Soto Álvarez, T | 1 |
| Sánchez Ocando, H | 1 |
| Heredia Revuelto, R | 1 |
| Cabañas, R | 1 |
| Schjesvold, FH | 3 |
| Delimpasi, S | 8 |
| Coriu, D | 1 |
| Legiec, W | 5 |
| Pour, L | 17 |
| Masszi, T | 12 |
| Doronin, V | 2 |
| Minarik, J | 13 |
| Salogub, G | 1 |
| Alekseeva, Y | 1 |
| Lazzaro, A | 4 |
| Maisnar, V | 12 |
| Mikala, G | 3 |
| Rosiñol, L | 29 |
| Symeonidis, A | 8 |
| Moody, V | 1 |
| Thuresson, M | 1 |
| Byrne, C | 1 |
| Harmenberg, J | 1 |
| Bakker, NA | 1 |
| Hájek, R | 46 |
| Vusqa, UT | 1 |
| Chahine, Z | 1 |
| Asawa, P | 1 |
| Sadashiv, S | 1 |
| Samhouri, Y | 1 |
| Lister, J | 1 |
| Li, Y | 10 |
| Ji, J | 2 |
| Lu, H | 4 |
| Qu, X | 1 |
| Vinogradova, O | 1 |
| Montes, YG | 1 |
| Ramasamy, K | 18 |
| Pompa, A | 6 |
| Lee, C | 5 |
| Mellqvist, UH | 8 |
| Fenk, R | 6 |
| Demarquette, H | 3 |
| Sati, H | 1 |
| Vorog, A | 1 |
| Labotka, R | 1 |
| Du, J | 7 |
| Darif, M | 1 |
| Malta, JS | 3 |
| Drummond, PLM | 3 |
| Silveira, LP | 3 |
| Costa, NL | 2 |
| Santos, RMMD | 3 |
| Machado, CJ | 1 |
| Reis, AMM | 3 |
| de Pádua, CAM | 1 |
| Terpos, E | 42 |
| Boccadoro, M | 77 |
| Katodritou, E | 10 |
| Bila, J | 3 |
| Einsele, H | 28 |
| Orfanidis, I | 2 |
| Gries, KS | 2 |
| Fastenau, J | 2 |
| Liu, K | 3 |
| He, J | 5 |
| Qiu, Y | 2 |
| Amin, H | 2 |
| Carson, R | 2 |
| Bahlis, NJ | 18 |
| Siegel, DS | 19 |
| Schiller, GJ | 3 |
| Samaras, C | 3 |
| Sebag, M | 5 |
| Berdeja, J | 3 |
| Ganguly, S | 4 |
| Matous, J | 5 |
| Song, K | 13 |
| Seet, CS | 3 |
| Acosta-Rivera, M | 2 |
| Bar, M | 2 |
| Quick, D | 2 |
| Anz, B | 2 |
| Fonseca, G | 2 |
| Chung, W | 5 |
| Lee, K | 8 |
| Mouro, J | 3 |
| Agarwal, A | 5 |
| Reece, D | 18 |
| Djebbari, F | 4 |
| Poynton, M | 2 |
| Sangha, G | 2 |
| Anderson, L | 2 |
| Maddams, R | 2 |
| Eyre, TA | 3 |
| Vallance, G | 3 |
| Basu, S | 7 |
| San-Miguel, J | 22 |
| Huang, JS | 2 |
| Cavo, M | 75 |
| Prince, HM | 26 |
| Malinge, L | 2 |
| Dubin, F | 4 |
| Anderson, KC | 113 |
| Jurczyszyn, A | 12 |
| Sunami, K | 10 |
| Frenzel, L | 3 |
| Guillonneau, S | 2 |
| Lin, PL | 2 |
| Bensfia, S | 2 |
| McCurdy, A | 3 |
| Venner, CP | 3 |
| Masih-Khan, E | 8 |
| Louzada, M | 2 |
| LeBlanc, R | 9 |
| Jimenez-Zepeda, VH | 6 |
| Kotb, R | 2 |
| Kardjadj, M | 1 |
| Mian, H | 1 |
| Stakiw, J | 2 |
| Aslam, M | 2 |
| Reiman, A | 2 |
| Gul, E | 2 |
| Bazarbachi, AH | 1 |
| Al Hamed, R | 1 |
| Malard, F | 5 |
| Bazarbachi, A | 2 |
| Harousseau, JL | 42 |
| Rachedi, F | 1 |
| Koiwai, K | 2 |
| Gaudel-Dedieu, N | 1 |
| Brillac, C | 2 |
| Nguyen, L | 2 |
| Wang, JN | 1 |
| Liu, T | 4 |
| Zhao, AL | 1 |
| Pan, BJ | 1 |
| Sun, J | 1 |
| Zhou, DB | 4 |
| Cao, XX | 1 |
| Duan, MH | 1 |
| Matsue, K | 6 |
| Matsumoto, M | 10 |
| Kuroda, J | 11 |
| Sugiura, I | 3 |
| Iwasaki, H | 4 |
| Kuwayama, S | 1 |
| Nishio, M | 1 |
| Iida, S | 18 |
| Togano, T | 3 |
| Andoh, S | 1 |
| Komuro, M | 1 |
| Mitsui, Y | 1 |
| Itoi, S | 1 |
| Hirai, R | 2 |
| Nakamura, M | 2 |
| Tanimura, A | 2 |
| Sekine, R | 3 |
| Takeshita, M | 2 |
| Miwa, A | 3 |
| Hagiwara, S | 4 |
| Sharma, A | 3 |
| Malik, PS | 1 |
| Gogia, A | 1 |
| Pathak, N | 1 |
| Sahoo, RK | 1 |
| Gupta, R | 2 |
| Prasad, CP | 1 |
| Kumar, L | 2 |
| Buonomo, M | 1 |
| Kabbur, G | 1 |
| El Jurdi, N | 1 |
| Giubellino, A | 1 |
| Schultz, B | 1 |
| Yamamoto, C | 1 |
| Minakata, D | 1 |
| Koyama, S | 1 |
| Sekiguchi, K | 1 |
| Fukui, Y | 1 |
| Murahashi, R | 1 |
| Nakashima, H | 1 |
| Matsuoka, S | 1 |
| Ikeda, T | 4 |
| Kawaguchi, SI | 1 |
| Toda, Y | 1 |
| Ito, S | 2 |
| Nagayama, T | 1 |
| Umino, K | 1 |
| Nakano, H | 1 |
| Morita, K | 3 |
| Yamasaki, R | 1 |
| Ashizawa, M | 1 |
| Ueda, M | 1 |
| Hatano, K | 1 |
| Sato, K | 4 |
| Ohmine, K | 1 |
| Fujiwara, SI | 1 |
| Kanda, Y | 3 |
| Drula, R | 1 |
| Iluta, S | 1 |
| Gulei, D | 1 |
| Iuga, C | 1 |
| Dima, D | 1 |
| Ghiaur, G | 1 |
| Buzoianu, AD | 1 |
| Ciechanover, A | 1 |
| Tomuleasa, C | 1 |
| Kawamura, S | 1 |
| Tamaki, M | 1 |
| Nakamura, Y | 2 |
| Kawamura, M | 1 |
| Takeshita, J | 1 |
| Yoshino, N | 1 |
| Misaki, Y | 1 |
| Yoshimura, K | 1 |
| Matsumi, S | 1 |
| Gomyo, A | 1 |
| Okada, Y | 1 |
| Akahoshi, Y | 1 |
| Kusuda, M | 1 |
| Kameda, K | 1 |
| Tanihara, A | 1 |
| Kimura, SI | 1 |
| Nakasone, H | 1 |
| Kako, S | 1 |
| Bruzzese, A | 1 |
| Derudas, D | 4 |
| Martino, EA | 2 |
| Rocco, S | 2 |
| Conticello, C | 10 |
| Califano, C | 3 |
| Giuliani, N | 9 |
| Mangiacavalli, S | 9 |
| Farina, G | 1 |
| Lombardo, A | 2 |
| Brunori, M | 11 |
| Rossi, E | 1 |
| Ria, R | 16 |
| Zambello, R | 17 |
| Di Renzo, N | 5 |
| Mele, G | 6 |
| Marcacci, G | 1 |
| Pietrantuono, G | 5 |
| Palumbo, G | 4 |
| Cascavilla, N | 8 |
| Cerchione, C | 1 |
| Belotti, A | 2 |
| Criscuolo, C | 1 |
| Uccello, G | 2 |
| Curci, P | 3 |
| Vigna, E | 3 |
| Mendicino, F | 1 |
| Iaccino, E | 1 |
| Mimmi, S | 1 |
| Botta, C | 1 |
| Vincelli, D | 2 |
| Sgherza, N | 1 |
| Bonalumi, A | 1 |
| Cupelli, L | 2 |
| Stocchi, R | 1 |
| Martino, M | 3 |
| Ballanti, S | 5 |
| Gangemi, D | 1 |
| Gagliardi, A | 1 |
| Gamberi, B | 3 |
| Tripepi, G | 2 |
| Frigeri, F | 1 |
| Consoli, U | 2 |
| Zamagni, E | 37 |
| Patriarca, F | 32 |
| De Stefano, V | 7 |
| Di Raimondo, F | 22 |
| Palmieri, S | 3 |
| Petrucci, MT | 41 |
| Offidani, M | 45 |
| Musto, P | 41 |
| Neri, A | 5 |
| Morabito, F | 17 |
| Gentile, M | 7 |
| Patrick, H | 1 |
| Rashid, S | 1 |
| Huang, SY | 11 |
| Wang, MC | 3 |
| Yeh, SP | 2 |
| Uchiyama, M | 1 |
| Iyama, S | 2 |
| Shimazaki, C | 15 |
| Lee, JH | 26 |
| Kaneko, H | 4 |
| Lin, TL | 1 |
| Tada, K | 1 |
| Suzuki, K | 21 |
| Rampotas, A | 1 |
| Panitsas, F | 1 |
| Basker, N | 1 |
| Salhan, B | 1 |
| Karim, F | 1 |
| Firas, AK | 1 |
| Gudger, A | 1 |
| Ngu, L | 1 |
| Lam, HPJ | 1 |
| Morgan, L | 1 |
| Young, J | 1 |
| Walker, M | 1 |
| Tsagkaraki, I | 1 |
| Chauhan, SR | 1 |
| Soutar, R | 2 |
| Triantafillou, M | 1 |
| Prideaux, S | 1 |
| Obeidalla, A | 1 |
| Bygrave, C | 1 |
| Ogiya, D | 1 |
| Murayama, N | 1 |
| Kamiya, Y | 1 |
| Saito, R | 1 |
| Shiraiwa, S | 1 |
| Suzuki, R | 2 |
| Machida, S | 1 |
| Tazume, K | 1 |
| Ando, K | 4 |
| Yamazaki, H | 1 |
| Bisht, K | 1 |
| Inchauspé, M | 2 |
| Casca, F | 1 |
| Naser, AY | 1 |
| Ofori-Asenso, R | 1 |
| Awawdeh, SA | 1 |
| Qadus, S | 1 |
| Alwafi, H | 1 |
| Liew, D | 1 |
| Costa, BA | 1 |
| Mouhieddine, TH | 1 |
| Richter, J | 6 |
| Hewamana, S | 1 |
| Gunasena, P | 1 |
| Jayasinghe, C | 1 |
| Skandarajah, T | 1 |
| Harischandra, M | 1 |
| Abeyaratne, S | 1 |
| Ekanayake, L | 1 |
| Somasundaram, G | 1 |
| Somiah, S | 1 |
| Srinivasan, V | 1 |
| Arseculeratne, G | 1 |
| Perera, N | 1 |
| Fernando, J | 1 |
| Faiz, M | 1 |
| Munasinghe, N | 1 |
| Mowlana, A | 1 |
| Deshapriya, S | 1 |
| Mawathakubura, S | 1 |
| Wickramarathna, C | 1 |
| Wijewickrama, A | 1 |
| Jayawardena, P | 1 |
| Perera, E | 1 |
| Peiris, N | 1 |
| Paranawithane, S | 1 |
| Perera, C | 1 |
| Kariyawasam, C | 1 |
| Munasinghe, S | 1 |
| De Silva, C | 1 |
| Wadanamby, R | 1 |
| Galagoda, G | 1 |
| Lin, TT | 1 |
| Wijesiriwardena, B | 1 |
| Balawardena, J | 1 |
| Fu, WJ | 6 |
| Wang, YF | 5 |
| Zhao, HG | 1 |
| Niu, T | 2 |
| Fang, BJ | 1 |
| Liao, AJ | 2 |
| Bai, H | 5 |
| Lu, J | 14 |
| Berringer, H | 1 |
| Heeg, B | 2 |
| Ruan, H | 1 |
| Dwarakanathan, HR | 1 |
| Johnston, S | 1 |
| Mendes, J | 1 |
| Lam, A | 2 |
| Bathija, S | 1 |
| Mackay, E | 1 |
| McVinnie, K | 1 |
| Innes, A | 1 |
| Nadal-Melsio, E | 1 |
| Atta, M | 1 |
| Deplano, S | 1 |
| Afari, J | 1 |
| Turner, C | 1 |
| Cohen, A | 4 |
| Bessudo, A | 2 |
| Jhangiani, H | 1 |
| Gabrail, N | 2 |
| Kubba, S | 1 |
| Neidhart, JD | 1 |
| Eades, BM | 1 |
| Kim, C | 2 |
| Kim, S | 2 |
| Gómez-Almaguer, D | 3 |
| de Moraes Hungria, VT | 2 |
| Chen, PH | 1 |
| Tung, HH | 1 |
| Lin, CH | 1 |
| Huang, KP | 1 |
| Ni, YL | 1 |
| Lin, CY | 1 |
| Kahraman, DS | 1 |
| Diniz, G | 1 |
| Ceylan, C | 1 |
| Guler, D | 1 |
| Sayhan, S | 1 |
| Cekdemir, D | 1 |
| Zhi, Y | 1 |
| Bao, S | 1 |
| Mao, J | 2 |
| Chai, G | 1 |
| Zhu, J | 3 |
| Liu, C | 1 |
| Chen, X | 5 |
| Owji, S | 1 |
| Dubin, DP | 1 |
| Yassky, D | 1 |
| Han, J | 1 |
| Tan, K | 1 |
| Jagannath, S | 36 |
| Parekh, S | 5 |
| Gulati, N | 1 |
| Potre, C | 1 |
| Borsi, E | 3 |
| Potre, O | 1 |
| Samfireag, M | 1 |
| Costachescu, D | 1 |
| Cerbu, B | 1 |
| Bratosin, F | 1 |
| Secosan, C | 1 |
| Negrean, RA | 1 |
| Ghandili, S | 3 |
| Alihodzic, D | 3 |
| Wiessner, C | 3 |
| Bokemeyer, C | 3 |
| Leypoldt, LB | 3 |
| Liao, KY | 3 |
| Liu, Y | 13 |
| Xiong, H | 3 |
| Chen, XM | 3 |
| Zhang, XW | 3 |
| Huang, CL | 3 |
| Iqbal, G | 3 |
| Brouwer, R | 4 |
| Stalker, V | 3 |
| Akhtar, S | 4 |
| Varghese, S | 3 |
| Schey, S | 16 |
| Drayson, M | 4 |
| Dunn, J | 3 |
| Krasavin, M | 2 |
| Adamchik, M | 2 |
| Bubyrev, A | 2 |
| Heim, C | 2 |
| Maiwald, S | 2 |
| Zhukovsky, D | 2 |
| Zhmurov, P | 2 |
| Bunev, A | 2 |
| Hartmann, MD | 2 |
| Seval, GC | 1 |
| Koyun, D | 1 |
| Topcuoglu, P | 1 |
| Yuksel, MK | 1 |
| Gurman, G | 1 |
| Ilhan, O | 1 |
| Zander, T | 3 |
| Pabst, T | 4 |
| Schär, S | 1 |
| Aebi, S | 2 |
| Mey, U | 2 |
| Novak, U | 2 |
| Lerch, E | 3 |
| Rhyner Agocs, G | 1 |
| Goede, J | 1 |
| Maniecka, Z | 1 |
| Hayoz, S | 1 |
| Rüfer, A | 1 |
| Renner, C | 6 |
| Driessen, C | 2 |
| Morè, S | 1 |
| Corvatta, L | 21 |
| Manieri, MV | 1 |
| Olivieri, A | 6 |
| Costa, LJ | 6 |
| Giri, S | 3 |
| Bal, S | 2 |
| Ravi, G | 1 |
| Godby, KN | 2 |
| Maximiliano, CL | 1 |
| Jaime, GC | 1 |
| Armando, VL | 1 |
| Vega, IL | 1 |
| Victoria, HG | 1 |
| Erika, MH | 1 |
| Brioli, A | 17 |
| Gengenbach, L | 1 |
| Mancuso, K | 7 |
| Binder, M | 1 |
| Ernst, T | 1 |
| Heidel, FH | 1 |
| Stauch, T | 1 |
| Hilgendorf, I | 1 |
| Hochhaus, A | 1 |
| von Lilienfeld-Toal, M | 7 |
| Meermeier, EW | 1 |
| Bergsagel, PL | 18 |
| Mioso, G | 1 |
| Gnesotto, L | 1 |
| Russo, I | 2 |
| Piaserico, S | 1 |
| Alaibac, M | 2 |
| Mohyuddin, GR | 3 |
| Kapur, R | 1 |
| Costa, L | 1 |
| He, HY | 1 |
| Li, L | 5 |
| Qiang, WT | 1 |
| Liu, J | 8 |
| Guo, P | 1 |
| Jiang, H | 13 |
| González-Calle, V | 1 |
| Gagelmann, N | 2 |
| Eikema, DJ | 1 |
| Koster, L | 1 |
| Netelenbos, T | 1 |
| McDonald, A | 1 |
| Anagnostopoulos, A | 14 |
| van Gorkom, G | 1 |
| Deconinck, E | 1 |
| Bulabois, CE | 2 |
| Bunjes, D | 2 |
| Arcese, W | 1 |
| Reményi, P | 1 |
| Itälä-Remes, M | 1 |
| Thurner, L | 1 |
| Bolaman, AZ | 1 |
| Nabil, Y | 1 |
| Lund, J | 3 |
| Labussière-Wallet, H | 1 |
| Hayden, PJ | 4 |
| Schönland, S | 2 |
| Yakoub-Agha, I | 13 |
| Mohan, M | 1 |
| Janz, S | 2 |
| Brazauskas, R | 1 |
| Dwinell, MB | 1 |
| Teng, BQ | 1 |
| Yun, G | 1 |
| Dong, J | 1 |
| Pasquini, MC | 7 |
| Giralt, S | 20 |
| Landau, H | 8 |
| Stadtmauer, E | 2 |
| Krishnan, A | 9 |
| D'Souza, A | 3 |
| Costa, IHFD | 1 |
| Menezes de Pádua, CA | 1 |
| Perego, G | 1 |
| Paris, L | 1 |
| Nozza, S | 1 |
| Stefanoni, P | 2 |
| Franzin, M | 1 |
| Slimano, F | 1 |
| Tournamille, JF | 1 |
| Bardin, C | 1 |
| Madelaine, I | 1 |
| Rioufol, C | 1 |
| Kopp, KO | 1 |
| Greer, ME | 1 |
| Glotfelty, EJ | 1 |
| Hsueh, SC | 1 |
| Tweedie, D | 1 |
| Kim, DS | 1 |
| Reale, M | 1 |
| Vargesson, N | 1 |
| Greig, NH | 1 |
| Bakker, LJ | 1 |
| Thielen, FW | 1 |
| Redekop, WK | 2 |
| Groot, CU | 1 |
| Blommestein, HM | 4 |
| Vaxman, I | 2 |
| Buadi, F | 12 |
| Lacy, MQ | 54 |
| Dingli, D | 26 |
| Hayman, S | 8 |
| Kourelis, T | 3 |
| Warsame, R | 3 |
| Hwa, Y | 1 |
| Fonder, A | 1 |
| Hobbs, M | 2 |
| Muchtar, E | 5 |
| Leung, N | 8 |
| Kapoor, P | 13 |
| Go, R | 2 |
| Lin, Y | 4 |
| Gonsalves, W | 2 |
| Siddiqui, M | 1 |
| Kyle, RA | 41 |
| Rajkumar, SV | 104 |
| Gertz, MA | 53 |
| Dispenzieri, A | 52 |
| Uno, S | 1 |
| Midorikawa, S | 3 |
| Inoue, K | 1 |
| Ichikawa, D | 2 |
| Ito, T | 8 |
| Yamaga, M | 1 |
| Katayama, S | 1 |
| Ota, M | 1 |
| Turner, R | 1 |
| Horvath, N | 2 |
| Kerridge, I | 1 |
| Lee, E | 1 |
| Morris, E | 1 |
| Sun, LF | 1 |
| Maples, KT | 1 |
| Hall, KH | 1 |
| Cao, Y | 4 |
| Joseph, NS | 2 |
| Hofmeister, CC | 19 |
| Kaufman, JL | 20 |
| Dhodapkar, M | 4 |
| Nooka, AK | 9 |
| Lonial, S | 50 |
| Harvey, RD | 1 |
| Kowalski, TW | 1 |
| Feira, MF | 1 |
| Lord, VO | 1 |
| Gomes, JDA | 1 |
| Giudicelli, GC | 1 |
| Fraga, LR | 1 |
| Sanseverino, MTV | 1 |
| Recamonde-Mendoza, M | 1 |
| Schuler-Faccini, L | 1 |
| Vianna, FSL | 1 |
| Filanovsky, K | 1 |
| Temper, N | 1 |
| Stanevsky, A | 2 |
| Shvidel, L | 1 |
| Davies, FE | 40 |
| Vogel, P | 1 |
| Dhanasiri, S | 5 |
| Le Nouveau, P | 1 |
| Laubach, J | 11 |
| Reeves, B | 1 |
| Rodriguez, C | 2 |
| Chari, A | 7 |
| Silbermann, R | 1 |
| Nathwani, N | 1 |
| Shah, N | 3 |
| Bumma, N | 1 |
| Holstein, SA | 10 |
| Costello, C | 2 |
| Jakubowiak, A | 7 |
| Wildes, TM | 3 |
| Orlowski, RZ | 25 |
| Shain, KH | 6 |
| Cowan, AJ | 1 |
| Dinner, S | 2 |
| Pei, H | 1 |
| Cortoos, A | 1 |
| Patel, S | 1 |
| Lin, TS | 1 |
| Usmani, SZ | 19 |
| Du, C | 2 |
| Fan, H | 1 |
| Mao, X | 2 |
| Xu, Y | 11 |
| Sui, W | 5 |
| Deng, S | 4 |
| Li, C | 2 |
| Zhao, J | 3 |
| Yi, S | 3 |
| Hao, M | 3 |
| Zou, D | 4 |
| Zhao, Y | 6 |
| Qiu, L | 9 |
| An, G | 7 |
| Xu, H | 5 |
| Chu, XX | 1 |
| Wang, W | 3 |
| Xia, Z | 2 |
| Leng, Y | 2 |
| Fang, B | 2 |
| Liang, Y | 2 |
| Li, W | 3 |
| Fu, C | 2 |
| Ke, X | 7 |
| Weng, J | 1 |
| Liu, L | 9 |
| Zhang, X | 5 |
| Huang, Z | 4 |
| Liu, A | 3 |
| Shi, Q | 2 |
| Gao, Y | 3 |
| Pan, L | 3 |
| Cai, Z | 6 |
| Wang, Z | 4 |
| Wang, Y | 8 |
| Fan, Y | 1 |
| Hou, M | 1 |
| Ma, Y | 2 |
| Hu, J | 2 |
| Zhou, J | 3 |
| Meng, H | 5 |
| Lu, X | 2 |
| Li, F | 6 |
| Ren, H | 1 |
| Huang, B | 1 |
| Shao, Z | 1 |
| Zhou, H | 1 |
| Hu, Y | 6 |
| Yang, S | 6 |
| Zheng, X | 3 |
| Wei, P | 3 |
| Pang, H | 2 |
| Yu, W | 1 |
| Gao, S | 4 |
| Yan, L | 1 |
| Jing, H | 1 |
| Ling, W | 1 |
| Zhang, J | 10 |
| Wang, F | 4 |
| Li, X | 11 |
| Tekinalp, A | 1 |
| Gedük, A | 1 |
| Akdeniz, A | 1 |
| Terzi Demirsoy, E | 1 |
| Gürsoy, V | 1 |
| Aslaner Ak, M | 1 |
| Bağcı, M | 1 |
| Seçilmiş, S | 1 |
| Keklik Karadağ, F | 1 |
| Oruç Uysal, A | 1 |
| Doğan, A | 3 |
| Demircioğlu, S | 1 |
| Erol, HA | 1 |
| Aslan, C | 1 |
| Özkalemkaş, F | 1 |
| Ertop, Ş | 1 |
| Dağlı, M | 1 |
| Dal, MS | 1 |
| Saydam, G | 2 |
| Merter, M | 1 |
| Ural, C | 1 |
| Çeneli, Ö | 1 |
| Atieh, T | 1 |
| Hubben, A | 1 |
| Faiman, B | 6 |
| Valent, J | 3 |
| Samaras, CJ | 1 |
| Khouri, J | 1 |
| Martínez-Baños, DM | 2 |
| Peñafiel, CR | 1 |
| Miguel, CE | 1 |
| Vela-Ojeda, J | 2 |
| Remaggi, G | 2 |
| Duarte, FB | 1 |
| Cao, C | 1 |
| Cugliari, MS | 1 |
| Santos, T | 1 |
| Machnicki, G | 1 |
| Fernandez, M | 1 |
| Grings, M | 1 |
| Ammann, EM | 1 |
| Lin, JH | 1 |
| Chen, YW | 1 |
| Wong, YN | 1 |
| Barreyro, P | 1 |
| Gaudy, A | 1 |
| Hwang, R | 1 |
| Palmisano, M | 3 |
| Chen, N | 4 |
| Xu, L | 5 |
| Chen, ZL | 1 |
| Hu, M | 2 |
| Tao, S | 1 |
| Chen, Y | 12 |
| Su, GH | 1 |
| Belch, A | 17 |
| Chen, WM | 4 |
| Renwick, W | 1 |
| Rose, C | 1 |
| Tempescul, A | 1 |
| Boyle, E | 2 |
| Manier, S | 3 |
| Attal, M | 43 |
| Lorraine Chretien, M | 1 |
| Ludwig, H | 42 |
| Guo, S | 7 |
| Sturniolo, M | 1 |
| Tinel, A | 1 |
| Silvia Monzini, M | 1 |
| Costa, B | 1 |
| Houck, V | 4 |
| Yves Mary, J | 1 |
| Malavasi, F | 1 |
| Lee, HC | 2 |
| Shah, JJ | 10 |
| Feng, L | 3 |
| Morphey, A | 1 |
| Johnson, RJ | 2 |
| Wesson, ET | 1 |
| Wang, ML | 2 |
| Alexanian, R | 12 |
| Thomas, SK | 4 |
| Weber, DM | 14 |
| Nielsen, LK | 1 |
| Stege, C | 1 |
| Lissenberg-Witte, B | 1 |
| van der Holt, B | 18 |
| Bos, G | 1 |
| Visser-Wisselaar, H | 3 |
| Hansson, M | 9 |
| van der Velden, A | 1 |
| Deenik, W | 2 |
| Coenen, J | 1 |
| Hinge, M | 1 |
| Klein, S | 2 |
| Tanis, B | 1 |
| Szatkowski, D | 2 |
| Leys, R | 1 |
| Sinnige, H | 4 |
| Haukås, E | 4 |
| van der Hem, K | 1 |
| Durian, M | 1 |
| Gimsing, P | 16 |
| van de Donk, N | 1 |
| Waage, A | 16 |
| Abildgaard, N | 8 |
| Leotta, S | 1 |
| Pirosa, MC | 1 |
| Markovic, U | 1 |
| Scalise, L | 1 |
| Bulla, A | 1 |
| Sapienza, G | 1 |
| Di Giorgio, MA | 1 |
| Curto Pelle, A | 1 |
| Leotta, V | 1 |
| Milone, G | 5 |
| Cupri, A | 1 |
| Vaddinelli, D | 1 |
| Villari, L | 1 |
| Pönisch, W | 5 |
| Knop, S | 15 |
| Egle, A | 2 |
| Hinke, A | 3 |
| Schreder, M | 8 |
| Lechner, D | 2 |
| Gunsilius, E | 3 |
| Petzer, A | 2 |
| Niederwieser, D | 6 |
| Willenbacher, W | 6 |
| Rumpold, H | 1 |
| Jelinek, T | 2 |
| Krenosz, KJ | 2 |
| Meckl, A | 1 |
| Nolte, S | 1 |
| Melchardt, T | 2 |
| Greil, R | 8 |
| Zojer, N | 13 |
| Zhao, Q | 2 |
| Song, P | 2 |
| Zhou, X | 5 |
| An, Z | 1 |
| Mei, J | 7 |
| Shao, J | 1 |
| Li, H | 3 |
| Wang, X | 9 |
| Guo, X | 1 |
| Zhai, Y | 1 |
| Barrio, S | 2 |
| Munawar, U | 1 |
| Zhu, YX | 8 |
| Giesen, N | 2 |
| Shi, CX | 8 |
| Viá, MD | 1 |
| Sanchez, R | 1 |
| Bruins, L | 2 |
| Demler, T | 1 |
| Müller, N | 1 |
| Haertle, L | 1 |
| Garitano, A | 1 |
| Steinbrunn, T | 2 |
| Danhof, S | 2 |
| Cuenca, I | 1 |
| Barrio-Garcia, C | 1 |
| Braggio, E | 9 |
| Rosenwald, A | 2 |
| Martinez-Lopez, J | 15 |
| Rasche, L | 4 |
| Raab, MS | 15 |
| Stewart, AK | 39 |
| Stühmer, T | 3 |
| Kortüm, KM | 3 |
| Poenisch, W | 3 |
| Panda, T | 1 |
| Das, S | 1 |
| Jena, RK | 2 |
| Das, BP | 1 |
| Rout, SB | 1 |
| Sekine, L | 1 |
| Ziegelmann, PK | 1 |
| Manica, D | 1 |
| Pithan, CDF | 1 |
| Sosnoski, M | 1 |
| Morais, VD | 1 |
| Falcetta, FS | 1 |
| Ribeiro, MR | 1 |
| Salazar, AP | 1 |
| Ribeiro, RA | 1 |
| Mo, CC | 1 |
| Paumgartten, FJR | 1 |
| Song, KW | 10 |
| Agajanian, R | 1 |
| Stockerl-Goldstein, K | 6 |
| Kaya, H | 1 |
| Malek, E | 1 |
| Talamo, G | 7 |
| Pierceall, WE | 4 |
| Zafar, F | 8 |
| Srinivasan, S | 6 |
| Soekojo, CY | 1 |
| Takezako, N | 5 |
| Asaoku, H | 5 |
| Kimura, H | 1 |
| Kosugi, H | 5 |
| Sakamoto, J | 1 |
| Gopalakrishnan, SK | 1 |
| Nagarajan, C | 2 |
| Wei, Y | 1 |
| Moorakonda, R | 1 |
| Lee, SL | 1 |
| Durie, B | 4 |
| Chng, WJ | 9 |
| Wäsch, R | 7 |
| van Beekhuizen, S | 1 |
| Gebregergish, SB | 1 |
| Nair, S | 2 |
| Pisini, M | 1 |
| Slavcev, M | 1 |
| Thom, H | 1 |
| Buchanan, V | 1 |
| Robinson, S | 2 |
| D'Souza, VK | 1 |
| Bjorklund, CC | 7 |
| Kang, J | 3 |
| Amatangelo, M | 3 |
| Polonskaia, A | 1 |
| Katz, M | 2 |
| Chiu, H | 1 |
| Couto, S | 5 |
| Wang, M | 29 |
| Ren, Y | 4 |
| Ortiz, M | 1 |
| Towfic, F | 3 |
| Flynt, JE | 1 |
| Pierceall, W | 1 |
| Trudel, S | 11 |
| Corzo, KP | 1 |
| Klippel, Z | 2 |
| Kimball, A | 1 |
| Tekle, C | 2 |
| Piechotta, V | 1 |
| Jakob, T | 2 |
| Langer, P | 1 |
| Monsef, I | 1 |
| Estcourt, LJ | 1 |
| Ocheni, S | 1 |
| Theurich, S | 1 |
| Kuhr, K | 2 |
| Scheckel, B | 1 |
| Adams, A | 2 |
| Skoetz, N | 1 |
| Sharpley, FA | 2 |
| Fourali, S | 1 |
| Kothari, J | 2 |
| Lynes, JA | 1 |
| McLain-Smith, S | 2 |
| Li, A | 1 |
| Wu, Q | 1 |
| Warnick, G | 1 |
| Li, S | 3 |
| Libby, EN | 3 |
| Garcia, DA | 1 |
| Lyman, GH | 1 |
| Sinit, RB | 1 |
| Hwang, DG | 1 |
| Vishnu, P | 1 |
| Peterson, JF | 1 |
| Aboulafia, DM | 3 |
| Wang, H | 5 |
| Lou, Y | 1 |
| Lin, P | 2 |
| Yang, M | 3 |
| Jin, J | 6 |
| Kastritis, E | 35 |
| Roussou, M | 16 |
| Gavriatopoulou, M | 15 |
| Kanellias, N | 6 |
| Migkou, M | 12 |
| Eleutherakis-Papaiakovou, E | 7 |
| Ziogas, DC | 3 |
| Fotiou, D | 4 |
| Ntanasis-Stathopoulos, I | 2 |
| Dialoupi, I | 1 |
| Giannouli, S | 1 |
| Tsirigotis, P | 1 |
| Mparmparousi, D | 2 |
| Spyropoulou-Vlachou, M | 2 |
| Xirokosta, A | 1 |
| Park, JJ | 1 |
| Huang, E | 2 |
| Monteleone, CA | 1 |
| Kane, MP | 1 |
| Cooper, DL | 2 |
| Meunier, M | 1 |
| Larabi, A | 1 |
| Schacherer, M | 1 |
| Deteix, C | 1 |
| Courby, S | 1 |
| Cahn, JY | 2 |
| Jung, KS | 1 |
| Kim, HJ | 17 |
| Kim, SH | 8 |
| Lee, JO | 4 |
| Shin, HJ | 7 |
| Fan, WJ | 3 |
| Fan, ZQ | 3 |
| Pan, YZ | 2 |
| Yang, K | 2 |
| Yin, JJ | 2 |
| Zhao, XC | 1 |
| Yao, H | 1 |
| Stork, M | 2 |
| Sandecká, V | 5 |
| Boichuk, I | 1 |
| Adam, Z | 12 |
| Krejci, M | 6 |
| Brozova, L | 2 |
| Sevcikova, S | 5 |
| Woods, A | 1 |
| Wooten, M | 1 |
| Thompson Heffner, L | 1 |
| Waller, E | 1 |
| Lee, HS | 6 |
| Kim, SJ | 7 |
| Kim, I | 2 |
| Yoon, DH | 5 |
| Suh, C | 9 |
| Mun, YC | 7 |
| Kim, MK | 4 |
| Lim, SN | 1 |
| Choi, CW | 2 |
| Kang, HJ | 5 |
| Moia, R | 1 |
| Boggio, E | 1 |
| Gigliotti, L | 1 |
| Crisà, E | 1 |
| De Paoli, L | 4 |
| Margiotta Casaluci, G | 1 |
| Rolla, R | 1 |
| Patriarca, A | 1 |
| Gaidano, G | 7 |
| Dianzani, U | 1 |
| Bruna, R | 1 |
| Stocker, N | 1 |
| Gaugler, B | 2 |
| Ricard, L | 1 |
| de Vassoigne, F | 1 |
| Marjanovic, Z | 1 |
| White, DJ | 3 |
| Cook, G | 22 |
| Leiba, M | 5 |
| Chiu, C | 5 |
| Qin, X | 4 |
| Okonkwo, L | 1 |
| Trivedi, S | 1 |
| Ukropec, J | 2 |
| Qi, M | 1 |
| Gau, YC | 1 |
| Hsiao, HH | 1 |
| Liu, YC | 1 |
| Yeh, TJ | 1 |
| Hagihara, M | 5 |
| Ide, S | 2 |
| Ohara, S | 2 |
| Uchida, T | 4 |
| Inoue, M | 4 |
| Hua, J | 4 |
| Mai, EK | 4 |
| Weisel, KC | 14 |
| Kunz, C | 3 |
| Hielscher, T | 5 |
| Merz, M | 4 |
| Munder, M | 2 |
| Lindemann, HW | 4 |
| Hügle-Dörr, B | 1 |
| Tichy, D | 1 |
| Huhn, S | 1 |
| Luntz, S | 2 |
| Jauch, A | 6 |
| Elmaagacli, A | 1 |
| Rabold, B | 1 |
| Fuhrmann, S | 1 |
| Brossart, P | 3 |
| Goerner, M | 2 |
| Bernhard, H | 1 |
| Hoffmann, M | 1 |
| Blau, IW | 7 |
| Hänel, M | 1 |
| Salwender, HJ | 3 |
| Murrieta-Álvarez, I | 1 |
| Steensma, DP | 2 |
| Olivares-Gazca, JC | 1 |
| Olivares-Gazca, M | 1 |
| León-Peña, A | 1 |
| Cantero-Fortiz, Y | 1 |
| García-Navarrete, YI | 1 |
| Cruz-Mora, A | 1 |
| Ruiz-Argüelles, A | 1 |
| Ruiz-Delgado, GJ | 2 |
| Ruiz-Argüelles, GJ | 3 |
| Steel, M | 1 |
| Donaldson, A | 1 |
| Walbaum, C | 1 |
| Moore, S | 1 |
| Tateno, S | 2 |
| Iida, M | 2 |
| Fujii, S | 9 |
| Suwa, T | 2 |
| Katayama, M | 1 |
| Tokuyama, H | 1 |
| Yamamoto, J | 2 |
| Sakamoto, S | 2 |
| Handa, H | 12 |
| Yamaguchi, Y | 2 |
| Diamond, B | 2 |
| Maclachlan, K | 2 |
| Chung, DJ | 5 |
| Lesokhin, AM | 5 |
| Ola Landgren, C | 1 |
| Wudhikarn, K | 1 |
| Wills, B | 1 |
| Maura, F | 2 |
| Turesson, I | 9 |
| Landgren, CO | 2 |
| Kazandjian, D | 5 |
| Dew, A | 1 |
| Hill, E | 1 |
| Lu, SX | 1 |
| Aschan, J | 4 |
| Dhakal, B | 2 |
| Narra, RK | 1 |
| Szabo, A | 1 |
| Smunt, TL | 1 |
| Ghose, S | 1 |
| Pathak, LK | 1 |
| Aryal, M | 1 |
| Hamadani, M | 7 |
| Chhabra, S | 1 |
| Hari, PN | 1 |
| Fernández, GI | 1 |
| Ribera, JM | 3 |
| Sabater, LA | 1 |
| Kassir, N | 1 |
| Zhou, S | 3 |
| Blank, A | 1 |
| Agis, H | 1 |
| Ferstl, B | 1 |
| Schub, N | 1 |
| Röllig, C | 4 |
| Winderlich, M | 1 |
| Griese, J | 1 |
| Härtle, S | 1 |
| Weirather, J | 1 |
| Jarutat, T | 1 |
| Peschel, C | 2 |
| Chatterjee, M | 2 |
| Sapet, M | 1 |
| Fouillet, L | 1 |
| Daguenet, E | 1 |
| Laurent, B | 1 |
| Guyotat, D | 1 |
| Le Jeune, C | 1 |
| Schütz, NP | 1 |
| Ochoa, P | 1 |
| Duarte, P | 1 |
| Yantorno, S | 1 |
| Corzo, A | 1 |
| Zabaljauregui, S | 1 |
| Shanley, C | 1 |
| Lopresti, S | 1 |
| Orlando, S | 1 |
| Verri, V | 1 |
| Quiroga, L | 1 |
| García, CA | 1 |
| Fernández, V | 1 |
| Fantl, D | 2 |
| Aoki, G | 1 |
| Sawazaki, A | 1 |
| Notsumata, K | 1 |
| Ushiogi, Y | 1 |
| Okafuji, K | 1 |
| Toya, D | 1 |
| Johnson, P | 1 |
| Byeff, P | 1 |
| Hus, M | 14 |
| Muelduer, E | 1 |
| Anttila, P | 6 |
| Krauth, MT | 2 |
| Lucio, P | 3 |
| Ben-Yehuda, D | 4 |
| Mendeleeva, L | 3 |
| Yu, X | 12 |
| Biyukov, T | 4 |
| Richardson, P | 46 |
| Shinagawa, A | 3 |
| Sakurai, S | 1 |
| Tamakoshi, H | 1 |
| Cornell, RF | 2 |
| Goldhaber, SZ | 1 |
| Engelhardt, BG | 1 |
| Moslehi, J | 2 |
| Jagasia, M | 1 |
| Harrell, S | 1 |
| Rubinstein, SM | 1 |
| Hall, R | 2 |
| Wyatt, H | 1 |
| Piazza, G | 1 |
| Dhillon, S | 1 |
| Moore, DC | 1 |
| Arnall, JR | 2 |
| Janes, A | 1 |
| Pineda-Roman, M | 12 |
| Manasanch, EE | 6 |
| Jain, P | 1 |
| Oriabure, O | 1 |
| Badillo, M | 2 |
| Berkova, Z | 2 |
| Ueno, H | 2 |
| Kikumto, M | 1 |
| Takebayashi, Y | 1 |
| Ishibashi, H | 1 |
| Takahashi, T | 5 |
| Yasutomi, H | 1 |
| Umemoto, K | 1 |
| Nakamichi, K | 1 |
| Saijo, M | 1 |
| Ichinohe, T | 2 |
| Maruyama, H | 1 |
| Tsukada, N | 3 |
| Bradbury, CA | 1 |
| Craig, Z | 1 |
| Pawlyn, C | 11 |
| Cairns, DA | 6 |
| Hockaday, A | 1 |
| Paterson, A | 1 |
| Jenner, MW | 4 |
| Jones, JR | 6 |
| Drayson, MT | 12 |
| Owen, RG | 11 |
| Kaiser, MF | 9 |
| Gregory, WM | 16 |
| Child, JA | 14 |
| Morgan, GJ | 41 |
| Jackson, GH | 14 |
| Miles Prince, H | 2 |
| Ocio, EM | 15 |
| Assadourian, S | 1 |
| Szudy-Szczyrek, A | 3 |
| Mlak, R | 3 |
| Mielnik, M | 3 |
| Szczyrek, M | 3 |
| Nowaczyńska, A | 1 |
| Homa-Mlak, I | 3 |
| Zmorzyński, S | 1 |
| Kuśmierczuk, K | 2 |
| Sompor, J | 1 |
| Filip, A | 1 |
| Małecka-Massalska, T | 3 |
| Chen, CI | 5 |
| Reece, DE | 18 |
| Kukreti, V | 10 |
| Tiedemann, R | 4 |
| Prica, A | 1 |
| Paul, H | 1 |
| Le, LW | 1 |
| Levina, O | 1 |
| Kakar, S | 1 |
| Lau, A | 1 |
| Chen, H | 6 |
| Chen, E | 1 |
| Motlló, C | 3 |
| Cejalvo, MJ | 2 |
| Martín-Sánchez, J | 1 |
| Bladé, J | 50 |
| García-Malo, MD | 1 |
| Dourdil, MV | 1 |
| García-Mateo, A | 1 |
| de Arriba, F | 11 |
| García-Sanz, R | 12 |
| de la Rubia, J | 12 |
| Lahuerta, JJ | 18 |
| San-Miguel, JF | 12 |
| Kim, GW | 2 |
| Yoo, J | 1 |
| Won, HR | 2 |
| Yeon, SK | 2 |
| Lee, SW | 1 |
| Lee, DH | 4 |
| Jeon, YH | 1 |
| Kwon, SH | 2 |
| Yeoh, KW | 1 |
| Thitsar, SM | 1 |
| Master, Z | 1 |
| Loh, Y | 1 |
| Tin, KM | 1 |
| Cutter, D | 1 |
| Mikhaeel, G | 1 |
| Sakano, S | 1 |
| Matsuyama, H | 1 |
| Ishikawa, H | 1 |
| Shindo, A | 1 |
| Ii, Y | 1 |
| Matsuura, K | 1 |
| Mizutani, M | 2 |
| Kawada, N | 1 |
| Tomimoto, H | 1 |
| Kuwahara-Ota, S | 1 |
| Shimura, Y | 3 |
| Steinebach, C | 2 |
| Isa, R | 1 |
| Yamaguchi, J | 1 |
| Nishiyama, D | 1 |
| Fujibayashi, Y | 1 |
| Takimoto-Shimomura, T | 1 |
| Mizuno, Y | 1 |
| Matsumura-Kimoto, Y | 2 |
| Tsukamoto, T | 2 |
| Chinen, Y | 2 |
| Kobayashi, T | 9 |
| Horiike, S | 2 |
| Taniwaki, M | 11 |
| Gütschow, M | 2 |
| Lim, SL | 2 |
| Han, BC | 2 |
| Shyamsunder, P | 2 |
| Koeffler, HP | 2 |
| Elba, S | 1 |
| Castellino, A | 1 |
| Soriasio, R | 1 |
| Castellino, C | 1 |
| Bonferroni, M | 1 |
| Mattei, D | 1 |
| Strola, G | 1 |
| Drandi, D | 4 |
| Mordini, N | 1 |
| Foglietta, M | 1 |
| Rapezzi, D | 1 |
| Celeghini, I | 1 |
| Grasso, M | 12 |
| Giordano, F | 1 |
| Fraternali Orcioni, G | 1 |
| Massaia, M | 4 |
| Bury-Kamińska, M | 1 |
| Podgajna, M | 1 |
| Mazurek, M | 2 |
| Krawczyk, J | 1 |
| Toor, SH | 1 |
| Satti, TM | 1 |
| Iftikhar, R | 1 |
| Mahmood, SK | 1 |
| Shamshad, GU | 1 |
| Rehman, JU | 1 |
| Steinhardt, MJ | 1 |
| Grathwohl, D | 1 |
| Meckel, K | 1 |
| Nickel, K | 1 |
| Leicht, HB | 1 |
| Krummenast, F | 1 |
| Chu, TH | 2 |
| Vo, MC | 4 |
| Park, HS | 2 |
| Lakshmi, TJ | 2 |
| Jung, SH | 12 |
| Striha, A | 2 |
| Collett, C | 2 |
| Waterhouse, A | 1 |
| Wilson, J | 1 |
| Taylor, C | 1 |
| Kishore, B | 5 |
| Garg, M | 1 |
| Williams, CD | 2 |
| Karunanithi, K | 1 |
| Russell, NH | 7 |
| Hefner, J | 1 |
| Bittrich, M | 1 |
| Strifler, S | 1 |
| Schoder, R | 1 |
| Gisslinger, B | 1 |
| Gisslinger, H | 10 |
| Susek, KH | 1 |
| Gran, C | 1 |
| Ljunggren, HG | 1 |
| Alici, E | 4 |
| Nahi, H | 10 |
| Laurent, V | 1 |
| Fronteau, C | 1 |
| Antier, C | 1 |
| Dupuis, P | 1 |
| Tessoulin, B | 3 |
| Gastinne, T | 3 |
| Mahé, B | 5 |
| Blin, N | 4 |
| Dubruille, V | 4 |
| Lok, A | 3 |
| Chevallier, P | 2 |
| Guillaume, T | 3 |
| Garnier, A | 2 |
| Peterlin, P | 3 |
| Le Bourgeois, A | 2 |
| Vantyghem, S | 1 |
| Godmer, P | 2 |
| Sadot, S | 1 |
| Loirat, M | 2 |
| Trebouet, A | 1 |
| Cormier, N | 1 |
| Le Gouill, S | 6 |
| Van Oekelen, O | 2 |
| Cho, HJ | 3 |
| Vishnuvardhan, N | 1 |
| Madduri, D | 2 |
| Ip, C | 1 |
| Lau, K | 2 |
| Florendo, E | 1 |
| Mancia, IS | 1 |
| Thomas, J | 1 |
| Verina, D | 1 |
| Chan, E | 1 |
| Zarychta, K | 1 |
| La, L | 1 |
| Strumolo, G | 1 |
| Melnekoff, DT | 1 |
| Leshchenko, VV | 1 |
| Kim-Schulze, S | 1 |
| Laganà, A | 1 |
| Hou, HA | 3 |
| Qiu, H | 3 |
| Tang, CH | 2 |
| Bao, L | 3 |
| Wang, S | 5 |
| Ding, K | 3 |
| Zhang, W | 3 |
| Yang, W | 1 |
| Li, B | 2 |
| Chen, B | 2 |
| Hua, L | 1 |
| Wang, L | 10 |
| Luo, J | 2 |
| Yang, Y | 7 |
| Xu, T | 1 |
| Huang, Y | 2 |
| Liu, P | 2 |
| Casal, E | 1 |
| Nguyen, TV | 1 |
| Cho, SF | 1 |
| Lin, L | 2 |
| Xing, L | 1 |
| Wen, K | 1 |
| Yu, T | 1 |
| Hsieh, PA | 1 |
| Munshi, N | 16 |
| Wahl, J | 1 |
| Matthes, K | 1 |
| Friedrich, M | 1 |
| Arvedson, T | 1 |
| Tai, YT | 17 |
| Amatangelo, MD | 1 |
| Rahman, A | 1 |
| Neri, P | 4 |
| Young, M | 1 |
| Serbina, N | 1 |
| Lamb, YN | 1 |
| Murase, Y | 1 |
| Mizutome, H | 1 |
| Asatsuma-Okumura, T | 1 |
| Shimizu, N | 1 |
| Kishi, T | 1 |
| Momose, S | 1 |
| Kizaki, M | 4 |
| Hinsley, S | 1 |
| Walker, K | 1 |
| Sherratt, D | 2 |
| Bailey, L | 1 |
| Reed, S | 1 |
| Flanagan, L | 4 |
| McKee, S | 1 |
| Brudenell Straw, F | 1 |
| Dawkins, B | 1 |
| Meads, D | 1 |
| Auner, HW | 2 |
| Cook, M | 4 |
| Brown, S | 1 |
| El-Cheikh, R | 1 |
| Mace, N | 1 |
| Swaminathan, N | 2 |
| Gupta, S | 3 |
| Dourado, C | 2 |
| Bahlis, N | 6 |
| Cheung, M | 1 |
| Chen, C | 23 |
| Shustik, C | 7 |
| Tosikyan, A | 2 |
| Anderson, K | 18 |
| Brown, D | 1 |
| Mahmoudjafari, Z | 1 |
| Atrash, S | 3 |
| Kawsar, H | 1 |
| Sigle, M | 1 |
| Shune, L | 2 |
| McGuirk, J | 2 |
| Wahab, A | 1 |
| Rafae, A | 1 |
| Faisal, MS | 1 |
| Mushtaq, K | 1 |
| Ehsan, H | 1 |
| Khakwani, M | 1 |
| Ashraf, A | 1 |
| Rehan, T | 1 |
| Ahmed, Z | 1 |
| Shah, Z | 1 |
| Khan, A | 1 |
| Anwer, F | 3 |
| Capra, M | 3 |
| Cole, C | 1 |
| Hungria, V | 1 |
| Vorobyev, V | 2 |
| Ruiz, EY | 1 |
| Yin, JY | 1 |
| Saleem, R | 2 |
| Hellet, M | 1 |
| Paiva, B | 13 |
| Vij, R | 20 |
| Jalowiec, KA | 1 |
| Andres, M | 1 |
| Taleghani, BM | 1 |
| Musa, A | 1 |
| Dickenmann, M | 1 |
| Angelillo-Scherrer, A | 1 |
| Rovó, A | 1 |
| Kremer Hovinga, JA | 1 |
| Kröger, N | 7 |
| Okoniewski, M | 1 |
| Diab, O | 1 |
| McClune, B | 4 |
| Zduniak, K | 1 |
| Gdesz-Birula, K | 1 |
| Woźniak, M | 1 |
| Duś-Szachniewicz, K | 1 |
| Ziółkowski, P | 1 |
| Röhner, L | 1 |
| Ng, YLD | 1 |
| Scheffold, A | 1 |
| Lindner, S | 3 |
| Köpff, S | 2 |
| Brandl, A | 2 |
| Beilhack, A | 2 |
| Krönke, J | 5 |
| Ainley, L | 1 |
| Chavda, SJ | 1 |
| Counsell, N | 1 |
| Cheesman, S | 3 |
| Newrick, F | 1 |
| Horder, J | 1 |
| Kyriakou, C | 3 |
| Papanikolaou, X | 4 |
| Sive, J | 1 |
| Lee, L | 1 |
| Wechalekar, A | 1 |
| Mehta, A | 1 |
| Popat, R | 5 |
| Rabin, N | 8 |
| Regidor, B | 1 |
| Swift, R | 3 |
| Emamy-Sadr, M | 1 |
| Tarhini, F | 1 |
| van de Donk, NWJC | 1 |
| Hebraud, B | 4 |
| Laribi, K | 3 |
| Jaccard, A | 7 |
| Dib, M | 10 |
| Slama, B | 4 |
| Dorvaux, V | 5 |
| Royer, B | 12 |
| Tacchetti, P | 29 |
| Pantani, L | 14 |
| Dozza, L | 1 |
| Crippa, C | 15 |
| Barbato, S | 1 |
| Tosi, P | 27 |
| Narni, F | 2 |
| Montefusco, V | 20 |
| Testoni, N | 4 |
| Spadano, A | 2 |
| Terragna, C | 10 |
| Pescosta, N | 10 |
| Marzocchi, G | 4 |
| Cellini, C | 12 |
| Galieni, P | 9 |
| Ronconi, S | 5 |
| Gobbi, M | 2 |
| Catalano, L | 13 |
| De Sabbata, G | 2 |
| Cangialosi, C | 8 |
| Ciambelli, F | 2 |
| Elice, F | 7 |
| Amare, GG | 1 |
| Meharie, BG | 1 |
| Belayneh, YM | 1 |
| Stege, CAM | 1 |
| Leys, RBL | 1 |
| Axelsson, P | 1 |
| Hieu Do, T | 1 |
| Knut-Bojanowska, D | 1 |
| van der Spek, E | 4 |
| Svirskaite, A | 2 |
| Klostergaard, A | 1 |
| Blimark, C | 3 |
| Ypma, PF | 2 |
| Poddighe, PJ | 2 |
| Stevens-Kroef, M | 5 |
| Hwa, YL | 3 |
| Buadi, FK | 21 |
| Go, RS | 6 |
| Hobbs, MA | 1 |
| Fonder, AL | 2 |
| Gonsalves, WI | 3 |
| Kourelis, TV | 3 |
| Hayman, SR | 25 |
| Siddiqui, MA | 1 |
| Korst, CLBM | 1 |
| Comba, IY | 1 |
| Chahin, A | 1 |
| Taj, H | 1 |
| Carilli, A | 1 |
| Mi, T | 1 |
| Kan, W | 1 |
| Xu, G | 3 |
| Jiang, X | 2 |
| Chien, N | 1 |
| Romeril, K | 3 |
| Baker, B | 2 |
| Goodman, H | 1 |
| Chan, H | 2 |
| Kuiper, R | 2 |
| van Duin, M | 2 |
| van Vliet, MH | 1 |
| van Beers, EH | 1 |
| Dumee, B | 1 |
| Vermeulen, M | 1 |
| Koenders, J | 1 |
| van der Velden, AWG | 1 |
| Beverloo, HB | 1 |
| Siggins, S | 1 |
| Gooding, S | 3 |
| Ansari-Pour, N | 1 |
| Ortiz Estévez, M | 1 |
| Chamberlain, PP | 1 |
| Tsai, KT | 1 |
| Flynt, E | 2 |
| Hirst, M | 1 |
| Rozelle, D | 1 |
| Dhiman, P | 1 |
| Vyas, P | 1 |
| Grosicki, S | 4 |
| Bednarczyk, M | 1 |
| Barchnicka, A | 1 |
| Grosicka, O | 1 |
| Cippitelli, M | 2 |
| Stabile, H | 1 |
| Kosta, A | 1 |
| Petillo, S | 1 |
| Gismondi, A | 1 |
| Santoni, A | 2 |
| Fionda, C | 2 |
| Hagiwara, M | 1 |
| Parikh, K | 3 |
| Pelletier, C | 1 |
| Delea, TE | 1 |
| Kee, A | 1 |
| Vozella, F | 1 |
| Siniscalchi, A | 7 |
| Rizzo, M | 2 |
| Za, T | 1 |
| Antolino, G | 1 |
| Coppetelli, U | 1 |
| Piciocchi, A | 1 |
| Andriani, A | 2 |
| Annibali, O | 2 |
| De Rosa, L | 4 |
| Cimino, G | 1 |
| La Verde, G | 2 |
| Cantonetti, M | 1 |
| di Toritto, TC | 2 |
| Pádua, CAM | 1 |
| Machado, TRL | 1 |
| Hauck, LM | 1 |
| Branagan, AR | 1 |
| Xu, ML | 1 |
| Flavell, RA | 1 |
| Dhodapkar, KM | 3 |
| Dhodapkar, MV | 5 |
| Anupindi, VR | 1 |
| Yeaw, J | 1 |
| Kudaravalli, S | 1 |
| Zavisic, S | 1 |
| Shah, D | 1 |
| Garderet, L | 26 |
| Kolb, B | 12 |
| Pei, L | 2 |
| Zhao, M | 1 |
| Liu, B | 1 |
| Bondili, SK | 1 |
| Bagal, B | 1 |
| Zawar, A | 1 |
| Ventrapati, P | 1 |
| Thorat, J | 1 |
| Gokarn, A | 1 |
| Punatar, S | 1 |
| Nayak, L | 1 |
| Bonda, A | 1 |
| Jain, H | 1 |
| Sengar, M | 1 |
| Khattry, N | 1 |
| Bensinger, WI | 8 |
| Chiron, M | 1 |
| Mikhael, J | 11 |
| Bernabei, L | 1 |
| Tian, L | 1 |
| Garfall, AL | 2 |
| Melenhorst, JJ | 1 |
| Lacey, SF | 1 |
| Stadtmauer, EA | 21 |
| Vogl, DT | 9 |
| Gonzalez, VE | 1 |
| Plesa, G | 1 |
| Young, RM | 1 |
| Waxman, A | 1 |
| Levine, BL | 1 |
| June, CH | 1 |
| Milone, MC | 1 |
| Cohen, AD | 4 |
| Milrod, CJ | 1 |
| Blevins, F | 1 |
| Hughes, D | 1 |
| Lerner, A | 1 |
| Sarosiek, S | 1 |
| Sanchorawala, V | 3 |
| Sloan, JM | 1 |
| Vlayen, S | 1 |
| Kint, N | 2 |
| Sirvent, M | 1 |
| González-Rodríguez, AP | 1 |
| Lavilla, E | 1 |
| de Coca, AG | 1 |
| Arguiñano, JM | 2 |
| Martí, JM | 1 |
| Cabañas, V | 1 |
| de Cabo, E | 1 |
| Encinas, C | 3 |
| Murillo, I | 1 |
| Hernández-Rivas, JÁ | 1 |
| Pérez-Persona, E | 1 |
| Casado, F | 1 |
| Sampol, A | 1 |
| García, R | 1 |
| Blanchard, MJ | 4 |
| Anguita, M | 1 |
| Lafuente, AP | 1 |
| Iñigo, B | 1 |
| López, A | 1 |
| Ribas, P | 1 |
| Arnao, M | 1 |
| Maldonado, R | 1 |
| San Miguel, JF | 24 |
| Arbab, A | 1 |
| Saada, V | 1 |
| Cotteret, S | 1 |
| Marzac, C | 1 |
| Ghez, D | 3 |
| Warzocha, K | 1 |
| Le Guennec, S | 1 |
| Menas, F | 1 |
| Maruyama, D | 2 |
| Tobinai, K | 3 |
| Kher, U | 2 |
| Farooqui, M | 2 |
| Liao, J | 2 |
| Marinello, P | 2 |
| Matsuda, K | 1 |
| Shimamoto, T | 1 |
| Piggin, A | 1 |
| Bergin, K | 1 |
| Yuen, F | 1 |
| Wallington-Beddoe, C | 1 |
| Sirdesai, S | 1 |
| Simpson, D | 3 |
| Vlummens, P | 1 |
| Risse, ML | 3 |
| Cheng, CN | 1 |
| Lien, PW | 1 |
| Huang, ST | 1 |
| Lin, FJ | 1 |
| Karanes, C | 4 |
| Raje, N | 24 |
| Sborov, D | 1 |
| Bianchi, G | 3 |
| Kanagavel, D | 2 |
| Baldini, L | 7 |
| Schecter, JM | 1 |
| Baker, R | 1 |
| Martinez, G | 1 |
| Asset, G | 1 |
| Atenafu, EG | 5 |
| Cherniawsky, H | 1 |
| Louzada, ML | 1 |
| Fiala, M | 3 |
| Gao, F | 1 |
| King, J | 1 |
| Goldsmith, S | 1 |
| Schroeder, MA | 1 |
| Barbarossa, A | 1 |
| Iacopetta, D | 1 |
| Sinicropi, MS | 1 |
| Franchini, C | 2 |
| Carocci, A | 2 |
| Delgado, J | 1 |
| Zienowicz, M | 1 |
| van Hennik, PB | 1 |
| Moreau, A | 2 |
| Gisselbrecht, C | 3 |
| Enzmann, H | 1 |
| Pignatti, F | 3 |
| Radocha, J | 5 |
| Heindorfer, A | 1 |
| Pavlíček, P | 3 |
| Sýkora, M | 2 |
| Jungová, A | 1 |
| Kessler, P | 2 |
| Wróbel, M | 2 |
| Starostka, D | 2 |
| Ullrychová, J | 1 |
| Stejskal, L | 1 |
| Straub, J | 4 |
| Pika, T | 6 |
| Vasquez, J | 2 |
| Ruiz, R | 1 |
| Aliaga, K | 1 |
| Valencia, F | 1 |
| Villena, M | 1 |
| Quintana, S | 1 |
| Vidaurre, T | 1 |
| Casanova, L | 1 |
| Nakazato, T | 5 |
| Sahara, N | 2 |
| Tamai, Y | 1 |
| Ishii, R | 1 |
| Tamaki, S | 1 |
| Wake, A | 1 |
| Tajika, K | 1 |
| Sakai, R | 1 |
| Aisa, Y | 3 |
| Fujisawa, S | 1 |
| Miyazaki, K | 4 |
| Irie, S | 1 |
| Tanaka, E | 1 |
| Higashihara, M | 2 |
| G Richardson, P | 1 |
| A Dimopoulos, M | 1 |
| Foster, MC | 1 |
| Poole, EM | 1 |
| Young, MH | 1 |
| Pietz, G | 1 |
| Whalen, E | 1 |
| Copeland, W | 1 |
| Thompson, E | 1 |
| Fox, BA | 1 |
| Newhall, KJ | 1 |
| Kalantri, SA | 1 |
| Nath, UK | 1 |
| Banerjee, D | 1 |
| Bhattacharyya, M | 1 |
| Sengsayadeth, S | 1 |
| Savani, BN | 2 |
| Holmberg, LA | 2 |
| Becker, PS | 3 |
| Bensinger, W | 10 |
| Lázaro Sierra, J | 1 |
| Carrasco, V | 1 |
| Cases, E | 1 |
| Gómez Gonzalez, C | 1 |
| Mugge, LO | 5 |
| Shen, ZX | 3 |
| Desjardins, P | 1 |
| Decaux, O | 12 |
| de Revel, T | 1 |
| Granell, M | 7 |
| Marit, G | 14 |
| Demuynck, H | 1 |
| Guthrie, TH | 1 |
| Ervin-Haynes, A | 9 |
| Marek, J | 2 |
| Chen, G | 6 |
| Lauwers-Cances, V | 3 |
| Escoffre, M | 3 |
| Payen, C | 3 |
| Mathiot, C | 11 |
| Fermand, JP | 16 |
| Rollet, S | 1 |
| Maglio, ME | 4 |
| Zeytoonjian, AA | 1 |
| Weller, EA | 2 |
| Jolobe, OM | 1 |
| Kellermann, L | 1 |
| Tischler, HJ | 1 |
| Kohnke, J | 1 |
| Knauf, W | 1 |
| Ying, L | 1 |
| YinHui, T | 1 |
| Yunliang, Z | 1 |
| Sun, H | 4 |
| Aguiar, PM | 1 |
| de Mendonça Lima, T | 1 |
| Colleoni, GWB | 2 |
| Storpirtis, S | 1 |
| Siegel, D | 17 |
| Mihaylov, GG | 3 |
| Goranova-Marinova, V | 4 |
| Rajnics, P | 3 |
| Suvorov, A | 3 |
| Niesvizky, R | 39 |
| Ro, S | 1 |
| Aggarwal, S | 2 |
| Palumbo, A | 142 |
| Langer, C | 7 |
| Reichle, A | 1 |
| Rösler, W | 1 |
| Hertenstein, B | 2 |
| Kunitz, A | 1 |
| Ostermann, H | 2 |
| Schäfer-Eckart, K | 1 |
| Ringhoffer, M | 1 |
| Günther, A | 1 |
| Junghanss, C | 1 |
| Biersack, H | 1 |
| Liebert, A | 1 |
| Held, S | 1 |
| Bargou, RC | 3 |
| Guan, HM | 1 |
| Badros, A | 15 |
| Hyjek, E | 1 |
| Ma, N | 1 |
| Lesokhin, A | 5 |
| Rapoport, AP | 4 |
| Kocoglu, M | 2 |
| Lederer, E | 1 |
| Philip, S | 1 |
| Milliron, T | 1 |
| Dell, C | 1 |
| Goloubeva, O | 4 |
| Singh, Z | 2 |
| Kootte, RS | 1 |
| Faber, LM | 2 |
| Chen, JF | 1 |
| Xiao, LF | 1 |
| Zhang, R | 1 |
| Zeng, ZH | 1 |
| Li, YX | 1 |
| Meng, XY | 1 |
| Ray, A | 4 |
| Das, DS | 4 |
| Song, Y | 4 |
| Macri, V | 1 |
| Brooks, CL | 1 |
| Chauhan, D | 23 |
| Roshal, M | 1 |
| Sabari, J | 1 |
| Nguyen, J | 1 |
| Gao, Q | 1 |
| Devlin, SM | 2 |
| Lendvai, N | 6 |
| Korde, N | 5 |
| Mailankody, S | 5 |
| Giralt, SA | 3 |
| Baz, R | 15 |
| Benson, DM | 11 |
| Wolf, J | 4 |
| Munster, P | 1 |
| Wack, C | 1 |
| Charpentier, E | 1 |
| Hari, P | 10 |
| Avivi, I | 2 |
| Minnema, MC | 12 |
| Berg, D | 3 |
| Lin, J | 3 |
| Gupta, N | 4 |
| Esseltine, DL | 9 |
| Sissung, TM | 2 |
| Peer, CJ | 3 |
| Venzon, DJ | 1 |
| Landgren, O | 10 |
| Figg, WD | 5 |
| Hou, J | 21 |
| Zhang, M | 5 |
| Jiang, B | 3 |
| Zhou, F | 3 |
| Shen, Z | 1 |
| Chang, N | 1 |
| Corradini, P | 20 |
| O'Gorman, P | 3 |
| Kaiser, M | 3 |
| Raymakers, R | 5 |
| Joao, C | 4 |
| Sternas, L | 11 |
| Slaughter, A | 1 |
| Hong, K | 5 |
| Herring, J | 2 |
| Zaki, M | 8 |
| Maharaj, S | 1 |
| Chang, S | 1 |
| Seegobin, K | 1 |
| Serrano-Santiago, I | 1 |
| Zuberi, L | 1 |
| Olszewski, AJ | 1 |
| Dusetzina, SB | 1 |
| Eaton, CB | 1 |
| Davidoff, AJ | 1 |
| Trivedi, AN | 1 |
| de Wit, E | 1 |
| Mercurio, A | 1 |
| Adriani, G | 1 |
| Catalano, A | 1 |
| Rao, L | 1 |
| Lentini, G | 1 |
| Cavalluzzi, MM | 1 |
| Vacca, A | 12 |
| Corbo, F | 1 |
| Sharkey, MM | 1 |
| McKavanagh, D | 1 |
| Walpole, E | 1 |
| Hollingworth, SA | 1 |
| Tian, C | 2 |
| Yang, H | 2 |
| Zhu, L | 3 |
| Zhang, Q | 2 |
| Cao, Z | 1 |
| Zhang, Y | 6 |
| Dougé, A | 1 |
| Lemal, R | 1 |
| Chaleteix, C | 7 |
| Chavarot, N | 1 |
| Lebbe, C | 1 |
| Thervet, E | 1 |
| Bouscary, D | 1 |
| Karras, A | 1 |
| Randall, K | 1 |
| Kaparou, M | 1 |
| Xenou, E | 1 |
| Paneesha, S | 1 |
| Kanellopoulos, A | 1 |
| Lovell, R | 1 |
| Holder, K | 1 |
| Suhr, J | 1 |
| Baker, L | 1 |
| Ryan, L | 1 |
| Nikolousis, E | 1 |
| Vigolo, S | 1 |
| Zuckermann, J | 1 |
| Bittencourt, RI | 1 |
| Silla, L | 1 |
| Pilger, DA | 1 |
| Suvannasankha, A | 2 |
| Fay, JW | 1 |
| Ifthikharuddin, JJ | 1 |
| Weiss, BM | 1 |
| Lentzsch, S | 17 |
| Comenzo, R | 6 |
| Nottage, K | 1 |
| Khokhar, NZ | 3 |
| Gibson, CJ | 6 |
| Yin, L | 1 |
| Tagde, A | 1 |
| Gali, R | 1 |
| Hideshima, T | 42 |
| Avigan, D | 3 |
| Kufe, D | 2 |
| de Oliveira, MB | 1 |
| Fook-Alves, VL | 1 |
| Eugenio, AIP | 1 |
| Fernando, RC | 1 |
| Sanson, LFG | 1 |
| de Carvalho, MF | 1 |
| Braga, WMT | 1 |
| Lopes-Aguiar, L | 1 |
| Delamain, MT | 1 |
| Brito, ABC | 1 |
| Lourenço, GJ | 1 |
| Costa, EFD | 1 |
| Oliveira, GB | 1 |
| Vassallo, J | 1 |
| De Souza, CA | 2 |
| Lima, CSP | 1 |
| Shpilberg, O | 6 |
| Walter-Croneck, A | 4 |
| Magen, H | 3 |
| Bleickardt, E | 6 |
| Poulart, V | 2 |
| Sheng, J | 2 |
| Sy, O | 1 |
| Katz, J | 2 |
| Singhal, A | 3 |
| Partanen, A | 1 |
| Valtola, J | 1 |
| Silvennoinen, R | 2 |
| Ropponen, A | 1 |
| Siitonen, T | 1 |
| Putkonen, M | 2 |
| Sankelo, M | 1 |
| Pelkonen, J | 1 |
| Mäntymaa, P | 1 |
| Varmavuo, V | 1 |
| Jantunen, E | 3 |
| Wu, D | 4 |
| Zhou, D | 1 |
| Du, X | 4 |
| Hanley, MJ | 2 |
| Hua, Z | 1 |
| Wang, B | 4 |
| Wang, GM | 1 |
| Yang, GZ | 1 |
| Huang, ZX | 3 |
| Zhong, YP | 5 |
| Jin, FY | 1 |
| Wang, XM | 1 |
| Fu, ZZ | 1 |
| Li, XL | 1 |
| Zhou, JF | 1 |
| Meng, FY | 1 |
| Huang, XJ | 2 |
| Thidemann Andersen, K | 1 |
| Klausen, T | 1 |
| Klarskov Andersen, M | 1 |
| Frost Andersen, N | 1 |
| Christian Frølund, U | 1 |
| Helleberg, C | 1 |
| Kjeldsen, E | 1 |
| Pedersen, P | 1 |
| Helm-Petersen, S | 1 |
| Preiss, B | 1 |
| Juul Vangsted, A | 1 |
| Minagawa, K | 2 |
| Falcon, CP | 1 |
| Matsui, T | 3 |
| Nakaya, A | 2 |
| Fujita, S | 1 |
| Satake, A | 1 |
| Nakanishi, T | 1 |
| Azuma, Y | 1 |
| Tsubokura, Y | 1 |
| Hotta, M | 1 |
| Yoshimura, H | 1 |
| Ishii, K | 3 |
| Nomura, S | 4 |
| Gay, F | 35 |
| Yu, Z | 14 |
| Winograd, B | 1 |
| Knight, RD | 12 |
| Díaz, T | 2 |
| Rodríguez, V | 1 |
| Lozano, E | 3 |
| Mena, MP | 1 |
| Calderón, M | 1 |
| Martínez, A | 1 |
| Tovar, N | 4 |
| Pérez-Galán, P | 1 |
| Roué, G | 1 |
| de Larrea, CF | 3 |
| Lokhorst, HM | 29 |
| Vellenga, E | 8 |
| Pfreundschuh, M | 2 |
| Kersten, MJ | 6 |
| Croockewit, S | 3 |
| Potamianou, A | 2 |
| Bos, GMJ | 2 |
| van Marwijk Kooy, M | 3 |
| Ypma, P | 1 |
| Duehrsen, U | 2 |
| Schaafsma, RM | 1 |
| Jarari, L | 1 |
| Tokunaga, E | 1 |
| Akiyama, H | 2 |
| Soloshonok, VA | 1 |
| Inoue, Y | 3 |
| Hara, H | 1 |
| Shibata, N | 1 |
| Lee, SE | 4 |
| Lee, M | 1 |
| Yim, SH | 1 |
| Kim, TW | 2 |
| Chung, YJ | 1 |
| Lairson, DR | 1 |
| Chan, W | 1 |
| Du, XL | 1 |
| Syed, YY | 1 |
| Hurd, DD | 2 |
| Weisdorf, DJ | 2 |
| Moreb, JS | 2 |
| van Besien, K | 4 |
| Gentile, TG | 1 |
| Isola, L | 2 |
| Maziarz, RT | 2 |
| Bashey, A | 2 |
| Qazilbash, MH | 7 |
| Schlossman, RL | 19 |
| Smith, SE | 1 |
| Hars, V | 2 |
| Owzar, K | 2 |
| Jiang, C | 2 |
| Boyd, M | 1 |
| Schultz, C | 1 |
| Wilson, M | 1 |
| Horowitz, MM | 4 |
| Shea, TC | 2 |
| Devine, SM | 6 |
| Linker, C | 2 |
| Johnson, DC | 4 |
| Lenive, O | 1 |
| Mitchell, J | 1 |
| Jackson, G | 3 |
| Owen, R | 4 |
| Walker, BA | 7 |
| Wardell, C | 2 |
| Cairns, D | 1 |
| Houlston, RS | 1 |
| Beck, J | 2 |
| Schwarzer, A | 3 |
| Gläser, D | 1 |
| Uhlig, J | 2 |
| Heyn, S | 2 |
| Kragl, B | 1 |
| Mohren, M | 2 |
| Hoffmann, FA | 3 |
| Lange, T | 2 |
| Schliwa, T | 1 |
| Zehrfeld, T | 3 |
| Becker, C | 1 |
| Kreibich, U | 2 |
| Winkelmann, C | 2 |
| Edelmann, T | 2 |
| Andrea, M | 1 |
| Bill, M | 1 |
| Jentzsch, M | 1 |
| Schwind, S | 1 |
| Cho, H | 1 |
| Lee, JB | 1 |
| Kim, SY | 1 |
| Moon, JH | 7 |
| Do, YR | 7 |
| Park, Y | 4 |
| Jo, JC | 6 |
| Lee, WS | 7 |
| Mikhael, JR | 16 |
| Baertsch, MA | 2 |
| Hundemer, M | 5 |
| Hernández-García, S | 1 |
| San-Segundo, L | 3 |
| González-Méndez, L | 1 |
| Corchete, LA | 5 |
| Misiewicz-Krzeminska, I | 1 |
| Martín-Sánchez, M | 1 |
| López-Iglesias, AA | 1 |
| Algarín, EM | 1 |
| Mogollón, P | 1 |
| Díaz-Tejedor, A | 1 |
| Paíno, T | 2 |
| Tunquist, B | 1 |
| Gutiérrez, NC | 6 |
| Díaz-Rodriguez, E | 3 |
| Garayoa, M | 3 |
| Miura, S | 1 |
| Kuroda, H | 4 |
| Yamada, M | 3 |
| Ameda, S | 1 |
| Sakano, H | 1 |
| Shibata, T | 1 |
| Uemura, N | 1 |
| Abe, T | 2 |
| Maeda, M | 3 |
| Kobune, M | 2 |
| Kato, J | 5 |
| Ailawadhi, S | 8 |
| LaPlant, BR | 1 |
| Laumann, KM | 4 |
| Roy, V | 17 |
| Fonseca, R | 39 |
| Sher, T | 7 |
| Reeder, CB | 9 |
| Lust, JA | 24 |
| Russell, SJ | 13 |
| Chanan-Khan, AA | 12 |
| Ríos-Tamayo, R | 1 |
| Martín-García, A | 1 |
| Alarcón-Payer, C | 1 |
| Sánchez-Rodríguez, D | 1 |
| de la Guardia, AMDVD | 1 |
| García Collado, CG | 1 |
| Jiménez Morales, A | 1 |
| Jurado Chacón, M | 1 |
| Cabeza Barrera, J | 1 |
| Sebastian, S | 2 |
| Pulini, S | 7 |
| Chen, L | 4 |
| Bhatnagar, V | 1 |
| Gormley, NJ | 3 |
| Luo, L | 2 |
| Shen, YL | 1 |
| Sridhara, R | 2 |
| Subramaniam, S | 1 |
| Shen, G | 1 |
| Ma, L | 1 |
| Shord, S | 1 |
| Goldberg, KB | 2 |
| Farrell, AT | 2 |
| McKee, AE | 1 |
| Pazdur, R | 4 |
| Tzogani, K | 1 |
| Camarero Jiménez, J | 1 |
| Garcia, I | 2 |
| Sancho-López, A | 2 |
| Martin, M | 1 |
| Demolis, P | 1 |
| Salmonson, T | 2 |
| Bergh, J | 1 |
| Laane, E | 3 |
| Jelicic, J | 1 |
| Dencic Fekete, M | 1 |
| Trajkovic, G | 1 |
| Sretenovic, A | 1 |
| Perunicic Jovanovic, M | 1 |
| Antic, D | 1 |
| Mihaljevic, B | 1 |
| Chang, JE | 2 |
| Yildizhan, E | 1 |
| Kaynar, L | 1 |
| Tiren, N | 1 |
| Canoz, O | 1 |
| Eser, B | 1 |
| Thakral, B | 1 |
| Wang, SA | 1 |
| Pelligra, CG | 2 |
| Chandler, C | 1 |
| Abouzaid, S | 2 |
| Scott, A | 1 |
| Weber, N | 1 |
| Tiley, C | 1 |
| Taper, J | 1 |
| Harrison, S | 4 |
| Chan, KL | 1 |
| Stark, R | 2 |
| Morris, K | 1 |
| Dodds, A | 1 |
| Ramanathan, S | 1 |
| Ramakrishna, R | 1 |
| Watson, AM | 1 |
| Auguston, B | 1 |
| Kwok, F | 1 |
| Warburton, P | 1 |
| Rowlings, P | 1 |
| Krejcik, J | 2 |
| Frerichs, KA | 1 |
| Nijhof, IS | 4 |
| van Kessel, B | 6 |
| van Velzen, JF | 1 |
| Bloem, AC | 3 |
| Broekmans, MEC | 1 |
| van Meerloo, J | 1 |
| Musters, RJP | 1 |
| Groen, RWJ | 1 |
| Plesner, T | 7 |
| Sasser, AK | 2 |
| Mutis, T | 7 |
| Tang, S | 1 |
| Cheng, B | 1 |
| Zhe, N | 1 |
| Ma, D | 2 |
| Xu, J | 2 |
| Guo, Y | 4 |
| Viterbo, L | 3 |
| Ganly, P | 4 |
| Pluta, A | 4 |
| Nagler, A | 10 |
| di Bacco, A | 3 |
| Khosa, R | 1 |
| Seth, S | 1 |
| Nangia, S | 1 |
| Lakshman, A | 1 |
| Singh, PP | 1 |
| Zeldenrust, SR | 9 |
| Büyükkaramikli, NC | 1 |
| de Groot, S | 2 |
| Fayter, D | 1 |
| Wolff, R | 1 |
| Armstrong, N | 1 |
| Stirk, L | 1 |
| Worthy, G | 1 |
| Albuquerque de Almeida, F | 1 |
| Kleijnen, J | 1 |
| Al, MJ | 1 |
| Frank, RD | 1 |
| Advani, P | 1 |
| Swaika, A | 2 |
| Temkit, M | 1 |
| Menghani, R | 1 |
| Sharma, M | 2 |
| Meghji, Z | 1 |
| Paulus, S | 1 |
| Khera, N | 1 |
| Hashmi, SK | 1 |
| Paulus, A | 2 |
| Kakar, TS | 1 |
| Hodge, DO | 1 |
| Colibaseanu, DT | 1 |
| Vizzini, MR | 1 |
| Colon-Otero, G | 1 |
| Hoy, SM | 1 |
| Blair, HA | 1 |
| Dimopoulos, K | 1 |
| Søgaard Helbo, A | 1 |
| Fibiger Munch-Petersen, H | 1 |
| Sjö, L | 1 |
| Christensen, J | 1 |
| Sommer Kristensen, L | 1 |
| Asmar, F | 1 |
| Hermansen, NEU | 1 |
| O'Connel, C | 1 |
| Liang, G | 1 |
| Grønbaek, K | 1 |
| Campbell, JP | 1 |
| Heaney, JLJ | 1 |
| Pandya, S | 1 |
| Afzal, Z | 1 |
| Gregory, W | 5 |
| Bunce, CM | 1 |
| Xu, W | 2 |
| Sun, X | 1 |
| Guo, H | 3 |
| Stampleman, L | 1 |
| Rosen, PJ | 1 |
| Klein, LM | 2 |
| Woliver, T | 2 |
| Flam, M | 2 |
| Nassir, Y | 4 |
| Maluso, T | 1 |
| Das, M | 1 |
| Van Sanden, S | 1 |
| Diels, J | 1 |
| Vogel, M | 1 |
| Salvini, M | 3 |
| Troia, R | 6 |
| Giudice, D | 1 |
| Pautasso, C | 4 |
| Huang, QC | 1 |
| Ding, JY | 1 |
| Gentili, S | 15 |
| Hui, AM | 4 |
| Corzo, K | 1 |
| Gonzalez-McQuire, S | 2 |
| Leleu, H | 1 |
| Mennini, FS | 1 |
| Flinois, A | 1 |
| Gazzola, C | 1 |
| Schoen, P | 1 |
| Campioni, M | 3 |
| DeCosta, L | 3 |
| Fink, L | 10 |
| Fouquet, G | 7 |
| Pegourie, B | 19 |
| Petillon, MO | 4 |
| Brechiniac, S | 3 |
| Rodon, P | 9 |
| Richez, V | 2 |
| Araujo, C | 4 |
| Wetterwald, M | 7 |
| Gössi, U | 1 |
| Jeker, B | 1 |
| Mansouri Taleghani, B | 1 |
| Bacher, U | 3 |
| Betticher, D | 2 |
| Egger, T | 1 |
| Kamitsuji, Y | 1 |
| Fuchida, SI | 4 |
| Shibayama, H | 4 |
| Uoshima, N | 3 |
| Yokota, I | 1 |
| Uchiyama, H | 2 |
| Yagi, H | 2 |
| Kosugi, S | 3 |
| Ishikawa, J | 1 |
| Matsuda, M | 3 |
| Ohta, K | 3 |
| Tanaka, H | 4 |
| Kobayashi, M | 6 |
| Wada, K | 1 |
| Imada, K | 1 |
| Hino, M | 2 |
| Matsumura, I | 5 |
| Kanakura, Y | 4 |
| Takaori-Kondo, A | 4 |
| Gueneau, P | 1 |
| Chretien, ML | 3 |
| Cransac-Miet, A | 1 |
| Aho, LS | 1 |
| Lafon, I | 4 |
| Favennec, C | 1 |
| Guy, J | 1 |
| Boulin, M | 2 |
| Mima, A | 1 |
| Nagahara, D | 1 |
| Tansho, K | 1 |
| Zhao, LJ | 1 |
| Khammar, Z | 1 |
| Ouazzani, M | 1 |
| Bennani, B | 1 |
| Oubelkacem, N | 1 |
| Berrady, R | 1 |
| Miura, M | 4 |
| Abumiya, M | 3 |
| Niioka, T | 3 |
| Kanno, S | 1 |
| Takahashi, N | 4 |
| Zhou, L | 4 |
| Obreja, M | 3 |
| Blaedel, J | 1 |
| Szabo, Z | 2 |
| Takemori, N | 1 |
| Imai, G | 1 |
| Hoshino, K | 1 |
| Ooi, A | 1 |
| Kojima, M | 1 |
| Tarín-Arzaga, L | 1 |
| Arredondo-Campos, D | 1 |
| Martínez-Pacheco, V | 1 |
| Martínez-González, O | 1 |
| Ramírez-López, A | 1 |
| Gómez-De León, A | 1 |
| Gutiérrez-Aguirre, CH | 1 |
| Cantú-Rodríguez, O | 1 |
| Jaime-Pérez, JC | 1 |
| Wakabayashi, M | 4 |
| Tsukasaki, K | 1 |
| Miyamoto, K | 1 |
| Yamamoto, K | 1 |
| Takatsuka, Y | 1 |
| Kusumoto, S | 3 |
| Kikukawa, Y | 1 |
| Masaki, Y | 1 |
| Hanamura, I | 1 |
| Asai, H | 1 |
| Nagai, H | 3 |
| Shimada, K | 1 |
| Tsukamoto, N | 4 |
| Mina, R | 11 |
| Cafro, AM | 5 |
| Spada, S | 5 |
| Fanin, R | 5 |
| Rossi, G | 2 |
| Bertazzoni, P | 1 |
| Anderson, SM | 1 |
| Beck, B | 1 |
| Sterud, S | 1 |
| Lockhorst, R | 1 |
| Ngorsuraches, S | 1 |
| Chen, M | 4 |
| Xu, C | 1 |
| Mao, B | 1 |
| Gherardin, NA | 1 |
| Loh, L | 1 |
| Admojo, L | 1 |
| Davenport, AJ | 1 |
| Richardson, K | 1 |
| Rogers, A | 1 |
| Darcy, PK | 1 |
| Jenkins, MR | 1 |
| Fairlie, DP | 1 |
| Kedzierska, K | 1 |
| McCluskey, J | 1 |
| Uldrich, AP | 1 |
| Neeson, PJ | 1 |
| Ritchie, DS | 4 |
| Godfrey, DI | 2 |
| Favier-Archinard, C | 1 |
| Leguelinel-Blache, G | 1 |
| Dubois, F | 1 |
| Le Gall, T | 1 |
| Bourquard, P | 1 |
| Passemard, N | 1 |
| Tora, S | 1 |
| Rey, A | 1 |
| Rossi, M | 1 |
| Chevallier, T | 1 |
| Cousin, C | 1 |
| Favier, M | 1 |
| Mushtaq, A | 2 |
| Kapoor, V | 1 |
| Latif, A | 1 |
| Iftikhar, A | 2 |
| Zahid, U | 2 |
| McBride, A | 1 |
| Abraham, I | 1 |
| Riaz, IB | 1 |
| Walavalkar, V | 1 |
| Adey, DB | 1 |
| Laszik, ZG | 1 |
| Jen, KY | 1 |
| Wu, T | 2 |
| Rao, K | 1 |
| Murthy, H | 1 |
| Muralidhar, NS | 1 |
| Rani, PK | 1 |
| Guo, HM | 1 |
| Sun, L | 2 |
| Liu, XJ | 2 |
| Nie, ZY | 1 |
| Luo, JM | 1 |
| Chasset, F | 1 |
| Arnaud, L | 1 |
| Francès, C | 1 |
| Bishnoi, A | 1 |
| Singh, V | 1 |
| Handa, S | 1 |
| Vinay, K | 1 |
| Kunkler, B | 1 |
| Salamango, D | 1 |
| DeBruine, ZJ | 1 |
| Ploch, C | 1 |
| Dean, S | 1 |
| Grossens, D | 1 |
| Hledin, MP | 1 |
| Marquez, GA | 1 |
| Madden, J | 1 |
| Schnell, A | 1 |
| Short, M | 1 |
| Burnatowska-Hledin, MA | 1 |
| Kyrtsonis, MC | 6 |
| Kyriakou, D | 2 |
| Spanoudakis, E | 2 |
| Vasilopoulos, G | 1 |
| Kioumi, A | 1 |
| Zikos, P | 3 |
| Aktypi, A | 1 |
| Briasoulis, E | 2 |
| Megalakaki, A | 1 |
| Repousis, P | 2 |
| Adamopoulos, I | 1 |
| Gogos, D | 1 |
| Kotsopoulou, M | 2 |
| Pappa, V | 1 |
| Papadaki, E | 1 |
| Nikolaou, E | 1 |
| Giannopoulou, E | 1 |
| Hatzimichael, E | 2 |
| Giannakoulas, N | 2 |
| Douka, V | 1 |
| Kokoviadou, K | 1 |
| Timotheatou, D | 1 |
| Alani, M | 1 |
| Lemaire, P | 1 |
| Storrar, NPF | 1 |
| Mathur, A | 1 |
| Johnson, PRE | 1 |
| Roddie, PH | 1 |
| Jarkovsky, J | 3 |
| Gregora, E | 4 |
| Fraňková, H | 1 |
| Treur, M | 1 |
| Bouwmeester, W | 1 |
| Dunn, TJ | 1 |
| Price, E | 1 |
| Coutré, SE | 2 |
| Gotlib, J | 1 |
| Berube, C | 1 |
| Kaufman, GP | 2 |
| Medeiros, BC | 2 |
| Liedtke, M | 4 |
| Burslem, GM | 1 |
| Ottis, P | 1 |
| Jaime-Figueroa, S | 1 |
| Morgan, A | 1 |
| Cromm, PM | 1 |
| Toure, M | 1 |
| Crews, CM | 1 |
| Charlinski, G | 3 |
| Grzasko, N | 10 |
| Janczarski, M | 1 |
| Szeremet, A | 1 |
| Waszczuk-Gajda, A | 1 |
| Bernatowicz, P | 1 |
| Swiderska, A | 1 |
| Guzicka-Kazimierczak, R | 1 |
| Lech-Maranda, E | 2 |
| Szczepaniak, A | 1 |
| Wichary, R | 1 |
| Dmoszynska, A | 19 |
| Reed-Guy, L | 1 |
| Hoteit, MA | 1 |
| Hude, I | 1 |
| Batinić, J | 1 |
| Kinda, SB | 1 |
| Pulanić, D | 1 |
| Luczkowska, K | 1 |
| Litwinska, Z | 1 |
| Paczkowska, E | 1 |
| Machalinski, B | 1 |
| Watanabe, N | 1 |
| Kitahara, H | 1 |
| Iwao, N | 1 |
| Ohta, Y | 3 |
| Koike, M | 1 |
| Komatsu, N | 7 |
| Lai, T | 1 |
| Zhou, XG | 1 |
| Wang, LP | 1 |
| Mei, JG | 2 |
| Zhai, YP | 2 |
| Li, CS | 1 |
| Ji, Y | 1 |
| Zhang, WP | 1 |
| Fu, LP | 1 |
| Oka, S | 3 |
| Ono, K | 3 |
| Nohgawa, M | 2 |
| Royle, KL | 1 |
| Bell, SE | 8 |
| Malecek, MK | 1 |
| Schroeder, M | 1 |
| Dukeman, J | 1 |
| Ghobadi, A | 1 |
| Wildes, T | 1 |
| Turnbull, AMJ | 1 |
| Karmiris, E | 1 |
| Anderson, DF | 1 |
| Chang, A | 1 |
| Nasti, TH | 1 |
| Khan, MK | 1 |
| Parashar, S | 1 |
| Boise, LH | 5 |
| Ahmed, R | 1 |
| Martello, M | 5 |
| Santacroce, B | 2 |
| Rocchi, S | 4 |
| Lejniece, S | 1 |
| Bekadja, MA | 1 |
| Stankovic, S | 1 |
| Durán, MS | 1 |
| Kochkareva, Y | 1 |
| Berthou, C | 6 |
| Masliak, Z | 3 |
| Pečeliūnas, V | 1 |
| Silva, J | 1 |
| Louw, V | 2 |
| Nemet, D | 1 |
| Borbényi, Z | 1 |
| Abadi, U | 1 |
| Pedersen, RS | 1 |
| Černelč, P | 1 |
| Couturier, C | 2 |
| Feys, C | 1 |
| Thoret-Bauchet, F | 1 |
| Bohn, JP | 1 |
| Peschel, I | 1 |
| Oberacher, H | 1 |
| Steurer, M | 2 |
| Zheng, Y | 2 |
| Shen, H | 1 |
| Feng, J | 1 |
| Tang, H | 1 |
| Zhang, N | 1 |
| Gao, G | 1 |
| Abonour, R | 10 |
| Wagner, L | 1 |
| Durie, BGM | 1 |
| Narang, M | 2 |
| Terebelo, HR | 1 |
| Gasparetto, CJ | 1 |
| Toomey, K | 2 |
| Hardin, JW | 2 |
| Kitali, A | 1 |
| Swern, AS | 4 |
| Rifkin, RM | 3 |
| Sivaraj, D | 2 |
| Green, MM | 2 |
| Kang, Y | 3 |
| Long, GD | 2 |
| Rizzieri, DA | 2 |
| Li, Z | 4 |
| Garrett, AH | 1 |
| McIntyre, JL | 1 |
| Chao, NJ | 2 |
| Qian, X | 2 |
| Bjorklund, C | 1 |
| Łączkowski, KZ | 1 |
| Baranowska-Łączkowska, A | 1 |
| Yang, MJ | 1 |
| Tomlinson, R | 1 |
| Soyer, N | 1 |
| Patır, P | 1 |
| Uysal, A | 1 |
| Duran, M | 1 |
| Ünal, HD | 1 |
| Durusoy, R | 1 |
| Tombuloğlu, M | 1 |
| Şahin, F | 1 |
| Töbü, M | 1 |
| Lee, HJ | 3 |
| Brown, SR | 3 |
| Hall, A | 2 |
| Streetly, M | 6 |
| Oakervee, H | 5 |
| Low, E | 3 |
| Cavenagh, J | 12 |
| Chehab, S | 1 |
| Panjic, EH | 1 |
| Gleason, C | 5 |
| Cella, D | 1 |
| McKendrick, J | 2 |
| Kudlac, A | 1 |
| Oukessou, A | 1 |
| Zyczynski, T | 1 |
| Davis, C | 1 |
| Pisani, F | 3 |
| Rizzi, R | 5 |
| Evangelista, A | 8 |
| Marcatti, M | 4 |
| Vallone, R | 1 |
| Storti, S | 1 |
| Bernardini, A | 3 |
| Centurioni, R | 7 |
| Aitini, E | 1 |
| Palmas, A | 2 |
| Angelucci, E | 3 |
| Ferrando, P | 1 |
| Baraldi, A | 3 |
| Meneghini, V | 2 |
| Grammatico, S | 1 |
| Korubo, KI | 1 |
| Madu, AJ | 1 |
| Okoye, HC | 1 |
| Nwogoh, B | 1 |
| Scott, AP | 1 |
| Berge, B | 1 |
| Lenain, P | 6 |
| Voog, E | 2 |
| Allangba, O | 2 |
| Jourdan, E | 1 |
| Brechignac, S | 3 |
| Eisenmann, JC | 3 |
| Glaisner, S | 2 |
| Loiseau, HA | 2 |
| Gourd, E | 1 |
| Jandial, A | 1 |
| Mishra, K | 1 |
| Lad, D | 1 |
| Prakash, G | 1 |
| Khadwal, A | 1 |
| Malhotra, P | 2 |
| Gajic, S | 1 |
| Callahan, EC | 1 |
| Brown, JK | 1 |
| Elicker, B | 1 |
| Ley, B | 1 |
| Blanc, PD | 1 |
| Velasco-Álvarez, D | 1 |
| Gorospe-Sarasúa, L | 1 |
| Fra-Fernández, S | 1 |
| Vertolli, U | 1 |
| Berno, T | 6 |
| Riva, M | 1 |
| Adami, F | 2 |
| Angelini, A | 1 |
| Calò, LA | 1 |
| Xu, XS | 1 |
| Gomez, D | 1 |
| Medvedova, E | 1 |
| Schecter, J | 3 |
| Jansson, R | 1 |
| Zhang, L | 8 |
| Sun, YN | 1 |
| Clemens, PL | 2 |
| Dytfeld, D | 7 |
| Hori, M | 2 |
| Popa McKiver, M | 1 |
| Jou, YM | 1 |
| Shelat, SG | 1 |
| Robbins, M | 2 |
| Rafferty, B | 1 |
| Hock, BD | 2 |
| Mulholland, KS | 1 |
| McKenzie, JL | 1 |
| Pearson, JF | 1 |
| MacPherson, SA | 1 |
| Croizier, C | 1 |
| Bailly, S | 1 |
| Burki, TK | 1 |
| Adamu, H | 1 |
| Mishkin, J | 1 |
| Bhutani, M | 6 |
| Mian, M | 2 |
| Badiali, S | 2 |
| Cappelletto, PC | 1 |
| Marcheselli, L | 2 |
| Luminari, S | 1 |
| Pascarella, A | 1 |
| Tagariello, G | 1 |
| Marabese, A | 2 |
| Mondello, P | 2 |
| Billio, A | 2 |
| Cortelazzo, S | 2 |
| Imam, F | 1 |
| Al-Harbi, NO | 1 |
| Al-Harbi, MM | 1 |
| Qamar, W | 1 |
| Aljerian, K | 1 |
| Belali, OM | 1 |
| Alsanea, S | 1 |
| Alanazi, AZ | 1 |
| Alhazzani, K | 1 |
| Xu, YJ | 2 |
| Xia, B | 2 |
| Wang, CY | 1 |
| Zhao, HF | 2 |
| Yang, HL | 3 |
| Wang, XF | 2 |
| Yu, Y | 2 |
| Zhang, YZ | 3 |
| Seifter, E | 1 |
| He, GL | 1 |
| Xu, DR | 1 |
| Zou, WY | 2 |
| He, SZ | 1 |
| Hussain, MJ | 1 |
| Robinson, MM | 1 |
| Hamadeh, I | 1 |
| Arnall, J | 1 |
| Friend, R | 2 |
| Symanowski, JT | 1 |
| Gong, CL | 1 |
| Studdert, AL | 1 |
| Breitkreutz, I | 10 |
| Raab, M | 1 |
| de la Calle, VG | 1 |
| Takeuchi, S | 2 |
| Shiragami, H | 2 |
| Shimazu, Y | 2 |
| Nougawa, M | 1 |
| Damnernsawad, A | 1 |
| Pan, J | 1 |
| Pravin, DP | 1 |
| Alkan, S | 1 |
| Tyner, JW | 1 |
| van Beurden-Tan, CHY | 2 |
| Franken, MG | 3 |
| Uyl-de Groot, CA | 5 |
| de Assis Pereira Hansen, C | 1 |
| Filho, JS | 1 |
| de Mattos Nascimento, M | 1 |
| Alves, FA | 1 |
| Neotti, T | 1 |
| D Almeida Costa, F | 1 |
| Gertz, M | 4 |
| Murakami, H | 15 |
| Kasamatsu, T | 2 |
| Murakami, J | 1 |
| Kiguchi, T | 2 |
| Kanematsu, T | 1 |
| Ogawa, D | 1 |
| Takamatsu, H | 3 |
| Ozaki, S | 10 |
| Miki, H | 5 |
| Takeo, T | 1 |
| Yamauchi, T | 2 |
| Morishita, T | 1 |
| Jiménez-Segura, R | 1 |
| Gironella, M | 6 |
| Abella, E | 1 |
| García-Guiñón, A | 1 |
| Cabezudo, E | 1 |
| Clapés, V | 1 |
| Soler, JA | 1 |
| Escoda, L | 1 |
| López-Pardo, J | 1 |
| Fernández de Larrea, C | 3 |
| Cibeira, MT | 12 |
| Isola, I | 1 |
| Weinhold, N | 1 |
| Ashby, C | 1 |
| Melchor, L | 2 |
| Johnson, D | 1 |
| Begum, DB | 1 |
| Ellis, S | 1 |
| Sherborne, AL | 1 |
| Greaves, M | 1 |
| Chen, J | 2 |
| Chen, HM | 1 |
| Wei, W | 2 |
| Peng, R | 1 |
| Shi, HT | 1 |
| Chen, XL | 1 |
| Wu, LX | 1 |
| Zhou, N | 1 |
| Mark, TM | 8 |
| Forsberg, PA | 2 |
| Rossi, AC | 2 |
| Pearse, RN | 6 |
| Pekle, KA | 1 |
| Perry, A | 2 |
| Boyer, A | 1 |
| Tegnestam, L | 2 |
| Jayabalan, D | 8 |
| Coleman, M | 15 |
| D'Arena, G | 2 |
| Galdo, G | 1 |
| Antunes, L | 1 |
| Rocha-Gonçalves, F | 1 |
| Chacim, S | 1 |
| Lefèvre, C | 1 |
| Pereira, M | 1 |
| Pereira, S | 1 |
| Zagorska, A | 1 |
| Bento, MJ | 1 |
| Qin, XQ | 1 |
| Li, ZJ | 2 |
| Liu, LT | 1 |
| Yang, LH | 1 |
| Ma, YP | 1 |
| Deng, SH | 2 |
| Sui, WW | 1 |
| Qin, Y | 2 |
| Feng, XY | 1 |
| Zang, MR | 1 |
| Yang, WJ | 1 |
| Zhang, YR | 2 |
| Yi, SH | 1 |
| Wang, TY | 1 |
| Lv, R | 1 |
| Zou, DH | 3 |
| Zhao, YZ | 3 |
| Qiu, LG | 6 |
| Barosi, G | 2 |
| Gale, RP | 1 |
| Fernández-Lázaro, D | 3 |
| Fernández-Lázaro, CI | 1 |
| Caballero García, A | 1 |
| Córdova Martínez, A | 1 |
| Auger-Quittet, S | 1 |
| Bareau, B | 1 |
| Cliquennois, M | 1 |
| Fuzibet, JG | 3 |
| Belhadj-Merzoug, K | 1 |
| Rey, P | 1 |
| Leyronnas, C | 1 |
| Zarnitsky, C | 2 |
| Bosson, JL | 1 |
| Pernod, G | 1 |
| Liu, Q | 2 |
| Talbot, A | 1 |
| Jullien, M | 1 |
| Bonnet, A | 2 |
| Bai, J | 2 |
| Feng, Y | 1 |
| Shen, Y | 4 |
| Huang, L | 3 |
| He, A | 1 |
| Omoto, E | 1 |
| Adachi, Y | 3 |
| Choi, I | 1 |
| Fujishima, N | 2 |
| Miyamoto, T | 4 |
| Maeda, A | 1 |
| Suzumiya, J | 1 |
| Yamamura, R | 1 |
| Nagafuji, K | 1 |
| Kuroda, Y | 8 |
| Yujiri, T | 1 |
| Takamatsu, Y | 2 |
| Harada, M | 1 |
| Akashi, K | 4 |
| Nitschmann, S | 2 |
| Zago, M | 3 |
| Besemer, B | 1 |
| Haenel, M | 2 |
| Duerig, J | 1 |
| Benner, A | 8 |
| Yang, R | 1 |
| Mengzhen, L | 1 |
| Ren, L | 1 |
| Mishra, AK | 2 |
| Yoshifuji, K | 1 |
| Toya, T | 1 |
| Adachi, H | 1 |
| Fujita, M | 2 |
| Wada, A | 1 |
| Konuma, R | 1 |
| Kishida, Y | 1 |
| Konishi, T | 1 |
| Nagata, A | 1 |
| Yamada, Y | 1 |
| Kaito, S | 1 |
| Kumagai, T | 1 |
| Inamoto, K | 1 |
| Akiyama, M | 2 |
| Igarashi, A | 2 |
| Najima, Y | 1 |
| Doki, N | 2 |
| Kakihana, K | 1 |
| Sakamaki, H | 2 |
| Ohashi, K | 4 |
| Barwick, BG | 1 |
| Jaye, DL | 1 |
| Gupta, VA | 2 |
| Auclair, D | 1 |
| Keats, JJ | 1 |
| Vertino, PM | 1 |
| Hassan, H | 1 |
| Lakhani, M | 1 |
| Sagar, F | 1 |
| Kamal, A | 1 |
| Ali, Z | 1 |
| Razzaq, F | 1 |
| Zar, MA | 1 |
| Hassan, SF | 1 |
| Safdar, A | 1 |
| Raychaudhuri, S | 1 |
| Bouchemla, N | 1 |
| Nadri, A | 1 |
| Chettati, M | 1 |
| Fadili, W | 1 |
| Laouad, I | 1 |
| Heffner, LT | 4 |
| Chocholska, S | 3 |
| Jankowska-Łęcka, O | 1 |
| Wan, N | 1 |
| Liang, Z | 1 |
| Xie, J | 1 |
| Lin, T | 1 |
| Zhang, T | 1 |
| Jiang, J | 1 |
| Kehm, H | 1 |
| Mangold, M | 1 |
| Cransac, A | 1 |
| Aho, S | 1 |
| Esparza, MAG | 1 |
| Majluf-Cruz, A | 1 |
| García-Chavez, J | 1 |
| Montiel-Cervantes, LA | 1 |
| Reyes-Maldonado, E | 1 |
| Hernandez-Caballero, A | 1 |
| Rodríguez-González, MG | 1 |
| Nooka, A | 3 |
| van de Donk, NW | 10 |
| Zhuang, S | 1 |
| Smith, E | 2 |
| Deraedt, W | 1 |
| Xiao, HF | 1 |
| Dong, ZG | 1 |
| Xu, WQ | 1 |
| Chen, XY | 1 |
| Xin, PL | 1 |
| Zhang, JY | 1 |
| Killock, D | 3 |
| Oakervee, HE | 1 |
| Banh, RH | 1 |
| D'Rozario, JM | 1 |
| Martínez, S | 1 |
| Extremera, S | 1 |
| Kahatt, C | 1 |
| Alfaro, V | 1 |
| Carella, AM | 10 |
| Cannell, P | 2 |
| Ryu, HW | 1 |
| Pastore, D | 1 |
| Fragasso, A | 3 |
| Guarini, A | 5 |
| Mazza, P | 3 |
| Pavone, V | 2 |
| Tarantini, G | 2 |
| Falcone, AP | 9 |
| Mele, A | 8 |
| Miccolis, MR | 1 |
| Palazzo, G | 3 |
| Quinto, AM | 1 |
| Reddiconto, G | 2 |
| Specchia, G | 2 |
| Capalbo, SF | 1 |
| Chai, K | 1 |
| Shih, S | 1 |
| Lewsey, R | 1 |
| Chen, K | 2 |
| McDiarmid, B | 1 |
| Jackson, S | 1 |
| Meguro, K | 1 |
| Sasaki, O | 1 |
| Takagi, T | 5 |
| Shah, J | 3 |
| Usmani, S | 4 |
| Berdeja, JG | 3 |
| Lyons, RM | 1 |
| Chang, YL | 1 |
| Blacklock, H | 2 |
| George, A | 1 |
| Chanan-Khan, A | 12 |
| Sherbenou, D | 2 |
| Benyamini, N | 1 |
| Ribrag, V | 1 |
| San Miguel, J | 17 |
| Kikuchi, J | 1 |
| Iha, H | 1 |
| Toyama-Sorimachi, N | 1 |
| Koyama, D | 1 |
| Izumi, T | 1 |
| Yasui, H | 2 |
| Suzuki, A | 1 |
| Furukawa, Y | 1 |
| Lee, YJ | 1 |
| Sohn, SK | 6 |
| Bae, SH | 2 |
| Leahy, J | 1 |
| Walsh, C | 1 |
| Scullen, T | 1 |
| Santo, L | 4 |
| Vallet, S | 5 |
| Fulciniti, M | 3 |
| Eda, H | 1 |
| Cirstea, D | 3 |
| Patel, K | 2 |
| Nemani, N | 1 |
| Yee, A | 1 |
| Mahindra, A | 9 |
| Slawinska-Brych, A | 1 |
| Zdzisinska, B | 1 |
| Mizerska-Dudka, M | 1 |
| Kandefer-Szerszen, M | 1 |
| Martin, TG | 2 |
| Alsina, M | 18 |
| Kunkel, LA | 1 |
| Wong, AF | 1 |
| Lee, S | 4 |
| Suzuki, T | 2 |
| Yoshida, T | 2 |
| Mori, F | 1 |
| Ito, A | 2 |
| Ri, M | 2 |
| Ishida, T | 7 |
| Komatsu, H | 2 |
| Niimi, A | 1 |
| Traynor, K | 1 |
| Amraoui, K | 1 |
| Maître, B | 1 |
| Jannière-Nartey, C | 1 |
| Dupuis, J | 1 |
| Sridhar, S | 1 |
| Dutta, TK | 1 |
| Basu, D | 1 |
| Watanabe, R | 1 |
| Tokuhira, M | 2 |
| García-Muñoz, R | 1 |
| Robles-de-Castro, D | 1 |
| Muñoz-Rodríguez, A | 1 |
| Rabasa, P | 1 |
| Yordanova, A | 1 |
| Neben, K | 16 |
| Witzens-Harig, M | 4 |
| Gütgemann, I | 1 |
| Moehler, T | 10 |
| Schmidt-Wolf, IG | 9 |
| Young, T | 1 |
| Chu, CM | 3 |
| Jimenez-Zepeda, V | 1 |
| Dangouloff-Ros, V | 1 |
| Cervera, P | 1 |
| Carbonell, N | 1 |
| Arrivé, L | 1 |
| Zou, Y | 4 |
| Sheng, Z | 7 |
| Yu, J | 5 |
| Abe, M | 9 |
| An, SY | 1 |
| An, CH | 1 |
| Choi, KS | 1 |
| Heo, MS | 1 |
| Briani, C | 5 |
| Torre, CD | 1 |
| Campagnolo, M | 3 |
| Lucchetta, M | 2 |
| Candiotto, L | 1 |
| Padua, L | 1 |
| Ermani, M | 2 |
| Cavaletti, G | 2 |
| Álvarez-Fernández, S | 1 |
| Ortiz-Ruiz, MJ | 1 |
| Parrott, T | 1 |
| Zaknoen, S | 1 |
| Burrows, FJ | 1 |
| Esparís-Ogando, A | 1 |
| Pandiella, A | 4 |
| Minvielle, S | 4 |
| Carter, SL | 1 |
| Laport, GG | 1 |
| Danbara, M | 1 |
| Tadera, N | 1 |
| Katayama, T | 1 |
| Aoki, T | 4 |
| Szalat, R | 2 |
| Benajiba, L | 2 |
| Regny, C | 1 |
| Caulier, A | 2 |
| Garciaz, S | 1 |
| Heintel, D | 4 |
| Rocci, A | 4 |
| Bolomsky, A | 4 |
| Caltagirone, S | 3 |
| Pfeifer, S | 1 |
| Jäger, U | 2 |
| Elkinson, S | 1 |
| McCormack, PL | 2 |
| Jungkunz-Stier, I | 1 |
| Zekl, M | 1 |
| Seggewiss-Bernhardt, R | 1 |
| Sellner, L | 1 |
| Heiss, C | 2 |
| Lehners, N | 1 |
| Egerer, G | 6 |
| Ho, AD | 19 |
| Bhutani, D | 1 |
| Zonder, J | 3 |
| Tageja, N | 4 |
| Ayash, L | 1 |
| Deol, A | 1 |
| Al-Kadhimi, Z | 1 |
| Abrams, J | 1 |
| Lum, L | 1 |
| Ratanatharathorn, V | 1 |
| Uberti, J | 1 |
| Abidi, MH | 2 |
| Gerrie, AS | 1 |
| Cheng, L | 1 |
| Panzarella, T | 1 |
| Stewart, KA | 2 |
| Trieu, Y | 3 |
| Anwer, S | 1 |
| Collings, F | 1 |
| Trace, K | 1 |
| Sun, Y | 1 |
| Sternberg, A | 1 |
| Sawyer, J | 3 |
| Rosenthal, A | 2 |
| Cottler-Fox, M | 4 |
| Epstein, J | 14 |
| Yaccoby, S | 7 |
| Sexton, R | 4 |
| Hoering, A | 16 |
| Heuck, CJ | 4 |
| Waheed, S | 10 |
| Chauhan, N | 2 |
| Johann, D | 2 |
| Muzaffar, J | 1 |
| Petty, N | 11 |
| Bailey, C | 4 |
| Crowley, J | 27 |
| van Rhee, F | 25 |
| Barlogie, B | 58 |
| Zamarin, D | 1 |
| Arcila, ME | 1 |
| Chimento, D | 2 |
| Weltz, J | 1 |
| Babu, D | 1 |
| Harada, T | 7 |
| Oda, A | 4 |
| Nakamura, S | 5 |
| Kagawa, K | 4 |
| Takeuchi, K | 3 |
| Matsumoto, T | 7 |
| Ali, A | 1 |
| Hothi, SS | 1 |
| Thompson, A | 1 |
| Malik, N | 1 |
| Mathieu, S | 1 |
| Soubrier, M | 1 |
| Tournadre, A | 1 |
| Dubost, JJ | 1 |
| Onishi, Y | 1 |
| Okitsu, Y | 1 |
| Katsuoka, Y | 1 |
| Fujiwara, T | 1 |
| Fukuhara, N | 2 |
| Ishizawa, K | 3 |
| Takagawa, M | 1 |
| Harigae, H | 1 |
| Maïga, S | 2 |
| Gomez-Bougie, P | 1 |
| Bonnaud, S | 1 |
| Gratas, C | 1 |
| Pellat-Deceunynck, C | 1 |
| Amiot, M | 2 |
| Cavallo, F | 25 |
| Saini, N | 2 |
| Patrizi, A | 1 |
| Venturi, M | 1 |
| Dika, E | 1 |
| Maibach, H | 1 |
| Brandi, G | 1 |
| Srivastava, G | 4 |
| Rana, V | 1 |
| Zeldenrust, S | 4 |
| Russell, S | 3 |
| Kyle, R | 2 |
| Renzulli, M | 1 |
| Remondini, D | 2 |
| Tagliafico, E | 1 |
| Martinelli, G | 3 |
| Roncaglia, E | 1 |
| Masini, L | 7 |
| Ledda, A | 5 |
| Dico, F | 1 |
| Wang, TF | 1 |
| Ahluwalia, R | 1 |
| Fiala, MA | 1 |
| Trinkaus, KM | 1 |
| Cox, DP | 1 |
| Jaenicke, M | 1 |
| Moliske, CC | 1 |
| Carson, KR | 1 |
| Tomasson, MH | 1 |
| Stockerl-Goldstein, KE | 1 |
| Uchihara, JN | 1 |
| Arakaki, H | 1 |
| Nagano, S | 1 |
| Mori, M | 2 |
| Kato, A | 2 |
| Ono, Y | 2 |
| Aoki, K | 1 |
| Arima, H | 1 |
| Takiuchi, Y | 1 |
| Tabata, S | 1 |
| Yanagita, S | 1 |
| Matsushita, A | 1 |
| Ishikawa, T | 3 |
| Imai, H | 2 |
| Vivas, AC | 1 |
| Chimento, SM | 1 |
| Herschthal, J | 1 |
| Spock, C | 1 |
| Alonso-Llamazares, J | 1 |
| Cerrato, C | 7 |
| Yang, B | 1 |
| Yu, RL | 1 |
| Chi, XH | 1 |
| Lu, XC | 1 |
| Pelliccia, S | 1 |
| Di Napoli, A | 1 |
| Naso, V | 1 |
| Alma, E | 1 |
| Rebecchini, C | 1 |
| Cox, MC | 1 |
| Wagner, I | 1 |
| Schmalfeld, M | 1 |
| Röhrborn, R | 1 |
| Hebenstreit, K | 1 |
| Al-Ali, HK | 1 |
| Jäkel, N | 1 |
| Gonzalez, MM | 1 |
| Kidd, L | 1 |
| Quesada, J | 1 |
| Nguyen, N | 1 |
| Isozumi, Y | 2 |
| Arai, R | 1 |
| Fujimoto, K | 1 |
| Koyama, T | 2 |
| Agrawal, S | 1 |
| Deshpande, A | 1 |
| Szymonifka, J | 7 |
| Mitchell, A | 2 |
| Keller, J | 2 |
| Roddie, H | 3 |
| Allietta, N | 2 |
| Broer, E | 2 |
| Mazier, MA | 1 |
| Angermund, R | 2 |
| Pochintesta, L | 1 |
| Cocito, F | 5 |
| Bernasconi, P | 1 |
| Cazzola, M | 3 |
| Nagamachi, Y | 2 |
| Yamauchi, N | 1 |
| Muramatsu, H | 1 |
| Okamoto, T | 1 |
| Inomata, H | 1 |
| Nozawa, E | 1 |
| Koyama, R | 1 |
| Ihara, K | 1 |
| Nishisato, T | 1 |
| Yamada, H | 1 |
| Yano, T | 1 |
| Tanaka, S | 1 |
| Kikuchi, S | 4 |
| Kawano, H | 1 |
| Inagaki, T | 1 |
| Kishi, M | 1 |
| Hirata, T | 1 |
| Kimura, S | 3 |
| Takechi, M | 1 |
| Koide, T | 1 |
| Iwai, M | 1 |
| Katayama, Y | 5 |
| Rawstron, AC | 1 |
| de Tute, RM | 1 |
| Szubert, AJ | 6 |
| Navarro-Coy, N | 1 |
| Feyler, S | 5 |
| Ross, FM | 10 |
| Bagratuni, T | 3 |
| Politou, M | 2 |
| Kostouros, E | 1 |
| Kanelias, N | 1 |
| Baladandayuthapani, V | 2 |
| Lin, HY | 3 |
| Jones, RJ | 3 |
| Kuiatse, I | 1 |
| Yang, J | 5 |
| Plonková, H | 2 |
| Gumulec, J | 2 |
| Roziaková, L | 2 |
| Mistrík, M | 2 |
| Chaudhary, L | 1 |
| Awan, F | 2 |
| Cumpston, A | 2 |
| Leadmon, S | 2 |
| Watkins, K | 2 |
| Tse, W | 1 |
| Craig, M | 3 |
| Nardone, B | 1 |
| Wu, S | 2 |
| Garden, BC | 1 |
| West, DP | 1 |
| Reich, LM | 1 |
| Lacouture, ME | 1 |
| Rabea, A | 1 |
| Cserti-Gazdewich, C | 1 |
| Tsang, R | 1 |
| Magarotto, V | 14 |
| Guglielmelli, T | 18 |
| Pezzatti, S | 5 |
| Ferrari, S | 1 |
| Oliva, S | 7 |
| Omedé, P | 10 |
| Passera, R | 6 |
| Chen, F | 4 |
| Yu, L | 6 |
| Meng, F | 4 |
| Ai, H | 3 |
| Wortman-Vayn, H | 1 |
| Zhang, D | 1 |
| Chojnacki, J | 1 |
| Du, Y | 1 |
| Fu, H | 1 |
| Grant, S | 1 |
| Zhang, S | 3 |
| Sekiguchi, Y | 3 |
| Asahina, T | 1 |
| Shimada, A | 2 |
| Sugimoto, K | 4 |
| Nakamura, N | 4 |
| Sawada, T | 3 |
| Noguchi, M | 3 |
| Miladinovic, B | 1 |
| Patel, A | 2 |
| Ho, VQ | 2 |
| Nishihori, T | 5 |
| Ochoa-Bayona, JL | 2 |
| Sullivan, DM | 3 |
| Dalton, WS | 3 |
| Djulbegovic, B | 3 |
| Tan, D | 1 |
| Teoh, G | 2 |
| Ong, KH | 1 |
| Goh, YT | 2 |
| Durie, BG | 15 |
| Moatti, M | 1 |
| Zohar, S | 1 |
| Mary, JY | 4 |
| Chevret, S | 2 |
| Miyao, K | 1 |
| Sakemura, R | 1 |
| Sakai, T | 1 |
| Tsushita, N | 1 |
| Kato, T | 1 |
| Niimi, K | 1 |
| Sawa, M | 1 |
| Zhang, RB | 1 |
| He, L | 1 |
| Ma, Z | 1 |
| Liu, SQ | 1 |
| Spina, A | 1 |
| Guaragna, G | 1 |
| Giannotta, A | 1 |
| Melpignano, A | 2 |
| Quarta, G | 4 |
| Walterova, L | 1 |
| Adamova, D | 1 |
| Melicharova, H | 2 |
| Bacovsky, J | 4 |
| Scudla, V | 7 |
| Lai, Y | 1 |
| Zhao, X | 3 |
| Jiang, Q | 1 |
| Huang, X | 3 |
| Seldin, DC | 1 |
| Finn, KT | 1 |
| Fennessey, SA | 1 |
| Mattar, B | 1 |
| Safah, HF | 1 |
| Dean, RM | 1 |
| Xu, M | 1 |
| Hou, Y | 1 |
| Sheng, L | 1 |
| Peng, J | 2 |
| Ortega, M | 1 |
| Mallo, M | 1 |
| Solé, F | 1 |
| Sánchez-Morata, C | 1 |
| López-Andreoni, L | 1 |
| Martínez-Morgado, N | 1 |
| Valcárcel, D | 1 |
| Vallespí, T | 1 |
| Vadikolia, C | 1 |
| Lalagianni, C | 1 |
| Papageorgiou, G | 1 |
| Matsouka, P | 1 |
| Karras, G | 1 |
| Anagnostopoulos, N | 9 |
| Michali, E | 2 |
| Tsakiridou, A | 1 |
| Tsionos, K | 2 |
| Anargyrou, K | 1 |
| Maniatis, A | 4 |
| El Husseiny, NM | 1 |
| Kasem, N | 1 |
| El Azeeim, HA | 1 |
| Mattar, MW | 1 |
| Desai, A | 1 |
| Cakana, A | 4 |
| Hernández, MT | 12 |
| Giraldo, P | 6 |
| López Corral, L | 1 |
| Palomera, L | 11 |
| Bargay, J | 8 |
| Prosper, F | 3 |
| López, J | 4 |
| Olavarría, E | 1 |
| Quintana, N | 2 |
| García, JL | 2 |
| Pamukçuoğlu, M | 1 |
| Emmez, H | 1 |
| Tunçcan, OG | 1 |
| Oner, AY | 1 |
| Cırak, MY | 1 |
| Senol, E | 1 |
| Sucak, GT | 3 |
| Klánová, M | 1 |
| Miyagishima, T | 1 |
| Tateno, T | 1 |
| Kasahara, KH | 1 |
| Sawada, K | 3 |
| Sogabe, S | 2 |
| Oda, H | 1 |
| Tardy, S | 1 |
| Bonnet, S | 1 |
| Gay, J | 1 |
| Debarri, H | 1 |
| Herbaux, C | 3 |
| Guidez, S | 3 |
| Michel, J | 1 |
| Serrier, C | 1 |
| Miljkovic, D | 1 |
| Avet Loiseau, H | 1 |
| Raja, KR | 1 |
| Plasil, M | 1 |
| Rihova, L | 2 |
| Pelcova, J | 1 |
| El-Amm, J | 1 |
| Tabbara, IA | 1 |
| Rollin-Sillaire, A | 1 |
| Delbeuck, X | 1 |
| Pollet, M | 1 |
| Mackowiak, MA | 1 |
| Lenfant, P | 1 |
| Noel, MP | 2 |
| Pasquier, F | 1 |
| Le Rhun, E | 1 |
| Rossi, D | 10 |
| Rota-Scalabrini, D | 1 |
| Santagostino, A | 1 |
| Baldi, I | 2 |
| Ise, M | 2 |
| Sakai, C | 2 |
| Kumagai, K | 2 |
| McCurdy, AR | 1 |
| Meadows, JP | 1 |
| Christoulas, D | 12 |
| Papatheodorou, A | 2 |
| Pouli, A | 6 |
| Michalis, E | 2 |
| Gkotzamanidou, M | 6 |
| Koulieris, E | 1 |
| Zervas, K | 12 |
| Greenberg, AJ | 1 |
| Walters, DK | 1 |
| Jelinek, DF | 1 |
| Smith, D | 4 |
| Stevens, J | 1 |
| Quinn, J | 3 |
| Ingram, W | 1 |
| Xu, YL | 1 |
| Zhang, XQ | 1 |
| Miguel, JS | 4 |
| Lacy, M | 6 |
| Banos, A | 7 |
| Ivanova, V | 4 |
| Jacques, C | 14 |
| Kavalerchik, E | 1 |
| Huang, M | 1 |
| Voelter, V | 1 |
| Kwak, JY | 2 |
| Ryoo, HM | 3 |
| Kim, YS | 2 |
| Park, SK | 1 |
| Jo, DY | 2 |
| Jun, HJ | 1 |
| Kim, KH | 1 |
| Abdullah, WZ | 1 |
| Roshan, TM | 1 |
| Hussin, A | 1 |
| Zain, WS | 1 |
| Abdullah, D | 1 |
| Baz, RC | 3 |
| Hussein, MA | 21 |
| Oliver, EF | 1 |
| Nardelli, LA | 2 |
| Nodzon, LA | 1 |
| Chan, AC | 1 |
| Neeson, P | 4 |
| Leeansyah, E | 1 |
| Tainton, K | 1 |
| Ritchie, D | 4 |
| Berzins, SP | 1 |
| Manios, E | 1 |
| Papadimitriou, C | 2 |
| Saito, T | 1 |
| Tsuruoka, Y | 1 |
| Nishio, Y | 1 |
| Suzuki, Y | 1 |
| Kato, M | 1 |
| Isobe, Y | 2 |
| Sakai, H | 1 |
| Takahashi, M | 1 |
| Miura, I | 1 |
| Lin, M | 2 |
| Niu, S | 2 |
| Lamm, W | 1 |
| Drach-Schauer, B | 1 |
| Eder, S | 1 |
| Drach, J | 11 |
| Yaqub, S | 1 |
| Ballester, G | 1 |
| Ballester, O | 2 |
| Yoon, JH | 2 |
| Shin, SH | 1 |
| Cho, BS | 2 |
| Eom, KS | 2 |
| Kim, YJ | 2 |
| Cho, SG | 2 |
| Kim, DW | 3 |
| Lee, JW | 4 |
| Min, WS | 2 |
| Park, CW | 1 |
| Gras, J | 1 |
| Burnette, BL | 1 |
| Harris, AM | 1 |
| Sloan, JA | 1 |
| Tilburt, JC | 1 |
| Atanackovic, D | 4 |
| Schilling, G | 3 |
| Bedewy, AM | 1 |
| El-Maghraby, SM | 1 |
| Uttervall, K | 2 |
| Liwing, J | 3 |
| Gahrton, G | 6 |
| Holmberg, E | 3 |
| Schuster, SR | 1 |
| Kortuem, KM | 4 |
| Bruins, LA | 4 |
| Schmidt, JE | 4 |
| Ahmann, G | 1 |
| Laplant, B | 4 |
| Champion, MD | 2 |
| Laumann, K | 9 |
| McCarthy, P | 3 |
| Zannetti, BA | 4 |
| Kanemura, N | 1 |
| Shibata, Y | 1 |
| Mabuchi, R | 1 |
| Nakamura, H | 2 |
| Kitagawa, J | 1 |
| Goto, N | 1 |
| Hara, T | 1 |
| Tsurumi, H | 2 |
| Moriwaki, H | 1 |
| Kropff, M | 9 |
| Lewis, P | 3 |
| Millar, S | 1 |
| Herth, I | 3 |
| Brandt, J | 1 |
| Heußel, CP | 1 |
| Galea, M | 1 |
| McMillan, N | 1 |
| Weir, C | 1 |
| Adam, P | 1 |
| Fend, F | 1 |
| Kanz, L | 4 |
| Kristinsson, SY | 4 |
| Tsuda, K | 2 |
| Tanimoto, T | 1 |
| Komatsu, T | 1 |
| Mahesh, S | 1 |
| Hu, LP | 1 |
| Yuan, WP | 1 |
| Cheng, T | 3 |
| Miceli, T | 1 |
| Mahlman, M | 1 |
| Bergsagel, LP | 1 |
| Reeder, C | 3 |
| Gastineau, DA | 4 |
| Winters, JL | 1 |
| Gandhi, AK | 5 |
| Mendy, D | 4 |
| Waldman, M | 1 |
| Rychak, E | 2 |
| Miller, K | 2 |
| Gaidarova, S | 2 |
| Breider, M | 3 |
| Carmel, G | 1 |
| Mahmoudi, A | 1 |
| Jackson, P | 1 |
| Abbasian, M | 1 |
| Cathers, BE | 2 |
| Schafer, PH | 4 |
| Daniel, TO | 3 |
| Lopez-Girona, A | 4 |
| Chopra, R | 5 |
| Pedrosa, F | 1 |
| Aróstegui, JI | 1 |
| Elena, M | 1 |
| Filella, X | 4 |
| Yagüe, J | 1 |
| Muppidi, S | 1 |
| Langston, A | 1 |
| Casbourne, D | 1 |
| Saxe, D | 1 |
| Chitta, K | 1 |
| Personett, D | 1 |
| Miller, KC | 8 |
| Thompson, KJ | 1 |
| Carr, J | 1 |
| Ansell, SM | 1 |
| Rivera, CE | 2 |
| Foran, J | 1 |
| Clave, E | 1 |
| Douay, C | 1 |
| Coman, T | 2 |
| Busson, M | 1 |
| Bompoint, C | 1 |
| Moins-Teisserenc, H | 1 |
| Glauzy, S | 1 |
| Carmagnat, M | 1 |
| Gorin, NC | 3 |
| Toubert, A | 1 |
| Pendón-Ruiz de Mier, MV | 1 |
| Alvarez-Lara, MA | 1 |
| Ojeda-López, R | 1 |
| Martín-Malo, A | 1 |
| Carracedo, J | 1 |
| Caballero-Villarraso, J | 1 |
| Alonso, C | 1 |
| Aljama, P | 1 |
| Martín-Gómez, MA | 1 |
| García-Marcos, SA | 1 |
| Caba-Molina, M | 1 |
| Palacios-Gómez, ME | 1 |
| Gómez-Morales, M | 1 |
| Claver-Ferré, C | 1 |
| Defina, M | 2 |
| Lazaryan, A | 1 |
| Reu, FJ | 1 |
| Habecker, B | 1 |
| Ann Karam, M | 1 |
| Reed, J | 3 |
| Hamilton, K | 1 |
| Waksman, J | 1 |
| Bruening, K | 2 |
| Srkalovic, G | 7 |
| Andresen, S | 4 |
| Kalaycio, M | 1 |
| Sweetenham, JW | 1 |
| Sobecks, R | 1 |
| Dean, R | 1 |
| Knight, R | 18 |
| Zeldis, JB | 22 |
| Wijermans, P | 6 |
| Victoria Mateos, M | 1 |
| Mazzone, C | 3 |
| Gottardi, D | 3 |
| José Lahuerta, J | 1 |
| Schaafsma, M | 4 |
| Juliusson, G | 7 |
| Isabel Turel, A | 1 |
| Marina Liberati, A | 1 |
| Cavalli, M | 4 |
| Rosso, S | 1 |
| Pascutti, F | 1 |
| Cunha, LL | 1 |
| Rizzatti, EG | 1 |
| Colleoni, GW | 3 |
| Park, J | 3 |
| Bae, EK | 1 |
| Choi, JH | 1 |
| Jung, WJ | 1 |
| Ahn, KS | 2 |
| Lu, G | 1 |
| Middleton, RE | 1 |
| Naniong, M | 1 |
| Ott, CJ | 1 |
| Mitsiades, CS | 17 |
| Wong, KK | 1 |
| Bradner, JE | 1 |
| Kaelin, WG | 1 |
| Udeshi, ND | 1 |
| Narla, A | 1 |
| Grauman, P | 1 |
| Hurst, SN | 1 |
| McConkey, M | 1 |
| Svinkina, T | 1 |
| Heckl, D | 1 |
| Comer, E | 1 |
| Ciarlo, C | 1 |
| Hartman, E | 1 |
| Schenone, M | 1 |
| Schreiber, SL | 1 |
| Carr, SA | 1 |
| Ebert, BL | 3 |
| Alzoman, NZ | 1 |
| Darwish, IA | 1 |
| Abuhejail, RM | 1 |
| Zhu, G | 1 |
| Shi, L | 3 |
| Zhan, F | 8 |
| Catacchio, I | 1 |
| Berardi, S | 2 |
| De Luisi, A | 2 |
| Caivano, A | 2 |
| Piccoli, C | 1 |
| Ruggieri, V | 1 |
| Frassanito, MA | 1 |
| Ribatti, D | 8 |
| Nico, B | 4 |
| Annese, T | 1 |
| Ruggieri, S | 1 |
| Minoia, C | 4 |
| Ditonno, P | 3 |
| Moschetta, M | 3 |
| Dammacco, F | 7 |
| Aldrin, A | 1 |
| Carlson, K | 3 |
| Enestig, J | 1 |
| Flogegård, M | 2 |
| Forsberg, K | 3 |
| Gruber, A | 2 |
| Haglöf Kviele, H | 1 |
| Johansson, P | 1 |
| Lauri, B | 1 |
| Swedin, A | 2 |
| Svensson, M | 1 |
| Näsman, P | 1 |
| Delasalle, K | 11 |
| Qazilbash, M | 4 |
| Handy, B | 2 |
| Weber, D | 15 |
| König, C | 1 |
| Kleber, M | 5 |
| Reinhardt, H | 2 |
| Hahn, T | 3 |
| Munemoto, S | 1 |
| Murata, R | 1 |
| Terasaki, Y | 1 |
| Nakajima, K | 1 |
| Nakao, S | 1 |
| Svedmyr, E | 1 |
| Lerner, R | 2 |
| Errico, A | 1 |
| Vassou, A | 2 |
| Kartasis, Z | 2 |
| Parcharidou, A | 1 |
| Michael, M | 1 |
| Gika, D | 8 |
| Konstantopoulos, K | 1 |
| Munker, R | 1 |
| Shi, R | 1 |
| Lin, D | 1 |
| Hayes, TG | 1 |
| Tsuji, D | 1 |
| Ikegame, A | 1 |
| Iwasa, M | 2 |
| Udaka, K | 1 |
| Kawai, S | 1 |
| Itoh, K | 1 |
| Yamada-Okabe, H | 1 |
| Uchiyama, A | 1 |
| Motegi, S | 1 |
| Yamada, K | 1 |
| Uehara, A | 1 |
| Ishikawa, O | 1 |
| Krieter, DH | 1 |
| Devine, E | 1 |
| Wanner, C | 1 |
| Storr, M | 1 |
| Krause, B | 1 |
| Lemke, HD | 1 |
| Perry, C | 1 |
| Polliack, A | 2 |
| Green, DJ | 1 |
| Burwick, N | 1 |
| Vesole, D | 6 |
| Zaki, MH | 7 |
| Xie, W | 4 |
| Ghobrial, IM | 16 |
| Munshi, NC | 28 |
| Mazumder, A | 10 |
| Vesole, DH | 17 |
| Colson, K | 3 |
| McKenney, M | 4 |
| Lunde, LE | 3 |
| Feather, J | 1 |
| Warren, D | 5 |
| Francis, D | 1 |
| Weller, E | 8 |
| Yao, Y | 1 |
| Wang, SX | 1 |
| Zhang, YK | 1 |
| Liu, G | 2 |
| Santalla Martínez, M | 1 |
| Blanco Cid, N | 1 |
| Dacal Quintas, R | 1 |
| Levi, A | 3 |
| Benevolo, G | 14 |
| Vincelli, ID | 1 |
| Franceschini, L | 1 |
| Marasca, R | 3 |
| Nozzoli, C | 13 |
| Cooper, K | 2 |
| Picot, J | 2 |
| Bryant, J | 2 |
| Clegg, A | 1 |
| Qian, J | 2 |
| Lan, Y | 1 |
| Lu, Y | 3 |
| Hong, B | 1 |
| Yi, Q | 3 |
| Giles, SL | 1 |
| Messiou, C | 1 |
| Collins, DJ | 1 |
| Morgan, VA | 1 |
| Simpkin, CJ | 1 |
| West, S | 1 |
| deSouza, NM | 1 |
| Tian, Z | 4 |
| Coffman, RL | 1 |
| Schey, SA | 8 |
| Miguel, JF | 4 |
| Mohamed, M | 1 |
| Brain, T | 1 |
| Khalafallah, A | 1 |
| Ghani, S | 1 |
| Al Ustwani, O | 1 |
| Khalid, B | 1 |
| Bogner, P | 1 |
| Grassi, M | 1 |
| Powell, J | 1 |
| Bhat, SA | 1 |
| Biran, N | 4 |
| Pratt, G | 3 |
| Lupparelli, G | 2 |
| Ciccone, G | 11 |
| Mocquard, J | 1 |
| Bourcier, J | 1 |
| Redelsperger, L | 1 |
| Chauvin, C | 1 |
| Thomaré, P | 1 |
| Shida, S | 1 |
| Kameoka, Y | 2 |
| Tagawa, H | 1 |
| Hirokawa, M | 1 |
| Mayes, PA | 1 |
| Acharya, C | 4 |
| Zhong, MY | 1 |
| Cea, M | 1 |
| Cagnetta, A | 1 |
| Craigen, J | 1 |
| Yates, J | 1 |
| Gliddon, L | 1 |
| Fieles, W | 1 |
| Hoang, B | 1 |
| Tunstead, J | 1 |
| Christie, AL | 1 |
| Kung, AL | 1 |
| Bowman, IA | 1 |
| Shah, M | 1 |
| Rodriguez, M | 1 |
| Quinn, R | 1 |
| Pekle, K | 6 |
| Ely, S | 5 |
| Chen-Kiang, S | 7 |
| Genadieva-Stavric, S | 1 |
| Fuchida, S | 5 |
| Tsudo, M | 2 |
| Scott, LJ | 3 |
| Titley, I | 1 |
| Vijayaraghavan, G | 1 |
| Stephens, C | 1 |
| Zeisig, A | 1 |
| Morilla, R | 1 |
| Saitoh, T | 4 |
| Itagaki, M | 1 |
| Yoshiki, Y | 2 |
| Hayashi, K | 1 |
| Lai, M | 1 |
| Morgan, G | 11 |
| Snowden, J | 1 |
| Bird, J | 2 |
| Bowcock, S | 1 |
| Wechalaker, A | 1 |
| Davies, F | 9 |
| Lin, CW | 1 |
| Lin, HH | 2 |
| Yao, M | 2 |
| Tang, JL | 2 |
| Wu, SJ | 2 |
| Chen, YC | 2 |
| Lu, HY | 1 |
| Chen, CY | 3 |
| Chou, WC | 1 |
| Tsay, W | 1 |
| Chou, SJ | 1 |
| Tien, HF | 2 |
| Busch, A | 1 |
| Zeh, D | 1 |
| Janzen, V | 1 |
| Wolf, D | 1 |
| Fingerhut, L | 1 |
| Hahn-Ast, C | 4 |
| Maurer, O | 1 |
| Hwang, SM | 1 |
| Hsu, LF | 1 |
| Liao, YH | 1 |
| Sheen, YS | 1 |
| Chuang, WH | 1 |
| Ghosh, N | 3 |
| Tucker, N | 1 |
| Zahurak, M | 1 |
| Wozney, J | 1 |
| Borrello, I | 12 |
| Huff, CA | 6 |
| Zelis, N | 1 |
| Devos, T | 1 |
| Dierickx, D | 1 |
| Janssens, A | 1 |
| Raddoux, J | 1 |
| Verhoef, G | 2 |
| Ahn, SY | 1 |
| Joo, YD | 3 |
| Lee, SM | 2 |
| Spina, F | 3 |
| Mussetti, A | 2 |
| Perrone, G | 12 |
| De Philippis, C | 1 |
| Dalto, S | 2 |
| Bonini, C | 1 |
| Rezzonico, F | 1 |
| Pennisi, M | 1 |
| Roncari, L | 1 |
| Soldarini, M | 1 |
| Dodero, A | 1 |
| Farina, L | 1 |
| Caprioli, C | 1 |
| Chang, WJ | 1 |
| Kang, ES | 1 |
| Lee, ST | 1 |
| Caraffa, P | 4 |
| Leoni, P | 17 |
| Sun, HL | 1 |
| Yeboah, E | 1 |
| Winter, A | 1 |
| Donato, F | 2 |
| Yee, AJ | 2 |
| Marcheselli, R | 3 |
| Mahindra, AK | 1 |
| Cirstea, DD | 1 |
| Scullen, TA | 1 |
| Burke, JN | 2 |
| Rodig, SJ | 1 |
| Zhong, X | 1 |
| Rowley, S | 2 |
| Logan, B | 2 |
| Weisdorf, D | 2 |
| Popplewell, LL | 2 |
| Riches, M | 1 |
| Hansen, CT | 1 |
| Pedersen, PT | 2 |
| Nielsen, LC | 1 |
| Ferreli, C | 1 |
| Atzori, L | 1 |
| Manunza, F | 1 |
| Pau, M | 1 |
| Caddori, A | 1 |
| Lee, MJ | 1 |
| Wickner, P | 1 |
| Fanning, L | 1 |
| Schlossman, R | 12 |
| Castells, M | 1 |
| Hamano, A | 1 |
| Shingaki, S | 2 |
| Abe, Y | 3 |
| Nakagawa, Y | 1 |
| Hattori, Y | 16 |
| Kedmi, M | 1 |
| Duek, A | 1 |
| Freidman, T | 1 |
| Weiss, M | 3 |
| Leiba, R | 1 |
| Avigdor, A | 3 |
| Noonan, KA | 1 |
| Rudraraju, L | 2 |
| Bui, M | 1 |
| Garcia, MK | 2 |
| Cohen, L | 1 |
| You, B | 1 |
| Chiang, J | 2 |
| Thomas, S | 2 |
| Romaguera, J | 2 |
| Wei, Q | 1 |
| Lee, R | 2 |
| Green, V | 1 |
| Paumgartten, FJ | 1 |
| Akkoyun, M | 1 |
| Ardıç, I | 1 |
| Balakan, O | 1 |
| Deniz, MS | 1 |
| Acar, G | 1 |
| Chang, XB | 3 |
| Langlais, P | 2 |
| Luo, M | 2 |
| Jedlowski, P | 3 |
| Oldziej, A | 1 |
| Bolkun, L | 1 |
| Galar, M | 1 |
| Kalita, J | 1 |
| Ostrowska, H | 1 |
| Romaniuk, W | 1 |
| Kloczko, J | 4 |
| Takashima, S | 1 |
| Kadowaki, M | 2 |
| Ito, Y | 4 |
| Takase, K | 2 |
| Shima, T | 2 |
| Yoshimoto, G | 2 |
| Kato, K | 2 |
| Muta, T | 1 |
| Shiratsuchi, M | 1 |
| Takenaka, K | 2 |
| Teshima, T | 1 |
| Kamimura, T | 3 |
| Tan, J | 1 |
| Lam-Po-Tang, M | 1 |
| Hutchison, CA | 2 |
| de Zoysa, JR | 1 |
| Rupa-Matysek, J | 2 |
| Gil, L | 2 |
| Wojtasińska, E | 1 |
| Nowicki, A | 2 |
| Kaźmierczak, M | 1 |
| Komarnicki, M | 5 |
| De Keersmaecker, B | 1 |
| Fostier, K | 1 |
| Corthals, J | 1 |
| Wilgenhof, S | 1 |
| Heirman, C | 1 |
| Aerts, JL | 1 |
| Thielemans, K | 1 |
| Schots, R | 3 |
| Veluswamy, RR | 1 |
| Ward, SC | 1 |
| Yum, K | 1 |
| Abramovitz, RB | 1 |
| Isola, LM | 1 |
| Hilden, P | 1 |
| Devlin, S | 1 |
| Tsakos, I | 1 |
| Redling, K | 1 |
| Koehne, G | 1 |
| Schaffer, WL | 1 |
| Jasielec, J | 2 |
| Griffith, KA | 3 |
| Lebovic, D | 3 |
| Al-Zoubi, A | 2 |
| Anderson, T | 3 |
| Detweiler-Short, K | 5 |
| Ahmed, A | 2 |
| Jobkar, T | 2 |
| Durecki, DE | 2 |
| McDonnell, K | 2 |
| Mietzel, M | 2 |
| Couriel, D | 2 |
| Kaminski, M | 2 |
| Jakubowiak, AJ | 12 |
| Ferrazzi, A | 1 |
| Oehrlein, K | 2 |
| Rendl, C | 1 |
| Hu, H | 1 |
| Jia, Y | 1 |
| Dasanu, CA | 4 |
| Bockorny, B | 1 |
| Alexandrescu, DT | 4 |
| Sharman, JP | 1 |
| Chmielecki, J | 1 |
| Morosini, D | 1 |
| Palmer, GA | 1 |
| Ross, JS | 1 |
| Stephens, PJ | 1 |
| Stafl, J | 1 |
| Miller, VA | 1 |
| Ali, SM | 1 |
| Kumar, A | 2 |
| Porwal, M | 1 |
| Verma, A | 1 |
| Oshima, K | 1 |
| Tsujimura, H | 1 |
| Robillard, N | 1 |
| Fruchart, C | 1 |
| Gentil, C | 1 |
| Huynh, A | 3 |
| Ferrero, S | 3 |
| Ladetto, M | 2 |
| Genuardi, E | 1 |
| Urbano, M | 1 |
| Rossini, F | 3 |
| Callea, V | 12 |
| Carovita, T | 1 |
| Pregno, P | 6 |
| Gao, M | 2 |
| Gao, L | 2 |
| Yang, G | 5 |
| Tao, Y | 2 |
| Tompkins, VS | 1 |
| Wu, X | 3 |
| Cheng, J | 1 |
| Malysz, J | 1 |
| Ochmann, M | 1 |
| Lamy, T | 2 |
| Loughran, TP | 1 |
| Coelho, I | 2 |
| Costa, C | 1 |
| Esteves, S | 2 |
| Joks, M | 1 |
| Machaczka, M | 1 |
| Skotnicki, AB | 5 |
| Highsmith, KN | 1 |
| Chen, SE | 1 |
| Horowitz, S | 1 |
| Huang, H | 4 |
| Peng, L | 1 |
| Fu, W | 6 |
| Zhang, C | 4 |
| Kim, MY | 2 |
| Sposto, R | 1 |
| Asano, H | 1 |
| Alamgir, A | 1 |
| Ram, R | 2 |
| Raanani, P | 4 |
| Yeshurun, M | 2 |
| Oniashvili, N | 1 |
| Yokota, N | 1 |
| Geng, C | 2 |
| Xi, H | 5 |
| Wei, N | 1 |
| Zhu, B | 1 |
| Teruel, AI | 8 |
| López de la Guía, A | 2 |
| Bengoechea, E | 4 |
| Pérez, M | 2 |
| Martínez, R | 5 |
| González, Y | 8 |
| Hernández, JM | 4 |
| Bello, JL | 3 |
| Peñalver, FJ | 3 |
| Martín-Mateos, ML | 3 |
| Montalbán, MA | 2 |
| López-Corral, L | 3 |
| García-Gómez, A | 1 |
| Delgado, M | 1 |
| Montero, JC | 1 |
| Khan, I | 2 |
| Dickson, J | 1 |
| D'Sa, S | 4 |
| Kiesewetter, B | 1 |
| Raderer, M | 2 |
| Zeng, W | 1 |
| Liu, Z | 2 |
| Zheng, M | 1 |
| Qin, S | 1 |
| Liu, W | 1 |
| Cerase, A | 1 |
| Anglin, P | 1 |
| Summers, BB | 1 |
| Cole, SW | 1 |
| Olin, JL | 1 |
| Stratton, K | 1 |
| Qu, P | 1 |
| Hansen, E | 1 |
| Steward, D | 3 |
| Panozzo, S | 1 |
| Fan, X | 1 |
| Tang, W | 1 |
| Pezzi, A | 7 |
| Peccatori, J | 3 |
| Ruggieri, M | 2 |
| Ben Yehuda, D | 3 |
| Caravita, T | 22 |
| Ribakovsky, E | 1 |
| Genuardi, M | 5 |
| Cafro, A | 1 |
| Rosenblatt, J | 2 |
| Catalano, J | 4 |
| Belch, AR | 4 |
| Pinto, A | 1 |
| Geraldes, C | 3 |
| Binder, D | 1 |
| Van Oostendorp, J | 1 |
| Neemat, K | 1 |
| Rania, K | 1 |
| Tarek, M | 1 |
| Hamdy, AA | 1 |
| Taniguchi, H | 1 |
| Imaizumi, Y | 1 |
| Makiyama, J | 1 |
| Sawayama, Y | 1 |
| Imanishi, D | 1 |
| Taguchi, J | 1 |
| Tsushima, H | 1 |
| Hata, T | 1 |
| Miyazaki, Y | 3 |
| Singla, A | 1 |
| Takasu, M | 1 |
| Tani, C | 1 |
| Kaichi, Y | 1 |
| Sakoda, Y | 1 |
| Kiguchi, M | 1 |
| Date, S | 1 |
| Sakai, A | 8 |
| Awai, K | 1 |
| Kumar, AK | 1 |
| Dakhil, C | 1 |
| Teeka Satyan, M | 1 |
| Haideri, N | 1 |
| Vincent Rajkumar, S | 6 |
| Koeppen, S | 1 |
| Jomen, W | 1 |
| Yoshida, M | 3 |
| Usami, M | 2 |
| Sakurai, T | 1 |
| Matsuno, T | 1 |
| Sato, M | 1 |
| Kanari, Y | 2 |
| Bories, C | 2 |
| Renaud, L | 2 |
| Javed, S | 1 |
| Hobeika, L | 1 |
| Self, SE | 1 |
| Velez, JC | 1 |
| Samaras, P | 1 |
| Pfrommer, S | 1 |
| Seifert, B | 1 |
| Petrausch, U | 1 |
| Mischo, A | 1 |
| Schmidt, A | 1 |
| Schanz, U | 1 |
| Nair, G | 1 |
| Bargetzi, M | 2 |
| Taverna, C | 3 |
| Stupp, R | 1 |
| Stenner-Liewen, F | 1 |
| Shah, RA | 1 |
| Orlowski, R | 6 |
| Nakaseko, C | 2 |
| Khan, MS | 1 |
| Muls, A | 1 |
| Sriskandarajah, P | 3 |
| Andreyev, HJ | 1 |
| Kovacs, MJ | 5 |
| Davies, GA | 1 |
| Chapman, JA | 3 |
| Voralia, M | 3 |
| Roy, J | 3 |
| Kouroukis, CT | 1 |
| Meyer, RM | 6 |
| Shepherd, L | 4 |
| Bátorová, A | 1 |
| Staňková, M | 1 |
| Bešše, L | 1 |
| Sedlaříková, L | 1 |
| Vrábel, D | 1 |
| Talbot, B | 1 |
| Wright, D | 1 |
| Basnayake, K | 1 |
| Tomita, S | 3 |
| Izumi, H | 2 |
| Lau, IJ | 2 |
| Aitchison, R | 1 |
| Blesing, N | 1 |
| Roberts, P | 2 |
| Peniket, A | 1 |
| Li, JS | 1 |
| Hussein, M | 12 |
| Weiss, L | 2 |
| Nagarwala, Y | 4 |
| Nakatani, E | 1 |
| Yin, H | 1 |
| Aziz, M | 1 |
| Sereduk, C | 1 |
| Champion, M | 1 |
| Keith Stewart, A | 3 |
| Groen, RW | 1 |
| Noort, WA | 1 |
| de Jong-Korlaar, R | 1 |
| Bakker, J | 1 |
| van Bueren, JJ | 1 |
| Parren, PW | 3 |
| Martens, AC | 1 |
| Rauch, E | 1 |
| Kuehr, T | 1 |
| Weißmann, A | 2 |
| Kasparu, H | 1 |
| Autzinger, EM | 1 |
| Müldür, E | 2 |
| Asselbergs, E | 1 |
| van Marwijk-Kooy, M | 4 |
| Broyl, A | 3 |
| de Weerdt, O | 4 |
| Lonergan, S | 1 |
| Lokhorst, H | 4 |
| Lee, D | 3 |
| Akehurst, R | 1 |
| Sakai, M | 2 |
| Kubota, T | 2 |
| Takaoka, M | 1 |
| Tsukuda, T | 1 |
| Arakawa, Y | 1 |
| Anabuki, K | 1 |
| Ikezoe, T | 2 |
| Togitani, K | 1 |
| Yokoyama, A | 2 |
| Amatya, R | 2 |
| Monzini, MS | 2 |
| Kvajo, M | 1 |
| Liao, E | 1 |
| Estevam, J | 2 |
| Rajkumar, V | 2 |
| Zang, M | 2 |
| Feng, X | 3 |
| Qi, J | 3 |
| Ru, K | 2 |
| Zojwalla, N | 2 |
| Tonda, ME | 1 |
| Yang, X | 4 |
| Xing, B | 2 |
| Teh, BW | 2 |
| Worth, LJ | 2 |
| Thursky, KA | 2 |
| Slavin, MA | 2 |
| Stowell, SA | 1 |
| Dermer, SJ | 1 |
| Lammerts van Bueren, JJ | 1 |
| Andre, P | 3 |
| Morel, Y | 1 |
| Kawano, Y | 2 |
| Glavey, S | 1 |
| Görgün, GT | 2 |
| Roccaro, AM | 2 |
| Montagnese, F | 1 |
| Portaro, S | 1 |
| Musumeci, O | 1 |
| Migliorato, A | 1 |
| Moggio, M | 1 |
| Fagiolari, G | 1 |
| Rodolico, C | 1 |
| Staderini, M | 2 |
| Veltroni, A | 1 |
| Longo, G | 2 |
| Bacchiarri, F | 1 |
| Donnini, I | 1 |
| Guarrera, A | 1 |
| Bosi, A | 7 |
| King, AJ | 1 |
| Katayama, K | 1 |
| Misawa, S | 1 |
| Sato, Y | 1 |
| Sobue, G | 1 |
| Yabe, I | 1 |
| Watanabe, O | 1 |
| Nishizawa, M | 1 |
| Kusunoki, S | 1 |
| Nakashima, I | 1 |
| Ikeda, S | 1 |
| Kohara, N | 1 |
| Kanda, T | 1 |
| Kira, J | 1 |
| Hanaoka, H | 1 |
| Kuwabara, S | 1 |
| Thielemans, B | 2 |
| Onraed, B | 1 |
| Lacotte, L | 1 |
| Legros, L | 1 |
| Baird, P | 1 |
| Leung, S | 1 |
| Hoang, H | 1 |
| Babalola, O | 1 |
| Devoe, CE | 1 |
| Wanchoo, R | 2 |
| Jhaveri, KD | 2 |
| Matsushita, M | 1 |
| Ozaki, Y | 1 |
| Hasegawa, Y | 1 |
| Terada, F | 1 |
| Tabata, N | 1 |
| Shiheido, H | 1 |
| Yanagawa, H | 1 |
| Oikawa, T | 1 |
| Matsuo, K | 1 |
| Du, W | 2 |
| Yamada, T | 3 |
| Hozumi, M | 1 |
| Takeda, Y | 1 |
| Sakaida, E | 1 |
| Ogura, T | 1 |
| Ando, H | 1 |
| Capalbo, S | 2 |
| Falcone, A | 8 |
| Iannitto, E | 1 |
| Rossini, B | 1 |
| Buquicchio, C | 1 |
| Polimeno, G | 2 |
| Duan, M | 1 |
| Wen, Y | 1 |
| Nobile, F | 1 |
| Ballerini, F | 3 |
| Motta, MR | 1 |
| Rizzi, S | 1 |
| Volpe, S | 2 |
| Li, Q | 1 |
| Asvadi, P | 1 |
| Cuddihy, A | 1 |
| Dunn, RD | 1 |
| Jiang, V | 1 |
| Wong, MX | 1 |
| Jones, DR | 1 |
| Hanaizi, Z | 1 |
| Flores, B | 1 |
| Hemmings, R | 1 |
| Camarero, J | 1 |
| Mayo, A | 1 |
| Nagi Reddy, SK | 1 |
| Gano, K | 1 |
| Dueck, AC | 1 |
| Liu, ZY | 1 |
| Zhang, GQ | 1 |
| Yu, WZ | 1 |
| Wang, XX | 1 |
| Sun, JR | 1 |
| Gao, N | 2 |
| Qiu, XH | 2 |
| Zhuang, Y | 2 |
| Ashjian, E | 1 |
| Redic, K | 1 |
| Thall, PF | 1 |
| Fox, PS | 1 |
| Bashir, Q | 3 |
| Parmar, S | 2 |
| Kebriaei, P | 3 |
| Nieto, Y | 3 |
| Popat, UR | 2 |
| Hosing, CM | 1 |
| Cornelison, A | 1 |
| Shpall, EJ | 2 |
| Champlin, RE | 5 |
| Kong, S | 1 |
| Collet, P | 1 |
| Marotte, H | 1 |
| Thomas, T | 2 |
| Okamura, I | 1 |
| Kimura, F | 1 |
| Brissot, E | 1 |
| Clavert, A | 2 |
| Roland, V | 2 |
| DeMarco, D | 3 |
| Caffrey, MK | 1 |
| Minuk, L | 1 |
| Canepa, L | 3 |
| Leyvraz, S | 4 |
| Ezaydi, Y | 1 |
| Giraldo-Castellano, P | 1 |
| Lemieux, B | 1 |
| Heaney, ML | 1 |
| Arikian, SR | 1 |
| Milentijevic, D | 1 |
| Binder, G | 4 |
| Hu, XH | 1 |
| Corvino, FA | 1 |
| Surinach, A | 1 |
| Allred, J | 2 |
| Hoskote, SS | 1 |
| Reddy, DR | 1 |
| Onigkeit, JA | 1 |
| Zaman, S | 2 |
| Shentu, S | 1 |
| Stellrecht, CM | 1 |
| Gandhi, V | 1 |
| Burke, MJ | 1 |
| George, E | 1 |
| Adler, AI | 1 |
| Rosebeck, S | 1 |
| Kandarpa, M | 2 |
| Mayampurath, A | 1 |
| Mellacheruvu, D | 1 |
| Alonge, MM | 1 |
| Ngoka, L | 1 |
| Volchenboum, S | 1 |
| Nesvizhskii, AI | 1 |
| Sreekumar, A | 1 |
| Fıratlı-Tuğlular, T | 2 |
| Song, MK | 1 |
| Chung, JS | 4 |
| Song, IC | 1 |
| Lee, GW | 3 |
| Lee, IS | 1 |
| Ma, G | 1 |
| Liu, S | 1 |
| Teng, Y | 1 |
| Su, Y | 1 |
| Kim, Y | 3 |
| Steiner, N | 1 |
| Nachbaur, D | 1 |
| König, P | 1 |
| Sehgal, K | 1 |
| Das, R | 1 |
| Deng, Y | 1 |
| Koduru, S | 1 |
| Hansel, D | 1 |
| Seropian, S | 1 |
| Cooper, D | 1 |
| Yao, X | 1 |
| Bay, JO | 3 |
| Simeon, V | 1 |
| Grossi, A | 1 |
| Guariglia, R | 1 |
| Villani, O | 1 |
| Cuomo, C | 1 |
| Musto, C | 1 |
| Tillotson, AL | 1 |
| Williams, C | 4 |
| Orti, G | 1 |
| Morris, C | 10 |
| Cavet, J | 1 |
| Verelst, SG | 2 |
| Huijgens, PC | 3 |
| Sun, JJ | 1 |
| Printz, C | 1 |
| Areethamsirikul, N | 1 |
| Qiao, SK | 1 |
| Guo, XN | 2 |
| Ren, JH | 2 |
| Ren, HY | 1 |
| Cottini, F | 1 |
| Ohguchi, H | 2 |
| Jakubikova, J | 2 |
| Gorgun, G | 4 |
| Mimura, N | 2 |
| Samur, MK | 1 |
| Cowens, KB | 1 |
| Paula, S | 1 |
| Anderson, JE | 1 |
| White, RE | 1 |
| Singh, A | 2 |
| Magrangeas, F | 1 |
| Dorfman, DM | 1 |
| Tsunemine, H | 1 |
| Yoshioka, S | 1 |
| Sakane, E | 1 |
| Akasaka, H | 1 |
| Ito, K | 1 |
| Kodaka, T | 1 |
| Spitzer, G | 1 |
| Zerbib, R | 4 |
| Caligiuri, MA | 3 |
| Bilotti, E | 5 |
| Richter, JR | 2 |
| McNeill, A | 3 |
| McBride, L | 5 |
| Raucci, L | 1 |
| Anand, P | 5 |
| Bednarz, U | 2 |
| Ivanovski, K | 2 |
| Smith, J | 1 |
| Batra, V | 1 |
| Aleman, A | 1 |
| Sims, T | 1 |
| Guerrero, L | 1 |
| Mato, A | 2 |
| Varga, C | 1 |
| O'Donnell, EK | 1 |
| Weinstock, M | 1 |
| Paba-Prada, C | 1 |
| Wu, KL | 5 |
| Cheah, CY | 1 |
| Oo, TH | 1 |
| Scott, GB | 2 |
| Carter, C | 1 |
| Parrish, C | 2 |
| Wood, PM | 2 |
| Flinn, IW | 1 |
| Rifkin, R | 4 |
| Charu, V | 1 |
| Clowney, B | 1 |
| Essell, J | 1 |
| Gaffar, Y | 1 |
| Warr, T | 1 |
| Neuwirth, R | 2 |
| Zhu, Y | 2 |
| Elliott, J | 1 |
| Niculescu, L | 2 |
| Reeves, J | 1 |
| Williams, N | 1 |
| Bowers, MA | 1 |
| Humphries, K | 1 |
| Efebera, Y | 4 |
| Devine, S | 2 |
| Saburi, M | 1 |
| Ohtsuka, E | 2 |
| Itani, K | 1 |
| Nagamatsu, K | 1 |
| Ikebe, T | 2 |
| Ogata, M | 2 |
| Saburi, Y | 2 |
| Lee, J | 1 |
| Tobias, J | 1 |
| Sun, W | 1 |
| An, N | 4 |
| Chen, S | 2 |
| Shen, M | 3 |
| Zhong, Y | 1 |
| Zhan, X | 1 |
| Podar, K | 13 |
| Ou, J | 1 |
| Bonaldi, L | 2 |
| Martines, A | 2 |
| Sechettin, E | 1 |
| De March, E | 3 |
| Branca, A | 1 |
| Lico, A | 2 |
| Minotto, C | 1 |
| Gurrieri, C | 1 |
| Temporin, F | 1 |
| Battistutta, C | 1 |
| Piazza, F | 2 |
| Cavraro, M | 1 |
| Trentin, L | 2 |
| Semenzato, G | 3 |
| Griffin, PT | 1 |
| Fulp, W | 2 |
| Vidriales, MB | 6 |
| Esteves, G | 3 |
| Robinson, D | 3 |
| Chaturvedi, S | 2 |
| Ataman, O | 1 |
| Enny, C | 2 |
| Feng, H | 2 |
| Jacobus, S | 3 |
| Teasdale, T | 1 |
| Zagouri, F | 3 |
| Cohen, C | 1 |
| Javaugue, V | 1 |
| El Karoui, K | 1 |
| Knebelmann, B | 3 |
| Touchard, G | 2 |
| Bridoux, F | 3 |
| Isoda, A | 1 |
| Sato, N | 3 |
| Miyazawa, Y | 2 |
| Matsumoto, Y | 1 |
| Koumoto, M | 1 |
| Ookawa, M | 1 |
| Sawamura, M | 6 |
| Yamasaki, S | 1 |
| Kohno, K | 2 |
| Okamura, S | 1 |
| Roschewski, M | 2 |
| Zingone, A | 3 |
| Kwok, M | 3 |
| Wu, P | 7 |
| Morrison, C | 1 |
| Costello, R | 3 |
| Burton, D | 2 |
| Mulquin, M | 2 |
| Zuchlinski, D | 2 |
| Lamping, L | 2 |
| Carpenter, A | 1 |
| Wall, Y | 1 |
| Carter, G | 2 |
| Cunningham, SC | 1 |
| Gounden, V | 1 |
| Peer, C | 1 |
| Maric, I | 3 |
| Calvo, KR | 2 |
| Braylan, R | 1 |
| Yuan, C | 2 |
| Stetler-Stevenson, M | 2 |
| Arthur, DC | 1 |
| Kong, KA | 1 |
| Weng, L | 1 |
| Faham, M | 1 |
| Lindenberg, L | 1 |
| Kurdziel, K | 1 |
| Choyke, P | 1 |
| Steinberg, SM | 2 |
| Figg, W | 1 |
| Wedel, W | 1 |
| Sofronescu, AG | 1 |
| Modi, D | 1 |
| Mamdani, H | 1 |
| Vettese, T | 1 |
| Majithia, N | 1 |
| Hwa, L | 1 |
| Romano, A | 3 |
| Parrinello, NL | 1 |
| Consoli, ML | 2 |
| Marchionni, L | 1 |
| Forte, S | 1 |
| Tan, M | 1 |
| Fong, R | 1 |
| Lo, M | 1 |
| Young, R | 1 |
| He, X | 1 |
| Jaffrey, SR | 1 |
| Scott, F | 1 |
| Muthalali, S | 1 |
| Mercieca, J | 1 |
| Rosenzweig, M | 1 |
| Lipe, B | 2 |
| Zonder, JA | 8 |
| Fredette, S | 1 |
| Bartlett, B | 1 |
| Ikeda, M | 1 |
| Meshitsuka, S | 1 |
| Fohrer, C | 1 |
| Le Grand, C | 1 |
| Prodhomme, C | 1 |
| Abruzzese, MP | 1 |
| Zingoni, A | 1 |
| Cecere, F | 1 |
| Vulpis, E | 1 |
| Peruzzi, G | 1 |
| Soriani, A | 1 |
| Molfetta, R | 1 |
| Paolini, R | 1 |
| Ricciardi, MR | 1 |
| Ma, E | 1 |
| Engebretson, AE | 1 |
| Duh, MS | 2 |
| Lafeuille, MH | 1 |
| Lefebvre, P | 1 |
| Cheng, WY | 1 |
| Dea, K | 1 |
| Rembert, D | 1 |
| Patt, D | 1 |
| Quick, M | 1 |
| Kaufman, J | 5 |
| Pisapia, G | 1 |
| Ingrosso, C | 1 |
| Buonanno, M | 1 |
| Spinosa, C | 1 |
| Prudenzano, A | 1 |
| Pricolo, G | 1 |
| Hardan, I | 3 |
| Boccadifuoco, L | 1 |
| Ogawa, Y | 2 |
| Kurihara, M | 1 |
| Doerr, T | 1 |
| Tinsley, SM | 1 |
| Kurtin, SE | 1 |
| Ridgeway, JA | 1 |
| Shimoyama, S | 1 |
| Sakamoto, H | 1 |
| Sato, T | 3 |
| Nguyen-Pham, TN | 2 |
| Thanh-Tran, HT | 1 |
| Lee, YK | 1 |
| Choi, NR | 1 |
| Hoang, MD | 1 |
| Zimmerman, T | 2 |
| Stockerl Goldstein, K | 1 |
| Birgin, A | 1 |
| Duarte, L | 2 |
| Maharaj, M | 1 |
| Levy, J | 1 |
| Wong, RS | 1 |
| Venkatakrishnan, K | 1 |
| Zhong, M | 1 |
| Dasilva, N | 1 |
| Song, Z | 1 |
| Adrian, F | 1 |
| Kawaguchi, M | 1 |
| Uchimura, N | 1 |
| Okuda, Y | 1 |
| Konuma, S | 1 |
| Nehashi, Y | 1 |
| Guerrini, S | 1 |
| Bucalossi, A | 2 |
| Cioffi Squitieri, N | 1 |
| Mazzei, FG | 1 |
| Volterrani, L | 1 |
| Mazzei, MA | 1 |
| Lee, H | 2 |
| Torti, L | 1 |
| Morelli, AM | 1 |
| Bacci, F | 1 |
| Di Bartolomeo, P | 1 |
| Sheikh, M | 1 |
| Wong, J | 1 |
| Dickens, E | 1 |
| Bullement, A | 1 |
| Elvidge, J | 2 |
| Gomes, CL | 1 |
| Pascucci, N | 1 |
| Smith, DD | 1 |
| Shay, G | 1 |
| Hazlehurst, L | 1 |
| Lynch, CC | 1 |
| Zheng, C | 2 |
| Cai, X | 2 |
| Shi, Y | 2 |
| Lin, B | 5 |
| Seo, M | 1 |
| Kim, H | 1 |
| Choi, Y | 2 |
| Cha, HJ | 1 |
| Lim, JH | 1 |
| Park, SH | 2 |
| Canella, A | 1 |
| Cordero Nieves, H | 1 |
| Cascione, L | 1 |
| Radomska, HS | 1 |
| Stiff, A | 1 |
| Consiglio, J | 1 |
| Caserta, E | 1 |
| Rizzotto, L | 1 |
| Zanesi, N | 1 |
| Stefano, V | 1 |
| Kaur, B | 1 |
| Mo, X | 1 |
| Byrd, JC | 5 |
| Pichiorri, F | 2 |
| Lu, L | 2 |
| Havens, CG | 1 |
| Ning, Y | 2 |
| Klippel, A | 1 |
| Thakurta, AG | 1 |
| Säily, M | 1 |
| Lundan, T | 1 |
| Heiskanen, J | 1 |
| Siitonen, TM | 1 |
| Kakko, S | 1 |
| Ollikainen, H | 1 |
| Terävä, V | 1 |
| Kutila, A | 1 |
| Launonen, K | 1 |
| Räsänen, A | 1 |
| Sikiö, A | 1 |
| Suominen, M | 1 |
| Bazia, P | 1 |
| Kananen, K | 1 |
| Selander, T | 1 |
| Kuittinen, T | 1 |
| Remes, K | 2 |
| Fink, EC | 1 |
| Bi, E | 1 |
| Hong, S | 1 |
| Trikha, M | 2 |
| Ichikawa, K | 2 |
| Song, X | 1 |
| Cong, Z | 1 |
| Wilson, K | 1 |
| Vu, T | 1 |
| Martín Ramos, ML | 1 |
| Pérez de Oteyza, J | 1 |
| Martín, J | 3 |
| Cabrera, C | 2 |
| Cedena, MT | 2 |
| Puig, N | 5 |
| Shao, JJ | 1 |
| Li, HQ | 1 |
| Cao, HQ | 1 |
| Guirguis, AA | 1 |
| Cavenagh, JD | 2 |
| Yiu, W | 2 |
| Berger, A | 1 |
| Hungria, VT | 2 |
| Crusoé, EQ | 1 |
| Maiolino, A | 2 |
| Bittencourt, R | 1 |
| Maciel, JF | 1 |
| Pessoa de Magalhaes, RJ | 1 |
| Almeida, MS | 1 |
| Cury, P | 1 |
| Hisgashi, F | 1 |
| Peres, AL | 2 |
| Chiattone, CS | 1 |
| Butrym, A | 3 |
| Rybka, J | 2 |
| Łacina, P | 2 |
| Gębura, K | 1 |
| Frontkiewicz, D | 1 |
| Bogunia-Kubik, K | 2 |
| Mazur, G | 2 |
| He, AL | 5 |
| Wang, JL | 2 |
| Zhao, WH | 1 |
| Aznab, M | 1 |
| Rezaei, M | 1 |
| Navabi, J | 1 |
| Moieni, A | 1 |
| Yang, DY | 1 |
| Guo, XL | 1 |
| Cai, XY | 1 |
| Guo, XF | 1 |
| Zhang, JN | 1 |
| Kim, JW | 1 |
| Kim, BS | 2 |
| Nam, SH | 2 |
| Choe, PG | 1 |
| Park, WB | 1 |
| Kalapanida, D | 2 |
| Liacos, CI | 1 |
| Tasidou, A | 1 |
| Matsouka, C | 7 |
| Levi, G | 1 |
| Proserpio, I | 1 |
| Viganò, CV | 1 |
| Dico, FA | 1 |
| Castellani, G | 1 |
| Caldini, A | 1 |
| Terreni, A | 1 |
| Berardi, M | 1 |
| Biagioli, T | 1 |
| Brogi, M | 1 |
| Yang, F | 1 |
| Chang, VT | 1 |
| Andersson, BS | 1 |
| Guan, X | 1 |
| Carella, A | 1 |
| Malfitano, A | 2 |
| Petrò, D | 1 |
| Campbell, P | 2 |
| Usnarska-Zubkiewicz, L | 3 |
| Dębski, J | 1 |
| Stella-Hołowiecka, B | 2 |
| Zaucha, JM | 1 |
| Januszczyk, J | 1 |
| Rymko, M | 1 |
| Torosian, T | 1 |
| Malenda, A | 1 |
| Urbańska-Ryś, H | 1 |
| Druzd-Sitek, A | 1 |
| Błońska, D | 1 |
| Urbanowicz, A | 1 |
| Hołojda, J | 1 |
| Pogrzeba, J | 1 |
| Rzepecki, P | 1 |
| Hałka, J | 1 |
| Subocz, E | 1 |
| Becht, R | 1 |
| Zdziarska, B | 1 |
| Bołkun, Ł | 1 |
| Kłoczko, J | 2 |
| Knopińska-Posłuszny, W | 1 |
| Zubkiewicz-Kucharska, A | 1 |
| Kuliczkowski, K | 2 |
| Rizzello, I | 2 |
| Grigorian, M | 1 |
| Nolan, R | 1 |
| Rice, G | 1 |
| Alemayehu, WG | 1 |
| Meijer, E | 3 |
| Wittebol, S | 9 |
| Tanis, BC | 2 |
| Cornelisse, PB | 2 |
| Bos, GM | 5 |
| Wijermans, PW | 6 |
| Cheung, MC | 1 |
| Derigs, HG | 1 |
| Eom, H | 2 |
| Van der Jagt, R | 1 |
| Rigaudeau, S | 1 |
| Jardel, H | 2 |
| Leupin, N | 2 |
| Storti, P | 2 |
| Toscani, D | 2 |
| Airoldi, I | 1 |
| Marchica, V | 1 |
| Bolzoni, M | 2 |
| Fiorini, E | 1 |
| Campanini, N | 1 |
| Martella, E | 1 |
| Mancini, C | 1 |
| Guasco, D | 2 |
| Ferri, V | 1 |
| Donofrio, G | 1 |
| Aversa, F | 1 |
| Sanchez-Abarca, LI | 1 |
| Hernández, J | 1 |
| Perez-Simon, JA | 2 |
| Wirth, D | 1 |
| Srivastava, K | 1 |
| Lehmacher, W | 1 |
| Hellmich, M | 1 |
| Dulmovits, BM | 1 |
| Appiah-Kubi, AO | 1 |
| Papoin, J | 1 |
| Hale, J | 1 |
| He, M | 1 |
| Al-Abed, Y | 1 |
| Didier, S | 1 |
| Gould, M | 1 |
| Husain-Krautter, S | 1 |
| Singh, SA | 1 |
| Chan, KW | 2 |
| Vlachos, A | 1 |
| Allen, SL | 1 |
| Taylor, N | 1 |
| Marambaud, P | 1 |
| An, X | 1 |
| Gallagher, PG | 1 |
| Mohandas, N | 1 |
| Lipton, JM | 1 |
| Liu, JM | 1 |
| Blanc, L | 1 |
| Tsao, LC | 2 |
| Singhal, AK | 2 |
| Shen, X | 1 |
| Shi, W | 1 |
| Ni, H | 1 |
| Ju, S | 1 |
| Neff, A | 1 |
| Savani, U | 1 |
| Wang, P | 1 |
| Cao, L | 1 |
| Lu, T | 1 |
| Fang, Q | 1 |
| Totani, H | 1 |
| Kato, C | 1 |
| Nakashima, T | 1 |
| Suzuki, N | 1 |
| Kanamori, T | 1 |
| Murakami, S | 3 |
| Masuda, A | 1 |
| Kinoshita, S | 1 |
| Narita, T | 1 |
| Musolino, C | 5 |
| Ruggeri, M | 1 |
| Bouchnita, A | 1 |
| Eymard, N | 1 |
| Moyo, TK | 1 |
| Koury, MJ | 1 |
| Volpert, V | 1 |
| Maiso, P | 2 |
| Rodriguez, I | 1 |
| Alignani, D | 1 |
| Burgos, L | 1 |
| Sanchez, ML | 1 |
| Barcena, P | 1 |
| Echeveste, MA | 2 |
| Johnson, SK | 1 |
| Orfao, A | 3 |
| Tazawa, S | 1 |
| Shiozawa, E | 1 |
| Homma, M | 1 |
| Arai, N | 1 |
| Kabasawa, N | 1 |
| Kawaguchi, Y | 1 |
| Fujiwara, S | 2 |
| Okino, K | 1 |
| Kobayashi, K | 1 |
| Yamochi, T | 1 |
| Tate, G | 1 |
| Nakamaki, T | 2 |
| Takimoto, M | 1 |
| Mehta, J | 10 |
| Terebelo, H | 1 |
| Lu, JJ | 1 |
| Kenvin, L | 3 |
| Benbouker, L | 1 |
| Manges, R | 2 |
| Gupta, M | 2 |
| Tendolkar, A | 1 |
| Lynch, M | 2 |
| Paliwal, P | 2 |
| van der Velden, AW | 1 |
| Coenen, JL | 1 |
| Szatkowski, DL | 1 |
| Brouwer, RE | 1 |
| Leys, MR | 1 |
| Sinnige, HA | 2 |
| van der Hem, KG | 1 |
| Durian, MF | 1 |
| Mattijssen, EV | 1 |
| Stevens-Kroef, MJ | 1 |
| Yasuda, M | 1 |
| Tachi, T | 1 |
| Umeda, M | 1 |
| Nagaya, K | 1 |
| Osawa, T | 1 |
| Ichihashi, A | 1 |
| Goto, H | 1 |
| Kasahara, S | 1 |
| Goto, C | 1 |
| Teramachi, H | 1 |
| Sato, H | 1 |
| Oi, N | 1 |
| Namba, K | 1 |
| Taniguchi, Y | 2 |
| Yahata, H | 1 |
| Komori, H | 1 |
| Kobayashi, H | 1 |
| Hung, KH | 1 |
| Su, ST | 1 |
| Hsu, PH | 1 |
| Wu, WJ | 1 |
| Chen, MJ | 1 |
| Chen, HY | 1 |
| Wu, PC | 1 |
| Lin, FR | 1 |
| Tsai, MD | 1 |
| Lin, KI | 1 |
| Qian, W | 2 |
| Lyu, WW | 1 |
| Zhao, QC | 1 |
| Song, DH | 1 |
| Zhang, JJ | 3 |
| Ding, ZX | 1 |
| Li, BY | 1 |
| Wei, CM | 1 |
| Mendoza, TR | 1 |
| Cleeland, C | 1 |
| Jin, L | 1 |
| He, H | 1 |
| Zeng, T | 2 |
| Fan, J | 1 |
| Chang, H | 6 |
| Bruno, B | 6 |
| Udd, KA | 3 |
| Vidisheva, A | 1 |
| Bravin, E | 2 |
| Ibrahim, E | 1 |
| Treisman, J | 1 |
| Masri, M | 1 |
| Kong, Y | 1 |
| Xie, B | 1 |
| Dai, B | 1 |
| Hirata, H | 1 |
| Shimizu, T | 1 |
| Otsuka, M | 1 |
| Terui, Y | 1 |
| Ogaki, Y | 1 |
| Shi, T | 1 |
| Leisten, J | 1 |
| Narla, RK | 1 |
| Raymon, HK | 1 |
| Caers, J | 2 |
| Heusschen, R | 1 |
| Minnema, M | 1 |
| Beguin, Y | 1 |
| Wolf, JL | 3 |
| Schlangen, K | 2 |
| Schreiner, W | 1 |
| Willenbacher, E | 1 |
| Weger, R | 1 |
| Rochau, U | 1 |
| Siebert, U | 1 |
| Barley, K | 1 |
| He, W | 1 |
| Agarwal, S | 1 |
| Yan, X | 1 |
| Tinelli, M | 1 |
| Turri, G | 1 |
| Pizzolo, G | 1 |
| Al-Ani, F | 1 |
| Bermejo, JM | 1 |
| Lavin, M | 1 |
| Brophy, TM | 1 |
| Rawley, O | 1 |
| O'Sullivan, JM | 1 |
| Browne, PV | 1 |
| Ryan, K | 1 |
| O'Connell, N | 1 |
| O'Donnell, JS | 1 |
| Soleymanian, T | 1 |
| Soleimani, A | 1 |
| Musavi, A | 1 |
| Mojtahedi, K | 1 |
| Hamid, G | 1 |
| Recchia, AG | 1 |
| Morabito, L | 1 |
| Loeliger, K | 1 |
| Poon, A | 1 |
| Simakova, O | 1 |
| Childs, R | 1 |
| Noel, P | 1 |
| Silver, S | 1 |
| Mo, C | 1 |
| Young, N | 1 |
| Sloand, E | 1 |
| Puyade, M | 1 |
| Chaoui, D | 1 |
| Luycx, O | 1 |
| Malfuson, JV | 1 |
| Biron, L | 1 |
| Planche, L | 2 |
| Zimmerman, TM | 4 |
| Talpaz, M | 1 |
| Reich, S | 1 |
| Banach, M | 1 |
| Skotnicki, A | 4 |
| Olszewska-Szopa, M | 1 |
| Park, E | 1 |
| Jung, CK | 1 |
| Kang, SW | 1 |
| Kim, BG | 1 |
| Jung, Y | 1 |
| Kim, TH | 1 |
| Lim, JY | 2 |
| Won, KA | 1 |
| Duma, N | 1 |
| Lee, MH | 3 |
| Jourdan, M | 1 |
| Cren, M | 1 |
| Schafer, P | 4 |
| Robert, N | 1 |
| Duperray, C | 1 |
| Vincent, L | 1 |
| Ceballos, P | 1 |
| Cartron, G | 1 |
| Rossi, JF | 1 |
| Moreaux, J | 1 |
| Klein, B | 4 |
| Leebeek, FW | 4 |
| Freitas, J | 1 |
| Gomes, F | 1 |
| Neves, M | 1 |
| Esteves, GV | 2 |
| Afifi, S | 1 |
| Michael, A | 1 |
| Schlenzka, J | 2 |
| Hillengaß, J | 1 |
| Wuchter, P | 1 |
| Schmidt-Hieber, M | 2 |
| Reimer, P | 1 |
| Graeven, U | 2 |
| Nogai, A | 1 |
| Martin, H | 4 |
| Noppeney, R | 1 |
| Das, A | 1 |
| Oronsky, B | 1 |
| Scicinski, J | 1 |
| Arana, P | 1 |
| Cordon, L | 1 |
| Flores-Montero, J | 1 |
| Martín-Ramos, ML | 2 |
| Van Dongen, JJ | 1 |
| Sandhu, I | 1 |
| Baker, BW | 1 |
| Jackson, SR | 1 |
| Simpson, DR | 1 |
| Berg, DT | 1 |
| Borg, S | 1 |
| Persson, U | 1 |
| Xiang, B | 1 |
| Zhu, H | 1 |
| Wu, Y | 1 |
| Guan, P | 1 |
| Zou, X | 1 |
| Valencia, CA | 1 |
| Dong, B | 1 |
| Xie, L | 1 |
| Ma, H | 1 |
| Dong, T | 1 |
| Shuai, X | 1 |
| Xu, Q | 2 |
| Hou, YX | 1 |
| Erickson, P | 1 |
| Mandarino, LJ | 1 |
| Stewart, K | 4 |
| Mizutani, S | 1 |
| Sasaki, N | 1 |
| Kiyota, M | 1 |
| Tatekawa, S | 1 |
| Maegawa, S | 1 |
| Nagoshi, H | 1 |
| Tando, S | 1 |
| Fushiki, S | 1 |
| Jiang, XX | 1 |
| Liu, HB | 2 |
| Chen, LM | 1 |
| Sanz, RG | 1 |
| Cooney, J | 1 |
| Gray, D | 1 |
| Saunders, O | 1 |
| Sternas, LA | 1 |
| Chalayer, E | 1 |
| Chapelle, C | 1 |
| Elalamy, I | 2 |
| Laporte, S | 1 |
| Tardy, B | 1 |
| Benedict, Á | 1 |
| Houisse, I | 1 |
| Tichy, E | 1 |
| Giannopoulou, A | 1 |
| Aggarwal, SK | 1 |
| Barber, BL | 1 |
| Panjabi, S | 1 |
| Miller, N | 1 |
| Simcock, M | 1 |
| Iakovaki, M | 2 |
| Panagiotidis, I | 1 |
| Castro, TB | 1 |
| Hallack Neto, AE | 1 |
| Atalla, A | 1 |
| Ribeiro, LC | 1 |
| Kreiniz, N | 1 |
| Khateeb, A | 1 |
| Gino-Moor, S | 1 |
| Tadmor, T | 1 |
| Nagy, Z | 1 |
| Bustany, S | 1 |
| Bourgeais, J | 1 |
| Tchakarska, G | 1 |
| Body, S | 1 |
| Hérault, O | 1 |
| Gouilleux, F | 1 |
| Sola, B | 1 |
| Moreau, S | 1 |
| Moumas, E | 2 |
| Abraham, J | 3 |
| Desport, E | 2 |
| Fernández-Sáiz, V | 1 |
| van Bebber, F | 1 |
| Garz, AK | 1 |
| Lemeer, S | 1 |
| Targosz, BS | 1 |
| Jacobs, L | 1 |
| Knorn, AM | 1 |
| Platzbecker, U | 2 |
| Germing, U | 2 |
| Haass, C | 1 |
| Schmid, B | 1 |
| Götze, KS | 1 |
| Kuster, B | 1 |
| Iempridee, T | 1 |
| Mertz, JE | 1 |
| Kenney, SC | 1 |
| Lin, HC | 1 |
| Dawson, CW | 1 |
| Dührsen, U | 1 |
| Hunter, H | 1 |
| Azais, I | 3 |
| Eek, R | 1 |
| Dakhil, S | 1 |
| Goncalves, C | 1 |
| Shu, C | 1 |
| Xia, T | 1 |
| Zhang, F | 1 |
| Hollmann, S | 1 |
| Tay, J | 2 |
| Han, M | 1 |
| Murugesan, A | 1 |
| Seftel, MD | 1 |
| Howsen-Jan, K | 1 |
| Xie, Y | 1 |
| Hay, AE | 1 |
| Djurfeldt, M | 1 |
| Chen, BE | 1 |
| Reiman, T | 3 |
| Ryu, DB | 1 |
| Kim, M | 2 |
| Choi, HJ | 1 |
| Shin, MG | 1 |
| Lee, SS | 3 |
| Hwang, EC | 1 |
| Jung, TY | 1 |
| Cho, MS | 1 |
| Yang, DH | 5 |
| Ahn, JS | 5 |
| Kim, YK | 7 |
| Wilk, CM | 1 |
| Heinzler, N | 1 |
| Boquoi, A | 1 |
| Cadeddu, RP | 1 |
| Strapatsas, T | 1 |
| Dienst, A | 1 |
| Majidi, F | 1 |
| Deenen, R | 1 |
| Bruns, I | 1 |
| Schroeder, T | 1 |
| Köhrer, K | 1 |
| Haas, R | 3 |
| Kobbe, G | 2 |
| Corral, LL | 1 |
| Ino, R | 1 |
| Gotoh, N | 1 |
| Mitsui, T | 1 |
| Shimizu, H | 1 |
| Yokohama, A | 1 |
| Rollison, DE | 1 |
| Komrokji, R | 1 |
| Hampras, S | 1 |
| Fisher, K | 1 |
| Olesnyckyj, M | 12 |
| Sullivan, D | 2 |
| Dalton, W | 3 |
| Mohammed, K | 1 |
| Dearden, CE | 1 |
| Boyd, KD | 5 |
| Mihaylov, G | 1 |
| Pozzi, S | 3 |
| Sacchi, S | 4 |
| Vincelli, I | 2 |
| Rivolti, E | 1 |
| Bari, A | 1 |
| Lovering, S | 1 |
| Miao, W | 1 |
| Bailie, T | 1 |
| Amato, D | 1 |
| Mitani, Y | 1 |
| Usami, E | 1 |
| Kimura, M | 1 |
| Nakao, T | 1 |
| Okada, K | 1 |
| Matsuoka, T | 1 |
| Kokuryou, T | 1 |
| Yoshimura, T | 1 |
| Yamakawa, M | 1 |
| Ma, X | 1 |
| Yu, H | 1 |
| Hu, C | 1 |
| Fan, L | 1 |
| Ran, X | 2 |
| Jacobus, SJ | 3 |
| Dreosti, LM | 1 |
| Jethava, Y | 1 |
| Zangari, M | 38 |
| Schinke, C | 1 |
| Thanendrarajan, S | 1 |
| Alapat, D | 1 |
| Tian, E | 2 |
| Stein, C | 1 |
| Khan, R | 1 |
| Avery, D | 1 |
| Smith, R | 1 |
| Iqbal, N | 1 |
| Tariq, MU | 1 |
| Shaikh, MU | 1 |
| Majid, H | 1 |
| Kasamatsu, Y | 1 |
| Shirano, M | 1 |
| Iida, K | 1 |
| Shimizu, S | 1 |
| Goto, T | 1 |
| Arkenau, HT | 1 |
| Lemech, C | 1 |
| Lassen, U | 1 |
| Lisby, S | 2 |
| Basse, L | 1 |
| Guckert, ME | 1 |
| Yeh, H | 1 |
| Xiao, Y | 2 |
| Miao, LL | 1 |
| Dalla Torre, C | 1 |
| Cacciavillani, M | 1 |
| Salvalaggio, A | 1 |
| Barilà, G | 2 |
| Chakraborty, R | 1 |
| Hogan, WJ | 3 |
| Majer, I | 1 |
| van de Wetering, G | 1 |
| Polanyi, Z | 1 |
| Krishna, A | 1 |
| Gray, E | 1 |
| Roy, A | 2 |
| Williams, ME | 3 |
| Katz, MS | 1 |
| Greipp, PR | 31 |
| Buchanan, J | 1 |
| Cocks, K | 3 |
| Tonda, M | 1 |
| Alcoceba, M | 1 |
| Chillon, MC | 1 |
| Jiménez, C | 1 |
| Prieto, I | 1 |
| García-Álvarez, M | 1 |
| Rapado, I | 1 |
| González Díaz, M | 1 |
| Sarasquete, ME | 1 |
| Garcia, D | 1 |
| Gailani, D | 1 |
| Supko, JG | 1 |
| Wallace, EE | 1 |
| Birrer, NE | 1 |
| Tamang, DL | 1 |
| Jones, SS | 1 |
| Wheeler, CA | 1 |
| Markelewicz, RJ | 1 |
| Franssen, LE | 1 |
| Koene, HR | 1 |
| Beeker, A | 1 |
| van Spronsen, DJ | 1 |
| Westerweel, PE | 1 |
| Oostvogels, R | 1 |
| van Velzen, J | 1 |
| Abudayyeh, A | 1 |
| Doshi, M | 1 |
| Edeani, A | 1 |
| Glezerman, IG | 1 |
| Monga, D | 1 |
| Rosner, M | 1 |
| Aghemo, E | 1 |
| Maracci, L | 2 |
| Wang, C | 2 |
| He, Z | 1 |
| Chen, Z | 1 |
| Mian, I | 1 |
| Milton, DR | 1 |
| Oran, B | 1 |
| Chen, SL | 8 |
| Müller, E | 1 |
| Bauer, S | 1 |
| Mottok, A | 1 |
| Scholz, CJ | 1 |
| Brünnert, D | 1 |
| Schraud, H | 1 |
| Kreßmann, S | 1 |
| Gil, LA | 1 |
| Cui, Q | 1 |
| Amachi, R | 1 |
| Teramachi, J | 1 |
| Bat-Erdene, A | 1 |
| Sogabe, K | 1 |
| Yoshida, S | 1 |
| Endo, I | 2 |
| Aihara, K | 1 |
| O'Rourke, L | 1 |
| Guckert, M | 1 |
| Ibata, S | 1 |
| Fujimi, A | 1 |
| Kamihara, Y | 1 |
| Konuma, Y | 1 |
| Tatekoshi, A | 1 |
| Hashimoto, A | 1 |
| Horiguchi, H | 1 |
| Murase, K | 1 |
| Takada, K | 2 |
| Miyanishi, K | 1 |
| Hirayama, Y | 1 |
| He, P | 1 |
| Guo, C | 1 |
| Sun, C | 3 |
| Yin, QS | 1 |
| Mi, RH | 1 |
| Wei, XD | 1 |
| Ferretti, V | 1 |
| Klersy, C | 2 |
| Varettoni, M | 5 |
| Cartia, CS | 1 |
| Vukas, R | 1 |
| Schmidt, L | 1 |
| Gao, Z | 1 |
| Gilani, M | 1 |
| Graef, T | 2 |
| Gambella, M | 1 |
| Gilestro, M | 1 |
| Muccio, VE | 1 |
| Saraci, E | 1 |
| Hwang, S | 1 |
| Woo, Y | 1 |
| Park, HJ | 1 |
| Paba Prada, CE | 1 |
| Longo, DL | 1 |
| Reneau, JC | 1 |
| Asante, D | 1 |
| van Houten, H | 1 |
| Sangaralingham, LR | 1 |
| Lerman, A | 1 |
| Herrmann, J | 1 |
| Schabel, C | 1 |
| Horger, M | 2 |
| Kum, S | 1 |
| Fritz, J | 1 |
| Ioanoviciu, SD | 1 |
| Bier, G | 1 |
| Kinoshita, G | 1 |
| Miyoshi, M | 1 |
| Pandya, D | 1 |
| Sung, AD | 1 |
| Sarantopoulos, S | 1 |
| Horwitz, ME | 1 |
| Lopez, RD | 1 |
| Sullivan, KM | 1 |
| Sanchez, L | 1 |
| Kotchetkov, R | 1 |
| Gagne, JJ | 1 |
| Landon, J | 1 |
| Avorn, J | 1 |
| Kesselheim, AS | 1 |
| Tochigi, T | 1 |
| Kikushige, Y | 1 |
| Mori, Y | 2 |
| Kamezaki, K | 1 |
| Pourabdollah, M | 1 |
| Bahmanyar, M | 1 |
| Anh-NguyenThi, T | 1 |
| Jaya Lakshmi, T | 1 |
| Bonello, F | 1 |
| Hinduja, A | 1 |
| Limaye, K | 1 |
| Ravilla, R | 1 |
| Sasapu, A | 1 |
| Wei, L | 2 |
| Torbey, M | 1 |
| Kwon, J | 1 |
| Han, JJ | 1 |
| Choi, YS | 1 |
| Xia, C | 1 |
| Ribeiro, M | 1 |
| Scott, S | 1 |
| Berenson, A | 2 |
| Vardanyan, S | 2 |
| David, M | 2 |
| Harutyunyan, NM | 2 |
| Gottlieb, J | 2 |
| Halleluyan, R | 2 |
| Sigsworth, R | 1 |
| Henderson, R | 2 |
| Cabrera César, E | 1 |
| Fernández Aguirre, MC | 1 |
| González Fernández, A | 1 |
| Kida, M | 1 |
| Hirao, M | 1 |
| Iizuka, H | 1 |
| Hangaishi, A | 1 |
| Usuki, K | 1 |
| Trébéden-Negre, H | 1 |
| Vieillard, V | 1 |
| Rosenzwajg, M | 1 |
| Cherai, M | 1 |
| Nguyen-Quoc, S | 1 |
| Tanguy, ML | 1 |
| Norol, F | 1 |
| Chow, E | 1 |
| Dao, K | 2 |
| Stadelmann, R | 1 |
| Burnier, M | 1 |
| Buclin, T | 2 |
| Kissling, S | 2 |
| Takubo, T | 1 |
| Kase, Y | 1 |
| Teresa Petrucci, M | 1 |
| Petrungaro, A | 2 |
| Greco, R | 1 |
| Grazia Recchia, A | 1 |
| Yu, YB | 2 |
| Chen, TY | 2 |
| Kao, WY | 1 |
| Chen, CC | 2 |
| Lin, SF | 1 |
| Lin, TH | 1 |
| Hua, Y | 1 |
| Puccio-Pick, M | 1 |
| Dunn, P | 1 |
| Kuchenbauer, F | 1 |
| Kull, M | 1 |
| Teleanu, V | 1 |
| Bullinger, L | 1 |
| Greiner, A | 1 |
| Kolmus, S | 1 |
| Straka, C | 2 |
| Döhner, H | 1 |
| Bargou, R | 2 |
| An, R | 1 |
| Panchabhai, SC | 1 |
| Van Wier, SA | 3 |
| Ahmann, GJ | 3 |
| Chesi, M | 2 |
| Guglieri-López, B | 1 |
| Pérez-Pitarch, A | 1 |
| Moes, DJ | 1 |
| Porta-Oltra, B | 1 |
| Climente-Martí, M | 1 |
| Guchelaar, HJ | 1 |
| Merino-Sanjuán, M | 1 |
| Hübl, W | 1 |
| Fritz, V | 1 |
| Willheim, M | 1 |
| Rajan, AM | 1 |
| Chtioui, H | 1 |
| Pruijm, M | 1 |
| Passey, C | 1 |
| Mora, J | 1 |
| Dodge, R | 1 |
| Gibiansky, L | 1 |
| Bello, A | 1 |
| Zuo, W | 1 |
| Zhu, X | 1 |
| Mei, Z | 1 |
| Deng, M | 1 |
| Lin, Q | 1 |
| Yin, Q | 1 |
| Schönfeld, K | 1 |
| Zuber, C | 1 |
| Pinkas, J | 1 |
| Häder, T | 1 |
| Bernöster, K | 1 |
| Uherek, C | 1 |
| Chaszczewska-Markowska, M | 1 |
| Song, T | 1 |
| Lin, X | 1 |
| Cang, Y | 1 |
| Hatsuse, M | 3 |
| Odaira, E | 1 |
| Okano, A | 5 |
| Manni, S | 1 |
| Carrino, M | 1 |
| Manzoni, M | 1 |
| Gianesin, K | 1 |
| Nunes, SC | 1 |
| Costacurta, M | 1 |
| Tubi, LQ | 1 |
| Macaccaro, P | 1 |
| Taiana, E | 1 |
| Cabrelle, A | 1 |
| Boudreault, JS | 1 |
| de la Guía, AL | 1 |
| Blanchard, M | 1 |
| Sampol, M | 1 |
| Etxebeste, M | 1 |
| Martínez-Martínez, R | 1 |
| Cibeira, M | 1 |
| Mateos, M | 1 |
| Beijers, AJ | 1 |
| Oerlemans, S | 1 |
| Mols, F | 1 |
| Eurelings, M | 1 |
| Vreugdenhil, A | 1 |
| van de Poll-Franse, LV | 1 |
| Piras, G | 1 |
| Uras, A | 1 |
| Asproni, R | 1 |
| Murineddu, M | 1 |
| Monne, M | 1 |
| Stradoni, R | 1 |
| Latte, G | 1 |
| Parisi, M | 1 |
| Calafiore, V | 1 |
| Ancora, F | 1 |
| La Fauci, A | 1 |
| Purnomo, L | 1 |
| McGuiness, CB | 1 |
| Wade, RL | 1 |
| Chic Acevedo, C | 1 |
| García Torres, E | 1 |
| Álvarez Rivas, MÁ | 1 |
| Lum, EL | 1 |
| Bunnapradist, S | 1 |
| Pham, T | 1 |
| Danovitch, G | 1 |
| Hamahata, K | 1 |
| Fernyhough, L | 1 |
| Corbett, G | 1 |
| Browett, P | 3 |
| Forsyth, C | 1 |
| Underhill, C | 3 |
| Trotman, J | 1 |
| Neylon, A | 1 |
| Link, E | 1 |
| Swern, A | 1 |
| Cowan, L | 1 |
| Giuliani, M | 1 |
| Janji, B | 1 |
| Berchem, G | 1 |
| Raza, S | 1 |
| Safyan, RA | 1 |
| Maciocia, N | 1 |
| Melville, A | 1 |
| Sharpley, F | 1 |
| Benjamin, R | 1 |
| Maciocia, P | 1 |
| Rismani, A | 1 |
| Cerner, A | 1 |
| Berenson, J | 2 |
| Badarinath, S | 1 |
| Cartmell, A | 2 |
| McIntyre, K | 1 |
| Lyons, R | 1 |
| Harb, W | 1 |
| Mohamed, H | 1 |
| Nourbakhsh, A | 1 |
| Ko, CW | 1 |
| Deisseroth, A | 1 |
| Nie, L | 1 |
| Kaminskas, E | 1 |
| Kormanik, N | 1 |
| Guarneri, D | 1 |
| Forsberg, P | 1 |
| Rossi, A | 2 |
| Pearse, R | 5 |
| Greenberg, J | 1 |
| Shore, T | 3 |
| Gergis, U | 1 |
| Mayer, S | 1 |
| Sanchez, E | 2 |
| Li, M | 2 |
| Wang, CS | 1 |
| Tang, G | 1 |
| Gillespie, A | 1 |
| Bechir, A | 1 |
| Haifa, R | 1 |
| Nesrine, BS | 1 |
| Emna, B | 1 |
| Senda, M | 1 |
| Asma, A | 1 |
| Amina, BB | 1 |
| Mrabet, S | 1 |
| Yosra, BY | 1 |
| Mondher, K | 1 |
| Abderrahim, K | 1 |
| Li, G | 1 |
| Vande Broek, I | 1 |
| Murphy, P | 1 |
| Bacon, P | 1 |
| Gilet, H | 1 |
| Arnould, B | 1 |
| Isnard, F | 1 |
| Gieseler, F | 1 |
| Musch, A | 1 |
| Falco, P | 21 |
| Mark, T | 9 |
| Stern, J | 1 |
| Furst, JR | 3 |
| LaRow, A | 2 |
| Harpel, J | 2 |
| Schuster, MW | 3 |
| Leonard, JP | 4 |
| Christos, PJ | 4 |
| Zhang, WG | 4 |
| Yang, HY | 3 |
| Tian, W | 3 |
| Hasselbalch, HC | 1 |
| Birgens, H | 1 |
| Dufva, IH | 1 |
| Dalseg, AM | 1 |
| Brown, Pde N | 1 |
| Jensen, MK | 1 |
| Vangsted, A | 1 |
| Munemasa, S | 2 |
| Okikawa, Y | 4 |
| Kubo, T | 1 |
| Shimose, S | 1 |
| Kimura, A | 4 |
| Mitsiades, C | 16 |
| Okawa, Y | 1 |
| Leitch, HA | 1 |
| Atkins, H | 1 |
| Canning, LA | 1 |
| Shaughnessy, JD | 15 |
| Bogers-Boer, L | 1 |
| Pasa, S | 1 |
| Altintas, A | 2 |
| Cil, T | 2 |
| Ustun, C | 2 |
| Bayan, K | 1 |
| Danis, R | 1 |
| Urakci, Z | 1 |
| Tuzun, Y | 1 |
| Ayyildiz, O | 2 |
| Furkert, K | 1 |
| Hoffmann, F | 3 |
| Naumann, R | 3 |
| Glasmacher, A | 9 |
| Kluin-Nelemans, HC | 2 |
| Ferenc, V | 1 |
| van Doormaal, JJ | 1 |
| van Iperen, C | 1 |
| Peters, WG | 1 |
| Akin, C | 1 |
| Valent, P | 1 |
| El-Cheikh, J | 4 |
| Bouabdallah, R | 2 |
| de Lavallade, H | 1 |
| Coso, D | 1 |
| de Collela, JM | 1 |
| Auran-Schleinitz, T | 1 |
| Gastaut, JA | 2 |
| Blaise, D | 4 |
| Juckett, MB | 1 |
| Kahl, BS | 1 |
| Gangnon, RE | 1 |
| Mitchell, TL | 1 |
| Longo, WL | 1 |
| Nucera, E | 1 |
| Schiavino, D | 1 |
| Hohaus, S | 1 |
| Leone, G | 2 |
| Buonomo, A | 1 |
| Lombardo, C | 1 |
| Patriarca, G | 1 |
| Levesque, E | 1 |
| Bradette, M | 1 |
| Klein, U | 3 |
| Kosely, F | 1 |
| Schmitt, S | 3 |
| Hegenbart, U | 4 |
| Hollmig, K | 8 |
| Alsayed, Y | 8 |
| Anaissie, E | 29 |
| Kumar, NS | 1 |
| Jenkins, B | 3 |
| Schiffer, CA | 1 |
| Burington, B | 1 |
| Yuan, ZG | 3 |
| Wang, DX | 2 |
| Chen, YB | 2 |
| Yellin, O | 2 |
| Bamia, C | 1 |
| Melakopoulos, I | 1 |
| Eleftherakis-Papaiakovou, E | 2 |
| Bamias, A | 3 |
| Srikanth, M | 3 |
| Ethell, ME | 2 |
| Potter, MN | 2 |
| Shaw, BE | 1 |
| Saso, RM | 1 |
| Dines, S | 2 |
| Farley, KL | 1 |
| Johnson, AJ | 2 |
| Muthusamy, N | 1 |
| Blum, KA | 1 |
| Schaaf, LJ | 2 |
| Grever, MR | 2 |
| Dalton, JT | 1 |
| Phelps, MA | 2 |
| Rozanski, M | 1 |
| Boldt, T | 1 |
| Ritter, U | 1 |
| Rohrberg, R | 1 |
| Schwalbe, E | 1 |
| Schirmer, V | 1 |
| Haas, A | 1 |
| Sasaki, M | 1 |
| Tsukune, Y | 1 |
| Kawahara, S | 1 |
| Hamano, Y | 1 |
| Ando, J | 2 |
| Tomomatsu, J | 1 |
| Tsutsui, M | 1 |
| Morris, TC | 3 |
| Kettle, PJ | 1 |
| Drake, M | 1 |
| Jones, FC | 1 |
| Hull, DR | 1 |
| Boyd, K | 3 |
| Morrison, A | 2 |
| Clarke, P | 1 |
| O'Reilly, P | 1 |
| Paydas, S | 1 |
| Heath, D | 1 |
| Croucher, P | 1 |
| van der Veer, MS | 2 |
| Aarts, T | 1 |
| Emmelot, M | 2 |
| Dyer, C | 2 |
| Corthals, S | 1 |
| Ramos, C | 1 |
| Dickens, NJ | 3 |
| Haessler, J | 5 |
| Baris, D | 1 |
| Van Ness, B | 2 |
| Qi, PJ | 1 |
| Li, YN | 1 |
| Xiao, ZJ | 1 |
| Polloni, C | 11 |
| Piersantelli, MN | 5 |
| Visani, G | 7 |
| Alesiani, F | 8 |
| Catarini, M | 12 |
| Burattini, M | 5 |
| Ferranti, M | 6 |
| Giuliodori, L | 4 |
| Candela, M | 6 |
| Marconi, M | 8 |
| Hazarika, M | 1 |
| Rock, E | 1 |
| Williams, G | 1 |
| Dagher, R | 1 |
| Booth, B | 1 |
| Farrell, A | 1 |
| Justice, R | 1 |
| D'Auria, F | 1 |
| Wang, YL | 1 |
| Lent, R | 3 |
| Agrawal, YP | 1 |
| Matthew, S | 1 |
| Mazumdar, M | 4 |
| Cesarman, E | 1 |
| Furman, RR | 1 |
| Tóthová, E | 3 |
| Labar, B | 2 |
| Egyed, M | 2 |
| Kuhn, I | 2 |
| Oliveira, AM | 1 |
| Maria, DA | 1 |
| Metzger, M | 1 |
| Linardi, C | 1 |
| Giorgi, RR | 1 |
| Moura, F | 1 |
| Martinez, GA | 1 |
| Bydlowski, SP | 1 |
| Novak, EM | 1 |
| Song, W | 3 |
| van der Vliet, HJ | 1 |
| Prabhala, R | 1 |
| Wang, R | 1 |
| Catley, L | 4 |
| Shammas, MA | 1 |
| Balk, SP | 1 |
| Exley, MA | 1 |
| Musallam, KM | 1 |
| Dahdaleh, FS | 1 |
| Shamseddine, AI | 1 |
| Taher, AT | 2 |
| Wyplosz, B | 1 |
| Lerolle, U | 1 |
| Israël-Biet, D | 1 |
| Dougados, J | 1 |
| Lillo-Le Louët, A | 1 |
| Pouchot, J | 1 |
| Wiernik, PH | 2 |
| Tighe, J | 1 |
| Behrens, J | 2 |
| Tsuyama, N | 1 |
| Nakaju, N | 1 |
| Mizuno, M | 1 |
| Ogawa, K | 1 |
| Nishisaka, T | 1 |
| Matsui, H | 1 |
| Samori, A | 4 |
| Kelley, TW | 1 |
| Karafa, M | 1 |
| Cook, JR | 1 |
| Islam, A | 1 |
| Ambrus, JL | 1 |
| Lü, S | 1 |
| Xu, X | 2 |
| Ni, X | 1 |
| Huang, C | 1 |
| Hu, X | 1 |
| Dabak, V | 1 |
| Kuriakose, P | 1 |
| Avvisati, G | 1 |
| Kitazoe, KI | 1 |
| Hiasa, M | 1 |
| Amou, H | 1 |
| Nakano, A | 2 |
| Hashimoto, T | 1 |
| Tuscano, JM | 2 |
| Ma, XR | 1 |
| Chen, YX | 2 |
| Cao, XM | 2 |
| Böckeler, M | 1 |
| Bianchi, L | 1 |
| Terracciano, LM | 1 |
| Mayer, F | 1 |
| Setty, AR | 1 |
| Li, YH | 3 |
| Huang, HM | 2 |
| Zhu, R | 1 |
| Gerecke, C | 1 |
| Liebisch, P | 3 |
| Topp, MS | 1 |
| Sezer, O | 6 |
| Vollmuth, C | 1 |
| Falk, K | 1 |
| Maeder, U | 1 |
| Chaudhry, V | 1 |
| Cornblath, DR | 1 |
| Polydefkis, M | 1 |
| Ferguson, A | 3 |
| Saad, AA | 1 |
| Higa, GM | 1 |
| Mileshkin, L | 10 |
| Seymour, JF | 5 |
| Milner, A | 1 |
| Westerman, D | 2 |
| Sugiyama, A | 1 |
| Nakabayashi, H | 1 |
| Kondo, M | 1 |
| Tominaga, T | 1 |
| Shinohara, K | 1 |
| Delimbassi, S | 1 |
| Zomas, A | 5 |
| Economopoulos, T | 1 |
| Novotová, E | 1 |
| Neuwirtová, R | 1 |
| Jonásová, A | 1 |
| Cetiner, S | 1 |
| Kahraman, SA | 1 |
| Aki, SZ | 1 |
| Kocakahyaoglu, B | 1 |
| Gultekin, SE | 1 |
| Cetiner, M | 1 |
| Haznedar, R | 4 |
| Gastari, V | 1 |
| Verrou, E | 3 |
| Hadjiaggelidou, C | 1 |
| Varthaliti, M | 1 |
| Georgiadou, S | 1 |
| Laschos, K | 1 |
| Xirou, P | 1 |
| Yiannaki, E | 2 |
| Constantinou, N | 1 |
| Markala, D | 1 |
| Fratoni, S | 1 |
| Santeusanio, G | 1 |
| Del Poeta, G | 1 |
| de Fabritiis, P | 3 |
| Roberts, AW | 1 |
| Prosser, IW | 1 |
| Bradstock, KF | 1 |
| Coyle, L | 1 |
| Gill, DS | 1 |
| Kettle, JK | 1 |
| Finkbiner, KL | 1 |
| Klenke, SE | 1 |
| Baker, RD | 1 |
| Henry, DW | 1 |
| Williams, CB | 1 |
| Prince, MH | 1 |
| Witzig, TE | 24 |
| Dalton, RJ | 1 |
| Fu, T | 2 |
| Roland, B | 1 |
| Horsman, DE | 1 |
| Mansoor, A | 1 |
| Bruyere, H | 1 |
| Stewart, DA | 1 |
| Yazganoğlu, KD | 1 |
| Tambay, E | 1 |
| Mete, O | 2 |
| Ozkaya, E | 1 |
| Geffray, L | 1 |
| Talamo, GP | 1 |
| Ibrahim, S | 1 |
| Claxton, D | 1 |
| Tricot, GJ | 1 |
| Fink, LM | 1 |
| Sung, B | 2 |
| Kunnumakkara, AB | 2 |
| Sethi, G | 4 |
| Guha, S | 2 |
| Aggarwal, BB | 4 |
| Zappasodi, P | 7 |
| Barbarano, L | 2 |
| Morra, E | 2 |
| Lazzarino, M | 5 |
| Arai, A | 1 |
| Hirota, A | 1 |
| Fukuda, T | 1 |
| Tohda, S | 1 |
| Terada, Y | 1 |
| Sasaki, S | 1 |
| Miura, O | 1 |
| Kodama, T | 2 |
| Miyata, A | 2 |
| Wakayama, T | 3 |
| Luraschi, A | 1 |
| Nozza, A | 3 |
| Balleari, E | 4 |
| Bruzzone, A | 1 |
| Popat, U | 1 |
| Saliba, R | 1 |
| Thandi, R | 1 |
| Hosing, C | 1 |
| Anderlini, P | 1 |
| Shpall, E | 1 |
| McMannis, J | 1 |
| Körbling, M | 1 |
| Alousi, A | 1 |
| Andersson, B | 1 |
| Khouri, I | 1 |
| de Lima, M | 1 |
| Jones, R | 2 |
| Champlin, R | 1 |
| Guillerm, G | 2 |
| Salles, B | 1 |
| Eschard, JP | 1 |
| Casassus, P | 4 |
| Virion, JM | 1 |
| Singhal, S | 8 |
| Irwin, D | 3 |
| Williams, SF | 1 |
| Badros, AZ | 4 |
| Zeldis, J | 11 |
| Tewari, P | 1 |
| Kenny, E | 1 |
| Staines, A | 1 |
| Chanock, S | 1 |
| Browne, P | 1 |
| Lawler, M | 1 |
| Musial, L | 1 |
| Padmanabhan, S | 2 |
| Mohr, A | 1 |
| Bernstein, ZP | 1 |
| Barcos, M | 1 |
| Patel, M | 2 |
| Iancu, D | 2 |
| Czuczman, MS | 2 |
| Magen-Nativ, H | 2 |
| Gafter-Gvili, A | 1 |
| Matsushima, H | 1 |
| Oda, T | 2 |
| Yamamoto, M | 2 |
| Sato, A | 1 |
| Hasejima, N | 1 |
| Takezawa, S | 1 |
| Somlo, G | 7 |
| Boccia, RV | 1 |
| Pietronigro, D | 1 |
| Bolejack, V | 6 |
| Crowley, JJ | 1 |
| Comenzo, RL | 4 |
| Bergsagel, L | 1 |
| Reseland, JE | 1 |
| Reppe, S | 1 |
| Olstad, OK | 1 |
| Hjorth-Hansen, H | 1 |
| Brenne, AT | 2 |
| Syversen, U | 1 |
| Iversen, PO | 1 |
| Thieu, KP | 1 |
| Rosenbach, M | 1 |
| Kist, JM | 1 |
| Lioznov, M | 2 |
| Hildebrandt, Y | 3 |
| Ayuk, F | 4 |
| Wolschke, C | 3 |
| Badbaran, A | 2 |
| Fehse, B | 2 |
| Zander, AR | 3 |
| Gajraj, E | 1 |
| Chung, H | 1 |
| Boysen, M | 1 |
| Barnett, DB | 1 |
| Longson, C | 1 |
| Ihorst, G | 3 |
| Deschler, B | 1 |
| Jakob, C | 1 |
| Koch, B | 2 |
| Ordeltova, M | 2 |
| Langova, K | 2 |
| Trussardi-Regnier, A | 1 |
| Lavenus, S | 1 |
| Gorisse, MC | 1 |
| Dufer, J | 1 |
| Tong, H | 1 |
| Hohl, RJ | 1 |
| De Matteo, M | 1 |
| Brunetti, AE | 1 |
| Maiorano, E | 1 |
| Cafforio, P | 1 |
| Silvestris, F | 3 |
| Kocer, B | 1 |
| Sucak, G | 3 |
| Kuruoglu, R | 1 |
| Aki, Z | 1 |
| Erdogmus, NI | 1 |
| Fujiwara, H | 1 |
| Iwama, K | 2 |
| Yamakura, M | 2 |
| Takeuchi, M | 2 |
| Eo, WK | 1 |
| Cheon, SH | 1 |
| Lee, SH | 1 |
| Jeong, JS | 1 |
| Chang, HK | 1 |
| Suh, KS | 1 |
| Kim, HY | 3 |
| He, B | 1 |
| Zhou, W | 1 |
| Gao, B | 1 |
| Gu, J | 1 |
| Li, JY | 2 |
| Yoon, HJ | 2 |
| Lee, N | 1 |
| Won, JH | 2 |
| Rhee, KH | 1 |
| Shin, HC | 1 |
| Machálková, K | 1 |
| Barbarousi, D | 1 |
| Primenou, E | 1 |
| Grapsa, I | 5 |
| Martin, MG | 1 |
| Allred, JB | 3 |
| Mandrekar, SJ | 6 |
| Casulli, AF | 2 |
| Ceccolini, M | 5 |
| Bigazzi, C | 1 |
| Stefani, P | 1 |
| Fiacchini, M | 1 |
| de Vivo, A | 3 |
| Baccarani, M | 15 |
| Boral, A | 1 |
| Okoli, K | 1 |
| Irani, F | 1 |
| Horvath, W | 1 |
| Escoubet-Lozach, L | 1 |
| Lin, IL | 1 |
| Jensen-Pergakes, K | 1 |
| Brady, HA | 1 |
| Muller, GW | 2 |
| Worland, PJ | 1 |
| Verhelle, D | 1 |
| Layzer, R | 1 |
| Carreau, N | 1 |
| Pallotti, MC | 2 |
| Petrucci, A | 3 |
| Zheng, W | 1 |
| Wei, G | 1 |
| Ye, X | 3 |
| Huang, W | 1 |
| Luo, Y | 1 |
| Xue, X | 1 |
| Scholte, JB | 2 |
| Potjewijd, J | 2 |
| Voogt, PJ | 2 |
| Custers, FL | 2 |
| Lie, KS | 1 |
| Avigan, DE | 2 |
| Doss, D | 7 |
| Warren, DL | 2 |
| Delaney, C | 2 |
| Segarra, M | 4 |
| Corbera-Bellalta, M | 1 |
| Vilardell, C | 1 |
| Esparza, J | 1 |
| Izco, N | 1 |
| Cid, MC | 4 |
| Kang, BW | 1 |
| Sym, SJ | 1 |
| Jang, G | 1 |
| Kim, SW | 1 |
| Lee, JS | 1 |
| Mihara, A | 3 |
| Sanada, Y | 2 |
| Kakimoto, T | 7 |
| Prommer, EE | 1 |
| Carreau, NA | 1 |
| van Oers, MH | 4 |
| von dem Borne, P | 1 |
| Schaafsma, R | 2 |
| Berenschot, H | 1 |
| Joosten, P | 2 |
| van Ammerlaan, R | 1 |
| Brown, RD | 2 |
| Kabani, K | 1 |
| Sze, DM | 2 |
| Aklilu, E | 1 |
| Gibson, J | 3 |
| Joshua, DE | 3 |
| Chang, DZ | 1 |
| Forman, A | 1 |
| Fang, W | 2 |
| Lemaire, O | 1 |
| Bourin, P | 2 |
| Laroche, M | 2 |
| Zemanova, M | 2 |
| Sirohi, B | 1 |
| Powles, R | 1 |
| Tricot, G | 31 |
| Polavaram, L | 1 |
| Finlayson, A | 1 |
| Michot, C | 1 |
| Guillot, B | 1 |
| Dereure, O | 1 |
| Smyth, MJ | 2 |
| Bonkowski, J | 1 |
| Vermeulen, LC | 1 |
| Kolesar, JM | 1 |
| Rowan, K | 1 |
| Camacho, E | 1 |
| Capo, G | 1 |
| McKinley, M | 1 |
| Potts, P | 1 |
| Becker, P | 1 |
| Hilger, J | 1 |
| Ciolli, S | 3 |
| Mannina, D | 1 |
| Piro, E | 2 |
| Pinotti, G | 1 |
| Pandey, MK | 1 |
| Schutzova, M | 1 |
| Koza, V | 1 |
| Krivanova, A | 2 |
| Buchler, T | 3 |
| Kralova, D | 1 |
| Zahradova, L | 5 |
| Vorlicek, J | 1 |
| Mayer, J | 3 |
| Vilanova, D | 1 |
| Atadja, P | 1 |
| Crusoe, E | 1 |
| Hernández-Iglesias, T | 1 |
| de Alava, E | 1 |
| Shao, W | 1 |
| Yao, YM | 1 |
| Bao, HY | 1 |
| Jiang, M | 1 |
| Shen, F | 1 |
| Zhu, MQ | 1 |
| Ruan, CG | 1 |
| Zhang, CY | 1 |
| Chen, BA | 1 |
| Pal, R | 2 |
| Monaghan, SA | 3 |
| Hassett, AC | 1 |
| Mapara, MY | 4 |
| Roodman, GD | 4 |
| Ragni, MV | 1 |
| Moscinski, L | 1 |
| List, A | 3 |
| Singh, AV | 1 |
| Ciccarelli, B | 1 |
| Palladino, MA | 1 |
| Ooba, N | 1 |
| Watanabe, H | 1 |
| Kubota, K | 1 |
| Jin, JY | 2 |
| Oh, SJ | 1 |
| Seong, CM | 3 |
| Kim, CS | 3 |
| Lee, DS | 3 |
| Elikowski, W | 1 |
| Lewandowska, M | 1 |
| Małek, M | 1 |
| Krokowicz, P | 1 |
| Piotrowska-Stelmaszyk, G | 1 |
| Zawilska, K | 1 |
| Brault, R | 1 |
| Debiais, F | 1 |
| Eswedi, A | 1 |
| Burnside, P | 1 |
| Panzner, K | 1 |
| Bakan, CE | 3 |
| Smith, MK | 2 |
| Elder, P | 4 |
| Krugh, D | 1 |
| O'Donnell, L | 1 |
| Kumiega, B | 1 |
| Wolska-Smoleń, T | 6 |
| Niparuck, P | 1 |
| Sorakhunpipitkul, L | 1 |
| Atichartakarn, V | 1 |
| Chuncharunee, S | 1 |
| Ungkanont, A | 1 |
| Aungchaisuksiri, P | 1 |
| Puavilai, T | 1 |
| Jootar, S | 1 |
| Kotwica, K | 1 |
| Rus, C | 5 |
| Iacobelli, M | 1 |
| Soulier, J | 1 |
| Reale, MA | 1 |
| Bauer, F | 2 |
| Hess, U | 5 |
| Ketterer, N | 3 |
| Sondergeld, P | 3 |
| Capone, L | 1 |
| Parton, A | 1 |
| Wu, L | 2 |
| Zhang, LH | 2 |
| Tran, T | 1 |
| Sapinoso, L | 1 |
| Xu, S | 1 |
| Hampton, G | 1 |
| Bartlett, JB | 5 |
| Yuan, Z | 3 |
| Nair, B | 4 |
| Lin, RJ | 1 |
| Curran, JJ | 1 |
| Song, J | 1 |
| Niewold, TB | 1 |
| Sweiss, NJ | 1 |
| Yuan, J | 1 |
| Shah, R | 1 |
| Kulharya, A | 1 |
| Mohty, B | 1 |
| Franklin, BE | 1 |
| Oprea, M | 1 |
| Franklin, SM | 1 |
| Kiatsimkul, P | 1 |
| Nugent, K | 1 |
| Raj, R | 1 |
| Cini, M | 2 |
| Valdré, L | 2 |
| Palareti, G | 3 |
| Legnani, C | 1 |
| Mparmparoussi, D | 3 |
| Psimenou, E | 5 |
| Efstathiou, E | 3 |
| Tozer, A | 2 |
| Bizzari, JP | 1 |
| Richards, T | 1 |
| Lee, JL | 3 |
| Choi, YJ | 1 |
| Leal da Costa, F | 2 |
| Garcia Sanz, R | 1 |
| Pagliano, G | 1 |
| Savini, A | 1 |
| Montanari, M | 5 |
| Fraticelli, P | 2 |
| Falcioni, S | 1 |
| Libourel, EJ | 1 |
| de Maat, MP | 2 |
| Patrick, HE | 1 |
| Bowcock, SJ | 3 |
| Chung, J | 2 |
| Shim, H | 1 |
| Finley-Oliver, E | 1 |
| Wood, M | 2 |
| Kneppers, E | 2 |
| Eeltink, CM | 1 |
| Huls, G | 2 |
| Koedam, J | 1 |
| Raymakers, RA | 2 |
| Schaafsma, MR | 4 |
| Sanpaolo, G | 2 |
| Federico, V | 1 |
| Crugnola, M | 1 |
| Kang, W | 1 |
| Cho, SH | 1 |
| Kim, SK | 1 |
| Chang, J | 1 |
| Park, MS | 1 |
| Miyazaki, M | 1 |
| Goto, K | 1 |
| Ikewaki, J | 1 |
| Uno, N | 1 |
| Imamura, T | 1 |
| Akagi, T | 1 |
| Kadota, J | 1 |
| Saito, M | 1 |
| Mori, A | 2 |
| Irie, T | 1 |
| Tanaka, M | 2 |
| Morioka, M | 1 |
| Kurahashi, S | 1 |
| Sawamoto, A | 1 |
| Adachi, T | 1 |
| Iwasaki, T | 1 |
| Suzuki, H | 1 |
| Sugimoto, T | 1 |
| Narimatsu, H | 1 |
| Hayakawa, F | 1 |
| Agata, M | 1 |
| Sameshima, Y | 1 |
| Kondo, T | 3 |
| Ishiyama, M | 1 |
| Yasunami, T | 1 |
| Kazama, H | 1 |
| Okamura, T | 1 |
| Yoshinaga, K | 1 |
| Shiseki, M | 1 |
| Mori, N | 1 |
| Yamada, O | 2 |
| Sagawa, K | 1 |
| Teramura, M | 1 |
| Motoji, T | 1 |
| Joyce, R | 1 |
| Kaster, S | 1 |
| Reske, T | 1 |
| Wang, HY | 1 |
| He, PC | 1 |
| Yang, BJ | 1 |
| Shao, LY | 1 |
| Shao, WB | 1 |
| Gonzalez de Castro, D | 1 |
| Davenport, EL | 1 |
| Nazha, A | 1 |
| Cook, R | 1 |
| Mangan, PA | 2 |
| Gardler, M | 1 |
| Hummel, K | 2 |
| Cunningham, K | 1 |
| Luger, SM | 2 |
| Porter, DL | 2 |
| Schuster, S | 1 |
| O'Doherty, U | 1 |
| Tendas, A | 1 |
| Ales, M | 1 |
| Perrotti, A | 2 |
| Niscola, P | 1 |
| Lie, AK | 3 |
| Chan, EY | 2 |
| Leung, YY | 1 |
| Cheung, SC | 1 |
| Chan, SY | 1 |
| Liang, R | 2 |
| Fayers, P | 1 |
| Ahlberg, L | 1 |
| Björkstrand, B | 1 |
| Dahl, IM | 1 |
| Gulbrandsen, N | 3 |
| Hjertner, O | 1 |
| Hjorth, M | 3 |
| Karlsson, T | 2 |
| Knudsen, LM | 2 |
| Nielsen, JL | 2 |
| Linder, O | 2 |
| Nesthus, I | 1 |
| Rolke, J | 2 |
| Strandberg, M | 1 |
| Sørbø, JH | 1 |
| Wisløff, F | 1 |
| Gmür, J | 1 |
| Gregor, M | 1 |
| Heim, D | 1 |
| Matthes, T | 1 |
| Mishra, A | 1 |
| Becknell, B | 1 |
| Baiocchi, RA | 1 |
| Greenfield, CN | 1 |
| Porcu, P | 1 |
| Rotem-Yehudar, R | 1 |
| Lozanski, G | 1 |
| Holánek, M | 1 |
| Micallef, IN | 2 |
| Marulkar, S | 1 |
| Gandhi, PJ | 1 |
| Calandra, G | 1 |
| McSweeney, PA | 1 |
| Blasi, N | 3 |
| Kortuem, M | 1 |
| Györik, S | 1 |
| Feilchenfeldt, J | 1 |
| Mazzucchelli, L | 1 |
| Quadri, F | 1 |
| Flinn, I | 2 |
| Noga, SJ | 2 |
| Callander, N | 2 |
| Bhandari, M | 1 |
| Grosman, D | 1 |
| Glass, J | 1 |
| Sahovic, EA | 1 |
| Shi, H | 3 |
| Webb, IJ | 2 |
| Méndez, CE | 1 |
| Hwang, BJ | 1 |
| Destian, S | 1 |
| Sinha, S | 3 |
| Dingli, DD | 1 |
| Ketterling, RP | 1 |
| Pinto, V | 1 |
| Castelli, A | 1 |
| Conconi, A | 1 |
| Termorshuizen, F | 3 |
| Ammerlaan, R | 1 |
| van der Griend, R | 2 |
| Higginson, I | 1 |
| Hazel, B | 2 |
| Ladon, D | 1 |
| Corderoy, S | 2 |
| Phekoo, K | 1 |
| Okamoto, S | 10 |
| Hatake, K | 1 |
| Lau, H | 1 |
| Takeshita, K | 1 |
| Takatoku, M | 3 |
| Hotta, T | 1 |
| Mazzarella, L | 1 |
| Cook, L | 1 |
| Szydlo, R | 2 |
| Saltarelli, F | 1 |
| Pavlu, J | 1 |
| Bua, M | 1 |
| Giles, C | 1 |
| Apperley, JF | 3 |
| Rahemtulla, A | 5 |
| de Castro, CM | 1 |
| Vrana, M | 1 |
| Jiang, Y | 2 |
| Lu, M | 1 |
| Xia, J | 1 |
| Ninan, MJ | 1 |
| Datta, YH | 1 |
| Fenchel, M | 1 |
| Konaktchieva, M | 1 |
| Kraus, S | 1 |
| Brodoefel, H | 1 |
| Claussen, CD | 1 |
| Kivivuori, SM | 1 |
| Lee, KP | 1 |
| Hus, I | 3 |
| Manko, J | 4 |
| Jedrzejczak, WW | 1 |
| Piszcz, J | 2 |
| Fielding, K | 1 |
| Skamene, S | 1 |
| Rotondo, RL | 1 |
| Roberge, D | 1 |
| Leonard, J | 3 |
| Jayabalan, DS | 2 |
| Yan, H | 1 |
| Gao, XD | 1 |
| Yu, Q | 1 |
| Mi, JQ | 1 |
| Calabrese, E | 1 |
| Soydan, E | 1 |
| Bandi, M | 2 |
| Nahar, S | 1 |
| Fabre, C | 1 |
| Roig, M | 1 |
| Ibáñez, A | 2 |
| Vera, JA | 1 |
| Aguilar, C | 1 |
| del Campo, R | 1 |
| González, N | 1 |
| Picón, I | 1 |
| Rodríguez, JN | 2 |
| Sanz, MA | 1 |
| Vangsted, AJ | 3 |
| Søeby, K | 1 |
| Klausen, TW | 3 |
| Andersen, NF | 4 |
| Gregersen, H | 3 |
| Vogel, U | 3 |
| Werge, T | 1 |
| Rasmussen, HB | 1 |
| Deeb, G | 1 |
| Lipson, EJ | 1 |
| Holanda, DG | 1 |
| McDevitt, MA | 1 |
| Fine, DM | 1 |
| Gao, W | 3 |
| Gutiérrez, N | 2 |
| de Paz, R | 1 |
| García-Laraña, J | 2 |
| Martín, A | 1 |
| Mediavilla, JD | 1 |
| Sureda, A | 3 |
| Ramos, ML | 1 |
| Rizzo, V | 1 |
| Qu, XY | 1 |
| Crupi, R | 1 |
| Short, KD | 3 |
| Tong, Y | 1 |
| Hornberger, J | 1 |
| Rickert, J | 1 |
| Dhawan, R | 2 |
| Löthgren, M | 1 |
| Wardell, CP | 3 |
| Saloura, V | 1 |
| Grivas, PD | 1 |
| Gajra, A | 1 |
| Moore, DF | 1 |
| Whittenberger, BF | 1 |
| Rajendran, P | 1 |
| Mey, UJ | 1 |
| Buchanan, D | 1 |
| Wilson, SS | 1 |
| Theodorescu, D | 1 |
| Jiang, A | 2 |
| Qi, C | 1 |
| Van Damme, P | 1 |
| Leonardi, G | 1 |
| Ozdogu, H | 2 |
| Aydogdu, I | 1 |
| Konuk, N | 1 |
| Kaygusuz, I | 1 |
| Karakus, S | 1 |
| Kaya, E | 1 |
| Ali, R | 1 |
| Gulbas, Z | 1 |
| Ozet, G | 1 |
| Goker, H | 1 |
| Undar, L | 1 |
| Chiecchio, L | 2 |
| Smith, EM | 1 |
| Hsu, AK | 2 |
| Tai, T | 1 |
| Trapani, JA | 1 |
| Spielberger, R | 2 |
| Frankel, P | 3 |
| Parker, P | 2 |
| Popplewell, L | 2 |
| Sahebi, F | 4 |
| Kogut, N | 1 |
| Snyder, D | 1 |
| Schultheiss, T | 1 |
| Forman, S | 1 |
| Wong, JY | 1 |
| Auwerda, JJ | 3 |
| Yuana, Y | 1 |
| Osanto, S | 1 |
| Bertina, RM | 1 |
| Such, E | 1 |
| Dabrowski, R | 1 |
| Weimann, A | 1 |
| Aicher, B | 1 |
| Lohneis, P | 1 |
| Busse, A | 1 |
| Thiel, E | 1 |
| Saglio, G | 3 |
| de Weers, M | 1 |
| Bakker, JM | 1 |
| Alpmann, P | 1 |
| Blaum-Feder, S | 1 |
| Krämer, S | 1 |
| Endo, T | 2 |
| Lu, D | 2 |
| Carson, D | 2 |
| Kashyap, R | 1 |
| Kumar, R | 2 |
| Mehta, AA | 1 |
| Venkatakrishnan, R | 1 |
| Jose, W | 1 |
| Palaniappan, M | 1 |
| Pavithran, K | 1 |
| Hozo, I | 1 |
| Wheatley, K | 1 |
| Connors, JM | 1 |
| Sutherland, HJ | 1 |
| Shepherd, JD | 1 |
| Hamata, L | 1 |
| Mourad, YA | 3 |
| Barnett, MJ | 1 |
| Broady, R | 1 |
| Forrest, DL | 1 |
| Hogge, DE | 1 |
| Nantel, SH | 1 |
| Narayanan, S | 1 |
| Nevill, TJ | 1 |
| Nitta, J | 1 |
| Power, MM | 1 |
| Toze, CL | 1 |
| Smith, CA | 1 |
| Le Moigne, M | 1 |
| Mazereeuw-Hautier, J | 1 |
| Bonnetblanc, JM | 1 |
| Astudillo, L | 1 |
| D'Incan, M | 1 |
| Bessis, D | 1 |
| Thomas, L | 1 |
| Debarbieux, S | 1 |
| Ammoury, A | 1 |
| Lamant, L | 1 |
| Paul, C | 1 |
| Yasuda, H | 2 |
| Sato, E | 1 |
| Inagaki, N | 1 |
| Aritaka, N | 2 |
| Hirano, T | 4 |
| Deliliers, GL | 1 |
| Ganeshan, P | 1 |
| Hakim, M | 1 |
| Sutlu, T | 1 |
| Jansson, M | 1 |
| Jeong, SJ | 1 |
| Kwon, TR | 1 |
| Jung, JH | 1 |
| Yun, SM | 1 |
| Han, I | 1 |
| Lee, SG | 1 |
| Kim, DK | 1 |
| Kang, M | 1 |
| Kortüm, M | 1 |
| Kang, MH | 1 |
| Ju, JH | 1 |
| Kim, HG | 1 |
| Kang, JH | 1 |
| Jeon, KN | 1 |
| Kim, HC | 1 |
| Pelosini, M | 2 |
| Ma, W | 1 |
| Wang, ZQ | 1 |
| Davis, RE | 1 |
| Kuhn, DJ | 1 |
| Kornblau, SM | 1 |
| Armoiry, X | 2 |
| Fagnani, F | 1 |
| Aulagner, G | 2 |
| Corthals, SL | 1 |
| Carrier, M | 1 |
| Le Gal, G | 1 |
| Wu, C | 1 |
| Lee, AY | 1 |
| Bravo, ML | 1 |
| Gentilini, F | 1 |
| da Costa, FL | 1 |
| Gnanapandithan, K | 1 |
| Singh, S | 1 |
| Varma, S | 1 |
| Ferrucci, A | 1 |
| Coluccia, AM | 1 |
| de Luca, E | 1 |
| Pieroni, L | 1 |
| Maffia, M | 1 |
| Urbani, A | 1 |
| Di Pietro, G | 2 |
| Ranieri, G | 1 |
| Basile, A | 1 |
| Tannemaat, MR | 1 |
| Vries, EP | 1 |
| Molendijk, WJ | 1 |
| Haan, J | 1 |
| Adamia, S | 1 |
| Kost-Alimova, M | 1 |
| Klippel, S | 1 |
| Cervi, D | 1 |
| Daley, JF | 1 |
| Cholujova, D | 1 |
| Kong, SY | 2 |
| Blotta, S | 1 |
| Ooi, M | 1 |
| Delmore, J | 1 |
| Sedlak, J | 1 |
| Rrodhe, S | 1 |
| Berruti, A | 1 |
| Brioni, A | 1 |
| Larocca, F | 1 |
| Tefferi, A | 1 |
| Nexø, BA | 1 |
| Larson, D | 1 |
| Awan, FT | 1 |
| Osman, S | 2 |
| Kochuparambil, ST | 2 |
| Gibson, L | 1 |
| Remick, SC | 1 |
| Jillella, A | 2 |
| Aguado, B | 2 |
| Ríos, E | 1 |
| Cánovas, A | 1 |
| Castillo, I | 1 |
| García, FL | 1 |
| Calvo, JM | 1 |
| Martínez-Chamorro, C | 2 |
| de la Serna, J | 1 |
| Rajpal, R | 1 |
| Dowling, P | 1 |
| Meiller, J | 1 |
| Clarke, C | 1 |
| Murphy, WG | 1 |
| O'Connor, R | 1 |
| Kell, M | 1 |
| Clynes, M | 1 |
| Rosa, J | 1 |
| Sydor, A | 1 |
| Zabawa-Hołyś, S | 1 |
| Nowak, J | 1 |
| Czapkowicz-Gryszkiewicz, L | 1 |
| Sułowicz, W | 1 |
| Ouyang, H | 1 |
| Mapara, M | 1 |
| Galson, DL | 1 |
| Messori, A | 2 |
| Maratea, D | 1 |
| Nelson, EA | 1 |
| Rodig, S | 1 |
| Unitt, C | 1 |
| Squires, M | 1 |
| González Rodríguez, AP | 2 |
| Pérez Persona, E | 1 |
| Mesa, MG | 1 |
| García Sánchez, PJ | 1 |
| Navarro, A | 1 |
| Fuster, D | 1 |
| Monzó, M | 1 |
| Malerba, L | 3 |
| Lazarus, HM | 2 |
| Sommers, SR | 1 |
| Arfons, LM | 1 |
| Fu, P | 1 |
| Ataergin, SA | 1 |
| Kaye, NM | 1 |
| Liu, F | 1 |
| Kindwall-Keller, TL | 1 |
| Cooper, BW | 1 |
| Laughlin, MJ | 1 |
| Creger, RJ | 1 |
| Barr, PM | 1 |
| Gerson, SL | 1 |
| Kaplan, D | 1 |
| Udvardy, M | 2 |
| Lyseng-Williamson, KA | 2 |
| Zannetti, B | 3 |
| Ammerlaan, AH | 1 |
| Fujita, H | 1 |
| Hishizawa, M | 1 |
| Kadowaki, N | 1 |
| Itoh, J | 1 |
| Fukatsu, A | 1 |
| Uchiyama, T | 1 |
| Joshua, D | 5 |
| Technau, K | 1 |
| Finke, J | 1 |
| Murata, Y | 1 |
| Miura, A | 1 |
| Satoh, M | 1 |
| Oguro, R | 1 |
| Yamanaka, C | 1 |
| Matsuura, Y | 1 |
| Akiba, T | 1 |
| Aotsuka, N | 1 |
| Tani, Y | 1 |
| Wakita, H | 1 |
| Kim, JH | 2 |
| Scialli, AR | 1 |
| Hanf, W | 1 |
| Delbès, S | 1 |
| Debiais, C | 1 |
| Lacotte-Thierry, L | 1 |
| Lashkari, A | 1 |
| Bellamy, W | 1 |
| O'Donnell, MR | 1 |
| Mohrbacher, AF | 1 |
| Forman, SJ | 3 |
| Chen, HX | 1 |
| Doroshow, JH | 1 |
| Gandara, DR | 1 |
| Citro, A | 1 |
| Sammassimo, S | 2 |
| Olivero, B | 1 |
| De Muro, M | 1 |
| Figaro, MK | 1 |
| Clayton, W | 1 |
| Usoh, C | 1 |
| Brown, K | 2 |
| Kassim, A | 2 |
| Lakhani, VT | 1 |
| Jagasia, S | 1 |
| Manfredi, D | 1 |
| Tan, W | 1 |
| Wilding, G | 1 |
| Hernandez-Ilizaliturri, FJ | 1 |
| Hong, F | 2 |
| Sood, R | 1 |
| Soniwala, S | 1 |
| Lawrence, W | 1 |
| Jamshed, S | 1 |
| Masood, A | 1 |
| Calvo-Villas, JM | 1 |
| Calle, C | 1 |
| García-Sánchez, R | 1 |
| Ramírez, G | 1 |
| Lu, XJ | 1 |
| Zhang, XH | 1 |
| Lai, YY | 1 |
| Zhu, HH | 1 |
| Kuwayama, Y | 1 |
| Yang, SH | 1 |
| Teng, HW | 1 |
| Hong, YC | 1 |
| Liu, CY | 1 |
| Yang, CF | 1 |
| Gau, JP | 1 |
| Liu, JH | 1 |
| Chang, TJ | 1 |
| Yen, JJ | 1 |
| Chen, PM | 1 |
| Chiou, TJ | 1 |
| Tzeng, CH | 1 |
| Hsiao, LT | 1 |
| Campagnaro, EL | 1 |
| Mietzel, MA | 1 |
| Harvey, CK | 1 |
| Wear, SM | 1 |
| Barrickman, JC | 1 |
| Tendler, CL | 1 |
| Kelley, SL | 2 |
| Kaminski, MS | 1 |
| Sullivan, E | 2 |
| Hoyle, C | 1 |
| Jiang, Z | 1 |
| Ito, C | 2 |
| Navarro Coy, N | 2 |
| Byrne, JL | 3 |
| Rudin, C | 3 |
| Neri, S | 1 |
| Ferrara, R | 1 |
| Vigliotti, ML | 1 |
| Zoboli, A | 1 |
| Pastorini, A | 1 |
| Fayers, PM | 1 |
| Hoshi, A | 1 |
| Matsumoto, A | 1 |
| Madan, S | 1 |
| Lust, J | 2 |
| Otto, S | 1 |
| Schreyer, C | 1 |
| Hafner, S | 1 |
| Mast, G | 1 |
| Ehrenfeld, M | 1 |
| Stürzenbaum, S | 1 |
| Pautke, C | 1 |
| Neuber, B | 2 |
| Tolliver, C | 1 |
| Schoenland, S | 1 |
| Mahmood, S | 1 |
| Cornelissen, JJ | 1 |
| Janssen, JJ | 1 |
| Huisman, C | 1 |
| Bruijnen, CP | 1 |
| Ishak, J | 1 |
| Rodrigues, F | 1 |
| Szostek, M | 2 |
| Helbig, G | 2 |
| Woszczyk, D | 1 |
| Adamczyk-Cioch, M | 2 |
| Jawniak, D | 4 |
| Morawska, M | 2 |
| Kozinska, J | 1 |
| Waciński, P | 1 |
| Allegra, A | 3 |
| Alonci, A | 3 |
| Penna, G | 2 |
| Russo, S | 3 |
| Gerace, D | 1 |
| Greve, B | 1 |
| D'Angelo, A | 2 |
| Catena, S | 2 |
| Chan, TS | 1 |
| Au, WY | 1 |
| Lam, K | 1 |
| Lam, YF | 1 |
| So, CC | 1 |
| Leung, AY | 1 |
| Tse, E | 2 |
| Brady, H | 1 |
| Hilgarth, B | 1 |
| Daniel, T | 1 |
| Anaissie, EJ | 4 |
| Coleman, EA | 2 |
| Goodwin, JA | 2 |
| Kennedy, RL | 1 |
| Lockhart, KD | 1 |
| Stewart, CB | 2 |
| Coon, SK | 2 |
| Zhou, B | 2 |
| Kuhn, D | 1 |
| Coates, S | 1 |
| Barker, A | 1 |
| Spurgeon, S | 1 |
| Piatkowska-Jakubas, B | 1 |
| Mensah-Glanowska, P | 1 |
| Hawrylecka, D | 1 |
| Walter, Z | 1 |
| Park, JS | 1 |
| Lee, SJ | 1 |
| Urata, C | 1 |
| Yoshimura, M | 1 |
| Itamura, H | 1 |
| Hisatomi, T | 1 |
| Kubota, Y | 1 |
| Fukushima, N | 1 |
| Sueoka, E | 1 |
| Fukushima, T | 1 |
| Nakamura, T | 1 |
| Iwao, H | 1 |
| Umehara, H | 1 |
| Geyer, HL | 1 |
| Viggiano, RW | 1 |
| Leslie, KO | 1 |
| Isola, M | 1 |
| Sperotto, A | 2 |
| Stuhler, G | 1 |
| Festuccia, M | 1 |
| Pandit-Taskar, N | 1 |
| Drullinsky, P | 1 |
| Schulman, P | 1 |
| Jhanwar, S | 1 |
| Hoover, E | 1 |
| Bello, C | 1 |
| Riedel, E | 2 |
| Nimer, SD | 3 |
| Chen, P | 1 |
| Rozewski, DM | 1 |
| Garr, CL | 1 |
| Hade, EM | 1 |
| Kraut, EH | 1 |
| Hicks, WJ | 1 |
| Chan, KK | 1 |
| Chen, CS | 2 |
| Farag, SS | 2 |
| Wémeau, M | 1 |
| Gauthier, J | 1 |
| Falanga, A | 2 |
| Yehuda, DB | 1 |
| Beggiato, E | 1 |
| Randriamalala, E | 1 |
| Lepeu, G | 1 |
| Lioure, B | 2 |
| Sebban, C | 1 |
| Traullé, C | 2 |
| Szturz, P | 1 |
| Klincová, M | 2 |
| Feit, J | 1 |
| Vašků, V | 1 |
| Almasi, M | 2 |
| Slaby, O | 1 |
| Kaisarova, P | 2 |
| Penka, M | 4 |
| Svachova, H | 1 |
| Uno, H | 2 |
| Henderson, KJ | 2 |
| Haug, JL | 1 |
| Van Wier, S | 1 |
| Möller, J | 1 |
| Nicklasson, L | 1 |
| Murthy, A | 1 |
| Hata, H | 6 |
| Nanni, C | 1 |
| Englaro, E | 1 |
| Buttignol, S | 1 |
| Carobolante, F | 1 |
| Fanti, S | 1 |
| Dimeski, G | 1 |
| Wood, P | 1 |
| Shuqing, L | 1 |
| Jianmin, Y | 1 |
| Chongmei, H | 1 |
| Hui, C | 1 |
| Boruah, PK | 1 |
| Bolesta, S | 1 |
| Shetty, SM | 1 |
| Bilińska, M | 1 |
| Szymczyk, M | 1 |
| Noga, L | 1 |
| Potoczek, S | 1 |
| Podemski, R | 1 |
| Alexander, MP | 1 |
| Nasr, SH | 1 |
| Watson, DC | 1 |
| Méndez, GP | 1 |
| Rennke, HG | 1 |
| Majolino, I | 1 |
| Tapper, WJ | 1 |
| Dagrada, G | 1 |
| Konn, ZJ | 1 |
| Gonzalez, D | 1 |
| Hockley, SL | 1 |
| Alyea, E | 1 |
| Antin, JH | 2 |
| Goodman, S | 1 |
| Laport, G | 1 |
| Ewell, M | 1 |
| Wu, J | 2 |
| Geller, NL | 1 |
| Maloney, DG | 1 |
| Schwamborn, K | 1 |
| Gorschlüter, M | 2 |
| Doss, S | 1 |
| Hay, N | 1 |
| Sutcliffe, F | 1 |
| Gabriel, IH | 1 |
| Hübel, K | 1 |
| Basak, GW | 1 |
| Douglas, KW | 1 |
| Jaksic, O | 1 |
| Koristek, Z | 1 |
| Lanza, F | 1 |
| Lemoli, R | 1 |
| Selleslag, D | 1 |
| Worel, N | 1 |
| Duarte, RF | 1 |
| Brown, JM | 1 |
| Coy, NN | 1 |
| Voillat, L | 5 |
| Maloisel, F | 1 |
| Damaj, G | 2 |
| Mori, S | 1 |
| Crawford, BS | 1 |
| Roddy, JV | 1 |
| Phillips, G | 2 |
| Collins, SM | 1 |
| Liang, J | 1 |
| Srivastava, S | 1 |
| Romagne, F | 1 |
| Bléry, M | 1 |
| Bonnafous, C | 1 |
| Clever, D | 1 |
| Chow, S | 1 |
| Cheung, CS | 1 |
| Howson-Jan, K | 2 |
| Xenocostas, A | 1 |
| Udi, J | 1 |
| Johnson, PR | 1 |
| Freeman, J | 1 |
| Fenaux, P | 1 |
| Cives, M | 2 |
| Milano, A | 1 |
| Khan, ML | 1 |
| Greipp, P | 2 |
| Zeldenhurst, S | 1 |
| Leif Bergsagel, P | 2 |
| Chen, RA | 1 |
| Tu, Y | 1 |
| Morita, Y | 1 |
| Shimada, T | 1 |
| Yamaguchi, T | 1 |
| Rai, S | 1 |
| Hirase, C | 1 |
| Emoto, M | 1 |
| Serizawa, K | 1 |
| Ojima, M | 1 |
| Tatsumi, Y | 1 |
| Ashida, T | 1 |
| Swain, TR | 1 |
| Kansurkar, SS | 1 |
| Swain, M | 1 |
| Baylon, HG | 1 |
| Robak, T | 3 |
| Goranov, S | 1 |
| Moehler, TM | 6 |
| Pattou, C | 1 |
| Lucy, L | 2 |
| Kueenburg, E | 1 |
| Albani, G | 1 |
| Pascutto, C | 1 |
| Eleftherakis-Papapiakovou, E | 1 |
| Nikitas, N | 2 |
| Gangatharan, SA | 1 |
| Carney, DA | 1 |
| Wolf, MM | 1 |
| Januszewicz, EH | 1 |
| Clegg, AJ | 1 |
| Thomas, A | 1 |
| Romeo, G | 1 |
| Cannavò, A | 2 |
| Scott, E | 1 |
| Carter, CR | 1 |
| Smalle, N | 1 |
| Cullen, K | 1 |
| Kallmeyer, C | 1 |
| Appel, A | 1 |
| Eudo, C | 1 |
| Petit, A | 1 |
| Mondon, K | 1 |
| Rippault, H | 1 |
| Dardaine, V | 1 |
| Constans, T | 1 |
| Hommet, C | 1 |
| Cottier, JP | 1 |
| Aimono, Y | 1 |
| Sato, W | 1 |
| Otani, E | 1 |
| Isa, S | 1 |
| Sawahata, T | 1 |
| Onozaki, M | 1 |
| Saito, Y | 1 |
| Ebata, S | 1 |
| Aoyama, Y | 1 |
| Hakozaki, M | 1 |
| Suzuki, M | 1 |
| Kudo, D | 1 |
| Monma, Y | 1 |
| Chikatsu, N | 1 |
| Cui, J | 1 |
| Wen, P | 1 |
| Jongen, JL | 1 |
| Merlini, G | 2 |
| Voorhees, P | 1 |
| Frankel, PH | 1 |
| Farol, L | 1 |
| Krishnan, AY | 2 |
| Cai, JL | 1 |
| Thomas, SH | 1 |
| Reburiano, E | 1 |
| Parker, PM | 1 |
| Spielberger, RT | 1 |
| Kogut, NM | 2 |
| Htut, M | 1 |
| Ruel, C | 2 |
| Murata-Collins, JL | 1 |
| Iino, M | 1 |
| Muthu Raja, KR | 2 |
| Kovarova, L | 1 |
| Chang, HJ | 1 |
| Srivastava, A | 1 |
| Pai, VR | 1 |
| Pennetier, M | 1 |
| Khot, A | 1 |
| Noonan, K | 3 |
| Emerling, A | 1 |
| Pasetti, MF | 1 |
| Shannon, E | 1 |
| Sandoval, F | 1 |
| Greig, N | 1 |
| Stagg, P | 1 |
| Figueiredo, A | 1 |
| Martins, HF | 1 |
| Mariz, JM | 1 |
| Horton, HM | 1 |
| Pong, E | 1 |
| Cemerski, S | 1 |
| Bernett, MJ | 1 |
| Nguyen, DH | 1 |
| Karki, S | 1 |
| Chu, SY | 1 |
| Lazar, GA | 1 |
| Desjarlais, JR | 1 |
| Muchhal, US | 1 |
| Bunner, P | 1 |
| Morrison, D | 1 |
| Speir, E | 1 |
| Deremer, D | 1 |
| Kota, V | 1 |
| Chen, MH | 1 |
| Qi, CX | 1 |
| Saha, MN | 1 |
| Gaballa, MR | 1 |
| Redman, K | 1 |
| Heyne, N | 1 |
| Airia, P | 1 |
| Schindler, R | 1 |
| Zickler, D | 1 |
| Cockwell, P | 2 |
| Grima, D | 1 |
| Hazell, K | 1 |
| Bourquelot, PM | 1 |
| Bengoudifa, BR | 1 |
| de Magalhaes-Silverman, M | 1 |
| Oriol-Rocafiguera, A | 1 |
| Rosettani, B | 1 |
| Redman, KC | 1 |
| Lunde, L | 1 |
| Labat, E | 1 |
| Espagnolle, N | 1 |
| Gadelorge, M | 1 |
| Cordelier, P | 1 |
| Fournié, JJ | 1 |
| Park, HC | 1 |
| Bae, SY | 1 |
| Brandenburg, N | 1 |
| Jaeger, D | 1 |
| Jeffels, M | 1 |
| Daniher, D | 1 |
| Cai, JH | 1 |
| Huang, BH | 1 |
| Liu, JR | 1 |
| Zheng, D | 1 |
| Sturm, I | 1 |
| Kuhn, S | 1 |
| Kazamel, T | 1 |
| Hilger, JD | 1 |
| Kim, DY | 1 |
| Kim, SD | 1 |
| Kang, YA | 1 |
| Seol, M | 1 |
| Lee, KH | 2 |
| Tufail, M | 1 |
| Bello, E | 1 |
| Olivo, K | 1 |
| Bendarz, U | 1 |
| Matsuzawa, N | 1 |
| Nakamura, K | 1 |
| Ishida, F | 1 |
| Ohmori, S | 1 |
| Gast, SM | 1 |
| Manara, R | 1 |
| Lessi, F | 1 |
| Citton, V | 1 |
| Jin, X | 1 |
| Kasyapa, CS | 1 |
| Castelli, R | 1 |
| Conforti, F | 1 |
| Grava, G | 1 |
| Cortelezzi, A | 1 |
| Hjertner, Ø | 1 |
| Andréasson, B | 1 |
| Billström, R | 1 |
| Carlsson, MS | 1 |
| Othzén, A | 1 |
| Ohya, E | 1 |
| Sekine, T | 1 |
| Turturro, F | 1 |
| Mulligan, G | 1 |
| Mitsis, D | 1 |
| Crocchiolo, R | 1 |
| Furst, S | 1 |
| Ladaique, P | 1 |
| Castagna, L | 1 |
| Faucher, C | 1 |
| Granata, A | 1 |
| Oudin, C | 1 |
| Lemarie, C | 1 |
| Calmels, B | 1 |
| Schiano De Colella, JM | 1 |
| Duran, S | 1 |
| Chabannon, C | 1 |
| O'Sullivan, A | 1 |
| Kennedy, RC | 1 |
| Abbas, M | 1 |
| Dai, L | 2 |
| Pregja, SL | 1 |
| Burt, S | 1 |
| Boyiadzis, M | 1 |
| Agha, M | 1 |
| Waas, J | 1 |
| Shuai, Y | 1 |
| Normolle, D | 1 |
| Tsuda, H | 1 |
| Yamasaki, H | 2 |
| Tsuji, T | 1 |
| Yokoo, E | 1 |
| Marchetti, M | 1 |
| Tura, S | 11 |
| Abbas, J | 1 |
| Hogan, KR | 1 |
| Kramer, C | 1 |
| McDonald, K | 1 |
| Butcher, CD | 1 |
| Littleton, A | 1 |
| Shoptaw, K | 1 |
| Stuart, RK | 1 |
| Vannata, B | 1 |
| Laurenti, L | 1 |
| Chiusolo, P | 1 |
| Sorà, F | 1 |
| Balducci, M | 1 |
| Sabatelli, M | 1 |
| Luigetti, M | 1 |
| Giannotta, C | 1 |
| Sica, S | 1 |
| Ashcroft, AJ | 1 |
| Donnarumma, D | 1 |
| Furlan, A | 1 |
| Dessanti, ML | 1 |
| Ferrara, F | 1 |
| Ocio, E | 1 |
| Cesarman-Maus, G | 1 |
| Matarraz, S | 1 |
| Diez-Campelo, M | 1 |
| Pérez, E | 1 |
| Fernyhough, LJ | 1 |
| Taylor, J | 1 |
| Pearson, J | 1 |
| Al-Sahmani, M | 1 |
| Trnavská, I | 1 |
| Antošová, M | 1 |
| Antošová, L | 1 |
| Kissová, J | 1 |
| Kaisarová, B | 1 |
| Buliková, A | 1 |
| Westland, C | 1 |
| Huang, YH | 1 |
| Tseng, SH | 1 |
| Wiktor-Jędrzejczak, W | 1 |
| Zodelava, M | 1 |
| Iosava, G | 1 |
| Radke, J | 1 |
| Herbein, L | 1 |
| Gentile, T | 1 |
| Gabriel, DA | 1 |
| Levitan, D | 1 |
| Postiglione, J | 1 |
| Bennett, E | 1 |
| Barry, S | 1 |
| Bressler, L | 1 |
| Kelly, M | 2 |
| Seiler, M | 1 |
| Rosenbaum, C | 1 |
| Michallet, M | 4 |
| Dumontet, C | 4 |
| Brown, RE | 1 |
| Stern, S | 1 |
| Kagoya, Y | 1 |
| Nannya, Y | 1 |
| Kurokawa, M | 1 |
| Iacobelli, S | 1 |
| Gratwohl, A | 1 |
| Onida, F | 1 |
| Koenecke, C | 1 |
| van Os, M | 1 |
| de Witte, T | 1 |
| Barrera, LN | 2 |
| Rushworth, SA | 2 |
| MacEwan, DJ | 2 |
| Barthelemy, M | 1 |
| Prod'homme, C | 1 |
| Le Ray, E | 1 |
| Samarcq, P | 1 |
| Terriou, L | 3 |
| Cossment, C | 1 |
| Boulanger, F | 1 |
| Kraftson, S | 1 |
| Ross, CW | 1 |
| Harvey, C | 1 |
| Sportelli, P | 1 |
| Poradosu, E | 1 |
| Gardner, L | 1 |
| Giusti, K | 1 |
| Kumar, N | 1 |
| Sharma, U | 1 |
| Singh, C | 1 |
| Singh, B | 1 |
| Nordgren, B | 1 |
| Al Sayed, Y | 1 |
| Ahmad, N | 1 |
| Liu, HS | 1 |
| Lau, CW | 1 |
| Yip, SF | 1 |
| Sim, J | 1 |
| Wan, TS | 1 |
| Ma, ES | 1 |
| Saboo, SS | 1 |
| Fennessy, F | 1 |
| Wu, SY | 1 |
| Yeh, YM | 1 |
| Chen, YP | 1 |
| Su, WC | 1 |
| Percy, L | 1 |
| Yong, KL | 2 |
| Goulston, C | 1 |
| Sanders, S | 1 |
| Lampas, M | 1 |
| Hanson, KE | 1 |
| Garnica, M | 1 |
| Oliveira-Duarte, G | 1 |
| Oliveira, LC | 1 |
| Mercante, DR | 1 |
| Miranda, EC | 1 |
| Quero, AA | 1 |
| Barros, JC | 1 |
| Tanaka, P | 1 |
| Magalhães, RP | 1 |
| Rego, EM | 1 |
| Lorand-Metze, I | 1 |
| Lima, CS | 1 |
| Renault, IZ | 1 |
| Chiattone, C | 1 |
| Nucci, M | 1 |
| Luptakova, K | 1 |
| Glotzbecker, B | 1 |
| Mills, H | 1 |
| Stroopinsky, D | 1 |
| Kufe, T | 1 |
| Vasir, B | 1 |
| Arnason, J | 1 |
| Tzachanis, D | 1 |
| Zwicker, JI | 1 |
| Joyce, RM | 1 |
| Levine, JD | 1 |
| Foà, R | 4 |
| Hellmann, A | 6 |
| Wada, N | 1 |
| Izaki, M | 1 |
| Yuki, H | 1 |
| Okuno, Y | 1 |
| Iyama, K | 1 |
| Mitsuya, H | 2 |
| Robak, M | 1 |
| Treliński, J | 1 |
| Chojnowski, K | 1 |
| Wang, A | 1 |
| Duan, Q | 1 |
| Han, Y | 1 |
| Zhu, W | 1 |
| Sun, Z | 1 |
| Vilas-Boas, F | 1 |
| Gonçalves, R | 1 |
| Sobrinho Simões, M | 1 |
| Lopes, J | 1 |
| Macedo, G | 1 |
| Hernández, D | 1 |
| López-Jiménez, J | 1 |
| Besalduch, J | 1 |
| Etxebeste, MA | 1 |
| Díaz-Mediavilla, J | 1 |
| Martínez, J | 1 |
| Pan, B | 1 |
| El Jarari, L | 2 |
| van der Velde, H | 1 |
| Lindemann, W | 1 |
| Goldschmidt, HM | 1 |
| Simone, V | 1 |
| Brunetti, O | 1 |
| Longo, V | 1 |
| Toor, AA | 1 |
| Payne, KK | 1 |
| Chung, HM | 1 |
| Sabo, RT | 1 |
| Hazlett, AF | 1 |
| Kmieciak, M | 1 |
| Sanford, K | 1 |
| Williams, DC | 1 |
| Clark, WB | 1 |
| Roberts, CH | 1 |
| McCarty, JM | 1 |
| Manjili, MH | 1 |
| Brower, V | 1 |
| Thaler, J | 1 |
| Ay, C | 1 |
| Pabinger, I | 1 |
| Zabelina, T | 2 |
| Klyuchnikov, E | 1 |
| Pflüger, KH | 1 |
| Burchert, A | 1 |
| Stübig, T | 2 |
| Hansen, T | 1 |
| Bertolini, F | 2 |
| Polo, M | 1 |
| Alexander, M | 2 |
| Kirsa, S | 2 |
| Mellor, JD | 2 |
| Jones-Bolin, S | 1 |
| Hunter, K | 1 |
| Ruggeri, B | 1 |
| Stringer, S | 1 |
| Bayraktar, UD | 1 |
| Ciurea, SO | 1 |
| Kennedy, R | 1 |
| Richards, K | 1 |
| Enderlin, C | 1 |
| McNatt, P | 1 |
| Lockhart, K | 1 |
| Ueda, T | 1 |
| Iino, R | 1 |
| Yokoyama, K | 2 |
| Asakura, K | 1 |
| Tsukada, Y | 1 |
| Ishizawa, J | 1 |
| Matsuki, E | 1 |
| Ikeda, Y | 8 |
| Nicholson, B | 1 |
| Kumar, KG | 1 |
| Carrasco, R | 1 |
| McDermott, JL | 1 |
| Leach, CA | 1 |
| Fulcinniti, M | 1 |
| Kodrasov, MP | 1 |
| Weinstock, J | 1 |
| Kingsbury, WD | 1 |
| Shah, PK | 1 |
| Altun, M | 1 |
| Kessler, BM | 1 |
| Murray, MY | 1 |
| Zaitseva, L | 1 |
| Bruce, JT | 1 |
| Tran, JM | 1 |
| Mastronarde, JG | 1 |
| Wood, KL | 1 |
| Kawada, H | 1 |
| Arima, N | 1 |
| Khan, RZ | 1 |
| Siez, ML | 1 |
| Molica, S | 1 |
| Freilone, R | 1 |
| Teoh, KC | 1 |
| Lingaratnam, S | 1 |
| Renault, A | 1 |
| Sébille, V | 1 |
| Grosbois, B | 5 |
| Bellissant, E | 1 |
| Ogura, K | 1 |
| Heinzelmann, M | 1 |
| Dreger, P | 1 |
| Zander, A | 1 |
| Ricci, D | 1 |
| Neparidze, N | 1 |
| Monesmith, T | 1 |
| Sundaram, R | 1 |
| Miesowicz, F | 1 |
| Seki, JT | 1 |
| Banglawala, S | 1 |
| Lentz, EM | 1 |
| Carulli, G | 1 |
| Cervetti, G | 1 |
| Rizzotti, P | 1 |
| Rotondo, F | 1 |
| Gaultney, JG | 1 |
| Tan, SS | 1 |
| Marcellus, DC | 2 |
| Macdonald, DA | 1 |
| Harnett, E | 1 |
| Couban, S | 1 |
| Beckhove, P | 1 |
| Meissner, T | 1 |
| Haas, J | 1 |
| Bachy, E | 1 |
| Socié, G | 1 |
| Uzunov, M | 1 |
| Bourhis, JH | 2 |
| Lapusan, S | 1 |
| Brebion, A | 1 |
| Vigouroux, S | 1 |
| Maury, S | 1 |
| François, S | 1 |
| Hermine, O | 2 |
| Milpied, N | 1 |
| Rubio, MT | 1 |
| Chen, HF | 1 |
| Li, ZY | 1 |
| Tang, JQ | 1 |
| Shen, HS | 1 |
| Cui, QY | 1 |
| Ren, YY | 1 |
| Qin, LM | 1 |
| Jin, LJ | 1 |
| Zhu, JJ | 1 |
| Ding, J | 1 |
| Wang, KY | 1 |
| Yu, ZQ | 1 |
| Wang, ZY | 1 |
| Wu, TQ | 1 |
| Bonomini, S | 1 |
| Todoerti, K | 1 |
| Agnelli, L | 1 |
| Rizzoli, V | 1 |
| Choi, PT | 1 |
| Lee, WK | 1 |
| Shahan, JL | 1 |
| Panu, LD | 1 |
| Hildebrandt, GC | 1 |
| Dunavin, NC | 1 |
| Phillips, GS | 1 |
| Penza, S | 1 |
| Greenfield, C | 1 |
| Rose, KS | 1 |
| Rieser, G | 1 |
| Merritt, L | 1 |
| Ketcham, J | 1 |
| Heerema, N | 1 |
| Chihara, D | 1 |
| Ugai, T | 1 |
| Sugihara, H | 1 |
| Nishida, Y | 1 |
| Normolle, DP | 1 |
| Gollin, SM | 1 |
| Takano, H | 1 |
| Ichikawa, A | 1 |
| Koshino, M | 1 |
| Hattori, K | 1 |
| Nagata, K | 1 |
| Park, H | 1 |
| Locke, FL | 1 |
| Buijs, A | 1 |
| Rosovsky, R | 1 |
| Tocco, D | 1 |
| Connell, B | 1 |
| Ghobrial, I | 3 |
| Lockridge, L | 1 |
| Bradwin, G | 1 |
| Doyle, M | 1 |
| Soiffer, RJ | 1 |
| Nixon, A | 1 |
| Loughney, N | 1 |
| Nardelli, L | 1 |
| Wear, S | 1 |
| Larkins, G | 1 |
| Haruyama, H | 1 |
| Pashos, C | 1 |
| Khan, Z | 1 |
| Smetana, J | 1 |
| Berankova, K | 1 |
| Zaoralova, R | 1 |
| Nemec, P | 1 |
| Greslikova, H | 1 |
| Kupska, R | 1 |
| Mikulasova, A | 1 |
| Frohlich, J | 1 |
| Kuglik, P | 1 |
| Teixeira, A | 1 |
| Mitchell, V | 1 |
| Sabry, W | 1 |
| Rubinger, M | 1 |
| Cantin, G | 1 |
| Tompkins, KA | 1 |
| Sussman, J | 1 |
| Brundage, M | 1 |
| Harnett, EL | 1 |
| Christos, P | 2 |
| Teitelbaum, A | 1 |
| Ba-Mancini, A | 2 |
| Henk, HJ | 1 |
| Garrison, LP | 1 |
| Wang, ST | 1 |
| Korves, C | 1 |
| Corzo, D | 1 |
| Senthilkumar, CS | 1 |
| Ganesh, N | 1 |
| Biermann, JS | 1 |
| Faber, EA | 1 |
| Hernandez-Illizaliturri, F | 1 |
| Meredith, R | 1 |
| Schriber, J | 1 |
| Treon, SP | 6 |
| Yahalom, J | 1 |
| Yunus, F | 1 |
| Shead, DA | 1 |
| Shortt, J | 1 |
| Johnstone, RW | 1 |
| Munugalavadla, V | 1 |
| Mariathasan, S | 1 |
| Slaga, D | 1 |
| Berry, L | 1 |
| Del Rosario, G | 1 |
| Yan, Y | 1 |
| Boe, M | 1 |
| Friedman, LS | 1 |
| Ebens, A | 1 |
| Hennache, B | 1 |
| Whitehill, G | 1 |
| Anderson, JL | 1 |
| Maguire, C | 1 |
| Pozotrigo, M | 1 |
| Adel, N | 1 |
| Reich, L | 2 |
| Pulik, M | 1 |
| Genet, P | 1 |
| Lionnet, F | 1 |
| Touahri, T | 1 |
| Siegel, E | 4 |
| Saghafifar, F | 3 |
| Fassas, A | 11 |
| Pérez-Encinas, M | 1 |
| Rabuñal Martínez, MJ | 1 |
| Bello López, JL | 1 |
| Ryoo, JJ | 2 |
| Cole, CE | 1 |
| Rassam, SM | 1 |
| Ward, SM | 1 |
| Turner, JT | 1 |
| Laffan, M | 1 |
| Horstman, AL | 1 |
| Cool, RM | 1 |
| Herrington, JD | 1 |
| Magro, L | 1 |
| Fawaz, A | 1 |
| Bauters, F | 2 |
| Delannoy, V | 1 |
| Dauriac, C | 1 |
| Monconduit, M | 3 |
| Duguet, C | 3 |
| Duhamel, A | 1 |
| Mytilineos, J | 1 |
| Preiss, A | 1 |
| Kraemer, A | 4 |
| Opelz, G | 1 |
| Cangini, D | 10 |
| Strasser, K | 1 |
| Stewart, JM | 1 |
| Krishnamurthy, S | 1 |
| Pittini, V | 1 |
| Teti, D | 1 |
| Arrigo, C | 3 |
| Aloi, G | 3 |
| Righi, M | 1 |
| Kamata, T | 1 |
| Yamaguchi, M | 1 |
| Takayama, N | 1 |
| Uchida, H | 1 |
| Shimada, N | 2 |
| Tanigawara, Y | 2 |
| Gachon, J | 1 |
| Grob, JJ | 1 |
| Richard, MA | 1 |
| Carrión Valero, F | 1 |
| Bertomeu González, V | 1 |
| Grover, JK | 2 |
| Uppal, G | 1 |
| Raina, V | 1 |
| Catley, LP | 1 |
| Kelly, K | 1 |
| Mechlowicz, J | 1 |
| Freeman, A | 3 |
| Deocampo, R | 1 |
| Rich, R | 2 |
| Balinski, K | 1 |
| Shuttleworth, GN | 1 |
| Cook, SD | 1 |
| Ropner, JE | 1 |
| Johnson, CL | 1 |
| Mahaffey, SC | 1 |
| Wezeman, MJ | 1 |
| Ferraro, G | 1 |
| Jones, SG | 1 |
| Dolan, G | 3 |
| Lengyel, K | 1 |
| Myers, B | 5 |
| Geyer, S | 3 |
| Iturria, N | 2 |
| González-Porras, JR | 2 |
| González, M | 3 |
| Jaslow, R | 1 |
| Kaplan, G | 1 |
| Lyons, L | 2 |
| Michaeli, J | 2 |
| Yata, K | 2 |
| Otsuki, T | 2 |
| Kurebayashi, J | 1 |
| Uno, M | 1 |
| Fujii, T | 1 |
| Yawata, Y | 2 |
| Takata, A | 1 |
| Hyodoh, F | 1 |
| Sugihara, T | 2 |
| Lee, CK | 5 |
| Thertulien, R | 5 |
| Muwalla, F | 4 |
| Mazher, S | 1 |
| Crawford, CL | 2 |
| Wu, H | 1 |
| Mirshahi, F | 1 |
| Soria, J | 1 |
| Mirshahi, M | 1 |
| Soria, C | 1 |
| Hayashi, T | 3 |
| Shaughnessy, J | 7 |
| McCoy, J | 2 |
| Jacobson, J | 5 |
| Rankin, K | 3 |
| Gavino, M | 1 |
| Elson, P | 1 |
| Trebisky, B | 1 |
| Karam, MA | 4 |
| Luo, SK | 3 |
| Hong, WD | 2 |
| Huang, JQ | 1 |
| Luo, S | 1 |
| Hong, W | 1 |
| Zhou, Z | 1 |
| Zou, W | 1 |
| Xiong, WJ | 1 |
| Zhou, ZH | 2 |
| Geyer, SM | 3 |
| Iturria, NL | 1 |
| Stirling, DI | 5 |
| Mohla, S | 1 |
| Weilbacher, KN | 1 |
| Cher, ML | 1 |
| Oyajobi, BO | 1 |
| Poznak, CV | 1 |
| Clohisy, DR | 1 |
| Waelput, F | 1 |
| Feremans, W | 1 |
| Heenen, M | 1 |
| Sternon, J | 1 |
| Trojan, A | 2 |
| Chasse, E | 1 |
| Gay, B | 1 |
| Pichert, G | 1 |
| Vicari, P | 1 |
| Ribas, C | 3 |
| Sampaio, M | 1 |
| Arantes, AM | 1 |
| Filho, JB | 1 |
| Segreto, RA | 1 |
| Bordin, JO | 1 |
| Ochiai, N | 2 |
| Uchida, R | 3 |
| Ashihara, E | 2 |
| Inaba, T | 2 |
| Fujita, N | 1 |
| Nishio, A | 1 |
| Nakagawa, M | 1 |
| Biagi, JJ | 4 |
| Mitchell, P | 1 |
| Grigg, A | 1 |
| Bell, R | 2 |
| Briggs, P | 1 |
| Lillie, K | 2 |
| Smith, JG | 1 |
| Haidar, JH | 1 |
| Nasr, MR | 1 |
| El-Sabban, ME | 1 |
| Daher, R | 1 |
| Thompson, JL | 1 |
| Hansen, LA | 1 |
| Pathak, RD | 1 |
| Jayaraj, K | 1 |
| Blonde, L | 1 |
| Hall, VC | 1 |
| El-Azhary, RA | 1 |
| Bouwhuis, S | 1 |
| Trippoli, S | 1 |
| Santarlasci, B | 1 |
| Younis, TH | 1 |
| Alam, A | 1 |
| Paplham, P | 2 |
| Spangenthal, E | 1 |
| Okafor, MC | 1 |
| Wölfler, A | 1 |
| Zollner, G | 1 |
| Weber, K | 1 |
| Sill, H | 1 |
| Linkesch, W | 1 |
| Nahum, K | 1 |
| Rechner, I | 1 |
| Brito-Babapulle, F | 1 |
| Fielden, J | 1 |
| Morgan, AE | 1 |
| Smith, WK | 1 |
| Levenson, JL | 1 |
| Rollins, G | 1 |
| Palmer, BD | 2 |
| Kestell, P | 2 |
| Baguley, BC | 2 |
| Muller, G | 4 |
| Ching, LM | 2 |
| Prosdocimo, S | 1 |
| Geromin, A | 1 |
| Zaja, F | 1 |
| Tsiara, S | 1 |
| Chaidos, A | 1 |
| Kapsali, H | 1 |
| Tzouvara, E | 1 |
| Bourantas, KL | 1 |
| Díaz García, B | 1 |
| de Pablo Gafas, A | 1 |
| Ferreiro Alvarez, MJ | 1 |
| Pitini, V | 2 |
| Micali, C | 1 |
| La Gattuta, G | 2 |
| Loprinzi, C | 1 |
| Santos, AB | 1 |
| Llamas, P | 1 |
| Román, A | 1 |
| Prieto, E | 1 |
| De Oña, R | 1 |
| De Velasco, JF | 1 |
| Tomás, JF | 1 |
| Harris, E | 1 |
| Samson, D | 2 |
| Eddleman, P | 1 |
| Cremer, FW | 3 |
| Westveer, P | 1 |
| Hoelzer, D | 1 |
| Abdalla, SH | 2 |
| Mahmoud, S | 1 |
| Andretta, C | 1 |
| Pace, L | 1 |
| Fonti, R | 1 |
| Annunziata, G | 1 |
| Rotoli, B | 1 |
| Semeraro, F | 1 |
| Merchionne, F | 2 |
| Coluccia, M | 1 |
| Boccarelli, A | 1 |
| Scavelli, C | 3 |
| Gernone, A | 1 |
| Battelli, F | 1 |
| Tabilio, A | 1 |
| Guidolin, D | 1 |
| Milone, JH | 1 |
| Prates, V | 1 |
| Bordone, J | 1 |
| Napal, J | 1 |
| Garcia, C | 1 |
| Johnson, R | 1 |
| Jones, RW | 1 |
| Drucker, L | 1 |
| Uziel, O | 1 |
| Tohami, T | 1 |
| Shapiro, H | 1 |
| Radnay, J | 1 |
| Yarkoni, S | 1 |
| Lahav, M | 1 |
| Lishner, M | 1 |
| Barbui, T | 3 |
| Fijnheer, R | 1 |
| De Groot, PG | 2 |
| O'Malley, DP | 1 |
| Dan, K | 1 |
| Yamaguchi, I | 1 |
| Saitoh, H | 1 |
| Takagi, M | 1 |
| Nonaka, Y | 1 |
| Nomura, T | 1 |
| Zhang, HB | 1 |
| Liu, JZ | 1 |
| Xiao, B | 1 |
| Chen, ZB | 1 |
| Wang, HJ | 1 |
| Takimoto, Y | 2 |
| Noda, M | 2 |
| Imagawa, J | 2 |
| Okita, H | 2 |
| Fujimura, K | 2 |
| Ko, BS | 1 |
| Hong, RL | 1 |
| Tsai, W | 1 |
| Wang, CH | 1 |
| Shen, MC | 1 |
| Kropff, MH | 1 |
| Lang, N | 1 |
| Bisping, G | 1 |
| Dominé, N | 1 |
| Innig, G | 1 |
| Hentrich, M | 1 |
| Mitterer, M | 2 |
| Südhoff, T | 1 |
| Heinecke, A | 1 |
| Koch, OM | 1 |
| Berdel, WE | 1 |
| Kienast, J | 1 |
| Wechalekar, AD | 1 |
| Sutton, D | 1 |
| Mehta, P | 4 |
| Lorenzi, A | 4 |
| Invernizzi, R | 1 |
| Vanelli, L | 1 |
| Bundy, KL | 1 |
| Therneau, TM | 1 |
| Litzow, MR | 3 |
| Christensen, BR | 1 |
| Pribula, CG | 1 |
| Walker, R | 2 |
| Kees, M | 2 |
| PAGNINI, G | 1 |
| DICARLO, R | 1 |
| Shamseddine, A | 2 |
| Taher, A | 2 |
| Pichardo, D | 1 |
| Rosen, S | 1 |
| Pantanowitz, L | 2 |
| Dezube, BJ | 2 |
| Kyrcz-Krzemień, S | 1 |
| Hołowiecki, J | 1 |
| Thompson, MA | 1 |
| Timm, MM | 1 |
| Haug, J | 1 |
| Barton, JC | 1 |
| Witzens, M | 1 |
| Fruehauf, S | 1 |
| Hartschuh, W | 1 |
| Gómez-Rangel, JD | 1 |
| Goldman, B | 1 |
| Jégo, C | 1 |
| Barbou, F | 1 |
| Laurent, P | 1 |
| Gisserot, O | 1 |
| Cellarier, G | 1 |
| Bonal, J | 1 |
| Bouchiat, C | 1 |
| Landais, C | 1 |
| de Jaureguiberry, JP | 1 |
| Dussarat, GV | 1 |
| MItsiades, N | 2 |
| Gong, B | 1 |
| Bonham, L | 1 |
| de Vries, P | 1 |
| Singer, JW | 1 |
| Hatzicharissi, E | 1 |
| Papaioannou, M | 2 |
| Mitsouli, Ch | 2 |
| Panagiotidis, P | 1 |
| Korantzis, J | 1 |
| Tzilianos, M | 1 |
| Kasper, B | 1 |
| Habeck, M | 1 |
| Schiff, D | 1 |
| Dalmau, J | 1 |
| Myers, DJ | 1 |
| Foldyna, D | 1 |
| Kamelander, J | 1 |
| Malphettes, M | 1 |
| Ural, AU | 2 |
| Yilmaz, MI | 1 |
| Avcu, F | 2 |
| Pekel, A | 1 |
| Zerman, M | 1 |
| Nevruz, O | 1 |
| Sengul, A | 1 |
| Yalcin, A | 1 |
| Molostvov, G | 1 |
| Morris, A | 1 |
| Rose, P | 1 |
| Stopeck, A | 1 |
| Morimoto, A | 1 |
| Tan, N | 1 |
| Lancet, J | 1 |
| Cooper, M | 1 |
| Hannah, A | 1 |
| Garcia-Manero, G | 1 |
| Faderl, S | 1 |
| Kantarjian, H | 1 |
| Cherrington, J | 1 |
| Albitar, M | 1 |
| Giles, FJ | 1 |
| Dimou, G | 1 |
| Sillaber, C | 1 |
| Ackermann, J | 2 |
| Lechner, K | 1 |
| Eriksson, T | 2 |
| Höglund, P | 1 |
| Don, BR | 1 |
| Vu, J | 1 |
| Scheffler, M | 1 |
| Kaysen, GA | 1 |
| Wellik, LE | 1 |
| Vats, K | 1 |
| Isoardo, G | 1 |
| Bergui, M | 1 |
| Durelli, L | 1 |
| Barbero, P | 1 |
| Bertola, A | 7 |
| Ciaramitaro, P | 1 |
| Bergamasco, B | 1 |
| Cocito, D | 1 |
| Santos, ES | 1 |
| Goodman, M | 1 |
| Byrnes, JJ | 1 |
| Fernandez, HF | 1 |
| Polo-Zarzuela, M | 1 |
| Barrenetxea, C | 1 |
| López, R | 1 |
| Grande-García, C | 1 |
| Vargas-Pabón, M | 1 |
| Gutiérrez, ON | 1 |
| Rodríguez, JA | 1 |
| Fuente, N | 1 |
| Mañe, JM | 1 |
| Barcelo, R | 1 |
| Muñoz, A | 1 |
| Perez-Hoyos, T | 1 |
| Lopez-Vivanco, G | 1 |
| Elhajj, I | 1 |
| Chehal, A | 1 |
| Fakhouri, F | 2 |
| Guerraoui, H | 1 |
| Presne, C | 1 |
| Peltier, J | 1 |
| Delarue, R | 1 |
| Muret, P | 1 |
| Potenza, L | 1 |
| Luppi, M | 1 |
| Morselli, M | 1 |
| Saviola, A | 1 |
| Ferrari, A | 1 |
| Riva, G | 1 |
| Marietta, M | 1 |
| Torelli, G | 1 |
| Noborio-Hatano, K | 1 |
| Takahashi, S | 1 |
| Muroi, K | 1 |
| Ozawa, K | 1 |
| Hamilos, G | 3 |
| Grigoraki, V | 3 |
| Poziopoulos, C | 1 |
| Xilouri, I | 1 |
| Zorzou, MP | 2 |
| Pałgan, K | 1 |
| Pałgan, I | 1 |
| Dredge, K | 1 |
| Dalgleish, AG | 2 |
| Coutsouvelis, J | 1 |
| Corallo, CE | 1 |
| Lenhoff, S | 2 |
| Westin, J | 2 |
| Wislöff, F | 1 |
| Anagnostou, D | 2 |
| Gibson, AD | 1 |
| Klem, J | 1 |
| Price, N | 1 |
| Reddy, GK | 1 |
| Fahdi, IE | 1 |
| Gaddam, V | 1 |
| Saucedo, JF | 1 |
| Kishan, CV | 1 |
| Vyas, K | 1 |
| Deneke, MG | 1 |
| Razek, H | 1 |
| Thorn, B | 1 |
| Bissett, JK | 1 |
| Anaisse, E | 1 |
| Mehta, JL | 1 |
| Hashiguchi, A | 1 |
| Kondoh, K | 1 |
| Hozumi, N | 1 |
| Sakamoto, M | 1 |
| Hata, J | 1 |
| Bressoud, A | 1 |
| Schwab, BZ | 1 |
| Capelli, D | 4 |
| Rupoli, S | 3 |
| Romstad, LH | 1 |
| Romundstad, P | 1 |
| Borset, M | 1 |
| Sundan, A | 1 |
| Spizzo, G | 1 |
| Gastl, G | 1 |
| Joglekar, S | 1 |
| Levin, M | 1 |
| Aymerich, M | 2 |
| Rozman, M | 3 |
| Arenillas, L | 1 |
| Esteve, J | 6 |
| Montserrat, E | 4 |
| Ghio, R | 1 |
| Colleoni, G | 1 |
| Almeida, M | 1 |
| Duch, CR | 1 |
| Ohashi, C | 1 |
| Segreto, R | 1 |
| Silva, MR | 1 |
| Liu, WM | 1 |
| Strauss, SJ | 1 |
| Chaplin, T | 1 |
| Shahin, S | 1 |
| Propper, DJ | 1 |
| Young, BD | 1 |
| Joel, SP | 1 |
| Malpas, JS | 1 |
| Rotta, M | 1 |
| Giaccone, L | 3 |
| Terulla, V | 2 |
| Airò, F | 2 |
| Rusconi, C | 1 |
| Desikan, R | 6 |
| Blood, E | 4 |
| Bosch, J | 1 |
| Patin, J | 3 |
| Fields, P | 1 |
| Clarke, IA | 1 |
| Ashan, G | 1 |
| Lenz, RA | 1 |
| Saver, J | 1 |
| Tonelli, M | 1 |
| Cameron, MG | 1 |
| Rybicki, L | 1 |
| Deitcher, SR | 1 |
| Kattke-Marchant, K | 1 |
| Eleutherakis-Papaiakovou, V | 1 |
| Imai, K | 1 |
| Kosaka, M | 2 |
| Ishii, A | 2 |
| Togawa, A | 1 |
| Takatsuki, K | 2 |
| Shimoni, A | 1 |
| Zagrivnaja, M | 1 |
| Schieder, H | 1 |
| Renges, H | 1 |
| Rosato, R | 1 |
| Ishitsuka, K | 2 |
| Iguchi, T | 3 |
| Eddlemon, P | 3 |
| de Savary, N | 1 |
| Vaidya, B | 1 |
| Wasser, K | 1 |
| Nosas, S | 1 |
| Heiss, J | 1 |
| Düber, C | 1 |
| Kauczor, HU | 1 |
| Delorme, S | 1 |
| Chung, F | 1 |
| Tingle, M | 1 |
| Montagut, C | 1 |
| Bosch, F | 1 |
| Villela, L | 2 |
| Comotti, B | 1 |
| Rodeghiero, F | 2 |
| van Marion, AM | 2 |
| Westveer, PH | 1 |
| Horiuchi, R | 1 |
| Nojima, Y | 2 |
| Kim, SS | 1 |
| Ahn, JY | 1 |
| Cho, EK | 1 |
| Shin, DB | 1 |
| Helgason, HH | 1 |
| Smit, WM | 1 |
| Hoyer, B | 1 |
| Steidl, U | 1 |
| Kondakci, M | 1 |
| Heuk, R | 1 |
| Ruf, L | 1 |
| Strupp, C | 2 |
| Neumann, F | 1 |
| Rohr, UP | 1 |
| Hildebrandt, B | 1 |
| Sakoda, M | 1 |
| Chen, CK | 1 |
| Zorzou, M | 1 |
| Tassidou, A | 1 |
| Soroka-Wojtaszko, M | 5 |
| Ciepluch, H | 1 |
| Sulek, K | 1 |
| Konopka, L | 1 |
| Duff, SB | 1 |
| Garban, F | 1 |
| Gratecos, N | 1 |
| Rio, B | 1 |
| Vernant, JP | 1 |
| Sotto, JJ | 1 |
| Jouet, JP | 1 |
| Bazzan, M | 1 |
| Kitamura, K | 1 |
| Takeuchi, J | 1 |
| Kanbe, E | 1 |
| Oka, H | 1 |
| Saiki, M | 1 |
| Aikawa, S | 1 |
| Kura, Y | 1 |
| Hatta, Y | 1 |
| Yamazaki, T | 1 |
| Sawada, U | 1 |
| Horie, T | 1 |
| Anand, G | 1 |
| Crivellato, E | 1 |
| Hovenga, S | 1 |
| Daenen, SM | 1 |
| de Wolf, JT | 1 |
| van Imhoff, GW | 1 |
| Sluiter, WJ | 1 |
| Chiruka, S | 1 |
| Chapman, CS | 1 |
| Schütt, P | 3 |
| Ebeling, P | 2 |
| Buttkereit, U | 3 |
| Brandhorst, D | 3 |
| Opalka, B | 3 |
| Hoiczyk, M | 1 |
| Flasshove, M | 2 |
| Hense, J | 1 |
| Bojko, P | 1 |
| Metz, K | 1 |
| Moritz, T | 3 |
| Seeber, S | 3 |
| Nowrousian, MR | 3 |
| Zhang, H | 1 |
| Vakil, V | 1 |
| Braunstein, M | 1 |
| Smith, EL | 1 |
| Maroney, J | 1 |
| Dai, K | 1 |
| Hussain, MM | 1 |
| Klueppelberg, U | 1 |
| Norin, AJ | 1 |
| Akman, HO | 1 |
| Ozçelik, T | 1 |
| Batuman, OA | 1 |
| Scarpace, SL | 1 |
| Roy, H | 1 |
| Matsushima, T | 2 |
| Nishimura, J | 1 |
| Nawata, H | 1 |
| Muta, K | 1 |
| Sadura, A | 1 |
| Lemancewicz, D | 1 |
| Dziecioł, J | 1 |
| Lebelt, A | 1 |
| Szkudlarek, M | 1 |
| Pagnucco, G | 1 |
| Cardinale, G | 1 |
| Gervasi, F | 1 |
| Vey, N | 1 |
| Bilger, K | 1 |
| Owen, OG | 1 |
| Bernardeschi, P | 2 |
| Dentico, P | 2 |
| Rossi, S | 3 |
| Fiorentini, G | 3 |
| Giustarini, G | 2 |
| Montenora, I | 1 |
| Turano, E | 2 |
| DiNino, KC | 1 |
| Jung, W | 1 |
| Zettl, F | 1 |
| Schroers, R | 1 |
| Plasmati, R | 2 |
| Pastorelli, F | 2 |
| Micol, JB | 1 |
| Guieze, R | 1 |
| Berthon, C | 1 |
| Kuhnovsky, F | 1 |
| Moreau, AS | 2 |
| Gardyn, J | 1 |
| Poser, M | 1 |
| Müller, S | 1 |
| Lindemann, M | 1 |
| Schmiedl, S | 1 |
| Grosse-Wilde, H | 1 |
| Shimoda, M | 1 |
| Satoh, T | 1 |
| del Giglio, A | 1 |
| Weinschenker, P | 1 |
| Manhani, AR | 1 |
| Carbonell, AL | 1 |
| Mitteldorf, CA | 1 |
| Nicci, C | 1 |
| Grafone, T | 2 |
| Hunt, BJ | 1 |
| Parmar, K | 1 |
| Onozawa, M | 1 |
| Hashino, S | 1 |
| Haneda, M | 1 |
| Horimoto, H | 1 |
| Izumiyama, K | 1 |
| Aldana, LP | 1 |
| Hamada, K | 1 |
| Asaka, M | 1 |
| Podhorecka, M | 2 |
| Bojarska-Junak, A | 2 |
| Rolinski, J | 2 |
| Skomra, D | 1 |
| Lau, LG | 1 |
| Yusof, N | 1 |
| Mow, BM | 1 |
| Roccaro, A | 2 |
| Shiraishi, N | 1 |
| Hamasaki, M | 1 |
| Laaksonen, S | 1 |
| Koskela, K | 1 |
| Voipio-Pulkki, LM | 1 |
| Falck, B | 1 |
| Ratterree, B | 1 |
| Gahres, N | 2 |
| Meisenberg, B | 2 |
| Takebe, N | 1 |
| Heyman, M | 2 |
| Zwiebel, J | 1 |
| Streicher, H | 1 |
| Gocke, CD | 1 |
| Tomic, D | 1 |
| Flaws, JA | 1 |
| Zhang, B | 1 |
| Fenton, RG | 2 |
| Cem Ar, M | 1 |
| Soysal, T | 1 |
| Hatemi, G | 1 |
| Salihoglu, A | 1 |
| Yazici, H | 1 |
| Ulku, B | 1 |
| Kocki, J | 1 |
| Mattioli, M | 1 |
| Bicciato, S | 1 |
| Thomson, K | 1 |
| Flory, A | 1 |
| Hanslip, J | 1 |
| Goldstone, AH | 1 |
| Koulova, L | 1 |
| Angtuaco, E | 2 |
| Walker, RC | 1 |
| Dong, L | 2 |
| Miceli, MH | 2 |
| Brown, R | 2 |
| Abdelkefi, A | 2 |
| Torjman, L | 2 |
| Ben Romdhane, N | 1 |
| Ladeb, S | 2 |
| El Omri, H | 1 |
| Ben Othman, T | 1 |
| Elloumi, M | 2 |
| Bellaj, H | 1 |
| Lakhal, A | 2 |
| Jeddi, R | 2 |
| Aissaouï, L | 2 |
| Saad, A | 2 |
| Hsaïri, M | 2 |
| Boukef, K | 2 |
| Dellagi, K | 2 |
| Ben Abdeladhim, A | 1 |
| Hatjiharissi, E | 3 |
| Hatjileontis, C | 1 |
| Kaloutsi, V | 2 |
| Galaktidou, G | 1 |
| Gerotziafas, G | 1 |
| Christakis, J | 1 |
| Heinrich, B | 1 |
| Gianfaldoni, G | 1 |
| Mannelli, F | 1 |
| Betti, S | 1 |
| Schmielau, J | 1 |
| Teschendorf, C | 1 |
| König, M | 1 |
| Schmiegel, W | 1 |
| Shibata, K | 1 |
| Shigeno, K | 1 |
| Shinjo, K | 1 |
| Naito, K | 1 |
| Hayashi, H | 1 |
| Ohnishi, K | 1 |
| Roberts, A | 2 |
| Ganju, V | 1 |
| Simmons, PJ | 1 |
| Milner, AD | 2 |
| Iulio, JD | 1 |
| Ramsay, R | 1 |
| Mihou, D | 3 |
| Tsimirika, K | 1 |
| Karkantaris, C | 1 |
| Voskaridou, E | 1 |
| Spriano, M | 1 |
| La Sala, A | 1 |
| Mantuano, S | 1 |
| Nobile, M | 1 |
| Melillo, L | 1 |
| Scalzulli, PR | 2 |
| Dell'Olio, M | 1 |
| Bodenizza, C | 1 |
| Greco, MM | 1 |
| Merla, E | 2 |
| Nunzi, M | 1 |
| Kabat, B | 2 |
| Avilés, A | 1 |
| Neri, N | 1 |
| Nambo, MJ | 1 |
| Cleto, S | 1 |
| Castañeda, C | 1 |
| Talavera, A | 1 |
| Huerta-Guzmán, J | 1 |
| Teo, SK | 1 |
| Russell, N | 2 |
| Prentice, HG | 1 |
| Esseltine, D | 1 |
| Burns, MJ | 1 |
| Kang, SH | 1 |
| Najarian, K | 1 |
| Rezvani, K | 1 |
| Milne, AE | 1 |
| Rose, PE | 1 |
| Scott, GL | 1 |
| Ambrosini, MT | 7 |
| Yamada, N | 2 |
| Okamoto, M | 2 |
| Duyvendak, M | 1 |
| Naunton, M | 1 |
| Kingma, BJ | 1 |
| Brouwers, JR | 1 |
| Stirling, D | 2 |
| Mazzotta, S | 1 |
| Pirrotta, MT | 1 |
| Lauria, F | 2 |
| Lane, SW | 1 |
| Gill, D | 1 |
| Mollee, PN | 1 |
| Rajkumar, VS | 1 |
| Crane, E | 1 |
| Leoni, F | 2 |
| Gigli, F | 1 |
| Rigacci, L | 1 |
| Rasmussen, E | 2 |
| El Mahou, S | 1 |
| Jamard, B | 1 |
| Constantin, A | 1 |
| Cantagrel, A | 1 |
| Mazières, B | 1 |
| Arnaud, C | 1 |
| Nicolucci, A | 1 |
| Valentini, M | 1 |
| Belfiglio, M | 1 |
| Delaini, F | 1 |
| Barbui, AM | 1 |
| Giussani, U | 1 |
| Rambaldi, A | 1 |
| Nowakowski, GS | 1 |
| Kottke-Marchant, K | 1 |
| McGowan, B | 1 |
| Jawde, RA | 2 |
| Li, XF | 2 |
| Coffey, R | 1 |
| Bae, J | 1 |
| Grewal, IS | 1 |
| Anderson, G | 1 |
| Gries, M | 1 |
| Kurihara, N | 1 |
| Honjo, T | 1 |
| Anderson, J | 1 |
| Donnenberg, V | 1 |
| Donnenberg, A | 1 |
| Roodman, D | 1 |
| Berrebi, A | 1 |
| Saunders, G | 1 |
| Klimek, VM | 1 |
| Kewalramani, T | 1 |
| Zimman, R | 1 |
| Drake, L | 1 |
| Riedel, ER | 1 |
| Hedvat, CV | 1 |
| Teruya-Feldstein, J | 1 |
| Filippa, DA | 1 |
| Fleisher, M | 1 |
| Maier, SK | 1 |
| Hammond, JM | 1 |
| van Oosterom, R | 1 |
| Adelmeijer, J | 1 |
| Lisman, T | 1 |
| Saka, B | 1 |
| Erten, N | 1 |
| Oztürk, G | 1 |
| Yilmaz, C | 1 |
| Dogan, O | 1 |
| Buyukbabani, N | 1 |
| Besisik, SK | 1 |
| Erdem, F | 1 |
| Gundogdu, M | 1 |
| Kiki, I | 1 |
| Capoĝlu, I | 1 |
| Scortechini, AR | 2 |
| Hahn, C | 1 |
| Orlopp, K | 1 |
| Schmidt-Wolf, I | 2 |
| Repoussis, P | 1 |
| Delibasi, S | 2 |
| Otrock, ZK | 1 |
| Mahfouz, RA | 1 |
| El-Hajj, II | 1 |
| Harb, MI | 1 |
| Sawaya, RA | 1 |
| Parente, R | 1 |
| Boni, P | 1 |
| Deng, A | 1 |
| Harvey, V | 1 |
| Sina, B | 1 |
| Strobel, D | 1 |
| Junkins-Hopkins, JM | 1 |
| Samuels, A | 1 |
| Oghilikhan, M | 1 |
| Gaspari, A | 1 |
| Sinha, R | 1 |
| Suppiah, R | 2 |
| Srkalovic, JG | 1 |
| Avonto, I | 7 |
| Yutaka, H | 1 |
| Mariko, Y | 1 |
| Shinichiro, O | 1 |
| Kunihiko, M | 1 |
| Yusuke, T | 1 |
| Yasuo, I | 1 |
| Terrier, B | 2 |
| Joly, D | 1 |
| Hummel, A | 1 |
| Klimek, P | 1 |
| Kiwan, E | 1 |
| Krishna, S | 2 |
| Fox, M | 1 |
| Capparella, V | 1 |
| Ceccarelli, M | 1 |
| Grazziutti, ML | 1 |
| Coiteux, V | 1 |
| Fung, H | 1 |
| Falk, PM | 1 |
| Rodriguez, R | 1 |
| Nakamura, R | 1 |
| Nademanee, A | 1 |
| Tin, R | 1 |
| Ilieva, P | 1 |
| Chang, DH | 1 |
| Liu, N | 1 |
| Klimek, V | 1 |
| Ferreri, AJ | 1 |
| Zijlmans, M | 1 |
| Ayuk, FA | 1 |
| Verdonck, LF | 1 |
| Brinker, BT | 1 |
| Waller, EK | 1 |
| Leong, T | 1 |
| Redei, I | 1 |
| Langston, AA | 1 |
| Burton, A | 1 |
| DeLap, RJ | 1 |
| McCarthy, DA | 1 |
| Macey, MG | 1 |
| Brown, KA | 1 |
| Folkman, J | 2 |
| Rogers, MS | 3 |
| Park, S | 1 |
| Kim, CC | 1 |
| Min, YH | 1 |
| Cho, KS | 1 |
| Lee, NR | 1 |
| Poloni, A | 1 |
| Bemardeschi, P | 1 |
| Sidra, G | 1 |
| Kusumi, E | 1 |
| Matsumura, T | 1 |
| Yuji, K | 1 |
| Tanaka, Y | 1 |
| Kami, M | 2 |
| Nabhan, C | 1 |
| Bitran, JD | 1 |
| Ueki, T | 1 |
| Matsumoto, H | 1 |
| Nakajima, H | 1 |
| Swieboda-Sadlej, A | 1 |
| Hanje, AJ | 1 |
| Shamp, JL | 1 |
| Thomas, FB | 1 |
| Meis, GM | 1 |
| Kalmadi, SR | 1 |
| Capella, S | 1 |
| Agrawal, N | 1 |
| Hsi, E | 1 |
| Walker, E | 2 |
| Desikan, KR | 1 |
| Kelly-Colson, K | 1 |
| McKenney, ML | 1 |
| Gorelik, S | 1 |
| Wu, A | 1 |
| Wride, K | 1 |
| Domínguez-Martínez, VJ | 1 |
| Yakoub Agha, I | 1 |
| Renaud, M | 2 |
| Grobois, B | 1 |
| Schwab, C | 1 |
| Irisawa, H | 1 |
| Uchiumi, H | 1 |
| Karasawa, M | 1 |
| Aouba, A | 1 |
| Diop, S | 1 |
| Clerc, J | 1 |
| Vasiliu, V | 1 |
| Munera, Y | 1 |
| Pandey, R | 1 |
| Shah, S | 1 |
| Patel, KM | 1 |
| Shah, PM | 1 |
| Shukla, SN | 1 |
| Parikh, BJ | 1 |
| Anand, A | 1 |
| Talati, SS | 1 |
| Panchal, H | 1 |
| Parikh, S | 1 |
| Thrutthel, S | 1 |
| Davies, MJ | 1 |
| Barrick, M | 1 |
| Doss, DS | 1 |
| Day, B | 1 |
| Ramiro, L | 1 |
| Torrebadell, M | 1 |
| Choueiri, TK | 1 |
| Ellis, Y | 1 |
| Brand, C | 1 |
| Chowta, MN | 1 |
| Chowta, NK | 1 |
| Console, G | 1 |
| Stelitano, C | 1 |
| Massara, E | 1 |
| Irrera, G | 1 |
| Messina, G | 1 |
| Iacopino, P | 1 |
| Sviggum, HP | 1 |
| Davis, MD | 1 |
| Sohlbach, K | 1 |
| Heinze, S | 1 |
| Shiratori, K | 1 |
| Sure, U | 1 |
| Pagenstecher, A | 1 |
| Neubauer, A | 1 |
| Kamikawa, R | 1 |
| Ikawa, K | 1 |
| Morikawa, N | 1 |
| Iwato, K | 1 |
| Sasaki, A | 1 |
| Ramadan, KM | 1 |
| McKenna, KE | 1 |
| Kenealy, M | 1 |
| Hönemann, D | 2 |
| Horton, C | 1 |
| Krishnan, B | 1 |
| Alvares, CL | 1 |
| Saso, R | 1 |
| McCormack, R | 1 |
| Treleaven, JG | 1 |
| Dimicelli, L | 1 |
| Depaolo, D | 1 |
| Landrigan, B | 1 |
| Doran, V | 1 |
| Marshal, P | 1 |
| Cherian, G | 1 |
| Thomas, DW | 1 |
| Rule, SA | 1 |
| D'Arco, A | 1 |
| Bennett, CL | 1 |
| Angelotta, C | 1 |
| Yarnold, PR | 1 |
| Evens, AM | 1 |
| Raisch, DW | 1 |
| Arzoumanian, V | 1 |
| Huston, A | 1 |
| Brown, J | 1 |
| Bhardwaj, A | 1 |
| Vadhan-Raj, S | 1 |
| Bueso-Ramos, C | 1 |
| Takada, Y | 1 |
| Gaur, U | 1 |
| Nair, AS | 2 |
| Shishodia, S | 1 |
| De Raeve, H | 1 |
| Vanderkerken, K | 1 |
| Wang, D | 2 |
| Tao, Z | 1 |
| Feaver, AA | 1 |
| McCune, DE | 1 |
| Mysliwiec, AG | 1 |
| Mysliwiec, V | 1 |
| Dürk, HA | 1 |
| Shimoma, J | 1 |
| Yanagisawa, K | 1 |
| Saito, B | 1 |
| Kawakami, K | 1 |
| Tomoyasu, S | 1 |
| Ghosh, S | 1 |
| Gopal, R | 1 |
| Advani, SH | 1 |
| Hirsh, J | 1 |
| Fausel, C | 1 |
| Juliar, BE | 1 |
| Yiannoutsos, CT | 1 |
| Fisher, WB | 1 |
| Ansari, RH | 1 |
| Wood, LL | 1 |
| Smith, GG | 1 |
| Cripe, LD | 1 |
| Fenton, R | 1 |
| Akpek, G | 2 |
| Harris, C | 1 |
| Ruehle, K | 1 |
| Westphal, S | 1 |
| Colla, S | 1 |
| Xiong, W | 1 |
| Stephens, O | 1 |
| Dicato, M | 1 |
| Khosravi Shahi, P | 1 |
| Díaz Muñoz de la Espada, VM | 1 |
| Sabin Domínguez, P | 1 |
| Encinas García, S | 1 |
| Arranz Arija, JA | 1 |
| Carrión Galindo, JR | 1 |
| Pérez Manga, G | 1 |
| González González, BJ | 1 |
| Hernández Nieto, L | 1 |
| Stoopler, ET | 1 |
| Schenkel, B | 2 |
| Martini, V | 1 |
| Gallucci, C | 1 |
| Del Bianco, P | 1 |
| Torromeo, C | 1 |
| Hoyer, RJ | 1 |
| Kalmadi, S | 1 |
| Melchert, M | 1 |
| Holt, Bv | 1 |
| Herrmann, D | 1 |
| Haenel, A | 1 |
| Strobeck, M | 1 |
| Phekoo, KJ | 1 |
| Mohiuddin, A | 3 |
| Woods, G | 1 |
| Barmparousi, D | 2 |
| Koutsoukou, V | 1 |
| Atay, AE | 1 |
| Isikdogan, A | 1 |
| Muftuoglu, E | 1 |
| Patil, S | 1 |
| Schwarer, A | 1 |
| McLean, C | 1 |
| Copelan, EA | 1 |
| Thornburg, A | 1 |
| Smith, P | 1 |
| Knox, K | 1 |
| Twigg, HL | 1 |
| Pathak, AK | 1 |
| Rumizen, M | 1 |
| Burger, P | 1 |
| Tassone, P | 1 |
| Goz, M | 1 |
| Eren, MN | 1 |
| Cakir, O | 1 |
| Chennuru, S | 1 |
| Baumann, MA | 1 |
| El Accaoui, RN | 1 |
| Shamseddeen, WA | 1 |
| Prasad, HK | 1 |
| Kaushal, V | 1 |
| Gurley, J | 1 |
| Adena, M | 1 |
| Smith, DK | 1 |
| Hertel, J | 1 |
| Girard, LP | 1 |
| Gregson, DB | 1 |
| Kartsios, C | 1 |
| Banti, A | 1 |
| Lazaridou, A | 1 |
| Phillips, J | 1 |
| Kujawa, J | 1 |
| Davis-Lorton, M | 1 |
| Hindenburg, A | 1 |
| Petropoulou, AD | 1 |
| Gerotziafas, GT | 1 |
| Samama, MM | 1 |
| Hatmi, M | 1 |
| Rendu, F | 1 |
| Boga, C | 1 |
| Yeral, M | 1 |
| Kizilkilic, E | 1 |
| Tamer, L | 1 |
| Strasser-Weippl, K | 1 |
| Gambell, P | 1 |
| Trivett, M | 1 |
| Hayakawa, Y | 1 |
| Smyth, M | 1 |
| Beshay, V | 1 |
| Simmons, P | 1 |
| Yang, C | 1 |
| Shao, K | 1 |
| Dalal, JS | 1 |
| Can, I | 1 |
| Thompson, J | 1 |
| Oota, M | 1 |
| Fukuhara, T | 1 |
| Fujii, H | 1 |
| Asou, N | 1 |
| Izuno, Y | 1 |
| Okubo, T | 1 |
| Ide, K | 1 |
| Kawakita, M | 1 |
| Petracci, E | 1 |
| Salvi, F | 2 |
| Bartolomei, I | 1 |
| Michelucci, R | 1 |
| Tassinari, CA | 1 |
| Fassas, AB | 2 |
| Naib, T | 2 |
| Jalbrzikowski, J | 3 |
| Liu, SV | 1 |
| Chong, EA | 1 |
| Schuster, SJ | 1 |
| Tsai, DE | 1 |
| Perl, A | 1 |
| Loren, AW | 1 |
| Goldstein, SC | 1 |
| Nasta, SD | 1 |
| Andreadis, C | 1 |
| Siegel, DL | 1 |
| Glatstein, E | 1 |
| Yildirim, ND | 1 |
| Ayer, M | 1 |
| Küçükkaya, RD | 1 |
| Alpay, N | 1 |
| Yenerel, MN | 1 |
| Yavuz, AS | 1 |
| Nalçaci, M | 1 |
| Ghobrial, J | 1 |
| Shah, SR | 1 |
| Tran, TM | 1 |
| Tariman, JD | 1 |
| Rao, KV | 1 |
| Bláha, V | 1 |
| Malý, J | 1 |
| Snively, A | 1 |
| Amen, K | 1 |
| McGee, L | 1 |
| Oestreicher, P | 1 |
| Liew, MS | 1 |
| Bishton, MJ | 1 |
| Januszewicz, H | 1 |
| Alatakis, S | 1 |
| Othman, TB | 1 |
| Romdhane, NB | 1 |
| Omri, HE | 1 |
| Belaaj, H | 1 |
| Ksouri, H | 1 |
| Hassen, AB | 1 |
| Msadek, F | 1 |
| Amouri, A | 1 |
| Louzir, H | 1 |
| Abdeladhim, AB | 1 |
| Koreth, J | 1 |
| Rawstron, A | 1 |
| Snowden, JA | 1 |
| Maisonneuve, H | 1 |
| Troncy, J | 1 |
| Martin, C | 1 |
| Jaubert, J | 1 |
| Anglaret, B | 1 |
| Matuszak, M | 1 |
| Lewandowski, K | 1 |
| Holzgrabe, U | 1 |
| Peest, D | 1 |
| Ganser, A | 1 |
| Perosa, F | 1 |
| Bagchi, S | 1 |
| Hussain, S | 1 |
| Browne, R | 1 |
| Tepler, J | 1 |
| Mathew, S | 2 |
| Yonemura, K | 1 |
| Hashimoto, Y | 3 |
| Uchino, M | 1 |
| Murphy, PT | 1 |
| O'Donnell, JR | 1 |
| List, AF | 1 |
| Wiley, KE | 1 |
| Martínez-Baños, D | 1 |
| Furst, J | 1 |
| De Sancho, M | 1 |
| Colado, E | 1 |
| Olazábal, J | 1 |
| Gotoh, A | 1 |
| Ohyashiki, K | 1 |
| Richards, TA | 1 |
| Darre, S | 1 |
| Marchand, V | 1 |
| Decaudin, D | 1 |
| Servois, V | 1 |
| Kirova, YM | 1 |
| Lin, RF | 1 |
| Wang, YR | 1 |
| Shen, WY | 1 |
| Wu, YJ | 1 |
| Zhang, JF | 1 |
| Fei, XM | 1 |
| Ge, Z | 1 |
| Harousseau, J | 1 |
| Montalbetti, L | 1 |
| Mazzone, A | 1 |
| Fava, S | 1 |
| Alkindi, S | 1 |
| Dennison, D | 1 |
| Pathare, A | 1 |
| Barge, R | 1 |
| Breitkreuz, I | 1 |
| Blau, I | 1 |
| Duersen, U | 1 |
| Matsui, W | 1 |
| Wang, Q | 1 |
| Barber, JP | 1 |
| Brennan, S | 1 |
| Smith, BD | 1 |
| McNiece, I | 1 |
| Ambinder, RF | 1 |
| Peacock, C | 1 |
| Watkins, DN | 1 |
| Haas, PS | 1 |
| Denz, U | 1 |
| Yachide-Noguchi, T | 1 |
| Nakazato, S | 1 |
| Sagawa, M | 1 |
| Paripati, H | 1 |
| Cabou, S | 1 |
| Dueck, A | 1 |
| Zepeda, VJ | 1 |
| Pirooz, N | 1 |
| Ehlenbeck, C | 1 |
| Slack, J | 1 |
| Leis, JF | 1 |
| Boesiger, J | 1 |
| Torloni, AS | 1 |
| Menon, SP | 1 |
| Minchom, A | 1 |
| Yates, LR | 1 |
| Ryali, MM | 1 |
| Nicolasora, NP | 1 |
| Reddy, P | 1 |
| Kaul, DR | 1 |
| Cheson, BD | 1 |
| Zhuang, SH | 1 |
| Sembongi, K | 1 |
| Sakurada, K | 1 |
| Itagaki, S | 1 |
| Iseki, K | 1 |
| Magalini, F | 1 |
| Stella, A | 1 |
| Sansoni, P | 1 |
| Bjorn, G | 1 |
| Streetly, MJ | 1 |
| Gyertson, K | 1 |
| Daniel, Y | 1 |
| Kazmi, M | 1 |
| Tsubokura, M | 1 |
| Jedrzejczak, W | 1 |
| Ravera, C | 1 |
| Cremers, S | 1 |
| Bilic, S | 1 |
| Neeman, T | 1 |
| Copeman, M | 1 |
| Schran, H | 1 |
| Lynch, K | 1 |
| Hicks, LK | 1 |
| Haynes, AE | 1 |
| Walker, IR | 1 |
| Herst, JA | 1 |
| Imrie, K | 1 |
| Casini, C | 1 |
| Breschi, C | 1 |
| Santini, V | 1 |
| Jeng, WJ | 1 |
| Kuo, MC | 1 |
| Shih, LY | 1 |
| Chu, PH | 1 |
| Batts, ED | 1 |
| Hegerfeldt, Y | 1 |
| Candoni, A | 1 |
| Simeone, E | 1 |
| Hirai, H | 1 |
| Akamatsu, S | 1 |
| Lafaras, C | 1 |
| Mandala, E | 1 |
| Platogiannis, D | 1 |
| Barbetakis, N | 1 |
| Bischiniotis, T | 1 |
| Barer, S | 1 |
| Gladney, SP | 1 |
| Montanaro, M | 1 |
| Capaldi, A | 1 |
| Dore, F | 1 |
| Forsyth, CJ | 1 |
| Cremer, PD | 1 |
| Torzillo, P | 1 |
| Iland, HJ | 1 |
| Young, GA | 1 |
| Larkin, M | 1 |
| Ayers, D | 2 |
| Roberson, P | 1 |
| Wilson, C | 2 |
| Zeddis, J | 1 |
| Kneller, A | 1 |
| Levi, I | 2 |
| Berkowicz, M | 1 |
| Ben-Bassat, I | 2 |
| Kishi, Y | 1 |
| Oki, Y | 1 |
| Machida, U | 1 |
| Celsing, F | 1 |
| Adriansson, M | 1 |
| Malm, C | 1 |
| Tournilhac, O | 1 |
| Sjak-Shie, NN | 1 |
| Vescio, RA | 1 |
| Yeh, YA | 1 |
| Pappas, AA | 1 |
| Flick, JT | 1 |
| Butch, AW | 1 |
| Schreiber, S | 1 |
| Obermair, A | 1 |
| Kaufmann, H | 2 |
| Urbauer, E | 2 |
| Aletaha, K | 1 |
| Chott, A | 1 |
| Huber, H | 1 |
| Gutheil, J | 1 |
| Finucane, D | 1 |
| Hawighorst, H | 1 |
| Max, R | 1 |
| van Kaick, G | 1 |
| Pini, M | 1 |
| Pietrasanta, D | 1 |
| Allione, B | 1 |
| Depaoli, L | 1 |
| Levis, A | 1 |
| Shima, Y | 2 |
| Zeiler, T | 1 |
| Wittmann, G | 1 |
| Zimmermann, R | 1 |
| Hintz, G | 1 |
| Huhn, D | 1 |
| Riess, H | 1 |
| Mellstedt, H | 1 |
| Politi, PM | 1 |
| Scerbo, F | 1 |
| Matus, G | 1 |
| Sautois, B | 1 |
| Fillet, G | 1 |
| Triolo, S | 1 |
| Gallo, E | 1 |
| Pileri, A | 1 |
| Ciepnuch, H | 1 |
| Pileri, SA | 1 |
| Goldman, DA | 1 |
| Perales, M | 2 |
| Tuset, M | 2 |
| Montoto, S | 2 |
| Cobo, F | 1 |
| Rafel, M | 1 |
| Nomdedeu, B | 1 |
| Anagnostara, A | 1 |
| Jost, L | 1 |
| Young, G | 1 |
| Gupta, D | 2 |
| Osman, K | 1 |
| Spencer, T | 2 |
| Spoon, D | 1 |
| Grimley, C | 1 |
| Cromer, J | 1 |
| Gopal, AV | 1 |
| Toor, A | 3 |
| Thomas, DA | 1 |
| Kantarjian, HM | 1 |
| Mingrone, W | 1 |
| Alietti, A | 1 |
| Ferrucci, PF | 1 |
| Cocorocchio, E | 1 |
| Peccatori, F | 1 |
| Cinieri, S | 1 |
| Mancuso, P | 1 |
| Corsini, C | 1 |
| Burlini, A | 1 |
| Zucca, E | 1 |
| Cineri, S | 1 |
| Kouvatseas, G | 1 |
| Galani, E | 1 |
| Kiamouris, C | 1 |
| Vervessou, E | 1 |
| Samantas, E | 1 |
| Economou, O | 1 |
| Panayiotidis, P | 1 |
| Christakis, I | 1 |
| Jákó, J | 1 |
| Vályi-Nagy, I | 1 |
| Camba, L | 1 |
| Pescarollo, A | 1 |
| Tresoldi, M | 1 |
| Bregni, M | 1 |
| Tuinmann, G | 1 |
| Hegewisch-Becker, S | 1 |
| Hossfeld, DK | 1 |
| D'Orazio, AI | 1 |
| Krasniqi, F | 1 |
| Desikan, RK | 1 |
| D'Amato, RJ | 2 |
| Ralph, P | 1 |
| Payvandi, F | 1 |
| Juturi, JV | 1 |
| Lieberman, I | 1 |
| Grigg, AP | 1 |
| Westerman, DW | 1 |
| Combe, B | 1 |
| Lundberg, LG | 1 |
| Palmblad, J | 1 |
| Azzarello, D | 1 |
| Orlandi, E | 1 |
| Astori, C | 1 |
| Bodenner, D | 1 |
| Berryman, T | 1 |
| Benramdane, R | 1 |
| Joseph, L | 1 |
| Sethi, R | 1 |
| Hough, A | 1 |
| Harik, S | 1 |
| Beris, P | 1 |
| Krawczyk, S | 1 |
| Ciepłuch, H | 2 |
| Whitfield, D | 1 |
| Baran, W | 1 |
| Birsner, AE | 1 |
| Shah, JH | 1 |
| Treston, AM | 1 |
| Cany, L | 1 |
| Fitoussi, O | 1 |
| Boiron, JM | 1 |
| González-Fraile, MI | 1 |
| Sierra, M | 1 |
| López, C | 1 |
| Scherer, A | 1 |
| Wittsack, HJ | 1 |
| Engelbrecht, V | 1 |
| Willers, R | 1 |
| Gattermann, N | 1 |
| Mödder, U | 1 |
| Ahmad, I | 1 |
| Islam, T | 1 |
| Wentling, D | 1 |
| Becker, JL | 1 |
| Alam, AR | 1 |
| Nousiainen, T | 1 |
| Johnston, RE | 1 |
| Domański, D | 1 |
| Mujagić, H | 1 |
| Chabner, BA | 1 |
| Mujagić, Z | 1 |
| Poulaki, V | 1 |
| Curley, MJ | 1 |
| Hussein, SA | 1 |
| Hassoun, PM | 1 |
| Nösslinger, T | 1 |
| Lee, FC | 1 |
| Bauduer, F | 1 |
| Nijsten, T | 1 |
| Meuleman, L | 1 |
| Schroyens, W | 1 |
| Wada, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of Daratumumab in Combination With Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) in the First Line Treatment of Transplant Eligible Subjects With Newly Diagnosed Multiple Myeloma[NCT02541383] | Phase 3 | 1,085 participants (Actual) | Interventional | 2015-09-30 | Active, not recruiting | ||
| A Phase 2, Open-Label, Multicenter, Dose-Escalation and Expansion Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma[NCT03567616] | Phase 2 | 8 participants (Actual) | Interventional | 2018-10-18 | Terminated (stopped due to Following results of the primary progression-free survival analysis from Study NCT02755597, company-sponsored MM studies were placed on partial clinical hold (PCH). Sponsor did not pursue release of the PCH for this study.) | ||
| A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy[NCT02004275] | Phase 1/Phase 2 | 118 participants (Actual) | Interventional | 2014-02-28 | Active, not recruiting | ||
| A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination With Pomalidomide, Carfilzomib and Dexamethasone Among High Risk Relapsed/ Refractory Multiple Myeloma Patients[NCT03104270] | Phase 2 | 13 participants (Actual) | Interventional | 2017-03-13 | Terminated (stopped due to The study was terminated early by Funding Sponsor due to low enrollment.) | ||
| A Randomized, Controlled, Open-label, Phase 3 Study of Melflufen/Dexamethasone Compared With Pomalidomide/Dexamethasone for Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Lenalidomide[NCT03151811] | Phase 3 | 495 participants (Actual) | Interventional | 2017-06-12 | Completed | ||
| A Phase 2, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma[NCT03170882] | Phase 2 | 122 participants (Actual) | Interventional | 2017-08-01 | Completed | ||
| A Phase 2, Multicenter, Multi-cohort, Open-label Study of Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following[NCT01946477] | Phase 2 | 186 participants (Actual) | Interventional | 2014-05-29 | Active, not recruiting | ||
| A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination With Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple[NCT02990338] | Phase 3 | 307 participants (Actual) | Interventional | 2016-12-22 | Completed | ||
| Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma[NCT02136134] | Phase 3 | 499 participants (Actual) | Interventional | 2014-08-15 | Active, not recruiting | ||
| A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor.[NCT03180736] | Phase 3 | 304 participants (Actual) | Interventional | 2017-06-12 | Active, not recruiting | ||
| An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma[NCT01998971] | Phase 1 | 242 participants (Actual) | Interventional | 2014-02-18 | Active, not recruiting | ||
| Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma[NCT05378971] | 15 participants (Anticipated) | Interventional | 2022-05-15 | Recruiting | |||
| Multicenter, Phase II, National and Open-label Study to Evaluate Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.[NCT05527340] | Phase 2 | 140 participants (Anticipated) | Interventional | 2022-09-30 | Not yet recruiting | ||
| An Open Label, Multicenter, Phase 2, Pilot Study, Evaluating Early Treatment With Bispecific T-cell Redirectors (Teclistamab and Talquetamab) in the Frontline Therapy of Newly Diagnosed High-risk Multiple Myeloma[NCT05849610] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-11-30 | Recruiting | ||
| Isatuximab in Combination With Lenalidomide-Dexamethasone Compared to Lenalidomide-Dexamethasone in Elderly Patients (Aged ≥70 Years) With Newly Diagnosed Myeloma: a Randomized Phase II Study (SGZ-2019-12650)[NCT04891809] | Phase 2 | 198 participants (Anticipated) | Interventional | 2021-10-20 | Recruiting | ||
| Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma[NCT02410694] | Phase 2 | 90 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| GEM21menos65. A Phase III Trial for NDMM Patients Who Are Candidates for ASCT Comparing Extended VRD Plus Early Rescue Intervention vs Isatuximab-VRD vs Isatuximab-V-Iberdomide-D[NCT05558319] | Phase 3 | 480 participants (Anticipated) | Interventional | 2022-10-31 | Not yet recruiting | ||
| Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis[NCT04943302] | Phase 2 | 0 participants (Actual) | Interventional | 2022-09-30 | Withdrawn (stopped due to PI left institution. Study not moving forward in her absence.) | ||
| A Phase 2 Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma Patients With t(11;14)[NCT06115135] | Phase 2 | 39 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | ||
| A Phase 1/2a, Open-Label, Multicentre, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of the Human Anti-CD 38 Antibody MOR03087 as Monotherapy and in Combination With Standard Therapy in Subjects With Relapsed/Refractory Multiple My[NCT01421186] | Phase 1/Phase 2 | 91 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Safety, Tolerability and Efficacy of Monoclonal CD38 Antibody Felzartamab in Late Antibody-Mediated Renal Allograft Rejection - A Phase 2 Pilot Trial[NCT05021484] | Phase 2 | 22 participants (Actual) | Interventional | 2021-10-06 | Active, not recruiting | ||
| An Open-label, Pharmacokinetic Study of Lenalidomide (Revlimid) and High-dose Dexamethasone Induction Therapy in Previously Untreated Multiple Myeloma Patients With Various Degrees of Renal Dysfunction - Validation of Official Dosing Guidelines for Renal [NCT01270932] | Phase 2 | 28 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Phase I/II, Multicenter, Open Label, Clinical Trial of Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients[NCT02384083] | Phase 1/Phase 2 | 47 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| A Phase 1/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 Monotherapy, or in Combination With Pomalidomide, With and Without Dexamethasone in Subjects With Relapsed or Refractory Multiple[NCT03287908] | Phase 1 | 174 participants (Actual) | Interventional | 2017-11-13 | Terminated (stopped due to business decision, not safety reasons.) | ||
| A Phase I/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 in Patients With Selected CD38+ Hematological Malignancies[NCT01084252] | Phase 1/Phase 2 | 351 participants (Actual) | Interventional | 2010-06-10 | Completed | ||
| A Phase 3, Prospective, Randomized Clinical Study of VELCADE-Thalidomide-Dexamethasone (VTD) Versus Thalidomide-Dexamethasone (TD) for Previously Untreated Multiple Myeloma (MM) Patients Who Are Candidates to Receive Double Autologous Transplantation[NCT01134484] | Phase 3 | 480 participants (Actual) | Interventional | 2006-05-31 | Active, not recruiting | ||
| A Phase 1b Study of SAR650984 (Isatuximab) in Combination With Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma[NCT02283775] | Phase 1 | 54 participants (Actual) | Interventional | 2015-05-15 | Completed | ||
| Randomized, Open Label, Multicenter Study Assessing The Clinical Benefit Of Isatuximab Combined With Carfilzomib (Kyprolis®) And Dexamethasone Versus Carfilzomib With Dexamethasone In Patients With Relapse And/Or Refractory Multiple Myeloma Previously Tre[NCT03275285] | Phase 3 | 302 participants (Actual) | Interventional | 2017-10-25 | Active, not recruiting | ||
| A Phase IB Multicenter, Open-label Study To Determine The Recommended Dose And Regimen Of Durvalumab (MEDI4736) Either As Monotherapy or In Combination With Pomalidomide (POM) With Or Without Low-Dose Dexamethasone (DEX) In Subjects With Relapsed And Refr[NCT02616640] | Phase 1 | 114 participants (Actual) | Interventional | 2016-01-11 | Active, not recruiting | ||
| A Phase III, Randomized, Open-label, 3-arm Study to Determine the Efficacy and Safety of Lenalidomide(REVLIMID) Plus Low-dose Dexamethasone When Given Until Progressive Disease or for 18 Four-week Cycles Versus the Combination of Melphalan, Prednisone, an[NCT00689936] | Phase 3 | 1,623 participants (Actual) | Interventional | 2008-08-21 | Completed | ||
| Randomized Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone to High-Dose Treatment With ASCT in the Initial Management of Myeloma in Patients up to 65 Years of Age[NCT01191060] | Phase 3 | 700 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| An Open Label, Multicenter, Phase II Study of Belantamab Mafodotin in Combination With VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients[NCT04802356] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-04-07 | Recruiting | ||
| A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma[NCT01080391] | Phase 3 | 792 participants (Actual) | Interventional | 2010-07-14 | Completed | ||
| 1454GCC: Phase I/II Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma[NCT02289222] | Phase 1/Phase 2 | 48 participants (Actual) | Interventional | 2014-12-30 | Terminated (stopped due to Due to the inclusion of an IMid in combination with pembrolizumab, Study Sponsor terminated the study.) | ||
| A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma[NCT01749969] | Phase 1 | 57 participants (Actual) | Interventional | 2013-02-06 | Completed | ||
| A Non-interventional Post Authorisation Registry of Patients Treated With Pomalidomide for Relapsed and Refractory Multiple Myeloma Who Have Received at Least Two Prior Treatment Regimens, Including Both Lenalidomide and Bortezomib, and Have Demonstrated [NCT02164955] | 775 participants (Actual) | Observational [Patient Registry] | 2014-06-26 | Completed | |||
| A Multicenter, Single-arm, Open-label Study With Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma[NCT01712789] | Phase 3 | 682 participants (Actual) | Interventional | 2012-11-06 | Completed | ||
| A Phase 1, Multicenter, Open Label, Dose-escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LDDEX) in Subjects With Relapsed or Refractory Multiple Myeloma (MM)[NCT01497093] | Phase 1 | 34 participants (Actual) | Interventional | 2012-02-15 | Completed | ||
| A Multi-Center Phase 2 Study of Daratumumab With Pomalidomide and Dexamethasone in Combination With All-Transretinoic Acid in Patients With Multiple Myeloma Previously Exposed to Daratumumab-Based Regimens[NCT04700176] | Phase 2 | 43 participants (Anticipated) | Interventional | 2022-05-02 | Recruiting | ||
| A Phase I/II Study of Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Patients With Newly Diagnosed Transplant Eligible Multiple Myeloma[NCT05199311] | Phase 1/Phase 2 | 66 participants (Anticipated) | Interventional | 2022-05-13 | Recruiting | ||
| A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma[NCT01564537] | Phase 3 | 722 participants (Actual) | Interventional | 2012-08-01 | Completed | ||
| A Non-interventional, Observational Post-marketing Registry of Multiple Myeloma Adult Patients Treated With Revlimid (Lenalidomide) in China[NCT01947309] | 176 participants (Actual) | Observational | 2013-11-30 | Terminated (stopped due to Business Decision) | |||
| A Phase III Randomized, Double-Blind Study of Maintenance Therapy With CC-5013 (NSC # 703813) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma[NCT00114101] | Phase 3 | 460 participants (Actual) | Interventional | 2004-12-15 | Active, not recruiting | ||
| Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study[NCT00574288] | Phase 2 | 104 participants (Actual) | Interventional | 2008-03-26 | Completed | ||
| An Open Label, International, Multicenter, Dose Escalating Phase I/II Trial Investigating the Safety of Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma[NCT01615029] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2012-06-30 | Active, not recruiting | ||
| Efficacy of Response-adapted Treatment Guided by Negative Minimal Residual Disease and Negative Imaging (MRDI) in Fit Patients Diagnosed With Multiple Myeloma Who Are Candidates for Bone Marrow Transplantation[NCT05697913] | 66 participants (Actual) | Interventional | 2014-07-01 | Completed | |||
| A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma[NCT01568866] | Phase 3 | 929 participants (Actual) | Interventional | 2012-06-20 | Completed | ||
| Observational Cohort Study Evaluating the Use and Efficacy of Pomalidomide in Patients With Multiple Myeloma in Routine Clinical Practice[NCT02902900] | 2,504 participants (Actual) | Observational | 2015-04-01 | Completed | |||
| A Phase 1 Study of Amrubicin in Combination With Lenalidomide and Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma[NCT01355705] | Phase 1/Phase 2 | 14 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| A Multi-center, Open-label Extended Access Program of Lenalidomide Plus Low-dose Dexamethasone in Chinese Subjects With Relapsed/Refactory Multiple Myeloma Who Participated in Study CC-5013-MM-021 for at Least One Year.[NCT02348528] | Phase 2 | 65 participants (Actual) | Interventional | 2012-09-11 | Completed | ||
| Connect® MM- The Multiple Myeloma Disease Registry[NCT01081028] | 3,011 participants (Actual) | Observational | 2009-09-01 | Active, not recruiting | |||
| A Multicenter, Single-Arm, Open-Label Treatment Use Protocol for Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma[NCT01632826] | 0 participants | Expanded Access | Approved for marketing | ||||
| A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial[NCT02244125] | Phase 2 | 100 participants (Actual) | Interventional | 2014-04-14 | Completed | ||
| An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)[NCT02654132] | Phase 2 | 117 participants (Actual) | Interventional | 2016-03-18 | Completed | ||
| A Phase 1, Multicenter, Open-label, Dose-escalation Study in Japan to Determine the Tolerated Dose and to Evaluate the Safety, Efficacy, and Pharmacokinetics of Pomalidomide Alone or in Combination With Dexamethasone in Patients With Refractory or Relapse[NCT01568294] | Phase 1 | 12 participants (Actual) | Interventional | 2012-04-01 | Completed | ||
| A Phase II Study of Dexamethasone (DECADRON®), Clarithromycin (BIAXIN®), and Pomalidomide (CC-4047®) for Subjects With Relapsed or Refractory Multiple Myeloma[NCT01159574] | Phase 2 | 121 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects[NCT01707407] | Phase 1 | 32 participants (Actual) | Interventional | 2012-09-01 | Completed | ||
| Phase 3B, Randomized Trail of Revlimid® (Lenalidomide) Versus Placebo Maintenance Therapy Following Melphalan Prednisone Velcade (Bortezomib) Induction Therapy In Newly Diagnosed Multiple Myeloma[NCT02112175] | Phase 3 | 46 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| A Phase III Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (KEYNOTE 183)[NCT02576977] | Phase 3 | 251 participants (Actual) | Interventional | 2015-10-19 | Terminated (stopped due to The study was terminated early due to business reasons) | ||
| Phase 1, Multicenter, Open-label, Dose-escalation Study of Sotatercept (ACE-011) in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma[NCT01562405] | Phase 1 | 33 participants (Actual) | Interventional | 2012-05-31 | Active, not recruiting | ||
| Multicenter Open Label Phase 2 Single Arm Study of Ixazomib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Characterized With Genomic Abnormalities of Adverse Adverse Prognostic[NCT03683277] | Phase 2 | 26 participants (Actual) | Interventional | 2019-11-03 | Terminated (stopped due to Recruitment issue, 26 patients enrolled instead of 70 initially planned) | ||
| Phase 1b Multicenter Dose Escalation Study of Carfilzomib With Lenalidomide and Dexamethasone for Safety and Activity in Relapsed Multiple Myeloma[NCT00603447] | Phase 1 | 84 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| A Phase II Study Incorporating Bone Marrow Microenvironment (ME) - Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DTPACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance[NCT00572169] | Phase 3 | 177 participants (Actual) | Interventional | 2006-11-30 | Active, not recruiting | ||
| A Phase 2 Study Incorporating Bone Marrow Microenvironment (ME) Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DT PACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance[NCT00081939] | Phase 2 | 303 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| A Prospective, Multicenter, Single Arm, Phase II Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone (BiRd Regimen) in the Treatment of the First Relapsed Multiple Myeloma[NCT04063189] | Phase 2 | 100 participants (Anticipated) | Interventional | 2017-03-21 | Recruiting | ||
| Thrombosis in Newly Diagnosed Multiple Myeloma Patients: a Clinical Audit of Intermediate Dose Low Molecular Weight Heparin[NCT05541978] | 140 participants (Actual) | Observational | 2022-09-01 | Completed | |||
| A Prospective, Observational Study, to Evaluate the Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for[NCT05218603] | 100 participants (Anticipated) | Observational | 2021-11-30 | Recruiting | |||
| A Phase II Trial of High-dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) in the Up-front Treatment of Multiple Myeloma[NCT02416206] | Phase 2 | 65 participants (Actual) | Interventional | 2015-04-27 | Completed | ||
| A Conceptual Study of Daratumumab Intensified Treatment to Eligible Multiple Myeloma New Patients- Cyclophosphamide, Thalidomide, Dexamethasone and Daratumumab Induction, Follow by Daratumumab Consolidation and Maintenance[NCT03792620] | Phase 3 | 20 participants (Anticipated) | Interventional | 2018-11-20 | Recruiting | ||
| The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Study[NCT03421132] | 250 participants (Anticipated) | Observational | 2018-02-20 | Recruiting | |||
| A Perspective, Single Center Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment[NCT06109233] | 80 participants (Anticipated) | Observational | 2023-12-30 | Not yet recruiting | |||
| A Multi-center, Open-Label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma[NCT01593410] | Phase 2 | 194 participants (Actual) | Interventional | 2010-08-01 | Completed | ||
| Multicenter Study of Pomalidomide, Cyclophosphamide, and Dexamethasone in Relapsed Refractory Myeloma: Safety Profile in Mexican Population[NCT03601624] | Phase 2 | 18 participants (Anticipated) | Interventional | 2018-09-01 | Recruiting | ||
| Etude Multicentrique Ouverte Randomisée de Phase III Comparant l'Association de VELCADE®-Dexaméthasone à la Chimiothérapie de Type VAD Pour le Traitement Des Patients Porteurs de Myélome Multiple de Novo Jusqu'à l'âge de 65 Ans[NCT00200681] | Phase 3 | 493 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With VBMCP-VBAD/Velcade Versus Thalidomide / Dexamethasone Versus Velcade / Thalidomide / Dexamethasone Followed by High Dose Intensive Therapy With Autolo[NCT00461747] | Phase 3 | 390 participants (Anticipated) | Interventional | 2006-03-31 | Completed | ||
| QUIREDEX: A National, Open-Label, Multicenter, Randomized, Phase III Study of Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression[NCT00480363] | Phase 3 | 120 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Randomized Phase 3 Study of Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma. An AMN Study[NCT03143049] | Phase 3 | 120 participants (Anticipated) | Interventional | 2017-09-13 | Recruiting | ||
| A Phase I/II, Multi-center, Open Label Study of Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma Relapsed and/or Refractory to Lenalidomide[NCT01166113] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| A Phase 3, Muticenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma[NCT01311687] | Phase 3 | 455 participants (Actual) | Interventional | 2011-03-11 | Completed | ||
| A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma[NCT02103335] | Phase 1 | 38 participants (Actual) | Interventional | 2014-06-05 | Completed | ||
| [NCT03023527] | Phase 1 | 6 participants (Actual) | Interventional | 2017-01-31 | Terminated (stopped due to Safety) | ||
| Open-label, Multi-center, Single Arm Study For The Safety And Efficacy Of Pomalidomide Monotherapy For Subjects With Refractory Or Relapsed And Refractory Multiple Myeloma. A Companion Study For Clinical Trial CC-4047-MM003[NCT01324947] | Phase 3 | 74 participants (Actual) | Interventional | 2011-03-01 | Completed | ||
| A Phase 1/2 Open Label Study of SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma[NCT02661022] | Phase 1/Phase 2 | 9 participants (Actual) | Interventional | 2016-01-31 | Terminated | ||
| Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®), Low Frequency Dexamethasone and Revlimid® (Dd-R) in Newly Diagnosed Multiple Myeloma[NCT00617591] | Phase 2 | 57 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| A Pilot Study on the Efficacy of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive by Next Generation Flow[NCT03992170] | Phase 2 | 50 participants (Anticipated) | Interventional | 2018-12-31 | Recruiting | ||
| Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury: a Prospective Cohort Study[NCT05429515] | Phase 4 | 50 participants (Anticipated) | Interventional | 2022-07-01 | Not yet recruiting | ||
| A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)[NCT00091624] | Phase 1 | 77 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| A Phase I/II Multicenter, Randomized, Open Label, Dose-Escalation Study To Determine The Maximum Tolerated Dose, Safety, And Efficacy Of CC-4047 Alone Or In Combination With Low-Dose Dexamethasone In Patients Wth Relapsed And Refractory Multiple Myeloma W[NCT00833833] | Phase 1/Phase 2 | 259 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Am Open-Label Phase II Study of the Safety and Efficacy of Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma[NCT00378209] | Phase 2 | 65 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| A Single-arm, Open, Prospective, Multi-center Study on Thalidomide Combined With First-line Chemotherapy and Monotherapy for Maintenance Treatment of Liver Metastases From Her2-negative Advanced Gastric Cancer[NCT05198856] | Phase 1/Phase 2 | 106 participants (Anticipated) | Interventional | 2022-03-10 | Not yet recruiting | ||
| A PHASE III, MULTI-CENTER, RANDOMIZED OPEN LABEL STUDY OF VELCADE, MELPHALAN, PREDNISONE AND THALIDOMIDE (V-MPT) Versus VELCADE, MELPHALAN, PREDNISONE (V-MP) IN ELDERLY UNTREATED MULTIPLE MYELOMA PATIENTS[NCT01063179] | Phase 3 | 511 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.[NCT05297240] | 170 participants (Anticipated) | Observational | 2022-03-24 | Recruiting | |||
| A Phase II Study of Thalidomide (THALOMID®), Clarithromycin (BIAXIN®), Lenalidomide(REVLIMID®), and Dexamethasone (DECADRON®) for Subjects With Newly Diagnosed Multiple Myeloma[NCT00538733] | Phase 2 | 26 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| An Open-Label Phase I Study of the Safety of and Efficacy of RAD001 in Combination With Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma[NCT00729638] | Phase 1 | 28 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Acupuncture for Chemo-induced Peripheral Neuropathy in Multiple Myeloma and Lymphoma Patients[NCT00891618] | Phase 2 | 27 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Phase II Study of Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma[NCT01351623] | Phase 2 | 44 participants (Actual) | Interventional | 2011-05-09 | Completed | ||
| IFM2008: Frontline Therapy in de Novo Multiple Myeloma Patients Under 65, (a Phase 2 Multicenter Trial)[NCT01206205] | Phase 2 | 31 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With Melphalan/Prednisone/Velcade Versus Thalidomide / Prednisone / Velcade and Maintenance Treatment With Thalidomide / Velcade Versus Prednisone / Velcad[NCT00443235] | Phase 3 | 260 participants (Anticipated) | Interventional | 2005-03-31 | Completed | ||
| Carfilzomib and Dexamethasone in Combination With Cyclophosphamide vs. Carfilzomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: a Phase II Randomized Controlled Trial[NCT03336073] | Phase 2 | 199 participants (Actual) | Interventional | 2017-12-18 | Active, not recruiting | ||
| A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS[NCT00551928] | Phase 3 | 402 participants (Actual) | Interventional | 2007-06-30 | Active, not recruiting | ||
| A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone as Post Autologous Transplant Consolidation in Patients With High-risk Multiple Myeloma[NCT02906332] | Phase 2 | 12 participants (Actual) | Interventional | 2016-12-12 | Terminated (stopped due to FDA Hold Due to Updated Risks) | ||
| A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma[NCT04009109] | Phase 2 | 188 participants (Anticipated) | Interventional | 2020-10-21 | Recruiting | ||
| A Randomized Phase III Study Of Thalidomide And Prednisone As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients With Multiple Myeloma[NCT00049673] | Phase 3 | 332 participants (Actual) | Interventional | 2002-10-15 | Completed | ||
| An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Re[NCT01217957] | Phase 1/Phase 2 | 65 participants (Actual) | Interventional | 2010-11-22 | Completed | ||
| Real-world Evidence of Carfilzomib, Lenalidomide, Dexamethasone Combination Therapy in Korean Relapsed and/or Refractory Multiple Myeloma Patients[NCT05495620] | 300 participants (Anticipated) | Observational | 2022-08-01 | Not yet recruiting | |||
| A Multicenter Open Label Phase II Study of Pomalidomide and Dexamethasone in Progressive Relapsed or Refractory Multiple Myeloma Patients With Deletion 17p or Translocation (4;14) Adverse Karyotypic Abnormalities-IFM2010-02[NCT01745640] | Phase 2 | 63 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Phase I Study of Carfilzomib-based Chemotherapy Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma[NCT03909412] | Phase 1 | 18 participants (Anticipated) | Interventional | 2019-10-08 | Recruiting | ||
| A Phase II Study of Combination of Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma[NCT00116961] | Phase 2 | 40 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| An Open-Label Phase I/II Study of the Safety and Efficacy of Bortezomib, Lenalidomide and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma[NCT00378105] | Phase 1/Phase 2 | 68 participants (Actual) | Interventional | 2006-09-30 | Active, not recruiting | ||
| Clinical and Pharmacodynamic Comparison of Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma[NCT01319422] | Phase 2 | 40 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse[NCT01217203] | Phase 1 | 15 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (MM)[NCT01239797] | Phase 3 | 646 participants (Actual) | Interventional | 2011-06-20 | Completed | ||
| Randomized Phase 3b Study of Three Treatment Regimens in Subjects With Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE, Thalidomide, and Dexamethasone Ver[NCT00507416] | Phase 3 | 502 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Vorinostat (SAHA) and Lenalidomide After Autologous Transplant for Patients With Multiple Myeloma[NCT00729118] | Phase 1 | 19 participants (Actual) | Interventional | 2008-09-26 | Completed | ||
| A Phase 2, Randomized Study of VELCADE® (Bortezomib), Dexamethasone, and Thalidomide Versus VELCADE® (Bortezomib), Dexamethasone, Thalidomide, and Cyclophosphamide in Subjects With Previously Untreated Multiple Myeloma Who Are Candidates for Autologous Tr[NCT00531453] | Phase 2 | 98 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid(TM))(MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose T[NCT00602641] | Phase 3 | 306 participants (Actual) | Interventional | 2008-02-29 | Active, not recruiting | ||
| Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: a Clinical and Correlative Pilot Study[NCT01572480] | Phase 2 | 55 participants (Actual) | Interventional | 2012-05-29 | Active, not recruiting | ||
| Role of the Host Microbiota and Il-17 in Favoring Multiple Myeloma Progression[NCT05712967] | 62 participants (Anticipated) | Observational | 2019-06-14 | Recruiting | |||
| Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Clinical and Correlative Phase II Study[NCT01402284] | Phase 2 | 45 participants (Actual) | Interventional | 2011-07-21 | Completed | ||
| A Phase I/II, Multicenter, Open-label, Dose-escalation Study of Bendamustine in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma[NCT01049945] | Phase 1/Phase 2 | 70 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| A Phase 1 Pharmacokinetic and Tolerability Study of Oral MLN9708 Plus Lenalidomide and Dexamethasone in Adult Asian Patients With Relapsed and/or Refractory Multiple Myeloma[NCT01645930] | Phase 1 | 43 participants (Actual) | Interventional | 2012-12-17 | Completed | ||
| A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma[NCT01464034] | Phase 1/Phase 2 | 136 participants (Actual) | Interventional | 2011-11-30 | Terminated (stopped due to Lack of enrollment) | ||
| A Comparative Study of Bortezomib-Thalidomide-Dexamethason and Bortezomib-Cyclophosphamide-Dexamethason in the Treatment of Monoclonal Immunoglobulin Light Chain Amyloidosis: A Prospective Randomized Controlled Trial（BTD-CHINA-TRIAL）[NCT04612582] | Phase 4 | 70 participants (Anticipated) | Interventional | 2020-01-01 | Recruiting | ||
| Lenalidomide to Reverse Drug Resistance After Lenvatinib Combined With PD-1 Inhibitors in the First-line Treatment of Advanced HCC ：a Prospective, Exploratory, Single-arm, Open-label, Multi-center Clinical Study[NCT05831969] | Phase 2 | 23 participants (Anticipated) | Interventional | 2023-06-05 | Not yet recruiting | ||
| Comparison of Immune Response Induced by Zoster Vaccine According to the Timing of Vaccination After Zoster Illness[NCT02704572] | 60 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| Comparison of Change in Humoral and Cellular Immunity Induced by Zoster Vaccine According to the Timing of Vaccination After Hematopoietic Stem Cell Transplantation[NCT03192319] | 86 participants (Actual) | Interventional | 2017-07-01 | Completed | |||
| A Phase 3, Multicentre, Randomized, Controlled Study to Determine the Efficacy and Safety of Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Stem Cell Transplant In Newly Diagnosed Multiple Myeloma Subjects[NCT01091831] | Phase 3 | 389 participants (Actual) | Interventional | 2009-07-31 | Active, not recruiting | ||
| A Phase 1b/2, Multicenter, Open-label, Dose-escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed Multiple Myeloma[NCT00742560] | Phase 2 | 101 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Venous Thromboembolism in Hematologic Malignancy and Hematopoietic Cell Transplant Patients: a Retrospective Study of Thrombosis / Bleeding Incidence and Prophylaxis Trends[NCT05396157] | 813 participants (Actual) | Observational | 2021-11-01 | Active, not recruiting | |||
| A Phase 3, Intergroup Multicentre, Randomized, Controlled 3 Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide in Combination With Dexamethasone (RD) Versus Melphalan, Prednisone and Lenalidomide (MPR) Versus Cyclophosphamide, P[NCT01093196] | Phase 3 | 660 participants (Anticipated) | Interventional | 2009-10-31 | Active, not recruiting | ||
| A National, Open-label, Multicenter, Randomized, Comparative Phase IIb Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd)[NCT01237249] | Phase 2 | 250 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| A Phase 2, Multicenter, Open-label, Single Arm Study of Lenalidomide (CC-5013) in Combination With Low-dose Dexamethasone in Japanese Patients With Previously Untreated Multiple Myeloma[NCT01698801] | Phase 2 | 26 participants (Actual) | Interventional | 2012-10-01 | Completed | ||
| Evaluation of Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide in Patients With Relapsed and Refractory Myeloma[NCT01432600] | Phase 1/Phase 2 | 80 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Rivaroxaban for Improvement of Thromboembolism Outcomes in Patients With Multiple Myeloma on Lenalidomide-based Therapy: RithMM Trial[NCT03428373] | Phase 2/Phase 3 | 86 participants (Anticipated) | Interventional | 2023-07-30 | Recruiting | ||
| Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma[NCT00461045] | Phase 2 | 15 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Phase I/II Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, (BdL) for the Treatment of Patients With Relapsed Myeloma.[NCT01686386] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2010-02-28 | Recruiting | ||
| An Observational Study of Cardiovascular Complications of Carfilzomib Treatment in Clinical Practice[NCT03543579] | 46 participants (Anticipated) | Observational | 2017-03-23 | Active, not recruiting | |||
| A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 (Ricolinostat) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma[NCT01583283] | Phase 1 | 38 participants (Actual) | Interventional | 2012-07-12 | Completed | ||
| A Phase 1 and Phase 2 Study of Lenalidomide (Revlimid) in Combination With Cyclophosphamide (Endoxan) and Prednison (REP) in Relapsed/Refractory Multiple Myeloma[NCT01352338] | Phase 1/Phase 2 | 82 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma[NCT02076009] | Phase 3 | 569 participants (Actual) | Interventional | 2014-05-23 | Active, not recruiting | ||
| A Phase I/IIa Trial of VTD-panobinostat Treatment and Panobinostat Maintenance in Relapsed and Relapsed/Refractory Multiple Myeloma Patients[NCT02145715] | Phase 1/Phase 2 | 54 participants (Anticipated) | Interventional | 2013-01-31 | Active, not recruiting | ||
| Phase 1 Multiple Ascending Dose Study of Elotuzumab (BMS-901608) in Combination With Lenalidomide/Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma in Japan[NCT01241292] | Phase 1 | 7 participants (Actual) | Interventional | 2011-01-14 | Completed | ||
| A Phase I Study of Single-centre, Open-label Clinical Trial to Evaluate HG146 Capsule in the Treatment of Relapsed and Refractory Multiple Myeloma[NCT03710915] | Phase 1 | 3 participants (Actual) | Interventional | 2019-01-12 | Terminated (stopped due to Company decision) | ||
| A Randomized Phase III Trial Of Thalidomide (NSC # 66847) Plus Dexamethasone Versus Dexamethasone In Newly Diagnosed Multiple Myeloma[NCT00033332] | Phase 3 | 0 participants | Interventional | 2002-04-30 | Completed | ||
| Phase III Study of Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma[NCT00892346] | Phase 3 | 80 participants (Anticipated) | Interventional | 2009-05-31 | Suspended (stopped due to No avaliability of melphlan in mainland China) | ||
| UARK 98-036, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Smoldering/Indolent Myeloma[NCT00083382] | Phase 2 | 83 participants (Actual) | Interventional | 1998-12-31 | Completed | ||
| Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma[NCT01042704] | Phase 1 | 29 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| An Open-Label Phase I/II Study of Bendamustine, Weekly Bortezomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma[NCT01484626] | Phase 1/Phase 2 | 3 participants (Actual) | Interventional | 2011-05-05 | Terminated (stopped due to Celgene would no longer supply lenalidomide for the study) | ||
| The Official Title is A Multi-center, Randomized, Parallel-group, Double-blind, Placebo Controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma.[NCT00424047] | Phase 3 | 351 participants (Actual) | Interventional | 2003-01-01 | Completed | ||
| A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma[NCT00056160] | Phase 3 | 353 participants (Actual) | Interventional | 2003-01-01 | Completed | ||
| A Randomized Phase III Study On The Effect Of Thalidomide Combined With Adriamycin, Dexamethasone (AD) And High Dose Melphalan In Patients With Multiple Myeloma[NCT00028886] | Phase 3 | 450 participants (Anticipated) | Interventional | 2001-03-31 | Active, not recruiting | ||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| Randomized Phase III Trial of Consolidation Therapy With Bortezomib (Velcade®)-Lenalidomide (Revlimid®) -Dexamethasone (VRD) Versus Bortezomib (Velcade®)-Dexamethasone (VD) for Patients With Multiple Myeloma Who Have Completed a Dexamethasone Based Induct[NCT00522392] | Phase 3 | 48 participants (Actual) | Interventional | 2007-09-30 | Terminated (stopped due to Slow accrual) | ||
| International, Multi-center, Prospective, Double Randomized, Open Phase III Study Evaluating Thalidomide/Dexamethasone Versus Melphalan/Prednisone as Induction Therapy and Thalidomide/Interferon-alpha Versus Interferon-alpha as Maintenance Therapy in Newl[NCT00205751] | Phase 2/Phase 3 | 350 participants (Anticipated) | Interventional | 2001-08-31 | Completed | ||
| A Multicenter Phase I/II Trial Evaluating the Safety and Efficacy of Lenalidomide (Revlimid, CC-5013) in Combination With Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma[NCT00306813] | Phase 1/Phase 2 | 53 participants (Anticipated) | Interventional | 2004-09-30 | Completed | ||
| A Multicentre, Randomized Phase III Study of Thalidomide Maintenance Treatment in Patients With Diffuse Large B-cell Lymphoma[NCT03016000] | Phase 3 | 226 participants (Anticipated) | Interventional | 2017-07-26 | Recruiting | ||
| A Multicenter, Single-Arm, Open-Label, Expanded Access Program for Lenalidomide With or Without Dexamethasone in Previously Treated Subjects With Multiple Myeloma[NCT00179647] | Phase 3 | 1,913 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| A Multicenter, Open-label Study to Determine the Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma[NCT00065351] | Phase 2 | 222 participants (Actual) | Interventional | 2003-07-01 | Completed | ||
| A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma[NCT03702725] | Phase 1 | 14 participants (Actual) | Interventional | 2019-08-29 | Active, not recruiting | ||
| A Phase II Trial Of Thalidomide/Dexamethasone Induction Followed By Tandem Melphalan Transplant And Prednisone/Thalidomide Maintenance (A BMT Study)[NCT00040937] | Phase 2 | 147 participants (Actual) | Interventional | 2002-06-30 | Completed | ||
| An Open, Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma[NCT01701076] | Phase 2 | 50 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| An Open-label, Phase II Study of Pomalidomide and Dexamethasone (PDex) for Previously Treated Patients With AL Amyloidosis.[NCT01510613] | Phase 2 | 28 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| An International, Multi-Center, Randomized, Open-Label Study of PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma[NCT00048230] | Phase 3 | 620 participants (Actual) | Interventional | 2002-06-30 | Completed | ||
| Study of Pomalidomide in Anal Cancer Precursors (SPACE): a Phase 2 Study of Immunomodulation in People With Persistent HPV-associated High Grade Squamous Intraepithelial Lesions[NCT03113942] | Phase 2 | 26 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
| (PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older[NCT01453088] | Phase 2 | 63 participants (Actual) | Interventional | 2010-06-24 | Terminated (stopped due to Lack of Accrual) | ||
| Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma[NCT01241708] | Phase 3 | 146 participants (Actual) | Interventional | 2010-04-08 | Completed | ||
| A Randomized Phase III Study of CC-5013 Plus Dexamethasone Versus CC-5013 Plus Low Dose Dexamethasone in Multiple Myeloma With Thalidomide Plus Dexamethasone Salvage Therapy for Non-Responders[NCT00098475] | Phase 3 | 452 participants (Actual) | Interventional | 2004-11-03 | Active, not recruiting | ||
| A Prospective Single-center Study on the Efficacy and Safety of Lenalidomide Combined With Azacitidine vs Azacitidine in the Treatment of MDS-RS[NCT06004765] | Phase 4 | 138 participants (Anticipated) | Interventional | 2023-08-31 | Not yet recruiting | ||
| Velcade®, Thalidomide, Dexamethasone (VTD) Induction Therapy Followed By Melphalan, Prednisone, Thalidomide (MPT) Maintenance As a First Line Treatment For The Patients With Multiple Myeloma Who Are Non-Transplant Candidates[NCT00320476] | Phase 2 | 35 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| A Phase I/II, Multi-Center, Open Label Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Advanced and Refractory Multiple Myeloma Patients[NCT00406978] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance[NCT01647165] | Phase 2 | 0 participants (Actual) | Interventional | 2012-07-11 | Withdrawn | ||
| A Phase 3 Study With Randomization to Melphalan/Prednisone/Thalidomide Versus Melphalan/Prednisone/Placebo to Patients With Previously Untreated Multiple Myeloma[NCT00218855] | Phase 3 | 363 participants (Actual) | Interventional | 2002-01-31 | Completed | ||
| Phase 1/2 Study of VELCADE® (Bortezomib), Dexamethasone, and Revlimid® (Lenalidomide) Versus VELCADE, Dexamethasone, Cyclophosphamide, and Revlimid Versus VELCADE, Dexamethasone and Cyclophosphamide in Subjects With Previously Untreated Multiple Myeloma[NCT00507442] | Phase 1/Phase 2 | 158 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Safety and Efficacy Assessments of Osalmid in the Treatment of Multiple Myeloma[NCT03670173] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2018-10-01 | Active, not recruiting | ||
| A Multicenter, Phase I Study to Determine the Maximum Tolerated Dose, Safety, Pharmacokinetics and Efficacy of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma[NCT00555100] | Phase 1 | 15 participants (Actual) | Interventional | 2007-07-01 | Completed | ||
| A Randomized Placebo-controlled Phase II Study of Clarithromycin or Placebo Combined With VCD Induction Therapy Prior to High-dose Melphalan With Stem Cell Support in Patients With Newly Diagnosed Multiple Myeloma[NCT02573935] | Phase 2 | 58 participants (Actual) | Interventional | 2015-01-31 | Terminated (stopped due to Suspected side effects to the combination of clarithromycin and VCD (bortezomib, cyclophosphamide and dexamethasone)) | ||
| Phase III Trial Comparing Dexamethasone (DEX) to the Combination of DEX + CC-5013 in Patients With Previously Untreated Multiple Myeloma[NCT00064038] | Phase 3 | 198 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Phase III Trial Comparing Treatment With Melphalan+Prednisolon (MP) With Melphalan+Prednisolon+Thalidomide (MPT) for Previously Untreated Elderly Patients With Multiple Myeloma[NCT00934154] | Phase 3 | 122 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Phase 1-2 Study of the Combination of Escalated Total Bone Marrow Irradiation (TBMI) by Helicoidal Tomotherapy and a Fixed High-dose Melphalan (140 mg/m²) Followed by Peripheral Stem Cell Rescue (PSC) in First Relapsed Multiple Myeloma.[NCT01794572] | Phase 1/Phase 2 | 13 participants (Actual) | Interventional | 2013-04-24 | Terminated (stopped due to Low patient recruitement rate and modification of the therapeutic standard) | ||
| Efficacy and Safety of Double Autologous Hematopoietic Stem Cell Transplantation With Sequential Use of Total Marrow Irradiation and High-dose Melphalan in Multiple Myeloma[NCT01665014] | Phase 2 | 50 participants (Anticipated) | Interventional | 2012-08-31 | Not yet recruiting | ||
| Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02446236] | Phase 1 | 27 participants (Actual) | Interventional | 2015-06-18 | Active, not recruiting | ||
| VELCADE (Bortezomib) and Thalidomide in Newly Diagnosed Patients With Multiple Myeloma[NCT00287872] | Phase 2 | 30 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| Multicenter, Interventional, Single-arm, Phase IV Study Evaluating Tolerability of Eribulin and Its Relationship With a Set of Polymorphisms in an Unselected Population of Female Patients With Metastatic Breast Cancer[NCT02864030] | Phase 4 | 200 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| A Phase II Trial of GM-CSF Plus Maintenance Pembrolizumab +/- Pemetrexed After Completion of First Line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer Patients With PDL-1 of 1%-49%[NCT04856176] | Phase 2 | 83 participants (Anticipated) | Interventional | 2022-01-03 | Recruiting | ||
| A Multi-Institutional Phase I/II Study of Revlimid® (Lenalidomide), Velcade® (Bortezomib), Dexamethasone, and Doxil®, (RVDD) Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma[NCT00724568] | Phase 1/Phase 2 | 74 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| A Phase II Trial of Revlimid, Cyclophosphamide, and Dexamethasone in Patients With > Newly Diagnosed Active Multiple Myeloma[NCT00478218] | Phase 2 | 53 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| A Study of Thalidomide, Bendamustine and Dexamethasone (BTD) Versus Bortezomib, Bendamustine and Dexamethasone (BBD) in Patients With Renal Failure Defined as a GFR Below 30 Mls/Min[NCT02424851] | Phase 2 | 31 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| A Phase II Trial of CC-4047 Plus Dexamethasone in Patients With Relapsed of Refractory Multiple Myeloma or Amyloidosis[NCT00558896] | Phase 2 | 378 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Bortezomib + Pegylated Liposomal Doxorubicin (Doxil) + Dexamethasone Followed by Thalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone for Patients With Symptomatic Untreated High-Risk or Primary Resistant Multiple Myeloma[NCT00458705] | Phase 2 | 45 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Phase 3 Study of Velcade (Bortezomib) Dexamethasone (VD) Versus Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) as an Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma[NCT00910897] | Phase 3 | 205 participants (Actual) | Interventional | 2008-03-31 | Active, not recruiting | ||
| Thalidomide-Dexamethasone Incorporated Into Double Autologous Stem-Cell Transplantation for Patients Less Than 65 Years of Age With Newly Diagnosed Multiple Myeloma[NCT01341262] | Phase 2 | 378 participants (Actual) | Interventional | 2002-03-31 | Completed | ||
| A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple[NCT00075829] | Phase 3 | 710 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| Multicenter, Randomized Study Comparing the Efficacy and Safety of Two Doses of Thalidomide (100 mg/Day Versus 400 mg/Day) in the Treatment of Subjects With Refractory or Relapsed Multiple Myeloma.[NCT00657488] | Phase 2/Phase 3 | 400 participants (Actual) | Interventional | 2001-12-01 | Completed | ||
| Randomised, Controlled, Open-labelled, Multi-centre Comparison of Thalidomide Versus High-dose Dexamethasone for the Treatment of Relapsed Refractory Multiple Myeloma[NCT00452569] | Phase 3 | 499 participants (Actual) | Interventional | 2006-02-01 | Completed | ||
| Revlimid to Augment Efficacy of Prevnar Vaccines in Patients With Relapsed or Refractory Myeloma[NCT00445484] | Phase 2 | 22 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma[NCT00420849] | Phase 3 | 587 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients With Relapsed/Refractory Multiple Myeloma[NCT01160484] | Phase 2 | 40 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| A Phase III, Multicentre, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study To Determine The Efficacy And Safety Of Lenalidomde (Revlimid®) In Combination With Melphalan And Prednisone Versus Placebo Plus Melphalan And Prednisone In[NCT00405756] | Phase 3 | 459 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Pilot Study of Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer After First-line Chemotherapy[NCT02018523] | Phase 1 | 7 participants (Actual) | Interventional | 2014-06-30 | Terminated (stopped due to Study did not enroll enough subjects to make a statistically sound conclusion.) | ||
| Relevance of Maintenance Therapy Using Lenalidomide (Revimid®) After Autologous Stem Cell Transplantation Patients Under the Age Of 65. (Open, Randomised, Multi-centric Trial Versus Placebo).[NCT00430365] | Phase 3 | 614 participants (Anticipated) | Interventional | 2006-06-30 | Completed | ||
| An Open-Label Phase I Study of the Safety of Perifosine in Combination With Lenalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma[NCT00415064] | Phase 1 | 32 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment w/ Carfilzomib, Lenalidomide (Revlimid®) and Dexamethasone (CRD) in Subjects w/ Newly Diagnosed, Previously Untreated Multiple Myeloma Requiring Syst[NCT01029054] | Phase 1/Phase 2 | 53 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| A Phase III Study for Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2 (TT2, UARK 98-026): Bortezomib, Thalidomide and Dexamethasone Versus Bortezomib, Melphalan, and Dexamethasone[NCT00573391] | Phase 3 | 5 participants (Actual) | Interventional | 2006-08-31 | Terminated (stopped due to low accrual) | ||
| Lenalidomide and Azacitidine for Adaptive Immunotherapy in Multiple Myeloma: Pilot Study of Autologous Lymphocyte Mobilization Following Immuno-modulatory Therapy[NCT01050790] | 17 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| A Phase III Randomized Trial of Thalidomide Plus Zoledronic Acid Versus Zoledronic Acid Alone in Patients With Early Stage Multiple Myeloma[NCT00432458] | Phase 3 | 68 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| Early Initiated Individualized Physical Training in Newly Diagnosed Multiple Myeloma Patients; Effects on Physical Function, Physical Activity, Quality of Life, Pain, and Bone Disease.[NCT02439112] | 102 participants (Actual) | Interventional | 2015-05-31 | Completed | |||
| Dose-finding Study of Lenalidomide as Maintenance Therapy in Multiple Myeloma After Allogeneic Stem Cell Transplantation[NCT00778752] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Phase I/II Trial of Combination of Lenalidomide (Revlimid, LEN) and Autologous Mature Dendritic Cells Pulsed With α-galactosyl Ceramide (α-GalCer; KRN7000) in Myeloma[NCT00698776] | Phase 1 | 6 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| A Randomized Phase II Dose Finding Study of Revlimid™ and Melphalan in Patients With Previously Untreated Multiple Myeloma[NCT00305812] | Phase 2 | 51 participants (Actual) | Interventional | 2006-03-09 | Completed | ||
| A Phase II Study of Clarithromycin (Biaxin), Lenalidomide (Revlimid), and Dexamethasone (Decadron) for Newly Diagnosed Subjects With Multiple Myeloma[NCT00151203] | Phase 2 | 50 participants (Anticipated) | Interventional | 2004-12-31 | Completed | ||
| A Multicenter Randomized Open Label Phase II Study of Pomalidomide and Dexamethasone in Relapse and Refractory Multiple Myeloma Patients Who Are Progressive and Did Not Achieve at Least a Partial Response to Bortezomib and Lenalidomide[NCT01053949] | Phase 2 | 84 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance[NCT01723839] | Phase 2 | 21 participants (Actual) | Interventional | 2012-02-22 | Completed | ||
| A Multicenter, Open Label Study of Oral Melphalan, Prednisone, and CC-5013 (Revlimid) (MPR) as Induction Therapy in Elderly Newly Diagnosed Multiple Myeloma Patients[NCT00396045] | Phase 1/Phase 2 | 54 participants | Interventional | 2005-01-31 | Completed | ||
| An International, Multicenter, Non-Randomized, Open-Labeled Study to Evaluate the Efficacy of Lower Dose Dexamethasone/Thalidomide and Higher Frequency ZOMETA(TM) in the Treatment of Previously Untreated Patients With Multiple Myeloma[NCT00263484] | Phase 2 | 56 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A National, Multi-Center, Open-Label Study of Velcade in Combination With Melphalan and Prednisone (V-MP) in Older Untreated Multiple Myeloma Patients.[NCT00388635] | Phase 1/Phase 2 | 60 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| A Phase II, Multi-Center, Open Label Study Of Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients[NCT00358020] | Phase 2 | 30 participants | Interventional | 2004-11-30 | Completed | ||
| Multicenter, Randomized, Double-blind, Phase III Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) With Alteration in 5q- and Anemia Without the Need of Transfusion.[NCT01243476] | Phase 3 | 61 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study[NCT04273529] | Phase 2 | 100 participants (Anticipated) | Interventional | 2020-02-20 | Not yet recruiting | ||
| A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma[NCT00540007] | Phase 2 | 80 participants (Actual) | Interventional | 2007-09-06 | Completed | ||
| The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study[NCT04273581] | Phase 2 | 40 participants (Anticipated) | Interventional | 2020-02-18 | Not yet recruiting | ||
| Lenalidomide Maintenance Therapy in Multiple Myeloma: A Phase II Clinical and Biomarker Study[NCT01675141] | Phase 2 | 11 participants (Actual) | Interventional | 2012-08-20 | Terminated (stopped due to Original investigator left the NIH and the primary outcome was not reached) | ||
| A Randomized Phase II Dose Finding Study Of Thalidomide And Prednisone As Maintenance Therapy Following Autologous Stem Cell Transplant In Patients With Multiple Myeloma[NCT00006890] | Phase 2 | 67 participants (Actual) | Interventional | 2000-07-12 | Completed | ||
| Phase I / II Study Of Carfilzomib (CFZ) Intensification Early After Autologous Transplantation (AHCT) For Plasma Cell Myeloma[NCT01658904] | Phase 1/Phase 2 | 3 participants (Actual) | Interventional | 2012-07-31 | Terminated (stopped due to study closed prematurely because investigator left National Institutes of Health) | ||
| Rapamycin-Resistant T Cell Therapy of Multiple Myeloma: Relapse Prevention and Relapse Therapy[NCT01239368] | Phase 1/Phase 2 | 34 participants (Actual) | Interventional | 2010-11-10 | Terminated (stopped due to Terminated due to insufficient accrual.) | ||
| Mobilization and Collection of Autologous Stem Cell for Transplantation (ASCT) for Plasma Cell Myeloma (PCM)[NCT01547806] | Phase 2 | 49 participants (Actual) | Interventional | 2012-02-22 | Completed | ||
| A Phase II Study Of Genasense In Combination With Thalidomide And Dexamethasone In Relapsed And Refractory Multiple Myeloma[NCT00049374] | Phase 2 | 0 participants | Interventional | 2002-09-30 | Completed | ||
| [NCT00207805] | Phase 3 | 202 participants | Interventional | 2003-05-31 | Completed | ||
| A Phase II Clinical Trial Of Thalidomide, Adramycin And Dexamethasone (TAD) As Initial Therapy For The Treatment Of Multiple Myeloma[NCT00008242] | Phase 2 | 0 participants | Interventional | 2000-08-31 | Completed | ||
| A Phase 2, Open-label, Prospective, Multicenter Study to Evaluate the Efficacy of Intravenous Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation[NCT01923935] | Phase 2 | 105 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy[NCT00083551] | Phase 3 | 668 participants (Actual) | Interventional | 1998-08-31 | Completed | ||
| Phase III, Prospective, Open Label, Multicenter, Randomized Trial of Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone as First Line Therapy in Myeloma Patients Aged >65.[NCT00232934] | Phase 3 | 400 participants | Interventional | 2002-01-31 | Completed | ||
| Thalidomide-Dexamethasone vs Alpha-Interferon-Dexamethasone as Maintenance Therapy After Thalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin Combination for[NCT00633542] | Phase 3 | 103 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| An Open-Label Study to Evaluate the Efficacy and Safety of Two CDC-501 Dose Regimens When Used Alone or in Combination With Dexamethasone for the Treatment Relapsed or Refractory Multiple Myeloma[NCT00044018] | Phase 2 | 102 participants (Actual) | Interventional | 2002-04-01 | Completed | ||
| TACTIC: a Phase II Study of TAS-102 Monotherapy and Thalidomide Plus TAS-102 as Third-line Therapy and Beyond in Patients With Advanced Colorectal Carcinoma[NCT05266820] | Phase 2 | 120 participants (Anticipated) | Interventional | 2021-10-01 | Recruiting | ||
| Evaluation of Plerixafor (Mozobil ™, AMD3100) in Combination With Chemotherapy and G-CSF for CD34+ Cell Mobilization[NCT01095757] | Phase 2 | 45 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma[NCT00644306] | Phase 3 | 232 participants (Actual) | Interventional | 2002-04-30 | Terminated (stopped due to survival advantage demonstrated) | ||
| Comparison of Melphalan-Prednisone(MP),MP-THALIDOMIDE,and Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma.[NCT00367185] | Phase 3 | 500 participants | Interventional | 2000-05-31 | Completed | ||
| A Phase I/II Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma[NCT01297764] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2011-04-30 | Active, not recruiting | ||
| A Phase II, Safety and Efficacy Study of Fixed Dose Radioimmunotherapy (Zevalin, Yttrium-90 Ibritumomab Tiuxetan) for Patients With Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma[NCT01207765] | Phase 2 | 8 participants (Actual) | Interventional | 2008-04-30 | Terminated (stopped due to changes in practice) | ||
| Clinical Study of Anti-CD19/BCMA Bispecific Chimeric Antigen Receptors (CARs) T Cell Therapy for Relapsed and Refractory Multiple Myeloma[NCT03706547] | Phase 1 | 20 participants (Anticipated) | Interventional | 2018-10-30 | Not yet recruiting | ||
| A Randomized Controlled Study of DOXIL/CAELYX (Doxorubicin HCL Liposome Injection) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma[NCT00103506] | Phase 3 | 646 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| A Multicenter, Randomized, Parallel-group , Double Blind, Placebo-controlled Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone as Induction Therapy for Previously Untreated Subjects With Multiple Myeloma[NCT00057564] | Phase 3 | 470 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| VELCADEXA: A National, Multi-Center, Open-Label Study of Pretransplant Induction With Alternating VELCADE and Dexamethasone (VEL/Dex) in Younger (< 65 Yrs) Untreated Multiple Myeloma Patients.[NCT00391157] | Phase 2 | 40 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Phase I/II Study Evaluating Rituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients With Mantle Cell Lymphoma[NCT00633594] | Phase 1/Phase 2 | 39 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [NCT02748772] | Phase 3 | 148 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
DOR for a given participant is defined as the number of days from the date of that participant's first documented response (Partial Response [PR] or better) to the date of first documented disease progression (PD) or death due to multiple myeloma (MM), whichever occurs first. If the participant with a documented response did not have an event of PD and the participant had not died due to MM, the participant's data was to be censored. (NCT03567616)
Timeframe: Approximately 15 months
| Intervention | days (Median) |
|---|---|
| Participants Positive for t(11;14) Translocation | 393.0 |
| Participants Negative for t(11;14) Translocation | NA |
| All Participants | 393.0 |
ORR is defined as the percentage of participants experiencing a stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) using the International Myeloma Working Group (IMWG) 2016 criteria for disease response and progression. CR= negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in bone marrow; sCR= CR + normal serum free light chain (FLC) ratio and absence of clonal cells in bone marrow; VGPR= serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein level + urine M-protein level < 100 mg per 24 hours; PR= ≥ 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥ 90% or to < 200 mg per 24 hours. (NCT03567616)
Timeframe: Approximately 15 months
| Intervention | percentage of participants (Number) |
|---|---|
| Participants Positive for t(11;14) Translocation | 66.7 |
| Participants Negative for t(11;14) Translocation | 60.0 |
| All Participants | 62.5 |
PFS is defined as the number of days from the date of first dose of any study drug to the date of disease progression or death, whichever occurs first. All disease progression was to be included regardless of whether the event occurred during or after the participant was taking any study drug. (NCT03567616)
Timeframe: Approximately 20 months
| Intervention | days (Median) |
|---|---|
| Participants Positive for t(11;14) Translocation | 220.0 |
| Participants Negative for t(11;14) Translocation | NA |
| All Participants | 320.0 |
TTP for a given participant is defined as the number of days from the date of first dose to the date of first documented disease progression (PD) or death due to multiple myeloma (MM), whichever occurs first. If the participant did not have an event of PD and the participant had not died due to MM, the participant's data was to be censored. (NCT03567616)
Timeframe: Approximately 15 months
| Intervention | days (Median) |
|---|---|
| Participants Positive for t(11;14) Translocation | 420.0 |
| Participants Negative for t(11;14) Translocation | NA |
| All Participants | 420.0 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section. (NCT03567616)
Timeframe: From first dose of study drug until 30 days following last dose of study drug (up to 70 weeks)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Any TEAE | TESAE | |
| Participants Negative for t(11;14) Translocation | 5 | 2 |
| Participants Positive for t(11;14) Translocation | 3 | 3 |
Disease response status is based on the IMWG criteria being held for two consecutive evaluations at least 4 weeks apart. Clinical benefit rate (CBR) is defined as proportion of patients with minimal response (MR) and better according to International Myeloma Working Group (IMWG) Uniform Response Criteria (Phase II) (NCT02004275)
Timeframe: 3 years
| Intervention | proportion of participants (Number) |
|---|---|
| Phase II Arm I (Pomalidomide, Dexamethasone) | .564 |
| Phase II Arm II (Pomalidomide, Dexamethasone, Ixazomib) | .737 |
Proportion of patients that went two of more cycles of treatment without discontinuing treatment for progression or intolerability. (NCT02004275)
Timeframe: 42 days
| Intervention | proportion of partcipants (Number) |
|---|---|
| Phase II Arm I (Pomalidomide, Dexamethasone) | .949 |
| Phase II Arm II (Pomalidomide, Dexamethasone, Ixazomib) | .921 |
(NCT02004275)
Timeframe: Up to 3 years
| Intervention | Months (Median) |
|---|---|
| Phase II Arm I (Pomalidomide, Dexamethasone) | 12.3 |
| Phase II Arm II (Pomalidomide, Dexamethasone, Ixazomib) | 23.7 |
These events are reported in the adverse events section of this report. (NCT02004275)
Timeframe: 44.5 months
| Intervention | participants with DLT (Number) |
|---|---|
| Phase 1 Dose Level 1 | 0 |
| Phase 1 Dose Level 2 | 0 |
| Phase 1 Dose Level 3 | 1 |
| Phase 1 Dose Level 4 | 1 |
(NCT02004275)
Timeframe: 39 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase 1 Dose Level 1 | 2 |
| Phase 1 Dose Level 2 | 3 |
| Phase 1 Dose Level 3 | 6 |
| Phase 1 Dose Level 4 | 5 |
The count of paitents that experenced an adverse event is reported in this section. A full table of these events is reported in the adverse event section of this report. (NCT02004275)
Timeframe: 92 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase II Arm I (Pomalidomide, Dexamethasone) | 22 |
| Phase II Arm II (Pomalidomide, Dexamethasone, Ixazomib) + Crossover Patients From Arm I | 33 |
| Phase 1 Dose Level 1 | 2 |
| Phase 1 Dose Level 2 | 2 |
| Phase 1 Dose Level 3 | 4 |
| Phase 1 Dose Level 4 | 6 |
For this protocol, dose-limiting toxicity (DLT) will be defined by the following adverse events at least possibly related to study therapy: Grade 3 or higher non-hematologic toxicity, with the following exceptions: Alopecia is not expected but would not be considered a DLT. Nausea, vomiting and diarrhea will only be considered a DLT if it cannot be adequately managed with optimal supportive care. Grade 3 or 4 hyperglycemia due to dexamethasone will only be considered a DLT if it cannot be controlled with appropriate therapy Grade 4 hematologic toxicity, with the following exceptions: Grade 4 lymphopenia is expected with this regimen and will not be construed as a DLT. Grade 4 neutropenia will only be considered a DLT if it lasts longer than 7 days despite appropriate supportive care. Grade 4 thrombocytopenia will only be considered a DLT if it lasts longer than 7 days or is associated with greater then or equal to grade 3 bleeding event (NCT02004275)
Timeframe: 28 days
| Intervention | participants with DLT (Number) |
|---|---|
| Phase 1 Dose Level 1 | 0 |
| Phase 1 Dose Level 2 | 0 |
| Phase 1 Dose Level 3 | 1 |
| Phase 1 Dose Level 4 | 1 |
ORR is defined as partial response (PR), very good partial response (VGPR), complete response (CR), or stringent complete response (sCR) according to International Myeloma Working Group (IMWG) Uniform Response Criteria (NCT02004275)
Timeframe: 3 years
| Intervention | proportion of participants (Number) |
|---|---|
| Arm I (Pomalidomide, Dexamethasone) | .436 |
| Arm II (Pomalidomide, Dexamethasone, Ixazomib) | .632 |
Overall survival was analyzed from the time of registration to the date of death or last known date living. Due to median OS time not being reached due to lack of deaths at the time of this report by either arm, the 2 year OS rate has been reported. This analysis censors living patients at 2 years. (NCT02004275)
Timeframe: 2 years
| Intervention | proportion of patients alive (Number) |
|---|---|
| Phase II Arm I (Pomalidomide, Dexamethasone) | .795 |
| Phase II Arm II (Pomalidomide, Dexamethasone, Ixazomib) | .784 |
progression-free survival (PFS), defined as the time from randomization to the date the International Myeloma Working Group (IMWG) criteria for disease progression is met. If a patient initiates another anti-cancer treatment prior to disease progression, they will be censored at the date of initiation of this treatment. Patients will be randomized to treatment using the Pocock-Simon algorithm balancing the distribution of the following stratification factors between the two treatment arms: 1) ISS 1-2 disease vs. ISS 3 disease (current ISS stage based off screening beta 2 microglobulin and albumin) 2) High risk cytogenetics features: yes vs. no High risk cytogenetics features include: del(1p), gain of 1q, t(4;14), t(14;16), t(14; 20), del(17p) 3) Prior treatment with a proteasome inhibitor: yes vs. no (NCT02004275)
Timeframe: 3 years
| Intervention | days (Median) |
|---|---|
| Phase II Arm I (Pomalidomide, Dexamethasone) | 228 |
| Phase II Arm II (Pomalidomide, Dexamethasone, Ixazomib) | 619 |
(NCT02004275)
Timeframe: Up to 3 years post-registration (at crossover)
| Intervention | months (Median) |
|---|---|
| Arm I (Pomalidomide, Dexamethasone) | 5.6 |
Pre-treatment patient-report of fatigue and overall quality of life (based on a 10-point Likert scale). A higher number indicates a better quality of life where 10 is the best outcome and 0 is the worst. (NCT02004275)
Timeframe: baseline
| Intervention | participants (Number) | |
|---|---|---|
| High QoL(7-10) | Medium or Low QoL (0-7) | |
| Arm I (Pomalidomide, Dexamethasone) | 21 | 16 |
| Arm II (Pomalidomide, Dexamethasone, Ixazomib) | 27 | 11 |
(NCT02004275)
Timeframe: Up to 3 years
| Intervention | proportion of partcipants (Number) | ||
|---|---|---|---|
| Overall Response Rate | Clinical Benefit Rate | Disease Control Rate | |
| Arm I(Pomalidomide, Dexamethasone) | .231 | .269 | .962 |
DOR defined as the duration in months from first documentation of a confirmed response to first evidence of confirmed disease progression or death due to any cause. (NCT03151811)
Timeframe: From first evidence of response until confirmed progression, or if no progression, 24 months after end of treatment
| Intervention | months (Median) |
|---|---|
| Arm A: Melflufen+Dexamethasone | 11.17 |
| Arm B: Pomalidomide+Dexamethasone | 11.07 |
ORR defined as the proportion of patients for whom the best overall confirmed response is stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR), as assessed by IRC. (NCT03151811)
Timeframe: From randomization until best response achieved before confirmed progression, or if no progression up to 24 months after end of treatment. Median time to best response was 2.1 and 2.0 months for Arm A and B, respectively.
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: Melflufen+Dexamethasone | 80 |
| Arm B: Pomalidomide+Dexamethasone | 67 |
Progression Free Survival defined as the duration in months from randomization until first evidence of confirmed disease progression, as assessed by the Independent Review Committee (IRC) according to the International Myeloma Working Group Uniform Response Criteria (IMWG-URC) (NCT03151811)
Timeframe: From randomization to time of progression, or, if no progression, 24 months after end of treatment
| Intervention | months (Median) |
|---|---|
| Arm A: Melflufen+Dexamethasone | 6.83 |
| Arm B: Pomalidomide+Dexamethasone | 4.93 |
Number of patients with treatment-emergent adverse events, including clinical laboratory and vital signs abnormalities, as assessed by CTCAE v4.0 will be presented. No formal statistical analysis will be performed for safety endpoints. (NCT03151811)
Timeframe: From start of dosing until 30 days after the last dose of study treatment, the median time frame for study treatment was 25.1 and 22.1 months for Arm A and B, respectively.
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: Melflufen+Dexamethasone | 226 |
| Arm B: Pomalidomide+Dexamethasone | 241 |
DOR: Time from first documentation of CR/PR/VGPR to first documentation of PD. Per IMWG criteria, PR:>=50% reduction of serum M protein+reduction in 24-hour urinary M protein by >=90% to <200 mg/24-hour or >=50% decrease in difference between involved and uninvolved FLC levels/ >=50% reduction in bone marrow plasma cells, if >=30% at Baseline/ >=50% reduction in size of soft tissue plasmacytomas. VGPR: serum+urine M-protein detectable by immunofixation but not on electrophoresis/ >=90% reduction in serum M-protein + urine M-protein level <100 mg/24-hour. CR:negative immunofixation on serum + urine+disappearance of soft tissue plasmacytomas+<5% plasma cells in bone marrow. PD:serum M-component increase >=0.5 g/dl or urine M-component increase >=200 mg/24-hour/ difference between involved and uninvolved FLC levels increase >10 mg/dl or bone marrow plasma cell >=10%/development of new/ increase in size of existing bone lesions or soft tissue plasmacytoma or development of hypercalcemia. (NCT03170882)
Timeframe: From date of first documentation of CR, VGPR or PR until first occurrence of confirmed disease progression or death due to any cause, whichever occurs first (Up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Pomalidomide 4 mg + Dexamethasone 40 mg | 14.3 |
| Ixazomib 4 mg + Dexamethasone 20 mg | 14.8 |
OS was defined as the time from randomization to death from any cause, up to 3 years are reported. (NCT03170882)
Timeframe: From date of randomization to death due to any cause (Up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Pomalidomide 4 mg + Dexamethasone 40 mg | NA |
| Ixazomib 4 mg + Dexamethasone 20 mg | 18.8 |
Overall Response Rate (ORR) was defined as the percentage of participants who achieved partial response (PR), very good partial response (VGPR), or complete response (CR) based on laboratory results and IRC assessment using modified IMWG criteria. PR: >=50% reduction of serum M protein + reduction in 24-hour urinary M protein by >=90% or to <200 mg/24-hour; if M protein is not measurable, >=50% decrease in difference between involved and uninvolved FLC levels is required; if not measurable by FLC, >=50% reduction in bone marrow plasma cells, when baseline value >=30% and; if present at baseline, >=50% reduction in size of soft tissue plasmacytomas is required. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or >=90% reduction in serum M-protein + urine M-protein level <100 mg/24-hour. CR: negative immunofixation on serum + urine; disappearance of soft tissue plasmacytomas; <5 % plasma cells in bone marrow. (NCT03170882)
Timeframe: From date of randomization until first documentation of CR, VGPR or PR (Up to approximately 3 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Pomalidomide 4 mg + Dexamethasone 40 mg | 41 |
| Ixazomib 4 mg + Dexamethasone 20 mg | 38 |
PFS: Time from randomization to first occurrence of confirmed progressive disease (PD) as assessed by investigator by International Myeloma Working Group(IMWG) response criteria/death from any cause, whichever occurs first. PD requires following: Increase of >=25 % from nadir in: Serum M component (increase must be >=0.5 gram per deciliter [g/dl]); Urine M-component (increase must be >=200 milligram [mg]/24-hour); In participants without measurable serum and urine M-protein levels difference between involved and uninvolved free light chain (FLC) increase of >10 mg/dl; In participants without measurable serum and urine M protein levels and without measurable disease by FLC level: bone marrow plasma cell percentage must be >=10%; Development of new/increase in size of existing bone lesions/soft tissue plasmacytomas; development of hypercalcemia (>11.5mg/dL corrected serum calcium) attributed solely to plasma cell proliferative disease. (NCT03170882)
Timeframe: From date of randomization until first occurrence of confirmed disease progression or death due to any cause, whichever occurs first (Up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Pomalidomide 4 mg + Dexamethasone 40 mg | 4.8 |
| Ixazomib 4 mg + Dexamethasone 20 mg | 7.1 |
TTP was defined as the time from the date of randomization to first documentation of PD. Per IMWG criteria, PD required 1 of the following: Increase of >=25% from nadir in: Serum M-component (increase must be >=0.5 g/dl; Urine M-component (increase must be >=200 mg/24-hour); In participants without measurable serum and urine M-protein levels difference between involved and uninvolved FLC levels increase of >10 mg/dl; In participants without measurable serum and urine M protein levels and without measurable disease by FLC level: Bone marrow plasma cell percentage must be >=10%; Development of new or increase in size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (>11.5 mg/dL corrected serum calcium) attributed solely to plasma cell proliferative disease. (NCT03170882)
Timeframe: From date of randomization until first occurrence of confirmed disease progression or death due to any cause, whichever occurs first (Up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Pomalidomide 4 mg + Dexamethasone 40 mg | 5.1 |
| Ixazomib 4 mg + Dexamethasone 20 mg | 8.4 |
Time to response was defined as the time from randomization to the first documentation of PR/VGPR/CR. Per IMWG criteria, PR: >=50% reduction of serum M protein + reduction in 24-hour urinary M protein by >=90% or to <200 mg/24-hour; if M-protein is not measurable, >=50% decrease in difference between involved and uninvolved FLC levels is required; if not measurable by FLC, >=50% reduction in bone marrow plasma cells, when Baseline value >=30% and; if present at Baseline, >=50% reduction in size of soft tissue plasmacytomas is required. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or >=90% reduction in serum M-protein + urine M-protein level <100 mg/24-hour. CR: negative immunofixation on serum + urine; disappearance of soft tissue plasmacytomas; <5% plasma cells in bone marrow. (NCT03170882)
Timeframe: From date of randomization until first documentation of CR, VGPR or PR (Up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Pomalidomide 4 mg + Dexamethasone 40 mg | 1.1 |
| Ixazomib 4 mg + Dexamethasone 20 mg | 2.0 |
Healthcare resources used during medical encounters included hospitalizations, emergency room stays, or outpatient visits. A hospitalization was defined as at least 1 overnight stay in an Intensive Care Unit and/or non-Intensive Care Unit (acute care unit, palliative care unit, and hospice). (NCT03170882)
Timeframe: Up to approximately 3 years
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Hospitalizations | Emergency Room Stays | Outpatient Visits | |
| Ixazomib 4 mg + Dexamethasone 20 mg | 23 | 11 | 32 |
| Pomalidomide 4 mg + Dexamethasone 40 mg | 16 | 9 | 29 |
The EORTC QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status/quality of life (QOL) scale. The physical domain consisted of 5 items covering participant's daily physical activities on a scale from 1 (not at all) to 4 (very much). Raw scores were linearly transformed to a total score between 0-100, with a high score indicating better physical functioning. (NCT03170882)
Timeframe: Baseline and End of Treatment (Up to 28 cycles, each cycle was of 28 days)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | End of Treatment | |
| Ixazomib 4 mg + Dexamethasone 20 mg | 67.9 | 56.5 |
| Pomalidomide 4 mg + Dexamethasone 40 mg | 67.0 | 52.4 |
The EORTC QLQ-MY20 has 20 items across 4 independent subscales, 2 symptoms scales (disease symptoms, side effects of treatment), and 2 functional subscales (body image, future perspective). Scores were averaged and transformed to 0-100 scale. Higher scores for the future perspective scale indicate better perspective of the future, for the body image scale indicate better body image and for the disease symptoms scale indicate higher level of symptomatology. (NCT03170882)
Timeframe: Baseline and End of Treatment (Up to 28 cycles, each cycle was of 28 days)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Disease Symptoms: Baseline | Disease Symptoms: End of Treatment | Side Effects of Treatment: Baseline | Side Effects of Treatment: End of Treatment | Body Image: Baseline | Body Image: End of Treatment | Future Perspective: Baseline | Future Perspective: End of Treatment | |
| Ixazomib 4 mg + Dexamethasone 20 mg | 72.4 | 68.9 | 81.4 | 77.8 | 82.9 | 83.7 | 67.5 | 64.0 |
| Pomalidomide 4 mg + Dexamethasone 40 mg | 73.2 | 73.5 | 81.0 | 74.4 | 81.5 | 75.0 | 58.8 | 57.9 |
The EORTC QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and a QOL scale. Most of the 30 items had 4 response levels (not at all, a little, quite a bit, and very much), with 2 questions relying on a 7-point numeric rating scale. Each subscale raw score were linearly transformed to a total score between 0 to 100. For the functional scales and the global health status/QOL scale, higher scores represent better QOL; for the symptom scales, lower scores represent better QOL. The Physical domain of the functional subscale is reported in the secondary outcome measure 7. (NCT03170882)
Timeframe: Baseline and End of Treatment (Up to 28 cycles, each cycle was of 28 days)
| Intervention | score on a scale (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Health Status/QoL: Baseline | Global Health Status/QoL: End of Treatment | Role (Functional Scale): Baseline | Role (Functional Scale): End of Treatment | Emotional (Functional Scale): Baseline | Emotional (Functional Scale): End of Treatment | Cognitive(Functional Scale): Baseline | Cognitive (Functional Scale): End of Treatment | Social (Functional Scale): Baseline | Social (Functional Scale): End of Treatment | Fatigue (Symptom Scale): Baseline | Fatigue (Symptom Scale): End of Treatment | Nausea/Vomiting (Symptom Scale): Baseline | Nausea/Vomiting (Symptom Scale): End of Treatment | Pain (Symptom Scale): Baseline | Pain (Symptom Scale): End of Treatment | Dyspnea (Symptom Scale): Baseline | Dyspnea (Symptom Scale): End of Treatment | Insomnia (Symptom Scale): Baseline | Insomnia (Symptom Scale): End of Treatment | Appetite Loss (Symptom Scale): Baseline | Appetite Loss (Symptom Scale): End of Treatment | Constipation (Symptom Scale): Baseline | Constipation (Symptom Scale): End of Treatment | Diarrhea (Symptom Scale): Baseline | Diarrhea (Symptom Scale): End of Treatment | Financial Difficulties (Symptom Scale): Baseline | Financial Difficulties (Symptom Scale): End of Treatment | |
| Ixazomib 4 mg + Dexamethasone 20 mg | 60.8 | 48.2 | 67.9 | 49.2 | 83.1 | 72.8 | 84.0 | 77.4 | 75.7 | 69.8 | 61.0 | 50.3 | 94.8 | 92.9 | 65.2 | 53.2 | 19.0 | 24.6 | 29.5 | 29.4 | 14.3 | 23.0 | 11.4 | 19.8 | 16.7 | 16.3 | 17.1 | 12.7 |
| Pomalidomide 4 mg + Dexamethasone 40 mg | 57.0 | 47.8 | 67.4 | 47.6 | 74.9 | 67.6 | 79.6 | 69.6 | 72.2 | 63.1 | 60.0 | 50.8 | 96.7 | 88.7 | 61.1 | 51.2 | 25.2 | 40.5 | 32.6 | 36.9 | 22.2 | 34.5 | 13.3 | 25.0 | 17.8 | 19.0 | 22.2 | 16.7 |
The EQ VAS records the respondent's self-rated health on a 20 centimeter (cm), vertical, visual analogue scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). The scores from all dimensions were combined into a single index score that was reported, where higher score was better quality of life. (NCT03170882)
Timeframe: Baseline and End of Treatment (Up to 28 cycles, each cycle was of 28 days)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | End of Treatment | |
| Ixazomib 4 mg + Dexamethasone 20 mg | 64.4 | 55.9 |
| Pomalidomide 4 mg + Dexamethasone 40 mg | 59.2 | 46.9 |
Duration of healthcare resources used during medical encounters including hospitalizations, emergency room stays, or outpatient visits was reported in days. A hospitalization was defined as at least 1 overnight stay in an Intensive Care Unit and/or non-Intensive Care Unit (acute care unit, palliative care unit, and hospice). (NCT03170882)
Timeframe: Up to approximately 3 years
| Intervention | days (Median) | ||
|---|---|---|---|
| Hospitalizations | Emergency Room Stays | Outpatient Visits | |
| Ixazomib 4 mg + Dexamethasone 20 mg | 1.0 | 1.0 | 3.0 |
| Pomalidomide 4 mg + Dexamethasone 40 mg | 2.0 | 1.0 | 4.0 |
EQ-5D-5L comprises of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each rated on 5 levels: 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extremely severe problems. Higher scores indicated greater levels of problems across the five dimensions. (NCT03170882)
Timeframe: End of Treatment (Up to 28 cycles, each cycle was of 28 days)
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mobility: 1 = I Have no Problems in Walking About | Mobility: 2 = I Have Slight Problems in Walking About | Mobility: 3 = I Have Moderate Problems in Walking About | Mobility: 4 = I Have Severe Problems in Walking About | Mobility: 5 = I am Unable to Walk About | Self-Care: 1 = I Have no Problems Washing or Dressing Myself | Self-Care: 2 = I Have Slight Problems Washing or Dressing Myself | Self-Care: 3 = I Have Moderate Problems Washing or Dressing Myself | Self-Care: 4 = I Have Severe Problems Washing or Dressing Myself | Self-Care: 5 = I am Unable to Wash or Dress Myself | Usual Activities: 1 = I Have no Problems Doing my Usual Activities | Usual Activities: 2 = I Have Slight Problems Doing my Usual Activities | Usual Activities: 3 = I Have Moderate Problems Doing my Usual Activities | Usual Activities: 4 = I Have Severe Problems Doing my Usual Activities | Usual Activities: 5 = I am Unable to do my Usual Activities | Pain/Discomfort: 1 = I Have no Pain or Discomfort | Pain/Discomfort: 2 = I Have Slight Pain or Discomfort | Pain/Discomfort: 3 = I Have Moderate Pain or Discomfort | Pain/Discomfort: 4 = I Have Severe Pain or Discomfort | Pain/Discomfort: 5 = I Have Extreme Pain or Discomfort | Anxiety/Depression: 1 = I Have no Pain or Discomfort | Anxiety/Depression: 2 = I Have no Pain or Discomfort | Anxiety/Depression: 3 = I Have no Pain or Discomfort | Anxiety/Depression: 4 = I Have no Pain or Discomfort | Anxiety/Depression: 5 = I Have no Pain or Discomfort | |
| Ixazomib 4 mg + Dexamethasone 20 mg | 9 | 12 | 11 | 8 | 1 | 21 | 10 | 4 | 4 | 2 | 10 | 9 | 12 | 7 | 3 | 8 | 10 | 15 | 6 | 2 | 19 | 13 | 6 | 1 | 2 |
| Pomalidomide 4 mg + Dexamethasone 40 mg | 5 | 6 | 8 | 8 | 0 | 13 | 6 | 5 | 3 | 0 | 4 | 7 | 8 | 7 | 1 | 3 | 5 | 13 | 6 | 0 | 6 | 8 | 11 | 2 | 0 |
CBR was defined as the percentage of participants achieving a MR or better as BOR. MR was defined as >= 25% but <= 49% reduction in serum M-protein and reduction in 24h urine M-protein by 50-89%, which still exceed 200 mg/24h; if present at baseline, >=50% reduction in size (SPD) of soft tissue plasmacytomas was also required. BOR was defined as the best sequential response, using the IRC's assessment of response, from the start of treatment until disease progression (provided that the progression is subsequently confirmed in case of progression requiring confirmation), death, initiation of further anti-myeloma treatment, or cut-off date, whichever occurs first. (NCT02990338)
Timeframe: From the date of randomization to the date of first documentation of progression, death, initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration 76.7 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Pd (Pomalidomide + Dexamethasone) | 46.4 |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 66.9 |
DOR:time from date of first IRC determined response(PR or better) to date of first IRC-PD or death, whichever occurred first.DOR was determined only for participants who had achieved a response of PR or better based on disease assessment by IRC.If progression or death was not observed,participant was censored at date of participants last progression-free tumor assessment prior to initiation of further anti-myeloma treatment(if any)and study cut-off date. PD(IMWG criteria):increase of >=25% from lowest confirmed value in any one of following criteria: serum M-protein (absolute increase must be >=0.5 g/dL), serum M-protein increase >=1g/dL if lowest M component was >=5g/dL;urine M-component (absolute increase must be >=200mg/24 hour),appearance of new lesion(s), >=50% increase from nadir in SPD of >1 lesion,or >=50% increase in the longest diameter of a previous lesion >1 cm in short axis. PR:>=50% reduction of serum M-protein and reduction in 24h urinary M-protein by >=90%/<200mg/24h. (NCT02990338)
Timeframe: From the date of the first IRC determined response to the date of first IRC progression or death, whichever occurred first (maximum duration 76.7 weeks)
| Intervention | months (Median) |
|---|---|
| Pd (Pomalidomide + Dexamethasone) | 11.07 |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 13.27 |
ORR (IMWG criteria): percentage of participants with stringent complete response(sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) as best overall response, assessed by IRC. sCR:negative immunofixation on serum and urine,disappearance of any soft tissue plasmacytomas,<5% plasma cells in bone marrow aspirates plus normal free light chain(FLC)ratio(0.26-1.65), absence of clonal cells in bone marrow biopsy.CR:negative immunofixation on serum and urine,disappearance of any soft tissue plasmacytomas,<5% plasma cells in bone marrow aspirates.VGPR: serum and urine M-protein detectable by immunofixation, not on electrophoresis/,>=90% reduction in serum M-protein plus urine M-protein level <100mg/24h/,>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma. PR: >=50% reduction of serum M-protein and reduction in 24h urinary M-protein by >=90%/<200mg/24h,if present at baseline,>=50% reduction in the size (SPD) of soft tissue plasmacytomas. (NCT02990338)
Timeframe: From the date of randomization to the date of first documentation of progression or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration 76.7 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Pd (Pomalidomide + Dexamethasone) | 35.3 |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 60.4 |
OS was defined as the time from the date of randomization to death from any cause. In the absence of confirmation of death, survival time was censored at the last date participant was known to be alive or at the cut-off date, whichever comes first. This pre-specified final analysis was performed when the 220 OS events were met. (NCT02990338)
Timeframe: From the date of randomization to date of death from any cause or data cut-off date, whichever was earlier (maximum duration 245.6 weeks)
| Intervention | months (Median) |
|---|---|
| Pd (Pomalidomide + Dexamethasone) | 17.71 |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 24.57 |
VGPR rate was defined as the percentage of participants achieving a VGPR or better as BOR. VGPR was defined as serum and urine M-protein detectable by immunofixation but not on electrophoresis or >=90% reduction in serum M-protein plus urine M-protein level <100 mg/24 h or >=90% decrease in the sum of maximal perpendicular diameter compared to baseline in soft tissue plasmacytoma. BOR was defined as the best sequential response, using the IRC's assessment of response, from the start of treatment until disease progression (provided that the progression is subsequently confirmed in case of progression requiring confirmation), death, initiation of further anti-myeloma treatment, or cut-off date, whichever occurs first. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas,<5% plasma cells in bone marrow aspirates. (NCT02990338)
Timeframe: From the date of randomization to the date of first documentation of progression, death, initiation of further anti-myeloma treatment, or data cut-off whichever comes first (maximum duration 76.7 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Pd (Pomalidomide + Dexamethasone) | 8.5 |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 31.8 |
PFS:time from date of randomization to date of first documentation of progressive disease (PD) determined by Independent Response Committee (IRC) or date of death from any cause, whichever comes first. If progression or death was not observed, participant was censored at date of last progression-free tumor assessment prior to study cut-off date. Analysis was performed by Kaplan-Meier method. PD as per International Myeloma Working Group (IMWG) criteria was defined as increase of >=25% from lowest confirmed value in any one of the following criteria: serum M-protein (the absolute increase must be >=0.5gram(g)/dL), serum M-protein increase >=1g/dL if lowest M component was >=5g/dL; urine M-component (absolute increase must be >=200mg/24hour), appearance of new lesion(s),>=50% increase from nadir in sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of >1 lesion, or >=50% increase in the longest diameter of a previous lesion >1 centimeter in short axis. (NCT02990338)
Timeframe: From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)
| Intervention | months (Median) |
|---|---|
| Pd (Pomalidomide + Dexamethasone) | 6.47 |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 11.53 |
PFS in high risk cytogenetic population was defined as PFS in subgroup of participants carrying high risk cytogenetic changes including del(17p), translocation (t)(4;14) or translocation t(14;16) assessed by fluorescence in situ hybridization (FISH). PFS was defined as the time from date of randomization to date of first documentation of PD (determined by IRC) or date of death from any cause, whichever comes first. PD defined as per IMWG criteria as: increase of >=25% from lowest confirmed value in any one of following criteria: serum M-protein (absolute increase must be >=0.5 g/dL), serum M-protein increase >=1 g/dL if lowest M component was >=5 g/dL; urine M-component (absolute increase must be >=200 mg/24hour), appearance of new lesion(s), >=50% increase from nadir in SPD of >1 lesion, or >=50% increase in the longest diameter of previous lesion >1 centimeter (cm) in short axis. (NCT02990338)
Timeframe: From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration 76.7 weeks)
| Intervention | months (Median) |
|---|---|
| Pd (Pomalidomide + Dexamethasone) | 3.745 |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 7.491 |
TTBR was defined as the time from randomization to the date of first occurrence of IRC determined BOR (PR or better) that was subsequently confirmed. PR was defined as >=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by >=90% or to <200 mg/24 h. In addition to the above listed criteria, if present at baseline, a >=50% reduction in the size (SPD) of soft tissue plasmacytomas was also required. BOR was defined as the best sequential response, using the IRC's assessment of response, from the start of treatment until disease progression (provided that the progression is subsequently confirmed in case of progression requiring confirmation), death, initiation of further anti-myeloma treatment, or cut-off date, whichever occurs first. (NCT02990338)
Timeframe: From the date of randomization to date of first occurrence of IRC determined best overall response or data cut-off whichever comes first (maximum duration 76.7 weeks)
| Intervention | months (Median) |
|---|---|
| Pd (Pomalidomide + Dexamethasone) | 5.06 |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 4.30 |
TT1R was defined as the time from randomization to the date of first IRC determined response (PR or better) that is subsequently confirmed. PR was defined as >=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by >=90% or to <200 mg/24 h. In addition to the above listed criteria, if present at baseline, a >=50% reduction in the size (SPD) of soft tissue plasmacytomas was also required. (NCT02990338)
Timeframe: From the date of randomization to the date of first IRC determined response, or death or data cut-off whichever comes first (maximum duration 76.7 weeks)
| Intervention | months (Median) |
|---|---|
| Pd (Pomalidomide + Dexamethasone) | 3.02 |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 1.94 |
TTP was defined as time from randomization to the date of first documentation of PD, as determined by the IRC. As per IMWG criteria, PD was defined for participants with increase of >= 25% from lowest confirmed value in any one of the following criteria: serum M-protein (the absolute increase must be >= 0.5 g/dL), serum M-protein increase >=1 g/dL if the lowest M component was >=5 g/dL; urine M-component (the absolute increase must be >=200 mg/24hour), appearance of new lesion(s), >=50% increase from nadir in SPD of >1 lesion, or >=50% increase in the longest diameter of a previous lesion >1 centimeter in short axis. (NCT02990338)
Timeframe: From the date of randomization to the date of first documentation of progression, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration 76.7 weeks)
| Intervention | months (Median) |
|---|---|
| Pd (Pomalidomide + Dexamethasone) | 7.75 |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 12.71 |
EORTC-Quality of Life Questionnaire (QLQ)-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. EORTC QLQ-C30 included GHS/ QOL, functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant. (NCT02990338)
Timeframe: Baseline, Day 1 of each cycle (Cycle 3, Cycle 6, Cycle 9, and Cycle 17)
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 1: Cycle 3 | Day 1: Cycle 6 | Day 1: Cycle 9 | Day 1: Cycle 17 | |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 60.10 | -1.22 | -0.16 | 0.41 | -1.92 |
| Pd (Pomalidomide + Dexamethasone) | 61.19 | -1.45 | -0.12 | 1.06 | -9.17 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. Disease symptoms domain is one of the four domain scores. Disease symptoms domain score used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0 -100 scale, where higher scores = more symptoms and lower health-related quality of life (HRQL) and lower score = less symptoms and more HRQL (NCT02990338)
Timeframe: Baseline, Day 1 of each cycle (Cycle 3, Cycle 6, Cycle 9, and Cycle 17)
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 1: Cycle 3 | Day 1: Cycle 6 | Day 1: Cycle 9 | Day 1: Cycle 17 | |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 24.12 | -2.07 | -3.30 | -4.66 | 0.00 |
| Pd (Pomalidomide + Dexamethasone) | 24.91 | -3.79 | -4.08 | -2.83 | -3.33 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. Side effects of treatment domain is one of the four domain scores. Side effects of treatment domain score used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale, where higher scores = more side effects and lower HRQL and lower scores = less side effects and better HRQL. (NCT02990338)
Timeframe: Baseline, Day 1 of each cycle (Cycle 3, Cycle 6, Cycle 9, and Cycle 17)
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 1: Cycle 3 | Day 1: Cycle 6 | Day 1: Cycle 9 | Day 1: Cycle 17 | |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 15.60 | 2.61 | 2.11 | 3.14 | 3.02 |
| Pd (Pomalidomide + Dexamethasone) | 17.49 | 1.69 | -0.13 | 1.43 | -2.93 |
The EQ-5D-5L is a standardized measure of health status that provides a general assessment of health and wellbeing. The EQ-5D descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has a 5-level response: no problems, slight problems, moderate problems, severe problems, and extreme problems. Response options are measured with a 5-point Likert scale (for the 5L version). The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state and lower score indicate worse health state. (NCT02990338)
Timeframe: Baseline, Day 1 of each cycle (Cycle 3, Cycle 6, Cycle 9, and Cycle 17)
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 1: Cycle 3 | Day 1: Cycle 6 | Day 1: Cycle 9 | Day 1: Cycle 17 | |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 0.71 | -0.01 | -0.00 | -0.01 | -0.01 |
| Pd (Pomalidomide + Dexamethasone) | 0.70 | -0.01 | 0.02 | -0.03 | -0.02 |
EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state utility index (descriptive system) and the EQ-5D-5L Visual Analog Scale. The Visual Analogue Scale is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. (NCT02990338)
Timeframe: Baseline, Day 1 of each cycle (Cycle 3, Cycle 6, Cycle 9, and Cycle 17)
| Intervention | centimeter (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 1: Cycle 3 | Day 1: Cycle 6 | Day 1: Cycle 9 | Day 1: Cycle 17 | |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 66.62 | 0.92 | 1.19 | 1.96 | -3.00 |
| Pd (Pomalidomide + Dexamethasone) | 65.38 | 0.26 | 2.49 | 4.42 | -1.70 |
ADA were categorized as: pre-existing, treatment induced and treatment boosted response. Pre-existing ADA was defined as ADA that were present in samples drawn during the pretreatment period (i.e., before the first isatuximab administration). Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without preexisting ADA, including participants without pretreatment samples. Treatment boosted ADA was defined as pre-existing ADA that increased at least 2 titer steps between pre-treatment and post-treatment. (NCT02990338)
Timeframe: From randomization up to 60 days after last dose of study drug (maximum duration 76.7 weeks)
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Pre-existing ADA | Treatment induced ADA | Treatment boosted ADA | |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 0 | 0 | 0 |
MRD was assessed by next-generation sequencing in bone marrow samples from participants who achieved CR, to determine the depth of response at the molecular level. IMWG criteria for CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and <5% plasma cells in bone marrow aspirates. MRD was classified as positive or negative at the minimum sensitivity of 1 in 10^5 nucleated cells. MRD negativity was defined as the absence of the dominant clonotype sequence(s) identified in the bone marrow aspirate collected at screening. MRD positivity was defined as the presence of the dominant clonotype sequence(s) identified in the bone marrow aspirate collected at screening. (NCT02990338)
Timeframe: Up to 76.7 weeks
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| MRD negative:1 in 10^4 | MRD negative:1 in 10^5 | MRD negative:1 in 10^6 | MRD positive:1 in 10^4 | MRD positive:1 in 10^5 | MRD positive:1 in 10^6 | |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 10 | 8 | 2 | 4 | 6 | 9 |
| Pd (Pomalidomide + Dexamethasone) | 0 | 0 | 0 | 2 | 2 | 2 |
Adverse Event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the treatment. TEAEs were defined as AEs that developed, worsened (according to the Investigator opinion), or became serious during the treatment period (time from the first dose of study treatments up to 30 days after last dose of study treatments). An SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event. (NCT02990338)
Timeframe: From randomization up to 30 days after last dose of study drug (maximum duration up to 241.6 weeks for Pd arm and 245.6 weeks for IPd arm)
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Any TEAE | Any treatment emergent SAE | Any TEAE leading to treatment discontinuation | |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 151 | 112 | 19 |
| Pd (Pomalidomide + Dexamethasone) | 146 | 91 | 22 |
BOR:best sequential response from start of treatment until disease progression, death, initiation of further anti-myeloma treatment/data cut-off, whichever comes first. Ordering of evaluations from best to worse was: sCR,CR,VGPR,PR, minimal response (MR), stable disease (SD), PD, and not evaluable.CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas,<5% plasma cells in bone marrow aspirates. sCR:CR as defined previously plus normal FLC ratio (0.26 to 1.65), absence of clonal cells in bone marrow biopsy. VGPR: serum and urine M-protein detectable by immunofixation,>=90% reduction in serum M-protein plus urine M-protein level <100mg/24h,>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma. PR: >=50% reduction of serum M-protein and reduction in 24h urinary M-protein by >=90%/<200mg/24h. MR:>=25% but <=49% reduction in serum M-protein and reduction in 24h urine M-protein by 50-89%. SD: Not meeting criteria for CR,VGPR,PR,MR/PD. (NCT02990338)
Timeframe: From the date of randomization until disease progression, or death, initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration 76.7 weeks)
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Stringent complete response | Complete response | Very good partial response | Partial response | Minimal response | Stable disease | Progressive Disease | Not evaluable | |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 0 | 4.5 | 27.3 | 28.6 | 6.5 | 21.4 | 3.9 | 4.5 |
| Pd (Pomalidomide + Dexamethasone) | 0.7 | 1.3 | 6.5 | 26.8 | 11.1 | 29.4 | 9.2 | 10.5 |
Accumulation Ratio was defined as the ratio of CEOI of Cycle 2 Day 1 versus Cycle 1 Day 1 and Cycle 4 Day 1 versus Cycle 1 Day 1, where CEOI was the plasma concentration at the end of infusion. (NCT02990338)
Timeframe: End of infusion on Cycle 1 Day 1, Cycle 2 Day 1, and Cycle 4 Day 1
| Intervention | ratio (Geometric Mean) | |
|---|---|---|
| C2D1 versus C1D1 | C4D1 versus C1D1 | |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 1.860 | 1.777 |
CEOI+1 hour was defined as the plasma concentration of isatuximab at 1 hour after end of infusion. (NCT02990338)
Timeframe: Cycle 1:1 hour after End of Infusion on Day 1; Cycle 4:1 hour after End of Infusion on Day 1
| Intervention | mcg/mL (Geometric Mean) | |
|---|---|---|
| C1D1 | C4D1 | |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 171.55 | 294.96 |
CEOI was defined as the plasma concentration at end of infusion. (NCT02990338)
Timeframe: End of infusion on Cycle(C)1 Day(D)1 and Cycle1 Day 15; Cycle 2 Day 1; and Cycle 4 Day 1
| Intervention | microgram per milliliter (mcg/mL) (Geometric Mean) | |||
|---|---|---|---|---|
| End of infusion: C1D1 | End of infusion: C1D15 | End of infusion: C2D1 | End of infusion: C4D1 | |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 163.05 | 269.20 | 299.85 | 279.31 |
Accumulation Ratio was defined as the ratio of Ctrough of Cycle 2 Day 1 versus Cycle 1 Day 8 and Cycle 4 Day 1 versus Cycle 1 Day 8, where Ctrough is the concentration prior to study drug administration. (NCT02990338)
Timeframe: Pre-infusion on Cycle 1 Day 8, Cycle 2 Day 1, and Cycle 4 Day 1
| Intervention | ratio (Geometric Mean) | |
|---|---|---|
| C2D1 versus C1D8 | C4D1 versus C1D8 | |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 2.689 | 2.620 |
Trough Concentration (Ctrough) is the concentration prior to study drug administration. (NCT02990338)
Timeframe: Pre-infusion on C1D1, C1D8, C1D15, C1D22, C2D1, C2D15, C3D1, C3D15, C4D1, C4D15, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1, C15D1, C16D1, C17D1, C18D1, C19D1, C20D1; End of treatment (EOT [30 days after last drug administration])
| Intervention | mcg/mL (Geometric Mean) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C1D1 | C1D8 | C1D15 | C1D22 | C2D1 | C2D15 | C3D1 | C3D15 | C4D1 | C4D15 | C5D1 | C6D1 | C7D1 | C8D1 | C9D1 | C10D1 | C11D1 | C12D1 | C13D1 | C14D1 | C15D1 | C16D1 | C17D1 | C18D1 | C19D1 | C20D1 | EOT | |
| IPd (Isatuximab + Pomalidomide + Dexamethasone) | 0.00 | 31.49 | 57.89 | 84.82 | 89.09 | 89.35 | 64.15 | 91.73 | 86.05 | 105.42 | 106.08 | 111.33 | 134.14 | 146.15 | 162.84 | 145.86 | 169.39 | 182.32 | 215.85 | 214.88 | 253.61 | 206.60 | 242.79 | 216.70 | 240.36 | 164.07 | 9.51 |
The Overall response rate was defined as the percentage of participants who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) according to the International Myeloma Working Group (IMWG) criteria, during the study or during follow up. IMWG criteria for PR: >=50% reduction of serum M-protein and reduction in 24 hour urinary M-protein by >=90% or to <200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of >=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria, in addition to the above criteria, if present at baseline, a >=50% reduction in the size of soft tissue plasmacytomas is also required. (NCT02136134)
Timeframe: Up to disease progression (approximately of 3 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Bortezomib + Dexamethasone (Vd) | 63.2 |
| Daratumumab + Bortezomib and Dexamethasone (DVd) | 82.9 |
Overall Survival was measured from the date of randomization to the date of the participant's death. (NCT02136134)
Timeframe: Up to the end of the study (approximately of 3 years)
| Intervention | months (Median) |
|---|---|
| Bortezomib + Dexamethasone (Vd) | NA |
| Daratumumab + Bortezomib and Dexamethasone (DVd) | NA |
Response rate of VGPR or better was defined as the percentage of participants who achieved VGPR and CR (including sCR) according to the IMWG criteria during or after the study treatment. IMWG criteria for VGPR: Serum and urine M-component detectable by immunofixation but not on electrophoresis, or >=90% reduction in serum M-protein plus urine M-protein <100 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of >90% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria, in addition to the above criteria, if present at baseline, a >=50% reduction in the size of soft tissue plasmacytomas is also required; CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and <5% PCs in bone marrow; sCR: CR and normal FLC ratio, absence of clonal PCs by immunohistochemistry, immunofluorescence or 2 to 4 color flow cytometry. (NCT02136134)
Timeframe: Up to disease progression (approximately of 3 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Bortezomib + Dexamethasone (Vd) | 29.1 |
| Daratumumab + Bortezomib and Dexamethasone (DVd) | 59.2 |
The Minimal Residual Disease negativity rate was defined as the percentage of participants who had negative MRD assessment at any timepoint after the first dose of study drugs by evaluation of bone marrow aspirates or whole blood. MRD was assessed in participants who achieved complete response or stringent complete response (CR/sCR). IMWG criteria for CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and <5% PCs in bone marrow; sCR: CR plus normal FLC ratio, absence of clonal PCs by immunohistochemistry, immunofluorescence or 2 to 4 color flow cytometry. (NCT02136134)
Timeframe: Up to disease progression (approximately of 3 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Bortezomib + Dexamethasone (Vd) | 2.8 |
| Daratumumab + Bortezomib and Dexamethasone (DVd) | 13.5 |
PFS was defined as duration from date of randomization to either progressive disease (PD)/death, whichever occurred first. PD was defined as meeting any one of following criteria: Increase of greater than equal to (>=)25 percent (%) in level of serum M-protein from lowest response value and absolute increase must be >=0.5 gram per deciliter (g/dL); Increase of >=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be >=200 mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of >=25% in difference between involved and uninvolved FLC levels from lowest response value and absolute increase must be >10 mg/dL; Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium >11.5 mg/dL) that can be attributed solely to PC proliferative disorder. (NCT02136134)
Timeframe: From the date of randomization to either progressive disease or death, whichever occurs first (approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Bortezomib + Dexamethasone (Vd) | 7.16 |
| Daratumumab + Bortezomib and Dexamethasone (DVd) | NA |
TTP was defined as time from date of randomization to date of first documented evidence of progressive disease (PD). PD was defined as meeting any one of following criteria: Increase of >=25% in level of serum M-protein from lowest response value and absolute increase must be >=0.5 g/dL; Increase of >=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be >=200 mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of >=25% in difference between involved and uninvolved free light chain (FLC) levels from lowest response value and absolute increase must be >10 milligram per deciliter (mg/dL); Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium >11.5 mg/dL) that can be attributed solely to Plasma Cell (PC) proliferative disorder. (NCT02136134)
Timeframe: From the date of randomization to the date of first documented evidence of progression or death due to PD whichever occurs first (approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Bortezomib + Dexamethasone (Vd) | 7.29 |
| Daratumumab + Bortezomib and Dexamethasone (DVd) | NA |
Comparison of Progression Free Survival between treatment arms (Daratumumab /Pomalidomide /Dexamethasone vs Pomalidomide / Dexamethasone)[ Time Frame: Assessed monthly from randomization until disease progression (PD) or death whichever occurs first (approximately up to 3 years)] Progression free survival is defined as the time, in months, from randomization to the date of the first documented PD or death due to any cause, whichever comes first. PD will be assessed by the investigator based on the analysis of serum and urine protein electrophoresis (sPEP and uPEP), serum and urine immunofixation (sIFE and uIFE), serum free light chain protein (sFLC),corrected serum calcium assessment, imaging and bone marrow assessments as per modified IMWG guidelines. (NCT03180736)
Timeframe: Assessed monthly from randomization until disease progression (PD) or death whichever occurs first (approximately up to 3 years)]
| Intervention | months (Median) |
|---|---|
| Daratumumab+Pomalidomide+Dexamethasone | 12.42 |
| Pomalidomide + Dexamethasone | 6.93 |
To assess the depth of response by analyzing the percentage of patients with Minimal Residual Disease (MRD) negativity (<10-5), considering the patients who have achieved CR or better, and patients with suspected CR/sCR. (NCT03180736)
Timeframe: From randomization to disease progression or subsequent antimyeloma therapy, assessed up to approximately 3 years.
| Intervention | percentage of participants (Number) |
|---|---|
| Daratumumab+Pomalidomide+Dexamethasone | 8.61 |
| Pomalidomide + Dexamethasone | 1.96 |
Duration of response will be restricted to the randomized subjects who achieve a best objective response of PR or better. It is measured from the time, in months, that the criteria for objective response are first met until the date of a progression event (according to the primary definition of PFS). (NCT03180736)
Timeframe: From informed consent until 30 days after last study treatment, assessed up to approximately 3 years.
| Intervention | months (Median) |
|---|---|
| Daratumumab+Pomalidomide+Dexamethasone | NA |
| Pomalidomide + Dexamethasone | 15.90 |
Worsening is defined as a decrease in score that is at least half of standard deviation from baseline values, where standard deviation is calculated from the scores at baseline combining both treatment groups. (NCT03180736)
Timeframe: Day 1 of each treatment cycle, at end of treatment, and every 4 weeks post treatment until PD (approximately up to 3 years)
| Intervention | months (Median) |
|---|---|
| Daratumumab+Pomalidomide+Dexamethasone | 4.01 |
| Pomalidomide + Dexamethasone | 3.84 |
"Worsening is defined as a decrease in score that is at least half of standard deviation from baseline values, where standard deviation is calculated from the scores at baseline combining both treatment groups.~The EQ-5D-5L is a 5 item questionnaire that assesses 5 domains including mobility, self care, usual activities, pain/discomfort, and anxiety/depression plus a visual analog scale rating health today" (NCT03180736)
Timeframe: Day 1 of each treatment cycle, at end of treatment, and every 4 weeks post treatment until PD (approximately up to 3 years)
| Intervention | months (Mean) |
|---|---|
| Daratumumab+Pomalidomide+Dexamethasone | 7.39 |
| Pomalidomide + Dexamethasone | 6.14 |
"Worsening is defined as a decrease in score that is at least half of standard deviation from baseline values, where standard deviation is calculated from the scores at baseline combining both treatment groups.~The EQ-5D-5L is a 5 item questionnaire that assesses 5 domains including mobility, self care, usual activities, pain/discomfort, and anxiety/depression plus a visual analog scale rating health today" (NCT03180736)
Timeframe: Day 1 of each treatment cycle, at end of treatment, and every 4 weeks post treatment until PD (approximately up to 3 years)
| Intervention | months (Mean) |
|---|---|
| Daratumumab+Pomalidomide+Dexamethasone | 3.78 |
| Pomalidomide + Dexamethasone | 2.86 |
Overall response rate is defined as the percentage of randomized subjects who achieve a best response of PR or better using modified IMWG criteria as their best overall response (NCT03180736)
Timeframe: Assessed monthly from Randomization until PD, (approximately up to 3 years)]
| Intervention | percentage of participants (Number) |
|---|---|
| Daratumumab+Pomalidomide+Dexamethasone | 68.87 |
| Pomalidomide + Dexamethasone | 46.41 |
Time to next therapy will be defined as the time, in months, from randomization to the date to next anti-neoplastic therapy or death from any cause, whichever comes first. (NCT03180736)
Timeframe: From randomization until the date to next anti-neoplastic therapy or death from any cause, whichever comes first (approximately up to 3 years)
| Intervention | months (Median) |
|---|---|
| Daratumumab+Pomalidomide+Dexamethasone | 23.23 |
| Pomalidomide + Dexamethasone | 11.83 |
"as monotherapy~in combination with dexamethasone~in combination with pomalidomide + dexamethasone~in combination with lenalidomide + dexamethasone" (NCT01421186)
Timeframe: First cycle of treatment
| Intervention | mg/kg (Number) |
|---|---|
| Part A: MOR03087 Biweekly Dose Escalation | 16 |
| Part B: MOR03087 Weekly Dose Escalation | 16 |
| Part C: MOR03087 Plus Dexamethasone | 16 |
| Part D: MOR03087 Plus Pomalidomide + Dexamethasone | 16 |
| Part E: MOR03087 Plus Lenalidomide + Dexamethasone | 16 |
Duration of response (Kaplan Meier estimates) (NCT01421186)
Timeframe: patients were observed up to 36 months
| Intervention | months (Median) |
|---|---|
| Part C: MOR03087 Plus Dexamethasone | 16.7 |
| Part D: MOR03087 Plus Pomalidomide + Dexamethasone | 21.2 |
| Part E: MOR03087 Plus Lenalidomide + Dexamethasone | 32.2 |
Number of participants who develop anti-MOR03087 antibodies, a measure of immunogenicity (NCT01421186)
Timeframe: during treatment period, maximum 3 years after 1st dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Part A: MOR03087 Biweekly Dose Escalation | 0 |
| Part B: MOR03087 Weekly Dose Escalation | 0 |
| Part C: MOR03087 Plus Dexamethasone | 0 |
| Part D: MOR03087 Plus Pomalidomide + Dexamethasone | 0 |
| Part E: MOR03087 Plus Lenalidomide + Dexamethasone | 0 |
number (#) of patients responding (# stringent complete response + # complete response + # very good partial response + # partial response) (NCT01421186)
Timeframe: maximum 3 years after 1st dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Part A: MOR03087 Biweekly Dose Escalation | 0 |
| Part B: MOR03087 Weekly Dose Escalation | 0 |
| Part C: MOR03087 Plus Dexamethasone | 5 |
| Part D: MOR03087 Plus Pomalidomide + Dexamethasone | 10 |
| Part E: MOR03087 Plus Lenalidomide + Dexamethasone | 11 |
PK analysis for MOR202 4, 8 and 16 mg/kg IV once weekly dose groups only, since serum concentrations of MOR202 were substantially affected by target mediated drug disposition effects for remaining dose groups (NCT01421186)
Timeframe: 56 days
| Intervention | mg*days/L (Mean) |
|---|---|
| 4 mg/kg QW | 3307.57 |
| 8 mg/kg QW | 7970.15 |
| 16 mg/kg QW | 18178.57 |
PK analysis for MOR202 4, 8 and 16 mg/kg IV once weekly dose groups only, since serum concentrations of MOR202 were substantially affected by target mediated drug disposition effects for remaining dose groups (NCT01421186)
Timeframe: up to 7 days after last MOR202 dose
| Intervention | µg/mL (Mean) |
|---|---|
| 4 mg/kg QW | 137.86 |
| 8 mg/kg QW | 311.67 |
| 16 mg/kg QW | 681.53 |
Progression-free survival (Kaplan Meier estimates) (NCT01421186)
Timeframe: patients were observed up to 36 months
| Intervention | months (Median) |
|---|---|
| Part A: MOR03087 Biweekly Dose Escalation | 1.1 |
| Part B: MOR03087 Weekly Dose Escalation | 2.1 |
| Part C: MOR03087 Plus Dexamethasone | 8.4 |
| Part D: MOR03087 Plus Pomalidomide + Dexamethasone | 15.9 |
| Part E: MOR03087 Plus Lenalidomide + Dexamethasone | 26.7 |
Time to Progression (Kaplan Meier estimate) (NCT01421186)
Timeframe: patients were observed for up to 36 months
| Intervention | months (Median) |
|---|---|
| Part A: MOR03087 Biweekly Dose Escalation | 1.1 |
| Part B: MOR03087 Weekly Dose Escalation | 2.1 |
| Part C: MOR03087 Plus Dexamethasone | 8.4 |
| Part D: MOR03087 Plus Pomalidomide + Dexamethasone | 15.9 |
| Part E: MOR03087 Plus Lenalidomide + Dexamethasone | 33.2 |
DOR: time from first response (PR or better) to first documented tumor progression/death. Progression as per EBMT: >25% increase in serum monoclonal paraprotein level, which must also be an absolute increase of >= 5 g/l: confirmed by >=1 repeated investigation; >25% increase in 24h urinary light chain excretion, which must also be an absolute increase of >=200 mg/24 h:confirmed by >=1 repeated investigation; >25% increase in plasma cells in a bone marrow aspirate/on trephine biopsy, which must also be an absolute increase of >= 10%; definite increase in size of existing bone lesions/soft tissue plasmacytomas; development of new bone lesions/soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium >11·5 mg/dl or 2·8 mmol/l) not attributable to any other cause. PR: >=50% reduction of serum M-protein, reduction in 24h urinary M-protein by >=90% or <200mg, >=50% reduction in size/number of soft tissue plasmacytomas, no increase in size/number of lytic bone lesions. (NCT01084252)
Timeframe: From the date of first response to the date of first documentation of progression or death (due to any cause) (maximum duration: 120 weeks)
| Intervention | months (Mean) |
|---|---|
| Phase 1: Isatuximab 1mg/kg Q2W | 20.21 |
| Phase 1: Isatuximab 5mg/kg Q2W | 7.16 |
| Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | 5.76 |
| Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | 10.70 |
| Phase 1: Isatuximab 10mg/kg QW | 14.31 |
| Phase 1: Isatuximab 20mg/kg Q2W | 3.94 |
| Phase 1: Isatuximab 20mg/kg QW | 8.82 |
TTR was defined as the time from first dose of isatuximab to first response (PR or better). PR: >=50% reduction of serum M-protein, reduction in 24 h urinary M-protein by >=90% or <200mg, >=50% reduction in size/number of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions. (NCT01084252)
Timeframe: From the date of first dose administration to the date of first response or death (due to any cause) (maximum duration: 120 weeks)
| Intervention | months (Mean) |
|---|---|
| Phase 1: Isatuximab 1mg/kg Q2W | 0.95 |
| Phase 1: Isatuximab 5mg/kg Q2W | 6.41 |
| Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | 2.52 |
| Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | 1.96 |
| Phase 1: Isatuximab 10mg/kg QW | 1.38 |
| Phase 1: Isatuximab 20mg/kg Q2W | 1.18 |
| Phase 1: Isatuximab 20mg/kg QW | 1.46 |
(NCT01084252)
Timeframe: Pre-dose, at the end of infusion, 1 hour and 168 hours post dose on Day 1 of Cycle 1
| Intervention | mcg*hour/mL (Geometric Mean) |
|---|---|
| Phase 2 Stage 2: Isatuximab Alone | 37096 |
| Phase 2 Stage 2: Isatuximab + Dexamethasone | 35423 |
(NCT01084252)
Timeframe: Cycle 1, Day 1: pre-dose, at the end of infusion, 168 and 336 hours post-infusion
| Intervention | mcg*hour/mL (Geometric Mean) |
|---|---|
| Phase 2 Stage 2: Isatuximab Alone | 91271 |
| Phase 2 Stage 2: Isatuximab + Dexamethasone | 86761 |
(NCT01084252)
Timeframe: Cycle 1, Day 1: pre-dose, at the end of infusion, 168, 336, and 672 hours post-infusion
| Intervention | mcg*hour/mL (Geometric Mean) |
|---|---|
| Phase 2 Stage 2: Isatuximab Alone | 236360 |
| Phase 2 Stage 2: Isatuximab + Dexamethasone | 226372 |
DLTs were assessed using the national cancer institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03. DLTs were defined as any Grade 3 or higher non-hematological toxicity (with the exception of allergic reaction/hypersensitivity), Grade 4 neutropenia and/or Grade 4 thrombocytopenia lasting longer than 5 days, attributed to isatuximab. Any other toxicity that the Investigator and the Sponsor deemed to be dose-limiting, regardless of the grade, was also considered as DLT. (NCT01084252)
Timeframe: Day 1 of Cycle 1 up to Day 14 of Cycle 2
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase 1:Isatuximab <=1 mg/kg Q2W | 1 |
| Phase 1: Isatuximab 3mg/kg Q2W | 1 |
| Phase 1: Isatuximab 5mg/kg Q2W | 0 |
| Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | 0 |
| Phase 1: Isatuximab 10 mg/kg QW | 0 |
| Phase 1: Isatuximab 20mg/kg Q2W | 0 |
| Phase 1: Isatuximab 20mg/kg QW | 0 |
Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment. (NCT01084252)
Timeframe: From Baseline up to 30 days after the last dose (maximum duration: 120 weeks )
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase 1: Isatuximab <=1mg/kg Q2W | 16 |
| Phase 1: Isatuximab 3mg/kg Q2W | 6 |
| Phase 1: Isatuximab 5mg/kg Q2W | 3 |
| Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | 26 |
| Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | 18 |
| Phase 1: Isatuximab 10 mg/kg QW | 6 |
| Phase 1: Isatuximab 20mg/kg Q2W | 7 |
| Phase 1: Isatuximab 20mg/kg QW | 6 |
DOR:Time from date of 1st IAC determined response (>= PR) that was subsequently confirmed, to date of first IAC determined PD/death, whichever happened earlier. updated IMWG criteria- PR:>=50% decrease in difference between involved and uninvolved FLC levels in place of M-protein criteria or a >=50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline a >=50% reduction in size of soft tissue plasmacytomas; PD: Increase of 25% from lowest response value in any of following: Serum M-protein >=0.5 g/dL absolute increase and/or urine M-protein >=200 mg/24 hours absolute increase and/or >10 mg/dL absolute increase in difference between involved and uninvolved FLC levels, >=10% bone marrow plasma cells (PCs), development of new bone lesions/soft tissue plasmacytomas or definite increase in size of existing bone lesions/soft tissue plasmacytomas, development of hypercalcemia (corrected serum calcium >11·5 mg/dl) attributed to PC proliferation disorder. (NCT01084252)
Timeframe: From the date of first response until disease progression or death or data cut-off (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
| Intervention | months (Mean) |
|---|---|
| Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W | 1.91 |
| Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W | 11.17 |
| Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | 7.31 |
| Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W | 8.11 |
Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment. (NCT01084252)
Timeframe: From Baseline up to 30 days after the last dose (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W | 22 |
| Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W | 24 |
| Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | 25 |
| Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W | 25 |
OS was defined as the time interval from the date of first Isatuximab administration to death from any cause. Analysis was performed by Kaplan-Meier method. (NCT01084252)
Timeframe: From the date of randomization to date of death from any cause (maximum duration 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
| Intervention | months (Median) |
|---|---|
| Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W | 15.277 |
| Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W | 18.628 |
| Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | NA |
| Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W | NA |
Clinical benefit: participants with sCR, CR, VGPR, PR or MR as per IMWG criteria, determined by IAC. CR: negative immunofixation on serum & urine, disappearance of any soft tissue plasmacytomas,<5% PCs in bone marrow aspirates. sCR: CR + normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. VGPR: serum & urine M-component detectable by immunofixation, not on electrophoresis/,>=90% reduction in serum M-component plus urine M-component level <100mg/24hours; PR: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours, ≥50% decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria or a ≥50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline, ≥50% size reduction in soft tissue plasmacytomas. MR:>=25 but <49% reduction in serum M-protein, reduction in 24h urine M-protein by 50-89%, 25-49% size reduction in soft tissue plasmacytomas. (NCT01084252)
Timeframe: From Baseline up to 30 days after the last dose (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
| Intervention | percentage of participants (Number) |
|---|---|
| Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W | 4.3 |
| Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W | 41.7 |
| Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | 32.0 |
| Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W | 36.0 |
OR defined as participants with stringent complete response (sCR) or complete response (CR) or very good partial response (VGPR) or partial response (PR) . Based on IMWG, CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and <=5% plasma cells in bone marrow; sCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or >=90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; PR: >=50% reduction of serum M-Protein and reduction in urinary M-protein by >=90% or to <200 mg/24 hours; >=50% decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria or a >=50% reduction in plasma cells in place of M-protein if present at baseline. (NCT01084252)
Timeframe: From the date of randomization until disease progression or death or data cut-off (maximum duration: 77 weeks )
| Intervention | percentage of participants (Number) |
|---|---|
| Phase 2 Stage 1a: Isatuximab 3 mg/kg | 4.3 |
| Phase 2 Stage 1a: Isatuximab 10 mg/kg | 29.2 |
| Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W and Then Q4W | 20.0 |
| Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W | 24.0 |
PFS was defined as the time interval from the date of first isatuximab administration to the date of the first IAC-confirmed disease progression (PD) or date of death due to any cause, whichever came first. As per IMWG criteria, PD: Increase of > 25% from lowest response value in any one or more of the following: Serum M-component and/or (the absolute increase must be > 0.5 g/dL), Urine M-component and/or (the absolute increase must be > 200 mg/24 h), > 10mg/dL decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria, >10% absolute percentage of bone marrow plasma cell, definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas, development of hypercalcemia (corrected serum calcium > 11.5 mg/dL or 2.65 mmol/L) that attributed solely to the plasma cell proliferative disorder. Analysis was performed by Kaplan-Meier method. (NCT01084252)
Timeframe: From the date of the first dose administration until progression or death, whichever occurred first (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
| Intervention | months (Median) |
|---|---|
| Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W | 2.1 |
| Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W | 9.6 |
| Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | 4.4 |
| Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W | 3.6 |
DOR: Time from date of 1st IAC determined response (>= PR) that was subsequently confirmed, to date of 1st IAC determined PD or death, whichever happened earlier. As per updated IMWG criteria-PR: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. ≥50% decrease in difference between involved and uninvolved FLC levels in place of M-protein criteria or ≥50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline ≥50% reduction in size of soft tissue plasmacytomas; PD: Increase of >25% from lowest response value in any one of following: Serum M-component (absolute increase must be >0.5 g/dL)4 and/or Urine M-component (absolute increase must be >200 mg/24 h) and/or >10 mg/dL absolute increase in difference between involved and uninvolved FLC levels, >=10% bone marrow plasma cell, development of hypercalcemia (corrected serum calcium >11.5 mg/dL) attributed solely to plasma cell proliferative disorder. (NCT01084252)
Timeframe: From the date of first response until disease progression or death or data cut-off (maximum duration: 97 weeks)
| Intervention | months (Mean) |
|---|---|
| Phase 2 Stage 2: Isatuximab Alone | 8.6 |
| Phase 2 Stage 2: Isatuximab + Dexamethasone | 10.9 |
AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment. (NCT01084252)
Timeframe: From Baseline up to 30 days after the last dose (maximum duration: 97 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase 2 Stage 2: Isatuximab Alone | 100 |
| Phase 2 Stage 2: Isatuximab + Dexamethasone | 51 |
OS was defined as the time interval from the date of first Isatuximab administration to death from any cause. Analysis was performed by Kaplan-Meier method. (NCT01084252)
Timeframe: From the date of randomization to date of death from any cause (maximum duration: 97 weeks)
| Intervention | months (Median) |
|---|---|
| Phase 2 Stage 2: Isatuximab Alone | 18.92 |
| Phase 2 Stage 2: Isatuximab + Dexamethasone | 17.25 |
Clinical benefit:participants with sCR, CR, VGPR, PR or MR, per IMWG criteria, determined by IAC. CR:negative immunofixation on serum & urine, disappearance of any soft tissue plasmacytomas,<5% plasma cells in bone marrow aspirates,normal FLC ratio(0.26-1.65) in participants with only FLC disease.sCR:CR+normal FLC ratio, absence of clonal cells in bone marrow biopsy.VGPR:serum & urine M-component detectable by immunofixation, not on electrophoresis/,>=90% reduction in serum M-component plus urine M-component level <100mg/24h/,>=90% decrease in difference between involved and uninvolved FLC levels; PR:>=50% reduction of serum M-protein, reduction in 24h urinary M-protein by >=90%/<200mg/24h,>50% decrease in difference between involved and uninvolved FLC in place of M-protein criteria, >=50% reduction in size/number of soft tissue plasmacytomas. MR:>=25 but <49% reduction in serum M-protein,reduction in 24h urine M-protein by 50-89%, 25-49% reduction in size of soft tissue plasmacytomas (NCT01084252)
Timeframe: From the date of randomization to the date of first documentation of progression or death (maximum duration: 97 weeks )
| Intervention | percentage of participants (Number) |
|---|---|
| Phase 2 Stage 2: Isatuximab Alone | 43.1 |
| Phase 2 Stage 2: Isatuximab + Dexamethasone | 54.5 |
OR: participants with sCR or CR or VGPR or PR. As per updated IMWG, CR: Negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and <=5% plasma cells in bone marrow; normal FLC ratio of 0.26-1.65 in participants with only FLC disease; sCR: CR and normal FLC ratio and no clonal cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or >=90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours, >90% decrease in the difference between involved and uninvolved FLC levels; PR: >=50% reduction of serum M-Protein and reduction in urinary M-protein by >=90% or to <200 mg/24 hours; >=50% decrease in the difference between involved and uninvolved FLC levels in place of M-protein criteria or >=50% reduction in plasma cells in place of M-protein if present at baseline. (NCT01084252)
Timeframe: From the date of randomization to date of death from any cause (maximum duration: 97 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Phase 2 Stage 2: Isatuximab Alone | 23.9 |
| Phase 2 Stage 2: Isatuximab + Dexamethasone | 43.6 |
PFS was defined as the time interval from the date of first isatuximab administration to the date of the first IAC-confirmed disease progression or the date of death due to any cause, whichever came first. As per IMWG criteria, PD: Increase of >25% from lowest response value in any one of the following: Serum M-component (the absolute increase must be >0.5 g/dL)4 and/or Urine M-component (the absolute increase must be >200 mg/24 h) and/or >10 mg/dL decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria, ≥10% bone marrow plasma cell, development of hypercalcemia (corrected serum calcium >11.5 mg/dL) attributed solely to the plasma cell proliferative disorder. Analysis was performed by Kaplan-Meier method. (NCT01084252)
Timeframe: From the date of the first dose administration until progression or death, whichever occurred first (maximum duration: 97 weeks)
| Intervention | months (Median) |
|---|---|
| Phase 2 Stage 2: Isatuximab Alone | 4.86 |
| Phase 2 Stage 2: Isatuximab + Dexamethasone | 10.15 |
Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab <=1mg/kg in participant flow). (NCT01084252)
Timeframe: For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 336 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 336 hr post-infusion
| Intervention | mcg*hour/mL (Geometric Mean) |
|---|---|
| Phase 1: Isatuximab 1 mg/kg Q2W | 222 |
| Phase 1: Isatuximab 3mg/kg Q2W | 3076 |
| Phase 1: Isatuximab 5mg/kg Q2W | 9546 |
| Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | 14876 |
| Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | 18967 |
| Phase 1: Isatuximab 10mg/kg QW | 30187 |
| Phase 1: Isatuximab 20mg/kg Q2W | 48003 |
| Phase 1: Isatuximab 20mg/kg QW | 71174 |
Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab <=1mg/kg in participant flow). (NCT01084252)
Timeframe: For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 168 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 168 hr post-infusion
| Intervention | mcg*hour/mL (Geometric Mean) |
|---|---|
| Phase 1: Isatuximab 1 mg/kg Q2W | 222 |
| Phase 1: Isatuximab 3mg/kg Q2W | 2624 |
| Phase 1: Isatuximab 5mg/kg Q2W | 7174 |
| Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | 11566 |
| Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | 13480 |
| Phase 1: Isatuximab 10mg/kg QW | 12680 |
| Phase 1: Isatuximab 20mg/kg Q2W | 32739 |
| Phase 1: Isatuximab 20mg/kg QW | 28405 |
ECOG performance status was measured on a 4 point scale to assess participant's performance status. 0=Normal, fully functional; 1=Fatigue without significant decrease in daily activity; 2=Fatigue with significant impairment of daily activities or bed rest <50% of waking hours; 3=Bed rest/sitting >50% of waking hours; 4=Bedridden or unable to care for self, where lower score indicated good performance status. Number of participants with Baseline ECOG PS score and corresponding changes to the best values (categorized as: Baseline ECOG 1, During Treatment ECOG 0; Baseline ECOG 2, During Treatment ECOG 0; Baseline ECOG 2, During Treatment ECOG 1) are reported. (NCT01084252)
Timeframe: At baseline, during treatment (Day 1 up to 120 weeks)
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Baseline ECOG 1, During Treatment ECOG 0 | Baseline ECOG 2, During Treatment ECOG 0 | Baseline ECOG 2, During Treatment ECOG 1 | |
| Phase 1: Isatuximab | 11 | 2 | 11 |
ECOG performance status was measured on a 4 point scale to assess participant's performance status. 0=Normal, fully functional; 1=Fatigue without significant decrease in daily activity; 2=Fatigue with significant impairment of daily activities or bed rest <50% of waking hours; 3=Bed rest/sitting>50% of waking hours; 4=Bedridden or unable to care for self, where higher score indicated worst performance status. Number of participants with Baseline ECOG PS score and corresponding changes to the worst values (categorized as: Baseline ECOG 0, During Treatment ECOG 1; Baseline ECOG 2, During Treatment ECOG 1; Baseline ECOG 0, During Treatment ECOG 2; Baseline ECOG 1, During Treatment ECOG 2; Baseline ECOG 0, During Treatment ECOG 3; Baseline ECOG 1, During Treatment ECOG 3; Baseline ECOG 2, During Treatment ECOG 3) are reported. (NCT01084252)
Timeframe: At baseline, during treatment (up to 120 weeks)
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline ECOG 0, During Treatment ECOG 1 | Baseline ECOG 2, During Treatment ECOG 1 | Baseline ECOG 0, During Treatment ECOG 2 | Baseline ECOG 1, During Treatment ECOG 2 | Baseline ECOG 0, During Treatment ECOG 3 | Baseline ECOG 1, During Treatment ECOG 3 | Baseline ECOG 2, During Treatment ECOG 3 | |
| Phase 1: Isatuximab | 8 | 1 | 3 | 20 | 1 | 2 | 1 |
OR defined as participants with complete response (CR) or partial response (PR) as best overall response (BOR). Clinical benefit: participants with minimal response (MR) or better as BOR. BOR: best sequential response from start of treatment through the entire study excluding any time point following start of other treatment. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, <5% plasma cells in bone marrow aspirates, no increase in size or number of lytic bone lesions. PR: >=50% reduction of serum M-protein, reduction in 24 h urinary M-protein by >=90% or <200mg, >=50% reduction in size/number of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions. MR: 25 to 49% reduction in serum M-protein, 50-89% reduction in 24h urine M-protein, 25-49% reduction in size of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions. (NCT01084252)
Timeframe: From the date of randomization to the date of first documentation of progression or death (due to any cause) (maximum duration: 120 weeks)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| OR | Clinical benefit | |
| Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | 16.7 | 27.8 |
| Phase 1: Isatuximab 10mg/kg QW | 33.3 | 33.3 |
| Phase 1: Isatuximab 1mg/kg Q2W | 33.3 | 33.3 |
| Phase 1: Isatuximab 20mg/kg Q2W | 14.3 | 28.6 |
| Phase 1: Isatuximab 20mg/kg QW | 28.6 | 42.9 |
| Phase 1: Isatuximab 3mg/kg Q2W | 0 | 20.0 |
| Phase 1: Isatuximab 5mg/kg Q2W | 33.3 | 33.3 |
| Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | 28.0 | 28.0 |
ADA response was categorized as: treatment induced and treatment boosted response. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period (defined as the time from the first isatuximab administration until end of Phase 1) in participants without preexisting ADA (defined as: ADA that were present in samples drawn before treatment), including participants without pre-treatment (before treatment) samples. Treatment boosted ADA was defined as pre-existing ADA that increased at least 2 titer steps between pre-treatment (before treatment) and post-treatment. (NCT01084252)
Timeframe: Up to 120 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Treatment-induced ADA | Treatment boosted ADA | |
| Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | 1 | 0 |
| Phase 1: Isatuximab 10mg/kg QW | 1 | 0 |
| Phase 1: Isatuximab 20mg/kg Q2W | 1 | 0 |
| Phase 1: Isatuximab 20mg/kg QW | 1 | 0 |
| Phase 1: Isatuximab 3mg/kg Q2W | 0 | 0 |
| Phase 1: Isatuximab 5mg/kg Q2W | 0 | 0 |
| Phase 1:Isatuximab <=1 mg/kg Q2W | 2 | 0 |
| Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | 1 | 0 |
ADA response was categorized as: treatment induced and treatment boosted response. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period (defined as the time from the first isatuximab administration until end of Phase 2 Stage 2) in participants without preexisting ADA (defined as: ADA that were present in samples drawn before treatment), including participants without pre-treatment (before treatment) samples. Treatment boosted ADA was defined as pre-existing ADA that increased at least 2 titer steps between pre-treatment (before treatment) and post-treatment. (NCT01084252)
Timeframe: Up to 97 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Treatment induced ADA | Treatment boosted ADA | |
| Phase 2 Stage 2: Isatuximab + Dexamethasone | 0 | 0 |
| Phase 2 Stage 2: Isatuximab Alone | 1 | 0 |
Serum/plasma markers included: tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1-β), interleukin 6 (IL-6) and interferon-gamma (IFN-Gamma). Due to change in planned analysis, data for high-sensitivity C-reactive protein (hs-CRP) and CD38 was not collected and analyzed. (NCT01084252)
Timeframe: Cycle 1 Day 1
| Intervention | picogram/milliliter (pg/mL) (Mean) | |||
|---|---|---|---|---|
| TNF alpha | IL-1 Beta | IL-6 | IFN Gamma | |
| Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | 503.462 | 547.770 | 173.004 | 568.806 |
| Phase 1: Isatuximab 10mg/kg QW | 342.664 | 327.957 | -8.109 | 627.089 |
| Phase 1: Isatuximab 20mg/kg Q2W | 307.319 | 305.914 | 274.616 | 448.387 |
| Phase 1: Isatuximab 20mg/kg QW | 412.541 | 293.307 | 165.295 | 1487.097 |
| Phase 1: Isatuximab 3mg/kg Q2W | 179.783 | 29.741 | 261.732 | 5.376 |
| Phase 1: Isatuximab 5mg/kg Q2W | 352.974 | 7.527 | 73.899 | 25.806 |
| Phase 1:Isatuximab <=1 mg/kg Q2W | 163.181 | 64.577 | 139.234 | 477.116 |
| Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | 340.799 | 299.058 | 148.594 | 445.772 |
Ceoi was defined as the plasma concentration of Isatuximab at end of infusion. Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab <=1mg/kg in participant flow). Analysis was performed on PK population: participants who gave informed consent, received at least one dose (even if incomplete) of isatuximab, had an assessable PK parameter. (NCT01084252)
Timeframe: Cycle 1 Day 1 and Cycle 3 Day 1: At the end of infusion
| Intervention | microgram per milliliter (mcg/mL) (Mean) |
|---|---|
| Cycle 1 Day 1 | |
| Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | 148.80000 |
| Phase 1: Isatuximab 0.3 mg/kg Q2W | 2.08667 |
| Phase 1: Isatuximab 1 mg/kg Q2W | 13.18333 |
| Phase 1: Isatuximab 20mg/kg Q2W | 400.33333 |
| Phase 1: Isatuximab 3mg/kg Q2W | 44.22500 |
| Phase 1: Isatuximab 5mg/kg Q2W | 125.50000 |
| Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | 171.43333 |
Ceoi was defined as the plasma concentration of Isatuximab at end of infusion. Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab <=1mg/kg in participant flow). Analysis was performed on PK population: participants who gave informed consent, received at least one dose (even if incomplete) of isatuximab, had an assessable PK parameter. (NCT01084252)
Timeframe: Cycle 1 Day 1 and Cycle 3 Day 1: At the end of infusion
| Intervention | microgram per milliliter (mcg/mL) (Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 3 Day 1 | |
| Phase 1: Isatuximab 10mg/kg QW | 173.33333 | 299.82500 |
| Phase 1: Isatuximab 20mg/kg QW | 334.33333 | 715.33333 |
Ctrough is the plasma concentration observed before treatment administration. For 1st category, the accumulation ratio was calculated by dividing Ctrough value of Cycle 2 Day 1 by Cycle 1 Day 8 and for second category, accumulation ratio was calculated by dividing Ctrough value of Cycle 4 Day 1 by Cycle 1 Day 8. (NCT01084252)
Timeframe: Cycle 2, Day 1; Cycle 1, Day 8; Cycle 4, Day 1
| Intervention | ratio (Mean) | |
|---|---|---|
| Cycle 2 Day 1/Cycle 1 Day 8 | Cycle 4 Day 1/Cycle 1 Day 8 | |
| Phase 2 Stage 2: Isatuximab + Dexamethasone | 3.24370 | 3.95950 |
| Phase 2 Stage 2: Isatuximab Alone | 521.38338 | 3.58378 |
(NCT01084252)
Timeframe: At Day 1, 8, and 22
| Intervention | mcg/mL (Geometric Mean) | ||
|---|---|---|---|
| Day 7 | Day 14 | Day 28 | |
| Phase 2 Stage 2: Isatuximab + Dexamethasone | 128 | 214 | 305 |
| Phase 2 Stage 2: Isatuximab Alone | 137 | 230 | 360 |
EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state. (NCT01084252)
Timeframe: Baseline, Day 1 of Cycles 4, 7, 10, 13, 16, 19, and EOT (anytime up to 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 day 1 | Cycle 7 day 1 | Cycle 10 day 1 | Cycle 13 day 1 | End of treatment | |
| Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | -4.78 | 9.00 | 10.33 | -9.00 | -10.00 |
| Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W | 4.89 | 1.00 | -2.60 | -5.00 | -9.00 |
EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state. (NCT01084252)
Timeframe: Baseline, Day 1 of Cycles 4, 7, 10, 13, 16, 19, and EOT (anytime up to 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Cycle 4 day 1 | Cycle 7 day 1 | Cycle 10 day 1 | Cycle 13 day 1 | Cycle 16 day 1 | End of treatment | |
| Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W | -5.75 | -2.50 | 0.50 | 14.00 | 5.00 | -18.50 |
EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state. (NCT01084252)
Timeframe: Baseline, Day 1 of Cycles 4, 7, 10, 13, 16, 19, and EOT (anytime up to 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
| Intervention | score on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 4 day 1 | Cycle 7 day 1 | Cycle 10 day 1 | Cycle 13 day 1 | Cycle 16 day 1 | Cycle 19 day 1 | End of treatment | |
| Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W | 2.00 | -6.00 | -10.33 | -5.00 | 0.67 | -5.50 | -11.60 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with MM. It has 4 subscales: body image, future perspective), and 2 symptoms scales (disease symptoms and side-effects of treatment). Disease symptoms subscale used 4-point scale ranged from 1= 'Not at All' to 4= 'Very Much'. Scores were averaged, and transformed to 0 -100 scale, where higher scores = more symptoms and lower health-related quality of life (HRQL) and lower score = less symptoms and more HRQL. (NCT01084252)
Timeframe: Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10 and EOT (anytime up to 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
| Intervention | score on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 day 1 | Cycle 3 day 1 | Cycle 4 day 1 | Cycle 5 day 1 | Cycle 6 day 1 | Cycle 7 day 1 | Cycle 8 day 1 | Cycle 9 day 1 | Cycle 10 day 1 | End of treatment | |
| Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W | -3.42 | -5.05 | -3.89 | 0.51 | 1.23 | -3.70 | -2.78 | -10.00 | 0.00 | 7.78 |
| Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | 0.93 | -5.98 | -10.00 | -9.03 | -15.08 | -18.06 | -15.28 | -16.67 | -15.28 | 24.07 |
| Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W | 5.56 | 7.94 | 8.33 | -6.94 | 8.33 | 2.78 | -5.56 | 5.56 | 0.00 | -9.72 |
| Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W | 2.61 | -1.52 | 0.62 | -6.67 | -6.94 | -11.11 | -4.17 | -6.94 | -6.67 | 25.00 |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (fatigue, nausea/vomiting, pain) & other single items. For each item, high score = high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health & quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 & 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant. (NCT01084252)
Timeframe: Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10 and End of Treatment (EOT: anytime up to 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)
| Intervention | score on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 day 1 | Cycle 3 day 1 | Cycle 4 day 1 | Cycle 5 day 1 | Cycle 6 day 1 | Cycle 7 day 1 | Cycle 8 day 1 | Cycle 9 day 1 | Cycle 10 day 1 | End of treatment | |
| Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W | 2.22 | -0.76 | -5.30 | 0.69 | -10.19 | -3.57 | -11.11 | -10.00 | -16.67 | -11.67 |
| Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W | -3.95 | 6.55 | 6.06 | 6.48 | 5.95 | 8.33 | 4.17 | 4.17 | 8.33 | -11.11 |
| Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W | -8.33 | 0.00 | 0.00 | 0.00 | 12.50 | 12.50 | 0.00 | -8.33 | -8.33 | 3.33 |
| Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W | 0.00 | -2.08 | 7.41 | 5.00 | 10.42 | 6.67 | 6.25 | 6.25 | 3.33 | -12.50 |
Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab <=1mg/kg in participant flow). Analysis was performed on PK population. (NCT01084252)
Timeframe: For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 168 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 168 hr post-infusion
| Intervention | mcg/mL (Geometric Mean) |
|---|---|
| Cycle 1 Day 1 | |
| Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | 154 |
| Phase 1: Isatuximab 0.3 mg/kg Q2W | 2.00 |
| Phase 1: Isatuximab 1 mg/kg Q2W | 12.4 |
| Phase 1: Isatuximab 20mg/kg Q2W | 457 |
| Phase 1: Isatuximab 3mg/kg Q2W | 53.7 |
| Phase 1: Isatuximab 5mg/kg Q2W | 126 |
| Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | 181 |
Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab <=1mg/kg in participant flow). Analysis was performed on PK population. (NCT01084252)
Timeframe: For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 168 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 168 hr post-infusion
| Intervention | mcg/mL (Geometric Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 3 Day 1 | |
| Phase 1: Isatuximab 10mg/kg QW | 181 | 265 |
| Phase 1: Isatuximab 20mg/kg QW | 343 | 712 |
Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab <=1mg/kg in participant flow). (NCT01084252)
Timeframe: Week 1, 2 and 3
| Intervention | mcg/mL (Geometric Mean) | ||
|---|---|---|---|
| Week 1 | Week 2 | Week 3 | |
| Phase 1: 5mg/kg Q2W | 15.3 | 1.39 | 42.7 |
| Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | 44.2 | 8.31 | 18.6 |
| Phase 1: Isatuximab 1 mg/kg Q2W | 0.00223 | 0.000800 | 0.000283 |
| Phase 1: Isatuximab 10 mg/kg QW | 20.7 | 55.1 | 75.9 |
| Phase 1: Isatuximab 20mg/kg Q2W | 113 | 63.9 | 91.0 |
| Phase 1: Isatuximab 20mg/kg QW | 108 | 194.8 | 347.3 |
| Phase 1: Isatuximab 3mg/kg Q2W | 1.44 | 0.181 | 0.460 |
| Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | 27.6 | 1.97 | 4.18 |
Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab <=1mg/kg in participant flow). Analysis was performed on PK population. (NCT01084252)
Timeframe: For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 168 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 168 hr post-infusion
| Intervention | hours (Median) |
|---|---|
| Cycle 1 Day 1 | |
| Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma) | 4.92 |
| Phase 1: Isatuximab 0.3 mg/kg Q2W | 2.49 |
| Phase 1: Isatuximab 1 mg/kg Q2W | 4.35 |
| Phase 1: Isatuximab 5mg/kg Q2W | 7.65 |
| Phase 1: Isatuximab 20mg/kg Q2W | 5.87 |
| Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma) | 4.28 |
| Phase 1: Isatuximab 3mg/kg Q2W | 6.99 |
Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab <=1mg/kg in participant flow). Analysis was performed on PK population. (NCT01084252)
Timeframe: For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 168 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 168 hr post-infusion
| Intervention | hours (Median) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 3 Day 1 | |
| Phase 1: Isatuximab 10mg/kg QW | 2.25 | 4.30 |
| Phase 1: Isatuximab 20mg/kg QW | 6.83 | 8.07 |
DOR: time (in months) from date of 1st IRC determined response for participants achieving PR/better to date of 1st documented PD determined by IRC/death, whichever happens 1st. If disease progression/death before analysis cut-off date was not observed, DOR was censored at date of last valid disease assessment performed prior to initiation of further anti-myeloma treatment/data cut-off date, whichever was 1st. PD (IMWG criteria): inc of >=25% from lowest confirmed value in any 1 of following criteria: serum M-protein (absolute inc must be >=0.5 g/dL), serum M-protein inc >=1g/dL if lowest M component was >=5g/dL; urine M-component (absolute inc must be >=200mg/24 hour),appearance of new lesion(s), >=50% inc from nadir in SPD of >1 lesion, or >=50% inc in the longest diameter of previous lesion >1 cm in short axis. PR: >=50% reduction of serum M-protein & reduction in 24h urinary M-protein by >=90%/<200mg/24 h. Estimated by Kaplan Meier method. (NCT03275285)
Timeframe: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
| Intervention | months (Median) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | NA |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | NA |
Complete response was defined as the participants with sCR and CR. IMWG response criteria for sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, <5% plasma cells in bone marrow aspirates plus normal free light chain (FLC) ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, <5% plasma cells in bone marrow aspirates. Complete response at the time of the final analysis was assessed with hydrashift isatuximab immunofixation electrophoresis (IFE) assay, which separated immunoglobulin G (IgG) isatuximab from IgG M protein. (NCT03275285)
Timeframe: From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 28.5 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 44.1 |
MRD negativity was defined as the percentage of participants for whom MRD was negative by next-generation sequencing at any timepoint after first dose of study treatment. Threshold for negativity is 10^-5. MRD status in a participant was negative if at least one result of the assessment was negative in the participant otherwise MRD was considered as positive (MRD status reported as positive, missing or unevaluable). CR: participants with sCR and CR. IMWG response criteria for sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, <5% plasma cells in bone marrow aspirates plus normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, <5% plasma cells in bone marrow aspirates. Complete response at the time of the final analysis was assessed with Hydrashift isatuximab IFE assay, which separated IgG isatuximab from IgG M protein. (NCT03275285)
Timeframe: From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 12.2 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 26.3 |
OR: participants with sCR, CR, VGPR & partial response (PR) as best overall response assessed by IRC using IMWG response criteria (from start of treatment until disease progression, death, initiation of further anti-myeloma treatment/cutoff date, whichever occurs 1st). sCR: negative immunofixation on serum & urine, disappearance of soft tissue plasmacytoma, <5% plasma cells in bone marrow aspirate (BMA) + normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum & urine, disappearance of soft tissue plasmacytoma, <5% plasma cells in BMA. VGPR: serum & urine M-protein detectable by immunofixation, not on electrophoresis/,>=90% reduction in serum M-protein + urine M-protein level <100mg/24h/,>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma. PR:>=50% reduction of serum M-protein & decrease in 24h urinary M-protein by >=90%/<200mg/24h, if present at baseline,>=50% decrease in SPD of soft tissue plasmacytoma. (NCT03275285)
Timeframe: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 82.9 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 86.6 |
VGPR or better: defined as participants with sCR, CR and VGPR as the best overall response (defined as best response from start of treatment until disease progression, death, initiation of further anti-myeloma treatment or cut-off date whichever occurs first) as per IRC. As per IMWG response criteria: sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, <5% plasma cells in BMAs plus normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, <5% plasma cells in BMAs. VGPR: serum and urine M-protein detectable by immunofixation, not on electrophoresis/,>=90% reduction in serum M-protein plus urine M-protein level <100mg/24h/,>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma. (NCT03275285)
Timeframe: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 56.1 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 72.6 |
Percentage of participants with sCR, CR and VGPR for whom MRD assessed by sequencing was negative at any time after first dose of study treatment. MRD was assessed centrally by next-generation sequencing in BM aspiration samples from participants who achieve VGPR or better, to determine depth of response at molecular level. VGPR or better: percentage of participants with sCR, CR and VGPR. sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, <5% plasma cells in bone marrow aspirates plus normal FLC ratio, absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, <5% plasma cells in bone marrow aspirates. VGPR: serum and urine M-protein detectable by immunofixation, not on electrophoresis/,>=90% reduction in serum M-protein plus urine M-protein level <100mg/24h/,>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma. (NCT03275285)
Timeframe: From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 13.8 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 33.5 |
Percentage of participants with sCR, CR and VGPR for whom MRD assessed by sequencing was negative at any time after first dose of study treatment. MRD was assessed centrally by next-generation sequencing in bone marrow aspiration samples from participants who achieve VGPR or better, to determine depth of response at molecular level. VGPR or better: percentage of participants with sCR, CR and VGPR. sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, <5% plasma cells in BMAs plus normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, <5% plasma cells in BMAs. VGPR: serum and urine M-protein detectable by immunofixation, not on electrophoresis/,>=90% reduction in serum M-protein plus urine M-protein level <100mg/24h/,>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma. (NCT03275285)
Timeframe: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 13.0 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 29.6 |
AUC was defined as area under the plasma concentration-time curve extrapolated to infinity according to the equation: AUC= AUClast + Clast/λz. AUC was calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab. (NCT03275285)
Timeframe: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
| Intervention | nanograms*hour/milliliter(ng*h/mL) (Mean) |
|---|---|
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 784 |
AUClast was defined as area under the plasma concentration versus time curve calculated from time 0 to last quantifiable concentration. AUClast was calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab. (NCT03275285)
Timeframe: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
| Intervention | ng*h/mL (Mean) |
|---|---|
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 779 |
Clast was defined as the last concentration observed above the lower limit of quantification. (NCT03275285)
Timeframe: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
| Intervention | ng/mL (Mean) |
|---|---|
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 3.00 |
CLss was defined as a quantitative measure of the rate at which a drug substance is removed from the body at steady state, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab. (NCT03275285)
Timeframe: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
| Intervention | Liters/hour (L/h) (Mean) |
|---|---|
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 466 |
Cmax was defined as the maximum concentration observed after the first infusion calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab. (NCT03275285)
Timeframe: Cycle 1: pre-dose (0 hour), 30 minutes (min), 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
| Intervention | nanogram/milliliter (ng/mL) (Mean) |
|---|---|
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 2090 |
AUCext was defined as the percentage of the extrapolation of AUC, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab. (NCT03275285)
Timeframe: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
| Intervention | percentage of AUC (Geometric Mean) |
|---|---|
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 0 |
T1/2 was defined as the time required for the concentration of the drug to reach half of its original value, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab. (NCT03275285)
Timeframe: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
| Intervention | hours (Median) |
|---|---|
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 0.860 |
Tlast was defined as the time of last concentration observed above the lower limit of quantification, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab. (NCT03275285)
Timeframe: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
| Intervention | hours (Median) |
|---|---|
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 4.50 |
Tmax was defined as the time to reach Cmax, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab. (NCT03275285)
Timeframe: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
| Intervention | hours (Median) |
|---|---|
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 0.54 |
Volume of Distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vss is the apparent volume of distribution at steady-state, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab. (NCT03275285)
Timeframe: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
| Intervention | Liters (Mean) |
|---|---|
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 453 |
Time (in months) from randomization to date of 1st documentation of progressive disease (PD)/date of death from any cause, whichever comes 1st. If PD & death are not observed before cut-off date/date of initiation of further anti-myeloma treatment, PFS was censored at date of last valid disease assessment not showing PD performed prior to initiation of further anti-myeloma treatment/cut-off date, whichever comes 1st. PD(IMWG criteria):any 1 of following:Increase(inc) of >=25% in serum M-component from nadir; serum M component inc >=1 g/dL in 2 consecutive assessment, if starting M component >=5 g/dL; and/or inc of >=25% in urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc >=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion if >1 lesion/ >=50% increase in longest diameter of previous soft tissue extramedullary disease lesion >1 cm in short axis. Estimated by Kaplan-Meier method. (NCT03275285)
Timeframe: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (median duration of follow-up was 20.73 months)
| Intervention | months (Median) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 19.15 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | NA |
Time (in months) from randomization to date of 1st documentation of PD/date of death from any cause, whichever comes 1st. If PD & death are not observed before cut-off date/date of initiation of further anti-myeloma treatment, PFS was censored at date of last valid disease assessment not showing PD/cut-off date, whichever comes 1st. Progressions/deaths occurring >8 weeks after last disease assessment were censored at earliest date of last valid disease assessment not showing PD before initiation of further anti-myeloma treatment & cut-off date. PD (per IMWG criteria): meeting any 1 criteria: Inc of >=25% in serum M-component from nadir; serum M component inc >=1 g/dL in 2 consecutive assessment, if starting M component was >=5 g/dL; and/or inc of >=25% in urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc >=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion >1 cm in short axis. (NCT03275285)
Timeframe: From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)
| Intervention | months (Median) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 20.76 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 41.66 |
Time (in months) from randomization to date of 1st PD documentation/death date, whichever is 1st. If PD & death not observed before cut-off date/date of further anti-myeloma treatment initiation, PFS censored at date of last valid disease assessment not showing PD performed prior to initiation of further anti-myeloma treatment/cut-off date, whichever was 1st. Progression/deaths occurring >8 weeks after last disease assessment censored at earliest date of last disease assessment without evidence of progression before initiation of new anti-myeloma treatment & cut-off date. PD (IMWG criteria): meeting any 1: Inc >=25% in Serum M-component from nadir; serum M component inc >=1 g/dL in 2 consecutive assessment, if starting M component >=5 g/dL; and/or inc >=25% in Urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc >=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion >1 cm short axis. (NCT03275285)
Timeframe: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
| Intervention | months (Median) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 20.27 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | NA |
PFS: time (in months) from randomization to date of first documentation of PD or date of death from any cause, whichever comes first. If PD and death are not observed before analysis cut-off date or date of initiation of further anti-myeloma treatment, PFS was censored at date of last valid disease assessment or analysis cut-off date, whichever comes first. PD as per IMWG criteria: any 1 of following: Inc of >=25% in Serum M-component from nadir; serum M component increase >=1 g/dL in 2 consecutive assessment, if starting M component was >=5 g/dL; and/or inc of >=25% in Urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc >=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion if >1 lesion/ >=50% inc in longest diameter of previous soft tissue extramedullary disease lesion >1 cm in short axis. PFS estimated by Kaplan-Meier method. (NCT03275285)
Timeframe: From randomization until the final analysis data cut-off date of 14 January 2022 (the median duration of follow-up was 43.96 months)
| Intervention | months (Median) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 19.15 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 35.65 |
PFS2 defined as time (in months) from date of randomization to date of 1st documentation of PD (as assessed by investigator) after initiation of further anti-myeloma treatment /death from any cause, whichever comes 1st. Participants alive without progression after initiation of further anti-myeloma treatment before analysis cut-off date, PFS2 censored at date of last follow-up visit not showing disease progression after initiation of further anti-myeloma treatment /analysis cut-off date, whichever comes 1st. As per IMWG criteria, PD: defined for participants with increase of >= 25% from lowest confirmed value in any 1 of following criteria: serum M-protein (absolute increase must be >= 0.5 g/dL), serum M-protein increase >=1 g/dL if lowest M component was >=5 g/dL; urine M-component (absolute increase must be >=200 mg/24hour), appearance of new lesion(s), >=50% increase from nadir in SPD of >1 lesion, or >=50% increase in longest diameter of previous lesion >1 centimeter short axis. (NCT03275285)
Timeframe: From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)
| Intervention | months (Median) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 35.58 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 47.18 |
Time to best response was defined as time (in months) from randomization to the date of first occurrence of IRC determined as best overall response (PR or better) that is subsequently confirmed. In absence of response, participants were censored at earliest date of last valid disease assessment before disease progression/death, date of last valid disease assessment before initiation of further anti-myeloma treatment (if any)/ analysis cut-off date, whichever was 1st. PR (IMWG criteria) was defined as >=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by >=90% or to <200 mg/24 h. In addition to above listed criteria, if present at baseline, a >=50% reduction in the size (SPD) of soft tissue plasmacytomas was also required. Best Overall Response was defined as the best response, using the IRC's assessment of response, from start of treatment until disease progression, death, initiation of further anti-myeloma treatment or cut-off date, whichever occurs 1st. (NCT03275285)
Timeframe: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
| Intervention | months (Median) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 3.78 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 4.60 |
Time to first response was defined as the time (in months) from randomization to the date of first IRC determined response (PR or better) that is subsequently confirmed. In the absence of response, participants were censored at the earliest of the date of the last valid disease assessment before disease progression or death, the date of the last valid disease assessment before initiation of a further anti-myeloma treatment (if any) or the analysis cut-off date, whichever comes first. PR per IMWG criteria was defined as >=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by >=90% or to <200 mg/24 h. In addition to the above listed criteria, if present at baseline, a >=50% reduction in the size (SPD) of soft tissue plasmacytomas was also required. (NCT03275285)
Timeframe: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
| Intervention | months (Median) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 1.12 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 1.08 |
TTP was defined as time in months from randomization to the date of first documentation of PD (as determined by the IRC). If progression was not observed before the analysis cut-off date or the date of initiation of further anti-myeloma treatment, TTP was censored at the date of the last valid disease assessment not showing disease progression performed prior to initiation of a further anti-myeloma treatment (if any) or the analysis cut-off date, whichever comes first. As per IMWG criteria, PD was defined for participants with inc of >= 25% from lowest confirmed value in any one of the following criteria: serum M-protein (the absolute inc must be >= 0.5 g/dL), serum M-protein inc >=1 g/dL if the lowest M component was >=5 g/dL; urine M-component (the absolute inc must be >=200 mg/24hour), appearance of new lesion(s), >=50% inc from nadir in SPD of >1 lesion, or >=50% inc in the longest diameter of a previous lesion >1 centimeter in short axis. (NCT03275285)
Timeframe: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
| Intervention | months (Median) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 20.27 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | NA |
EORTC QLQ-C30 is a cancer-specific instrument that contains 30 items & provides multidimensional assessment of HRQL. EORTC QLQ-C30 includes global health status/quality of life (GHS/QOL), functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 are 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale & are 7-point scale (1/Very Poor to 7/Excellent). GHS total score is calculated as ([{Q29+Q30}/2]-1)/6*100. Answers are converted into grading scale, with values between 0 (worse outcome) to100 (best outcome). High score represents a favorable outcome with best quality of life for participant. Results reported for primary analysis with data cut-off date 7-Feb-2020. (NCT03275285)
Timeframe: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
| Intervention | score on a scale (Mean) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | Cycle 3 Day 1 | Cycle 4 Day 1 | Cycle 5 Day 1 | Cycle 6 Day 1 | Cycle 7 Day 1 | Cycle 8 Day 1 | Cycle 9 Day 1 | Cycle 10 Day 1 | Cycle 11 Day 1 | Cycle 12 Day 1 | Cycle 13 Day 1 | Cycle 14 Day 1 | Cycle 15 Day 1 | Cycle 16 Day 1 | Cycle 17 Day 1 | Cycle 18 Day 1 | Cycle 19 Day 1 | Cycle 20 Day 1 | Cycle 21 Day 1 | Cycle 22 Day 1 | Cycle 23 Day 1 | Cycle 24 Day 1 | Cycle 25 Day 1 | End of Treatment | |
| Carfilzomib + Dexamethasone (Kd) | 1.52 | 4.17 | 3.58 | 3.60 | 3.13 | 4.22 | 3.82 | 6.60 | 4.91 | 4.34 | 8.59 | 7.08 | 9.75 | 5.26 | 6.33 | 7.27 | 8.70 | 12.40 | 10.78 | 12.50 | 17.98 | 15.56 | 14.81 | 15.00 | -6.14 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | -1.60 | 0.05 | -1.89 | -1.23 | -1.44 | -1.77 | -1.06 | -0.78 | -1.21 | -1.10 | 0.84 | -1.26 | -0.98 | 0.16 | -1.07 | 0.00 | -0.36 | -1.23 | -1.05 | -1.85 | 0.31 | 3.15 | 0.38 | 3.13 | -11.90 |
"EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. It is used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to treatment or the disease. It consists of one question and scores are based on the 4-point Likert scale ranging from Not at all to Very much. Body image score is calculated as: (1 - [Q47-1]/3)*100. Scores are averaged, and transformed to scale ranging from 0 to 100. A higher score represents a better quality of life." (NCT03275285)
Timeframe: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
| Intervention | score on a scale (Mean) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | Cycle 3 Day 1 | Cycle 4 Day 1 | Cycle 5 Day 1 | Cycle 6 Day 1 | Cycle 7 Day 1 | Cycle 8 Day 1 | Cycle 9 Day 1 | Cycle 10 Day 1 | Cycle 11 Day 1 | Cycle 12 Day 1 | Cycle 13 Day 1 | Cycle 14 Day 1 | Cycle 15 Day 1 | Cycle 16 Day 1 | Cycle 17 Day 1 | Cycle 18 Day 1 | Cycle 19 Day 1 | Cycle 20 Day 1 | Cycle 21 Day 1 | Cycle 22 Day 1 | Cycle 23 Day 1 | Cycle 24 Day 1 | Cycle 25 Day 1 | End of Treatment | |
| Carfilzomib + Dexamethasone (Kd) | -1.29 | 1.98 | -1.65 | -0.69 | -1.83 | -0.77 | -5.16 | -2.14 | -1.80 | -1.85 | -2.05 | -3.89 | -4.52 | 0.00 | -1.31 | -1.42 | 1.48 | 0.00 | 0.00 | -4.76 | -8.77 | -13.33 | -25.93 | -53.33 | -5.65 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | -1.27 | 1.27 | -1.10 | -2.89 | -1.60 | -3.03 | -0.25 | -1.02 | -1.33 | -0.55 | -0.55 | -2.63 | -3.24 | -2.22 | -2.94 | -1.98 | -1.77 | -3.70 | -0.76 | -3.20 | -1.85 | -5.41 | -3.03 | -8.33 | -9.36 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. It is used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to treatment or the disease. Disease symptoms domain is one of the four domain scores. Disease symptoms domain consist of 6 questions and the score uses 4-point scale (1 'Not at All' to 4 'Very Much'). Disease Symptoms Domain Score is calculated as ([{Q31+Q32+Q33+Q34+Q35+Q36}/6]-1)/3*100. Scores are averaged, and transformed to 0-100 scale, where higher scores = more symptoms and lower HRQL. (NCT03275285)
Timeframe: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
| Intervention | score on a scale (Mean) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | Cycle 3 Day 1 | Cycle 4 Day 1 | Cycle 5 Day 1 | Cycle 6 Day 1 | Cycle 7 Day 1 | Cycle 8 Day 1 | Cycle 9 Day 1 | Cycle 10 Day 1 | Cycle 11 Day 1 | Cycle 12 Day 1 | Cycle 13 Day 1 | Cycle 14 Day 1 | Cycle 15 Day 1 | Cycle 16 Day 1 | Cycle 17 Day 1 | Cycle 18 Day 1 | Cycle 19 Day 1 | Cycle 20 Day 1 | Cycle 21 Day 1 | Cycle 22 Day 1 | Cycle 23 Day 1 | Cycle 24 Day 1 | Cycle 25 Day 1 | End of Treatment | |
| Carfilzomib + Dexamethasone (Kd) | -5.34 | -8.28 | -5.45 | -5.78 | -6.11 | -6.64 | -6.94 | -5.65 | -5.56 | -3.24 | -5.30 | -7.69 | -8.66 | -5.56 | -8.06 | -7.57 | -7.16 | -7.18 | -11.93 | -9.72 | -9.94 | -5.56 | -6.17 | -12.22 | 2.35 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | -3.40 | -7.42 | -7.46 | -6.37 | -6.16 | -4.78 | -5.47 | -5.51 | -4.98 | -7.10 | -6.89 | -5.95 | -7.08 | -5.19 | -5.77 | -4.29 | -3.78 | -3.64 | -3.54 | -3.81 | -5.35 | -6.01 | -9.60 | -14.58 | 1.75 |
"EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. It is used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to treatment or the disease. It consists of three questions and the scores are based on the 4-point Likert scale ranging from Not at all to Very much. Future Perspective score is calculated as (1 - ([{Q48+Q49+Q50}/3] -1)/3)*100. Scores are averaged and transformed to scale ranging from 0 to 100. A higher score represents a better quality of life." (NCT03275285)
Timeframe: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
| Intervention | score on a scale (Mean) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | Cycle 3 Day 1 | Cycle 4 Day 1 | Cycle 5 Day 1 | Cycle 6 Day 1 | Cycle 7 Day 1 | Cycle 8 Day 1 | Cycle 9 Day 1 | Cycle 10 Day 1 | Cycle 11 Day 1 | Cycle 12 Day 1 | Cycle 13 Day 1 | Cycle 14 Day 1 | Cycle 15 Day 1 | Cycle 16 Day 1 | Cycle 17 Day 1 | Cycle 18 Day 1 | Cycle 19 Day 1 | Cycle 20 Day 1 | Cycle 21 Day 1 | Cycle 22 Day 1 | Cycle 23 Day 1 | Cycle 24 Day 1 | Cycle 25 Day 1 | End of Treatment | |
| Carfilzomib + Dexamethasone (Kd) | 0.54 | 4.84 | 6.60 | 7.67 | 8.42 | 8.17 | 7.41 | 7.26 | 8.56 | 8.02 | 6.84 | 11.11 | 8.85 | 9.55 | 12.42 | 12.29 | 11.36 | 9.21 | 10.13 | 10.32 | 8.77 | 9.63 | 1.23 | -4.44 | -3.95 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 7.57 | 9.70 | 8.55 | 7.56 | 9.97 | 8.47 | 10.54 | 8.57 | 11.56 | 12.02 | 11.48 | 10.72 | 11.31 | 12.28 | 11.76 | 10.89 | 7.33 | 8.40 | 9.60 | 10.65 | 12.14 | 12.61 | 16.16 | 15.28 | -3.70 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. Side effects of treatment domain is one of the four domain scores. Side effects of treatment domain consists of 10 questions and the score uses a 4-point scale (1 'Not at All' to 4 'Very Much'). Side Effects of Treatment Score (MYSE) is calculated as ([{Q37+Q38+Q39+Q40+Q41+Q42+Q43+Q44+Q45+Q46}/10]-1)/3*100. Scores are averaged, and transformed to 0-100 scale, where higher scores = more side effects and lower HRQL and lower scores = less side effects and better HRQL. (NCT03275285)
Timeframe: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
| Intervention | score on a scale (Mean) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | Cycle 3 Day 1 | Cycle 4 Day 1 | Cycle 5 Day 1 | Cycle 6 Day 1 | Cycle 7 Day 1 | Cycle 8 Day 1 | Cycle 9 Day 1 | Cycle 10 Day 1 | Cycle 11 Day 1 | Cycle 12 Day 1 | Cycle 13 Day 1 | Cycle 14 Day 1 | Cycle 15 Day 1 | Cycle 16 Day 1 | Cycle 17 Day 1 | Cycle 18 Day 1 | Cycle 19 Day 1 | Cycle 20 Day 1 | Cycle 21 Day 1 | Cycle 22 Day 1 | Cycle 23 Day 1 | Cycle 24 Day 1 | Cycle 25 Day 1 | End of Treatment | |
| Carfilzomib + Dexamethasone (Kd) | 1.23 | 0.44 | 0.83 | 1.91 | 2.08 | 1.47 | 1.53 | 1.68 | 2.07 | 3.38 | 1.20 | 0.82 | 1.08 | 1.85 | 0.99 | 2.74 | 2.37 | 2.76 | -0.17 | 3.17 | 3.55 | 7.85 | 12.35 | 11.85 | 4.63 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 1.41 | 0.84 | 0.99 | 2.36 | 1.61 | 2.14 | 2.86 | 1.49 | 2.68 | 2.03 | 3.04 | 2.12 | 1.71 | 1.87 | 2.58 | 4.10 | 2.95 | 2.16 | 2.05 | 2.74 | 1.51 | -1.39 | -2.54 | -3.50 | 5.56 |
The EQ-5D-5L is a standardized measure of health status that provides a general assessment of health utility and consist in 2 sections a descriptive system comprising 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and Visual Analog Scale (VAS). Each dimension has a 5-level response: no problems, slight problems, moderate problems, severe problems, and extreme problems. Response options are measured with a 5-point Likert scale. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state and lower score indicate worse health state. (NCT03275285)
Timeframe: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
| Intervention | score on a scale (Mean) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | Cycle 3 Day 1 | Cycle 4 Day 1 | Cycle 5 Day 1 | Cycle 6 Day 1 | Cycle 7 Day 1 | Cycle 8 Day 1 | Cycle 9 Day 1 | Cycle 10 Day 1 | Cycle 11 Day 1 | Cycle 12 Day 1 | Cycle 13 Day 1 | Cycle 14 Day 1 | Cycle 15 Day 1 | Cycle 16 Day 1 | Cycle 17 Day 1 | Cycle 18 Day 1 | Cycle 19 Day 1 | Cycle 20 Day 1 | Cycle 21 Day 1 | Cycle 22 Day 1 | Cycle 23 Day 1 | Cycle 24 Day 1 | Cycle 25 Day 1 | End of Treatment | |
| Carfilzomib + Dexamethasone (Kd) | 0.05 | 0.06 | 0.02 | 0.04 | 0.03 | 0.06 | 0.06 | 0.05 | 0.06 | 0.04 | 0.03 | 0.06 | 0.06 | 0.05 | 0.06 | 0.05 | 0.02 | 0.03 | 0.06 | 0.03 | 0.05 | 0.05 | 0.04 | 0.05 | -0.03 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 0.04 | 0.05 | 0.05 | 0.04 | 0.05 | 0.04 | 0.05 | 0.04 | 0.03 | 0.05 | 0.02 | 0.03 | 0.04 | 0.05 | 0.04 | 0.03 | 0.04 | 0.03 | 0.03 | 0.02 | 0.02 | 0.00 | 0.03 | 0.04 | -0.08 |
The EQ-5D-5L is a standardized measure of health status that provides a general assessment of health utility and consist of 2 sections; descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and a VAS. The VAS records the respondent's self-rated health on a 20 centimeter (cm) vertical VAS; the scale went from 0 (worst imaginable health state) to 100 (best imaginable health state). This information can be used as a quantitative measure of health as judged by the individual respondents. (NCT03275285)
Timeframe: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
| Intervention | score on a scale (Mean) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | Cycle 3 Day 1 | Cycle 4 Day 1 | Cycle 5 Day 1 | Cycle 6 Day 1 | Cycle 7 Day 1 | Cycle 8 Day 1 | Cycle 9 Day 1 | Cycle 10 Day 1 | Cycle 11 Day 1 | Cycle 12 Day 1 | Cycle 13 Day 1 | Cycle 14 Day 1 | Cycle 15 Day 1 | Cycle 16 Day 1 | Cycle 17 Day 1 | Cycle 18 Day 1 | Cycle 19 Day 1 | Cycle 20 Day 1 | Cycle 21 Day 1 | Cycle 22 Day 1 | Cycle 23 Day 1 | Cycle 24 Day 1 | Cycle 25 Day 1 | End of Treatment | |
| Carfilzomib + Dexamethasone (Kd) | 2.42 | 4.70 | 6.03 | 3.40 | 2.80 | 0.64 | 1.48 | -0.14 | 2.76 | 3.86 | 5.29 | 6.81 | 7.95 | 4.96 | 3.94 | 5.04 | 3.71 | 7.44 | 6.18 | 7.25 | 5.58 | 6.33 | 5.11 | 9.20 | -4.40 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 0.60 | 3.47 | 2.29 | 2.35 | 1.24 | 2.24 | 2.40 | 2.93 | 2.82 | 3.77 | 3.63 | 4.94 | 4.72 | 3.23 | 4.56 | 4.97 | 3.83 | 3.69 | 4.20 | 3.26 | 2.35 | 6.44 | 4.50 | 5.00 | -7.80 |
ADA were categorized as: pre-existing, treatment induced, and treatment boosted response. Pre-existing ADA was defined as ADA that were present in samples drawn during the pretreatment period (i.e., before the first isatuximab administration). Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA, including participants without pretreatment samples. Treatment boosted ADA was defined as pre-existing ADA with an increase in titer during the ADA on-study observation period. (NCT03275285)
Timeframe: From first dose of study treatment up to 30 days after last dose of study treatment (maximum duration: 111 weeks)
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Pre-existing ADA | Treatment induced ADA | Treatment boosted ADA | |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 0 | 0 | 0 |
RR comprises of complete RR (CR renal), partial RR (PR renal) & minor RR (MR renal). CR renal was defined as an improvement in estimated glomerular filtration rate (eGFR) from <50 mL/min/1.73m^2 at Baseline to >=60 mL/min/1.73m^2 in at least 1 assessment during the treatment period (time from first dose of study treatment up to 30 days after last dose of study treatment); PR renal was defined as improvement in eGFR from <15 mL/min/1.73m^2 at baseline to at least 1 assessment in the range of 30 to 60 mL/min/1.73m^2 during the on-treatment-period and MR renal was defined as an improvement in eGFR from <15 mL/min/1.73m^2 at Baseline to at least 1 assessment in the range of 15 to 30 mL/min/1.73m^2 during the on-treatment-period or from 15 to 30 mL/min/1.73m^2 at Baseline to at least 1 assessment in the range of 30 to 60 mL/min/1.73m^2 during the on-treatment-period. (NCT03275285)
Timeframe: From the first dose of study treatment to 30 days following the last administration of study treatment (maximum duration: up to 114 weeks)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| CR Renal | MR Renal | |
| Carfilzomib + Dexamethasone (Kd) | 4 | 1 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 13 | 4 |
Adverse Event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the treatment. TEAEs were defined as AEs that developed, worsened, or became serious during the treatment period (time from the first dose of study treatments up to 30 days after last dose of study treatments). An SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability / incapacity, was a congenital anomaly/birth defect, was a medically important event. (NCT03275285)
Timeframe: From first dose of study treatment up to 30 days after last dose of study treatment (maximum duration: up to 208 weeks for Kd arm and 215 weeks for IKd arm)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Any TEAE | Any treatment emergent SAE | |
| Carfilzomib + Dexamethasone (Kd) | 119 | 73 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 175 | 124 |
Ceoi is the plasma concentration observed at the end of intravenous infusion. (NCT03275285)
Timeframe: End of infusion on Cycle 1 Day 1 and Cycle 1 Day 15; Cycle 2 Day 1
| Intervention | microgram/milliliter (mcg/mL) (Mean) | ||
|---|---|---|---|
| Cycle 1 Day 1 | Cycle 1 Day 15 | Cycle 2 Day 1 | |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 274.01 | 380.28 | 522.74 |
Ctrough was the plasma concentration observed just before treatment administration during repeated dosing. (NCT03275285)
Timeframe: Pre-infusion on Cycle 1 Day 1, Day 8, Day 15 and Day 22, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1, Cycle 7 Day 1, Cycle 8 Day 1, Cycle 9 Day 1 and Cycle 10 Day 1
| Intervention | mcg/mL (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | Cycle 1 Day 8 | Cycle 1 Day 15 | Cycle 1 Day 22 | Cycle 2 Day 1 | Cycle 3 Day 1 | Cycle 4 Day 1 | Cycle 5 Day 1 | Cycle 6 Day 1 | Cycle 7 Day 1 | Cycle 8 Day 1 | Cycle 9 Day 1 | Cycle 10 Day 1 | |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 3.66 | 82.14 | 180.02 | 252.63 | 324.28 | 295.78 | 342.48 | 389.25 | 427.16 | 433.22 | 490.51 | 486.07 | 490.08 |
Time to second-line anti-myeloma therapy was defined as time from randomization to the start of another non-protocol anti-myeloma therapy. (NCT00689936)
Timeframe: From date of randomization until the data cut-off of 24 May 2013; median follow-up for all participants was 23.0 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 39.1 |
| Lenalidomide and Dexamethasone Rd18 | 28.5 |
| Melphalan + Prednisone + Thalidomide (MPT) | 26.7 |
Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment; data cut-off date of 21 January 2016; median follow-up for responders was 19.9 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 31.5 |
| Lenalidomide and Dexamethasone Rd18 | 21.5 |
| Melphalan + Prednisone + Thalidomide (MPT) | 22.1 |
Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median follow-up for responders was 20.1 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 35.0 |
| Lenalidomide and Dexamethasone Rd18 | 22.1 |
| Melphalan + Prednisone + Thalidomide (MPT) | 22.3 |
Overall survival was defined as the time between randomization and death. Participants, who died, regardless of the cause of death, were considered to have had an event. All participants who were lost to follow-up prior to the end of the trial or who were withdrawn from the trial were censored at the time of last contact. Participants who were still being treated were censored at the last available date the participant was known to be alive. (NCT00689936)
Timeframe: From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 48.3 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 59.1 |
| Lenalidomide and Dexamethasone Rd18 | 62.3 |
| Melphalan + Prednisone + Thalidomide (MPT) | 49.1 |
Time to second-line anti-myeloma therapy is defined as time from randomization to the start of another non-protocol anti-myeloma therapy. Those who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy. (NCT00689936)
Timeframe: From date of randomization until the data cut-off of date 21 January 2016; median follow-up for all participants was 23.0 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 36.7 |
| Lenalidomide and Dexamethasone Rd18 | 28.5 |
| Melphalan + Prednisone + Thalidomide (MPT) | 26.7 |
TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by IRAC based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death. (NCT00689936)
Timeframe: From date of randomization until the data cut-off of 24 May 2013; median follow-up for all participants was 16.1 months.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 16.9 |
| Lenalidomide and Dexamethasone Rd18 | 17.2 |
| Melphalan + Prednisone + Thalidomide (MPT) | 14.1 |
TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by the investigators assessment based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death. (NCT00689936)
Timeframe: From date of randomization until the data cut-off date of 21 January 2016; median follow up for all participants was 16.1 months.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 16.9 |
| Lenalidomide and Dexamethasone Rd18 | 17.2 |
| Melphalan + Prednisone + Thalidomide (MPT) | 14.1 |
PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's). (NCT00689936)
Timeframe: From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 17.7 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 26.0 |
| Lenalidomide and Dexamethasone Rd18 | 21.0 |
| Melphalan + Prednisone + Thalidomide (MPT) | 21.9 |
PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's). (NCT00689936)
Timeframe: From date of randomization until the data cut-off date of 24 May 2013. Median follow-up time for all participants was 17.1 months.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 25.5 |
| Lenalidomide and Dexamethasone Rd18 | 20.7 |
| Melphalan + Prednisone + Thalidomide (MPT) | 21.2 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | Percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 70.0 |
| Lenalidomide and Dexamethasone Rd18 | 69.7 |
| Melphalan + Prednisone + Thalidomide (MPT) | 58.2 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 80.4 |
| Lenalidomide and Dexamethasone Rd18 | 81.6 |
| Melphalan + Prednisone + Thalidomide (MPT) | 70.6 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of particpants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 80.4 |
| Lenalidomide and Dexamethasone Rd18 | 74.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | 61.0 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 60.5 |
| Lenalidomide and Dexamethasone Rd18 | 76.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | 57.5 |
Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment; data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 46.2 |
| Lenalidomide and Dexamethasone Rd18 | 53.1 |
| Melphalan + Prednisone + Thalidomide (MPT) | 45.7 |
Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 80.7 |
| Lenalidomide and Dexamethasone Rd18 | 78.6 |
| Melphalan + Prednisone + Thalidomide (MPT) | 67.5 |
Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined as: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 75.1 |
| Lenalidomide and Dexamethasone Rd18 | 73.4 |
| Melphalan + Prednisone + Thalidomide (MPT) | 62.3 |
The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria assessed by the investigator. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 1.8 |
| Lenalidomide and Dexamethasone Rd18 | 1.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | 2.8 |
The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 1.8 |
| Lenalidomide and Dexamethasone Rd18 | 1.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | 2.8 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Appetite Loss Scale is scored between 0 and 100, with a high score indicating a higher level of appetite loss. Negative change from Baseline values indicate improvement in appetite and positive values indicate worsening of appetite. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 2.9 | -3.3 | -8.6 | -6.4 | -5.1 | -7.5 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 1.3 | -5.9 | -9.8 | -7.3 | -8.1 | -1.0 |
| Melphalan + Prednisone + Thalidomide (MPT) | 1.0 | -6.2 | -13.5 | -10.5 | -12.2 | -2.6 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Cognitive Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1, (Baseline) then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -1.7 | 1.8 | 0.9 | -1.2 | -2.8 | -2.6 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -1.2 | -0.7 | -0.9 | -1.6 | -2.2 | -4.9 |
| Melphalan + Prednisone + Thalidomide (MPT) | -1.8 | -1.5 | -0.3 | -0.6 | -0.7 | -7.1 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Constipation Scale is scored between 0 and 100, with a high score indicating a higher level of constipation. Negative change from Baseline values indicate improvement in constipation and positive values indicate worsening of constipation. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 6.3 | 0.0 | -5.1 | -5.2 | -5.9 | -7.5 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 8.3 | 1.8 | -2.4 | -2.4 | -4.5 | -7.9 |
| Melphalan + Prednisone + Thalidomide (MPT) | 18.4 | 13.9 | 6.8 | 3.7 | 0.0 | -2.2 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Diarrhea Scale is scored between 0 and 100, with a high score indicating a higher level of diarrhea. Negative change from Baseline values indicate improvement in diarrhea and positive values indicate worsening of diarrhea. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 2.3 | 3.4 | 6.0 | 9.1 | 10.9 | 6.4 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 3.8 | 3.7 | 8.2 | 11.8 | 14.8 | 10.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | -0.6 | -2.4 | -2.2 | -2.5 | -1.7 | -0.5 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnoea Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 3.6 | -1.9 | -2.9 | -1.6 | 2.9 | 0.8 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 0.9 | -0.8 | -2.3 | -3.5 | -1.8 | -1.0 |
| Melphalan + Prednisone + Thalidomide (MPT) | 4.2 | 2.0 | 0.1 | -1.6 | 0.4 | 7.8 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 0.1 | 3.9 | 5.8 | 4.9 | 3.1 | 3.7 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 0.6 | 3.8 | 4.6 | 4.6 | 5.8 | 2.6 |
| Melphalan + Prednisone + Thalidomide (MPT) | 1.0 | 2.1 | 5.5 | 5.1 | 5.1 | -0.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 4.4 | -3.4 | -5.9 | -2.3 | 0.1 | -1.6 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 2.6 | -2.5 | -3.7 | -4.3 | -3.1 | 0.3 |
| Melphalan + Prednisone + Thalidomide (MPT) | 2.8 | -1.8 | -4.5 | -3.9 | -4.3 | 2.7 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Financial Difficulties Scale is scored between 0 and 100, with a high score indicating a higher level of financial difficulties. Negative change from Baseline values indicate improvement in financial difficulties and positive values indicate worsening of financial difficulties. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -0.3 | -0.4 | -0.3 | 1.6 | 1.8 | 0.5 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 2.1 | 1.9 | 1.4 | 0.4 | 2.0 | 1.9 |
| Melphalan + Prednisone + Thalidomide (MPT) | 0.5 | 1.9 | 0.7 | 1.1 | 0.4 | 5.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Insomnia Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 3.2 | -1.3 | -1.9 | 1.1 | 1.4 | -1.6 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 2.1 | 0.2 | -1.2 | -1.0 | -0.5 | -5.2 |
| Melphalan + Prednisone + Thalidomide (MPT) | -10.5 | -8.9 | -11.6 | -9.6 | -6.0 | -4.5 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Nausea/Vomiting Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -0.5 | -2.5 | -4.0 | -3.6 | -2.7 | -4.2 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 1.8 | -1.1 | -1.3 | -2.2 | -2.3 | 0.4 |
| Melphalan + Prednisone + Thalidomide (MPT) | 4.0 | -1.2 | -3.9 | -3.9 | -3.9 | 1.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Pain Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -4.4 | -13.1 | -16.1 | -14.7 | -12.4 | -7.9 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -5.4 | -13.4 | -14.4 | -14.0 | -14.4 | -8.0 |
| Melphalan + Prednisone + Thalidomide (MPT) | -7.8 | -12.1 | -13.4 | -14.3 | -14.7 | -6.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -1.4 | 4.7 | 7.6 | 7.4 | 6.8 | 3.0 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -1.7 | 3.4 | 4.7 | 5.0 | 6.9 | -0.1 |
| Melphalan + Prednisone + Thalidomide (MPT) | -0.9 | 2.2 | 5.3 | 6.9 | 8.3 | -0.1 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Role Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -4.6 | 6.3 | 8.6 | 9.4 | 9.1 | 3.8 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -2.7 | 2.4 | 6.3 | 7.8 | 8.0 | -0.3 |
| Melphalan + Prednisone + Thalidomide (MPT) | -2.4 | 4.1 | 8.2 | 11.8 | 14.5 | -1.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Social Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -2.2 | 2.0 | 5.2 | 3.8 | 3.2 | 2.7 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -4.3 | 0.7 | 4.0 | 2.9 | 4.2 | -1.2 |
| Melphalan + Prednisone + Thalidomide (MPT) | -1.4 | 2.4 | 3.4 | 5.8 | 6.0 | -3.5 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in QOL or functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Study discontinuation | |
| Lenalidomide and Dexamethasone Rd18 | -1.3 | 4.7 | 5.4 | 3.2 | 5.7 | 5.0 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 0.4 | 4.8 | 5.9 | 4.8 | 6.4 | -0.1 |
| Melphalan + Prednisone + Thalidomide (MPT) | 1.0 | 4.3 | 6.1 | 6.5 | 4.8 | 0.3 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the body image scale, a higher score indicates a better body image. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -1.5 | 0.8 | 1.5 | -0.4 | -0.3 | 1.8 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -4.5 | -1.7 | -1.4 | -1.4 | -2.3 | -5.6 |
| Melphalan + Prednisone + Thalidomide (MPT) | -1.6 | -3.0 | -2.8 | -2.6 | -1.1 | -5.6 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score indicates more severe disease symptom(s). (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -4.1 | -10.0 | -9.9 | -8.7 | -6.2 | -4.5 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -4.0 | -9.1 | -8.8 | -7.8 | -8.7 | -3.5 |
| Melphalan + Prednisone + Thalidomide (MPT) | -4.4 | -7.0 | -7.9 | -6.5 | -7.9 | -3.7 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the future perspective scale, a higher score indicates a better perspective of the future. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 3.9 | 9.2 | 12.3 | 12.1 | 11.7 | 8.8 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 4.7 | 8.5 | 9.8 | 10.8 | 12.7 | 5.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | 3.3 | 6.3 | 8.0 | 10.0 | 9.5 | 3.2 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score represents a more severe overall side effect of treatment. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 4.0 | 1.2 | -0.4 | 1.2 | 2.3 | -1.0 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 2.5 | 1.0 | 1.7 | 1.9 | 2.2 | 0.6 |
| Melphalan + Prednisone + Thalidomide (MPT) | 5.6 | 3.5 | 2.9 | 4.7 | 4.3 | 3.8 |
EQ-5D is a self-administered questionnaire that assesses health-related quality of life. The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 levels of response: No problem (1), some problems (2), and extreme problems (3). A unique EQ-5D health state is defined by combining one level from each of the five dimensions into a single utility index score. EQ-5D index values range from -0.59 to 1.00 where higher EQ-5D scores represent better health status. A positive change from baseline score indicates improvement in health status and better health state. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
| Melphalan + Prednisone + Thalidomide (MPT) | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
A TEAE is any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event. (NCT00689936)
Timeframe: From first dose of study drug through 28 days following the discontinuation visit from active treatment phase; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | Participants (Number) | ||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ≥ 1 adverse event (AE) | ≥ 1 grade (Gr) 3 or 4 AE | ≥ 1 grade (Gr) 5 AE | ≥ 1 serious adverse event (SAE) | ≥ 1 AE related to Lenalidomide/Dex/Mel/Pred/Thal | ≥ 1 AE related to Lenalidomide | ≥ 1 AE related to dexamethasone | ≥ 1 AE related to melphalan | ≥ 1 AE related to prednisone | ≥ 1 AE related to thalidomide | ≥1 AE related to Lenalidomide/Dex or Mel/Pred/Thal | ≥ 1 Gr 3 or 4 AE related to Len/Dex/Mel/Pred/Thal | ≥ 1 grade 3 or 4 AE related to Lenalidomide | ≥ 1 grade 3 or 4 AE related to dexamethasone | ≥ 1 grade 3 or 4 AE related to melphalan | ≥ 1 grade 3 or 4 AE related to prednisone | ≥ 1 grade 3 or 4 AE related to Thalidomide | ≥1Gr 3 or 4 AE related to Len/Dex or Mel/Pred/Thal | ≥ 1 Grade 5 AE related to Len/Dex/Mel/Pred/Thal | ≥ 1 Grade 5 AE related to Lenalidomide | ≥ 1 Grade 5 AE related to Dexamethasone | ≥ 1 Grade 5 AE related to melphalan | ≥ 1 Grade 5 AE related to prednisone | ≥ 1 Grade 5 AE related to Thalidomide | ≥1 Grade 5 AE related to Len/Dex or Mel/Pred/Thal | ≥1 SAE related to Len/Dex/Mel/Pred/Thal | ≥1 SAE related to Lenalidomide | ≥1 SAE related to dexamethasone | ≥1 SAE related to melphalan | ≥1 SAE related to prednisone | ≥1 SAE related to thalidomide | ≥1 SAE related to Len/Dex or Mel/Pred/Thal | ≥1AE leading to Len/Dex/Mel/Pred/Thal Withdrawal | ≥1 AE leading to Lenalidomide withdrawal | ≥1 AE leading to dexamethasone withdrawal | ≥1 AE leading to melphalan withdrawal | ≥1 AE leading to prednisone withdrawal | ≥1 AE leading to Thalidomide withdrawal | ≥1AE leading to Len/DexOR Mel/Pred/Thal Withdrawal | ≥1AE leading to Len/Dex/Mel/Pred/Thal reduction | ≥1 AE leading to Lenalidomide reduction | ≥1 AE leading to dexamethasone reduction | ≥1 AE leading to melphalan reduction | ≥1 AE leading to prednisone reduction | ≥1 AE leading to thalidomide reduction | ≥1AE leading to Len/Dex or Mel/Pred/Thal reduction | ≥1 AE leading to Rd or MPT interruption | ≥1 AE leading to Lenalidomide interruption | ≥1 AE leading to dexamethasone interruption | ≥1 AE leading to melphalan interruption | ≥1 AE leading to prednisone interruption | ≥1 AE leading to Thalidomide interruption | ≥1 AE leading to Len and Dex or MPT interruption | |
| Lenalidomide and Dexamethasone Rd18 | 536 | 433 | 36 | 308 | 501 | 481 | 410 | 0 | 0 | 0 | 269 | 326 | 290 | 177 | 0 | 0 | 0 | 104 | 11 | 9 | 7 | 0 | 0 | 0 | 5 | 158 | 130 | 97 | 0 | 0 | 0 | 64 | 109 | 93 | 104 | 0 | 0 | 0 | 84 | 214 | 155 | 118 | 0 | 0 | 0 | 20 | 321 | 301 | 280 | 0 | 0 | 0 | 241 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 529 | 453 | 50 | 359 | 506 | 482 | 429 | 0 | 0 | 0 | 269 | 373 | 342 | 229 | 0 | 0 | 0 | 131 | 17 | 12 | 16 | 0 | 0 | 0 | 11 | 195 | 165 | 130 | 0 | 0 | 0 | 95 | 157 | 109 | 152 | 0 | 0 | 0 | 96 | 279 | 203 | 170 | 0 | 0 | 0 | 30 | 368 | 353 | 319 | 0 | 0 | 0 | 290 |
| Melphalan + Prednisone + Thalidomide (MPT) | 539 | 480 | 38 | 270 | 527 | 0 | 0 | 441 | 326 | 493 | 145 | 423 | 0 | 0 | 307 | 118 | 316 | 49 | 10 | 0 | 0 | 6 | 5 | 5 | 2 | 142 | 0 | 0 | 75 | 62 | 94 | 27 | 153 | 0 | 0 | 83 | 78 | 146 | 71 | 348 | 0 | 0 | 199 | 47 | 254 | 2 | 419 | 0 | 0 | 328 | 324 | 388 | 249 |
Neutrophil counts was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | participants (Number) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal Baseline Grade to Normal Postbaseline Grade | Normal Baseline Grade to Grade 1 postbaseline | Normal Baseline Grade to Grade 2 postbaseline | Normal Baseline Grade to Grade 3 postbaseline | Normal Baseline Grade to Grade 4 postbaseline | Grade 1 Baseline to Normal postbaseline | Grade1 Baseline to Grade 1 postbaseline | Grade 1 Baseline to Grade 2 postbaseline | Grade 1 Baseline to Grade 3 postbaseline | Grade 1 Baseline to Grade 4 postbaseline | Grade 2 Baseline to normal postbaseline | Grade 2 Baseline to Grade 1 postbaseline | Grade 2 Baseline to Grade 2 postbaseline | Grade 2 Baseline to Grade 3 postbaseline | Grade 2 Baseline to Grade 4 postbaseline | Grade 3 Baseline to Normal postbaseline | Grade 3 Baseline to Grade 1 postbaseline | Grade 3 Baseline to Grade 2 postbaseline | Grade 3 Baseline to Grade 3 postbaseline | Grade3 Baseline to Grade 4 postbaseline | Grade 4 Baseline to Normal postbaseline Grade | Grade 4 Baseline to Grade 1 postbaseline Grade | Grade 4 Baseline to Grade 2 postbaseline | Grade 4 Baseline Grade to Grade 3 postbaseline | Grade 4 Baseline to Grade 4 postbaseline | |
| Lenalidomide and Dexamethasone Rd18 | 133 | 85 | 109 | 71 | 30 | 6 | 11 | 15 | 30 | 4 | 0 | 1 | 11 | 18 | 5 | 0 | 0 | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 103 | 96 | 121 | 70 | 21 | 7 | 8 | 17 | 25 | 9 | 1 | 1 | 14 | 18 | 9 | 0 | 0 | 2 | 2 | 0 | 0 | 1 | 0 | 0 | 0 |
| Melphalan + Prednisone + Thalidomide (MPT) | 37 | 79 | 128 | 141 | 45 | 2 | 2 | 11 | 20 | 21 | 0 | 1 | 7 | 21 | 10 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Renal function was assessed for participants from baseline to the most extreme value in creatinine clearance calculated using the Cockcroft-Gault estimation. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CrCl< 30 mL/min to CrCl< 30 mL/min | CrCl < 30 mL/min to CrCl ≥ 30 but < 50 mL/min | CrCl < 30 mL/min to CrCl ≥ 50 but < 80 mL/min | CrCl< 30 mL/min to ≥ 80 mL/min | CrCl≥ 30 but < 50 mL/min to < 30 mL/min | CrCl ≥ 30 but < 50 mL/min to CrCl ≥ 30 but < 50 mL | CrCl ≥ 30 but < 50 mL/min to CrCl ≥ 50 but < 80 mL | CrCl ≥ 30 but < 50 mL/min to ≥ 80 mL/min | CrCl ≥ 50 but < 80 mL to CrCl< 30 mL/min | CrCl ≥ 50 but < 80 mL to CrCl ≥ 30 but < 50 mL/min | CrCl ≥ 50 but < 80 mL to CrCl ≥ 50 but < 80 mL/min | CrCl ≥ 50 but < 80 mL to ≥ 80 mL/min | CrCl ≥ 80 mL/min to CrCl< 30 mL/min | CrCl ≥ 80 mL/min to CrCl ≥ 30 but < 50 mL/min | CrCl ≥ 80 mL/min to CrCl ≥ 50 but < 80 mL/min | CrCl ≥ 80 mL/min to CrCl ≥ 80 mL/min | |
| Lenalidomide and Dexamethasone Rd18 | 17 | 14 | 8 | 2 | 2 | 41 | 55 | 12 | 0 | 1 | 130 | 99 | 1 | 0 | 10 | 114 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 15 | 18 | 7 | 2 | 1 | 37 | 67 | 9 | 0 | 4 | 112 | 107 | 0 | 0 | 6 | 109 |
| Melphalan + Prednisone + Thalidomide (MPT) | 19 | 19 | 5 | 0 | 0 | 41 | 65 | 2 | 0 | 4 | 102 | 97 | 0 | 0 | 9 | 121 |
Hemoglobin was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | participants (Number) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal Baseline Grade to Normal Postbaseline Grade | Normal Baseline Grade to Grade 1 postbaseline | Normal Baseline Grade to Grade 2 postbaseline | Normal Baseline Grade to Grade 3 postbaseline | Normal Baseline Grade to Grade 4 postbaseline | Grade 1 Baseline to Normal postbaseline | Grade 1 Baseline to Grade 1 postbaseline | Grade1 Baseline to Grade 2 postbaseline | Grade 1 Baseline to Grade 3 postbaseline | Grade 1 Baseline to Grade 4 postbaseline | Grade 2 Baseline to normal postbaseline | Grade 2 Baseline to Grade 1 postbaseline | Grade 2 Baseline to Grade 2 postbaseline | Grade 2 Baseline to Grade 3 postbaseline | Grade 2 Baseline to Grade 4 postbaseline | Grade 3 Baseline to Normal postbaseline | Grade 3 Baseline to Grade 1 postbaseline | Grade 3 Baseline to Grade 2 postbaseline | Grade 3 Baseline to Grade 3 postbaseline | Grade 3 Baseline to Grade 4 postbaseline | Grade 4 Baseline to Normal postbaseline | Grade 4 Baseline to Grade 1 postbaseline | Grade 4 Baseline to Grade 2 postbaseline | Grade 4 Baseline to Grade 3 postbaseline | Grade 4 Baseline to Grade 4 postbaseline | |
| Lenalidomide and Dexamethasone Rd18 | 10 | 30 | 8 | 1 | 0 | 0 | 126 | 123 | 17 | 5 | 0 | 12 | 135 | 41 | 9 | 0 | 1 | 4 | 8 | 3 | 0 | 0 | 0 | 1 | 1 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 6 | 39 | 8 | 0 | 0 | 0 | 106 | 128 | 25 | 2 | 0 | 8 | 125 | 48 | 4 | 0 | 0 | 12 | 10 | 5 | 0 | 0 | 0 | 0 | 1 |
| Melphalan + Prednisone + Thalidomide (MPT) | 9 | 25 | 4 | 1 | 0 | 0 | 110 | 123 | 20 | 4 | 0 | 14 | 133 | 47 | 11 | 0 | 0 | 10 | 10 | 2 | 0 | 0 | 1 | 0 | 2 |
Improvement in platelets was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal Baseline Grade to Normal Postbaseline Grade | Normal Baseline Grade to Grade 1 postbaseline | Normal Baseline Grade to Grade 2 postbaseline | Normal Baseline Grade to Grade 3 postbaseline | Normal Baseline Grade to Grade 4 postbaseline | Grade1 Baseline to Normal postbaseline Grade | Grade 1 Baseline to Grade 1 postbaseline | Grade 1 Baseline to Grade 2 postbaseline | Grade 1 Baseline to Grade 3 postbaseline | Grade 1 Baseline to Grade 4 postbaseline | Grade 2 Baseline to normal postbaseline Grade | Grade 2 Baseline to Grade 1 postbaseline | Grade 2 Baseline to Grade 2 postbaseline | Grade 2 Baseline to Grade 3 postbaseline | Grade 2 Baseline to Grade 4 postbaseline | Grade 3 Baseline to Normal postbaseline Grade | Grade 3 Baseline to Grade 1 postbaseline | Grade 3 Baseline to Grade 2 postbaseline | Grade 3 Baseline to Grade 3 postbaseline | Grade 3 Baseline to Grade 4 postbaseline | |
| Lenalidomide and Dexamethasone Rd18 | 197 | 211 | 30 | 12 | 5 | 3 | 38 | 19 | 12 | 1 | 0 | 1 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 1 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 197 | 216 | 24 | 15 | 4 | 1 | 34 | 15 | 10 | 2 | 0 | 0 | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 2 |
| Melphalan + Prednisone + Thalidomide (MPT) | 165 | 208 | 27 | 31 | 11 | 6 | 51 | 7 | 10 | 1 | 0 | 2 | 1 | 2 | 2 | 0 | 0 | 1 | 1 | 0 |
Disease control rate was defined as the percentage of participants who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), minimal response (MR), or stable disease (SD) lasting ≥ 8 weeks according to International Myeloma Working Group - Uniform Response Criteria (IMWG-URC) (MR was determined using European Group for Blood and Marrow Transplantation criteria). (NCT01080391)
Timeframe: From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Dexamethasone (Rd) | 87.1 |
| Carfilzomib, Lenalidomide, and Dexamethasone (CRd) | 92.7 |
Duration of disease control (DDC) was calculated for participants who achieved disease control. DDC was defined as the time in months from randomization to the earlier of documented progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for PFS. (NCT01080391)
Timeframe: From randomization through the data cutoff date of 16 June 2014. Longest follow-up time was approximately 46 months.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Dexamethasone (Rd) | 18.9 |
| Carfilzomib, Lenalidomide, and Dexamethasone (CRd) | 28.7 |
Duration of response (DOR) was calculated for participants who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). Duration of response was defined as the time in months from the initial start of response (PR or better) to the earlier of documented progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for PFS. (NCT01080391)
Timeframe: From randomization through the data cutoff date of 16 June 2014. Longest follow-up time was approximately 42 months.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Dexamethasone (Rd) | 21.2 |
| Carfilzomib, Lenalidomide, and Dexamethasone (CRd) | 28.6 |
Overall response rate is defined as the percentage of participants who achieved either a confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) as their best response based on the Independent Review Committee (IRC) assessed response outcome. Response was determined using the International Myeloma Working Group - Uniform Response Criteria (IMWG-URC). (NCT01080391)
Timeframe: From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Dexamethasone (Rd) | 66.7 |
| Carfilzomib, Lenalidomide, and Dexamethasone (CRd) | 87.1 |
Overall survival (OS) was defined as the duration from randomization to death due to any cause. Participants who were still alive were censored at the date when the participant was last known to be alive or the data cutoff date, whichever occurred earlier. (NCT01080391)
Timeframe: From randomization through the data cutoff date of 28 April 2017 for the final analysis of overall survival; median follow up time was 67.1 months in each treatment group.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Dexamethasone (Rd) | 40.4 |
| Carfilzomib, Lenalidomide, and Dexamethasone (CRd) | 48.3 |
Kaplan-Meier estimate of median time from randomization to progressive disease (PD) or all-cause death. PD was assessed using International Myeloma Working Group-Uniform Response Criteria (IMWG-URC). One or more conditions were required to meet PD: 2 consecutive rising serum or urine M-protein from central lab; documented new bone lesion(s) or soft tissue plasmacytoma(s) or increased size of existing bone lesion(s) or plasmacytoma(s); or confirmed hypercalcemia due solely to plasma cell proliferative disorder (local lab greater than 11.5 mg/dL on 2 separate occasions). Censoring conditions (censoring dates) were: no post-baseline disease assessment (DA) (randomization date); started non-protocol systemic anticancer treatment before PD or death (last DA date before such treatment); died or had PD after more than 1 missed DA (last DA date without PD before the first missed visit); or were alive and without documentation of PD, including lost to follow-up without PD (last DA date). (NCT01080391)
Timeframe: From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Dexamethasone (Rd) | 17.6 |
| Carfilzomib, Lenalidomide, and Dexamethasone (CRd) | 26.3 |
Health-related quality of life was assessed with the use of the European Organization for Research and Treatment of Cancer Quality of Life Core Module (QLQ-C30) questionnaire, a validated instrument in multiple myeloma patients. Scores range from 0 to 100, with higher scores indicating better health related quality of life. (NCT01080391)
Timeframe: Cycle 1 Day 1 (Baseline), Day 1 of Cycles 3, 6, 12, 18
| Intervention | scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 1 Day 1 (Baseline) | Cycle 3, Day 1 | Cycle 6, Day 1 | Cycle 12, Day 1 | Cycle 18, Day 1 | |
| Carfilzomib, Lenalidomide, and Dexamethasone (CRd) | 58.3 | 59.9 | 62.5 | 62.7 | 64.3 |
| Lenalidomide and Dexamethasone (Rd) | 58.1 | 56.8 | 58.9 | 57.3 | 59.9 |
Establish the safety and tolerability of Pomalidomide and Dexamethasone in combination with MK-3475 (NCT02289222)
Timeframe: 24 month
| Intervention | Participants (Count of Participants) |
|---|---|
| Pomalidomide, Dexamethasone & MK-3475 | 48 |
PFS will be measured in all participants. Survival and PFS functions were estimated using the Kaplan-Meier method. The Cox regression model was used to assess the following plausible risk factors for OS and PFS: age, isotype, number of cycles of therapy, and cytogenetic profile. (NCT02289222)
Timeframe: PFS assessments will take place after starting study therapy with MD-3475 and will continue until the start of a new anti-neoplastic therapy, disease progression, death, or the end of study up to an average of 24 months.
| Intervention | Months (Median) |
|---|---|
| Pomalidomide, Dexamethasone & MK-3475 | 17.4 |
The identification of a biomarker for response by evaluating PD-1/PDL-1 expression in patients' bone marrow aspirate samples will be analyzed in order to help select patients for future anti-PD-1 therapy. The main exploratory biomarker analysis was to examine potential correlation between expression of PD-1 on T cells and PD-L1 on myeloma cells with clinical outcome using the following parameters: response rate focusing on responses ≥ very good partial response (VGPR) and PFS. SAS software (v.9.4; SAS Institute, Inc, Cary, NC) was used for statistical analyses. (NCT02289222)
Timeframe: Tissue sample collection will take place before starting study therapy with MK-3475 at baseline and again at time of relapse as defined by the International Myeloma Working Group Response Criteria (Average of up to 24months)
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Negative | Weak Positive | Positive | |
| Pomalidomide, Dexamethasone & MK-3475 | 10 | 6 | 13 |
Duration of response, calculated for responders only, was defined as time from the initial documented response (SCR, CR, VGPR or PR) to the first confirmed disease progression, or death if no disease progression was recorded. Participants without a documented progression were censored at the time of their last tumor assessment. (NCT01712789)
Timeframe: From enrollment to the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months
| Intervention | Months (Median) |
|---|---|
| Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) | 7.9 |
Overall survival was calculated as the time from study enrollment, defined as the IVRS enrollment date, until death due to any cause. Participants who did not have death data at the time of study end/analysis were censored at the time they were last known to be alive. (NCT01712789)
Timeframe: From enrollment to the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months
| Intervention | Months (Median) |
|---|---|
| Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) | 11.9 |
Progression free survival was calculated as the time from study enrollment, defined as the IVRS enrollment date, until either PD or death (any cause). Participants without an event (either a documented PD or death) at the time of study end were censored at the time of their last documented disease assessment or at the IVRS enrollment date if no disease assessment was conducted. (NCT01712789)
Timeframe: From enrollment to the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months
| Intervention | Months (Median) |
|---|---|
| Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) | 4.6 |
Time to progression was calculated as the time from study enrollment until first recorded disease progression as determined by the site investigator based on the IMWG criteria, or until death due to progression. Participants not experiencing a documented progression were censored at the time of their last tumor assessment (or at the time of trial enrollment if no assessment was conducted). (NCT01712789)
Timeframe: From enrollment to the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months
| Intervention | Months (Median) |
|---|---|
| Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) | 4.8 |
Overall response rate (ORR) was defined as the percentage of participants with a stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) according to the International Myeloma Working Group uniform response criteria (IMWG URC) assessed by the Investigator. Responses must have been confirmed at at least 2 consecutive assessments before the institution of any new therapy with no known evidence of progressive or new bone lesions (NCT01712789)
Timeframe: Response was assessed at each treatment cycle and at treatment discontinuation; median duration of treatment with pomalidomide and LD-dex was 21.4 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) | 33.4 |
Pharmacokinetic (PK) parameters are derived from pomalidomide concentration versus time data. (NCT01712789)
Timeframe: Cycles 1, 2, 3, 4, 5, 6
| Intervention | Liters/hour (Median) |
|---|---|
| Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) | 6.02 |
Pharmacokinetic (PK) parameters are derived from Pomalidomide concentration versus time data. (NCT01712789)
Timeframe: Cycles 1, 2, 3, 4, 5, 6
| Intervention | Liters (Median) |
|---|---|
| Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) | 75.10 |
Time to response was defined as the time from treatment enrollment to the first documentation of response (sCR, CR, VGPR or PR) based on IMWG criteria. (NCT01712789)
Timeframe: Response was assessed at each treatment cycle and at treatment discontinuation; median duration of treatment with pomalidomide and LD-dex was 21.4 weeks
| Intervention | Weeks (Median) |
|---|---|
| Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) | 8.1 |
"An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, regardless of etiology. Any worsening (i.e., any significant adverse change in the frequency or intensity of a pre- existing condition) was considered an AE. The severity of AEs were graded based on the symptoms according to version 4.0 of the National Cancer Institute Common Terminology Criteria for Adverse Events. Second primary malignancies were monitored as events of interest and considered as part of the assessment of AEs.~A SAE = AE occurring at any dose that:~Results in death;~Is life-threatening~Requires inpatient hospitalization or prolongation of existing hospitalization~Results in persistent or significant disability/incapacity~Is a congenital anomaly/birth defect" (NCT01712789)
Timeframe: From the first dose of study treatment up to 28 days following the last dose of study treatment. The median duration of treatment with pomalidomide and LD-dex was 21.4 weeks.
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ≥ TEAE | ≥ 1 TEAE Related to Pomalidomide (POM) | ≥ 1 TEAE Related to LD-Dex | ≥ 1 TEAE Related to Either POM or LD-Dex | ≥ 1 Grade (Gr) 3 or 4 TEAE | ≥ 1 Gr 3 or 4 TEAE Related to (R/T) POM | ≥ 1 Gr 3 or 4 TEAE R/T LD-Dex | ≥ 1 Gr 3 or 4 TEAE R/T Either POM or LD-Dex | ≥ 1 Grade 5 TEAE | ≥ 1 Grade 5 TEAE R/T POM | ≥ 1 Grade 5 TEAE R/T LD-Dex | ≥ 1 Grade 5 TEAE R/T either POM or LD-Dex | ≥ 1 Serious TEAE | ≥ 1 Serious TEAE R/T POM | ≥ 1 Serious TEAE R/T LD-Dex | ≥ 1 Serious TEAE R/T Either POM or LD-Dex | ≥ 1 Serious TEAE Leading to (L/T)Stopping of POM | ≥ 1 Serious TEAE L/T Stopping of LD-Dex | ≥1 Serious TEAE L/T Stopping either POM or LD-Dex | ≥ 1 TEAE L/T to Stopping of POM | ≥ 1 TEAE L/T to Stopping of LD-DEX | ≥ 1 TEAE L/T to Stopping of Either POM or LD-DEX | ≥1 Study Drug Related TEAE (L/T) Stopping POM | ≥1 Study Drug Related TEAE L/T Stopping LD-Dex | ≥1 Drug Related TEAE L/T Stopping LD-Dex or POM | ≥ 1 TEAE L/T to Reduction (R/D) of POM | ≥ 1 TEAE L/T to R/D of LD-DEX | ≥ 1 TEAE L/T to R/D of Either POM or LD-DEX | ≥ 1 Study Drug Related TEAE L/T to R/D of POM | ≥ 1 Study Drug Related TEAE L/T to R/D of LD-DEX | ≥1 StudyDrug Related TEAE L/T to R/D POM or LD-DEX | ≥ 1 TEAE L/T to Interruption (I/R) of POM | ≥ 1 TEAE L/T to I/R of LD-DEX | ≥ 1 TEAE L/T to I/R of either POM or LD-DEX | ≥ 1 Study Drug Related TEAE L/T to I/R of POM | ≥ 1 Study Drug Related TEAE L/T to I/R of LD-DEX | ≥1 StudyDrug Related TEAE L/T to I/R POM or LD-DEX | |
| Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) | 673 | 527 | 448 | 575 | 606 | 417 | 226 | 448 | 127 | 14 | 16 | 18 | 448 | 187 | 146 | 215 | 36 | 34 | 37 | 54 | 61 | 63 | 30 | 19 | 38 | 164 | 150 | 244 | 142 | 135 | 224 | 455 | 434 | 470 | 294 | 185 | 333 |
DOR was measured as the time in months from the date of first documentation of a confirmed response of PR or better (CR [including sCR] + PR+ VGPR) to the date of the first documented disease progression (PD) among participants who responded to the treatment. Response was assessed by the investigator using International Myeloma Working Group (IMWG) Criteria. (NCT01564537)
Timeframe: Day 1 of each cycle (every 4 weeks) until disease progression up to approximately 38 months
| Intervention | months (Median) |
|---|---|
| Ixazomib+ Lenalidomide + Dexamethasone | 26.0 |
| Placebo + Lenalidomide + Dexamethasone | 21.7 |
Overall survival (OS) is defined as the time from the date of randomization to the date of death. High-risk participants are defined as participants carrying cytogenic abnormalities: del(17), translocation t(4;14), or t(14;16) as reported by the central laboratory combined with those cases that lacked a central laboratory result but with known del (17), t(4;14), or t(14;16) by local laboratory. Cytogenetic abnormalities of del(13) and +1q are not included in the analysis. Participants without documentation of death at the time of the analysis were censored at the date when they were last known to be alive. Data is only reported for high-risk participants. (NCT01564537)
Timeframe: From the time of screening until disease progression and thereafter every 12 weeks until death or study termination (up to approximately 97 months)
| Intervention | months (Median) |
|---|---|
| Ixazomib+ Lenalidomide + Dexamethasone | 46.9 |
| Placebo + Lenalidomide + Dexamethasone | 30.9 |
ORR was defined as the percentage of participants with Complete Response (CR) including stringent complete response (sCR), very good partial response (VGPR) and Partial Response (PR) assessed by the IRC using IMWG criteria. Percentages are rounded off to single decimal. (NCT01564537)
Timeframe: Day 1 of each cycle (every 4 weeks) until disease progression up to approximately 27 months(approximate median follow-up 15 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Ixazomib+ Lenalidomide + Dexamethasone | 78.3 |
| Placebo + Lenalidomide + Dexamethasone | 71.5 |
Data is reported for percentage of participants defined by polymorphism defined by polymorphisms in proteasome genes, such as polymorphism P11A in PSMB1 gene. Percentages are rounded off to single decimal. (NCT01564537)
Timeframe: Day 1 of each cycle (every 4 weeks) until disease progression up to approximately 27 months (approximate median follow-up 15 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Ixazomib+ Lenalidomide + Dexamethasone | 80.3 |
| Placebo + Lenalidomide + Dexamethasone | 75.7 |
Overall survival is defined as the time from the date of randomization to the date of death. Participants without documentation of death at the time of the analysis were censored at the date when they were last known to be alive. (NCT01564537)
Timeframe: From date of randomization until death (up to approximately 97 months)
| Intervention | months (Median) |
|---|---|
| Ixazomib+ Lenalidomide + Dexamethasone | 53.6 |
| Placebo + Lenalidomide + Dexamethasone | 51.6 |
Overall survival is defined as the time from the date of randomization to the date of death. The high-risk participants whose myeloma carried del(17) subgroup was defined as the cases reported as positive for del(17) by the central laboratory combined with those cases that lacked a central laboratory result but with known del (17) by local laboratory. Participants without documentation of death at the time of the analysis were censored at the date when they were last known to be alive. Data is only reported high-risk participants with Del(17). (NCT01564537)
Timeframe: From the time of screening until disease progression and thereafter every 12 weeks until death or study termination (up to approximately 97 months)
| Intervention | months (Median) |
|---|---|
| Ixazomib+ Lenalidomide + Dexamethasone | 42.2 |
| Placebo + Lenalidomide + Dexamethasone | 29.4 |
Response was assessed by the IRC using International Myeloma Working Group (IMWG) Criteria. CR is defined as negative immunofixation on the serum and urine and; disappearance of any soft tissue plasmacytomas and; < 5% plasma cells in bone marrow. VGPR is defined as Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level < 100 mg per 24 hours. Percentages are rounded off to single decimal. (NCT01564537)
Timeframe: Day 1 of each cycle (every 4 weeks) until disease progression up to approximately 27 months (approximate median follow-up 15 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Ixazomib + Lenalidomide + Dexamethasone | 48.1 |
| Placebo + Lenalidomide + Dexamethasone | 39.0 |
Progression Free Survival (PFS) is defined as the time from the date of randomization to the date of first documentation of disease progression or death due to any cause, whichever occurs first. Response was assessed by independent review committee (IRC) using IMWG response criteria. High-risk participants are defined as participants carrying cytogenic abnormalities: del(17), translocation t(4;14), or t(14;16) as reported by the central laboratory combined with those cases that lacked a central laboratory result but with known del (17), t(4;14), or t(14;16) by local laboratory. Cytogenetic abnormalities of del(13) and +1q are not included in the analysis. (NCT01564537)
Timeframe: From date of randomization until disease progression or death up to approximately 38 months (approximate median follow-up 15 months)
| Intervention | months (Median) |
|---|---|
| Ixazomib+ Lenalidomide + Dexamethasone | 18.7 |
| Placebo + Lenalidomide + Dexamethasone | 9.3 |
Progression Free Survival (PFS) is defined as the time from the date of randomization to the date of first documentation of disease progression (PD) or death due to any cause, whichever occurs first. Response including PD was assessed by independent review committee (IRC) using the International Myeloma Working Group (IMWG) response criteria. PD requires 1 of the following: Increase of ≥ 25% from nadir in: Serum M-component (absolute increase ≥ 0.5 g/dl); Urine M-component (absolute increase ≥ 200 mg/24 hours); In patients without measurable serum and urine M-protein levels the difference between involved and uninvolved free light chain (FLC) levels (absolute increase > 10 mg/dl); Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium > 11.5 mg/dl) attributed solely to plasma cell proliferative disease. Status evaluated every 4 weeks until disease progression (PD) was confirmed. (NCT01564537)
Timeframe: From date of randomization until disease progression or death up to approximately 27 months (approximate median follow-up 15 months)
| Intervention | months (Median) |
|---|---|
| Ixazomib+ Lenalidomide + Dexamethasone | 20.6 |
| Placebo + Lenalidomide + Dexamethasone | 14.7 |
TTP was measured as the time in months from the first dose of study treatment to the date of the first documented progressive disease (PD) as assessed by the IRC using IMWG criteria. (NCT01564537)
Timeframe: Day 1 of each cycle (every 4 weeks) until disease progression up to approximately 27 months (approximate median follow-up 15 months)
| Intervention | months (Median) |
|---|---|
| Ixazomib+ Lenalidomide + Dexamethasone | 22.4 |
| Placebo + Lenalidomide + Dexamethasone | 17.6 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer participants. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact).The EORTC-QLQ-C30 Global Health Status/QOL Scale is scored between 0 and 100, where higher scores indicate better Global Health Status/QOL. Negative changes from baseline indicate deterioration in QOL or functioning and positive changes indicate improvement. Scores are linearly transformed to a 0-100 scale. High scores for the global and functional domains indicate higher quality of life or functioning. Higher scores on the symptom scales represent higher levels of symptomatology or problems. (NCT01564537)
Timeframe: Baseline, EOT and follow-up (up to approximately 97 months)
| Intervention | score on a scale (Mean) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Health Index: Baseline | Global Health Index: End of Treatment | Physical Functioning: Baseline | Physical Functioning: EOT | Role Functioning: Baseline | Role Functioning: EOT | Emotional Functioning: Baseline | Emotional Functioning: EOT | Cognitive Functioning: Baseline | Cognitive Functioning: EOT | Social Functioning: Baseline | Social Functioning: EOT | Fatigue: Baseline | Fatigue: EOT | Pain: Baseline | Pain: EOT | Nausea and Vomiting: Baseline | Nausea and Vomiting: EOT | Dyspnea: Baseline | Dyspnea: EOT | Insomnia: Baseline | Insomnia: EOT | Appetite Loss: Baseline | Appetite Loss: EOT | Constipation: Baseline | Constipation: EOT | Diarrhea: Baseline | Diarrhea: EOT | Financial Difficulties: Baseline | Financial Difficulties: EOT | |
| Ixazomib+ Lenalidomide + Dexamethasone | 58.4 | -6.0 | 70.0 | -4.7 | 68.4 | -8.6 | 75.1 | -2.1 | 81.9 | -7.6 | 77.9 | -6.9 | 38.4 | 6.0 | 38.0 | 2.7 | 5.0 | 3.4 | 21.2 | 5.7 | 27.4 | 0.9 | 16.9 | 4.7 | 12.2 | -1.3 | 6.3 | 17.2 | 16.7 | 0.5 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer participants. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact).The EORTC-QLQ-C30 Global Health Status/QOL Scale is scored between 0 and 100, where higher scores indicate better Global Health Status/QOL. Negative changes from baseline indicate deterioration in QOL or functioning and positive changes indicate improvement. Scores are linearly transformed to a 0-100 scale. High scores for the global and functional domains indicate higher quality of life or functioning. Higher scores on the symptom scales represent higher levels of symptomatology or problems. (NCT01564537)
Timeframe: Baseline, EOT and follow-up (up to approximately 97 months)
| Intervention | score on a scale (Mean) | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Health Index: Baseline | Global Health Index: End of Treatment | Global Health Index: Last Follow-up | Physical Functioning: Baseline | Physical Functioning: EOT | Physical Functioning: Last Follow-up | Role Functioning: Baseline | Role Functioning: EOT | Role Functioning: Last Follow-up | Emotional Functioning: Baseline | Emotional Functioning: EOT | Emotional Functioning: Last Follow-up | Cognitive Functioning: Baseline | Cognitive Functioning: EOT | Cognitive Functioning: Last Follow-up | Social Functioning: Baseline | Social Functioning: EOT | Social Functioning: Last Follow-up | Fatigue: Baseline | Fatigue: EOT | Fatigue: Last Follow-up | Pain: Baseline | Pain: EOT | Pain: Last Follow-up | Nausea and Vomiting: Baseline | Nausea and Vomiting: EOT | Nausea and Vomiting: Last Follow-up | Dyspnea: Baseline | Dyspnea: EOT | Dyspnea: Last Follow-up | Insomnia: Baseline | Insomnia: EOT | Insomnia: Last Follow-up | Appetite Loss: Baseline | Appetite Loss: EOT | Appetite Loss: Last Follow-up | Constipation: Baseline | Constipation: EOT | Constipation: Last Follow-up | Diarrhea: Baseline | Diarrhea: EOT | Diarrhea: Last Follow-up | Financial Difficulties: Baseline | Financial Difficulties: EOT | Financial Difficulties: Last Follow-up | |
| Placebo + Lenalidomide + Dexamethasone | 56.4 | -6.0 | 16.7 | 67.3 | -6.2 | 0.0 | 64.4 | -8.6 | -16.7 | 75.3 | -6.1 | -25.0 | 81.6 | -5.8 | -50.0 | 75.3 | -7.9 | 0.0 | 39.5 | 6.7 | 22.2 | 38.5 | 3.8 | 0.0 | 6.0 | 0.6 | 33.3 | 23.7 | 2.3 | 0.0 | 30.5 | -0.5 | 33.3 | 15.3 | 6.5 | 0.0 | 13.5 | 2.2 | 33.3 | 8.1 | 10.8 | 0.0 | 18.6 | 1.3 | -33.3 |
The EORTC-QLQ-MY-20 is a patient-completed, 20-question quality of life questionnaire that has 4 independent subscales, 2 functional subscales (body image, future perspective), and 2 symptoms scales (disease symptoms and side-effects of treatment). The participant answers questions about their health during the past week using a 4-point scale where 1=Not at All to 4=Very Much. A negative change from Baseline indicates improvement. Scores are linearly transformed to a 0-100 scale. Higher scores on the symptom scales (e.g. Disease Symptoms, Side Effects of Treatment) represent higher levels of symptomatology or problems. High scores for Body Image and Future Perspective represent better quality of life or functioning. (NCT01564537)
Timeframe: Baseline, EOT and follow-up (up to approximately 97 months)
| Intervention | score on a scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Disease Symptoms: Baseline | Disease Symptoms: EOT | Side Effects of Treatment: Baseline | Side Effects of Treatment: EOT | Side Effects of Treatment: Last Follow-up | Body Image: Baseline | Body Image: EOT | Body Image: Last Follow-up | Future Perspective: Baseline | Future Perspective: EOT | Future Perspective: Last Follow-up | |
| Placebo + Lenalidomide + Dexamethasone | 30.41 | -2.58 | 17.97 | 4.43 | 37.04 | 79.48 | -5.38 | -33.3 | 60.26 | -2.75 | -11.11 |
The EORTC-QLQ-MY-20 is a patient-completed, 20-question quality of life questionnaire that has 4 independent subscales, 2 functional subscales (body image, future perspective), and 2 symptoms scales (disease symptoms and side-effects of treatment). The participant answers questions about their health during the past week using a 4-point scale where 1=Not at All to 4=Very Much. A negative change from Baseline indicates improvement. Scores are linearly transformed to a 0-100 scale. Higher scores on the symptom scales (e.g. Disease Symptoms, Side Effects of Treatment) represent higher levels of symptomatology or problems. High scores for Body Image and Future Perspective represent better quality of life or functioning. (NCT01564537)
Timeframe: Baseline, EOT and follow-up (up to approximately 97 months)
| Intervention | score on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Disease Symptoms: Baseline | Disease Symptoms: EOT | Disease Symptoms: Last Follow-up | Side Effects of Treatment: Baseline | Side Effects of Treatment: EOT | Body Image: Baseline | Body Image: EOT | Future Perspective: Baseline | Future Perspective: EOT | |
| Ixazomib+ Lenalidomide + Dexamethasone | 29.71 | -2.35 | 1.11 | 17.23 | 4.52 | 78.00 | -0.27 | 56.99 | 2.76 |
Eastern Cooperative Oncology Group (ECOG) performance score, laboratory values, vital sign measurements and reported adverse events (AEs) were collected and assessed to evaluate the safety of therapy throughout the study. An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly; or a medically important event. (NCT01564537)
Timeframe: From the date of signing of the informed consent form through 30 days after the last dose of study drug up to approximately 115 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| TEAEs | SAEs | |
| Ixazomib+ Lenalidomide + Dexamethasone | 359 | 205 |
| Placebo + Lenalidomide + Dexamethasone | 357 | 201 |
"Pain response was defined as 30% reduction from Baseline in Brief Pain Inventory-Short Form (BPI-SF) worst pain score over the last 24 hours without an increase in analgesic (oral morphine equivalents) use at 2 consecutive evaluations. The BPI-SF contains 15 items designed to capture the pain severity (worst, least, average, and now [current pain]), pain location, medication to relieve the pain, and the interference of pain with various daily activities including general activity, mood, walking activity, normal work, relations with other people, sleep, and enjoyment of life. The pain severity items are rated on a 0 to 10 scale where: 0=no pain and 10=pain as bad as you can imagine and averaged for a total score of 0 (best) to 10 (Worst)." (NCT01564537)
Timeframe: Baseline and end of treatment (EOT) (up to approximately 38 months)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Baseline | EOT | |
| Ixazomib+ Lenalidomide + Dexamethasone | 345 | 145 |
| Placebo + Lenalidomide + Dexamethasone | 351 | 153 |
(NCT01564537)
Timeframe: Pre-dose and post-dose at multiple timepoints up to Cycle 10 Day 1 (each cycle length = 28 days)
| Intervention | μg/mL (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1, 1 Hour Post-Dose | Cycle 1 Day 1, 4 Hours Post-Dose | Cycle 1 Day 14, Pre-Dose | Cycle 2 Day 1, Pre-Dose | Cycle 2 Day 14, Pre-Dose | Cycle 3 Day 1, Pre-Dose | Cycle 4 Day 1, Pre-Dose | Cycle 5 Day 1, Pre-Dose | Cycle 6 Day 1, Pre-Dose | Cycle 7 Day 1, Pre-Dose | Cycle 8 Day 1, Pre-Dose | Cycle 9 Day 1, Pre-Dose | Cycle 10 Day 1, Pre-Dose | |
| Placebo + Lenalidomide + Dexamethasone | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
(NCT01564537)
Timeframe: Pre-dose and post-dose at multiple timepoints up to Cycle 10 Day 1 (each cycle length = 28 days)
| Intervention | μg/mL (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | Cycle 1 Day 1, 1 Hour Post-Dose | Cycle 1 Day 1, 4 Hours Post-Dose | Cycle 1 Day 14, Pre-Dose | Cycle 2 Day 1, Pre-Dose | Cycle 2 Day 14, Pre-Dose | Cycle 3 Day 1, Pre-Dose | Cycle 4 Day 1, Pre-Dose | Cycle 5 Day 1, Pre-Dose | Cycle 6 Day 1, Pre-Dose | Cycle 7 Day 1, Pre-Dose | Cycle 8 Day 1, Pre-Dose | Cycle 9 Day 1, Pre-Dose | Cycle 10 Day 1, Pre-Dose | |
| Ixazomib+ Lenalidomide + Dexamethasone | 4.79 | 36.3 | 15.6 | 6.83 | 2.4 | 7.12 | 2.48 | 2.41 | 2.42 | 2.57 | 2.71 | 2.37 | 2.51 | 2.82 |
Patients who develop progression (defined in primary outcome measure), died or develop a new primary malignancy (cancer) will summarized in this outcome. (NCT00114101)
Timeframe: Duration of study (up to 10 years)
| Intervention | participants (Number) |
|---|---|
| Lenalidomide Maintenance | 92 |
| Placebo Maintenance | 133 |
Overall Survival was measured from the date of randomization to date of death due to any cause. OS was estimated using the Kaplan Meier method. (NCT00114101)
Timeframe: Duration of study (up to 10 years)
| Intervention | months (Median) |
|---|---|
| Lenalidomide Maintenance | NA |
| Placebo Maintenance | NA |
"Time to progression (TTP) was defined as the date of transplant to date of progression or death due to any cause, whichever occurs first. TTP was estimated using the Kaplan Meier method.~Progression was defined per the International Myeloma Working Group definition as one more of the following:~25% increase in serum M-component (absolute increase >= 0.5g/dl)~25% increase in urine M-component (absolute increase >= 200mg/24hour~25% increase in the difference between involved and uninvolved Free Light Chain levels (absolute increase >= 10mg/dl)~25 % increase in bone marrow plasma cell percentage (absolute increase of >=10%)~Definite development of new bone lesion or soft tissue plasmacytomas~Development of hypercalcemia" (NCT00114101)
Timeframe: Duration of study (up to 10years)
| Intervention | months (Median) |
|---|---|
| Lenalidomide Maintenance | 39 |
| Placebo Maintenance | 21 |
"Response was defined according to International Myeloma Working Group criteria (2006)~Complete Response: Complete disappearance of M-protein from serum & urine on immunofixation, normalization of Free Light Chain (FLC) ratio & <5% plasma cells in bone marrow (BM)~Partial Response: >= 50% reduction in serum M-Component and/or Urine M-Component >= 90% reduction or <200 mg per 24 hours; or >= 50% decrease in difference between involved and uninvolved FLC levels~Marginal Response: 25-49% reduction in serum M-component & urine M-component by 50-89% which still exceeds 200mg/24hour~Progressive Disease: Defined in primary outcome measure~Stable Disease: Not meeting any of the criteria above" (NCT00114101)
Timeframe: Day 100
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Complete response | Partial response | Marginal response | Stable disease | Progressive disease | Unknown | |
| Lenalidomide Maintenance | 67 | 115 | 11 | 38 | 0 | 0 |
| Placebo Maintenance | 79 | 109 | 5 | 32 | 3 | 1 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. (NCT00574288)
Timeframe: Up to Week 28 (for Part 1) and up to approximately 2.5 years (for Part 2)
| Intervention | participants (Number) |
|---|---|
| Part 1: Daratumumab Less Than (<) 4 mg/kg | 19 |
| Part 1: Daratumumab 4 mg/kg | 3 |
| Part 1:Daratumumab 8 mg/kg | 3 |
| Part 1: Daratumumab 16 mg/kg | 3 |
| Part 1:Daratumumab 24 mg/kg | 3 |
| Part 2: Daratumumab 8 mg/kg | 30 |
| Part 2: Daratumumab 16 mg/kg | 41 |
Overall response defined as percentage of participants who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). Per IMWG criteria, sCR: is defined as normal free light chain (FLC) ratio, and absence of clonal plasma cells (PCs) by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and < 5 % plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or >= 90% reduction in serum M-protein plus urine M-protein level < 100mg/24 hours; PR: >= 50 % reduction of serum M-protein and reduction in 24 hour urinary M-protein by >= 90% or to <200 mg/24 hours; if the serum and urine M-protein are not measurable, a decrease of >=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. (NCT00574288)
Timeframe: Up to Week 28 (for Part 1) and Week 27 (for Part 2)
| Intervention | percentage of participants (Number) |
|---|---|
| Part 1: Daratumumab 4 mg/kg | 33.3 |
| Part 1:Daratumumab 8 mg/kg | 0 |
| Part 1: Daratumumab 16 mg/kg | 33.3 |
| Part 1:Daratumumab 24 mg/kg | 66.7 |
| Part 2: Daratumumab 8 mg/kg | 10.0 |
| Part 2: Daratumumab 16 mg/kg | 35.7 |
Duration of response was calculated from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the International Myeloma Working Group (IMWG) criteria. (NCT00574288)
Timeframe: Up to Week 27
| Intervention | months (Median) |
|---|---|
| Daratumumab 8 mg/kg | 6.9 |
| Daratumumab 16 mg/kg | NA |
Overall Survival (OS) was defined as the number of days from administration of the first infusion (Day 1) to date of death. Median Overall Survival was estimated by using the Kaplan-Meier method. (NCT00574288)
Timeframe: Approximately 3 years
| Intervention | months (Median) |
|---|---|
| Daratumumab 8 mg/kg | 18.2 |
| Daratumumab 16 mg/kg | 34.3 |
Progression free survival (PFS) was defined as the time between the date of first dose of daratumumab and either disease progression or death, whichever occurs first. (NCT00574288)
Timeframe: Up to Week 27
| Intervention | months (Median) |
|---|---|
| Daratumumab 8 mg/kg | 2.4 |
| Daratumumab 16 mg/kg | 5.6 |
TTP was defined as the number of days from the date of first infusion (Day 1) to the date of first record of disease progression. Disease progression (IMWG criteria): increase of 25 percent (%) from lowest response level in Serum M-component and/or (the absolute increase must be >=0.5 g/dL); urine M-component and/or (the absolute increase must be >=200 mg/24 hour; only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels (absolute increase must be >10 mg/dL); Development of hypercalcemia (corrected serum calcium >11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder. Median TTP was estimated by using the Kaplan-Meier method. (NCT00574288)
Timeframe: Up to Week 27
| Intervention | months (Median) |
|---|---|
| Daratumumab 8 mg/kg | 2.4 |
| Daratumumab 16 mg/kg | 5.6 |
Time to first response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better). Time to best response was defined as the time between the date of first dose of daratumumab and the date of the initial evaluation of the best response (PR or better) to treatment. Kaplan-Meier method was used to estimate the distribution of time to response and time to best response. (NCT00574288)
Timeframe: Up to Week 28
| Intervention | months (Median) | |
|---|---|---|
| Time to first response | Time to best response | |
| Daratumumab 16 mg/kg | 8.4 | 8.4 |
| Daratumumab 8 mg/kg | NA | NA |
| Part 1: Daratumumab 4 mg/kg | NA | NA |
| Part 1:Daratumumab 24 mg/kg | 1.9 | 1.9 |
Time to first response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better). Time to best response was defined as the time between the date of first dose of daratumumab and the date of the initial evaluation of the best response (PR or better) to treatment. Time to VGPR (very good partial response) was defined as the time from the date of first dose of daratumumab to the date of initial documentation of VGPR response. The Kaplan-Meier method was used to estimate time to response. (NCT00574288)
Timeframe: Up to Week 27
| Intervention | months (Mean) | |
|---|---|---|
| Time to first response | Time to best response | |
| Daratumumab 8 mg/kg | 1.36 | 1.36 |
Time to first response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better). Time to best response was defined as the time between the date of first dose of daratumumab and the date of the initial evaluation of the best response (PR or better) to treatment. Time to VGPR (very good partial response) was defined as the time from the date of first dose of daratumumab to the date of initial documentation of VGPR response. The Kaplan-Meier method was used to estimate time to response. (NCT00574288)
Timeframe: Up to Week 27
| Intervention | months (Mean) | ||
|---|---|---|---|
| Time to first response | Time to best response | Time to VGPR or better response | |
| Daratumumab 16 mg/kg | 1.33 | 2.46 | 0.49 |
ORR is defined as percentage of participants who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). International Myeloma Working Group (IMWG) criteria- CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and less than (<) 5 percentage (%) plasma cells in bone marrow; sCR: CR+Normal free light chain ratio and absence of clonal cells in bone marrow by immunohistochemistry or immuno fluorescence; PR: greater than equal to (>=) 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by >= 90 percentage (%) or to <200 mg/24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level <100 mg per 24 hour. (NCT01615029)
Timeframe: Up to 3 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Phase 1: 2 mg/kg Daratumumab + Lenalidomide and Dexamethasone | 100.0 |
| Phase 1: 4 mg/kg Daratumumab + Lenalidomide and Dexamethasone | 100.0 |
| Phase 1: 8 mg/kg Daratumumab + Lenalidomide and Dexamethasone | 75.0 |
| Phase 1: 16 mg/kg Daratumumab + Lenalidomide and Dexamethasone | 66.7 |
Duration of response was calculated from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the International Myeloma Working Group (IMWG) criteria. (NCT01615029)
Timeframe: Up to 3 years
| Intervention | Months (Median) |
|---|---|
| Phase 2: 16 mg/kg Daratumumab + Lenalidomide and Dexamethasone | NA |
Overall Survival (OS) was defined as the number of days from administration of the first infusion (Day 1) to date of death. Median Overall Survival was estimated by using the Kaplan Meier method. (NCT01615029)
Timeframe: Up to 3 years
| Intervention | Months (Median) |
|---|---|
| Phase 2: 16 mg/kg Daratumumab + Lenalidomide and Dexamethasone | NA |
ORR is defined as percentage of participants who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). IMWG criteria- CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and less than (<) 5 percentage (%) plasma cells in bone marrow; sCR: CR+Normal free light chain ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; PR: greater than eqaul to (>=) 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by >= 90 percentage (%) or to <200 mg/24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level <100 mg per 24 hour. (NCT01615029)
Timeframe: Up to 3 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Phase 2: 16 mg/kg Daratumumab + Lenalidomide and Dexamethasone | 81.3 |
Progression free survival (PFS) was defined as the time between the date of first dose of daratumumab and either disease progression or death, whichever occurs first. (NCT01615029)
Timeframe: Up to 3 years
| Intervention | Months (Median) |
|---|---|
| Phase 2: 16 mg/kg Daratumumab + Lenalidomide and Dexamethasone | NA |
TTP was defined as the number of days from the date of first infusion (Day 1) to the date of first record of disease progression. Disease progression (IMWG criteria): increase of >=25 percent (%) from lowest response level in Serum M-component and/or (the absolute increase must be >=0.5 g/dL) Urine M-component and/or (the absolute increase must be >=200 mg/24 hour; only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase must be >10 mg/dL; Bone marrow plasma cell percentage: the absolute % must be >=10 %; Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium >11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder. Median TTP was estimated by using the Kaplan-Meier method. (NCT01615029)
Timeframe: Up to 3 years
| Intervention | Months (Median) |
|---|---|
| Phase 2: 16 mg/kg Daratumumab + Lenalidomide and Dexamethasone | NA |
Time to first response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better). Time to best response was defined as the time between the date of first dose of daratumumab and the date of the initial evaluation of the best response (PR or better) to treatment. (NCT01615029)
Timeframe: Up to 3 years
| Intervention | Months (Mean) | |
|---|---|---|
| Time to first response | Time to best response | |
| Phase 1: 16 mg/kg Daratumumab + Lenalidomide and Dexamethasone | 2.25 | 5.47 |
| Phase 1: 2 mg/kg Daratumumab + Lenalidomide and Dexamethasone | 0.83 | 3.12 |
| Phase 1: 4 mg/kg Daratumumab + Lenalidomide and Dexamethasone | 1.14 | 12.54 |
| Phase 1: 8 mg/kg Daratumumab + Lenalidomide and Dexamethasone | 1.27 | 9.75 |
Time to first response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better). Time to best response was defined as the time between the date of first dose of daratumumab and the date of the initial evaluation of the best response (PR or better) to treatment. (NCT01615029)
Timeframe: Up to 3 years
| Intervention | Months (Mean) | |
|---|---|---|
| Time to first response | Time to best response | |
| Phase 2: 16 mg/kg Daratumumab + Lenalidomide and Dexamethasone | 1.55 | 5.60 |
Duration of response (DOR) was calculated for participants who achieved an sCR, CR, VGPR, or PR. Duration of response is defined as the time from first evidence of PR or better to confirmation of disease progression or death due to any cause. Median duration of response was estimated using the Kaplan-Meier method. Participants with no baseline disease assessments, starting a new anticancer therapy before documentation of disease progression or death, death or disease progression immediately after more than 1 consecutively missed disease assessment visit, or alive without documentation of disease progression before the data cut-off date were censored. (NCT01568866)
Timeframe: From randomization until the data cut-off date of 10 November 2014; median follow-up time for DOR was 9.4 and 10.4 months for each treatment group respectively.
| Intervention | months (Median) |
|---|---|
| Bortezomib + DEX | 10.4 |
| Carfilzomib + DEX | 21.3 |
"Disease response was evaluated according to the IMWG-URC by the IRC. Overall response was defined as the percentage of participants with a best overall response of partial response (PR), very good PR (VGPR), complete response (CR) or stringent CR (sCR).~sCR: As for CR, normal serum free light chain (SFLC) ratio and no clonal cells in bone marrow (BM).~CR: No immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and < 5% plasma cells in BM biopsy; VGPR: Serum and urine M-protein detectable by immunofixation but not electrophoresis or ≥ 90% reduction in serum M-protein with urine M-protein <100 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline.~PR: ≥ 50% reduction of serum M-protein and reduction in urine M-protein by ≥ 90% or to < 200 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline." (NCT01568866)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 10 November 2014; median duration of treatment was 27 weeks in the bortezomib group and 40 weeks in the carfilzomib treatment group.
| Intervention | percentage of participants (Number) |
|---|---|
| Bortezomib + DEX | 62.6 |
| Carfilzomib + DEX | 76.9 |
"Overall survival (OS) is defined as the time from randomization to the date of death (whatever the cause). Participants who were alive or lost to follow-up as of the data analysis cut-off date were censored at the patient's date of last contact (last known to be alive).~Median overall survival was estimated using the Kaplan-Meier method." (NCT01568866)
Timeframe: From randomization until the data cut-off date of 03 January 2017; median follow-up time for OS was 36.9 and 37.5 months for each treatment group respectively.
| Intervention | months (Median) |
|---|---|
| Bortezomib + DEX | 40.0 |
| Carfilzomib + DEX | 47.6 |
"Neuropathy events were defined as Grade 2 or higher peripheral neuropathy as specified by peripheral neuropathy Standardised Medical Dictionary for Regulatory Activities (MedDRA) Query, narrow (scope) (SMQN) terms.~Peripheral neuropathy was assessed by neurologic exam and graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03:~Grade 1: Asymptomatic; Grade 2: Moderate symptoms, limiting instrumental activities of daily living (ADL) Grade 3: Severe symptoms; limiting self-care ADL; Grade 4: Life-threatening consequences, urgent intervention indicated; Grade 5: Death." (NCT01568866)
Timeframe: From the first dose of study drug up to 30 days after the last dose of study drug as of the data cut-off date of 10 November 2014; median duration of treatment was 27 weeks in the bortezomib group and 40 weeks in the carfilzomib treatment group.
| Intervention | percentage of participants (Number) |
|---|---|
| Bortezomib + DEX | 32.0 |
| Carfilzomib + DEX | 6.0 |
"A significant reduction in LVEF was defined as a ≥ 10% decrease (absolute change) from baseline in participants whose baseline LVEF is ≤ 55%.~For participants with LVEF > 55% at baseline, a significant change was defined as a decrease in LVEF to < 45%." (NCT01568866)
Timeframe: Baseline and 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Bortezomib + DEX | 2.6 |
| Carfilzomib + DEX | 0.0 |
"Progression-free survival (PFS) was defined as the time from randomization to the earlier of disease progression or death due to any cause. Participants were evaluated for disease response and progression according to the International Myeloma Working Group-Uniform Response Criteria (IMWG-URC) as assessed by an Independent Review Committee (IRC).~Median PFS was estimated using the Kaplan-Meier method. Participants with no baseline disease assessments, starting a new anticancer therapy before documentation of disease progression or death, death or disease progression immediately after more than 1 consecutively missed disease assessment visit, or alive without documentation of disease progression before the data cut-off date were censored." (NCT01568866)
Timeframe: From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively
| Intervention | months (Median) |
|---|---|
| Bortezomib + DEX | 9.4 |
| Carfilzomib + DEX | 18.7 |
Pulmonary artery pressure was measured using transthoracic echocardiogram. (NCT01568866)
Timeframe: Baseline and Weeks 12, 24 and 36 and at end of treatment (median duration of treatment was 27 weeks in the bortezomib group and 40 weeks in the carfilzomib treatment group).
| Intervention | mmHg (Mean) | |||
|---|---|---|---|---|
| Week 12 (n=34, 30) | Week 24 (n=22, 20) | Week 36 (n=12, 14) | End of Treatment (n=21, 14) | |
| Bortezomib + DEX | 0.3 | 1.7 | 4.0 | 3.4 |
| Carfilzomib + DEX | 2.8 | 3.4 | 2.6 | 0.9 |
Right ventricular function was assessed by measuring fractional area change (FAC) on echocardiogram. (NCT01568866)
Timeframe: Baseline and Weeks 12, 24 and 36 and at end of treatment (median duration of treatment was 27 weeks in the bortezomib group and 40 weeks in the carfilzomib treatment group).
| Intervention | percent fractional area change (Mean) | |||
|---|---|---|---|---|
| Week 12 (n=40, 40) | Week 24 (n=26, 31) | Week 36 (n=15, 18) | End of Treatment (n=23, 18) | |
| Bortezomib + DEX | -0.7 | 0.7 | -0.5 | 0.4 |
| Carfilzomib + DEX | -1.1 | -1.0 | -0.5 | -1.9 |
(NCT01355705)
Timeframe: 140 days
| Intervention | days (Median) |
|---|---|
| Amrubicin + Lenalidomide + Dexamethasone | 133 |
"Progression-free survival (PFS) is alive and free from progression, per the modified International Myeloma Working Group Uniform Response Criteria, defined as any of:~Serum monoclonal protein ≥ 125% baseline and/or ≥ +0.5 g/dL from baseline,~Urine monoclonal protein ≥ 125% baseline and/or ≥ +200 mg/24 hour from baseline~New or increased bone lesions or plasmacytomas~Serum calcium > 11.5 mg/dL (attributed to increased plasma cells)" (NCT01355705)
Timeframe: 9 months
| Intervention | days (Median) |
|---|---|
| Amrubicin + Lenalidomide + Dexamethasone | 96 |
(NCT01355705)
Timeframe: 9 months
| Intervention | days (Median) |
|---|---|
| Amrubicin + Lenalidomide + Dexamethasone | 92 |
"Modified International Myeloma Working Group Uniform Response Criteria:~Complete (CR)=~Negative for monoclonal protein (MP) in urine (U) and serum (S) +~No tissue plasmacytomas (PC) +~<5% plasma cells (PCs) in marrow (M)~Stringent CR (sCR)= CR with normal light chain ratio+ no PCs in M~Near CR (nCR)= CR, except MP persists in U and S~Partial (PR)= S MP ≤50%, + U MP ≤90% or <200 mg/24 hours (hr)~Very Good PR (VGPR)= in S MP ≤90%, + U MP <100 mg/24 hr~Minimal (MR)=~S MP ≤51-75%, +~If light chain is excreted, reduced 50-89%/24 hr that is also >200 mg/24 hr, +~No increase in lytic bone lesions~Progressive disease (PD)= any of:~S MP ≥125% and/or ≥+0.5 g/dL,~U MP ≥125% and/or ≥+200 mg/24 hr~New or increased bone lesions/PC~S calcium >11.5 mg/dL (attributed to increased PCs)~PD after CR/sCR=~Reappearance of S or U MP~≥5% clonal PCs in M~New PC, lytic bone lesions, hypercalcemia~Stable Disease (SD)= Not CR, VGPR, MR, PR, or PD" (NCT01355705)
Timeframe: 12 weeks
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response (CR) rate | Very Good Partial Response (VGPR) Rate | Total CR + VGPR | Partial Response (PR) Rate | Overall Response Rate (ORR = CR + VGPR + PR) | |
| Amrubicin + Lenalidomide + Dexamethasone | 0 | 7.6 | 7.6 | 15.4 | 23 |
"ORR is defined as the percentage of participants who achieved a best overall response (BOR) of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) using the modified International Myeloma Working Group (IMWG) criteria described as follows, as per investigator's assessment~CR: Negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in bone marrow~sCR: CR, as defined above, plus the following: Normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence~VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or >= 90% reduction in serum M-protein level plus urine M-protein level < 100 mg per 24 hour~PR: >= 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by >= 90% or to < 200 mg per 24 hour." (NCT02654132)
Timeframe: From first dose to disease progression (up to approximately 21 months)
| Intervention | Percent of participants (Number) |
|---|---|
| E-Pd Cohort | 58.3 |
| Pd Cohort | 24.6 |
OS is the time from randomization to the date of death from any cause. The survival time for participants who had not died was censored at the last known alive date. OS was censored at the date of randomization for subjects who were randomized but had no follow-up. (NCT02654132)
Timeframe: From randomization to death (up to approximately 52 months)
| Intervention | Months (Median) |
|---|---|
| E-Pd Cohort | 29.80 |
| Pd Cohort | 17.41 |
"PFS is defined as the time from randomization to the date of the first documented tumor progression or death due to any cause. Progressive disease response criteria were defined as an increase of 25% from lowest response value in any one or more of the following:~1. Serum M-component and/or 2. Urine M-component and/or 3. Only in patients without measurable serum and urine M-protein levels: the difference between involved and uninvolved FLC levels 4. Bone marrow plasma cell percentage; Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia that can be attributed solely to the plasma cell proliferative disorder" (NCT02654132)
Timeframe: From randomization to date of progression or death (up to approximately 21 months)
| Intervention | Months (Median) |
|---|---|
| E-Pd Cohort | 10.25 |
| Pd Cohort | 4.70 |
(NCT01159574)
Timeframe: From start of treatment, to date of disease progression
| Intervention | days (Mean) |
|---|---|
| All Patients | 272 |
(NCT01159574)
Timeframe: From baseline to cycle of maximum response, which occurred on average after 2 cycles; 1 cycle = 28 days
| Intervention | cycles (Mean) |
|---|---|
| All Patients | 2.19 |
Disease control rate was the percentage of participants who achieved confirmed sCR, CR, VGPR, PR, minimal response (MR) or have demonstrated stable disease (SD) for at least 12 weeks prior to any evidence of progression. PD was development of or an increase in the size of bone lesions or soft tissue plasmacytomas. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND <5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum FLC assay ratio and absence of clonal cells in bone marrow by immunohistochemistry/fluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component <100 mg/24 hr; PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to <200 mg/24 hours. The data cutoff date was July 9, 2018. (NCT02576977)
Timeframe: Up to approximately 30 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Pembrolizumab+Pomalidomide+Dexamethasone | 88.1 |
| Standard of Care (SOC) Pomalidomide+Dexamethasone | 84.8 |
ORR was defined as the percentage of the participants in the analysis population who achieved at least a partial response (stringent complete response [sCR]+complete response [CR]+very good partial response [VGPR]+partial response [PR]) according to the IMWG. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND <5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component <100 mg/24 hr; PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to <200 mg/24 hours. The database cutoff date was July 9, 2018. (NCT02576977)
Timeframe: Up to approximately 30 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Pembrolizumab+Pomalidomide+Dexamethasone | 37.3 |
| Standard of Care (SOC) Pomalidomide+Dexamethasone | 42.4 |
Overall survival is defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Median overall survival was calculated from the product-limit (Kaplan-Meier) method for censored data. The database cutoff date was August 3, 2020. (NCT02576977)
Timeframe: Up to approximately 54 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab+Pomalidomide+Dexamethasone | 21.0 |
| Standard of Care (SOC) Pomalidomide+Dexamethasone | 39.6 |
An adverse event was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study. Database cutoff was August 3, 2020. (NCT02576977)
Timeframe: Up to approximately 54 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab+Pomalidomide+Dexamethasone | 26 |
| Standard of Care (SOC) Pomalidomide+Dexamethasone | 10 |
An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study. Database cutoff was August 3, 2020. (NCT02576977)
Timeframe: Up to approximately 54 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab+Pomalidomide+Dexamethasone | 122 |
| Standard of Care (SOC) Pomalidomide+Dexamethasone | 119 |
Progression free survival was defined as the time from randomization to the first documented disease progression, or death due to any cause, whichever occurred first. PFS was assessed by CAC blinded central review according to the IMWG criteria based on the development of new bone lesions or soft tissue plasmacytomas or on a definite increase in the size of existing bone lesions or soft tissue plasmacytomas. Median PFS was calculated from the product-limit (Kaplan-Meier) method for censored data. The database cutoff date was July 9, 2018. (NCT02576977)
Timeframe: Up to approximately 30 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab+Pomalidomide+Dexamethasone | 5.7 |
| Standard of Care (SOC) Pomalidomide+Dexamethasone | 7.4 |
"Dose-limiting toxicity was defined as any of the following events assessed as related to carfilzomib, lenalidomide, or dexamethasone: Nonhematologic~≥ Grade 2 neuropathy with pain~≥ Grade 3 nonhematologic toxicity (excluding nausea, vomiting, diarrhea, hyperglycemia due to dexamethasone, and rash due to lenalidomide)~≥ Grade 3 nausea, vomiting, or diarrhea uncontrolled by maximal supportive therapy~≥ Grade 4 fatigue persisting > 7 days~Treatment delay for toxicity > 21 days~Hematologic~Grade 4 neutropenia (absolute neutrophil count [ANC] < 500/mm³) > 7 days~Febrile neutropenia (ANC < 1,000/mm³ with fever ≥ 38.3ºC)~Grade 4 thrombocytopenia (platelets < 25,000/mm³) for > 7 days despite holding treatment, or Grade 3 or 4 thrombocytopenia associated with bleeding~Treatment delay for toxicity > 21 days.~The maximum-tolerated dose was defined as the dose level below which a drug-related DLT was observed in ≥ 33% of participants in a cohort." (NCT00603447)
Timeframe: Cycle 1, 28 days
| Intervention | participants (Number) |
|---|---|
| 1: CFZ 15 mg/m² + LEN 10 mg | 0 |
| 2: CFZ 15 mg/m² + LEN 15 mg | 0 |
| 3: CFZ 15 mg/m² + LEN 20 mg | 0 |
| 4: CFZ 20 mg/m² + LEN 20 mg | 0 |
| 5: CFZ 20 mg/m² + LEN 25 mg | 0 |
| 6: CFZ 20/27 mg/m² + LEN 25 mg | 1 |
"Treatment-related are those AEs with possible or probable relationship to carfilzomib, lenalidomide or dexamethasone as assessed by the Investigator. The severity of each adverse event was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0, per the following: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death.~Serious adverse events were defined as AEs meeting one of the following: death, life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect in the offspring of an exposed participant, important medical events that may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above, or pregnancy or suspected pregnancy." (NCT00603447)
Timeframe: From the first dose of study drug until 30 days after the last dose; 1 to 52 months, with an average of 12 months.
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Any adverse event | Treatment-related adverse event | Grade 3 or higher adverse event | Treatment-related Grade 3 or higher adverse event | Serious adverse event | AE leading to discontinuation of any study drug | AE leading to discontinuation of carfilzomib | Deaths within 30 days of last dose of study drug | |
| 1: CFZ 15 mg/m² + LEN 10 mg | 6 | 4 | 5 | 1 | 3 | 1 | 0 | 0 |
| 2: CFZ 15 mg/m² + LEN 15 mg | 6 | 5 | 6 | 4 | 3 | 1 | 0 | 0 |
| 3: CFZ 15 mg/m² + LEN 20 mg | 8 | 8 | 8 | 7 | 4 | 3 | 1 | 0 |
| 4: CFZ 20 mg/m² + LEN 20 mg | 6 | 4 | 6 | 4 | 4 | 4 | 2 | 0 |
| 5: CFZ 20 mg/m² + LEN 25 mg | 6 | 6 | 6 | 6 | 3 | 2 | 1 | 0 |
| 6: CFZ 20/27 mg/m² + LEN 25 mg | 8 | 8 | 8 | 8 | 6 | 3 | 1 | 0 |
| 7: CFZ 20/27 mg/m² + LEN 25 mg | 44 | 43 | 41 | 38 | 22 | 18 | 9 | 3 |
In patients with no confirmed Partial Response, Near Complete Response, or Complete Response, progression was defined as a >25% increase from baseline in myeloma protein production or other signs of disease progression such as hypercalcemia, etc. (NCT00081939)
Timeframe: 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Study Treatment | 77 |
(NCT02416206)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| BeEAM | 28 |
(NCT02416206)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| BeEAM | 60 |
(NCT02416206)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| BeEAM | 37 |
Duration of response (calculated for responders only) is defined as time from the initial documented response (partial response or better) to confirmed disease progression, based on IMWG criteria assessed by the Independent Response Adjudication Committee. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 35.1 |
| High-Dose Dexamethasone | 28.1 |
Overall survival is calculated as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 07 September 2012. Maximum time on follow-up for survival was 70 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | NA |
| High-Dose Dexamethasone | 34.0 |
Overall survival is calculated as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 29 August 2017. Maximum time on follow-up for survival was 324 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 56.1 |
| High-Dose Dexamethasone | 35.3 |
Overall survival is calculated as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up for survival was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 54.0 |
| High-Dose Dexamethasone | 34.9 |
Objective response is defined as a best overall response of stringent complete response (SCR), complete response (CR), very good partial response (VGPR) or partial response (PR) based on the Independent Response Adjudication Committee: SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to < 200 mg/24 hours. In addition to the above, if present at baseline a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 23.5 |
| High-Dose Dexamethasone | 3.9 |
Objective response defined as a best overall response of complete response (CR) or partial response (PR) based on the Independent Response Adjudication Committee: CR requires all of the following: - Absence of original monoclonal paraprotein in serum and urine by immunofixation maintained at least 42 days. - <5% plasma cell in bone marrow aspirate and on bone marrow biopsy, if performed. - No increase in size or number of lytic bone lesions. - Disappearance of soft tissue plasmacytomas. PR requires all of the following: - ≥ 50% reduction in level of serum monoclonal paraprotein, maintained at least 42 days. - Reduction in 24-hour urinary light chain extraction by ≥ 90% or to < 200 mg, maintained at least 42 days. - For patients with non-secretory myeloma, ≥ 50% reduction in plasma cells in bone marrow aspirate and on biopsy, if performed, for at least 42 days. - ≥ 50% reduction in the size of soft tissue plasmacytomas. - No increase in size or number of lytic bone lesions. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 22.2 |
| High-Dose Dexamethasone | 3.3 |
Progression-free survival was calculated as the time from randomization to disease progression as determined by the Independent Response Adjudication Committee based on the International Myeloma Working Group Uniform Response criteria (IMWG), or death on study, whichever occurred earlier. Progressive disease required 1 of the following: • Increase of ≥ 25% from nadir in: o Serum M-component (absolute increase ≥ 0.5 g/dl); o Urine M-component (absolute increase ≥ 200 mg/24 hours); o Bone marrow plasma cell percentage (absolute % ≥ 10%); • Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas; • Development of hypercalcemia (corrected serum calcium > 11.5 mg/dl) attributed solely to plasma cell proliferative disease. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 07 September 2012. Maximum duration of follow-up for PFS assessments was 57 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 15.7 |
| High-Dose Dexamethasone | 8.0 |
Progression-free survival was calculated as the time from randomization to disease progression as determined by the Independent Response Adjudication Committee based on the International Myeloma Working Group Uniform Response criteria (IMWG), or death on study, whichever occurred earlier. Progressive disease requires 1 of the following: • Increase of ≥ 25% from nadir in: o Serum M-component (absolute increase ≥ 0.5 g/dl); o Urine M-component (absolute increase ≥ 200 mg/24 hours); o Bone marrow plasma cell percentage (absolute % ≥ 10%); • Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas; • Development of hypercalcemia (corrected serum calcium > 11.5 mg/dl) attributed solely to plasma cell proliferative disease. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum duration of follow-up for PFS assessments was 74 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 16.0 |
| High-Dose Dexamethasone | 8.1 |
"Time to improvement in bone pain is defined as the time from randomization to at least one category improvement from Baseline in bone pain category. Bone pain was categorized (from best to worst) according to answers to the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for patients with Multiple Myeloma Module (QLQ-MY20), Question 1, Have you had bone aches or pain?: 1) Not at all, 2) A little, 3) Quite a bit, or 4) Very much." (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 5.7 |
| High-Dose Dexamethasone | 4.1 |
Time to improvement in ECOG performance status defined as the time from randomization until at least a one category improvement from Baseline in ECOG performance status score. The categories of the ECOG Performance Status Scale are as follows: -0: Fully active, able to carry on all pre-disease performance without restriction; -1: Restricted in physically strenuous activity but ambulatory and able to carry our work of a light or sedentary nature, e.g., light housework, office work; -2: Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours. Patients with a score of 3, 4 or 5 were excluded from participating in the study. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 8.1 |
| High-Dose Dexamethasone | 4.3 |
Time to improvement in renal function is defined as the time from randomization to at least one category improvement from Baseline in renal function. Renal Function was categorized as (from best to worst): - Normal: creatinine clearance ≥80 mL/min; - Grade 1: creatinine clearance ≥60 to <80 mL/min; - Grade 2 : creatinine clearance ≥45 to < 60 mL/min. Participants with creatinine clearance < 45 mL/min at baseline were excluded from the study. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 4.6 |
| High-Dose Dexamethasone | 4.1 |
Time to progression (TTP) is calculated as the time from randomization to the first documented progression confirmed by a blinded, independent Response Adjudication Committee and based on the International Myeloma Working Group Uniform Response criteria (IMWG). Progressive disease requires 1 of the following: • Increase of ≥ 25% from nadir in: o Serum M-component (absolute increase ≥ 0.5 g/dl); o Urine M-component (absolute increase ≥ 200 mg/24 hours); o Bone marrow plasma cell percentage (absolute % ≥ 10%); • Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas; • Development of hypercalcemia (corrected serum calcium > 11.5 mg/dl) attributed solely to plasma cell proliferative disease. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 20.0 |
| High-Dose Dexamethasone | 9.0 |
Time to response is calculated as the time from randomization to the initial documented response (partial response or better) based on IMWG criteria. SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to < 200 mg/24 hours. If present at baseline a ≥ 50% reduction in size of soft tissue plasmacytomas is also required. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 8.1 |
| High-Dose Dexamethasone | 10.5 |
Time to increased hemoglobin, defined as the time from randomization to at least one category improvement from Baseline in common terminology criteria for adverse events (CTCAE) grade for hemoglobin level. Hemoglobin categories are: 1) Normal; 2) CTCAE Grade 1: < lower limit of normal (LLN) to 10.0 g/dL; 3) CTCAE Grade 2: < 10.0 to <8.0 g/dL. Participants with CTCAE Grade 3 anemia or worse at Baseline were excluded from the study. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 3.4 |
| High-Dose Dexamethasone | 1.3 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5 Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | -2.87 | -5.66 | -6.31 | -8.64 | -4.17 |
| Pomalidomide Plus Low-Dose Dexamethasone | 1.22 | 2.40 | 2.44 | 1.91 | 0.19 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom). (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5 Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | 4.03 | 7.76 | 9.43 | 9.47 | 10.49 |
| Pomalidomide Plus Low-Dose Dexamethasone | 2.43 | 3.26 | 1.71 | 0.21 | 0.99 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Pain Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reductions in pain (i.e. improvement in symptom) and positive values indicate increases in pain (i.e. worsening of symptom). (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5 Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | 0.36 | 2.83 | 3.03 | 2.47 | 10.19 |
| Pomalidomide Plus Low-Dose Dexamethasone | -2.70 | -3.58 | -2.41 | -1.64 | -2.40 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5 Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | -3.96 | -9.69 | -8.08 | -5.43 | -4.81 |
| Pomalidomide Plus Low-Dose Dexamethasone | -2.32 | -0.56 | 0.17 | 0.91 | 0.54 |
The European Organization for Research and Treatment of Cancer QoL Questionnaire for Patients with Multiple Myeloma (EORTC QLQ-MY20) is a 20-question tool used in clinical research to assess health-related quality of life in multiple myeloma patients. The QLQ-MY20 includes four domains (Disease Symptoms, Side-Effects of Treatment, Body Image and Future Perspective). The EORTC QLQ-MY20 Side Effects Scale is scored between 0 and 100, with a high score reflecting a higher level of symptoms. Negative change from Baseline values indicate reduction in side effects (i.e.improvement in symptom) and positive values indicate increase in side effects (i.e. worsening of symptom). (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5 Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | 2.61 | 5.35 | 7.46 | 6.89 | 7.30 |
| Pomalidomide Plus Low-Dose Dexamethasone | 2.71 | 3.26 | 3.73 | 4.74 | 4.55 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in QOL or functioning and positive values indicate improvement. (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5 Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | -3.75 | -2.36 | -3.03 | 0.00 | -0.93 |
| Pomalidomide Plus Low-Dose Dexamethasone | 0.52 | 2.67 | 0.80 | 0.51 | -2.51 |
The European Organization for Research and Treatment of Cancer QoL Questionnaire for Patients with Multiple Myeloma (EORTC QLQ-MY20) is a 20-question tool used in clinical research to assess health-related quality of life in multiple myeloma patients. The QLQ-MY20 includes four domains (Disease Symptoms, Side-Effects of Treatment, Body Image and Future Perspective). The EORTC QLQ-MY20 Disease Symptoms Scale is scored between 0 and 100, with a high score reflecting a higher level of symptoms. Negative change from Baseline values indicate reduction (i.e. improvement) in symptoms and positive values indicate increase (i.e. worsening) of symptoms. (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5 Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | -1.07 | 0.97 | 1.35 | 1.48 | 2.12 |
| Pomalidomide Plus Low-Dose Dexamethasone | -0.50 | -1.36 | -1.15 | -0.53 | 0.60 |
"EQ-5D is a self-administered questionnaire that assesses health-related quality of life (QOL). The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 levels of response: No problem (1), some problems (2), and extreme problems (3). A unique EQ-5D health state is defined by combining one level from each of the five dimensions into a single utility index score. EQ-5D index values range from -0.59 to 1.00 where an EQ-5D score of 1.00 equals perfect health, a score of 0 equals death and a score of -0.59 equals worst imaginable health state. A positive change from Baseline score indicates improvement in health status. A negative change from Baseline score indicates worsening in health status. Negative scores represent the possible though unlikely situation that a patient's QOL is worse than death, i.e. they would rather be dead than living with that QOL" (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5, Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | -0.02 | -0.06 | -0.07 | -0.04 | -0.12 |
| Pomalidomide Plus Low-Dose Dexamethasone | -0.03 | 0.01 | 0.04 | 0.01 | 0.03 |
An adverse event is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event. The Investigator assessed the relationship of each AE to study drug and graded the severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0): Grade 1 = Mild (no limitation in activity or intervention required); Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required); Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); Grade 4 = Life-threatening; Grade 5 = Death. (NCT01311687)
Timeframe: From first dose of study drug through to 30 days after the last dose as of the end of the study (29 August 2017); maximum time on treatment was 297, 269, and 239 weeks in the Pomalidomide + LD-Dex, HD-Dex, and cross-over groups respectively.
| Intervention | Participants (Count of Participants) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any adverse event | Grade 3-4 adverse events | AE related to pomalidomide | AE related to dexamethasone | AE related to either study drug | Grade 3-4 AE related to pomalidomide | Grade 3-4 AE related to dexamethasone | Grade 3-4 AE related to either study drug | Grade 5 adverse events | Serious adverse events (SAEs) | SAE related to pomalidomide | SAE related to dexamethasone | SAE related to either study drug | SAE leading to discontinuation of pomalidomide | SAE leading to discontinuation of dexamethasone | SAE leading to discontinuation of either study dru | AE leading to discontinuation of pomalidomide | AE leading to discontinuation of dexamethasone | AE leading to discontinuation of either study drug | |
| HD-Dex / Pomalidomide | 11 | 8 | 11 | 5 | 11 | 6 | 2 | 6 | 1 | 4 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| High-Dose Dexamethasone | 149 | 127 | 0 | 115 | 115 | 0 | 70 | 70 | 21 | 80 | 0 | 36 | 36 | 0 | 14 | 14 | 0 | 16 | 16 |
| Pomalidomide Plus Low-Dose Dexamethasone | 298 | 266 | 251 | 205 | 271 | 199 | 114 | 212 | 46 | 195 | 89 | 73 | 98 | 20 | 20 | 23 | 30 | 34 | 38 |
Time to worsening in quality of life domains was calculated as the time from Baseline to the first worsened minimally important difference (MID), defined as the smallest change in a QOL score considered important to patients that would lead the patient or clinician to consider a change in therapy. MID thresholds were calculated in Standard Error of Measurement (SEM) units using the Baseline QOL data. Based on the MID, participants were classified as worsened according to the following: For the EORTC QLQ-C30 global health status and functional scales and the EQ-5D health utility score, participants were classified as worsened if their change from Baseline score was less than -1 SEM. For the EORTC QLQ-C30 symptom scores (fatigue and pain) and EORTC QLQ-MY20 disease symptoms and side effects scales, participants were classified as worsened if their change from Baseline score was greater than 1 SEM. See previous outcome measures for definitions of each scale. (NCT01311687)
Timeframe: Assessed on Day 1 of the first 6 treatment cycles.
| Intervention | days (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Global Health Status | Physical Functioning | Emotional Functioning | Fatigue | Pain | Disease Symptoms | Side Effects of Treatment | Health Utility | |
| High-Dose Dexamethasone | 57 | 67 | 85 | 57 | 85 | 106 | 85 | 162 |
| Pomalidomide Plus Low-Dose Dexamethasone | 71 | 128 | 146 | 58 | 92 | 127 | 90 | 225 |
"Progression-free survival was calculated as the time from randomization to disease progression as determined by the Investigator based on the International Myeloma Working Group Uniform Response criteria (IMWG), or death on study, whichever occurred earlier.~Progressive disease requires 1 of the following:~Increase of ≥ 25% from nadir in:~Serum M-component (absolute increase ≥ 0.5 g/dl)~Urine M-component (absolute increase ≥ 200 mg/24 hours)~In patients without measurable serum and urine M-protein levels the difference between involved and uninvolved free light chain (FLC) levels (absolute increase > 100 mg/dl)~Bone marrow plasma cell percentage (absolute % ≥ 10%)~Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas." (NCT01324947)
Timeframe: From randomization through the follow-up phase; Maximum duration of follow-up for PFS was 90.3 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide | 16.0 |
Duration of Response (calculated for responders only) is defined as the time from the initial documented response (partial response or better) to confirmed disease progression by the investigator based on IMWG criteria. (NCT01324947)
Timeframe: From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum duration of response follow-up was 90.3 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide | 28.3 |
Overall survival was calculated as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented. (NCT01324947)
Timeframe: From randomization through the follow-up phase; Maximum time on follow-up was 141.1 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide | 33.6 |
"Time to progression (TTP) was calculated as the time from randomization to the first documented progression confirmed by the investigator and based on the International Myeloma Working Group Uniform Response criteria (IMWG).~Progressive disease requires 1 of the following:~Increase of ≥ 25% from nadir in:~Serum M-component (absolute increase ≥ 0.5 g/dl)~Urine M-component (absolute increase ≥ 200 mg/24 hours)~In patients without measurable serum and urine M-protein levels the difference between involved and uninvolved free light chain (FLC) levels (absolute increase > 100 mg/dl)~Bone marrow plasma cell percentage (absolute % ≥ 10%)~Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas.~Development of hypercalcemia (corrected serum calcium > 11.5 mg/dl) attributed solely to plasma cell proliferative disease." (NCT01324947)
Timeframe: From randomization through the follow-up phase; up to the data-cut off of 31 July 2014; Maximum time to progression follow-up was 90.3 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide | 19.0 |
"Objective response defined as a best overall response of stringent complete response (SCR), complete response (CR), very good partial response (VGPR) or partial response (PR) based on Investigator Assessment.~SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; PR: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. A ≥50% decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria or a ≥50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas." (NCT01324947)
Timeframe: From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Pomalidomide | 23.0 |
"Objective response defined as a best overall response of complete response (CR) or partial response (PR) based on the CR and requires all of the following:~Absence of original monoclonal paraprotein in serum and urine by immunofixation maintained at least 42 days.~<5% plasma cell in bone marrow aspirate and on bone marrow biopsy, if performed.~No increase in size or number of lytic bone lesions.~Disappearance of soft tissue plasmacytomas.~PR requires all of the following:~≥50% reduction in level of serum monoclonal paraprotein, maintained at least 42 days.~Reduction in 24-hour urinary light chain extraction by ≥90% or to <200 mg, maintained at least 42 days.~For patients with non-secretory myeloma, ≥50% reduction in plasma cells in bone marrow aspirate and on biopsy, if performed, for at least 42 days." (NCT01324947)
Timeframe: From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Pomalidomide | 20.3 |
Time to Response was calculated as the time from enrollment to the initial response (PR or better) based on IMWG and assessed by the investigator. (NCT01324947)
Timeframe: From randomization through the follow-up phase; up to the data-cut off of 31 July 2014; Maximum time to response was 23.1 weeks
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide | 8.3 |
"An adverse event is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A serious AE is any AE occurring at any dose that:~Results in death;~Is life-threatening;~Requires or prolongs existing inpatient hospitalization;~Results in persistent or significant disability/incapacity;~Is a congenital anomaly/birth defect;~Constitutes an important medical event.~The Investigator assessed the relationship of each AE to study drug and graded the severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0):~Grade 1 = Mild (no limitation in activity or intervention required); Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required);-Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); Grade 4 = Life-threatening; Grade 5 = Death" (NCT01324947)
Timeframe: From first dose of study drug through to 30 days after the last dose, until the data cut-off date of 31 July 2014. Maximum time on treatment was 94.1 weeks.
| Intervention | participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any adverse event | Grade 3-4 adverse event | AE related to pomalidomide | Grade 3-4 AE related to pomalidomide | Grade 5 AE | ≥1 Serious AE (SAE) | ≥1 SAE related to pomalidomide | ≥1 SAE leading to stopping pomalidomide | ≥AE leading to discontinuation of pomalidomide | ≥1 study drug related AE leading to stopping POM | ≥1 AE leading to reduction of pomalidomide | ≥1 study drug related AE leading to reducing POM | ≥1 AE leading to interruption of pomalidomide | ≥ 1 study drug related interruption of POM | |
| Pomalidomide | 73 | 64 | 51 | 33 | 19 | 52 | 15 | 6 | 8 | 1 | 11 | 9 | 41 | 25 |
To evaluate the safety of single agent SL-401 in an initial run-in cycle in patients with multiple myeloma (NCT02661022)
Timeframe: For a 28-day cycle, Cycle 1
| Intervention | Participants (Count of Participants) |
|---|---|
| SL-401 7 µg/kg/Day | 7 |
| SL-401 9 µg/kg/Day | 2 |
To evaluate the safety of single agent SL-401 in an initial run-in cycle in patients with multiple myeloma (NCT02661022)
Timeframe: Up to 12 months
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| At Least 1 Treatment-Related Treatment-Emergent Adverse Event | Fatigue | Nausea | Pyrexia | Hypoalbuminaemia | Chills | Insomnia | Aspartate aminotransferase increased | Constipation | Dizziness | Flushing | Headache | Hypophosphataemia | Neutropenia | Oedema peripheral | Thrombocytopenia | |
| SL-401 7 µg/kg/Day | 7 | 5 | 5 | 4 | 4 | 4 | 3 | 2 | 2 | 3 | 3 | 2 | 2 | 3 | 3 | 2 |
| SL-401 9 µg/kg/Day | 2 | 1 | 1 | 2 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 |
Overall response rate is defined as complete response + very good partial response + partial response and clinical benefit rate (CR + VGPR + PR + minimal response [MR]) based on International Myeloma Working Group-defined response criteria and the duration of response (DOR) in relapsed refractory multiple myeloma (RRMM) patients. (NCT02661022)
Timeframe: Up to 12 Months
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Overall Response Rate | Complete Response | Stringent Complete Response | Very Good Partial Response | Partial Response | Minimal Response | Stable Disease | Progressive Disease | Progressive Disease or Death After Overall Response | Censored | |
| SL-401 7 µg/kg/Day | 5 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 1 | 4 |
| SL-401 9 µg/kg/Day | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Per International Myeloma Working Group Response Criteria, progression/progressive disease is defined as increase of >25% from lowest response value in any 1 of the following: serum M-component (the absolute increase must be >0.5 g/dL)4 and/or urine M-component (the absolute increase must be >200 mg/24 h) and/or; only in patients without measurable serum and urine M-protein, the difference between involved and uninvolved FLC levels. The absolute increase must be >10 mg/dL; only in patients without measurable serum and urine M-protein and without measurable disease by FLC levels; bone marrow plasma cell percentage (absolute % must be ≥10%); definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium >11.5 mg/dL) that can be attributed solely to the plasma cell proliferative disorder. (NCT02661022)
Timeframe: Up to 12 Months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Disease Progression | Death | Censored | PFS at 6 Months | PFS at 12 Months | |
| SL-401 7 µg/kg/Day | 1 | 0 | 4 | 4 | 1 |
| SL-401 9 µg/kg/Day | 0 | 0 | 1 | 0 | 0 |
To evaluate the safety of single agent SL-401 in an initial run-in cycle in patients with multiple myeloma (MM) (NCT02661022)
Timeframe: Up to 12 Months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| At Least 1 TEAE Leading to Discontinuation of Study Drug | Capillary leak syndrome | Metastatic malignant melanoma | Pancreatitis | Thrombocytopenia | |
| SL-401 7 µg/kg/Day | 1 | 0 | 1 | 0 | 0 |
| SL-401 9 µg/kg/Day | 1 | 1 | 0 | 1 | 1 |
Percentage of participants with Overall Survival in response to Dd-R in newly diagnosed multiple myeloma patients with active disease. Overall survival is time from study entry to death of any cause. (NCT00617591)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Induction and Maintenance Therapy | 79.6 |
PFS: Time from study entry to progression/relapse or death from study entry to death of any cause, assessed using International Myeloma Working Group Response Definitions. Progressive Disease (PD): One of the following criteria must be met: a. Increase of 25% or greater in serum M protein (absolute increase greater or equal to 0.5g/dl); b. Increase of 25% or greater in urine M protein (absolute increase greater than 200 mg/24h); c. Increase of 25% or greater in the difference between the involved and uninvolved free light chain (absolute increase greater than 10 mg/dl); d. Increase of 25% or greater in bone marrow plasma cell percentage (absolute percent greater than 5% in case the patient was in CR and 10% otherwise); i.e. Definite development of new bone lesions or soft tissue plasmacytomas, or increase in the size of existing plasmacytomas by greater or equal to 25%. Development of hypercalcemia (serum calcium > 11.5 mg/dl) attributable only to the plasma cell dyscrasia. (NCT00617591)
Timeframe: 24 Months
| Intervention | months (Median) |
|---|---|
| Induction and Maintenance Therapy | 28 |
ORR assessed using International Myeloma Working Group Response Definitions. Partial Remission (PR): A greater than 50% reduction in the serum paraprotein, and if present, a greater than 90% reduction in the urine M protein excretion. Patients must also have a decrease by 50% in the size of soft tissue plasmacytoma. If serum and urine M protein are not measurable, a 50% or greater decreased in the difference of the involved and uninvolved free light chain. Very Good Partial Remission (VGPR): Detectable serum and urine M component on immunofixation but not on electrophoresis or 90% or greater reduction in serum M protein with less than 100 mg/24 h of urinary M protein. Complete Remission (CR): The presence of less than 5% bone marrow plasmacytosis and the disappearance of all evidence of serum and urine M-components on electrophoresis as well as by immunofixation. In addition, soft tissue plasmacytoma must have disappeared. (NCT00617591)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Induction and Maintenance Therapy | 77.2 |
Quality of response: % Complete Response (CR) + Very Good Partial Remission (VGPR) to induction Dd-R as assessed using International Myeloma Working Group Response Definitions. Very Good Partial Remission (VGPR): Detectable serum and urine M component on immunofixation but not on electrophoresis or 90% or greater reduction in serum M protein with less than 100 mg/24 h of urinary M protein. Complete Remission (CR): The presence of less than 5% bone marrow plasmacytosis and the disappearance of all evidence of serum and urine M-components on electrophoresis as well as by immunofixation. In addition, soft tissue plasmacytoma must have disappeared. (NCT00617591)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Induction and Maintenance Therapy | 42.1 |
"Tolerability of full dose Revlimid® with full dose Doxil® in combination with reduced schedule dexamethasone was to be assessed during Cycle 1 and at the start of Cycle 2 using, whenever possible, the National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) v3.0.~Due to increased neutropenia and fatigue, toxicities were reviewed after the first 29 participants were enrolled." (NCT00617591)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Percentage with Dose Reductions Required | Percentage Receiving < 4 Cycles of Therapy | Percentage Who Discontinued After Only 1 Cycle | Percentage with Grade 3/4 Neutropenia | Percentage with Grade 3/4 Fatigue | |
| Induction at Initial Full Dose | 24 | 20 | 13.79 | 48 | 20 |
"The maximum tolerated dose was defined as the highest dose level at which no more than 1 of 6 participants experiences a DLT within the first 28-day cycle.~DLTs were defined as:~Grade 4 neutropenia or thrombocytopenia~Febrile neutropenia~Grade 3 or 4 nausea, vomiting or diarrhea despite optimal symptomatic treatment~Serum transaminase > 20 * upper limit of normal (ULN)~Serum transaminase > 5 * ULN for >= 7 days~Delay of the start of cycle 2 by >7 days due to pomalidomide-related adverse event" (NCT00833833)
Timeframe: Up to Day 28 (Cycle 1)
| Intervention | participants (Number) |
|---|---|
| Phase 1: 2 mg Pomalidomide | 1 |
| Phase 1: 3 mg Pomalidomide | 1 |
| Phase 1: 4 mg Pomalidomide | 2 |
| Phase 1: 5 mg Pomalidomide | 4 |
"Duration of myeloma response is defined as the time from when the response criteria are first met for partial response (PR) or better, until the first date the response criteria are met for progressive disease (PD) or until the participant dies from any cause, whichever occurs first. Duration of response for participants last known to be alive with no progression after a complete response (CR) or PR was censored at the date of last adequate response assessment. Participants with confirmed responses that occur after receiving any other anti-myeloma therapy (except for adding dexamethasone to the pomalidomide treatment arm), including radiation therapy initiated after baseline, was censored at the last adequate assessment prior to the initiation of such treatment.~Response was assessed by the Independent Response Adjudication Committee (IRAC) using European Group for Blood and Bone Marrow Transplant (EBMT) criteria as described in the previous outcome." (NCT00833833)
Timeframe: up to 70 weeks
| Intervention | weeks (Median) |
|---|---|
| Phase 2: Pomalidomide + Dexamethasone | 32.1 |
| Phase 2: Pomalidomide | NA |
"Overall survival was defined as the time between randomization and death. Participants who die, regardless of the cause of the death, were considered to have had an event. All participants who were lost to follow-up prior to the end of the trial or who were withdrawn from the trial were censored at the time of last contact. Participants who were still being treated were censored at the last available date the subject was known to be alive, or clinical cut-off date if it was earlier.~Data collection is ongoing and future data results will be included as available." (NCT00833833)
Timeframe: up to 70 weeks
| Intervention | weeks (Median) |
|---|---|
| Phase 2: Pomalidomide + Dexamethasone | 62.6 |
| Phase 2: Pomalidomide | 59.3 |
"Progression free survival (PFS) is the time from randomization to the first documentation of disease progression or death from any cause during study, whichever occurs earlier. Disease progression was assessed by the Independent Response Adjudication Committee (IRAC).~For the primary PFS analysis, participants who withdrew for any reason or received another antimyeloma therapy (except adding dexamethasone to the Phase 2: Pomalidomide arm) without documented PD (as determined by the IRAC review) were censored on the date of their last adequate response assessment, prior to receiving any other anti-myeloma therapy. Subjects who were still active at the time of the data cut-off date without PD (as determined by the IRAC) were censored on the date of their last adequate response assessment.~Data collection is ongoing and future data results will be included as available." (NCT00833833)
Timeframe: up to 67 weeks
| Intervention | weeks (Median) |
|---|---|
| Phase 2: Pomalidomide + Dexamethasone | 16.6 |
| Phase 2: Pomalidomide | 10.7 |
"Percentage of participants with the progression-free survival events: disease progression and death. Disease progression was assessed by the Independent Response Adjudication Committee (IRAC).~Data collection is ongoing and future data results will be included as available." (NCT00833833)
Timeframe: up to 67 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Phase 2: Pomalidomide + Dexamethasone | 76.1 |
| Phase 2: Pomalidomide | 75.0 |
"Time to myeloma response is defined as the time from randomization to the time the response criteria for complete response (CR) or partial response (PR) are first met.~Response was assessed by the Independent Response Adjudication Committee (IRAC) using European Group for Blood and Bone Marrow Transplant (EBMT) criteria as described previously.~Data collection is ongoing and future data results will be included as available." (NCT00833833)
Timeframe: up to 70 weeks
| Intervention | weeks (Median) |
|---|---|
| Phase 2: Pomalidomide + Dexamethasone | 8.1 |
| Phase 2: Pomalidomide | 8.9 |
"TEAEs that occurred during Phase 1 after dexamethasone was added to pomalidomide treatment.~Relation to study drug was assessed by the Investigator as either suspected or not suspected. Counts represent the suspected relationship. Severity was assessed using National Cancer Institute Common Toxicity Terminology Criteria for Adverse Events version 3.0 (NCI CTCAE v3.0): 1= Mild 2= Moderate 3= Severe 4= Life-threatening and 5= Death related to AE. Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above.~Data collection is ongoing and future data results will be included as available." (NCT00833833)
Timeframe: Up to week 126
| Intervention | percentage of participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 or more (1+) AE | 1+ AE related to pomalidomide | 1+ AE related to dexamethasone | 1+ severity grade 3-4 AE | 1+ severity grade 3-4 AE related to pomalidomide | 1+ severity grade 3-4 AE related to dexamethasone | 1+ serious AE (SAE) | 1+ SAE related to pomalidomide | 1+ SAE related to dexamethasone | 1+ AE leading to discontinuation of pomalidomide | 1+ AE -- discontinuation of dexamethasone | 1+AE -dose reduction/interruption of pomalidomide | 1+ AE-dose reduction/interruption of dexamethasone | 1+related AE-reduction/interruption of pomalidomid | 1+related AE-reduction/interruption of dexamethaso | |
| Phase 1: 2 mg Pomalidomide | 100.0 | 100.0 | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Phase 1: 3 mg Pomalidomide | 100.0 | 75.0 | 75.0 | 75.0 | 75.0 | 75.0 | 75.0 | 25.0 | 50.0 | 25.0 | 25.0 | 50.0 | 75.0 | 25.0 | 75.0 |
| Phase 1: 4 mg Pomalidomide | 90.0 | 80.0 | 70.0 | 70.0 | 20.0 | 20.0 | 40.0 | 20.0 | 10.0 | 20.0 | 20.0 | 40.0 | 60.0 | 20.0 | 20.0 |
| Phase 1: 5 mg Pomalidomide | 100.0 | 100.0 | 85.7 | 57.1 | 42.9 | 0.0 | 28.6 | 0.0 | 0.0 | 0.0 | 0.0 | 71.4 | 71.4 | 57.1 | 42.9 |
"Relation to study drug was assessed by the Investigator as either suspected or not suspected. Counts represent the suspected relationship. Severity was assessed using National Cancer Institute Common Toxicity Terminology Criteria for Adverse Events version 3.0 (NCI CTCAE v3.0): 1= Mild 2= Moderate 3= Severe 4= Life-threatening and 5= Death related to AE. Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above.~Data collection is ongoing and future data results will be included as available." (NCT00833833)
Timeframe: Up to week 104
| Intervention | percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 or more (1+) AE | 1+ AE related to pomalidomide | 1+ severity grade 3-4 AE | 1+ severity grade 3-4 AE related to pomalidomide | 1+ serious AE (SAE) | 1+ SAE related to pomalidomide | 1+ AE leading to discontinuation of pomalidomide | 1+AE-dose reduction/interruption of pomalidomide | 1+related AE-reduction/interruption of pomalidomid | |
| Phase 1: 2 mg Pomalidomide | 100.0 | 66.7 | 83.3 | 33.3 | 50.0 | 0.0 | 16.7 | 16.7 | 0.0 |
| Phase 1: 3 mg Pomalidomide | 100.0 | 75.0 | 37.5 | 25.0 | 12.5 | 12.5 | 0.0 | 75.0 | 37.5 |
| Phase 1: 4 mg Pomalidomide | 100.0 | 85.7 | 78.6 | 42.9 | 42.9 | 7.1 | 21.4 | 42.9 | 28.6 |
| Phase 1: 5 mg Pomalidomide | 100.0 | 100.0 | 80.0 | 70.0 | 30.0 | 10.0 | 0.0 | 80.0 | 70.0 |
"Relation to study drug was assessed by the Investigator as either suspected or not suspected. Counts represent the suspected relationship. Severity was assessed using National Cancer Institute Common Toxicity Terminology Criteria for Adverse Events version 3.0 (NCI CTCAE v3.0): 1= Mild 2= Moderate 3= Severe 4= Life-threatening and 5= Death related to AE. Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above.~Data collection is ongoing and future data results will be included as available." (NCT00833833)
Timeframe: Up to week 70
| Intervention | percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 or more (1+) AE | 1+ AE related to pomalidomide | 1+ severity grade 3-4 AE | 1+ severity grade 3-4 AE related to pomalidomide | 1+ serious AE (SAE) | 1+ SAE related to pomalidomide | 1+ AE leading to discontinuation of pomalidomide | 1+related AE --discontinuation of pomalidomide | 1+AE - reduction of pomalidomide | 1+ AE - interruption of pomalidomide | 1+ related AE - interruption of pomalidomide | 1+related AE - reduction of pomalidomide | |
| Phase 2: Pomalidomide (Overall) | 100.0 | 88.8 | 89.7 | 67.3 | 67.3 | 20.6 | 12.1 | 3.7 | 29.9 | 58.9 | 32.7 | 24.3 |
| Phase 2: Pomalidomide (Pom + Dex Only) | 93.4 | 68.9 | 70.5 | 44.3 | 47.5 | 19.7 | 3.3 | 1.6 | 9.8 | 36.1 | 21.3 | 8.2 |
| Phase 2: Pomalidomide (Pom Only) | 99.1 | 87.9 | 84.1 | 58.9 | 46.7 | 9.3 | 10.3 | 2.8 | 25.2 | 47.7 | 24.3 | 20.6 |
| Phase 2: Pomalidomide + Dexamethasone | 100.0 | 89.3 | 88.4 | 62.5 | 61.6 | 17.9 | 8.0 | 1.8 | 20.5 | 63.4 | 27.7 | 17.9 |
"IRAC used EBMT criteria to assess myeloma response:~Complete Response (CR)-absence of serum and urine monoclonal paraprotein for 6 weeks, plus no increase in size or number of lytic bone lesions, plus other factors)~Partial Response (PR)-not all CR criteria, plus >=50% reduction in serum monoclonal paraprotein plus others~Minimal Response (MR)- 25-49% reduction in serum monoclonal paraprotein plus others~Stable Disease (SD)- not MR or progressive disease (PD)~Progressive Disease (PD)- reappearance of monoclonal paraprotein, lytic bone lesions, other~Not Evaluable (NE).~Data collection is ongoing and future data results will be included as available." (NCT00833833)
Timeframe: up to 70 weeks
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Complete response (CR) | Partial response (PR) | Minimal response (MR) | Stable disease (SD) | Progressive disease (PD) | Not evaluable | |
| Phase 2: Pomalidomide | 0.0 | 9.3 | 15.7 | 46.3 | 15.7 | 13.0 |
| Phase 2: Pomalidomide + Dexamethasone | 0.9 | 29.2 | 15.0 | 35.4 | 6.2 | 13.3 |
Duration of response will be measured as the time from initiation of a response to first documentation of disease progression or death, or date last known progression-free and alive for those who have not progressed or died. (NCT00378209)
Timeframe: Assessed at a median follow-up of 44 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide, Dexamethasone, Bortezomib Combination | 8.7 |
"Response assessed by the European Group for Blood and Marrow Transplant (EBMT) criteria, modified to include nCR and VGPR from the international uniform response criteria (IMWG).~Objective response was defined by the achievement of at least Partial Response (PR) or better (CR-complete response, nCR-near complete response, and VGPR-very good partial response)." (NCT00378209)
Timeframe: Assessed every cycle for up to 8 cycles and best response was reported
| Intervention | percentage of treated patients (Number) |
|---|---|
| Lenalidomide, Dexamethasone, Bortezomib Combination | 64 |
defined as time from treatment initiation to death, or last known to be alive for those who had not died (NCT00378209)
Timeframe: assesed at a median follow-up of 44 months
| Intervention | month (Median) |
|---|---|
| Lenalidomide, Dexamethasone, Bortezomib Combination | 30 |
Progression-free survival is defined as the time from registration to the disease progression or death from any cause, censored at date last known progression-free for those who have not progressed or died. (NCT00378209)
Timeframe: aassesed at a median follow-up of 44 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide, Dexamethasone, Bortezomib Combination | 9.5 |
"Response assessed by the European Group for Blood and Marrow Transplant (EBMT) criteria, modified to include nCR and VGPR from the international uniform response criteria (IMWG).~Progressive disease (PD) required one or more of the following:~>25% increased in serum monoclonal paraprotein (must also be an absolute increase of at least 5 g/L and confirmed on a repeat investigation) >25% increased in 24-hour urinary light chain excretion (must also be an absolute increase of at least 200 mg/24 h and confirmed on a repeat investigation) >25% increased in plasma cells in a bone marrow aspirate or on trephine biopsy (must also be an absolute increase of at least 10%) Definite increase in the size of existing lytic bone lesions or soft tissue plasmacytomas.~Development of new bone lesions or soft tissue plasmacytomas (not including compression fracture).~Development of hypercalcemia (corrected serum calcium >11.5 mg/dL or 2.8 mmol/L not attributable to any other cause)." (NCT00378209)
Timeframe: 6 months after therapy
| Intervention | percentage of treated patients (Number) |
|---|---|
| Lenalidomide, Dexamethasone, Bortezomib Combination | 75 |
(NCT00538733)
Timeframe: from baseline to the time of first event that lead to removal from study (defined as progression, death, withdrawal of consent, or removal for toxicity)
| Intervention | months (Median) |
|---|---|
| T-BiRD Therapy (All Patients) | 21.5 |
Median Time to maximum response, reported in cycles of treatment. One cycle = 28 days. (NCT00538733)
Timeframe: from baseline to cycle with maximum response
| Intervention | cycles (Median) |
|---|---|
| T-BiRD Therapy (All Patients) | 4 |
"Progression determined using International Myeloma Working Group criteria, as defined below.~An increase of > 25% from lowest response value one or more of the following:~Serum M-component and/or (the absolute increase must be > 0.5 g/dL)*~Urine M-component and/or (the absolute increase must be > 200 mg/24 h)~Only in patients without measurable serum and urine M-protein levels; the difference between involved and uninvolved FLC levels. The absolute increase must be > 10 mg/dL~Bone marrow plasma cell percentage; the absolute percentage must be > 10%~Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas~Development of hypercalcaemia (corrected serum calcium > 11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder *if starting serum M protein is greater then 5 g/dL, absolute increase of 1g/dL is sufficient to determine relapse." (NCT00538733)
Timeframe: From start of treatment, to the date of first progression
| Intervention | months (Median) |
|---|---|
| T-BiRD Therapy (All Patients) | 35.6 |
Objective response rate, defined according to the International Myeloma Working Group (IMWG) criteria as greater then or equal to a Partial Response (PR). The best response was recorded. The IMWG criteria can be found here: imwg.myeloma.org/international-myeloma-working-group-imwg-uniform-response-criteria-for-multiple-myeloma/ (NCT00538733)
Timeframe: This was collected from patients for their duration on study treatment. Only the best response was recorded. Best responses were reported at any point of the study, from start of treatment up until removal of study, which occurred up to 57.4 cycles
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| sCR (stringent complete response) | VGPR (very good partial response) | PR (partial response) | SD (stable disease) | |
| T-BiRD Therapy (All Patients) | 2 | 9 | 9 | 5 |
"Functional Assessment of Cancer Treatment - Gynecologic Oncology Group Neurotoxicity Scale (FACT/GOG-Ntx) Version 4 used to assess efficacy of acupuncture for treatment-induced peripheral neuropathy among multiple myeloma and/or lymphoma patients. Severity of neuropathy measured by FACT-GOG-Ntx total score assessment where 11-item questionnaire 5 point rating scale (0=not at all and 4=equals very much). FACT/GOG-Ntx Total Score ranges from 0 (best possible outcome) to 44 (worst possible outcome)." (NCT00891618)
Timeframe: Baseline to Week 13. Assessments at baseline, once per week during the two treatment phases of the study, and one month (week 13) after the last acupuncture treatment.
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline (n=19) | Week 4 (n=18) | Week 9 (n=15) | Week 13 (n=15) | |
| Acupuncture | 20.8 | 16.7 | 9.9 | 13.2 |
Assessed by the investigator per International Myeloma Working Group criteria(IMWG) uniform response criteria. Result reflects number of participants whose best overall response qualified as sCR, CR, or VGPR in 2 year follow up period. (NCT02906332)
Timeframe: Every 3 weeks (day 1 of every 21-day treatment cycle +/- 7 days) through 12 weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Lenalidomide | 11 |
Safety will be assessed by quantifying the toxicities and grades experienced by subjects who have received pembrolizumab (MK-3475), lenalidomide and dexamethasone, including serious adverse events (SAEs). Result reflects count of participants who experienced an SAE. (NCT02906332)
Timeframe: Up to 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Lenalidomide | 1 |
Assessed at 12 months; Subjects without documented PD or death will be censored at the last disease assessment date. Those who died without documented PD will be censored at the time of death. Result reflects count of participants who had progressed at 12 months. (NCT02906332)
Timeframe: Time from Day 0 (transplant) and date of enrollment to study completion (through 12 weeks) by investigator assessment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Lenalidomide | 10 |
PFS will be assessed from the date of ASCT, with day 0 defined as date of stem cell infusion (if tandem transplant the 2nd of 2 transplants will be used) until the date of progression, defined as the date at which the patient starts the next line of therapy or the date of death. (NCT02906332)
Timeframe: Up to 3 years
| Intervention | months (Median) |
|---|---|
| Pembrolizumab + Lenalidomide | 27.6 |
MTD of ixazomib will be determined by assessing adverse events and serious adverse events, clinical laboratory values, neurotoxicity grading, and vital sign measurements. (NCT01217957)
Timeframe: Until occurrence of progressive disease or unacceptable toxicity (Up to 336 days)
| Intervention | mg/m^2 (Number) |
|---|---|
| Phase 1: Ixazomib + Lenalidomide + Dexamethasone | 2.97 |
The accumulation ratio (Rac) was estimated as the ratio of AUC(0-168) on Day 15 to the AUC(0-168) on Day 1. AUC(0-168) is the area under the plasma concentration-time curve from time 0 to 168 hours postdose for ixazomib. (NCT01217957)
Timeframe: Cycle 1, Day 15
| Intervention | Ratio (Geometric Mean) |
|---|---|
| Phase 1: Ixazomib 1.68 mg/m^2 + Lenalidomide + Dexamethasone | NA |
| Phase 1: Ixazomib 2.23 mg/m^2 + Lenalidomide + Dexamethasone | 1.849 |
| Phase 1: Ixazomib 2.97 mg/m^2 + Lenalidomide + Dexamethasone | 2.051 |
RP2D will be determined based on number and type of adverse event and serious adverse events, assessments of clinical laboratory values, neurotoxicity grading, and treatment discontinuation. (NCT01217957)
Timeframe: Until occurrence of progressive disease or unacceptable toxicity (Up to 336 days)
| Intervention | mg/m^2 (Number) |
|---|---|
| Phase 1: Ixazomib + Lenalidomide + Dexamethasone | 2.23 |
1-year survival rate is defined as the percentage of participants still alive at year after the first dose of stud drug. (NCT01217957)
Timeframe: 1 year after first dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| Phase 2: Ixazomib 4.0 mg + Lenalidomide + Dexamethasone | 92 |
| Phase 2: Ixazomib 4.0 mg/2.23 + Lenalidomide + Dexamethasone | 92 |
DOR was measured as the time in months from the date of first documentation of a confirmed response (CR + PR+ VGPR) to the date of the first documented disease progression (PD). Response was assessed by the investigator using International Myeloma Working Group (IMWG) Criteria. CR=negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and < 5% plasma cells in bone marrow. VGPR=Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level < 100 mg per 24 hours. (NCT01217957)
Timeframe: Up to 787 days
| Intervention | months (Median) |
|---|---|
| Phase 2: Ixazomib 4.0 mg + Lenalidomide + Dexamethasone | NA |
| Phase 2: Ixazomib 4.0 mg/2.23 + Lenalidomide + Dexamethasone | NA |
ORR was defined as the percentage of participants with Complete (CR) + Very Good Partial Response (VGPR) assessed by the investigatory using International Myeloma Working Group (IMWG) Criteria. CR=Negative immunofixation on the serum and urine and; disappearance of any soft tissue plasmacytomas and; < 5% plasma cells in bone marrow. VGPR=Serum and urine M-protein detectable by immunofixation but not on electrophoresis or; 90% or greater reduction in serum M-protein plus urine M-protein level < 100 mg per 24 hours. (NCT01217957)
Timeframe: Until occurrence of progressive disease or unacceptable toxicity (Up to 787 days)
| Intervention | percentage of participants (Number) |
|---|---|
| Phase 2: Ixazomib 4.0 mg + Lenalidomide + Dexamethasone | 59 |
| Phase 2: Ixazomib 4.0mg/2.23 + Lenalidomide + Dexamethasone | 62 |
ORR was defined as the percentage of participants with CR, VGPR and Partial Response (PR) assessed by the investigator using IMWG criteria. CR=Negative immunofixation on the serum and urine + Disappearance of any soft tissue plasmacytomas and < 5% plasma cells in bone marrow. PR=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 90% or to < 200 mg per 24 hours. VGPR= Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level < 100 mg per 24 hours. (NCT01217957)
Timeframe: Up to 787 days
| Intervention | percentage of participants (Number) |
|---|---|
| Phase 2: Ixazomib 4.0 mg + Lenalidomide + Dexamethasone | 88 |
| Phase 2: Ixazomib 4.0 mg/2.23 + Lenalidomide + Dexamethasone | 88 |
OS was measured as the time in months from the first dose of study treatment to the date of death + 1 day. (NCT01217957)
Timeframe: From the first dose of study treatment to the date of death (up to 787 days)
| Intervention | participants (Median) |
|---|---|
| Phase 2: Ixazomib 4.0 mg + Lenalidomide + Dexamethasone | NA |
| Phase 2: Ixazomib 4.0 mg/2.23 + Lenalidomide + Dexamethasone | NA |
PFS was measured as the time in months from the first dose of study treatment to the date of the first documented PD or death. (NCT01217957)
Timeframe: Up to 787 days
| Intervention | months (Median) |
|---|---|
| Phase 2: Ixazomib 4.0 mg + Lenalidomide + Dexamethasone | 14.98 |
| Phase 2: Ixazomib 4.0 mg/2.23 + Lenalidomide + Dexamethasone | NA |
Time to Best Response was measured as the time in months from the first dose of study treatment to the date of first documented documentation of a confirmed response of partial response (PR) or better. (NCT01217957)
Timeframe: Up to 787 days
| Intervention | months (Median) |
|---|---|
| Phase 2: Ixazomib 4.0 mg + Lenalidomide + Dexamethasone | 2.96 |
| Phase 2: Ixazomib 4.0 mg/2.23 + Lenalidomide + Dexamethasone | 3.01 |
TTP was measured as the time in months from the first dose of study treatment to the date of the first documented progressive disease (PD). (NCT01217957)
Timeframe: From the first dose of study treatment to the date of first documented progressive disease (Up to 787 days)
| Intervention | months (Median) |
|---|---|
| Phase 2: Ixazomib 4.0 mg + Lenalidomide + Dexamethasone | NA |
| Phase 2: Ixazomib 4.0 mg/2.23 + Lenalidomide + Dexamethasone | NA |
AUC(0-168) is a measure of the area under the plasma concentration-time curve from time 0 to 168 hours postdose for Ixazomib. (NCT01217957)
Timeframe: Cycle 1, Days 1 and 15
| Intervention | hr*ng/mL (Geometric Mean) | |
|---|---|---|
| Day 1 (n=1, 3, 4, 1) | Day 15 (n=2, 3, 3, 1) | |
| Phase 1: Ixazomib 1.68 mg/m^2 + Lenalidomide + Dexamethasone | NA | 834.608 |
| Phase 1: Ixazomib 2.23 mg/m^2 + Lenalidomide + Dexamethasone | 587.667 | 1083.998 |
| Phase 1: Ixazomib 2.97 mg/m^2 + Lenalidomide + Dexamethasone | 923.484 | 1831.324 |
| Phase 1: Ixazomib 3.95 mg/m^2 + Lenalidomide + Dexamethasone | NA | NA |
Cmax: Maximum Observed Plasma Concentration (Cmax) is the peak plasma concentration of ixazomib obtained directly from the plasma concentration-time curve. (NCT01217957)
Timeframe: Cycle 1, Days 1 and 15
| Intervention | ng/mL (Geometric Mean) | |
|---|---|---|
| Day 1 (n=1, 3, 4, 1) | Day 15 (n=2, 3, 4, 1) | |
| Phase 1: Ixazomib 1.68 mg/m^2 + Lenalidomide + Dexamethasone | NA | 11.999 |
| Phase 1: Ixazomib 2.23 mg/m^2 + Lenalidomide + Dexamethasone | 22.303 | 31.368 |
| Phase 1: Ixazomib 2.97 mg/m^2 + Lenalidomide + Dexamethasone | 94.779 | 53.517 |
| Phase 1: Ixazomib 3.95 mg/m^2 + Lenalidomide + Dexamethasone | NA | NA |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly; or a medically important event. (NCT01217957)
Timeframe: Until occurrence of progressive disease or unacceptable toxicity (Up to 336 days)
| Intervention | participants (Number) | |
|---|---|---|
| Any AE | SAE | |
| Phase 1: Ixazomib 1.68 mg/m^2 + Lenalidomide + Dexamethasone | 3 | 2 |
| Phase 1: Ixazomib 2.23 mg/m^2 + Lenalidomide + Dexamethasone | 3 | 3 |
| Phase 1: Ixazomib 2.97 mg/m^2 + Lenalidomide + Dexamethasone | 6 | 1 |
| Phase 1: Ixazomib 3.95 mg/m^2 + Lenalidomide + Dexamethasone | 3 | 2 |
Tmax: Time to reach the first maximum observed plasma concentration (Cmax), equal to time (hours) to Cmax, obtained directly from the plasma concentration-time curve. (NCT01217957)
Timeframe: Cycle 1, Days 1 and 15
| Intervention | hours (Median) | |
|---|---|---|
| Day 1 (n=1, 3, 4, 1) | Day 15 (n=2, 3, 4, 1) | |
| Phase 1: Ixazomib 1.68 mg/m^2 + Lenalidomide + Dexamethasone | 1.020 | 4.165 |
| Phase 1: Ixazomib 2.23 mg/m^2 + Lenalidomide + Dexamethasone | 1.520 | 1.000 |
| Phase 1: Ixazomib 2.97 mg/m^2 + Lenalidomide + Dexamethasone | 1.060 | 1.015 |
| Phase 1: Ixazomib 3.95 mg/m^2 + Lenalidomide + Dexamethasone | 0.250 | 2.000 |
Response was assessed by the investigator using International Myeloma Working Group (IMWG) Criteria. CR is defined as negative immunofixation on the serum and urine and; disappearance of any soft tissue plasmacytomas and; < 5% plasma cells in bone marrow. VGPR is defined as Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level < 100 mg per 24 hours. (NCT01217957)
Timeframe: After Cycles 3, 6 and 9 (Up to 787 days)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| After 3 cycles | After 6 cycles | After 9 cycles | |
| Phase 2: Ixazomib 4.0 mg + Lenalidomide + Dexamethasone | 35 | 47 | 57 |
| Phase 2: Ixazomib 4.0 mg/2.23 + Lenalidomide + Dexamethasone | 37 | 48 | 58 |
Response was assessed by the investigator using International Myeloma Working Group (IMWG) Criteria. CR=Negative immunofixation on the serum and urine + Disappearance of any soft tissue plasmacytomas and < 5% plasma cells in bone marrow. sCR= CR + Normal free light chain (FLC) ratio and Absence of clonal cells in bone marrow. PR=≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to < 200 mg per 24 hours. VGPR= Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level < 100 mg per 24 hours. nCR=Positive immunofixation analysis of serum or urine as the only evidence of disease. Disappearance of any soft tissue plasmacytomas and < 5% plasma cells in bone marrow. MR=25% to 49% reduction in serum paraprotein and 50% to 89% reduction in urine light chain excretion for 6 weeks. (NCT01217957)
Timeframe: Cycles 3, 6, 9 and 12 (Up to 787 days)
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| CR | sCR | VGPR | nCR | PR | MR | |
| Phase 2: Ixazomib 4.0 mg + Lenalidomide + Dexamethasone | 20 | 6 | 39 | 2 | 67 | 6 |
| Phase 2: Ixazomib 4.0 mg/2.23 + Lenalidomide + Dexamethasone | 23 | 10 | 38 | 2 | 65 | 6 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly; or a medically important event. (NCT01217957)
Timeframe: Until occurrence of progressive disease or unacceptable toxicity (Up to 787 days)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Grade 3 or Higher AEs | SAEs | AEs Resulting in Treatment Discontinuation | |
| Phase 2 :Ixazomib 4.0 mg + Lenalidomide + Dexamethasone | 76 | 40 | 8 |
| Phase 2: Ixazomib 4.0 mg/2.23 + Lenalidomide + Dexamethasone | 75 | 43 | 8 |
Overall survival was measured from treatment initiation to death, censored at the date patients were last known to be alive for those who had not died. (NCT00378105)
Timeframe: Survival rate at 18 months
| Intervention | Percentage of participants (Number) |
|---|---|
| All Patients | 97 |
"PD from European Bone Marrow Transplant (EBMT) Response Criteria Required one or more:~>25% increased in the level of serum monoclonal paraprotein, which must also be an absolute increase of at least 5 g/L and confirmed on a repeat investigation, or >25% increased in 24-hour urinary light chain excretion (must also be an absolute increase of at least 200 mg/24 h and confirmed on a repeat investigation), or >25% increased in plasma cells in a bone marrow aspirate or biopsy (must also be an absolute increase of at least 10%) Definite increase in the size of existing lytic bone lesions or soft tissue plasmacytomas.~Development of new bone lesions or soft tissue plasmacytomas (not including compression fracture).~Development of hypercalcemia (corrected serum calcium >11.5 mg/dL or 2.8 mmol/L not attributable to any other cause).~PFS was measured from treatment initiation to progression or death, censored at the date patients were last known to be alive and disease free" (NCT00378105)
Timeframe: PFS rate at 18 months
| Intervention | Percentage of participants (Number) |
|---|---|
| All Patients | 75 |
Overall Response (OR) was defined as partial response (PR) or better. Response was assessed according to European Group for Blood and Marrow Transplant criteria, modified to include nCR and VGPR, from the International Uniform Response Criteria. (NCT00378105)
Timeframe: Full response assessment was conducted at the end of cycle 8 (average of168 days) and after cycle 4 (84 days) for patients proceeding to transplant.
| Intervention | percentage of participants (Number) |
|---|---|
| Phase 1 Population | 100 |
| Phase II Population | 100 |
| Total | 100 |
Duration of response was measured from first response to progression or death, censored at the date patients were last known to be alive and disease free for patients who had not progressed or died. (NCT00378105)
Timeframe: Response rate at 18 months
| Intervention | Percentage of participants (Number) |
|---|---|
| All Patients | 68 |
All partial and complete responses must be confirmed with another efficacy assessment in no less than 4 weeks apart. (NCT01319422)
Timeframe: Efficacy assessments will be made after the first two cycles of therapy (approximately 56 days--each cycle is 28 days)
| Intervention | percentage of participants (Number) |
|---|---|
| Pomalidomide 2 mg/d on 28 Days/28 Day Cycle | 15.8 |
| Pomalidomide 4 mg/d on 21 Days/28 Day Cycle | 20.0 |
All partial and complete responses must be confirmed with another efficacy assessment in no less than 4 weeks apart. (NCT01319422)
Timeframe: After the initial efficacy assessment at the completion of cycle 2 (at approximately 56 days), efficacy assessments will be made after every other cycle (approximately every 56 days).
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| cycle 4 | cycle 6 | cycle 8 | cycle 10 | cycle 12 | cycle 14 | |
| Pomalidomide 2 mg/d on 28 Days/28 Day Cycle | 15.8 | 21.0 | 21.0 | 21.0 | 21.0 | 21.0 |
| Pomalidomide 4 mg/d on 21 Days/28 Day Cycle | 40.0 | 40.0 | 45.0 | 45.0 | 45.0 | 45.0 |
"The change from baseline of the mean score of pain interference at the end of treatment using the Brief Pain Inventory-Short Form (BPI-SF). The BPI-SF is a self administered questionnaire developed to assess the severity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The BPI-SF uses 0 (No pain, No interference) to 10 (Pain as bad as you can imagine, Highest imaginable interference) numeric rating scale." (NCT01239797)
Timeframe: From baseline up to approximately 38 months
| Intervention | Score on a scale (Mean) |
|---|---|
| Lenalidomide + Dexamethasone + Elotuzumab | 0.95 |
| Lenalidomide + Dexamethasone | 0.48 |
"The change from baseline of the mean score of pain severity at the end of treatment using the Brief Pain Inventory-Short Form (BPI-SF). The BPI-SF is a self administered questionnaire developed to assess the severity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The BPI-SF uses 0 (No pain, No interference) to 10 (Pain as bad as you can imagine, Highest imaginable interference) numeric rating scale." (NCT01239797)
Timeframe: From baseline up to approximately 38 months
| Intervention | Score on a scale (Mean) |
|---|---|
| Lenalidomide + Dexamethasone + Elotuzumab | 0.52 |
| Lenalidomide + Dexamethasone | -0.04 |
"Overall survival is defined as the time from randomization to the date of death from any cause. If a subject has not died, their survival time will be censored at the date of last contact (last known alive date). A subject will be censored at the date of randomization if they were randomized but had no follow-up. (Based on Kaplan Meier estimates)" (NCT01239797)
Timeframe: Randomization to the date of death from any cause (up to approximately 9 years)
| Intervention | Months (Median) |
|---|---|
| Lenalidomide + Dexamethasone + Elotuzumab | 48.30 |
| Lenalidomide + Dexamethasone | 39.62 |
Primary definition of Progression-free survival (PFS) defined as the time from randomization to the date of first documented tumor progression or death due to any cause. Participants were censored at the last adequate assessment prior to the start of any subsequent systemic-therapy or at the last adequate assessment prior to 2 missing assessments (> 10 weeks). Participants who died more than 10 weeks after the randomization date and had no on-treatment assessment were censored at the randomization date. Clinical deterioration was not considered progression. The primary analysis of PFS was based on the primary definition using the Independent Review Committee (IRC) tumor assessment using the European Group for Blood and Bone Marrow Transplant (EBMT) criteria. Tumor assessments were made every 4 weeks (±1 week) relative to the first dose of study medication. (NCT01239797)
Timeframe: From randomization up to 326 events (up to approximately 38 months)
| Intervention | Months (Median) |
|---|---|
| Lenalidomide + Dexamethasone + Elotuzumab | 19.35 |
| Lenalidomide + Dexamethasone | 14.85 |
"The time from randomization to the date of first documented tumor progression or death due to any cause. Participants were censored at the last adequate assessment prior to the start of any subsequent systemic-therapy or at the last adequate assessment prior to 2 missing assessments (> 10 weeks). Participants who died more than 10 weeks after the randomization date and had no on-treatment assessment were censored at the randomization date. Clinical deterioration was not considered progression. Tumor assessments were made every 4 weeks (±1 week) relative to the first dose of study medication based on Independent Review Committee (IRC) tumor assessment using the European Group for Blood and Bone Marrow Transplant (EBMT) criteria.~Note: This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until 06-Jul-2018)" (NCT01239797)
Timeframe: From randomization up to to the date of first documented tumor progression or death (up to approximately 85 months)
| Intervention | Months (Median) |
|---|---|
| Lenalidomide + Dexamethasone + Elotuzumab | 19.42 |
| Lenalidomide + Dexamethasone | 14.92 |
Objective response rate (ORR) defined as the percentage of participants with a best response on-study of partial response (PR) or better (stringent CR [sCR], complete response [CR], very good partial response [VGPR], and partial response [PR]) based on the Independent Review Committee (IRC) assessment of best response using the European Group for Blood and Bone Marrow Transplant (EBMT) assessment criteria. Participants were censored at the last adequate assessment prior to the start of any subsequent systemic-therapy or at the last adequate assessment prior to 2 missing assessments (> 10 weeks). Participants who died more than 10 weeks after the randomization date and had no on-treatment assessment were censored at the randomization date. Clinical deterioration was not considered progression. Assessments were made every 4 weeks. (NCT01239797)
Timeframe: From randomization up to approximately 38 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Lenalidomide + Dexamethasone + Elotuzumab | 78.5 |
| Lenalidomide + Dexamethasone | 65.5 |
Duration of response is defined in participants with an overall response as the time between first documentation of response and disease progression. Responders without disease progression were censored at the last clinical assessment of response. (NCT00507416)
Timeframe: From first documented response until disease progression. Median follow-up time was 43 months.
| Intervention | months (Median) |
|---|---|
| Bortezomib and Dexamethasone | 18.3 |
| Bortezomib, Thalidomide, and Dexamethasone | 22.4 |
| Bortezomib, Melphalan and Prednisone | 19.8 |
Overall survival is defined as the time between randomization and death. Participants still alive at the cutoff date or lost to follow-up were censored at the date of last contact. (NCT00507416)
Timeframe: From randomization until death. Median follow-up time was 43 months.
| Intervention | months (Median) |
|---|---|
| Bortezomib and Dexamethasone | 49.8 |
| Bortezomib, Thalidomide, and Dexamethasone | 51.5 |
| Bortezomib, Melphalan and Prednisone | 53.1 |
Participants with a best overall response of complete response, defined as negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and <5% plasma cells in bone marrow. Response was assessed by the Investigator using the IMWG uniform response criteria. (NCT00507416)
Timeframe: Response assessed every other cycle, for up to 13 cycles (49 weeks).
| Intervention | percentage of participants (Number) |
|---|---|
| Bortezomib and Dexamethasone | 3 |
| Bortezomib, Thalidomide, and Dexamethasone | 4 |
| Bortezomib, Melphalan and Prednisone | 4 |
"Complete response is defined by negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and <5% plasma cells in bone marrow.~Very good partial response is defined by serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level <100 mg per 24 hours.~Response was assessed by the Investigator using the IMWG uniform response criteria." (NCT00507416)
Timeframe: Response assessed every other cycle for up to 13 cycles (49 weeks).
| Intervention | percentage of participants (Number) |
|---|---|
| Bortezomib and Dexamethasone | 37 |
| Bortezomib, Thalidomide, and Dexamethasone | 51 |
| Bortezomib, Melphalan and Prednisone | 41 |
"Overall response defined as a best overall response of complete response (CR), very good partial response (VGPR) or partial response (PR), assessed by the Investigator using the IMWG uniform response criteria.~CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and <5% plasma cells in bone marrow.~VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein plus urine M-protein level <100 mg per 24 hours (h).~PR requires 1 of the following:~≥50% reduction of serum M-protein and 24-h urinary M-protein by ≥ 90% or to <200 mg/24 h, or~If M-protein not measurable, a ≥50% decrease in the difference between involved and uninvolved FLC levels, or~If FLC not measurable, a ≥ 50% reduction in plasma cells, provided baseline bone marrow plasma cell percentage was ≥30%.~If present at baseline, a ≥50% reduction in the size of soft tissue plasmacytomas is also required." (NCT00507416)
Timeframe: Response assessed every other cycle for up to 13 cycles (49 weeks).
| Intervention | percentage of participants (Number) |
|---|---|
| Bortezomib and Dexamethasone | 73 |
| Bortezomib, Thalidomide, and Dexamethasone | 80 |
| Bortezomib, Melphalan and Prednisone | 70 |
"PFS is defined as the time from randomization to disease progression or death, whichever occurs first. Participants who did not progress and were still alive at the cut-off date were censored at the date of last contact. Response was assessed by the Investigator using the International Myeloma Working Group (IMWG) uniform response criteria.~Progressive disease requires 1 of the following:~Increase of ≥ 25% from nadir in:~Serum M-component (absolute increase ≥ 0.5 g/dl)~Urine M-component (absolute increase ≥ 200 mg/24 hours)~In patients without measurable serum and urine M-protein levels the difference between involved and uninvolved free light chain (FLC) levels (absolute increase > 100 mg/dl)~Bone marrow plasma cell percentage (absolute % ≥ 10%)~Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas.~Development of hypercalcemia (corrected serum calcium > 11.5 mg/dl) attributed solely to plasma cell proliferative disease" (NCT00507416)
Timeframe: From randomization until disease progression. Median follow-up time was 43 months.
| Intervention | months (Median) |
|---|---|
| Bortezomib and Dexamethasone | 14.7 |
| Bortezomib, Thalidomide, and Dexamethasone | 15.4 |
| Bortezomib, Melphalan and Prednisone | 17.3 |
Time to alternative therapy is defined as the time between randomization and alternative therapy. Participants who did not receive alternative therapy were censored at the time of last contact. (NCT00507416)
Timeframe: From randomization until alternative therapy. Median follow-up time was 43 months.
| Intervention | months (Median) |
|---|---|
| Bortezomib and Dexamethasone | 19.7 |
| Bortezomib, Thalidomide, and Dexamethasone | 24.5 |
| Bortezomib, Melphalan and Prednisone | 19.0 |
"The European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact).~The EORTC QLQ-C30 Global Health Status/QOL Scale is scored between 0 and 100, where higher scores indicate better Global Health Status/QOL. Negative changes from baseline indicate deterioration in QOL or functioning and positive changes indicate improvement." (NCT00507416)
Timeframe: Baseline and Day 1 of Cycles 3, 5, 7, 9, 11 and 13
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Cycle 3, Day 1 (n=129, 115, 125) | Cycle 5, Day 1 (n=114, 98, 107) | Cycle 7, Day 1 (n=89, 79, 84) | Cycle 9, Day 1 (n=87, 66, 67) | Cycle 11, Day 1 (n=71, 61, 65) | Cycle 13, Day 1 (n=67, 52, 61) | |
| Bortezomib and Dexamethasone | 1.3 | -4.9 | -3.3 | -4.2 | -11.6 | -10.2 |
| Bortezomib, Melphalan and Prednisone | 2.0 | -0.4 | -4.7 | -1.0 | 2.8 | 1.0 |
| Bortezomib, Thalidomide, and Dexamethasone | -4.4 | -6.1 | -8.6 | -8.1 | -7.9 | -8.5 |
"Percent of Participants Achieving Overall Combined Complete Response (CR) (CR w/normalized serum κ:λ ratio + CR + Near Complete Response (nCR)) following stem cell transplantation.~CR criteria: negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas and <5% plasma cells in bone marrow.~κ:λ ratio: normal free light chain (FLC) ratio~nCR criteria: positive immunofixation analysis of serum or urine as the only evidence of disease; disappearance of any soft tissue plasmacytomas and <5% plasma cells in bone marrow." (NCT00531453)
Timeframe: all data included in clinical database as of 10 April 2009
| Intervention | percentage of participants (Number) |
|---|---|
| Three Drug Regimen (VDT) | 76 |
| Four Drug Regimen (VDTC) | 78 |
"Percent of Particpants Achieving Overall combined complete response (CR w/normalized serum κ:λ ratio + CR + near complete response (nCR)) following induction therapy.~CR criteria: negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas and <5% plasma cells in bone marrow.~κ:λ ratio: normal free light chain (FLC) ratio~nCR criteria: positive immunofixation analysis of serum or urine as the only evidence of disease; disappearance of any soft tissue plasmacytomas and <5% plasma cells in bone marrow." (NCT00531453)
Timeframe: all data included in clinical database as of 10 April 2009
| Intervention | percentage of participants (Number) |
|---|---|
| Three Drug Regimen (VDT) | 51 |
| Four Drug Regimen (VDTC) | 44 |
A combined scale was used to assess the quality of life (QOL) comprising of the well established and validated functional well-being (FWB) and physical well-being (PWB) components of FACT-G version 4 (14 questions), which will address the physical and functional well-being of multiple myeloma patients plus the FACT-neurotoxicity (NTX, 11 questions), which will evaluate symptoms of neurotoxicity. This pooled scale is referred to as the FACT Ntx TOI. The FACT-Ntx TOI has 25 items and the score ranges from 0 (worst possible outcome) to 100 (best possible outcome). (NCT00602641)
Timeframe: Administered at registration, the beginning of cycle 7 d1, the end of cycle 12 d28, then at the end of cycle 18, 24, and 38 d28. For patients who discontinue treatment early, assessed at time of discontinuation and at the next quarterly follow-up visit.
| Intervention | units on a scale (Mean) |
|---|---|
| Arm I (MPT-T) | -2.8 |
| Arm II (mPR-R) | 3.3 |
Overall survival was defined as time from randomization to death from any cause. (NCT00602641)
Timeframe: Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually for 10 years from the date of randomization.
| Intervention | months (Median) |
|---|---|
| Arm I (MPT-T) | 52.6 |
| Arm II (mPR-R) | 47.7 |
PFS is defined as the time from randomization to the earlier of progression or death of any cause. (NCT00602641)
Timeframe: Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually for 10 years from the date of randomization.
| Intervention | months (Median) |
|---|---|
| Arm I (MPT-T) | 21.0 |
| Arm II (mPR-R) | 18.7 |
Response evaluation was based on the International Myeloma Working Group (IMWG) response criteria. VGPR rate was defined as patients achieving at least VGPR which include patients who achieving complete response (CR) and VGPR. CR refers to patients who have complete disappearance of an M-protein and no evidence of myeloma in the bone marrow. VGPR refers to patients who meet the following criteria: Serum and urine M-component detectable by immunofixation but not on electrophoresis; Or 90% or greater reduction in serum M-component plus urine M-component <100 mg per 24 hours; If the serum and urine M protein are unmeasurable and the immunoglobulin free light chain parameter is being used to measure response, a ≥ 90% decrease in the difference between involved and uninvolved free light chain (FLC) levels is required in place of the M protein criteria. (NCT00602641)
Timeframe: Assessed every cycle (1 cycle=28 days) for the first 12 cycles, and then every 2 cycles while on treatment. Post treatment assessed every 3 months < 2 years from study entry, every 6 months if 2-5 years, every 12 months if 6-10 years from study entry.
| Intervention | proportion of participants (Number) |
|---|---|
| Arm I (MPT-T) | 0.247 |
| Arm II (mPR-R) | 0.316 |
Biochemical progression free survival is defined as the time from enrollment in the study until development of overt clinical multiple myeloma (end organ damage or myeloma-defining event) or death, and progressive disease by International Myeloma Working Group (IMWG) criteria. Progression is any one of the following: Increase of ≥25% from lowest response value in the following on 2 consecutive measurements: Serum M-component and/or (the absolute increase must be ≥0.5g/dl). The serum M-component increases of ≥1 gm/dl are sufficient to define relapse if starting M-component is ≥0.5g/dl. Urine M-component and/or (the absolute must be ≥200mg/24h. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain (FLC) levels. The absolute increase must be >10mg/dl. Bone marrow plasma cell percentage: the absolute % must be ≥10%. (NCT01572480)
Timeframe: time from enrollment in the study until development of overt clinical multiple myeloma (end organ damage or myeloma-defining event) or death, and progressive disease by IMWG criteria, up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| All Participants | 76.6 |
Clinical progression was assessed by the International Myeloma Working Group Criteria for Multiple Myeloma. Progression is any one of the following: Increase of ≥25% from lowest response value in the following on 2 consecutive measurements: Serum M-component and/or (the absolute increase must be ≥0.5g/dl). The serum M-component increases of ≥1 gm/dl are sufficient to define relapse if starting M-component is ≥0.5g/dl. Urine M-component and/or (the absolute must be ≥200mg/24h. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain (FLC) levels. The absolute increase must be >10mg/dl. Bone marrow plasma cell percentage: the absolute % must be ≥10%. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in size of existing bone lesions or soft tissue plasmacytomas. Development of hypercalcemia that can be attributed solely to the plasma cell proliferative disorder. (NCT01572480)
Timeframe: time from enrollment in the study until development of overt clinical multiple myeloma (end organ damage or myeloma-defining event) or death, up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| All Participants | 90.7 |
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01572480)
Timeframe: Date treatment consent signed to date off study, approximately 117 months and 1 day.
| Intervention | Participants (Count of Participants) |
|---|---|
| All Participants | 54 |
Percentage of participants that have Minimal Residual Disease (MRD)-negative Complete Response (CR) for a minimum of 1 year estimated along with a 95% two-sided confidence interval. MRDnegative Complete Response (CR) is defined as absence of phenotypically aberrant clonal plasma cells by flow cytometry on bone marrow aspirates using the eight-color two tube approach with a minimum sensitivity of 1 in 10^5 nucleated cells or higher. (NCT01572480)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| All Participants | 63 |
MRDnegative Complete Response (CR) per the IMWHG criteria is defined as absence of phenotypically aberrant clonal plasma cells by flow cytometry on bone marrow aspirates using the eight-color two tube approach with a minimum sensitivity of 1 in 10^5 nucleated cells or higher. (NCT01572480)
Timeframe: 8 months
| Intervention | percentage of participants (Number) |
|---|---|
| All Participants | 70.4 |
Overall response is defined as the percentage of participants who have a partial response (PR), very good partial response (VGPR), complete response (CR), or stringent complete response (sCR) defined by the International Myeloma Working Group Criteria for Multiple Myeloma out of all evaluable participants. PR is ≥50% reduction if serum M-protein and reduction in 24-hour(h) urinary M-protein by ≥90% or to <200mg per 24h. If the serum and urine M-protein are unmeasurable, a ≥50% decrease in the difference between involved and uninvolved free light chain (FLC) levels is required in place of the M-protein criteria. VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis. CR is negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≥5% plasma cells in bone marrow. sCR is complete response plus normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence. (NCT01572480)
Timeframe: time measurement criteria are met for best response until the first date that recurrent or progressive disease is met, up to 5 years
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Overall Response Rate | Partial Response | Very Good Partial Response | Complete Response | Stringent Complete Response | |
| All Participants | 100 | 5.5 | 18.5 | 0 | 75.9 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01402284)
Timeframe: 4 years and 9 months and 2 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Carfilzomib, Lenalidomide, and Dexamethasone | 45 |
Response is assessed by the International Myeloma Working Group Criteria. Patients who attained a partial response or better (BoR) response by the end of induction. Partial response is ≥50% reduction of serum M-protein and reduction in 24h urinary M-protein. (NCT01402284)
Timeframe: 48.3 months
| Intervention | percentage of participants (Number) |
|---|---|
| Carfilzomib, Lenalidomide, and Dexamethasone | 97.8 |
OS is defined as the time of start of treatment to death from any cause. (NCT01402284)
Timeframe: up to 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Carfilzomib, Lenalidomide, and Dexamethasone | 89.5 |
Response is assessed by the International Myeloma Working Group Criteria. DOR is measured from the time measurement criteria are met for a partial response or better until first date that recurrent or progressive disease is objectively documented. Partial response is ≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein by ≥90% or to <200mg per 24h. Progressive disease requires any one or more of the following: increase of ≥25% from lowest response value in the following on 2 consecutive measurements: serum M-component and/or (the absolute increase must be ≥0.5g/dl). Urine M-component and/or (the absolute increase must be ≥200mg/24h. Only in patients without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain (FLC) levels. The absolute increase must be >10mg/dl. Bone marrow plasma cell percentage: the absolute % must be ≥10%. (NCT01402284)
Timeframe: 48 months
| Intervention | percentage of participants (Number) |
|---|---|
| Carfilzomib, Lenalidomide, and Dexamethasone | 81.1 |
PFS is defined as time of start of treatment to time of progression or death, whichever occurs first. Response is assessed by the International Myeloma Working Group Criteria. Progressive disease requires any one or more of the following: increase of ≥25% from lowest response value in the following on 2 consecutive measurements: serum M-component and/or (the absolute increase must be ≥0.5g/dl). Urine M-component and/or (the absolute increase must be ≥200mg/24h. Only in patients without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain (FLC) levels. The absolute increase must be >10mg/dl. Bone marrow plasma cell percentage: the absolute % must be ≥10%. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in size of existing bone lesions or soft tissue plasmacytomas. Development of hypercalcemia that can be attributed solely to the plasma cell proliferative disorder. (NCT01402284)
Timeframe: 48 months
| Intervention | percentage of participants (Number) |
|---|---|
| Carfilzomib, Lenalidomide, and Dexamethasone | 79.2 |
Response is assessed by the International Myeloma Working Group Criteria. Complete response is negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow. MRD is defined by M-spike, plasma cell burden, and abnormal free light chains. Immunophenotyping is performed by multi-parametric flow cytometry. (NCT01402284)
Timeframe: Day 100
| Intervention | percentage of participants (Number) |
|---|---|
| Carfilzomib, Lenalidomide, and Dexamethasone | 44.4 |
Response is assessed by the International Myeloma Working Group Criteria. MRD is defined by M-spike, plasma cell burden, and abnormal free light chains (FLC). Complete response is negative immunofixation on serum, and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow. Stringent complete response (sCR) is normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence. Near complete response (nCR) is the absence of myeloma protein on electrophoresis, independent of immunofixation status. Very good partial response (VGPR) is serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level <100mg per 24h. Overall response rate (ORR) is patients who attained a partial response (PR) (≥50% reduction of serum M-protein and reduction in 24h urinary M-protein) or better (BoR) response. (NCT01402284)
Timeframe: up to 2 years
| Intervention | percentage of participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| sCR/CR after 8 cycles | MRDnegCR after 8 cycles | nCR after 8 cycles | ≥VGPR after 8 cycles | ORR after 8 cycles | sCR after 8 cycles | sCR/CR after 1 year | sCR after 1 year | CR after 1 year | MRDnegCR after 1 year' | nCR after 1 year | ≥VGPR after 1 year | ORR after 1 year | sCR/CR after 2 years | sCR after 2 years | CR after 2 years | MRDnegCR after 2 years* | nCR after 2 years | ≥VGPR after 2 years | ORR after 2 years | |
| Carfilzomib, Lenalidomide, and Dexamethasone | 46.7 | 44.4 | 20 | 89 | 97.8 | 46.7 | 62.2 | 60.0 | 2.2 | 53.5 | 11.1 | 89 | 97.8 | 64.4 | 62.2 | 2.2 | 46.2 | 11.1 | 91.1 | 97.8 |
"Complete response (CR)~- Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and <5% plasma cells in bone marrow.~Stringent complete response (sCR) - A CR plus normal FLC ratio and no clonal cells in bone marrow~Near complete response (nCR) A CR, with the persistence of original monoclonal protein~Very good partial response (VGPR)~- Serum and urine M-component detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-component plus urine M-component <100 mg per 24 h~Partial response (PR)~≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein by ≥90% or to <200 mg per 24 h.~a ≥50% decrease in the difference between involved and uninvolved FLC levels~or a ≥50% reduction in plasma cells is required in place of M-protein, if ≥30% at baseline." (NCT01049945)
Timeframe: Up to 6 cycles of treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Maximum Tolerated Dose, Dose Level 4 | 44 |
"The Maximum Tolerated Dose (MTD) is the dose level below that at which a dose limiting toxicity (DLT) is observed in ≥ 33% (i.e., ≥ 2 of 6) subjects in a cohort. A dose limiting toxicity is defined as one of the following adverse events in the Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 deemed at least possibly related to treatment:~Grade 2 neuropathy with pain~Any grade 3 Non-Hematologic toxicity~Any grade Non-Hematologic event requiring a dose reduction in cycle 1 or delaying the next cycle by >14 days.~Grade 4 neutropenia~Febrile neutropenia~Grade 4 thrombocytopenia~Grade 3 thrombocytopenia associated with bleeding~Any Hematologic event requiring a dose reduction in cycle 1 or a delay in the next cycle of treatment by >14 days.~We are reporting the results of this endpoint as the number of DLTs per dose level." (NCT01049945)
Timeframe: One cycle of treatment
| Intervention | Dose Limiting Toxic Events (Number) |
|---|---|
| Phase I, Dose Level 1 | 0 |
| Phase I, Dose Level 2 | 1 |
| Phase I, Dose Level 3 | 0 |
| Phase I, Dose Level 4 | 0 |
| Phase I, Dose Level 5 | 2 |
DOR is the time from the date the patient's objective status is first noted to be PR or better to the earliest date of progression (PD=Increase of > 25% from lowest response value in Serum/Urine M-component) is documented. Treatment response was assessed using the International Myeloma Working Group uniform criteria. Complete response (CR)=Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and <5% plasma cells in bone marrow. Stringent complete response (sCR)=A CR plus normal FLC ratio and no clonal cells in bone marrow. Near complete response (nCR)=A CR, with the persistence of original monoclonal protein. Very good partial response (VGPR) =Serum and urine M-component detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-component plus urine M-component <100 mg per 24 h, Partial response (PR)=≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein by ≥90% or to <200 mg per 24 h. (NCT01049945)
Timeframe: Up to 2 years from study completion
| Intervention | months (Median) |
|---|---|
| Maximum Tolerated Dose, Dose Level 4 | 24.4 |
The event-free survival time is defined as the time from registration to disease progression (PD=Increase of > 25% from lowest response value in Serum/Urine M-component) while receiving bendamustine, lenalidomide, and dexamethasone, death due to any cause, or subsequent treatment for multiple myeloma. The distribution of event-free survival will be estimated using the method of Kaplan-Meier. Treatment response was assessed using the International Myeloma Working Group uniform criteria. (NCT01049945)
Timeframe: Up to 2 years from study completion
| Intervention | months (Median) |
|---|---|
| Maximum Tolerated Dose, Dose Level 4 | 5.6 |
The overall survival time is defined as the time from registration to death due to any cause. The distribution of overall survival will be estimated using the method of Kaplan-Meier. The overall survival rate at 6 months is defined as the percentage of participants who are alive at 6 months. (NCT01049945)
Timeframe: at 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Maximum Tolerated Dose, Dose Level 4 | 87 |
The progression-free survival time is defined as the time from registration to disease progression (PD=Increase of > 25% from lowest response value in Serum/Urine M-component) while receiving bendamustine, lenalidomide, and dexamethasone or death due to any cause, whichever comes first. The distribution of progression-free survival will be estimated using the method of Kaplan-Meier. Treatment response was assessed using the International Myeloma Working Group uniform criteria. (NCT01049945)
Timeframe: Up to 2 years from study completion
| Intervention | months (Median) |
|---|---|
| Maximum Tolerated Dose, Dose Level 4 | 11.8 |
(NCT01645930)
Timeframe: Cycle 1, Day 1 pre-dose and multiple time-points (up to 168 hours) post-dose
| Intervention | hr*ng/mL (Mean) |
|---|---|
| Ixazomib+Lenalidomide+Dexamethasone | 685.9 |
(NCT01645930)
Timeframe: Cycle 1, Day 15 pre-dose and multiple time-points (up to 336 hours) post-dose
| Intervention | hr*ng/mL (Mean) |
|---|---|
| Ixazomib+Lenalidomide+Dexamethasone | 1746.0 |
(NCT01645930)
Timeframe: Cycle 1, Day 1 pre-dose and multiple time-points (up to 168 hours) post-dose
| Intervention | ng/mL (Mean) |
|---|---|
| Ixazomib+Lenalidomide+Dexamethasone | 37.57 |
(NCT01645930)
Timeframe: Cycle 1, Day 15 pre-dose and multiple time-points (up to 336 hours) post-dose
| Intervention | ng/mL (Mean) |
|---|---|
| Ixazomib+Lenalidomide+Dexamethasone | 57.57 |
DOR was defined as the length of time between the date of first documented response (PR, VGPR, or CR) and the date of first documented progressive disease (PD). According to IMWG criteria: CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in bone marrow; PR: ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to <200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein plus urine M-protein level <100 mg per 24 hour. (NCT01645930)
Timeframe: From date of documentation of a confirmed response to date of progressive disease, (approximately 20 months)
| Intervention | months (Median) |
|---|---|
| Ixazomib+Lenalidomide+Dexamethasone | 12.9 |
DLT was defined as any of the following AEs that were considered by investigator to be possibly related to therapy: 1. Grade 4 neutropenia lasting at least 7 consecutive days; 2. Grade 3 neutropenia with fever and/or infection; 3. Grade 4 thrombocytopenia at least 7 consecutive days; 4. Grade 3 thrombocytopenia with clinically significant bleeding; 5. Platelet count <10,000/mm^3; 6. Grade 2 peripheral neuropathy with pain or ≥Grade 3 peripheral neuropathy; 7. Grade 3 or greater nausea and / or emesis despite the use of optimal anti-emetic prophylaxis; 8. Grade 3 or greater diarrhea that occurred despite maximal supportive therapy; 9. Any other Grade 3 or greater nonhematologic toxicity with the following exceptions: Grade 3 arthralgia/myalgia, <1 week Grade 3 fatigue; 10. A delay of >2 weeks in the subsequent cycle of treatment; 11. Other combination study drug-related nonhematologic toxicities ≥Grade 2 that, in the opinion of the investigator, required discontinuation of study drug. (NCT01645930)
Timeframe: Cycle 1 (up to Day 28)
| Intervention | participants (Number) |
|---|---|
| Ixazomib+Lenalidomide+Dexamethasone | 2 |
Percentage of participants who achieve or maintain any best response category during the treatment period were reported. Best response includes complete response (CR), very good partial response (VGPR), and partial response (PR). Response was assessed according to IMWG criteria. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in bone marrow; PR: ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to <200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein plus urine M-protein level <100 mg per 24 hour. (NCT01645930)
Timeframe: From Cycle 1, Day 1 to Cycle 3, Day 1 until disease progression (approximately 20 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Ixazomib+Lenalidomide+Dexamethasone | 53.5 |
(NCT01645930)
Timeframe: Cycle 1, Day 1 pre-dose and multiple time-points (up to 168 hours) post-dose
| Intervention | hours (Median) |
|---|---|
| Ixazomib+Lenalidomide+Dexamethasone | 1.5 |
(NCT01645930)
Timeframe: Cycle 1, Day 15 pre-dose and multiple time-points (up to 336 hours) post-dose
| Intervention | hours (Median) |
|---|---|
| Ixazomib+Lenalidomide+Dexamethasone | 2.0 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or was a medically important event. (NCT01645930)
Timeframe: From the first dose of study drug through 30 days after the last dose of study drug (up to 577 days)
| Intervention | participants (Number) | |
|---|---|---|
| AEs | SAEs | |
| Ixazomib+Lenalidomide+Dexamethasone | 43 | 18 |
Clinically significant laboratory abnormalities were defined as any test results which were observed beyond the clinically acceptable limits as per the discretion of investigator. Clinical laboratory tests included chemistry, hematology and urinalysis tests. (NCT01645930)
Timeframe: From the first dose of study drug through 30 days after the last dose of study drug (up to 577 days)
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alanine Aminotransferase Increased | Aspartate Aminotransferase Increased | Blood Creatinine Increased | Haemoglobin Decreased | Neutrophil Count Decreased | Platelet Count Decreased | Anaemia | Febrile Neutropenia | Neutropenia | Thrombocytopenia | Hyperglycaemia | Hypocalcaemia | Hypokalaemia | Hypomagnesaemia | Hyponatraemia | Hypophosphataemia | |
| Ixazomib+Lenalidomide+Dexamethasone | 2 | 1 | 1 | 1 | 2 | 4 | 6 | 1 | 12 | 8 | 1 | 3 | 5 | 1 | 1 | 2 |
The number of participants who meet markedly abnormal criteria for vital signs, included diastolic and systolic blood pressure, heart rate, oral temperature, respiratory rate, and body weight. (NCT01645930)
Timeframe: From the first dose of study drug through 30 days after the last dose of study drug (up to 577 days)
| Intervention | participants (Number) | |
|---|---|---|
| Grade 1 or 2 Hypertension | Grade 2 Hypotension | |
| Ixazomib+Lenalidomide+Dexamethasone | 4 | 1 |
Duration of response is defined as the time from the initial objective response to disease progression or death, whichever occurs first. The distribution of duration of response was estimated for each treatment group using Kaplan-Meier methodology. Point estimates and 95% CIs for the median for the duration of response distribution are provided. (NCT00742560)
Timeframe: From first dose of elotuzumab (phase 1) or randomization (phase 2) until 60 days following the last infusion (or before initiation of new therapy), up to 101 months
| Intervention | months (Median) |
|---|---|
| Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1) | 4.47 |
| Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1) | 9.92 |
| Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1) | NA |
| Total (Phase 1) | NA |
| Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2) | 34.83 |
| Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 2) | 29.01 |
| Total (Phase 2) | 29.24 |
MTD was determined by testing increasing doses up to 20 mg/kg once daily dose escalation cohorts 1 to 3 with 3 patients each. MTD reflects highest dose of drug that did not cause an unacceptable side effect (dose limiting toxicity [DLT]) in more than 30% of patients; e.g., hematologic toxicities like Common Toxicity Criteria for Adverse Events (CTCAE) Grade 4 neutropenia in specific conditions, platelets < 10,000 cells/mm^3 that do not recover to 25,000 cells/mm^3; and specific non-hematologic/biochemical toxicities CTCAE Grade 3 or 4 (except fatigue and Grade 3 infections); CTCAE version 3.0 were used. (NCT00742560)
Timeframe: 4 weeks
| Intervention | mg/kg (Number) |
|---|---|
| Phase 1 Elotuzumab + Lenalidomide and Dexamethasone | 20 |
ORR: Percentage of participants with confirmed complete response (CR; negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and ≤5% plasma cells in bone marrow), partial response (PR; ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to ≤200 mg per 24 hour; if serum and urine M-protein are unmeasurable, a ≥50% decrease in the difference between involved and uninvolved free light chain (FLC] levels is required in place of the M-protein criteria; if serum and urine M-protein are unmeasurable, and serum FLC is also unmeasurable, a ≥50% reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma cell percentage was ≥30%; and, if present at baseline, a ≥50% reduction in the size of soft tissue plasmacytomas), very good PR (VGPR; normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence), or stringent CR (sCR; CR plus VGPR). (NCT00742560)
Timeframe: From first dose of elotuzumab until 60 days following the last infusion (or before initiation of new therapy), up to 100.5 months
| Intervention | percentage of participants (Number) |
|---|---|
| Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1) | 100 |
| Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1) | 100 |
| Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1) | 77.3 |
| Total (Phase 1) | 82.1 |
ORR: Percentage of participants with confirmed complete response (CR; negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and ≤5% plasma cells in bone marrow), partial response (PR; ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to ≤200 mg per 24 hour; if serum and urine M-protein are unmeasurable, a ≥50% decrease in the difference between involved and uninvolved free light chain (FLC] levels is required in place of the M-protein criteria; if serum and urine M-protein are unmeasurable, and serum FLC is also unmeasurable, a ≥50% reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma cell percentage was ≥30%; and, if present at baseline, a ≥50% reduction in the size of soft tissue plasmacytomas), very good PR (VGPR; normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence), or stringent CR (sCR; CR plus VGPR). (NCT00742560)
Timeframe: From date of randomization until 60 days following the last infusion (or before initiation of new therapy), up to 101 months
| Intervention | percentage of participants (Number) |
|---|---|
| Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2) | 91.7 |
| Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 2) | 75.7 |
| Total (Phase 2) | 83.6 |
Treatment-emergent (post-dose) positive elotuzumab-specific ADA is differentiated from pre-existing (positive at the predose time point) positive elotuzumab-specific ADA. The percentage of participants with confirmed treatment-emergent ADA overall by dose is provided. (NCT00742560)
Timeframe: From screening through 60-day follow up period (up to 101 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone | 0 |
| Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone | 6 |
| Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone | 5 |
PFS is defined as the time from first dose (phase 1) or time from randomization (phase 2) to disease progression or death. The distribution of PFS was estimated for each treatment group using Kaplan-Meier methodology. Point estimates and 95% CIs for the median for the PFS distribution are provided. (NCT00742560)
Timeframe: From first dose of elotuzumab (phase 1) or randomization (phase 2) until 60 days following the last infusion (or before initiation of new therapy), up to 101 months
| Intervention | months (Median) |
|---|---|
| Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1) | 6.08 |
| Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1) | 22.23 |
| Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1) | NA |
| Total (Phase 1) | 32.92 |
| Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2) | 32.49 |
| Elotuzumab 10 mg/kg Administered as an IV Infusion in Combinat | 25.00 |
| Total (Phase 2) | 28.62 |
TTP is defined as the time from first dose (phase 1) or time from randomization (phase 2) to disease progression. The distribution of TTP was estimated for each treatment group using Kaplan-Meier methodology. Point estimates and 95% CIs for the median for the TTP distribution are provided. (NCT00742560)
Timeframe: From first dose of elotuzumab (phase 1) or randomization (phase 2) until 60 days following the last infusion (or before initiation of new therapy), up to 101 months
| Intervention | months (Median) |
|---|---|
| Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1) | 6.08 |
| Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1) | 11.53 |
| Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1) | 52.93 |
| Total (Phase 1) | 52.93 |
| Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2) | 32.49 |
| Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 2) | 19.94 |
| Total (Phase 2) | 28.16 |
Blood samples were collected during Phase 1, Cycle 1, prior to elotuzumab infusion (time 0 hours) and 30 minutes (0.5 hours) and 4 hours post-infusion (Day 1), 30 minutes (0.5 hours) post-infusion (Day 8 and Day 15), or 30 minutes (0.5 hours), 2 hours, and 4 hours post-infusion (Day 15). Blood samples were collected during Phase 2, Cycle 1, prior to elotuzumab infusion (time 0 hours) and 30 minutes (0.5 hours), 2 hours, and 4 hours post-infusion (Day 1), 30 minutes (0.5 hours) and 2 hours post-infusion (Day 8 and Day 15), or 30 minutes (0.5 hours), 2 hours, and 4 hours post-infusion (Day 15). The samples were analyzed for the concentration of elotuzumab using validated analytical methods. Mean serum concentrations on Cycle 1, Days 1, 8, 15, and 22 (measured in μg/mL) are reported overall (across Phase 1 and Phase 2) by dose. (NCT00742560)
Timeframe: Cycle 1: Days 1 (pre-infusion and 0.5, 2 and 4 hours post-infusion), 8 (pre-infusion and 0.5 and 2 hours post-infusion), 15 (pre-infusion and 0.5 hours and 2 hours post-infusion), and 22 (pre-infusion and 0.5, 2, and 4 hours post-infusion)
| Intervention | μg/mL (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1: 0 hours | Day 1: 0.5 hours | Day 1: 4 hours | Day 8: 0 hours | Day 8: 0.5 hours | Day 15: 0 hours | Day 15: 0.5 hours | Day 22: 0 hours | Day 22: 0.5 hours | Day 22: 2 hours | Day 22: 4 hours | |
| Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone | 0.00 | 78.48 | 85.56 | 32.44 | 133.37 | 49.84 | 140.09 | 61.93 | 168.61 | 268.53 | 128.94 |
Blood samples were collected during Phase 1, Cycle 1, prior to elotuzumab infusion (time 0 hours) and 30 minutes (0.5 hours) and 4 hours post-infusion (Day 1), 30 minutes (0.5 hours) post-infusion (Day 8 and Day 15), or 30 minutes (0.5 hours), 2 hours, and 4 hours post-infusion (Day 15). Blood samples were collected during Phase 2, Cycle 1, prior to elotuzumab infusion (time 0 hours) and 30 minutes (0.5 hours), 2 hours, and 4 hours post-infusion (Day 1), 30 minutes (0.5 hours) and 2 hours post-infusion (Day 8 and Day 15), or 30 minutes (0.5 hours), 2 hours, and 4 hours post-infusion (Day 15). The samples were analyzed for the concentration of elotuzumab using validated analytical methods. Mean serum concentrations on Cycle 1, Days 1, 8, 15, and 22 (measured in μg/mL) are reported overall (across Phase 1 and Phase 2) by dose. (NCT00742560)
Timeframe: Cycle 1: Days 1 (pre-infusion and 0.5, 2 and 4 hours post-infusion), 8 (pre-infusion and 0.5 and 2 hours post-infusion), 15 (pre-infusion and 0.5 hours and 2 hours post-infusion), and 22 (pre-infusion and 0.5, 2, and 4 hours post-infusion)
| Intervention | μg/mL (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1: 0 hours | Day 1: 0.5 hours | Day 1: 2 hours | Day 1: 4 hours | Day 8: 0 hours | Day 8: 0.5 hours | Day 8: 2 hours | Day 15: 0 hours | Day 15: 0.5 hours | Day 22: 0 hours | Day 22: 0.5 hours | Day 22: 2 hours | Day 22: 4 hours | |
| Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone | 0.00 | 217.90 | 213.31 | 251.34 | 92.47 | 281.53 | 268.35 | 111.11 | 282.29 | 135.92 | 310.03 | 298.85 | 538.88 |
| Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone | 0.00 | 434.20 | 388.58 | 525.98 | 168.55 | 593.80 | 520.97 | 298.82 | 661.91 | 308.02 | 699.70 | 704.48 | 981.16 |
During Phase 1, a list of 118 pre-defined MedDRA preferred terms that had been adjudicated to be clinically relevant to infusion reactions by a safety committee was used to search for TEAEs that could potentially be associated with an infusion reaction following elotuzumab administration. Examples of these terms included angioedema, bronchospasm, chills, flushing, pyrexia, rash and urticaria. During Phase 2, the method for capturing TEAEs associated with an infusion reaction was modified to include investigators' designation of AEs judged as clinically relevant infusion reactions. The number of participants infusion reactions are provided overall and by highest toxicity grade (CTCAE v 3.0). (NCT00742560)
Timeframe: Cycles 1 and 2: Days 1, 8, 15, and 22 (day of infusion of elotuzumab) and Days 2, 9, 16, and 23 (day following infusion); and Cycles 3 and greater: Days 1 and 15 (day of infusion) and Days 2 and 16 (day after infusion) (up to 95 months)
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any reaction | Grade 5 | Grade 4 | Grade 3 | Grade 2 | Grade 1 | |
| Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1) | 3 | 0 | 0 | 0 | 1 | 2 |
| Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2) | 5 | 0 | 0 | 1 | 1 | 3 |
| Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1) | 20 | 0 | 1 | 2 | 5 | 12 |
| Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 2) | 3 | 0 | 0 | 0 | 1 | 2 |
| Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1) | 2 | 0 | 0 | 0 | 0 | 2 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either definitely related, probably related, possibly related or unrelated. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section. (NCT00742560)
Timeframe: Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 60 days after the last dose of study drug (up to 95 months)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Any TEAE | Any TESAE | TEAEs ≥ Grade 3 | TEAEs related to study drug | TESAEs related to study drug | |
| Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1) | 3 | 3 | 3 | 3 | 0 |
| Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2) | 36 | 21 | 32 | 29 | 2 |
| Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1) | 22 | 12 | 19 | 16 | 2 |
| Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 2) | 37 | 21 | 25 | 26 | 5 |
| Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1) | 3 | 0 | 2 | 3 | 0 |
Plasma cell myeloma cytogenetic subtype was assessed at the screening visit using standard karyotyping and/or fluorescence in situ hybridization. The number of participants in each cytogenetic risk category are provided: High Risk (International Staging System [ISS] stage II or III and t(4;14) or del(17p) abnormality); Standard Risk (not high or low risk); and Low Risk (ISS stage I or II and absence of t(4;14), del(17p) and 1q21 abnormalities AND age < 55). (NCT00742560)
Timeframe: Screening (up to 14 days prior to dosing)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| High Risk | Standard Risk | Low Risk | Not Reported | |
| Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1) | 0 | 3 | 0 | 0 |
| Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2) | 1 | 30 | 2 | 3 |
| Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1) | 0 | 17 | 3 | 2 |
| Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 2) | 3 | 24 | 3 | 7 |
| Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1) | 1 | 2 | 0 | 0 |
Duration of response was calculated for the responders as the time from the initial documented response (CR or VGPR or PR) to the first documented progression or death due to any cause, whichever occurred first. Duration of response for participants last known to be alive with no progression after a CR, VGPR, or PR were censored at the date of last adequate response assessment. (NCT01698801)
Timeframe: From the first dose of study drug treatment until the data cut-off date of 15 July2014. Median follow up time was 61.6 weeks.
| Intervention | months (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | NA |
"Number of Complete Responses (CR) plus Very Good Partial Response (VGPR) plus Partial Response (PR) based on the International Myeloma Working Group criteria (IMWG). Any participant who achieved a CR, VGPR, or PR while on study treatment was defined as a responder.~CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to < 200 mg/24 hours. In addition to the above, if present at baseline a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required." (NCT01698801)
Timeframe: From first dose until the data cut-off date of 15 July 2014. Median time on follow-up was 61.6 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide Plus Dexamethasone | 87.5 |
The time from the start of study treatment to death due to any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented. (NCT01698801)
Timeframe: From the first dose of study drug treatment until the data cut-off date of 15 July 2014. Median follow up is 14.2 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 17.71 |
PFS was calculated as the time from the first dose date to the first documented progression based on IWG criteria or death due to any cause, whichever occurred first. If progression or death was not documented at the time of data cutoff date, these observations were censored at the last adequate assessment date showing evidence of no progression or death. (NCT01698801)
Timeframe: From the first dose of study drug treatment until the data cut-off date of 15 July 2014. Median follow-up for PFS assessments was 61.6 weeks.
| Intervention | months (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | NA |
"Time to response was calculated for the responders as the time from the first dose date to the initial documented response (CR, VGPR or PR).~CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to < 200 mg/24 hours. If present at baseline a ≥ 50% reduction in size of soft tissue plasmacytomas is also required." (NCT01698801)
Timeframe: From the first dose of study drug treatment until the data cut-off date of 15 July 2014. Median follow-up time was 61.6 weeks.
| Intervention | months (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 1.97 |
An adverse event is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event. The Investigator assessed the relationship of each AE to study drug and graded the severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0): Grade 1 = Mild (no limitation in activity or intervention required); Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required);-Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); Grade 4 = Life-threatening; Grade 5 = Death. (NCT01698801)
Timeframe: From first dose of study drug treatment through to 28 days after the last dose, until the data cut-off date of 15 July 2014; median treatment duration was 60 weeks
| Intervention | participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any adverse event | TEAE related to study drug | TEAE related to Lenalidomide | TEAE related to Dexamethasone | Grade 3-4 adverse event | Grade 3-4 adverse event related to any study drug | Grade 3-4 adverse event related to Lenalidomide | Grade 3-4 adverse event related to Dexamethasone | Serious TEAE | Serious TEAE related to any study drug | Serious TEAE related to Lenalidomide | Serious TEAE related to Dexamethasone | TEAE leading to discontinuation of either drug | TEAE leading to discontinuation of lenalidomide | TEAE leading to discontinuation of dexamethasone | Related TEAE discontinuation of either drug | Related TEAE discontinuation of lenalidomide | Related TEAE discontinuation of dexamethasone | |
| Lenalidomide Plus Dexamethasone | 26 | 25 | 25 | 20 | 18 | 15 | 15 | 4 | 11 | 8 | 8 | 3 | 4 | 4 | 2 | 4 | 4 | 0 |
The maximum tolerated dose of oral weekly cyclophosphamide in milligrams (mg), in combination with pomalidomide and dexamethasone. Dose Escalation of Cyclophosphamide, orallly (PO) days 1, 8, 15 as follows: Level 1: 300 mg; Level 2: 400 mg; Level 3: 500 mg. The period for assessment of Dose Limiting Toxicity (DLT) is the first cycle (28 days). The following toxicities will be considered dose limiting if encountered only in the phase I portion of the study: Febrile neutropenia; Grade 3 or 4 non-hematologic toxicity related to treatment with pomalidomide or cyclophosphamide; Participants must have received optimal symptomatic treatment for Grade 3 or 4 nausea, vomiting, or diarrhea to be considered a DLT; Grade 4 transaminitis; Grade 3 transaminitis must be present for ≥ 7 days to be considered a DLT; Grade 4 thrombocytopenia for 7 or more days; Grade 4 neutropenia for 7 or more days. (NCT01432600)
Timeframe: 28 Days
| Intervention | mg (Number) |
|---|---|
| A: Dose Escalation of Cyclophosphamide | 400 |
Overall survival per treatment arm. Overall survival is defined as the time from start of treatment to death of any cause. (NCT01432600)
Timeframe: 36 Months
| Intervention | months (Median) |
|---|---|
| B: Pomalidomide and Dexamethasone | 16.8 |
| C: Pomalidomide, Dexamethasone, Cyclophosphamide | NA |
Progression free survival per treatment arm. Progressive Disease (PD) requires one of the following, increase of greater than or equal to 25% from baseline in: Serum M-component; Urine M-component; The difference between involved and uninvolved sFLC levels; The size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia. (NCT01432600)
Timeframe: 36 Months
| Intervention | months (Median) |
|---|---|
| B: Pomalidomide and Dexamethasone | 4.4 |
| C: Pomalidomide, Dexamethasone, Cyclophosphamide | 9.5 |
Overall response, Minimal Remission (MR) or better per treatment arm, using the uniform response criteria by the International Myeloma Working Group (IMWG) of pomalidomide in combination with high dose dexamethasone with or without cyclophosphamide in participants with relapsed and refractory myeloma. In addition, Minimal response was incorporated in those response criteria as this is a valid endpoint in patients with relapsed or refractory myeloma. MR: 25-49% reduction in serum paraprotein and a 50-89% reduction in urine light chain excretion; A 25-49% reduction in the size of soft tissue plasmacytoma must be demonstrated is applicable. (NCT01432600)
Timeframe: 36 Months
| Intervention | percentage of participants (Number) |
|---|---|
| B: Pomalidomide and Dexamethasone | 38.9 |
| C: Pomalidomide, Dexamethasone, Cyclophosphamide | 64.7 |
Phase II: Participants with Grade 3 or 4 adverse events at least possibly related to the study treatment in 5% of participants in the Phase 2 portion, by AE category, assessed by the National Cancer Institute Common Terminology Criteria (NCI CTC) version 4.0. (NCT01432600)
Timeframe: Up to 48 Months
| Intervention | percentage of participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anemia | Febrile neutropenia | Fatigue | Flu-like symptoms | Lung infection | Sepsis | Upper respiratory infection | Lymphodemia | Neutropenia | Thrombocytopenia | Leukopenia | Hyperglycemia | Hyponatremia | Hypophosphatemia | Hypoxia | Confusion | Pneumonitis | Thromboembolic event | |
| B: Pomalidomide and Dexamethasone | 11.4 | 11.4 | 8.6 | 0 | 11.4 | 0 | 0 | 11.4 | 31.4 | 5.7 | 14.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| C: Pomalidomide, Dexamethasone, Cyclophosphamide | 24.2 | 12.1 | 1.21 | 0 | 9.1 | 9.1 | 6.1 | 9.1 | 51.5 | 15.2 | 12.1 | 6.1 | 6.1 | 0 | 0 | 6.1 | 9.1 | 6.1 |
| D: Crossover Arm | 5.9 | 0 | 0 | 5.9 | 5.9 | 0 | 0 | 11.8 | 23.5 | 0 | 5.9 | 0 | 0 | 5.9 | 5.9 | 0 | 0 | 0 |
Duration of treatment is defined as the last dose date minus the first dose date of the dose cohort plus 1 expressed in weeks. (NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.
| Intervention | weeks (Mean) |
|---|---|
| MRZ 0.5 mg/m^2 | 6.09 |
(NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.
| Intervention | cycles (Mean) |
|---|---|
| MRZ 0.5 mg/m^2 | 2.6 |
Disease response and progression were determined by the investigator using the International Myeloma Working Group Uniform Response Criteria (IMWG-URC). Overall response rate includes patients with a best response of PR of better. Stringent complete response (CR) includes immunophenotypic CR and molecular CR in addition to stringent CR. (NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Stringent Complete Response (sCR) or better | Complete Response (CR) | Very Good Partial Response (VGPR) | Partial Response (PR) | Minimal Response (MR) | Stable Disease (SD) | Progressive Disease (PD) | Not Evaluated | |
| MRZ 0.5 mg/m^2 | 0 | 0 | 0 | 0 | 0 | 4 | 9 | 2 |
A patient was counted in a cycle if the patient received at least one dose of study drug during the cycle. (NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Cycle 1 | Cycle 2 | Cycle 3 | Cycle 4 | Cycle 5 | Cycle 6 | |
| MRZ 0.5 mg/m^2 | 15 | 12 | 6 | 3 | 2 | 1 |
"Adverse events were graded using NCI-CTCAE (version 4.3). TEAEs are defined as any adverse event with an onset date between the date of first dose and 30 days after the date of last dose of any study drug.~Treatment-related adverse events are adverse events considered related to at least one study drug by the investigator (NPI-002, dexamethasone), including those with unknown relationship." (NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| At least one TEAE | At least one treatment related TEAE | At least one NPI-0052 related TEAE | At least one grade ≥3 TEAE | At least one treatment related grade ≥3 TEAE | At least one NPI-0052 related grade ≥3 TEAE | At least one serious TEAE | At least one treatment related serious TEAE | At least one NPI-0052 related serious TEAE | |
| MRZ 0.5 mg/m^2 | 15 | 14 | 13 | 12 | 8 | 5 | 7 | 4 | 1 |
"Adverse events were graded using NCI-CTCAE (version 4.3). TEAEs are defined as any adverse event with an onset date between the date of first dose and 30 days after the date of last dose of any study drug.~Treatment-related adverse events are adverse events considered related to at least one study drug by the investigator (NPI-002, dexamethasone), including those with unknown relationship." (NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.
| Intervention | TEAEs (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Number of TEAEs | Number of treatment related TEAEs | Number of NPI-0052 related TEAEs | Number of grade ≥3 TEAEs | Number of treatment related grade ≥3 TEAEs | Number of NPI-0052 realted grade ≥3 TEAEs | Number of serious TEAEs | Number of treatment related serious TEAEs | Number of NPI-0052 related serious TEAEs | |
| MRZ 0.5 mg/m^2 | 149 | 73 | 50 | 41 | 16 | 9 | 21 | 5 | 1 |
DOR was defined for participants with confirmed response (PR or better) as time between first documentation of response and disease progression/death due to PD, whichever occurs first. PD was defined as meeting any one of following criteria: Increase of >=25% in level of serum M-protein from lowest response value and absolute increase must be >=0.5g/dL; Increase of >=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be >=200mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of >=25% in difference between involved and uninvolved FLC levels from lowest response value and absolute increase must be >10mg/dL; Definite increase in size of existing bone lesions/soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium >11.5mg/dL) that can be attributed solely to PC proliferative disorder. (NCT02076009)
Timeframe: From randomization to the date of first documented evidence of PD (up to 21 months)
| Intervention | months (Median) |
|---|---|
| Lenalidomide, Low-dose Dexamethasone (Rd) | 17.4 |
| Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | NA |
Overall response rate was defined as the percentage of participants who achieved a partial response (PR) or better according to the International Myeloma Working Group (IMWG) criteria, during or after study treatment. IMWG criteria for PR: >=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by >=90% or to <200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of >=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria, in addition to the above criteria, if present at baseline, a >=50% reduction in the size of soft tissue plasmacytomas is also required. (NCT02076009)
Timeframe: From randomization to disease progression (up to 21 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide, Low-dose Dexamethasone (Rd) | 76.4 |
| Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | 92.9 |
Overall survival was measured from the date of randomization to the date of the participant's death. (NCT02076009)
Timeframe: From randomization to date of death due to any cause (up to 87.5 months)
| Intervention | months (Median) |
|---|---|
| Lenalidomide, Low-dose Dexamethasone (Rd) | 51.84 |
| Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | 67.58 |
VGPR or better is defined as the percentage of participants who achieved VGPR, complete response (CR) and stringent complete response (sCR) according to the International Myeloma Working Group criteria (IMWG). IMWG criteria for VGPR: Serum and urine M-component detectable by immunofixation but not on electrophoresis, or >=90% reduction in serum M-protein plus urine M-protein <100 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of >90% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. In addition to the above criteria, if present at baseline, a >=50% reduction in the size of soft tissue plasmacytomas is also required; CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and <5% PCs in bone marrow; sCR: CR and normal FLC ratio, absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4 color flow cytometry. (NCT02076009)
Timeframe: From randomization to disease progression (up to 21 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide, Low-dose Dexamethasone (Rd) | 44.2 |
| Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | 75.8 |
PFS: duration from date of randomization to either progressive disease (PD)/death, whichever occurred first. PD: defined as meeting any 1 of following criteria: Increase of greater than equal to (>=)25 percent(%) in level of serum M-protein from lowest response value and absolute increase must be >=0.5 gram per deciliter (g/dL); Increase of >=25% in 24-hours(h) urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be >=200 mg/24h; Only in participants without measurable serum and urine M-protein levels: increase of >=25% in difference between involved and uninvolved free light chain (FLC) levels from lowest response value and absolute increase must be >10 mg/dL; Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium >11.5 mg/dL) attributed solely to plasma cell (PC) proliferative disorder. (NCT02076009)
Timeframe: From randomization to either disease progression or death whichever occurs first (up to 21 months)
| Intervention | months (Median) |
|---|---|
| Lenalidomide, Low-dose Dexamethasone (Rd) | 18.43 |
| Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | NA |
TTP was defined as time from date of randomization to date of first documented evidence of progressive disease (PD). PD was defined as meeting any one of following criteria: Increase of >=25% in level of serum M-protein from lowest response value and absolute increase must be >=0.5 g/dL; Increase of >=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be >=200 mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of >=25% in difference between involved and uninvolved free light chain (FLC) levels from lowest response value and absolute increase must be >10 milligram per deciliter (mg/dL); Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium >11.5 mg/dL) that can be attributed solely to plasma cell (PC) proliferative disorder. (NCT02076009)
Timeframe: From randomization to disease progression (up to 21 months)
| Intervention | months (Median) |
|---|---|
| Lenalidomide, Low-dose Dexamethasone (Rd) | 18.43 |
| Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | NA |
Time to response was defined as the time between the date of randomization and the first efficacy evaluation that the participant met all criteria for partial response (PR) or better. (NCT02076009)
Timeframe: From randomization up to first documented CR or PR (up to 21 months)
| Intervention | months (Median) |
|---|---|
| Lenalidomide, Low-dose Dexamethasone (Rd) | 1.3 |
| Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | 1.0 |
Time to subsequent anticancer treatment was defined as the time from randomization to the start of subsequent anticancer treatment or death due to progressive disease (PD), whichever occurs first. (NCT02076009)
Timeframe: From randomization to date of start of subsequent anticancer treatment or death due to PD, whichever occured first (up to 87.5 months)
| Intervention | months (Median) |
|---|---|
| Lenalidomide, Low-dose Dexamethasone (Rd) | 23.1 |
| Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | 69.3 |
Minimal residual disease was assessed for all participants who achieved a complete response (CR) or stringent complete response (sCR). CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and <5% PCs in bone marrow; sCR: CR and normal FLC ratio, absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4 color flow cytometry. The MRD negativity rate was defined as the percentage of participants who had negative MRD assessment at any time point after the first dose of study drugs by evaluation of bone marrow aspirates or whole blood at 10^ minus (-) 4, 10^-5, 10^-6 threshold. (NCT02076009)
Timeframe: From randomization to the date of first documented evidence of PD (up to 87.5 months)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| MRD negative rate (10^-4) | MRD negative rate (10^-5) | MRD negative rate (10^-6) | |
| Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | 40.6 | 33.2 | 13.3 |
| Lenalidomide, Low-dose Dexamethasone (Rd) | 10.2 | 6.7 | 1.8 |
The detection of anti-elotuzumab anti-drug antibodies (ADAs) in human serum was performed using a validated bridging electrochemiluminescence immunoassay (ECLA) on the Meso Scale Discovery (MSD) platform. Sample collection was performed prior to administration of elotuzumab at Day 1 of each cycle. (NCT01241292)
Timeframe: First dose (Day 1) to last dose plus 60 days (assessed up to January 2017, approximately 71 months)
| Intervention | participants (Number) |
|---|---|
| Elotuzumab 10 mg/kg | 3 |
| Elotuzumab 20 mg/kg | 0 |
Vital signs (body temperature, seated blood pressure, heart rate, and respiration rate) were recorded at screening on Days 1, 8, 15, and 22 of Cycles 1 and 2, on Days 1 and 15 of Cycle 3, and at the end of treatment. Blood pressure (Diastolic and Systolic) and heart rate were recorded after the participant sat quietly for at least 5 minutes. Clinical relevance of vital sign data was determined by the investigator. (NCT01241292)
Timeframe: First dose (Day 1) to last dose plus 60 days (assessed up to January 2017, approximately 71 months)
| Intervention | participants (Number) |
|---|---|
| Elotuzumab 10 mg/kg | 0 |
| Elotuzumab 20 mg/kg | 0 |
The quantification of elotuzumab in human serum was performed using a validated enzyme-linked immunosorbent assay (ELISA). Cmax was measured in micrograms per milliliter (µg/mL). Samples of serum were obtained at: Cycle 1, Day 1: 0 hour (h), 30 minutes (min) 2 h post dose; Day 8: 0h, 2 h; Day 15: 0h, 30 min; Day 22: 0h, 30min, 2h. Cycle 2, Day 1, 22 0h, 2h. Cycle 3, Day 1: 0h, 30h, 2h; Day 15: 0h. (NCT01241292)
Timeframe: Days 1, 8, 15 and 22 of cycle 1, Days 1 and 22 of cycle 2, Days 1 and 15 of cycle 3
| Intervention | µg/mL (Geometric Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=3,3) | Cycle 1 Day 8 (n=3,3) | Cycle 1 Day 15 (n=3,3) | Cycle 1 Day 22 (n=3,2) | Cycle 2 Day 1 (n=3,3) | Cycle 2 Day 22 (n=3,3) | Cycle 3 Day 1 (n=3,3) | |
| Elotuzumab 10 mg/kg | 173 | 237 | 297 | 234 | 240 | 270 | 286 |
| Elotuzumab 20 mg/kg | 376 | 549 | 652 | 724 | 671 | 844 | 972 |
The quantification of elotuzumab in human serum was performed using a validated enzyme-linked immunosorbent assay (ELISA). Cmin was measured in micrograms per milliliter (µg/mL). Samples of serum were obtained at: Cycle 1, Day 1: 0 hour (h), 30 minutes (min) 2 h post dose; Day 8: 0h, 2 h; Day 15: 0h, 30 min; Day 22: 0h, 30min, 2h. Cycle 2, Day 1, 22 0h, 2h. Cycle 3, Day 1: 0h, 30h, 2h; Day 15: 0h. (NCT01241292)
Timeframe: Days 8, 15 and 22 of cycle 1, Days 1 and 22 of cycle 2, Days 1 and 15 of cycle 3
| Intervention | µg/mL (Geometric Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 8 (n=3,3) | Cycle 1 Day 15 (n=3,3) | Cycle 1 Day 22 (n=3,2) | Cycle 2 Day 1 (n=3,2) | Cycle 2 Day 22 (n=3,3) | Cycle 3 Day 1 (n=3,3) | Cycle 3 Day 15 (n=3,3) | |
| Elotuzumab 10 mg/kg | 59.1 | 97.0 | 24.6 | 25.8 | 57.8 | 77.2 | 59.4 |
| Elotuzumab 20 mg/kg | 165 | 252 | 280 | 389 | 547 | 579 | 466 |
Complete response (CR) and Partial Response (PR) were based on the European Group for Blood and Bone Marrow Transplant (EBMT) Criteria. Very Good Partial response was derived from the International Myeloma Working Group (IMWG) criteria. Participants who had a reduction in M-protein or plasmacytoma but did not meet the EBMT criteria for PR were classified as minimal response (MR). Hematologic, radiologic and/or clinical assessments were done every cycle starting with cycle 2. Each cycle is 4 weeks in length (Day 1, Day 8, Day 15, Day 22). Cycle 2 began on study Day 29. CR=negative immunofixation 6 weeks, <5% plasma cells, no increase in size or number of lytic lesions, complete disappearance of extramedullary plasmacytoma. PR=≥50%reduction in M-protein for 6 weeks, ≥90% reduction of urinary light chain excretion or < 200 mg/24hours for 6 weeks, ≥50% reduction in size of extramedullary plasmacytoma present at baseline, no increase in size or number of lytic lesions. (NCT01241292)
Timeframe: Cycle 2 (Study Day 29) to last dose (assessed up to January 2017, approximately 71 months)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Complete Response | Very Good Partial Response | Partial Response | Minimal Response | |
| Elotuzumab 10 mg/kg | 0 | 1 | 1 | 1 |
| Elotuzumab 20 mg/kg | 1 | 2 | 0 | 0 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4= Potentially Life-threatening or disabling. Data cut-off February 2014. (NCT01241292)
Timeframe: First dose (Day 1) to last dose plus 60 days (assessed up to January 2017, approximately 71 months)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| All SAEs Any Grade | Grade 3-4 SAEs | AEs Leading to Discontinuation | Grade 3-4 AEs | Deaths | |
| Elotuzumab 10 mg/kg | 2 | 1 | 0 | 3 | 0 |
| Elotuzumab 20 mg/kg | 3 | 3 | 1 | 3 | 0 |
NCI CTCAE, version 3.0 was used to measure toxicity scale. Sodium high (H) Gr 1:>ULN - 150; Gr 2: >150 - 155; Gr 3: >155 - 160; Gr 4: >160 mmol/L; Sodium low(L) Gr 1:
Timeframe: First dose (Day 1) to last dose plus 60 days (assessed up to January 2017, approximately 71 months)
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Potassium High, Any Grade | Potassium High, Grade 3-4 | Potassium Low, Any Grade | Potassium Low, Grade 3-4 | Sodium High, Any Grade | Sodium High, Grade 3-4 | Sodium Low, Any Grade | Sodium Low, Grade 3-4 | |
| Elotuzumab 10 mg/kg | 0 | 0 | 3 | 0 | 1 | 0 | 2 | 0 |
| Elotuzumab 20 mg/kg | 2 | 0 | 2 | 1 | 2 | 0 | 3 | 0 |
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 was used to measure toxicity scale. Lower Limits of Normal (LLN). Hemoglobin Gr 1:
Timeframe: First dose (Day 1) to last dose plus 60 days (assessed up to January 2017, approximately 71 months)
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin Any Grade | Hemoglobin Grade 3-4 | Lymphocytes Any Grade | Lymphocytes Grade 3-4 | Neutrophils Any Grade | Neutrophils Grade 3-4 | Platelet Count Any Grade | Platelet Count Grade 3-4 | Leukocytes Any Grade | Leukocytes Grade 3-4 | |
| Elotuzumab 10 mg/kg | 3 | 0 | 3 | 3 | 3 | 2 | 3 | 1 | 3 | 2 |
| Elotuzumab 20 mg/kg | 3 | 1 | 3 | 3 | 3 | 3 | 2 | 0 | 3 | 1 |
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 was used to measure toxicity scale. Lower Limits of Normal (LLN). Upper Limits of Normal (ULN). Alanine transaminase (ALT); Aspartate aminotransferase (AST); Alkaline phosphatase (ALP). ALT Grade (Gr)1:>1.0 to 2.5*ULN; Gr 2: >2.5 to 5.0*ULN; Gr 3: >5.0 to 20.0*ULN; Gr 4: >20.0*ULN. AST Gr 1: >1.0 to 2.5*ULN; Gr 2: >2.5 to 5.0*ULN; Gr 3: >5.0 to 20.0*ULN; Gr 4: >20.0*ULN. Total bilirubin Gr 1: >1.0 to 1.5*ULN; Gr 2: >1.5 to 3.0*ULN; Gr 3: >3.0 to 10..0*ULN; Gr 4: >10.0.0*ULN. ALP (U/L) Gr1:>1.0 to 2.5*ULN, Gr2:>2.5 to 5.0*ULN, Gr3:>5.0 to 20.0*ULN, Gr4:>20.0*ULN. Albumin (low) Gr 1:
Timeframe: First dose (Day 1) to last dose plus 60 days (assessed up to January 2017, approximately 71 months)
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Albumin Any Grade | Albumin Grade 3-4 | ALP Any Grade | ALP Grade 3-4 | ALT Any Grade | ALT Grade 3-4 | AST Any Grade | AST Grade 3-4 | Creatinine Any Grade | Creatinine Grade 3-4 | Bilirubin Total Any Grade | Bilirubin Total Grade 3-4 | |
| Elotuzumab 10 mg/kg | 3 | 0 | 1 | 0 | 2 | 1 | 1 | 1 | 0 | 0 | 1 | 0 |
| Elotuzumab 20 mg/kg | 3 | 0 | 2 | 0 | 2 | 1 | 2 | 1 | 2 | 0 | 0 | 0 |
"Best response to study treatment as defined by protocol-specific response criteria:~Complete Response (CR) = absence of urine and serum M-components by immunofixation; bone marrow should be adequately cellular (>20%) with <1% monoclonal plasma cells by DNA-clg flow cytometry; serum calcium level must be normal; no new bone lesions nor enlargement of existing lesions; Normalization of serum concentrations of normal immunoglobulins is not required for CR. Partial Response (PR) = Reduction by > 75% in serum myeloma protein production; Decrease in monoclonal marrow plasmacytosis to <5%; Decrease in Bence-Jones proteinuria by >90%; No new lytic bone lesions or soft tissue plasmacytoma.~Treatment Failures/Progressive Disease (PD) = Such patients do not fulfill the above criteria and/or have new lytic lesions (but not compression fractures), hypercalcemia, or other new manifestations of disease." (NCT00083382)
Timeframe: 2 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| Treatment Failure/Progressive Disease | Partial Response | Complete Response | |
| Thalidomide + Bisphosphonate | 56 | 17 | 10 |
Duration of response was calculated for responders and defined as the time from the first observation of a response (e.g., the first time that the appropriate decrease in M-protein level was observed for confirmed responders) to the first documented progression or relapse. Response duration was censored at the last adequate assessment showing evidence of no progression. (NCT00424047)
Timeframe: Up to data cut off of 03 August 2005; up to 24 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 67.6 |
| Placebo Plus Dexamethasone | 33.3 |
Duration of response was calculated for responders and defined as the time from the first observation of a response (e.g., the first time that the appropriate decrease in M-protein level was observed for confirmed responders) to the first documented progression or relapse. Response duration was censored at the last adequate assessment showing evidence of no progression. (NCT00424047)
Timeframe: Up to data cut off of 03 Mar 2008; up to 51 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 68.1 |
| Placebo Plus Dexamethasone | 33.3 |
OS was calculated as the time from randomization to death from any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented. (NCT00424047)
Timeframe: Randomization to data cut off of 03 August 2005; up to 24 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | NA |
| Placebo Plus Dexamethasone | NA |
OS was calculated as the time from randomization to death from any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented. (NCT00424047)
Timeframe: Randomization to data cut off of 02 March 2008; up to 51 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 161.9 |
| Placebo Plus Dexamethasone | 133.3 |
Time to progression was calculated as the time from randomization to the first occurrence of disease progression, as determined by a detailed review of all the myeloma response assessment data using the Bladé criteria (Bladé, 1998). Disease progression was also based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia. (NCT00424047)
Timeframe: From randomization up to cut-off date of 03 August 2005; up to 24 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 52.1 |
| Placebo Plus Dexamethasone | 20.1 |
Time to progression was calculated as the time from randomization to the first occurrence of disease progression, as determined by a detailed review of all the myeloma response assessment data using the Bladé criteria (Bladé, 1998). Disease progression was also based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia. (NCT00424047)
Timeframe: From randomization up to cut-off date of 02 March 2008; up to 51 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 52.4 |
| Placebo Plus Dexamethasone | 20.1 |
Time from randomization to the date of the first occurrence of a symptomatic SRE (clinical need for radiotherapy or surgery to bone). (NCT00424047)
Timeframe: Up to unblinding data cut off of 03 August 2005; up to 24 months
| Intervention | participants (Number) |
|---|---|
| Lenalidomide Plus Dexamethasone | NA |
| Placebo Plus Dexamethasone | NA |
The time to first worsening of the ECOG performance status was calculated as the time from randomization to the date of the first worsening compared with the last ECOG evaluation obtained prior to randomization. Data were censored at the last date that the participant was known to be unchanged or improved from before randomization for the participants who had not had worsened at the time of the analysis and for the patients who were lost to follow-up before worsening in the ECOG performance status was documented. (NCT00424047)
Timeframe: Randomization to cut off date of 03 August 2005; up to 24 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 10.1 |
| Placebo Plus Dexamethasone | 12.3 |
The time to first worsening of the ECOG performance status was calculated as the time from randomization to the date of the first worsening compared with the last ECOG evaluation obtained prior to randomization. Data were censored at the last date that the participant was known to be unchanged or improved from before randomization for the participants who had not had worsened at the time of the analysis and for the patients who were lost to follow-up before worsening in the ECOG performance status was documented. (NCT00424047)
Timeframe: Randomization to cut off date of 02 March 2008; up to 51 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 10.1 |
| Placebo Plus Dexamethasone | 12.3 |
Complete Response (CR): Disappearance of monoclonal paraprotein and maintained for ≥ 6 weeks . Remission Response (RR):75-99% reduction in the level of the serum monoclonal paraprotein compared to baseline; 90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR): 50-74% reduction in the level of monoclonal paraprotein compared to baseline; 50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD): Criteria for PR or PD have not been met. Plateau Phase: If PR, stable monoclonal paraprotein values (within 25% above or below nadir)/stable soft tissue plasmacytomas maintained for at least 3 months. Progressive Disease (PD): Reappearance of serum or urinary monoclonal paraprotein on immunofixation or electrophoresis on two consecutive occasions at least one week apart. Increase of percentage of plasma cells in bone marrow aspirate or biopsy to ≥ 5%. Development of at least one new lytic bone lesion or soft tissue plasmacytoma. (NCT00424047)
Timeframe: Randomization to data cut-off of 02 Mar 2008; up to 51 months
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Stable Disease (SD) | Progressive Disease (PD) | Not Evaluable (NE) those without response data | |
| Lenalidomide Plus Dexamethasone | 17.0 | 42.6 | 28.4 | 3.4 | 8.5 |
| Placebo Plus Dexamethasone | 4.0 | 19.4 | 56.6 | 14.3 | 5.7 |
"An AE is any sign, symptom, illness, or diagnosis that appears or worsens during the course of the study. Treatment-emergent AEs (TEAEs) are any AE occurring or worsening on or after the first treatment of the study drug and within 30 days after the last cycle end date of study drug. A serious AE = any AE which results in death; is life-threatening; requires or prolongs existing inpatient hospitalization; results in persistent or significant disability is a congenital anomaly/birth defect; constitutes an important medical event.~The severity of AEs were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE, Version 2.0): Grade 1 = Mild (no limitation in activity or intervention required); Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required); Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); Grade 4 = Life-threatening; Grade 5 = Death." (NCT00424047)
Timeframe: From first dose of study drug through to 30 days after the last dose, until the data cut-off date of 25 June 2013; up to 90 months
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ≥ 1 Adverse Event | ≥ 1 Serious Adverse Event | ≥ 1 AE leading to study drug discontinuation | ≥ 1 AE leading to dose reduction or interruption | ≥ 1 Drug-Related Adverse Event | ≥ 1 Drug-Related Serious Adverse Event | ≥Death within ≤ 30 days of last dose of study drug | ≥ 1 Grade 1 or Higher Adverse Event | ≥ 1 Grade 2 or Higher Adverse Event | ≥ 1 Grade 3 or Higher Adverse Event | ≥ 1 Grade 4 or Higher Adverse Event | |
| Lenalidomide Plus Dexamethasone | 176 | 105 | 46 | 137 | 160 | 54 | 17 | 176 | 168 | 146 | 52 |
| Placebo Plus Dexamethasone | 175 | 79 | 31 | 100 | 151 | 30 | 20 | 175 | 167 | 119 | 37 |
Complete Response (CR): Disappearance of monoclonal paraprotein and maintained for ≥ 6 weeks . Remission Response (RR):75-99% reduction in the level of the serum monoclonal paraprotein compared to baseline; 90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR): 50-74% reduction in the level of monoclonal paraprotein compared to baseline; 50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD): Criteria for PR or PD have not been met. Plateau Phase: If PR, stable monoclonal paraprotein values (within 25% above or below nadir)/stable soft tissue plasmacytomas maintained for at least 3 months. Progressive Disease (PD): Reappearance of serum or urinary monoclonal paraprotein on immunofixation or electrophoresis on two consecutive occasions at least one week apart. Increase of percentage of plasma cells in bone marrow aspirate or biopsy to ≥ 5%. Development of at least one new lytic bone lesion or soft tissue plasmacytoma. (NCT00424047)
Timeframe: Randomization to 03 August 2005; up to 24 months
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Stable Disease (SD) | Progressive Disease (PD) | Not Evaluable (NE) those without response data | |
| Lenalidomide Plus Dexamethasone | 15.3 | 43.8 | 29.0 | 2.8 | 9.1 |
| Placebo Plus Dexamethasone | 4.0 | 19.4 | 56.6 | 14.3 | 5.7 |
The overall confirmed response that was maintained for ≥6 weeks. Complete Response (CR):Disappearance of monoclonal paraprotein. Remission Response (RR):75-99% reduction in monoclonal paraprotein/90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR):50-74% reduction in monoclonal paraprotein/50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD):Criteria for PR or PD not met. Plateau Phase:If PR, stable monoclonal paraprotein (within 25% above or below nadir)/stable soft tissue plasmacytomas. Progressive Disease (PD):Disease worsens. (NCT00056160)
Timeframe: Up to Unblinding (07 Jun 2005)
| Intervention | Participants (Number) |
|---|---|
| CC-5013/Dex | 107 |
| Placebo/Dex | 34 |
Overall survival was calculated as the time from randomization to death from any cause. (NCT00056160)
Timeframe: 170 weeks (median overall survival of CC-5013/Dex treatment group)
| Intervention | Weeks (Median) |
|---|---|
| CC-5013/Dex | 170.1 |
| Placebo/Dex | 136.4 |
The time to first worsening on the ECOG Performance Scale was calculated as the time from randomization to the date of the first worsening compared to the last ECOG evaluation obtained prior to randomization. (NCT00056160)
Timeframe: 30 weeks (mean time to first worsening of ECOG performance status for CC-5013/Dex treatment group)
| Intervention | Weeks (Mean) |
|---|---|
| CC-5013/Dex | 29.9 |
| Placebo/Dex | 15.0 |
Time to progression (TTP) was calculated as the time from randomization to the first documentation of progressive disease based on the myeloma response determination criteria developed by Bladé et. al., Br J Haematol 1998; 102:1115-1123. (NCT00056160)
Timeframe: 60 weeks (median Time To Progression of CC-5013/Dex treatment group)
| Intervention | Weeks (Median) |
|---|---|
| CC-5013/Dex | 60.1 |
| Placebo/Dex | 20.1 |
The combined score on the FACT-Ntx TOI is of interest. The FACT-Ntx TOI has 25 items and the score ranges from 0 (worst possible quality of life) -100 (best possible quality of life). The primary QOL endpoint is defined as the change in the FACT-Ntx TOI score from registration to 6 months post consolidation treatment. (NCT00522392)
Timeframe: Baseline and 6 months post consolidation treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Arm A (VRD) | -7.9 |
| Arm B (VD) | -2.6 |
Overall survival is defined as the time from randomization to death or date of last known alive. The OS results are based on data as of April 2014. (NCT00522392)
Timeframe: Assessed every 3 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, every 12 months if patient is 6-10 years from study entry, up to 10 years
| Intervention | Months (Median) |
|---|---|
| Arm A (VRD) | 64.0 |
| Arm B (VD) | NA |
"Progression-free survival was defined as the time from randomization to the earliest documentation of disease progression (PD) or death. If a patient died without evidence of PD, the patient was considered an event if death occurred within 3 months of the last disease assessment. Patients who died outside of the specified interval or patients who were alive without evidence of PD were censored at the date of last disease assessment.~The PFS results are based on data as of August 2012, while overall survival (OS) was updated in April 2014. Given the early termination and limited sample size, data management efforts to update PFS were not pursued." (NCT00522392)
Timeframe: Assessed every 3 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, every 12 months if patient is 6-10 years from study entry, up to 10 years
| Intervention | Months (Median) |
|---|---|
| Arm A (VRD) | NA |
| Arm B (VD) | 17.4 |
"CR:~Patients with complete disappearance of an M-protein and no evidence of myeloma in the bone marrow are considered to have CR. To be considered CR, patients must meet all of the following criteria:~Negative immunofixation on the serum and urine at two consecutive times~Disappearance of any soft tissue plasmacytomas~≤5% plasma cells in bone marrow~If serum and urine M protein are unmeasurable and the immunoglobulin free light chain (FLC) parameter is being used, patients must have a normal ratio of 0.26-1.65 at two consecutive times~VGPR:~Serum and urine M-component detectable by immunofixation but not on electrophoresis OR~>=90% reduction in serum M-component plus urine M-component <100 mg per 24 hours (by SPEP and UPEP)~If the serum and urine M protein are unmeasurable and the immunoglobulin FLC parameter is being used, a >90% decrease in the difference between involved and uninvolved FLC levels is required in place of the M protein criteria" (NCT00522392)
Timeframe: Assessed at the end of each cycle, every 3 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, every 12 months if patient is 6-10 years from study entry, up to 10 years
| Intervention | Proportion of patients (Number) |
|---|---|
| Arm A (VRD) | 0.625 |
| Arm B (VD) | 0.188 |
Data from all subjects who received any study drug were included in the analysis. Adverse events were classified using the Medical Dictionary for Regulatory Activities (MedDRA) classification system. A subject having the same event more than once was counted only once. Adverse events were summarized by worst NCI (National Cancer Institute) CTCAE (Common Terminology Criteria for Adverse Events) VERSION 3.0 grade. Incidence was defined as the number of subjects who experienced an adverse event within their period of participation in this study. (NCT00179647)
Timeframe: Median time-on-study=18.3 weeks
| Intervention | Participants (Number) |
|---|---|
| Lenalidomide | 1877 |
To assess Grade 3-5 AE related to thalidomide/dexamethasone when administered as a pre-transplant induction regimen. (NCT00040937)
Timeframe: Induction
| Intervention | Participants (Number) |
|---|---|
| Induction/PBSC Mobilization | 2 |
(NCT00040937)
Timeframe: 4-7 years
| Intervention | proportion surviving at 4 years (Number) |
|---|---|
| Treatment Arm | .64 |
(NCT01453088)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Auto Transplant High Dose Melphalan | 27 |
| Auto Transplant High Dose Melphalan+Bortezomib | 27 |
Progression free survival of elderly patients with multiple myeloma treated with either high-dose melphalan versus high-dose melphalan and bortezomib at 3 years (NCT01453088)
Timeframe: Participants will be followed post transplant for a minimum of 3 years, and after that may be monitored as part of the study indefinitely
| Intervention | Participants (Count of Participants) |
|---|---|
| Auto Transplant High Dose Melphalan | 13 |
| Auto Transplant High Dose Melphalan+Bortezomib | 11 |
"Objective response is defined as either complete response (CR) or partial response (PR). Patients who have complete disappearance of an M-protein and no evidence of myeloma in the bone marrow are considered to have CR. PR requires all the following: (1) ≥50% reduction in the level of the serum monoclonal paraprotein. (2) Reduction in 24-hour urinary light chain excretion either by ≥90% or to <200 mg. (3)For patients with non-secretory (or oligosecretory) myeloma only, a ≥50% reduction in plasma cells in a bone marrow aspirate and on trephine biopsy must be documented. (4)50% reduction in size of soft tissue plasmacytoma (by radiography or clinical examination). (5) No increase in the number or size of lytic bone lesions (development of a compression fracture does not exclude response).~As the expansion phase was a substudy terminated early with only 7 patients enrolled, the clinical results presented are mainly for the first phase only." (NCT00098475)
Timeframe: Assessed every 4 weeks for 16 weeks during Step 1
| Intervention | Proportion of patients (Number) |
|---|---|
| Arm I (Lenalidomide, Dexamethasone) | 0.79 |
| Arm II (Lenalidomide, Low-dose Dexamethasone) | 0.683 |
"Objective response is defined as either complete response (CR) or partial response (PR). Patients who have complete disappearance of an M-protein and no evidence of myeloma in the bone marrow are considered to have CR. PR requires all the following: (1) ≥50% reduction in the level of the serum monoclonal paraprotein. (2) Reduction in 24-hour urinary light chain excretion either by ≥90% or to <200 mg. (3)For patients with non-secretory (or oligosecretory) myeloma only, a ≥50% reduction in plasma cells in a bone marrow aspirate and on trephine biopsy must be documented. (4)50% reduction in size of soft tissue plasmacytoma (by radiography or clinical examination). (5) No increase in the number or size of lytic bone lesions (development of a compression fracture does not exclude response).~As the expansion phase was a substudy terminated early with only 7 patients enrolled, the clinical results presented are mainly for the first phase only." (NCT00098475)
Timeframe: Assessed every 4 weeks for 16 weeks during Step 2
| Intervention | Proportion of patients (Number) |
|---|---|
| Arm I (Lenalidomide, Dexamethasone) | 0 |
| Arm II (Lenalidomide, Low-dose Dexamethasone) | 0 |
"Duration of response is the time from date of first documented confirmed response to date of first documented progressive disease. A confirmed response is a response that has been observed on at least two consecutive assessments.~Disease progression requires any one or more of the following: serum m-protein increase >= 25% from nadir(absolute increase >= 0.5 g/dL); Urine m-protein increase >= 25% from nadir(absolute increase >= 200 mg/24 hr), bone marrow plasma cell percentage increase >= 25% from nadir(absolute increase >= 10%), new bone lesion or soft tissue plasmacytomas." (NCT00507442)
Timeframe: Up to 48 weeks or until disease progression
| Intervention | days (Median) |
|---|---|
| V-DR | NA |
| VDCR | NA |
| V-DC | NA |
| VDC-mod | NA |
Evaluate the safety and tolerability of the combination therapy (NCT00507442)
Timeframe: From first dose of study drug through the 30 day post-treatment AE assessment visit
| Intervention | participants (Number) |
|---|---|
| V-DR | 42 |
| VDCR | 65 |
| V-DC | 33 |
| VDC-mod | 17 |
"Complete response requires negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and < 5% plasma cells in bone marrow.~Very good partial response requires serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level < 100 mg per 24 h" (NCT00507442)
Timeframe: Up to 48 weeks or until disease progression
| Intervention | participants (Number) |
|---|---|
| V-DR | 21 |
| VDCR | 23 |
| V-DC | 13 |
| VDC-mod | 9 |
"Complete response requires negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and < 5% plasma cells in bone marrow.~Near Complete response requires positive immunofixation on the serum and/or urine and disappearance of any soft tissue plasmacytomas and < 5% plasma cells in bone marrow." (NCT00507442)
Timeframe: Up to 48 weeks or until disease progression
| Intervention | participants (Number) |
|---|---|
| V-DR | 17 |
| VDCR | 14 |
| V-DC | 10 |
| VDC-mod | 8 |
"Overall Response includes complete response and partial response.~Complete response requires negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and < 5% plasma cells in bone marrow.~Partial response requires at least 50% reduction of serum M-protein and reduction in 24-h urinary M-protein by at least 90% or to < 200 mg per 24 hour." (NCT00507442)
Timeframe: Up to 48 weeks or until disease progression
| Intervention | participants (Number) |
|---|---|
| V-DR | 35 |
| VDCR | 35 |
| V-DC | 24 |
| VDC-mod | 17 |
Stringent Complete Response is defined as complete response plus normal free light chain (kappa/lambda) ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence. (NCT00507442)
Timeframe: Up to 48 weeks or until disease progression
| Intervention | participants (Number) |
|---|---|
| V-DR | 7 |
| VDCR | 6 |
| V-DC | 3 |
| VDC-mod | 5 |
Overall survival is defined as time from the date of randomization to the date of death (NCT00507442)
Timeframe: Up to 48 weeks or until death
| Intervention | days (Median) |
|---|---|
| V-DR | NA |
| VDCR | NA |
| V-DC | NA |
| VDC-mod | NA |
(NCT00507442)
Timeframe: survival probability at 1 year after randomization
| Intervention | percentage of patients (Number) |
|---|---|
| V-DR | 100 |
| VDCR | 91.6 |
| V-DC | 100 |
| VDC-mod | 100 |
"Progression-free survival is defined as time from the date of randomization to the date of the first documented progressive disease or death.~Disease progression requires any one or more of the following: serum m-protein increase >= 25% from nadir(absolute increase >= 0.5 g/dL); Urine m-protein increase >= 25% from nadir(absolute increase >= 200 mg/24 hr), bone marrow plasma cell percentage increase >= 25% from nadir(absolute increase >= 10%), new bone lesion or soft tissue plasmacytomas." (NCT00507442)
Timeframe: Up to 48 weeks or until disease progression/death
| Intervention | days (Median) |
|---|---|
| V-DR | NA |
| VDCR | 631 |
| V-DC | NA |
| VDC-mod | NA |
"Time to disease progression is defined as time from the date of randomization to the date of first documented progressive disease.~Disease progression requires any one or more of the following: serum m-protein increase >= 25% from nadir(absolute increase >= 0.5 g/dL); Urine m-protein increase >= 25% from nadir(absolute increase >= 200 mg/24 hr), bone marrow plasma cell percentage increase >= 25% from nadir(absolute increase >= 10%), new bone lesion or soft tissue plasmacytomas." (NCT00507442)
Timeframe: Up to 48 weeks or until disease progression
| Intervention | days (Median) |
|---|---|
| V-DR | NA |
| VDCR | NA |
| V-DC | NA |
| VDC-mod | NA |
Time to response is defined as time from date of randomization to the date of the first documentation of a confirmed response. confirmed response is a response that has been observed on at least two consecutive assessments. (NCT00507442)
Timeframe: Up to 48 weeks or until disease response
| Intervention | days (Median) |
|---|---|
| V-DR | 49 |
| VDCR | 50 |
| V-DC | 55 |
| VDC-mod | 49 |
"Progression is defined as a > 25% increase from baseline in myeloma protein production or other signs of disease progression such as hypercalcemia, etc.~In patients with a confirmed Partial Remission, Remission, or Complete Remission, relapse is defined as the first occurrence of any of the following: 1) a myeloma protein increase by than 100% from the lowest level recorded on study, provided the absolute magnitude of this increase is at least 1g/dL for a serum monoclonal protein or at least 500 mg/24 hrs of urine M-protein; 2) a myeloma protein increase above the response criteria for Partial Remission, with the same requirements for the absolute magnitude of the protein increase; 3)reappearance of any myeloma peak that had disappeared while on protocol treatment, provided it meets the same requirements listed above; 4) increase in the size and number of lytic bone lesions recognized on radiographs." (NCT00064038)
Timeframe: From date of initial registration to date of progression/relapse of disease or death from any cause, whichever came first, up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide+Dexamethasone | 78 |
| Dexamethasone | 52 |
Compare the toxicity profile of these regimens, including thrombotic complications, in these patients, based on CTCAE v. 3.0. (NCT00064038)
Timeframe: From time of initiating study treatment until discontinuation of study treatment or of open-label REVLIMID + LOW DOSE DEX, whichever comes last, up to 5 years
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT, SGPT (serum glutamic pyruvic transaminase) | AST, SGOT | Albumin, serum-low (hypoalbuminemia) | Anorexia | Apnea | Arthritis (non-septic) | Aspiration | Ataxia (incoordination) | Bilirubin (hyperbilirubinemia) | CNS cerebrovascular ischemia | Calcium, serum-high (hypercalcemia) | Calcium, serum-low (hypocalcemia) | Cardiopulmonary arrest, cause unknown (non-fatal) | Cataract | Cognitive disturbance | Colitis | Colitis, infectious (e.g., Clostridium difficile) | Confusion | Constipation | Creatinine | Cystitis | Dehydration | Dermatology/Skin-Other (Specify) | Diarrhea | Dizziness | Dyspnea (shortness of breath) | Edema: limb | Encephalopathy | Fatigue (asthenia, lethargy, malaise) | Febrile neutropenia | Fever in absence of neutropenia, ANC lt1.0x10e9/L | Fracture | Gastritis (including bile reflux gastritis) | Gastrointestinal-Other (Specify) | Glomerular filtration rate | Glucose, serum-high (hyperglycemia) | Glucose, serum-low (hypoglycemia) | Heartburn/dyspepsia | Hemoglobin | Hemorrhage, CNS | Hemorrhage, GI - Colon | Hypertension | Hypotension | Hypoxia | INR (of prothrombin time) | Inf (clin/microbio) w/Gr 3-4 neuts - Blood | Inf (clin/microbio) w/Gr 3-4 neuts - Bronchus | Inf (clin/microbio) w/Gr 3-4 neuts - Lung | Inf (clin/microbio) w/Gr 3-4 neuts - Up aerodigest | Inf (clin/microbio) w/Gr 3-4 neuts - Upper airway | Inf w/normal ANC or Gr 1-2 neutrophils - Bladder | Inf w/normal ANC or Gr 1-2 neutrophils - Bronchus | Inf w/normal ANC or Gr 1-2 neutrophils - Colon | Inf w/normal ANC or Gr 1-2 neutrophils - Lung | Inf w/normal ANC or Gr 1-2 neutrophils - Skin | Inf w/normal ANC or Gr 1-2 neutrophils - UTI | Inf w/normal ANC or Gr 1-2 neutrophils - Up airway | Inf w/normal ANC or Gr 1-2 neutrophils - Wound | Inf w/normal ANC or Gr 1-2 neutrophils -Nerve-cran | Infection with unknown ANC - Lung (pneumonia) | Infection with unknown ANC - Upper airway NOS | Infection-Other (Specify) | Insomnia | Joint-function | Left ventricular diastolic dysfunction | Left ventricular systolic dysfunction | Leukocytes (total WBC) | Lymphopenia | Mood alteration - agitation | Mood alteration - anxiety | Mood alteration - depression | Mucositis/stomatitis (clinical exam) - Oral cavity | Muscle weakness, not d/t neuropathy - Extrem-lower | Muscle weakness, not d/t neuropathy - body/general | Musculoskeletal/Soft Tissue-Other (Specify) | Nausea | Neuropathy: motor | Neuropathy: sensory | Neutrophils/granulocytes (ANC/AGC) | Ocular/Visual-Other (Specify) | Ophthalmoplegia/diplopia (double vision) | Opportunistic inf associated w/gt=Gr 2 lymphopenia | PTT (Partial thromboplastin time) | Pain - Abdomen NOS | Pain - Back | Pain - Bladder | Pain - Bone | Pain - Extremity-limb | Pain - Head/headache | Pain - Joint | Pain - Muscle | Pain - Pain NOS | Pain - Stomach | Pain-Other (Specify) | Pancreatic endocrine: glucose intolerance | Perforation, GI - Colon | Perforation, GI - Small bowel NOS | Phosphate, serum-low (hypophosphatemia) | Platelets | Pneumonitis/pulmonary infiltrates | Potassium, serum-low (hypokalemia) | Prolonged QTc interval | Proteinuria | Pulmonary/Upper Respiratory-Other (Specify) | Rash/desquamation | Rash: acne/acneiform | Rash: erythema multiforme | Renal failure | SVT and nodal arrhythmia - Atrial fibrillation | Sodium, serum-high (hypernatremia) | Sodium, serum-low (hyponatremia) | Somnolence/depressed level of consciousness | Speech impairment (e.g., dysphasia or aphasia) | Syncope (fainting) | Thrombosis/embolism (vascular access-related) | Thrombosis/thrombus/embolism | Thrombotic microangiopathy | Thyroid function, low (hypothyroidism) | Tinnitus | Vision-blurred vision | Vomiting | Weight loss | |
| Crossover to Rev+Dex | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 3 | 0 | 2 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 3 | 0 | 1 | 2 | 0 | 2 | 1 | 8 | 1 | 0 | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 8 | 1 | 0 | 2 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 7 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 3 | 2 | 3 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 0 | 0 | 3 | 1 | 1 | 0 | 0 | 5 | 0 | 0 | 0 | 1 | 0 | 1 |
| Dexamethasone | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 1 | 1 | 1 | 2 | 1 | 0 | 12 | 0 | 1 | 1 | 0 | 0 | 0 | 18 | 0 | 1 | 5 | 0 | 0 | 3 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 3 | 1 | 2 | 1 | 0 | 0 | 0 | 1 | 1 | 6 | 0 | 0 | 0 | 5 | 5 | 1 | 1 | 8 | 1 | 3 | 4 | 2 | 1 | 1 | 4 | 6 | 0 | 1 | 0 | 1 | 2 | 2 | 0 | 3 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 4 | 4 | 2 | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 2 | 1 | 2 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 3 | 1 | 0 |
| Lenalidomide and Dexamethasone | 1 | 2 | 1 | 2 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 7 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 5 | 1 | 4 | 0 | 0 | 19 | 1 | 1 | 0 | 0 | 1 | 0 | 5 | 1 | 0 | 6 | 1 | 1 | 0 | 3 | 4 | 1 | 1 | 1 | 5 | 1 | 1 | 2 | 0 | 1 | 1 | 2 | 2 | 3 | 1 | 0 | 1 | 1 | 0 | 4 | 1 | 0 | 1 | 14 | 10 | 1 | 1 | 11 | 0 | 1 | 9 | 0 | 2 | 0 | 3 | 21 | 1 | 0 | 2 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 3 | 3 | 1 | 0 | 0 | 0 | 1 | 0 | 5 | 7 | 3 | 6 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 1 | 2 | 19 | 1 | 1 | 1 | 2 | 2 | 0 |
Clinical evaluations of disease response were determined with each cycle. Bone marrow biopsies were done at baseline and at study termination. Clinical responses were defined by the International Myeloma Working Group criteria: Stringent Complete Response (SCR), CR and normal free light chain ratio and no clonal cells in bone marrow; Complete Response (CR), Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; Very Good Partial Response (VGPR), Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours; Partial Response (PR), ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to < 200 mg/24 hours. Objective response is defined as a best overall response of SCR, CR, VGPR, or PR. (NCT00287872)
Timeframe: 1-6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Bortezomib and Thalidomide | 81.5 |
Neuropathy was monitored using Total Neuropathy Score reduced (TNSr). (NCT00287872)
Timeframe: 1-6 months
| Intervention | participants (Number) |
|---|---|
| Bortezomib and Thalidomide | 19 |
(NCT00287872)
Timeframe: 1-6 months
| Intervention | months (Median) |
|---|---|
| Bortezomib and Thalidomide | 2 |
"Partial Response:~50% reduction in the level of serum monoclonal protein for at least two determinations six weeks apart.~If present, reduction in 24-hour urinary light chain excretion by either, greater than or equal to 90%, or to <200 mg for at least two determinations six weeks apart.~50% reduction in the size of soft tissue plasmacytomas (by clinical or radiographic examination) for at least six weeks.~No increase in size or number of lytic bone lesions (development of compression fracture does not exclude response).~Complete Response:~Disappearance of the original monoclonal protein from the blood and urine on at least two determinations for a minimum of six weeks.~<5% plasma cells in the bone marrow on at least two determinations for a minimum of six weeks.~No increase in the size or number of lytic bone lesions." (NCT00724568)
Timeframe: 24 weeks (8, 21-day cycles)
| Intervention | percentage of patients (Number) |
|---|---|
| Combination Drug Therapy | 96 |
"Dose Level 1:~15 mg Revlimid daily on days 1-14 followed by 7-day rest every 21 days 1.3 mg/m2 Velcade daily on days 1, 4, 8 and 11 20 mg dexamethasone daily on Days 1, 2, 4, 5, 8, 9, 11, 12* and 20 mg/m2 Doxil daily on day 4~Dose Level 2:~20 mg Revlimid daily on days 1-14 followed by 7-day rest every 21 days 1.3 mg/m2 Velcade daily on days 1, 4, 8 and 11 20 mg dexamethasone daily on Days 1, 2, 4, 5, 8, 9, 11, 12* and 20 mg/m2 Doxil daily on day 4~Dose Level 3:~25 mg Revlimid daily on days 1-14 followed by 7-day rest every 21 days 1.3 mg/m2 Velcade daily on days 1, 4, 8 and 11 20 mg dexamethasone daily on Days 1, 2, 4, 5, 8, 9, 11, 12* and 20 mg/m2 Doxil daily on day 4~Dose Level 4:~25 mg Revlimid daily on days 1-14 followed by 7-day rest every 21 days 1.3 mg/m2 Velcade daily on days 1, 4, 8 and 11 20 mg dexamethasone daily on Days 1, 2, 4, 5, 8, 9, 11, 12* and 30 mg/m2 Doxil daily on day 4" (NCT00724568)
Timeframe: 1 month post treatment
| Intervention | mg (Number) | |||
|---|---|---|---|---|
| Revlimid | VELCADE | Dexamethasone | Doxil | |
| Combination Drug Therapy | 25 | 1.3 | 20 | 30 |
Duration of response was calculated from the documentation (date) of first response (CR, VGPR, or PR) until the date of progression or last follow-up in the subset of patients who responded. The median DOR with 95%CI was estimated using the Kaplan Meier method. (NCT00478218)
Timeframe: up to 5 years
| Intervention | months (Median) |
|---|---|
| LCD (Cyclophosphamide 300 mg/m^2) | 26.1 |
| LCD (Cyclophosphamide 300 mg) | NA |
"Response that was confirmed on 2 consecutive evaluations during treatment~Complete Response(CR): Complete disappearance of M-protein from serum & urine on immunofixation, normalization of Free Light Chain (FLC) ratio & <5% plasma cells in bone marrow (BM)~Very Good Partial Response(VGPR): >=90% reduction in serum M-component; Urine M-Component <100 mg per 24 hours; <=5% plasma cells in BM~Partial Response PR): >= 50% reduction in serum M-Component and/or Urine M-Component >= 90% reduction or <200 mg per 24 hours; or >= 50% decrease in difference between involved and uninvolved FLC levels" (NCT00478218)
Timeframe: Duration of Treatment (up to 5 years)
| Intervention | participants (Number) |
|---|---|
| LCD (Cyclophosphamide 300 mg/m^2) | 28 |
| LCD (Cyclophosphamide 300 mg) | 16 |
OS was defined as the time from registration to death of any cause. Participants were followed for a maximum of 5 years from randomization. The median OS with 95%CI was estimated using the Kaplan Meier method. (NCT00478218)
Timeframe: up to 5 years
| Intervention | months (Median) |
|---|---|
| LCD (Cyclophosphamide 300 mg/m^2) | NA |
| LCD (Cyclophosphamide 300 mg) | NA |
"PFS was defined as the time from registration to progression or death due to any cause. The median PFS with 95%CI was estimated using the Kaplan Meier method.> Progression was defined as any one or more of the following:> An increase of 25% from lowest confirmed response in:>~Serum M-component (absolute increase >= 0.5g/dl)>~Urine M-component (absolute increase >= 200mg/24hour>~Difference between involved and uninvolved Free Light Chain levels (absolute increase >= 10mg/dl>~Bone marrow plasma cell percentage (absolute increase of >=10%)" (NCT00478218)
Timeframe: up to 5 years
| Intervention | months (Median) |
|---|---|
| LCD (Cyclophosphamide 300 mg/m^2) | 27 |
| LCD (Cyclophosphamide 300 mg) | NA |
(NCT02424851)
Timeframe: End of week 6 (after receiving two cycles of therapy)
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (BBD) | 13 |
| Arm B (BTD) | 3 |
(NCT02424851)
Timeframe: 1 month post end of treatment and 1 year post randomisation
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (BBD) | 9 |
| Arm B (BTD) | 13 |
(NCT02424851)
Timeframe: End of weeks 3, 6, 9, 12 (after receiving 4 cycles of therapy), 30 days after final treatment and 12 months after randomisation
| Intervention | Events (Number) | |
|---|---|---|
| Serious adverse events | Adverse events | |
| Arm A (BBD) | 2 | 3 |
| Arm B (BTD) | 0 | 6 |
"The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension is scored on a scale of 1 to 3: 1 (no problems), 2 (some problems), and 3 (extreme problems). Higher score equates to a worse outcome.~As stated in the official EQ-5D user guide, patient responses to the 5 questions were converted into a single index value as per Dolan P (1997). Modeling valuations for EuroQol health states. Med Care 35(11):1095-108. These index values, with country specific value sets, facilitate the calculation of quality-adjusted life years (QALYs) that are used to inform economic evaluations of health care interventions. In the UK, the values range from -0.594 to +1." (NCT02424851)
Timeframe: Baseline and 1 month follow up
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline | 1 month FU | |
| Arm A (BBD) | 0.72 | 0.69 |
| Arm B (BTD) | 0.69 | 0.80 |
(NCT02424851)
Timeframe: End of 2nd treatment cycle, week 6
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Partial response | Minor response | No repsonse | |
| Arm A (BBD) | 2 | 9 | 4 |
| Arm B (BTD) | 0 | 7 | 6 |
Duration of response was calculated from the documentation (date) of first response (CR, VGPR, or PR) until the date of progression or last follow-up in the subset of patients who responded. Kaplan Meier method was used to compute this outcome. (NCT00558896)
Timeframe: Duration of study (up to 5 years)
| Intervention | months (Median) |
|---|---|
| Relapsed Myeloma (<4 Prior Regimens): Low Dose | 21.3 |
| Lenalidomide Refractory Myeloma: Low Dose | 8.2 |
| Bortezomib/Lenalidomide Refractory/Relapsed Myeloma: Low Dose | 15.6 |
| Bortezomib/Lenalidomide Relapsed/Refractory Myeloma: High Dose | 3.1 |
| Relapsed Myeloma (< 4 Prior Regimens): High Dose | NA |
| Relapsed/Refractory Myeloma: High Dose | 8.3 |
| Relapsed Amyloidosis: Low Dose | 19 |
"PFS was defined as the time from registration to progression or death due to any cause. PFS was analyzed using Kaplan Meier method.~Progression was defined as any one or more of the following:~25% increase in serum M-component (absolute increase >= 0.5g/dl)~25% increase in urine M-component (absolute increase >= 200mg/24hour~25% increase in the difference between involved and uninvolved Free Light Chain levels (absolute increase >= 10mg/dl)~25% increase in bone marrow plasma cell percentage (absolute increase of >=10%)~Definite development of new bone lesion or soft tissue plasmacytomas" (NCT00558896)
Timeframe: Duration of study (up to 5 years)
| Intervention | months (Median) |
|---|---|
| Relapsed Myeloma (<4 Prior Regimens): Low Dose | 13 |
| Lenalidomide Refractory Myeloma: Low Dose | 5 |
| Bortezomib/Lenalidomide Refractory/Relapsed Myeloma: Low Dose | 6.4 |
| Bortezomib/Lenalidomide Relapsed/Refractory Myeloma: High Dose | 3.3 |
| Relapsed Myeloma (< 4 Prior Regimens): High Dose | 7.7 |
| Relapsed/Refractory Myeloma: High Dose | 4.3 |
| Relapsed Amyloidosis: Low Dose | 14.1 |
"Response that was confirmed on 2 consecutive evaluations~Complete Response(CR): Complete disappearance of M-protein from serum and urine on immunofixation, normalization of Free Light Chain (FLC) ratio and <5% plasma cells in bone marrow.~Very Good Partial Response(VGPR): >=90% reduction in serum M-component; Urine M-Component <100mg per 24hours; <=5% plasma cells in bone marrow.~Partial Response(PR): >=50% reduction in serum M-component and/or Urine M-Component >=90% reduction or <200mg per 24hours; or >=50% decrease in difference between involved and uninvolved FLC levels." (NCT00558896)
Timeframe: Duration of study (up to 3 years)
| Intervention | participants (Number) |
|---|---|
| Relapsed Myeloma (<4 Prior Regimens): Low Dose | 39 |
| Lenalidomide Refractory Myeloma: Low Dose | 11 |
| Bortezomib/Lenalidomide Refractory/Relapsed Myeloma: Low Dose | 9 |
| Bortezomib/Lenalidomide Relapsed/Refractory Myeloma: High Dose | 10 |
| Relapsed Myeloma (< 4 Prior Regimens): High Dose | 23 |
| Relapsed/Refractory Myeloma: High Dose | 25 |
| Relapsed Amyloidosis: Low Dose | 16 |
The response of myeloma to BDDTD will be assessed by standard electrophoretic and immunofixation tests of blood and urine for a monoclonal protein (M protein), and bone marrow aspirate and biopsy. These tests will be performed at enrollment and at the conclusion of therapy. (NCT00458705)
Timeframe: 2 years
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Complete Response | Near Complete Response | Partial Response | Stable Disease | Progression of Disease | Very Good Partial Response | |
| Combination Therapy | 10 | 8 | 10 | 2 | 3 | 7 |
Patients are considered experiencing an event when they progress. Deaths without progression are considered as a competing risk. Patients initiating non-protocol anti-myeloma therapy are considered to have progressed on this protocol. (NCT00075829)
Timeframe: Year 3
| Intervention | percentage of patients (Number) |
|---|---|
| Auto-Auto Standard Risk | 50 |
| Auto-Allo Standard Risk | 46 |
| Auto-Auto High Risk | 57 |
| Auto-Allo High Risk | 38 |
TRM is defined as death occurring in a patient from causes other than relapse or progression. (NCT00075829)
Timeframe: Year 3
| Intervention | percentage of participants (Number) |
|---|---|
| Auto-Auto Standard Risk | 4 |
| Auto-Allo Standard Risk | 11 |
| Auto-Auto High Risk | 11 |
| Auto-Allo High Risk | 22 |
Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients will receive a second transplant according to treatment assignments. (NCT00075829)
Timeframe: Year 1
| Intervention | days (Median) |
|---|---|
| Auto-Auto Standard Risk | 98 |
| Auto-Allo Standard Risk | 105 |
| Auto-Auto High Risk | 101 |
| Auto-Allo High Risk | 111 |
The event is death from any cause, patients alive at the time of last observation are considered censored. (NCT00075829)
Timeframe: Year 3
| Intervention | percentage of participants (Number) |
|---|---|
| Auto-Auto High Risk | 67 |
| Auto-Allo High Risk | 59 |
Patients are considered a failure for this endpoint if they die or if they progress or relapse. (NCT00075829)
Timeframe: Year 3
| Intervention | percentage of patients (Number) |
|---|---|
| Auto-Auto Standard Risk | 46 |
| Auto-Allo Standard Risk | 43 |
| Auto-Auto High Risk | 33 |
| Auto-Allo High Risk | 40 |
Incidence and severity of chronic GVHD will be scored according to the BMT clinical trials network Manual of Procedures. (NCT00075829)
Timeframe: Years 1 and 2
| Intervention | percentage of patients (Number) | |
|---|---|---|
| 1 year | 2 years | |
| Auto-Allo Standard Risk | 47 | 54 |
Incidence and severity of GVHD will be scored according to the BMT clinical trials network Manual of Procedures. (NCT00075829)
Timeframe: Day 100
| Intervention | percentage of patients (Number) | |
|---|---|---|
| Grades II-IV | Grades III-IV | |
| Auto-Allo Standard Risk | 26 | 9 |
The event is death from any cause, patients alive at the time of last observation are considered censored. (NCT00075829)
Timeframe: Years 1, 2, and 3
| Intervention | percentage of patients (Number) | ||
|---|---|---|---|
| 1 year | 2 years | 3 years | |
| Auto-Allo Standard Risk | 91 | 85 | 77 |
| Auto-Auto Standard Risk | 95 | 89 | 80 |
Serum IgG levels against the PVC serotype were measured by ELISA (NCT00445484)
Timeframe: basline and 8 weeks after second vaccination
| Intervention | fold change (Mean) |
|---|---|
| Vaccine Started 14 Days Prior to Lenalidomide | 9.42 |
| Vaccine Started 45 Days After Lenalidomide | 11.95 |
Serum IgG levels against the PVC serotype were measured by ELISA (NCT00445484)
Timeframe: basline and 8 weeks after second vaccination
| Intervention | fold change (Mean) |
|---|---|
| Vaccine Started 14 Days Prior to Lenalidomide | 2.025 |
| Vaccine Started 45 Days After Lenalidomide | 2.12 |
Serum IgG levels against the PVC serotype were measured by ELISA (NCT00445484)
Timeframe: basline and 8 weeks after second vaccination
| Intervention | fold change (Mean) |
|---|---|
| Vaccine Started 14 Days Prior to Lenalidomide | 4.1 |
| Vaccine Started 45 Days After Lenalidomide | 2.42 |
Serum IgG levels against the PVC serotype were measured by ELISA (NCT00445484)
Timeframe: basline and 8 weeks after second vaccination
| Intervention | fold change (Mean) |
|---|---|
| Vaccine Started 14 Days Prior to Lenalidomide | 3.69 |
| Vaccine Started 45 Days After Lenalidomide | 7.58 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the appetite loss scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 0.4 |
| Lenalidomide - Subpopulation From UK + Ireland | 3.3 |
| Lenalidomide - Subpopulation From Spain | -4.5 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of cognitive functioning. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -1.9 |
| Lenalidomide - Subpopulation From UK + Ireland | -4.9 |
| Lenalidomide - Subpopulation From Spain | 3.5 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the constipation scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 1.1 |
| Lenalidomide - Subpopulation From UK + Ireland | 7.9 |
| Lenalidomide - Subpopulation From Spain | 2.6 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the diarrhea scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 8.6 |
| Lenalidomide - Subpopulation From UK + Ireland | 8.1 |
| Lenalidomide - Subpopulation From Spain | 9.0 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the dyspnoea scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 2.7 |
| Lenalidomide - Subpopulation From UK + Ireland | 2.7 |
| Lenalidomide - Subpopulation From Spain | -0.9 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of emotional functioning. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -0.2 |
| Lenalidomide - Subpopulation From UK + Ireland | -4.0 |
| Lenalidomide - Subpopulation From Spain | -0.7 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the fatigue scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 2.6 |
| Lenalidomide - Subpopulation From UK + Ireland | 5.3 |
| Lenalidomide - Subpopulation From Spain | 1.0 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a problem scale like the financial problems scale = higher level of financial problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 2.0 |
| Lenalidomide - Subpopulation From UK + Ireland | 0.8 |
| Lenalidomide - Subpopulation From Spain | 0.9 |
EORTQ QLC-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better quality of life. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 1.1 |
| Lenalidomide - Subpopulation From UK + Ireland | -1.8 |
| Lenalidomide - Subpopulation From Spain | -2.2 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the insomnia scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -3.8 |
| Lenalidomide - Subpopulation From UK + Ireland | 2.2 |
| Lenalidomide - Subpopulation From Spain | -1.8 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the nausea/vomiting scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 1.0 |
| Lenalidomide - Subpopulation From UK + Ireland | 0.1 |
| Lenalidomide - Subpopulation From Spain | -2.2 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the pain scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -3.9 |
| Lenalidomide - Subpopulation From UK + Ireland | -5.2 |
| Lenalidomide - Subpopulation From Spain | -6.6 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of physical functioning. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -3.6 |
| Lenalidomide - Subpopulation From UK + Ireland | -2.9 |
| Lenalidomide - Subpopulation From Spain | -1.8 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of role functioning. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -2.4 |
| Lenalidomide - Subpopulation From UK + Ireland | -1.5 |
| Lenalidomide - Subpopulation From Spain | -2.6 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of social functioning. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -5.2 |
| Lenalidomide - Subpopulation From UK + Ireland | -5.3 |
| Lenalidomide - Subpopulation From Spain | -3.1 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the body image scale, higher scores = better body image. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -4.3 |
| Lenalidomide - Subpopulation From UK + Ireland | -2.0 |
| Lenalidomide - Subpopulation From Spain | -5.3 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the disease symptoms scale = higher level of symptomatology. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -2.4 |
| Lenalidomide - Subpopulation From UK + Ireland | -1.2 |
| Lenalidomide - Subpopulation From Spain | -3.9 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the future perspective scale, higher score = better perspective of the future. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 5.8 |
| Lenalidomide - Subpopulation From UK + Ireland | 3.4 |
| Lenalidomide - Subpopulation From Spain | 4.4 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the side effects scale = higher level of symptomatology. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 4.9 |
| Lenalidomide - Subpopulation From UK + Ireland | 4.7 |
| Lenalidomide - Subpopulation From Spain | 2.0 |
Time between first dose and when a TEAE for peripheral neuropathy was reported. The mean is the univariate mean without adjusting for censoring. The treatment duration was used for censored participants. (NCT00420849)
Timeframe: up to 124 weeks
| Intervention | weeks (Mean) |
|---|---|
| Lenalidomide Plus Dexamethasone | 25.6 |
Time between first dose and when a TEAE for venous thromboembolic event was reported. The mean is the univariate mean without adjusting for censoring. The treatment duration was used for censored participants. (NCT00420849)
Timeframe: up to 124 weeks
| Intervention | weeks (Mean) |
|---|---|
| Lenalidomide Plus Dexamethasone | 26.5 |
"Counts of study participants who had treatment-emergent adverse events (TEAEs) defined as any reported AE that started on or after the first day of study drug dosing. A participant with multiple occurrences of an adverse event within a category is counted only once in that category.~National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) was used by investigators to assess TEAEs. Severity scale ranges from 0 (none) to 5 (death). Grade 3=severe AE; Grade 4=life threatening or disabling AE; Grade 5=death." (NCT00420849)
Timeframe: up to 123 weeks
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| At least one treatment-emergent AE (TEAE) | At least one TEAE related to study drug | At least one TEAE with severity grade of 3 or 4 | At least one serious AE (SAE) | |
| Lenalidomide Plus Dexamethasone | 586 | 519 | 471 | 340 |
Number of participants with at least one peripheral neuropathy treatment-emergent adverse event (TEAE), and number of participants reporting AEs coded to preferred terms that comprise the search terms for peripheral neuropathy in MedDRA version 9.0 are listed. A participant with multiple occurrences of a TEAE was counted only once for that category. (NCT00420849)
Timeframe: up to 124 weeks
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| At least one TEAE of peripheral neuropathy | Neuropathy peripheral | Peripheral sensory neuropathy | Neuralgia | Peripheral motor neuropathy | Polyneuropathy | Sensory disturbance | |
| Lenalidomide Plus Dexamethasone | 84 | 46 | 33 | 5 | 2 | 2 | 1 |
Number of participants with at least one venous thromboembolic treatment-emergent adverse event (TEAE), and number of participants reporting AEs coded to preferred terms that comprise the search terms for venous thromboembolic events in MedDRA version 9.0 are listed. A participant with multiple occurrences of a TEAE was counted only once for that category. (NCT00420849)
Timeframe: up to 124 weeks
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| At least one venous thromboembolic event | Deep vein thrombosis | Pulmonary embolism | Thrombophlebitis | Venous thrombosis limb | |
| Lenalidomide Plus Dexamethasone | 60 | 38 | 23 | 7 | 1 |
(NCT01160484)
Timeframe: First evidence of PR or better (for overall response) and MR or better (for clinical benefit response) to start of disease progression or death.
| Intervention | months (Median) |
|---|---|
| DVD-R Single Arm | 12 |
time that patients were monitored for disease progression and overall survival (NCT01160484)
Timeframe: Follow-up visits for disease progression and overall survival every 3 months after study discontinuation. After progression, follow-up visits for survival status every 6 months or until alternate therapy needs to be started or death intervenes
| Intervention | months (Median) |
|---|---|
| DVD-R Single Arm | 11 |
(NCT01160484)
Timeframe: Time from the start of treatment to progressive disease or until death
| Intervention | months (Median) |
|---|---|
| DVD-R Single Arm | 9 |
(NCT01160484)
Timeframe: Up to 7.5 months (eight 28-day cycles)
| Intervention | months (Median) |
|---|---|
| DVD-R Single Arm | 2 |
(NCT01160484)
Timeframe: Up to 7.5 months (eight 28-day cycles)
| Intervention | months (Median) |
|---|---|
| DVD-R Single Arm | 1 |
(NCT01160484)
Timeframe: Time from the start of treatment to progressive disease
| Intervention | months (Median) |
|---|---|
| DVD-R Single Arm | 9 |
The investigator will evaluate each patient for response to therapy according to criteria augmented from those developed by Bladé et al., 1998 presented below (Table 7-1). Assessment of disease response will be performed prior to drug administration on Day 1 of Cycles 2 8 and at the End of Study Treatment visit. If a patient is determined to have complete response (CR), very good partial response (VGPR), partial response (PR), or minor response (MR), then assessment of disease response is to be performed 4 weeks later to confirm the response. (NCT01160484)
Timeframe: Up to 7.5 months (eight 28-day cycles)
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| CR | VGPR | PR | Objective Response (CR+VGPR+PR) | MR | Clinical Benefit (CR+VGPR+PR+MR) | Estable disease | Progressive disease | |
| DVD-R Single Arm | 8 | 4 | 7 | 19 | 14 | 33 | 4 | 2 |
"Data as of 11 May 2010 cutoff. Duration of myeloma response was defined as the time from the initial response date to the earlier of progressive disease (PD) as determined by the CAC or death on study. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry [EBMT/IBMTR/ABMTR] criteria.~PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia." (NCT00405756)
Timeframe: Up to 149 weeks
| Intervention | weeks (Median) |
|---|---|
| MPR+R | 121.6 |
| MPR+p | 56.1 |
| MPp+p | 55.4 |
Data as of 11 May 2010 cutoff. Time to the next antimyeloma therapy was defined as time from randomization to the start of another non-protocol antimyeloma therapy. Participants who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy. (NCT00405756)
Timeframe: Up to 168 weeks
| Intervention | weeks (Median) |
|---|---|
| MPR+R | 128.9 |
| MPR+p | 66.1 |
| MPp+p | 66.3 |
Data as of 11 May 2010 cutoff. Overall survival (OS) was defined as the time between randomization and death. Participants who died, regardless of the cause of death, were considered to have had an event. Participants who were lost to follow-up prior to the end of the trial, or who were withdrawn from the trial, were censored at the time of last contact. Participants who were still being treated were censored at the last available date available, or clinical cut-off date, if it was earlier. (NCT00405756)
Timeframe: up to 177 weeks
| Intervention | weeks (Median) |
|---|---|
| MPR+R | NA |
| MPR+p | NA |
| MPp+p | NA |
"Data as of 11 May 2010 cutoff. PFS was calculated as the time from randomization to the earlier of the first documentation of progressive disease (PD) as determined by the CAC, or death on study due to any cause. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry [EBMT/IBMTR/ABMTR] criteria.~PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia." (NCT00405756)
Timeframe: up to 165 weeks
| Intervention | weeks (Median) |
|---|---|
| MPR+R | 136.1 |
| MPR+p | 62.1 |
| MPp+p | 56.1 |
"Data as of 11 May 2010 cutoff. PFS calculated from the start of the Maintenance period to the earlier of the first documentation of progressive disease (PD) as determined by the CAC, or death on study due to any cause.~PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry [EBMT/IBMTR/ABMTR] criteria.~PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia." (NCT00405756)
Timeframe: Approximately week 37 (start of cycle 10) to week 165
| Intervention | weeks (Median) |
|---|---|
| MPR+R | 112.0 |
| MPR+p | 32.3 |
"Data as of 11 May 2010 cutoff. TTP was the time between randomization and disease progression as determined by the CAC. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry [EBMT/IBMTR/ABMTR] criteria.~PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia." (NCT00405756)
Timeframe: up to 165 weeks
| Intervention | weeks (Median) |
|---|---|
| MPR+R | 148.1 |
| MPR+p | 62.7 |
| MPp+p | 61.3 |
Data as of 11 May 2010 cutoff. Time to first response was defined as the time from start of treatment until first response as assessed by the Central Assessment Committee (CMC) based on European Group for Blood and Marrow Transplantation (EBMT) criteria. (NCT00405756)
Timeframe: Up to 66 weeks
| Intervention | weeks (Mean) |
|---|---|
| MPR+R | 10.0 |
| MPR+p | 9.3 |
| MPp+p | 16.2 |
Data as of 11 May 2010 cutoff. EORTC QLC-C30 is a 30-item questionnaire to assess the quality of life in cancer patients. EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); two used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better quality of life. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=114,121,125) | Cycle 7 - approximately Month 7 (n=96,108,110) | Cycle 10 - approximately Month 10 (n=84,86,96) | Cycle 13 - approximately Month 13 (n=70,70,82) | Cycle 16 - approximately Month 16 (n=61,50,62) | |
| MPp+p | 6.1 | 4.2 | 6.2 | 5.4 | 8.1 |
| MPR+p | 5.6 | 8.1 | 8.8 | 8.8 | 7.2 |
| MPR+R | 2.3 | 8.0 | 12.4 | 7.6 | 10.7 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the appetite loss scale = higher level of symptomatology/problems. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=119,125,130) | Cycle 7 - approximately Month 7 (n=99,111,111) | Cycle 10 - approximately Month 10 (n=87,93,96) | Cycle 13 - approximately Month 13 (n=75,72,83) | Cycle 16 - approximately Month 16 (n=64,52,63) | |
| MPp+p | -5.6 | -5.7 | -8.0 | -4.8 | -6.4 |
| MPR+p | 1.9 | -5.7 | -5.4 | -8.8 | -16.0 |
| MPR+R | 1.7 | -3.7 | -5.0 | -6.2 | -7.8 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of cognitive functioning. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=115,125,128) | Cycle 7 - approximately Month 7 (n=98,111,113) | Cycle 10 - approximately Month 10 (n=87,92,97) | Cycle 13 - approximately Month 13 (n=73,73,83) | Cycle 16 - approximately Month 16 (n=63,52,63) | |
| MPp+p | 1.3 | 0.7 | -2.7 | -1.4 | -4.0 |
| MPR+p | -2.0 | 0.1 | -4.4 | -3.0 | -3.5 |
| MPR+R | 0.3 | 2.9 | 1.0 | -0.0 | 0.3 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the constipation scale = higher level of symptomatology/problems. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=114,124,128) | Cycle 7 - approximately Month 7 (n=96,111,112) | Cycle 10 - approximately Month 10 (n=86,93,97) | Cycle 13 - approximately Month 13 (n=73,73,81) | Cycle 16 - approximately Month 16 (n=63,51,62) | |
| MPp+p | -4.9 | -2.7 | -1.7 | -3.3 | -2.2 |
| MPR+p | 4.8 | 0.6 | -1.1 | -2.7 | -5.2 |
| MPR+R | -1.8 | -3.5 | -5.0 | -5.0 | -1.6 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the diarrhea scale = higher level of symptomatology/problems. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=115,125,124) | Cycle 7 - approximately Month 7 (n=98,109,112) | Cycle 10 - approximately Month 10 (n=87,92,95) | Cycle 13 - approximately Month 13 (n=73,73,80) | Cycle 16 - approximately Month 16 (n=63,52,61) | |
| MPp+p | 3.2 | 0.9 | -0.0 | 0.8 | 0.5 |
| MPR+p | 1.9 | -1.2 | 1.4 | -1.4 | 1.3 |
| MPR+R | 2.3 | 3.4 | 1.1 | 5.5 | 10.6 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the dyspnoea scale = higher level of symptomatology/problems. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=117,126,126) | Cycle 7 - approximately Month 7 (n=100,110,110) | Cycle 10 - approximately Month 10 (n=86,93,96) | Cycle 13 - approximately Month 13 (n=73,73,81) | Cycle 16 - approximately Month 16 (n=62,53,62) | |
| MPp+p | -0.0 | 2.1 | 3.8 | -0.0 | 1.6 |
| MPR+p | -6.4 | -8.5 | -4.3 | -2.3 | -6.3 |
| MPR+R | -2.6 | -1.7 | -4.3 | -5.0 | -3.2 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of emotional functioning. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=115,125,128) | Cycle 7 - approximately Month 7 (n=98,111,112) | Cycle 10 - approximately Month 10 (n=86,92,97) | Cycle 13 - approximately Month 13 (n=73,73,83) | Cycle 16 - approximately Month 16 (n=63,52,63) | |
| MPp+p | 6.8 | 5.0 | 4.7 | 6.6 | 6.9 |
| MPR+p | 2.7 | 4.2 | 1.6 | 1.1 | -0.2 |
| MPR+R | 4.8 | 8.8 | 9.0 | 8.2 | 9.9 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the fatigue scale = higher level of symptomatology/problems. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=120,127,129) | Cycle 7 - approximately Month 7 (n=100,112,110) | Cycle 10 - approximately Month 10 (n=87,95,95) | Cycle 13 - approximately Month 13 (n=74,74,82) | Cycle 16 - approximately Month 16 (n=64,53,62) | |
| MPp+p | -5.1 | -5.7 | -6.9 | -7.5 | -4.1 |
| MPR+p | -5.5 | -9.5 | -7.5 | -10.7 | -9.7 |
| MPR+R | -3.0 | -7.6 | -7.5 | -7.1 | -10.0 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a problem scale like the financial problems scale = higher level of financial problems. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=111,123,125) | Cycle 7 - approximately Month 7 (n=94,111,112) | Cycle 10 - approximately Month 10 (n=84,92,97) | Cycle 13 - approximately Month 13 (n=70,72,83) | Cycle 16 - approximately Month 16 (n=61,52,63) | |
| MPp+p | -2.9 | -2.1 | -1.7 | -4.0 | -5.3 |
| MPR+p | -1.1 | -0.6 | 0.7 | -0.5 | -0.6 |
| MPR+R | 2.4 | 2.1 | 6.0 | 4.8 | 1.6 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the insomnia scale = higher level of symptomatology/problems. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=118,124,128) | Cycle 7 - approximately Month 7 (n=100,109,111) | Cycle 10 - approximately Month 10 (n=87,94,96) | Cycle 13 - approximately Month 13 (n=75,73,83) | Cycle 16 - approximately Month 16 (n=64,53,63) | |
| MPp+p | -5.0 | -5.7 | -1.7 | -6.8 | -3.7 |
| MPR+p | -1.6 | -6.4 | -2.5 | 0.9 | -0.6 |
| MPR+R | 2.0 | -1.0 | -5.0 | -4.9 | -4.7 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the nausea/vomiting scale = higher level of symptomatology/problems. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=120,127,130) | Cycle 7 - approximately Month 7 (n=99,112,112) | Cycle 10 - approximately Month 10 (n=87,95,97) | Cycle 13 - approximately Month 13 (n=75,72,83) | Cycle 16 - approximately Month 16 (n=64,52,62) | |
| MPp+p | -0.0 | 0.7 | 0.3 | -0.4 | -1.3 |
| MPR+p | -1.3 | -0.7 | -1.4 | -3.0 | -4.2 |
| MPR+R | 3.3 | 0.5 | 1.9 | 0.7 | 1.0 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the pain scale = higher level of symptomatology/problems. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=120,127,129) | Cycle 7 - approximately Month 7 (n=100,112,113) | Cycle 10 - approximately Month 10 (n=88,95,97) | Cycle 13 - approximately Month 13 (n=74,74,83) | Cycle 16 - approximately Month 16 (n=64,53,63) | |
| MPp+p | -13.4 | -11.5 | -9.8 | -12.1 | -12.2 |
| MPR+p | -13.8 | -16.5 | -15.6 | -14.9 | -11.0 |
| MPR+R | -14.4 | -17.8 | -17.2 | -13.7 | -20.3 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of physical functioning. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=120,127,130) | Cycle 7 - approximately Month 7 (n=100,112,112) | Cycle 10 - approximately Month 10 (n=88,95,96) | Cycle 13 - approximately Month 13 (n=75,74,83) | Cycle 16 - approximately Month 16 (n=64,53,63) | |
| MPp+p | 4.5 | 2.7 | 5.1 | 3.3 | 1.1 |
| MPR+p | 3.3 | 8.1 | 8.5 | 9.7 | 7.6 |
| MPR+R | 1.9 | 8.2 | 8.9 | 8.6 | 10.0 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of role functioning. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=119,127,130) | Cycle 7 - approximately Month 7 (n=99,112,113) | Cycle 10 - approximately Month 10 (n=86,95,95) | Cycle 13 - approximately Month 13 (n=74,74,82) | Cycle 16 - approximately Month 16 (n=64,53,63) | |
| MPp+p | 7.4 | 6.9 | 5.6 | 5.7 | 7.1 |
| MPR+p | 3.0 | 8.0 | 7.5 | 11.7 | 8.5 |
| MPR+R | 1.8 | 5.7 | 9.3 | 9.7 | 12.2 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of social functioning. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=115,125,127) | Cycle 7 - approximately Month 7 (n=98,111,112) | Cycle 10 - approximately Month 10 (n=87,92,97) | Cycle 13 - approximately Month 13 (n=72,73,83) | Cycle 16 - approximately Month 16 (n=63,52,63) | |
| MPp+p | 6.0 | 6.1 | 4.1 | 6.2 | 9.8 |
| MPR+p | 0.3 | 4.4 | 4.5 | 7.5 | 6.1 |
| MPR+R | 5.1 | 8.3 | 10.9 | 11.8 | 13.2 |
Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the disease symptoms scale = higher level of symptomatology. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=113,121,127) | Cycle 7 - approximately Month 7 (n=96,109,112) | Cycle 10 - approximately Month 10 (n=85,91,95) | Cycle 13 - approximately Month 13 (n=72,73,82) | Cycle 16 - approximately Month 16 (n=62,51,62) | |
| MPp+p | -5.4 | -6.0 | -5.4 | -6.3 | -3.3 |
| MPR+p | -8.7 | -9.7 | -7.1 | -8.8 | -5.9 |
| MPR+R | -8.9 | -9.0 | -7.9 | -7.2 | -10.5 |
Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the body image scale, higher scores = better body image. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=110,117,119) | Cycle 7 - approximately Month 7 (n=88,104,108) | Cycle 10 - approximately Month 10 (n=79,83,94) | Cycle 13 - approximately Month 13 (n=68,72,79) | Cycle 16 - approximately Month 16 (n=59,52,61) | |
| MPp+p | 4.5 | 5.2 | 3.9 | 5.1 | 2.7 |
| MPR+p | -0.3 | 2.6 | -4.0 | -0.5 | 6.4 |
| MPR+R | 2.1 | 3.8 | 7.6 | 1.0 | 3.4 |
Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the future perspective scale, higher score = better perspective of the future. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=112,121,124) | Cycle 7 - approximately Month 7 (n=93,108,112) | Cycle 10 - approximately Month 10 (n=83,88,97) | Cycle 13 - approximately Month 13 (n=71,73,81) | Cycle 16 - approximately Month 16 (n=62,52,62) | |
| MPp+p | 7.6 | 9.8 | 14.5 | 11.9 | 14.4 |
| MPR+p | 4.3 | 7.7 | 6.6 | 6.3 | 7.7 |
| MPR+R | 4.7 | 14.6 | 17.3 | 17.3 | 18.5 |
Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the side effects scale = higher level of symptomatology. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=113,120,125) | Cycle 7 - approximately Month 7 (n=95,108,111) | Cycle 10 - approximately Month 10 (n=85,89,94) | Cycle 13 - approximately Month 13 (n=72,72,81) | Cycle 16 - approximately Month 16 (n=62,50,61) | |
| MPp+p | 0.6 | 1.8 | 0.3 | 0.3 | -0.9 |
| MPR+p | 0.1 | -1.7 | 0.0 | -1.0 | -2.9 |
| MPR+R | 1.3 | 0.4 | -1.6 | -3.8 | -2.1 |
Data as of 11 May 2010 cutoff. Best response was determined by the Central Assessment Committee (CAC) based on the European Group for Blood and Marrow Transplantation (EBMT) criteria: Complete Response (CR)-absence of serum and urine monoclonal paraprotein for 6 weeks, plus no increase in size or number of bone lesions, plus other factors); Partial Response (PR)-not all CR criteria, plus >=50% reduction in serum monoclonal paraprotein plus others; Stable Disease (SD)- not PR or PD; Progressive Disease (PD)- reappearance of monoclonal paraprotein, bone lesions, other; Not Evaluable (NE). (NCT00405756)
Timeframe: Up to 165 weeks
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Complete response (CR) | Partial response (PR) | Stable disease (SD) | Progressive disease (PD) | Response not evaluable (NE) | |
| MPp+p | 5 | 72 | 70 | 0 | 7 |
| MPR+p | 5 | 99 | 40 | 2 | 7 |
| MPR+R | 15 | 102 | 28 | 0 | 7 |
Data as of 11 May 2010 cutoff. Participant counts in different categories of TEAEs during the double-blind treatment period. A TEAE is as any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. Dose reduction includes reduction with or without interruption. (NCT00405756)
Timeframe: Up to 169 weeks (Double-blind therapy period plus 4 weeks)
| Intervention | participants (Number) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >=1 adverse event (AE) | >=1 CTCAE grade 3-4 AE | >=1 CTCAE grade 5 AE | >=1 serious AE (SAE) | >=1 AE related to Lenaldomide/Placebo | >=1 AE related to Melphalan | >=1AE related to Prednisone | >=1 Grade 3-4 AE related to Lenaldomide/Placebo | >=1 Grade 3-4 AE related to Melphalan | >=1 Grade 3-4 AE related to Prednisone | >=1 Grade 5 AE related to Lenalidomide/Placebo | >=1 Grade 5 AE related to Melphalan | >=1 Grade 5 AE related to Prednisone | >=1 SAE related to Lenalidomide/Placebo | >=1 SAE related to Melphalan | >=1 SAE related to Prednisone | >=1 AE leading to Lenalidomide/Placebo withdrawal | >=1 AE leading to Melphalan withdrawal | >=1 AE leading to Prednisone withdrawal | >=1 AE leading to Lenalidomide/Plac dose reduction | >=1 AE leading to Melphalan dose reduction | >=1 AE leading to Prednisone dose reduction | >=1 AE leading to Lenalidomide/Plac dose interrupt | >=1 AE leading to Melphalan dose interruption | >=1 AE leading to Prednisone dose interruption | |
| MPp+p | 153 | 107 | 7 | 56 | 131 | 126 | 93 | 68 | 62 | 22 | 2 | 3 | 1 | 11 | 11 | 5 | 14 | 10 | 10 | 26 | 21 | 5 | 51 | 0 | 15 |
| MPR+p | 151 | 129 | 6 | 62 | 145 | 134 | 94 | 117 | 110 | 29 | 2 | 1 | 1 | 32 | 24 | 16 | 24 | 19 | 19 | 70 | 58 | 7 | 82 | 1 | 39 |
| MPR+R | 150 | 137 | 7 | 66 | 148 | 140 | 87 | 128 | 118 | 32 | 3 | 3 | 1 | 38 | 27 | 19 | 26 | 20 | 20 | 71 | 47 | 15 | 92 | 5 | 28 |
Determine the MTD of Carfilzomib when combined with Lenalidomide and Dexamethasone. The estimated time to determine the MTD is 6 months. (NCT01029054)
Timeframe: 6 Months
| Intervention | mg/m^2 (Number) |
|---|---|
| Carfilzomib, Lenalidomide w/Dexamethasone | 36 |
"The Progression Free Survival (PFS) rate will be determined at 12 and 24 months post treatment.~Progressive Disease (PD) is defined as an increase of greater than or equal to 25% from lowest response level in serum M-component and/ or urine M-component and/ or the difference between involved or uninvolved SFLC levels and/ or bone marrow % plasma cells. PD may also be the development of new bone lesions or soft tissue plasmacytomas or the increase in size of existing lesions. PD may also be the development of hypercalcemia." (NCT01029054)
Timeframe: 12 Months and 24 Months Post Treatment
| Intervention | percentage of patients (Number) | |
|---|---|---|
| Percentage of Patients Without Progression at 12 m | Percentage of Patients Without Progression at 24 m | |
| Carfilzomib, Lenalidomide w/Dexamethasone | 97 | 92 |
"The percentage of patients that achieve at least a sCR (Stringent Complete Response), at least a VGPR (Very Good Partial Response) and at least a PR (Partial Response) will be determined.~sCR is defined as:~Negative immunofixation on the serum and urine and~Disappearance of any soft tissue plasmacytomas and~< 5% plasma cells in bone marrow and~Normal SFLC ratio and~Absence of clonal cells in bone marrow~VGPR is defined as:~Serum and urine M-protein detectable by immunofixation but not on electrophoresis or~≥ 90% reduction in serum M-component with urine M-component < 100 mg per 24 hours~PR is defined as:~≥ 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥ 90% or to < 200 mg per 24 hours~If present at baseline, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required" (NCT01029054)
Timeframe: 4 Months After Treatment Start
| Intervention | percentage of patients (Number) | ||
|---|---|---|---|
| % of patients that achieve at least a sCR | % of patients that achieve at least a VGPR | % of patients that achieve at least a PR | |
| Carfilzomib, Lenalidomide w/Dexamethasone | 42 | 81 | 98 |
16 of 17 patients proceeded to transplant. 6 month CR rate post transplant was 8/16 (50%). (NCT01050790)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| 5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant | 50 |
Time to progression post transplant: For patients not in Complete Response (CR), progressive disease requires one or more: >25% increase in the level of the serum monoclonal paraprotein(absolute increase of at least 0.5 g/dL); > 25% increase in 24-hour urinary light chain excretion(absolute increase of at least 200m/24 hours). Increase plasma cells in a bone marrow aspirate( absolute increase of at least 10%). Definite increase in the size of existing bone lesions or soft tissue plasmacytomas. Development of new bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum Ca > 11.5 mg/dL or > 2.65 mmol/L) not attributable to any other cause. All relapse categories require two consecutive assessments made any time before classification as relapse or progressive disease. (NCT01050790)
Timeframe: 28 months
| Intervention | months (Median) |
|---|---|
| 5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant | 14.9 |
Six patients tested have demonstrated CTA up-regulation in either unfractionated bone marrow (n = 4) or CD138+ cells (n = 2). CTA (CTAG1B)-specific T cell response has been observed in all three patients tested and persists following SCT. (NCT01050790)
Timeframe: 3 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CTA up-regulation | CD138+ cells | unfractionated bone marrow | CTA (CTAG1B)-specific T cell response | |
| 5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant | 6 | 2 | 4 | 3 |
Time frame is post 2nd and 3rd cycles of rev/aza and after stem cell transplant engraftment. (NCT01050790)
Timeframe: 6 months
| Intervention | participants (Number) | ||
|---|---|---|---|
| mobilize lymphocytes | lymphocytes infused post transplant | not able to mobilize stem cells/no transplant | |
| 5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant | 17 | 16 | 1 |
"Survival and event-free survival curves (any event of fatality, relapse, acute or chronic GVHD) with Kaplan-Meier curves. The incidence curve for relapse - accounting for the competing risk of fatality - is plotted with step-wise curves. The R statistical software (version 2.15) was used for all time-to-event analyses, with the survival package used for survival curves, and the cmprsk package used for all competing risk curves.~Results: The one-year survival rate is 93.3% (SE = 0.4%), and the two-year survival rate is 86.1% (SE = 0.9%)." (NCT01050790)
Timeframe: 1 year to 2 years
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| one- year survival rate | two-year survival rate | one-year relapse rate | two-year relapse rate | one-year event free survival rate | two-year event free survival rate | |
| 5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant | 93.3 | 86.1 | 12.5 | 19.2 | 87.5 | 67.3 |
Time frame includes after stem cell transplant engraftment. Toxicity post ALI infusion: 1 patient grade 1 hypertension 90 min post infusion. Toxicity post Rev maintenance: 1 patient not tolerated, 1 patient dose decreased due to counts. (NCT01050790)
Timeframe: 6 months
| Intervention | participants (Number) | |
|---|---|---|
| Toxicity post ALI infusion | Toxicity post Rev maintenance | |
| 5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant | 1 | 2 |
PFS at 12 months is a dichotomized outcome indicating whether or not a participant was progression free (and alive) at 12 months from the date of randomization. (NCT00432458)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|---|
| Arm I: Thal/ZLD | 30 |
| Arm II: ZLD | 18 |
Duration of response (DOR) is defined as the time from first documentation of response (CR, VGPR or PR) to disease progression. The median DOR with 95% CI was estimated using the Kaplan Meier method (NCT00432458)
Timeframe: time from start of response to progression (up to 5 years)
| Intervention | years (Median) |
|---|---|
| Arm I: Thal/ZLD | 3.3 |
"Response is defined as follows:~CR: Complete disappearance of M-protein from serum & urine on immunofixation, <5% plasma cells in bone marrow (BM)~VGPR: >=90% reduction in serum M-component; Urine M-Component <100 mg per 24 hours; <=5% plasma cells in BM~PR: >= 50% reduction in serum M-Component and/or Urine M-Component >= 90% reduction or <200 mg per 24 hours; or >= 50% decrease in difference between involved and uninvolved FLC levels" (NCT00432458)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|---|
| Arm I: Thal/ZLD | 13 |
| Arm II: ZLD | 0 |
"Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 2.~Description of Grades:~Grade 1: Mild Grade 2: Moderate Grade 3: Severe Grade 4: Life-threatening Grade 5: Death" (NCT00432458)
Timeframe: During treatment (up to 5 years)
| Intervention | participants (Number) |
|---|---|
| Arm I: Thal/ZLD | 17 |
| Arm II: ZLD | 13 |
Time to disease progression (TTP) was defined as the time from randomization to the earliest documentation of disease progression. Participants were followed for a maximum of 5 years from registration. The median OS with 95% CI was estimated using the Kaplan Meier method, a two-sided (stratified) log-rank test was calculated. (NCT00432458)
Timeframe: randomization to progression (up to 5 years)
| Intervention | years (Median) |
|---|---|
| Arm I: Thal/ZLD | 2.4 |
| Arm II: ZLD | 1.2 |
Time to treatment failure (TTF) was defined as the time from randomization to the date at which the patient was removed from (protocol) treatment due to disease progression, unacceptable toxicity, participant refusal or death. The median TTF with 95% CI was estimated using the Kaplan Meier method (NCT00432458)
Timeframe: time from randomization to treatment failure (up to 5 years)
| Intervention | months (Median) |
|---|---|
| Arm I: Thal/ZLD | 16.5 |
| Arm II: ZLD | 11.1 |
Analysis of the Primary Endpoint: The complete responses will be estimated by the number of patients with CR divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 4 cycles
| Intervention | Percentage of Participants (Number) |
|---|---|
| FCR With Lenalidomide | 45 |
Analysis of the other Secondary Endpoints: The overall response rate will be estimated by the number of patients with complete and partial responses divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 6 cycles
| Intervention | Percentage of Participants (Number) |
|---|---|
| FCR With Lenalidomide | 95 |
"Cytostatic overall response rate = CR + PR + SD greater than or equal to 6 months~Definitions per 2007 Cheson Lymphoma Response Criteria" (NCT00540007)
Timeframe: From 6 months through 3.5 years after study entry
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 15 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 18 |
-Duration of response: defined as the interval from the date of response (CR or PR) is documented to the date of progression, taking as reference the smallest measurements recorded since the treatment started (NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | months (Median) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 3.68 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 4.08 |
-Event-free survival (time to treatment failure) is measured from the time from study entry to any treatment failure including disease progression, or discontinuation of treatment for any reason (eg, disease progression, toxicity, patient preference, initiation of new treatment without documented progression, or death). (NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | months (Median) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 3.78 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 3.93 |
"Overall response rate = CR + PR~Definitions per 2007 Cheson Lymphoma Response Criteria" (NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 21.0 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 28.6 |
Overall survival is defined as the time from entry onto the clinical trial until death as a result of any cause. (NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | months (Median) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 17.434 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 23.717 |
(NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | months (Median) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 3.78 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 3.93 |
-Time to progression (TTP) is defined as the time from study entry until documented lymphoma progression or death as a result of lymphoma. (NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | months (Median) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 3.68 |
| Cohort 2 | 4.08 |
"Adverse events were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0~The higher the grade the worse the adverse event was considered" (NCT00540007)
Timeframe: 30 days following the completion of treatment
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenia | Leukopenia | Anemia | Lymphopenia | Thrombocytopenia | Fatigue | AST | ALT | Bilirubin | Sensory neuropathy | Dehydration | Infection without neutropenia | Infection with neutropenia | Edema | Dyspnea | Pleural effusion | Alkaline phosphatase | Abdominal pain | Low potassium | Low sodium | Low albumin | Low calcium | High calcium | Low phosphorus | Hearing loss | Thrombosis/embolism | Rash | Febrile neutropenia | Pneumonia | High potassium | Hyperuricemia | Confusion | Dizziness | Speech impairment | Chest pain | Extremity pain | Muscle pain | Secondary malignancy - MDS | |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 18 | 11 | 10 | 9 | 7 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cohort 2 | 20 | 13 | 4 | 10 | 8 | 2 | 1 | 1 | 2 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 1 |
Duration of response is defined as time from response to disease progression or death. Progression is assessed by the International Myeloma Workshop Consensus Panel Criteria. Progressive disease requires any one or more of the following: increase of ≥25% from baseline or lowest response value in Serum M component, Urine M component, free light chain or bone marrow plasma cell percentage. Lowest response value does not need to be a confirmed value. Serum M-component absolute increase must be ≥0.5 g/dl. The serum M-component increases of ≥1 gm/dl are sufficient to define relapse if starting M-component is ≥5 g/dl. Urine M-component absolute increase must be ≥200mg/24h. Only in patients without measureable serum and urine M-protein levels: the absolute increase in difference between involved and uninvolved free light chain levels must be >10mg/dl. (NCT01675141)
Timeframe: participants were followed for the duration of their treatment, an average of 2 years
| Intervention | Months (Median) |
|---|---|
| Lenalidomide Maintenance Therapy for Multiple Myeloma | NA |
Here is the number of serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01675141)
Timeframe: 37 months and 12 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Lenalidomide Maintenance Therapy for Multiple Myeloma | 11 |
PFS is defined as the time from study entry until progression or death. Progression is assessed by the International Myeloma Workshop Consensus Panel Criteria. Progressive disease requires any one or more of the following: increase of ≥25% from baseline or lowest response value in Serum M component, Urine M component, free light chain or bone marrow plasma cell percentage. Lowest response value does not need to be a confirmed value. Serum M-component absolute increase must be ≥0.5 g/dl. The serum M-component increases of ≥1 gm/dl are sufficient to define relapse if starting M-component is ≥5 g/dl. Urine M-component absolute increase must be ≥200mg/24h. Only in patients without measureable serum and urine M-protein levels: the absolute increase in difference between involved and uninvolved free light chain levels must be >10mg/dl. (NCT01675141)
Timeframe: participants were followed for the duration of their treatment, an average of 2 years
| Intervention | months (Median) |
|---|---|
| Lenalidomide Maintenance Therapy for Multiple Myeloma | NA |
Engraftment failure is defined as the failure to achieve neutrophil engraftment by day 21; defined from day 0, day of autologous hematopoietic cell transplantation (AHCT), as the first of three consecutive days on which the patient's absolute neutrophil count is greater than 0.5x10(9)/l following the nadir. Transplant related mortality is defined as any subject who dies in the first 100 days post-AHCT of any non-relapse related cause. (NCT01658904)
Timeframe: up to day 100
| Intervention | participants (Number) |
|---|---|
| Cohort 1- CFZ 20 mg/m^2 (Day 1,2) | 0 |
Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT01658904)
Timeframe: 8 months and 15 days
| Intervention | participants (Number) |
|---|---|
| Cohort 1- CFZ 20 mg/m^2 (Day 1,2) | 1 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01239368)
Timeframe: Date treatment consent signed to last date off study, 81 months and 6 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 - 1x10(5) T Cells/kg | 1 |
| Cohort 2 - 5x10(5) T Cells/kg | 1 |
| Cohort 3 - 1x10(6) T Cells/kg | 1 |
| Cohort 4 - 3x10(6) T Cells/kg | 2 |
| Cohort 5 - 5x10(6) T Cells/kg | 5 |
| Cohort 5B - 5x10(6) T Cells/kg | 2 |
| Cohort 6 - 15x10(6) T Cells/kg | 3 |
| Cohort 7 - 45x10(6) T Cells/kg | 0 |
| Cohort A - Th1/Tc1.Rapa Prevention of Relapse | 1 |
| Cohort B - Th1/Tc1.Rapa for Relapsed Multiple Myeloma | 4 |
Progressive disease is assessed by the Consensus of the International Myeloma Working Group criteria and is defined as one or more of the following: Increases of greater or equal to 25% in serum M-component (minimum absolute increase of 0.5 g/dl) or urine M-component (minimum absolute increase of 200mg/24h) or percentage of bone marrow plasma cells (minimum absolute percentage of 10%) or size of bone lesions or new plasmacytoma, or development of hypercalcemia solely attributable to the disease. (NCT01239368)
Timeframe: Study completion at 22 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort A - Th1/Tc1.Rapa Prevention of Relapse | 1 |
Patients whose tumors shrunk and were disease free after therapy in cohort B. Partial response and complete response were assessed by the Consensus of the International Myeloma Working Group criteria. Partial response is defined as 50% or greater reduction in serum M-protein and 90% or greater reduction in 24-h urinary M-protein (or to less than 200 mg per 24h), 50% or greater reduction in the size of soft tissue plasmacytomas, if present at baseline, no evidence of progressive or new bone lesions if radiographic studies were performed (X-rays not required in absence of clinical indication). Complete response is defined as negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and 5% or less plasma cells in bone marrow and no evidence of progressive or new bone lesion if radiographic studies were performed. Progressive disease is increases of ≥25% in serum M-component/urine M-component, or size of bone lesions. (NCT01239368)
Timeframe: Study completion at 22 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort B - Th1/Tc1.Rapa for Relapsed Multiple Myeloma | 2 |
Participants were assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0) (NCT01239368)
Timeframe: 2 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 - 1x10(5) T Cells/kg | 0 |
| Cohort 2 - 5x10(5) T Cells/kg | 0 |
| Cohort 3 - 1x10(6) T Cells/kg | 0 |
| Cohort 4 - 3x10(6) T Cells/kg | 0 |
| Cohort 5 - 5x10(6) T Cells/kg | 0 |
| Cohort 5B - - 5x10(6) T Cells/kg | 0 |
| Cohort 6 - 15x10(6) T Cells/kg | 0 |
| Cohort 7- 45x10(6) T Cells/kg | 0 |
| Cohort A - Th1/Tc1.Rapa Prevention of Relapse | 0 |
| Cohort B - Th1/Tc1.Rapa Prevention of Relapse | 0 |
Progenitor cells by apheresis was determined by flow cytometry. (NCT01547806)
Timeframe: Through Day 2 of collection
| Intervention | Number of CD34 cells per kg/BW (x 10EE6) (Mean) |
|---|---|
| Hematopoietic Progenitor Cells | 6.4 |
Progenitor cells by apheresis was determined by flow cytometry. (NCT01547806)
Timeframe: Through Day 2 of collection
| Intervention | Number of CD34 cells per kg/BW (x 10EE6) (Median) |
|---|---|
| Hematopoietic Progenitor Cells | 6.3 |
The cryopreserved stem cells are stored under Good Manufacturing Practice (GMP) conditions in the National Institutes of Health (NIH) Department of Transfusion Medicine until a referring physician requests the products for standard clinical care. (NCT01547806)
Timeframe: Indefinitely until a referring physician requests the product for standard clinical care or until product(s) is no longer needed and disposed of
| Intervention | products (Number) |
|---|---|
| Hematopoietic Progenitor Cells (HPC) | 49 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01547806)
Timeframe: 27 months and 27 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Hematopoietic Progenitor Cells (HPC) | 16 |
Progenitor cells by apheresis was determined by flow cytometry. The stated goal was a minimum dose of 2x10EE^6/kg following apheresis. (NCT01547806)
Timeframe: Day 1 of apheresis
| Intervention | percentage of patients (Number) |
|---|---|
| Hematopoietic Progenitor Cells (HPC) | 98 |
Progenitor cells by apheresis was determined by flow cytometry. (NCT01547806)
Timeframe: Through Day 2 of collection
| Intervention | percentage of patients (Number) |
|---|---|
| Hematopoietic Progenitor Cells | 2 |
Percentage of patents achieving collecting the minimum but not optimal CD34 cell number. (NCT01547806)
Timeframe: Day one of collection
| Intervention | percentage of patients (Number) |
|---|---|
| Hematopoietic Progenitor Cells | 31 |
Progenitor cells by apheresis was determined by flow cytometry. (NCT01547806)
Timeframe: Through Day 2 of collection
| Intervention | Number of CD34 cells per kg/BW (x 10EE6) (Median) |
|---|---|
| Hematopoietic Progenitor Cells | 6.3 |
Progenitor cells by apheresis was determined by flow cytometry. (NCT01547806)
Timeframe: Through Day 2 of collection
| Intervention | Number of CD34 cells per kg/BW (x 10EE6) (Number) | |
|---|---|---|
| 25th percentile | 75th percentile | |
| Hematopoietic Progenitor Cells | 4.0 | 8.0 |
Here is the percentage of patients that achieved or did not achieve 5 x 10^6 CD34 cells/kg in a single apheresis. (NCT01547806)
Timeframe: Through Day 2 of collection
| Intervention | percentage of patients (Number) | |
|---|---|---|
| Achieved 5 x 10EE CD34 cells/kg | Did not achieve 5 x 10EE CD34 cells/kg | |
| Hematopoietic Progenitor Cells | 65 | 35 |
Percentage of patients that required Plerixafor injection in addition to G-CSF mobilization or none at all (NCT01547806)
Timeframe: One week of mobilization therapy
| Intervention | percentage of patients (Number) | |
|---|---|---|
| Plerixafor + G-CSF | Only G-CSF (no plerixafor) | |
| Hematopoietic Progenitor Cells | 47 | 53 |
Overall Survival at six years after initiating protocol therapy (NCT00083551)
Timeframe: 6 Years
| Intervention | percentage of participants (Number) |
|---|---|
| Thalidomide | 65 |
| No Thalidomide | 58 |
(NCT01095757)
Timeframe: Within the first 4 days following the first dose of Plerixafor
| Intervention | days (Mean) |
|---|---|
| Multiple Myeloma | 12.4 |
| Lymphoma | 12.105 |
(NCT01095757)
Timeframe: Within the first 4 days following the first dose of Plerixafor
| Intervention | participants (Number) |
|---|---|
| Multiple Myeloma | 10 |
| Lymphoma | 23 |
(NCT01095757)
Timeframe: Within the first 4 days following the first dose of Plerixafor
| Intervention | participants (Number) |
|---|---|
| Multiple Myeloma | 9 |
| Lymphoma | 17 |
Number of days from stem cell infusion (day +0) to day of neutrophil engraftment (first of three consecutive days with absolute neutrophil count > 500) (NCT01207765)
Timeframe: Transplant through day 42
| Intervention | Days (Median) |
|---|---|
| Zevalin | 13 |
Efficacy: objective response rate (CR + PR) at 12 and 104 days following radioimmunotherapy. Safety: the rate of occurrence of defined toxic events including non-engraftment and unacceptable biodistribution of 90Y Zevalin occurring by day +42 following transplant. Response determined according to Blade' Criteria (Bladé J, Br J Haematol.1998 Sep;102(5):1115-23) for multiple myeloma; Response based on reduction of monoclonal protein (M-protein) from initial presentation. (NCT01207765)
Timeframe: Through day +104 following immunotherapy
| Intervention | participants (Number) | ||
|---|---|---|---|
| CR/PR at +12 days | CR/PR at +104 days | Participants with toxic events | |
| Zevalin | 1 | 5 | 5 |
A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. (NCT00103506)
Timeframe: Up to 1 year and 11 months (From date of first participant randomization [20 December 2004] to cut-off date for safety update (28 November 2006)
| Intervention | Participants (Number) |
|---|---|
| Velcade (Bortezomib) Monotherapy | 105 |
| Doxil/Caelyx Plus Velcade (Bortezomib) | 120 |
The OS is defined as the time from the date of first dose of study drug to date of death from any cause. If the participant is alive or the vital status is unknown, the participant will be censored at the date the participant will be last known to be alive. (NCT00103506)
Timeframe: Up to 9 years and 5 months (From date of first participant randomization [20 December 2004] to cut-off date for final survival analysis (16 May 2014)
| Intervention | months (Median) |
|---|---|
| Velcade (Bortezomib) Monotherapy | 30.8 |
| Doxil/Caelyx Plus Velcade (Bortezomib) | 33.0 |
Median time to progression of disease is assessed according to International Myeloma Working Group (IMWG) criteria or death from any cause. IMWG criteria: increase of >=25% from lowest level in Serum M-component or (the absolute increase must be >=0.5 gram per deciliter [g/dL]); Urine M component or (the absolute increase must be >=200 milligram per 24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase >10 mg/dL. Bone marrow plasma cell percentage >=10%. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing. Development of hypercalcemia. Participants who died or dropped out due to any reason without progression will be censored with the day of death or drop-out, respectively and who are alive at the end of the study without any progression was censored with the last available date. (NCT00103506)
Timeframe: Up to 1 year and 4 months (From date of first participant randomization [20 December 2004] up to interim analysis cut-off date [28 April 2006])
| Intervention | Months (Median) |
|---|---|
| Velcade (Bortezomib) Monotherapy | 6.5 |
| Doxil/Caelyx Plus Velcade (Bortezomib) | 9.3 |
"Measured from the documented beginning of response (CR or PR) to the time of relapse. This is measured in responders per Non-Hodgkin's Lymphoma Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007.) CR: complete disappearance of detectable clinical evidence of disease and disease-related symptoms; PR: 50% or greater decrease in sum of product of diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses, no increase in size of other nodes, liver or spleen, no new disease sites, patients with CR and persistent morphologic bone marrow involvement.~Duration of Response will be examined using time-to-event analysis methods. Kaplan-Meier figures will be generated and the log-rank test will be used to examine differences existing between various levels of stratification." (NCT00633594)
Timeframe: Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years or until documented disease progression
| Intervention | months (Median) |
|---|---|
| Phase I Participants (10 mg/15 mg Lenalidomide) | 25.72 |
| Phase II Participants (10 mg Lenalidomide) | 17.81 |
Measured from the documented beginning of response (CR or PR) to the time of relapse. This is measured in responders per Non-Hodgkin's Lymphoma Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007.) CR: complete disappearance of detectable clinical evidence of disease and disease-related symptoms; PR: 50% or greater decrease in sum of product of diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses, no increase in size of other nodes, liver or spleen, no new disease sites, patients with CR and persistent morphologic bone marrow involvement. (NCT00633594)
Timeframe: Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years or until documented disease progression
| Intervention | months (Median) |
|---|---|
| Previously Treated Participants | 17.94 |
| Previously Untreated Participants | 21.09 |
"Determination of the maximum tolerated dose (MTD) of lenalidomide combined with bortezomib and rituximab, defined as the highest dose at which ≤1 of 6 patients experiences a dose-limiting toxicity according to the NCI CTCAE v. 4.03.~MTD of Lenalidomide was tested, included with 1.3 mg/m2 subcutaneous (D1, 4, 8, 11) bortezomib, 375 mg/m2 (D1, 8, 15 of Cycle 1, D1 on subsequent cycles) rituximab.~Three dose limiting toxicities were reported in two patients (grade 4 neutropenia and grade 3 neuropathy, grade 3 rash)" (NCT00633594)
Timeframe: Collected from day of first dose to the end of the first treatment cycle, up to 21 days
| Intervention | mg lenalidomide, orally, daily, day 1-14 (Number) |
|---|---|
| Phase I Participants (10 mg/15 mg Lenalidomide) | 10 |
Response to treatment (Complete Response (CR) or Partial Response (PR)) determined using Non-Hodgkin's Lymphoma Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007.) CR: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms; PR: 50% or greater decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or extranodal masses, no increase in the size of other nodes, liver or spleen, no new sites of disease, patients who achieve CR but have persistent morphologic bone marrow involvement; Stable Disease (SD): failing to attain PR or CR, but not fulfilling criteria for progressive disease; Progressive Disease (PD)/Relapse: appearance of new lesions more than 1.5 cm in any axis, 50% or greater increase from nadir SPD of any previously involved sites, 50% or greater increase in the longest diameter of any single previously identified node or extranodal mass more than 1 cm in short axis. (NCT00633594)
Timeframe: Every 6 weeks until treatment discontinuation then every 3 months thereafter, projected average 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase I Participants (10 mg/15 mg Lenalidomide) | 12 |
| Phase II Participants (10 mg Lenalidomide) | 21 |
Response to treatment (Complete Response (CR) or Partial Response (PR)) determined using Non-Hodgkin's Lymphoma Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007.) CR: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms; PR: 50% or greater decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or extranodal masses, no increase in the size of other nodes, liver or spleen, no new sites of disease, patients who achieve CR but have persistent morphologic bone marrow involvement; Stable Disease (SD): failing to attain PR or CR, but not fulfilling criteria for progressive disease; Progressive Disease (PD)/Relapse: appearance of new lesions more than 1.5 cm in any axis, 50% or greater increase from nadir SPD of any previously involved sites, 50% or greater increase in the longest diameter of any single previously identified node or extranodal mass more than 1 cm in short axis. (NCT00633594)
Timeframe: Every 6 weeks until treatment discontinuation then every 3 months thereafter, projected average 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Previously Treated Participants | 8 |
| Previously Untreated Participants | 25 |
"Defined as the date of study entry to the date of death.~Overall Survival will be examined using time-to-event analysis methods. Kaplan-Meier figures will be generated and the log-rank test will be used to examine differences existing between various levels of stratification" (NCT00633594)
Timeframe: Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years, then every 6 months after documented disease progression
| Intervention | months (Median) |
|---|---|
| Phase I Participants (10 mg/15 mg Lenalidomide) | 51.45 |
| Phase II Participants (10 mg Lenalidomide) | 35.35 |
"Defined as the date of study entry to the date of death.~Overall Survival will be examined using time-to-event analysis methods. Kaplan-Meier figures will be generated and the log-rank test will be used to examine differences existing between various levels of stratification" (NCT00633594)
Timeframe: Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years, then every 6 months after documented disease progression
| Intervention | months (Median) |
|---|---|
| Previously Treated Participants | 28.4189 |
| Previously Untreated Participants | 71.2608 |
"Defined as the time from entry onto study until lymphoma progression or death from any cause.~Progression Free Survival will be examined using time-to-event analysis methods. Kaplan-Meier figures will be generated and the log-rank test will be used to examine differences existing between various levels of stratification." (NCT00633594)
Timeframe: Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years, then every 6 months after documented disease progression
| Intervention | months (Median) |
|---|---|
| Phase I Participants (10 mg/15 mg Lenalidomide) | 27.70 |
| Phase II Participants (10 mg Lenalidomide) | 19.35 |
"Defined as the time from entry onto study until lymphoma progression or death from any cause.~Progression Free Survival will be examined using time-to-event analysis methods. Kaplan-Meier figures will be generated and the log-rank test will be used to examine differences existing between various levels of stratification." (NCT00633594)
Timeframe: Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years, then every 6 months after documented disease progression
| Intervention | months (Median) |
|---|---|
| Previously Treated Participants | 12.4517 |
| Previously Untreated Participants | 25.2649 |
"Measured from the time of study entry to the documented beginning of response (CR or PR). This is measured in responders per Non-Hodgkin's Lymphoma Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007.) CR: complete disappearance of detectable clinical evidence of disease and disease-related symptoms; PR: 50% or greater decrease in sum of product of diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses, no increase in size of other nodes, liver or spleen, no new disease sites, patients with CR and persistent morphologic bone marrow involvement.~Time to Best Response will be examined using time-to-event analysis methods. Kaplan-Meier figures will be generated and the log-rank test will be used to examine differences existing between various levels of stratification." (NCT00633594)
Timeframe: Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years
| Intervention | days (Median) |
|---|---|
| Phase I Participants (10 mg/15 mg Lenalidomide) | 63.50 |
| Phase II Participants (10 mg Lenalidomide) | 71.50 |
Measured from the time of study entry to the documented beginning of response (CR or PR). This is measured in responders per Non-Hodgkin's Lymphoma Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007.) CR: complete disappearance of detectable clinical evidence of disease and disease-related symptoms; PR: 50% or greater decrease in sum of product of diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses, no increase in size of other nodes, liver or spleen, no new disease sites, patients with CR and persistent morphologic bone marrow involvement. (NCT00633594)
Timeframe: Every 3 months (+/- 2 weeks) after discontinuation of study treatment for 2 years
| Intervention | months (Median) |
|---|---|
| Previously Treated Participants | 2.04 |
| Previously Untreated Participants | 2.37 |
"A count of affected participants with non-serious adverse events (regardless of relationship to study treatments) occurring in >= 15% of treated patients enrolled in the Phase II section of the study.~Lenalidomide DL-1 dose (10 mg orally, once daily (PO QD)) Day 1-14 followed by 7 days of rest, Rituximab 375 mg/m2 IV Days 1, 8, and 15 of Cycle 1; Cycles 2-6: 375 mg/m2 IV Day 1, Bortezomib 1.3 mg/m2 subcutaneous Days 1, 4, 8, and 11 for Cycles 1-6" (NCT00633594)
Timeframe: Collected from day of first dose to 30 days after the last dose of study medication, a maximum of 18 weeks and 30 days after last study treatment
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rash | Fatigue | Thrombocytopenia | Leukopenia | Nausea | Diarrhea | Edema | Hyperglycemia | Peripheral Neuropathy | Neutropenia | Hypoalbuminemia | Constipation | Hypocalcemia | Pain in Extremity | Anemia | Cough | Fever | Dehydration | Pruritus | Dyspnea | Hyponatremia | Insomnia | Abdominal Pain | Dizziness | Hypokalemia | Weight Loss | Anorexia | Erythema | Hypomagnesemia | Allergic Reaction | Chills | Hyperhidrosis | Myalgia | Headache | Mucositis | Hypoglycemia | |
| Phase II - Lenalidomide 10mg PO QD | 19 | 18 | 16 | 13 | 12 | 11 | 11 | 11 | 10 | 10 | 10 | 9 | 9 | 9 | 8 | 8 | 8 | 7 | 7 | 7 | 7 | 6 | 6 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 |
622 reviews available for thalidomide and Multiple Myeloma
| Article | Year |
|---|---|
A review on the treatment of multiple myeloma with small molecular agents in the past five years.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Deubiquitinating Enzym | 2022 |
Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma.
Topics: Anticoagulants; Humans; Lenalidomide; Multiple Myeloma; Risk Factors; Thalidomide; Venous Thromboemb | 2022 |
Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell T | 2022 |
Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML.
Topics: Bortezomib; Deubiquitinating Enzymes; Drug Discovery; Humans; Lenalidomide; Leukemia, Myeloid, Acute | 2022 |
Real World Adherence to and Persistence With Oral Oncolytics in Multiple Myeloma: A Systematic Review and Meta-analysis.
Topics: Humans; Lenalidomide; Medication Adherence; Melphalan; Multiple Myeloma; Panobinostat; Pharmaceutica | 2022 |
What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunologic Factors; | 2022 |
Multiple myeloma in Latin America.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematopoietic Stem Cell Transplantati | 2022 |
Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Glycine; Humans; Lenali | 2022 |
The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Thalidomide | 2022 |
The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Thalidomide | 2022 |
The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Thalidomide | 2022 |
The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Thalidomide | 2022 |
The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Thalidomide | 2022 |
The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Thalidomide | 2022 |
The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Thalidomide | 2022 |
The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Thalidomide | 2022 |
The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Thalidomide | 2022 |
A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders.
Topics: Humans; Immunomodulating Agents; Multiple Myeloma; Neurodegenerative Diseases; Neuroinflammatory Dis | 2023 |
A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2023 |
Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: A systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bortezomib; D | 2019 |
Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Melphalan; Multipl | 2020 |
Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Borte | 2019 |
B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Marrow; Humans; Immunologic Factors; Lenalidomide; | 2019 |
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future.
Topics: Adaptive Clinical Trials as Topic; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Prot | 2020 |
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.
Topics: Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Ag | 2020 |
Second malignancies in multiple myeloma; emerging patterns and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Disease-Free S | 2020 |
The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies-back to the future!
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dr | 2020 |
Modern treatments and future directions for newly diagnosed multiple myeloma patients.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bortezomib; Cli | 2020 |
Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bortezomib; Clinical Trials, Phase II | 2020 |
Isatuximab: First Approval.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethas | 2020 |
Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma.
Topics: Antibodies, Monoclonal; Bortezomib; Dexamethasone; Drug Therapy, Combination; Hematopoietic Stem Cel | 2020 |
Acquired hemophilia A and plasma cell neoplasms: a case report and review of the literature.
Topics: Aged; Factor VIII; Hemophilia A; Humans; Lenalidomide; Male; Multiple Myeloma; Plasmacytoma; Thalido | 2020 |
The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; | 2021 |
A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide.
Topics: Cytokines; Drug Repositioning; Female; Humans; Immunosuppressive Agents; Infant, Newborn; Kidney Neo | 2021 |
Sequencing multiple myeloma therapies with and after antibody therapies.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezom | 2020 |
Should all newly diagnosed MM patients receive CD38 antibody-based treatment?
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
Consensus statement on the treatment of transplant-eligible patients with newly diagnosed multiple myeloma in New Zealand.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bortezomib; Consensus; | 2020 |
New regimens and directions in the management of newly diagnosed multiple myeloma.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy | 2021 |
Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Proliferatio | 2021 |
Lessons Learned Treating Patients with Multiple Myeloma in Resource-Constrained Settings.
Topics: Antineoplastic Agents; Bortezomib; Developing Countries; Dexamethasone; Humans; Immunosuppressive Ag | 2021 |
An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethas | 2021 |
Recent Advances in the Development of Thalidomide-Related Compounds as Anticancer Drugs.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Female; Humans; Multiple Myeloma; Peripheral Nervous | 2022 |
Posttransplant maintenance therapy in multiple myeloma: the changing landscape.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Hematopoietic Stem Cell Transplantation; | 2017 |
Two cases of permanent indwelling catheter for long-term administration of intrapleural chemotherapy.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezom | 2017 |
Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Humans; Immunologic Factors; Incidence; Infections; Lenalidomide; Mortality; | 2017 |
Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses.
Topics: Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Thalidomide | 2017 |
Daratumumab for the treatment of multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Clini | 2017 |
Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myelom | 2017 |
Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2017 |
A Mini-Review on Thalidomide: Chemistry, Mechanisms of Action, Therapeutic Potential and Anti-Angiogenic Properties in Multiple Myeloma.
Topics: Angiogenesis Inhibitors; Humans; Multiple Myeloma; Neovascularization, Pathologic; Thalidomide; Tumo | 2017 |
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
Topics: Adult; Aged; Angiogenesis Inhibitors; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Surv | 2017 |
Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
Topics: Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; | 2017 |
[Effective BiRd Therapy after the Addition of Clarithromycin for Lenalidomide and Dexamethasone Resistant Multiple Myeloma Ineligible for Stem Cell Transplantation].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethaso | 2017 |
Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Design; Humans; Immunologic Fact | 2017 |
Cereblon: A Protein Crucial to the Multiple Functions of Immunomodulatory Drugs as well as Cell Metabolism and Disease Generation.
Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Proliferation; Cells; Humans; Immunologic Factor | 2017 |
Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethas | 2018 |
Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Dose-Re | 2017 |
Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedu | 2017 |
Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Drug Administr | 2018 |
Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans | 2017 |
Fixed duration vs continuous therapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Disease-Free | 2017 |
Management of multiple myeloma in the relapsed/refractory patient.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Humans; Immuno | 2017 |
Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Boron | 2018 |
[Research Advance in Light Chain Escape of Multiple Myeloma -Review].
Topics: Bortezomib; Humans; Immunoglobulin G; Immunoglobulin Light Chains; Multiple Myeloma; Neoplasm Recurr | 2017 |
Triplet vs. doublet drug regimens for managing multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Glycine; Histone Deacetylase Inhibit | 2018 |
Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies.
Topics: Drug Therapy, Combination; Evidence-Based Medicine; Humans; Immunocompromised Host; Immunologic Fact | 2018 |
Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm | 2018 |
[Research and Applications Progress of Lenalidomide in Relapsed / Refractory Blood System Diseases -Review].
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic | 2018 |
Immunomodulatory effects of CD38-targeting antibodies.
Topics: Adenosine; ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibod | 2018 |
Optimizing therapy in bortezomib-exposed patients with multiple myeloma.
Topics: Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Thalid | 2018 |
Pathophysiology of drug-induce peripheral neuropathy in patients with multiple myeloma.
Topics: Animals; Antineoplastic Agents; Bortezomib; Humans; MicroRNAs; Multiple Myeloma; Nerve Growth Factor | 2018 |
Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trial
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modalit | 2018 |
[Molecular Mechanism of CRBN in the Activity of Lenalidomid eagainst Myeloma--Review].
Topics: Adaptor Proteins, Signal Transducing; Cullin Proteins; Humans; Hydrogen Peroxide; Multiple Myeloma; | 2018 |
Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; | 2018 |
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; | 2018 |
[Daratumumab for multiple myeloma].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Borte | 2018 |
Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Back Pain; Female; Humans; Ibuprofen; Imm | 2018 |
The VAD Scheme versus Thalidomide plus VAD for Reduction of Vascular Endothelial Growth Factor in Multiple Myeloma: A Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Humans; Microvessels; Mul | 2018 |
[First-line treatment of multiple myeloma].
Topics: Antineoplastic Agents; Bortezomib; Germany; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurre | 2019 |
Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; H | 2019 |
Risk adapted post-transplant maintenance in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Hematopoietic Ste | 2019 |
[Immunomodulator drugs for the treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immunologic Factors; Immunomo | 2018 |
Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, | 2019 |
Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem-Cell Transplantation: Systematic Review and Network Meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; H | 2019 |
Cost-effectiveness of lenalidomide plus low-dose dexamethasone for newly diagnosed multiple myeloma patients ineligible for stem cell transplantation in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; China; Combined Modality Therapy; Cost-B | 2019 |
Current approaches for the treatment of multiple myeloma.
Topics: Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Stem Cell Tra | 2013 |
Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.
Topics: Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; | 2013 |
Continuous treatment with new agents for newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Hu | 2013 |
Pomalidomide: first global approval.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Drug Approval; Graft vs Host Disease; Hu | 2013 |
Therapeutic strategies for the treatment of multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytokines; Gene Expression | 2013 |
Diagnosis and therapy of multiple myeloma.
Topics: Age Factors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalido | 2013 |
Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.
Topics: Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Randomized | 2013 |
Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.
Topics: Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Randomized | 2013 |
Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.
Topics: Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Randomized | 2013 |
Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.
Topics: Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Randomized | 2013 |
Safety and effectiveness of low-dose lenalidomide therapy for multiple myeloma complicated with bortezomib-associated interstitial pneumonia.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Immunologic Factors; Lenalid | 2013 |
[Thalidomide in the treatment of multiple myeloma: focus on combination with bortezomib].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Hu | 2013 |
[Lenalidomide maintenance therapy in patients with multiple myeloma].
Topics: Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Multiple | 2013 |
Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis.
Topics: Angiogenesis Inhibitors; Exanthema; Humans; Incidence; Lenalidomide; Multiple Myeloma; Thalidomide | 2013 |
Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Clinical | 2013 |
Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Clinical | 2013 |
Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Clinical | 2013 |
Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Clinical | 2013 |
A case of extramedullary plasmablastic plasmacytoma successfully treated using a combination of thalidomide and dexamethasone and a review of the medical literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Male; Middle Aged; Multiple M | 2013 |
How lenalidomide is changing the treatment of patients with multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunosuppressive Age | 2013 |
Role of thalidomide in the treatment of patients with multiple myeloma.
Topics: Antineoplastic Agents; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; I | 2013 |
Therapeutic effects of thalidomide in hematologic disorders: a review.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Graft vs Host Disease; Hematologic Neoplasms; Hum | 2013 |
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Tri | 2013 |
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Tri | 2013 |
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Tri | 2013 |
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Tri | 2013 |
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Tri | 2013 |
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Tri | 2013 |
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Tri | 2013 |
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Tri | 2013 |
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Tri | 2013 |
[Multiple myeloma].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Mai | 2013 |
Emerging therapies in multiple myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Histone Deacetylas | 2015 |
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma.
Topics: Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as | 2013 |
Pomalidomide.
Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Immunomodulation; Multiple Myeloma; Thalidomi | 2013 |
Management of double-refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boron | 2013 |
Bortezomib in combination with thalidomide or lenalidomide or doxorubicin regimens for the treatment of multiple myeloma: a meta-analysis of 14 randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Doxorubicin; Humans; Lenalidomide; Multi | 2014 |
Bortezomib and lenalidomide as front-line therapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Mul | 2014 |
Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezom | 2013 |
Pomalidomide for patients with multiple myeloma.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Drug Approval; Drug Evaluation, Preclini | 2013 |
Second autologous transplant as salvage therapy in multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 2013 |
Initial treatment of transplant candidates with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Evidence-Based Medicine; | 2013 |
New developments in post-transplant maintenance treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Gl | 2013 |
Role of consolidation therapy in transplant eligible multiple myeloma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; | 2013 |
Novel generation of agents with proven clinical activity in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunologic Factor | 2013 |
Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as | 2013 |
Multiple myeloma: Defining the high-risk patient and determining the optimal treatment strategy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cl | 2013 |
Role of consolidation/maintenance therapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherap | 2013 |
Initial treatment of transplant-ineligible patients in multiple myeloma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Chromosome Aberrations; Glucocor | 2014 |
Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients.
Topics: Angiogenesis Inhibitors; Autografts; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantat | 2013 |
[New drugs in the treatment of multiple myeloma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2014 |
Update on second primary malignancies in multiple myeloma: a focused review.
Topics: Antineoplastic Agents; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasms, Secon | 2014 |
The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.
Topics: Boronic Acids; Bortezomib; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Multiple Myel | 2014 |
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.
Topics: Age Factors; Clinical Trials as Topic; Dexamethasone; Drug Administration Schedule; Humans; Immunolo | 2014 |
Risk stratification in multiple myeloma, part 2: the significance of genetic risk factors in the era of currently available therapies.
Topics: Angiogenesis Inhibitors; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 13; Chr | 2013 |
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
Topics: Angiogenesis Inhibitors; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasms, Second Primar | 2014 |
New approaches to management of multiple myeloma.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Boronic Ac | 2014 |
Pomalidomide: a review of its use in patients with recurrent multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Pro | 2014 |
Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; H | 2014 |
Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Multiple Myeloma; Thalidomide | 2014 |
Monoclonal antibodies currently in Phase II and III trials for multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Boronic A | 2014 |
Lenalidomide.
Topics: Animals; Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; N | 2014 |
Pomalidomide.
Topics: Animals; Antineoplastic Agents; Humans; Multiple Myeloma; Thalidomide | 2014 |
Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II | 2014 |
Impact of pomalidomide therapy in multiple myeloma: a recent survey.
Topics: Animals; Clinical Trials as Topic; Female; Humans; Immunologic Factors; Male; Multiple Myeloma; Thal | 2014 |
Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Double-Blind Method; Hematopoietic Stem Cell Transpla | 2014 |
The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherap | 2015 |
Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Multiple Myeloma; Oligopeptides; Survival Ra | 2014 |
Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II | 2014 |
Novel agents in CNS myeloma treatment.
Topics: Animals; Blood-Brain Barrier; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Multiple Myelo | 2014 |
Pomalidomide for the management of refractory multiple myeloma.
Topics: Drug Resistance, Neoplasm; Humans; Immunologic Factors; Multiple Myeloma; Thalidomide | 2014 |
Current challenges in the management of patients with relapsed/refractory multiple myeloma.
Topics: Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple M | 2011 |
Treatment-related adverse events in patients with relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney; Multiple Myeloma; Nervous System D | 2011 |
Current advances in non-proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Recu | 2011 |
Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2014 |
Maintenance therapy for multiple myeloma.
Topics: Angiogenesis Inhibitors; Combined Modality Therapy; Humans; Lenalidomide; Maintenance Chemotherapy; | 2014 |
Relapsed and refractory multiple myeloma: new therapeutic strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; | 2014 |
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human; Cyclo | 2014 |
Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationshi | 2014 |
Pomalidomide for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Hu | 2014 |
[Supportive care in multiple myeloma for continuing anti-myeloma therapies].
Topics: Anemia; Bone Density Conservation Agents; Bone Diseases, Metabolic; Boronic Acids; Bortezomib; Dipho | 2014 |
[Treatment of transplant-eligible symptomatic multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bendamustine Hydrochloride; Boronic Acid | 2014 |
[Current status of clinical trials of novel agents for multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2014 |
[Treatment of untreated multiple myeloma patients ineligible for autologous stem cell transplantation].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; | 2014 |
[Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
Topics: Administration, Oral; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Immun | 2014 |
[Cereblon - a new target of therapy in the treatment of multiple myeloma].
Topics: Adaptor Proteins, Signal Transducing; Biomarkers, Tumor; Cullin Proteins; Gene Expression; Humans; I | 2014 |
Current treatment landscape for relapsed and/or refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell T | 2015 |
Novel drug combinations for the management of relapsed/refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Disease Management; Disease | 2014 |
Targeting the bone marrow microenvironment in multiple myeloma.
Topics: Angiogenesis Inhibitors; Animals; Bone Marrow; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Tr | 2015 |
Managing multiple myeloma in the over 70s: a review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bone Density Co | 2015 |
[Thalidomide teratogenicity and its direct target identification].
Topics: Adaptor Proteins, Signal Transducing; Animals; Humans; Molecular Targeted Therapy; Multiple Myeloma; | 2015 |
Maintenance Therapy in Multiple Myeloma: Novel Concepts in Clinical Practice from Recent Clinical Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Humans; Mainte | 2016 |
[Successful treatment with melphalan, dexamethasone and thalidomide for relapsed idiopathic light chain deposit disease: a case report and literature review].
Topics: Dexamethasone; Humans; Melphalan; Multiple Myeloma; Recurrence; Thalidomide | 2015 |
Pooled analysis of the reports of pomalidomide after failure of lenalidomide and (or) bortezomib for multiple myeloma.
Topics: Age Factors; Aged; Aged, 80 and over; Bortezomib; Clinical Trials as Topic; Female; Humans; Lenalido | 2016 |
Treatment-related symptom management in patients with multiple myeloma: a review.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; H | 2015 |
Management of relapsed multiple myeloma after autologous stem cell transplant.
Topics: Autografts; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple My | 2015 |
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Pr | 2015 |
[Progress of research on clarithromycin for treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Humans; Multiple Myeloma; Thalidomid | 2015 |
Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Histone Deacetylase Inhibitors; Humans; Immunologic | 2016 |
Lenalidomide in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Disease-Fr | 2015 |
Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Humans; Induction C | 2015 |
Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as | 2015 |
The risk of secondary primary malignancies after therapy for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dr | 2015 |
Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.
Topics: Biomarkers; Cytogenetic Analysis; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Lenalidomi | 2015 |
Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Topics: Angiogenesis Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Top | 2015 |
[Successful treatment of relapsed and refractory multiple myeloma by using clarithromycin-lenalidomide, low-dose dexamethasone(BiRd), and melphalan-prednisolone(MP)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Humans; | 2015 |
Pomalidomide (Pomalyst) for multiple myeloma.
Topics: Animals; Clinical Trials as Topic; Humans; Immunologic Factors; Multiple Myeloma; Thalidomide | 2015 |
Multiple myeloma: from front-line to relapsed therapies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2015 |
Treatment for patients with newly diagnosed multiple myeloma in 2015.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; D | 2015 |
An update on the use of lenalidomide for the treatment of multiple myeloma.
Topics: Dexamethasone; Disease-Free Survival; Drug Therapy, Combination; Humans; Immunologic Factors; Lenali | 2015 |
Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials as Topic; Humans; Multiple Myeloma; | 2015 |
[Pomalidomide for multiple myeloma].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Molecular Conformation; Multiple Myeloma; S | 2015 |
Practical Management of Lenalidomide-Related Rash.
Topics: Exanthema; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Multiple Myeloma; Thalidomide | 2015 |
Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
Topics: Bone and Bones; Bone Marrow; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Humans; Len | 2016 |
The novel mechanism of lenalidomide activity.
Topics: Animals; Humans; Ikaros Transcription Factor; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndro | 2015 |
Bone formation following lenalidomide-dexamethasone combination therapy in cases of multiple myeloma refractory to high-dose chemotherapy with bortezomib and autologous peripheral blood stem cell transplantation: report of a case and review of the literat
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Immunologi | 2015 |
Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond.
Topics: Angiogenesis Inhibitors; Animals; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; | 2015 |
Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
Topics: Disease-Free Survival; Humans; Immunosuppressive Agents; Infections; Lenalidomide; Maintenance Chemo | 2016 |
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Borte | 2016 |
Maintenance therapy for multiple myeloma in the era of novel agents.
Topics: Clinical Trials, Phase III as Topic; Dexamethasone; Disease-Free Survival; Flow Cytometry; Hematolog | 2015 |
First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, | 2016 |
Venous thromboembolism in hematopoietic stem cell transplant recipients.
Topics: Allografts; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Mu | 2016 |
Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis.
Topics: Disease-Free Survival; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Prednisone; Th | 2016 |
Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multip | 2016 |
The safety of pomalidomide for the treatment of multiple myeloma.
Topics: Clinical Trials as Topic; Cohort Studies; Humans; Immunologic Factors; Meta-Analysis as Topic; Multi | 2016 |
The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Dexamethasone; Diphosphonates; Disease Progression; Europe | 2016 |
Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis.
Topics: Bortezomib; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Randomized Controlled Tri | 2016 |
Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
Topics: Anti-Inflammatory Agents; Anticoagulants; Aspirin; Dexamethasone; Fibrinolytic Agents; Heparin, Low- | 2016 |
Sorafenib for the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Proliferatio | 2016 |
[Significant changes in diagnostic and therapeutic procedures in smoldering multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Disease Progressio | 2015 |
Treatment of relapsed and refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; H | 2016 |
Nuances in the Management of Older People With Multiple Myeloma.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Dexamethasone; | 2016 |
Update of thrombosis in multiple myeloma.
Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; | 2016 |
Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2016 |
New Targets and New Agents in High-Risk Multiple Myeloma.
Topics: Cancer Vaccines; GTP Phosphohydrolases; Humans; Immunomodulation; Membrane Proteins; Molecular Targe | 2016 |
Are maintenance and continuous therapies indicated for every patient with multiple myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Hematopoietic | 2016 |
[Multiple myeloma and other plasma cell dyscrasias].
Topics: Bortezomib; Female; Humans; Immunologic Factors; Male; Multiple Myeloma; Proteasome Inhibitors; Thal | 2016 |
Pomalidomide in the management of relapsed multiple myeloma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Multiple Myeloma; Neoplasm Recurrence, Loca | 2016 |
Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Management; Drug Resistance, Neoplasm; Human | 2017 |
The molecular mechanism of thalidomide analogs in hematologic malignancies.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Casein Kinase I; Gene Expression Regula | 2016 |
Is Maintenance Therapy for Everyone?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Decision-Making; Dis | 2016 |
Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2016 |
Concise review - Treatment of multiple myeloma in the very elderly: How do novel agents fit in?
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib | 2016 |
Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis.
Topics: Antineoplastic Agents; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Fact | 2016 |
Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice.
Topics: Bortezomib; Consolidation Chemotherapy; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemo | 2016 |
Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Humans; Immunologic Factors; Lenalidomide; Multiple | 2017 |
Current treatments for renal failure due to multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; H | 2016 |
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2017 |
Stem Cell Transplantation in Multiple Myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bortezomib; Clinical Trials as Top | 2017 |
The role of maintenance therapy in multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalid | 2016 |
Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2017 |
Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
Topics: Antineoplastic Agents; Boron Compounds; Dose-Response Relationship, Drug; Glycine; Humans; Immunolog | 2017 |
Daratumumab: monoclonal antibody therapy to treat multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic | 2016 |
Practical Considerations in Managing Relapsed Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell T | 2017 |
Practical Considerations in Managing Relapsed Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell T | 2017 |
Practical Considerations in Managing Relapsed Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell T | 2017 |
Practical Considerations in Managing Relapsed Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell T | 2017 |
Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Human | 2017 |
An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Pr | 2017 |
Quincke's edema and hypersensitivity pneumonitis induced by lenalidomide for multiple myeloma.
Topics: Alveolitis, Extrinsic Allergic; Angioedema; Angiogenesis Inhibitors; Humans; Lenalidomide; Male; Mid | 2016 |
Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, | 2017 |
Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression.
Topics: Animals; B7-H1 Antigen; Disease Progression; Humans; Killer Cells, Natural; Lenalidomide; Multiple M | 2017 |
Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peripheral Ne | 2017 |
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.
Topics: Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Thalidomide | 2017 |
Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bort | 2017 |
Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Male; Mice; Mice, SC | 2017 |
Carfilzomib-containing combinations as frontline therapy for multiple myeloma: A meta-analysis of 13 trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Tr | 2017 |
Treatment of plasma cell dyscrasias with lenalidomide.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bor | 2008 |
Maintenance treatment in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Therapy, Combination; | 2008 |
Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates.
Topics: Antineoplastic Agents; Blood Coagulation; Fibrinolytic Agents; Humans; Lenalidomide; Multiple Myelom | 2008 |
[Lenalidomide. Treatment of multiple myeloma].
Topics: Antineoplastic Agents; Drug Interactions; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2008 |
Pathogenesis and treatment of renal failure in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; T | 2008 |
Lenalidomide and its role in the management of multiple myeloma.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinica | 2008 |
Frontline treatment of multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antib | 2008 |
Treatment of relapsed and refractory myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II | 2008 |
Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Drug Interactions; Female; Humans; Immun | 2008 |
A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Constipation; De | 2008 |
New drugs in multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as T | 2008 |
Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myelom | 2009 |
The role of novel drugs in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Mul | 2008 |
[Treatment for multiple myeloma: current status and future strategy in Japan].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bor | 2008 |
Advances in therapy of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Fr | 2008 |
Role of thalidomide in previously untreated patients with multiple myeloma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Drug Synergism; Drug Therapy, Combin | 2008 |
Practical considerations for multiple myeloma: an overview of recent data and current options.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Lenalidomide; M | 2008 |
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
Topics: Arsenic Trioxide; Arsenicals; Aspirin; Boronic Acids; Bortezomib; Heparin, Low-Molecular-Weight; Hum | 2009 |
Treatment of newly diagnosed myeloma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bo | 2009 |
Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2009 |
United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Humans; Imm | 2009 |
Multiple myeloma: epidemiology and therapeutic options.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Dexamethasone; Hematop | 2008 |
Diagnosis and the current trends in multiple myeloma therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy, Combinatio | 2008 |
Treatment of multiple myeloma in the targeted therapy era.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as | 2009 |
Initial therapy in multiple myeloma: investigating the new treatment paradigm.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Co | 2009 |
Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Mul | 2009 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therap | 2009 |
Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature.
Topics: Adult; Antineoplastic Agents; Arteries; Female; Humans; Immunosuppressive Agents; Middle Aged; Multi | 2009 |
Multiple myeloma and systemic lupus erythematosus in a young woman.
Topics: Adult; Dexamethasone; Female; Humans; Immunoglobulin A; Immunosuppressive Agents; Lupus Erythematosu | 2009 |
The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Immunosuppressive Age | 2009 |
Palliative oncology: thalidomide.
Topics: Angiogenesis Inhibitors; Constipation; Cytokines; Drug Eruptions; Humans; Hydrolysis; Hypotension, O | 2010 |
Novel therapies in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; L | 2009 |
Multiple myeloma, painful neuropathy, acupuncture?
Topics: Acupuncture Therapy; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Mye | 2009 |
Lenalidomide in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Hum | 2009 |
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antibody-Dependent Cell Cytotoxicity; Antineoplas | 2010 |
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antibody-Dependent Cell Cytotoxicity; Antineoplas | 2010 |
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antibody-Dependent Cell Cytotoxicity; Antineoplas | 2010 |
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antibody-Dependent Cell Cytotoxicity; Antineoplas | 2010 |
The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Costs; Drug Interaction | 2010 |
Immunomodulatory compounds (IMiDs) in the treatment of multiple myeloma.
Topics: Clinical Trials, Phase III as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Th | 2009 |
[Hematopoietic stem cell transplantation for multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; | 2009 |
[New treatment strategies for multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II | 2009 |
How to treat elderly patients with multiple myeloma: combination of therapy or sequencing.
Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Prot | 2009 |
How to treat a newly diagnosed young patient with multiple myeloma.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chrom | 2009 |
Novel therapies for relapsed myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2009 |
ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; | 2009 |
New treatments for myeloma.
Topics: Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lenalidomide | 2010 |
Current multiple myeloma treatment strategies with novel agents: a European perspective.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Ch | 2010 |
Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis.
Topics: Cytokines; Humans; Immunologic Factors; Multiple Myeloma; Neovascularization, Pathologic; Primary My | 2010 |
New developments in the treatment of patients with multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic A | 2010 |
Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous Syste | 2010 |
Lenalidomide in multiple myeloma: current role and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Humans; Len | 2010 |
Advances in treatment for relapses and refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; | 2010 |
[Molecular-targeted therapy of multiple myeloma].
Topics: Boronic Acids; Bortezomib; Drug Delivery Systems; Humans; Immunologic Factors; Lenalidomide; Multipl | 2010 |
Mechanism of action of immunomodulatory agents in multiple myeloma.
Topics: Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Myeloma; Thalidomide | 2010 |
Role of autologous stem cell transplantation in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as | 2007 |
Treatment of relapsed and refractory myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; De | 2009 |
Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.
Topics: Aged; Antineoplastic Agents; Biopsy, Needle; Bone Marrow; Bone Marrow Transplantation; Boronic Acids | 2010 |
[The use of lenalidomide in the treatment of multiple myeloma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Dexamethasone; Humans; Lenalidomide; Multipl | 2010 |
Management of treatment-related adverse events in patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disorders of Excessive Somnolence; Gastrointestina | 2010 |
Multiple myeloma - current issues and controversies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Management; Humans; Lenalidomide; Multiple | 2010 |
Optimising patient outcomes in myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Management; Humans; Lenalidomide; Multiple | 2010 |
Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Hu | 2010 |
Intracranial multifocal dural involvement in multiple myeloma: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Cyclophosphami | 2010 |
Cost-effectiveness of lenalidomide in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Lenalidomid | 2010 |
Post-transplant lymphoproliferative disorder presenting as multiple myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
Progress in allogeneic transplantation for multiple myeloma.
Topics: Antineoplastic Agents; Cyclophosphamide; Disease-Free Survival; Graft vs Host Disease; Hematopoietic | 2010 |
[Thalidomide in oncological and hematological diseases].
Topics: Angiogenesis Inhibitors; Female; Hematologic Diseases; Humans; Multiple Myeloma; Neoplasms; Pregnanc | 2010 |
Development of target-specific treatments in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Histone Deacetylase Inhibitor | 2010 |
Drug-mediated and cellular immunotherapy in multiple myeloma.
Topics: Antibody-Dependent Cell Cytotoxicity; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Boronic | 2010 |
Plasma cell leukaemia and other aggressive plasma cell malignancies.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Leukemia, Plas | 2010 |
The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II | 2010 |
Lenalidomide: a synthetic compound with an evolving role in cancer management.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematologic Di | 2010 |
Thromboembolism with immunomodulatory agents in the treatment of multiple myeloma.
Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; Immunologic F | 2011 |
[Current treatment strategies for multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Diphosphonates; Dose-Resp | 2010 |
Rare bladder tumors: caveat emptor.
Topics: Abnormalities, Drug-Induced; Disease Progression; Female; Humans; Lenalidomide; Male; Multiple Myelo | 2010 |
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Incidence; Multiple Myeloma; Peripheral Ne | 2010 |
Multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Genomic Instability; Hema | 2010 |
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
Topics: Boronic Acids; Bortezomib; Glomerular Filtration Rate; Hematopoietic Stem Cell Transplantation; Huma | 2010 |
Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Hu | 2010 |
Plasma cell leukemia: concepts and management.
Topics: Aged; Antigens, CD20; Antineoplastic Agents; Boronic Acids; Bortezomib; CD56 Antigen; Humans; Lenali | 2010 |
Multiple myeloma.
Topics: Anemia; Bone Diseases; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhi | 2011 |
Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2011 |
Lenalidomide mode of action: linking bench and clinical findings.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Clinical Trials as | 2010 |
Multiple myeloma in the elderly: when to treat, when to go to transplant.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematopoietic Stem Cell Transpl | 2010 |
Ten years of improvement in the management of multiple myeloma: 2000-2010.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality T | 2010 |
Clinical impact of chromosomal aberrations in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Hematopoietic Stem Cell Tr | 2011 |
Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Graft vs Host Di | 2011 |
Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Middle A | 2011 |
Thrombosis in multiple myeloma.
Topics: Humans; Lenalidomide; Multiple Myeloma; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolis | 2010 |
Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.
Topics: Cohort Studies; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Venous Thromboembolism | 2011 |
Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.
Topics: Cohort Studies; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Venous Thromboembolism | 2011 |
Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.
Topics: Cohort Studies; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Venous Thromboembolism | 2011 |
Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.
Topics: Cohort Studies; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Venous Thromboembolism | 2011 |
Management of older patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boro | 2011 |
Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Mu | 2011 |
New immunomodulatory drugs in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immunologic Factors; Lenalido | 2011 |
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Mu | 2011 |
Treatment of newly diagnosed myeloma in patients not eligible for transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; D | 2011 |
Treatment of newly diagnosed multiple myeloma in transplant-eligible patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2011 |
The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Lenalidomide; Mu | 2011 |
Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as | 2011 |
Treatment options for relapsed and refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; | 2011 |
Advances in the biology and treatment of bone disease in multiple myeloma.
Topics: Biopsy; Bone Density Conservation Agents; Bone Diseases; Bone Marrow Cells; Bone Remodeling; Clinica | 2011 |
Pomalidomide therapy for myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Hu | 2011 |
Lenalidomide - current understanding of mechanistic properties.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2011 |
Management of the adverse effects of lenalidomide in multiple myeloma.
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; | 2011 |
Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comorbidity; | 2011 |
Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ce | 2011 |
Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.
Topics: Drug Therapy, Combination; Humans; Multiple Myeloma; Precision Medicine; Proteasome Inhibitors; Thal | 2011 |
Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; | 2011 |
Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose | 2011 |
Therapy of relapsed and refractory multiple myeloma.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2011 |
[New insights in the treatment of myeloma with renal failure].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2011 |
Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Multiple Myeloma; Pyr | 2011 |
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Hum | 2011 |
Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Multiple Myeloma | 2012 |
Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Topics: Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; | 2012 |
Genomic stratification of multiple myeloma treated with novel agents.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Genomics; Humans; Lenalido | 2012 |
[IMiDs in hematology].
Topics: Chronic Disease; Hematologic Neoplasms; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphoi | 2011 |
[Current treatment strategies with novel agents for multiple myeloma].
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Drug Design; Drug Th | 2011 |
[Development of novel agents for multiple myeloma; now and the future].
Topics: Animals; Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Benzoquinones; Benzylamines; | 2011 |
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; I | 2011 |
Continuous treatment in multiple myeloma - ready for prime time?
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dexamethasone | 2011 |
Spotlight on lenalidomide in relapsed or refractory multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexame | 2011 |
Renal crescentic alpha heavy chain deposition disease: a report of 3 cases and review of the literature.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cuti | 2011 |
[Treatment of multiple myeloma by immunomodulatory drugs].
Topics: Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Thalidomide | 2011 |
Advances in the autologous and allogeneic transplantation strategies for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Hematopoietic Stem Cell T | 2011 |
The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.
Topics: Administration, Oral; Antineoplastic Agents; Disease Progression; Dose-Response Relationship, Drug; | 2012 |
Lenalidomide in multiple myeloma: current experimental and clinical data.
Topics: Animals; Antineoplastic Agents; Apoptosis; Clinical Trials as Topic; Humans; Immune System; Lenalido | 2012 |
The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic | 2011 |
Postrelapse survival rate correlates with first-line treatment strategy with thalidomide in patients with newly diagnosed multiple myeloma: a meta-analysis.
Topics: Angiogenesis Inhibitors; Humans; Meta-Analysis as Topic; Multiple Myeloma; Neoplasm Recurrence, Loca | 2012 |
Management of treatment-emergent peripheral neuropathy in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Early Diagnosis; Humans; Immunologic Factors; Incidence; Multiple Myeloma | 2012 |
Clinical experience with thalidomide and lenalidomide in multiple myeloma.
Topics: Adrenal Cortex Hormones; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Che | 2012 |
[Thrombotic complications following the treatment of multiple myeloma with new agents].
Topics: Anthracyclines; Anticoagulants; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Dru | 2011 |
Advantageous use of lenalidomide in multiple myeloma: discussion of three case studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Male; Mul | 2012 |
Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as T | 2012 |
Management of myeloma-associated renal dysfunction in the era of novel therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Mul | 2012 |
A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Incidence; Kaplan-Meier Estim | 2012 |
Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Immunologic Factors; Multiple Myeloma; Myel | 2012 |
Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Le | 2012 |
Deciphering the mystery of thalidomide teratogenicity.
Topics: Adaptor Proteins, Signal Transducing; Animals; Chick Embryo; Female; Fibroblast Growth Factor 8; Hum | 2012 |
Latest advances and current challenges in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multipl | 2012 |
[Lenalidomide in hematological malignancies---review].
Topics: Angiogenesis Inhibitors; Hematologic Neoplasms; Humans; Lenalidomide; Multiple Myeloma; Myelodysplas | 2012 |
Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.
Topics: Animals; Antineoplastic Agents; Humans; Immunologic Factors; Multiple Myeloma; Thalidomide; Tumor Mi | 2012 |
[Multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Evidence-Based Practice; | 2012 |
Novel therapies in monoclonal gammopathies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Humans; I | 2012 |
Thrombosis in multiple myeloma (MM).
Topics: Anthracyclines; Antineoplastic Agents, Hormonal; Dexamethasone; Humans; Immunologic Factors; Lenalid | 2012 |
European perspective on multiple myeloma treatment strategies: update following recent congresses.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Congresses as Topic; Europe; Humans; Lenalidomide; | 2012 |
Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis.
Topics: Adrenal Cortex Hormones; Aged; Algorithms; Antineoplastic Agents; Disease-Free Survival; Humans; Mai | 2012 |
Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dexamethasone; Humans; Lenalidomide; | 2012 |
Lenalidomide in multiple myeloma: Current status and future potential.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2012 |
Thalidomide: chemistry, therapeutic potential and oxidative stress induced teratogenicity.
Topics: Animals; Apoptosis; Humans; Multiple Myeloma; Oxidative Stress; Teratogens; Thalidomide; Tumor Necro | 2012 |
(Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Hu | 2012 |
Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemical and Drug Induc | 2012 |
The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Topics: Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid | 2012 |
Novel lenalidomide-based combinations for treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide | 2013 |
Lenalidomide maintenance for multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Clinical Trials, Phase | 2012 |
Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials.
Topics: Antineoplastic Agents; Fibrinolytic Agents; Humans; Lenalidomide; Models, Biological; Multiple Myelo | 2012 |
Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Disease-Fre | 2012 |
Multiple myeloma: improved outcomes with new therapeutic approaches.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Im | 2012 |
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.
Topics: Aged; Aged, 80 and over; Female; Hematologic Diseases; Humans; Male; Multiple Myeloma; Randomized Co | 2013 |
Thalidomide thromboprophylaxis in multiple myeloma: a review of current evidence.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Multiple Myelom | 2012 |
Achieving an early myeloma response in patients with kidney impairment.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexa | 2012 |
Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexa | 2012 |
Fifty years of melphalan use in hematopoietic stem cell transplantation.
Topics: Adenine Nucleotides; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemoth | 2013 |
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Gene Expression; Humans; Immunologic Factors; Interferon Regul | 2013 |
Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.
Topics: Aged; Amyloidosis; Bence Jones Protein; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; | 2012 |
[Update on treatment of multiple myeloma: including myeloma kidney and molecular targeting drugs].
Topics: Boronic Acids; Bortezomib; Drug Design; Humans; Immunologic Factors; Kidney Neoplasms; Lenalidomide; | 2012 |
Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calibration; Disease Prog | 2012 |
How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comprehension; Drug-Relat | 2012 |
Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; | 2012 |
What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?
Topics: Bone Diseases; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Fractures, Bone; H | 2012 |
[Successful treatment with lenalidomide plus dexamethasone for multiple myeloma complicated with systemic amyloidosis].
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Therapy, Combinatio | 2012 |
Novel immunomodulatory compounds in multiple myeloma.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Disease-Free Survival; Humans; Immunologic Factor | 2013 |
Current therapeutic strategy for multiple myeloma.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone | 2013 |
Lenalidomide-based combined therapy induced alterations in serum proteins of multiple myeloma patient: a follow-up case report and overview of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Proteins; Female; Follow-Up Studies; Hu | 2012 |
Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Diphosphonates; | 2013 |
Induction therapy for newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamet | 2013 |
Part II: role of maintenance therapy in transplant-ineligible patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamet | 2013 |
Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.
Topics: Animals; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Epigenesis, Genetic | 2013 |
Lenalidomide versus thalidomide based regimens as first-line therapy for patients with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Immunosuppressive Agents; Lenalidomide; Mult | 2013 |
Thalidomide in the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Humans; Multiple Myeloma; Thalidomide | 2001 |
Novel therapies for multiple myeloma.
Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cy | 2002 |
Current therapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Therapy, Combination | 2002 |
Thalidomide for the treatment of relapsed and refractory multiple myeloma.
Topics: Cell Division; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Humans; Multiple | 2002 |
[Thalidomide: new uses for an old drug].
Topics: Angiogenesis Inhibitors; Drug Approval; Erythema Nodosum; Graft vs Host Disease; Humans; Immune Syst | 2002 |
Thalidomide treatment in multiple myeloma.
Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Hum | 2002 |
New developments and treatment in multiple myeloma: new drugs in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Cysteine Endopeptidases; Diphosphonates; Female; Humans; Male; Multienzyme Co | 2002 |
Thalidomide and immunomodulatory drugs as cancer therapy.
Topics: Adjuvants, Immunologic; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Humans; Immun | 2002 |
[High dose chemotherapy and hematopoietic stem cell transplantation in patients with myeloma].
Topics: Humans; Melphalan; Multiple Myeloma; Radiotherapy, Adjuvant; Stem Cell Transplantation; Thalidomide | 2001 |
Thalidomide in multiple myeloma--from the clinic to the laboratory.
Topics: Clinical Trials as Topic; Forecasting; Humans; Immunosuppressive Agents; Multiple Myeloma; Research; | 2002 |
Novel therapies for multiple myeloma.
Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bo | 2003 |
Myeloma and the newly diagnosed patient: a focus on treatment and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Clinical Trials as Topi | 2002 |
Moving disease biology from the laboratory to the clinic.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion Molecu | 2002 |
High-dose therapy and immunomodulatory drugs in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; | 2002 |
Low-dose thalidomide in myeloma: efficacy and biologic significance.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Clinical Trials as Topic; Cytokines; Humans; Multiple | 2002 |
Multiple myeloma: how far have we come?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Diagnosis, Differential; Humans; Multip | 2003 |
[Multiple myeloma and neovascularization].
Topics: Animals; Humans; Multiple Myeloma; Neovascularization, Pathologic; Thalidomide | 2002 |
[Renaissance of thalidomide].
Topics: Humans; Immunosuppressive Agents; Multiple Myeloma; Skin Diseases; Thalidomide | 2002 |
Thalidomide dosing in patients with relapsed or refractory multiple myeloma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Multiple | 2003 |
Pharmacotherapy of multiple myeloma: an economic perspective.
Topics: Aged; Cost-Benefit Analysis; Drug Therapy; Economics, Pharmaceutical; Humans; Melphalan; Middle Aged | 2003 |
Thalidomide for erythema nodosum leprosum and other applications.
Topics: Animals; Cachexia; Erythema Nodosum; Graft vs Host Disease; Humans; Leprosy, Lepromatous; Multiple M | 2003 |
Advances in the treatment of multiple myeloma: the role of thalidomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Salvage The | 2003 |
Novel therapies in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Mul | 2003 |
[Thalidomide treatment in multiple myeloma].
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase | 2003 |
Thalidomide in the management of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Management; Humans; Multiple Myeloma; Thalid | 2002 |
Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Humans; Middle Aged; Multipl | 2003 |
Early changes in bone marrow morphology induced by thalidomide in refractory myeloma patients.
Topics: Angiogenesis Inhibitors; Bone Marrow; Drug Administration Schedule; Humans; Multiple Myeloma; Thalid | 2003 |
Treatment of multiple myeloma.
Topics: Amyloidosis; Antineoplastic Agents, Alkylating; Gene Expression Profiling; History, 20th Century; Hi | 2004 |
Therapy strategies for multiple myeloma: current status.
Topics: Adjuvants, Immunologic; Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agen | 2003 |
Thalidomide-associated gynecomasty in a patient with multiple myeloma.
Topics: Aged; Gynecomastia; Humans; Multiple Myeloma; Remission Induction; Thalidomide | 2003 |
Recent developments and future directions in the treatment of multiple myeloma.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals | 2003 |
Thalidomide-based treatment for HIV-associated multiple myeloma: a case report.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Bone Marrow Examination; CD4 Lymph | 2003 |
Editorial comment: multiple myeloma and HIV infection--causal or casual coincidence?
Topics: Anti-HIV Agents; Causality; Diagnosis, Differential; HIV Infections; HIV-1; Humans; Immunosuppressiv | 2003 |
Treatment of plasma cell dyscrasias with thalidomide and its derivatives.
Topics: Adjuvants, Immunologic; Dexamethasone; Drug Therapy, Combination; Forecasting; Humans; Multiple Myel | 2003 |
[Left atrial thrombus in multiple myeloma treated with thalidomide].
Topics: Aged; Female; Heart Atria; Heart Diseases; Humans; Multiple Myeloma; Thalidomide; Thrombosis | 2003 |
[Thalidomide and others: new treatment for myeloma].
Topics: Angiogenesis Inhibitors; Cysteine Endopeptidases; Humans; Multienzyme Complexes; Multiple Myeloma; P | 2003 |
Thalidomide: from teratogen to anti-angiogenic.
Topics: Angiogenesis Inhibitors; Humans; Male; Multiple Myeloma; Neoplasms; Prostatic Neoplasms; Thalidomide | 2001 |
[Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide].
Topics: Angiogenesis Inhibitors; Carrier Proteins; Humans; Intercellular Signaling Peptides and Proteins; In | 2003 |
Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.
Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Con | 2003 |
Thalidomide in relapsed/refractory multiple myeloma: pivotal trials conducted outside the United States.
Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Aus | 2003 |
Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease.
Topics: Adjuvants, Immunologic; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy P | 2003 |
The role of immunomodulatory drugs in multiple myeloma.
Topics: Adjuvants, Immunologic; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinic | 2003 |
Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.
Topics: Adjuvants, Immunologic; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy P | 2003 |
[Thalidomide--new prospective therapy in oncology].
Topics: Analgesics; Angiogenesis Inhibitors; Antineoplastic Agents; Cachexia; Clinical Trials as Topic; Huma | 2003 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
Antiangiogenic therapy in hematologic malignancies.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Multiple | 2004 |
[Thalidomide: (re)discovery of a not very dear old molecule].
Topics: Aged; Angiogenesis Inhibitors; Female; Humans; Male; Multiple Myeloma; Myelodysplastic Syndromes; Ne | 2003 |
Multiple myeloma: the role of transplant and novel treatment strategies.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezom | 2004 |
The promise of thalidomide: evolving indications.
Topics: Cachexia; Carcinoma, Renal Cell; Clinical Trials as Topic; Erythema Nodosum; Graft vs Host Disease; | 2004 |
Recent advances in the management of multiple myeloma.
Topics: Antineoplastic Agents; Bone Marrow; Disease Management; Humans; Immunologic Factors; Multiple Myelom | 2004 |
New drugs for treatment of multiple myeloma.
Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Ars | 2004 |
Thalidomide in cancer medicine.
Topics: Angiogenesis Inhibitors; Cachexia; Clinical Trials as Topic; Graft vs Host Disease; Humans; Multiple | 2004 |
Plasma cell disorders in HIV-infected patients: from benign gammopathy to multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; HIV Infect | 2004 |
Thalidomide for the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Dexamethasone; Fibroblast Growth Factor 2; | 2004 |
[New pharmacological availability of thalidomide based on experience in patients with multiple myeloma].
Topics: Animals; Blood Vessels; Clinical Trials, Phase II as Topic; Ectromelia; Erythema Nodosum; Female; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Hematopoietic cancer and angiogenesis.
Topics: Angiogenesis Inhibitors; Cell Proliferation; Disease Progression; Endothelium, Vascular; Hematologic | 2004 |
Targeting multiple myeloma cells and their bone marrow microenvironment.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Boronic Acids; Bortezomib; C | 2004 |
Evolving treatment strategies for myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2005 |
[Thalidomide: mechanisms of action and new insights in hematology].
Topics: Amyloidosis; Angiogenesis Inhibitors; Clinical Trials as Topic; Cytokines; Follow-Up Studies; Foreca | 2005 |
Thalidomide: present and future in multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; H | 2005 |
New treatment strategies for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Dose-Response | 2004 |
[Multiple myeloma--recent advances in diagnosis and treatment].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2005 |
Clinical update: novel targets in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance | 2004 |
Targeted therapy in multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as T | 2005 |
Treatment of myeloma in patients not eligible for transplantation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Hu | 2005 |
Novel approaches to the management of myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boro | 2005 |
Unusual cutaneous involvement during plasma cell leukaemia phase in a multiple myeloma patient after treatment with thalidomide: a case report and review of the literature.
Topics: Humans; Immunosuppressive Agents; Leukemia, Plasma Cell; Leukemic Infiltration; Male; Middle Aged; M | 2005 |
Current treatment options for myeloma.
Topics: Age Factors; Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone | 2005 |
Multiple myeloma: challenges and opportunities.
Topics: Antineoplastic Agents; Humans; Multiple Myeloma; Thalidomide | 2005 |
Perspectives for combination therapy to overcome drug-resistant multiple myeloma.
Topics: 2-Methoxyestradiol; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2005 |
Novel biological therapies for the treatment of multiple myeloma.
Topics: Apoptosis Regulatory Proteins; Biological Therapy; Drug Delivery Systems; Enzyme Inhibitors; HSP90 H | 2005 |
IMiDs: a novel class of immunomodulators.
Topics: Angiogenesis Inhibitors; Clinical Trials, Phase I as Topic; Humans; Immunologic Factors; Lenalidomid | 2005 |
Properties of thalidomide and its analogues: implications for anticancer therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Cell Adhesion Molecules; Clinical Trials, | 2005 |
Future directions in multiple myeloma treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Proliferation; Clinical Tria | 2005 |
The current status of thalidomide in the management of multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boro | 2005 |
The future role of thalidomide in multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Proto | 2005 |
Multiple myeloma: diagnosis and treatment.
Topics: Algorithms; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Dexametha | 2005 |
Thalidomide and dexamethasone: therapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Dexamethasone; Humans; Multiple Myeloma; | 2005 |
Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide.
Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multi | 2005 |
Evolving role of stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Boronic | 2005 |
Evolving role of stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Boronic | 2005 |
Evolving role of stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Boronic | 2005 |
Evolving role of stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Boronic | 2005 |
Induction therapy before transplantation in multiple myeloma: new strategies to achieve complete response.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bor | 2005 |
Immunomodulatory drugs in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Cytokines; Humans; Immunologic Factors; Lenalidomide; Multiple Myelo | 2005 |
Thalidomide and thrombosis.
Topics: Angiogenesis Inhibitors; Drug Screening Assays, Antitumor; Heparin; Humans; Multiple Myeloma; Thalid | 2003 |
Drug insight: thalidomide as a treatment for multiple myeloma.
Topics: Animals; Bone Marrow Cells; Cell Adhesion; Cell Proliferation; Cell Survival; Humans; Immunosuppress | 2005 |
Immunomodulatory drugs.
Topics: Humans; Immunosuppressive Agents; Interleukin-12; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Mul | 2005 |
Treatment paradigms for the newly diagnosed patient with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Le | 2005 |
Lenalidomide: patient management strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, | 2005 |
Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Dexamethasone; | 2005 |
Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, | 2005 |
Overview of drug therapy for multiple myeloma.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Tr | 2005 |
Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
Topics: Animals; Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; MEDLINE; Multiple Myel | 2006 |
Thalidomide in multiple myeloma.
Topics: Humans; Multiple Myeloma; Survival Analysis; Thalidomide | 2006 |
Current therapeutic uses of lenalidomide in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2006 |
A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma.
Topics: Clinical Trials, Phase II as Topic; Data Collection; Dose-Response Relationship, Drug; Drug Administ | 2006 |
[New strategy for the treatment of multiple myeloma].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenical | 2005 |
[Treatment of multiple myeloma].
Topics: Adult; Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Middle Aged; Multi | 2006 |
New treatments for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; | 2005 |
Novel treatment approaches for patients with multiple myeloma.
Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Cell Proliferation; Clinical Trials, Phase I as | 2006 |
Immunomodulatory analogues of thalidomide in the treatment of multiple myeloma.
Topics: Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Thalidomide | 2006 |
[Prognostic factors and new treatments of multiple myeloma].
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2006 |
Treatment of multiple myeloma: an emphasis on new developments.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic | 2006 |
[New treatment strategy of multiple myeloma for cure].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell T | 2006 |
[The plasma cell myeloma--molecular pathogenesis and target therapies].
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2006 |
Thalidomide and lenalidomide in the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2006 |
[Current therapy for multiple myeloma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; | 2005 |
The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as T | 2006 |
The use of thalidomide in myeloma therapy as an effective anticancer drug.
Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Remodeling; Cell Proliferation; Humans; Killer | 2006 |
The role of thalidomide in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dex | 2006 |
Emerging role of novel combinations for induction therapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Tri | 2006 |
Advancing access to myeloma treatment: administration, side effects, and implications for survival.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Health Services Accessibil | 2006 |
Advances in the treatment of multiple myeloma: a nursing perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2006 |
Lenalidomide in multiple myeloma.
Topics: Angiogenesis Inhibitors; Bone Marrow; Clinical Trials as Topic; Combined Modality Therapy; Humans; L | 2006 |
Advances in oral therapy in the treatment of multiple myeloma.
Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Agents; Dexamethasone; Drug Monitoring | 2006 |
[New drugs for myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; | 2006 |
Thalidomide and lenalidomide in multiple myeloma.
Topics: Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Remission Induction; Thalidomide | 2006 |
Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2006 |
Thalidomide in multiple myeloma: past, present and future.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, | 2006 |
[Recent progress in diagnosis of and therapy for multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Hematopoietic Stem Cell | 2006 |
Current status of new drugs for the treatment of patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; | 2006 |
Investigational treatments for multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.
Topics: Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasms; Thalidomide; Thromboembolism | 2006 |
Immunomodulatory drugs as a therapy for multiple myeloma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cytokines; Humans; Immunologic Factors; Multiple Myeloma; | 2006 |
Thalidomide in multiple myeloma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Immunolog | 2006 |
Maintenance therapy for multiple myeloma with particular emphasis on thalidomide.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Humans; Int | 2006 |
Risk of thrombosis with lenalidomide and its prevention with aspirin.
Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; | 2007 |
Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2006 |
[Thalidomide and dexamethasone in the treatment of multiple myeloma: progressing step by step].
Topics: Dexamethasone; Drug Therapy, Combination; Humans; Multiple Myeloma; Thalidomide | 2007 |
An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Clinical Trials as Topic; Disease-Free Survival; Drug Re | 2007 |
The emerging role of novel therapies for the treatment of relapsed myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Ther | 2007 |
Thrombosis in multiple myeloma.
Topics: Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Agents; Blood Coagulation Factors; Cytokines | 2007 |
Lenalidomide: the emerging role of a novel targeted agent in malignancies.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Lenalidomide; Multiple Myeloma; M | 2007 |
Emerging drugs in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalid | 2007 |
The thalidomide saga.
Topics: Antineoplastic Agents; Cytokines; Fibroblast Growth Factor 2; Humans; Immunosuppressive Agents; Lymp | 2007 |
[Recent progress in the treatment of multiple myeloma].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Diphosphonates; Drug Desi | 2007 |
[Treatment of multiple myeloma with thalidomide and immunomodulatory drugs].
Topics: Humans; Immunologic Factors; Multiple Myeloma; Thalidomide | 2007 |
Thalidomide and thrombosis. A meta-analysis.
Topics: Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Agents, Hormonal; Dexamethasone; Humans; Mul | 2007 |
[New treatment of multiple myeloma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineopl | 2007 |
Pegylated liposomal doxorubicin and immunomodulatory drug combinations in multiple myeloma: rationale and clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin; Drug-Related | 2007 |
Isolated thrombocytopenia induced by thalidomide in a patient with multiple myeloma: case report and review of literature.
Topics: Dose-Response Relationship, Drug; Humans; Middle Aged; Multiple Myeloma; Platelet Count; Thalidomide | 2007 |
New drugs for myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Lenalidomide; Mu | 2007 |
Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison.
Topics: Animals; Blood Proteins; Boronic Acids; Bortezomib; Cell Transplantation; Humans; Immunoglobulins; M | 2007 |
Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Cli | 2007 |
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2007 |
Tandem transplants in the treatment of multiple myeloma. Pro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; | 2004 |
Lenalidomide in myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multipl | 2007 |
Initial Therapy of Multiple Myeloma in Patients who are Candidates for Stem Cell Transplantation.
Topics: Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Hematopoietic Stem Cell Transpl | 2007 |
Novel therapeutic avenues in myeloma: changing the treatment paradigm.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase I | 2007 |
Lenalidomide in myelodysplastic syndrome and multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenali | 2007 |
Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma.
Topics: Anorexia; Antineoplastic Agents; Apoptosis; Constipation; Diarrhea; Drug Eruptions; Drug Monitoring; | 2007 |
Lenalidomide in the treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as T | 2007 |
Targeted treatments to improve stem cell outcome: old and new drugs.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Delivery Systems; Hematopoietic Stem Cell Tra | 2007 |
Novel therapies in myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Hu | 2007 |
[An old drug as a carcinostatic. The new career of thalidomide].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Erythema Nodosum; Humans; Immunologic Factors; Multi | 2007 |
[Therapy of multiple myeloma: indications and options].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2007 |
New therapies in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Mu | 2007 |
Management of relapsed and relapsed refractory myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as | 2007 |
[Brief report: stroke in multiple myeloma patient treated with thalidomide].
Topics: Aged; Anticoagulants; Aspirin; Embolism, Paradoxical; Foramen Ovale, Patent; Humans; Male; Multiple | 2007 |
The treatment of relapsed and refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; | 2007 |
Clinical updates and nursing considerations for patients with multiple myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; | 2007 |
Multiple myeloma and treatment-related thromboembolism: oncology nurses' role in prevention, assessment, and diagnosis.
Topics: Antineoplastic Agents; Drug Monitoring; Early Diagnosis; Humans; Immunosuppressive Agents; Lenalidom | 2007 |
[Diagnosis and management guideline for multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2007 |
[Chemotherapy for multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamet | 2007 |
[Role of interferon for the treatment of myeloma].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Interferon alpha | 2007 |
[Application and safety of thalidomide in the treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Drug-Related Sid | 2007 |
[Development of thalidomide analogs for the treatment of multiple myeloma (MM)].
Topics: Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as | 2007 |
[Role of bortezomib in the treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; | 2007 |
[Role of stem cell transplantation in treatment of multiple myeloma].
Topics: Age Factors; Aged; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Tra | 2007 |
[Molecular targeting therapy for multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; | 2007 |
Thalidomide in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multip | 2007 |
Lenalidomide in multiple myeloma.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalido | 2007 |
Frontline treatment in multiple myeloma patients not eligible for stem-cell transplantation.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Top | 2007 |
[Advances in therapeutic strategies for multiple myeloma].
Topics: Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Humans; Len | 2007 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
An update on drug combinations for treatment of myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; | 2008 |
Lenalidomide: a new therapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Humans; Len | 2008 |
Thalidomide for treatment of multiple myeloma: 10 years later.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug and Narcotic Control; Humans; Multiple Myeloma | 2008 |
Multiple myeloma: novel approaches for relapsed disease.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Mu | 2007 |
Lenalidomide for the treatment of B-cell malignancies.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Gene | 2008 |
A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma.
Topics: Disease Progression; Humans; Immunosuppressive Agents; Multiple Myeloma; Thalidomide; Treatment Outc | 2008 |
New tubulin polymerization inhibitor derived from thalidomide: implications for anti-myeloma therapy.
Topics: Humans; Multiple Myeloma; Thalidomide; Tubulin Modulators | 2008 |
Individualizing treatment of patients with myeloma in the era of novel agents.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Geriatric Assessment; | 2008 |
Current therapy of myeloma induced renal failure.
Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; T | 2008 |
Thalidomide and lenalidomide: Mechanism-based potential drug combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow; Humans; Immune System; Lenal | 2008 |
Lenalidomide in the treatment of multiple myeloma: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immunologic Factors; Lenalido | 2008 |
[Bone marrow angiogenesis in multiple myeloma: new insights into the pathogenesis, and development of a new therapeutic approach].
Topics: Angiogenesis Inhibitors; Bone Marrow; Clinical Trials as Topic; Humans; Multiple Myeloma; Neovascula | 2000 |
Recent advances in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Chromosome | 2000 |
A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
Topics: Angiogenesis Inhibitors; Bone Marrow; Cytokines; Humans; Multiple Myeloma; Neovascularization, Patho | 2000 |
[Treatment of multiple myeloma].
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Diphosphonates; Humans; Immunotherapy; Multiple | 2000 |
Treatment approaches for relapsing and refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Hema | 2000 |
[Thalidomide. Clinical trials in cancer].
Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Multiple Myeloma; | 2000 |
Thalidomide in multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; D | 2000 |
Thalidomide use: past history and current implications for practice.
Topics: Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Humans; Multiple Myeloma; Oncology Nursin | 2001 |
Thalidomide in the management of multiple myeloma.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Humans; Multiple Myeloma; Survival Analysis; Thal | 2001 |
Current status of thalidomide in the treatment of cancer.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Multiple Myeloma; | 2001 |
[Role of thalidomide in the treatment of multiple myeloma].
Topics: Antineoplastic Agents; Bone Marrow; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neovascular | 2001 |
[New indications for thalidomide?].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiogenesis Inhibitors; Animals; Anti-HIV Agents; A | 2001 |
Angiogenesis-dependent diseases.
Topics: Angiogenesis Inhibitors; Animals; Humans; Leukemia; Multiple Myeloma; Neovascularization, Pathologic | 2001 |
Angiogenesis in multiple myeloma.
Topics: Angiogenesis Inhibitors; Bone Marrow; Humans; Multiple Myeloma; Neovascularization, Pathologic; Prog | 2001 |
Thalidomide in the management of multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II a | 2001 |
Therapeutic application of thalidomide in multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; D | 2001 |
Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma.
Topics: Angiogenesis Inhibitors; Cytokines; Humans; Multiple Myeloma; Structure-Activity Relationship; Thali | 2001 |
Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adjuvants, Immunologic; Angiogenesis Inhibitors; Antineoplastic | 2001 |
Recent advances in treatment of multiple myeloma and Waldenström's macroglobulinemia.
Topics: Antineoplastic Agents; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; M | 2001 |
Multiple myeloma: present and future.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplant | 2002 |
Thalidomide: new indications?
Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Humans; Multiple Myeloma; Neoplasm Metastasis; Neov | 2001 |
Antiangiogenic therapy in multiple myeloma.
Topics: Angiogenesis Inhibitors; Drug Therapy, Combination; Endothelial Growth Factors; Humans; Lymphokines; | 2001 |
[New observations support the significance of angiogenesis in myeloma].
Topics: Angiogenesis Inhibitors; Cytokines; Humans; Multiple Myeloma; Neovascularization, Pathologic; Thalid | 2001 |
Thalidomide: emerging role in cancer medicine.
Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Humans; Multiple | 2002 |
Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms | 2002 |
Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezo | 2002 |
Treatment of myeloma: recent developments.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Ch | 2002 |
[New trends in the therapy of myeloma].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 2000 |
Mechanisms of action and potential therapeutic uses of thalidomide.
Topics: Clinical Trials as Topic; Humans; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Risk Asses | 2002 |
Thalidomide in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical | 2002 |
Smoldering, asymptomatic stage 1, and indolent myeloma.
Topics: Alkylating Agents; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Diet Therapy; Dip | 2000 |
Multiple myeloma.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Clinical Trials as Topic; Combined Modality Ther | 2000 |
577 trials available for thalidomide and Multiple Myeloma
| Article | Year |
|---|---|
3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dex | 2021 |
Limited benefits of thalidomide and dexamethasone maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients: a prospective phase II multi-center study in Korea.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematopoietic Stem Cell Transplantati | 2022 |
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; | 2022 |
Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.
Topics: Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols | 2021 |
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label,
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bor | 2021 |
A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Dexam | 2021 |
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethas | 2021 |
Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethaso | 2021 |
A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hu | 2022 |
Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethaso | 2022 |
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; COVID-19 Drug Treatment; Dexamethasone; Female | 2022 |
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron | 2022 |
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenal | 2022 |
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2022 |
Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hu | 2022 |
Phase 2 study of oral thalidomide-cyclophosphamide-dexamethasone for recurrent/refractory adult Langerhans cell histiocytosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Histiocytosi | 2022 |
Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethaso | 2022 |
Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Leukopen | 2022 |
Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Dexamethason | 2022 |
Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Dexamethason | 2022 |
Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Dexamethason | 2022 |
Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Dexamethason | 2022 |
Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Re | 2023 |
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Mal | 2023 |
Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Re | 2023 |
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2020 |
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2020 |
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2020 |
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2020 |
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2020 |
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2020 |
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2020 |
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2020 |
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2020 |
A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2019 |
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Melphalan; Multiple Myeloma; P | 2020 |
Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dex | 2019 |
Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2020 |
Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cyclophosphamide; Dexamethasone; | 2019 |
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2019 |
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2019 |
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2019 |
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2019 |
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2019 |
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2019 |
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2019 |
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2019 |
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2019 |
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2019 |
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2019 |
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2019 |
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2019 |
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2019 |
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2019 |
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2019 |
The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma.
Topics: Aged; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Registries; Retrospective Studies; Thali | 2020 |
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamid | 2020 |
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Re | 2020 |
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Consoli | 2020 |
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; | 2020 |
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplasti | 2020 |
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplasti | 2020 |
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplasti | 2020 |
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplasti | 2020 |
Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; | 2020 |
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
Topics: Aged; Comorbidity; Consolidation Chemotherapy; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Imm | 2020 |
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; | 2020 |
Phase I/II study of high dose pomalidomide with G-CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free | 2020 |
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; De | 2020 |
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2021 |
Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexa | 2021 |
Serum brain-derived neurotrophic factor (BDNF) concentration predicts polyneuropathy and overall survival in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Bortezomib; Brain-Derived Neurotrophic Factor; Di | 2020 |
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Co | 2021 |
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Humans; Multiple My | 2020 |
Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bor | 2020 |
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexameth | 2021 |
The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a prote
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Clinical Trials, Phase II as Topic; | 2020 |
Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Dexamethasone; Dise | 2020 |
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2021 |
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; F | 2020 |
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; | 2020 |
Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-1
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Dexamethasone; Glycine; | 2020 |
Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial.
Topics: Aged; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Thalidomide | 2020 |
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; H | 2021 |
Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2021 |
B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B-Ce | 2021 |
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2021 |
Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia | 2021 |
A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16-02 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia; Boron Com | 2021 |
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2021 |
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; | 2021 |
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Topics: Administration, Intravenous; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Dexa | 2021 |
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Topics: Administration, Intravenous; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Dexa | 2021 |
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Topics: Administration, Intravenous; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Dexa | 2021 |
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Topics: Administration, Intravenous; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Dexa | 2021 |
EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.
Topics: Adult; Antibodies, Monoclonal, Humanized; Dexamethasone; Humans; Multiple Myeloma; Neutropenia; Thal | 2021 |
Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamid | 2021 |
Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; An | 2021 |
Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Immunological; B7-H1 Antigen; Drug Therapy, Combinati | 2021 |
Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2017 |
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; | 2017 |
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; | 2017 |
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; | 2017 |
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; | 2017 |
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; | 2017 |
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; | 2017 |
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; | 2017 |
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; | 2017 |
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; | 2017 |
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2017 |
Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2017 |
Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2017 |
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2017 |
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2017 |
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2017 |
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2017 |
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2017 |
Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemoth | 2017 |
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens.
Topics: Autografts; Disease-Free Survival; Female; Glutathione Transferase; Humans; Male; Multiple Myeloma; | 2017 |
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethaso | 2017 |
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boron Compound | 2017 |
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.
Topics: Adolescent; Adult; Aged; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Hematopoieti | 2018 |
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.
Topics: Adult; Double-Blind Method; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Huma | 2017 |
Neutral tumor evolution in myeloma is associated with poor prognosis.
Topics: Exome; Female; Gene Frequency; Genetic Drift; Humans; Immunologic Factors; Immunosuppressive Agents; | 2017 |
Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survi | 2017 |
Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; D | 2018 |
Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up St | 2018 |
FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Dis | 2017 |
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal; B-Lymphocytes; Cell Line, Tumor; Dexamethasone; | 2017 |
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal; B-Lymphocytes; Cell Line, Tumor; Dexamethasone; | 2017 |
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal; B-Lymphocytes; Cell Line, Tumor; Dexamethasone; | 2017 |
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal; B-Lymphocytes; Cell Line, Tumor; Dexamethasone; | 2017 |
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Chromosome Aberrations | 2017 |
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxor | 2018 |
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Dexamethasone; Disease-Free | 2018 |
Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free | 2018 |
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dexamethasone; Follow-Up Studies; Hu | 2018 |
Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma.
Topics: Female; Humans; Immunity, Cellular; Interferon-gamma; Killer Cells, Natural; Lenalidomide; Male; Muc | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clodronic Acid; Consolidati | 2018 |
Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle | 2018 |
Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Fe | 2019 |
Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethaso | 2018 |
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2018 |
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2018 |
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2018 |
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2018 |
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2018 |
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; | 2019 |
Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study).
Topics: Asian People; Disease-Free Survival; Humans; Japan; Maintenance Chemotherapy; Multiple Myeloma; Pros | 2019 |
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clonal Evolution; Exome Seq | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2019 |
Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; M | 2019 |
Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; M | 2019 |
Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; M | 2019 |
Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; M | 2019 |
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2019 |
Serum platelet factor 4 is a promising predictor in newly diagnosed patients with multiple myeloma treated with thalidomide and VAD regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Disea | 2019 |
Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; | 2019 |
Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Humans; Mal | 2019 |
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2019 |
Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; | 2019 |
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chemother | 2019 |
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chemother | 2019 |
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chemother | 2019 |
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chemother | 2019 |
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Depsipep | 2019 |
Report of phase I and II trials of melphalan, prednisolone, and thalidomide triplet combination therapy versus melphalan and prednisolone doublet combination therapy in Japanese patients with newly diagnosed multiple myeloma ineligible for autologous stem
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Autografts; D | 2019 |
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2019 |
Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diarr | 2013 |
Sorafenib in patients with refractory or recurrent multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2013 |
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation.
Topics: Adult; Aged; Dexamethasone; Female; Gene Expression Profiling; Humans; Male; Middle Aged; Multiple M | 2013 |
Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2013 |
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2013 |
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Combined Modality Thera | 2013 |
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Combined Modality Thera | 2013 |
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Combined Modality Thera | 2013 |
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Combined Modality Thera | 2013 |
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Combined Modality Thera | 2013 |
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Combined Modality Thera | 2013 |
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Combined Modality Thera | 2013 |
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Combined Modality Thera | 2013 |
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Combined Modality Thera | 2013 |
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dise | 2013 |
A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Dexamethasone | 2013 |
A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Dexamethasone | 2013 |
A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Dexamethasone | 2013 |
A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Dexamethasone | 2013 |
Modeling of experts' divergent prior beliefs for a sequential phase III clinical trial.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Bayes Theorem; Drug Therapy, Combina | 2013 |
Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Dexamet | 2013 |
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2013 |
Flow cytometry-based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Cohort Stud | 2014 |
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2013 |
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2013 |
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2013 |
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2013 |
Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Chromosome Aberrations; Diphosphonates; Hum | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Fema | 2013 |
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diarr | 2013 |
Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Female; Hem | 2014 |
Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy.
Topics: Cytokines; Female; Humans; Immunologic Factors; Lenalidomide; Lymphocyte Count; Male; Multiple Myelo | 2014 |
Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezom | 2013 |
Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Marrow Transplantation; Combined Modality Therapy; | 2013 |
Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans | 2014 |
Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.
Topics: Administration, Intravenous; Adult; Aged; Anti-HIV Agents; Benzylamines; Cyclams; Female; Granulocyt | 2014 |
Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2014 |
Value of novel agents and intensive therapy for patients with multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Middle Age | 2014 |
A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Disease Progression; Female; Hematopoietic Stem Cell Transplan | 2014 |
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2014 |
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2014 |
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2014 |
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2014 |
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2014 |
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2014 |
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2014 |
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2014 |
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2014 |
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2014 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free | 2014 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free | 2014 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free | 2014 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free | 2014 |
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2014 |
Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2014 |
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Female; Gene Expression Pro | 2014 |
Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Female; Hematopoietic Stem | 2014 |
Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2014 |
Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Electroacupuncture; | 2014 |
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2014 |
Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélo
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Mod | 2014 |
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2015 |
Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Diseas | 2014 |
A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotr | 2014 |
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Surviv | 2014 |
Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Fe | 2015 |
Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma.
Topics: Antineoplastic Agents; Humans; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.
Topics: Actin Cytoskeleton; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axons; | 2014 |
Autologous transplantation and maintenance therapy in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Comb | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Combined Modality The | 2015 |
Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Huma | 2014 |
Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anemia; Dexamethasone; Female; Glomerular Filtration R | 2015 |
Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Foll | 2015 |
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bias; Cross-Over Studies; Dexamethasone; Dose- | 2015 |
Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cross-Sectional Studies; Dexamethasone; Dose-Respons | 2015 |
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2014 |
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2014 |
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2014 |
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2014 |
Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrat | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Clinical Protocols; Double-Blind Method; Female; Hematologic Agents; Humans; Japan; Male; Mul | 2015 |
Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, | 2015 |
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation.
Topics: Autografts; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Mobilization; Humans; Inducti | 2015 |
The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Cyclophosphamide | 2015 |
Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; De | 2015 |
Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Humans; Len | 2015 |
Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; China; Dexamethasone; Disease-Free | 2015 |
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Sectional Studies; De | 2015 |
Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomid | 2015 |
Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2015 |
Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2015 |
Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2015 |
Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2015 |
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.
Topics: Angiogenesis Inhibitors; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Killer Cells, | 2015 |
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.
Topics: Angiogenesis Inhibitors; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Killer Cells, | 2015 |
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.
Topics: Angiogenesis Inhibitors; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Killer Cells, | 2015 |
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.
Topics: Angiogenesis Inhibitors; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Killer Cells, | 2015 |
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2015 |
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2015 |
Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; | 2015 |
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Community | 2015 |
Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Disea | 2015 |
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression | 2015 |
Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bortezomib; Cyclophosphamid | 2015 |
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Fema | 2015 |
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Foll | 2015 |
Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide.
Topics: Aged; Aged, 80 and over; Female; Fibrin Fibrinogen Degradation Products; Humans; Lenalidomide; Male; | 2015 |
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents.
Topics: Adult; Aged; Aged, 80 and over; Blood Cell Count; Drugs, Investigational; Female; Humans; Induction | 2015 |
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberratio | 2015 |
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Surviv | 2015 |
Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma.
Topics: Aged; Antineoplastic Agents; Asian People; Dexamethasone; Disease-Free Survival; Female; Humans; Jap | 2015 |
Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2015 |
Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.
Topics: Adult; Aged; Antineoplastic Agents; Asia; Boron Compounds; Dexamethasone; Female; Glycine; Humans; L | 2015 |
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Ma | 2015 |
A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma.
Topics: Adult; Aged; Autografts; Cyclophosphamide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem | 2016 |
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethaso | 2016 |
Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Hematopoietic S | 2016 |
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Cyclophosph | 2015 |
Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Bortezomib; Dexamethaso | 2016 |
Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; | 2016 |
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Creatinine; Dexameth | 2016 |
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Cell Proliferation; Demography; Dexamethasone; Fe | 2016 |
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cohort Studies; Dexamethasone; Dru | 2016 |
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.
Topics: Aged; Aged, 80 and over; Demography; Disease-Free Survival; Drug Therapy, Combination; Female; Follo | 2016 |
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.
Topics: Aged; Bortezomib; Cell Adhesion Molecules; Dexamethasone; Disease Progression; Down-Regulation; Drug | 2016 |
Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2016 |
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
Topics: Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Lenalidomide; Maintenance Chemothera | 2016 |
Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Dexamethasone | 2016 |
Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome | 2016 |
Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study.
Topics: Aged; Aged, 80 and over; Dexamethasone; Disease Progression; Female; Humans; Japan; Kaplan-Meier Est | 2016 |
Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2016 |
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; D | 2016 |
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2016 |
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2016 |
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantatio
Topics: Adult; Aged; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; | 2016 |
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological | 2016 |
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological | 2016 |
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological | 2016 |
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological | 2016 |
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resista | 2016 |
Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resista | 2016 |
Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resista | 2016 |
Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resista | 2016 |
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2016 |
Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Creatinine; Dexamethasone; D | 2016 |
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamet | 2016 |
Lenalidomide consolidation treatment in patients with multiple myeloma suppresses myelopoieses but spares erythropoiesis.
Topics: Angiogenesis Inhibitors; Bone Marrow; Consolidation Chemotherapy; Erythropoiesis; Fetal Hemoglobin; | 2016 |
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies | 2016 |
Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2016 |
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free | 2016 |
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2017 |
Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Dexame | 2016 |
Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Dose | 2016 |
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethas | 2016 |
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethas | 2016 |
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethas | 2016 |
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethas | 2016 |
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethas | 2016 |
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethas | 2016 |
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethas | 2016 |
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethas | 2016 |
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethas | 2016 |
The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bortezomib; Cyclophosphamid | 2017 |
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Adminis | 2016 |
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Histone Deacetylase Inh | 2016 |
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2016 |
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2016 |
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2016 |
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2016 |
Low-dose lenalidomide and dexamethasone combination treatment in elderly patients with relapsed and refractory multiple myeloma.
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2017 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplasti | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Dexamethasone; Drug Therapy, Combination; Female; Humans; L | 2017 |
A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free | 2017 |
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease- | 2016 |
Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Boron Compounds; Dexamethasone; | 2017 |
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Surviv | 2017 |
IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Doxor | 2017 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap | 2017 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap | 2017 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap | 2017 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap | 2017 |
Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial.
Topics: Bortezomib; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Interfer | 2017 |
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2017 |
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamet | 2017 |
A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dr | 2017 |
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Maximum To | 2017 |
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.
Topics: Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Cyclophosphami | 2008 |
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
Topics: Antineoplastic Agents; B-Cell Activating Factor; Bone Remodeling; Bone Resorption; Boronic Acids; Bo | 2008 |
Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma.
Topics: Adolescent; Adult; Aged; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunosuppressive | 2008 |
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Diphosphonates; Disease Progression; Di | 2008 |
[Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2008 |
Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.
Topics: Chromatography, Liquid; Flavonoids; Humans; Lenalidomide; Multiple Myeloma; Piperidines; Recurrence; | 2008 |
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality | 2008 |
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality | 2008 |
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality | 2008 |
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality | 2008 |
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality | 2008 |
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality | 2008 |
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality | 2008 |
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality | 2008 |
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality | 2008 |
Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethaso | 2008 |
Tailored thromboprophylaxis for patients with multiple myeloma treated by IMIDs.
Topics: Aspirin; Chemoprevention; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Thrombosis | 2008 |
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; | 2008 |
Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; | 2009 |
Update on recent developments for patients with newly diagnosed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; | 2008 |
Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2008 |
Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Prog | 2008 |
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Dexamethasone; | 2009 |
Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.
Topics: Adult; Aged; Aged, 80 and over; Chi-Square Distribution; Dexamethasone; Disease-Free Survival; Drug | 2009 |
Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Boronic Acids; Borte | 2009 |
[Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level].
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2008 |
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Doxorubici | 2009 |
Predicting durable remissions following thalidomide therapy for relapsed myeloma.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Follow-Up Studies; Humans; Male; Middle | 2009 |
[Bortezomib combined with other drugs for treating 60 cases of multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Huma | 2009 |
Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modalit | 2009 |
Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modalit | 2009 |
Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modalit | 2009 |
Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modalit | 2009 |
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; M | 2009 |
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Aberrations; Chromosome Deletion; | 2009 |
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Aberrations; Chromosome Deletion; | 2009 |
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Aberrations; Chromosome Deletion; | 2009 |
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Aberrations; Chromosome Deletion; | 2009 |
Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Female; Humans; Male; Middle Aged; Multiple Myeloma; P | 2009 |
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relations | 2009 |
Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death | 2009 |
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Dosage Calculations | 2009 |
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Dosage Calculations | 2009 |
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Dosage Calculations | 2009 |
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Dosage Calculations | 2009 |
Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Doxorubicin; Female; Humans; Male; Mi | 2009 |
Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).
Topics: Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Hematopoietic Stem Cell Transpla | 2009 |
Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma.
Topics: Adiponectin; Cell Line, Tumor; Energy Metabolism; Female; Gene Expression Regulation, Neoplastic; Hu | 2009 |
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2009 |
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boro | 2009 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2009 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2009 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2009 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2009 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2009 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2009 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2009 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2009 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2009 |
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose- | 2010 |
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose- | 2010 |
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose- | 2010 |
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose- | 2010 |
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose- | 2010 |
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose- | 2010 |
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose- | 2010 |
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose- | 2010 |
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose- | 2010 |
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose- | 2010 |
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose- | 2010 |
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose- | 2010 |
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose- | 2010 |
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose- | 2010 |
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose- | 2010 |
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose- | 2010 |
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; | 2010 |
Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma.
Topics: Clone Cells; Combined Modality Therapy; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Hum | 2009 |
Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2010 |
Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophospha | 2010 |
Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multip
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Fema | 2010 |
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuv | 2010 |
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Humans; Melphalan; | 2010 |
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dise | 2010 |
Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
Topics: Activated Protein C Resistance; Adult; Aged; Anticoagulants; Case-Control Studies; Dexamethasone; Fa | 2010 |
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Dise | 2010 |
Induction treatment with cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female | 2010 |
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy | 2010 |
ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2010 |
Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2010 |
Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Lenal | 2010 |
Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug R | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Disease-Free Survival; Fema | 2010 |
XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2010 |
Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Resistance, N | 2011 |
A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineopla | 2010 |
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Male; Mel | 2010 |
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Male; Mel | 2010 |
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Male; Mel | 2010 |
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Male; Mel | 2010 |
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Male; Mel | 2010 |
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Male; Mel | 2010 |
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Male; Mel | 2010 |
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Male; Mel | 2010 |
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Male; Mel | 2010 |
Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.
Topics: Angiogenesis Inhibitors; Follow-Up Studies; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Re | 2010 |
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyc | 2010 |
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meie | 2010 |
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meie | 2010 |
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meie | 2010 |
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meie | 2010 |
The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Dose-R | 2010 |
Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug- | 2010 |
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2010 |
Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: a Chinese experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Dexamethason | 2010 |
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies | 2010 |
Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma.
Topics: Aged; Antineoplastic Agents; Constipation; Disease Progression; Disease-Free Survival; Drug Administ | 2010 |
Bortezomib plus thalidomide for newly diagnosed multiple myeloma in China.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineopl | 2010 |
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2010 |
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2010 |
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2010 |
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2010 |
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Surviv | 2010 |
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Surviv | 2010 |
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Surviv | 2010 |
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Surviv | 2010 |
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Dexamet | 2010 |
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Dexamet | 2010 |
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Dexamet | 2010 |
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Dexamet | 2010 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Hu | 2010 |
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Stu | 2011 |
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Stu | 2011 |
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Stu | 2011 |
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Stu | 2011 |
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Stu | 2011 |
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Stu | 2011 |
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Stu | 2011 |
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Stu | 2011 |
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Stu | 2011 |
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cluster Analysis; Cyclophosphamide; Dexamethasone; D | 2011 |
Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma.
Topics: Ablation Techniques; Adult; Aged; Antineoplastic Agents; Bone Marrow; Combined Modality Therapy; Dex | 2011 |
Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma.
Topics: Ablation Techniques; Adult; Aged; Antineoplastic Agents; Bone Marrow; Combined Modality Therapy; Dex | 2011 |
Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma.
Topics: Ablation Techniques; Adult; Aged; Antineoplastic Agents; Bone Marrow; Combined Modality Therapy; Dex | 2011 |
Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma.
Topics: Ablation Techniques; Adult; Aged; Antineoplastic Agents; Bone Marrow; Combined Modality Therapy; Dex | 2011 |
Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control | 2011 |
Thalidomide after lenalidomide: a possible treatment regimen in relapse refractory multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Sch | 2011 |
Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins | 2010 |
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy | 2010 |
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy | 2010 |
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy | 2010 |
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy | 2010 |
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy | 2010 |
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy | 2010 |
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy | 2010 |
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy | 2010 |
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy | 2010 |
Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2011 |
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2011 |
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2011 |
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2011 |
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Incidence; Multiple Myeloma; | 2011 |
Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Im | 2012 |
Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Compassionate Use Trials; Cross-Sectional Stu | 2011 |
Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; DNA Repair; Drug Resistance, Neoplasm; Fema | 2011 |
Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi | 2011 |
Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Female; Glucocorticoids; Humans; Immunos | 2011 |
Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2011 |
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2011 |
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined C | 2011 |
[The efficacy and safety of bortezomib plus thalidomide in treatment of newly diagnosed multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myelom | 2011 |
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineopla | 2011 |
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 2011 |
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 2011 |
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 2011 |
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 2011 |
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 2011 |
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 2011 |
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 2011 |
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 2011 |
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 2011 |
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects a | 2011 |
Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethaso | 2011 |
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Cyclophosphamide; Cycl | 2011 |
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bo | 2011 |
Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone | 2011 |
Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezo | 2012 |
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2012 |
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP B | 2011 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2011 |
Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone.
Topics: Aged; Antineoplastic Agents; Chromosome Aberrations; Dexamethasone; Female; Gene Expression Profilin | 2011 |
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.
Topics: Adult; Aged; Aged, 80 and over; Dexamethasone; Fluorodeoxyglucose F18; Glucocorticoids; Hematopoieti | 2011 |
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Antineopla | 2012 |
Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; In Situ Hybridi | 2011 |
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Glomerular | 2011 |
The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.
Topics: Acetyltransferases; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Chr | 2011 |
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; F | 2011 |
Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma.
Topics: Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Male; M | 2011 |
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Antineoplastic Agents; Benzylamines; Compassionate Use | 2012 |
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Clinical Trials as Topic; Female; Humans; M | 2012 |
Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Immunosuppressive Agents; Male; Midd | 2012 |
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female | 2012 |
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female | 2012 |
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female | 2012 |
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female | 2012 |
Bortezomib-dexamethasone or vincristine-doxorubicin-dexamethasone as induction therapy followed by thalidomide as maintenance therapy in untreated multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; B | 2011 |
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Dexamethas | 2012 |
Similar neurotoxicity of an alternating compared to a continuous low-dose schedule of thalidomide for relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration | 2012 |
Emergence of central nervous system myeloma in the era of novel agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Central Nerv | 2012 |
Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2012 |
Lower dose dexamethasone/thalidomide and zoledronic acid every 3 weeks in previously untreated multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diphosphonates; Female; | 2012 |
Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cancer Vaccines; Cohort Studies; Female; Humans; Imm | 2012 |
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Diarrhea; Drug Admi | 2012 |
Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2012 |
Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; C | 2012 |
Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose | 2012 |
A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2012 |
Two cycles of the PS-341/bortezomib, adriamycin, and dexamethasone combination followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Mod | 2012 |
Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2012 |
Influence of cytochrome P450 2C19 gene variations on pharmacokinetic parameters of thalidomide in Japanese patients.
Topics: Aged; Amyloidosis; Antineoplastic Agents; Aryl Hydrocarbon Hydroxylases; Asian People; Cytochrome P- | 2012 |
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2012 |
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Boronic | 2012 |
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Boronic | 2012 |
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Boronic | 2012 |
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Boronic | 2012 |
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Boronic | 2012 |
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Boronic | 2012 |
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Boronic | 2012 |
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Boronic | 2012 |
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Boronic | 2012 |
Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma.
Topics: Aged; Antineoplastic Agents; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunothe | 2012 |
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2012 |
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2012 |
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2012 |
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2012 |
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2012 |
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2012 |
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2012 |
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2012 |
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2012 |
Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2012 |
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disea | 2012 |
Lenalidomide after stem-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Female; Follow-Up St | 2012 |
Lenalidomide after stem-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Female; Follow-Up St | 2012 |
Lenalidomide after stem-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Female; Follow-Up St | 2012 |
Lenalidomide after stem-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Female; Follow-Up St | 2012 |
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Female; Follow-Up St | 2012 |
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Female; Follow-Up St | 2012 |
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Female; Follow-Up St | 2012 |
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Female; Follow-Up St | 2012 |
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Female; Follow-Up St | 2012 |
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Female; Follow-Up St | 2012 |
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Female; Follow-Up St | 2012 |
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Female; Follow-Up St | 2012 |
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Female; Follow-Up St | 2012 |
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomi
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2012 |
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh | 2012 |
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 2012 |
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 2012 |
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 2012 |
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 2012 |
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2012 |
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2012 |
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2012 |
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2012 |
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2012 |
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2012 |
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2012 |
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2012 |
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2012 |
Improved response with post-ASCT consolidation by low dose thalidomide, cyclophosphamide and dexamethasone as first line treatment for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Drug A | 2012 |
Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combined Modal | 2012 |
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2012 |
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2012 |
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2012 |
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2012 |
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2012 |
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2012 |
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2012 |
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2012 |
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2012 |
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2012 |
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2012 |
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2012 |
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2012 |
Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Boroni | 2012 |
Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Female; Humans; Lenalidomid | 2013 |
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2012 |
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2012 |
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2012 |
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2012 |
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Drug | 2013 |
Effects of exercise on fatigue, sleep, and performance: a randomized trial.
Topics: Adult; Affect; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2012 |
Post-transplant consolidation therapy using thalidomide alone for the patients with multiple myeloma: a feasibility study in Japanese population.
Topics: Adult; Antineoplastic Agents; Asian People; Consolidation Chemotherapy; Female; Hematopoietic Stem C | 2012 |
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomid | 2013 |
Predictive factors of survival after thalidomide therapy in advanced multiple myeloma: long-term follow-up of a prospective multicenter nonrandomized phase II study in 120 patients.
Topics: Aged; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; | 2012 |
Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
Topics: Adult; Aged; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Immunologic | 2013 |
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophospha | 2013 |
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Dendritic Cells; Drug Synergism; Female; Gal | 2013 |
Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Len | 2013 |
Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma.
Topics: Aged; Antigens, CD; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Enzyme- | 2013 |
Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2013 |
High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Gene Expression; Humans; Maintenance Ch | 2013 |
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Induction Chemother | 2013 |
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2013 |
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2013 |
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2013 |
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2013 |
A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2013 |
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.
Topics: Academies and Institutes; Antineoplastic Combined Chemotherapy Protocols; Canada; Female; Hematopoie | 2013 |
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2013 |
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2013 |
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2013 |
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2013 |
Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2- | 2002 |
Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Gene Frequency; Genotype; Haplotypes; Humans; | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; beta 2-Microglobulin; Body Height; Body Weight; C-Reactive | 2002 |
Early results of total therapy II in multiple myeloma: implications of cytogenetics and FISH.
Topics: Aged; Chromosome Aberrations; Cytogenetic Analysis; Follow-Up Studies; Humans; In Situ Hybridization | 2002 |
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2003 |
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2003 |
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2003 |
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2003 |
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2003 |
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2003 |
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2003 |
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2003 |
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2003 |
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2003 |
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2003 |
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2003 |
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2003 |
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2003 |
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2003 |
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2003 |
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Re | 2003 |
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Re | 2003 |
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Re | 2003 |
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Re | 2003 |
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; H | 2003 |
Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethason | 2003 |
An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Maxi | 2003 |
[Single-agent thalidomide for advanced and refractory multiple myeloma].
Topics: Aged; Aged, 80 and over; Constipation; Disease Progression; Disorders of Excessive Somnolence; Femal | 2003 |
Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Ischem | 2003 |
[Preliminary results of monotherapy with thalidomide in recurrent and treatment resistant cases of multiple myeloma].
Topics: Adult; Aged; Drug Resistance; Female; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Stem | 2003 |
Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Bone Marrow; Disease-Free Survival; Female; | 2003 |
Modifications to therapy for multiple myeloma: pegylated liposomal Doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexa | 2003 |
Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorub | 2004 |
Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Male; M | 2003 |
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitor | 2004 |
Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis.
Topics: Adult; Aged; Confidence Intervals; Female; Humans; Immunosuppressive Agents; Kidney Failure, Chronic | 2003 |
Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dexamethasone; Humans; Microcirculation | 2004 |
The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Cy | 2004 |
Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents | 2004 |
Early response predicts thalidomide efficiency in patients with advanced multiple myeloma.
Topics: Adult; Aged; Blood Proteins; Dose-Response Relationship, Drug; Female; Hemoglobins; Humans; Immunogl | 2004 |
Bradycardia during therapy for multiple myeloma with thalidomide.
Topics: Bradycardia; Humans; Immunosuppressive Agents; Multiple Myeloma; Thalidomide | 2004 |
Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy.
Topics: Aged; Aged, 80 and over; Constipation; Disorders of Excessive Somnolence; Dose-Response Relationship | 2004 |
A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressive Agents; Logistic Mo | 2004 |
Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Cyclophosphamide; Dexamethasone; Dise | 2004 |
Thalidomide-induced severe neutropenia during treatment of multiple myeloma.
Topics: Adult; Aged; Bone Marrow; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; | 2004 |
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.
Topics: Disease Progression; Disease-Free Survival; Female; Humans; Intercellular Adhesion Molecule-1; Inter | 2004 |
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Middle Ag | 2004 |
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Cytokines; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mu | 2004 |
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Middle Aged; Mul | 2004 |
Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disea | 2004 |
Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma.
Topics: Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Middle Aged; Multipl | 2004 |
Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma.
Topics: Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Middle Aged; Multipl | 2004 |
Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma.
Topics: Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Middle Aged; Multipl | 2004 |
Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma.
Topics: Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Middle Aged; Multipl | 2004 |
Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anticoagulants; Enoxaparin; Female; Follow-Up Studies; Humans; | 2004 |
[Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy].
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antin | 2004 |
Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy.
Topics: Adolescent; Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dexamethaso | 2004 |
Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma.
Topics: Boronic Acids; Bortezomib; Cost-Benefit Analysis; Delphi Technique; Economics, Pharmaceutical; Femal | 2004 |
Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fibrinolytic Agents; Humans; Multiple Myeloma; | 2004 |
Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Dose- | 2005 |
Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; | 2005 |
Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Surviv | 2004 |
Chemoresistant myeloma: phase II clinical study with low-dose thalidomide plus high-dose dexamethasone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Sedimentation; Dexame | 2004 |
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh | 2005 |
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh | 2005 |
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh | 2005 |
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh | 2005 |
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh | 2005 |
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh | 2005 |
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh | 2005 |
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh | 2005 |
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh | 2005 |
Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
Topics: Aged; Cause of Death; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Humans | 2005 |
The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma.
Topics: Administration, Oral; CD8-Positive T-Lymphocytes; Cytokines; Enzyme-Linked Immunosorbent Assay; Flow | 2005 |
Thalidomide therapy and polyneuropathy in myeloma patients.
Topics: Action Potentials; Adult; Aged; Disease Progression; Female; Humans; Immunosuppressive Agents; Male; | 2005 |
Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Dexamethasone; Femal | 2005 |
Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 2005 |
Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Fem | 2005 |
First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma.
Topics: Adult; Age Factors; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; F | 2005 |
Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Human | 2005 |
The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytokines; Dexamethasone; Female; | 2004 |
A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; An | 2005 |
The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Remodeling; Dexamethas | 2005 |
Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Huma | 2006 |
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
Topics: Adult; Aged; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Tests; Humans; Lenalidomi | 2005 |
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
Topics: Adult; Aged; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Tests; Humans; Lenalidomi | 2005 |
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
Topics: Adult; Aged; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Tests; Humans; Lenalidomi | 2005 |
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
Topics: Adult; Aged; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Tests; Humans; Lenalidomi | 2005 |
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
Topics: Adult; Aged; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Tests; Humans; Lenalidomi | 2005 |
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
Topics: Adult; Aged; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Tests; Humans; Lenalidomi | 2005 |
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
Topics: Adult; Aged; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Tests; Humans; Lenalidomi | 2005 |
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
Topics: Adult; Aged; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Tests; Humans; Lenalidomi | 2005 |
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
Topics: Adult; Aged; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Tests; Humans; Lenalidomi | 2005 |
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
Topics: Adult; Aged; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Tests; Humans; Lenalidomi | 2005 |
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
Topics: Adult; Aged; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Tests; Humans; Lenalidomi | 2005 |
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
Topics: Adult; Aged; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Tests; Humans; Lenalidomi | 2005 |
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
Topics: Adult; Aged; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Tests; Humans; Lenalidomi | 2005 |
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
Topics: Adult; Aged; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Tests; Humans; Lenalidomi | 2005 |
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
Topics: Adult; Aged; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Tests; Humans; Lenalidomi | 2005 |
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
Topics: Adult; Aged; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Tests; Humans; Lenalidomi | 2005 |
Novel therapy in multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease- | 2005 |
Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protoc | 2005 |
Eastern Cooperative Oncology Group E1A00: phase III randomized study of dexamethasone with or without thalidomide in patients with newly diagnosed multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Dexamet | 2003 |
CC-5013 MM 0017: a multicenter, randomized, parallel-group, double-blind, placebo-controlled study of CC-5013 plus dexamethasone versus dexamethasone alone in previously treated subjects with multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Dexamet | 2003 |
Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose | 2006 |
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Aspirin; Dexamethasone; Doxorubicin; D | 2005 |
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; D | 2006 |
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; D | 2006 |
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; D | 2006 |
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; D | 2006 |
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; D | 2006 |
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; D | 2006 |
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; D | 2006 |
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; D | 2006 |
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; D | 2006 |
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; D | 2006 |
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; D | 2006 |
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; D | 2006 |
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; D | 2006 |
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; D | 2006 |
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; D | 2006 |
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; D | 2006 |
Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxor | 2006 |
Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bloo | 2005 |
Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2006 |
Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free | 2006 |
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
Topics: Adult; Aged; Alkaline Phosphatase; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Biom | 2006 |
Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pr | 2006 |
Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free | 2006 |
Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free | 2006 |
Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free | 2006 |
Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients.
Topics: Analysis of Variance; Angiogenesis Inhibitors; Female; Humans; Infections; Iron Overload; Male; Midd | 2006 |
Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Female; Humans; Male; | 2006 |
The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64.
Topics: Adult; Aged; Apoptosis; Blood Platelets; Female; Humans; Immunologic Factors; Male; Middle Aged; Mul | 2006 |
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Dexamethasone; Disease Progression; | 2006 |
Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): results, prognostic factors and side effects in eight patients previously treated with multiple myeloma.
Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Sedim | 2003 |
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2006 |
Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Dexamethasone; Disease-Free Survival; Dose-Response Relatio | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma?
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; | 2006 |
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Diseases; Diphosphonates; Disease-Free Su | 2006 |
Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.
Topics: Aged; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Electrophysiology; Female; Humans; | 2006 |
Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Lenalidomide; Mal | 2006 |
Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients.
Topics: Adult; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Dose-Response Relationship | 2007 |
The pharmacokinetics of low-dose thalidomide in Japanese patients with refractory multiple myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Area Under Curve; Asian People; Capsules; Dose-Respon | 2006 |
Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism.
Topics: Aged; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male | 2006 |
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Dexamethasone; Dip | 2006 |
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Toleran | 2007 |
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease.
Topics: Aged; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Moda | 2007 |
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2007 |
Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; C | 2006 |
Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Humans; Leukemia, Plasma Cell; Male | 2007 |
Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic S | 2007 |
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2007 |
Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; | 2007 |
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bone Marrow Cells; Boronic | 2007 |
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2007 |
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antine | 2007 |
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplas | 2007 |
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2007 |
Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma.
Topics: Adult; Aged; Dexamethasone; Dose-Response Relationship, Drug; Female; Humans; Leukopenia; Male; Midd | 2007 |
Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
Topics: Action Potentials; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Female; Follow-Up St | 2007 |
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Creatinine; Dexamethasone; Humans; Lenalidomide; Mul | 2007 |
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; D | 2007 |
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationsh | 2007 |
Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial.
Topics: Adult; Angiogenesis Inhibitors; Blood Proteins; Combined Modality Therapy; Disease-Free Survival; Fe | 2008 |
Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial.
Topics: Adult; Angiogenesis Inhibitors; Blood Proteins; Combined Modality Therapy; Disease-Free Survival; Fe | 2008 |
Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial.
Topics: Adult; Angiogenesis Inhibitors; Blood Proteins; Combined Modality Therapy; Disease-Free Survival; Fe | 2008 |
Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial.
Topics: Adult; Angiogenesis Inhibitors; Blood Proteins; Combined Modality Therapy; Disease-Free Survival; Fe | 2008 |
Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients.
Topics: Aged; Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Combi | 2007 |
Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2007 |
A new standard of care for elderly patients with myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2008 |
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2008 |
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2008 |
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexa | 2008 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Gene Expression Pro | 2007 |
[Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Constipation; Cytara | 2007 |
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Da | 2008 |
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxo | 2008 |
Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.
Topics: Adult; Aged; Antineoplastic Agents; Blood Cell Count; Dexamethasone; Dose-Response Relationship, Dru | 2008 |
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2008 |
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2008 |
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2008 |
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2008 |
Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Combined Modality Ther | 2008 |
Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Creatinine; Diph | 2008 |
Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma: prognostic factors and unique toxicity profile.
Topics: Adult; Aged; Disease-Free Survival; Female; Humans; Immunosuppressive Agents; Male; Maximum Tolerate | 2008 |
The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2008 |
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Fema | 2008 |
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.
Topics: Angiogenesis Inhibitors; Chromosome Aberrations; Cytogenetics; Disease-Free Survival; Follow-Up Stud | 2008 |
First thalidomide clinical trial in multiple myeloma: a decade.
Topics: Chromosome Aberrations; Disease-Free Survival; Follow-Up Studies; Humans; Immunoglobulin lambda-Chai | 2008 |
Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Drug Evaluati | 2008 |
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2008 |
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2008 |
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2008 |
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2008 |
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2008 |
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2008 |
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2008 |
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2008 |
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2008 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Thalidomide therapy in refractory solid tumour patients.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Drug Administration Schedule; Female; Human | 2000 |
[Functional magnetic resonance tomography in the diagnosis and therapy monitoring in multiple myeloma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogeni | 2000 |
Low-dose of thalidomide in the treatment of refractory myeloma.
Topics: Aged; Angiogenesis Inhibitors; Female; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide; Tre | 2000 |
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Dexamethasone; DNA Replication; Doxorubicin; Drug Resi | 2000 |
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Dexamethasone; DNA Replication; Doxorubicin; Drug Resi | 2000 |
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Dexamethasone; DNA Replication; Doxorubicin; Drug Resi | 2000 |
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Dexamethasone; DNA Replication; Doxorubicin; Drug Resi | 2000 |
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Dexamethasone; DNA Replication; Doxorubicin; Drug Resi | 2000 |
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Dexamethasone; DNA Replication; Doxorubicin; Drug Resi | 2000 |
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Dexamethasone; DNA Replication; Doxorubicin; Drug Resi | 2000 |
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Dexamethasone; DNA Replication; Doxorubicin; Drug Resi | 2000 |
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Dexamethasone; DNA Replication; Doxorubicin; Drug Resi | 2000 |
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Dexamethasone; DNA Replication; Doxorubicin; Drug Resi | 2000 |
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Dexamethasone; DNA Replication; Doxorubicin; Drug Resi | 2000 |
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Dexamethasone; DNA Replication; Doxorubicin; Drug Resi | 2000 |
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Dexamethasone; DNA Replication; Doxorubicin; Drug Resi | 2000 |
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Dexamethasone; DNA Replication; Doxorubicin; Drug Resi | 2000 |
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Dexamethasone; DNA Replication; Doxorubicin; Drug Resi | 2000 |
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Dexamethasone; DNA Replication; Doxorubicin; Drug Resi | 2000 |
Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Middle Aged; Multiple M | 2001 |
Thalidomide treatment of resistant or relapsed multiple myeloma patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; | 2001 |
Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation.
Topics: Adult; Angiogenesis Inhibitors; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middl | 2001 |
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; beta 2-Microglobulin; Hematopoietic Stem Cell Transp | 2001 |
Thalidomide for previously untreated indolent or smoldering multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Female; Humans; Male; Middle Aged; Multi | 2001 |
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.
Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation Facto | 2001 |
Thalidomide and dexamethasone combination for refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Antineopla | 2001 |
High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
Topics: Adult; Affect; Aged; Angiogenesis Inhibitors; Constipation; Dizziness; Dose-Response Relationship, D | 2001 |
Thalidomide and thrombosis in patients with multiple myeloma.
Topics: Aged; Antineoplastic Agents; Drug Synergism; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomid | 2001 |
Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion.
Topics: Adult; Aged; Angiogenesis Inhibitors; Cytokines; Endothelial Growth Factors; Female; Fibroblast Grow | 2001 |
Thalidomide in patients with advanced multiple myeloma.
Topics: Agranulocytosis; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Female; Follow-Up Studie | 2000 |
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Biomarkers; Bone Marrow Cells; Cell Culture Techniques; Endothelial Growth Factors; Fem | 2002 |
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
Topics: Activated Protein C Resistance; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood C | 2002 |
Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2002 |
Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Blood Cell Count; Dose-Response Relationship, Drug; Female; Humans; | 2002 |
Thromboembolic events during treatment with thalidomide.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2002 |
1532 other studies available for thalidomide and Multiple Myeloma
| Article | Year |
|---|---|
Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma.
Topics: China; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Therapeutic Equivalency | 2021 |
Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Re | 2021 |
Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14).
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myelom | 2022 |
Improvement of erythema elevatum diutinum refractory to dapsone following treatment for underlying multiple myeloma.
Topics: Antineoplastic Agents; Bortezomib; Dapsone; Dermatologic Agents; Dexamethasone; Humans; Male; Middle | 2021 |
Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dex | 2022 |
Joint modelling and simulation of M-protein dynamics and progression-free survival for alternative isatuximab dosing with pomalidomide/dexamethasone.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, | 2022 |
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.
Topics: Biomarkers; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2022 |
Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene | 2021 |
Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1.
Topics: Drug Resistance, Neoplasm; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; L | 2022 |
Allopurinol-Induced DRESS and Neosensitization to Thalidomide: Complex Management and Diagnosis in a Patient With Multiple Myeloma.
Topics: Allopurinol; Drug Hypersensitivity Syndrome; Humans; Multiple Myeloma; Thalidomide | 2022 |
Three Cases of Lenalidomide Therapy for Multiple Myeloma and Subsequent Development of Secondary B-ALL.
Topics: Aged; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pancytopenia; Thalidomide | 2022 |
Pomalidomide-based therapy for extramedullary multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Female; Humans; Male; Middle Aged; Multiple Myeloma; Progression-Free | 2022 |
Effect of therapeutic regimens and polypharmacy on health-related quality of life of people with multiple myeloma: a cross-sectional study in Belo Horizonte, Brazil.
Topics: Bortezomib; Brazil; Cross-Sectional Studies; Humans; Multiple Myeloma; Polypharmacy; Quality of Life | 2022 |
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multi | 2022 |
Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2022 |
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Topics: Aged; Antibodies, Monoclonal, Humanized; Dexamethasone; Humans; Multiple Myeloma; Thalidomide | 2022 |
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Dexamethasone; Humans; Multiple Myeloma; Neo | 2022 |
Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; | 2022 |
Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethaso | 2022 |
Delayed-onset cutaneous eruption associated with lenalidomide in setting of multiple myeloma.
Topics: Exanthema; Humans; Lenalidomide; Multiple Myeloma; Skin; Thalidomide | 2021 |
Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Ana | 2022 |
Successful Treatment of the TEMPI Syndrome with Pomalidomide Plus Dexamethasone Followed by Autologous Stem Cell Transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell T | 2022 |
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Fo | 2022 |
Generic Lenalidomide: An opportunity to address the balance of administrative burden and drug safety.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2022 |
Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hu | 2022 |
Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; COVID-19; C | 2022 |
Low cerebrospinal fluid-to-plasma ratios of orally administered lenalidomide mediated by its low cell membrane permeability in patients with hematologic malignancies.
Topics: Animals; Cell Membrane Permeability; Female; Hematologic Neoplasms; Humans; Lenalidomide; Multiple M | 2022 |
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hu | 2022 |
Response and Survival Estimates of Patients With Plasma Cell Myeloma in a Resource-Constrained Setting Using Protocols From High-Income Countries: A Single-Center Experience From Sri Lanka.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Developed Countries; D | 2022 |
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, | 2022 |
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, | 2022 |
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, | 2022 |
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, | 2022 |
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, | 2022 |
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, | 2022 |
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, | 2022 |
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, | 2022 |
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, | 2022 |
A case of chronic neutrophilic leukemia and multiple myeloma showing the benefits of lenalidomide and cyclophosphamide therapy in treating both conditions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Humans; Lenalidomid | 2022 |
Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Mul | 2022 |
A case report of secondary synchronous diagnosis of multiple myeloma and systemic lupus erythematosus after breast cancer treatment: A CARE-compliant article.
Topics: Aged; Antibodies, Monoclonal; Breast Neoplasms; Female; Glycoproteins; Humans; Hydrocortisone; Hydro | 2022 |
Evaluation of the Prognostic Significance of Cereblon Protein Expression in Multiple Myeloma.
Topics: Adaptor Proteins, Signal Transducing; Humans; Immunoglobulin A; Immunoglobulin G; Multiple Myeloma; | 2022 |
Dupilumab in Multiple Myeloma: A Case Series.
Topics: Antibodies, Monoclonal, Humanized; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2022 |
Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; | 2022 |
VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Huma | 2023 |
VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Huma | 2023 |
VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Huma | 2023 |
VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Huma | 2023 |
VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Huma | 2023 |
VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Huma | 2023 |
VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Huma | 2023 |
VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Huma | 2023 |
VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Huma | 2023 |
Synthesis of novel glutarimide ligands for the E3 ligase substrate receptor Cereblon (CRBN): Investigation of their binding mode and antiproliferative effects against myeloma cell lines.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Humans; Multiple Myeloma; Peptide Hydrolases | 2023 |
Synthesis of novel glutarimide ligands for the E3 ligase substrate receptor Cereblon (CRBN): Investigation of their binding mode and antiproliferative effects against myeloma cell lines.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Humans; Multiple Myeloma; Peptide Hydrolases | 2023 |
Synthesis of novel glutarimide ligands for the E3 ligase substrate receptor Cereblon (CRBN): Investigation of their binding mode and antiproliferative effects against myeloma cell lines.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Humans; Multiple Myeloma; Peptide Hydrolases | 2023 |
Synthesis of novel glutarimide ligands for the E3 ligase substrate receptor Cereblon (CRBN): Investigation of their binding mode and antiproliferative effects against myeloma cell lines.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Humans; Multiple Myeloma; Peptide Hydrolases | 2023 |
Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; M | 2023 |
Real-world assessment of treatment patterns and outcomes in patients with relapsed-refractory multiple myeloma in an Italian haematological tertiary care centre.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple | 2023 |
Drug class refractoriness, not number of prior lines of therapy, properly classify patients with relapsed and refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Re | 2023 |
Mechanisms Contributing to Acquired Activated Protein C Resistance in Patients Treated with Thalidomide: A Molecular Dynamics Study.
Topics: Activated Protein C Resistance; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; | 2023 |
Pomalidomide combinations are a safe and effective option after daratumumab failure.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Dru | 2023 |
Revisiting checkpoint inhibitors for myeloma: maintenance after stem cell transplant.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Le | 2023 |
Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021;137(22):3027-3036.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple | 2023 |
Exacerbation of psoriasis induced by lenalidomide in a patient with multiple myeloma.
Topics: Humans; Lenalidomide; Multiple Myeloma; Patients; Psoriasis; Thalidomide | 2023 |
Inclusion criteria of currently enrolling T-cell engaging trials in multiple myeloma: Should we be focusing on lines of prior therapy?
Topics: Humans; Immunotherapy, Adoptive; Lenalidomide; Multiple Myeloma; T-Lymphocytes; Thalidomide | 2023 |
[The efficacy and safety analysis of pomalidomide in the treatment of relapsed/refractory multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Re | 2023 |
Lenalidomide maintenance based on a genetic profile.
Topics: Genetic Profile; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Th | 2023 |
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bortezomib; Dexamethasone; Humans; Lenal | 2023 |
Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy.
Topics: Bortezomib; Chemokine CXCL10; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Mainten | 2023 |
Real-world effectiveness and safety of multiple myeloma treatments based on thalidomide and bortezomib: A retrospective cohort study from 2009 to 2020 in a Brazilian metropolis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Brazil; Female; Hematopoietic Stem Cell | 2023 |
Treating multiple myeloma in the era of new drugs: What is the right choice?
Topics: Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Thalidomide | 2023 |
[Access and safety of dexamethasone in multiple myeloma patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Mul | 2023 |
Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma.
Topics: Follow-Up Studies; Humans; Kaplan-Meier Estimate; Multiple Myeloma; Randomized Controlled Trials as | 2023 |
Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Multiple Myeloma; POEMS Syndrome; Thalidomid | 2023 |
Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Electronic Heal | 2023 |
Fever, Pancytopenia, and Tender Erythematous Plaques in a Patient With Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Erythema; Humans; Lenalidomide; Multi | 2023 |
Response adaptive salvage with KTd and ASCT for functional high-risk multiple myeloma-The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell T | 2023 |
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction.
Topics: Black or African American; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous Sy | 2023 |
A New Strategy for the Old Challenge of Thalidomide: Systems Biology Prioritization of Potential Immunomodulatory Drug (IMiD)-Targeted Transcription Factors.
Topics: Adaptor Proteins, Signal Transducing; beta Catenin; Humans; Immunologic Factors; Immunomodulating Ag | 2023 |
Vanishing bile duct syndrome in a patient with multiple myeloma treated with bortizomib, lenalidomide and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Ducts; Cholestasis; Dexamethasone; Humans; Lena | 2023 |
The age-dependent changes in risk weights of the prognostic factors for multiple myeloma.
Topics: Aged; Bortezomib; Humans; Multiple Myeloma; Prognosis; Retrospective Studies; Thalidomide | 2023 |
[The efficacy and safety of bortezomib, pomalidomide and dexamethasone regimen in the treatment of relapsed/refractory multiple myeloma].
Topics: Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Thalidomide | 2023 |
Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; M | 2023 |
Pomalidomide-based maintenance post-autologous hematopoietic cell transplantation in multiple myeloma: a case series.
Topics: Aged; Female; Hematopoietic Stem Cell Transplantation; Humans; Maintenance Chemotherapy; Male; Middl | 2019 |
Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008-2016.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Comorbidity; D | 2020 |
Population Pharmacokinetic Model to Assess the Impact of Disease State on Thalidomide Pharmacokinetics.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Fema | 2020 |
[Effects of Clinical Characteristics, Laboratory Parameters and Treatment Regimens on Prognosis of Patients with Multiple Myeloma].
Topics: Amyloidosis; Humans; Multiple Myeloma; Prognosis; Retrospective Studies; Thalidomide | 2019 |
Editorial: Immunotherapy in Multiple Myeloma.
Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Age | 2019 |
Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy.
Topics: Angiogenesis Inhibitors; Female; Hematopoietic Stem Cell Transplantation; Humans; Magnetic Resonance | 2019 |
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Mul | 2020 |
Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Female; Humans; Immunoglobulin D; | 2019 |
IKZF1/3 and CRL4
Topics: Adaptor Proteins, Signal Transducing; Humans; Ikaros Transcription Factor; Multiple Myeloma; Mutatio | 2020 |
Hematological, Biochemical and Renal Changes in Patients of Multiple Myeloma Treated with Bortezomib Based Triple Drug Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; | 2019 |
Pomalidomide in lenalidomide-refractory multiple myeloma: Far from futile.
Topics: Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Treatment Failure | 2020 |
The tale of lenalidomide clinical superiority over thalidomide and regulatory and cost-effectiveness issues.
Topics: Angiogenesis Inhibitors; Brazil; Cost-Benefit Analysis; Drug and Narcotic Control; Drug Costs; Human | 2019 |
Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update?
Topics: Dexamethasone; Humans; Multiple Myeloma; Oligopeptides; Thalidomide | 2019 |
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomid
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; H | 2020 |
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Clinical Trial | 2020 |
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Clinical Trial | 2020 |
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Clinical Trial | 2020 |
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Clinical Trial | 2020 |
Incorporating isatuximab in the treatment of multiple myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Dexamethasone; Humans; Multiple Myeloma; | 2019 |
In response to: Treatment of patients with multiple myeloma progressing on frontline therapy with lenalidomide, Moreau et al., 2019.
Topics: Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2019 |
Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myelom | 2020 |
Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta 2-Microglobulin; Biomarkers; Bone Marrow | 2020 |
Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2019 |
Pomalidomide desensitization for hypersensitivity: A case report.
Topics: Aged; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Immunologic Factors; Mult | 2020 |
Pyoderma gangrenosum induced by lenalidomide in a case of multiple myeloma.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Substitution; | 2020 |
Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexameth | 2020 |
[Effect of Pomalidomide on Activity of Myeloma Cell Line MM1.S and Expression of CRBN].
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Multi | 2019 |
Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Cyclophosphamide; Dexamethasone; Female; | 2019 |
Daratumumab-associated hemophagocytic lymphohistiocytosis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Human | 2020 |
Anti-rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Bortezomi | 2020 |
Daratumumab prevents programmed death ligand-1 expression on antigen-presenting cells in de novo multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Antibodies, Monoclonal; B7-H1 Antigen; Dendritic Cells; Down-Reg | 2020 |
Case report of coexistence of myeloproliferative neoplasms and multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Bortezomib; Dexameth | 2020 |
[Pomalidomide/cyclophosphamide/dexamethasone combination therapy for relapsed/refractory multiple myeloma accompanied by extramedullary lesions].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Hematopoietic Stem | 2020 |
Treatment of Persons with Multiple Myeloma in Underprivileged Circumstances: Real-World Data from a Single Institution.
Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bortezomib; Dexame | 2020 |
Comparison of thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant eligible.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Multiple Myeloma; Retros | 2020 |
Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Drug Administra | 2020 |
Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Genome-Wide Association Study; Humans; Multi | 2020 |
Tuberculosis during lenalidomide maintenance in a patient with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Maintenance Chemotherapy; Mult | 2021 |
Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Ba | 2020 |
[Proteinuria in multiple myeloma: Be careful to iatrogeny].
Topics: Aged; Antineoplastic Agents; Autografts; Biopsy; Bortezomib; Dexamethasone; Female; Glomeruloscleros | 2020 |
Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentin
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; F | 2020 |
[Ultra high-risk refractory multiple myeloma with a complex karyotype including t(14;19)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosomes, Human, Pair 14; Chrom | 2020 |
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; | 2020 |
Dialysis Independence Following Combination Daratumumab, Thalidomide, Bortezomib, Cyclophosphamide, and Dexamethasone in Multiple Myeloma With Severe Renal Failure.
Topics: Adult; Antibodies, Monoclonal; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Male; Multiple M | 2020 |
Pomalidomide-associated progressive multifocal leukoencephalopathy in multiple myeloma: cortical susceptibility-weighted imaging hypointense findings prior to clinical deterioration.
Topics: Aged; Clinical Deterioration; Dexamethasone; Female; Humans; Immunologic Factors; JC Virus; Leukoenc | 2020 |
[Ⅰ.Current Treatment Strategies for Transplant-Eligible Newly Diagnosed Multiple Myeloma].
Topics: Bortezomib; Humans; Multiple Myeloma; Thalidomide | 2020 |
Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Contai
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Dexamethason | 2020 |
Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen.
Topics: Aged; Blood Platelets; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Lymphocyte Count | 2020 |
An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myelom | 2020 |
A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzene Derivatives; Cell Line, Tumor; Ce | 2020 |
Pleural plasmacytomas - the role of radiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Cycloph | 2020 |
Myasthenia gravis with anti-muscle-specific tyrosine kinase antibodies during therapy for multiple myeloma: a case report.
Topics: Antineoplastic Agents; Autoantibodies; Bortezomib; Humans; Male; Middle Aged; Multiple Myeloma; Myas | 2020 |
Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.
Topics: Cell Line, Tumor; Chemokine CCL5; Coculture Techniques; Humans; Interferon Regulatory Factors; Intra | 2020 |
Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor.
Topics: Animals; Azepines; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Ki | 2020 |
Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Bortez | 2020 |
Bortezomib-based Triplet Regimens for Remission Induction in Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; | 2020 |
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethaso | 2021 |
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy | 2020 |
Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Cell Proliferation; Cell- an | 2021 |
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineo | 2021 |
A Clinician's Perspective of Elotuzumab in the Treatment of Relapsed or Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, | 2019 |
A Clinician's Perspective of Elotuzumab in the Treatment of Relapsed or Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, | 2019 |
Outcome of COVID-19 in multiple myeloma patients in relation to treatment.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Cohort Stud | 2020 |
Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell M | 2021 |
Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bort | 2020 |
The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.
Topics: Animals; Humans; Immunomodulation; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Pharmaceutical | 2020 |
Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; | 2020 |
ARID2 is a pomalidomide-dependent CRL4
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromosomal Proteins, Non-Histone; Drug Resistance, Neoplas | 2020 |
Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; An | 2020 |
Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient.
Topics: Bortezomib; Dexamethasone; Humans; Imatinib Mesylate; Immunoglobulin G; Leukemia, Myelogenous, Chron | 2020 |
Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient.
Topics: Bortezomib; Dexamethasone; Humans; Imatinib Mesylate; Immunoglobulin G; Leukemia, Myelogenous, Chron | 2020 |
Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient.
Topics: Bortezomib; Dexamethasone; Humans; Imatinib Mesylate; Immunoglobulin G; Leukemia, Myelogenous, Chron | 2020 |
Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient.
Topics: Bortezomib; Dexamethasone; Humans; Imatinib Mesylate; Immunoglobulin G; Leukemia, Myelogenous, Chron | 2020 |
Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Re | 2021 |
Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials a | 2020 |
Maintenance regimens after a second autologous transplant for multiple myeloma.
Topics: Autografts; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Thalidomide; Transpla | 2021 |
The Assessment of the Combined Treatment of 5-ALA Mediated Photodynamic Therapy and Thalidomide on 4T1 Breast Carcinoma and 2H11 Endothelial Cell Line.
Topics: Aminolevulinic Acid; Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Endothe | 2020 |
Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Line, Tumor; Cell Survival; Female; HEK293 Cells | 2021 |
DT-PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexa | 2021 |
Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; | 2021 |
Induction therapy before autologous HSCT: a proper preparation pays off?
Topics: Bortezomib; Dexamethasone; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Multi | 2020 |
Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide.
Topics: Adrenergic beta-Antagonists; Humans; Multiple Myeloma; Prognosis; Thalidomide; Treatment Outcome | 2021 |
[Multiple myeloma with light chain deposition disease showing needle-like crystal inclusions in plasma cells and macrophages in multiple organs].
Topics: Humans; Lenalidomide; Macrophages; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Thalidomide | 2020 |
Pomalidomide and dexamethasone in myelomatous pleural effusion.
Topics: Dexamethasone; Drainage; Dyspnea; Humans; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Pleural | 2020 |
Design, synthesis and biological evaluation of thioether-containing lenalidomide and pomalidomide derivatives with anti-multiple myeloma activity.
Topics: Animals; Cell Proliferation; Drug Design; Female; Humans; Immunologic Factors; Lenalidomide; Mice; M | 2021 |
Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2021 |
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Drug Resistance, Neoplasm; Genetic Vari | 2021 |
Elotuzumab in the treatment of relapsed and refractory multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell | 2021 |
Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neopl | 2021 |
Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antine | 2021 |
Adherence to thalidomide in patients with multiple myeloma: A cross-sectional study in a Brazilian metropolis.
Topics: Adolescent; Adult; Brazil; Cross-Sectional Studies; Humans; Immunologic Factors; Medication Adherenc | 2022 |
Role of MBD3-SOX2 axis in residual myeloma following pomalidomide.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; DNA-Binding Proteins; Gene Expression Regulation, Neopla | 2021 |
Real-world treatment patterns in relapsed/refractory multiple myeloma: Clinical and economic outcomes in patients treated with pomalidomide or daratumumab.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans | 2022 |
Cereblon modulator CC-885 induces CRBN-dependent ubiquitination and degradation of CDK4 in multiple myeloma.
Topics: Animals; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Humans; Male; Mice, Inbred BALB C; | 2021 |
Real-World Outcomes With Generic Pomalidomide in Relapsed Refractory Multiple Myeloma-Experience From a Tertiary Care Cancer Center.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Retrospecti | 2021 |
Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs.
Topics: Black or African American; Humans; Hyperpigmentation; Immunologic Factors; Incidence; Lenalidomide; | 2021 |
Immunomodulators in newly diagnosed multiple myeloma: current and future concepts.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Immunologic | 2021 |
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 2021 |
Plasma cell dedifferentiation in refractory multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Dedifferentiation | 2021 |
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
Topics: Abnormal Karyotype; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplasti | 2021 |
Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Bortezomib; Female; Health Expenditures; Humans; Lenalidomide; Male; | 2021 |
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds | 2021 |
A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multi | 2021 |
Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamid | 2021 |
Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; F | 2021 |
Case of lymphadenopathy with lytic bone lesions.
Topics: Bortezomib; Dexamethasone; Diagnosis, Differential; Humans; Incidental Findings; Lenalidomide; Lymph | 2017 |
Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Combined Modality Therapy; Con | 2017 |
Dementia and multiple myeloma.
Topics: Aged; Back Pain; Blood Viscosity; Dementia; Dexamethasone; Female; Glucocorticoids; Headache; Humans | 2017 |
Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cardiova | 2017 |
[Clinical Effects of Different Chemotherapeutic Regimens on the Patients with Multiple Myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Doxorubicin; Humans; Mult | 2017 |
Hepatitis E during lenalidomide treatment for multiple myeloma in complete remission.
Topics: Aged; Female; Hepatitis E; Humans; Immunologic Factors; Lenalidomide; Liver Function Tests; Maintena | 2017 |
Bortezomib, Thalidomide, and Dexamethasone (VTD) Induction Results in Better Overall Survival than Adriamycin, Thalidomide, and Dexamethasone (ATD) Induction in Previously Untreated Myeloma Patients Eligible for Transplants.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubici | 2017 |
A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Resorption; Cell Line, Tumor; Cell Proliferation; Ce | 2017 |
Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Hematopoietic Stem Cell Transplantation; | 2017 |
Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lena | 2017 |
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as T | 2017 |
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as T | 2017 |
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as T | 2017 |
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as T | 2017 |
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as T | 2017 |
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as T | 2017 |
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as T | 2017 |
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as T | 2017 |
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as T | 2017 |
Spotlight on pomalidomide: could less be more?
Topics: Adjuvants, Immunologic; Dexamethasone; Drug Administration Schedule; Drug Costs; Humans; Multiple My | 2017 |
Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.
Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Aged, 80 and over; Antineoplastic Age | 2017 |
Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting.
Topics: Adult; Aged; Aged, 80 and over; Australia; Electronic Prescribing; Female; Humans; Immunologic Facto | 2017 |
Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; B | 2017 |
[Pomalidomide for multiple myeloma].
Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Multiple Myeloma; Thalidomide | 2017 |
Bortezomib Does Not Prevent the Occurrence of Kaposi's Sarcoma in Patients with Haematological Malignancies: Two Case Reports.
Topics: Aged; Amyloidosis; Antineoplastic Agents; Bortezomib; Female; Humans; Immunologic Factors; Lenalidom | 2017 |
Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cisplatin; Combined Modality Therapy; Cy | 2017 |
Comparison of cyclophosphamide-thalidomide-dexamethasone to bortezomib-cyclophosphamide-dexamethasone as induction therapy for multiple myeloma patients in Brazil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Female; | 2017 |
Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematopoietic Stem Cell Transplantati | 2018 |
MUC1-C is a target in lenalidomide resistant multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Computational Biol | 2017 |
Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis | 2017 |
Impact of lenalidomide-based induction therapy on the mobilization of CD34
Topics: Aged; Antigens, CD34; Case-Control Studies; Female; Graft Survival; Hematopoietic Stem Cell Mobiliza | 2017 |
[A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Dexamethasone; Disease | 2017 |
Causes of early death in multiple myeloma patients treated with high-dose therapy followed by autologous stem cell transplantation: A study based on the nationwide Danish Multiple Myeloma Registry.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bortezomib; Cyclophosphamid | 2017 |
Very-Low-Dose Lenalidomide for Elderly and/or Frail Multiple Myeloma Patients: Lower Might Be Better.
Topics: Aged; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2017 |
Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World Experience.
Topics: Aged; Aged, 80 and over; Dexamethasone; Female; Humans; Immunologic Factors; Japan; Lenalidomide; Ma | 2017 |
The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Topics: Acetamides; Aged; Aged, 80 and over; Animals; Apoptosis; Azepines; Cell Line, Tumor; Cell Proliferat | 2017 |
Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Caspase Inhibitors; Caspases; Cell Cycle; | 2017 |
Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Circulating MicroRNA; Dexamethasone; Drug Resistance | 2017 |
Improved survival in Medicare patients with multiple myeloma: findings from a large nationwide and population-based cohort.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Female; Humans; Kaplan-Meier Estimate; L | 2017 |
Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy.
Topics: Adult; Aged; Aged, 80 and over; Bortezomib; Female; Humans; Lenalidomide; Male; Middle Aged; Models, | 2017 |
Maintenance Lenalidomide After Transplantation in Multiple Myeloma Prolongs Survival-In Most.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Transp | 2017 |
Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Humans; Multiple Myeloma; Survival Analysis; | 2018 |
The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cells, C | 2017 |
IMiD-induced gene expression profiling predicts multiple myeloma prognosis.
Topics: Gene Expression Profiling; Humans; Multiple Myeloma; Prognosis; Thalidomide | 2017 |
The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Eligibility Determin | 2017 |
Maintenance lenalidomide could be most relevant after first-line therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2017 |
A case of multiple myeloma with navicular bone involvement.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Immunologic Factors; | 2017 |
"Hof" in pronormoblasts: pure erythroid leukemia mimicking plasma cell myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cyclophosphamide; Cytoplasm; Dexa | 2017 |
Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexam | 2017 |
Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexam | 2017 |
Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexam | 2017 |
Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexam | 2017 |
'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Drug Resistance, Neoplasm; Humans; Immuno | 2018 |
Histone deacetylase inhibitor BG45-mediated HO-1 expression induces apoptosis of multiple myeloma cells by the JAK2/STAT3 pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; | 2018 |
Metachronous solitary plasmacytoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Diphosphonates; Di | 2017 |
Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide | 2018 |
Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian; Black or African American; Bortezomib; Female | 2017 |
Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Benzamides; Biphenyl Compounds; Cell Line, Tumor; | 2018 |
[Expert consensus for the diagnosis and treatment of patients with renal impairment of multiple myeloma].
Topics: Consensus; Creatinine; Dexamethasone; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chain | 2017 |
Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.
Topics: Aged; Antineoplastic Agents; Cyclophosphamide; Dexamethasone; Female; Humans; Male; Middle Aged; Mon | 2017 |
The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Female; Humans; Immunologic Factors; Lenalidomi | 2018 |
Lenalidomide plus dexamethasone in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; | 2018 |
Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical T | 2018 |
Therapy sequencing strategies in multiple myeloma: who, what and why?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2018 |
Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progressio | 2018 |
Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2018 |
Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft.
Topics: Adult; Aged; Autografts; Disease-Free Survival; Humans; Lenalidomide; Maintenance Chemotherapy; Midd | 2018 |
Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.
Topics: Adult; Aged; Aged, 80 and over; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combinati | 2018 |
Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Successful treatment of nephrotic syndrome induced by lambda light chain deposition disease using lenalidomide: A case report and review of the literature
.
Topics: Aged, 80 and over; Female; Humans; Immunoglobulin lambda-Chains; Immunologic Factors; Lenalidomide; | 2018 |
[Effects of Thalidomide on the Ratio of Th17 to Treg Cells in Peripheral Blood and Expression of IL-17 and IL-35 in Patients with Multiple Myeloma].
Topics: Flow Cytometry; Humans; Interleukin-17; Interleukins; Multiple Myeloma; T-Lymphocytes, Regulatory; T | 2018 |
[Digital ischemia revealing multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cryoglobulinemia; Dexamethasone; F | 2018 |
The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Clarithromycin; Dexamethasone; H | 2018 |
Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical | 2018 |
Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical | 2018 |
Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical | 2018 |
Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical | 2018 |
A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2018 |
Impact of the affordability of novel agents in patients with multiple myeloma: Real-world data of current clinical practice in Mexico.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Drug Costs; | 2018 |
Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Humans; Lenalidomide; Male; Middle Aged; Mul | 2019 |
[Development of a standardized guide for optimizing drug adherence information to be dispensed during a pharmaceutical counseling with a multiple myeloma patient: Initial validation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Counseling; Dexamethasone; Female; | 2018 |
Severe Renal Allograft Rejection Resulting from Lenalidomide Therapy for Multiple Myeloma: Case Report.
Topics: Antineoplastic Agents; Female; Graft Rejection; Humans; Kidney Transplantation; Lenalidomide; Middle | 2018 |
Multiple myeloma masquerading as diabetic macular oedema.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Large-Core Needle; Bone Marrow; Cycl | 2018 |
Microvesicles shed from bortezomib-treated or lenalidomide-treated human myeloma cells inhibit angiogenesis in vitro.
Topics: Bortezomib; Cell Line, Tumor; Cell Movement; Cell-Derived Microparticles; Coculture Techniques; Down | 2018 |
Next-Generation Drugs Targeting the Cereblon Ubiquitin Ligase.
Topics: Dexamethasone; Humans; Multiple Myeloma; Thalidomide; Ubiquitin; Ubiquitin-Protein Ligases | 2018 |
Thromboprophylaxis and thalidomide in the noncancer setting: Toward an algorithm that is based on patient risk factors and underlying disease?
Topics: Algorithms; Humans; Multiple Myeloma; Risk Factors; Thalidomide; Venous Thromboembolism | 2018 |
Thalidomide and thromboprophylaxis for dermatologic indications: An unmet need for more evidence.
Topics: Drug Tolerance; Humans; Lupus Erythematosus, Cutaneous; Multiple Myeloma; Thalidomide; Venous Thromb | 2018 |
CUL5 is required for thalidomide-dependent inhibition of cellular proliferation.
Topics: Biomarkers; Cell Nucleus; Cell Proliferation; Cells, Cultured; Cullin Proteins; Endothelial Cells; H | 2018 |
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2018 |
IgM k multiple myeloma with monoclonal surface immunoglobulin expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Bortezomib; Dexamethasone; Female | 2018 |
Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dise | 2019 |
Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cz | 2018 |
Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships.
Topics: Adaptor Proteins, Signal Transducing; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; P | 2018 |
The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Acute Liver Failure Associated With Pomalidomide Therapy for Multiple Myeloma.
Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Humans; Liver Failure, Acute; Liver F | 2018 |
Successful Treatment of Recurrent Gastrointestinal Bleeding Due to Small Intestine Angiodysplasia and Multiple Myeloma with Thalidomide: Two Birds with One Stone
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Humans; Intestine, Small | 2018 |
Retroperitoneal relapse in an older patient with multiple myeloma during pomalidomide and dexamethasone treatment.
Topics: Aged; Antineoplastic Agents, Hormonal; Dexamethasone; Female; Humans; Immunologic Factors; Multiple | 2018 |
[Cost-Effectiveness Analysis of Different Chemotherapy Regimens in the Treatment of Patients with Multiple Myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Cyclophosphamide; | 2018 |
[Clinical Efficacy and Safety of Different Doses of Dexamethasone Combined with Bortezomib and Thalidomide for Treating Patients with Multiple Myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Hu | 2018 |
Successful retreatment with lenalidomide for relapsed and refractory multiple myeloma previously treated with bortezomib, lenalidomide and pomalidomide.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; | 2018 |
Multiple Myeloma Patients Ineligible for Randomized Controlled Trials Have Poorer Outcomes Irrespective of Treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Multiple Myeloma; Randomized Controlled Tria | 2018 |
Active IgGκ Multiple Myeloma Presenting With Crystalline Keratopathy.
Topics: Aged; Antineoplastic Agents; Bortezomib; Corneal Diseases; Dexamethasone; Drug Therapy, Combination; | 2018 |
Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Dexamethasone | 2018 |
Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Dose-Res | 2018 |
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2018 |
Second-generation immunomodulatory drugs in leptomeningeal myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Immunologic Facto | 2019 |
Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; | 2018 |
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Computation | 2019 |
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Computation | 2019 |
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Computation | 2019 |
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Computation | 2019 |
Recent studies on the thalidomide and its derivatives.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Humans; Multiple Myeloma; Neoplasms; Neovascular | 2018 |
Multiple myeloma: Updated approach to management in 2018.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; beta 2-Microglobulin; Bortezomib; Disease Management; | 2018 |
Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/\
refractory multiple myeloma: a real-life experience
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model.
Topics: Animals; Antineoplastic Agents; Cancer Vaccines; Cell Line, Tumor; Combined Modality Therapy; Cytoki | 2018 |
CRISPRing the CRL4
Topics: Adaptor Proteins, Signal Transducing; Cullin Proteins; Humans; Lenalidomide; Multiple Myeloma; Pepti | 2018 |
Bortezomib Prescription Pattern for the Treatment of Multiple Myeloma by Hematologists in Nigeria.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethas | 2018 |
Pomalidomide - Author Reply.
Topics: Australia; Humans; Multiple Myeloma; Neoplasms, Plasma Cell; Thalidomide | 2019 |
Thalidomide for myeloma: still here?
Topics: Angiogenesis Inhibitors; Humans; Multiple Myeloma; Thalidomide | 2018 |
Combination therapy for first relapse of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide | 2018 |
Real world experience with "generic" pomalidomide in relapsed refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Humans; Multiple Myeloma; Thalidomide | 2019 |
Pulmonary toxicity associated with pomalidomide.
Topics: Antineoplastic Agents; Humans; Lung; Male; Middle Aged; Multiple Myeloma; Pneumonia; Pulmonary Fibro | 2018 |
Extramedullary Multiple Myeloma With Pleural Involvement: A Rare Clinical Entity.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2019 |
A unique case of rapidly progressive glomerulonephritis following dexamethasone/bortezomib/thalidomide treatment for myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Fema | 2018 |
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy P | 2018 |
Immunotherapy Combinations in Multiple Myeloma - Known Unknowns.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2018 |
Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bortezomib | 2019 |
Elotuzumab in multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, | 2018 |
Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
Topics: Adult; Antibodies, Monoclonal; Cyclophosphamide; Dexamethasone; Female; Heart Failure; Hematopoietic | 2019 |
Apremilast ameliorates carfilzomib-induced pulmonary inflammation and vascular injuries.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Disease Models, Animal; | 2019 |
[Clinical Analysis of Maintenance Therapy with Thalidomine and Bortezomib for Multiple Myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Surviv | 2018 |
Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Re | 2019 |
Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost-effectiveness analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexam | 2019 |
Lenalidomide as maintenance for every newly diagnosed patient with multiple myeloma.
Topics: Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Thalidomide | 2019 |
[Successful Treatment with Pomalidomide, Bortezomib, and Dexamethasone in a Patient with Frail Refractory and Relapsed Multiple Myeloma with Extramedullary Disease].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female | 2018 |
Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azepines; | 2019 |
[Thalidomide].
Topics: Angiogenesis Inhibitors; Humans; Multiple Myeloma; Thalidomide | 2016 |
[Pomalidomide].
Topics: Angiogenesis Inhibitors; Humans; Multiple Myeloma; Thalidomide | 2016 |
Extramedullary Manifestation of Multiple Myeloma in the Oral Cavity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; Fata | 2018 |
Commentary on "Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma" by Giovanni Barosi and Robert Peter Gale.
Topics: Autografts; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2019 |
Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplas | 2019 |
[Life Quality and Its Related Factors of Patients with Multiple Myeloma during Maintenance Therapy].
Topics: Cross-Sectional Studies; Humans; Multiple Myeloma; Quality of Life; Thalidomide | 2019 |
[Clinical Application of R-ISS Staging System in 412 Newly Diagnosed Patients with Multiple Myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Multiple Myeloma; Neoplasm Stagi | 2019 |
Thalidomide-induced psoriasis in a patient with multiple myeloma.
Topics: Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Psoriasis; Severity of Illnes | 2019 |
Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal.
Topics: Age Factors; Aged; Antineoplastic Agents; Boron Compounds; Bortezomib; Drug Costs; Female; Glycine; | 2019 |
Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study.
Topics: Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Retrospective Stu | 2019 |
Response to the Commentary on "Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma".
Topics: Autografts; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2019 |
[Multiple myeloma treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Multiple Myeloma; Neoplasm Recur | 2018 |
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 2019 |
[Treatment of multiple myeloma with elotuzumab plus pomalidomide and dexamethasone].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2019 |
Epstein-Barr virus infection is associated with clinical characteristics and poor prognosis of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cells, Cultured; DNA, Viral; Epstein-Bar | 2019 |
Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells.
Topics: Antibodies, Monoclonal; Biomarkers, Tumor; Bortezomib; Cell Line, Tumor; Dexamethasone; Enzyme-Linke | 2019 |
Successful hematopoietic stem-cell mobilization with plerixafor plus granulocyte-colony stimulating factor in multiple myeloma patients treated with pomalidomide.
Topics: Adult; Benzylamines; Cyclams; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Fact | 2019 |
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
Topics: Antineoplastic Agents; DNA Copy Number Variations; Drug Resistance, Neoplasm; Enhancer Elements, Gen | 2019 |
[Renal failure revealing multiple myeloma with preexisting lesions on radiological images].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chest Pain; Cyclophosphamide; Dexamethasone; Dyspnea | 2018 |
Recycling therapies for myeloma: The need for prospective trials.
Topics: Antibodies, Monoclonal; Dexamethasone; Humans; Multiple Myeloma; Prospective Studies; Thalidomide; T | 2019 |
Redefining the treatment paradigm for multiple myeloma.
Topics: Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2019 |
Polymorphisms in the promotor region of the CRBN gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Female; Genetic Predisposition to Disease; Humans; Immunosuppressive | 2019 |
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
Topics: Adaptor Proteins, Signal Transducing; Carbon-13 Magnetic Resonance Spectroscopy; Cell Line, Tumor; C | 2019 |
Comments on: High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany.
Topics: Germany; Group Practice; Hematology; Humans; Immunologic Factors; Multiple Myeloma; Patient Complian | 2020 |
Registering a CD38 antibody upfront for multiple myeloma.
Topics: Antibodies, Monoclonal; Bortezomib; Cell Transplantation; Dexamethasone; Humans; Multiple Myeloma; T | 2019 |
[Evaluation and Comparison of Thromboelastography and Conventional Coagulation Tests for Blood Coagulation Function in Children with Henoch-Schönlein Purpura].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation; Child; Dexamethasone; Humans; IgA | 2019 |
New daratumumab quadruplets and triplets for newly diagnosed MM.
Topics: Antibodies, Monoclonal; Bortezomib; Cell Transplantation; Dexamethasone; Humans; Multiple Myeloma; T | 2019 |
HDAC6‑selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma.
Topics: Apoptosis; Benzene Derivatives; Cell Proliferation; Drug Synergism; Histone Deacetylase 6; Histone D | 2019 |
Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the 'Rete Ematologica Pugliese E Basilicata'.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2019 |
Facing lenalidomide-refractory myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Dexamethasone; Humans; Lenalidomide; Mult | 2019 |
Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bort | 2019 |
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Sche | 2019 |
Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Pro | 2020 |
Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; In | 2019 |
Assessing the impact of a matching-adjusted indirect comparison in a Bayesian network meta-analysis.
Topics: Bayes Theorem; Computer Simulation; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; N | 2019 |
Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy.
Topics: Activins; Angiogenesis Inhibitors; Antibodies, Neutralizing; Antineoplastic Agents; Cell Differentia | 2013 |
Induction of apoptosis in multiple myeloma cells by a statin-thalidomide combination can be enhanced by p38 MAPK inhibition.
Topics: Apoptosis; Caspases; Cell Line, Tumor; Enzyme Activation; Gene Expression Regulation, Leukemic; Huma | 2013 |
Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamet | 2013 |
Successful salvage therapy using lenalidomide in a patient with relapsed multiple myeloma after allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; M | 2013 |
Pomalidomide approved for multiple myeloma.
Topics: Antineoplastic Agents; Drug Approval; Drug Labeling; Humans; Multiple Myeloma; Thalidomide; United S | 2013 |
Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; Drug Administration Schedule; Fatal | 2013 |
Clinical profile of multiple myeloma and effect of thalidomide based treatment on its outcome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dexamethasone; Female; Hum | 2011 |
"IM iD"eally treating multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resis | 2013 |
Efficacy of thalidomide-based therapy following lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2013 |
Lenalidomide-induced regenerative macronodules infarction in a cirrhosis patient.
Topics: Angiogenesis Inhibitors; Focal Nodular Hyperplasia; Humans; Infarction; Lenalidomide; Liver; Liver C | 2013 |
[Molecular targeting agents for multiple myeloma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib | 2012 |
Multiple myeloma presenting as plasmacytoma of the jaws showing prominent bone formation during chemotherapy.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; A | 2013 |
Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myel | 2013 |
Potent antimyeloma activity of a novel ERK5/CDK inhibitor.
Topics: Animals; Blotting, Western; Boronic Acids; Bortezomib; CDC2 Protein Kinase; Cell Cycle; Cell Line, T | 2013 |
Multiple myeloma: so much progress, but so many unsolved questions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2013 |
Anatomy of a successful practice-changing study: a Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group collaboration.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Cooperative Behavior; Humans; Lenalidomide; Mult | 2013 |
Lenalidomide-induced acute lung injury in case of multiple myeloma.
Topics: Acute Lung Injury; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Male; Middl | 2013 |
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2013 |
High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2013 |
Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells.
Topics: Apoptosis; Cell Degranulation; Cell Line, Tumor; Cell Proliferation; Cytokines; Dasatinib; Humans; I | 2014 |
Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free | 2013 |
Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
Topics: Aged; Antineoplastic Agents; Blood Component Removal; Boronic Acids; Bortezomib; Dexamethasone; Fema | 2013 |
D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethas | 2013 |
Cerebrospinal fluid penetrance of lenalidomide in meningeal myeloma.
Topics: Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Thalidomide | 2013 |
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acid | 2013 |
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acid | 2013 |
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acid | 2013 |
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acid | 2013 |
Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance.
Topics: Humans; Immunologic Factors; Incidence; Lenalidomide; Multiple Myeloma; Prognosis; Thalidomide | 2013 |
Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Dexamethasone; F | 2013 |
Negative chronotropic effects and coronary ischaemic abnormalities following thalidomide therapy.
Topics: Aged; Bradycardia; Coronary Vasospasm; Electrocardiography; Humans; Immunosuppressive Agents; Male; | 2013 |
Neutrophilic dermatosis of the dorsal hands during thalidomide treatment.
Topics: Aged; Antineoplastic Agents; Hand Dermatoses; Humans; Male; Multiple Myeloma; Neutrophils; Skin Dise | 2014 |
Addition of clarithromycin to lenalidomide/low-dose dexamethasone was effective in a case of relapsed myeloma after long-term use of lenalidomide.
Topics: Clarithromycin; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Huma | 2013 |
Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferat | 2013 |
Lenalidomide in the treatment of plasma cell dyscrasia: state of the art and perspectives.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; | 2013 |
Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Discovery; Dr | 2014 |
Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2013 |
The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resista | 2014 |
[The appearance of t(9;22)(q34;q11.2) in BJP-λ type multiple myeloma during maintenance therapy including lenalidomide].
Topics: Bence Jones Protein; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 22; Chromosomes, Human, Pai | 2013 |
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Disseminated keratotic spicules: a rare manifestation in multiple myeloma and successful response to lenalidomide.
Topics: Diagnosis, Differential; Humans; Immunologic Factors; Keratosis; Lenalidomide; Male; Middle Aged; Mu | 2013 |
Very long-lasting remission of refractory T-large granular lymphocytes leukemia and myeloma by lenalidomide treatment.
Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Humans; Lenalidomide; Leukemia, Large | 2013 |
Acute myelofibrosis and acute lymphoblastic leukemia in an elderly patient with previously treated multiple myeloma.
Topics: Aged; Blood Cell Count; Bone Marrow; Humans; Immunohistochemistry; Lenalidomide; Maintenance Chemoth | 2013 |
Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma.
Topics: Blood Coagulation; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Dexamethasone; Humans; Le | 2013 |
A unique presentation of multiple myeloma in an HIV patient.
Topics: Aged; HIV; HIV Infections; HIV Seropositivity; Humans; Male; Multiple Myeloma; Radiography; Thalidom | 2013 |
Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Cisplatin; Dexamethasone; Doxorubicin; F | 2013 |
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, | 2013 |
New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Humans; Multiple Myeloma; Oligopeptides; Proteasome I | 2013 |
Very low-dose lenalidomide therapy for elderly multiple myeloma patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Dexamethasone; Drug Administration Schedule; Drug The | 2013 |
[New treatment strategies for multiple myeloma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphal | 2013 |
Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.
Topics: Acenocoumarol; Age Factors; Antineoplastic Agents; Aspirin; Female; Genetic Predisposition to Diseas | 2013 |
Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.
Topics: Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Cell A | 2014 |
Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
Topics: Adult; Aged; Anti-Bacterial Agents; Antigens, CD34; Antineoplastic Agents; Benzylamines; Boronic Aci | 2013 |
Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Central Nerv | 2013 |
Design and biological characterization of hybrid compounds of curcumin and thalidomide for multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Curcumin; Dose-Response Rela | 2013 |
Sequence of novel agents in multiple myeloma: an instrumental variable analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2013 |
The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2013 |
Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boro | 2014 |
[Synergistic effect and mechanism of baicalein in combination with lenalidomide-induced apoptosis of myeloma cells].
Topics: Apoptosis; Cell Line, Tumor; Drug Synergism; Flavanones; Humans; Lenalidomide; Multiple Myeloma; Tha | 2013 |
Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomi | 2014 |
Pomalidomide in the treatment of relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; | 2013 |
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2013 |
CXCR4 is a good survival prognostic indicator in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2013 |
5q- syndrome and multiple myeloma diagnosed simultaneously and successful treated with lenalidomide.
Topics: Abnormal Karyotype; Aged; Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Chromo | 2013 |
"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dex | 2014 |
Multiple myeloma: a descriptive study of 217 Egyptian patients.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 2014 |
Brain abscess caused by Nocardia cyriacigeorgica in two patients with multiple myeloma: novel agents, new spectrum of infections.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Abscess; Female; Ho | 2014 |
[Successful treatment of an HIV-positive multiple myeloma patient with high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation and maintenance therapy with lenalidomide].
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Male; Middle Aged; Multiple My | 2013 |
Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Dru | 2013 |
Memory loss during lenalidomide treatment: a report on two cases.
Topics: Adult; Aged; Angiogenesis Inhibitors; Humans; Immunologic Factors; Lenalidomide; Male; Memory Disord | 2013 |
Meningeal myelomatosis developed after treatment with novel agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cerebrospinal Fluid | 2013 |
[II. Immunomodulation for multiple myeloma].
Topics: Bone Marrow Transplantation; Glucosides; Humans; Immunomodulation; Lenalidomide; Multiple Myeloma; P | 2013 |
Transplants for the elderly in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidom | 2013 |
The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Rem | 2014 |
Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Prol | 2013 |
Myeloma presenting during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; | 2014 |
Haematological cancer: Treatment of smoldering multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Multiple Myelom | 2013 |
[Myeloma therapy(2) Treatment of transplant-ineligible patients].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Lenalidomide; M | 2013 |
Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome A | 2014 |
Increased PAC-1 expression among patients with multiple myeloma on concurrent thalidomide and warfarin.
Topics: Aged; Antibodies, Monoclonal; Anticoagulants; Blood Platelets; Female; Gene Expression; Humans; Immu | 2013 |
VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Remodeling; Bone Resorption; Boron | 2014 |
Recombinant thrombomodulin improved Stevens-Johnson syndrome with high serum high-mobility group-B1 DNA-binding protein induced by lenalidomide administered to treat multiple myeloma.
Topics: HMGB1 Protein; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recombinant Proteins; Stev | 2013 |
Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2013 |
Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2014 |
Haematological cancer: a step before the next leap?
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Drug Resistance, Neoplasm; Hematologic Neoplasms; | 2013 |
Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in multiple myeloma patients?
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2014 |
Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melph | 2014 |
The clinical significance of cereblon expression in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tu | 2014 |
Initial treatment of nontransplant patients with multiple myeloma.
Topics: Age Factors; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Human | 2013 |
"A fortuitous combination of circumstances".
Topics: Cyclophosphamide; Female; Humans; Male; Multiple Myeloma; Prednisone; Thalidomide | 2013 |
Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.
Topics: Aged; Antineoplastic Agents; Cytokines; Humans; Immunologic Factors; Lenalidomide; Male; Multiple My | 2014 |
[Acute dyspnea, subfebrile temperatures and chills in a patient with multiple myeloma].
Topics: Acute Disease; Aged; Comorbidity; Dexamethasone; Dyspnea; Hematopoietic Stem Cell Transplantation; H | 2014 |
Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma.
Topics: Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide; Treatment Outcome | 2014 |
Diplopia and variable ptosis as the sole initial findings in a case of orbital plasmacytoma and multiple myeloma.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Blepharoptosis; Bone Marrow Cells; Cyclophosphamide; Dexa | 2015 |
Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.
Topics: B-Lymphocytes; Female; Hodgkin Disease; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Mult | 2014 |
Treatment for high-risk smoldering myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Multiple Myelom | 2013 |
Treatment for high-risk smoldering myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Multiple Myelom | 2013 |
Treatment for high-risk smoldering myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Multiple Myelom | 2013 |
Treatment for high-risk smoldering myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Multiple Myelom | 2013 |
Treatment for high-risk smoldering myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Multiple Myelom | 2013 |
[The prognostic impact of 1p21 deletion on newly diagnosed multiple myeloma patients receiving thalidomide-based first-line treatment].
Topics: Chromosome Deletion; Chromosomes, Human, Pair 1; Female; Humans; In Situ Hybridization, Fluorescence | 2013 |
Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity.
Topics: Adaptor Proteins, Signal Transducing; Alternative Splicing; Antibodies, Monoclonal; Antibody Specifi | 2014 |
Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma.
Topics: Adult; Aged; Antibodies, Neoplasm; Antibody Specificity; Antineoplastic Combined Chemotherapy Protoc | 2014 |
Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2014 |
AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tum | 2014 |
Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis.
Topics: Adult; Antigens, Surface; Antineoplastic Agents; Case-Control Studies; Consolidation Chemotherapy; H | 2014 |
Effectiveness of haemodiafiltration with ultrafiltrate regeneration in the reduction of light chains in multiple myeloma with renal failure.
Topics: Acute Kidney Injury; Adsorption; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids | 2013 |
Myeloma kidney: the importance of assessing the response by monitoring free light chains in serum.
Topics: Acute Kidney Injury; Anemia; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Drug Monitoring; Drug | 2013 |
Treatment of smoldering multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Multiple Myelom | 2013 |
Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2014 |
Understanding myeloma cancer stem cells.
Topics: Animals; Carcinogenesis; Cell Proliferation; Humans; Immunosuppressive Agents; Mice; Multiple Myelom | 2013 |
Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neop | 2014 |
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Cell Line, Tumor; HEK293 Cells; Humans; | 2014 |
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; HEK293 Cells; Humans; Ikaros Transcription Factor; Interleu | 2014 |
A highly sensitive polyclonal antibody-based ELISA for therapeutic monitoring and pharmacokinetic studies of lenalidomide.
Topics: Animals; Cattle; Cloning, Molecular; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immune Sera; | 2014 |
Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Prog | 2014 |
HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Drug R | 2014 |
Potential new risks of lenalidomide.
Topics: Autoimmune Diseases; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2014 |
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.
Topics: Adult; Age Distribution; Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineop | 2014 |
Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients.
Topics: Acyclovir; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibiotic Prophylaxis; Antiviral Agent | 2014 |
Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Fem | 2013 |
Bendamustine in combination with high-dose radiotherapy and thalidomide is effective in treatment of multiple myeloma with central nervous system involvement.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Central Nervous System; Combined Modality Therapy | 2014 |
Haematological cancer: Ikaros--not a myth for myeloma.
Topics: Antineoplastic Agents; Humans; Ikaros Transcription Factor; Multiple Myeloma; Peptide Hydrolases; Te | 2014 |
Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Glomerular | 2014 |
Multiple myeloma and other malignancies: a pilot study from the Houston VA.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Humans; Incidence; Kaplan-Meier Estimate; | 2014 |
How long can we let the myeloma smolder?
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Multiple Myelom | 2014 |
Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; An | 2013 |
Case of angioedema and urticaria induced by lenalidomide.
Topics: Aged; Angioedema; Female; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide; | 2014 |
Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis.
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; | 2014 |
Lenalidomide and T-cell homeostasis: tolerating immune reconstitution after autologous stem cell transplant.
Topics: Antineoplastic Agents; Homeostasis; Humans; Lenalidomide; Multiple Myeloma; T-Lymphocyte Subsets; Th | 2014 |
Acquired Fanconi syndrome with proximal tubular cytoplasmic fibrillary inclusions of λ light chain restriction.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acid | 2014 |
An overview of the progress in the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Drug Therapy, Combination; Humans; Immunologic Factors; Lenalidomide; Multi | 2014 |
Medicine. How thalidomide works against cancer.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Humans; Ikaros Transcription Factor; Le | 2014 |
Bortezomib-induced lung toxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxo | 2014 |
Multiple myeloma and second malignancies.
Topics: Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasms, Second Primary; Registries; Thalido | 2014 |
Comparative cost-effectiveness models for the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Di | 2014 |
Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.
Topics: Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antigens, Surface; Apoptosis; | 2014 |
Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophospha | 2014 |
A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Dend | 2014 |
Dramatic response of diffuse osteosclerosis secondary to multiple myeloma using thalidomide with melphalan and prednisolone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Melphalan; Multiple Myeloma; O | 2014 |
Periorbital necrobiotic xanthogranuloma treated successfully with novel multiple myeloma therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Dexamethasone; Female; Humans; Lenalidomid | 2013 |
Lenalidomide and second malignancies in myeloma patients.
Topics: Angiogenesis Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Thalidom | 2014 |
Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2014 |
A limited sampling model to estimate exposure to lenalidomide in multiple myeloma patients.
Topics: Angiogenesis Inhibitors; Area Under Curve; Asian People; Female; Humans; Lenalidomide; Male; Multipl | 2014 |
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B-Cell Maturation Antigen; B-Lym | 2014 |
Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2014 |
The impact of long-term lenalidomide exposure on the cellular composition of bone marrow.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Flow Cytometry; Hematopoiesis; Humans; Immunologic Fact | 2014 |
Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortez | 2014 |
United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; C | 2014 |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemoth | 2014 |
Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients.
Topics: Aged; Female; Humans; Immunologic Factors; Immunologic Memory; Immunomodulation; Immunophenotyping; | 2014 |
The osteoblastogenesis potential of adipose mesenchymal stem cells in myeloma patients who had received intensive therapy.
Topics: Adipose Tissue; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Treatment with lenalidomide (Revlimid®), cyclophosphamide (Endoxan®) and prednisone (REP) in relapsed/refractory multiple myeloma patients: results of a single centre retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; H | 2014 |
Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide.
Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Hematopoietic Stem Cell Transplantation; Humans | 2014 |
Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Constipation; Cycl | 2014 |
Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2015 |
Thalidomide-induced granuloma annulare.
Topics: Aged; Granuloma Annulare; Hand; Humans; Immunosuppressive Agents; Male; Multiple Myeloma; Thalidomid | 2014 |
Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
Topics: Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Hypersensitivity, Delayed; Immu | 2014 |
Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrat | 2014 |
Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbolines; Clarithromycin; Dexamethasone; Humans; I | 2014 |
Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
Topics: Antineoplastic Combined Chemotherapy Protocols; Back Pain; Biopsy; Bone Density Conservation Agents; | 2014 |
Thalidomide and its analogues: comparative clinical efficacy and safety, and cost-effectiveness.
Topics: Angiogenesis Inhibitors; Cost-Benefit Analysis; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2014 |
Case images: Isolated thrombus-like mass in a patient with multiple myeloma.
Topics: Angiogenesis Inhibitors; Aorta; Diagnosis, Differential; Humans; Ischemic Attack, Transient; Male; M | 2014 |
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; alpha Karyopherins; Anti-Inflammatory Agents; Biomarkers, Tumo | 2014 |
Assessment of proteasome concentration and chymotrypsin-like activity in plasma of patients with newly diagnosed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chymotrypsin; Enzyme | 2014 |
Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemo | 2014 |
Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008-2012.
Topics: Aged; Antineoplastic Agents; Antineoplastic Protocols; Biopsy; Boronic Acids; Bortezomib; Dexamethas | 2014 |
Inhibitory effects of bortezomib on platelet aggregation in patients with multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Huma | 2014 |
Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; | 2014 |
Adverse drug reaction: pomalidomide-induced liver injury.
Topics: Chemical and Drug Induced Liver Injury; Humans; Male; Middle Aged; Multiple Myeloma; Stem Cell Trans | 2014 |
Allogeneic transplantation in multiple myeloma: a potential renaissance in the era of novel therapies?
Topics: Angiogenesis Inhibitors; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male | 2014 |
Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Drug Admini | 2014 |
Psoriasis induced by thalidomide in a patient with multiple myeloma.
Topics: Angiogenesis Inhibitors; Female; Humans; Middle Aged; Multiple Myeloma; Psoriasis; Thalidomide; Tumo | 2014 |
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Boronic | 2014 |
Clinical analysis of six cases of multiple myeloma first presenting with coagulopathy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Sedimentation; Boronic Acids; Bor | 2014 |
Pyoderma gangrenosum due to lenalidomide use for multiple myeloma.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Blood Cell Count; Fatal Outcome; Humans; Knee; Lenalidom | 2015 |
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2014 |
[Immunomodulatory drugs (IMiDs)].
Topics: Antineoplastic Agents; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasms; Thali | 2014 |
Hepatic extramedullary disease in multiple myeloma with 17p deletion.
Topics: Aneuploidy; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; | 2014 |
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Proto | 2014 |
Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma--real life experience of a tertiary cancer center.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studie | 2015 |
First line and salvage therapy with total therapy 3-based treatment for multiple myeloma- an extended single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethas | 2014 |
Peripheral neuropathy exacerbated by lenalidomide in a patient with multiple myeloma.
Topics: Fatal Outcome; Humans; Immunologic Factors; Leg; Lenalidomide; Male; Middle Aged; Multiple Myeloma; | 2014 |
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Cel | 2015 |
An alternative dosing strategy of lenalidomide for patients with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomi | 2015 |
Underlying autoimmune diseases are not aggravated during treatment with lenalidomide in patients with mucosa-associated lymphoid tissue lymphoma: author's reply.
Topics: Autoimmune Diseases; Humans; Immunologic Factors; Male; Multiple Myeloma; Thalidomide | 2015 |
Underlying autoimmune diseases are not aggravated during treatment with lenalidomide in patients with mucosa-associated lymphoid tissue lymphoma.
Topics: Autoimmune Diseases; Humans; Immunologic Factors; Male; Multiple Myeloma; Thalidomide | 2015 |
Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2014 |
[Clinical response of multiple myeloma treated by first-line autologous stem cell transplantation combined with thalidomide as maintenance treatment].
Topics: Adult; Aged; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple My | 2014 |
Current treatment for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; M | 2014 |
Effect of 13q deletion on IL-6 production in patients with multiple myeloma: a hypothesis may hold true.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Case-Control Studies; Chromosome Dele | 2014 |
[Successful treatment with a combination of lenalidomide and dexamethasone for cryoglobulinemia associated with multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cryoglobulinemia; Dexamethasone; Female; Human | 2014 |
A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi | 2014 |
Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Biopsy; Boroni | 2014 |
[Three cases of lenalidomide-resistant IgA myeloma for which a response was regained after the addition of clarithromycin].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Humans; Imm | 2014 |
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Topics: Acute Kidney Injury; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic | 2014 |
Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.
Topics: Adult; Age Factors; Aged; Antigens, CD34; Antineoplastic Agents, Phytogenic; Cell Count; Drug Therap | 2015 |
Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents.
Topics: Acute Disease; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib; | 2015 |
Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment.
Topics: Aged; Bile Acids and Salts; Diarrhea; Female; Humans; Lenalidomide; Malabsorption Syndromes; Male; M | 2014 |
The importance of screening for serum free light chains in suspected cases of multiple myeloma and their impact on the kidney.
Topics: Aged; Antineoplastic Agents; Biopsy; Bone Marrow; Boronic Acids; Bortezomib; Dexamethasone; Diagnosi | 2014 |
A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Examination; Boronic | 2014 |
Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; | 2015 |
Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.
Topics: Angiogenesis Inhibitors; Apoptosis; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm | 2015 |
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Animals; Antibody-Dependent Cell Cytotoxicity; Bortezomib; Cell | 2015 |
Successful re-administration of lenalidomide after lenalidomide-induced pulmonary alveolar hemorrhage in a patient with refractory myeloma.
Topics: Hemorrhage; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pulmonary Alveoli; Thalidomid | 2015 |
Drug rehab.
Topics: Humans; Models, Molecular; Multiple Myeloma; Thalidomide | 2014 |
Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital.
Topics: Aged; Antineoplastic Agents; Australia; Boronic Acids; Bortezomib; Cost of Illness; Female; Humans; | 2015 |
Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma.
Topics: Benzylamines; Cyclams; Cyclophosphamide; Data Collection; Hematopoietic Stem Cell Transplantation; H | 2015 |
Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.
Topics: Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy P | 2015 |
Sporadic late-onset nemaline myopathy in a woman with multiple myeloma successfully treated with lenalidomide/dexamethasone.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Dexamethasone; Female; Humans; Lenalidomide; Middle | 2015 |
Haematological cancer: ASPIRE for unprecedented benefit with carfilzomib in MM.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Multiple Myelom | 2015 |
Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2015 |
Population pharmacokinetics of pomalidomide.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Immunologic F | 2015 |
Multiple myeloma: is a shift toward continuous therapy needed to move forward?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib; Humans; Immunologic Factors; Lenalidomid | 2015 |
A case of acute kidney injury from crystal nephropathy secondary to pomalidomide and levofloxacin use.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Levofloxa | 2016 |
A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Evaluation, Preclinica | 2015 |
[Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Mul | 2015 |
[Thalidomide, cereblon and multiple myeloma].
Topics: Adaptor Proteins, Signal Transducing; Humans; Ikaros Transcription Factor; Multiple Myeloma; Peptide | 2015 |
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese".
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2015 |
MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide.
Topics: Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antigens, Neoplasm; Antineoplastic Age | 2015 |
[Hypercoagulable state in patients with multiple myeloma].
Topics: Blood Coagulation Tests; Fibrin Fibrinogen Degradation Products; Fibrinogen; Humans; Multiple Myelom | 2015 |
[Latest advances on the maintenance therapy of multiple myeloma].
Topics: Boronic Acids; Bortezomib; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; L | 2015 |
Severe hypocalcemia due to lenalidomide.
Topics: Aged; Calcium; Humans; Hypocalcemia; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Seve | 2015 |
[Thalidomide-associated hypothyroidism in a patient with multiple myeloma].
Topics: Aged; Constipation; Humans; Hypothyroidism; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Thyro | 2015 |
Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Cytokines; Female; Flow Cytometry; Follow-Up Studies; Humans; Lenalid | 2015 |
When less is more: results Herald 'paradigm shift' in treating newly diagnosed multiple myeloma patients.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Clinical Trials, Phase III as Topic; Congr | 2014 |
Zeroing in on cereblon.
Topics: Adaptor Proteins, Signal Transducing; Carrier Proteins; Cullin Proteins; Gene Expression Regulation, | 2015 |
Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
Topics: Adult; Aged; Bortezomib; Costs and Cost Analysis; Disease Progression; Female; Humans; Lenalidomide; | 2015 |
Precipitation of ventricular bigeminy by DMSO during autologous haematopoietic stem cell transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Atrioventricular Block; Bortezomib; Cryoprotec | 2015 |
Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
Topics: Animals; Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dex | 2015 |
NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib.
Topics: Boronic Acids; Bortezomib; Disease-Free Survival; Drug Approval; Humans; Lenalidomide; Multiple Myel | 2015 |
Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groups.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Agents; Disease-Free Survival; Drug Therapy, | 2015 |
[Antimyeloma drugs].
Topics: Angiogenesis Inhibitors; Humans; Kidney Diseases; Multiple Myeloma; Risk Factors; Thalidomide; Venou | 2015 |
[Complications and managements in treatment of melphalan, prednisone and new agents].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Molecu | 2015 |
Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrati | 2015 |
Thalidomide and multiple myeloma serum synergistically induce a hemostatic imbalance in endothelial cells in vitro.
Topics: Adult; Angiogenesis Inhibitors; Antigens, CD; Coagulants; Dexamethasone; Endothelial Cells; Endothel | 2015 |
Modulation of cereblon levels by anti-myeloma agents.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor | 2016 |
Long-term control in a patient with refractory multiple myeloma by oral cyclophosphamide and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Humans; Mid | 2015 |
[Carfilzomib in multiple myeloma relapses].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cl | 2015 |
[Overview].
Topics: Animals; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Multiple My | 2015 |
CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon.
Topics: ADP-ribosyl Cyclase 1; Animals; Bortezomib; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Th | 2015 |
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Ital
Topics: Aged; Aging; Antigens, CD34; Biomarkers; Cell Count; Cell Separation; Cyclophosphamide; Female; Gran | 2015 |
A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Computer Simula | 2016 |
Pooled analysis of pomalidomide for treating patients with multiple myeloma.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Meta-Analysis | 2015 |
Treatment of relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Multiple Myelom | 2015 |
Treatment of relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Multiple Myelom | 2015 |
New treatments highlighted for lymphoma and multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Chemothe | 2015 |
Pomalidomide. A last-line treatment option for multiple myeloma.
Topics: Antineoplastic Agents; Humans; Multiple Myeloma; Recurrence; Thalidomide | 2014 |
Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma.
Topics: Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Multiple Myeloma; Proteasome | 2015 |
Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Flow Cytometry; Histone Deacetylase | 2015 |
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antigen-Presenting Cells; B7-H1 Antigen; Bone Marrow; Cell Line, Tumor; Cell | 2015 |
Multiple myeloma: new uses for available agents, excitement for the future.
Topics: Antineoplastic Agents; Humans; Multiple Myeloma; Oligopeptides; Practice Guidelines as Topic; Protea | 2015 |
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Female; Foll | 2015 |
Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Female; Humans; Lenalidomide; Multiple Myeloma; Purpura, | 2015 |
Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Antineopla | 2015 |
Development of acquired hemophilia A during treatment of multiple myeloma with lenalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Hemophilia A; Hum | 2015 |
17P deleted multiple myeloma presenting with intracranial disease: durable remission after tailored management.
Topics: Autografts; Bortezomib; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 17; Consolida | 2016 |
[Clinical observations of lenalidomide combination chemotherapy for relapsing or refractory multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Beijing; Humans; Lenalidomide; Multiple Myeloma; Neo | 2015 |
Toward optimizing pomalidomide therapy in MM patients.
Topics: Angiogenesis Inhibitors; Female; Humans; Male; Multiple Myeloma; Thalidomide | 2015 |
[Cytotoxity of pomalidomide combined CAR-T cell for multiple myeloma cell RPMI8226 and U266].
Topics: Cell Line, Tumor; Coculture Techniques; Enzyme-Linked Immunosorbent Assay; Humans; Multiple Myeloma; | 2015 |
Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; | 2015 |
A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cisplatin; Cyclophosphamide | 2015 |
Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; D | 2015 |
Dose-adjusted Lenalidomide Combined with Low-dose Dexamethasone Rescues Older Patients with Bortezomib-resistant Multiple Myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethaso | 2015 |
Multiple Myeloma--Better Drugs Ask for More Stringent Evaluations.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Huma | 2015 |
Transiently Pink-Tinged Serum in a Patient With Multiple Myeloma and Anemia Undergoing Lenalidomide Treatment.
Topics: Anemia; Antineoplastic Agents; Female; Hemolysis; Humans; Lenalidomide; Middle Aged; Multiple Myelom | 2015 |
Pomalidomide-Induced Pulmonary Toxicity in Multiple Myeloma.
Topics: Aged; Biopsy; Bronchoalveolar Lavage Fluid; Diagnosis, Differential; Humans; Immunologic Factors; Lu | 2015 |
Outcomes of primary refractory multiple myeloma and the impact of novel therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezom | 2015 |
Lenalidomide and secondary acute lymphoblastic leukemia: a case series.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Humans; Immunologic Factors; Lenalidomide; Male; Middle | 2017 |
A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; HEK293 Cells; Humans; Lenalidomide; Multiple | 2015 |
Life-threatening bowel perforation while on thalidomide-based triplet regimen for multiple myeloma: a retrospective case series.
Topics: Aged; Aged, 80 and over; Diverticulitis; Female; Humans; Intestinal Perforation; Male; Middle Aged; | 2016 |
Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clini | 2015 |
[Graft-versus-host disease associated with lenalidomide maintenance after allogeneic transplantation for relapsed/refractory multiple myeloma].
Topics: Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalid | 2015 |
The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antigens, Differentiation, T-Lymphocyte; Cell Line, Tumor; Female; Hi | 2015 |
Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Follow- | 2016 |
How I treat high-risk myeloma.
Topics: Aged; Antineoplastic Agents; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Im | 2015 |
Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myeloma patients aged 65 years or older: a retrospective single Institutional analysis.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2015 |
[A Newly Diagnosed Case of Multiple Myeloma in Which Lenalidomide Was Continued after Surgery for a Pancreatic Neuroendocrine Tumor That Developed during Lenalidomide Maintenance Therapy].
Topics: Aged; Female; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Pancreatic Neoplasm | 2015 |
Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma.
Topics: Angiogenesis Inhibitors; Animals; Cancer Vaccines; Cell Line, Tumor; Combined Modality Therapy; Dend | 2015 |
SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.
Topics: Actins; ADP-ribosyl Cyclase 1; Antibodies, Monoclonal, Humanized; Apoptosis; Genes, p53; Humans; Lys | 2016 |
[Successful treatment of venous thromboembolism with a Factor Xa inhibitor, edoxaban, in patients with lenalidomide-treated multiple myeloma].
Topics: Aged; Factor Xa Inhibitors; Female; Humans; Lenalidomide; Multiple Myeloma; Pyridines; Thalidomide; | 2015 |
Ischemic colitis diagnosed by magnetic resonance imaging during lenalidomide treatment in a patient with relapsed multiple myeloma.
Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Colitis, Ischemic; Combined M | 2016 |
The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Disease-Free Survival | 2015 |
Visceral leishmaniasis in relapsed and overtreated multiple myeloma in the era of high dose and "novel agent" therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Cyclophosphamide; Dexamethasone; H | 2015 |
Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs.
Topics: Aged; Antineoplastic Agents; Bortezomib; Cost-Benefit Analysis; Female; Humans; Lenalidomide; Male; | 2015 |
Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Demography; Dexamethasone; | 2015 |
Mass-forming extramedullary hematopoiesis in multiple myeloma: 18F-FDG PET/CT is useful in excluding extramedullary myeloma involvement.
Topics: Biomarkers; Biopsy; Bone Marrow; Female; Fluorodeoxyglucose F18; Hematopoiesis, Extramedullary; Huma | 2016 |
HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blotting, Western; Cell Proliferation; Drug Resistance, | 2015 |
Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Flow Cytome | 2015 |
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Hematop | 2015 |
CD4⁺ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma.
Topics: Angiogenesis Inhibitors; Animals; CD4-Positive T-Lymphocytes; Immunomodulation; Lenalidomide; Male; | 2015 |
Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
Topics: Adaptor Proteins, Signal Transducing; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chem | 2015 |
[Novel agents in multiple myeloma treatment].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Multiple Myeloma; Oligopeptides; Protein Ki | 2015 |
Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosomes, Human, Pair 11 | 2016 |
Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Comorbidity; Female; Humans | 2016 |
Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; | 2015 |
Clarithromycin Synergistically Enhances Thalidomide Cytotoxicity in Myeloma Cells.
Topics: Clarithromycin; Drug Synergism; Humans; Immunosuppressive Agents; Multiple Myeloma; Signal Transduct | 2016 |
It's Time to Take Clarithromycin Seriously in Multiple Myeloma.
Topics: Clarithromycin; Humans; Immunosuppressive Agents; Multiple Myeloma; Thalidomide | 2016 |
Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethaso | 2016 |
Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combin | 2015 |
[Effects of Thalidomide on Peripheral Blood Th17 Cells of Patients with Multiple Myeloma].
Topics: Case-Control Studies; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; In | 2015 |
Evaluation of low-dose thalidomide as induction and maintenance therapy in patients with multiple myeloma not eligible for stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Immunosuppressive Agent | 2017 |
Lenalidomide affect expression level of cereblon protein in multiple myeloma cell line RPMI8226.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Blotting, Western; Bortezomib; Cell Line, Tumor; Hu | 2015 |
Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Female; Herpes Zoster; Herpesviru | 2015 |
Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Female; Herpes Zoster; Herpesviru | 2015 |
Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Female; Herpes Zoster; Herpesviru | 2015 |
Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Female; Herpes Zoster; Herpesviru | 2015 |
TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease | 2016 |
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Di | 2016 |
New patterns of relapse in multiple myeloma: a case of "light chain escape" in which FLC predicted relapse earlier than urine and serum immunofixation.
Topics: Bence Jones Protein; Bendamustine Hydrochloride; Blood Protein Electrophoresis; Bortezomib; Dexameth | 2016 |
Continued role for ASCT in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Transplantation; Hum | 2015 |
Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients--Report of the Polish Myeloma Group.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Immunologic Factors; Lenalidomi | 2016 |
The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis.
Topics: Antineoplastic Agents; Bortezomib; China; Female; Humans; Induction Chemotherapy; Male; Middle Aged; | 2015 |
A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Community Pharmacy Services; Fees, Pharmaceutical; Female; Humans; Lenalido | 2016 |
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.
Topics: Animals; Caspase 3; Cyclin-Dependent Kinase Inhibitor p27; Disease Models, Animal; Gene Expression R | 2016 |
Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors.
Topics: Adult; Anemia, Sickle Cell; beta-Globins; Carrier Proteins; Erythroid Precursor Cells; Erythropoiesi | 2016 |
Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells.
Topics: Aged; Apoptosis; Apoptosis Regulatory Proteins; B-Cell Activating Factor; Cell Line, Tumor; Cell Pro | 2016 |
Potential crosstalk of the interleukin-6-heme oxygenase-1-dependent mechanism involved in resistance to lenalidomide in multiple myeloma cells.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Coculture Techniques; Dr | 2016 |
Bone marrow infiltration by multiple myeloma causes anemia by reversible disruption of erythropoiesis.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Marrow; Bortez | 2016 |
CD200 Expression on Plasma Cell Myeloma Cells is Associated with the Efficacies of Bortezomib, Lenalidomide and Thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2015 |
Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide.
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Male; Me | 2016 |
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexameth | 2016 |
The Establishment of Indicators of Thrombocytopenia in Patients Receiving Lenalidomide Therapy.
Topics: Aged; Aged, 80 and over; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Platelet | 2015 |
[Quality of Life Is Associated with Combined Lenalidomide and Dexamethasone Treatment in Japanese Patients with Relapsed or Refractory Multiple Myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; M | 2015 |
Aiolos collaborates with Blimp-1 to regulate the survival of multiple myeloma cells.
Topics: Angiogenesis Inhibitors; Antibodies; Apoptosis; Base Sequence; Binding Sites; Cell Line, Tumor; Cull | 2016 |
A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide.
Topics: Carcinoma; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nasophary | 2015 |
[Efficacy and prognostic factors of induction therapy combined with autologous stem cell transplantation in 201 patients with multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Humans; Multiple | 2016 |
Allogeneic transplantation for multiple myeloma: yes, no or maybe?
Topics: Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Thalidomide; Transplantation, Hom | 2016 |
Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Per | 2016 |
Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Dexamethason | 2016 |
Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Dose-Res | 2016 |
MRD-driven treatment paradigm for newly diagnosed transplant eligible multiple myeloma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Multiple Myeloma; Thalidomide; Transplants | 2016 |
Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Dexamethasone; Drug | 2016 |
Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Bortezomib; Female; Hematopoietic Ste | 2016 |
Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Disease Management; Exanthema; Female; Huma | 2016 |
Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?
Topics: Bortezomib; Humans; Lenalidomide; Leukemia, Plasma Cell; Multiple Myeloma; Prognosis; Retrospective | 2016 |
Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy.
Topics: Aged; Anticoagulants; Drug Administration Schedule; Hemorrhage; Humans; Lenalidomide; Male; Middle A | 2016 |
Outcome of patients with multiple myeloma and renal failure on novel regimens.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Ira | 2016 |
Monoclonal gammopathy-associated pure red cell aplasia.
Topics: Adult; Aged; Bone Marrow; Dexamethasone; Diagnosis, Differential; Female; Humans; Immunoglobulins; L | 2016 |
Haematological cancer: PomCyDex - a lower-cost option in refractory myeloma?
Topics: Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2016 |
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Combined Modalit | 2016 |
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Combined Modalit | 2016 |
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Combined Modalit | 2016 |
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Combined Modalit | 2016 |
[Thalidomide induced peripheral neuropathy in multiple myeloma patients].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carpal Tunnel Syndrome; Female; Humans; Male; | 2015 |
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Boron Compounds; Bortezomib; Cell Line, Tumor; Cell | 2016 |
Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female | 2017 |
The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea.
Topics: Adult; Aged; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppr | 2016 |
Differential effects of lenalidomide during plasma cell differentiation.
Topics: Antineoplastic Agents; Cell Differentiation; Cells, Cultured; Hematopoietic Stem Cell Transplantatio | 2016 |
Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment.
Topics: Aged; Aged, 80 and over; Cohort Studies; Fatigue; Female; Humans; Immunologic Factors; Lenalidomide; | 2016 |
Lenalidomide - the new melphalan?
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Melphalan; Multiple Myeloma; T | 2016 |
A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azetidines; Bortezomib; DNA (Cytosine-5-)-Methyltransfera | 2016 |
Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit An | 2016 |
Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bortezomib; C-Reactive Protein; Chromosome Aberrations; Ch | 2016 |
Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Argonaute Proteins; Cell Line, Tumor; Cell Prolifer | 2016 |
Quadruple Cancers of Non-producing Multiple Myeloma, Cholangiocellular Carcinoma, and Two Different Thyroid Cancers.
Topics: Aged; Bile Duct Neoplasms; Bortezomib; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; C | 2016 |
[Clinical Analysis of Multiple Myeloma Patients Aged over 80 Years].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; | 2016 |
[Curative Efficacy of Lenalidomide plus Low Dose Dexamethasone for Multiple Myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Ifosfamide; Lenalidomide; Mul | 2016 |
An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2016 |
Does the choice of thrombotic prophylactic drug depend on the known risk factors of patients with multiple myeloma in clinical practice?
Topics: Aged; Angiogenesis Inhibitors; Anticoagulants; Aspirin; Female; Heparin, Low-Molecular-Weight; Human | 2016 |
Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexamethasone; Disease-Free S | 2016 |
Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; He | 2016 |
Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Achievement of hemodialysis discontinuation with lenalidomide and dexamethasone therapy in a refractory BJP-type multiple myeloma patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Male; Middle Ag | 2016 |
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2016 |
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2016 |
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2016 |
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2016 |
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2016 |
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2016 |
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2016 |
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2016 |
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2016 |
Acute Renal Failure Associated with Lenalidomide Treatment in Multiple Myeloma: A Rare Occurrence?
Topics: Acute Kidney Injury; Aged; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Mul | 2016 |
Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells.
Topics: Cell Adhesion; Cell Line, Tumor; Cell Movement; Chemokines; Cyclin D1; Drug Resistance, Neoplasm; Ex | 2016 |
Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.
Topics: Adaptor Proteins, Signal Transducing; Basigin; Cell Cycle Proteins; Humans; Immunologic Factors; Imm | 2016 |
Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression.
Topics: Animals; Cell Line, Tumor; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Ikaros Trans | 2016 |
LC-MS/MS method for simultaneous determination of thalidomide, lenalidomide, cyclophosphamide, bortezomib, dexamethasone and adriamycin in serum of multiple myeloma patients.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib; Chromatography, Liquid; Cyclophosphamide | 2016 |
Canadian cost analysis comparing maintenance therapy with bortezomib versus lenalidomide for patients with multiple myeloma post autologous stem cell transplant.
Topics: Antineoplastic Agents; Bortezomib; Canada; Combined Modality Therapy; Costs and Cost Analysis; Follo | 2016 |
A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Genetic Predisposition to Disease; Hematopoi | 2016 |
[Efficacy Comparison of Low dose Thalidomide Combined with Modified VCMP and VAD regimens for Treatment of Aged MM Patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Humans; | 2016 |
Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dexamethasone; Disease Progression; Female; | 2016 |
Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression.
Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy | 2016 |
Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; | 2017 |
Multiple myeloma--translation of trial results into reality.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; B | 2016 |
Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Female; Humans; Lenalido | 2017 |
The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Combined Modality Therapy; Drug Resistance, Neoplasm | 2017 |
Hair repigmentation associated with thalidomide use for the treatment of multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Female; Hair Color; Humans; Multiple Myeloma; Thalidomide | 2016 |
Risk factors for neutropenia with lenalidomide plus dexamethasone therapy for multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2016 |
Pleural effusion as a manifestation of multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Diagnosis, Differen | 2016 |
Multiple Medium Amoebic Liver Abscesses Successfully Treated with Medication and Comprehensive Percutaneous Catheter Drainage.
Topics: Catheterization; Drainage; Female; Humans; Immunologic Factors; Lenalidomide; Liver Abscess, Amebic; | 2016 |
[Expression of PIGF and Its receptor Flt-1 in Patients with Multiple Myeloma and their Correlation with Chemotherapeutic Efficacy].
Topics: Bone Marrow; Humans; Membrane Proteins; Multiple Myeloma; Thalidomide; Vascular Endothelial Growth F | 2016 |
Lenalidomide long-term neurotoxicity: Clinical and neurophysiologic prospective study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Drug Resi | 2016 |
Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data.
Topics: Antineoplastic Agents; Bortezomib; Drug Therapy, Combination; Female; Humans; Hydroxamic Acids; Indo | 2017 |
Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Clinical Trials, Phase III as Topi | 2016 |
Therapeutic drug monitoring enables safe and effective lenalidomide therapy in patients with multiple myeloma on hemodialysis.
Topics: Aged; Angiogenesis Inhibitors; Drug Monitoring; Female; Humans; Lenalidomide; Male; Middle Aged; Mul | 2016 |
Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.
Topics: Bortezomib; Female; Genotype; Humans; Male; Multiple Myeloma; Peripheral Nervous System Diseases; Po | 2017 |
Maintenance lenalidomide after transplantation: How much is enough?
Topics: Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2016 |
Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Disease-Free Surviva | 2016 |
[A clinical analysis of 69 newly diagnosed multiple myeloma patients with renal insufficiency].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Surviv | 2016 |
Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expre | 2017 |
Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexameth | 2017 |
Expansion of Th
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Diphosphonates; Humans; Imidazol | 2017 |
Therapeutic experience of vincristine/cyclophosphamide/melphalan or mitoxantrone/prednisone combination therapy plus thalidomide as first-line induction therapy for newly diagnosed multiple myeloma in a single institution of China.
Topics: Antineoplastic Combined Chemotherapy Protocols; China; Cyclophosphamide; Disease-Free Survival; Fema | 2017 |
Efficacy and Safety of Danshen Compound Tablets in Preventing Thalidomide-Associated Thromboembolism in Patients with Multiple Myeloma: A Multicenter Retrospective Study.
Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Female; Fibrin Fibrinog | 2016 |
The possible role of burden of therapy on the risk of myeloma extramedullary spread.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; | 2017 |
Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Humans; Hy | 2016 |
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Consolidation Chemotherapy; Disea | 2017 |
Toxic epidermal necrolysis induced by thalidomide and dexamethasone treatment for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Interactions; Female; Humans; Mi | 2017 |
Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cardiotoxicity; H | 2017 |
Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Bone and Bones; Bone Marro | 2016 |
Panobinostat in multiple myeloma.
Topics: Bortezomib; Dexamethasone; Humans; Hydroxamic Acids; Multiple Myeloma; Panobinostat; Thalidomide | 2016 |
Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Dr | 2017 |
Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2017 |
Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cohort Studies; Dexamethasone; Female; Humans; Immun | 2017 |
Mobilization of human immature hematopoietic progenitors through combinatory use of bortezomib and immunomodulatory drugs.
Topics: Aged; Antigens, CD34; Blood Cells; Bone Marrow Cells; Bortezomib; Dexamethasone; Drug Therapy, Combi | 2017 |
High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide.
Topics: Adult; Aged; Disease-Free Survival; Female; Humans; Ikaros Transcription Factor; Lenalidomide; Male; | 2016 |
Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma.
Topics: Biomarkers; Cell Survival; Cytokines; Dendritic Cells; Humans; Immunologic Factors; Immunomodulation | 2017 |
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bortezom | 2017 |
Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study.
Topics: Acute Kidney Injury; Antineoplastic Agents; Case-Control Studies; Cerebral Hemorrhage; Hospital Mort | 2016 |
Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2017 |
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bortezomib; Disease Progression; Gene Expression; Humans; | 2017 |
Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; | 2017 |
Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi | 2017 |
Lung Toxicity after Lenalidomide Treatment in a Patient with Multiple Myeloma.
Topics: Dexamethasone; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Lung Diseases, Interstiti | 2017 |
Efficacy of pomalidomide in a multiple myeloma patient requiring hemodialysis.
Topics: Aged; Angiogenesis Inhibitors; Humans; Male; Multiple Myeloma; Renal Dialysis; Renal Insufficiency, | 2016 |
Polyvalent immunoglobulins, platelet lysate and lenalidomide: cocktail for polyfunctional NK cells expansion for multiple myeloma.
Topics: Blood Platelets; Cell Proliferation; Culture Media; Female; Humans; Immunoglobulins; Killer Cells, N | 2017 |
Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure.
Topics: Aged; Angiogenesis Inhibitors; Female; Humans; Kidney Failure, Chronic; Lenalidomide; Multiple Myelo | 2017 |
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.
Topics: Administration, Oral; Adult; Aged; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Middle | 2017 |
A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; R | 2017 |
[Advances of CRBN in Immunomodulatory Drugs for Multiple Myeloma-Review].
Topics: Adaptor Proteins, Signal Transducing; Humans; Multiple Myeloma; Peptide Hydrolases; Prognosis; Thali | 2016 |
Multiple myeloma cells' capacity to decompose H
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Survival; Endoplasmic Reticulum Stress; | 2017 |
Population pharmacokinetics of lenalidomide in multiple myeloma patients.
Topics: Angiogenesis Inhibitors; Body Surface Area; Creatinine; Humans; Lenalidomide; Models, Biological; Mu | 2017 |
IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.
Topics: Biomarkers, Tumor; Bone Marrow Cells; Dexamethasone; Gene Expression; Humans; Ikaros Transcription F | 2017 |
Treatment of newly diagnosed myeloma: Bortezomib-based triplet.
Topics: Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Male; Middle Aged; Multi | 2016 |
Combination therapy for fit (younger and older) newly diagnosed multiple myeloma patients: Data support carfilzomib, lenalidomide, and dexamethasone independent of cytogenetic risk status.
Topics: Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; | 2016 |
Recommend maintenance therapy with lenalidomide in multiple myeloma.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; | 2016 |
Pharmacokinetics of Pomalidomide in a Patient Receiving Hemodialysis Using a High-Cutoff Filter.
Topics: Equipment Design; Humans; Immunologic Factors; Male; Membranes, Artificial; Middle Aged; Multiple My | 2017 |
Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy, | 2017 |
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2017 |
Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma.
Topics: Adaptor Proteins, Signal Transducing; Alleles; Antineoplastic Combined Chemotherapy Protocols; B-Lym | 2016 |
Activation of c-Abl Kinase Potentiates the Anti-myeloma Drug Lenalidomide by Promoting DDA1 Protein Recruitment to the CRL4 Ubiquitin Ligase.
Topics: Angiogenesis Inhibitors; Cell Line, Tumor; Cell Survival; Dexamethasone; DNA-Binding Proteins; Gene | 2017 |
Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta Catenin; Bortezomib; Casein Kinase I; Ce | 2017 |
The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry.
Topics: Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Mu | 2017 |
Pomalidomide: when expectations are understated.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug | 2017 |
Pomalidomide in heavily pretreated refractory multiple myeloma: a case report.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neopla | 2017 |
Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dr | 2017 |
Real-World Treatment Patterns, Time to Next Treatment, and Economic Outcomes in Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide or Carfilzomib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Costs and Cost Analysis; Dexamethasone; Disease Prog | 2017 |
[Cold agglutinin disease of IgA class as early manifestation of multiple myeloma and resolution after treatment with new anti-myeloma drugs].
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Acute Kidney Allograft Rejection Precipitated by Lenalidomide Treatment for Multiple Myeloma.
Topics: Adrenal Cortex Hormones; Aged; Antilymphocyte Serum; Deprescriptions; Female; Graft Rejection; Human | 2017 |
Successful management of venous thromboembolism with apixaban in a multiple myeloma patient on lenalidomide therapy.
Topics: Aged; Factor Xa Inhibitors; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazoles; Pyridones; Thal | 2017 |
Renal failure in multiple myeloma: something new on the horizon.
Topics: Dexamethasone; Humans; Multiple Myeloma; Renal Insufficiency; Thalidomide | 2017 |
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexameth | 2017 |
FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, | 2017 |
Multiple myeloma associated with an Evan's syndrome.
Topics: Acidosis, Lactic; Adrenal Cortex Hormones; Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Ch | 2016 |
Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Comorbid | 2017 |
[Treatment of myeloma in the elderly].
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Marrow Transplantation; Boronic Acid | 2008 |
[Effects of thalidomide on CD4(+)CD25(+) T regulatory cells in patients with multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Huma | 2008 |
The emperor's new clothes or the current practice of clinical trials for multiple myeloma in the USA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; | 2008 |
Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
Topics: Alkaline Phosphatase; Apoptosis; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Boronic | 2008 |
New treatments in multiple myeloma: beyond optimal treatment.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Lenalidom | 2008 |
Duration of survival in patients with myeloma treated with thalidomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Humans; Multiple Myeloma; Prognos | 2008 |
Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Syne | 2009 |
Two cases of bacterial meningitis accompanied by thalidomide therapy in patients with multiple myeloma: is thalidomide associated with bacterial meningitis?
Topics: Angiogenesis Inhibitors; Humans; Male; Meningitis, Bacterial; Middle Aged; Multiple Myeloma; Thalido | 2009 |
Lenalidomide therapy in systemic mastocytosis.
Topics: Aged; Female; Humans; Lenalidomide; Male; Mast Cells; Mastocytosis, Systemic; Middle Aged; Multiple | 2009 |
Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow | 2008 |
Desensitization to thalidomide in a patient with multiple myeloma.
Topics: Aged; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Immunosuppressive Agents; | 2008 |
Hepatotoxicity as a rare but serious side effect of thalidomide.
Topics: Adult; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Liver Diseases | 2009 |
Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; F | 2009 |
Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide.
Topics: Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; M | 2009 |
Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma.
Topics: Antineoplastic Agents; Cytoskeleton; Dexamethasone; Drug Resistance, Neoplasm; Gene Expression Profi | 2008 |
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Boronic Aci | 2009 |
Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethas | 2008 |
Thalidomide may induce interstitial pneumonia preferentially in Japanese patients.
Topics: Asian People; Hematopoietic Stem Cell Transplantation; Humans; Lung Diseases, Interstitial; Male; Mi | 2009 |
Aspirin as thromboprophylaxis in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspirin; Chemoprevention; Humans; Lenalidomide; Mult | 2008 |
Myeloma patient wins fight for drug not yet approved by NICE.
Topics: Antineoplastic Agents; Drug Approval; England; Humans; Lenalidomide; Male; Middle Aged; Multiple Mye | 2008 |
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III a | 2008 |
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III a | 2008 |
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III a | 2008 |
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III a | 2008 |
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.
Topics: Case-Control Studies; Clinical Trials as Topic; Cytokines; Data Collection; DNA Repair; Gene Express | 2008 |
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.
Topics: Case-Control Studies; Clinical Trials as Topic; Cytokines; Data Collection; DNA Repair; Gene Express | 2008 |
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.
Topics: Case-Control Studies; Clinical Trials as Topic; Cytokines; Data Collection; DNA Repair; Gene Express | 2008 |
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.
Topics: Case-Control Studies; Clinical Trials as Topic; Cytokines; Data Collection; DNA Repair; Gene Express | 2008 |
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.
Topics: Case-Control Studies; Clinical Trials as Topic; Cytokines; Data Collection; DNA Repair; Gene Express | 2008 |
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.
Topics: Case-Control Studies; Clinical Trials as Topic; Cytokines; Data Collection; DNA Repair; Gene Express | 2008 |
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.
Topics: Case-Control Studies; Clinical Trials as Topic; Cytokines; Data Collection; DNA Repair; Gene Express | 2008 |
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.
Topics: Case-Control Studies; Clinical Trials as Topic; Cytokines; Data Collection; DNA Repair; Gene Express | 2008 |
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.
Topics: Case-Control Studies; Clinical Trials as Topic; Cytokines; Data Collection; DNA Repair; Gene Express | 2008 |
[The efficacy of thalidomide for multiple myeloma: a clinical analysis of 102 Chinese patients].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up St | 2008 |
Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapy.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; C-Reactive Protein | 2008 |
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examinat | 2008 |
The current landscape of multiple myeloma treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2008 |
Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cell Line, Tumor; Chemokine CXCL12; Enzyme- | 2009 |
Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.
Topics: Antigens, CD1; Cell Line; Cytotoxicity, Immunologic; Humans; Immunotherapy; Killer Cells, Natural; L | 2008 |
Thalidomide-induced pneumonitis.
Topics: Aged; Angiogenesis Inhibitors; Humans; Male; Multiple Myeloma; Pneumonia; Thalidomide; Tomography, X | 2008 |
A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma.
Topics: Anemia, Aplastic; Antineoplastic Agents; Biopsy; Humans; Lenalidomide; Male; Middle Aged; Multiple M | 2009 |
Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
Topics: Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cel | 2008 |
Novel agents in myeloma: an exciting saga.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Im | 2009 |
[Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2008 |
Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Nucleus; Clinical Trials, Ph | 2009 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Le | 2008 |
Induction therapy in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Co | 2008 |
Thalidomide-induced severe hepatotoxicity.
Topics: Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Fatal Outcome; Female; Humans; | 2009 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Di | 2008 |
Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Proliferation; Cell Survival; Cocu | 2009 |
Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangitis; Hepatic Artery; Humans; Immunoglo | 2009 |
A 62-year-old man with wrist and hand pain.
Topics: Amyloidosis; Anti-Inflammatory Agents; Arthralgia; Colchicine; Dexamethasone; Diagnosis, Differentia | 2009 |
Lenalidomide in renal insufficiency--balancing the risks and benefits.
Topics: Antineoplastic Agents; Area Under Curve; Humans; Lenalidomide; Multiple Myeloma; Renal Insufficiency | 2009 |
[Effect of cytochrome CYP2C19 on the anti-myeloma activity of thalidomide in vitro].
Topics: Apoptosis; Aryl Hydrocarbon Hydroxylases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cytochro | 2008 |
Health department sets up cost sharing deal for multiple myeloma drug.
Topics: Antineoplastic Agents; Cost Sharing; Cost-Benefit Analysis; Humans; Lenalidomide; Multiple Myeloma; | 2009 |
Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2008 |
[Multiple myeloma with variant type translocation, t(8;22)(q24;q11.2)].
Topics: Administration, Oral; Aged; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 8; Dexamethasone; | 2009 |
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).
Topics: Age Factors; Aged; Analysis of Variance; Boronic Acids; Bortezomib; Drug Evaluation; Female; Greece; | 2009 |
[Lenalidomid (Revlimid) in the treatment of multiple myeloma--first experience in the Czech Republic].
Topics: Antineoplastic Agents; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomid | 2008 |
[Antiangiogenic activity of thalidomide in vitro mediated by cytochrome CYP2C19].
Topics: Angiogenesis Inhibitors; Apoptosis; Aryl Hydrocarbon Hydroxylases; Cell Cycle; Cell Proliferation; C | 2009 |
Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Resorption; Dexamethasone; Diphosphonates; Femal | 2009 |
Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?
Topics: Aged; Aged, 80 and over; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myelo | 2009 |
Cutaneous involvement in multiple myeloma and bortezomib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Fema | 2009 |
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone.
Topics: Adult; Aged; Chromosome Aberrations; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidom | 2009 |
Interstitial granulomatous drug reaction due to thalidomide.
Topics: Aged; Antibodies, Antinuclear; Female; Granuloma; Humans; Multiple Myeloma; Thalidomide | 2009 |
[Therapeutic news in multiple myeloma. Congress of the French National Society of Internal Medicine, December 2008, Bordeaux].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezom | 2009 |
Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
Topics: Activated Protein C Resistance; Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Combined Che | 2009 |
Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids | 2009 |
Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Ret | 2009 |
Hematology: Lenalidomide plus dexamethasone is effective in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III a | 2009 |
New drugs in multiple myeloma and the significance of autologous stem cell transplants.
Topics: Antineoplastic Agents; Humans; Multiple Myeloma; Oligopeptides; Stem Cell Transplantation; Thalidomi | 2009 |
[Analysis of plasma concentration of thalidomide in Japanese patients of multiple myeloma with renal dysfunction].
Topics: Aged; Asian People; Humans; Immunosuppressive Agents; Kidney; Male; Middle Aged; Multiple Myeloma; R | 2009 |
A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh | 2009 |
Lenalidomide: new drug. Myeloma: many questions remain unanswered.
Topics: Antineoplastic Agents; Dexamethasone; Drug Approval; Drug Therapy, Combination; France; Humans; Lena | 2008 |
Unusual myeloma relapse after thalidomide therapy: the dark side of the moon?
Topics: Humans; Immunophenotyping; Multiple Myeloma; Recurrence; Thalidomide | 2009 |
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2009 |
Genetic variants in XRRC5 may predict development of venous thrombotic events in myeloma patients on thalidomide.
Topics: Angiogenesis Inhibitors; Case-Control Studies; DNA Helicases; Genetic Predisposition to Disease; Hum | 2009 |
Total therapy-based treatment for multiple myeloma--a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 2010 |
[Case of thalidomide-induced interstitial pneumonia].
Topics: Aged; Humans; Lung Diseases, Interstitial; Male; Multiple Myeloma; Thalidomide; Tomography, X-Ray Co | 2009 |
Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Hematopoietic Stem Cell Tra | 2009 |
Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Hematopoietic Stem Cell Tra | 2009 |
Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Hematopoietic Stem Cell Tra | 2009 |
Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Hematopoietic Stem Cell Tra | 2009 |
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2009 |
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therap | 2009 |
Neutrophilic dermatosis complicating lenalidomide therapy.
Topics: Antineoplastic Agents; Biopsy; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Skin; Sw | 2009 |
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.
Topics: Hematopoietic Stem Cell Transplantation; HLA-DR Antigens; Humans; Killer Cells, Natural; Lenalidomid | 2010 |
Lenalidomide for the treatment of relapsed multiple myeloma.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Health Care Rationing; Humans; Lenalidomide; Multiple | 2009 |
Thalidomide: new indication. For elderly myeloma patients: some improvement in first-line treatment.
Topics: Aged; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; Eu | 2009 |
Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin | 2009 |
[A clinical analysis of 25 cases of multiple myeloma complicated by extramedullary plasmacytomas].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2009 |
Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic A | 2009 |
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Clinical Tri | 2009 |
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Clinical Tri | 2009 |
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Clinical Tri | 2009 |
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Clinical Tri | 2009 |
Thalidomide alters nuclear architecture without ABCB1 gene modulation in drug-resistant myeloma cells.
Topics: Acetylation; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Casse | 2009 |
Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Biosynthetic Pathways; Blotting, Western; Cell Line, Tumor; Cell S | 2010 |
Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide.
Topics: Antineoplastic Agents; Bone Morphogenetic Protein 2; Boronic Acids; Bortezomib; Case-Control Studies | 2010 |
Clinical and electrophysiological evaluation of patients with thalidomide-induced neuropathy.
Topics: Action Potentials; Adolescent; Adult; Aged; Electromyography; Electrophysiology; Female; Humans; Imm | 2009 |
Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years.
Topics: Aged; Aged, 80 and over; Dexamethasone; Humans; Immunoglobulin D; Immunoglobulin G; Immunosuppressiv | 2010 |
Toxic epidermal necrolysis following thalidomide and dexamethasone treatment for multiple myeloma: a case report.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Dexamethasone; | 2010 |
[Effect of thalidomide combined with dexamethasone on multiple myeloma KM3 cells].
Topics: Cell Line, Tumor; Dexamethasone; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apopto | 2009 |
Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Humans; Incidence; Korea; Male; Mid | 2010 |
[Lenalidomide in the treatment of multiple myeloma].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Huma | 2009 |
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2009 |
Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report.
Topics: Aged, 80 and over; Antineoplastic Agents; Humans; Lenalidomide; Male; Multiple Myeloma; Plasma Cells | 2009 |
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; D | 2009 |
Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromatin; Cyclin-Dependent Kinase Inhibitor p21; Gene Expr | 2009 |
Myeloma-associated polyneuropathy responding to lenalidomide.
Topics: Adult; Female; Humans; Lenalidomide; Multiple Myeloma; Paraneoplastic Polyneuropathy; Thalidomide | 2009 |
Thalidomide maintenance in multiple myeloma: certainties and controversies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Glucocorticoids; Humans; | 2009 |
Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; | 2009 |
[Interstitial pneumonitis as an adverse effect of thalidomide].
Topics: Aged; Angiogenesis Inhibitors; Humans; Lung Diseases, Interstitial; Male; Multiple Myeloma; Thalidom | 2009 |
Relapse/Refractory myeloma patient: potential treatment guidelines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Mul | 2009 |
Hematology: Thalidomide maintenance in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 13; Clinical Trials, Phase | 2009 |
Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways.
Topics: B-Lymphocytes; Blotting, Western; Cell Adhesion; Cell Movement; Cells, Cultured; Gelatinases; Humans | 2010 |
Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2011 |
Refractory plasmablastic type myeloma with multiple extramedullary plasmacytomas and massive myelomatous effusion: remarkable response with a combination of thalidomide and dexamethasone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Male; Multiple Myeloma; | 2009 |
Towards a new standard of care for patients with myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Drug; Dru | 2010 |
DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Combin | 2010 |
Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation | 2010 |
Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Drug Ther | 2010 |
Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Drug Ther | 2010 |
Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Drug Ther | 2010 |
Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Drug Ther | 2010 |
Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents.
Topics: Acneiform Eruptions; Aged; Boronic Acids; Bortezomib; Candida albicans; Candidiasis; Desonide; Dexam | 2010 |
Researchers debate best use of stem cell transplants in patients with multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2009 |
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2010 |
Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Betulinic Acid; Blotting, Western; Boronic Acids; Bort | 2010 |
Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Disease Progression; Hematopoietic Stem Cell Transplantation | 2009 |
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor | 2010 |
[Effects of thalidomide on Annexin II gene regulation].
Topics: Annexin A2; Cell Line; Endothelial Cells; Endothelium, Vascular; Humans; Multiple Myeloma; RNA, Mess | 2009 |
[Effect of TNF-alpha gene polymorphism on outcome of thalidomide-based regimens for multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Female; Genotype; Humans; Male; Middle Aged; Multiple Myeloma; Polym | 2009 |
Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.
Topics: Antineoplastic Agents; Cell Differentiation; Cells, Cultured; Down-Regulation; Granulocyte Colony-St | 2010 |
Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.
Topics: Antineoplastic Agents; Cell Differentiation; Cells, Cultured; Down-Regulation; Granulocyte Colony-St | 2010 |
Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.
Topics: Antineoplastic Agents; Cell Differentiation; Cells, Cultured; Down-Regulation; Granulocyte Colony-St | 2010 |
Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.
Topics: Antineoplastic Agents; Cell Differentiation; Cells, Cultured; Down-Regulation; Granulocyte Colony-St | 2010 |
Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Cell Survival; Disease M | 2010 |
Resolving a double standard for risk management of thalidomide: an evaluation of two different risk management programmes in Japan.
Topics: Commerce; Drug Approval; Humans; Japan; Legislation, Drug; Multiple Myeloma; Off-Label Use; Physicia | 2010 |
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agent | 2010 |
[Pulmonary embolism as a first manifestation of synchronous occurrence of two neoplasms].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dexamethasone; Heparin, Low | 2009 |
Treatment of multiple myeloma: 2009 update.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; De | 2009 |
[Regulatory effect of thalidomide on the expression of costimulatory molecules in patients with multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; B7-1 Antigen; Cell Line, Tumor; Female; Gene Expression Regulation, | 2009 |
Thalidomide-induced phrenic nerve paralysis.
Topics: Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Dis | 2010 |
Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.
Topics: Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Com | 2010 |
[IgA multiple myeloma with adverse prognostic factors--a case report].
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pa | 2009 |
Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Huma | 2010 |
[Interstitial pneumonitis as an adverse effect of thalidomide].
Topics: Aged; Angiogenesis Inhibitors; Humans; Lung Diseases, Interstitial; Male; Multiple Myeloma; Thalidom | 2009 |
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Dr | 2010 |
Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined | 2010 |
Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.
Topics: Adenosine Triphosphate; Apoptosis; Biomarkers, Tumor; Blotting, Western; Caspase Inhibitors; Caspase | 2010 |
Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Neop | 2010 |
Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies | 2010 |
Lenalidomide for the treatment of cryoglobulinemia and undifferentiated spondyloarthropathy in a patient with multiple myeloma.
Topics: Adult; Antineoplastic Agents; Cryoglobulinemia; HLA-B27 Antigen; Humans; Lenalidomide; Lumbar Verteb | 2010 |
Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boro | 2010 |
Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Asthenia; Boronic Acids; Bortezomib; Humans; Multipl | 2010 |
Chest nodule in a patient with multiple myeloma.
Topics: Aged; Biopsy; Humans; Immunosuppressive Agents; Male; Multiple Myeloma; Skin Neoplasms; Thalidomide; | 2010 |
Lenalidomide-induced interstitial lung disease.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Diagnosis, Differential; Dinoprostone; Femal | 2010 |
Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Creatinine; Drug Resistance, Neoplasm; Drug T | 2010 |
Multiple myeloma patients experience high response rate with new three-drug combination.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Tri | 2009 |
Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma.
Topics: Aged; Consensus; Europe; Guidelines as Topic; Humans; Melphalan; Multiple Myeloma; Prednisone; Risk | 2010 |
High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Tri | 2010 |
Ultra low dose thalidomide in myeloma revisited.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cycl | 2010 |
Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; | 2010 |
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials as Topic; Compassionate U | 2010 |
Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient.
Topics: Aged; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lung Diseases, Interstitial; Male; Multiple | 2010 |
[Retrospective analysis of thalidomide therapy in patients with relapsed/refractory multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Dexamethasone; Disease-Free Survival; Drug Therapy, Combination; Fem | 2010 |
[Picture in clinical hematology no.42].
Topics: Aged; Anticoagulants; Female; Heparin; Humans; Multiple Myeloma; Pulmonary Embolism; Thalidomide; To | 2010 |
[Analysis of high-risk multiple myeloma patients treated with high-dose chemotherapy].
Topics: Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Humans; Male; Multiple Myeloma; Periphera | 2010 |
[Factors affecting the response of thalidomide therapy for patients with multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Constipation; Dexamethasone; Disease-Free Survival; Drug Eruptions; | 2010 |
The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Feasibility Studies; Female; Histone Deacet | 2010 |
[Changes of gene expression profile in human myeloma cell line induced by thalidomide].
Topics: Cell Line, Tumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Multipl | 2010 |
Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen.
Topics: Antigens, CD34; Antineoplastic Agents; Blood Component Removal; Cyclophosphamide; Drug Therapy, Comb | 2011 |
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2010 |
Treatment of newly diagnosed multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as | 2008 |
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
Topics: Antibodies, Monoclonal; Antigen-Antibody Complex; Antigens, CD; Antineoplastic Agents; Apoptosis Reg | 2010 |
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Pha | 2010 |
Clinical management of myeloma--state of the art.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; | 2010 |
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; M | 2010 |
Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide.
Topics: Antigens, CD34; Antineoplastic Agents; Benzylamines; Blood Component Removal; Cyclams; Female; Granu | 2011 |
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; | 2010 |
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Dexame | 2010 |
Lenalidomide-induced hypersensitivity pneumonitis.
Topics: Adrenal Cortex Hormones; Aged; Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Antineoplastic | 2010 |
A case of lenalidomide-induced hypersensitivity pneumonitis.
Topics: Aged; Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Diagnosis, Differential; Drug Hypersens | 2010 |
Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Le | 2010 |
Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytogenetic Analys | 2010 |
Safe and effective use of plerixafor plus G-CSF in dialysis-dependent renal failure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Combined Modality Therapy; Cyclams; De | 2010 |
Frontline regimens for multiple myeloma patients.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; D | 2010 |
High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2011 |
Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Mod | 2010 |
Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results.
Topics: Aged; Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Magnetic Res | 2010 |
The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma--a report by the Polish Myeloma Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; De | 2010 |
Necrosis following skull base irradiation and stem cell transplant for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cranial Irradiation; Dexamethasone; Diphosphonates; | 2010 |
[Clinical study of multiple myeloma: a report of 182 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxor | 2010 |
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.
Topics: Antineoplastic Agents; Bone Marrow Cells; Cell Line, Tumor; Cytokines; Epigenesis, Genetic; Humans; | 2010 |
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.
Topics: Antineoplastic Agents; Bone Marrow Cells; Cell Line, Tumor; Cytokines; Epigenesis, Genetic; Humans; | 2010 |
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.
Topics: Antineoplastic Agents; Bone Marrow Cells; Cell Line, Tumor; Cytokines; Epigenesis, Genetic; Humans; | 2010 |
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.
Topics: Antineoplastic Agents; Bone Marrow Cells; Cell Line, Tumor; Cytokines; Epigenesis, Genetic; Humans; | 2010 |
Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Fema | 2010 |
Hematology: Is thalidomide combination a new option for myeloma?
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Dexamethasone | 2010 |
No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Boronic | 2010 |
Lenalidomide-induced acute interstitial nephritis.
Topics: Acute Disease; Antineoplastic Agents; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; N | 2010 |
Optimising bortezomib in newly diagnosed multiple myeloma.
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2010 |
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrati | 2010 |
Clinical features of multiple myeloma invasion of the central nervous system in Chinese patients.
Topics: Adult; Aged; Brain; Central Nervous System; Dexamethasone; Female; Humans; Magnetic Resonance Imagin | 2010 |
Lenalidomide for bortezomib-resistant multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Health Status Ind | 2010 |
Lenalidomide efficacy in bortezomib-resistant myeloma.
Topics: Acute Kidney Injury; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resis | 2010 |
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; D | 2010 |
Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation; Boronic Acids; Borte | 2011 |
Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2011 |
High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Female; Gene Expression Profi | 2010 |
Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway.
Topics: Antineoplastic Agents; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell P | 2010 |
Sinus bradycardia related to methadone in a patient with myeloma receiving thalidomide therapy.
Topics: Analgesics, Opioid; Arrhythmia, Sinus; Fentanyl; Humans; Immunosuppressive Agents; Male; Methadone; | 2010 |
Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberratio | 2010 |
International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cli | 2011 |
First-line treatment of elderly multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Ph | 2010 |
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy.
Topics: Aged; Anti-Inflammatory Agents; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Blot | 2011 |
DEPTOR expression and response to thalidomide: toward a new therapeutic target in multiple myeloma?
Topics: Angiogenesis Inhibitors; Biomarkers, Pharmacological; Gene Expression Regulation, Neoplastic; Humans | 2010 |
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bor | 2012 |
Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
Topics: Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy P | 2011 |
In vivo efficacy of griseofulvin against multiple myeloma.
Topics: Animals; Antifungal Agents; Antineoplastic Agents; Apoptosis; beta Catenin; Cell Line, Tumor; Ciclop | 2011 |
Cranial nerve palsy in multiple myeloma and solitary plasmacytoma.
Topics: Abducens Nerve Diseases; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2010 |
Multiple myeloma presenting as eosinophilic pleural effusion.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diagnosis, Differential; Eosino | 2010 |
Long-term disease control in multiple myeloma: the impact of the dual mechanism of action of lenalidomide. Introduction and overview.
Topics: Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immu | 2010 |
Lenalidomide: an update on evidence from clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Disease Pro | 2010 |
Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; | 2010 |
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Mod | 2011 |
[Clinical characteristics, outcome of scleromyxoedema: a retrospective multicentre study].
Topics: Adrenal Cortex Hormones; Adult; Aged; Biopsy; Combined Modality Therapy; Diagnosis, Differential; Fe | 2010 |
Successful treatment of extramedullary tumors with low-dose thalidomide in patients with multiple myeloma.
Topics: Aged; Dose-Response Relationship, Drug; Female; Humans; Multiple Myeloma; Sarcoma, Myeloid; Thalidom | 2010 |
A new standard of care in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; C | 2010 |
Significantly reduced regulatory T cell population in patients with untreated multiple myeloma.
Topics: Adult; Aged; Case-Control Studies; Cell Proliferation; Female; Flow Cytometry; Follow-Up Studies; Fo | 2011 |
Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tum | 2011 |
Total therapy 2 in treatment of multiple myeloma: questions about gene expression profiling and treatment-related mortality.
Topics: Angiogenesis Inhibitors; Chromosome Aberrations; Clinical Trials as Topic; Gene Expression Profiling | 2011 |
Thalidomide induced nonspecific interstitial pneumonia in patient with relapsed multiple myeloma.
Topics: Female; Humans; Lung Diseases, Interstitial; Middle Aged; Multiple Myeloma; Thalidomide | 2010 |
Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy | 2011 |
Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.
Topics: Antineoplastic Agents; beta Catenin; Casein Kinase Ialpha; Cell Line, Tumor; Cyclin D1; Drug Resista | 2011 |
Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2011 |
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Gene | 2011 |
Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Inflam | 2011 |
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm R | 2011 |
Development of multiple myeloma in a case of longstanding ankylosing spondylitis: more than a coincidence?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Dexamethaso | 2011 |
Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Animals; Apoptosis Regulatory Proteins; Bone Marrow Cells; Cel | 2011 |
Fatal ischemic stroke in a patient receiving lenalidomide for multiple myeloma.
Topics: Anticoagulants; Antineoplastic Agents; Coma; Fatal Outcome; Female; Heparin, Low-Molecular-Weight; H | 2011 |
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; ATP-Binding Cassette Transporters; Bone Marrow Cells | 2011 |
Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Inci | 2011 |
Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Denmark; Female; Genetic Associ | 2011 |
Recent advances in myeloma treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomid | 2011 |
A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Enzyme-Linked Immunosorbent Assay; Female; Gene Expressi | 2011 |
Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi | 2011 |
[Withdrawal of maintenance dialysis in a patient with diagnosed multiple myeloma and renal failure as a consequence of effective anti-tumor treatment].
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone | 2010 |
IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM.
Topics: Apoptosis; Blotting, Western; CCAAT-Enhancer-Binding Protein-beta; Cell Separation; Down-Regulation; | 2011 |
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Aurora Kinase B; Aurora Ki | 2011 |
Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events.
Topics: Adrenal Insufficiency; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asth | 2011 |
Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Biomarkers; Boronic Acids; Bortezomib; Case-Con | 2011 |
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Topics: Activated Protein C Resistance; Aged; Anticoagulants; Aspirin; Boronic Acids; Bortezomib; Dexamethas | 2011 |
Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cell Division; | 2011 |
Durable hematological response and improvement of nephrotic syndrome on thalidomide therapy in a patient with refractory light chain deposition disease.
Topics: Adult; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immun | 2011 |
Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Stevens-John | 2012 |
Spontaneous huge hematoma in the abdominal wall after lenalidomide.
Topics: Abdomen, Acute; Abdominal Wall; Antineoplastic Agents; Female; Hematoma; Humans; Lenalidomide; Middl | 2011 |
Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Angiogenesis Inhibitors; Antineoplastic Agents | 2011 |
Thalidomide: the tragedy of birth defects and the effective treatment of disease.
Topics: Abnormalities, Drug-Induced; Angiogenesis Inhibitors; Animals; Dose-Response Relationship, Drug; Ect | 2011 |
History of multiple myeloma.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Bence Jones Protein; Boronic Acids; Bortezomib; History, | 2011 |
Allogeneic transplantation in multiple myeloma.
Topics: Animals; Boronic Acids; Bortezomib; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; | 2011 |
Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberratio | 2011 |
Role of maintenance therapy after autologous stem cell transplant for multiple myeloma: lessons for cancer therapy.
Topics: Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Health Services Accessibili | 2011 |
Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytogenetics; Dexamethasone; Humans; Immunogl | 2011 |
Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: results of a retrospective case review.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hematologic Neoplasms; Humans; Incidence; Le | 2011 |
Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma.
Topics: Humans; Lenalidomide; Multiple Myeloma; Salvage Therapy; Survival Analysis; Thalidomide; Treatment O | 2011 |
[Effect of different regimens on bone disease of multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Resorption; | 2011 |
Diffuse alveolar hemorrhage associated with lenalidomide.
Topics: Aged; Antineoplastic Agents; Hemorrhage; Humans; Lenalidomide; Male; Multiple Myeloma; Pulmonary Alv | 2011 |
International Staging System predicts prognosis of Chinese patients with multiple myeloma across different calendar periods with application of novel agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Female; Humans; Male; Middle Ag | 2012 |
Calciphylaxis, occurring 10 weeks after hypercalcaemia, in a patient with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arterioles; Calciphylaxis; Chelation Therapy; Cyclop | 2011 |
Metabolism of thalidomide by human liver microsome cytochrome CYP2C19 is required for its antimyeloma and antiangiogenic activities in vitro.
Topics: Angiogenesis Inhibitors; Apoptosis; Aryl Hydrocarbon Hydroxylases; Cell Cycle; Cell Line, Tumor; Cel | 2012 |
Lenalidomide is active for extramedullary disease in refractory multiple myeloma.
Topics: Aged, 80 and over; Antineoplastic Agents; Humans; Lenalidomide; Male; Multiple Myeloma; Plasmacytoma | 2012 |
Activation of coagulation by a thalidomide-based regimen.
Topics: Annexin A5; Anticoagulants; Antineoplastic Agents; Blood Coagulation; Blood Coagulation Factors; Cel | 2011 |
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Dexamethasone; Female; Humans; Immunologic Factors; Lenalidomide | 2011 |
Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2012 |
Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Cell Line, Tumor; Cells, Cultured; Cytokines; Down-Regulation; Epitopes, T- | 2011 |
Cost effectiveness of treatments for relapsed/refractory multiple myeloma: response to a methodology. RE: Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The cost effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swed
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Kapl | 2011 |
Donor cell leukaemia after allogeneic haematopoietic SCT followed by prolonged thalidomide maintenance for multiple myeloma.
Topics: Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Living Donors; Ma | 2012 |
Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cell Proliferation; Dose-R | 2011 |
Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Epoetin Alfa; Erythropoietin; Female; Humans; Male; Middle | 2012 |
In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Biological Availability; Blotting, | 2011 |
Reducing neurotoxicity in the management of multiple myeloma.
Topics: Antineoplastic Agents; Humans; Immunologic Factors; Multiple Myeloma; Nervous System Diseases; Salva | 2011 |
Reversible pulmonary toxicity due to lenalidomide.
Topics: Antineoplastic Agents; Cough; Dyspnea; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Th | 2012 |
Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma.
Topics: Antineoplastic Agents; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Humans; | 2011 |
[High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma patients--single center experience].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Ma | 2011 |
Lenalidomide in combination with dexamethasone induced rhabdomyolysis in a multiple myeloma patient treated with pravastatin.
Topics: Dexamethasone; Female; Humans; Male; Multiple Myeloma; Thalidomide | 2011 |
Rapid response of plasmacytomas to lenalidomide plus low-dose dexamethasone therapy in a patient with relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Middle | 2011 |
Acute lung toxicity related to pomalidomide.
Topics: Acute Disease; Aged; Antineoplastic Agents; Female; Humans; Lung; Lung Diseases; Male; Middle Aged; | 2011 |
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Graft vs Host | 2012 |
Multiple myeloma associated IgA pemphigus: treatment with bortezomib- and lenalidomide-based regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Immunoglo | 2011 |
Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Female; Gene Frequency; Genetic Asso | 2011 |
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers | 2011 |
Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cl | 2011 |
Sudden significant total protein concentration change: not an analytical problem.
Topics: Aged; Antineoplastic Agents; Blood Proteins; Boronic Acids; Bortezomib; Humans; Lenalidomide; Male; | 2011 |
Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2011 |
A third-generation IMiD for MM.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hu | 2011 |
Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma.
Topics: Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Multiple Myeloma; Stevens-Johnson Syndrom | 2011 |
[Thalidomide-induced sensory neuropaty in patients with multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Electrodiagnosis; Female; Humans; Male; Middle Aged; Multiple Myelom | 2011 |
NICE guidance on bortezomib and thalidomide for first-line treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Dr | 2011 |
Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantati | 2012 |
Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; | 2012 |
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigen-Antibody Complex; Antine | 2011 |
Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; | 2012 |
Posterior reversible encephalopathy syndrome in a patient with multiple myeloma treated with thalidomide.
Topics: Female; Humans; Middle Aged; Multiple Myeloma; Posterior Leukoencephalopathy Syndrome; Thalidomide | 2012 |
Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Dep | 2012 |
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2012 |
Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide.
Topics: Aged; Antineoplastic Agents; Cytokines; Female; Fever; Humans; Lenalidomide; Male; Middle Aged; Mult | 2011 |
Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cholestasis, Intrahepa | 2012 |
Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Female; Haplotypes; Humans; Male; Middle Aged; Multiple Myelom | 2012 |
Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2011 |
Myeloma and second primary cancers.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Myeloid; Melphalan; Multiple Myeloma; Myelody | 2011 |
Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQB1*0602.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Dexamethasone; Drug Eruptions; Femal | 2012 |
What is the benefit of maintenance therapy with lenalidomide or bortezomib after autologous stem cell transplantation in multiple myeloma and what is the risk of developing a secondary primary malignancy?
Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multip | 2011 |
Effect of combined dexamethasone/lenalidomide therapy on NK cell-receptor levels in myeloma patients.
Topics: Antineoplastic Agents; Dexamethasone; Drug Resistance, Neoplasm; Humans; Killer Cells, Natural; Mult | 2011 |
Drugs: More shots on target.
Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Re | 2011 |
Cerebral venous thrombosis in an individual with multiple myeloma treated with lenalidomide.
Topics: Aged, 80 and over; Antineoplastic Agents; Female; Humans; Intracranial Thrombosis; Lenalidomide; Mul | 2011 |
[Reported use of thalidomide in multiple myeloma: presentation of problems in the Thaled® outpatient department].
Topics: Aged; Aged, 80 and over; Ambulatory Care Facilities; Angiogenesis Inhibitors; Female; Humans; Male; | 2011 |
Interstitial pneumonitis associated with the immunomodulatory drugs thalidomide and lenalidomide.
Topics: Antineoplastic Agents; Humans; Immunomodulation; Immunosuppressive Agents; Lenalidomide; Lung Diseas | 2012 |
Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dexamethasone; Drug Administration S | 2012 |
Is the low-thalidomide dose MPT regimen beneficial?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Humans; Melphalan; Multiple Myeloma; Pre | 2011 |
A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; C | 2011 |
Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Prog | 2012 |
Drug interaction between lenalidomide and itraconazole.
Topics: Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Bindin | 2012 |
M(yeloma)IXing up T maintenance.
Topics: Angiogenesis Inhibitors; Female; Humans; Maintenance Chemotherapy; Male; Multiple Myeloma; Thalidomi | 2012 |
Lenalidomide alone or lenalidomide plus dexamethasone significantly inhibit IgG and IgM in vitro... A possible explanation for their mechanism of action in treating multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cells, Cultured; Dexamethasone; Human | 2012 |
Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antigens, CD; Anti | 2012 |
Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
Topics: Adult; Aged; Antigens, CD34; Blood Platelets; Cyclophosphamide; Drug Administration Schedule; Drug D | 2012 |
p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
Topics: Adult; Aged; Antineoplastic Agents; Canada; Cell Nucleus; Chromosomes, Human, Pair 17; Dexamethasone | 2012 |
Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.
Topics: Acute Kidney Injury; Aged; Boronic Acids; Bortezomib; Combined Modality Therapy; Databases, Factual; | 2012 |
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; | 2012 |
Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Line, Tumor; | 2012 |
A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2012 |
[Maintenance therapies of thalidomine and interferon-α in multiple myeloma].
Topics: Female; Humans; Interferon-alpha; Male; Multiple Myeloma; Retrospective Studies; Survival Rate; Thal | 2011 |
Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dexamethasone; Female; Humans; Lenalidomide; | 2012 |
Timing of the high-dose therapy in the area of new drugs.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Melphalan; Mult | 2011 |
Thromboprophylaxis in multiple myeloma: is the evidence there?
Topics: Antineoplastic Agents; Aspirin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Immunomo | 2012 |
In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma.
Topics: Animals; beta Catenin; Cell Line, Tumor; Disease Models, Animal; Diuretics; Drug Therapy, Combinatio | 2012 |
Pachymeningeal involvement in POEMS syndrome: dramatic cerebral MRI improvement after lenalidomide therapy.
Topics: Aged; Castleman Disease; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Humans; | 2012 |
Multiple myeloma and immunomodulation: regulating the regulatory cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclic AMP; Dexamethasone; Glucocorticoids; Humans; | 2012 |
[Case report: Reversible posterior leukoencephalopathy associated with the treatment of multiple myeloma: a case report].
Topics: Antineoplastic Agents; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Posterior Leukoe | 2012 |
Thalidomide and lenalidomide: overview of the French pharmacovigilance database.
Topics: Databases, Factual; France; Hematologic Diseases; Humans; Immunosuppressive Agents; Lenalidomide; Mu | 2012 |
Hair repigmentation associated with the use of lenalidomide: graying may not be an irreversible process!
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Cell Differentiation; Cell Movement; Cytokines; Hair Col | 2013 |
Therapy with lenalidomide plus dexamethasone-induced bone formation in a patient with refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium; Dexamethasone; Female; Humans; Lenali | 2012 |
Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.
Topics: Aged; Algorithms; Antigens, CD34; Benzylamines; Cyclams; Female; Filgrastim; Granulocyte Colony-Stim | 2012 |
Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined | 2012 |
Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy.
Topics: Activins; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone and Bones; Case-Control Studie | 2012 |
1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberratio | 2012 |
Multiple myeloma: treatment evolution.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Immunosuppressi | 2012 |
Frontline treatment of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Hu | 2012 |
Novel therapeutics in multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Histone Deacetylase Inhibitors; Humans; Hydroxamic Ac | 2012 |
Stem cell transplantation for multiple myeloma: current and future status.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Developing Countries; History, 20th Century; Histo | 2012 |
Targeted therapy of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Molecular Tar | 2012 |
Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?
Topics: Antigens, CD; Antineoplastic Agents; Bone Marrow Cells; Female; Humans; Immunophenotyping; Lenalidom | 2012 |
Survival of myeloma patients following the introduction of thalidomide as a second-line therapy: a retrospective study at a single New Zealand centre.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Hospital Mortality; Humans; Middle Aged; Multiple My | 2013 |
[Prognostic significance of morphology in multiple myeloma].
Topics: Aged; Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Fe | 2012 |
Corneal snowflakes.
Topics: Antineoplastic Agents; Biopsy; Bone Marrow; Cornea; Corneal Opacity; Crystallins; Diagnosis, Differe | 2012 |
Lenalidomide in myeloma--a high-maintenance friend.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; | 2012 |
Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales.
Topics: Adult; Computer Simulation; Cost-Benefit Analysis; Dexamethasone; Drug Therapy, Combination; Female; | 2013 |
Bortezomib induces heme oxygenase-1 expression in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Heme Oxygena | 2012 |
Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubici | 2012 |
Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
Topics: Antineoplastic Agents; Humans; Immunologic Factors; Multiple Myeloma; Myelodysplastic Syndromes; Tha | 2012 |
Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations.
Topics: Cohort Studies; Humans; Infections; Lenalidomide; Multiple Myeloma; Thalidomide | 2012 |
Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin | 2013 |
Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2012 |
Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Cyclophos | 2012 |
Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Cohort Studies; Dexamethasone; Drug Resist | 2012 |
Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation.
Topics: Aged; Antiviral Agents; Boronic Acids; Bortezomib; Cytomegalovirus; Cytomegalovirus Infections; Fema | 2012 |
Lenalidomide enhances anti-myeloma cellular immunity.
Topics: Antineoplastic Agents; Cancer Vaccines; Cell Proliferation; Dendritic Cells; Humans; Immunity, Cellu | 2013 |
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Prog | 2012 |
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2013 |
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.
Topics: Aged; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA Methylation; DN | 2012 |
Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation Te | 2012 |
[It is not necessary to use novel agents to all patients with newly diagnosed myeloma as an initial therapy].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; | 2012 |
Lenalidomide: second cancers.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, | 2012 |
Lenalidomide for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphal | 2012 |
Effective treatment of pomalidomide in central nervous system myelomatosis.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Humans; Male; Middle Aged; Multiple Myeloma | 2013 |
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexa | 2013 |
CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Cell Line, Tumor; Dexamethas | 2012 |
Pomalidomide and myeloma meningitis.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Humans; Male; Multiple Myeloma; Thalidomide | 2013 |
Second to none.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; | 2012 |
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic A | 2012 |
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amides; Antineoplastic Agents; Boronic Acids; Bortezom | 2013 |
Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lung Diseases; Male; Middle Aged; | 2012 |
How to select among available options for the treatment of multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Mod | 2012 |
Second primary malignancies and myeloma therapy: fad or fact?
Topics: Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Stem Cell Transplantation; Thalid | 2012 |
Role of carfilzomib in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclin | 2012 |
Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anticoagulants; Aspirin; Cancer Care Facili | 2013 |
Attainment of a stringent complete response in multiple myeloma with thalidomide monotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Immunoglobulin Light Chains; Immunol | 2012 |
Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; CD4-Positive T-Lymphocytes; Cyclophosphamide; | 2012 |
Lenalidomide is effective for the treatment of bortezomib-resistant extramedullary disease in patients with multiple myeloma: report of 2 cases.
Topics: Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidom | 2013 |
Desensitization to lenalidomide in a patient with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Lenalidomide; Ma | 2013 |
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus doxorubicin and dexamethasone as induction therapy in previously untreated multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2013 |
Long-term complete remission in a multiple myeloma patient after Stevens-Johnson syndrome due to lenalidomide therapy.
Topics: Aged; Female; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Stevens-Johnson Syndrome; | 2013 |
Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2013 |
Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dex | 2012 |
Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy.
Topics: Adult; Antineoplastic Agents; Female; France; Graft vs Host Disease; Hematopoietic Stem Cell Transpl | 2013 |
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; D | 2013 |
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; D | 2013 |
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; D | 2013 |
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; D | 2013 |
Clinical study of thalidomide combined with dexamethasone for the treatment of elderly patients with newly diagnosed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free | 2012 |
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
Topics: Antineoplastic Agents; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Cell Survival; | 2013 |
Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Combined Modal | 2013 |
Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone.
Topics: Amines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Combi | 2012 |
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hema | 2013 |
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hema | 2013 |
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hema | 2013 |
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hema | 2013 |
Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide.
Topics: Aged; Biopsy; Bone Marrow; Cytogenetic Analysis; Female; Humans; Immunologic Factors; In Situ Hybrid | 2013 |
A retrospective cohort study of venous thromboembolism(VTE) in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of throm
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Female; Humans; Incidence; Japan; Male; Mid | 2013 |
Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female | 2013 |
Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Coagulati | 2013 |
High frequencies of response after limited primary therapy for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2013 |
Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma.
Topics: Aged; Female; Humans; Immunosuppressive Agents; In Situ Hybridization, Fluorescence; Maintenance Che | 2013 |
Total cost comparison in relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Fees, Pharmaceutical; Health Expend | 2013 |
Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrat | 2013 |
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Clinical Trials, Phase II as Topic; | 2013 |
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Clinical Trials, Phase II as Topic; | 2013 |
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Clinical Trials, Phase II as Topic; | 2013 |
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Clinical Trials, Phase II as Topic; | 2013 |
Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Health Care Costs; Health Resources | 2013 |
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenan
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Controlled Clinical | 2013 |
Initial success, frequent recurrence: tomorrow's multiple myeloma treatments and the value of subtype analysis. Interview with David Siegel.
Topics: Antineoplastic Agents; Cancer Vaccines; Humans; Lenalidomide; Managed Care Programs; Multiple Myelom | 2012 |
Multiple myeloma, version 1.2013.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; B | 2013 |
The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; C | 2014 |
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD11b Antigen; Cell Line, Tumor; Cell Proliferatio | 2013 |
Can NKT cells extinguish smoldering myeloma?
Topics: Dendritic Cells; Female; Galactosylceramides; Humans; Killer Cells, Natural; Lenalidomide; Male; Mul | 2013 |
Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center.
Topics: Adult; Age Factors; Aged; Cyclophosphamide; Data Collection; Female; Granulocyte Colony-Stimulating | 2013 |
Thalidomide-associated gynecomasty in a patient with multiple myeloma.
Topics: Gynecomastia; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2002 |
Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B | 2002 |
Is thalidomide effective for the treatment of gastrointestinal bleeding in hereditary hemorrhagic telangiectasia?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Electrocoagulation; Gastrointestinal Hemorrhag | 2002 |
Thromboembolism in patients on thalidomide for myeloma.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Dose-Response Relationship, Drug; Humans; Immunosuppr | 2002 |
Correspondence re: K. Neben et al., high plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7: 2675-2681, 2001.
Topics: Angiogenesis Inhibitors; Disease Progression; Endothelial Growth Factors; Fibroblast Growth Factor 2 | 2002 |
Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Dr | 2002 |
Efficacy of a low dose of thalidomide in advanced multiple myeloma.
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2002 |
Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Blood Cell Count; Combined Modality Therapy; Diseas | 2002 |
[Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Incidence; Multiple Myeloma; | 2002 |
Fine-needle aspiration cytology of a case of HIV-associated anaplastic myeloma.
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Adult; Anti-HIV Agents; Antigens, CD; Biomarkers, Tumor; | 2002 |
Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF.
Topics: Angiogenesis Inhibitors; Endothelial Growth Factors; Fibroblast Growth Factor 2; Humans; Intercellul | 2002 |
Thalidomide for the treatment of refractory multiple myeloma: association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome.
Topics: Adult; Aged; Endothelial Growth Factors; Female; Fibroblast Growth Factor 2; Humans; Intercellular S | 2002 |
[Thrombotic accidents induced by thalidomide: two cases].
Topics: Adult; Aged; Female; Humans; Immunosuppressive Agents; Lupus Vulgaris; Male; Melanoma; Multiple Myel | 2002 |
[Lung toxicity due to thalidomide].
Topics: Aged; Cough; Dyspnea; Follow-Up Studies; Humans; Immunosuppressive Agents; Lung; Male; Multiple Myel | 2002 |
The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma.
Topics: Adult; Aged; Constipation; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Immunosuppress | 2002 |
Vanishing corneal epithelial crystals following thalidomide induced resolution of myeloma related paraproteinaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Corneal Diseases; Cyclophosphamide; Doxo | 2002 |
Antimyeloma efficacy of thalidomide in the SCID-hu model.
Topics: Angiogenesis Inhibitors; Animals; Biotransformation; Bone Transplantation; Cell Division; Endothelia | 2002 |
Geraldine Ferraro. The fight of her life. Interview by Jo Cavallo.
Topics: Aged; Antineoplastic Agents; Diphosphonates; Female; Humans; Immunosuppressive Agents; Multiple Myel | 2002 |
Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions.
Topics: Aged; Creatinine; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Immunosuppressive Agents | 2002 |
Thalidomide in combination with cyclophosphamide and dexamethasone (thacydex) is effective in soft-tissue plasmacytomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clavicle; Cyclophosphamide; Dexamethasone; Dru | 2002 |
Expression of angiogenic factors including VEGFs and the effects of hypoxia and thalidomide on human myeloma cells.
Topics: Angiogenesis Inducing Agents; Apoptosis; Cell Cycle; Cell Hypoxia; Humans; Multiple Myeloma; Thalido | 2003 |
Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr | 2002 |
Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr | 2002 |
Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr | 2002 |
Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr | 2002 |
Thalidomide-induced neuropathy.
Topics: Humans; Immunosuppressive Agents; Multiple Myeloma; Peripheral Nervous System Diseases; Thalidomide | 2002 |
[Therapeutic effectiveness of thalidomide to multiple myeloma and its mechanism].
Topics: Aged; Angiogenesis Inhibitors; Antigens, CD34; Bone Marrow; Constipation; Endothelial Growth Factors | 2002 |
[Thalidomide inhibits the angiogenic activity of culture supernatants of multiple myeloma cell line].
Topics: Angiogenesis Inhibitors; Bone Marrow; Cell Division; Cell Movement; Cells, Cultured; Culture Media, | 2002 |
Thalidomide in multiple myeloma: current status and future prospects.
Topics: Abnormalities, Drug-Induced; Adjuvants, Immunologic; Angiogenesis Inhibitors; Antineoplastic Combine | 2003 |
Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, P | 2003 |
Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Melphalan; Mult | 2002 |
[In vitro inhibition and mechanism of multiple myeloma cells growth by thalidomide].
Topics: Angiogenesis Inhibitors; Cell Division; Dose-Response Relationship, Drug; Humans; Interleukin-6; Mul | 2002 |
[Influence of thalidomide on interleukin-6 and its transmission in multiple myeloma patients].
Topics: Aged; Angiogenesis Inhibitors; Female; Humans; Interleukin-6; Male; Middle Aged; Multiple Myeloma; R | 2002 |
[Combination of thalidomide and rituximab in suppressing myeloma cells in vitro].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2002 |
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Drug Administration | 2003 |
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.
Topics: Angiogenesis Inhibitors; Animals; B-Lymphocytes; Female; Humans; Immunosuppressive Agents; Injection | 2003 |
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.
Topics: Angiogenesis Inhibitors; Animals; B-Lymphocytes; Female; Humans; Immunosuppressive Agents; Injection | 2003 |
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.
Topics: Angiogenesis Inhibitors; Animals; B-Lymphocytes; Female; Humans; Immunosuppressive Agents; Injection | 2003 |
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.
Topics: Angiogenesis Inhibitors; Animals; B-Lymphocytes; Female; Humans; Immunosuppressive Agents; Injection | 2003 |
Third North American Symposium on Skeletal Complications of Malignancy: summary of the scientific sessions.
Topics: Animals; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Cell Transformation, Neoplastic; Clinical Tr | 2003 |
Moving disease biology from the lab to the clinic.
Topics: Bone Marrow; Boronic Acids; Bortezomib; Cell Division; Drug Delivery Systems; Heterocyclic Compounds | 2003 |
Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma.
Topics: Chemical and Drug Induced Liver Injury; Female; Humans; Immunosuppressive Agents; Liver; Middle Aged | 2003 |
Can thalidomide be effective to treat plasma cell leptomeningeal infiltration?
Topics: Female; Humans; Meningeal Neoplasms; Middle Aged; Multiple Myeloma; Neoplasm Invasiveness; Plasma Ce | 2003 |
[Thalidomide therapy in patients with refractory or relapsed multiple myeloma].
Topics: Aged; Female; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2002 |
Signet ring-like light chain myeloma with systemic spread.
Topics: Anemia; Antineoplastic Agents; Bone Marrow Examination; Combined Modality Therapy; Diagnostic Errors | 2003 |
Thalidomide-associated hyperglycemia and diabetes: case report and review of literature.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Blood Glucose; Colonic Neoplasms; Diabetes Mel | 2003 |
Dermatologic side effects of thalidomide in patients with multiple myeloma.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2003 |
Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma.
Topics: Humans; Hypertension, Pulmonary; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Peri | 2003 |
Fatal sepsis after thalidomide/dexamethasone treatment in two patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Fatal Outcome; Female; Humans; | 2003 |
BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Disease Progres | 2002 |
Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capillary Leak Syndrome; Combined Modality Th | 2003 |
[Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
Topics: Aged; Angiogenesis Inhibitors; Bone Marrow; Cell Adhesion; Endothelial Growth Factors; Female; Fibro | 2003 |
On the use of thalidomide as an antiangiogenic agent in the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Humans; Microcirculation; Multiple Myeloma; Thalidomide | 2003 |
Reversible dementia due to thalidomide therapy for multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Dementia; Humans; Male; Multiple Myeloma; Thalidomide; Tremor | 2003 |
New treatment option emerges for newly diagnosed multiple myeloma.
Topics: Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Humans; Multiple Myeloma; Thalid | 2002 |
Thalidomide metabolites in mice and patients with multiple myeloma.
Topics: Angiogenesis Inhibitors; Animals; Biotransformation; Case-Control Studies; Chromatography, Liquid; H | 2003 |
Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modal | 2003 |
Thalidomide administration for the treatment of resistant plasma cell leukemia.
Topics: Adjuvants, Immunologic; Aged; Angiogenesis Inhibitors; Drug Tolerance; Female; Humans; Leukemia, Pla | 2003 |
[Lung toxicity due to thalidomide].
Topics: Cough; Dyspnea; Humans; Immunosuppressive Agents; Lung; Lung Diseases; Multiple Myeloma; Radiography | 2003 |
Why not start with thalidomide?
Topics: Angiogenesis Inhibitors; Decision Making; Ethics, Medical; Female; Humans; Middle Aged; Multiple Mye | 2003 |
Thalidomide and dexamethasone for resistant multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplas | 2003 |
Thalidomide and dexamethasone for resistant multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplas | 2003 |
Thalidomide and dexamethasone for resistant multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplas | 2003 |
Thalidomide and dexamethasone for resistant multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplas | 2003 |
Evaluation of thrombophylic states in myeloma patients receiving thalidomide: a reasonable doubt.
Topics: Angiogenesis Inhibitors; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide; Venous Thrombosis | 2003 |
Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia.
Topics: Acute Kidney Injury; Aged; Angiogenesis Inhibitors; Female; Humans; Hyperkalemia; Male; Middle Aged; | 2003 |
Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosp | 2003 |
Thalidomide in relapsed or refractory multiple myeloma: how much and for how long?
Topics: Aged; Antineoplastic Agents; Dexamethasone; Drug Monitoring; Humans; Middle Aged; Multiple Myeloma; | 2003 |
99mTc-sestaMIBI scintigraphy in thalidomide-treated refractory or relapsed multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Dexamethasone; Female; Humans; M | 2003 |
Endothelial cells in the bone marrow of patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Marrow; Capillaries; Case-Control Studies; Cell Separation | 2003 |
Response to single-agent thalidomide and eligibility to undergo autotransplant for patients with multiple myeloma refractory to VAD.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Drug Resista | 2003 |
DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2003 |
Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma.
Topics: Adenomatous Polyposis Coli Protein; Antigens, CD; DNA-Binding Proteins; GC Rich Sequence; Humans; Im | 2003 |
Thalidomide and thrombosis in multiple myeloma.
Topics: Humans; Multiple Myeloma; Risk; Thalidomide; Thrombosis; Treatment Outcome | 2003 |
Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cross-Sectional Studies; Factor VIII; Female; | 2003 |
A rosette by any other name...
Topics: Adult; Angiogenesis Inhibitors; Bone Marrow Cells; Humans; Male; Multiple Myeloma; Rosette Formation | 2003 |
Thalidomide as a targeted therapy for multiple myeloma.
Topics: Angiogenesis Inhibitors; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Multiple Myeloma | 2003 |
Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis.
Topics: Humans; Immunoglobulin D; Immunosuppressive Agents; Kidney Failure, Chronic; Male; Middle Aged; Mult | 2003 |
[The changes of gene expression in multiple myeloma treated with thalidomide].
Topics: Angiogenesis Inhibitors; Bone Marrow Cells; DNA, Complementary; Gene Expression Regulation, Neoplast | 2003 |
Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma.
Topics: Aged; Dexamethasone; Drug Interactions; Female; Glucocorticoids; Humans; Leukocyte Count; Male; Midd | 2003 |
Thalidomide as anti-inflammatory therapy for multiple myeloma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Multiple Myeloma; Neoplasm Staging; Thalidomide | 2003 |
Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma.
Topics: Adult; Aged; Blood Cell Count; Case-Control Studies; Graft Survival; Hematopoiesis; Hematopoietic St | 2003 |
[TREATMENT OF EXPERIMENTAL TUMORS WITH THALIDOMIDE].
Topics: Animals; Carcinoma; Carcinoma, Ehrlich Tumor; Mice; Multiple Myeloma; Neoplasms; Neoplasms, Experime | 1963 |
Thalidomide and dexamethasone therapy of myeloma in a patient with previously untreated B-chronic lymphocytic leukemia.
Topics: Aged; Clone Cells; Dexamethasone; Fatal Outcome; Female; Humans; Leukemia, Lymphocytic, Chronic, B-C | 2003 |
Thalidomide: new indication. A last resort in myeloma.
Topics: Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Drug Approval; Drug Therapy, Combination; | 2003 |
Correspondence re: J. Lu et al., thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res., 9: 1680-1688, 2003.
Topics: Angiogenesis Inhibitors; Animals; Humans; Mice; Multiple Myeloma; Thalidomide | 2003 |
Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide.
Topics: Biomarkers; Disease Progression; Follow-Up Studies; Humans; Immunosuppressive Agents; Membrane Prote | 2003 |
Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide.
Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Aut | 2004 |
Pegylated-interferon induced severe bone marrow hypoplasia in a patient with multiple myeloma receiving thalidomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Diseases; Drug Interactions | 2003 |
For investigational targeted drugs, combination trials pose challenges.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; A | 2003 |
Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
Topics: Acyltransferases; Antineoplastic Agents; Caspase 3; Caspase 7; Caspase Inhibitors; Caspases; Cell Li | 2003 |
Combination therapy of Thalidomide and Peginterferon in patients with progressive multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Humans; Interfero | 2004 |
Australia approves thalidomide.
Topics: Antineoplastic Agents; Australia; Drug Approval; Humans; Multiple Myeloma; Thalidomide | 2003 |
Anti-GAD antibody positive stiff-limb syndrome in multiple myeloma.
Topics: Female; Glutamate Decarboxylase; Humans; Immunoglobulin G; Middle Aged; Multiple Myeloma; Stiff-Pers | 2003 |
[Desirable and undesirable effects of thalidomide in patients with multiple myeloma].
Topics: Female; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2003 |
The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide.
Topics: Antineoplastic Agents; Apoptosis; Calcium; Cell Cycle; Cell Division; Dexamethasone; Diphosphonates; | 2003 |
The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures.
Topics: Angiogenesis Inhibitors; Apoptosis; Coculture Techniques; Cytokines; Depression, Chemical; Endotheli | 2004 |
Low dose thalidomide in patients with relapsed or refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cy | 2003 |
Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features.
Topics: Adult; Aged; Antineoplastic Agents; Axons; Evoked Potentials, Motor; Evoked Potentials, Somatosensor | 2004 |
Thalidomide effects in the post-transplantation setting in patients with multiple myeloma.
Topics: Aged; Antigens, CD34; Drug Evaluation; Female; Follow-Up Studies; Graft Survival; Humans; Male; Midd | 2004 |
Tumor lysis syndrome in a multiple myeloma treated with thalidomide.
Topics: Antineoplastic Agents; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide; Tumor Lysis Syndrom | 2004 |
Hb H disease and multiple myeloma.
Topics: Aged; alpha-Thalassemia; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Female; Humans | 2004 |
Thalidomide in patients with multiple myeloma and renal failure.
Topics: Aged; Angiogenesis Inhibitors; Female; Humans; Hyperkalemia; Kidney Failure, Chronic; Male; Middle A | 2004 |
Thrombotic complications associated with thalidomide in multiple myeloma: an old problem with new questions and quandaries in decision-making.
Topics: Aged; Decision Making; Female; Humans; Male; Middle Aged; Multiple Myeloma; Practice Guidelines as T | 2004 |
[Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Male; Middle Ag | 2004 |
Thalidomide-induced bradycardia and its management.
Topics: Aged; Bradycardia; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiograp | 2004 |
[Targeted in therapies multiple myeloma].
Topics: Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Multiple | 2004 |
Discordant response or progression in patients with myeloma treated with thalidomide-based regimens.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Mye | 2004 |
45th Annual Meeting of the American Society of Hematology December 6-9, 2003.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2004 |
Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Topics: Adult; Aged; Angiogenesis Inhibitors; Blood Proteins; Bone Marrow; Female; Fibroblast Growth Factor | 2004 |
Response to thalidomide in multiple myeloma: impact of angiogenic factors.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Angiogenic Proteins; Cytokines; Female; Human | 2004 |
Possible multiple myeloma dedifferentiation following thalidomide therapy: a report of four cases.
Topics: Aged; Aged, 80 and over; Cell Differentiation; Disease Progression; Fatal Outcome; Female; Humans; M | 2004 |
Response of plasmacytomas to low-dose thalidomide in a patient with refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Humans; Male; Mandibular Neoplasms; Middle Aged; Multiple Myeloma; Plasmacy | 2004 |
s-thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line.
Topics: Angiogenesis Inhibitors; Apoptosis; Cell Line, Tumor; Cell Survival; DNA, Neoplasm; Gene Expression | 2004 |
Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cells.
Topics: Aged; Cell Division; Disease Progression; Drug Resistance; Humans; Integrin alpha5; Male; Multiple M | 2004 |
Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone.
Topics: Adult; Aged; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Mutation; Thalidomi | 2004 |
Thalidomide: tragic past and promising future.
Topics: Angiogenesis Inhibitors; Female; Humans; Infant, Newborn; Multiple Myeloma; Pregnancy; Teratogens; T | 2004 |
Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma.
Topics: Clinical Trials as Topic; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Thalidom | 2004 |
Venous sinus thrombosis in a patient taking thalidomide.
Topics: Aged; Angiogenesis Inhibitors; Female; Humans; Multiple Myeloma; Radiography; Sinus Thrombosis, Intr | 2004 |
Extramedullary multiple myeloma escapes the effect of thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Marrow Neoplasms; Dose-Response Relati | 2004 |
Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Case-Control Studies; Comorbidity; Female; Humans; | 2004 |
[Thalidomide treatment of patients with refractory myeloma in the institutes participating in the Japan Myeloma Study Group].
Topics: Female; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2004 |
Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.
Topics: Adult; Combined Modality Therapy; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hu | 2004 |
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Division; Cell Line, Tumor; Drug Synergism | 2004 |
Novel immunomodulatory therapies in the treatment of multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Humans; Immunosu | 2004 |
Severe hypothyroidism after thalidomide treatment.
Topics: Humans; Hypothyroidism; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2004 |
Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Animals; Area Under Curve; Chromatography, | 2004 |
Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Fatal Outcome; Female; Humans; Male; Middle Aged; Multiple My | 2004 |
Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Agents; Drug Synergism; Erythropoieti | 2004 |
Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma.
Topics: Antineoplastic Agents; Combined Modality Therapy; Drug Resistance; Humans; Immunoglobulins, Intraven | 2004 |
Unstable plasma thalidomide concentration in patients with refractory multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Biomarkers; Dose-Response Relationship, Drug; Female; Humans; Male; M | 2004 |
Acute exacerbation of chronic hepatitis B during thalidomide therapy for multiple myeloma: a case report.
Topics: Angiogenesis Inhibitors; Hepatitis B, Chronic; Humans; Klebsiella Infections; Male; Middle Aged; Mul | 2004 |
Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasmacytomas.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Humans; Middle Aged; Multiple Myel | 2005 |
Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Humans; Multiple Myeloma; Recurrence; Thali | 2005 |
[Interstitial pneumonia during treatment with thalidomide in a patient with multiple myeloma].
Topics: Aged; Humans; Lung Diseases, Interstitial; Male; Multiple Myeloma; Thalidomide | 2004 |
Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Angiogenesis Inhibitors; beta 2-Microglobulin; Clinical Tr | 2004 |
An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; beta 2-Microglobulin; Drug Resistance, Neoplasm; Female; H | 2004 |
Salvage therapy options for myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Doxo | 2004 |
Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).
Topics: Adult; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle | 2005 |
[Multiple myeloma of the IgD-lambda type invading CNS].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; Doxorubicin; Drug Therapy | 2004 |
How drug's rebirth as treatment for cancer fueled price rises.
Topics: Drug Industry; HIV Wasting Syndrome; Humans; Multiple Myeloma; Neoplasms; Thalidomide | 2004 |
Severe tremors associated with use of thalidomide.
Topics: Aged; Female; Humans; Male; Multiple Myeloma; Severity of Illness Index; Thalidomide; Tremor | 2005 |
Circulating endothelial progenitor cells in multiple myeloma: implications and significance.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Cells, Cultured; Endothelium, Vascular; Fem | 2005 |
Arterial thrombosis in four patients treated with thalidomide.
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Drug Therapy, Combination; Female; Humans; Intracranial | 2005 |
Selective cyclooxygenase 2 inhibitor NS-398 induces apoptosis in myeloma cells via a Bcl-2 independent pathway.
Topics: Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibi | 2005 |
Influence of thalidomide on megakaryocytes in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Megakaryocytes; Middle Aged; Multiple Myel | 2004 |
Single-agent thalidomide induces response in T-cell lymphoma.
Topics: Aged; Aged, 80 and over; Female; Humans; Immunosuppressive Agents; Lymphoma, T-Cell; Male; Middle Ag | 2005 |
Trials investigate first-line thalidomide in multiple myeloma.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Hormonal; A | 2005 |
Rib pain and increased cough.
Topics: Biopsy; Cough; Diagnosis, Differential; Humans; Male; Middle Aged; Multiple Myeloma; Nurse Practitio | 2005 |
[Multiple myeloma -- therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Combined | 2005 |
Thalidomide with continuous low-dose dexamethasone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Humans; | 2005 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous Syste | 2005 |
In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment.
Topics: Antigens, Surface; Cell Differentiation; Dendritic Cells; Granulocyte-Macrophage Colony-Stimulating | 2005 |
Pulmonary hypertension and thalidomide therapy in multiple myeloma.
Topics: Fatal Outcome; Female; Humans; Hypertension, Pulmonary; Middle Aged; Multiple Myeloma; Thalidomide | 2005 |
Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.
Topics: Antineoplastic Agents; Asthenia; Biopsy; Bone Marrow Cells; Boronic Acids; Bortezomib; Female; Human | 2005 |
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Dexa | 2005 |
Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis.
Topics: Aged; Aged, 80 and over; Biomarkers; Female; Fibrin Fibrinogen Degradation Products; Hemostasis; Hum | 2005 |
Side effects and good effects from new chemotherapeutic agents. Case 2. Thalidomide-induced interstitial pneumonitis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lung Diseases, Interstitial; M | 2005 |
Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Pro | 2005 |
Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma.
Topics: Cryoglobulinemia; Dexamethasone; Disease Management; Drug Therapy, Combination; Female; Humans; Midd | 2005 |
Long-term thalidomide therapy resulted in lack of mdr1 gene expression in a patient with primary resistant multiple myeloma.
Topics: Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance, Neoplasm; Humans; Ma | 2005 |
Treatment options for older myeloma patients. From the Multiple Myeloma Research Foundation.
Topics: Age Factors; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Drug Therapy, Combination; Hu | 2005 |
Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Marrow; Cells, Cultured; Culture Media | 2005 |
[Therapeutic outcomes in systemic lymphatic diseases and plasmacytoma. New hope for palliative patients].
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lymphoma; M | 2005 |
Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Female; Humans; Hypertension, Pulmonary; Middle Aged; Multiple Myeloma; Neo | 2005 |
Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Fr | 2005 |
Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Female | 2005 |
Etodolac induces apoptosis and inhibits cell adhesion to bone marrow stromal cells in human myeloma cells.
Topics: Apoptosis; Bone Marrow Cells; Caspase 3; Caspases; Cell Adhesion; Cell Line; Cell Proliferation; Cyc | 2006 |
Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disea | 2005 |
Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disea | 2005 |
Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disea | 2005 |
Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disea | 2005 |
New strategies for MGUS and smoldering multiple myeloma.
Topics: Diphosphonates; Disease Management; Disease Progression; Drug Design; Humans; Immunoglobulin kappa-C | 2004 |
Future directions in haematology: beyond multiple myeloma.
Topics: Angiogenesis Inhibitors; Animals; Blood Transfusion; Clinical Trials, Phase II as Topic; Cytokines; | 2005 |
New therapies for the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Platelet | 2005 |
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.
Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cel | 2005 |
Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clone Cells; Disease Progression; Dose-Respons | 2005 |
Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Evaluation; Female; | 2005 |
Multiple myeloma: the present and the future.
Topics: Antineoplastic Agents, Alkylating; Bone Diseases; Boronic Acids; Bortezomib; Diphosphonates; Humans; | 2005 |
Thalidomide-associated thrombocytopenia.
Topics: Administration, Oral; Aged; Dexamethasone; Female; Humans; Melphalan; Multiple Myeloma; Neutropenia; | 2005 |
New agents and approaches in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Mu | 2003 |
Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis.
Topics: Aged; Agranulocytosis; Antineoplastic Agents; Female; Humans; Leukocyte Count; Multiple Myeloma; Tha | 2005 |
Role of VAD in the initial treatment of multiple myeloma.
Topics: Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopla | 2005 |
Treatment options and considerations for the newly diagnosed myeloma patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Enoxapar | 2005 |
Do new therapeutic approaches (autotransplants, thalidomide, dexamethasone) improve the survival of patients with multiple myeloma followed in a rheumatology department?
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow Transplantation; Dexamethasone; Diphosphonates; Drug The | 2006 |
Thalidomide and dexamethasone in patients with multiple myeloma not undergoing upfront autologous stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Case Management; Case-Control Studies; Clinical Tria | 2005 |
Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case Management; Cohort Studies; Combin | 2005 |
Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case Management; Clinical Trials, Phase | 2005 |
Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytokines; Dexamethasone; Humans; Immunologic Factor | 2005 |
Thalidomide therapy and deep venous thrombosis in multiple myeloma.
Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Immunosuppressive Agents; Multiple | 2005 |
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
Topics: Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Apoptosis; CD40 Antigens; CD40 Ligand; | 2005 |
Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; | 2006 |
Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1.
Topics: Angiogenesis Inhibitors; Bone Resorption; Cell Differentiation; Cells, Cultured; Dose-Response Relat | 2006 |
New treatment approaches in multiple myeloma.
Topics: Aged; Boronic Acids; Bortezomib; Congresses as Topic; Female; Humans; Incidence; Israel; Male; Middl | 2005 |
Kappa light chain myeloma with initial cutaneous involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dexamethasone; Drug Resistance, Neoplas | 2006 |
Autoimmune thyroiditis during thalidomide treatment.
Topics: Autoantibodies; Female; Humans; Iodide Peroxidase; Middle Aged; Multiple Myeloma; Thalidomide; Thyro | 2006 |
Combo drug therapy beneficial for new cases of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myelom | 2006 |
Should we screen patients for inherited thrombophilia before starting thalidomide?
Topics: Administration, Oral; Aged; Antigens; Cerebral Infarction; Humans; Immunosuppressive Agents; Male; M | 2006 |
Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Ag | 2006 |
Thalidomide for the treatment of leptomeningeal multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Fat | 2006 |
Reversible paraparesis in multiple myeloma with renal failure.
Topics: Acute Kidney Injury; Combined Modality Therapy; Follow-Up Studies; Humans; Hyperkalemia; Kidney Func | 2006 |
Lovastatin and thalidomide have a combined effect on the rate of multiple myeloma cell apoptosis in short term cell cultures.
Topics: Apoptosis; bcl-2-Associated X Protein; Drug Synergism; Drug Therapy, Combination; Humans; Kinetics; | 2006 |
The changing landscape of myeloma therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Hematopoietic Stem Cell T | 2006 |
Progress in the treatment of multiple myeloma.
Topics: Aged; Antineoplastic Agents, Alkylating; Disease-Free Survival; Drug Therapy, Combination; Humans; I | 2006 |
Stimulation of erythropoiesis by thalidomide in multiple myeloma patients: its influence on FasL, TRAIL and their receptors on erythroblasts.
Topics: Adult; Aged; Apoptosis Regulatory Proteins; Erythroblasts; Erythropoiesis; Fas Ligand Protein; Femal | 2006 |
Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Ma | 2005 |
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications.
Topics: Antigen Presentation; Cells, Cultured; Galactosylceramides; Humans; Killer Cells, Natural; Lenalidom | 2006 |
Hematologic malignancies: from clinical science to clinical practice - 2nd European Congress.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematologic Neoplasms; Hum | 2006 |
Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Graft vs Host Disease; Humans; Immunosuppr | 2006 |
Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
Topics: Adult; Aged; Cause of Death; Cohort Studies; Combined Modality Therapy; Dose-Response Relationship, | 2006 |
Thalidomide gives food for thought in multiple myeloma.
Topics: Adult; Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; H | 2006 |
[The effect of cyclophosphamide, thalidomide and dexamethasone combination therapy in relapsed/refractory multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Drug Administ | 2006 |
Bisphosphonates may potentiate effects of thalidomide-dexamethasone combination in advanced multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dexamethasone; Diphosphonates; Human | 2006 |
Lenalidomide and venous thrombosis in multiple myeloma.
Topics: Anti-Inflammatory Agents; Dexamethasone; Drug Therapy, Combination; Erythropoietin; Humans; Lenalido | 2006 |
Lenalidomide and venous thrombosis in multiple myeloma.
Topics: Anti-Inflammatory Agents; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Multiple M | 2006 |
[Guideline for the appropriate use of thalidomide in the treatment of multiple myeloma].
Topics: Abnormalities, Drug-Induced; Dexamethasone; Drug Therapy, Combination; Humans; Informed Consent; Man | 2005 |
Thalidomide for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Gene Expression Profiling | 2006 |
A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bo | 2006 |
Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Humans; Multiple My | 2006 |
Thalidomide in elderly patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Immunosuppress | 2006 |
Thalidomide and dexamethasone for newly diagnosed multiple myeloma: is this really the standard of care?
Topics: Antineoplastic Agents; Dexamethasone; Humans; Multiple Myeloma; Thalidomide | 2006 |
Pneumatosis coli after thalidomide treatment.
Topics: Constipation; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Palliative Care | 2006 |
Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspirin; Dexamethasone; Fibrinolytic Agents; Humans; | 2006 |
Thalidomide-induced severe hepatotoxicity.
Topics: Aged; Antineoplastic Agents; Biopsy; Chemical and Drug Induced Liver Injury; Dexamethasone; Female; | 2006 |
Very low doses of thalidomide as single agent in relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Dexamethasone; Female; Humans; Immunosuppressive | 2006 |
Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Enoxapari | 2006 |
[Deep vein thrombosis and pulmonary embolism in a patient with multiple myeloma treated with thalidomide and dexamethasone].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Dexamethasone; Drug Administration Schedul | 2006 |
Thyroid gland plasmacytoma with a dramatic and persistent complete response under thalidomide and dexamethasone-associated treatment.
Topics: Aged; Antineoplastic Agents, Hormonal; Dexamethasone; Female; Humans; Immunosuppressive Agents; Mult | 2006 |
A rare complication in a case of multiple myeloma on therapy with thalidomide and dexamethasone--reversible posterior lobe leukoencephalopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Diseases; Dexamethasone; Female; Humans | 2006 |
[A cure for multiple myeloma?].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; L | 2006 |
Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Borte | 2006 |
Hypothyroidism caused by thalidomide.
Topics: Adult; Angiogenesis Inhibitors; Female; Humans; Hypothyroidism; Multiple Myeloma; Obesity; Thalidomi | 2006 |
Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma.
Topics: Amyloidosis; Anti-Inflammatory Agents; Clinical Trials as Topic; Dexamethasone; Drug Eruptions; Drug | 2006 |
Thrombomodulin levels are not modified during thalidomide treatment.
Topics: Female; Humans; Immunosuppressive Agents; Male; Multiple Myeloma; Thalidomide; Thrombomodulin; Throm | 2006 |
Encephalopathy in a patient after long-term treatment with thalidomide.
Topics: Angiogenesis Inhibitors; Brain Diseases; Drug Administration Schedule; Humans; Magnetic Resonance Im | 2006 |
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bor | 2006 |
New drugs for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug | 2006 |
Anticoagulation regimens for thalidomide and lenalidomide.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Heparin, Low-Molecular-Weight; Human | 2006 |
Myeloma, thalidomide and thrombosis.
Topics: Humans; Multiple Myeloma; Thalidomide; Thrombosis | 2006 |
The troublesome toxicity of peripheral neuropathy with thalidomide.
Topics: Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Risk Factors; Thalidomide | 2006 |
The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-
Topics: Adult; Aged; Antineoplastic Agents; Case-Control Studies; Cyclophosphamide; Dexamethasone; Doxorubic | 2006 |
The efficacy of low dose thalidomide in refractory/relapsed myeloma: a retrospective audit.
Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multip | 2006 |
Advances in the treatment of elderly patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Melphalan; Multiple Mye | 2006 |
Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Follow-Up Studies; Humans; Immu | 2006 |
Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.
Topics: Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Caspase 3; Cell Proliferation; Cel | 2007 |
Novel agents for multiple myeloma treatment.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Delivery Systems; Dr | 2006 |
Prognostic factors for the efficacy of thalidomide in the treatment of multiple myeloma: a clinical study of 110 patients in China.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; China; Dexamethasone; Disease-Free Survival; F | 2006 |
Thalidomide-induced organizing pneumonia.
Topics: Adult; Angiogenesis Inhibitors; Cryptogenic Organizing Pneumonia; Humans; Immunosuppressive Agents; | 2006 |
[Positive immunoregulation of thalidomide on human peripheral blood mononuclear cell cultures].
Topics: Adjuvants, Immunologic; Adult; CD8-Positive T-Lymphocytes; Cell Proliferation; Cells, Cultured; Cyto | 2006 |
[A case of IgG kappa-type multiple myeloma complicated with carinii pneumonia following thalidomide administration].
Topics: Aged; Female; Humans; Immunoglobulin G; Immunoglobulin kappa-Chains; Multiple Myeloma; Pneumonia, Pn | 2006 |
Myelomatous pleural effusion.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorub | 2006 |
The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells.
Topics: Antineoplastic Agents; Cells, Cultured; Gene Expression Regulation, Neoplastic; Humans; Intercellula | 2007 |
Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Dexam | 2007 |
[Effectivity of thalidomide and dexamethasone for the treatment of refractory multiple myeloma: a retrospective study of 36 consecutive cases].
Topics: Adult; Aged; Aged, 80 and over; Dexamethasone; Drug Therapy, Combination; Female; Humans; Male; Midd | 2007 |
Medical management update: multiple myeloma.
Topics: Adrenal Cortex Hormones; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Combined | 2007 |
Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Multiple Myeloma; Pyrazi | 2007 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortez | 2007 |
Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis.
Topics: Amyloidosis; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Captopril; Ches | 2007 |
Multiple myeloma therapies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benz | 2007 |
Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide | 2007 |
[Low-dose thalidomide in refractory and relapsing multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multipl | 2007 |
Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: long term follow up and disease control after subsequent treatments.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 2007 |
Thalidomide-associated arterial thrombosis: two case reports.
Topics: Angiogenesis Inhibitors; Humans; Male; Middle Aged; Multiple Myeloma; Risk Factors; Thalidomide; Thr | 2007 |
Urinary cytology in multiple myeloma.
Topics: Acute Kidney Injury; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Fat | 2008 |
Thalidomide-induced fulminant hepatic failure.
Topics: Fatal Outcome; Female; Humans; Immunosuppressive Agents; Liver Failure, Acute; Middle Aged; Multiple | 2007 |
Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide.
Topics: Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Dys | 2007 |
Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Capsaicin; Caspase 3; Ca | 2007 |
Arterial thrombosis and thalidomide.
Topics: Arteries; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide; Thrombosis | 2008 |
Deep vein thrombosis occurring on treatment of patients receiving thalidomide with erythropoietin.
Topics: Aged; Erythropoietin; Hematinics; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myel | 2007 |
Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemot | 2007 |
Community-acquired lung abscess caused by Legionella micdadei in a myeloma patient receiving thalidomide treatment.
Topics: Anti-Bacterial Agents; Azithromycin; Community-Acquired Infections; Humans; Immunosuppressive Agents | 2007 |
Bortezomib and lenalidomide effective in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Mul | 2007 |
IgG multiple myeloma presented with ulcerative pyoderma gangrenosum.
Topics: Dexamethasone; Humans; Male; Middle Aged; Multiple Myeloma; Pyoderma Gangrenosum; Thalidomide; Ulcer | 2007 |
Successful desensitization in a patient with lenalidomide hypersensitivity.
Topics: Adult; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Lenalidomide; Multiple M | 2007 |
In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Blood Coagulation; Female; Humans; Male; Middle Aged; Multiple Myelo | 2008 |
Thalidomide in combination with dexamethasone-induced rhabdomyolysis in a patient with refractory myeloma.
Topics: Antineoplastic Agents, Hormonal; Dexamethasone; Drug Therapy, Combination; Humans; Immunoglobulin A; | 2007 |
Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow; CD57 An | 2007 |
Refractory multiple myeloma treated with homoharringtonine: report of two cases.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Tri | 2007 |
Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Aryl Hydrocarbon | 2007 |
Oral melphalan, dexamethasone, and thalidomide for the treatment of refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Hu | 2007 |
Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; D | 2007 |
Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Hu | 2007 |
Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment.
Topics: Aged; Aged, 80 and over; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myelo | 2007 |
Advances in the treatment of MDS, multiple myeloma, and CLL.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Leukemia, L | 2007 |
Managing patients with multiple myeloma and mantle cell lymphoma: where are we now?
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Lymphoma, M | 2007 |
Multiple myeloma patient care: treatment options and nursing considerations.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Immunologic Factors; Lena | 2007 |
Lenalidomide, a thalidomide derivative, shows promise in various applications.
Topics: Antineoplastic Agents; Drug Monitoring; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Synd | 2007 |
Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoco | 2008 |
Spinal epidural lipomatosis in myeloma.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Dexamethasone; Disease Progression; Humans; Lenalido | 2007 |
Multiple myeloma in a 50-year-old with an HLA-identical sibling.
Topics: Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Hematopoietic Stem Cell Transplanta | 2007 |
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2007 |
Bortezomib in combination with thalidomide and dexamethasone--a successful treatment regimen in refractory extramedullary multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Ma | 2008 |
Lenalidomide in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Thalid | 2007 |
Lenalidomide-induced severe hepatotoxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Drug Resista | 2007 |
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2007 |
Thalidomide induced impotence in male hematology patients: a common but ignored complication?
Topics: Adult; Aged; Erectile Dysfunction; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2007 |
Lenalidomide--the phoenix rises.
Topics: Antineoplastic Agents; Drug Design; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Tha | 2007 |
Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 2008 |
Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 2008 |
Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 2008 |
Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 2008 |
How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide.
Topics: Antineoplastic Agents; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; Multiple Myeloma; Thalid | 2007 |
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Female; Heparin, Low-Molecul | 2007 |
Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
Topics: Aged; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Drug Administration Schedule; | 2008 |
Concurrent radiation therapy and lenalidomide in myeloma patient.
Topics: Antineoplastic Agents; Combined Modality Therapy; Dexamethasone; Humans; Lenalidomide; Male; Middle | 2008 |
[Effects of As2O3, dexamethasone and thalidomide on apoptosis and cytoplasmic [Ca2+] of myeloma cell line U266].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Cell Line, Tumor; Cytoplasm | 2007 |
Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Male; Middle A | 2008 |
Arterial and venous thrombotic complications with thalidomide in multiple myeloma.
Topics: Administration, Oral; Aged; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple My | 2008 |
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
Topics: Animals; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Clone Cell | 2008 |
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
Topics: Animals; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Clone Cell | 2008 |
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
Topics: Animals; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Clone Cell | 2008 |
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
Topics: Animals; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Clone Cell | 2008 |
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
Topics: Animals; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Clone Cell | 2008 |
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
Topics: Animals; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Clone Cell | 2008 |
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
Topics: Animals; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Clone Cell | 2008 |
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
Topics: Animals; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Clone Cell | 2008 |
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
Topics: Animals; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Clone Cell | 2008 |
Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
Topics: Aged; Angiogenic Proteins; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Capillarie | 2008 |
Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multiple Myeloma; | 2008 |
Novel tubulin-polymerization inhibitor derived from thalidomide directly induces apoptosis in human multiple myeloma cells: possible anti-myeloma mechanism of thalidomide.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Division; Cell Line, Tumor; Drug Screening Assays, | 2008 |
Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Granulocyt | 2008 |
Thromboembolic events with lenalidomide-based therapy for multiple myeloma.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combinati | 2008 |
Ultra low dose thalidomide in elderly patients with myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedul | 2008 |
Biopsy-proven adenoviral diarrhea responding to low-dose cidofovir.
Topics: Adenoviridae; Adenovirus Infections, Human; Aged; Antigens, Viral; Antiviral Agents; Biopsy; Cidofov | 2008 |
A new method for determination of both thalidomide enantiomers using HPLC systems.
Topics: Angiogenesis Inhibitors; Chromatography, High Pressure Liquid; Female; Humans; Molecular Structure; | 2008 |
Completely reversible agranulocytosis in a multiple myeloma patient treated with thalidomide-dexamethasone.
Topics: Aged; Agranulocytosis; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Dexamethasone; Drug | 2008 |
Despite potential side effects, two drugs make a comeback.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Crohn Disease; Dru | 2008 |
Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; F | 2008 |
Controversies regarding the use of dexamethasone in patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Ph | 2008 |
Treatment for elderly patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Human | 2008 |
Treatment for elderly patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasm Recurrence, Loc | 2008 |
[Effect of CYP2C19 gene polymorphism on efficacy of thalidomide-based regimens for the treatment of multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-4 | 2007 |
Pulmonary embolism in a patient with multiple myeloma receiving thalidomide-dexamethasone therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Male; Multiple Myeloma; | 2008 |
Azotemia associated with use of lenalidomide in plasma cell dyscrasias.
Topics: Acute Kidney Injury; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azotemia; Dexameth | 2008 |
Extramedullary progression of multiple myeloma under thalidomide therapy despite concomitant response of medullary disease.
Topics: Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2008 |
The effects of thalidomide on chemotactic migration of multiple myeloma cell lines.
Topics: Antineoplastic Agents; Cell Line; Chemokine CXCL12; Chemotaxis; Humans; Multiple Myeloma; Plasma Cel | 2008 |
Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dexamethasone; Echocardiography; Female; Heart Dis | 2008 |
Multiple myeloma presenting with advanced renal failure: a case report and new treatment options.
Topics: Adult; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Male; Multiple M | 2008 |
Thalidomide responsive chronic pulmonary GVHD.
Topics: Adrenal Cortex Hormones; Adult; Bone Marrow Transplantation; Bronchiolitis Obliterans; Cyclosporine; | 1996 |
Thalidomide shows promising results in patients with multiple myeloma.
Topics: Antineoplastic Agents; Humans; Immunosuppressive Agents; Multiple Myeloma; Thalidomide | 1999 |
Low-dose thalidomide seems to be effective in multiple myeloma.
Topics: Dose-Response Relationship, Drug; Humans; Multiple Myeloma; Thalidomide; Treatment Outcome | 1999 |
Thalidomide--a revival story.
Topics: Angiogenesis Inhibitors; Bone Marrow; Humans; Multiple Myeloma; Thalidomide | 1999 |
Thalidomide--a revival story.
Topics: Angiogenesis Inhibitors; Bone Marrow; Humans; Multiple Myeloma; Thalidomide | 1999 |
Thalidomide--a revival story.
Topics: Angiogenesis Inhibitors; Bone Marrow; Humans; Multiple Myeloma; Thalidomide | 1999 |
Thalidomide--a revival story.
Topics: Angiogenesis Inhibitors; Bone Marrow; Humans; Multiple Myeloma; Thalidomide | 1999 |
Thalidomide--a revival story.
Topics: Angiogenesis Inhibitors; Bone Marrow; Humans; Multiple Myeloma; Thalidomide | 1999 |
Thalidomide--a revival story.
Topics: Angiogenesis Inhibitors; Bone Marrow; Humans; Multiple Myeloma; Thalidomide | 1999 |
Thalidomide--a revival story.
Topics: Angiogenesis Inhibitors; Bone Marrow; Humans; Multiple Myeloma; Thalidomide | 1999 |
Thalidomide--a revival story.
Topics: Angiogenesis Inhibitors; Bone Marrow; Humans; Multiple Myeloma; Thalidomide | 1999 |
Thalidomide--a revival story.
Topics: Angiogenesis Inhibitors; Bone Marrow; Humans; Multiple Myeloma; Thalidomide | 1999 |
Thalidomide--a revival story.
Topics: Angiogenesis Inhibitors; Bone Marrow; Humans; Multiple Myeloma; Thalidomide | 1999 |
Thalidomide--a revival story.
Topics: Angiogenesis Inhibitors; Bone Marrow; Humans; Multiple Myeloma; Thalidomide | 1999 |
Thalidomide--a revival story.
Topics: Angiogenesis Inhibitors; Bone Marrow; Humans; Multiple Myeloma; Thalidomide | 1999 |
Thalidomide--a revival story.
Topics: Angiogenesis Inhibitors; Bone Marrow; Humans; Multiple Myeloma; Thalidomide | 1999 |
Thalidomide--a revival story.
Topics: Angiogenesis Inhibitors; Bone Marrow; Humans; Multiple Myeloma; Thalidomide | 1999 |
Thalidomide--a revival story.
Topics: Angiogenesis Inhibitors; Bone Marrow; Humans; Multiple Myeloma; Thalidomide | 1999 |
Thalidomide--a revival story.
Topics: Angiogenesis Inhibitors; Bone Marrow; Humans; Multiple Myeloma; Thalidomide | 1999 |
Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug.
Topics: Adult; Aged; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Drug Resistance, Multiple; F | 2000 |
Thalidomide in multiple myeloma.
Topics: Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Humans; Multiple Myeloma; Neoplasm Stagin | 2000 |
Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Bence Jones Protein; Drug Administration Schedule; Female; Hum | 2000 |
[Importance of thalidomide in the treatment of cancer].
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Humans; Multiple Myeloma; Neoplasms; Neovas | 2000 |
Thalidomide--a treatment for cancer?
Topics: Angiogenesis Inhibitors; Humans; Multiple Myeloma; Thalidomide | 2000 |
Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2000 |
A case of aggressive multiple myeloma with cleaved, multilobated, and monocytoid nuclei, and no serum monoclonal gammopathy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cell Cycle; Cisplatin; Cycl | 2000 |
Thalidomide in the treatment of relapsed multiple myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Connectin; Disease-Free Surv | 2000 |
Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Marrow; Chromosome Deletion; Chromosom | 2000 |
Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma.
Topics: Dexamethasone; Drug Interactions; Drug Therapy, Combination; Glucocorticoids; Humans; Male; Middle A | 2000 |
Thalidomide shows promise as cancer treatment.
Topics: Angiogenesis Inhibitors; Humans; Multiple Myeloma; Thalidomide | 2000 |
The effect of virus inactivation on coagulation factors in therapeutic plasma.
Topics: Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Multiple Myeloma; Thalidomide | 2000 |
Progress in the understanding of the biology and the treatment of multiple myeloma--a cure might be around the corner.
Topics: Cell Differentiation; Forecasting; Growth Substances; Humans; Immunosuppressive Agents; Multiple Mye | 2000 |
[How I treat... refractory multiple myeloma with thalidomide].
Topics: Aged; Aged, 80 and over; Blood Protein Electrophoresis; Blood Proteins; Cytokines; Humans; Immunosup | 2000 |
[Thalidomide: the revival].
Topics: Angiogenesis Inhibitors; Behcet Syndrome; Humans; Immunosuppressive Agents; Lupus Erythematosus, Sys | 2001 |
The irreplaceable image. Thalidomide in refractory myeloma patients: early changes in bone marrow cellularity.
Topics: Bone Marrow; Humans; Multiple Myeloma; Thalidomide | 2001 |
Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas.
Topics: Aged; Bone Marrow Cells; Connectin; Drug Administration Schedule; Female; Humans; Immunosuppressive | 2001 |
Thalidomide: near complete regression of extramedullary bulk in refractory multiple myeloma.
Topics: Humans; Immunosuppressive Agents; Middle Aged; Multiple Myeloma; Thalidomide | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Topics: Adjuvants, Immunologic; Case-Control Studies; Cytotoxicity, Immunologic; Humans; Immunophenotyping; | 2001 |
Deep venous thrombosis and thalidomide therapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Multiple Myeloma; Thalidomide; Venous Thromb | 2001 |
Thalidomide and low-dose dexamethasone in myeloma treatment.
Topics: Dexamethasone; Drug Therapy, Combination; Glucocorticoids; Humans; Immunosuppressive Agents; Multipl | 2001 |
Thalidomide in the treatment of plasma cell malignancies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Multiple Myeloma; Thalidomide; Waldenstrom M | 2001 |
The revitalization of thalidomide.
Topics: Angiogenesis Inhibitors; Humans; Multiple Myeloma; Thalidomide; Treatment Outcome | 2001 |
Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Endothelial Growth Factors; Fem | 2001 |
Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma.
Topics: Adult; Bone Marrow; Bone Marrow Neoplasms; Brain Neoplasms; Disease Progression; Humans; Male; Middl | 2001 |
Complete resolution of reflex sympathetic dystrophy with thalidomide treatment.
Topics: Activities of Daily Living; Adult; Angiogenesis Inhibitors; Female; Humans; Immunosuppressive Agents | 2001 |
Thalidomide is effective for extramedullary relapse of multiple myeloma post-allogeneic bone marrow transplantation.
Topics: Angiogenesis Inhibitors; Bone Marrow Transplantation; Humans; Multiple Myeloma; Recurrence; Thalidom | 2001 |
37th Annual American Society of Clinical Oncology Meeting. San Francisco, CA. May 12-15, 2001.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiat | 2001 |
Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Etoposide; Female; | 2001 |
Thalidomide in refractory and relapsing multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm | 2001 |
Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions.
Topics: Adult; Angiogenesis Inhibitors; Drug Therapy, Combination; Female; Glucocorticoids; Hematopoietic St | 2001 |
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.
Topics: Angiogenesis Inhibitors; Bone Marrow Cells; Cell Adhesion; Cell Communication; Coculture Techniques; | 2001 |
Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation.
Topics: Adult; Antineoplastic Agents; Bone Marrow Transplantation; Female; Graft vs Host Disease; Humans; In | 2001 |
Diabetic foot disease in a patient with multiple myeloma receiving thalidomide.
Topics: Angiogenesis Inhibitors; Collateral Circulation; Combined Modality Therapy; Diabetes Mellitus, Type | 2002 |
Thalidomide in multiple myeloma: state of art.
Topics: Humans; Immunosuppressive Agents; Multiple Myeloma; Salvage Therapy; Thalidomide; Treatment Outcome | 2002 |
Advantages of using thalidomide for the management of refractory myeloma patients.
Topics: Aged; Ambulatory Care; Disease Management; Drug Evaluation; Humans; Immunosuppressive Agents; Middle | 2002 |
Hypothyroidism in patients with multiple myeloma following treatment with thalidomide.
Topics: Adult; Clinical Trials as Topic; Female; Humans; Hypothyroidism; Male; Middle Aged; Multiple Myeloma | 2002 |
[Evaluation of blood morphology in patients with refractory multiple myeloma treated with thalidomide].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Erythrocyte Count; Female; Hemoglobins; | 2001 |
Is thalidomide a true anti-angiogenic molecule in multiple myeloma?
Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Animals; Humans; Multiple Myeloma; Thalidomide | 2002 |
S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice.
Topics: 3T3 Cells; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Burkitt Lymphoma; Carcinoma, Lew | 2002 |
Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma.
Topics: Antineoplastic Agents; Female; Humans; Middle Aged; Multiple Myeloma; Thalidomide; Tumor Lysis Syndr | 2002 |
The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free | 2002 |
[Dynamic contrast-enhanced MRI for evaluating bone marrow microcirculation in malignant hematological diseases before and after thalidomide therapy].
Topics: Adult; Aged; Angiogenesis Inhibitors; Bone Marrow; Contrast Media; Female; Gadolinium DTPA; Humans; | 2002 |
Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2002 |
Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers; Drug Evaluation; Endothelial Growth Factors; Femal | 2002 |
Comment on thalidomide usage in myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Middle Aged; Multip | 2002 |
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.
Topics: Adjuvants, Immunologic; Apoptosis; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Drug Synergis | 2002 |
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.
Topics: Adjuvants, Immunologic; Apoptosis; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Drug Synergis | 2002 |
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.
Topics: Adjuvants, Immunologic; Apoptosis; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Drug Synergis | 2002 |
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.
Topics: Adjuvants, Immunologic; Apoptosis; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Drug Synergis | 2002 |
Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma.
Topics: Angiogenesis Inhibitors; Female; Herpes Simplex; Herpes Zoster; Humans; Middle Aged; Multiple Myelom | 2002 |
Second response to lower-dose thalidomide in a patient with multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Humans; Male; Multiple Myeloma; Tha | 2002 |
Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma.
Topics: Aged; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, P | 2002 |
Thalidomide-induced morbilliform rash: diagnosis and continuation of therapy, premedicated with methylprednisolone.
Topics: Aged; Anti-Inflammatory Agents; Drug Eruptions; Humans; Immunosuppressive Agents; Male; Methylpredni | 2002 |
Synergistic growth inhibition of YM529 with biologic response modifiers (BRMs) in myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Diphosphonates; Drug Synergism; Human | 2002 |
[Thalidomide for the treatment of refractory multiple myeloma].
Topics: Adult; Aged; Angiogenesis Inhibitors; Endothelial Growth Factors; Female; Humans; Lymphokines; Male; | 2002 |
Analysis of durability of response to thalidomide treatment for relapsed myeloma patients.
Topics: Aged; Aged, 80 and over; Dexamethasone; Drug Therapy, Combination; Female; Follow-Up Studies; Humans | 2002 |